Naloxone	B-UNK
reverses	O
the	O
antihypertensive	B-UNK
effect	B-UNK
of	O
clonidine	B-CHEMICAL
.	O
In	O
unanesthetized	O
,	O
spontaneously	B-UNK
hypertensive	I-UNK
rats	I-UNK
the	O
decrease	B-UNK
in	O
blood	B-UNK
pressure	I-UNK
and	I-UNK
heart	I-UNK
rate	I-UNK
produced	B-UNK
by	O
intravenous	B-UNK
clonidine	B-UNK
,	O
5	O
to	O
20	O
micrograms	B-UNK
/	O
kg	B-UNK
,	O
was	O
inhibited	B-UNK
or	O
reversed	B-UNK
by	O
nalozone	O
,	O
0.2	O
to	O
2	O
mg	B-UNK
/	O
kg	B-UNK
.	O
The	O
hypotensive	B-UNK
effect	B-UNK
of	O
100	O
mg	B-UNK
/	O
kg	B-UNK
alpha	B-UNK
-	O
methyldopa	B-UNK
was	O
also	O
partially	O
reversed	B-UNK
by	O
naloxone	B-CHEMICAL
.	O
Naloxone	B-CHEMICAL
alone	O
did	O
not	O
affect	B-UNK
either	O
blood	B-UNK
pressure	I-UNK
or	O
heart	B-UNK
rate	I-UNK
.	O
In	O
brain	B-UNK
membranes	B-UNK
from	O
spontaneously	B-UNK
hypertensive	I-UNK
rats	I-UNK
clonidine	B-UNK
,	O
10(-8	O
)	O
to	O
10(-5	O
)	O
M	O
,	O
did	O
not	O
influence	B-UNK
stereoselective	O
binding	B-UNK
of	O
[	O
3H]-naloxone	O
(	O
8	O
nM	B-UNK
)	O
,	O
and	O
naloxone	B-UNK
,	O
10(-8	O
)	O
to	O
10(-4	O
)	O
M	O
,	O
did	O
not	O
influence	B-UNK
clonidine	B-CHEMICAL
-	O
suppressible	O
binding	B-UNK
of	O
[	O
3H]-dihydroergocryptine	O
(	O
1	O
nM	B-UNK
)	O
.	O
These	O
findings	B-UNK
indicate	O
that	O
in	O
spontaneously	B-UNK
hypertensive	I-UNK
rats	I-UNK
the	O
effects	O
of	O
central	B-UNK
alpha	B-UNK
-	O
adrenoceptor	B-UNK
stimulation	B-UNK
involve	B-UNK
activation	B-UNK
of	O
opiate	B-UNK
receptors	B-UNK
.	O
As	O
naloxone	B-UNK
and	O
clonidine	B-CHEMICAL
do	O
not	O
appear	O
to	O
interact	O
with	O
the	O
same	O
receptor	B-UNK
site	B-UNK
,	O
the	O
observed	O
functional	B-UNK
antagonism	B-UNK
suggests	O
the	O
release	B-UNK
of	O
an	O
endogenous	B-UNK
opiate	B-CHEMICAL
by	O
clonidine	B-UNK
or	O
alpha	B-UNK
-	O
methyldopa	B-UNK
and	O
the	O
possible	O
role	O
of	O
the	O
opiate	B-UNK
in	O
the	O
central	B-UNK
control	B-UNK
of	O
sympathetic	B-UNK
tone	B-UNK
.	O

Lidocaine	B-UNK
-	O
induced	O
cardiac	B-DISEASE
asystole	I-DISEASE
.	O
Intravenous	B-UNK
administration	O
of	O
a	O
single	B-UNK
50-mg	O
bolus	B-UNK
of	O
lidocaine	B-CHEMICAL
in	O
a	O
67-year	O
-	O
old	O
man	B-UNK
resulted	B-UNK
in	O
profound	B-UNK
depression	B-DISEASE
of	O
the	O
activity	B-UNK
of	O
the	O
sinoatrial	B-UNK
and	O
atrioventricular	B-UNK
nodal	O
pacemakers	O
.	O
The	O
patient	B-UNK
had	O
no	O
apparent	B-UNK
associated	O
conditions	O
which	O
might	O
have	O
predisposed	O
him	O
to	O
the	O
development	B-UNK
of	O
bradyarrhythmias	B-DISEASE
;	O
and	O
,	O
thus	O
,	O
this	O
probably	O
represented	O
a	O
true	O
idiosyncrasy	O
to	O
lidocaine	B-CHEMICAL
.	O

Suxamethonium	B-UNK
infusion	B-UNK
rate	B-UNK
and	O
observed	O
fasciculations	B-DISEASE
.	O
A	O
dose	B-UNK
-	O
response	B-UNK
study	B-UNK
.	O
Suxamethonium	B-UNK
chloride	B-UNK
(	O
Sch	O
)	O
was	O
administered	O
i.v	B-UNK
.	O
to	O
36	O
adult	B-UNK
males	B-UNK
at	O
six	O
rates	B-UNK
:	O
0.25	O
mg	B-UNK
s-1	O
to	O
20	O
mg	B-UNK
s-1	O
.	O
The	O
infusion	B-UNK
was	O
discontinued	O
either	O
when	O
there	O
was	O
no	O
muscular	B-UNK
response	B-UNK
to	O
tetanic	O
stimulation	B-UNK
of	O
the	O
ulnar	O
nerve	B-UNK
or	O
when	O
Sch	O
120	O
mg	B-UNK
was	O
exceeded	O
.	O
Six	O
additional	B-UNK
patients	B-UNK
received	O
a	O
30-mg	O
i.v	B-UNK
.	O
bolus	B-UNK
dose	B-UNK
.	O
Fasciculations	B-DISEASE
in	O
six	O
areas	B-UNK
of	O
the	O
body	B-UNK
were	O
scored	B-UNK
from	O
0	O
to	O
3	O
and	O
summated	O
as	O
a	O
total	B-UNK
fasciculation	B-DISEASE
score	O
.	O
The	O
times	B-UNK
to	O
first	O
fasciculation	B-UNK
,	O
twitch	O
suppression	B-UNK
and	O
tetanus	B-DISEASE
suppression	B-UNK
were	O
inversely	O
related	O
to	O
the	O
infusion	B-UNK
rates	B-UNK
.	O
Fasciculations	B-UNK
in	O
the	O
six	O
areas	B-UNK
and	O
the	O
total	B-UNK
fasciculation	B-UNK
score	O
were	O
related	O
directly	O
to	O
the	O
rate	B-UNK
of	O
infusion	B-UNK
.	O
Total	B-UNK
fasciculation	B-UNK
scores	O
in	O
the	O
30-mg	O
bolus	B-UNK
group	B-UNK
and	O
the	O
5-mg	O
s-1	O
and	O
20-mg	O
s-1	O
infusion	B-UNK
groups	B-UNK
were	O
not	O
significantly	B-UNK
different	O
.	O

Galanthamine	O
hydrobromide	O
,	O
a	O
longer	O
acting	O
anticholinesterase	O
drug	B-UNK
,	O
in	O
the	O
treatment	B-UNK
of	O
the	O
central	B-UNK
effects	O
of	O
scopolamine	B-UNK
(	O
Hyoscine	O
)	O
.	O
Galanthamine	O
hydrobromide	O
,	O
an	O
anticholinesterase	O
drug	B-UNK
capable	O
of	O
penetrating	O
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
,	O
was	O
used	O
in	O
a	O
patient	B-UNK
demonstrating	O
central	B-UNK
effects	O
of	O
scopolamine	B-UNK
(	O
hyoscine	O
)	O
overdosage	O
.	O
It	O
is	O
longer	O
acting	O
than	O
physostigmine	O
and	O
is	O
used	O
in	O
anaesthesia	B-UNK
to	O
reverse	B-UNK
the	O
non-depolarizing	O
neuromuscular	B-UNK
block	B-UNK
.	O
However	O
,	O
studies	B-UNK
into	O
the	O
dose	B-UNK
necessary	O
to	O
combating	O
scopolamine	B-CHEMICAL
intoxication	B-UNK
are	O
indicated	O
.	O

Effects	O
of	O
uninephrectomy	O
and	O
high	B-UNK
protein	B-UNK
feeding	O
on	O
lithium	B-CHEMICAL
-	O
induced	O
chronic	B-UNK
renal	I-UNK
failure	I-UNK
in	O
rats	B-UNK
.	O
Rats	B-UNK
with	O
lithium	B-CHEMICAL
-	O
induced	O
nephropathy	B-UNK
were	O
subjected	O
to	O
high	B-UNK
protein	B-UNK
(	O
HP	O
)	O
feeding	O
,	O
uninephrectomy	O
(	O
NX	B-UNK
)	O
or	O
a	O
combination	B-UNK
of	O
these	O
,	O
in	O
an	O
attempt	O
to	O
induce	B-UNK
glomerular	B-UNK
hyperfiltration	O
and	O
further	O
progression	B-UNK
of	O
renal	B-DISEASE
failure	I-DISEASE
.	O
Newborn	B-UNK
female	B-UNK
Wistar	B-UNK
rats	I-UNK
were	O
fed	B-UNK
a	O
lithium	B-CHEMICAL
-	O
containing	O
diet	B-UNK
(	O
50	O
mmol	B-UNK
/	O
kg	B-UNK
)	O
for	O
8	O
weeks	B-UNK
and	O
then	O
randomized	B-UNK
to	O
normal	O
diet	B-UNK
,	O
HP	O
diet	B-UNK
(	O
40	O
vs	O
.	O
19	O
%	O
)	O
,	O
NX	B-UNK
or	O
HP+NX	O
for	O
another	O
8	O
weeks	B-UNK
.	O
Corresponding	O
non-lithium	O
pretreated	B-UNK
groups	B-UNK
were	O
generated	B-UNK
.	O
When	O
comparing	B-UNK
all	O
lithium	B-UNK
treated	I-UNK
versus	O
non-lithium-treated	O
groups	B-UNK
,	O
lithium	B-UNK
caused	B-UNK
a	O
reduction	O
in	O
glomerular	B-UNK
filtration	I-UNK
rate	I-UNK
(	O
GFR	B-UNK
)	O
without	O
significant	B-UNK
changes	O
in	O
effective	B-UNK
renal	B-UNK
plasma	B-UNK
flow	B-UNK
(	O
as	O
determined	B-UNK
by	O
a	O
marker	B-UNK
secreted	O
into	O
the	O
proximal	B-UNK
tubules	O
)	O
or	O
lithium	B-UNK
clearance	B-UNK
.	O
Consequently	O
,	O
lithium	B-UNK
pretreatment	B-UNK
caused	B-UNK
a	O
fall	B-UNK
in	O
filtration	B-UNK
fraction	B-UNK
and	O
an	O
increase	B-UNK
in	O
fractional	B-UNK
Li	B-UNK
excretion	B-UNK
.	O
Lithium	B-UNK
also	O
caused	B-UNK
proteinuria	B-UNK
and	O
systolic	B-UNK
hypertension	B-UNK
in	O
absence	O
of	O
glomerulosclerosis	B-UNK
.	O
HP	O
failed	B-UNK
to	O
accentuante	O
progression	B-UNK
of	O
renal	B-UNK
failure	I-UNK
and	O
in	O
fact	B-UNK
tended	O
to	O
increase	B-UNK
GFR	B-UNK
and	O
decrease	B-UNK
plasma	B-UNK
creatinine	B-UNK
levels	O
in	O
lithium	B-UNK
pretreated	B-UNK
rats	B-UNK
.	O
NX	B-UNK
caused	B-UNK
an	O
additive	O
deterioration	B-UNK
in	O
GFR	B-UNK
which	O
,	O
however	O
,	O
was	O
ameliorated	B-UNK
by	O
HP	O
.	O
NX+HP	O
caused	B-UNK
a	O
further	O
rise	B-UNK
in	O
blood	B-UNK
pressure	I-UNK
in	O
Li	B-UNK
-	O
pretreated	B-UNK
rats	B-UNK
.	O
The	O
results	B-UNK
indicate	O
that	O
Li	B-UNK
-	O
induced	O
nephropathy	B-DISEASE
,	O
even	O
when	O
the	O
GFR	B-UNK
is	O
only	O
modestly	O
reduced	B-UNK
,	O
is	O
associated	O
with	O
proteinuria	B-UNK
and	O
arterial	B-UNK
systolic	B-UNK
hypertension	B-UNK
.	O
In	O
this	O
model	B-UNK
of	O
chronic	B-UNK
renal	I-UNK
failure	I-UNK
the	O
decline	B-UNK
in	O
GFR	B-UNK
is	O
not	O
accompanied	B-UNK
by	O
a	O
corresponding	O
fall	B-UNK
in	O
effective	B-UNK
renal	B-UNK
plasma	B-UNK
flow	B-UNK
,	O
which	O
may	O
be	O
the	O
functional	B-UNK
expression	B-UNK
of	O
the	O
formation	B-UNK
of	O
nonfiltrating	O
atubular	O
glomeruli	B-UNK
.	O
The	O
fractional	B-UNK
reabsorption	B-UNK
of	O
tubular	B-UNK
fluid	B-UNK
by	O
the	O
proximal	B-UNK
tubules	O
is	O
reduced	B-UNK
,	O
leaving	O
the	O
distal	B-UNK
delivery	B-UNK
unchanged.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	B-UNK
)	O

Treatment	B-UNK
of	O
Crohn'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
with	O
fusidic	O
acid	B-UNK
:	O
an	O
antibiotic	B-UNK
with	O
immunosuppressive	B-UNK
properties	B-UNK
similar	B-UNK
to	O
cyclosporin	B-UNK
.	O
Fusidic	O
acid	B-UNK
is	O
an	O
antibiotic	B-UNK
with	O
T	O
-	O
cell	B-UNK
specific	B-UNK
immunosuppressive	B-UNK
effects	O
similar	B-UNK
to	O
those	O
of	O
cyclosporin	B-UNK
.	O
Because	O
of	O
the	O
need	O
for	O
the	O
development	B-UNK
of	O
new	O
treatments	O
for	O
Crohn'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
,	O
a	O
pilot	B-UNK
study	I-UNK
was	O
undertaken	B-UNK
to	O
estimate	B-UNK
the	O
pharmacodynamics	O
and	O
tolerability	B-UNK
of	O
fusidic	O
acid	B-UNK
treatment	B-UNK
in	O
chronic	B-UNK
active	B-UNK
,	O
therapy	O
-	O
resistant	B-UNK
patients	B-UNK
.	O
Eight	O
Crohn'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
patients	B-UNK
were	O
included	B-UNK
.	O
Fusidic	O
acid	B-UNK
was	O
administered	O
orally	O
in	O
a	O
dose	B-UNK
of	O
500	O
mg	B-UNK
t.d.s	O
.	O
and	O
the	O
treatment	B-UNK
was	O
planned	O
to	O
last	O
8	O
weeks	B-UNK
.	O
The	O
disease	B-UNK
activity	B-UNK
was	O
primarily	O
measured	B-UNK
by	O
a	O
modified	B-UNK
individual	B-UNK
grading	O
score	O
.	O
Five	O
of	O
8	O
patients	B-UNK
(	O
63	O
%	O
)	O
improved	O
during	O
fusidic	O
acid	B-UNK
treatment	B-UNK
:	O
3	O
at	O
two	O
weeks	B-UNK
and	O
2	O
after	O
four	O
weeks	B-UNK
.	O
There	O
were	O
no	O
serious	O
clinical	B-UNK
side	O
effects	O
,	O
but	O
dose	B-UNK
reduction	I-UNK
was	O
required	B-UNK
in	O
two	O
patients	B-UNK
because	O
of	O
nausea	B-UNK
.	O
Biochemically	O
,	O
an	O
increase	B-UNK
in	O
alkaline	B-UNK
phosphatases	O
was	O
noted	B-UNK
in	O
5	O
of	O
8	O
cases	B-UNK
(	O
63	O
%	O
)	O
,	O
and	O
the	O
greatest	B-UNK
increases	B-UNK
were	O
seen	O
in	O
those	O
who	O
had	O
elevated	B-UNK
levels	O
prior	B-UNK
to	O
treatment	B-UNK
.	O
All	O
reversed	B-UNK
to	O
pre	B-UNK
-	O
treatment	B-UNK
levels	O
after	O
cessation	B-UNK
of	O
treatment	B-UNK
.	O
The	O
results	B-UNK
of	O
this	O
pilot	B-UNK
study	I-UNK
suggest	B-UNK
that	O
fusidic	O
acid	B-UNK
may	O
be	O
of	O
benefit	O
in	O
selected	O
chronic	B-UNK
active	B-UNK
Crohn'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
patients	B-UNK
in	O
whom	O
conventional	B-UNK
treatment	B-UNK
is	O
ineffective	B-UNK
.	O
Because	O
there	O
seems	O
to	O
exist	O
a	O
scientific	O
rationale	B-UNK
for	O
the	O
use	O
of	O
fusidic	O
acid	B-UNK
at	O
the	O
cytokine	O
level	B-UNK
in	O
inflammatory	B-UNK
bowel	B-UNK
disease	B-UNK
,	O
we	O
suggest	B-UNK
that	O
the	O
role	O
of	O
this	O
treatment	B-UNK
should	O
be	O
further	O
investigated	B-UNK
.	O

Electrocardiographic	B-UNK
evidence	B-UNK
of	O
myocardial	B-DISEASE
injury	I-DISEASE
in	O
psychiatrically	O
hospitalized	B-UNK
cocaine	B-UNK
abusers	B-UNK
.	O
The	O
electrocardiograms	O
(	O
ECG	B-UNK
)	O
of	O
99	O
cocaine	B-UNK
-	O
abusing	O
patients	B-UNK
were	O
compared	O
with	O
the	O
ECGs	O
of	O
50	O
schizophrenic	B-DISEASE
controls	B-UNK
.	O
Eleven	O
of	O
the	O
cocaine	B-UNK
abusers	B-UNK
and	O
none	O
of	O
the	O
controls	B-UNK
had	O
ECG	B-UNK
evidence	B-UNK
of	O
significant	B-UNK
myocardial	B-UNK
injury	I-UNK
defined	B-UNK
as	O
myocardial	B-UNK
infarction	I-UNK
,	O
ischemia	B-UNK
,	O
and	O
bundle	B-DISEASE
branch	I-DISEASE
block	I-DISEASE
.	O

Sulpiride	B-CHEMICAL
-	O
induced	O
tardive	B-DISEASE
dystonia	I-DISEASE
.	O
Sulpiride	B-CHEMICAL
is	O
a	O
selective	B-UNK
D2-receptor	O
antagonist	B-UNK
with	O
antipsychotic	B-UNK
and	O
antidepressant	B-UNK
properties	B-UNK
.	O
Although	O
initially	B-UNK
thought	B-UNK
to	O
be	O
free	B-UNK
of	O
extrapyramidal	B-UNK
side	I-UNK
effects	I-UNK
,	O
sulpiride	B-CHEMICAL
-	O
induced	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
and	O
parkinsonism	B-UNK
have	O
been	O
reported	B-UNK
occasionally	O
.	O
We	O
studied	O
a	O
37-year	O
-	O
old	O
man	B-UNK
who	O
developed	O
persistent	B-UNK
segmental	B-UNK
dystonia	B-DISEASE
within	O
2	O
months	B-UNK
after	O
starting	B-UNK
sulpiride	B-CHEMICAL
therapy	O
.	O
We	O
could	O
not	O
find	O
any	O
previous	B-UNK
reports	B-UNK
of	O
sulpiride	B-CHEMICAL
-	O
induced	O
tardive	B-DISEASE
dystonia	I-DISEASE
.	O

Ocular	B-UNK
and	O
auditory	B-UNK
toxicity	B-UNK
in	O
hemodialyzed	O
patients	B-UNK
receiving	B-UNK
desferrioxamine	B-CHEMICAL
.	O
During	O
an	O
18-month	O
period	B-UNK
of	O
study	B-UNK
41	O
hemodialyzed	O
patients	B-UNK
receiving	B-UNK
desferrioxamine	B-CHEMICAL
(	O
10	O
-	O
40	O
mg	B-UNK
/	O
kg	B-UNK
BW/3	O
times	B-UNK
weekly	B-UNK
)	O
for	O
the	O
first	O
time	O
were	O
monitored	O
for	O
detection	B-UNK
of	O
audiovisual	B-DISEASE
toxicity	I-DISEASE
.	O
6	O
patients	B-UNK
presented	B-UNK
clinical	B-UNK
symptoms	B-UNK
of	O
visual	B-UNK
or	O
auditory	B-UNK
toxicity	B-UNK
.	O
Moreover	O
,	O
detailed	O
ophthalmologic	O
and	O
audiologic	O
studies	B-UNK
disclosed	O
abnormalities	B-UNK
in	O
7	O
more	O
asymptomatic	O
patients	B-UNK
.	O
Visual	B-DISEASE
toxicity	I-DISEASE
was	O
of	O
retinal	B-UNK
origin	B-UNK
and	O
was	O
characterized	B-UNK
by	O
a	O
tritan	O
-	O
type	B-UNK
dyschromatopsy	B-DISEASE
,	O
sometimes	O
associated	O
with	O
a	B-DISEASE
loss	I-DISEASE
of	I-DISEASE
visual	I-DISEASE
acuity	I-DISEASE
and	O
pigmentary	O
retinal	B-UNK
deposits	B-UNK
.	O
Auditory	B-UNK
toxicity	B-UNK
was	O
characterized	B-UNK
by	O
a	O
mid-	O
to	O
high	B-UNK
-	O
frequency	B-UNK
neurosensorial	O
hearing	B-UNK
loss	I-UNK
and	O
the	O
lesion	B-UNK
was	O
of	O
the	O
cochlear	O
type	B-UNK
.	O
Desferrioxamine	B-CHEMICAL
withdrawal	B-UNK
resulted	B-UNK
in	O
a	O
complete	B-UNK
recovery	B-UNK
of	O
visual	B-UNK
function	B-UNK
in	O
1	O
patient	B-UNK
and	O
partial	B-UNK
recovery	B-UNK
in	O
3	O
,	O
and	O
a	O
complete	B-UNK
reversal	B-UNK
of	O
hearing	B-UNK
loss	I-UNK
in	O
3	O
patients	B-UNK
and	O
partial	B-UNK
recovery	B-UNK
in	O
3	O
.	O
This	O
toxicity	B-DISEASE
appeared	B-UNK
in	O
patients	B-UNK
receiving	B-UNK
the	O
higher	B-UNK
doses	I-UNK
of	O
desferrioxamine	B-CHEMICAL
or	O
coincided	O
with	O
the	O
normalization	B-UNK
of	O
ferritin	O
or	O
aluminium	O
serum	B-UNK
levels	O
.	O
The	O
data	B-UNK
indicate	O
that	O
audiovisual	B-DISEASE
toxicity	I-DISEASE
is	O
not	O
an	O
infrequent	O
complication	B-UNK
in	O
hemodialyzed	O
patients	B-UNK
receiving	B-UNK
desferrioxamine	B-CHEMICAL
.	O
Periodical	O
audiovisual	O
monitoring	B-UNK
should	O
be	O
performed	B-UNK
on	O
hemodialyzed	O
patients	B-UNK
receiving	B-UNK
the	O
drug	B-UNK
in	O
order	B-UNK
to	O
detect	B-UNK
adverse	B-UNK
effects	I-UNK
as	O
early	B-UNK
as	O
possible	O
.	O

Myasthenia	B-DISEASE
gravis	I-DISEASE
presenting	O
as	O
weakness	B-UNK
after	O
magnesium	B-UNK
administration	O
.	O
We	O
studied	O
a	O
patient	B-UNK
with	O
no	O
prior	B-UNK
history	B-UNK
of	O
neuromuscular	B-UNK
disease	B-UNK
who	O
became	O
virtually	O
quadriplegic	O
after	O
parenteral	B-UNK
magnesium	B-UNK
administration	O
for	O
preeclampsia	O
.	O
The	O
serum	B-UNK
magnesium	B-CHEMICAL
concentration	B-UNK
was	O
3.0	O
mEq	B-UNK
/	O
L	O
,	O
which	O
is	O
usually	O
well	O
tolerated	B-UNK
.	O
The	O
magnesium	B-UNK
was	O
stopped	O
and	O
she	O
recovered	O
over	O
a	O
few	O
days	B-UNK
.	O
While	O
she	O
was	O
weak	O
,	O
2-Hz	O
repetitive	B-UNK
stimulation	B-UNK
revealed	O
a	O
decrement	O
without	O
significant	B-UNK
facilitation	O
at	O
rapid	B-UNK
rates	B-UNK
or	O
after	O
exercise	B-UNK
,	O
suggesting	O
postsynaptic	B-UNK
neuromuscular	B-UNK
blockade	B-UNK
.	O
After	O
her	O
strength	O
returned	B-UNK
,	O
repetitive	B-UNK
stimulation	B-UNK
was	O
normal	O
,	O
but	O
single	B-UNK
fiber	O
EMG	O
revealed	O
increased	B-UNK
jitter	O
and	O
blocking	B-UNK
.	O
Her	O
acetylcholine	B-UNK
receptor	B-UNK
antibody	B-UNK
level	B-UNK
was	O
markedly	O
elevated	B-UNK
.	O
Although	O
paralysis	B-UNK
after	O
magnesium	B-UNK
administration	O
has	O
been	O
described	O
in	O
patients	B-UNK
with	O
known	O
myasthenia	B-DISEASE
gravis	I-DISEASE
,	O
it	O
has	O
not	O
previously	B-UNK
been	O
reported	B-UNK
to	O
be	O
the	O
initial	B-UNK
or	O
only	O
manifestation	B-UNK
of	O
the	O
disease	B-UNK
.	O
Patients	B-UNK
who	O
are	O
unusually	O
sensitive	B-UNK
to	O
the	O
neuromuscular	B-UNK
effects	O
of	O
magnesium	B-UNK
should	O
be	O
suspected	O
of	O
having	O
an	O
underlying	B-UNK
disorder	B-DISEASE
of	I-DISEASE
neuromuscular	I-DISEASE
transmission	I-DISEASE
.	O

Chloroacetaldehyde	O
and	O
its	O
contribution	B-UNK
to	O
urotoxicity	O
during	O
treatment	B-UNK
with	O
cyclophosphamide	B-UNK
or	O
ifosfamide	B-CHEMICAL
.	O
An	O
experimental	B-UNK
study	B-UNK
/	O
short	B-UNK
communication	O
.	O
Based	B-UNK
on	O
clinical	B-UNK
data	B-UNK
,	O
indicating	O
that	O
chloroacetaldehyde	O
(	O
CAA	B-UNK
)	O
is	O
an	O
important	B-UNK
metabolite	B-UNK
of	O
oxazaphosphorine	O
cytostatics	O
,	O
an	O
experimental	B-UNK
study	B-UNK
was	O
carried	O
out	O
in	O
order	B-UNK
to	O
elucidate	O
the	O
role	O
of	O
CAA	B-UNK
in	O
the	O
development	B-UNK
of	O
hemorrhagic	B-UNK
cystitis	I-UNK
.	O
The	O
data	B-UNK
demonstrate	O
that	O
CAA	B-UNK
after	O
i.v	B-UNK
.	O
administration	O
does	O
not	O
contribute	B-UNK
to	O
bladder	B-DISEASE
damage	I-DISEASE
.	O
When	O
instilled	O
directly	O
into	O
the	O
bladder	B-UNK
,	O
CAA	B-UNK
exerts	B-UNK
urotoxic	O
effects	O
,	O
it	O
is	O
,	O
however	O
,	O
susceptible	O
to	O
detoxification	O
with	O
mesna	B-CHEMICAL
.	O

Source	O
of	O
pain	B-UNK
and	O
primitive	O
dysfunction	B-UNK
in	O
migraine	B-UNK
:	O
an	O
identical	B-UNK
site	B-UNK
?	O
Twenty	O
common	B-UNK
migraine	B-DISEASE
patients	B-UNK
received	O
a	O
one	O
sided	O
frontotemporal	O
application	B-UNK
of	O
nitroglycerin	B-CHEMICAL
(	O
10	O
patients	B-UNK
)	O
or	O
placebo	B-UNK
ointment	O
(	O
10	O
patients	B-UNK
)	O
in	O
a	O
double	B-UNK
blind	I-UNK
study	I-UNK
.	O
Early	B-UNK
onset	B-UNK
migraine	B-UNK
attacks	B-UNK
were	O
induced	O
by	O
nitroglycerin	B-UNK
in	O
seven	O
out	O
of	O
10	O
patients	B-UNK
versus	O
no	O
patient	B-UNK
in	O
the	O
placebo	B-UNK
group	B-UNK
.	O
Subsequently	B-UNK
20	O
migraine	B-DISEASE
patients	B-UNK
,	O
who	O
developed	O
an	O
early	B-UNK
onset	B-UNK
attack	B-UNK
with	O
frontotemporal	O
nitroglycerin	B-UNK
,	O
received	O
the	O
drug	B-UNK
in	O
a	O
second	O
induction	B-UNK
test	B-UNK
at	O
other	O
body	B-UNK
areas	B-UNK
.	O
No	O
early	B-UNK
onset	B-UNK
migraine	B-UNK
was	O
observed	O
.	O
Thus	O
the	O
migraine	B-DISEASE
-	O
inducing	O
effect	B-UNK
of	O
nitroglycerin	B-CHEMICAL
seems	O
to	O
depend	O
on	O
direct	B-UNK
stimulation	B-UNK
of	O
the	O
habitual	O
site	B-UNK
of	O
pain	B-UNK
,	O
suggesting	O
that	O
the	O
frontotemporal	O
region	B-UNK
is	O
of	O
crucial	O
importance	B-UNK
in	O
the	O
development	B-UNK
of	O
a	O
migraine	B-DISEASE
crisis	O
.	O
This	O
is	O
not	O
consistent	B-UNK
with	O
a	O
CNS	B-UNK
origin	B-UNK
of	O
migraine	B-UNK
attack	I-UNK
.	O

Clotiazepam	B-CHEMICAL
-	O
induced	O
acute	B-DISEASE
hepatitis	I-DISEASE
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
patient	B-UNK
who	O
developed	O
acute	B-UNK
hepatitis	I-UNK
with	O
extensive	B-DISEASE
hepatocellular	I-DISEASE
necrosis	I-DISEASE
,	O
7	O
months	B-UNK
after	O
the	O
onset	B-UNK
of	O
administration	O
of	O
clotiazepam	B-CHEMICAL
,	O
a	O
thienodiazepine	O
derivative	O
.	O
Clotiazepam	B-CHEMICAL
withdrawal	B-UNK
was	O
followed	O
by	O
prompt	B-UNK
recovery	B-UNK
.	O
The	O
administration	O
of	O
several	O
benzodiazepines	B-UNK
,	O
chemically	O
related	O
to	O
clotiazepam	B-CHEMICAL
,	O
did	O
not	O
interfere	O
with	O
recovery	B-UNK
and	O
did	O
not	O
induce	B-UNK
any	O
relapse	B-UNK
of	O
hepatitis	B-UNK
.	O
This	O
observation	B-UNK
shows	O
that	O
clotiazepam	B-CHEMICAL
can	O
induce	B-UNK
acute	B-DISEASE
hepatitis	I-DISEASE
and	O
suggests	O
that	O
there	O
is	O
no	O
cross	B-UNK
hepatotoxicity	B-UNK
between	O
clotiazepam	B-CHEMICAL
and	O
several	O
benzodiazepines	B-UNK
.	O

Arterial	B-UNK
hypertension	B-DISEASE
as	O
a	O
complication	B-UNK
of	O
prolonged	B-UNK
ketoconazole	B-UNK
treatment	B-UNK
.	O
Two	O
of	O
14	O
patients	B-UNK
with	O
Cushing'	O
s	O
syndrome	B-UNK
treated	O
on	O
a	O
long	B-UNK
-	O
term	O
basis	B-UNK
with	O
ketoconazole	B-UNK
developed	O
sustained	B-UNK
hypertension	B-DISEASE
.	O
In	O
both	O
cases	B-UNK
normal	O
plasma	B-UNK
and	O
urinary	B-UNK
free	B-UNK
cortisol	B-UNK
levels	O
had	O
been	O
achieved	O
following	O
ketoconazole	B-UNK
therapy	O
,	O
yet	O
continuous	B-UNK
blood	B-UNK
pressure	I-UNK
monitoring	B-UNK
demonstrated	O
hypertension	B-UNK
31	O
(	O
patient	B-UNK
1	O
)	O
and	O
52	O
weeks	B-UNK
(	O
patient	B-UNK
2	O
)	O
after	O
treatment	B-UNK
.	O
In	O
patient	B-UNK
1	O
,	O
plasma	B-UNK
levels	O
of	O
deoxycorticosterone	O
and	O
11-deoxycortisol	B-CHEMICAL
were	O
elevated	B-UNK
.	O
In	O
patient	B-UNK
2	O
,	O
in	O
addition	B-UNK
to	O
an	O
increase	B-UNK
in	O
both	O
deoxycorticosterone	O
and	O
11-deoxycortisol	B-CHEMICAL
levels	O
,	O
plasma	B-UNK
aldosterone	B-UNK
values	O
were	O
raised	B-UNK
,	O
with	O
a	O
concomitant	B-UNK
suppression	B-UNK
of	O
renin	B-UNK
levels	O
.	O
Our	O
findings	B-UNK
show	O
that	O
long	B-UNK
-	O
term	O
treatment	B-UNK
with	O
high	B-UNK
doses	I-UNK
of	O
ketoconazole	B-CHEMICAL
may	O
induce	B-UNK
enzyme	B-UNK
blockade	B-UNK
leading	B-UNK
to	O
mineralocorticoid	O
-	O
related	O
hypertension	B-UNK
.	O

Effects	O
of	O
an	O
inhibitor	B-UNK
of	O
angiotensin	B-UNK
converting	I-UNK
enzyme	I-UNK
(	O
Captopril	B-UNK
)	O
on	O
pulmonary	B-UNK
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
due	O
to	O
intravascular	B-UNK
coagulation	B-UNK
in	O
the	O
rat	B-UNK
.	O
Induction	B-UNK
of	O
intravascular	B-UNK
coagulation	B-UNK
and	O
inhibition	B-UNK
of	O
fibrinolysis	O
by	O
injection	B-UNK
of	O
thrombin	B-UNK
and	O
tranexamic	B-UNK
acid	I-UNK
(	O
AMCA	O
)	O
in	O
the	O
rat	B-UNK
gives	O
rise	B-UNK
to	O
pulmonary	B-UNK
and	O
renal	B-UNK
insufficiency	I-UNK
resembling	O
that	O
occurring	O
after	O
trauma	O
or	O
sepsis	B-DISEASE
in	O
man	B-UNK
.	O
Injection	B-UNK
of	O
Captopril	B-CHEMICAL
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
an	O
inhibitor	B-UNK
of	O
angiotensin	B-UNK
converting	I-UNK
enzyme	I-UNK
(	O
ACE	B-UNK
)	O
,	O
reduced	B-UNK
both	O
pulmonary	B-UNK
and	O
renal	B-UNK
insufficiency	I-UNK
in	O
this	O
rat	B-UNK
model	B-UNK
.	O
The	O
lung	B-UNK
weights	O
were	O
lower	B-UNK
and	O
PaO2	O
was	O
improved	O
in	O
rats	B-UNK
given	O
this	O
enzyme	B-UNK
-	O
blocking	B-UNK
agent	B-UNK
.	O
The	O
contents	O
of	O
albumin	B-UNK
in	O
the	O
lungs	O
were	O
not	O
changed	O
,	O
indicating	O
that	O
Captopril	B-UNK
did	O
not	O
influence	B-UNK
the	O
extravasation	O
of	O
protein	B-UNK
.	O
Renal	B-UNK
damage	I-UNK
as	O
reflected	O
by	O
an	O
increase	B-UNK
in	O
serum	B-UNK
urea	B-UNK
and	O
in	O
kidney	B-UNK
weight	B-UNK
was	O
prevented	B-UNK
by	O
Captopril	B-UNK
.	O
The	O
amount	O
of	O
fibrin	B-UNK
in	O
the	O
kidneys	B-UNK
was	O
also	O
considerably	O
lower	B-UNK
than	O
in	O
animals	B-UNK
which	O
received	O
thrombin	B-UNK
and	O
AMCA	O
alone	O
.	O
It	O
is	O
suggested	B-UNK
that	O
the	O
effects	O
of	O
Captopril	B-CHEMICAL
on	O
the	O
lungs	O
may	O
be	O
attributable	B-UNK
to	O
a	O
vasodilatory	O
effect	B-UNK
due	O
to	O
a	O
reduction	O
in	O
the	O
circulating	O
level	B-UNK
of	O
Angiotension	O
II	B-UNK
and	O
an	O
increase	B-UNK
in	O
prostacyclin	O
(	O
secondary	B-UNK
to	O
an	O
increase	B-UNK
in	O
bradykinin	B-CHEMICAL
)	O
.	O
Captopril	B-UNK
may	O
,	O
by	O
the	O
same	O
mechanism	B-UNK
,	O
reduce	B-UNK
the	O
increase	B-UNK
in	O
glomerular	B-UNK
filtration	I-UNK
that	O
is	O
known	O
to	O
occur	O
after	O
an	O
injection	B-UNK
of	O
thrombin	B-UNK
,	O
thereby	O
diminishing	O
the	O
aggregation	B-UNK
of	O
fibrin	B-UNK
monomers	O
in	O
the	O
glomeruli	B-UNK
,	O
with	O
the	O
result	B-UNK
that	O
less	O
fibrin	B-UNK
will	O
be	O
deposited	O
and	O
thus	O
less	O
kidney	B-UNK
damage	B-UNK
will	O
be	O
produced	B-UNK
.	O

A	O
randomized	B-UNK
comparison	B-UNK
of	O
labetalol	B-UNK
and	O
nitroprusside	B-UNK
for	O
induced	B-UNK
hypotension	I-UNK
.	O
In	O
a	O
randomized	B-UNK
study	B-UNK
,	O
labetalol	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
and	O
nitroprusside	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
were	O
compared	O
in	O
20	O
patients	B-UNK
(	O
10	O
in	O
each	O
group	B-UNK
)	O
scheduled	O
for	O
major	B-UNK
orthopedic	O
procedures	B-UNK
.	O
Each	O
patient	B-UNK
was	O
subjected	O
to	O
an	O
identical	B-UNK
anesthetic	B-UNK
protocol	O
and	O
similar	B-UNK
drug	B-UNK
-	O
induced	O
reductions	B-UNK
in	O
mean	O
arterial	B-UNK
blood	I-UNK
pressure	I-UNK
(	O
BP	B-UNK
)	O
(	O
50	O
to	O
55	O
mmHg	B-UNK
)	O
.	O
Nitroprusside	B-UNK
infusion	B-UNK
was	O
associated	O
with	O
a	O
significant	B-UNK
(	O
p	O
less	O
than	O
0.05	O
)	O
increase	B-UNK
in	O
heart	B-UNK
rate	I-UNK
and	O
cardiac	B-UNK
output	I-UNK
;	O
rebound	O
hypertension	B-UNK
was	O
observed	O
in	O
three	O
patients	B-UNK
after	O
discontinuation	B-UNK
of	O
nitroprusside	B-UNK
.	O
Labetalol	B-UNK
administration	O
was	O
not	O
associated	O
with	O
any	O
of	O
these	O
findings	B-UNK
.	O
Arterial	B-UNK
PO2	O
decreased	B-UNK
in	O
both	O
groups	B-UNK
.	O
It	O
was	O
concluded	O
that	O
labetalol	B-UNK
offers	O
advantages	O
over	O
nitroprusside	B-UNK
.	O

Chronic	B-UNK
carbamazepine	B-CHEMICAL
treatment	B-UNK
in	O
the	O
rat	B-UNK
:	O
efficacy	B-UNK
,	O
toxicity	B-UNK
,	O
and	O
effect	B-UNK
on	O
plasma	B-UNK
and	O
tissue	B-UNK
folate	B-UNK
concentrations	B-UNK
.	O
Folate	B-UNK
depletion	B-UNK
has	O
often	O
been	O
a	O
problem	O
in	O
chronic	B-UNK
antiepileptic	B-UNK
drug	I-UNK
(	O
AED	O
)	O
therapy	O
.	O
Carbamazepine	B-UNK
(	O
CBZ	B-CHEMICAL
)	O
,	O
a	O
commonly	B-UNK
used	O
AED	O
,	O
has	O
been	O
implicated	B-UNK
in	O
some	O
clinical	B-UNK
studies	B-UNK
.	O
A	O
rat	B-UNK
model	B-UNK
was	O
developed	O
to	O
examine	B-UNK
the	O
effects	O
of	O
chronic	B-UNK
CBZ	B-CHEMICAL
treatment	B-UNK
on	O
folate	B-UNK
concentrations	B-UNK
in	O
the	O
rat	B-UNK
.	O
In	O
the	O
course	O
of	O
developing	B-UNK
this	O
model	B-UNK
,	O
a	O
common	B-UNK
vehicle	B-UNK
,	O
propylene	B-CHEMICAL
glycol	I-CHEMICAL
,	O
by	O
itself	O
in	O
high	B-UNK
doses	I-UNK
,	O
was	O
found	O
to	O
exhibit	B-UNK
protective	B-UNK
properties	B-UNK
against	O
induced	O
seizures	B-UNK
and	O
inhibited	B-UNK
weight	B-DISEASE
gain	I-DISEASE
.	O
Seizures	B-DISEASE
induced	O
by	O
hexafluorodiethyl	O
ether	O
(	O
HFDE	O
)	O
were	O
also	O
found	O
to	O
be	O
a	O
more	O
sensitive	B-UNK
measure	B-UNK
of	O
protection	B-UNK
by	O
CBZ	B-UNK
than	O
seizures	B-UNK
induced	O
by	O
maximal	B-UNK
electroshock	O
(	O
MES	O
)	O
.	O
Oral	B-UNK
administration	O
of	O
CBZ	B-UNK
as	O
an	O
aqueous	O
suspension	O
every	O
8	O
h	O
at	O
a	O
dose	B-UNK
of	O
250	O
mg	B-UNK
/	O
kg	B-UNK
was	O
continuously	B-UNK
protective	B-UNK
against	O
HFDE	O
-	O
induced	O
seizures	B-UNK
and	O
was	O
minimally	O
toxic	B-UNK
as	O
measured	B-UNK
by	O
weight	B-UNK
gain	I-UNK
over	O
8	O
weeks	B-UNK
of	O
treatment	B-UNK
.	O
The	O
CBZ	B-UNK
levels	O
measured	B-UNK
in	O
plasma	B-UNK
and	O
brain	B-UNK
of	O
these	O
animals	B-UNK
,	O
however	O
,	O
were	O
below	O
those	O
normally	O
considered	B-UNK
protective	B-UNK
.	O
This	O
treatment	B-UNK
with	O
CBZ	B-UNK
had	O
no	O
apparent	B-UNK
adverse	B-UNK
effect	I-UNK
on	O
folate	B-UNK
concentrations	B-UNK
in	O
the	O
rat	B-UNK
,	O
and	O
,	O
indeed	O
,	O
the	O
folate	B-UNK
concentration	B-UNK
increased	B-UNK
in	O
liver	B-UNK
after	O
6	O
weeks	B-UNK
of	O
treatment	B-UNK
and	O
in	O
plasma	B-UNK
at	O
8	O
weeks	B-UNK
of	O
treatment	B-UNK
.	O

Inhibition	B-UNK
of	O
sympathoadrenal	O
activity	B-UNK
by	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
in	O
dogs	B-UNK
.	O
In	O
six	O
conscious	B-UNK
,	O
trained	B-UNK
dogs	B-UNK
,	O
maintained	O
on	O
a	O
normal	O
sodium	B-UNK
intake	B-UNK
of	O
2	O
to	O
4	O
mEq	B-UNK
/	O
kg	B-UNK
/	O
day	O
,	O
sympathetic	B-UNK
activity	B-UNK
was	O
assessed	B-UNK
as	O
the	O
release	B-UNK
rate	B-UNK
of	O
norepinephrine	B-CHEMICAL
and	O
epinephrine	B-CHEMICAL
during	O
15-minute	O
i.v	B-UNK
.	O
infusions	B-UNK
of	O
human	B-UNK
alpha	B-UNK
-	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
.	O
Mean	O
arterial	B-UNK
pressure	I-UNK
(	O
as	O
a	O
percentage	B-UNK
of	O
control	B-UNK
+	O
/-	O
SEM	B-UNK
)	O
during	O
randomized	B-UNK
infusions	B-UNK
of	O
0.03	O
,	O
0.1	O
,	O
0.3	O
,	O
or	O
1.0	O
microgram	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
was	O
99	O
+	O
/-	O
1	O
,	O
95	O
+	O
/-	O
1	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
93	O
+	O
/-	O
1	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
or	O
79	O
+	O
/-	O
6	O
%	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
respectively	O
,	O
but	O
no	O
tachycardia	B-UNK
and	O
no	O
augmentation	O
of	O
the	O
norepinephrine	B-CHEMICAL
release	B-UNK
rate	B-UNK
(	O
up	O
to	O
0.3	O
microgram	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
)	O
were	O
observed	O
,	O
which	O
is	O
in	O
contrast	B-UNK
to	O
comparable	O
hypotension	B-UNK
induced	O
by	O
hydralazine	O
or	O
nitroglycerin	B-CHEMICAL
.	O
The	O
release	B-UNK
rate	B-UNK
of	O
epinephrine	B-CHEMICAL
(	O
control	B-UNK
,	O
6.7	O
+	O
/-	O
0.6	O
ng	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
)	O
declined	O
immediately	B-UNK
during	O
infusions	B-UNK
of	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
to	O
a	O
minimum	B-UNK
of	O
49	O
+	O
/-	O
5	O
%	O
of	O
control	B-UNK
(	O
p	O
less	O
than	O
0.001	O
)	O
during	O
0.1	O
microgram	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
and	O
to	O
63	O
+	O
/-	O
5	O
%	O
(	O
0.1	O
greater	B-UNK
than	O
p	O
greater	B-UNK
than	O
0.05	O
)	O
or	O
95	O
+	O
/-	O
13	O
%	O
(	O
not	O
significant	B-UNK
)	O
during	O
0.3	O
or	O
1.0	O
microgram	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
.	O
Steady	O
state	B-UNK
arterial	B-UNK
plasma	B-UNK
concentrations	I-UNK
of	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
were	O
39	O
+	O
/-	O
10	O
pg	B-UNK
/	O
ml	B-UNK
(	O
n	O
=	O
6	O
)	O
during	O
infusions	B-UNK
of	O
saline	B-UNK
and	O
284	O
+	O
/-	O
24	O
pg	B-UNK
/	O
ml	B-UNK
(	O
n	O
=	O
6	O
)	O
and	O
1520	O
+	O
/-	O
300	O
pg	B-UNK
/	O
ml	B-UNK
(	O
n	O
=	O
9	O
)	O
during	O
0.03	O
and	O
0.1	O
microgram	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
infusions	B-UNK
of	O
the	O
factor.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	B-UNK
)	O

Death	B-UNK
from	O
chemotherapy	O
in	O
gestational	B-DISEASE
trophoblastic	I-DISEASE
disease	I-DISEASE
.	O
Multiple	B-UNK
cytotoxic	B-UNK
drug	B-UNK
administration	O
is	O
the	O
generally	B-UNK
accepted	O
treatment	B-UNK
of	O
patients	B-UNK
with	O
a	O
high	B-UNK
-	O
risk	B-UNK
stage	B-UNK
of	O
choriocarcinoma	B-DISEASE
.	O
Based	B-UNK
on	O
this	O
principle	O
a	O
27-year	O
old	O
woman	B-UNK
,	O
classified	O
as	O
being	O
in	O
the	O
high	B-UNK
-	O
risk	B-UNK
group	B-UNK
(	O
Goldstein	O
and	O
Berkowitz	O
score	O
:	O
11	O
)	O
,	O
was	O
treated	O
with	O
multiple	B-UNK
cytotoxic	B-UNK
drugs	B-UNK
.	O
The	O
multiple	B-UNK
drug	B-UNK
schema	O
consisted	B-UNK
of	O
:	O
Etoposide	B-CHEMICAL
16.213	O
,	O
Methotrexate	B-UNK
,	O
Cyclophosphamide	B-UNK
,	O
Actomycin	O
-	O
D	O
,	O
and	O
Cisplatin	B-CHEMICAL
.	O
On	O
the	O
first	O
day	O
of	O
the	O
schedule	B-UNK
,	O
moderate	B-UNK
high	B-UNK
doses	I-UNK
of	O
Methotrexate	B-UNK
,	O
Etoposide	B-CHEMICAL
and	O
Cyclophosphamide	B-CHEMICAL
were	O
administered	O
.	O
Within	O
8	O
hours	B-UNK
after	O
initiation	B-UNK
of	O
therapy	O
the	O
patient	B-UNK
died	O
with	O
a	O
clinical	B-UNK
picture	O
resembling	O
massive	B-UNK
pulmonary	B-UNK
obstruction	B-UNK
due	O
to	O
choriocarcinomic	O
tissue	B-UNK
plugs	O
,	O
probably	O
originating	O
from	O
the	O
uterus	O
.	O
Formation	B-UNK
of	O
these	O
plugs	O
was	O
probably	O
due	O
to	O
extensive	B-UNK
tumor	B-UNK
necrosis	B-DISEASE
at	O
the	O
level	B-UNK
of	O
the	O
walls	O
of	O
the	O
major	B-UNK
uterine	O
veins	O
,	O
which	O
resulted	B-UNK
in	O
an	O
open	B-UNK
exchange	O
of	O
tumor	B-DISEASE
plugs	O
to	O
the	O
vascular	B-UNK
spaces	O
;	O
decrease	B-UNK
in	O
tumor	B-UNK
tissue	B-UNK
coherence	O
secondary	B-UNK
to	O
chemotherapy	O
may	O
have	O
further	O
contributed	B-UNK
to	O
the	O
formation	B-UNK
of	O
tumor	B-DISEASE
emboli	O
.	O
In	O
view	B-UNK
of	O
the	O
close	B-UNK
time	O
association	B-UNK
between	O
the	O
start	B-UNK
of	O
chemotherapy	O
and	O
the	O
acute	B-UNK
onset	B-UNK
of	O
massive	B-UNK
embolism	B-DISEASE
other	O
explanations	O
,	O
such	O
as	O
spontaneous	B-UNK
necrosis	B-UNK
,	O
must	O
be	O
considered	B-UNK
less	O
likely	O
.	O
Patients	B-UNK
with	O
large	B-UNK
pelvic	O
tumor	B-UNK
loads	O
are	O
,	O
according	O
to	O
existing	B-UNK
classifications	O
,	O
at	O
high	B-UNK
risk	I-UNK
to	O
die	O
and	O
to	O
develop	B-UNK
drug	B-UNK
resistance	B-UNK
.	O
Notwithstanding	O
these	O
facts	O
our	O
findings	B-UNK
suggest	B-UNK
that	O
these	O
patients	B-UNK
might	O
benefit	O
from	O
relatively	O
mild	B-UNK
initial	B-UNK
treatment	B-UNK
,	O
especially	O
true	O
for	O
patients	B-UNK
not	O
previously	B-UNK
exposed	B-UNK
to	O
this	O
drug	B-UNK
.	O
Close	B-UNK
observation	B-UNK
of	O
the	O
response	B-UNK
status	B-UNK
both	O
clinically	B-UNK
and	O
with	O
beta-hCG	O
values	O
may	O
indicate	O
whether	O
and	O
when	O
more	O
agressive	O
combination	B-UNK
chemotherapy	O
should	O
be	O
started.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	B-UNK
)	O

Sexual	B-UNK
dysfunction	I-UNK
among	O
patients	B-UNK
with	O
arthritis	B-DISEASE
.	O
The	O
relationship	B-UNK
of	O
arthritis	B-DISEASE
and	O
sexual	B-DISEASE
dysfunction	I-DISEASE
was	O
investigated	B-UNK
among	O
169	O
patients	B-UNK
with	O
rheumatoid	B-UNK
arthritis	I-UNK
,	O
osteoarthritis	B-DISEASE
and	O
spondyloarthropathy	O
,	O
130	O
of	O
whom	O
were	O
pair	O
-	O
matched	O
to	O
controls	B-UNK
.	O
Assessments	O
of	O
marital	O
happiness	O
and	O
depressed	B-DISEASE
mood	I-DISEASE
were	O
also	O
made	O
using	O
the	O
CES	O
-	O
D	O
and	O
the	O
Azrin	O
Marital	O
Happiness	O
Scale	B-UNK
(	O
AMHS	O
)	O
.	O
Sexual	B-DISEASE
dysfunctions	I-DISEASE
were	O
found	O
to	O
be	O
common	B-UNK
among	O
patients	B-UNK
and	O
controls	B-UNK
,	O
the	O
majority	O
in	O
both	O
groups	B-UNK
reporting	B-UNK
one	O
or	O
more	O
dysfunctions	B-UNK
.	O
Impotence	B-DISEASE
was	O
more	O
common	B-UNK
among	O
male	B-UNK
patients	B-UNK
than	O
controls	B-UNK
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
co-morbidity	O
and	O
the	O
taking	B-UNK
of	O
methotrexate	B-CHEMICAL
.	O
Depressed	B-DISEASE
mood	I-DISEASE
was	O
more	O
common	B-UNK
among	O
patients	B-UNK
and	O
was	O
associated	O
with	O
certain	O
sexual	B-UNK
difficulties	O
,	O
but	O
not	O
with	O
impotence	B-DISEASE
.	O
Marital	O
unhappiness	O
,	O
as	O
indicated	O
by	O
AMHS	O
scores	O
,	O
was	O
not	O
associated	O
with	O
arthritis	B-UNK
but	O
was	O
associated	O
with	O
sexual	B-UNK
dysfunction	I-UNK
,	O
sexual	B-UNK
dissatisfaction	O
and	O
being	O
female	B-UNK
.	O

Does	O
paracetamol	B-CHEMICAL
cause	O
urothelial	O
cancer	B-UNK
or	O
renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
?	O
The	O
risk	B-UNK
of	O
developing	B-UNK
renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
or	O
cancer	B-UNK
of	O
the	O
renal	B-UNK
pelvis	O
,	O
ureter	O
or	O
bladder	B-UNK
associated	O
with	O
consumption	B-UNK
of	O
either	O
phenacetin	B-CHEMICAL
or	O
paracetamol	B-UNK
was	O
calculated	B-UNK
from	O
data	B-UNK
acquired	B-UNK
by	O
questionnaire	B-UNK
from	O
381	O
cases	B-UNK
and	O
808	O
controls	B-UNK
.	O
The	O
risk	B-UNK
of	O
renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
was	O
increased	B-UNK
nearly	O
20-fold	O
by	O
consumption	B-UNK
of	O
phenacetin	B-CHEMICAL
,	O
which	O
also	O
increased	B-UNK
the	O
risk	B-UNK
for	O
cancer	B-DISEASE
of	O
the	O
renal	B-UNK
pelvis	O
and	O
bladder	B-UNK
but	O
not	O
for	O
ureteric	O
cancer	B-UNK
.	O
By	O
contrast	B-UNK
,	O
we	O
were	O
unable	O
to	O
substantiate	O
an	O
increased	B-UNK
risk	B-UNK
from	O
paracetamol	B-UNK
consumption	B-UNK
for	O
renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
or	O
any	O
of	O
these	O
cancers	B-UNK
although	O
there	O
was	O
a	O
suggestion	O
of	O
an	O
association	B-UNK
with	O
cancer	B-DISEASE
of	I-DISEASE
the	I-DISEASE
ureter	I-DISEASE
.	O

Dapsone	B-CHEMICAL
-	O
associated	O
Heinz	O
body	B-UNK
hemolytic	B-UNK
anemia	I-UNK
in	O
a	O
Cambodian	O
woman	B-UNK
with	O
hemoglobin	B-UNK
E	O
trait	O
.	O
A	O
Cambodian	O
woman	B-UNK
with	O
hemoglobin	B-UNK
E	O
trait	O
(	O
AE	O
)	O
and	O
leprosy	B-DISEASE
developed	O
a	O
Heinz	O
body	B-UNK
hemolytic	B-UNK
anemia	I-UNK
while	O
taking	B-UNK
a	O
dose	B-UNK
of	O
dapsone	B-CHEMICAL
(	O
50	O
mg	B-UNK
/	O
day	O
)	O
not	O
usually	O
associated	O
with	O
clinical	B-UNK
hemolysis	B-UNK
.	O
Her	O
red	B-UNK
blood	B-UNK
cells	B-UNK
(	O
RBCs	O
)	O
had	O
increased	B-UNK
incubated	O
Heinz	O
body	B-UNK
formation	B-UNK
,	O
decreased	B-UNK
reduced	B-UNK
glutathione	B-CHEMICAL
(	O
GSH	B-UNK
)	O
,	O
and	O
decreased	B-UNK
GSH	B-UNK
stability	B-UNK
.	O
The	O
pentose	O
phosphate	B-CHEMICAL
shunt	O
activity	B-UNK
of	O
the	O
dapsone	B-CHEMICAL
-	O
exposed	B-UNK
AE	O
RBCs	O
was	O
increased	B-UNK
compared	O
to	O
normal	O
RBCs	O
.	O
Although	O
the	O
AE	O
RBCs	O
from	O
an	O
individual	B-UNK
not	O
taking	B-UNK
dapsone	B-CHEMICAL
had	O
increased	B-UNK
incubated	O
Heinz	O
body	B-UNK
formation	B-UNK
,	O
the	O
GSH	B-UNK
content	B-UNK
and	O
GSH	B-UNK
stability	B-UNK
were	O
normal	O
.	O
The	O
pentose	O
phosphate	B-UNK
shunt	O
activity	B-UNK
of	O
the	O
non-dapsone-exposed	O
AE	O
RBCs	O
was	O
decreased	B-UNK
compared	O
to	O
normal	O
RBCs	O
.	O
Thus	O
,	O
AE	O
RBCs	O
appear	O
to	O
have	O
an	O
increased	B-UNK
sensitivity	B-UNK
to	O
oxidant	B-UNK
stress	B-DISEASE
both	O
in	O
vitro	B-UNK
and	O
in	O
vivo	B-UNK
,	O
since	O
dapsone	B-CHEMICAL
does	O
not	O
cause	O
hemolytic	B-UNK
anemia	I-UNK
at	O
this	O
dose	B-UNK
in	O
hematologically	O
normal	O
individuals	B-UNK
.	O
Given	O
the	O
influx	O
of	O
Southeast	O
Asians	O
into	O
the	O
United	O
States	B-UNK
,	O
oxidant	B-UNK
medications	B-UNK
should	O
be	O
used	O
with	O
caution	B-UNK
,	O
especially	O
if	O
an	O
infection	B-DISEASE
is	O
present	B-UNK
,	O
in	O
individuals	B-UNK
of	O
ethnic	O
backgrounds	O
that	O
have	O
an	O
increased	B-UNK
prevalence	B-UNK
of	O
hemoglobin	B-UNK
E.	O

Severe	B-UNK
complications	B-UNK
of	O
antianginal	O
drug	B-UNK
therapy	O
in	O
a	O
patient	B-UNK
identified	B-UNK
as	O
a	O
poor	O
metabolizer	O
of	O
metoprolol	B-CHEMICAL
,	O
propafenone	O
,	O
diltiazem	B-CHEMICAL
,	O
and	O
sparteine	B-CHEMICAL
.	O
A	O
47-year	O
-	O
old	O
patient	B-UNK
suffering	O
from	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
was	O
admitted	B-UNK
to	O
the	O
CCU	O
in	O
shock	B-UNK
with	O
III	B-UNK
.	O
AV	B-DISEASE
block	I-DISEASE
,	O
severe	B-UNK
hypotension	B-UNK
,	O
and	O
impairment	B-UNK
of	O
ventricular	B-UNK
function	B-UNK
.	O
One	O
week	B-UNK
prior	B-UNK
to	O
admission	B-UNK
a	O
therapy	O
with	O
standard	B-UNK
doses	B-UNK
of	O
metoprolol	B-CHEMICAL
(	O
100	O
mg	B-UNK
t.i.d	O
.	O
and	O
then	O
100	O
mg	B-UNK
b.i.d	O
.	O
)	O
had	O
been	O
initiated	O
.	O
Two	O
days	B-UNK
before	O
admission	B-UNK
diltiazem	B-CHEMICAL
(	O
60	O
mg	B-UNK
b.i.d	O
.	O
)	O
was	O
prescribed	B-UNK
in	O
addition	B-UNK
.	O
Analyses	B-UNK
of	O
a	O
blood	B-UNK
sample	B-UNK
revealed	O
unusually	O
high	B-UNK
plasma	B-UNK
concentrations	I-UNK
of	O
metoprolol	B-CHEMICAL
(	O
greater	B-UNK
than	O
3000	O
ng	B-UNK
/	O
ml	B-UNK
)	O
and	O
diltiazem	B-CHEMICAL
(	O
526	O
ng	B-UNK
/	O
ml	B-UNK
)	O
.	O
The	O
patient	B-UNK
recovered	O
within	O
1	O
week	B-UNK
following	O
discontinuation	B-UNK
of	O
antianginal	O
therapy	O
.	O
Three	O
months	B-UNK
later	O
the	O
patient	B-UNK
was	O
exposed	B-UNK
to	O
a	O
single	B-UNK
dose	B-UNK
of	O
metoprolol	B-CHEMICAL
,	O
diltiazem	B-UNK
,	O
propafenone	O
(	O
since	O
he	O
had	O
received	O
this	O
drug	B-UNK
in	O
the	O
past	B-UNK
)	O
,	O
and	O
sparteine	B-CHEMICAL
(	O
as	O
a	O
probe	O
for	O
the	O
debrisoquine	O
/	O
sparteine	B-CHEMICAL
type	B-UNK
polymorphism	O
of	O
oxidative	B-UNK
drug	B-UNK
metabolism	B-UNK
)	O
.	O
It	O
was	O
found	O
that	O
he	O
was	O
a	O
poor	O
metabolizer	O
of	O
all	O
four	O
drugs	B-UNK
,	O
indicating	O
that	O
their	O
metabolism	B-UNK
is	O
under	O
the	O
same	O
genetic	B-UNK
control	B-UNK
.	O
Therefore	O
,	O
patients	B-UNK
belonging	O
to	O
the	O
poor	O
-	O
metabolizer	O
phenotype	B-UNK
of	O
sparteine	B-CHEMICAL
/	O
debrisoquine	O
polymorphism	O
in	O
drug	B-UNK
metabolism	B-UNK
,	O
which	O
constitutes	O
6.4	O
%	O
of	O
the	O
German	O
population	B-UNK
,	O
may	O
experience	B-UNK
adverse	B-DISEASE
drug	I-DISEASE
reactions	I-DISEASE
when	O
treated	O
with	O
standard	B-UNK
doses	B-UNK
of	O
one	O
of	O
these	O
drugs	B-UNK
alone	O
.	O
Moreover	O
,	O
the	O
coadministration	O
of	O
these	O
frequently	B-UNK
used	O
drugs	B-UNK
is	O
expected	B-UNK
to	O
be	O
especially	O
harmful	O
in	O
this	O
subgroup	B-UNK
of	O
patients	B-UNK
.	O

Triazolam	O
-	O
induced	O
brief	O
episodes	B-UNK
of	O
secondary	B-UNK
mania	B-UNK
in	O
a	O
depressed	B-DISEASE
patient	B-UNK
.	O
Large	B-UNK
doses	B-UNK
of	O
triazolam	O
repeatedly	B-UNK
induced	O
brief	O
episodes	B-UNK
of	O
mania	B-UNK
in	O
a	O
depressed	B-UNK
elderly	B-UNK
woman	B-UNK
.	O
Features	B-UNK
of	O
organic	B-UNK
mental	B-UNK
disorder	B-UNK
(	O
delirium	B-UNK
)	O
were	O
not	O
present	B-UNK
.	O
Manic	B-UNK
excitement	O
was	O
coincident	O
with	O
the	O
duration	B-UNK
of	O
action	B-UNK
of	O
triazolam	O
.	O
The	O
possible	O
contribution	B-UNK
of	O
the	O
triazolo	O
group	B-UNK
to	O
changes	O
in	O
affective	B-UNK
status	B-UNK
is	O
discussed	O
.	O

On	O
the	O
mechanisms	B-UNK
of	O
the	O
development	B-UNK
of	O
tolerance	B-UNK
to	O
the	O
muscular	B-UNK
rigidity	B-UNK
produced	B-UNK
by	O
morphine	B-UNK
in	O
rats	B-UNK
.	O
The	O
development	B-UNK
of	O
tolerance	B-UNK
to	O
the	O
muscular	B-UNK
rigidity	B-DISEASE
produced	B-UNK
by	O
morphine	B-UNK
was	O
studied	O
in	O
rats	B-UNK
.	O
Saline	B-UNK
-	O
pretreated	B-UNK
controls	B-UNK
given	O
a	O
test	B-UNK
dose	B-UNK
of	O
morphine	B-CHEMICAL
(	O
20	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
showed	O
a	O
pronounced	B-UNK
rigidity	B-UNK
recorded	O
as	O
tonic	B-UNK
activity	B-UNK
in	O
the	O
electromyogram	O
.	O
Rats	B-UNK
treated	O
for	O
11	O
days	B-UNK
with	O
morphine	B-UNK
and	O
withdrawn	O
for	O
36	O
-	O
40	O
h	O
showed	O
differences	B-UNK
in	O
the	O
development	B-UNK
of	O
tolerance	B-UNK
:	O
about	O
half	B-UNK
of	O
the	O
animals	B-UNK
showed	O
a	O
rigidity	B-UNK
after	O
the	O
test	B-UNK
dose	B-UNK
of	O
morphine	B-CHEMICAL
that	O
was	O
not	O
significantly	B-UNK
less	O
than	O
in	O
the	O
controls	B-UNK
and	O
were	O
akinetic	B-DISEASE
(	O
A	O
group	B-UNK
)	O
.	O
The	O
other	O
rats	B-UNK
showed	O
a	O
strong	B-UNK
decrease	B-UNK
in	O
the	O
rigidity	B-UNK
and	O
the	O
occurrence	B-UNK
of	O
stereotyped	O
(	O
S	O
)	O
licking	O
and	O
/	O
or	O
gnawing	O
in	O
presence	O
of	O
akinetic	B-DISEASE
or	O
hyperkinetic	O
(	O
K	O
)	O
behaviour	B-UNK
(	O
AS	O
/	O
KS	O
group	B-UNK
)	O
,	O
suggesting	O
signs	B-UNK
of	O
dopaminergic	B-UNK
activation	B-UNK
.	O
The	O
rigidity	B-UNK
was	O
considerably	O
decreased	B-UNK
in	O
both	O
groups	B-UNK
after	O
20	O
days	B-UNK
'	O
treatment	B-UNK
.	O
In	O
a	O
further	O
series	B-UNK
of	O
experiments	B-UNK
,	O
haloperidol	B-UNK
(	O
0.2	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
was	O
used	O
in	O
order	B-UNK
to	O
block	B-UNK
the	O
dopaminergic	B-UNK
activation	B-UNK
and	O
to	O
estimate	B-UNK
the	O
real	B-UNK
degree	B-UNK
of	O
the	O
tolerance	B-UNK
to	O
the	O
rigidity	B-DISEASE
without	O
any	O
dopaminergic	B-UNK
interference	B-UNK
.	O
Haloperidol	B-UNK
enhanced	B-UNK
the	O
rigidity	B-UNK
in	O
the	O
A	O
group	B-UNK
.	O
However	O
,	O
the	O
level	B-UNK
in	O
the	O
AS	O
/	O
KS	O
group	B-UNK
remained	B-UNK
considerably	O
lower	B-UNK
than	O
in	O
the	O
A	O
group	B-UNK
.	O
The	O
results	B-UNK
suggest	B-UNK
that	O
rigidity	B-UNK
,	O
which	O
is	O
assumed	O
to	O
be	O
due	O
to	O
an	O
action	B-UNK
of	O
morphine	B-CHEMICAL
in	O
the	O
striatum	B-UNK
,	O
can	O
be	O
antagonized	B-UNK
by	O
another	O
process	O
leading	B-UNK
to	O
dopaminergic	B-UNK
activation	B-UNK
in	O
the	O
striatum	B-UNK
.	O
Nevertheless	O
,	O
there	O
occurs	O
some	O
real	B-UNK
tolerance	B-UNK
to	O
this	O
effect	B-UNK
.	O
The	O
rapid	B-UNK
alternations	O
of	O
rigidity	B-UNK
and	O
the	O
signs	B-UNK
of	O
dopaminergic	B-UNK
activation	B-UNK
observed	O
in	O
the	O
animals	B-UNK
of	O
the	O
AS	O
/	O
KS	O
group	B-UNK
might	O
be	O
due	O
to	O
rapid	B-UNK
shifts	O
in	O
the	O
predominance	O
of	O
various	O
DA	B-UNK
-	O
innervated	O
structures	B-UNK
.	O

Compression	B-DISEASE
neuropathy	I-DISEASE
of	O
the	O
radial	O
nerve	B-UNK
due	O
to	O
pentazocine	B-CHEMICAL
-	O
induced	O
fibrous	B-DISEASE
myopathy	I-DISEASE
.	O
Fibrous	B-DISEASE
myopathy	I-DISEASE
is	O
a	O
common	B-UNK
,	O
well	O
-	O
known	O
side	O
effect	B-UNK
of	O
repeated	B-UNK
pentazocine	B-CHEMICAL
injection	B-UNK
.	O
However	O
,	O
compression	B-DISEASE
neuropathy	I-DISEASE
due	O
to	O
fibrotic	O
muscle	B-UNK
affected	B-UNK
by	O
pentazocine	B-CHEMICAL
-	O
induced	O
myopathy	B-DISEASE
has	O
not	O
previously	B-UNK
been	O
reported	B-UNK
.	O
In	O
a	O
37-year	O
-	O
old	O
woman	B-UNK
with	O
documented	O
pentazocine	B-CHEMICAL
-	O
induced	O
fibrous	B-DISEASE
myopathy	I-DISEASE
of	O
triceps	O
and	O
deltoid	O
muscles	B-UNK
bilaterally	B-UNK
and	O
a	O
three	O
-	O
week	B-UNK
history	B-UNK
of	O
right	O
wrist	O
drop	B-UNK
,	O
electrodiagnostic	O
examination	B-UNK
showed	O
a	O
severe	B-UNK
but	O
partial	B-UNK
lesion	B-UNK
of	O
the	O
right	O
radial	O
nerve	B-UNK
distal	B-UNK
to	O
the	O
branches	O
to	O
the	O
triceps	O
,	O
in	O
addition	B-UNK
to	O
the	O
fibrous	B-DISEASE
myopathy	I-DISEASE
.	O
Surgery	B-UNK
revealed	O
the	O
right	O
radial	O
nerve	B-UNK
to	O
be	O
severely	O
compressed	O
by	O
the	O
densely	O
fibrotic	O
lateral	B-UNK
head	B-UNK
of	O
the	O
triceps	O
.	O
Decompression	O
and	O
neurolysis	O
were	O
performed	B-UNK
with	O
good	O
subsequent	B-UNK
recovery	B-UNK
of	O
function	B-UNK
.	O

Recurrent	B-UNK
reversible	B-UNK
acute	B-UNK
renal	I-UNK
failure	I-UNK
from	O
amphotericin	B-UNK
.	O
A	O
patient	B-UNK
with	O
cryptogenic	O
cirrhosis	B-UNK
and	O
disseminated	O
sporotrichosis	B-DISEASE
developed	O
acute	B-UNK
renal	I-UNK
failure	I-UNK
immediately	B-UNK
following	O
the	O
administration	O
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
on	O
four	O
separate	B-UNK
occasions	B-UNK
.	O
The	O
abruptness	O
of	O
the	O
renal	B-DISEASE
failure	I-DISEASE
and	O
its	O
reversibility	O
within	O
days	B-UNK
suggests	O
that	O
there	O
was	O
a	O
functional	B-UNK
component	B-UNK
to	O
the	O
renal	B-UNK
dysfunction	I-UNK
.	O
We	O
propose	O
that	O
amphotericin	B-UNK
,	O
in	O
the	O
setting	B-UNK
of	O
reduced	B-UNK
effective	B-UNK
arterial	B-UNK
volume	B-UNK
,	O
may	O
activate	O
tubuloglomerular	O
feedback	O
,	O
thereby	O
contributing	O
to	O
acute	B-UNK
renal	I-UNK
failure	I-UNK
.	O

Pneumonitis	B-DISEASE
with	O
pleural	O
and	O
pericardial	B-DISEASE
effusion	I-DISEASE
and	O
neuropathy	B-UNK
during	O
amiodarone	B-UNK
therapy	O
.	O
A	O
patient	B-UNK
with	O
sinuatrial	O
disease	B-UNK
and	O
implanted	B-UNK
pacemaker	B-UNK
was	O
treated	O
with	O
amiodarone	B-UNK
(	O
maximum	B-UNK
dose	B-UNK
1000	O
mg	B-UNK
,	O
maintenance	B-UNK
dose	B-UNK
800	O
mg	B-UNK
daily	B-UNK
)	O
for	O
10	O
months	B-UNK
,	O
for	O
control	B-UNK
of	O
supraventricular	O
tachyarrhythmias	B-UNK
.	O
He	O
developed	O
pneumonitis	B-DISEASE
,	O
pleural	O
and	O
pericardial	O
effusions	O
,	O
and	O
a	O
predominantly	B-UNK
proximal	B-UNK
motor	B-UNK
neuropathy	B-UNK
.	O
Immediate	O
but	O
gradual	B-UNK
improvement	B-UNK
followed	O
withdrawal	B-UNK
of	O
amiodarone	B-UNK
and	O
treatment	B-UNK
with	O
prednisolone	B-UNK
.	O
Review	B-UNK
of	O
this	O
and	O
previously	B-UNK
reported	I-UNK
cases	B-UNK
indicates	O
the	O
need	O
for	O
early	B-UNK
diagnosis	B-UNK
of	O
amiodarone	B-UNK
pneumonitis	B-DISEASE
,	O
immediate	O
withdrawal	B-UNK
of	O
amiodarone	B-UNK
,	O
and	O
prompt	B-UNK
but	O
continued	O
steroid	B-UNK
therapy	O
to	O
ensure	O
full	O
recovery	B-UNK
.	O

Indomethacin	B-UNK
-	O
induced	O
renal	B-DISEASE
insufficiency	I-DISEASE
:	O
recurrence	B-UNK
on	O
rechallenge	O
.	O
We	O
have	O
reported	B-UNK
a	O
case	B-UNK
of	O
acute	B-UNK
oliguric	O
renal	B-UNK
failure	I-UNK
with	O
hyperkalemia	B-UNK
in	O
a	O
patient	B-UNK
with	O
cirrhosis	B-UNK
,	O
ascites	B-DISEASE
,	O
and	O
cor	B-DISEASE
pulmonale	I-DISEASE
after	O
indomethacin	B-UNK
therapy	O
.	O
Prompt	B-UNK
restoration	O
of	O
renal	B-UNK
function	I-UNK
followed	O
drug	B-UNK
withdrawal	B-UNK
,	O
while	O
re-exposure	O
to	O
a	O
single	B-UNK
dose	B-UNK
of	O
indomethacin	B-UNK
caused	B-UNK
recurrence	B-UNK
of	O
acute	B-UNK
reversible	B-UNK
oliguria	B-DISEASE
.	O
Our	O
case	B-UNK
supports	O
the	O
hypothesis	B-UNK
that	O
endogenous	B-UNK
renal	B-UNK
prostaglandins	B-CHEMICAL
play	O
a	O
role	O
in	O
the	O
maintenance	B-UNK
of	O
renal	B-UNK
blood	B-UNK
flow	I-UNK
when	O
circulating	O
plasma	B-UNK
volume	B-UNK
is	O
diminished	B-UNK
.	O
Since	O
nonsteroidal	B-UNK
anti-inflammatory	O
agents	B-UNK
interfere	O
with	O
this	O
compensatory	B-UNK
mechanism	B-UNK
and	O
may	O
cause	O
acute	B-UNK
renal	I-UNK
failure	I-UNK
,	O
they	O
should	O
be	O
used	O
with	O
caution	B-UNK
in	O
such	O
patients	B-UNK
.	O

Comparison	B-UNK
of	O
the	O
subjective	B-UNK
effects	O
and	O
plasma	B-UNK
concentrations	I-UNK
following	O
oral	B-UNK
and	O
i.m	O
.	O
administration	O
of	O
flunitrazepam	O
in	O
volunteers	B-UNK
.	O
Flunitrazepam	O
0.5	O
,	O
1.0	O
or	O
2.0	O
mg	B-UNK
was	O
given	O
by	O
the	O
oral	B-UNK
or	O
i.m	O
.	O
routes	O
to	O
groups	B-UNK
of	O
volunteers	B-UNK
and	O
its	O
effects	O
compared	O
.	O
Plasma	B-UNK
concentrations	I-UNK
of	O
the	O
drug	B-UNK
were	O
estimated	O
by	O
gas	O
-	O
liquid	O
chromatography	O
,	O
in	O
a	O
smaller	B-UNK
number	B-UNK
of	O
the	O
subjects	B-UNK
.	O
The	O
most	O
striking	O
effect	B-UNK
was	O
sedation	B-UNK
which	O
increased	B-UNK
with	O
the	O
dose	B-UNK
,	O
2	O
mg	B-UNK
producing	O
deep	B-UNK
sleep	B-UNK
although	O
the	O
subjects	B-UNK
could	O
still	O
be	O
aroused	O
.	O
The	O
effects	O
of	O
i.m	O
.	O
administration	O
were	O
apparent	B-UNK
earlier	B-UNK
and	O
sometimes	O
lasted	B-UNK
longer	O
than	O
those	O
following	O
oral	B-UNK
administration	O
.	O
Dizziness	B-UNK
was	O
less	O
marked	O
than	O
sedation	B-UNK
,	O
but	O
increased	B-UNK
with	O
the	O
dose	B-UNK
.	O
There	O
was	O
pain	B-UNK
on	O
i.m	O
.	O
injection	B-UNK
of	O
flunitrazepam	O
significantly	B-UNK
more	O
often	O
than	O
with	O
isotonic	O
saline	B-UNK
.	O
Plasma	B-UNK
concentrations	I-UNK
varied	O
with	O
dose	B-UNK
and	O
route	O
and	O
corresponded	O
qualitatively	O
with	O
the	O
subjective	B-UNK
effects	O
.	O
The	O
drug	B-UNK
was	O
still	O
present	B-UNK
in	O
measurable	O
quantities	O
after	O
24	O
h	O
even	O
with	O
the	O
smallest	O
dose	B-UNK
.	O

Changes	O
in	O
heart	B-UNK
size	B-UNK
during	O
long	B-UNK
-	O
term	O
timolol	B-CHEMICAL
treatment	B-UNK
after	O
myocardial	B-UNK
infarction	I-UNK
.	O
The	O
effect	B-UNK
of	O
long	B-UNK
-	O
term	O
timolol	B-UNK
treatment	B-UNK
on	O
heart	B-UNK
size	B-UNK
after	O
myocardial	B-UNK
infarction	I-UNK
was	O
evaluated	B-UNK
by	O
X	O
-	O
ray	O
in	O
a	O
double-blind	O
study	B-UNK
including	O
241	O
patients	B-UNK
(	O
placebo	B-UNK
126	O
,	O
timolol	B-CHEMICAL
115	O
)	O
.	O
The	O
follow	O
-	O
up	O
period	B-UNK
was	O
12	O
months	B-UNK
.	O
The	O
timolol	B-UNK
-	O
treated	O
patients	B-UNK
showed	O
a	O
small	B-UNK
but	O
significant	B-UNK
increase	B-UNK
in	O
heart	B-UNK
size	B-UNK
from	O
baseline	B-UNK
in	O
contrast	B-UNK
to	O
a	O
decrease	B-UNK
in	O
the	O
placebo	B-UNK
group	B-UNK
.	O
These	O
differences	B-UNK
may	O
be	O
caused	B-UNK
by	O
timolol	B-UNK
-	O
induced	O
bradycardia	B-UNK
and	O
a	O
compensatory	B-UNK
increase	B-UNK
in	O
end	B-UNK
-	O
diastolic	B-UNK
volume	B-UNK
.	O
The	O
timolol	B-CHEMICAL
-	O
related	O
increase	B-UNK
in	O
heart	B-UNK
size	B-UNK
was	O
observed	O
only	O
in	O
patients	B-UNK
with	O
normal	O
and	O
borderline	O
heart	B-UNK
size	B-UNK
.	O
In	O
patients	B-UNK
with	O
cardiomegaly	B-DISEASE
,	O
the	O
increase	B-UNK
in	O
heart	B-UNK
size	B-UNK
was	O
similar	B-UNK
in	O
both	O
groups	B-UNK
.	O
After	O
re-infarction	O
,	O
heart	B-UNK
size	B-UNK
increased	B-UNK
in	O
the	O
placebo	B-UNK
group	B-UNK
and	O
remained	B-UNK
unchanged	I-UNK
in	O
the	O
timolol	B-UNK
group	B-UNK
.	O

Vitamin	B-UNK
D3	I-UNK
toxicity	B-DISEASE
in	O
dairy	O
cows	B-UNK
.	O
Large	B-UNK
parenteral	B-UNK
doses	B-UNK
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
(	O
15	O
to	O
17.5	O
x	O
10(6	O
)	O
IU	B-UNK
vitamin	B-CHEMICAL
D3	I-CHEMICAL
)	O
were	O
associated	O
with	O
prolonged	B-UNK
hypercalcemia	B-UNK
,	O
hyperphosphatemia	B-DISEASE
,	O
and	O
large	B-UNK
increases	B-UNK
of	O
vitamin	B-UNK
D3	I-UNK
and	O
its	O
metabolites	B-UNK
in	O
the	O
blood	B-UNK
plasma	B-UNK
of	O
nonlactating	O
nonpregnant	O
and	O
pregnant	B-UNK
Jersey	O
cows	B-UNK
.	O
Calcium	B-UNK
concentrations	B-UNK
1	O
day	O
postpartum	O
were	O
higher	B-UNK
in	O
cows	B-UNK
treated	O
with	O
vitamin	B-UNK
D3	I-UNK
about	O
32	O
days	B-UNK
prepartum	O
(	O
8.8	O
mg/100	O
ml	B-UNK
)	O
than	O
in	O
control	B-UNK
cows	B-UNK
(	O
5.5	O
mg/100	O
ml	B-UNK
)	O
.	O
None	O
of	O
the	O
cows	B-UNK
treated	O
with	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
showed	O
signs	B-UNK
of	O
milk	B-DISEASE
fever	I-DISEASE
during	O
the	O
peripartal	O
period	B-UNK
;	O
however	O
,	O
22	O
%	O
of	O
the	O
control	B-UNK
cows	B-UNK
developed	O
clinical	B-UNK
signs	B-UNK
of	O
milk	B-DISEASE
fever	I-DISEASE
during	O
this	O
period	B-UNK
.	O
Signs	B-UNK
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
toxicity	B-UNK
were	O
not	O
observed	O
in	O
nonlactating	O
nonpregnant	O
cows	B-UNK
;	O
however	O
,	O
pregnant	B-UNK
cows	B-UNK
commonly	B-UNK
developed	O
severe	B-UNK
signs	B-UNK
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
toxicity	B-UNK
and	O
10	O
of	O
17	O
cows	B-UNK
died	O
.	O
There	O
was	O
widespread	B-UNK
metastatic	B-UNK
calcification	B-UNK
in	O
the	O
cows	B-UNK
that	O
died	O
.	O
Because	O
of	O
the	O
extreme	O
toxicity	B-UNK
of	O
vitamin	B-UNK
D3	I-UNK
in	O
pregnant	B-UNK
Jersey	O
cows	B-UNK
and	O
the	O
low	B-UNK
margin	O
of	O
safety	B-UNK
between	O
doses	B-UNK
of	O
vitamin	B-CHEMICAL
D3	I-CHEMICAL
that	O
prevent	B-UNK
milk	B-DISEASE
fever	I-DISEASE
and	O
doses	B-UNK
that	O
induce	B-UNK
milk	B-DISEASE
fever	I-DISEASE
,	O
we	O
concluded	O
that	O
vitamin	B-UNK
D3	I-UNK
cannot	O
be	O
used	O
practically	O
to	O
prevent	B-UNK
milk	B-DISEASE
fever	I-DISEASE
when	O
injected	B-UNK
several	O
weeks	B-UNK
prepartum	O
.	O

Diseases	B-UNK
of	O
peripheral	B-UNK
nerves	B-UNK
as	O
seen	O
in	O
the	O
Nigerian	O
African	O
.	O
The	O
anatomical	O
and	O
aetiological	O
diagnoses	O
of	O
peripheral	B-UNK
nerve	B-UNK
disease	B-UNK
excluding	O
its	O
primary	B-UNK
benign	O
and	O
malignant	B-UNK
disorders	B-UNK
,	O
as	O
seen	O
in	O
358	O
Nigerians	O
are	O
presented	B-UNK
.	O
There	O
is	O
a	O
male	B-UNK
preponderance	O
and	O
the	O
peak	B-UNK
incidence	B-UNK
is	O
in	O
the	O
fourth	B-UNK
decade	O
.	O
Sensori	B-DISEASE
-	I-DISEASE
motor	I-DISEASE
neuropathy	I-DISEASE
was	O
the	O
commonest	O
presentation	B-UNK
(	O
50	O
%	O
)	O
.	O
Guillain	O
-	O
Barr	O
  	O
syndrome	B-UNK
was	O
the	O
commonest	O
identifiable	O
cause	O
(	O
15.6	O
%	O
)	O
,	O
accounting	O
for	O
half	B-UNK
of	O
the	O
cases	B-UNK
with	O
motor	B-UNK
neuropathy	B-UNK
.	O
Peripheral	B-UNK
neuropathy	I-UNK
due	O
to	O
nutritional	O
deficiency	B-UNK
of	O
thiamine	O
and	O
riboflavin	O
was	O
common	B-UNK
(	O
10.1	O
%	O
)	O
and	O
presented	B-UNK
mainly	O
as	O
sensory	O
and	O
sensori	B-DISEASE
-	I-DISEASE
motor	I-DISEASE
neuropathy	I-DISEASE
.	O
Diabetes	B-UNK
mellitus	I-UNK
was	O
the	O
major	B-UNK
cause	O
of	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O
Isoniazid	B-UNK
was	O
the	O
most	O
frequent	B-UNK
agent	B-UNK
in	O
drug	B-UNK
-	O
induced	O
neuropathy	B-UNK
.	O
Migraine	B-UNK
(	O
20	O
%	O
)	O
was	O
not	O
an	O
uncommon	O
cause	O
of	O
cranial	B-DISEASE
neuropathy	I-DISEASE
although	O
malignancies	B-DISEASE
arising	O
from	O
the	O
reticuloendothelial	O
system	O
or	O
related	O
structures	B-UNK
of	O
the	O
head	B-UNK
and	I-UNK
neck	I-UNK
were	O
more	O
frequent	B-UNK
(	O
26	O
%	O
)	O
.	O
In	O
26.5	O
%	O
of	O
all	O
the	O
cases	B-UNK
,	O
the	O
aetiology	O
of	O
the	O
neuropathy	B-DISEASE
was	O
undetermined	O
.	O
Heredofamilial	O
and	O
connective	B-DISEASE
tissue	I-DISEASE
disorders	I-DISEASE
were	O
rare	B-UNK
.	O
Some	O
of	O
the	O
factors	B-UNK
related	O
to	O
the	O
clinical	B-UNK
presentation	B-UNK
and	O
pathogenesis	B-UNK
of	O
the	O
neuropathies	O
are	O
briefly	O
discussed	O
.	O

A	O
double-blind	O
study	B-UNK
of	O
the	O
efficacy	B-UNK
and	I-UNK
safety	I-UNK
of	O
dothiepin	B-CHEMICAL
hydrochloride	I-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
major	B-UNK
depressive	B-DISEASE
disorder	I-DISEASE
.	O
In	O
a	O
6-week	O
double-blind	O
parallel	O
treatment	B-UNK
study	B-UNK
,	O
dothiepin	B-CHEMICAL
and	O
amitriptyline	O
were	O
compared	O
to	O
placebo	B-UNK
in	O
the	O
treatment	B-UNK
of	O
33	O
depressed	B-UNK
outpatients	O
.	O
Dothiepin	B-CHEMICAL
and	O
amitriptyline	O
were	O
equally	B-UNK
effective	B-UNK
in	O
alleviating	O
the	O
symptoms	B-UNK
of	O
depressive	B-DISEASE
illness	I-DISEASE
,	O
and	O
both	O
were	O
significantly	B-UNK
superior	B-UNK
to	O
placebo	B-UNK
.	O
The	O
overall	O
incidence	B-UNK
of	O
side	O
effects	O
and	O
the	O
frequency	B-UNK
and	O
severity	B-UNK
of	O
blurred	B-DISEASE
vision	I-DISEASE
,	O
dry	B-DISEASE
mouth	I-DISEASE
,	O
and	O
drowsiness	B-UNK
were	O
significantly	B-UNK
less	O
with	O
dothiepin	B-CHEMICAL
than	O
with	O
amitriptyline	O
.	O
Dothiepin	B-CHEMICAL
also	O
produced	B-UNK
fewer	B-UNK
CNS	B-UNK
and	O
cardiovascular	B-UNK
effects	O
.	O
There	O
were	O
no	O
clinically	B-UNK
important	B-UNK
changes	O
in	O
laboratory	B-UNK
parameters	O
.	O
Dothiepin	B-CHEMICAL
thus	O
was	O
found	O
to	O
be	O
an	O
effective	B-UNK
antidepressant	B-UNK
drug	B-UNK
associated	O
with	O
fewer	B-UNK
side	O
effects	O
than	O
amitriptyline	O
in	O
the	O
treatment	B-UNK
of	O
depressed	B-UNK
outpatients	O
.	O

Behavioral	B-UNK
effects	O
of	O
diazepam	B-UNK
and	O
propranolol	B-CHEMICAL
in	O
patients	B-UNK
with	O
panic	B-DISEASE
disorder	I-DISEASE
and	O
agoraphobia	B-DISEASE
.	O
The	O
effects	O
of	O
oral	B-UNK
doses	B-UNK
of	O
diazepam	B-UNK
(	O
single	B-UNK
dose	B-UNK
of	O
10	O
mg	B-UNK
and	O
a	O
median	B-UNK
dose	B-UNK
of	O
30	O
mg	B-UNK
/	O
day	O
for	O
2	O
weeks	B-UNK
)	O
and	O
propranolol	B-CHEMICAL
(	O
single	B-UNK
dose	B-UNK
of	O
80	O
mg	B-UNK
and	O
a	O
median	B-UNK
dose	B-UNK
of	O
240	O
mg	B-UNK
/	O
day	O
for	O
2	O
weeks	B-UNK
)	O
on	O
psychological	B-UNK
performance	B-UNK
of	O
patients	B-UNK
with	O
panic	B-UNK
disorders	B-UNK
and	O
agoraphobia	B-DISEASE
were	O
investigated	B-UNK
in	O
a	O
double-blind	O
,	O
randomized	B-UNK
and	O
crossover	B-UNK
design	B-UNK
.	O
Both	O
drugs	B-UNK
impaired	B-UNK
immediate	O
free	B-UNK
recall	B-UNK
but	O
the	O
decrease	B-UNK
was	O
greater	B-UNK
for	O
diazepam	B-UNK
than	O
propranolol	B-UNK
.	O
Delayed	B-UNK
free	B-UNK
recall	B-UNK
was	O
also	O
impaired	B-UNK
but	O
the	O
two	O
drugs	B-UNK
did	O
not	O
differ	B-UNK
.	O
Patients	B-UNK
tapped	O
faster	O
after	O
propranolol	B-UNK
than	O
diazepam	B-UNK
and	O
they	O
were	O
more	O
sedated	O
after	O
diazepam	B-CHEMICAL
than	O
propranolol	B-UNK
.	O
After	O
2	O
weeks	B-UNK
of	O
treatment	B-UNK
,	O
patients	B-UNK
tested	B-UNK
5	O
-	O
8	O
h	O
after	O
the	O
last	O
dose	B-UNK
of	O
medication	O
did	O
not	O
show	O
any	O
decrement	O
of	O
performance	B-UNK
.	O
These	O
results	B-UNK
are	O
similar	B-UNK
to	O
those	O
previously	B-UNK
found	O
in	O
healthy	B-UNK
subjects	I-UNK
.	O
Accumulation	B-UNK
of	O
drugs	B-UNK
was	O
not	O
reflected	O
in	O
prolonged	B-UNK
behavioral	B-DISEASE
impairment	I-DISEASE
.	O

Effect	B-UNK
of	O
aspirin	B-UNK
on	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	O
-	O
induced	O
epithelial	B-UNK
proliferation	B-UNK
in	O
the	O
urinary	B-UNK
bladder	I-UNK
and	O
forestomach	B-UNK
of	O
the	O
rat	B-UNK
.	O
The	O
co-administration	O
of	O
aspirin	B-UNK
with	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	O
(	O
FANFT	O
)	O
to	O
rats	B-UNK
resulted	B-UNK
in	O
a	O
reduced	B-UNK
incidence	B-UNK
of	O
FANFT	O
-	O
induced	O
bladder	B-DISEASE
carcinomas	I-DISEASE
but	O
a	O
concomitant	B-UNK
induction	B-UNK
of	O
forestomach	B-UNK
tumors	B-DISEASE
.	O
An	O
autoradiographic	O
study	B-UNK
was	O
performed	B-UNK
on	O
male	B-UNK
F-344	O
rats	B-UNK
fed	B-UNK
diet	B-UNK
containing	O
FANFT	O
at	O
a	O
level	B-UNK
of	O
0.2	O
%	O
and	O
/	O
or	O
aspirin	B-UNK
at	O
a	O
level	B-UNK
of	O
0.5	O
%	O
to	O
evaluate	B-UNK
the	O
effect	B-UNK
of	O
aspirin	B-UNK
on	O
the	O
increased	B-UNK
cell	B-UNK
proliferation	I-UNK
induced	O
by	O
FANFT	O
in	O
the	O
forestomach	B-UNK
and	O
bladder	B-UNK
.	O
FANFT	O
-	O
induced	O
cell	B-UNK
proliferation	I-UNK
in	O
the	O
bladder	B-UNK
was	O
significantly	B-UNK
suppressed	O
by	O
aspirin	B-UNK
co-administration	O
after	O
4	O
weeks	B-UNK
but	O
not	O
after	O
12	O
weeks	B-UNK
.	O
In	O
the	O
forestomach	B-UNK
,	O
and	O
also	O
in	O
the	O
liver	B-UNK
,	O
aspirin	B-UNK
did	O
not	O
affect	B-UNK
the	O
FANFT	O
-	O
induced	O
increase	B-UNK
in	O
labeling	O
index	B-UNK
.	O
The	O
present	B-UNK
results	B-UNK
are	O
consistent	B-UNK
with	O
the	O
carcinogenicity	O
experiment	B-UNK
suggesting	O
that	O
different	O
mechanisms	B-UNK
are	O
involved	B-UNK
in	O
FANFT	O
carcinogenesis	B-DISEASE
in	O
the	O
bladder	B-UNK
and	O
forestomach	B-UNK
,	O
and	O
that	O
aspirin'	O
s	O
effect	B-UNK
on	O
FANFT	O
in	O
the	O
forestomach	B-UNK
is	O
not	O
due	O
to	O
an	O
irritant	O
effect	B-UNK
associated	O
with	O
increased	B-UNK
cell	B-UNK
proliferation	I-UNK
.	O
Also	O
,	O
there	O
appears	B-UNK
to	O
be	O
an	O
adaptation	O
by	O
the	O
rats	B-UNK
to	O
the	O
chronic	B-UNK
ingestion	B-UNK
of	O
aspirin	B-UNK
.	O

Provocation	O
of	O
postural	O
hypotension	B-UNK
by	O
nitroglycerin	B-CHEMICAL
in	O
diabetic	B-DISEASE
autonomic	I-DISEASE
neuropathy	I-DISEASE
?	O
The	O
effect	B-UNK
of	O
nitroglycerin	B-UNK
on	O
heart	B-UNK
rate	I-UNK
and	O
systolic	B-UNK
blood	I-UNK
pressure	I-UNK
was	O
compared	O
in	O
5	O
normal	O
subjects	B-UNK
,	O
12	O
diabetic	B-UNK
subjects	B-UNK
without	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
,	O
and	O
5	O
diabetic	B-UNK
subjects	B-UNK
with	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O
The	O
magnitude	B-UNK
and	O
time	O
course	O
of	O
the	O
increase	B-UNK
in	O
heart	B-UNK
rate	I-UNK
and	O
the	O
decrease	B-UNK
in	O
systolic	B-UNK
blood	I-UNK
pressure	I-UNK
after	O
nitroglycerin	B-UNK
were	O
similar	B-UNK
in	O
the	O
normal	O
and	O
diabetic	B-UNK
subjects	B-UNK
without	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
,	O
whereas	O
a	O
lesser	O
increase	B-UNK
in	O
heart	B-UNK
rate	I-UNK
and	O
a	O
greater	B-UNK
decrease	B-UNK
in	O
systolic	B-UNK
blood	I-UNK
pressure	I-UNK
occurred	B-UNK
in	O
the	O
diabetic	B-DISEASE
subjects	B-UNK
with	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O
It	O
is	O
therefore	O
suggested	B-UNK
that	O
caution	B-UNK
should	O
be	O
exercised	O
when	O
prescribing	B-UNK
vasodilator	O
drugs	B-UNK
in	O
diabetic	B-UNK
patients	B-UNK
,	O
particularly	O
those	O
with	O
autonomic	B-DISEASE
neuropathy	I-DISEASE
.	O

Characterization	O
of	O
estrogen	B-CHEMICAL
-	O
induced	O
adenohypophyseal	B-DISEASE
tumors	I-DISEASE
in	O
the	O
Fischer	O
344	O
rat	B-UNK
.	O
Pituitary	B-DISEASE
tumors	I-DISEASE
were	O
induced	O
in	O
F344	B-UNK
female	B-UNK
rats	I-UNK
by	O
chronic	B-UNK
treatment	B-UNK
with	O
diethylstilbestrol	B-CHEMICAL
(	O
DES	B-UNK
,	O
8	O
-	O
10	O
mg	B-UNK
)	O
implanted	B-UNK
subcutaneously	B-UNK
in	O
silastic	O
capsules	O
.	O
Over	O
a	O
range	B-UNK
of	O
1	O
-	O
150	O
days	B-UNK
of	O
DES	B-UNK
treatment	B-UNK
,	O
pairs	O
of	O
control	B-UNK
and	O
DES-treated	O
rats	B-UNK
were	O
sacrificed	O
,	O
and	O
their	O
pituitaries	O
dissociated	O
enzymatically	O
into	O
single	B-UNK
-	O
cell	B-UNK
preparations	B-UNK
.	O
The	O
cell	B-UNK
populations	O
were	O
examined	B-UNK
regarding	O
total	B-UNK
cell	B-UNK
recovery	B-UNK
correlated	B-UNK
with	O
gland	O
weight	B-UNK
,	O
intracellular	B-UNK
prolactin	B-UNK
(	O
PRL	B-UNK
)	O
content	B-UNK
and	O
subsequent	B-UNK
release	B-UNK
in	O
primary	B-UNK
culture	B-UNK
,	O
immunocytochemical	O
PRL	B-UNK
staining	B-UNK
,	O
density	B-UNK
and	O
/	O
or	O
size	B-UNK
alterations	B-UNK
via	O
separation	O
on	O
Ficoll	O
-	O
Hypaque	O
and	O
by	O
unit	B-UNK
gravity	O
sedimentation	O
,	O
and	O
cell	B-UNK
cycle	B-UNK
analysis	B-UNK
,	O
after	O
acriflavine	O
DNA	B-UNK
staining	B-UNK
,	O
by	O
laser	B-UNK
flow	B-UNK
cytometry	O
.	O
Total	B-UNK
cell	B-UNK
yields	O
from	O
DES-treated	O
pituitaries	O
increased	B-UNK
from	O
1.3	O
times	B-UNK
control	B-UNK
yields	O
at	O
8	O
days	B-UNK
of	O
treatment	B-UNK
to	O
58.9	O
times	B-UNK
control	B-UNK
values	O
by	O
day	O
150	O
.	O
Intracellular	B-UNK
PRL	B-UNK
content	B-UNK
ranged	B-UNK
from	O
1.9	O
to	O
9.4	O
times	B-UNK
control	B-UNK
levels	O
,	O
and	O
PRL	B-UNK
release	B-UNK
in	O
vitro	B-UNK
was	O
significantly	B-UNK
and	O
consistently	O
higher	B-UNK
than	O
controls	B-UNK
,	O
after	O
at	O
least	O
8	O
days	B-UNK
of	O
DES	B-UNK
exposure	B-UNK
.	O
Beyond	O
8	O
days	B-UNK
of	O
DES	B-UNK
exposure	B-UNK
,	O
the	O
immunochemically	O
PRL	B-UNK
-	O
positive	B-UNK
proportion	B-UNK
of	O
cells	B-UNK
increased	B-UNK
to	O
over	O
50	O
%	O
of	O
the	O
total	B-UNK
population	B-UNK
.	O
Increased	B-UNK
density	B-UNK
and	O
/	O
or	O
size	B-UNK
and	O
PRL	B-UNK
content	B-UNK
were	O
indicated	O
for	O
the	O
majority	O
of	O
the	O
PRL	B-UNK
cell	B-UNK
population	B-UNK
in	O
both	O
types	B-UNK
of	O
separation	O
protocols	B-UNK
.	O
All	O
these	O
effects	O
of	O
DES	B-UNK
were	O
more	O
pronounced	B-UNK
among	O
previously	B-UNK
ovariectomized	O
animals	B-UNK
.	O
The	O
data	B-UNK
extend	O
the	O
findings	B-UNK
of	O
other	O
investigators	O
,	O
further	O
establishing	O
the	O
DES-induced	O
tumor	B-UNK
as	O
a	O
model	B-UNK
for	O
study	B-UNK
of	O
PRL	B-UNK
cellular	B-UNK
control	B-UNK
mechanisms	B-UNK
.	O

Triamterene	O
nephrolithiasis	B-DISEASE
complicating	O
dyazide	B-CHEMICAL
therapy	O
.	O
A	O
case	B-UNK
of	O
triamterene	O
nephrolithiasis	B-DISEASE
is	O
reported	B-UNK
in	O
a	O
man	B-UNK
after	O
4	O
years	B-UNK
of	O
hydrochlorothiazide	O
-	O
triamterene	O
therapy	O
for	O
hypertension	B-UNK
.	O
The	O
stone	O
passed	O
spontaneously	B-UNK
and	O
was	O
found	O
to	O
contain	O
a	O
triamterene	O
metabolite	B-UNK
admixed	O
with	O
uric	B-UNK
acid	I-UNK
salts	O
.	O
Factors	B-UNK
affecting	O
triamterene	O
nephrolithiasis	B-UNK
are	O
discussed	O
and	O
2	O
previously	B-UNK
reported	I-UNK
cases	B-UNK
are	O
reviewed	B-UNK
.	O

Metabolic	B-UNK
involvement	B-UNK
in	O
adriamycin	B-UNK
cardiotoxicity	B-UNK
.	O
The	O
cardiotoxic	B-UNK
effects	O
of	O
adriamycin	B-UNK
were	O
studied	O
in	O
mammalian	O
myocardial	B-UNK
cells	B-UNK
in	O
culture	B-UNK
as	O
a	O
model	B-UNK
system	O
.	O
Adriamycin	B-CHEMICAL
inhibited	B-UNK
cell	B-UNK
growth	B-UNK
and	O
the	O
rhythmic	O
contractions	B-UNK
characteristic	B-UNK
of	O
myocardial	B-UNK
cells	B-UNK
in	O
culture	B-UNK
.	O
A	O
possible	O
involvement	B-UNK
of	O
energy	O
metabolism	B-UNK
was	O
suggested	B-UNK
previously	B-UNK
,	O
and	O
in	O
this	O
study	B-UNK
the	O
adenylate	O
energy	O
charge	O
and	O
phosphorylcreatine	O
mole	O
fraction	B-UNK
were	O
determined	B-UNK
in	O
the	O
adriamycin	B-CHEMICAL
-	O
treated	O
cells	B-UNK
.	O
The	O
adenylate	O
energy	O
charge	O
was	O
found	O
to	O
be	O
significantly	B-UNK
decreased	B-UNK
,	O
while	O
the	O
phophorylcreatine	O
mole	O
fraction	B-UNK
was	O
unchanged	B-UNK
.	O
Such	O
disparity	O
suggests	O
an	O
inhibition	B-UNK
of	O
creatine	B-UNK
phosphokinase	O
.	O
The	O
addition	B-UNK
of	O
1	O
mM	B-UNK
adenosine	B-UNK
to	O
the	O
myocardial	B-UNK
cell	B-UNK
cultures	B-UNK
markedly	O
increases	B-UNK
the	O
ATP	B-CHEMICAL
concentration	B-UNK
through	O
a	O
pathway	B-UNK
reportedly	O
leading	B-UNK
to	O
a	O
compartmentalized	O
ATP	B-UNK
pool	O
.	O
In	O
the	O
adriamycin	B-UNK
-	O
treated	O
cells	B-UNK
,	O
the	O
addition	B-UNK
of	O
adenosine	B-UNK
increased	B-UNK
the	O
adenylate	O
charge	O
and	O
,	O
concomitant	B-UNK
with	O
this	O
inrcease	O
,	O
the	O
cells	B-UNK
'	O
functional	B-UNK
integrity	O
,	O
in	O
terms	B-UNK
of	O
percentage	B-UNK
of	O
beating	B-UNK
cells	B-UNK
and	O
rate	B-UNK
of	O
contractions	B-UNK
,	O
was	O
maintained	O
.	O

Age	B-UNK
-	O
dependent	B-UNK
sensitivity	B-UNK
of	O
the	O
rat	B-UNK
to	O
neurotoxic	B-UNK
effects	O
of	O
streptomycin	B-CHEMICAL
.	O
Streptomycin	B-CHEMICAL
sulfate	B-UNK
(	O
300	O
mg	B-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
)	O
was	O
injected	B-UNK
for	O
various	O
periods	O
into	O
preweanling	O
rats	B-UNK
and	O
for	O
3	O
weeks	B-UNK
into	O
weanling	O
rats	B-UNK
.	O
Beginning	B-UNK
at	O
8	O
days	B-UNK
of	O
age	B-UNK
,	O
body	B-UNK
movement	B-UNK
and	O
hearing	B-UNK
were	O
examined	B-UNK
for	O
6	O
and	O
up	O
to	O
17	O
weeks	B-UNK
,	O
respectively	O
.	O
Abnormal	B-DISEASE
movements	I-DISEASE
and	O
deafness	B-DISEASE
occurred	B-UNK
only	O
in	O
rats	B-UNK
treated	O
during	O
the	O
preweaning	O
period	B-UNK
;	O
within	O
this	O
period	B-UNK
the	O
greatest	B-UNK
sensitivities	O
for	O
these	O
abnormalities	B-UNK
occurred	B-UNK
from	O
2	O
to	O
11	O
-	O
17	O
and	O
5	O
to	O
11	O
days	B-UNK
of	O
age	B-UNK
,	O
respectively	O
,	O
indicating	O
that	O
the	O
cochlea	O
is	O
more	O
sensitive	B-UNK
to	O
streptomycin	B-CHEMICAL
than	O
the	O
site	B-UNK
(	O
vestibular	O
or	O
central	B-UNK
)	O
responsible	B-UNK
for	O
the	O
dyskinesias	B-UNK
.	O

Crescentic	O
fibrillary	O
glomerulonephritis	B-UNK
associated	O
with	O
intermittent	B-UNK
rifampin	B-UNK
therapy	O
for	O
pulmonary	B-UNK
tuberculosis	B-DISEASE
.	O
This	O
case	B-UNK
study	B-UNK
reveals	O
an	O
unusual	B-UNK
finding	O
of	O
rapidly	O
proliferative	O
crescentic	O
glomerulonephritis	B-UNK
in	O
a	O
patient	B-UNK
treated	O
with	O
rifampin	B-CHEMICAL
who	O
had	O
no	O
other	O
identifiable	O
causes	O
for	O
developing	B-UNK
this	O
disease	B-UNK
.	O
This	O
patient	B-UNK
underwent	O
a	O
10-month	O
regimen	B-UNK
of	O
rifampin	B-UNK
and	O
isoniazid	B-UNK
for	O
pulmonary	B-UNK
tuberculosis	B-UNK
and	O
was	O
discovered	O
to	O
have	O
developed	O
signs	B-UNK
of	O
severe	B-UNK
renal	B-UNK
failure	I-UNK
five	O
weeks	B-UNK
after	O
completion	O
of	O
therapy	O
.	O
Renal	B-UNK
biopsy	B-UNK
revealed	O
severe	B-UNK
glomerulonephritis	B-UNK
with	O
crescents	O
,	O
electron	B-UNK
dense	O
fibrillar	O
deposits	B-UNK
and	O
moderate	B-UNK
lymphocytic	O
interstitial	B-UNK
infiltrate	O
.	O
Other	O
possible	O
causes	O
of	O
rapidly	O
progressive	B-UNK
glomerulonephritis	B-UNK
were	O
investigated	B-UNK
and	O
ruled	O
out	O
.	O
This	O
report	B-UNK
documents	O
the	O
unusual	B-UNK
occurrence	B-UNK
of	O
rapidly	O
progressive	B-UNK
glomerulonephritis	B-DISEASE
with	O
crescents	O
and	O
fibrillar	O
glomerulonephritis	B-UNK
in	O
a	O
patient	B-UNK
treated	O
with	O
rifampin	B-UNK
.	O

Time	O
course	O
of	O
lipid	B-UNK
peroxidation	I-UNK
in	O
puromycin	B-UNK
aminonucleoside	I-UNK
-	O
induced	O
nephropathy	B-UNK
.	O
Reactive	B-UNK
oxygen	I-UNK
species	I-UNK
have	O
been	O
implicated	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
acute	B-UNK
puromycin	B-UNK
aminonucleoside	I-UNK
(	O
PAN)-induced	O
nephropathy	B-UNK
,	O
with	O
antioxidants	B-UNK
significantly	B-UNK
reducing	B-UNK
the	O
proteinuria	B-UNK
.	O
The	O
temporal	B-UNK
relationship	B-UNK
between	O
lipid	B-UNK
peroxidation	I-UNK
in	O
the	O
kidney	B-UNK
and	O
proteinuria	B-UNK
was	O
examined	B-UNK
in	O
this	O
study	B-UNK
.	O
Rats	B-UNK
were	O
treated	O
with	O
a	O
single	B-UNK
IV	B-UNK
injection	B-UNK
of	O
puromycin	B-UNK
aminonucleoside	I-UNK
,	O
(	O
PAN	B-UNK
,	O
7.5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
and	O
24	O
hour	B-UNK
urine	B-UNK
samples	O
were	O
obtained	B-UNK
prior	B-UNK
to	O
sacrifice	O
on	O
days	B-UNK
3,5,7,10,17,27,41	O
(	O
N	O
=	O
5	O
-	O
10	O
per	O
group	B-UNK
)	O
.	O
The	O
kidneys	B-UNK
were	O
removed	B-UNK
,	O
flushed	O
with	O
ice	B-CHEMICAL
cold	O
TRIS	B-CHEMICAL
buffer	I-CHEMICAL
.	O
Kidney	B-UNK
cortices	O
from	O
each	O
animal	B-UNK
were	O
used	O
to	O
prepare	O
homogenates	O
.	O
Tissue	B-UNK
lipid	B-UNK
peroxidation	I-UNK
was	O
measured	B-UNK
in	O
whole	O
homogenates	O
as	O
well	O
as	O
in	O
lipid	B-UNK
extracts	O
from	O
homogenates	O
as	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
reactive	B-UNK
substances	O
.	O
Proteinuria	B-UNK
was	O
evident	O
at	O
day	O
5	O
,	O
peaked	O
at	O
day	O
7	O
and	O
persisted	O
to	O
day	O
27	O
.	O
Lipid	B-UNK
peroxidation	I-UNK
in	O
homogenates	O
was	O
maximal	B-UNK
at	O
day	O
3	O
and	O
declined	O
rapidly	O
to	O
control	B-UNK
levels	O
by	O
day	O
17	O
.	O
This	O
study	B-UNK
supports	O
the	O
role	O
of	O
lipid	B-UNK
peroxidation	I-UNK
in	O
mediating	O
the	O
proteinuric	O
injury	B-UNK
in	O
PAN	B-UNK
nephropathy	B-UNK
.	O

Clomipramine	B-CHEMICAL
-	O
induced	O
sleep	B-UNK
disturbance	B-UNK
does	O
not	O
impair	O
its	O
prolactin	B-UNK
-	O
releasing	B-UNK
action	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
undertaken	B-UNK
to	O
examine	B-UNK
the	O
role	O
of	O
sleep	B-UNK
disturbance	B-UNK
,	O
induced	O
by	O
clomipramine	B-CHEMICAL
administration	O
,	O
on	O
the	O
secretory	O
rate	B-UNK
of	O
prolactin	B-UNK
(	O
PRL	B-UNK
)	O
in	O
addition	B-UNK
to	O
the	O
direct	B-UNK
drug	B-UNK
effect	B-UNK
.	O
Two	O
groups	B-UNK
of	O
supine	O
subjects	B-UNK
were	O
studied	O
under	O
placebo	B-UNK
-	O
controlled	B-UNK
conditions	O
,	O
one	O
during	O
the	O
night	B-UNK
,	O
when	O
sleeping	O
(	O
n	O
=	O
7	O
)	O
and	O
the	O
other	O
at	O
daytime	O
,	O
when	O
awake	O
(	O
n	O
=	O
6	O
)	O
.	O
Each	O
subject	O
received	O
a	O
single	B-UNK
50	O
mg	B-UNK
dose	B-UNK
of	O
clomipramine	B-CHEMICAL
given	O
orally	O
2	O
hours	B-UNK
before	O
blood	B-UNK
collection	B-UNK
.	O
Plasma	B-UNK
PRL	B-UNK
concentrations	B-UNK
were	O
analysed	B-UNK
at	O
10	O
min	B-UNK
intervals	B-UNK
and	O
underlying	B-UNK
secretory	O
rates	B-UNK
calculated	B-UNK
by	O
a	O
deconvolution	O
procedure	B-UNK
.	O
For	O
both	O
experiments	B-UNK
the	O
drug	B-UNK
intake	B-UNK
led	B-UNK
to	O
significant	B-UNK
increases	I-UNK
in	O
PRL	B-UNK
secretion	B-UNK
,	O
acting	O
preferentially	O
on	O
tonic	B-UNK
secretion	B-UNK
as	O
pulse	B-UNK
amplitude	B-UNK
and	O
frequency	B-UNK
did	O
not	O
differ	B-UNK
significantly	B-UNK
from	O
corresponding	O
control	B-UNK
values	O
.	O
During	O
the	O
night	B-UNK
clomipramine	B-CHEMICAL
ingestion	B-UNK
altered	B-UNK
the	O
complete	B-UNK
sleep	B-UNK
architecture	O
in	O
that	O
it	O
suppressed	O
REM	O
sleep	B-UNK
and	O
the	O
sleep	B-UNK
cycles	B-UNK
and	O
induced	O
increased	B-UNK
wakefulness	O
.	O
As	O
the	O
relative	B-UNK
increase	B-UNK
in	O
PRL	B-UNK
secretion	B-UNK
expressed	B-UNK
as	O
a	O
percentage	B-UNK
of	O
the	O
mean	O
did	O
not	O
significantly	B-UNK
differ	B-UNK
between	O
the	O
night	B-UNK
and	O
day	O
time	O
studies	B-UNK
(	O
46	O
+	O
/-	O
19	O
%	O
vs	O
34	O
+	O
/-	O
10	O
%	O
)	O
,	O
it	O
can	O
be	O
concluded	O
that	O
the	O
observed	O
sleep	B-UNK
disturbance	B-UNK
did	O
not	O
interfere	O
with	O
the	O
drug	B-UNK
action	B-UNK
per	O
se	B-DISEASE
.	O
The	O
presence	O
of	O
REM	O
sleep	B-UNK
was	O
shown	B-UNK
not	O
to	O
be	O
a	O
determining	O
factor	B-UNK
either	O
for	O
secretory	O
pulse	B-UNK
amplitude	B-UNK
and	O
frequency	B-UNK
,	O
as	O
,	O
for	O
both	O
,	O
mean	O
nocturnal	O
values	O
were	O
similar	B-UNK
with	O
and	O
without	O
prior	B-UNK
clomipramine	B-CHEMICAL
ingestion	B-UNK
.	O

Angioedema	B-UNK
following	O
the	O
intravenous	B-UNK
administration	O
of	O
metoprolol	B-UNK
.	O
A	O
72-year	O
-	O
old	O
woman	B-UNK
was	O
admitted	B-UNK
to	O
the	O
hospital	B-UNK
with	O
"	O
flash	O
"	O
pulmonary	B-DISEASE
edema	I-DISEASE
,	O
preceded	B-UNK
by	O
chest	B-UNK
pain	I-UNK
,	O
requiring	O
intubation	O
.	O
Her	O
medical	B-UNK
history	B-UNK
included	B-UNK
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
with	O
previous	B-UNK
myocardial	B-UNK
infarctions	O
,	O
hypertension	B-UNK
,	O
and	O
diabetes	B-UNK
mellitus	I-UNK
.	O
A	O
history	B-UNK
of	O
angioedema	B-UNK
secondary	B-UNK
to	O
lisinopril	O
therapy	O
was	O
elicited	B-UNK
.	O
Current	B-UNK
medications	B-UNK
did	O
not	O
include	O
angiotensin	O
-	O
converting	B-UNK
enzyme	I-UNK
inhibitors	B-UNK
or	O
beta-blockers	O
.	O
She	O
had	O
no	O
previous	B-UNK
beta-blocking	O
drug	B-UNK
exposure	B-UNK
.	O
During	O
the	O
first	O
day	O
of	O
hospitalization	B-UNK
(	O
while	O
intubated	O
)	O
,	O
intravenous	B-UNK
metoprolol	B-UNK
was	O
given	O
,	O
resulting	B-UNK
in	O
severe	B-UNK
angioedema	B-DISEASE
.	O
The	O
angioedema	B-UNK
resolved	O
after	O
therapy	O
with	O
intravenous	B-UNK
steroids	B-UNK
and	O
diphenhydramine	B-CHEMICAL
hydrochloride	B-UNK
.	O

Effect	B-UNK
of	O
coniine	B-CHEMICAL
on	O
the	O
developing	B-UNK
chick	O
embryo	O
.	O
Coniine	B-UNK
,	O
an	O
alkaloid	O
from	O
Conium	O
maculatum	O
(	O
poison	O
hemlock	O
)	O
,	O
has	O
been	O
shown	B-UNK
to	O
be	O
teratogenic	O
in	O
livestock	O
.	O
The	O
major	B-UNK
teratogenic	O
outcome	B-UNK
is	O
arthrogryposis	B-DISEASE
,	O
presumably	O
due	O
to	O
nicotinic	B-UNK
receptor	B-UNK
blockade	B-UNK
.	O
However	O
,	O
coniine	B-UNK
has	O
failed	B-UNK
to	O
produce	B-UNK
arthrogryposis	B-DISEASE
in	O
rats	B-UNK
or	O
mice	B-UNK
and	O
is	O
only	O
weakly	O
teratogenic	O
in	O
rabbits	O
.	O
The	O
purpose	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
evaluate	B-UNK
and	O
compare	B-UNK
the	O
effects	O
of	O
coniine	B-CHEMICAL
and	O
nicotine	B-UNK
in	O
the	O
developing	B-UNK
chick	O
.	O
Concentrations	B-UNK
of	O
coniine	B-CHEMICAL
and	O
nicotine	B-UNK
sulfate	B-UNK
were	O
0.015	O
%	O
,	O
0.03	O
%	O
,	O
0.075	O
%	O
,	O
0.15	O
%	O
,	O
0.75	O
%	O
,	O
1.5	O
%	O
,	O
3	O
%	O
,	O
and	O
6	O
%	O
and	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
,	O
respectively	O
.	O
Both	O
compounds	B-UNK
caused	B-UNK
deformations	B-DISEASE
and	O
lethality	B-UNK
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
manner	I-UNK
.	O
All	O
concentrations	B-UNK
of	O
nicotine	B-UNK
sulfate	B-UNK
caused	B-UNK
some	O
lethality	B-UNK
but	O
a	O
no	O
effect	B-UNK
level	B-UNK
for	O
coniine	B-CHEMICAL
lethality	B-UNK
was	O
0.75	O
%	O
.	O
The	O
deformations	B-DISEASE
caused	B-UNK
by	O
both	O
coniine	B-CHEMICAL
and	O
nicotine	B-CHEMICAL
sulfate	B-UNK
were	O
excessive	B-DISEASE
flexion	I-DISEASE
or	I-DISEASE
extension	I-DISEASE
of	I-DISEASE
one	I-DISEASE
or	I-DISEASE
more	I-DISEASE
toes	I-DISEASE
.	O
No	O
histopathological	B-UNK
alterations	B-UNK
or	O
differences	B-UNK
in	O
bone	B-UNK
formation	B-UNK
were	O
seen	O
in	O
the	O
limbs	B-UNK
or	O
toes	O
of	O
any	O
chicks	O
from	O
any	O
group	B-UNK
;	O
however	O
,	O
extensive	B-UNK
cranial	B-DISEASE
hemorrhage	I-DISEASE
occurred	B-UNK
in	O
all	O
nicotine	B-CHEMICAL
sulfate	B-UNK
-	O
treated	O
chicks	O
.	O
There	O
was	O
a	O
statistically	B-UNK
significant	I-UNK
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
decrease	B-UNK
in	O
movement	B-UNK
in	O
coniine	B-UNK
and	O
nicotine	B-UNK
sulfate	B-UNK
treated	O
chicks	O
as	O
determined	B-UNK
by	O
ultrasound	B-UNK
.	O
Control	B-UNK
chicks	O
were	O
in	O
motion	O
an	O
average	B-UNK
of	O
33.67	O
%	O
of	O
the	O
time	O
,	O
while	O
coniine	B-UNK
-	O
treated	O
chicks	O
were	O
only	O
moving	B-UNK
8.95	O
%	O
of	O
a	O
5-min	O
interval	B-UNK
,	O
and	O
no	O
movement	B-UNK
was	O
observed	O
for	O
nicotine	B-CHEMICAL
sulfate	B-UNK
treated	O
chicks	O
.	O
In	O
summary	B-UNK
,	O
the	O
chick	O
embryo	O
provides	O
a	O
reliable	O
and	O
simple	O
experimental	B-UNK
animal	B-UNK
model	I-UNK
of	O
coniine	B-UNK
-	O
induced	O
arthrogryposis	B-DISEASE
.	O
Data	B-UNK
from	O
this	O
model	B-UNK
support	B-UNK
a	O
mechanism	B-UNK
involving	O
nicotinic	B-UNK
receptor	B-UNK
blockade	B-UNK
with	O
subsequent	B-UNK
decreased	B-UNK
fetal	B-UNK
movement	B-UNK
.	O

Epidural	B-UNK
blood	B-UNK
flow	I-UNK
during	O
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
or	O
trimethaphan	O
induced	B-UNK
hypotension	I-UNK
.	O
To	O
evaluate	B-UNK
the	O
effect	B-UNK
of	O
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
(	O
PGE1	O
)	O
or	O
trimethaphan	O
(	O
TMP	B-UNK
)	O
induced	B-UNK
hypotension	I-UNK
on	O
epidural	B-UNK
blood	B-UNK
flow	I-UNK
(	O
EBF	O
)	O
during	O
spinal	B-UNK
surgery	B-UNK
,	O
EBF	O
was	O
measured	B-UNK
using	O
the	O
heat	O
clearance	B-UNK
method	B-UNK
in	O
30	O
patients	B-UNK
who	O
underwent	O
postero	O
-	O
lateral	B-UNK
interbody	O
fusion	O
under	O
isoflurane	B-UNK
anaesthesia	B-UNK
.	O
An	O
initial	B-UNK
dose	B-UNK
of	O
0.1	O
microgram.kg-1.min-1	O
of	O
PGE1	O
(	O
15	O
patients	B-UNK
)	O
,	O
or	O
10	O
micrograms.kg-1.min-1	O
of	O
TMP	B-UNK
(	O
15	O
patients	B-UNK
)	O
was	O
administered	O
intravenously	O
after	O
the	O
dural	O
opening	O
and	O
the	O
dose	B-UNK
was	O
adjusted	B-UNK
to	O
maintain	O
the	O
mean	O
arterial	B-UNK
blood	I-UNK
pressure	I-UNK
(	O
MAP	B-UNK
)	O
at	O
about	O
60	O
mmHg	B-UNK
.	O
The	O
hypotensive	B-DISEASE
drug	B-UNK
was	O
discontinued	O
at	O
the	O
completion	O
of	O
the	O
operative	B-UNK
procedure	B-UNK
.	O
After	O
starting	B-UNK
PGE1	O
or	O
TMP	B-UNK
,	O
MAP	B-UNK
and	O
rate	B-UNK
pressure	B-UNK
product	B-UNK
(	O
RPP	O
)	O
decreased	B-UNK
significantly	B-UNK
compared	O
with	O
preinfusion	O
values	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
degree	B-UNK
of	O
hypotension	B-DISEASE
due	O
to	O
PGE1	O
remained	B-UNK
constant	O
until	O
60	O
min	B-UNK
after	O
its	O
discontinuation	B-UNK
.	O
Heart	B-UNK
rate	I-UNK
(	O
HR	B-UNK
)	O
did	O
not	O
change	B-UNK
in	O
either	O
group	B-UNK
.	O
EBFF	O
did	O
not	O
change	B-UNK
during	O
PGE1	O
infusion	B-UNK
whereas	O
in	O
the	O
TMP	B-UNK
group	B-UNK
,	O
EBF	O
decreased	B-UNK
significantly	B-UNK
at	O
30	O
and	O
60	O
min	B-UNK
after	O
the	O
start	B-UNK
of	O
TMP	B-UNK
(	O
preinfusion	O
:	O
45.9	O
+	O
/-	O
13.9	O
ml/100g	O
/	O
min	B-UNK
.	O
30	O
min	B-UNK
:	O
32.3	O
+	O
/-	O
9.9	O
ml/100	O
g	O
/	O
min	B-UNK
(	O
P	O
<	O
0.05	O
)	O
.	O
60	O
min	B-UNK
:	O
30	O
+	O
/-	O
7.5	O
ml/100	O
g	O
/	O
min	B-UNK
(	O
P	O
<	O
0.05	O
)	O
)	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
PGE1	O
may	O
be	O
preferable	O
to	O
TMP	B-UNK
for	O
hypotensive	B-DISEASE
anaesthesia	B-UNK
in	O
spinal	B-UNK
surgery	B-UNK
because	O
TMP	B-UNK
decreased	B-UNK
EBF	O
.	O

Immunohistochemical	B-UNK
studies	B-UNK
with	O
antibodies	B-UNK
to	O
neurofilament	O
proteins	B-UNK
on	O
axonal	B-DISEASE
damage	I-DISEASE
in	O
experimental	B-UNK
focal	B-UNK
lesions	B-UNK
in	O
rat	B-UNK
.	O
Immunohistochemistry	B-UNK
with	O
monoclonal	O
antibodies	B-UNK
against	O
neurofilament	O
(	O
NF	B-UNK
)	O
proteins	B-UNK
of	O
middle	B-UNK
and	O
high	B-UNK
molecular	B-UNK
weight	I-UNK
class	B-UNK
,	O
NF	B-UNK
-	O
M	O
and	O
NF	B-UNK
-	O
H	O
,	O
was	O
used	O
to	O
study	B-UNK
axonal	B-DISEASE
injury	I-DISEASE
in	O
the	O
borderzone	O
of	O
focal	B-UNK
lesions	B-UNK
in	O
rats	B-UNK
.	O
Focal	B-UNK
injury	B-UNK
in	O
the	O
cortex	B-UNK
was	O
produced	B-UNK
by	O
infusion	B-UNK
of	O
lactate	B-UNK
at	O
acid	B-UNK
pH	B-UNK
or	O
by	O
stab	O
caused	B-UNK
by	O
needle	B-UNK
insertion	O
.	O
Infarcts	O
in	O
substantia	B-UNK
nigra	I-UNK
pars	O
reticulata	O
were	O
evoked	B-UNK
by	O
prolonged	B-UNK
pilocarpine	B-UNK
-	O
induced	O
status	B-UNK
epilepticus	I-UNK
.	O
Immunohistochemical	B-UNK
staining	B-UNK
for	O
NFs	O
showed	O
characteristic	B-UNK
terminal	B-UNK
clubs	O
of	O
axons	O
in	O
the	O
borderzone	O
of	O
lesions	B-UNK
.	O
Differences	B-UNK
in	O
the	O
labelling	O
pattern	B-UNK
occurred	B-UNK
with	O
different	O
antibodies	B-UNK
which	O
apparently	O
depended	O
on	O
molecular	B-UNK
weight	I-UNK
class	B-UNK
of	O
NFs	O
and	O
phosphorylation	O
state	B-UNK
.	O
These	O
immunohistochemical	B-UNK
changes	O
of	O
NFs	O
can	O
serve	O
as	O
a	O
marker	B-UNK
for	O
axonal	B-DISEASE
damage	I-DISEASE
in	O
various	O
experimental	B-UNK
traumatic	O
or	O
ischemic	B-DISEASE
lesions	B-UNK
.	O

Increase	B-UNK
of	O
Parkinson	O
disability	B-UNK
after	O
fluoxetine	B-UNK
medication	O
.	O
Depression	B-UNK
is	O
a	O
major	B-UNK
clinical	B-UNK
feature	O
of	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
.	O
We	O
report	B-UNK
the	O
increased	B-UNK
amount	O
of	O
motor	B-DISEASE
disability	I-DISEASE
in	O
four	O
patients	B-UNK
with	O
idiopathic	B-UNK
Parkinson'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
after	O
exposure	B-UNK
to	O
the	O
antidepressant	B-UNK
fluoxetine	B-UNK
.	O
The	O
possibility	O
of	O
a	O
clinically	B-UNK
relevant	B-UNK
dopamine	B-UNK
-	O
antagonistic	O
capacity	O
of	O
fluoxetine	B-UNK
in	O
Parkinson'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
patients	B-UNK
must	O
be	O
considered	B-UNK
.	O

Acetaminophen	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
.	O
Through	O
30	O
years	B-UNK
of	O
widespread	B-UNK
use	O
,	O
acetaminophen	B-UNK
has	O
been	O
shown	B-UNK
to	O
be	O
a	O
remarkably	O
safe	O
medication	O
in	O
therapeutic	B-UNK
dosages	B-UNK
.	O
The	O
potential	B-UNK
for	O
acetaminophen	B-CHEMICAL
to	O
produce	B-UNK
cardiovascular	B-DISEASE
toxicities	I-DISEASE
is	O
very	O
low	B-UNK
.	O
However	O
,	O
acetaminophen	B-UNK
has	O
been	O
demonstrated	O
to	O
produce	B-UNK
symptoms	B-UNK
of	O
anaphylaxis	B-DISEASE
,	O
including	O
hypotension	B-UNK
,	O
in	O
sensitive	B-UNK
individuals	B-UNK
.	O
This	O
article	O
describes	B-UNK
two	O
critically	B-DISEASE
ill	I-DISEASE
patients	B-UNK
in	O
whom	O
transient	B-UNK
episodes	B-UNK
of	O
hypotension	B-UNK
reproducibly	O
developed	O
after	O
administration	O
of	O
acetaminophen	B-CHEMICAL
.	O
Other	O
symptoms	B-UNK
of	O
allergic	B-DISEASE
reactions	I-DISEASE
were	O
not	O
clinically	B-UNK
detectable	O
.	O
The	O
hypotensive	B-DISEASE
episodes	B-UNK
were	O
severe	B-UNK
enough	O
to	O
require	O
vasopressor	O
administration	O
.	O
The	O
reports	B-UNK
illustrate	O
the	O
need	O
for	O
clinicians	B-UNK
to	O
consider	O
acetaminophen	B-CHEMICAL
in	O
patients	B-UNK
with	O
hypotension	B-DISEASE
of	O
unknown	O
origin	B-UNK
.	O

Acute	B-UNK
hepatitis	B-DISEASE
,	I-DISEASE
autoimmune	I-DISEASE
hemolytic	B-UNK
anemia	I-UNK
,	O
and	O
erythroblastocytopenia	B-DISEASE
induced	O
by	O
ceftriaxone	B-CHEMICAL
.	O
An	O
80-yr	O
-	O
old	O
man	B-UNK
developed	O
acute	B-UNK
hepatitis	I-UNK
shortly	B-UNK
after	O
ingesting	O
oral	B-UNK
ceftriaxone	B-CHEMICAL
.	O
Although	O
the	O
transaminases	O
gradually	O
returned	B-UNK
to	O
baseline	B-UNK
after	O
withholding	O
the	O
beta	B-UNK
lactam	O
antibiotic	B-UNK
,	O
there	O
was	O
a	O
gradual	B-UNK
increase	B-UNK
in	O
serum	B-UNK
bilirubin	B-UNK
and	O
a	O
decrease	B-UNK
in	O
hemoglobin	B-UNK
concentration	B-UNK
caused	B-UNK
by	O
an	O
autoimmune	B-DISEASE
hemolytic	I-DISEASE
anemia	I-DISEASE
and	O
erythroblastocytopenia	B-DISEASE
.	O
These	O
responded	O
to	O
systemic	B-UNK
steroids	B-UNK
and	O
immunoglobulins	O
.	O
Despite	O
the	O
widespread	B-UNK
use	O
of	O
these	O
agents	B-UNK
this	O
triad	O
of	O
side	O
effects	O
has	O
not	O
previously	B-UNK
been	O
reported	B-UNK
in	O
connection	O
with	O
beta	B-UNK
lactam	O
antibiotics	B-UNK
.	O

Adverse	B-UNK
effects	I-UNK
of	O
the	O
atypical	B-UNK
antipsychotics	B-CHEMICAL
.	O
Collaborative	O
Working	B-UNK
Group	B-UNK
on	O
Clinical	B-UNK
Trial	I-UNK
Evaluations	O
.	O
Adverse	B-UNK
effects	I-UNK
of	O
antipsychotics	B-UNK
often	O
lead	B-UNK
to	O
noncompliance	O
.	O
Thus	O
,	O
clinicians	B-UNK
should	O
address	O
patients	B-UNK
'	O
concerns	B-UNK
about	O
adverse	B-UNK
effects	I-UNK
and	O
attempt	O
to	O
choose	O
medications	B-UNK
that	O
will	O
improve	B-UNK
their	O
patients	B-UNK
'	O
quality	B-UNK
of	I-UNK
life	I-UNK
as	O
well	O
as	O
overall	O
health	B-UNK
.	O
The	O
side	O
effect	B-UNK
profiles	B-UNK
of	O
the	O
atypical	B-UNK
antipsychotics	B-CHEMICAL
are	O
more	O
advantageous	O
than	O
those	O
of	O
the	O
conventional	B-UNK
neuroleptics	B-CHEMICAL
.	O
Conventional	B-UNK
agents	B-UNK
are	O
associated	O
with	O
unwanted	O
central	B-UNK
nervous	I-UNK
system	I-UNK
effects	O
,	O
including	O
extrapyramidal	B-UNK
symptoms	I-UNK
(	O
EPS	B-UNK
)	O
,	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
,	O
sedation	B-UNK
,	O
and	O
possible	O
impairment	B-UNK
of	O
some	O
cognitive	B-UNK
measures	B-UNK
,	O
as	O
well	O
as	O
cardiac	B-UNK
effects	O
,	O
orthostatic	B-UNK
hypotension	I-UNK
,	O
hepatic	B-UNK
changes	O
,	O
anticholinergic	B-UNK
side	O
effects	O
,	O
sexual	B-UNK
dysfunction	I-UNK
,	O
and	O
weight	B-UNK
gain	I-UNK
.	O
The	O
newer	O
atypical	B-UNK
agents	B-UNK
have	O
a	O
lower	B-UNK
risk	B-UNK
of	O
EPS	B-UNK
,	O
but	O
are	O
associated	O
in	O
varying	O
degrees	B-UNK
with	O
sedation	B-UNK
,	O
cardiovascular	B-UNK
effects	O
,	O
anticholinergic	B-UNK
effects	O
,	O
weight	B-UNK
gain	I-UNK
,	O
sexual	B-UNK
dysfunction	I-UNK
,	O
hepatic	B-UNK
effects	O
,	O
lowered	B-UNK
seizure	B-DISEASE
threshold	B-UNK
(	O
primarily	O
clozapine	B-CHEMICAL
)	O
,	O
and	O
agranulocytosis	B-DISEASE
(	O
clozapine	B-CHEMICAL
only	O
)	O
.	O
Since	O
the	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
specific	B-UNK
adverse	B-UNK
effects	I-UNK
differ	B-UNK
among	O
the	O
various	O
atypicals	O
,	O
the	O
clinician	O
should	O
carefully	B-UNK
consider	O
which	O
side	O
effects	O
are	O
most	O
likely	O
to	O
lead	B-UNK
to	O
the	O
individual'	O
s	O
dissatisfaction	O
and	O
noncompliance	O
before	O
choosing	O
an	O
antipsychotic	B-UNK
for	O
a	O
particular	O
patient	B-UNK
.	O

Effects	O
of	O
tetrandrine	O
and	O
fangchinoline	B-CHEMICAL
on	O
experimental	B-UNK
thrombosis	B-UNK
in	O
mice	B-UNK
and	O
human	B-UNK
platelet	B-DISEASE
aggregation	I-DISEASE
.	O
Tetrandrine	O
(	O
TET	O
)	O
and	O
fangchinoline	B-CHEMICAL
(	O
FAN	O
)	O
are	O
two	O
naturally	O
occurring	O
analogues	O
with	O
a	O
bisbenzylisoquinoline	O
structure	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
undertaken	B-UNK
to	O
investigate	B-UNK
the	O
effects	O
of	O
TET	O
and	O
FAN	O
on	O
the	O
experimental	B-UNK
thrombosis	B-UNK
induced	O
by	O
collagen	O
plus	O
epinephrine	B-UNK
(	O
EP	O
)	O
in	O
mice	B-UNK
,	O
and	O
platelet	B-UNK
aggregation	I-UNK
and	O
blood	B-DISEASE
coagulation	I-DISEASE
in	O
vitro	B-UNK
.	O
In	O
the	O
in	O
vivo	B-UNK
study	B-UNK
,	O
the	O
administration	O
(	O
50	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
of	O
TET	O
and	O
FAN	O
in	O
mice	B-UNK
showed	O
the	O
inhibition	B-UNK
of	O
thrombosis	B-UNK
by	O
55	O
%	O
and	O
35	O
%	O
,	O
respectively	O
,	O
while	O
acetylsalicylic	O
acid	B-UNK
(	O
ASA	B-CHEMICAL
,	O
50	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
,	O
a	O
positive	B-UNK
control	B-UNK
,	O
showed	O
only	O
30	O
%	O
inhibition	B-UNK
.	O
In	O
the	O
vitro	B-UNK
human	B-UNK
platelet	B-UNK
aggregations	O
induced	O
by	O
the	O
agonists	B-UNK
used	O
in	O
tests	B-UNK
,	O
TET	O
and	O
FAN	O
showed	O
the	O
inhibitions	O
dose	B-UNK
dependently	I-UNK
.	O
In	O
addition	B-UNK
,	O
neither	O
TET	O
nor	O
FAN	O
showed	O
any	O
anticoagulation	B-UNK
activities	B-UNK
in	O
the	O
measurement	B-UNK
of	O
the	O
activated	B-UNK
partial	B-UNK
thromboplastin	O
time	O
(	O
APTT	O
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
and	O
thrombin	B-UNK
time	O
(	O
TT	O
)	O
using	O
human	B-UNK
-	O
citrated	O
plasma	B-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
antithrombosis	O
of	O
TET	O
and	O
FAN	O
in	O
mice	B-UNK
may	O
be	O
mainly	O
related	O
to	O
the	O
antiplatelet	O
aggregation	B-UNK
activities	B-UNK
.	O

Gemcitabine	B-UNK
plus	O
vinorelbine	B-CHEMICAL
in	O
nonsmall	O
cell	B-UNK
lung	I-UNK
carcinoma	B-UNK
patients	B-UNK
age	B-UNK
70	O
years	B-UNK
or	O
older	B-UNK
or	O
patients	B-UNK
who	O
cannot	O
receive	B-UNK
cisplatin	B-CHEMICAL
.	O
Oncopaz	O
Cooperative	O
Group	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Although	O
the	O
prevalence	B-UNK
of	O
nonsmall	O
cell	B-UNK
lung	I-UNK
carcinoma	B-UNK
(	O
NSCLC	B-UNK
)	O
is	O
high	B-UNK
among	O
elderly	B-UNK
patients	B-UNK
,	O
few	O
data	B-UNK
are	O
available	O
regarding	O
the	O
efficacy	B-UNK
and	O
toxicity	B-DISEASE
of	O
chemotherapy	O
in	O
this	O
group	B-UNK
of	O
patients	B-UNK
.	O
Recent	B-UNK
reports	B-UNK
indicate	O
that	O
single	B-UNK
agent	I-UNK
therapy	O
with	O
vinorelbine	B-CHEMICAL
(	O
VNB	O
)	O
or	O
gemcitabine	B-UNK
(	O
GEM	B-UNK
)	O
may	O
obtain	O
a	O
response	B-UNK
rate	B-UNK
of	O
20	O
-	O
30	O
%	O
in	O
elderly	B-UNK
patients	B-UNK
,	O
with	O
acceptable	O
toxicity	B-DISEASE
and	O
improvement	B-UNK
in	O
symptoms	B-UNK
and	O
quality	B-UNK
of	I-UNK
life	I-UNK
.	O
In	O
the	O
current	B-UNK
study	B-UNK
the	O
efficacy	B-UNK
and	O
toxicity	B-DISEASE
of	O
the	O
combination	B-UNK
of	O
GEM	B-UNK
and	O
VNB	O
in	O
elderly	B-UNK
patients	B-UNK
with	O
advanced	B-UNK
NSCLC	B-UNK
or	O
those	O
with	O
some	O
contraindication	O
to	O
receiving	B-UNK
cisplatin	B-CHEMICAL
were	O
assessed	B-UNK
.	O
METHODS	B-UNK
:	O
Forty	O
-	O
nine	O
patients	B-UNK
with	O
advanced	B-UNK
NSCLC	B-UNK
were	O
included	B-UNK
,	O
38	O
of	O
whom	O
were	O
age	B-UNK
>	O
/=	O
70	O
years	B-UNK
and	O
11	O
were	O
age	B-UNK
<	O
70	O
years	B-UNK
but	O
who	O
had	O
some	O
contraindication	O
to	O
receiving	B-UNK
cisplatin	B-UNK
.	O
All	O
patients	B-UNK
were	O
evaluable	B-UNK
for	O
response	B-UNK
and	O
toxicity	B-DISEASE
.	O
Treatment	B-UNK
was	O
comprised	O
of	O
VNB	O
,	O
25	O
mg	B-UNK
/	O
m(2	O
)	O
,	O
plus	O
GEM	B-UNK
,	O
1000	O
mg	B-UNK
/	O
m(2	O
)	O
,	O
both	O
on	O
Days	B-UNK
1	O
,	O
8	O
,	O
and	O
15	O
every	O
28	O
days	B-UNK
.	O
Patients	B-UNK
received	O
a	O
minimum	B-UNK
of	O
three	O
courses	B-UNK
unless	O
progressive	B-UNK
disease	B-UNK
was	O
detected	B-UNK
.	O
RESULTS	B-UNK
:	O
One	O
hundred	O
sixty	O
-	O
five	O
courses	B-UNK
were	O
administered	O
,	O
with	O
a	O
median	B-UNK
of	O
3	O
.	O
6	O
courses	B-UNK
per	O
patient	B-UNK
.	O
The	O
overall	O
response	B-UNK
rate	B-UNK
was	O
26	O
%	O
(	O
95	O
%	O
confidence	O
interval	B-UNK
,	O
15	O
-	O
41	O
%	O
)	O
.	O
Two	O
patients	B-UNK
attained	O
a	O
complete	B-UNK
response	B-UNK
(	O
4	O
%	O
)	O
and	O
11	O
patients	B-UNK
(	O
22	O
%	O
)	O
achieved	O
a	O
partial	B-UNK
response	I-UNK
.	O
Eastern	O
Cooperative	O
Oncology	B-UNK
Group	B-UNK
performance	B-UNK
status	B-UNK
improved	O
in	O
35	O
%	O
of	O
those	O
patients	B-UNK
with	O
an	O
initial	B-UNK
value	O
>	O
0	O
,	O
whereas	O
relief	O
of	O
at	O
least	O
1	O
symptom	B-UNK
without	O
worsening	B-UNK
of	O
other	O
symptoms	B-UNK
was	O
noted	B-UNK
in	O
27	O
patients	B-UNK
(	O
55	O
%	O
)	O
.	O
The	O
median	B-UNK
time	O
to	O
progression	B-UNK
was	O
16	O
weeks	B-UNK
and	O
the	O
1-year	O
survival	B-UNK
rate	B-UNK
was	O
33	O
%	O
.	O
Toxicity	B-UNK
was	O
mild	B-UNK
.	O
Six	O
patients	B-UNK
(	O
12	O
%	O
)	O
had	O
World	B-UNK
Health	B-UNK
Organization	B-UNK
Grade	B-UNK
3	O
-	O
4	O
neutropenia	B-UNK
,	O
2	O
patients	B-UNK
(	O
4	O
%	O
)	O
had	O
Grade	B-UNK
3	O
-	O
4	O
thrombocytopenia	B-DISEASE
,	O
and	O
2	O
patients	B-UNK
(	O
4	O
%	O
)	O
had	O
Grade	B-UNK
3	O
neurotoxicity	B-DISEASE
.	O
Three	O
patients	B-UNK
with	O
severe	B-UNK
neutropenia	B-DISEASE
(	O
6	O
%	O
)	O
died	O
of	O
sepsis	B-DISEASE
.	O
The	O
median	B-UNK
age	I-UNK
of	O
those	O
patients	B-UNK
developing	B-UNK
Grade	B-UNK
3	O
-	O
4	O
neutropenia	B-UNK
was	O
significantly	B-UNK
higher	I-UNK
than	O
that	O
of	O
the	O
remaining	O
patients	B-UNK
(	O
75	O
years	B-UNK
vs	O
.	O
72	O
years	B-UNK
;	O
P	O
=	O
0.047	O
)	O
.	O
CONCLUSIONS	B-UNK
:	O
The	O
combination	B-UNK
of	O
GEM	B-UNK
and	O
VNB	O
is	O
moderately	O
active	B-UNK
and	O
well	O
tolerated	B-UNK
except	O
in	O
patients	B-UNK
age	B-UNK
>	O
/=	O
75	O
years	B-UNK
.	O
This	O
age	B-UNK
group	B-UNK
had	O
an	O
increased	B-UNK
risk	B-UNK
of	O
myelosuppression	B-DISEASE
.	O
Therefore	O
the	O
prophylactic	B-UNK
use	O
of	O
granulocyte	O
-	O
colony	O
stimulating	B-UNK
factor	B-UNK
should	O
be	O
considered	B-UNK
with	O
this	O
treatment	B-UNK
.	O
New	O
chemotherapy	O
combinations	B-UNK
with	O
higher	B-UNK
activity	B-UNK
and	O
lower	B-UNK
toxicity	B-UNK
are	O
needed	B-UNK
for	O
elderly	B-UNK
patients	B-UNK
with	O
advanced	B-UNK
NSCLC	B-UNK
.	O

Warfarin	B-CHEMICAL
-	O
induced	O
artery	B-DISEASE
calcification	I-DISEASE
is	O
accelerated	B-UNK
by	O
growth	B-UNK
and	O
vitamin	B-UNK
D.	O
The	O
present	B-UNK
studies	B-UNK
demonstrate	O
that	O
growth	B-UNK
and	O
vitamin	B-UNK
D	I-UNK
treatment	B-UNK
enhance	B-UNK
the	O
extent	B-UNK
of	O
artery	B-UNK
calcification	I-UNK
in	O
rats	B-UNK
given	O
sufficient	B-UNK
doses	B-UNK
of	O
Warfarin	B-CHEMICAL
to	O
inhibit	O
gamma	B-UNK
-	O
carboxylation	O
of	O
matrix	B-UNK
Gla	O
protein	B-UNK
,	O
a	O
calcification	B-DISEASE
inhibitor	B-UNK
known	O
to	O
be	O
expressed	B-UNK
by	O
smooth	B-UNK
muscle	I-UNK
cells	B-UNK
and	O
macrophages	O
in	O
the	O
artery	B-UNK
wall	B-UNK
.	O
The	O
first	O
series	B-UNK
of	O
experiments	B-UNK
examined	B-UNK
the	O
influence	B-UNK
of	O
age	B-UNK
and	O
growth	B-UNK
status	B-UNK
on	O
artery	B-UNK
calcification	I-UNK
in	O
Warfarin	B-UNK
-	O
treated	B-UNK
rats	I-UNK
.	O
Treatment	B-UNK
for	O
2	O
weeks	B-UNK
with	O
Warfarin	B-UNK
caused	B-UNK
massive	B-UNK
focal	B-UNK
calcification	B-DISEASE
of	I-DISEASE
the	I-DISEASE
artery	I-DISEASE
media	B-UNK
in	O
20-day	O
-	O
old	O
rats	B-UNK
and	O
less	O
extensive	B-UNK
focal	B-UNK
calcification	B-DISEASE
in	O
42-day	O
-	O
old	O
rats	B-UNK
.	O
In	O
contrast	B-UNK
,	O
no	O
artery	B-UNK
calcification	I-UNK
could	O
be	O
detected	B-UNK
in	O
10-month	O
-	O
old	O
adult	B-UNK
rats	B-UNK
even	O
after	O
4	O
weeks	B-UNK
of	O
Warfarin	B-UNK
treatment	B-UNK
.	O
To	O
directly	O
examine	B-UNK
the	O
importance	B-UNK
of	O
growth	B-UNK
to	O
Warfarin	B-CHEMICAL
-	O
induced	O
artery	B-DISEASE
calcification	I-DISEASE
in	O
animals	B-UNK
of	O
the	O
same	O
age	B-UNK
,	O
20-day	O
-	O
old	O
rats	B-UNK
were	O
fed	B-UNK
for	O
2	O
weeks	B-UNK
either	O
an	O
ad	O
libitum	O
diet	B-UNK
or	O
a	O
6-g	O
/	O
d	O
restricted	B-UNK
diet	B-UNK
that	O
maintains	O
weight	B-UNK
but	O
prevents	O
growth	B-UNK
.	O
Concurrent	B-UNK
treatment	B-UNK
of	O
both	O
dietary	B-UNK
groups	B-UNK
with	O
Warfarin	B-CHEMICAL
produced	B-UNK
massive	B-UNK
focal	B-UNK
calcification	B-DISEASE
of	I-DISEASE
the	I-DISEASE
artery	I-DISEASE
media	B-UNK
in	O
the	O
ad	O
libitum	O
-	O
fed	B-UNK
rats	B-UNK
but	O
no	O
detectable	O
artery	B-DISEASE
calcification	I-DISEASE
in	O
the	O
restricted	B-UNK
-	O
diet	B-UNK
,	O
growth	B-UNK
-	O
inhibited	B-UNK
group	B-UNK
.	O
Although	O
the	O
explanation	O
for	O
the	O
association	B-UNK
between	O
artery	B-DISEASE
calcification	I-DISEASE
and	O
growth	B-UNK
status	B-UNK
cannot	O
be	O
determined	B-UNK
from	O
the	O
present	B-UNK
study	B-UNK
,	O
there	O
was	O
a	O
relationship	B-UNK
between	O
higher	B-UNK
serum	B-UNK
phosphate	B-CHEMICAL
and	O
susceptibility	B-UNK
to	O
artery	B-UNK
calcification	I-UNK
,	O
with	O
30	O
%	O
higher	B-UNK
levels	O
of	O
serum	B-UNK
phosphate	B-CHEMICAL
in	O
young	B-UNK
,	O
ad	O
libitum	O
-	O
fed	B-UNK
rats	B-UNK
compared	O
with	O
either	O
of	O
the	O
groups	B-UNK
that	O
was	O
resistant	B-UNK
to	O
Warfarin	B-CHEMICAL
-	O
induced	O
artery	B-UNK
calcification	I-UNK
,	O
ie	O
,	O
the	O
10-month	O
-	O
old	O
rats	B-UNK
and	O
the	O
restricted	B-UNK
-	O
diet	B-UNK
,	O
growth	B-UNK
-	O
inhibited	B-UNK
young	B-UNK
rats	B-UNK
.	O
This	O
observation	B-UNK
suggests	O
that	O
increased	B-UNK
susceptibility	B-UNK
to	O
Warfarin	B-UNK
-	O
induced	O
artery	B-DISEASE
calcification	I-DISEASE
could	O
be	O
related	O
to	O
higher	B-UNK
serum	B-UNK
phosphate	B-CHEMICAL
levels	O
.	O
The	O
second	O
set	O
of	O
experiments	B-UNK
examined	B-UNK
the	O
possible	O
synergy	O
between	O
vitamin	B-UNK
D	I-UNK
and	O
Warfarin	B-UNK
in	O
artery	B-DISEASE
calcification	I-DISEASE
.	O
High	B-UNK
doses	I-UNK
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
are	O
known	O
to	O
cause	O
calcification	B-DISEASE
of	I-DISEASE
the	I-DISEASE
artery	I-DISEASE
media	B-UNK
in	O
as	O
little	O
as	O
3	O
to	O
4	O
days	B-UNK
.	O
High	B-UNK
doses	I-UNK
of	O
the	O
vitamin	B-UNK
K	O
antagonist	B-UNK
Warfarin	B-UNK
are	O
also	O
known	O
to	O
cause	O
calcification	B-DISEASE
of	I-DISEASE
the	I-DISEASE
artery	I-DISEASE
media	B-UNK
,	O
but	O
at	O
treatment	B-UNK
times	B-UNK
of	O
2	O
weeks	B-UNK
or	O
longer	O
yet	O
not	O
at	O
1	O
week	B-UNK
.	O
In	O
the	O
current	B-UNK
study	B-UNK
,	O
we	O
investigated	B-UNK
the	O
synergy	O
between	O
these	O
2	O
treatments	O
and	O
found	O
that	O
concurrent	B-UNK
Warfarin	B-UNK
administration	O
dramatically	O
increased	B-UNK
the	O
extent	B-UNK
of	O
calcification	B-DISEASE
in	O
the	O
media	B-UNK
of	O
vitamin	B-UNK
D	I-UNK
-	O
treated	B-UNK
rats	I-UNK
at	O
3	O
and	O
4	O
days	B-UNK
.	O
There	O
was	O
a	O
close	B-UNK
parallel	O
between	O
the	O
effect	B-UNK
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
dose	B-UNK
on	O
artery	B-DISEASE
calcification	I-DISEASE
and	O
the	O
effect	B-UNK
of	O
vitamin	B-UNK
D	I-UNK
dose	B-UNK
on	O
the	O
elevation	B-UNK
of	O
serum	B-UNK
calcium	I-UNK
,	O
which	O
suggests	O
that	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
may	O
induce	B-UNK
artery	B-DISEASE
calcification	I-DISEASE
through	O
its	O
effect	B-UNK
on	O
serum	B-UNK
calcium	I-UNK
.	O
Because	O
Warfarin	B-CHEMICAL
treatment	B-UNK
had	O
no	O
effect	B-UNK
on	O
the	O
elevation	B-UNK
in	O
serum	B-UNK
calcium	I-UNK
produced	B-UNK
by	O
vitamin	B-UNK
D	I-UNK
,	O
the	O
synergy	O
between	O
Warfarin	B-UNK
and	O
vitamin	B-UNK
D	I-UNK
is	O
probably	O
best	O
explained	O
by	O
the	O
hypothesis	B-UNK
that	O
Warfarin	B-UNK
inhibits	B-UNK
the	O
activity	B-UNK
of	O
matrix	B-UNK
Gla	O
protein	B-UNK
as	O
a	O
calcification	B-DISEASE
inhibitor	B-UNK
.	O
High	B-UNK
levels	O
of	O
matrix	B-UNK
Gla	O
protein	B-UNK
are	O
found	O
at	O
sites	B-UNK
of	O
artery	B-UNK
calcification	I-UNK
in	O
rats	B-UNK
treated	O
with	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
plus	O
Warfarin	B-UNK
,	O
and	O
chemical	B-UNK
analysis	B-UNK
showed	O
that	O
the	O
protein	B-UNK
that	O
accumulated	O
was	O
indeed	O
not	O
gamma	B-UNK
-	O
carboxylated	O
.	O
These	O
observations	B-UNK
indicate	O
that	O
although	O
the	O
gamma	B-UNK
-	O
carboxyglutamate	O
residues	O
of	O
matrix	B-UNK
Gla	O
protein	B-UNK
are	O
apparently	O
required	B-UNK
for	O
its	O
function	B-UNK
as	O
a	O
calcification	B-DISEASE
inhibitor	B-UNK
,	O
they	O
are	O
not	O
required	B-UNK
for	O
its	O
accumulation	B-UNK
at	O
calcification	B-DISEASE
sites	B-UNK
.	O

Antidepressant	B-UNK
-	O
induced	O
mania	B-UNK
in	O
bipolar	B-UNK
patients	B-UNK
:	O
identification	O
of	O
risk	B-UNK
factors	I-UNK
.	O
BACKGROUND	B-UNK
:	O
Concerns	B-UNK
about	O
possible	O
risks	B-UNK
of	O
switching	B-UNK
to	O
mania	B-UNK
associated	O
with	O
antidepressants	B-UNK
continue	B-UNK
to	O
interfere	O
with	O
the	O
establishment	O
of	O
an	O
optimal	B-UNK
treatment	B-UNK
paradigm	B-UNK
for	O
bipolar	B-DISEASE
depression	I-DISEASE
.	O
METHOD	B-UNK
:	O
The	O
response	B-UNK
of	O
44	O
patients	B-UNK
meeting	O
DSM	B-UNK
-	O
IV	B-UNK
criteria	B-UNK
for	O
bipolar	B-DISEASE
disorder	I-DISEASE
to	O
naturalistic	O
treatment	B-UNK
was	O
assessed	B-UNK
for	O
at	O
least	O
6	O
weeks	B-UNK
using	O
the	O
Montgomery	O
-	O
Asberg	O
Depression	B-UNK
Rating	B-UNK
Scale	I-UNK
and	O
the	O
Bech	O
-	O
Rafaelson	O
Mania	B-UNK
Rating	B-UNK
Scale	I-UNK
.	O
Patients	B-UNK
who	O
experienced	B-UNK
a	O
manic	B-UNK
or	O
hypomanic	O
switch	O
were	O
compared	O
with	O
those	O
who	O
did	O
not	O
on	O
several	O
variables	B-UNK
including	O
age	B-UNK
,	O
sex	B-UNK
,	O
diagnosis	B-UNK
(	O
DSM	B-UNK
-	O
IV	B-UNK
bipolar	B-DISEASE
I	I-DISEASE
vs	O
.	O
bipolar	B-DISEASE
II	I-DISEASE
)	O
,	O
number	B-UNK
of	O
previous	B-UNK
manic	B-UNK
episodes	B-UNK
,	O
type	B-UNK
of	O
antidepressant	B-UNK
therapy	O
used	O
(	O
electroconvulsive	O
therapy	O
vs	O
.	O
antidepressant	B-UNK
drugs	B-UNK
and	O
,	O
more	O
particularly	O
,	O
selective	B-UNK
serotonin	B-UNK
reuptake	I-UNK
inhibitors	B-UNK
[	O
SSRIs	O
]	O
)	O
,	O
use	O
and	O
type	B-UNK
of	O
mood	B-UNK
stabilizers	O
(	O
lithium	B-CHEMICAL
vs	O
.	O
anticonvulsants	O
)	O
,	O
and	O
temperament	O
of	O
the	O
patient	B-UNK
,	O
assessed	B-UNK
during	O
a	O
normothymic	O
period	B-UNK
using	O
the	O
hyperthymia	O
component	B-UNK
of	O
the	O
Semi-structured	O
Affective	B-UNK
Temperament	O
Interview	O
.	O
RESULTS	B-UNK
:	O
Switches	O
to	O
hypomania	O
or	O
mania	B-UNK
occurred	B-UNK
in	O
27	O
%	O
of	O
all	O
patients	B-UNK
(	O
N	O
=	O
12	O
)	O
(	O
and	O
in	O
24	O
%	O
of	O
the	O
subgroup	B-UNK
of	O
patients	B-UNK
treated	O
with	O
SSRIs	O
[	O
8/33	O
]	O
)	O
;	O
16	O
%	O
(	O
N	O
=	O
7	O
)	O
experienced	B-UNK
manic	B-UNK
episodes	B-UNK
,	O
and	O
11	O
%	O
(	O
N	O
=	O
5	O
)	O
experienced	B-UNK
hypomanic	O
episodes	B-UNK
.	O
Sex	B-UNK
,	O
age	B-UNK
,	O
diagnosis	B-UNK
(	O
bipolar	B-DISEASE
I	I-DISEASE
vs	O
.	O
bipolar	B-DISEASE
II	I-DISEASE
)	O
,	O
and	O
additional	B-UNK
treatment	B-UNK
did	O
not	O
affect	B-UNK
the	O
risk	B-UNK
of	O
switching	B-UNK
.	O
The	O
incidence	B-UNK
of	O
mood	B-UNK
switches	O
seemed	O
not	O
to	O
differ	B-UNK
between	O
patients	B-UNK
receiving	B-UNK
an	O
anticonvulsant	B-UNK
and	O
those	O
receiving	B-UNK
no	O
mood	B-UNK
stabilizer	O
.	O
In	O
contrast	B-UNK
,	O
mood	B-UNK
switches	O
were	O
less	O
frequent	B-UNK
in	O
patients	B-UNK
receiving	B-UNK
lithium	B-CHEMICAL
(	O
15	O
%	O
,	O
4/26	O
)	O
than	O
in	O
patients	B-UNK
not	O
treated	O
with	O
lithium	B-UNK
(	O
44	O
%	O
,	O
8/18	O
;	O
p	O
=	O
.04	O
)	O
.	O
The	O
number	B-UNK
of	O
previous	B-UNK
manic	B-UNK
episodes	B-UNK
did	O
not	O
affect	B-UNK
the	O
probability	B-UNK
of	O
switching	B-UNK
,	O
whereas	O
a	O
high	B-UNK
score	O
on	O
the	O
hyperthymia	O
component	B-UNK
of	O
the	O
Semistructured	O
Affective	B-UNK
Temperament	O
Interview	O
was	O
associated	O
with	O
a	O
greater	B-UNK
risk	B-UNK
of	O
switching	B-UNK
(	O
p	O
=	O
.008	O
)	O
.	O
CONCLUSION	B-UNK
:	O
The	O
frequency	B-UNK
of	O
mood	B-UNK
switching	B-UNK
associated	O
with	O
acute	B-UNK
antidepressant	B-UNK
therapy	O
may	O
be	O
reduced	B-UNK
by	O
lithium	B-CHEMICAL
treatment	B-UNK
.	O
Particular	O
attention	B-UNK
should	O
be	O
paid	O
to	O
patients	B-UNK
with	O
a	O
hyperthymic	O
temperament	O
,	O
who	O
have	O
a	O
greater	B-UNK
risk	B-UNK
of	O
mood	B-UNK
switches	O
.	O

Caffeine	B-UNK
-	O
induced	O
cardiac	B-DISEASE
arrhythmia	I-DISEASE
:	O
an	O
unrecognised	O
danger	O
of	O
healthfood	O
products	B-UNK
.	O
We	O
describe	O
a	O
25-year	O
-	O
old	O
woman	B-UNK
with	O
pre	B-UNK
-	O
existing	B-UNK
mitral	B-DISEASE
valve	I-DISEASE
prolapse	I-DISEASE
who	O
developed	O
intractable	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
after	O
consuming	O
a	O
"	O
natural	B-UNK
energy	O
"	O
guarana	O
health	B-UNK
drink	O
containing	O
a	O
high	B-UNK
concentration	B-UNK
of	O
caffeine	B-CHEMICAL
.	O
This	O
case	B-UNK
highlights	O
the	O
need	O
for	O
adequate	B-UNK
labelling	O
and	O
regulation	B-UNK
of	O
such	O
products	B-UNK
.	O

Bladder	B-UNK
retention	B-UNK
of	O
urine	B-UNK
as	O
a	O
result	B-UNK
of	O
continuous	B-UNK
intravenous	B-UNK
infusion	B-UNK
of	O
fentanyl	B-UNK
:	O
2	O
case	B-UNK
reports	I-UNK
.	O
Sedation	B-UNK
has	O
been	O
commonly	B-UNK
used	O
in	O
the	O
neonate	O
to	O
decrease	B-UNK
the	O
stress	B-DISEASE
and	O
pain	B-UNK
from	O
the	O
noxious	O
stimuli	B-UNK
and	O
invasive	B-UNK
procedures	B-UNK
in	O
the	O
neonatal	B-UNK
intensive	B-UNK
care	I-UNK
unit	I-UNK
,	O
as	O
well	O
as	O
to	O
facilitate	O
synchrony	O
between	O
ventilator	O
and	O
spontaneous	B-UNK
breaths	O
.	O
Fentanyl	B-UNK
,	O
an	O
opioid	B-UNK
analgesic	B-UNK
,	O
is	O
frequently	B-UNK
used	O
in	O
the	O
neonatal	B-UNK
intensive	B-UNK
care	I-UNK
unit	I-UNK
setting	B-UNK
for	O
these	O
very	O
purposes	O
.	O
Various	O
reported	B-UNK
side	O
effects	O
of	O
fentanyl	B-CHEMICAL
administration	O
include	O
chest	B-DISEASE
wall	I-DISEASE
rigidity	I-DISEASE
,	O
hypotension	B-UNK
,	O
respiratory	B-DISEASE
depression	I-DISEASE
,	O
and	O
bradycardia	B-DISEASE
.	O
Here	O
,	O
2	O
cases	B-UNK
of	O
urinary	B-UNK
bladder	I-UNK
retention	B-UNK
leading	B-UNK
to	O
renal	B-UNK
pelvocalyceal	O
dilatation	O
mimicking	O
hydronephrosis	B-DISEASE
as	O
a	O
result	B-UNK
of	O
continuous	B-UNK
infusion	I-UNK
of	O
fentanyl	B-CHEMICAL
are	O
reported	B-UNK
.	O

Combined	B-UNK
antiretroviral	O
therapy	O
causes	O
cardiomyopathy	B-UNK
and	O
elevates	O
plasma	B-UNK
lactate	B-UNK
in	O
transgenic	B-UNK
AIDS	B-UNK
mice	B-UNK
.	O
Highly	B-UNK
active	B-UNK
antiretroviral	O
therapy	O
(	O
HAART	B-UNK
)	O
is	O
implicated	B-UNK
in	O
cardiomyopathy	B-DISEASE
(	O
CM	B-UNK
)	O
and	O
in	O
elevated	B-UNK
plasma	B-UNK
lactate	B-UNK
(	O
LA	O
)	O
in	O
AIDS	B-UNK
through	O
mechanisms	B-UNK
of	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
.	O
To	O
determine	B-UNK
mitochondrial	B-UNK
events	B-UNK
from	O
HAART	B-UNK
in	O
vivo	B-UNK
,	O
8-week	O
-	O
old	O
hemizygous	O
transgenic	B-UNK
AIDS	B-DISEASE
mice	B-UNK
(	O
NL4	O
-	O
3Delta	O
gag	O
/	O
pol	O
;	O
TG	B-UNK
)	O
and	O
wild	O
-	O
type	B-UNK
FVB	O
/	O
n	O
littermates	O
were	O
treated	O
with	O
the	O
HAART	B-UNK
combination	B-UNK
of	O
zidovudine	B-UNK
,	O
lamivudine	B-CHEMICAL
,	O
and	O
indinavir	B-UNK
or	O
vehicle	B-UNK
control	B-UNK
for	O
10	O
days	B-UNK
or	O
35	O
days	B-UNK
.	O
At	O
termination	O
of	O
the	O
experiments	B-UNK
,	O
mice	B-UNK
underwent	O
echocardiography	B-UNK
,	O
quantitation	O
of	O
abundance	B-UNK
of	O
molecular	B-UNK
markers	B-UNK
of	O
CM	B-UNK
(	O
ventricular	B-UNK
mRNA	B-UNK
encoding	O
atrial	B-CHEMICAL
natriuretic	I-CHEMICAL
factor	I-CHEMICAL
[	O
ANF	B-CHEMICAL
]	O
and	O
sarcoplasmic	O
calcium	B-CHEMICAL
ATPase	B-UNK
[	O
SERCA2	O
]	O
)	O
,	O
and	O
determination	B-UNK
of	O
plasma	B-UNK
LA	O
.	O
Myocardial	B-UNK
histologic	B-UNK
features	B-UNK
were	O
analyzed	O
semiquantitatively	O
and	O
results	B-UNK
were	O
confirmed	B-UNK
by	O
transmission	B-UNK
electron	B-UNK
microscopy	I-UNK
.	O
After	O
35	O
days	B-UNK
in	O
the	O
TG	B-UNK
+	O
HAART	B-UNK
cohort	B-UNK
,	O
left	B-UNK
ventricular	I-UNK
mass	B-UNK
increased	B-UNK
160	O
%	O
by	O
echocardiography	B-UNK
.	O
Molecularly	O
,	O
ANF	B-CHEMICAL
mRNA	B-UNK
increased	B-UNK
250	O
%	O
and	O
SERCA2	O
mRNA	B-UNK
decreased	B-UNK
57	O
%	O
.	O
Biochemically	O
,	O
LA	O
was	O
elevated	B-UNK
(	O
8.5	O
+	O
/-	O
2.0	O
mM	B-UNK
)	O
.	O
Pathologically	O
,	O
granular	O
cytoplasmic	B-UNK
changes	O
were	O
found	O
in	O
cardiac	B-UNK
myocytes	B-UNK
,	O
indicating	O
enlarged	O
,	O
damaged	O
mitochondria	B-UNK
.	O
Findings	B-UNK
were	O
confirmed	B-UNK
ultrastructurally	O
.	O
No	O
changes	O
were	O
found	O
in	O
other	O
cohorts	O
.	O
After	O
10	O
days	B-UNK
,	O
only	O
ANF	B-CHEMICAL
was	O
elevated	B-UNK
,	O
and	O
only	O
in	O
the	O
TG	B-UNK
+	O
HAART	B-UNK
cohort	B-UNK
.	O
Results	B-UNK
show	O
that	O
cumulative	B-UNK
HAART	B-UNK
caused	B-UNK
mitochondrial	B-UNK
CM	B-UNK
with	O
elevated	B-UNK
LA	O
in	O
AIDS	B-DISEASE
transgenic	B-UNK
mice	B-UNK
.	O

Oral	B-UNK
contraceptives	I-UNK
and	O
the	O
risk	B-UNK
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
.	O
BACKGROUND	B-UNK
:	O
An	O
association	B-UNK
between	O
the	O
use	O
of	O
oral	B-UNK
contraceptives	I-UNK
and	O
the	O
risk	B-UNK
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
has	O
been	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
studies	B-UNK
.	O
We	O
investigated	B-UNK
this	O
association	B-UNK
,	O
according	O
to	O
the	O
type	B-UNK
of	O
progestagen	O
included	B-UNK
in	O
third	O
-	O
generation	B-UNK
(	O
i.e	B-UNK
.	O
,	O
desogestrel	B-CHEMICAL
or	O
gestodene	O
)	O
and	O
second	O
-	O
generation	B-UNK
(	O
i.e	B-UNK
.	O
,	O
levonorgestrel	O
)	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
,	O
the	O
dose	B-UNK
of	O
estrogen	B-CHEMICAL
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
prothrombotic	O
mutations	B-UNK
METHODS	B-UNK
:	O
In	O
a	O
nationwide	O
,	O
population	B-UNK
-	O
based	B-UNK
,	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
,	O
we	O
identified	B-UNK
and	O
enrolled	O
248	O
women	B-UNK
18	O
through	O
49	O
years	B-UNK
of	I-UNK
age	I-UNK
who	O
had	O
had	O
a	O
first	O
myocardial	B-DISEASE
infarction	I-DISEASE
between	O
1990	O
and	O
1995	O
and	O
925	O
control	B-UNK
women	B-UNK
who	O
had	O
not	O
had	O
a	O
myocardial	B-UNK
infarction	I-UNK
and	O
who	O
were	O
matched	O
for	O
age	B-UNK
,	O
calendar	O
year	O
of	O
the	O
index	B-UNK
event	B-UNK
,	O
and	O
area	B-UNK
of	O
residence	O
.	O
Subjects	B-UNK
supplied	O
information	B-UNK
on	O
oral	B-UNK
-	O
contraceptive	O
use	O
and	O
major	B-UNK
cardiovascular	B-UNK
risk	B-UNK
factors	I-UNK
.	O
An	O
analysis	B-UNK
for	O
factor	B-CHEMICAL
V	I-CHEMICAL
Leiden	I-CHEMICAL
and	O
the	O
G20210A	O
mutation	B-UNK
in	O
the	O
prothrombin	O
gene	B-UNK
was	O
conducted	B-UNK
in	O
217	O
patients	B-UNK
and	O
763	O
controls	B-UNK
RESULTS	B-UNK
:	O
The	O
odds	B-UNK
ratio	I-UNK
for	O
myocardial	B-DISEASE
infarction	I-DISEASE
among	O
women	B-UNK
who	O
used	O
any	O
type	B-UNK
of	O
combined	B-UNK
oral	B-CHEMICAL
contraceptive	I-CHEMICAL
,	O
as	O
compared	O
with	O
nonusers	O
,	O
was	O
2.0	O
(	O
95	B-UNK
percent	I-UNK
confidence	I-UNK
interval	I-UNK
,	O
1.5	O
to	O
2.8	O
)	O
.	O
The	O
adjusted	B-UNK
odds	B-UNK
ratio	I-UNK
was	O
2.5	O
(	O
95	B-UNK
percent	I-UNK
confidence	I-UNK
interval	I-UNK
,	O
1.5	O
to	O
4.1	O
)	O
among	O
women	B-UNK
who	O
used	O
second	O
-	O
generation	B-UNK
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
and	O
1.3	O
(	O
95	B-UNK
percent	I-UNK
confidence	I-UNK
interval	I-UNK
,	O
0.7	O
to	O
2.5	O
)	O
among	O
those	O
who	O
used	O
third	O
-	O
generation	B-UNK
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
.	O
Among	O
women	B-UNK
who	O
used	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
,	O
the	O
odds	B-UNK
ratio	I-UNK
was	O
2.1	O
(	O
95	B-UNK
percent	I-UNK
confidence	I-UNK
interval	I-UNK
,	O
1.5	O
to	O
3.0	O
)	O
for	O
those	O
without	O
a	O
prothrombotic	O
mutation	B-UNK
and	O
1.9	O
(	O
95	B-UNK
percent	I-UNK
confidence	I-UNK
interval	I-UNK
,	O
0.6	O
to	O
5.5	O
)	O
for	O
those	O
with	O
a	O
mutation	B-UNK
CONCLUSIONS	B-UNK
:	O
The	O
risk	B-UNK
of	O
myocardial	B-UNK
infarction	I-UNK
was	O
increased	B-UNK
among	O
women	B-UNK
who	O
used	O
second	O
-	O
generation	B-UNK
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
.	O
The	O
results	B-UNK
with	O
respect	B-UNK
to	O
the	O
use	O
of	O
third	O
-	O
generation	B-UNK
oral	B-UNK
contraceptives	I-UNK
were	O
inconclusive	O
but	O
suggested	B-UNK
that	O
the	O
risk	B-UNK
was	O
lower	B-UNK
than	O
the	O
risk	B-UNK
associated	O
with	O
second	O
-	O
generation	B-UNK
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
.	O
The	O
risk	B-UNK
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
was	O
similar	B-UNK
among	O
women	B-UNK
who	O
used	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
whether	O
or	O
not	O
they	O
had	O
a	O
prothrombotic	O
mutation	B-UNK
.	O

Effects	O
of	O
5-HT1B	O
receptor	B-UNK
ligands	B-UNK
microinjected	O
into	O
the	O
accumbal	O
shell	O
or	O
core	B-UNK
on	O
the	O
cocaine	B-UNK
-	O
induced	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
in	O
rats	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
designed	B-UNK
to	O
examine	B-UNK
the	O
effect	B-UNK
of	O
5-HT1B	O
receptor	B-UNK
ligands	B-UNK
microinjected	O
into	O
the	O
subregions	O
of	O
the	O
nucleus	B-UNK
accumbens	B-UNK
(	O
the	O
shell	O
and	O
the	O
core	B-UNK
)	O
on	O
the	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
induced	O
by	O
cocaine	B-CHEMICAL
in	O
rats	B-UNK
.	O
Male	B-UNK
Wistar	I-UNK
rats	I-UNK
were	O
implanted	B-UNK
bilaterally	B-UNK
with	O
cannulae	O
into	O
the	O
accumbens	B-UNK
shell	O
or	O
core	B-UNK
,	O
and	O
then	O
were	O
locally	O
injected	B-UNK
with	O
GR	B-UNK
55562	O
(	O
an	O
antagonist	B-UNK
of	O
5-HT1B	O
receptors	B-UNK
)	O
or	O
CP	B-DISEASE
93129	O
(	O
an	O
agonist	B-UNK
of	O
5-HT1B	O
receptors	B-UNK
)	O
.	O
Given	O
alone	O
to	O
any	O
accumbal	O
subregion	O
,	O
GR	B-UNK
55562	O
(	O
0.1	O
-	O
10	O
microg	B-UNK
/	O
side	O
)	O
or	O
CP	B-UNK
93129	O
(	O
0.1	O
-	O
10	O
microg	B-UNK
/	O
side	O
)	O
did	O
not	O
change	B-UNK
basal	B-UNK
locomotor	B-UNK
activity	I-UNK
.	O
Systemic	B-UNK
cocaine	B-CHEMICAL
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
)	O
significantly	B-UNK
increased	B-UNK
the	O
locomotor	B-UNK
activity	I-UNK
of	O
rats	B-UNK
.	O
GR	B-UNK
55562	O
(	O
0.1	O
-	O
10	O
microg	B-UNK
/	O
side	O
)	O
,	O
administered	O
intra-accumbens	O
shell	O
prior	B-UNK
to	O
cocaine	B-UNK
,	O
dose	B-UNK
-	O
dependently	B-UNK
attenuated	B-UNK
the	O
psychostimulant	O
-	O
induced	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
.	O
Such	O
attenuation	O
was	O
not	O
found	O
in	O
animals	B-UNK
which	O
had	O
been	O
injected	B-UNK
with	O
GR	B-UNK
55562	O
into	O
the	O
accumbens	B-UNK
core	B-UNK
.	O
When	O
injected	B-UNK
into	O
the	O
accumbens	B-UNK
shell	O
(	O
but	O
not	O
the	O
core	B-UNK
)	O
before	O
cocaine	B-CHEMICAL
,	O
CP	B-UNK
93129	O
(	O
0.1	O
-	O
10	O
microg	B-UNK
/	O
side	O
)	O
enhanced	B-UNK
the	O
locomotor	B-UNK
response	B-UNK
to	O
cocaine	B-UNK
;	O
the	O
maximum	B-UNK
effect	B-UNK
being	O
observed	O
after	O
10	O
microg	B-UNK
/	O
side	O
of	O
the	O
agonist	B-UNK
.	O
The	O
later	O
enhancement	B-UNK
was	O
attenuated	B-UNK
after	O
intra-accumbens	O
shell	O
treatment	B-UNK
with	O
GR	B-UNK
55562	O
(	O
1	O
microg	B-UNK
/	O
side	O
)	O
.	O
Our	O
findings	B-UNK
indicate	O
that	O
cocaine	B-UNK
induced	O
hyperlocomotion	O
is	O
modified	B-UNK
by	O
5-HT1B	O
receptor	B-UNK
ligands	B-UNK
microinjected	O
into	O
the	O
accumbens	B-UNK
shell	O
,	O
but	O
not	O
core	B-UNK
,	O
this	O
modification	O
consisting	O
in	O
inhibitory	B-UNK
and	O
facilitatory	O
effects	O
of	O
the	O
5-HT1B	O
receptor	B-UNK
antagonist	I-UNK
(	O
GR	B-UNK
55562	O
)	O
and	O
agonist	B-UNK
(	O
CP	B-UNK
93129	O
)	O
,	O
respectively	O
.	O
In	O
other	O
words	B-UNK
,	O
the	O
present	B-UNK
results	B-UNK
suggest	B-UNK
that	O
the	O
accumbal	O
shell	O
5-HT1B	O
receptors	B-UNK
play	O
a	O
permissive	O
role	O
in	O
the	O
behavioural	O
response	B-UNK
to	O
the	O
psychostimulant	O
.	O

Ticlopidine	B-UNK
-	O
induced	O
cholestatic	B-UNK
hepatitis	I-UNK
.	O
OBJECTIVE	B-UNK
:	O
To	O
report	B-UNK
2	O
cases	B-UNK
of	O
ticlopidine	B-CHEMICAL
-	O
induced	O
cholestatic	B-UNK
hepatitis	I-UNK
,	O
investigate	B-UNK
its	O
mechanism	B-UNK
,	O
and	O
compare	B-UNK
the	O
observed	O
main	B-UNK
characteristics	B-UNK
with	O
those	O
of	O
the	O
published	B-UNK
cases	B-UNK
.	O
CASE	B-UNK
SUMMARIES	O
:	O
Two	O
patients	B-UNK
developed	O
prolonged	B-UNK
cholestatic	B-UNK
hepatitis	I-UNK
after	O
receiving	B-UNK
ticlopidine	B-UNK
following	O
percutaneous	B-UNK
coronary	B-UNK
angioplasty	O
,	O
with	O
complete	B-UNK
remission	I-UNK
during	O
the	O
follow	O
-	O
up	O
period	B-UNK
.	O
T	O
-	O
cell	B-UNK
stimulation	B-UNK
by	O
therapeutic	B-UNK
concentration	B-UNK
of	O
ticlopidine	B-CHEMICAL
was	O
demonstrated	O
in	O
vitro	B-UNK
in	O
the	O
patients	B-UNK
,	O
but	O
not	O
in	O
healthy	B-UNK
controls	B-UNK
.	O
DISCUSSION	B-UNK
:	O
Cholestatic	B-UNK
hepatitis	I-UNK
is	O
a	O
rare	B-UNK
complication	B-UNK
of	O
the	O
antiplatelet	O
agent	B-UNK
ticlopidine	B-CHEMICAL
;	O
several	O
cases	B-UNK
have	O
been	O
reported	B-UNK
but	O
few	O
in	O
the	O
English	O
literature	B-UNK
.	O
Our	O
patients	B-UNK
developed	O
jaundice	B-UNK
following	O
treatment	B-UNK
with	O
ticlopidine	B-UNK
and	O
showed	O
the	O
clinical	B-UNK
and	O
laboratory	B-UNK
characteristics	B-UNK
of	O
cholestatic	B-UNK
hepatitis	I-UNK
,	O
which	O
resolved	O
after	O
discontinuation	B-UNK
of	O
the	O
drug	B-UNK
.	O
Hepatitis	B-UNK
may	O
develop	B-UNK
weeks	B-UNK
after	O
discontinuation	B-UNK
of	O
the	O
drug	B-UNK
and	O
may	O
run	O
a	O
prolonged	B-UNK
course	O
,	O
but	O
complete	B-UNK
remission	I-UNK
was	O
observed	O
in	O
all	O
reported	B-UNK
cases	B-UNK
.	O
An	O
objective	B-UNK
causality	O
assessment	B-UNK
revealed	O
that	O
the	O
adverse	B-UNK
drug	B-UNK
event	B-UNK
was	O
probably	O
related	O
to	O
the	O
use	O
of	O
ticlopidine	B-UNK
.	O
The	O
mechanisms	B-UNK
of	O
this	O
ticlopidine	B-UNK
-	O
induced	O
cholestasis	B-DISEASE
are	O
unclear	O
.	O
Immune	B-UNK
mechanisms	B-UNK
may	O
be	O
involved	B-UNK
in	O
the	O
drug'	O
s	O
hepatotoxicity	B-UNK
,	O
as	O
suggested	B-UNK
by	O
the	O
T	O
-	O
cell	B-UNK
stimulation	B-UNK
study	B-UNK
reported	B-UNK
here	O
.	O
CONCLUSIONS	B-UNK
:	O
Cholestatic	B-UNK
hepatitis	I-UNK
is	O
a	O
rare	B-UNK
adverse	B-UNK
effect	I-UNK
of	O
ticlopidine	B-CHEMICAL
that	O
may	O
be	O
immune	B-UNK
mediated	B-UNK
.	O
Patients	B-UNK
receiving	B-UNK
the	O
drug	B-UNK
should	O
be	O
monitored	O
with	O
liver	B-UNK
function	I-UNK
tests	I-UNK
along	O
with	O
complete	B-UNK
blood	B-UNK
cell	B-UNK
counts	B-UNK
.	O
This	O
complication	B-UNK
will	O
be	O
observed	O
even	O
less	O
often	O
in	O
the	O
future	B-UNK
as	O
ticlopidine	B-CHEMICAL
is	O
being	O
replaced	O
by	O
the	O
newer	O
antiplatelet	O
agent	B-UNK
clopidogrel	B-CHEMICAL
.	O

Epithelial	B-UNK
sodium	B-UNK
channel	I-UNK
(	O
ENaC	B-UNK
)	O
subunit	O
mRNA	B-UNK
and	O
protein	B-UNK
expression	I-UNK
in	O
rats	B-UNK
with	O
puromycin	B-UNK
aminonucleoside	I-UNK
-	O
induced	O
nephrotic	B-UNK
syndrome	I-UNK
.	O
In	O
experimental	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
,	O
urinary	B-UNK
sodium	B-UNK
excretion	B-UNK
is	O
decreased	B-UNK
during	O
the	O
early	B-UNK
phase	B-UNK
of	O
the	O
disease	B-UNK
.	O
The	O
molecular	B-UNK
mechanism(s	O
)	O
leading	B-UNK
to	O
salt	B-CHEMICAL
retention	B-UNK
has	O
not	O
been	O
completely	O
elucidated	O
.	O
The	O
rate	B-UNK
-	O
limiting	B-UNK
constituent	O
of	O
collecting	O
duct	B-UNK
sodium	B-CHEMICAL
transport	B-UNK
is	O
the	O
epithelial	B-UNK
sodium	B-UNK
channel	I-UNK
(	O
ENaC	B-UNK
)	O
.	O
We	O
examined	B-UNK
the	O
abundance	B-UNK
of	O
ENaC	B-UNK
subunit	O
mRNAs	O
and	O
proteins	B-UNK
in	O
puromycin	B-UNK
aminonucleoside	I-UNK
(	O
PAN)-induced	O
nephrotic	B-UNK
syndrome	I-UNK
.	O
The	O
time	O
courses	B-UNK
of	O
urinary	B-UNK
sodium	B-UNK
excretion	B-UNK
,	O
plasma	B-UNK
aldosterone	B-UNK
concentration	B-UNK
and	O
proteinuria	B-DISEASE
were	O
studied	O
in	O
male	B-UNK
Sprague	O
-	O
Dawley	O
rats	B-UNK
treated	O
with	O
a	O
single	B-UNK
dose	B-UNK
of	O
either	O
PAN	B-UNK
or	O
vehicle	B-UNK
.	O
The	O
relative	B-UNK
amounts	B-UNK
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNAs	O
were	O
determined	B-UNK
in	O
kidneys	B-UNK
from	O
these	O
rats	B-UNK
by	O
real	B-UNK
-	O
time	O
quantitative	B-UNK
TaqMan	O
PCR	B-UNK
,	O
and	O
the	O
amounts	B-UNK
of	O
proteins	B-UNK
by	O
Western	B-UNK
blot	O
.	O
The	O
kinetics	O
of	O
urinary	B-UNK
sodium	B-UNK
excretion	B-UNK
and	O
the	O
appearance	B-UNK
of	O
proteinuria	B-UNK
were	O
comparable	O
with	O
those	O
reported	B-UNK
previously	B-UNK
.	O
Sodium	B-CHEMICAL
retention	B-UNK
occurred	B-UNK
on	O
days	B-UNK
2	O
,	O
3	O
and	O
6	O
after	O
PAN	B-UNK
injection	B-UNK
.	O
A	O
significant	B-UNK
up	O
-	O
regulation	B-UNK
of	O
alphaENaC	O
and	O
betaENaC	O
mRNA	B-UNK
abundance	B-UNK
on	O
days	B-UNK
1	O
and	O
2	O
preceded	B-UNK
sodium	B-CHEMICAL
retention	B-UNK
on	O
days	B-UNK
2	O
and	O
3	O
.	O
Conversely	O
,	O
down	O
-	O
regulation	B-UNK
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
mRNA	B-UNK
expression	B-UNK
on	O
day	O
3	O
occurred	B-UNK
in	O
the	O
presence	O
of	O
high	B-UNK
aldosterone	B-UNK
concentrations	B-UNK
,	O
and	O
was	O
followed	O
by	O
a	O
return	B-UNK
of	O
sodium	B-CHEMICAL
excretion	B-UNK
to	O
control	B-UNK
values	O
.	O
The	O
amounts	B-UNK
of	O
alphaENaC	O
,	O
betaENaC	O
and	O
gammaENaC	O
proteins	B-UNK
were	O
not	O
increased	B-UNK
during	O
PAN	B-UNK
-	O
induced	O
sodium	B-UNK
retention	B-UNK
.	O
In	O
conclusion	B-UNK
,	O
ENaC	B-UNK
mRNA	B-UNK
expression	B-UNK
,	O
especially	O
alphaENaC	O
,	O
is	O
increased	B-UNK
in	O
the	O
very	O
early	B-UNK
phase	B-UNK
of	O
the	O
experimental	B-UNK
model	B-UNK
of	O
PAN	B-UNK
-	O
induced	O
nephrotic	B-UNK
syndrome	I-UNK
in	O
rats	B-UNK
,	O
but	O
appears	B-UNK
to	O
escape	B-UNK
from	O
the	O
regulation	B-UNK
by	O
aldosterone	B-UNK
after	O
day	O
3	O
.	O

NO	O
-	O
induced	O
migraine	B-UNK
attack	I-UNK
:	O
strong	B-UNK
increase	B-UNK
in	O
plasma	B-UNK
calcitonin	B-UNK
gene	B-UNK
-	O
related	O
peptide	B-UNK
(	O
CGRP	B-UNK
)	O
concentration	B-UNK
and	O
negative	B-UNK
correlation	B-UNK
with	O
platelet	B-UNK
serotonin	B-CHEMICAL
release	B-UNK
.	O
The	O
aim	B-UNK
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
investigate	B-UNK
changes	O
in	O
the	O
plasma	B-UNK
calcitonin	B-UNK
gene	B-UNK
-	O
related	O
peptide	B-UNK
(	O
CGRP	B-UNK
)	O
concentration	B-UNK
and	O
platelet	B-UNK
serotonin	B-UNK
(	O
5-hydroxytriptamine	B-CHEMICAL
,	O
5-HT	B-CHEMICAL
)	O
content	B-UNK
during	O
the	O
immediate	O
headache	B-DISEASE
and	O
the	O
delayed	B-UNK
genuine	O
migraine	B-UNK
attack	I-UNK
provoked	O
by	O
nitroglycerin	B-UNK
.	O
Fifteen	O
female	B-UNK
migraineurs	O
(	O
without	O
aura	B-UNK
)	O
and	O
eight	O
controls	B-UNK
participated	O
in	O
the	O
study	B-UNK
.	O
Sublingual	O
nitroglycerin	B-CHEMICAL
(	O
0.5	O
mg	B-UNK
)	O
was	O
administered	O
.	O
Blood	B-UNK
was	O
collected	O
from	O
the	O
antecubital	O
vein	B-UNK
four	O
times	B-UNK
:	O
60	O
min	B-UNK
before	O
and	O
after	O
the	O
nitroglycerin	B-CHEMICAL
application	B-UNK
,	O
and	O
60	O
and	O
120	O
min	B-UNK
after	O
the	O
beginning	B-UNK
of	O
the	O
migraine	B-UNK
attack	I-UNK
(	O
mean	O
344	O
and	O
404	O
min	B-UNK
;	O
12	O
subjects	B-UNK
)	O
.	O
In	O
those	O
subjects	B-UNK
who	O
had	O
no	O
migraine	B-UNK
attack	I-UNK
(	O
11	O
subjects	B-UNK
)	O
a	O
similar	B-UNK
time	O
schedule	B-UNK
was	O
used	O
.	O
Plasma	B-UNK
CGRP	B-CHEMICAL
concentration	B-UNK
increased	B-UNK
significantly	B-UNK
(	O
P<0.01	O
)	O
during	O
the	O
migraine	B-UNK
attack	I-UNK
and	O
returned	B-UNK
to	O
baseline	B-UNK
after	O
the	O
cessation	B-UNK
of	O
the	O
migraine	B-UNK
.	O
In	O
addition	B-UNK
,	O
both	O
change	B-UNK
and	O
peak	B-UNK
,	O
showed	O
significant	B-UNK
positive	B-UNK
correlations	O
with	O
migraine	B-UNK
headache	B-DISEASE
intensity	B-UNK
(	O
P<0.001	O
)	O
.	O
However	O
,	O
plasma	B-UNK
CGRP	B-UNK
concentrations	B-UNK
failed	B-UNK
to	O
change	B-UNK
during	O
immediate	O
headache	B-UNK
and	O
in	O
the	O
subjects	B-UNK
with	O
no	O
migraine	B-UNK
attack	I-UNK
.	O
Basal	B-UNK
CGRP	B-CHEMICAL
concentration	B-UNK
was	O
significantly	B-UNK
higher	I-UNK
and	O
platelet	B-UNK
5-HT	B-CHEMICAL
content	B-UNK
tended	O
to	O
be	O
lower	B-UNK
in	O
subjects	B-UNK
who	O
experienced	B-UNK
a	O
migraine	B-UNK
attack	I-UNK
.	O
Platelet	B-UNK
serotonin	B-UNK
content	B-UNK
decreased	B-UNK
significantly	B-UNK
(	O
P<0.01	O
)	O
after	O
nitroglycerin	B-UNK
in	O
subjects	B-UNK
with	O
no	O
migraine	B-UNK
attack	I-UNK
but	O
no	O
consistent	B-UNK
change	B-UNK
was	O
observed	O
in	O
patients	B-UNK
with	O
migraine	B-UNK
attack	I-UNK
.	O
In	O
conclusion	B-UNK
,	O
the	O
fact	B-UNK
that	O
plasma	B-UNK
CGRP	B-UNK
concentration	B-UNK
correlates	B-UNK
with	O
the	O
timing	O
and	O
severity	B-UNK
of	O
a	O
migraine	B-DISEASE
headache	B-UNK
suggests	O
a	O
direct	B-UNK
relationship	B-UNK
between	O
CGRP	B-CHEMICAL
and	O
migraine	B-UNK
.	O
In	O
contrast	B-UNK
,	O
serotonin	B-UNK
release	B-UNK
from	O
platelets	O
does	O
not	O
provoke	O
migraine	B-UNK
,	O
it	O
may	O
even	O
counteract	O
the	O
headache	B-DISEASE
and	O
the	O
concomitant	B-UNK
CGRP	B-CHEMICAL
release	B-UNK
in	O
this	O
model	B-UNK
.	O

Coronary	B-DISEASE
aneurysm	I-DISEASE
after	O
implantation	O
of	O
a	O
paclitaxel	B-UNK
-	O
eluting	O
stent	O
.	O
Formation	B-UNK
of	O
coronary	B-DISEASE
aneurysm	I-DISEASE
is	O
a	O
rare	B-UNK
complication	B-UNK
of	O
stenting	O
with	O
bare	O
metal	O
stents	O
,	O
but	O
based	B-UNK
on	O
experimental	B-UNK
studies	B-UNK
drug	B-UNK
-	O
eluting	O
stents	O
may	O
induce	B-UNK
toxic	B-UNK
effects	I-UNK
on	O
the	O
vessel	O
wall	B-UNK
with	O
incomplete	O
stent	O
apposition	O
,	O
aneurysm	B-UNK
formation	B-UNK
and	O
with	O
the	O
potential	B-UNK
of	O
stent	O
thrombosis	B-DISEASE
or	O
vessel	O
rupture	B-DISEASE
.	O
We	O
present	B-UNK
a	O
43-year	O
-	O
old	O
man	B-UNK
who	O
developed	O
a	O
coronary	B-DISEASE
aneurysm	I-DISEASE
in	O
the	O
right	O
coronary	B-UNK
artery	I-UNK
6	O
months	B-UNK
after	O
receiving	B-UNK
a	O
paclitaxel	B-UNK
-	O
eluting	O
stent	O
.	O
The	O
patient	B-UNK
was	O
asymptomatic	O
and	O
the	O
aneurysm	B-UNK
was	O
detected	B-UNK
in	O
a	O
routine	B-UNK
control	B-UNK
.	O
Angiography	B-UNK
and	O
intracoronary	B-UNK
ultrasound	B-UNK
demonstrated	O
lack	B-UNK
of	O
contact	O
between	O
stent	O
and	O
vessel	O
wall	B-UNK
in	O
a	O
15-mm	O
long	B-UNK
segment	B-UNK
with	O
maximal	B-UNK
aneurysm	B-UNK
diameter	B-UNK
of	O
6.0	O
mm	B-UNK
.	O
The	O
patient	B-UNK
was	O
successfully	O
treated	O
with	O
a	O
graft	B-UNK
stent	O
.	O

Behavioral	B-UNK
effects	O
of	O
urotensin	O
-	O
II	B-UNK
centrally	B-UNK
administered	O
in	O
mice	B-UNK
.	O
Urotensin	O
-	O
II	B-UNK
(	O
U	O
-	O
II	B-UNK
)	O
receptors	B-UNK
are	O
widely	B-UNK
distributed	O
in	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
.	O
Intracerebroventricular	O
(	O
i.c.v	B-UNK
.	O
)	O
injection	B-UNK
of	O
U	O
-	O
II	B-UNK
causes	O
hypertension	B-UNK
and	O
bradycardia	B-UNK
and	O
stimulates	O
prolactin	B-UNK
and	O
thyrotropin	B-CHEMICAL
secretion	B-UNK
.	O
However	O
,	O
the	O
behavioral	B-UNK
effects	O
of	O
centrally	B-UNK
administered	O
U	O
-	O
II	B-UNK
have	O
received	O
little	O
attention	B-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
we	O
tested	B-UNK
the	O
effects	O
of	O
i.c.v	B-UNK
.	O
injections	B-UNK
of	O
U	O
-	O
II	B-UNK
on	O
behavioral	B-UNK
,	O
metabolic	B-UNK
,	O
and	O
endocrine	O
responses	O
in	O
mice	B-UNK
.	O
Administration	O
of	O
graded	O
doses	B-UNK
of	O
U	O
-	O
II	B-UNK
(	O
1	O
-	O
10,000	O
ng	B-UNK
/	O
mouse	B-UNK
)	O
provoked	O
:	O
(	O
1	O
)	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
reduction	O
in	O
the	O
number	B-UNK
of	O
head	B-UNK
dips	O
in	O
the	O
hole	O
-	O
board	O
test	B-UNK
;	O
(	O
2	O
)	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
reduction	O
in	O
the	O
number	B-UNK
of	O
entries	O
in	O
the	O
white	B-UNK
chamber	O
in	O
the	O
black	O
-	O
and	O
-	O
white	B-UNK
compartment	O
test	B-UNK
,	O
and	O
in	O
the	O
number	B-UNK
of	O
entries	O
in	O
the	O
central	B-UNK
platform	O
and	O
open	B-UNK
arms	O
in	O
the	O
plus	O
-	O
maze	B-UNK
test	B-UNK
;	O
and	O
(	O
3	O
)	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
increase	B-UNK
in	O
the	O
duration	B-UNK
of	O
immobility	O
in	O
the	O
forced	O
-	O
swimming	O
test	B-UNK
and	O
tail	B-UNK
suspension	O
test	B-UNK
.	O
Intracerebroventricular	O
injection	B-UNK
of	O
U	O
-	O
II	B-UNK
also	O
caused	B-UNK
an	O
increase	B-UNK
in	O
:	O
food	B-UNK
intake	B-UNK
at	O
doses	B-UNK
of	O
100	O
and	O
1,000	O
ng	B-UNK
/	O
mouse	B-UNK
,	O
water	B-UNK
intake	B-UNK
at	O
doses	B-UNK
of	O
100	O
-	O
10,000	O
ng	B-UNK
/	O
mouse	B-UNK
,	O
and	O
horizontal	O
locomotion	B-UNK
activity	B-UNK
at	O
a	O
dose	B-UNK
of	O
10,000	O
ng	B-UNK
/	O
mouse	B-UNK
.	O
Whatever	O
was	O
the	O
dose	B-UNK
,	O
the	O
central	B-UNK
administration	O
of	O
U	O
-	O
II	B-UNK
had	O
no	O
effect	B-UNK
on	O
body	B-UNK
temperature	B-UNK
,	O
nociception	O
,	O
apomorphine	B-UNK
-	O
induced	O
penile	B-UNK
erection	O
and	O
climbing	B-UNK
behavior	B-UNK
,	O
and	O
stress	B-DISEASE
-	O
induced	O
plasma	B-UNK
corticosterone	B-CHEMICAL
level	B-UNK
.	O
Taken	O
together	O
,	O
the	O
present	B-UNK
study	B-UNK
demonstrates	O
that	O
the	O
central	B-UNK
injection	B-UNK
of	O
U	O
-	O
II	B-UNK
at	O
doses	B-UNK
of	O
1	O
-	O
10,000	O
ng	B-UNK
/	O
mouse	B-UNK
induces	O
anxiogenic-	O
and	O
depressant	O
-	O
like	O
effects	O
in	O
mouse	B-UNK
.	O
These	O
data	B-UNK
suggest	I-UNK
that	O
U	O
-	O
II	B-UNK
may	O
be	O
involved	B-UNK
in	O
some	O
aspects	O
of	O
psychiatric	B-UNK
disorders	B-UNK
.	O

Recurrent	B-UNK
dysphonia	B-DISEASE
and	O
acitretin	O
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
woman	B-UNK
complaining	O
of	O
dysphonia	B-DISEASE
while	O
she	O
was	O
treated	O
by	O
acitretin	O
.	O
Her	O
symptoms	B-UNK
totally	O
regressed	O
after	O
drug	B-UNK
withdrawal	B-UNK
and	O
reappeared	O
when	O
acitretin	O
was	O
reintroduced	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	B-UNK
of	O
acitretin	O
-	O
induced	O
dysphonia	B-DISEASE
.	O
This	O
effect	B-UNK
may	O
be	O
related	O
to	O
the	O
pharmacological	B-UNK
effect	B-UNK
of	O
this	O
drug	B-UNK
on	O
mucous	O
membranes	B-UNK
.	O

Pharmacological	B-UNK
modulation	B-UNK
of	O
pain	B-UNK
-	O
related	O
brain	B-UNK
activity	B-UNK
during	O
normal	O
and	O
central	B-UNK
sensitization	B-UNK
states	B-UNK
in	O
humans	B-UNK
.	O
Abnormal	B-UNK
processing	O
of	O
somatosensory	O
inputs	O
in	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
(	O
central	B-UNK
sensitization	B-UNK
)	O
is	O
the	O
mechanism	B-UNK
accounting	O
for	O
the	O
enhanced	B-UNK
pain	B-UNK
sensitivity	B-UNK
in	O
the	O
skin	B-UNK
surrounding	O
tissue	B-UNK
injury	B-UNK
(	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
)	O
.	O
Secondary	B-UNK
hyperalgesia	I-UNK
shares	O
clinical	B-UNK
characteristics	B-UNK
with	O
neurogenic	O
hyperalgesia	B-DISEASE
in	O
patients	B-UNK
with	O
neuropathic	B-DISEASE
pain	I-DISEASE
.	O
Abnormal	B-UNK
brain	B-UNK
responses	O
to	O
somatosensory	O
stimuli	B-UNK
have	O
been	O
found	O
in	O
patients	B-UNK
with	O
hyperalgesia	B-UNK
as	O
well	O
as	O
in	O
normal	O
subjects	B-UNK
during	O
experimental	B-UNK
central	B-UNK
sensitization	B-UNK
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
assess	B-UNK
the	O
effects	O
of	O
gabapentin	B-CHEMICAL
,	O
a	O
drug	B-UNK
effective	B-UNK
in	O
neuropathic	B-DISEASE
pain	I-DISEASE
patients	B-UNK
,	O
on	O
brain	B-UNK
processing	O
of	O
nociceptive	B-UNK
information	B-UNK
in	O
normal	O
and	O
central	B-UNK
sensitization	B-UNK
states	B-UNK
.	O
Using	O
functional	B-UNK
magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
(	O
fMRI	O
)	O
in	O
normal	O
volunteers	B-UNK
,	O
we	O
studied	O
the	O
gabapentin	B-CHEMICAL
-	O
induced	O
modulation	B-UNK
of	O
brain	B-UNK
activity	B-UNK
in	O
response	B-UNK
to	O
nociceptive	B-UNK
mechanical	B-UNK
stimulation	B-UNK
of	O
normal	O
skin	B-UNK
and	O
capsaicin	B-UNK
-	O
induced	O
secondary	B-UNK
hyperalgesia	I-UNK
.	O
The	O
dose	B-UNK
of	O
gabapentin	B-CHEMICAL
was	O
1,800	O
mg	B-UNK
per	O
os	O
,	O
in	O
a	O
single	B-UNK
administration	O
.	O
We	O
found	O
that	O
(	O
i	O
)	O
gabapentin	B-CHEMICAL
reduced	B-UNK
the	O
activations	O
in	O
the	O
bilateral	B-UNK
operculoinsular	O
cortex	B-UNK
,	O
independently	O
of	O
the	O
presence	O
of	O
central	B-UNK
sensitization	B-UNK
;	O
(	O
ii	B-UNK
)	O
gabapentin	B-CHEMICAL
reduced	B-UNK
the	O
activation	B-UNK
in	O
the	O
brainstem	B-UNK
,	O
only	O
during	O
central	B-UNK
sensitization	B-UNK
;	O
(	O
iii	B-UNK
)	O
gabapentin	B-CHEMICAL
suppressed	O
stimulus	B-UNK
-	O
induced	O
deactivations	O
,	O
only	O
during	O
central	B-UNK
sensitization	B-UNK
;	O
this	O
effect	B-UNK
was	O
more	O
robust	O
than	O
the	O
effect	B-UNK
on	O
brain	B-UNK
activation	B-UNK
.	O
The	O
observed	O
drug	B-UNK
-	O
induced	O
effects	O
were	O
not	O
due	O
to	O
changes	O
in	O
the	O
baseline	B-UNK
fMRI	O
signal	B-UNK
.	O
These	O
findings	B-UNK
indicate	O
that	O
gabapentin	B-CHEMICAL
has	O
a	O
measurable	O
antinociceptive	B-UNK
effect	B-UNK
and	O
a	O
stronger	O
antihyperalgesic	O
effect	B-UNK
most	O
evident	O
in	O
the	O
brain	B-UNK
areas	B-UNK
undergoing	B-UNK
deactivation	O
,	O
thus	O
supporting	O
the	O
concept	O
that	O
gabapentin	B-CHEMICAL
is	O
more	O
effective	B-UNK
in	O
modulating	O
nociceptive	B-UNK
transmission	B-UNK
when	O
central	B-UNK
sensitization	B-UNK
is	O
present	B-UNK
.	O

MDMA	B-UNK
polydrug	B-UNK
users	B-UNK
show	O
process	O
-	O
specific	B-UNK
central	B-UNK
executive	O
impairments	B-UNK
coupled	O
with	O
impaired	B-UNK
social	B-UNK
and	O
emotional	B-UNK
judgement	O
processes	B-UNK
.	O
In	O
recent	B-UNK
years	B-UNK
working	B-UNK
memory	B-UNK
deficits	B-UNK
have	O
been	O
reported	B-UNK
in	O
users	B-UNK
of	O
MDMA	B-UNK
(	O
3,4-methylenedioxymethamphetamine	B-CHEMICAL
,	O
ecstasy	B-UNK
)	O
.	O
The	O
current	B-UNK
study	B-UNK
aimed	B-UNK
to	O
assess	B-UNK
the	O
impact	B-UNK
of	O
MDMA	B-UNK
use	O
on	O
three	O
separate	B-UNK
central	B-UNK
executive	O
processes	B-UNK
(	O
set	O
shifting	O
,	O
inhibition	B-UNK
and	O
memory	B-UNK
updating	O
)	O
and	O
also	O
on	O
"	O
prefrontal	O
"	O
mediated	B-UNK
social	B-UNK
and	O
emotional	B-UNK
judgement	O
processes	B-UNK
.	O
Fifteen	O
polydrug	B-UNK
ecstasy	B-UNK
users	I-UNK
and	O
15	O
polydrug	B-UNK
non-ecstasy	O
user	O
controls	B-UNK
completed	O
a	O
general	B-UNK
drug	B-UNK
use	O
questionnaire	B-UNK
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	B-UNK
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	B-UNK
(	O
memory	B-UNK
updating	O
)	O
,	O
Inhibition	B-UNK
of	O
Return	B-UNK
(	O
inhibition	B-UNK
)	O
,	O
an	O
emotional	B-UNK
intelligence	O
scale	B-UNK
,	O
the	O
Tromso	O
Social	B-UNK
Intelligence	O
Scale	B-UNK
and	O
the	O
Dysexecutive	O
Questionnaire	B-UNK
(	O
DEX	B-CHEMICAL
)	O
.	O
Compared	O
with	O
MDMA	B-UNK
-	O
free	B-UNK
polydrug	B-UNK
controls	B-UNK
,	O
MDMA	B-UNK
polydrug	B-UNK
users	B-UNK
showed	O
impairments	B-UNK
in	O
set	O
shifting	O
and	O
memory	B-UNK
updating	O
,	O
and	O
also	O
in	O
social	B-UNK
and	O
emotional	B-UNK
judgement	O
processes	B-UNK
.	O
The	O
latter	O
two	O
deficits	B-UNK
remained	B-UNK
significant	B-UNK
after	O
controlling	B-UNK
for	O
other	O
drug	B-UNK
use	O
.	O
These	O
data	B-UNK
lend	O
further	O
support	B-UNK
to	O
the	O
proposal	O
that	O
cognitive	B-UNK
processes	B-UNK
mediated	B-UNK
by	O
the	O
prefrontal	O
cortex	B-UNK
may	O
be	O
impaired	B-UNK
by	O
recreational	B-UNK
ecstasy	B-UNK
use	O
.	O

Severe	B-UNK
citrate	B-UNK
toxicity	B-DISEASE
complicating	O
volunteer	O
apheresis	O
platelet	B-UNK
donation	O
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
severe	B-UNK
citrate	B-UNK
toxicity	B-UNK
during	O
volunteer	O
donor	B-UNK
apheresis	O
platelet	B-UNK
collection	B-UNK
.	O
The	O
donor	B-UNK
was	O
a	O
40-year	O
-	O
old	O
female	B-UNK
,	O
first	O
-	O
time	O
apheresis	O
platelet	B-UNK
donor	B-UNK
.	O
Past	B-UNK
medical	B-UNK
history	B-UNK
was	O
remarkable	O
for	O
hypertension	B-UNK
,	O
hyperlipidemia	O
,	O
and	O
depression	B-UNK
.	O
Reported	B-UNK
medications	B-UNK
included	B-UNK
bumetanide	O
,	O
pravastatin	B-CHEMICAL
,	O
and	O
paroxetine	B-CHEMICAL
.	O
Thirty	B-UNK
minutes	B-UNK
from	O
the	O
start	B-UNK
of	O
the	O
procedure	B-UNK
,	O
the	O
donor	B-UNK
noted	B-UNK
tingling	O
around	O
the	O
mouth	B-UNK
,	O
hands	O
,	O
and	O
feet	O
.	O
She	O
then	O
very	O
rapidly	O
developed	O
acute	B-UNK
onset	B-UNK
of	O
severe	B-UNK
facial	B-UNK
and	O
extremity	O
tetany	B-DISEASE
.	O
Empirical	O
treatment	B-UNK
with	O
intravenous	B-UNK
calcium	B-CHEMICAL
gluconate	I-CHEMICAL
was	O
initiated	O
,	O
and	O
muscle	B-UNK
contractions	B-UNK
slowly	O
subsided	O
over	O
approximately	B-UNK
10	O
to	O
15	O
minutes	B-UNK
.	O
The	O
events	B-UNK
are	O
consistent	B-UNK
with	O
a	O
severe	B-UNK
reaction	B-UNK
to	O
calcium	B-UNK
chelation	O
by	O
sodium	B-CHEMICAL
citrate	I-CHEMICAL
anticoagulant	B-UNK
resulting	B-UNK
in	O
symptomatic	B-UNK
systemic	B-UNK
hypocalcemia	B-DISEASE
.	O
Upon	O
additional	B-UNK
retrospective	B-UNK
analysis	B-UNK
,	O
it	O
was	O
noted	B-UNK
that	O
bumetanide	O
is	O
a	O
loop	O
diuretic	B-UNK
that	O
may	O
cause	O
significant	B-UNK
hypocalcemia	B-DISEASE
.	O
We	O
conclude	O
that	O
careful	B-UNK
screening	B-UNK
for	O
medications	B-UNK
and	O
underlying	B-UNK
conditions	O
predisposing	O
to	O
hypocalcemia	B-DISEASE
is	O
recommended	O
to	O
help	O
prevent	B-UNK
severe	B-UNK
reactions	B-UNK
due	O
to	O
citrate	B-UNK
toxicity	B-DISEASE
.	O
Laboratory	B-UNK
measurement	B-UNK
of	O
pre	B-UNK
-	O
procedure	B-UNK
serum	B-UNK
calcium	I-UNK
levels	O
in	O
selected	O
donors	O
may	O
identify	B-UNK
cases	B-UNK
requiring	O
heightened	O
vigilance	O
.	O
The	O
case	B-UNK
also	O
illustrates	O
the	O
importance	B-UNK
of	O
maintaining	O
preparedness	O
for	O
managing	O
rare	B-UNK
but	O
serious	O
reactions	B-UNK
in	O
volunteer	O
apheresis	O
blood	B-UNK
donors	O
.	O

Proteinuria	B-UNK
after	O
conversion	B-UNK
to	O
sirolimus	B-UNK
in	O
renal	B-UNK
transplant	I-UNK
recipients	B-UNK
.	O
Sirolimus	B-CHEMICAL
(	O
SRL	B-UNK
)	O
is	O
a	O
new	O
,	O
potent	B-UNK
immunosuppressive	B-UNK
agent	B-UNK
.	O
More	O
recently	B-UNK
,	O
proteinuria	B-DISEASE
has	O
been	O
reported	B-UNK
as	O
a	O
consequence	B-UNK
of	O
sirolimus	B-CHEMICAL
therapy	O
,	O
although	O
the	O
mechanism	B-UNK
has	O
remained	B-UNK
unclear	O
.	O
We	O
retrospectively	O
examined	B-UNK
the	O
records	B-UNK
of	O
25	O
renal	B-UNK
transplant	I-UNK
patients	B-UNK
,	O
who	O
developed	O
or	O
displayed	O
increased	B-UNK
proteinuria	B-UNK
after	O
SRL	B-UNK
conversion	B-UNK
.	O
The	O
patient	B-UNK
cohort	B-UNK
(	O
14	O
men	B-UNK
,	O
11	O
women	B-UNK
)	O
was	O
treated	O
with	O
SRL	B-UNK
as	O
conversion	B-UNK
therapy	O
,	O
due	O
to	O
chronic	B-DISEASE
allograft	I-DISEASE
nephropathy	I-DISEASE
(	O
CAN	O
)	O
(	O
n	O
=	O
15	O
)	O
neoplasia	O
(	O
n	O
=	O
8)	O
;	O
Kaposi'	B-DISEASE
s	I-DISEASE
sarcoma	I-DISEASE
,	O
Four	O
skin	B-UNK
cancers	B-UNK
,	O
One	O
intestinal	B-UNK
tumors	B-DISEASE
,	O
One	O
renal	B-UNK
cell	B-UNK
carsinom	O
)	O
or	O
BK	O
virus	B-UNK
nephropathy	B-DISEASE
(	O
n	O
=	O
2	O
)	O
.	O
SRL	B-UNK
was	O
started	O
at	O
a	O
mean	O
of	O
78	O
+	O
/-	O
42	O
(	O
15	O
to	O
163	O
)	O
months	B-UNK
after	O
transplantation	B-UNK
.	O
Mean	O
follow	O
-	O
up	O
on	O
SRL	B-UNK
therapy	O
was	O
20	O
+	O
/-	O
12	O
(	O
6	O
to	O
43	O
)	O
months	B-UNK
.	O
Proteinuria	B-UNK
increased	B-UNK
from	O
0.445	O
(	O
0	O
to	O
1.5	O
)	O
g	O
/	O
d	O
before	O
conversion	B-UNK
to	O
3.2	O
g	O
/	O
dL	B-UNK
(	O
0.2	O
to	O
12	O
)	O
after	O
conversion	B-UNK
(	O
P	O
=	O
0.001	O
)	O
.	O
Before	O
conversion	B-UNK
8	O
(	O
32	O
%	O
)	O
patients	B-UNK
had	O
no	O
proteinuria	B-UNK
,	O
whereas	O
afterwards	O
all	O
patients	B-UNK
had	O
proteinuria	B-UNK
.	O
In	O
28	O
%	O
of	O
patients	B-UNK
proteinuria	B-UNK
remained	B-UNK
unchanged	I-UNK
,	O
whereas	O
it	O
increased	B-UNK
in	O
68	O
%	O
of	O
patients	B-UNK
.	O
In	O
40	O
%	O
it	O
increased	B-UNK
by	O
more	O
than	O
100	O
%	O
.	O
Twenty	O
-	O
eight	O
percent	B-UNK
of	O
patients	B-UNK
showed	O
increased	B-UNK
proteinuria	B-UNK
to	O
the	O
nephrotic	B-UNK
range	B-UNK
.	O
Biopsies	B-UNK
performed	B-UNK
in	O
five	O
patients	B-UNK
revealed	O
new	O
pathological	B-UNK
changes	O
:	O
One	O
membranoproliferative	O
glomerulopathy	O
and	O
interstitial	B-UNK
nephritis	I-UNK
.	O
These	O
patients	B-UNK
showed	O
persistently	O
good	O
graft	B-UNK
function	B-UNK
.	O
Serum	B-UNK
creatinine	I-UNK
values	O
did	O
not	O
change	B-UNK
significantly	B-UNK
:	O
1.98	O
+	O
/-	O
0.8	O
mg	B-UNK
/	O
dL	B-UNK
before	O
SRL	B-UNK
therapy	O
and	O
2.53	O
+	O
/-	O
1.9	O
mg	B-UNK
/	O
dL	B-UNK
at	O
last	O
follow	O
-	O
up	O
(	O
P	O
=	O
.14	O
)	O
.	O
Five	O
grafts	O
were	O
lost	O
and	O
the	O
patients	B-UNK
returned	B-UNK
to	O
dialysis	B-UNK
.	O
Five	O
patients	B-UNK
displayed	O
CAN	O
and	O
Kaposi'	B-DISEASE
s	I-DISEASE
sarcoma	I-DISEASE
.	O
Mean	O
urinary	B-UNK
protein	I-UNK
of	O
patients	B-UNK
who	O
returned	B-UNK
to	O
dialysis	B-UNK
was	O
1.26	O
(	O
0.5	O
to	O
3.5	O
)	O
g	O
/	O
d	O
before	O
and	O
4.7	O
(	O
3	O
to	O
12	O
)	O
g	O
/	O
d	O
after	O
conversion	B-UNK
(	O
P	O
=	O
.01	O
)	O
.	O
Mean	O
serum	B-UNK
creatinine	I-UNK
level	B-UNK
before	O
conversion	B-UNK
was	O
2.21	O
mg	B-UNK
/	O
dL	B-UNK
and	O
thereafter	O
,	O
4.93	O
mg	B-UNK
/	O
dL	B-UNK
(	O
P	O
=	O
.02	O
)	O
.	O
Heavy	B-UNK
proteinuria	B-UNK
was	O
common	B-UNK
after	O
the	O
use	O
of	O
SRL	B-UNK
as	O
rescue	O
therapy	O
for	O
renal	B-UNK
transplantation	B-UNK
.	O
Therefore	O
,	O
conversion	B-UNK
should	O
be	O
considered	B-UNK
for	O
patients	B-UNK
who	O
have	O
not	O
developed	O
advanced	B-UNK
CAN	O
and	O
proteinuria	B-UNK
.	O
The	O
possibility	O
of	O
de	B-UNK
novo	I-UNK
glomerular	B-UNK
pathology	B-UNK
under	O
SRL	B-UNK
treatment	B-UNK
requires	O
further	O
investigation	B-UNK
by	O
renal	B-UNK
biopsy	B-UNK
.	O

In	O
vitro	B-UNK
characterization	O
of	O
parasympathetic	O
and	O
sympathetic	B-UNK
responses	O
in	O
cyclophosphamide	B-UNK
-	O
induced	B-UNK
cystitis	I-UNK
in	O
the	O
rat	B-UNK
.	O
In	O
cyclophosphamide	B-UNK
-	O
induced	B-UNK
cystitis	I-UNK
in	O
the	O
rat	B-UNK
,	O
detrusor	O
function	B-UNK
is	O
impaired	B-UNK
and	O
the	O
expression	B-UNK
and	O
effects	O
of	O
muscarinic	B-UNK
receptors	B-UNK
altered	B-UNK
.	O
Whether	O
or	O
not	O
the	O
neuronal	B-UNK
transmission	B-UNK
may	O
be	O
affected	B-UNK
by	O
cystitis	B-DISEASE
was	O
presently	O
investigated	B-UNK
.	O
Responses	O
of	O
urinary	B-UNK
strip	O
preparations	B-UNK
from	O
control	B-UNK
and	O
cyclophosphamide	B-UNK
-	O
pretreated	B-UNK
rats	B-UNK
to	O
electrical	B-UNK
field	B-UNK
stimulation	B-UNK
and	O
to	O
agonists	B-UNK
were	O
assessed	B-UNK
in	O
the	O
absence	O
and	O
presence	O
of	O
muscarinic	B-UNK
,	O
adrenergic	B-UNK
and	O
purinergic	O
receptor	B-UNK
antagonists	I-UNK
.	O
Generally	B-UNK
,	O
atropine	B-UNK
reduced	B-UNK
contractions	B-UNK
,	O
but	O
in	O
contrast	B-UNK
to	O
controls	B-UNK
,	O
it	O
also	O
reduced	B-UNK
responses	O
to	O
low	B-UNK
electrical	B-UNK
field	B-UNK
stimulation	B-UNK
intensity	B-UNK
(	O
1	O
-	O
5	O
Hz	B-UNK
)	O
in	O
inflamed	O
preparations	B-UNK
.	O
In	O
both	O
types	B-UNK
,	O
purinoceptor	O
desensitization	O
with	O
alpha	B-UNK
,	O
beta	B-UNK
-	O
methylene	O
adenosine-5'-triphosphate	O
(	O
alpha	B-UNK
,	O
beta	B-UNK
-	O
meATP	O
)	O
caused	B-UNK
further	O
reductions	B-UNK
at	O
low	B-UNK
frequencies	B-UNK
(	O
<	O
10	O
Hz	B-UNK
)	O
.	O
The	O
muscarinic	B-UNK
receptor	B-UNK
antagonists	I-UNK
atropine	B-UNK
,	O
4-diphenylacetoxy	B-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methylpiperidine	I-CHEMICAL
(	O
4-DAMP	B-CHEMICAL
)	O
(	O
'	O
M(1)/M(3)/M(5)-selective	O
'	O
)	O
,	O
methoctramine	O
(	O
'	O
M(2)-selective	O
'	O
)	O
and	O
pirenzepine	O
(	O
'	O
M(1)-selective	O
'	O
)	O
antagonized	B-UNK
the	O
tonic	B-UNK
component	B-UNK
of	O
the	O
electrical	B-UNK
field	B-UNK
stimulation	B-UNK
-	O
evoked	B-UNK
contractile	B-UNK
response	B-UNK
more	O
potently	O
than	O
the	O
phasic	O
component	B-UNK
.	O
4-DAMP	B-CHEMICAL
inhibited	B-UNK
the	O
tonic	B-UNK
contractions	B-UNK
in	O
controls	B-UNK
more	O
potently	O
than	O
methoctramine	O
and	O
pirenzepine	O
.	O
In	O
inflamed	O
preparations	B-UNK
,	O
the	O
muscarinic	B-UNK
receptor	B-UNK
antagonism	B-UNK
on	O
the	O
phasic	O
component	B-UNK
of	O
the	O
electrical	B-UNK
field	B-UNK
stimulation	B-UNK
-	O
evoked	B-UNK
contraction	B-UNK
was	O
decreased	B-UNK
and	O
the	O
pirenzepine	O
and	O
4-DAMP	B-CHEMICAL
antagonism	B-UNK
on	O
the	O
tonic	B-UNK
component	B-UNK
was	O
much	O
less	O
efficient	O
than	O
in	O
controls	B-UNK
.	O
In	O
contrast	B-UNK
to	O
controls	B-UNK
,	O
methoctramine	O
increased	B-UNK
--	O
instead	O
of	O
decreased	B-UNK
--	O
the	O
tonic	B-UNK
responses	O
at	O
high	B-UNK
frequencies	B-UNK
.	O
While	O
contractions	B-UNK
to	O
carbachol	B-UNK
and	O
ATP	B-CHEMICAL
were	O
the	O
same	O
in	O
inflamed	O
and	O
in	O
control	B-UNK
strips	O
when	O
related	O
to	O
a	O
reference	B-UNK
potassium	B-UNK
response	B-UNK
,	O
isoprenaline	B-CHEMICAL
-	O
induced	O
relaxations	O
were	O
smaller	B-UNK
in	O
inflamed	O
strips	O
.	O
Thus	O
,	O
in	O
cystitis	B-UNK
substantial	O
changes	O
of	O
the	O
efferent	O
functional	B-UNK
responses	O
occur	O
.	O
While	O
postjunctional	O
beta-adrenoceptor-mediated	O
relaxations	O
are	O
reduced	B-UNK
,	O
effects	O
by	O
prejunctional	O
inhibitory	B-UNK
muscarinic	B-UNK
receptors	B-UNK
may	O
be	O
increased	B-UNK
.	O

Associations	B-UNK
between	O
use	O
of	O
benzodiazepines	B-UNK
or	O
related	O
drugs	B-UNK
and	O
health	B-UNK
,	O
physical	B-UNK
abilities	O
and	O
cognitive	B-UNK
function	I-UNK
:	O
a	O
non-randomised	O
clinical	B-UNK
study	B-UNK
in	O
the	O
elderly	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
To	O
describe	O
associations	B-UNK
between	O
the	O
use	O
of	O
benzodiazepines	B-UNK
or	O
related	O
drugs	B-UNK
(	O
BZDs	B-CHEMICAL
/	O
RDs	O
)	O
and	O
health	B-UNK
,	O
functional	B-UNK
abilities	O
and	O
cognitive	B-UNK
function	I-UNK
in	O
the	O
elderly	B-UNK
.	O
METHODS	B-UNK
:	O
A	O
non-randomised	O
clinical	B-UNK
study	B-UNK
of	O
patients	B-UNK
aged	B-UNK
>	O
or	O
=	O
65	O
years	B-UNK
admitted	B-UNK
to	O
acute	B-UNK
hospital	B-UNK
wards	O
during	O
1	O
month	B-UNK
.	O
164	O
patients	B-UNK
(	O
mean	O
age	B-UNK
+	O
/-	O
standard	B-UNK
deviation	O
[	O
SD	B-DISEASE
]	O
81.6	O
+	O
/-	O
6.8	O
years	B-UNK
)	O
were	O
admitted	B-UNK
.	O
Of	O
these	O
,	O
nearly	O
half	B-UNK
(	O
n	O
=	O
78	O
)	O
had	O
used	O
BZDs	B-CHEMICAL
/	O
RDs	O
before	O
admission	B-UNK
,	O
and	O
the	O
remainder	O
(	O
n	O
=	O
86	O
)	O
were	O
non-users	O
.	O
Cognitive	B-UNK
ability	B-UNK
was	O
assessed	B-UNK
by	O
the	O
Mini-Mental	O
State	B-UNK
Examination	B-UNK
(	O
MMSE	O
)	O
.	O
Patients	B-UNK
scoring	O
>	O
or	O
=	O
20	O
MMSE	O
sum	O
points	B-UNK
were	O
interviewed	O
(	O
n	O
=	O
79	O
)	O
and	O
questioned	O
regarding	O
symptoms	B-UNK
and	O
functional	B-UNK
abilities	O
during	O
the	O
week	B-UNK
prior	B-UNK
to	O
admission	B-UNK
.	O
Data	B-UNK
on	O
use	O
of	O
BZDs	B-CHEMICAL
/	O
RDs	O
before	O
admission	B-UNK
,	O
current	B-UNK
medications	B-UNK
and	O
discharge	B-UNK
diagnoses	O
were	O
collected	O
from	O
medical	B-UNK
records	I-UNK
.	O
Health	B-UNK
,	O
physical	B-UNK
abilities	O
and	O
cognitive	B-UNK
function	I-UNK
were	O
compared	O
between	O
BZD	O
/	O
RD	O
users	B-UNK
and	O
non-users	O
,	O
and	O
adjustments	O
were	O
made	O
for	O
confounding	B-UNK
variables	B-UNK
.	O
The	O
residual	B-UNK
serum	B-UNK
concentrations	I-UNK
of	O
oxazepam	O
,	O
temazepam	O
and	O
zopiclone	O
were	O
analysed	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
mean	O
+	O
/-	O
SD	B-UNK
duration	B-UNK
of	O
BZD	O
/	O
RD	O
use	O
was	O
7	O
+	O
/-	O
7	O
years	B-UNK
(	O
range	B-UNK
1	O
-	O
31	O
)	O
.	O
Two	O
or	O
three	O
BZDs	B-CHEMICAL
/	O
RDs	O
were	O
concomitantly	B-UNK
taken	O
by	O
26	O
%	O
of	O
users	B-UNK
(	O
n	O
=	O
20	O
)	O
.	O
Long	B-UNK
-	O
term	O
use	O
of	O
these	O
drugs	B-UNK
was	O
associated	O
with	O
female	B-UNK
sex	B-UNK
and	O
use	O
of	O
a	O
higher	B-UNK
number	B-UNK
of	O
drugs	B-UNK
with	O
effects	O
on	O
the	O
CNS	B-UNK
,	O
which	O
tended	O
to	O
be	O
related	O
to	O
diagnosed	B-UNK
dementia	B-DISEASE
.	O
After	O
adjustment	B-UNK
for	O
these	O
variables	B-UNK
as	O
confounders	O
,	O
use	O
of	O
BZDs	B-CHEMICAL
/	O
RDs	O
was	O
not	O
associated	O
with	O
cognitive	B-UNK
function	I-UNK
as	O
measured	B-UNK
by	O
the	O
MMSE	O
.	O
However	O
,	O
use	O
of	O
BZDs	B-CHEMICAL
/	O
RDs	O
was	O
associated	O
with	O
dizziness	B-DISEASE
,	O
inability	O
to	O
sleep	B-UNK
after	O
awaking	O
at	O
night	B-UNK
and	O
tiredness	O
in	O
the	O
mornings	O
during	O
the	O
week	B-UNK
prior	B-UNK
to	O
admission	B-UNK
and	O
with	O
stronger	O
depressive	B-DISEASE
symptoms	I-DISEASE
measured	B-UNK
at	O
the	O
beginning	B-UNK
of	O
the	O
hospital	B-UNK
stay	O
.	O
Use	O
of	O
BZDs	B-CHEMICAL
/	O
RDs	O
tended	O
to	O
be	O
associated	O
with	O
a	O
reduced	B-UNK
ability	B-UNK
to	O
walk	O
and	O
shorter	O
night	B-UNK
-	O
time	O
sleep	B-UNK
during	O
the	O
week	B-UNK
prior	B-UNK
to	O
admission	B-UNK
.	O
A	O
higher	B-UNK
residual	B-UNK
serum	B-UNK
concentration	B-UNK
of	O
temazepam	O
correlated	B-UNK
with	O
a	O
lower	B-UNK
MMSE	O
sum	O
score	O
after	O
adjustment	B-UNK
for	O
confounding	B-UNK
variables	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Long	B-UNK
-	O
term	O
use	O
and	O
concomitant	B-UNK
use	O
of	O
more	O
than	O
one	O
BZD	O
/	O
RD	O
were	O
common	B-UNK
in	O
elderly	B-UNK
patients	B-UNK
hospitalised	O
because	O
of	O
acute	B-UNK
illnesses	O
.	O
Long	B-UNK
-	O
term	O
use	O
was	O
associated	O
with	O
daytime	O
and	O
night	B-UNK
-	O
time	O
symptoms	B-UNK
indicative	O
of	O
poorer	O
health	B-UNK
and	O
potentially	O
caused	B-UNK
by	O
the	O
adverse	B-UNK
effects	I-UNK
of	O
these	O
drugs	B-UNK
.	O

Acute	B-UNK
vocal	B-DISEASE
fold	I-DISEASE
palsy	I-DISEASE
after	O
acute	B-UNK
disulfiram	B-CHEMICAL
intoxication	B-UNK
.	O
Acute	B-UNK
peripheral	B-UNK
neuropathy	I-UNK
caused	B-UNK
by	O
a	O
disulfiram	B-CHEMICAL
overdose	B-UNK
is	O
very	O
rare	B-UNK
and	O
there	O
is	O
no	O
report	B-UNK
of	O
it	O
leading	B-UNK
to	O
vocal	B-DISEASE
fold	I-DISEASE
palsy	I-DISEASE
.	O
A	O
49-year	O
-	O
old	O
woman	B-UNK
was	O
transferred	O
to	O
our	O
department	B-UNK
because	O
of	O
quadriparesis	O
,	O
lancinating	O
pain	B-UNK
,	O
sensory	O
loss	B-UNK
,	O
and	O
paresthesia	B-DISEASE
of	O
the	O
distal	B-UNK
limbs	B-UNK
.	O
One	O
month	B-UNK
previously	B-UNK
,	O
she	O
had	O
taken	O
a	O
single	B-UNK
high	B-UNK
dose	I-UNK
of	O
disulfiram	B-UNK
(	O
130	O
tablets	B-UNK
of	O
ALCOHOL	B-UNK
STOP	O
TAB	O
,	O
Shin	O
-	O
Poong	O
Pharm	O
.	O
Co	B-CHEMICAL
.	O
,	O
Ansan	O
,	O
Korea	O
)	O
in	O
a	O
suicide	B-DISEASE
attempt	O
.	O
She	O
was	O
not	O
an	O
alcoholic	O
.	O
For	O
the	O
first	O
few	O
days	B-UNK
after	O
ingestion	B-UNK
,	O
she	O
was	O
in	O
a	O
confused	O
state	B-UNK
and	O
had	O
mild	B-UNK
to	O
moderate	B-UNK
ataxia	B-DISEASE
and	O
giddiness	O
.	O
She	O
noticed	O
hoarseness	B-DISEASE
and	O
distally	O
accentuated	O
motor	B-UNK
and	O
sensory	O
dysfunction	B-UNK
after	O
she	O
had	O
recovered	O
from	O
this	O
state	B-UNK
.	O
A	O
nerve	B-UNK
conduction	B-UNK
study	B-UNK
was	O
consistent	B-UNK
with	O
severe	B-UNK
sensorimotor	O
axonal	B-UNK
polyneuropathy	B-DISEASE
.	O
Laryngeal	O
electromyography	O
(	O
thyroarytenoid	O
muscle	B-UNK
)	O
showed	O
ample	O
denervation	O
potentials	B-UNK
.	O
Laryngoscopy	O
revealed	O
asymmetric	O
vocal	B-UNK
fold	B-UNK
movements	B-UNK
during	O
phonation	O
.	O
Her	O
vocal	B-UNK
change	B-UNK
and	O
weakness	B-UNK
began	B-UNK
to	O
improve	B-UNK
spontaneously	B-UNK
about	O
3	O
weeks	B-UNK
after	O
transfer	O
.	O
This	O
was	O
a	O
case	B-UNK
of	O
acute	B-UNK
palsy	B-UNK
of	O
the	O
recurrent	B-UNK
laryngeal	O
nerve	B-UNK
and	O
superimposed	O
severe	B-UNK
acute	B-UNK
sensorimotor	O
axonal	B-UNK
polyneuropathy	B-DISEASE
caused	B-UNK
by	O
high	B-UNK
-	O
dose	B-UNK
disulfiram	B-UNK
intoxication	B-UNK
.	O

Higher	B-UNK
optical	B-UNK
density	B-UNK
of	O
an	O
antigen	B-UNK
assay	B-UNK
predicts	O
thrombosis	B-UNK
in	O
patients	B-UNK
with	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-UNK
.	O
OBJECTIVES	B-UNK
:	O
To	O
correlate	B-UNK
optical	B-UNK
density	B-UNK
and	O
percent	B-UNK
inhibition	B-UNK
of	O
a	O
two	O
-	O
step	B-UNK
heparin	B-UNK
-	O
induced	O
thrombocytopenia	B-UNK
(	O
HIT	B-UNK
)	O
antigen	B-UNK
assay	B-UNK
with	O
thrombosis	B-UNK
;	O
the	O
assay	B-UNK
utilizes	O
reaction	B-UNK
inhibition	B-UNK
characteristics	B-UNK
of	O
a	O
high	B-UNK
heparin	B-CHEMICAL
concentration	B-UNK
.	O
PATIENTS	B-UNK
AND	I-UNK
METHODS	I-UNK
:	O
Patients	B-UNK
with	O
more	O
than	O
50	O
%	O
decrease	B-UNK
in	O
platelet	B-UNK
count	I-UNK
or	O
thrombocytopenia	B-UNK
(	O
<	O
150	O
x	O
10(9)/L	O
)	O
after	O
exposure	B-UNK
to	O
heparin	B-UNK
,	O
who	O
had	O
a	O
positive	B-UNK
two	O
-	O
step	B-UNK
antigen	B-UNK
assay	B-UNK
[	O
optical	B-UNK
density	B-UNK
(	O
OD	B-UNK
)	O
>	O
0.4	O
and	O
>	O
50	O
inhibition	B-UNK
with	O
high	B-UNK
concentration	B-UNK
of	O
heparin	B-UNK
]	O
were	O
included	B-UNK
in	O
the	O
study	B-UNK
.	O
RESULTS	B-UNK
:	O
Forty	O
of	O
94	O
HIT	B-UNK
patients	B-UNK
had	O
thrombosis	B-UNK
at	O
diagnosis	B-UNK
;	O
54/94	O
had	O
isolated	B-UNK
-	O
HIT	B-UNK
without	O
thrombosis	B-UNK
.	O
Eight	O
of	O
the	O
isolated	B-UNK
-	O
HIT	B-UNK
patients	B-UNK
developed	O
thrombosis	B-DISEASE
within	O
the	O
next	O
30	O
d	O
;	O
thus	O
,	O
a	O
total	B-UNK
of	O
48	O
patients	B-UNK
had	O
thrombosis	B-DISEASE
at	O
day	O
30	O
.	O
At	O
diagnosis	B-UNK
there	O
was	O
no	O
significant	B-UNK
difference	I-UNK
in	O
OD	B-UNK
between	O
HIT	B-UNK
patients	B-UNK
with	O
thrombosis	B-DISEASE
and	O
those	O
with	O
isolated	B-UNK
-	O
HIT	B-UNK
.	O
However	O
,	O
OD	B-UNK
was	O
significantly	B-UNK
higher	I-UNK
in	O
all	O
patients	B-UNK
with	O
thrombosis	B-DISEASE
(	O
n	O
=	O
48	O
,	O
1.34	O
+	O
/-	O
0.89	O
)	O
,	O
including	O
isolated	B-UNK
-	O
HIT	B-UNK
patients	B-UNK
who	O
later	O
developed	O
thrombosis	B-UNK
within	O
30	O
d	O
(	O
n	O
=	O
8	O
,	O
1.84	O
+	O
/-	O
0.64	O
)	O
as	O
compared	O
to	O
isolated	B-UNK
-	O
HIT	B-UNK
patients	B-UNK
who	O
did	O
not	O
develop	B-UNK
thrombosis	B-DISEASE
(	O
0.96	O
+	O
/-	O
0.75	O
;	O
P	O
=	O
0.011	O
and	O
P	O
=	O
0.008	O
)	O
.	O
The	O
Receiver	O
Operative	B-UNK
Characteristic	B-UNK
Curve	B-UNK
showed	O
that	O
OD	B-UNK
>	O
1.27	O
in	O
the	O
isolated	B-UNK
-	O
HIT	B-UNK
group	B-UNK
had	O
a	O
significantly	B-UNK
higher	I-UNK
chance	O
of	O
developing	B-UNK
thrombosis	B-UNK
by	O
day	O
30	O
.	O
None	O
of	O
these	O
groups	B-UNK
showed	O
significant	B-UNK
difference	I-UNK
in	O
percent	B-UNK
inhibition	B-UNK
.	O
Multivariate	B-UNK
analysis	B-UNK
showed	O
a	O
2.8-fold	O
increased	B-UNK
risk	B-UNK
of	O
thrombosis	B-UNK
in	O
females	B-UNK
.	O
Similarly	B-UNK
,	O
thrombotic	B-UNK
risk	B-UNK
increased	B-UNK
with	O
age	B-UNK
and	O
OD	B-UNK
values	O
.	O
CONCLUSION	B-UNK
:	O
Higher	B-UNK
OD	B-UNK
is	O
associated	O
with	O
significant	B-UNK
risk	B-UNK
of	O
subsequent	B-UNK
thrombosis	B-UNK
in	O
patients	B-UNK
with	O
isolated	B-UNK
-	O
HIT	B-UNK
;	O
percent	B-UNK
inhibition	B-UNK
,	O
however	O
,	O
was	O
not	O
predictive	B-UNK
.	O

Central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
associated	O
with	O
clomiphene	O
-	O
induced	O
ovulation	O
.	O
OBJECTIVE	B-UNK
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
associated	O
with	O
clomiphene	O
citrate	B-UNK
(	O
CC	B-UNK
)	O
.	O
DESIGN	B-UNK
:	O
Case	B-UNK
study	B-UNK
.	O
SETTING	B-UNK
:	O
Ophthalmology	O
clinic	B-UNK
of	O
an	O
academic	O
hospital	B-UNK
.	O
PATIENT(S	O
):	O
A	O
36-year	O
-	O
old	O
woman	B-UNK
referred	B-UNK
from	O
the	O
infertility	B-DISEASE
clinic	B-UNK
for	O
blurred	B-DISEASE
vision	I-DISEASE
.	O
INTERVENTION(S	O
):	O
Ophthalmic	B-UNK
examination	B-UNK
after	O
CC	B-CHEMICAL
therapy	O
.	O
MAIN	B-UNK
OUTCOME	B-UNK
MEASURE(S	O
):	O
Central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
after	O
ovulation	O
induction	B-UNK
with	O
CC	B-UNK
.	O
RESULT(S	O
):	O
A	O
36-year	O
-	O
old	O
Chinese	B-UNK
woman	B-UNK
developed	O
central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
after	O
eight	O
courses	B-UNK
of	O
CC	B-CHEMICAL
.	O
A	O
search	B-UNK
of	O
the	O
literature	B-UNK
on	O
the	O
thromboembolic	B-UNK
complications	B-DISEASE
of	O
CC	B-CHEMICAL
does	O
not	O
include	O
this	O
severe	B-UNK
ophthalmic	B-UNK
complication	B-UNK
,	O
although	O
mild	B-UNK
visual	B-UNK
disturbance	B-UNK
after	O
CC	B-CHEMICAL
intake	B-UNK
is	O
not	O
uncommon	O
.	O
CONCLUSION(S	O
):	O
This	O
is	O
the	O
first	O
reported	B-UNK
case	B-UNK
of	O
central	B-DISEASE
retinal	I-DISEASE
vein	I-DISEASE
occlusion	I-DISEASE
after	O
treatment	B-UNK
with	O
CC	B-UNK
.	O
Extra	O
caution	B-UNK
is	O
warranted	O
in	O
treating	O
infertility	B-DISEASE
patients	B-UNK
with	O
CC	B-CHEMICAL
,	O
and	O
patients	B-UNK
should	O
be	O
well	O
informed	O
of	O
this	O
side	O
effect	B-UNK
before	O
commencement	O
of	O
therapy	O
.	O

Nicotine	B-UNK
-	O
induced	O
nystagmus	B-UNK
correlates	B-UNK
with	O
midpontine	O
activation	B-UNK
.	O
The	O
pathomechanism	O
of	O
nicotine	B-UNK
-	O
induced	O
nystagmus	B-UNK
(	O
NIN	O
)	O
is	O
unknown	O
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
delineate	O
brain	B-UNK
structures	B-UNK
that	O
are	O
involved	B-UNK
in	O
NIN	O
generation	B-UNK
.	O
Eight	O
healthy	B-UNK
volunteers	I-UNK
inhaled	B-UNK
nicotine	B-CHEMICAL
in	O
darkness	O
during	O
a	O
functional	B-UNK
magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
(	O
fMRI	O
)	O
experiment	B-UNK
;	O
eye	B-UNK
movements	B-UNK
were	O
registered	O
using	O
video-oculography	O
.	O
NIN	O
correlated	B-UNK
with	O
blood	B-UNK
oxygen	B-UNK
level	B-UNK
-	O
dependent	B-UNK
(	O
BOLD	O
)	O
activity	B-UNK
levels	O
in	O
a	O
midpontine	O
site	B-UNK
in	O
the	O
posterior	B-UNK
basis	B-UNK
pontis	O
.	O
NIN	O
-	O
induced	O
midpontine	O
activation	B-UNK
may	O
correspond	O
to	O
activation	B-UNK
of	O
the	O
dorsomedial	O
pontine	O
nuclei	B-UNK
and	O
the	O
nucleus	B-UNK
reticularis	O
tegmenti	O
pontis	O
,	O
structures	B-UNK
known	O
to	O
participate	O
in	O
the	O
generation	B-UNK
of	O
multidirectional	O
saccades	O
and	O
smooth	B-UNK
pursuit	O
eye	B-UNK
movements	B-UNK
.	O

Protective	B-UNK
effect	I-UNK
of	O
verapamil	B-UNK
on	O
gastric	B-UNK
hemorrhagic	B-UNK
ulcers	B-UNK
in	O
severe	B-UNK
atherosclerotic	B-DISEASE
rats	B-UNK
.	O
Studies	B-UNK
concerning	O
with	O
pathogenesis	B-UNK
of	O
gastric	B-UNK
hemorrhage	B-UNK
and	O
mucosal	O
ulceration	O
produced	B-UNK
in	O
atherosclerotic	B-DISEASE
rats	B-UNK
are	O
lacking	B-UNK
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
is	O
to	O
examine	B-UNK
the	O
role	O
of	O
gastric	B-UNK
acid	B-UNK
back	O
-	O
diffusion	B-UNK
,	O
mast	O
cell	B-UNK
histamine	B-UNK
release	B-UNK
,	O
lipid	B-UNK
peroxide	O
(	O
LPO	O
)	O
generation	B-UNK
and	O
mucosal	O
microvascular	O
permeability	B-UNK
in	O
modulating	O
gastric	B-UNK
hemorrhage	B-DISEASE
and	O
ulcer	B-DISEASE
in	O
rats	B-UNK
with	O
atherosclerosis	B-UNK
induced	O
by	O
coadministration	O
of	O
vitamin	B-UNK
D2	B-UNK
and	O
cholesterol	B-UNK
.	O
Additionally	B-UNK
,	O
the	O
protective	B-UNK
effect	I-UNK
of	O
verapamil	B-CHEMICAL
on	O
this	O
ulcer	B-DISEASE
model	B-UNK
was	O
evaluated	B-UNK
.	O
Male	B-UNK
Wistar	I-UNK
rats	I-UNK
were	O
challenged	O
intragastrically	O
once	O
daily	B-UNK
for	O
9	O
days	B-UNK
with	O
1.0	O
ml	B-UNK
/	O
kg	B-UNK
of	O
corn	O
oil	B-UNK
containing	O
vitamin	B-UNK
D2	B-UNK
and	O
cholesterol	B-UNK
to	O
induce	B-UNK
atherosclerosis	B-DISEASE
.	O
Control	B-UNK
rats	B-UNK
received	O
corn	O
oil	B-UNK
only	O
.	O
After	O
gastric	B-UNK
surgery	B-UNK
,	O
rat	B-UNK
stomachs	O
were	O
irrigated	O
for	O
3	O
h	O
with	O
either	O
simulated	O
gastric	B-UNK
juice	O
or	O
normal	B-UNK
saline	I-UNK
.	O
Gastric	B-UNK
acid	B-UNK
back	O
-	O
diffusion	B-UNK
,	O
mucosal	O
LPO	O
generation	B-UNK
,	O
histamine	B-UNK
concentration	B-UNK
,	O
microvascular	O
permeability	B-UNK
,	O
luminal	B-CHEMICAL
hemoglobin	B-UNK
content	B-UNK
and	O
ulcer	B-DISEASE
areas	B-UNK
were	O
determined	B-UNK
.	O
Elevated	B-UNK
atherosclerotic	B-DISEASE
parameters	O
,	O
such	O
as	O
serum	B-UNK
calcium	I-UNK
,	O
total	B-UNK
cholesterol	B-UNK
and	O
low	B-UNK
-	O
density	B-UNK
lipoprotein	O
concentration	B-UNK
were	O
obtained	B-UNK
in	O
atherosclerotic	B-DISEASE
rats	B-UNK
.	O
Severe	B-UNK
gastric	B-UNK
ulcers	B-UNK
accompanied	B-UNK
with	O
increased	B-UNK
ulcerogenic	O
factors	B-UNK
,	O
including	O
gastric	B-UNK
acid	B-UNK
back	O
-	O
diffusion	B-UNK
,	O
histamine	B-UNK
release	B-UNK
,	O
LPO	O
generation	B-UNK
and	O
luminal	B-CHEMICAL
hemoglobin	B-UNK
content	B-UNK
were	O
also	O
observed	O
in	O
these	O
rats	B-UNK
.	O
Moreover	O
,	O
a	O
positive	B-UNK
correlation	B-UNK
of	O
histamine	B-UNK
to	O
gastric	B-UNK
hemorrhage	B-DISEASE
and	O
to	O
ulcer	B-DISEASE
was	O
found	O
in	O
those	O
atherosclerotic	B-DISEASE
rats	B-UNK
.	O
This	O
hemorrhagic	B-UNK
ulcer	B-DISEASE
and	O
various	O
ulcerogenic	O
parameters	O
were	O
dose	B-UNK
-	O
dependently	B-UNK
ameliorated	B-UNK
by	O
daily	B-UNK
intragastric	O
verapamil	B-CHEMICAL
.	O
Atherosclerosis	B-UNK
could	O
produce	B-UNK
gastric	B-UNK
hemorrhagic	B-UNK
ulcer	B-DISEASE
via	O
aggravation	O
of	O
gastric	B-UNK
acid	B-UNK
back	O
-	O
diffusion	B-UNK
,	O
LPO	O
generation	B-UNK
,	O
histamine	B-CHEMICAL
release	B-UNK
and	O
microvascular	O
permeability	B-UNK
that	O
could	O
be	O
ameliorated	B-UNK
by	O
verapamil	B-UNK
in	O
rats	B-UNK
.	O

Adriamycin	B-UNK
-	O
induced	O
autophagic	O
cardiomyocyte	B-UNK
death	B-UNK
plays	O
a	O
pathogenic	O
role	O
in	O
a	O
rat	B-UNK
model	B-UNK
of	O
heart	B-DISEASE
failure	I-DISEASE
.	O
BACKGROUND	B-UNK
:	O
The	O
mechanisms	B-UNK
underlying	B-UNK
heart	B-DISEASE
failure	I-DISEASE
induced	O
by	O
adriamycin	B-UNK
are	O
very	O
complicated	O
and	O
still	O
unclear	O
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
investigate	B-UNK
whether	O
autophagy	O
was	O
involved	B-UNK
in	O
the	O
progression	B-UNK
of	O
heart	B-UNK
failure	I-UNK
induced	O
by	O
adriamycin	B-UNK
,	O
so	O
that	O
we	O
can	O
develop	B-UNK
a	O
novel	O
treatment	B-UNK
strategy	B-UNK
for	O
heart	B-DISEASE
failure	I-DISEASE
.	O
METHODS	B-UNK
:	O
3-methyladenine	B-CHEMICAL
(	O
3MA	B-CHEMICAL
)	O
,	O
a	O
specific	B-UNK
inhibitor	B-UNK
on	O
autophagy	O
was	O
used	O
in	O
a	O
heart	B-UNK
failure	I-UNK
model	B-UNK
of	O
rats	B-UNK
induced	O
by	O
adriamycin	B-CHEMICAL
.	O
Neonatal	B-UNK
cardiomyocytes	B-UNK
were	O
isolated	B-UNK
from	O
Sprague	O
-	O
Dawley	O
rat	B-UNK
hearts	B-UNK
and	O
randomly	B-UNK
divided	B-UNK
into	I-UNK
controls	B-UNK
,	O
an	O
adriamycin	B-CHEMICAL
-	O
treated	O
group	B-UNK
,	O
and	O
a	O
3MA	B-CHEMICAL
plus	O
adriamycin	B-CHEMICAL
-	O
treated	O
group	B-UNK
.	O
We	O
then	O
examined	B-UNK
the	O
morphology	O
,	O
expression	B-UNK
of	O
beclin	O
1	O
gene	B-UNK
,	O
mitochondrial	B-UNK
permeability	B-UNK
transition	O
(	O
MPT	O
)	O
,	O
and	O
Na+-K+	O
ATPase	B-UNK
activity	B-UNK
in	O
vivo	B-UNK
.	O
We	O
also	O
assessed	B-UNK
cell	B-UNK
viability	O
,	O
mitochondrial	B-UNK
membrane	B-UNK
potential	B-UNK
changes	O
and	O
counted	O
autophagic	O
vacuoles	O
in	O
cultured	B-UNK
cardiomyocytes	B-UNK
.	O
In	O
addition	B-UNK
,	O
we	O
analyzed	O
the	O
expression	B-UNK
of	O
autophagy	O
associated	O
gene	B-UNK
,	O
beclin	O
1	O
using	O
RT	O
-	O
PCR	B-UNK
and	O
Western	B-UNK
blotting	O
in	O
an	O
animal	B-UNK
model	I-UNK
.	O
RESULTS	B-UNK
:	O
3MA	B-CHEMICAL
significantly	B-UNK
improved	O
cardiac	B-UNK
function	B-UNK
and	O
reduced	B-UNK
mitochondrial	B-UNK
injury	B-UNK
.	O
Furthermore	O
,	O
adriamycin	B-UNK
induced	O
the	O
formation	B-UNK
of	O
autophagic	O
vacuoles	O
,	O
and	O
3MA	B-CHEMICAL
strongly	O
downregulated	O
the	O
expression	B-UNK
of	O
beclin	O
1	O
in	O
adriamycin	B-CHEMICAL
-	O
induced	O
failing	O
heart	B-UNK
and	O
inhibited	B-UNK
the	O
formation	B-UNK
of	O
autophagic	O
vacuoles	O
.	O
CONCLUSION	B-UNK
:	O
Autophagic	O
cardiomyocyte	B-UNK
death	B-DISEASE
plays	O
an	O
important	B-UNK
role	O
in	O
the	O
pathogenesis	B-UNK
of	O
heart	B-UNK
failure	I-UNK
in	O
rats	B-UNK
induced	O
by	O
adriamycin	B-UNK
.	O
Mitochondrial	B-UNK
injury	B-UNK
may	O
be	O
involved	B-UNK
in	O
the	O
progression	B-UNK
of	O
heart	B-UNK
failure	I-UNK
caused	B-UNK
by	O
adriamycin	B-UNK
via	O
the	O
autophagy	O
pathway	B-UNK
.	O

Confusion	B-UNK
,	O
a	O
rather	O
serious	O
adverse	B-UNK
drug	I-UNK
reaction	I-UNK
with	O
valproic	B-UNK
acid	I-UNK
:	O
a	O
review	B-UNK
of	O
the	O
French	O
Pharmacovigilance	O
database	B-UNK
.	O
INTRODUCTION	B-UNK
:	O
Confusion	B-UNK
is	O
an	O
adverse	B-UNK
drug	I-UNK
reaction	I-UNK
frequently	B-UNK
observed	O
with	O
valproic	B-UNK
acid	I-UNK
.	O
Some	O
case	B-UNK
reports	I-UNK
are	O
published	B-UNK
in	O
the	O
literature	B-UNK
but	O
no	O
systematic	B-UNK
study	B-UNK
from	O
a	O
sample	B-UNK
of	O
patients	B-UNK
has	O
been	O
published	B-UNK
.	O
We	O
performed	B-UNK
this	O
study	B-UNK
in	O
order	B-UNK
to	O
describe	O
the	O
main	B-UNK
characteristics	B-UNK
of	O
this	O
adverse	B-UNK
drug	I-UNK
reaction	I-UNK
.	O
METHODS	B-UNK
:	O
Using	O
the	O
French	O
Pharmacovigilance	O
database	B-UNK
,	O
we	O
selected	O
the	O
cases	B-UNK
of	O
confusion	B-UNK
reported	B-UNK
since	O
1985	O
with	O
valproic	B-UNK
acid	I-UNK
.	O
RESULTS	B-UNK
:	O
272	O
cases	B-UNK
of	O
confusion	B-UNK
were	O
reported	B-UNK
with	O
valproic	B-UNK
acid	I-UNK
:	O
153	O
women	B-UNK
and	O
119	O
men	B-UNK
.	O
Confusion	B-DISEASE
mostly	O
occurred	B-UNK
during	O
the	O
two	O
first	O
weeks	B-UNK
following	O
valproic	B-UNK
acid	I-UNK
exposure	B-UNK
(	O
39.7	O
%	O
)	O
.	O
It	O
was	O
"	O
serious	O
"	O
for	O
almost	O
2/3	O
of	O
the	O
patients	B-UNK
(	O
62.5	O
%	O
)	O
and	O
its	O
outcome	B-UNK
favourable	O
in	O
most	O
of	O
the	O
cases	B-UNK
(	O
82	O
%	O
)	O
.	O
The	O
occurrence	B-UNK
of	O
this	O
ADR	B-UNK
was	O
more	O
frequent	B-UNK
in	O
patients	B-UNK
aged	B-UNK
between	O
61	O
and	O
80	O
years	B-UNK
.	O
CONCLUSION	B-UNK
:	O
This	O
work	O
shows	O
that	O
confusion	B-DISEASE
with	O
valproic	B-UNK
acid	I-UNK
is	O
a	O
serious	O
,	O
rather	O
frequent	B-UNK
but	O
reversible	B-UNK
adverse	B-UNK
drug	I-UNK
reaction	I-UNK
.	O
It	O
occurs	O
especially	O
in	O
older	B-UNK
patients	B-UNK
and	O
during	O
the	O
first	O
two	O
weeks	B-UNK
of	O
treatment	B-UNK
.	O

Learning	B-UNK
and	I-UNK
memory	I-UNK
deficits	B-UNK
in	O
ecstasy	B-UNK
users	I-UNK
and	O
their	O
neural	B-UNK
correlates	B-UNK
during	O
a	O
face	B-UNK
-	O
learning	B-UNK
task	B-UNK
.	O
It	O
has	O
been	O
consistently	O
shown	B-UNK
that	O
ecstasy	B-UNK
users	I-UNK
display	O
impairments	B-UNK
in	O
learning	B-UNK
and	I-UNK
memory	I-UNK
performance	B-UNK
.	O
In	O
addition	B-UNK
,	O
working	B-UNK
memory	B-UNK
processing	O
in	O
ecstasy	B-UNK
users	I-UNK
has	O
been	O
shown	B-UNK
to	O
be	O
associated	O
with	O
neural	B-UNK
alterations	B-UNK
in	O
hippocampal	B-UNK
and	O
/	O
or	O
cortical	B-UNK
regions	B-UNK
as	O
measured	B-UNK
by	O
functional	B-UNK
magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
(	O
fMRI	O
)	O
.	O
Using	O
functional	B-UNK
imaging	B-UNK
and	O
a	O
face	B-UNK
-	O
learning	B-UNK
task	B-UNK
,	O
we	O
investigated	B-UNK
neural	B-UNK
correlates	B-UNK
of	O
encoding	O
and	O
recalling	O
face	B-UNK
-	O
name	O
associations	B-UNK
in	O
20	O
recreational	B-UNK
drug	B-UNK
users	B-UNK
whose	O
predominant	B-UNK
drug	B-UNK
use	O
was	O
ecstasy	B-CHEMICAL
and	O
20	O
controls	B-UNK
.	O
To	O
address	O
the	O
potential	B-UNK
confounding	B-UNK
effects	O
of	O
the	O
cannabis	O
use	O
of	O
the	O
ecstasy	B-UNK
using	O
group	B-UNK
,	O
a	O
second	O
analysis	B-UNK
included	B-UNK
14	O
previously	B-UNK
tested	B-UNK
cannabis	O
users	B-UNK
(	O
Nestor	O
,	O
L.	O
,	O
Roberts	O
,	O
G.	O
,	O
Garavan	O
,	O
H.	O
,	O
Hester	O
,	O
R.	O
,	O
2008	O
.	O
Deficits	B-UNK
in	O
learning	B-UNK
and	I-UNK
memory	I-UNK
:	O
parahippocampal	O
hyperactivity	B-UNK
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	O
users	B-UNK
.	O
Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O
Ecstasy	B-UNK
users	I-UNK
performed	B-UNK
significantly	B-UNK
worse	O
in	O
learning	B-UNK
and	I-UNK
memory	I-UNK
compared	O
to	O
controls	B-UNK
and	O
cannabis	O
users	B-UNK
.	O
A	O
conjunction	B-UNK
analysis	B-UNK
of	O
the	O
encode	O
and	O
recall	B-UNK
phases	O
of	O
the	O
task	B-UNK
revealed	O
ecstasy	B-UNK
-	O
specific	B-UNK
hyperactivity	B-UNK
in	O
bilateral	B-UNK
frontal	B-UNK
regions	B-UNK
,	O
left	B-UNK
temporal	B-UNK
,	O
right	O
parietal	O
,	O
bilateral	B-UNK
temporal	B-UNK
,	O
and	O
bilateral	B-UNK
occipital	O
brain	B-UNK
regions	B-UNK
.	O
Ecstasy	B-UNK
-	O
specific	B-UNK
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	B-UNK
anterior	B-UNK
cingulated	O
cortex	B-UNK
(	O
ACC	B-UNK
)	O
and	O
left	B-UNK
posterior	B-UNK
cingulated	O
cortex	B-UNK
.	O
In	O
both	O
ecstasy	B-UNK
and	O
cannabis	O
groups	B-UNK
brain	B-UNK
activation	B-UNK
was	O
decreased	B-UNK
in	O
the	O
right	O
medial	B-UNK
frontal	B-UNK
gyrus	B-UNK
,	O
left	B-UNK
parahippocampal	O
gyrus	B-UNK
,	O
left	B-UNK
dorsal	B-UNK
cingulate	O
gyrus	B-UNK
,	O
and	O
left	B-UNK
caudate	O
.	O
These	O
results	B-UNK
elucidated	O
ecstasy	B-CHEMICAL
-	O
related	O
deficits	B-UNK
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	B-UNK
to	O
cannabis	O
use	O
.	O
These	O
ecstasy	B-UNK
-	O
specific	B-UNK
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	B-UNK
to	O
the	O
neurotoxic	B-UNK
effects	O
of	O
ecstasy	B-CHEMICAL
.	O

Prolonged	B-UNK
elevation	B-UNK
of	O
plasma	B-UNK
argatroban	B-UNK
in	O
a	O
cardiac	B-UNK
transplant	B-UNK
patient	B-UNK
with	O
a	O
suspected	O
history	B-UNK
of	O
heparin	B-CHEMICAL
-	O
induced	O
thrombocytopenia	B-UNK
with	O
thrombosis	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Direct	B-UNK
thrombin	B-UNK
inhibitors	B-UNK
(	O
DTIs	O
)	O
provide	O
an	O
alternative	B-UNK
method	B-UNK
of	O
anticoagulation	B-UNK
for	O
patients	B-UNK
with	O
a	O
history	B-UNK
of	O
heparin	B-UNK
-	O
induced	O
thrombocytopenia	B-UNK
(	O
HIT	B-UNK
)	O
or	O
HIT	B-UNK
with	O
thrombosis	B-DISEASE
(	O
HITT	O
)	O
undergoing	B-UNK
cardiopulmonary	B-UNK
bypass	B-UNK
(	O
CPB	O
)	O
.	O
In	O
the	O
following	O
report	B-UNK
,	O
a	O
65-year	O
-	O
old	O
critically	B-DISEASE
ill	I-DISEASE
patient	B-UNK
with	O
a	O
suspected	O
history	B-UNK
of	O
HITT	O
was	O
administered	O
argatroban	B-UNK
for	O
anticoagulation	B-UNK
on	O
bypass	B-UNK
during	O
heart	B-UNK
transplantation	B-UNK
.	O
The	O
patient	B-UNK
required	B-UNK
massive	B-UNK
transfusion	B-UNK
support	B-UNK
(	O
55	O
units	B-UNK
of	O
red	B-UNK
blood	B-UNK
cells	B-UNK
,	O
42	O
units	B-UNK
of	O
fresh	O
-	O
frozen	O
plasma	B-UNK
,	O
40	O
units	B-UNK
of	O
cryoprecipitate	O
,	O
40	O
units	B-UNK
of	O
platelets	O
,	O
and	O
three	O
doses	B-UNK
of	O
recombinant	O
Factor	B-UNK
VIIa	O
)	O
for	O
severe	B-UNK
intraoperative	B-UNK
and	O
postoperative	B-UNK
bleeding	B-DISEASE
.	O
STUDY	B-UNK
DESIGN	B-UNK
AND	O
METHODS	B-UNK
:	O
Plasma	B-UNK
samples	O
from	O
before	O
and	O
after	O
CPB	O
were	O
analyzed	O
postoperatively	B-UNK
for	O
argatroban	B-UNK
concentration	B-UNK
using	O
a	O
modified	B-UNK
ecarin	O
clotting	O
time	O
(	O
ECT	O
)	O
assay	B-UNK
.	O
RESULTS	B-UNK
:	O
Unexpectedly	O
high	B-UNK
concentrations	B-UNK
of	O
argatroban	B-UNK
were	O
measured	B-UNK
in	O
these	O
samples	O
(	O
range	B-UNK
,	O
0	O
-	O
32	O
microg	B-UNK
/	O
mL	B-UNK
)	O
,	O
and	O
a	O
prolonged	B-UNK
plasma	B-UNK
argatroban	B-UNK
half	B-UNK
life	B-UNK
(	O
t(1/2	O
)	O
)	O
of	O
514	O
minutes	B-UNK
was	O
observed	O
(	O
published	B-UNK
elimination	O
t(1/2	O
)	O
is	O
39	O
-	O
51	O
minutes	B-UNK
[	O
<	O
or	O
=	O
181	O
minutes	B-UNK
with	O
hepatic	B-UNK
impairment	B-UNK
]	O
)	O
.	O
CONCLUSIONS	B-UNK
:	O
Correlation	B-UNK
of	O
plasma	B-UNK
argatroban	B-UNK
concentration	B-UNK
versus	O
the	O
patient'	B-UNK
s	I-UNK
coagulation	B-UNK
variables	B-UNK
and	O
clinical	B-UNK
course	O
suggest	B-UNK
that	O
prolonged	B-UNK
elevated	B-UNK
levels	O
of	O
plasma	B-UNK
argatroban	B-UNK
may	O
have	O
contributed	B-UNK
to	O
the	O
patient'	B-UNK
s	I-UNK
extended	B-UNK
coagulopathy	B-DISEASE
.	O
Because	O
DTIs	O
do	O
not	O
have	O
reversal	B-UNK
agents	B-UNK
,	O
surgical	B-UNK
teams	O
and	O
transfusion	B-UNK
services	O
should	O
remain	O
aware	B-UNK
of	O
the	O
possibility	O
of	O
massive	B-UNK
transfusion	B-UNK
events	B-UNK
during	O
anticoagulation	B-UNK
with	O
these	O
agents	B-UNK
.	O
This	O
is	O
the	O
first	O
report	B-UNK
to	O
measure	B-UNK
plasma	B-UNK
argatroban	B-UNK
concentration	B-UNK
in	O
the	O
context	O
of	O
CPB	O
and	O
extended	B-UNK
coagulopathy	B-DISEASE
.	O

Antituberculosis	O
therapy	O
-	O
induced	O
acute	B-UNK
liver	I-UNK
failure	I-UNK
:	O
magnitude	B-UNK
,	O
profile	B-UNK
,	O
prognosis	O
,	O
and	O
predictors	B-UNK
of	O
outcome	B-UNK
.	O
Antituberculosis	O
therapy	O
(	O
ATT)-associated	O
acute	B-UNK
liver	I-UNK
failure	I-UNK
(	O
ATT	B-UNK
-	O
ALF	B-DISEASE
)	O
is	O
the	O
commonest	O
drug	B-UNK
-	O
induced	O
ALF	B-UNK
in	O
South	O
Asia	O
.	O
Prospective	B-UNK
studies	B-UNK
on	O
ATT	B-UNK
-	O
ALF	B-UNK
are	O
lacking	B-UNK
.	O
The	O
current	B-UNK
study	B-UNK
prospectively	O
evaluated	B-UNK
the	O
magnitude	B-UNK
,	O
clinical	B-UNK
course	O
,	O
outcome	B-UNK
,	O
and	O
prognostic	O
factors	B-UNK
in	O
ATT	B-UNK
-	O
ALF	B-UNK
.	O
From	O
January	B-UNK
1986	O
to	O
January	B-UNK
2009	O
,	O
1223	O
consecutive	B-UNK
ALF	B-UNK
patients	B-UNK
were	O
evaluated	B-UNK
:	O
ATT	B-UNK
alone	O
was	O
the	O
cause	O
in	O
70	O
(	O
5.7	O
%	O
)	O
patients	B-UNK
.	O
Another	O
15	O
(	O
1.2	O
%	O
)	O
had	O
ATT	B-UNK
and	O
simultaneous	B-UNK
hepatitis	B-DISEASE
virus	B-UNK
infection	B-DISEASE
.	O
In	O
44	O
(	O
62.8	O
%	O
)	O
patients	B-UNK
,	O
ATT	B-UNK
was	O
prescribed	B-UNK
empirically	O
without	O
definitive	O
evidence	B-UNK
of	O
tuberculosis	B-UNK
.	O
ATT	B-UNK
-	O
ALF	B-UNK
patients	B-UNK
were	O
younger	B-UNK
(	O
32.87	O
[	O
+	O
/-15.8	O
]	O
years	B-UNK
)	O
,	O
and	O
49	O
(	O
70	O
%	O
)	O
of	O
them	O
were	O
women	B-UNK
.	O
Most	O
had	O
hyperacute	O
presentation	B-UNK
;	O
the	O
median	B-UNK
icterus	O
encephalopathy	B-DISEASE
interval	B-UNK
was	O
4.5	O
(	O
0	O
-	O
30	O
)	O
days	B-UNK
.	O
The	O
median	B-UNK
duration	B-UNK
of	O
ATT	B-UNK
before	O
ALF	B-UNK
was	O
30	O
(	O
7	O
-	O
350	O
)	O
days	B-UNK
.	O
At	O
presentation	B-UNK
,	O
advanced	B-UNK
encephalopathy	B-DISEASE
and	O
cerebral	B-UNK
edema	I-UNK
were	O
present	B-UNK
in	O
51	O
(	O
76	O
%	O
)	O
and	O
29	O
(	O
41.4	O
%	O
)	O
patients	B-UNK
,	O
respectively	O
.	O
Gastrointestinal	B-UNK
bleed	O
,	O
seizures	B-UNK
,	O
infection	B-UNK
,	O
and	O
acute	B-UNK
renal	I-UNK
failure	I-UNK
were	O
documented	O
in	O
seven	O
(	O
10	O
%	O
)	O
,	O
five	O
(	O
7.1	O
%	O
)	O
,	O
26	O
(	O
37.1	O
%	O
)	O
,	O
and	O
seven	O
(	O
10	O
%	O
)	O
patients	B-UNK
,	O
respectively	O
.	O
Compared	O
with	O
hepatitis	B-DISEASE
E	I-DISEASE
virus	B-UNK
(	O
HEV	O
)	O
and	O
non-A	O
non-E-induced	O
ALF	B-UNK
,	O
ATT	B-UNK
-	O
ALF	B-UNK
patients	B-UNK
had	O
nearly	O
similar	B-UNK
presentations	O
except	O
for	O
older	B-UNK
age	B-UNK
and	O
less	O
elevation	B-UNK
of	O
liver	B-UNK
enzymes	B-UNK
.	O
The	O
mortality	B-UNK
rate	I-UNK
among	O
patients	B-UNK
with	O
ATT	B-UNK
-	O
ALF	B-UNK
was	O
high	B-UNK
(	O
67.1	O
%	O
,	O
n	O
=	O
47	O
)	O
,	O
and	O
only	O
23	O
(	O
32.9	O
%	O
)	O
patients	B-UNK
recovered	O
with	O
medical	B-UNK
treatment	B-UNK
.	O
In	O
multivariate	B-UNK
analysis	B-UNK
,	O
three	O
factors	B-UNK
independently	O
predicted	O
mortality	B-UNK
:	O
serum	B-UNK
bilirubin	B-UNK
(	O
>	O
or=10.8	O
mg	B-UNK
/	O
dL	B-UNK
)	O
,	O
prothrombin	O
time	O
(	O
PT	O
)	O
prolongation	B-UNK
(	O
>	O
or=26	O
seconds	B-UNK
)	O
,	O
and	O
grade	B-UNK
III	B-UNK
/	O
IV	B-UNK
encephalopathy	B-UNK
at	O
presentation	B-UNK
.	O
CONCLUSION	B-UNK
:	O
ATT	B-UNK
-	O
ALF	B-UNK
constituted	O
5.7	O
%	O
of	O
ALF	B-UNK
at	O
our	O
center	B-UNK
and	O
had	O
a	O
high	B-UNK
mortality	B-UNK
rate	I-UNK
.	O
Because	O
the	O
mortality	B-UNK
rate	I-UNK
is	O
so	O
high	B-UNK
,	O
determining	O
which	O
factors	B-UNK
are	O
predictors	B-UNK
is	O
less	O
important	B-UNK
.	O
A	O
high	B-UNK
proportion	B-UNK
of	O
patients	B-UNK
had	O
consumed	O
ATT	B-UNK
empirically	O
,	O
which	O
could	O
have	O
been	O
prevented	B-UNK
.	O

Central	B-UNK
nervous	I-UNK
system	I-UNK
complications	B-UNK
during	O
treatment	B-UNK
of	O
acute	B-UNK
lymphoblastic	I-UNK
leukemia	I-UNK
in	O
a	O
single	B-UNK
pediatric	B-UNK
institution	B-UNK
.	O
Central	B-UNK
nervous	I-UNK
system	I-UNK
(	O
CNS	B-UNK
)	O
complications	B-UNK
during	O
treatment	B-UNK
of	O
childhood	O
acute	B-UNK
lymphoblastic	I-UNK
leukemia	I-UNK
(	O
ALL	O
)	O
remain	O
a	O
challenging	O
clinical	B-UNK
problem	O
.	O
Outcome	B-UNK
improvement	B-UNK
with	O
more	O
intensive	B-UNK
chemotherapy	O
has	O
significantly	B-UNK
increased	B-UNK
the	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
adverse	B-UNK
events	I-UNK
.	O
This	O
study	B-UNK
analyzed	O
the	O
incidence	B-UNK
of	O
neurological	B-UNK
complications	B-UNK
during	O
ALL	O
treatment	B-UNK
in	O
a	O
single	B-UNK
pediatric	B-UNK
institution	B-UNK
,	O
focusing	O
on	O
clinical	B-UNK
,	O
radiological	O
,	O
and	O
electrophysiological	B-UNK
findings	B-UNK
.	O
Exclusion	O
criteria	B-UNK
included	B-UNK
CNS	B-UNK
leukemic	B-DISEASE
infiltration	I-DISEASE
at	O
diagnosis	B-UNK
,	O
therapy	O
-	O
related	O
peripheral	B-UNK
neuropathy	I-UNK
,	O
late	B-UNK
-	O
onset	B-UNK
encephalopathy	B-UNK
,	O
or	O
long	B-UNK
-	O
term	O
neurocognitive	O
defects	B-UNK
.	O
During	O
a	O
9-year	O
period	B-UNK
,	O
we	O
retrospectively	O
collected	O
27	O
neurological	B-UNK
events	B-UNK
(	O
11	O
%	O
)	O
in	O
as	O
many	O
patients	B-UNK
,	O
from	O
253	O
children	B-UNK
enrolled	O
in	O
the	O
ALL	O
front	O
-	O
line	B-UNK
protocol	O
.	O
CNS	B-UNK
complications	B-DISEASE
included	B-UNK
posterior	B-UNK
reversible	B-UNK
leukoencephalopathy	B-DISEASE
syndrome	B-UNK
(	O
n	O
=	O
10	O
)	O
,	O
stroke	B-UNK
(	O
n	O
=	O
5	O
)	O
,	O
temporal	B-UNK
lobe	I-UNK
epilepsy	I-UNK
(	O
n	O
=	O
2	O
)	O
,	O
high	B-UNK
-	O
dose	B-UNK
methotrexate	B-CHEMICAL
toxicity	B-UNK
(	O
n	O
=	O
2	O
)	O
,	O
syndrome	B-DISEASE
of	I-DISEASE
inappropriate	I-DISEASE
antidiuretic	I-DISEASE
hormone	I-DISEASE
secretion	B-UNK
(	O
n	O
=	O
1	O
)	O
,	O
and	O
other	O
unclassified	O
events	B-UNK
(	O
n	O
=	O
7	O
)	O
.	O
In	O
conclusion	B-UNK
,	O
CNS	B-UNK
complications	B-UNK
are	O
frequent	B-UNK
events	B-UNK
during	O
ALL	O
therapy	O
,	O
and	O
require	O
rapid	B-UNK
detection	B-UNK
and	O
prompt	B-UNK
treatment	B-UNK
to	O
limit	B-UNK
permanent	B-UNK
damage	B-UNK
.	O

Safety	B-UNK
of	O
capecitabine	O
:	O
a	O
review	B-UNK
.	O
IMPORTANCE	B-UNK
OF	O
THE	O
FIELD	B-UNK
:	O
Fluoropyrimidines	O
,	O
in	O
particular	O
5-fluorouracil	B-CHEMICAL
(	O
5-FU	B-CHEMICAL
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	B-UNK
for	O
several	O
solid	O
tumors	B-UNK
,	O
including	O
colorectal	O
,	O
breast	B-UNK
and	O
head	B-UNK
and	I-UNK
neck	I-UNK
cancers	B-UNK
,	O
for	O
>	O
40	O
years	B-UNK
.	O
AREAS	B-UNK
COVERED	O
IN	O
THIS	O
REVIEW	B-UNK
:	O
This	O
article	O
reviews	O
the	O
pharmacology	B-UNK
and	O
efficacy	B-UNK
of	O
capecitabine	O
with	O
a	O
special	B-UNK
emphasis	O
on	O
its	O
safety	B-UNK
.	O
WHAT	O
THE	O
READER	O
WILL	O
GAIN	B-UNK
:	O
The	O
reader	O
will	O
gain	B-UNK
better	O
insight	O
into	O
the	O
safety	B-UNK
of	O
capecitabine	O
in	O
special	B-UNK
populations	O
such	O
as	O
patients	B-UNK
with	O
advanced	B-UNK
age	B-UNK
,	O
renal	B-UNK
and	O
kidney	B-UNK
disease	B-UNK
.	O
We	O
also	O
explore	B-UNK
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	O
administration	O
.	O
TAKE	O
HOME	B-UNK
MESSAGE	O
:	O
Capecitabine	O
is	O
an	O
oral	B-UNK
prodrug	O
of	O
5-FU	B-CHEMICAL
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	B-UNK
/	O
efficacy	B-UNK
profile	B-UNK
.	O
It	O
has	O
shown	B-UNK
promising	O
results	B-UNK
alone	O
or	O
in	O
combination	B-UNK
with	O
other	O
chemotherapeutic	B-UNK
agents	B-UNK
in	O
colorectal	O
,	O
breast	B-UNK
,	O
pancreaticobiliary	O
,	O
gastric	B-UNK
,	O
renal	B-UNK
cell	B-UNK
and	O
head	B-UNK
and	I-UNK
neck	I-UNK
cancers	B-DISEASE
.	O
The	O
most	O
commonly	B-UNK
reported	B-UNK
toxic	B-UNK
effects	I-UNK
of	O
capecitabine	O
are	O
diarrhea	B-DISEASE
,	O
nausea	B-DISEASE
,	O
vomiting	B-UNK
,	O
stomatitis	B-DISEASE
and	O
hand	B-DISEASE
-	I-DISEASE
foot	I-DISEASE
syndrome	I-DISEASE
.	O
Capecitabine	O
has	O
a	O
well	O
-	O
established	B-UNK
safety	B-UNK
profile	B-UNK
and	O
can	O
be	O
given	O
safely	B-UNK
to	O
patients	B-UNK
with	O
advanced	B-UNK
age	B-UNK
,	O
hepatic	B-UNK
and	O
renal	B-UNK
dysfunctions	B-UNK
.	O

Effects	O
of	O
pallidal	O
neurotensin	B-CHEMICAL
on	O
haloperidol	B-CHEMICAL
-	O
induced	O
parkinsonian	B-UNK
catalepsy	B-UNK
:	O
behavioral	B-UNK
and	O
electrophysiological	B-UNK
studies	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
The	O
globus	B-UNK
pallidus	I-UNK
plays	O
a	O
critical	B-UNK
role	O
in	O
movement	B-UNK
regulation	B-UNK
.	O
Previous	B-UNK
studies	I-UNK
have	O
indicated	O
that	O
the	O
globus	B-UNK
pallidus	I-UNK
receives	O
neurotensinergic	O
innervation	O
from	O
the	O
striatum	B-UNK
,	O
and	O
systemic	B-UNK
administration	O
of	O
a	O
neurotensin	B-CHEMICAL
analog	B-UNK
could	O
produce	B-UNK
antiparkinsonian	B-UNK
effects	O
.	O
The	O
present	B-UNK
study	B-UNK
aimed	B-UNK
to	O
investigate	B-UNK
the	O
effects	O
of	O
pallidal	O
neurotensin	B-CHEMICAL
on	O
haloperidol	B-UNK
-	O
induced	O
parkinsonian	B-UNK
symptoms	B-UNK
.	O
METHODS	B-UNK
:	O
Behavioral	B-UNK
experiments	B-UNK
and	O
electrophysiological	B-UNK
recordings	O
were	O
performed	B-UNK
in	O
the	O
present	B-UNK
study	B-UNK
.	O
RESULTS	B-UNK
:	O
Bilateral	B-UNK
infusions	B-UNK
of	O
neurotensin	B-CHEMICAL
into	O
the	O
globus	B-UNK
pallidus	I-UNK
reversed	B-UNK
haloperidol	B-CHEMICAL
-	O
induced	O
parkinsonian	B-DISEASE
catalepsy	B-UNK
in	O
rats	B-UNK
.	O
Electrophysiological	B-UNK
recordings	O
showed	O
that	O
microinjection	B-UNK
of	O
neurotensin	B-CHEMICAL
induced	O
excitation	O
of	O
pallidal	O
neurons	B-UNK
in	O
the	O
presence	O
of	O
systemic	B-UNK
haloperidol	B-UNK
administration	O
.	O
The	O
neurotensin	B-CHEMICAL
type-1	O
receptor	B-UNK
antagonist	I-UNK
SR48692	O
blocked	B-UNK
both	O
the	O
behavioral	B-UNK
and	O
the	O
electrophysiological	B-UNK
effects	O
induced	O
by	O
neurotensin	B-CHEMICAL
.	O
CONCLUSION	B-UNK
:	O
Activation	B-UNK
of	O
pallidal	O
neurotensin	B-CHEMICAL
receptors	B-UNK
may	O
be	O
involved	B-UNK
in	O
neurotensin	B-CHEMICAL
-	O
induced	O
antiparkinsonian	B-UNK
effects	O
.	O

Antihypertensive	B-CHEMICAL
drugs	I-CHEMICAL
and	O
depression	B-UNK
:	O
a	O
reappraisal	O
.	O
Eighty	B-UNK
-	O
nine	O
new	O
referral	O
hypertensive	B-UNK
out	O
-	O
patients	B-UNK
and	O
46	O
new	O
referral	O
non-hypertensive	O
chronically	B-UNK
physically	O
ill	O
out	O
-	O
patients	B-UNK
completed	O
a	O
mood	B-UNK
rating	B-UNK
scale	I-UNK
at	O
regular	B-UNK
intervals	B-UNK
for	O
one	O
year	O
.	O
The	O
results	B-UNK
showed	O
a	O
high	B-UNK
prevalence	B-UNK
of	O
depression	B-DISEASE
in	O
both	O
groups	B-UNK
of	O
patients	B-UNK
,	O
with	O
no	O
preponderance	O
in	O
the	O
hypertensive	B-UNK
group	B-UNK
.	O
Hypertensive	B-DISEASE
patients	B-UNK
with	O
psychiatric	B-UNK
histories	O
had	O
a	O
higher	B-UNK
prevalence	B-UNK
of	O
depression	B-UNK
than	O
the	O
comparison	B-UNK
patients	B-UNK
.	O
This	O
was	O
accounted	O
for	O
by	O
a	O
significant	B-UNK
number	B-UNK
of	O
depressions	B-DISEASE
occurring	O
in	O
methyl	B-UNK
dopa	B-UNK
treated	O
patients	B-UNK
with	O
psychiatric	B-UNK
histories	O
.	O

Pulmonary	B-UNK
shunt	O
and	O
cardiovascular	B-UNK
responses	O
to	O
CPAP	O
during	O
nitroprusside	B-CHEMICAL
-	O
induced	B-UNK
hypotension	I-UNK
.	O
The	O
effects	O
of	O
continuous	B-UNK
positive	B-UNK
airway	B-UNK
pressure	B-UNK
(	O
CPAP	O
)	O
on	O
cardiovascular	B-UNK
dynamics	O
and	O
pulmonary	B-UNK
shunt	O
(	O
QS	O
/	O
QT	B-UNK
)	O
were	O
investigated	B-UNK
in	O
12	O
dogs	B-UNK
before	O
and	O
during	O
sodium	B-UNK
nitroprusside	I-UNK
infusion	B-UNK
that	O
decreased	B-UNK
mean	O
arterial	B-UNK
blood	I-UNK
pressure	I-UNK
40	O
-	O
50	O
per	B-UNK
cent	I-UNK
.	O
Before	O
nitroprusside	B-UNK
infusion	B-UNK
,	O
5	O
cm	B-DISEASE
H2O	O
CPAP	O
significantly	B-UNK
,	O
P	O
less	O
than	O
.05	O
,	O
decreased	B-UNK
arterial	B-UNK
blood	I-UNK
pressure	I-UNK
,	O
but	O
did	O
not	O
significantly	B-UNK
alter	O
heart	B-UNK
rate	I-UNK
,	O
cardiac	B-UNK
output	I-UNK
,	O
systemic	B-UNK
vascular	I-UNK
resistance	I-UNK
,	O
or	O
QS	O
/	O
QT	B-UNK
.	O
Ten	O
cm	B-UNK
H2O	O
CPAP	O
before	O
nitroprusside	B-CHEMICAL
infusion	B-UNK
produced	B-UNK
a	O
further	O
decrease	B-DISEASE
in	I-DISEASE
arterial	I-DISEASE
blood	I-DISEASE
pressure	I-DISEASE
and	O
significantly	B-UNK
increased	B-UNK
heart	B-UNK
rate	I-UNK
and	O
decreased	B-DISEASE
cardiac	I-DISEASE
output	I-DISEASE
and	O
QS	O
/	O
QT	B-UNK
.	O
Nitroprusside	B-UNK
caused	B-UNK
significant	B-UNK
decreases	B-DISEASE
in	I-DISEASE
arterial	I-DISEASE
blood	I-DISEASE
pressure	I-DISEASE
and	O
systemic	B-UNK
vascular	I-UNK
resistance	I-UNK
and	O
increases	B-UNK
in	O
heart	B-UNK
rate	I-UNK
,	O
but	O
did	O
not	O
change	B-UNK
cardiac	B-UNK
output	I-UNK
or	O
QS	O
/	O
QT	B-UNK
.	O
Five	O
cm	B-DISEASE
H2O	O
CPAP	O
during	O
nitroprusside	B-UNK
did	O
not	O
further	O
alter	O
any	O
of	O
the	O
above	O
-	O
mentioned	O
variables	B-UNK
.	O
However	O
,	O
10	O
cm	B-DISEASE
H2O	O
CPAP	O
decreased	B-UNK
arterial	B-UNK
blood	I-UNK
pressure	I-UNK
,	O
cardiac	B-UNK
output	I-UNK
,	O
and	O
QS	O
/	O
QT	B-UNK
.	O
These	O
data	B-UNK
indicate	O
that	O
nitroprusside	B-CHEMICAL
infusion	B-UNK
rates	B-UNK
that	O
decrease	B-UNK
mean	O
arterial	B-UNK
blood	I-UNK
pressure	I-UNK
by	O
40	O
-	O
50	O
per	B-UNK
cent	I-UNK
do	O
not	O
change	B-UNK
cardiac	B-UNK
output	I-UNK
or	O
QS	O
/	O
QT	B-UNK
.	O
During	O
nitroprusside	B-UNK
infusion	B-UNK
low	B-UNK
levels	O
of	O
CPAP	O
do	O
not	O
markedly	O
alter	O
cardiovascular	B-UNK
dynamics	O
,	O
but	O
high	B-UNK
levels	O
of	O
CPAP	O
(	O
10	O
cm	B-UNK
H2O	O
)	O
,	O
while	O
decreasing	B-UNK
QS	O
/	O
QT	B-UNK
,	O
produce	B-UNK
marked	O
decreases	B-DISEASE
in	I-DISEASE
arterial	I-DISEASE
blood	I-DISEASE
pressure	I-DISEASE
and	O
cardiac	B-UNK
output	I-UNK
.	O

Mediation	O
of	O
enhanced	B-UNK
reflex	B-UNK
vagal	O
bradycardia	B-UNK
by	O
L	O
-	O
dopa	B-UNK
via	O
central	B-UNK
dopamine	B-CHEMICAL
formation	B-UNK
in	O
dogs	B-UNK
.	O
L	O
-	O
Dopa	B-UNK
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
decreased	B-UNK
blood	B-UNK
pressure	I-UNK
and	I-UNK
heart	I-UNK
rate	I-UNK
after	O
extracerebral	O
decarboxylase	O
inhibition	B-UNK
with	O
MK-486	O
(	O
25	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
in	O
anesthetize	O
MAO	O
-	O
inhibited	B-UNK
dogs	B-UNK
.	O
In	O
addition	B-UNK
,	O
reflex	B-UNK
bradycardia	B-UNK
caused	B-UNK
by	O
injected	B-UNK
norepinephrine	B-UNK
was	O
significantly	B-UNK
enhanced	B-UNK
by	O
L	O
-	O
dopa	B-UNK
,	O
DL	B-UNK
-	O
Threo	O
-	O
dihydroxyphenylserine	O
had	O
no	O
effect	B-UNK
on	O
blood	B-UNK
pressure	I-UNK
,	O
heart	B-UNK
rate	I-UNK
or	O
reflex	B-UNK
responses	O
to	O
norepinephrine	B-UNK
.	O
FLA-63	O
,	O
a	O
dopamine	B-UNK
-	O
beta	B-UNK
-	O
oxidase	B-UNK
inhibitor	B-UNK
,	O
did	O
not	O
have	O
any	O
effect	B-UNK
on	O
the	O
hypotension	B-DISEASE
,	O
bradycardia	B-DISEASE
or	O
reflex	B-UNK
-	O
enhancing	B-UNK
effect	B-UNK
of	O
L	O
-	O
dopa	B-UNK
.	O
Pimozide	O
did	O
not	O
affect	B-UNK
the	O
actions	B-UNK
of	O
L	O
-	O
dopa	B-UNK
on	O
blood	B-UNK
pressure	I-UNK
and	I-UNK
heart	I-UNK
rate	I-UNK
but	O
completely	O
blocked	B-UNK
the	O
enhancement	B-UNK
of	O
reflexes	O
.	O
Removal	O
of	O
the	O
carotid	B-UNK
sinuses	O
caused	B-UNK
an	O
elevation	B-UNK
blood	B-UNK
pressure	I-UNK
and	I-UNK
heart	I-UNK
rate	I-UNK
and	O
abolished	O
the	O
negative	B-UNK
chronotropic	O
effect	B-UNK
of	O
norepinephrine	B-UNK
.	O
However	O
,	O
L	O
-	O
dopa	B-UNK
restored	B-UNK
the	O
bradycardia	B-UNK
caused	B-UNK
by	O
norepinephrine	B-UNK
in	O
addition	B-UNK
to	O
decreasing	B-UNK
blood	B-UNK
pressure	I-UNK
and	I-UNK
heart	I-UNK
rate	I-UNK
.	O
5-HTP	B-CHEMICAL
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
decreased	B-UNK
blood	B-UNK
pressure	I-UNK
and	I-UNK
heart	I-UNK
rate	I-UNK
and	O
decreased	B-UNK
the	O
reflex	B-UNK
bradycardia	B-UNK
to	O
norepinephrine	B-UNK
.	O
It	O
is	O
concluded	O
that	O
L	O
-	O
dopa	B-UNK
enhances	B-UNK
reflex	B-UNK
bradycardia	B-UNK
through	O
central	B-UNK
alpha	B-UNK
-	O
receptor	B-UNK
stimulation	B-UNK
.	O
Furthermore	O
,	O
the	O
effects	O
are	O
mediated	B-UNK
through	O
dopamine	B-UNK
rather	O
than	O
norepinephrine	B-UNK
and	O
do	O
not	O
require	O
the	O
carotid	B-UNK
sinus	B-UNK
baroreceptors	O
.	O

Cocaine	B-UNK
-	O
induced	O
myocardial	B-UNK
infarction	I-UNK
:	O
clinical	B-UNK
observations	B-UNK
and	O
pathogenetic	O
considerations	O
.	O
Clinical	B-UNK
and	O
experimental	B-UNK
data	B-UNK
published	B-UNK
to	O
date	B-UNK
suggest	B-UNK
several	O
possible	O
mechanisms	B-UNK
by	O
which	O
cocaine	B-UNK
may	O
result	B-UNK
in	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O
In	O
individuals	B-UNK
with	O
preexisting	O
,	O
high	B-UNK
-	O
grade	B-UNK
coronary	B-UNK
arterial	B-UNK
narrowing	O
,	O
acute	B-UNK
myocardial	I-UNK
infarction	I-UNK
may	O
result	B-UNK
from	O
an	O
increase	B-UNK
in	O
myocardial	B-UNK
oxygen	B-UNK
demand	O
associated	O
with	O
cocaine	B-UNK
-	O
induced	O
increase	B-UNK
in	O
rate	B-UNK
-	O
pressure	B-UNK
product	B-UNK
.	O
In	O
other	O
individuals	B-UNK
with	O
no	O
underlying	B-UNK
atherosclerotic	B-DISEASE
obstruction	I-DISEASE
,	O
coronary	B-DISEASE
occlusion	I-DISEASE
may	O
be	O
due	O
to	O
spasm	B-DISEASE
,	O
thrombus	O
,	O
or	O
both	O
.	O
With	O
regard	B-UNK
to	O
spasm	B-DISEASE
,	O
the	O
clinical	B-UNK
findings	B-UNK
are	O
largely	O
circumstantial	O
,	O
and	O
the	O
locus	O
of	O
cocaine	B-UNK
-	O
induced	O
vasoconstriction	B-UNK
remains	O
speculative	O
.	O
Although	O
certain	O
clinical	B-UNK
and	O
experimental	B-UNK
findings	B-UNK
support	B-UNK
the	O
hypothesis	B-UNK
that	O
spasm	B-DISEASE
involves	O
the	O
epicardial	O
,	O
medium	B-UNK
-	O
size	B-UNK
vessels	B-UNK
,	O
other	O
data	B-UNK
suggest	I-UNK
intramural	O
vasoconstriction	B-UNK
.	O
Diffuse	B-UNK
intramural	O
vasoconstriction	B-UNK
is	O
not	O
consistent	B-UNK
with	O
reports	B-UNK
of	O
segmental	B-UNK
,	O
discrete	O
infarction	B-UNK
.	O
Whereas	O
certain	O
in	O
vivo	B-UNK
data	B-UNK
suggest	I-UNK
that	O
these	O
effects	O
are	O
alpha	B-UNK
-	O
mediated	B-UNK
,	O
other	O
in	O
vitro	B-UNK
data	B-UNK
suggest	I-UNK
the	O
opposite	O
.	O
The	O
finding	O
of	O
cocaine	B-CHEMICAL
-	O
induced	O
vasoconstriction	B-UNK
in	O
segments	B-UNK
of	O
(	O
noninnervated	O
)	O
human	B-UNK
umbilical	O
artery	B-UNK
suggests	O
that	O
the	O
presence	O
or	O
absence	O
of	O
intact	B-UNK
innervation	O
is	O
not	O
sufficient	B-UNK
to	O
explain	O
the	O
discrepant	O
data	B-UNK
involving	O
the	O
possibility	O
of	O
alpha	B-UNK
-	O
mediated	B-UNK
effects	O
.	O
Finally	B-UNK
,	O
the	O
contribution	B-UNK
of	O
a	O
primary	B-UNK
,	O
thrombotic	B-UNK
effect	B-UNK
of	O
cocaine	B-UNK
has	O
not	O
been	O
excluded	B-UNK
.	O

Rabbit	B-DISEASE
syndrome	I-DISEASE
,	O
antidepressant	B-UNK
use	O
,	O
and	O
cerebral	B-UNK
perfusion	B-UNK
SPECT	B-UNK
scan	O
findings	B-UNK
.	O
The	O
rabbit	B-DISEASE
syndrome	I-DISEASE
is	O
an	O
extrapyramidal	B-UNK
side	I-UNK
effect	B-UNK
associated	O
with	O
chronic	B-UNK
neuroleptic	B-UNK
therapy	O
.	O
Its	O
occurrence	B-UNK
in	O
a	O
patient	B-UNK
being	O
treated	O
with	O
imipramine	O
is	O
described	O
,	O
representing	O
the	O
first	O
reported	B-UNK
case	B-UNK
of	O
this	O
syndrome	B-UNK
in	O
conjunction	B-UNK
with	O
antidepressants	B-UNK
.	O
Repeated	B-UNK
cerebral	B-UNK
perfusion	B-UNK
SPECT	B-UNK
scans	O
revealed	O
decreased	B-DISEASE
basal	I-DISEASE
ganglia	I-DISEASE
perfusion	I-DISEASE
while	O
the	O
movement	B-UNK
disorder	B-UNK
was	O
present	B-UNK
,	O
and	O
a	O
return	B-UNK
to	O
normal	O
perfusion	B-UNK
when	O
the	O
rabbit	B-DISEASE
syndrome	I-DISEASE
resolved	O
.	O

Acute	B-UNK
bronchodilating	O
effects	O
of	O
ipratropium	O
bromide	O
and	O
theophylline	B-UNK
in	O
chronic	B-DISEASE
obstructive	I-DISEASE
pulmonary	I-DISEASE
disease	I-DISEASE
.	O
The	O
bronchodilator	O
effects	O
of	O
a	O
single	B-UNK
dose	B-UNK
of	O
ipratropium	O
bromide	O
aerosol	O
(	O
36	O
micrograms	B-UNK
)	O
and	O
short	B-UNK
-	O
acting	O
theophylline	B-CHEMICAL
tablets	B-UNK
(	O
dose	B-UNK
titrated	O
to	O
produce	B-UNK
serum	B-UNK
levels	O
of	O
10	O
-	O
20	O
micrograms	B-UNK
/	O
mL	B-UNK
)	O
were	O
compared	O
in	O
a	O
double-blind	O
,	O
placebo	B-UNK
-	O
controlled	B-UNK
crossover	B-UNK
study	I-UNK
in	O
21	O
patients	B-UNK
with	O
stable	B-UNK
,	O
chronic	B-DISEASE
obstructive	I-DISEASE
pulmonary	I-DISEASE
disease	I-DISEASE
.	O
Mean	O
peak	B-UNK
forced	O
expiratory	O
volume	B-UNK
in	O
1	O
second	O
(	O
FEV1	O
)	O
increases	B-UNK
over	O
baseline	B-UNK
and	O
the	O
proportion	B-UNK
of	O
patients	B-UNK
attaining	O
at	O
least	O
a	O
15	O
%	O
increase	B-UNK
in	O
the	O
FEV1	O
(	O
responders	O
)	O
were	O
31	O
%	O
and	O
90	O
%	O
,	O
respectively	O
,	O
for	O
ipratropium	O
and	O
17	O
%	O
and	O
50	O
%	O
,	O
respectively	O
,	O
for	O
theophylline	B-CHEMICAL
.	O
The	O
average	B-UNK
FEV1	O
increases	B-UNK
during	O
the	O
6-hour	O
observation	B-UNK
period	I-UNK
were	O
18	O
%	O
for	O
ipratropium	O
and	O
8	O
%	O
for	O
theophylline	B-UNK
.	O
The	O
mean	O
duration	B-UNK
of	O
action	B-UNK
was	O
3.8	O
hours	B-UNK
with	O
ipratropium	O
and	O
2.4	O
hours	B-UNK
with	O
theophylline	B-UNK
.	O
While	O
side	O
effects	O
were	O
rare	B-UNK
,	O
those	O
experienced	B-UNK
after	O
theophylline	B-UNK
use	O
did	O
involve	B-UNK
the	O
cardiovascular	B-UNK
and	O
gastrointestinal	B-UNK
systems	B-UNK
.	O
These	O
results	B-UNK
show	O
that	O
ipratropium	O
is	O
a	O
more	O
potent	B-UNK
bronchodilator	O
than	O
oral	B-UNK
theophylline	B-CHEMICAL
in	O
patients	B-UNK
with	O
chronic	B-DISEASE
airflow	I-DISEASE
obstruction	I-DISEASE
.	O

Irreversible	B-UNK
damage	B-UNK
to	O
the	O
medullary	B-UNK
interstitium	O
in	O
experimental	B-UNK
analgesic	B-UNK
nephropathy	B-UNK
in	O
F344	B-UNK
rats	B-UNK
.	O
Renal	B-DISEASE
papillary	I-DISEASE
necrosis	I-DISEASE
(	O
RPN	B-DISEASE
)	O
and	O
a	O
decreased	B-UNK
urinary	B-UNK
concentrating	O
ability	B-UNK
developed	O
during	O
continuous	B-UNK
long	B-UNK
-	O
term	O
treatment	B-UNK
with	O
aspirin	B-UNK
and	O
paracetamol	B-UNK
in	O
female	B-UNK
Fischer	O
344	O
rats	B-UNK
.	O
Renal	B-UNK
structure	B-UNK
and	O
concentrating	O
ability	B-UNK
were	O
examined	B-UNK
after	O
a	O
recovery	B-UNK
period	B-UNK
of	O
up	O
to	O
18	O
weeks	B-UNK
,	O
when	O
no	O
analgesics	B-UNK
were	O
given	O
,	O
to	O
investigate	B-UNK
whether	O
the	O
analgesic	B-UNK
-	O
induced	O
changes	O
were	O
reversible	B-UNK
.	O
There	O
was	O
no	O
evidence	B-UNK
of	O
repair	B-UNK
to	O
the	O
damaged	O
medullary	B-UNK
interstitial	B-UNK
matrix	B-UNK
,	O
or	O
proliferation	B-UNK
of	O
remaining	O
undamaged	O
type	B-UNK
1	O
medullary	B-UNK
interstitial	B-UNK
cells	B-UNK
after	O
the	O
recovery	B-UNK
period	B-UNK
following	O
analgesic	B-UNK
treatment	B-UNK
.	O
The	O
recovery	B-UNK
of	O
urinary	B-UNK
concentrating	O
ability	B-UNK
was	O
related	O
to	O
the	O
length	B-UNK
of	O
analgesic	B-UNK
treatment	B-UNK
and	O
the	O
extent	B-UNK
of	O
the	O
resulting	B-UNK
inner	O
medullary	B-UNK
structural	B-UNK
damage	B-UNK
.	O
During	O
the	O
early	B-UNK
stages	B-UNK
of	O
analgesic	B-UNK
treatment	B-UNK
,	O
the	O
changes	O
in	O
urinary	B-UNK
concentrating	O
ability	B-UNK
were	O
reversible	B-UNK
,	O
but	O
after	O
prolonged	B-UNK
analgesic	B-UNK
treatment	B-UNK
,	O
maximum	B-UNK
urinary	B-UNK
concentrating	O
ability	B-UNK
failed	B-UNK
to	O
recover	O
.	O
This	O
study	B-UNK
shows	O
that	O
prolonged	B-UNK
analgesic	B-UNK
treatment	B-UNK
in	O
Fischer	O
344	O
rats	B-UNK
causes	O
progressive	B-UNK
and	O
irreversible	B-UNK
damage	B-UNK
to	O
the	O
interstitial	B-UNK
matrix	B-UNK
and	O
type	B-UNK
1	O
interstitial	B-UNK
cells	B-UNK
leading	B-UNK
to	O
RPN	B-DISEASE
.	O
The	O
associated	O
urinary	B-UNK
concentrating	O
defect	B-UNK
is	O
reversible	B-UNK
only	O
during	O
the	O
early	B-UNK
stages	B-UNK
of	O
structural	B-UNK
damage	B-UNK
to	O
the	O
inner	O
medulla	B-UNK
.	O

Less	O
frequent	B-UNK
lithium	B-CHEMICAL
administration	O
and	O
lower	B-UNK
urine	B-UNK
volume	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
This	O
study	B-UNK
was	O
designed	B-UNK
to	O
determine	B-UNK
whether	O
patients	B-UNK
maintained	O
on	O
a	O
regimen	B-UNK
of	O
lithium	B-CHEMICAL
on	O
a	O
once	O
-	O
per	O
-	O
day	O
schedule	B-UNK
have	O
lower	B-UNK
urine	B-UNK
volumes	O
than	O
do	O
patients	B-UNK
receiving	B-UNK
multiple	B-UNK
doses	B-UNK
per	O
day	O
.	O
METHOD	B-UNK
:	O
This	O
was	O
a	O
cross-sectional	O
study	B-UNK
of	O
85	O
patients	B-UNK
from	O
a	O
lithium	B-UNK
clinic	B-UNK
who	O
received	O
different	O
dose	B-UNK
schedules	O
.	O
Patients	B-UNK
were	O
admitted	B-UNK
to	O
the	O
hospital	B-UNK
for	O
measurement	B-UNK
of	O
lithium	B-UNK
level	B-UNK
,	O
creatinine	B-UNK
clearance	I-UNK
,	O
urine	B-UNK
volume	B-UNK
,	O
and	O
maximum	B-UNK
osmolality	B-UNK
.	O
RESULTS	B-UNK
:	O
Multiple	B-UNK
daily	B-UNK
doses	B-UNK
of	O
lithium	B-UNK
were	O
associated	O
with	O
higher	B-UNK
urine	B-UNK
volumes	O
.	O
The	O
dosing	O
schedule	B-UNK
,	O
duration	B-UNK
of	O
lithium	B-UNK
treatment	B-UNK
,	O
and	O
daily	B-UNK
dose	I-UNK
of	O
lithium	B-CHEMICAL
did	O
not	O
affect	B-UNK
maximum	B-UNK
osmolality	B-UNK
or	O
creatinine	B-UNK
clearance	I-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Urine	B-UNK
volume	B-UNK
can	O
be	O
reduced	B-UNK
by	O
giving	O
lithium	B-UNK
once	O
daily	B-UNK
and	O
/	O
or	O
by	O
lowering	B-UNK
the	O
total	B-UNK
daily	B-UNK
dose	I-UNK
.	O
Lithium	B-UNK
-	O
induced	O
polyuria	B-UNK
seems	O
to	O
be	O
related	O
to	O
extrarenal	O
as	O
well	O
as	O
to	O
renal	B-UNK
effects	O
.	O

Effect	B-UNK
of	O
adriamycin	B-CHEMICAL
combined	B-UNK
with	O
whole	O
body	B-UNK
hyperthermia	B-UNK
on	O
tumor	B-UNK
and	O
normal	O
tissues	B-UNK
.	O
Thermal	O
enhancement	B-UNK
of	O
Adriamycin	B-CHEMICAL
-	O
mediated	B-UNK
antitumor	B-UNK
activity	I-UNK
and	O
normal	O
tissue	B-UNK
toxicities	B-DISEASE
by	O
whole	O
body	B-UNK
hyperthermia	B-DISEASE
were	O
compared	O
using	O
a	O
F344	B-UNK
rat	B-UNK
model	B-UNK
.	O
Antitumor	B-UNK
activity	I-UNK
was	O
studied	O
using	O
a	O
tumor	B-UNK
growth	B-UNK
delay	B-UNK
assay	B-UNK
.	O
Acute	B-UNK
normal	O
tissue	B-UNK
toxicities	B-DISEASE
(	O
i.e	B-UNK
.	O
,	O
leukopenia	B-DISEASE
and	O
thrombocytopenia	B-UNK
)	O
and	O
late	B-UNK
normal	O
tissue	B-UNK
toxicities	B-DISEASE
(	O
i.e	B-UNK
.	O
,	O
myocardial	B-UNK
and	O
kidney	B-UNK
injury	B-UNK
)	O
were	O
evaluated	B-UNK
by	O
functional	B-UNK
/	O
physiological	B-UNK
assays	O
and	O
by	O
morphological	B-UNK
techniques	O
.	O
Whole	O
body	B-UNK
hyperthermia	B-UNK
(	O
120	O
min	B-UNK
at	O
41.5	O
degrees	B-UNK
C	O
)	O
enhanced	B-UNK
both	O
Adriamycin	B-UNK
-	O
mediated	B-UNK
antitumor	B-UNK
activity	I-UNK
and	O
toxic	B-UNK
side	O
effects	O
.	O
The	O
thermal	O
enhancement	B-UNK
ratio	B-UNK
calculated	B-UNK
for	O
antitumor	B-UNK
activity	I-UNK
was	O
1.6	O
.	O
Thermal	O
enhancement	B-UNK
ratios	O
estimated	O
for	O
"	O
acute	B-UNK
"	O
hematological	O
changes	O
were	O
1.3	O
,	O
whereas	O
those	O
estimated	O
for	O
"	O
late	B-UNK
"	O
damage	B-UNK
(	O
based	B-UNK
on	O
morphological	B-UNK
cardiac	B-UNK
and	O
renal	B-DISEASE
lesions	I-DISEASE
)	O
varied	O
between	O
2.4	O
and	O
4.3	O
.	O
Thus	O
,	O
while	O
whole	O
body	B-UNK
hyperthermia	B-UNK
enhances	B-UNK
Adriamycin	B-UNK
-	O
mediated	B-UNK
antitumor	B-UNK
effect	B-UNK
,	O
normal	O
tissue	B-UNK
toxicity	B-UNK
is	O
also	O
increased	B-UNK
,	O
and	O
the	O
potential	B-UNK
therapeutic	B-UNK
gain	B-UNK
of	O
the	O
combined	B-UNK
modality	O
treatment	B-UNK
is	O
eroded	O
.	O

Prazosin	B-UNK
-	O
induced	O
stress	B-DISEASE
incontinence	I-DISEASE
.	O
A	O
case	B-UNK
of	O
genuine	O
stress	B-DISEASE
incontinence	I-DISEASE
due	O
to	O
prazosin	B-UNK
,	O
a	O
common	B-UNK
antihypertensive	B-UNK
drug	B-UNK
,	O
is	O
presented	B-UNK
.	O
Prazosin	B-CHEMICAL
exerts	B-UNK
its	O
antihypertensive	B-UNK
effects	O
through	O
vasodilatation	O
caused	B-UNK
by	O
selective	B-UNK
blockade	B-UNK
of	O
postsynaptic	B-UNK
alpha-1	O
adrenergic	B-UNK
receptors	B-UNK
.	O
As	O
an	O
alpha	B-UNK
-	O
blocker	B-UNK
,	O
it	O
also	O
exerts	B-UNK
a	O
significant	B-UNK
relaxant	O
effect	B-UNK
on	O
the	O
bladder	B-UNK
neck	B-UNK
and	O
urethra	O
.	O
The	O
patient'	B-UNK
s	I-UNK
clinical	B-UNK
course	O
is	O
described	O
and	O
correlated	B-UNK
with	O
initial	B-UNK
urodynamic	O
studies	B-UNK
while	O
on	O
prazosin	B-CHEMICAL
and	O
subsequent	B-UNK
studies	B-UNK
while	O
taking	B-UNK
verapamil	B-UNK
.	O
Her	O
incontinence	B-UNK
resolved	O
with	O
the	O
change	B-UNK
of	O
medication	O
.	O
The	O
restoration	O
of	O
continence	O
was	O
accompanied	B-UNK
by	O
a	O
substantial	O
rise	B-UNK
in	O
maximum	B-UNK
urethral	O
pressure	B-UNK
,	O
maximum	B-UNK
urethral	O
closure	O
pressure	B-UNK
,	O
and	O
functional	B-UNK
urethral	O
length	B-UNK
.	O
Patients	B-UNK
who	O
present	B-UNK
with	O
stress	B-DISEASE
incontinence	I-DISEASE
while	O
taking	B-UNK
prazosin	B-UNK
should	O
change	B-UNK
their	O
antihypertensive	B-UNK
medication	O
before	O
considering	O
surgery	B-UNK
,	O
because	O
their	O
incontinence	B-UNK
may	O
resolve	O
spontaneously	B-UNK
with	O
a	O
change	B-UNK
in	O
drug	B-UNK
therapy	O
.	O

Myocardial	B-UNK
infarction	I-UNK
following	O
sublingual	O
administration	O
of	O
isosorbide	O
dinitrate	O
.	O
A	O
78-year	O
-	O
old	O
with	O
healed	O
septal	B-UNK
necrosis	B-UNK
suffered	O
a	O
recurrent	B-UNK
myocardial	B-UNK
infarction	I-UNK
of	O
the	O
anterior	B-UNK
wall	B-UNK
following	O
the	O
administration	O
of	O
isosorbide	O
dinitrate	O
5	O
mg	B-UNK
sublingually	O
.	O
After	O
detailing	O
the	O
course	O
of	O
events	B-UNK
,	O
we	O
discuss	B-UNK
the	O
role	O
of	O
paradoxical	B-UNK
coronary	B-DISEASE
spasm	I-DISEASE
and	O
hypotension	B-DISEASE
-	O
mediated	B-UNK
myocardial	B-UNK
ischemia	I-UNK
occurring	O
downstream	O
to	O
significant	B-UNK
coronary	B-DISEASE
arterial	I-DISEASE
stenosis	I-DISEASE
in	O
the	O
pathophysiology	B-UNK
of	O
acute	B-DISEASE
coronary	I-DISEASE
insufficiency	I-DISEASE
.	O

Fluoxetine	B-UNK
-	O
induced	O
akathisia	B-UNK
:	O
clinical	B-UNK
and	O
theoretical	O
implications	B-UNK
.	O
Five	O
patients	B-UNK
receiving	B-UNK
fluoxetine	B-UNK
for	O
the	O
treatment	B-UNK
of	O
obsessive	B-DISEASE
compulsive	I-DISEASE
disorder	I-DISEASE
or	O
major	B-DISEASE
depression	I-DISEASE
developed	O
akathisia	B-UNK
.	O
The	O
typical	B-UNK
fluoxetine	B-CHEMICAL
-	O
induced	O
symptoms	B-UNK
of	O
restlessness	B-DISEASE
,	O
constant	O
pacing	B-UNK
,	O
purposeless	O
movements	B-UNK
of	O
the	O
feet	O
and	O
legs	O
,	O
and	O
marked	O
anxiety	B-UNK
were	O
indistinguishable	O
from	O
those	O
of	O
neuroleptic	B-UNK
-	O
induced	O
akathisia	B-UNK
.	O
Three	O
patients	B-UNK
who	O
had	O
experienced	B-UNK
neuroleptic	B-UNK
-	O
induced	O
akathisia	B-UNK
in	O
the	O
past	B-UNK
reported	B-UNK
that	O
the	O
symptoms	B-UNK
of	O
fluoxetine	B-UNK
-	O
induced	O
akathisia	B-UNK
were	O
identical	B-UNK
,	O
although	O
somewhat	O
milder	O
.	O
Akathisia	B-UNK
appeared	B-UNK
to	O
be	O
a	O
common	B-UNK
side	O
effect	B-UNK
of	O
fluoxetine	B-CHEMICAL
and	O
generally	B-UNK
responded	O
well	O
to	O
treatment	B-UNK
with	O
the	O
beta-adrenergic	O
antagonist	B-UNK
propranolol	B-UNK
,	O
dose	B-UNK
reduction	I-UNK
,	O
or	O
both	O
.	O
The	O
authors	B-UNK
suggest	B-UNK
that	O
fluoxetine	B-UNK
-	O
induced	O
akathisia	B-UNK
may	O
be	O
caused	B-UNK
by	O
serotonergically	O
mediated	B-UNK
inhibition	B-UNK
of	O
dopaminergic	B-UNK
neurotransmission	B-UNK
and	O
that	O
the	O
pathophysiology	B-UNK
of	O
fluoxetine	B-CHEMICAL
-	O
induced	O
akathisia	B-UNK
and	O
tricyclic	B-UNK
antidepressant	I-UNK
-	O
induced	O
"	O
jitteriness	O
"	O
may	O
be	O
identical	B-UNK
.	O

Chronic	B-DISEASE
active	I-DISEASE
hepatitis	I-DISEASE
associated	O
with	O
diclofenac	B-CHEMICAL
sodium	I-CHEMICAL
therapy	O
.	O
Diclofenac	B-CHEMICAL
sodium	I-CHEMICAL
(	O
Voltarol	O
,	O
Geigy	O
Pharmaceuticals	O
)	O
is	O
a	O
non-steroidal	O
anti-inflammatory	O
derivative	O
of	O
phenylacetic	B-CHEMICAL
acid	I-CHEMICAL
.	O
Although	O
generally	B-UNK
well	O
-	O
tolerated	B-UNK
,	O
asymptomatic	O
abnormalities	B-DISEASE
of	I-DISEASE
liver	I-DISEASE
function	I-DISEASE
have	O
been	O
recorded	O
and	O
,	O
less	O
commonly	B-UNK
,	O
severe	B-UNK
hepatitis	B-UNK
induced	O
by	O
diclofenac	B-UNK
.	O
The	O
patient	B-UNK
described	O
developed	O
chronic	B-DISEASE
active	I-DISEASE
hepatitis	I-DISEASE
after	O
six	O
months	B-UNK
therapy	O
with	O
diclofenac	B-CHEMICAL
sodium	I-CHEMICAL
which	O
progressed	O
despite	O
the	O
withdrawal	B-UNK
of	O
the	O
drug	B-UNK
,	O
a	O
finding	O
not	O
previously	B-UNK
reported	I-UNK
.	O

Stroke	B-UNK
associated	O
with	O
cocaine	B-UNK
use	O
.	O
We	O
describe	O
eight	O
patients	B-UNK
in	O
whom	O
cocaine	B-CHEMICAL
use	O
was	O
related	O
to	O
stroke	B-DISEASE
and	O
review	B-UNK
39	O
cases	B-UNK
from	O
the	O
literature	B-UNK
.	O
Among	O
these	O
47	O
patients	B-UNK
the	O
mean	O
(	O
+	O
/-	O
SD	B-UNK
)	O
age	B-UNK
was	O
32.5	O
+	O
/-	O
12.1	O
years	B-UNK
;	O
76	O
%	O
(	O
34/45	O
)	O
were	O
men	B-UNK
.	O
Stroke	B-UNK
followed	O
cocaine	B-UNK
use	O
by	O
inhalation	O
,	O
intranasal	O
,	O
intravenous	B-UNK
,	O
and	O
intramuscular	B-UNK
routes	O
.	O
Intracranial	B-DISEASE
aneurysms	I-DISEASE
or	O
arteriovenous	B-DISEASE
malformations	I-DISEASE
were	O
present	B-UNK
in	O
17	O
of	O
32	O
patients	B-UNK
studied	O
angiographically	O
or	O
at	O
autopsy	B-UNK
;	O
cerebral	B-DISEASE
vasculitis	I-DISEASE
was	O
present	B-UNK
in	O
two	O
patients	B-UNK
.	O
Cerebral	B-DISEASE
infarction	I-DISEASE
occurred	B-UNK
in	O
10	O
patients	B-UNK
(	O
22	O
%	O
)	O
,	O
intracerebral	B-UNK
hemorrhage	I-UNK
in	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
in	O
13	O
(	O
29	O
%	O
)	O
.	O
These	O
data	B-UNK
indicate	O
that	O
(	O
1	O
)	O
the	O
apparent	B-UNK
incidence	B-UNK
of	O
stroke	B-DISEASE
related	O
to	O
cocaine	B-CHEMICAL
use	O
is	O
increasing	B-UNK
;	O
(	O
2	O
)	O
cocaine	B-CHEMICAL
-	O
associated	O
stroke	B-UNK
occurs	O
primarily	O
in	O
young	B-UNK
adults	B-UNK
;	O
(	O
3	O
)	O
stroke	B-UNK
may	O
follow	O
any	O
route	O
of	O
cocaine	B-CHEMICAL
administration	O
;	O
(	O
4	O
)	O
stroke	B-UNK
after	O
cocaine	B-CHEMICAL
use	O
is	O
frequently	B-UNK
associated	O
with	O
intracranial	B-DISEASE
aneurysms	I-DISEASE
and	O
arteriovenous	B-DISEASE
malformations	I-DISEASE
;	O
and	O
(	O
5	O
)	O
in	O
cocaine	B-CHEMICAL
-	O
associated	O
stroke	B-UNK
,	O
the	O
frequency	B-UNK
of	O
intracranial	B-UNK
hemorrhage	B-UNK
exceeds	O
that	O
of	O
cerebral	B-DISEASE
infarction	I-DISEASE
.	O

Glyburide	O
-	O
induced	O
hepatitis	B-UNK
.	O
Drug	B-UNK
-	O
induced	O
hepatotoxicity	B-UNK
,	O
although	O
common	B-UNK
,	O
has	O
been	O
reported	B-UNK
only	O
infrequently	O
with	O
sulfonylureas	O
.	O
For	O
glyburide	O
,	O
a	O
second	O
-	O
generation	B-UNK
sulfonylurea	O
,	O
only	O
two	O
brief	O
reports	B-UNK
of	O
hepatotoxicity	B-UNK
exist	O
.	O
Two	O
patients	B-UNK
with	O
type	B-UNK
II	B-UNK
diabetes	B-UNK
mellitus	I-UNK
developed	O
an	O
acute	B-DISEASE
hepatitis	I-DISEASE
-	I-DISEASE
like	I-DISEASE
syndrome	I-DISEASE
soon	O
after	O
initiation	B-UNK
of	O
glyburide	O
therapy	O
.	O
There	O
was	O
no	O
serologic	O
evidence	B-UNK
of	O
viral	B-UNK
infection	B-DISEASE
,	O
and	O
a	O
liver	B-UNK
biopsy	I-UNK
sample	B-UNK
showed	O
a	O
histologic	B-UNK
pattern	B-UNK
consistent	B-UNK
with	O
drug	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
hepatitis	I-DISEASE
.	O
Both	O
patients	B-UNK
recovered	O
quickly	O
after	O
stopping	B-UNK
glyburide	O
therapy	O
and	O
have	O
remained	B-UNK
well	O
for	O
a	O
follow	O
-	O
up	O
period	B-UNK
of	O
1	O
year	O
.	O
Glyburide	O
can	O
produce	B-UNK
an	O
acute	B-DISEASE
hepatitis	I-DISEASE
-	I-DISEASE
like	I-DISEASE
illness	I-DISEASE
in	O
some	O
persons	B-UNK
.	O

Systolic	B-UNK
pressure	B-UNK
variation	O
is	O
greater	B-UNK
during	O
hemorrhage	B-DISEASE
than	O
during	O
sodium	B-UNK
nitroprusside	I-UNK
-	O
induced	B-UNK
hypotension	I-UNK
in	O
ventilated	O
dogs	B-UNK
.	O
The	O
systolic	B-UNK
pressure	B-UNK
variation	O
(	O
SPV	O
)	O
,	O
which	O
is	O
the	O
difference	B-UNK
between	O
the	O
maximal	B-UNK
and	O
minimal	B-UNK
values	O
of	O
the	O
systolic	B-UNK
blood	I-UNK
pressure	I-UNK
(	O
SBP	B-UNK
)	O
after	O
one	O
positive	B-UNK
-	O
pressure	B-UNK
breath	O
,	O
was	O
studied	O
in	O
ventilated	O
dogs	B-UNK
subjected	O
to	O
hypotension	B-DISEASE
.	O
Mean	O
arterial	B-UNK
pressure	I-UNK
was	O
decreased	B-UNK
to	O
50	O
mm	B-UNK
Hg	I-UNK
for	O
30	O
minutes	B-UNK
either	O
by	O
hemorrhage	B-UNK
(	O
HEM	O
,	O
n	O
=	O
7	O
)	O
or	O
by	O
continuous	B-UNK
infusion	I-UNK
of	O
sodium	B-UNK
nitroprusside	I-UNK
(	O
SNP	B-UNK
,	O
n	O
=	O
7	O
)	O
.	O
During	O
HEM	O
-	O
induced	B-UNK
hypotension	I-UNK
the	O
cardiac	B-UNK
output	I-UNK
was	O
significantly	B-UNK
lower	I-UNK
and	O
systemic	B-UNK
vascular	I-UNK
resistance	I-UNK
higher	B-UNK
compared	O
with	O
that	O
in	O
the	O
SNP	B-UNK
group	B-UNK
.	O
The	O
systemic	B-UNK
,	O
central	B-UNK
venous	B-UNK
,	O
pulmonary	B-UNK
capillary	B-UNK
wedge	O
pressures	B-UNK
,	O
and	O
heart	B-UNK
rates	B-UNK
,	O
were	O
similar	B-UNK
in	O
the	O
two	O
groups	B-UNK
.	O
Analysis	B-UNK
of	O
the	O
respiratory	B-UNK
changes	O
in	O
the	O
arterial	B-UNK
pressure	I-UNK
waveform	O
enabled	O
differentiation	O
between	O
the	O
two	O
groups	B-UNK
.	O
The	O
SPV	O
during	O
hypotension	B-DISEASE
was	O
15.7	O
+	O
/-	O
6.7	O
mm	B-UNK
Hg	I-UNK
in	O
the	O
HEM	O
group	B-UNK
,	O
compared	O
with	O
9.1	O
+	O
/-	O
2.0	O
mm	B-UNK
Hg	I-UNK
in	O
the	O
SNP	B-UNK
group	B-UNK
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
The	O
delta	B-UNK
down	O
,	O
which	O
is	O
the	O
measure	B-UNK
of	O
decrease	B-UNK
of	O
SBP	B-UNK
after	O
a	O
mechanical	B-UNK
breath	O
,	O
was	O
20.3	O
+	O
/-	O
8.4	O
and	O
10.1	O
+	O
/-	O
3.8	O
mm	B-UNK
Hg	I-UNK
in	O
the	O
HEM	O
and	O
SNP	B-UNK
groups	B-UNK
,	O
respectively	O
,	O
during	O
hypotension	B-UNK
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O
It	O
is	O
concluded	O
that	O
increases	B-UNK
in	O
the	O
SPV	O
and	O
the	O
delta	B-UNK
down	O
are	O
characteristic	B-UNK
of	O
a	O
hypotensive	B-UNK
state	B-UNK
due	O
to	O
a	O
predominant	B-UNK
decrease	B-UNK
in	O
preload	O
.	O
They	O
are	O
thus	O
more	O
important	B-UNK
during	O
absolute	B-UNK
hypovolemia	B-DISEASE
than	O
during	O
deliberate	O
hypotension	B-UNK
.	O

Drug	B-UNK
-	O
induced	O
arterial	B-UNK
spasm	B-UNK
relieved	O
by	O
lidocaine	B-UNK
.	O
Case	B-UNK
report	I-UNK
.	O
Following	O
major	B-UNK
intracranial	B-UNK
surgery	B-UNK
in	O
a	O
35-year	O
-	O
old	O
man	B-UNK
,	O
sodium	B-UNK
pentothal	O
was	O
intravenously	O
infused	B-UNK
to	O
minimize	O
cerebral	B-DISEASE
ischaemia	I-DISEASE
.	O
Intense	B-UNK
vasospasm	B-UNK
with	O
threatened	O
gangrene	B-DISEASE
arose	O
in	O
the	O
arm	O
used	O
for	O
the	O
infusion	B-UNK
.	O
Since	O
the	O
cranial	B-UNK
condition	B-UNK
precluded	O
use	O
of	O
more	O
usual	O
methods	B-UNK
,	O
lidocaine	B-UNK
was	O
given	O
intra-arterially	O
,	O
with	O
careful	B-UNK
cardiovascular	B-UNK
monitoring	B-UNK
,	O
to	O
counteract	O
the	O
vasospasm	B-UNK
.	O
The	O
treatment	B-UNK
was	O
rapidly	O
successful	O
.	O

Cerebral	B-UNK
blood	B-UNK
flow	I-UNK
and	O
metabolism	B-UNK
during	O
isoflurane	B-CHEMICAL
-	O
induced	B-UNK
hypotension	I-UNK
in	O
patients	B-UNK
subjected	O
to	O
surgery	B-UNK
for	O
cerebral	B-DISEASE
aneurysms	I-DISEASE
.	O
Cerebral	B-UNK
blood	B-UNK
flow	I-UNK
and	O
cerebral	B-UNK
metabolic	B-UNK
rate	B-UNK
for	O
oxygen	B-UNK
were	O
measured	B-UNK
during	O
isoflurane	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
in	O
10	O
patients	B-UNK
subjected	O
to	O
craniotomy	O
for	O
clipping	O
of	O
a	O
cerebral	B-DISEASE
aneurysm	I-DISEASE
.	O
Flow	B-UNK
and	O
metabolism	B-UNK
were	O
measured	B-UNK
5	O
-	O
13	O
days	B-UNK
after	O
the	O
subarachnoid	B-UNK
haemorrhage	B-UNK
by	O
a	O
modification	O
of	O
the	O
classical	O
Kety	O
-	O
Schmidt	O
technique	B-UNK
using	O
xenon-133	O
i.v	B-UNK
.	O
Anaesthesia	B-UNK
was	O
maintained	O
with	O
an	O
inspired	O
isoflurane	B-CHEMICAL
concentration	B-UNK
of	O
0.75	O
%	O
(	O
plus	O
67	O
%	O
nitrous	O
oxide	O
in	O
oxygen	B-CHEMICAL
)	O
,	O
during	O
which	O
CBF	O
and	O
CMRO2	O
were	O
34.3	O
+	O
/-	O
2.1	O
ml/100	O
g	O
min-1	O
and	O
2.32	O
+	O
/-	O
0.16	O
ml/100	O
g	O
min-1	O
at	O
PaCO2	O
4.1	O
+	O
/-	O
0.1	O
kPa	O
(	O
mean	O
+	O
/-	O
SEM	B-UNK
)	O
.	O
Controlled	B-UNK
hypotension	B-DISEASE
to	O
an	O
average	B-UNK
MAP	B-UNK
of	O
50	O
-	O
55	O
mm	B-UNK
Hg	I-UNK
was	O
induced	O
by	O
increasing	B-UNK
the	O
dose	B-UNK
of	O
isoflurane	B-UNK
,	O
and	O
maintained	O
at	O
an	O
inspired	O
concentration	B-UNK
of	O
2.2	O
+	O
/-	O
0.2	O
%	O
.	O
This	O
resulted	B-UNK
in	O
a	O
significant	B-UNK
decrease	B-UNK
in	O
CMRO2	O
(	O
to	O
1.73	O
+	O
/-	O
0.16	O
ml/100	O
g	O
min-1	O
)	O
,	O
while	O
CBF	O
was	O
unchanged	B-UNK
.	O
After	O
the	O
clipping	O
of	O
the	O
aneurysm	B-DISEASE
the	O
isoflurane	B-CHEMICAL
concentration	B-UNK
was	O
reduced	B-UNK
to	O
0.75	O
%	O
.	O
There	O
was	O
a	O
significant	B-UNK
increase	B-UNK
in	O
CBF	O
,	O
although	O
CMRO2	O
was	O
unchanged	B-UNK
,	O
compared	O
with	O
pre	B-UNK
-	O
hypotensive	B-UNK
values	O
.	O
These	O
changes	O
might	O
offer	O
protection	B-UNK
to	O
brain	B-UNK
tissue	B-UNK
during	O
periods	O
of	O
induced	B-UNK
hypotension	I-UNK
.	O

Allergic	B-DISEASE
reaction	I-DISEASE
to	O
5-fluorouracil	B-CHEMICAL
infusion	B-UNK
.	O
An	O
allergic	B-DISEASE
reaction	I-DISEASE
consisting	O
of	O
angioneurotic	B-DISEASE
edema	I-DISEASE
secondary	B-UNK
to	O
continuous	B-UNK
infusion	I-UNK
5-fluorouracil	B-CHEMICAL
occurred	B-UNK
in	O
a	O
patient	B-UNK
with	O
recurrent	B-UNK
carcinoma	B-DISEASE
of	I-DISEASE
the	I-DISEASE
oral	I-DISEASE
cavity	I-DISEASE
,	O
cirrhosis	B-UNK
,	O
and	O
cisplatin	B-CHEMICAL
-	O
induced	O
impaired	B-UNK
renal	B-UNK
function	I-UNK
.	O
This	O
reaction	B-UNK
occurred	B-UNK
during	O
the	O
sixth	O
and	O
seventh	O
courses	B-UNK
of	O
infusional	O
chemotherapy	O
.	O
Oral	B-UNK
diphenhydramine	B-CHEMICAL
and	O
prednisone	B-CHEMICAL
were	O
ineffective	B-UNK
in	O
preventing	O
the	O
recurrence	B-DISEASE
of	O
the	O
allergic	B-DISEASE
reaction	I-DISEASE
.	O
Discontinuance	O
of	O
effective	B-UNK
chemotherapy	O
in	O
this	O
patient	B-UNK
during	O
partial	B-UNK
remission	B-UNK
resulted	B-UNK
in	O
fatal	B-UNK
disease	B-DISEASE
progression	I-DISEASE
.	O

Amiodarone	B-UNK
-	O
induced	O
sinoatrial	B-DISEASE
block	I-DISEASE
.	O
We	O
observed	O
sinoatrial	B-DISEASE
block	I-DISEASE
due	O
to	O
chronic	B-UNK
amiodarone	B-UNK
administration	O
in	O
a	O
5-year	O
-	O
old	O
boy	B-UNK
with	O
primary	B-UNK
cardiomyopathy	B-UNK
,	O
Wolff	B-DISEASE
-	I-DISEASE
Parkinson	I-DISEASE
-	I-DISEASE
White	I-DISEASE
syndrome	I-DISEASE
and	O
supraventricular	B-DISEASE
tachycardia	I-DISEASE
.	O
Reduction	O
in	O
the	O
dosage	B-UNK
of	O
amiodarone	B-UNK
resulted	B-UNK
in	O
the	O
disappearance	O
of	O
the	O
sinoatrial	B-DISEASE
block	I-DISEASE
and	O
the	O
persistence	O
of	O
asymptomatic	O
sinus	B-DISEASE
bradycardia	I-DISEASE
.	O

Possible	O
teratogenicity	O
of	O
sulphasalazine	B-UNK
.	O
Three	O
infants	B-UNK
,	O
born	B-UNK
of	O
two	O
mothers	O
with	O
inflammatory	B-UNK
bowel	B-UNK
disease	B-DISEASE
who	O
received	O
treatment	B-UNK
with	O
sulphasalazine	B-CHEMICAL
throughout	O
pregnancy	B-UNK
,	O
were	O
found	O
to	O
have	O
major	B-UNK
congenital	B-DISEASE
anomalies	I-DISEASE
.	O
In	O
the	O
singleton	O
pregnancy	B-UNK
,	O
the	O
mother	B-UNK
had	O
ulcerative	B-DISEASE
colitis	I-DISEASE
,	O
and	O
the	O
infant	B-UNK
,	O
a	O
male	B-UNK
,	O
had	O
coarctation	B-DISEASE
of	I-DISEASE
the	I-DISEASE
aorta	I-DISEASE
and	O
a	O
ventricular	B-UNK
septal	B-UNK
defect	B-UNK
.	O
In	O
the	O
twin	O
pregnancy	B-UNK
,	O
the	O
mother	B-UNK
had	O
Crohn'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
.	O
The	O
first	O
twin	O
,	O
a	O
female	B-UNK
,	O
had	O
a	O
left	B-UNK
Potter	B-DISEASE
-	I-DISEASE
type	I-DISEASE
IIa	I-DISEASE
polycystic	I-DISEASE
kidney	I-DISEASE
and	O
a	O
rudimentary	O
left	B-UNK
uterine	O
cornu	O
.	O
The	O
second	O
twin	O
,	O
a	O
male	B-UNK
,	O
had	O
some	O
features	B-UNK
of	O
Potter'	O
s	O
facies	B-DISEASE
,	O
hypoplastic	O
lungs	O
,	O
absent	B-DISEASE
kidneys	I-DISEASE
and	I-DISEASE
ureters	I-DISEASE
,	O
and	O
talipes	B-DISEASE
equinovarus	O
.	O
Despite	O
reports	B-UNK
to	O
the	O
contrary	O
,	O
it	O
is	O
suggested	B-UNK
that	O
sulphasalazine	B-UNK
may	O
be	O
teratogenic	O
.	O

Veno	B-DISEASE
-	I-DISEASE
occlusive	I-DISEASE
liver	I-DISEASE
disease	I-DISEASE
after	O
dacarbazine	O
therapy	O
(	O
DTIC	O
)	O
for	O
melanoma	B-DISEASE
.	O
A	O
case	B-UNK
of	O
veno	O
-	O
occlusive	O
disease	B-DISEASE
of	O
the	O
liver	B-UNK
with	O
fatal	B-UNK
outcome	B-UNK
after	O
dacarbazine	O
(	O
DTIC	O
)	O
therapy	O
for	O
melanoma	B-DISEASE
is	O
reported	B-UNK
.	O
There	O
was	O
a	O
fulminant	B-UNK
clinical	B-UNK
course	O
from	O
start	B-UNK
of	O
symptoms	B-UNK
until	O
death	B-UNK
.	O
At	O
autopsy	B-UNK
the	O
liver	B-UNK
was	O
enlarged	O
and	O
firm	O
with	O
signs	B-UNK
of	O
venous	B-DISEASE
congestion	I-DISEASE
.	O
Small-	O
and	O
medium	B-UNK
-	O
sized	O
hepatic	B-UNK
veins	O
were	O
blocked	B-UNK
by	O
thrombosis	B-DISEASE
.	O
Eosinophilic	B-UNK
infiltrations	O
were	O
found	O
around	O
the	O
vessels	B-UNK
.	O
Published	B-UNK
cases	B-UNK
from	O
the	O
literature	B-UNK
are	O
reviewed	B-UNK
and	O
pertinent	O
features	B-UNK
discussed	O
.	O

A	O
case	B-UNK
of	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
caused	B-UNK
by	O
metoclopramide	B-UNK
.	O
Abnormal	B-DISEASE
involuntary	I-DISEASE
movements	I-DISEASE
appeared	B-UNK
in	O
the	O
mouth	B-UNK
,	O
tongue	B-UNK
,	O
neck	B-UNK
and	O
abdomen	O
of	O
a	O
64-year	O
-	O
old	O
male	B-UNK
patient	B-UNK
after	O
he	O
took	O
metoclopramide	B-UNK
for	O
gastrointestinal	B-UNK
disorder	B-UNK
in	O
a	O
regimen	B-UNK
of	O
30	O
mg	B-UNK
per	O
day	O
for	O
a	O
total	B-UNK
of	O
about	O
260	O
days	B-UNK
.	O
The	O
symptoms	B-UNK
exacerbated	O
to	O
a	O
maximum	B-UNK
in	O
a	O
month	B-UNK
.	O
When	O
the	O
metoclopramide	B-UNK
administration	O
was	O
discontinued	O
,	O
the	O
abnormal	B-DISEASE
movements	I-DISEASE
gradually	O
improved	O
to	O
a	O
considerable	O
extent	B-UNK
.	O
Attention	B-UNK
to	O
the	O
possible	O
induction	B-UNK
of	O
specific	B-UNK
tardive	B-DISEASE
dyskinesia	I-DISEASE
is	O
called	O
for	O
in	O
the	O
use	O
of	O
this	O
drug	B-UNK
.	O

Further	O
observations	B-UNK
on	O
the	O
electrophysiologic	O
effects	O
of	O
oral	B-UNK
amiodarone	B-UNK
therapy	O
.	O
A	O
case	B-UNK
is	O
presented	B-UNK
of	O
a	O
reversible	B-UNK
intra-Hisian	O
block	B-UNK
occurring	O
under	O
amiodarone	B-UNK
treatment	B-UNK
for	O
atrial	B-DISEASE
tachycardia	I-DISEASE
in	O
a	O
patient	B-UNK
without	O
clear	B-UNK
intraventricular	O
conduction	B-UNK
abnormalities	B-UNK
.	O
His	O
bundle	B-UNK
recordings	O
showed	O
an	O
atrial	B-DISEASE
tachycardia	I-DISEASE
with	O
intermittent	B-UNK
exit	O
block	B-UNK
and	O
greatly	O
prolonged	B-UNK
BH	O
and	O
HV	O
intervals	B-UNK
(	O
40	O
and	O
100	O
msec	O
,	O
respectively	O
)	O
.	O
Thirty	B-UNK
days	B-UNK
after	O
amiodarone	B-CHEMICAL
discontinuation	B-UNK
,	O
His	O
bundle	B-UNK
electrograms	O
showed	O
atrial	B-DISEASE
flutter	I-DISEASE
without	O
intra-Hisian	O
or	O
infra-Hisian	O
delay	B-UNK
.	O
Amiodarone	B-UNK
should	O
be	O
used	O
with	O
caution	B-UNK
during	O
long	B-UNK
-	O
term	O
oral	B-UNK
therapy	O
in	O
patients	B-UNK
with	O
or	O
without	O
clear	B-UNK
intraventricular	O
conduction	B-UNK
defects	B-UNK
.	O

Busulfan	B-UNK
-	O
induced	O
hemorrhagic	B-UNK
cystitis	I-UNK
.	O
A	O
case	B-UNK
of	O
a	O
busulfan	B-UNK
-	O
induced	O
hemorrhage	B-UNK
cystitis	B-DISEASE
is	O
reported	B-UNK
.	O
Spontaneous	B-UNK
resolution	B-UNK
occurred	B-UNK
following	O
cessation	B-UNK
of	O
the	O
drug	B-UNK
.	O
The	O
similarity	O
between	O
the	O
histologic	B-UNK
appearances	O
of	O
busulfan	B-UNK
cystitis	B-UNK
and	O
both	O
radiation	B-UNK
and	O
cyclophosphamide	B-UNK
-	O
induced	B-UNK
cystitis	I-UNK
is	O
discussed	O
and	O
the	O
world	B-UNK
literature	B-UNK
reviewed	B-UNK
.	O
In	O
view	B-UNK
of	O
the	O
known	O
tendency	O
of	O
busulfan	B-UNK
to	O
induce	B-UNK
cellular	B-UNK
atypia	O
and	O
carcinoma	B-DISEASE
in	O
other	O
sites	B-UNK
,	O
periodic	O
urinary	B-UNK
cytology	O
is	O
suggested	B-UNK
in	O
patients	B-UNK
on	O
long	B-UNK
-	O
term	O
therapy	O
.	O

Rebound	O
hypertensive	B-UNK
after	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
prevented	B-UNK
by	O
saralasin	B-CHEMICAL
in	O
rats	B-UNK
.	O
The	O
role	O
of	O
the	O
renin	B-UNK
--	O
angiotensin	O
system	O
in	O
the	O
maintenance	B-UNK
of	O
blood	B-UNK
pressure	I-UNK
during	O
halothane	B-UNK
anesthesia	B-UNK
and	O
sodium	B-UNK
nitroprusside	I-UNK
(	O
SNP)-induced	O
hypotension	B-UNK
was	O
evaluated	B-UNK
.	O
Control	B-UNK
rats	B-UNK
received	O
halothane	B-CHEMICAL
anesthesia	B-UNK
(	O
1	O
MAC	O
)	O
for	O
one	O
hour	B-UNK
,	O
followed	O
by	O
SNP	B-UNK
infusion	B-UNK
,	O
40	O
microgram	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
,	O
for	O
30	O
min	B-UNK
,	O
followed	O
by	O
a	O
30-min	O
recovery	B-UNK
period	B-UNK
.	O
A	O
second	O
group	B-UNK
of	O
rats	B-UNK
was	O
treated	O
identically	O
and	O
,	O
in	O
addition	B-UNK
,	O
received	O
an	O
infusion	B-UNK
of	O
saralasin	B-CHEMICAL
(	O
a	O
competitive	O
inhibitor	B-UNK
of	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
)	O
throughout	O
the	O
experimental	B-UNK
period	B-UNK
.	O
In	O
each	O
group	B-UNK
,	O
SNP	B-UNK
infusion	B-UNK
resulted	B-UNK
in	O
an	O
initial	B-UNK
decrease	B-UNK
in	O
blood	B-UNK
pressure	I-UNK
from	O
86	O
torr	O
and	O
83	O
torr	O
,	O
respectively	O
,	O
to	O
48	O
torr	O
.	O
During	O
the	O
SNP	B-UNK
infusion	B-UNK
the	O
control	B-UNK
animals	I-UNK
demonstrated	O
a	O
progressive	B-UNK
increase	B-UNK
in	O
blood	B-UNK
pressure	I-UNK
to	O
61	O
torr	O
,	O
whereas	O
the	O
saralasin	B-CHEMICAL
-	O
treated	B-UNK
animals	I-UNK
showed	O
no	O
change	B-UNK
.	O
Following	O
discontinuation	B-UNK
of	O
SNP	B-UNK
,	O
blood	B-UNK
pressure	I-UNK
in	O
the	O
control	B-UNK
animals	I-UNK
rebounded	O
to	O
94	O
torr	O
,	O
as	O
compared	O
with	O
78	O
torr	O
in	O
the	O
saralasin	B-CHEMICAL
-	O
treated	B-UNK
rats	I-UNK
.	O
This	O
study	B-UNK
indicates	O
that	O
with	O
stable	B-UNK
halothane	B-CHEMICAL
anesthesia	B-UNK
,	O
the	O
partial	B-UNK
recovery	B-UNK
of	O
blood	B-UNK
pressure	I-UNK
during	O
SNP	B-UNK
infusion	B-UNK
and	O
the	O
post-SNP	O
rebound	O
of	O
blood	B-UNK
pressure	I-UNK
can	O
be	O
completely	O
blocked	B-UNK
by	O
saralasin	B-CHEMICAL
.	O
This	O
demonstrates	O
the	O
participation	O
of	O
the	O
renin	B-UNK
--	O
angiotensin	O
system	O
in	O
antagonizing	O
the	O
combined	B-UNK
hypotensive	B-UNK
effects	O
of	O
halothane	B-UNK
and	O
SNP	B-UNK
.	O

Toxic	B-DISEASE
hepatitis	I-DISEASE
induced	O
by	O
antithyroid	B-CHEMICAL
drugs	I-CHEMICAL
:	O
four	O
cases	B-UNK
including	O
one	O
with	O
cross-reactivity	O
between	O
carbimazole	B-UNK
and	O
benzylthiouracil	O
.	O
OBJECTIVE	B-UNK
:	O
This	O
study	B-UNK
was	O
conducted	B-UNK
to	O
assess	B-UNK
the	O
occurrence	B-UNK
of	O
hepatic	B-UNK
adverse	B-UNK
effects	I-UNK
encountered	O
with	O
antithyroid	B-CHEMICAL
drugs	I-CHEMICAL
.	O
METHODS	B-UNK
:	O
Retrospective	B-UNK
review	B-UNK
of	O
medical	B-UNK
records	I-UNK
of	O
236	O
patients	B-UNK
with	O
hyperthyroidism	B-DISEASE
admitted	B-UNK
in	O
our	O
department	B-UNK
(	O
in-	O
or	O
out	O
-	O
patients	B-UNK
)	O
from	O
1986	O
to	O
1992	O
.	O
RESULTS	B-UNK
:	O
Four	O
patients	B-UNK
(	O
1.7	O
%	O
)	O
were	O
identified	B-UNK
with	O
toxic	B-DISEASE
hepatitis	I-DISEASE
which	O
could	O
reasonably	O
be	O
attributed	B-UNK
to	O
the	O
use	O
of	O
antithyroid	B-UNK
agent	B-UNK
.	O
Two	O
patients	B-UNK
had	O
a	O
cholestatic	B-UNK
hepatitis	I-UNK
induced	O
by	O
carbimazole	B-UNK
(	O
N	O
 	O
omercazole	O
)	O
.	O
Two	O
others	O
had	O
a	O
mixed	B-UNK
(	O
cholestatic	B-DISEASE
and	O
cytolytic	O
)	O
hepatitis	B-UNK
following	O
carbimazole	B-UNK
.	O
One	O
of	O
the	O
latter	O
two	O
patients	B-UNK
further	O
experienced	B-UNK
a	O
cytolytic	O
hepatitis	B-UNK
which	O
appeared	B-UNK
after	O
Benzylthiouracil	O
(	O
Basd	O
 	O
ne	O
)	O
had	O
replaced	O
carbimazole	B-UNK
.	O
Biological	B-UNK
features	B-UNK
of	O
hepatitis	B-UNK
disappeared	O
in	O
all	O
cases	B-UNK
after	O
cessation	B-UNK
of	O
the	O
incriminated	O
drug	B-UNK
,	O
while	O
biliary	B-UNK
,	O
viral	B-UNK
and	O
immunological	O
searches	O
were	O
negative	B-UNK
.	O
Only	O
2	O
patients	B-UNK
of	O
our	O
retrospective	B-UNK
study	I-UNK
experienced	B-UNK
a	O
mild	B-UNK
or	O
severe	B-UNK
neutropenia	B-DISEASE
.	O
CONCLUSION	B-UNK
:	O
Toxic	B-DISEASE
hepatitis	I-DISEASE
is	O
a	O
potential	B-UNK
adverse	B-UNK
effect	I-UNK
of	O
antithyroid	B-CHEMICAL
drugs	I-CHEMICAL
which	O
warrants	O
,	O
as	O
for	O
haematological	B-UNK
disturbances	B-UNK
,	O
a	O
pre	B-UNK
-	O
therapeutic	B-UNK
determination	B-UNK
and	O
a	O
careful	B-UNK
follow	O
-	O
up	O
of	O
relevant	B-UNK
biological	B-UNK
markers	B-UNK
.	O
Moreover	O
,	O
hepatotoxicity	B-UNK
may	O
not	O
be	O
restricted	B-UNK
to	O
one	O
class	B-UNK
of	O
antithyroid	B-CHEMICAL
agents	I-CHEMICAL
.	O

Study	B-UNK
of	O
the	O
role	O
of	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folinic	B-UNK
acid	I-UNK
supplementation	B-UNK
in	O
preventing	O
hematologic	B-UNK
toxicity	B-UNK
of	O
zidovudine	B-UNK
.	O
A	O
prospective	B-UNK
,	O
randomized	B-UNK
study	B-UNK
was	O
conducted	B-UNK
to	O
evaluate	B-UNK
the	O
role	O
of	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folinic	B-UNK
acid	I-UNK
supplementation	B-UNK
in	O
preventing	O
zidovudine	B-CHEMICAL
(	O
ZDV)-induced	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
.	O
Seventy	B-UNK
-	O
five	O
human	B-UNK
immunodeficiency	B-UNK
virus	I-UNK
(	O
HIV)-infected	O
patients	B-UNK
with	O
CD4	B-UNK
+	O
cell	B-UNK
counts	B-UNK
<	O
500	O
/	O
mm3	B-UNK
were	O
randomized	B-UNK
to	I-UNK
receive	I-UNK
either	O
ZDV	O
(	O
500	O
mg	B-UNK
daily	B-UNK
)	O
alone	O
(	O
group	B-UNK
I	O
,	O
n	O
=	O
38	O
)	O
or	O
in	O
combination	B-UNK
with	O
folinic	B-UNK
acid	I-UNK
(	O
15	O
mg	B-UNK
daily	B-UNK
)	O
and	O
intramascular	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
(	O
1000	O
micrograms	B-UNK
monthly	O
)	O
(	O
group	B-UNK
II	I-UNK
,	O
n	O
=	O
37	O
)	O
.	O
Finally	B-UNK
,	O
15	O
patients	B-UNK
were	O
excluded	B-UNK
from	O
the	O
study	B-UNK
(	O
noncompliance	O
14	O
,	O
death	B-UNK
1	O
)	O
;	O
thus	O
,	O
60	O
patients	B-UNK
(	O
31	O
in	O
group	B-UNK
I	O
and	O
29	O
in	O
group	B-UNK
II	I-UNK
)	O
were	O
eligible	O
for	O
analysis	B-UNK
.	O
No	O
significant	B-UNK
differences	B-UNK
between	O
groups	B-UNK
were	O
found	O
at	O
enrollment	O
.	O
During	O
the	O
study	B-UNK
,	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folate	B-UNK
levels	O
were	O
significantly	B-UNK
higher	I-UNK
in	O
group	B-UNK
II	I-UNK
patients	B-UNK
;	O
however	O
,	O
no	O
differences	B-UNK
in	O
hemoglobin	B-UNK
,	O
hematocrit	O
,	O
mean	O
corpuscular	O
volume	B-UNK
,	O
and	O
white	B-UNK
-	O
cell	B-UNK
,	O
neutrophil	B-UNK
and	O
platelet	B-UNK
counts	B-UNK
were	O
observed	O
between	O
groups	B-UNK
at	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	B-UNK
.	O
Severe	B-UNK
hematologic	B-UNK
toxicity	B-UNK
(	O
neutrophil	B-UNK
count	B-UNK
<	O
1000	O
/	O
mm3	B-UNK
and	O
/	O
or	O
hemoglobin	B-UNK
<	O
8	O
g	O
/	O
dl	B-UNK
)	O
occurred	B-UNK
in	O
4	O
patients	B-UNK
assigned	O
to	O
group	B-UNK
I	O
and	O
7	O
assigned	O
to	O
group	B-UNK
II	I-UNK
.	O
There	O
was	O
no	O
correlation	B-UNK
between	O
vitamin	B-CHEMICAL
B12	I-CHEMICAL
or	O
folate	B-UNK
levels	O
and	O
development	B-UNK
of	O
myelosuppression	B-UNK
.	O
Vitamin	B-CHEMICAL
B12	I-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
supplementation	B-UNK
of	O
ZDV	O
therapy	O
does	O
not	O
seem	O
useful	O
in	O
preventing	O
or	O
reducing	B-UNK
ZDV	O
-	O
induced	O
myelotoxicity	O
in	O
the	O
overall	O
treated	O
population	B-UNK
,	O
although	O
a	O
beneficial	B-UNK
effect	I-UNK
in	O
certain	O
subgroups	B-UNK
of	O
patients	B-UNK
cannot	O
be	O
excluded	B-UNK
.	O

Acute	B-UNK
confusion	B-UNK
induced	O
by	O
a	O
high	B-UNK
-	O
dose	B-UNK
infusion	B-UNK
of	O
5-fluorouracil	B-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
.	O
A	O
61-year	O
-	O
old	O
man	B-UNK
was	O
treated	O
with	O
combination	B-UNK
chemotherapy	O
incorporating	O
cisplatinum	O
,	O
etoposide	B-UNK
,	O
high	B-UNK
-	O
dose	B-UNK
5-fluorouracil	B-CHEMICAL
(	O
2,250	O
mg	B-UNK
/	O
m2/24	O
hours	B-UNK
)	O
and	O
folinic	B-UNK
acid	I-UNK
for	O
an	O
inoperable	O
gastric	B-UNK
adenocarcinoma	B-DISEASE
.	O
He	O
developed	O
acute	B-UNK
neurologic	B-UNK
symptoms	B-UNK
of	O
mental	B-UNK
confusion	B-DISEASE
,	O
disorientation	B-DISEASE
and	O
irritability	B-DISEASE
,	O
and	O
then	O
lapsed	O
into	O
a	O
deep	B-UNK
coma	B-DISEASE
,	O
lasting	B-UNK
for	O
approximately	B-UNK
40	O
hours	B-UNK
during	O
the	O
first	O
dose	B-UNK
(	O
day	O
2	O
)	O
of	O
5-fluorouracil	B-CHEMICAL
and	O
folinic	B-UNK
acid	I-UNK
infusion	B-UNK
.	O
This	O
complication	B-UNK
reappeared	O
on	O
day	O
25	O
during	O
the	O
second	O
dose	B-UNK
of	O
5-fluorouracil	B-CHEMICAL
and	O
folinic	B-CHEMICAL
acid	I-CHEMICAL
,	O
which	O
were	O
then	O
the	O
only	O
drugs	B-UNK
given	O
.	O
Because	O
folinic	B-UNK
acid	I-UNK
was	O
unlikely	O
to	O
be	O
associated	O
with	O
this	O
condition	B-UNK
,	O
neurotoxicity	B-DISEASE
due	O
to	O
high	B-UNK
-	O
dose	B-UNK
5-fluorouracil	B-CHEMICAL
was	O
highly	B-UNK
suspected	O
.	O
The	O
pathogenesis	B-UNK
of	O
5-fluorouracil	B-CHEMICAL
neurotoxicity	B-UNK
may	O
be	O
due	O
to	O
a	O
Krebs	O
cycle	B-UNK
blockade	B-UNK
by	O
fluoroacetate	O
and	O
fluorocitrate	O
,	O
thiamine	B-DISEASE
deficiency	I-DISEASE
,	O
or	O
dihydrouracil	B-CHEMICAL
dehydrogenase	B-UNK
deficiency	B-UNK
.	O
High	B-UNK
-	O
dose	B-UNK
5-fluorouracil	B-CHEMICAL
/	O
folinic	B-UNK
acid	I-UNK
infusion	B-UNK
therapy	O
has	O
recently	B-UNK
become	O
a	O
popular	O
regimen	B-UNK
for	O
various	O
cancers	B-UNK
.	O
It	O
is	O
necessary	O
that	O
both	O
oncologists	O
and	O
neurologists	O
be	O
fully	B-UNK
aware	B-UNK
of	O
this	O
unusual	B-UNK
complication	B-UNK
.	O

Effect	B-UNK
of	O
switching	B-UNK
carbamazepine	B-UNK
to	O
oxcarbazepine	O
on	O
the	O
plasma	B-UNK
levels	O
of	O
neuroleptics	B-CHEMICAL
.	O
A	O
case	B-UNK
report	I-UNK
.	O
Carbamazepine	B-UNK
was	O
switched	O
to	O
its	O
10-keto	O
analogue	B-UNK
oxcarbazepine	O
among	O
six	O
difficult	O
-	O
to	O
-	O
treat	B-UNK
schizophrenic	B-UNK
or	O
organic	B-UNK
psychotic	B-UNK
patients	B-UNK
using	O
concomitantly	B-UNK
haloperidol	B-UNK
,	O
chlorpromazine	B-CHEMICAL
or	O
clozapine	B-CHEMICAL
.	O
This	O
change	B-UNK
resulted	B-UNK
within	O
2	O
-	O
4	O
weeks	B-UNK
in	O
the	O
50	O
-	O
200	O
%	O
increase	B-UNK
in	O
the	O
plasma	B-UNK
levels	O
of	O
these	O
neuroleptics	B-CHEMICAL
and	O
the	O
appearance	B-UNK
of	O
extrapyramidal	B-DISEASE
symptoms	I-DISEASE
.	O
None	O
of	O
the	O
patients	B-UNK
showed	O
any	O
clinical	B-UNK
deteriotation	O
during	O
the	O
following	O
3	O
-	O
6	O
months	B-UNK
.	O
The	O
results	B-UNK
of	O
this	O
case	B-UNK
report	I-UNK
support	B-UNK
the	O
idea	O
that	O
in	O
contrast	B-UNK
with	O
carbamazepine	B-UNK
oxcarbazepine	O
does	O
not	O
induce	B-UNK
the	O
hepatic	B-UNK
microsomal	O
enzyme	B-UNK
systems	B-UNK
regulating	O
the	O
inactivation	O
of	O
antipsychotic	B-CHEMICAL
drugs	I-CHEMICAL
.	O

Erythema	B-DISEASE
multiforme	I-DISEASE
and	O
hypersensitivity	B-UNK
myocarditis	B-UNK
caused	B-UNK
by	O
ampicillin	O
.	O
OBJECTIVE	B-UNK
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
erythema	B-DISEASE
multiforme	I-DISEASE
and	O
hypersensitivity	B-UNK
myocarditis	B-DISEASE
caused	B-UNK
by	O
ampicillin	O
.	O
CASE	B-UNK
SUMMARY	I-UNK
:	O
A	O
13-year	O
-	O
old	O
boy	B-UNK
was	O
treated	O
with	O
ampicillin	O
and	O
gentamicin	B-CHEMICAL
because	O
of	O
suspected	O
septicemia	O
.	O
Medications	B-UNK
were	O
discontinued	O
when	O
erythema	B-DISEASE
multiforme	I-DISEASE
and	O
congestive	B-UNK
heart	I-UNK
failure	I-UNK
caused	B-UNK
by	O
myocarditis	B-DISEASE
occurred	B-UNK
.	O
The	O
patient	B-UNK
was	O
treated	O
with	O
methylprednisolone	B-UNK
and	O
gradually	O
improved	O
.	O
Macrophage	O
-	O
migration	O
inhibition	B-UNK
(	O
MIF	O
)	O
test	B-UNK
with	O
ampicillin	O
was	O
positive	B-UNK
.	O
DISCUSSION	B-UNK
:	O
After	O
most	O
infections	B-UNK
causing	O
erythema	B-DISEASE
multiforme	I-DISEASE
and	O
myocarditis	B-UNK
were	O
ruled	O
out	O
,	O
a	O
drug	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
allergic	I-DISEASE
reaction	I-DISEASE
was	O
suspected	O
.	O
Positive	B-UNK
MIF	O
test	B-UNK
for	O
ampicillin	O
showed	O
sensitization	B-UNK
of	O
the	O
patient'	B-UNK
s	I-UNK
lymphocytes	B-UNK
to	O
ampicillin	O
.	O
CONCLUSIONS	B-UNK
:	O
Hypersensitivity	B-UNK
myocarditis	B-UNK
is	O
a	O
rare	B-UNK
and	O
dangerous	O
manifestation	B-UNK
of	O
allergy	B-DISEASE
to	O
penicillins	O
.	O

Immediate	O
allergic	B-DISEASE
reactions	I-DISEASE
to	O
amoxicillin	O
.	O
A	O
large	B-UNK
group	B-UNK
of	O
patients	B-UNK
with	O
suspected	O
allergic	B-DISEASE
reactions	I-DISEASE
to	O
beta-lactam	O
antibiotics	B-UNK
was	O
evaluated	B-UNK
.	O
A	O
detailed	O
clinical	B-UNK
history	B-UNK
,	O
together	O
with	O
skin	B-UNK
tests	B-UNK
,	O
RAST	O
(	O
radioallergosorbent	O
test	B-UNK
)	O
,	O
and	O
controlled	B-UNK
challenge	B-UNK
tests	B-UNK
,	O
was	O
used	O
to	O
establish	O
whether	O
patients	B-UNK
allergic	B-UNK
to	O
beta-lactam	O
antibiotics	B-UNK
had	O
selective	B-UNK
immediate	O
allergic	B-UNK
responses	O
to	O
amoxicillin	O
(	O
AX	B-CHEMICAL
)	O
or	O
were	O
cross-reacting	O
with	O
other	O
penicillin	B-CHEMICAL
derivatives	O
.	O
Skin	B-UNK
tests	B-UNK
were	O
performed	B-UNK
with	O
benzylpenicilloyl	O
-	O
poly	O
-	O
L	O
-	O
lysine	O
(	O
BPO	O
-	O
PLL	O
)	O
,	O
benzylpenicilloate	O
,	O
benzylpenicillin	O
(	O
PG	B-UNK
)	O
,	O
ampicillin	O
(	O
AMP	B-CHEMICAL
)	O
,	O
and	O
AX	B-UNK
.	O
RAST	O
for	O
BPO	O
-	O
PLL	O
and	O
AX	B-CHEMICAL
-	O
PLL	O
was	O
done	O
.	O
When	O
both	O
skin	B-UNK
test	B-UNK
and	O
RAST	O
for	O
BPO	O
were	O
negative	B-UNK
,	O
single	B-UNK
-	O
blind	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
challenge	B-UNK
tests	B-UNK
were	O
done	O
to	O
ensure	O
tolerance	B-UNK
of	O
PG	B-UNK
or	O
sensitivity	B-UNK
to	O
AX	B-UNK
.	O
A	O
total	B-UNK
of	O
177	O
patients	B-UNK
were	O
diagnosed	B-UNK
as	O
allergic	B-UNK
to	O
beta-lactam	O
antibiotics	B-UNK
.	O
We	O
selected	O
the	O
54	O
(	O
30.5	O
%	O
)	O
cases	B-UNK
of	O
immediate	O
AX	B-UNK
allergy	B-DISEASE
with	O
good	O
tolerance	B-UNK
of	O
PG	B-UNK
.	O
Anaphylaxis	B-DISEASE
was	O
seen	O
in	O
37	O
patients	B-UNK
(	O
69	O
%	O
)	O
,	O
the	O
other	O
17	O
(	O
31	O
%	O
)	O
having	O
urticaria	B-DISEASE
and	O
/	O
or	O
angioedema	B-UNK
.	O
All	O
the	O
patients	B-UNK
were	O
skin	B-UNK
test	B-UNK
negative	B-UNK
to	O
BPO	O
;	O
49	O
of	O
51	O
(	O
96	O
%	O
)	O
were	O
also	O
negative	B-UNK
to	O
MDM	O
,	O
and	O
44	O
of	O
46	O
(	O
96	O
%	O
)	O
to	O
PG	B-UNK
.	O
Skin	B-UNK
tests	B-UNK
with	O
AX	B-UNK
were	O
positive	B-UNK
in	O
34	O
(	O
63	O
%	O
)	O
patients	B-UNK
.	O
RAST	O
was	O
positive	B-UNK
for	O
AX	B-UNK
in	O
22	O
patients	B-UNK
(	O
41	O
%	O
)	O
and	O
to	O
BPO	O
in	O
just	O
5	O
(	O
9	O
%	O
)	O
.	O
None	O
of	O
the	O
sera	O
with	O
negative	B-UNK
RAST	O
for	O
AX	B-UNK
were	O
positive	B-UNK
to	O
BPO	O
.	O
Challenge	B-UNK
tests	B-UNK
with	O
AX	B-CHEMICAL
were	O
performed	B-UNK
in	O
23	O
subjects	B-UNK
(	O
43	O
%	O
)	O
to	O
establish	O
the	O
diagnosis	B-UNK
of	O
immediate	O
allergic	B-DISEASE
reaction	I-DISEASE
to	O
AX	B-UNK
,	O
and	O
in	O
15	O
cases	B-UNK
(	O
28	O
%	O
)	O
both	O
skin	B-UNK
test	B-UNK
and	O
RAST	O
for	O
AX	B-CHEMICAL
were	O
negative	B-UNK
.	O
PG	B-UNK
was	O
well	O
tolerated	B-UNK
by	O
all	O
54	O
patients	B-UNK
.	O
We	O
describe	O
the	O
largest	O
group	B-UNK
of	O
AX	B-CHEMICAL
-	O
allergic	B-UNK
patients	B-UNK
who	O
have	O
tolerated	B-UNK
PG	B-UNK
reported	B-UNK
so	O
far	O
.	O
Diagnosis	B-UNK
of	O
these	O
patients	B-UNK
can	O
be	O
achieved	O
only	O
if	O
specific	B-UNK
AX	B-CHEMICAL
-	O
related	O
reagents	O
are	O
employed	B-UNK
.	O
Further	O
studies	B-UNK
are	O
necessary	O
to	O
determine	B-UNK
the	O
exact	O
extent	B-UNK
of	O
this	O
problem	O
and	O
to	O
improve	B-UNK
the	O
efficacy	B-UNK
of	O
diagnostic	B-UNK
methods	B-UNK
.	O

Persistent	B-UNK
paralysis	B-DISEASE
after	O
prolonged	B-UNK
use	O
of	O
atracurium	B-CHEMICAL
in	O
the	O
absence	O
of	O
corticosteroids	B-CHEMICAL
.	O
Neuromuscular	B-UNK
blocking	B-UNK
agents	B-UNK
(	O
NMBAs	O
)	O
are	O
often	O
used	O
for	O
patients	B-UNK
requiring	O
prolonged	B-UNK
mechanical	B-UNK
ventilation	B-UNK
.	O
Reports	B-UNK
of	O
persistent	B-UNK
paralysis	B-UNK
after	O
the	O
discontinuance	O
of	O
these	O
drugs	B-UNK
have	O
most	O
often	O
involved	B-UNK
aminosteroid	O
-	O
based	B-UNK
NMBAs	O
such	O
as	O
vecuronium	O
bromide	O
,	O
especially	O
when	O
used	O
in	O
conjunction	B-UNK
with	O
corticosteroids	B-UNK
.	O
Atracurium	B-CHEMICAL
besylate	O
,	O
a	O
short	B-UNK
-	O
acting	O
benzylisoquinolinium	O
NMBA	O
that	O
is	O
eliminated	O
independently	O
of	O
renal	B-UNK
or	O
hepatic	B-UNK
function	B-UNK
,	O
has	O
also	O
been	O
associated	O
with	O
persistent	B-UNK
paralysis	B-UNK
,	O
but	O
only	O
when	O
used	O
with	O
corticosteroids	B-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
atracurium	B-CHEMICAL
-	O
related	O
paralysis	B-DISEASE
persisting	O
for	O
approximately	B-UNK
50	O
hours	B-UNK
in	O
a	O
patient	B-UNK
who	O
was	O
not	O
treated	O
with	O
corticosteroids	B-CHEMICAL
.	O

Habitual	O
use	O
of	O
acetaminophen	B-UNK
as	O
a	O
risk	B-UNK
factor	I-UNK
for	O
chronic	B-UNK
renal	I-UNK
failure	I-UNK
:	O
a	O
comparison	B-UNK
with	O
phenacetin	B-CHEMICAL
.	O
Six	O
epidemiologic	O
studies	B-UNK
in	O
the	O
United	O
States	B-UNK
and	O
Europe	O
indicate	O
that	O
habitual	O
use	O
of	O
phenacetin	B-CHEMICAL
is	O
associated	O
with	O
the	O
development	B-UNK
of	O
chronic	B-UNK
renal	I-UNK
failure	I-UNK
and	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-UNK
)	O
,	O
with	O
a	O
relative	B-UNK
risk	I-UNK
in	O
the	O
range	B-UNK
of	O
4	O
to	O
19	O
.	O
As	O
a	O
result	B-UNK
of	O
these	O
and	O
other	O
studies	B-UNK
,	O
phenacetin	B-CHEMICAL
has	O
now	O
been	O
withdrawn	O
from	O
the	O
market	O
in	O
most	O
countries	O
.	O
However	O
,	O
three	O
case	B-UNK
control	B-UNK
studies	B-UNK
,	O
one	O
each	O
in	O
North	B-UNK
Carolina	O
,	O
northern	O
Maryland	O
,	O
and	O
West	O
Berlin	O
,	O
Germany	O
,	O
showed	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-CHEMICAL
is	O
also	O
associated	O
with	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
and	O
ESRD	B-DISEASE
,	O
with	O
a	O
relative	B-UNK
risk	I-UNK
in	O
the	O
range	B-UNK
of	O
2	O
to	O
4	O
.	O
These	O
studies	B-UNK
suggest	B-UNK
that	O
both	O
phenacetin	B-CHEMICAL
and	O
acetaminophen	B-UNK
may	O
contribute	B-UNK
to	O
the	O
burden	O
of	O
ESRD	B-UNK
,	O
with	O
the	O
risk	B-UNK
of	O
the	O
latter	O
being	O
somewhat	O
less	O
than	O
that	O
of	O
the	O
former	O
.	O
This	O
apparent	B-UNK
difference	B-UNK
in	O
risk	B-UNK
may	O
not	O
be	O
due	O
to	O
differences	B-UNK
in	O
nephrotoxic	B-UNK
potential	B-UNK
of	O
the	O
drugs	B-UNK
themselves	O
.	O
A	O
lower	B-UNK
relative	B-UNK
risk	I-UNK
would	O
be	O
expected	B-UNK
for	O
acetaminophen	B-CHEMICAL
if	O
the	O
risk	B-UNK
of	O
both	O
drugs	B-UNK
in	O
combination	B-UNK
with	O
other	O
analgesics	B-UNK
was	O
higher	B-UNK
than	O
the	O
risk	B-UNK
of	O
either	O
agent	B-UNK
alone	O
.	O
Thus	O
,	O
acetaminophen	B-CHEMICAL
has	O
been	O
used	O
both	O
as	O
a	O
single	B-UNK
agent	I-UNK
and	O
in	O
combination	B-UNK
with	O
other	O
analgesics	B-UNK
,	O
whereas	O
phenacetin	B-CHEMICAL
was	O
available	O
only	O
in	O
combinations	B-UNK
.	O
The	O
possibility	O
that	O
habitual	O
use	O
of	O
acetaminophen	B-CHEMICAL
alone	O
increases	B-UNK
the	O
risk	B-UNK
of	O
ESRD	B-UNK
has	O
not	O
been	O
clearly	O
demonstrated	O
,	O
but	O
cannot	O
be	O
dismissed	O
.	O

Reduction	O
of	O
heparan	O
sulphate	B-UNK
-	O
associated	O
anionic	B-UNK
sites	B-UNK
in	O
the	O
glomerular	B-UNK
basement	B-UNK
membrane	I-UNK
of	O
rats	B-UNK
with	O
streptozotocin	B-UNK
-	O
induced	O
diabetic	B-UNK
nephropathy	I-UNK
.	O
Heparan	O
sulphate	B-UNK
-	O
associated	O
anionic	B-UNK
sites	B-UNK
in	O
the	O
glomerular	B-UNK
basement	B-UNK
membrane	I-UNK
were	O
studied	O
in	O
rats	B-UNK
8	O
months	B-UNK
after	O
induction	B-UNK
of	O
diabetes	B-UNK
by	O
streptozotocin	B-CHEMICAL
and	O
in	O
age-	O
adn	O
sex	B-UNK
-	O
matched	O
control	B-UNK
rats	B-UNK
,	O
employing	O
the	O
cationic	O
dye	O
cuprolinic	O
blue	O
.	O
Morphometric	O
analysis	B-UNK
at	O
the	O
ultrastructural	B-UNK
level	B-UNK
was	O
performed	B-UNK
using	O
a	O
computerized	O
image	O
processor	O
.	O
The	O
heparan	O
sulphate	B-UNK
specificity	O
of	O
the	O
cuprolinic	O
blue	O
staining	B-UNK
was	O
demonstrated	O
by	O
glycosaminoglycan	O
-	O
degrading	O
enzymes	B-UNK
,	O
showing	O
that	O
pretreatment	B-UNK
of	O
the	O
sections	B-UNK
with	O
heparitinase	O
abolished	O
all	O
staining	B-UNK
,	O
whereas	O
chondroitinase	O
ABC	O
had	O
no	O
effect	B-UNK
.	O
The	O
majority	O
of	O
anionic	B-UNK
sites	B-UNK
(	O
74	O
%	O
in	O
diabetic	B-DISEASE
and	O
81	O
%	O
in	O
control	B-UNK
rats	B-UNK
)	O
were	O
found	O
within	O
the	O
lamina	B-UNK
rara	O
externa	O
of	O
the	O
glomerular	B-UNK
basement	B-UNK
membrane	I-UNK
.	O
A	O
minority	O
of	O
anionic	B-UNK
sites	B-UNK
were	O
scattered	O
throughout	O
the	O
lamina	B-UNK
densa	O
and	O
lamina	B-UNK
rara	O
interna	O
,	O
and	O
were	O
significantly	B-UNK
smaller	B-UNK
than	O
those	O
in	O
the	O
lamina	B-UNK
rara	O
externa	O
of	O
the	O
glomerular	B-UNK
basement	B-UNK
membrane	I-UNK
(	O
p<0.001	O
and	O
p<0.01	O
for	O
diabetic	B-UNK
and	O
control	B-UNK
rats	B-UNK
,	O
respectively	O
)	O
.	O
Diabetic	B-UNK
rats	B-UNK
progressively	O
developed	O
albuminuria	B-DISEASE
reaching	O
40.3	O
(	O
32.2	O
-	O
62.0	O
)	O
mg/24	O
h	O
after	O
8	O
months	B-UNK
in	O
contrast	B-UNK
to	O
the	O
control	B-UNK
animals	I-UNK
(	O
0.8	O
(	O
0.2	O
-	O
0.9	O
)	O
mg/24	O
h	O
,	O
p<0.002	O
)	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
number	B-UNK
of	O
heparan	O
sulphate	B-UNK
anionic	B-UNK
sites	B-UNK
and	O
the	O
total	B-UNK
anionic	B-UNK
site	B-UNK
surface	B-UNK
(	O
number	B-UNK
of	O
anionic	B-UNK
sites	B-UNK
x	O
mean	O
anionic	B-UNK
site	B-UNK
surface	B-UNK
)	O
in	O
the	O
lamina	B-UNK
rara	O
externa	O
of	O
the	O
glomerular	B-UNK
basement	B-UNK
membrane	I-UNK
was	O
reduced	B-UNK
by	O
19	O
%	O
(	O
p<0.021	O
)	O
and	O
by	O
26	O
%	O
(	O
p<0.02	O
)	O
,	O
respectively	O
.	O
Number	B-UNK
and	O
total	B-UNK
anionic	B-UNK
site	B-UNK
surface	B-UNK
in	O
the	O
remaining	O
part	O
of	O
the	O
glomerular	B-UNK
basement	B-UNK
membrane	I-UNK
(	O
lamina	B-UNK
densa	O
and	O
lamina	B-UNK
rara	O
interna	O
)	O
were	O
not	O
significantly	B-UNK
changed	O
.	O
We	O
conclude	O
that	O
in	O
streptozotocin	B-UNK
-	O
diabetic	B-UNK
rats	B-UNK
with	O
an	O
increased	B-UNK
urinary	B-UNK
albumin	B-UNK
excretion	B-UNK
,	O
a	O
reduced	B-UNK
heparan	O
sulphate	B-UNK
charge	O
barrier	B-UNK
/	O
density	B-UNK
is	O
found	O
at	O
the	O
lamina	B-UNK
rara	O
externa	O
of	O
the	O
glomerular	B-UNK
basement	B-UNK
membrane	I-UNK
.	O

Effect	B-UNK
of	O
some	O
anticancer	O
drugs	B-UNK
and	O
combined	B-UNK
chemotherapy	O
on	O
renal	B-UNK
toxicity	I-UNK
.	O
The	O
nephrotoxic	B-UNK
action	B-UNK
of	O
anticancer	O
drugs	B-UNK
such	O
as	O
nitrogranulogen	O
(	O
NG	B-UNK
)	O
,	O
methotrexate	B-UNK
(	O
MTX	B-UNK
)	O
,	O
5-fluorouracil	B-CHEMICAL
(	O
5-FU	B-CHEMICAL
)	O
and	O
cyclophosphamide	B-UNK
(	O
CY	B-UNK
)	O
administered	O
alone	O
or	O
in	O
combination	B-UNK
[	O
MTX	B-UNK
+	O
5-FU	B-CHEMICAL
+	O
CY	B-UNK
(	O
CMF	O
)	O
]	O
was	O
evaluated	B-UNK
in	O
experiments	B-UNK
on	O
Wistar	B-UNK
rats	I-UNK
.	O
After	O
drug	B-UNK
administration	O
,	O
creatinine	B-CHEMICAL
concentrations	B-UNK
in	O
the	O
plasma	B-UNK
and	O
in	O
the	O
urine	B-UNK
of	O
the	O
rats	B-UNK
were	O
determined	B-UNK
,	O
as	O
well	O
as	O
creatinine	B-UNK
clearance	I-UNK
.	O
Histopathologic	O
evaluation	B-UNK
of	O
the	O
kidneys	B-UNK
was	O
also	O
performed	B-UNK
.	O
After	O
MTX	B-UNK
administration	O
a	O
significant	B-UNK
increase	B-UNK
(	O
p	O
=	O
0.0228	O
)	O
in	O
the	O
plasma	B-UNK
creatinine	B-UNK
concentration	I-UNK
and	O
a	O
significant	B-UNK
(	O
p	O
=	O
0.0001	O
)	O
decrease	B-UNK
in	O
creatinine	B-UNK
clearance	I-UNK
was	O
noted	B-UNK
compared	O
to	O
controls	B-UNK
.	O
After	O
the	O
administration	O
of	O
NG	B-UNK
,	O
5-FU	B-CHEMICAL
and	O
CY	B-CHEMICAL
neither	O
a	O
statistically	B-UNK
significant	I-UNK
increase	B-UNK
in	O
creatinine	B-UNK
concentration	I-UNK
nor	O
an	O
increase	B-UNK
in	O
creatinine	B-UNK
clearance	I-UNK
was	O
observed	O
compared	O
to	O
the	O
group	B-UNK
receiving	B-UNK
no	O
cytostatics	O
.	O
Following	O
polytherapy	O
according	O
to	O
the	O
CMF	B-CHEMICAL
regimen	I-CHEMICAL
,	O
a	O
statistically	B-UNK
significant	I-UNK
decrease	B-UNK
(	O
p	O
=	O
0.0343	O
)	O
in	O
creatinine	B-UNK
clearance	I-UNK
was	O
found	O
,	O
but	O
creatinine	B-UNK
concentration	I-UNK
did	O
not	O
increase	B-UNK
significantly	B-UNK
compared	O
to	O
controls	B-UNK
.	O
CY	B-UNK
caused	B-UNK
hemorrhagic	B-UNK
cystitis	I-UNK
in	O
40	O
%	O
of	O
rats	B-UNK
,	O
but	O
it	O
did	O
not	O
cause	O
this	O
complication	B-UNK
when	O
combined	B-UNK
with	O
5-FU	B-CHEMICAL
and	O
MTX	B-UNK
.	O
Histologic	B-UNK
changes	O
were	O
found	O
in	O
rat	B-UNK
kidneys	B-UNK
after	O
administration	O
of	O
MTX	B-UNK
,	O
CY	B-CHEMICAL
and	O
NG	B-UNK
,	O
while	O
no	O
such	O
change	B-UNK
was	O
observed	O
after	O
5-FU	B-CHEMICAL
and	O
joint	O
administration	O
of	O
MTX	B-UNK
+	O
5-FU	B-CHEMICAL
+	O
CY	B-UNK
compared	O
to	O
controls	B-UNK
.	O
Our	O
studies	B-UNK
indicate	O
that	O
nephrotoxicity	B-UNK
of	O
MTX	B-UNK
+	O
5-FU	B-CHEMICAL
+	O
CY	B-UNK
administered	O
jointly	O
is	O
lower	B-UNK
than	O
in	O
monotherapy	B-UNK
.	O

Lithium	B-UNK
-	O
associated	O
cognitive	B-DISEASE
and	I-DISEASE
functional	I-DISEASE
deficits	I-DISEASE
reduced	B-UNK
by	O
a	O
switch	O
to	O
divalproex	O
sodium	B-CHEMICAL
:	O
a	O
case	B-UNK
series	I-UNK
.	O
BACKGROUND	B-UNK
:	O
Lithium	B-UNK
remains	O
a	O
first	O
-	O
line	B-UNK
treatment	B-UNK
for	O
the	O
acute	B-UNK
and	O
maintenance	B-UNK
treatment	B-UNK
of	O
bipolar	B-DISEASE
disorder	I-DISEASE
.	O
Although	O
much	O
has	O
been	O
written	O
about	O
the	O
management	B-UNK
of	O
the	O
more	O
common	B-UNK
adverse	B-UNK
effects	I-UNK
of	O
lithium	B-UNK
,	O
such	O
as	O
polyuria	B-DISEASE
and	O
tremor	B-UNK
,	O
more	O
subtle	O
lithium	B-UNK
side	O
effects	O
such	O
as	O
cognitive	B-UNK
deficits	I-UNK
,	O
loss	B-UNK
of	O
creativity	O
,	O
and	O
functional	B-UNK
impairments	B-UNK
remain	O
understudied	O
.	O
This	O
report	B-UNK
summarizes	O
our	O
experience	B-UNK
in	O
switching	B-UNK
bipolar	B-DISEASE
patients	B-UNK
from	O
lithium	B-UNK
to	O
divalproex	O
sodium	B-UNK
to	O
alleviate	O
such	O
cognitive	B-DISEASE
and	I-DISEASE
functional	I-DISEASE
impairments	I-DISEASE
.	O
METHOD	B-UNK
:	O
Open	B-UNK
,	O
case	B-UNK
series	I-UNK
design	B-UNK
.	O
RESULTS	B-UNK
:	O
We	O
report	B-UNK
seven	O
cases	B-UNK
where	O
substitution	O
of	O
lithium	B-CHEMICAL
,	O
either	O
fully	B-UNK
or	O
partially	O
,	O
with	O
divalproex	O
sodium	B-UNK
was	O
extremely	O
helpful	O
in	O
reducing	B-UNK
the	O
cognitive	B-DISEASE
,	I-DISEASE
motivational	I-DISEASE
,	I-DISEASE
or	I-DISEASE
creative	I-DISEASE
deficits	I-DISEASE
attributed	B-UNK
to	O
lithium	B-UNK
in	O
our	O
bipolar	B-UNK
patients	B-UNK
.	O
CONCLUSION	B-UNK
:	O
In	O
this	O
preliminary	B-UNK
report	B-UNK
,	O
divalproex	O
sodium	B-UNK
was	O
a	O
superior	B-UNK
alternative	B-UNK
to	O
lithium	B-CHEMICAL
in	O
bipolar	B-UNK
patients	B-UNK
experiencing	O
cognitive	B-UNK
deficits	I-UNK
,	O
loss	B-UNK
of	O
creativity	O
,	O
and	O
functional	B-UNK
impairments	B-UNK
.	O

Treatment	B-UNK
of	O
previously	B-UNK
treated	O
metastatic	B-UNK
breast	I-UNK
cancer	I-UNK
by	O
mitoxantrone	B-CHEMICAL
and	O
48-hour	O
continuous	B-UNK
infusion	I-UNK
of	O
high	B-UNK
-	O
dose	B-UNK
5-FU	B-CHEMICAL
and	O
leucovorin	O
(	O
MFL	O
):	O
low	B-UNK
palliative	O
benefit	O
and	O
high	B-UNK
treatment	B-UNK
-	O
related	O
toxicity	B-UNK
.	O
For	O
previously	B-UNK
treated	O
advanced	B-UNK
breast	B-UNK
cancer	I-UNK
,	O
there	O
is	O
no	O
standard	B-UNK
second	O
-	O
line	B-UNK
therapy	O
.	O
Combination	B-UNK
chemotherapy	O
with	O
mitoxantrone	B-CHEMICAL
,	O
high	B-UNK
-	O
dose	B-UNK
5-fluorouracil	B-CHEMICAL
(	O
5-FU	B-CHEMICAL
)	O
and	O
leucovorin	O
(	O
MFL	O
regimen	B-UNK
)	O
had	O
been	O
reported	B-UNK
as	O
an	O
effective	B-UNK
and	O
well	O
tolerated	B-UNK
regimen	B-UNK
.	O
From	O
October	O
1993	O
to	O
November	B-UNK
1995	O
,	O
we	O
treated	O
13	O
patients	B-UNK
with	O
previously	B-UNK
chemotherapy	O
-	O
treated	O
metastatic	B-UNK
breast	I-UNK
cancer	I-UNK
by	O
mitoxantrone	B-CHEMICAL
,	O
12	O
mg	B-UNK
/	O
m2	B-UNK
,	O
on	O
day	O
1	O
and	O
continuous	B-UNK
infusion	I-UNK
of	O
5-FU	B-CHEMICAL
,	O
3000	O
mg	B-UNK
/	O
m2	B-UNK
,	O
together	O
with	O
leucovorin	O
,	O
300	O
mg	B-UNK
/	O
m2	B-UNK
,	O
for	O
48	O
h	O
from	O
day	O
1	O
to	O
2	O
.	O
Each	O
course	O
of	O
chemotherapy	O
was	O
given	O
every	O
4	O
weeks	B-UNK
.	O
Most	O
of	O
these	O
patients	B-UNK
had	O
more	O
than	O
two	O
metastatic	B-UNK
sites	B-UNK
,	O
with	O
lung	B-UNK
metastasis	O
predominant	B-UNK
.	O
Seven	O
patients	B-UNK
had	O
been	O
treated	O
with	O
anthracycline	B-UNK
.	O
Seven	O
patients	B-UNK
had	O
previously	B-UNK
received	O
radiotherapy	B-UNK
and	O
seven	O
had	O
received	O
hormone	B-UNK
therapy	O
.	O
Median	B-UNK
number	B-UNK
of	O
courses	B-UNK
of	O
MFL	O
regimen	B-UNK
given	O
was	O
six	O
and	O
the	O
median	B-UNK
cumulative	B-UNK
dose	I-UNK
of	O
mitoxantrone	B-CHEMICAL
was	O
68.35	O
mg	B-UNK
/	O
m2	B-UNK
.	O
One	O
patient	B-UNK
had	O
complete	B-UNK
response	B-UNK
,	O
seven	O
had	O
stable	B-UNK
disease	B-UNK
,	O
none	O
had	O
partial	B-UNK
response	I-UNK
and	O
five	O
had	O
progressive	B-UNK
disease	B-UNK
.	O
The	O
overall	O
objective	B-UNK
response	B-UNK
rate	B-UNK
was	O
7.6	O
%	O
.	O
The	O
median	B-UNK
follow	O
-	O
up	O
period	B-UNK
was	O
14	O
months	B-UNK
.	O
Median	B-UNK
survival	B-UNK
was	O
16	O
months	B-UNK
.	O
Median	B-UNK
progression	B-UNK
-	O
free	B-UNK
survival	B-UNK
was	O
5	O
months	B-UNK
.	O
A	O
complete	B-UNK
responder	O
had	O
relapse	B-UNK
-	O
free	B-UNK
survival	B-UNK
up	O
to	O
17	O
months	B-UNK
.	O
Major	B-UNK
toxicities	B-UNK
were	O
cardiotoxicity	B-UNK
and	O
leukopenia	B-DISEASE
.	O
Eight	O
patients	B-UNK
were	O
dead	O
in	O
the	O
last	O
follow	O
-	O
up	O
;	O
two	O
of	O
them	O
died	O
of	O
treatment	B-UNK
-	O
related	O
toxicity	B-UNK
.	O
The	O
MFL	O
regimen	B-UNK
achieves	O
little	O
palliative	O
benefit	O
and	O
induces	O
severe	B-UNK
toxicity	B-DISEASE
at	O
a	O
fairly	O
high	B-UNK
rate	B-UNK
.	O
Administration	O
of	O
this	O
regimen	B-UNK
to	O
breast	B-UNK
cancer	I-UNK
patients	B-UNK
who	O
have	O
been	O
treated	O
by	O
chemotherapy	O
and	O
those	O
with	O
impaired	B-UNK
heart	B-UNK
function	B-UNK
requires	O
careful	B-UNK
attention	B-UNK
.	O

Upregulation	B-UNK
of	O
the	O
expression	B-UNK
of	O
vasopressin	B-CHEMICAL
gene	B-UNK
in	O
the	O
paraventricular	O
and	O
supraoptic	O
nuclei	B-UNK
of	O
the	O
lithium	B-CHEMICAL
-	O
induced	O
diabetes	B-UNK
insipidus	I-UNK
rat	B-UNK
.	O
The	O
expression	B-UNK
of	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
(	O
AVP	B-UNK
)	O
gene	B-UNK
in	O
the	O
paraventricular	O
(	O
PVN	O
)	O
and	O
supraoptic	O
nuclei	B-UNK
(	O
SON	O
)	O
was	O
investigated	B-UNK
in	O
rats	B-UNK
with	O
lithium	B-UNK
(	O
Li)-induced	O
polyuria	B-UNK
,	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
and	O
radioimmunoassay	O
.	O
The	O
male	B-UNK
Wistar	I-UNK
rats	I-UNK
consuming	O
a	O
diet	B-UNK
that	O
contained	B-UNK
LiCl	O
(	O
60	O
mmol	B-UNK
/	O
kg	B-UNK
)	O
for	O
4	O
weeks	B-UNK
developed	O
marked	O
polyuria	B-UNK
.	O
The	O
Li	B-UNK
-	O
treated	B-UNK
rats	I-UNK
produced	B-UNK
a	O
large	B-UNK
volume	B-UNK
of	O
hypotonic	O
urine	B-UNK
with	O
low	B-UNK
ionic	O
concentrations	B-UNK
.	O
Plasma	B-UNK
sodium	B-CHEMICAL
concentrations	B-UNK
were	O
found	O
to	O
be	O
slightly	O
increased	B-UNK
in	O
the	O
Li	B-UNK
-	O
treated	B-UNK
rats	I-UNK
compared	O
with	O
those	O
in	O
controls	B-UNK
.	O
Plasma	B-UNK
concentration	I-UNK
of	O
AVP	B-CHEMICAL
and	O
transcripts	O
of	O
AVP	B-UNK
gene	B-UNK
in	O
the	O
PVN	O
and	O
SON	O
were	O
significantly	B-UNK
increased	B-UNK
in	O
the	O
Li	B-UNK
-	O
treated	B-UNK
rats	I-UNK
compared	O
with	O
controls	B-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
dehydration	B-DISEASE
and	O
/	O
or	O
the	O
activation	B-UNK
of	O
visceral	O
afferent	B-UNK
inputs	O
may	O
contribute	B-UNK
to	O
the	O
elevation	B-UNK
of	O
plasma	B-UNK
AVP	B-CHEMICAL
and	O
the	O
upregulation	B-UNK
of	O
AVP	B-UNK
gene	B-UNK
expression	I-UNK
in	O
the	O
PVN	O
and	O
the	O
SON	O
of	O
the	O
Li	B-UNK
-	O
induced	O
diabetes	B-UNK
insipidus	I-UNK
rat	B-UNK
.	O

Suxamethonium	B-UNK
-	O
induced	O
cardiac	B-DISEASE
arrest	I-DISEASE
and	O
death	B-UNK
following	O
5	O
days	B-UNK
of	O
immobilization	O
.	O
The	O
present	B-UNK
report	B-UNK
describes	I-UNK
a	O
case	B-UNK
of	O
cardiac	B-UNK
arrest	I-UNK
and	O
subsequent	B-UNK
death	B-DISEASE
as	O
a	O
result	B-UNK
of	O
hyperkalaemia	O
following	O
the	O
use	O
of	O
suxamethonium	B-UNK
in	O
a	O
23-year	O
-	O
old	O
Malawian	O
woman	B-UNK
.	O
Five	O
days	B-UNK
after	O
the	O
onset	B-UNK
of	O
the	O
symptoms	B-UNK
of	O
meningitis	B-DISEASE
,	O
the	O
patient	B-UNK
aspirated	O
stomach	O
contents	O
and	O
needed	B-UNK
endotracheal	O
intubation	O
.	O
Forty	O
seconds	B-UNK
after	O
injection	B-UNK
of	O
suxamethonium	B-UNK
,	O
bradycardia	B-UNK
and	O
cardiac	B-UNK
arrest	I-UNK
occurred	B-UNK
.	O
Attempts	O
to	O
resuscitate	O
the	O
patient	B-UNK
were	O
not	O
successful	O
.	O
The	O
serum	B-UNK
level	B-UNK
of	O
potassium	B-UNK
was	O
observed	O
to	O
be	O
8.4	O
mequiv	O
L-1	O
.	O
Apart	O
from	O
the	O
reduction	O
in	O
the	O
patient'	B-UNK
s	I-UNK
level	B-UNK
of	O
consciousness	B-UNK
,	O
there	O
were	O
no	O
signs	B-UNK
of	O
motor	B-UNK
neurone	O
damage	B-UNK
or	O
of	O
any	O
of	O
the	O
other	O
known	O
predisposing	O
conditions	O
for	O
hyperkalaemia	O
following	O
the	O
administration	O
of	O
suxamethonium	B-CHEMICAL
.	O
It	O
is	O
postulated	O
that	O
her	O
death	B-UNK
was	O
caused	B-UNK
by	O
hypersensitivity	B-UNK
to	O
suxamethonium	B-UNK
,	O
associated	O
with	O
her	O
5-day	O
immobilization	O
.	O

An	O
unusual	B-UNK
toxic	B-UNK
reaction	B-UNK
to	O
axillary	O
block	B-UNK
by	O
mepivacaine	O
with	O
adrenaline	B-UNK
.	O
An	O
increase	B-UNK
in	O
blood	B-UNK
pressure	I-UNK
,	O
accompanied	B-UNK
by	O
atrial	B-UNK
fibrillation	I-UNK
,	O
agitation	B-UNK
,	O
incomprehensible	O
shouts	O
and	O
loss	B-UNK
of	O
consciousness	B-UNK
,	O
was	O
observed	O
in	O
an	O
elderly	B-UNK
,	O
ASA	B-CHEMICAL
classification	O
group	B-UNK
II	I-UNK
,	O
cardiovascularly	O
medicated	O
male	B-UNK
,	O
12	O
min	B-UNK
after	O
performance	B-UNK
of	O
axillary	O
block	B-UNK
with	O
mepivacaine	O
850	O
mg	B-UNK
containing	O
adrenaline	B-UNK
0.225	O
mg	B-UNK
,	O
for	O
correction	O
of	O
Dupuytren'	O
s	O
contracture	B-DISEASE
.	O
After	O
intravenous	B-UNK
administration	O
of	O
labetalol	B-UNK
,	O
metoprolol	B-UNK
and	O
midazolam	B-UNK
the	O
patient'	B-UNK
s	I-UNK
condition	B-UNK
improved	O
,	O
and	O
15	O
min	B-UNK
later	O
he	O
woke	O
up	O
.	O
The	O
block	B-UNK
was	O
successful	O
and	O
surgery	B-UNK
was	O
conducted	B-UNK
as	O
scheduled	O
despite	O
persisting	O
atrial	B-UNK
fibrillation	I-UNK
.	O
Postoperatively	B-UNK
,	O
the	O
patient	B-UNK
refused	O
DC	O
cardioversion	O
and	O
was	O
treated	O
medically	O
.	O
Both	O
the	O
temporal	B-UNK
relationship	B-UNK
of	O
events	B-UNK
and	O
the	O
response	B-UNK
to	O
treatment	B-UNK
suggest	B-UNK
that	O
a	O
rapid	B-UNK
systemic	B-UNK
absorption	O
of	O
mepivacaine	O
with	O
adrenaline	B-UNK
and	O
/	O
or	O
interaction	B-UNK
of	O
these	O
drugs	B-UNK
with	O
the	O
patient'	B-UNK
s	I-UNK
cardiovascular	B-UNK
medications	B-UNK
were	O
responsible	B-UNK
for	O
the	O
perioperative	O
complications	B-UNK
.	O

Clinical	B-UNK
and	O
histopathologic	O
examination	B-UNK
of	O
renal	B-UNK
allografts	O
treated	O
with	O
tacrolimus	B-UNK
(	O
FK506	B-UNK
)	O
for	O
at	O
least	O
one	O
year	O
.	O
BACKGROUND	B-UNK
:	O
We	O
clinically	B-UNK
and	O
pathologically	O
analyzed	O
renal	B-UNK
allografts	O
from	O
1	O
9	O
renal	B-UNK
transplant	I-UNK
patients	B-UNK
treated	O
with	O
tacrolimus	B-UNK
(	O
FK506	B-UNK
)	O
for	O
more	O
than	O
1	O
year	O
.	O
METHODS	B-UNK
:	O
Twenty	O
-	O
six	O
renal	B-UNK
allograft	B-UNK
biopsy	B-UNK
specimens	O
from	O
1	O
9	O
renal	B-UNK
transplant	I-UNK
patients	B-UNK
who	O
underwent	O
transplantations	O
between	O
1991	O
and	O
1993	O
were	O
evaluated	B-UNK
.	O
Thirteen	B-UNK
biopsies	B-UNK
were	O
performed	B-UNK
from	O
stable	B-UNK
functioning	B-UNK
renal	B-UNK
allografts	O
with	O
informed	O
consent	O
(	O
nonepisode	O
biopsy	B-UNK
)	O
and	O
the	O
other	O
13	O
were	O
from	O
dysfunctional	O
renal	B-UNK
allografts	O
with	O
a	O
clinical	B-UNK
indication	O
for	O
biopsy	B-UNK
(	O
episode	B-UNK
biopsy	B-UNK
)	O
.	O
RESULTS	B-UNK
:	O
The	O
main	B-UNK
pathologic	O
diagnoses	O
(	O
some	O
overlap	O
)	O
were	O
acute	B-UNK
rejection	B-UNK
(	O
AR	O
;	O
n	O
=	O
4	O
)	O
,	O
chronic	B-UNK
rejection	B-UNK
(	O
CR	B-UNK
;	O
n=5	O
)	O
,	O
AR+CR	O
(	O
n	O
=	O
4	O
)	O
,	O
recurrent	B-UNK
IgA	O
nephropathy	B-UNK
(	O
n	O
=	O
5	O
)	O
,	O
normal	O
findings	B-UNK
(	O
n	O
=	O
2	O
)	O
,	O
minimal	B-UNK
-	O
type	B-UNK
chronic	B-UNK
FK506	B-UNK
nephropathy	B-DISEASE
(	O
n	O
=	O
9	O
)	O
,	O
and	O
mild	B-UNK
-	O
type	B-UNK
FK506	B-UNK
nephropathy	B-UNK
(	O
n	O
=	O
11	O
)	O
.	O
Of	O
the	O
nonepisode	O
biopsies	B-UNK
,	O
7	O
and	O
4	O
biopsies	B-UNK
showed	O
minimal	B-UNK
-	O
type	B-UNK
and	O
mild	B-UNK
-	O
type	B-UNK
chronic	B-UNK
FK506	B-UNK
nephropathy	B-UNK
,	O
respectively	O
.	O
Chronic	B-UNK
FK506	B-UNK
nephropathy	B-UNK
consisted	B-UNK
of	O
rough	O
and	O
foamy	O
tubular	B-UNK
vacuolization	O
(	O
5	O
biopsies	B-UNK
)	O
,	O
arteriolopathy	O
(	O
angiodegeneration	O
of	O
the	O
arteriolar	O
wall	B-UNK
;	O
20	O
biopsies	B-UNK
)	O
,	O
focal	B-UNK
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
(	O
4	O
biopsies	B-UNK
)	O
and	O
the	O
striped	O
form	B-UNK
of	O
interstitial	B-UNK
fibrosis	B-UNK
(	O
11	O
biopsies	B-UNK
)	O
.	O
The	O
serum	B-UNK
creatinine	I-UNK
levels	I-UNK
of	O
patients	B-UNK
in	O
the	O
mild	B-UNK
-	O
type	B-UNK
chronic	B-UNK
FK506	B-UNK
nephropathy	B-DISEASE
group	B-UNK
,	O
which	O
included	B-UNK
7	O
episode	B-UNK
biopsies	B-UNK
,	O
were	O
statistically	B-UNK
higher	B-UNK
than	O
those	O
in	O
the	O
minimum	B-UNK
-	O
type	B-UNK
chronic	B-UNK
FK506-nephropathy	O
group	B-UNK
(	O
P	O
<	O
0.001	O
)	O
.	O
CONCLUSIONS	B-UNK
:	O
This	O
study	B-UNK
demonstrates	O
that	O
chronic	B-UNK
FK506	B-UNK
nephropathy	B-UNK
consists	O
primarily	O
of	O
arteriolopathy	O
manifesting	O
as	O
insudative	O
hyalinosis	O
of	O
the	O
arteriolar	O
wall	B-UNK
,	O
and	O
suggests	O
that	O
mild	B-UNK
-	O
type	B-UNK
chronic	B-UNK
FK506	B-UNK
nephropathy	B-UNK
is	O
a	O
condition	B-UNK
which	O
may	O
lead	B-UNK
to	O
deterioration	B-UNK
of	O
renal	B-UNK
allograft	B-UNK
function	B-UNK
.	O

Memory	B-UNK
facilitation	O
and	O
stimulation	B-UNK
of	O
endogenous	B-UNK
nerve	B-UNK
growth	B-UNK
factor	I-UNK
synthesis	B-UNK
by	O
the	O
acetylcholine	B-UNK
releaser	O
PG-9	O
.	O
The	O
effects	O
of	O
PG-9	O
(	O
3alpha	B-CHEMICAL
-	I-CHEMICAL
tropyl	I-CHEMICAL
2-(p	I-CHEMICAL
-	I-CHEMICAL
bromophenyl)propionate	I-CHEMICAL
)	O
,	O
the	O
acetylcholine	B-UNK
releaser	O
,	O
on	O
memory	B-UNK
processes	B-UNK
and	O
nerve	B-UNK
growth	B-UNK
factor	I-UNK
(	O
NGF	B-UNK
)	O
synthesis	B-UNK
were	O
evaluated	B-UNK
.	O
In	O
the	O
mouse	B-UNK
passive	B-UNK
-	O
avoidance	B-UNK
test	B-UNK
,	O
PG-9	O
(	O
10	O
-	O
30	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
,	O
administered	O
20	O
min	B-UNK
before	O
the	O
training	B-UNK
session	B-UNK
,	O
prevented	B-UNK
amnesia	B-UNK
induced	O
by	O
both	O
the	O
non	O
selective	B-UNK
antimuscarinic	O
drug	B-UNK
scopolamine	B-CHEMICAL
and	O
the	O
M1-selective	O
antagonist	B-UNK
S-(-)-ET-126	O
.	O
In	O
the	O
same	O
experimental	B-UNK
conditions	O
,	O
PG-9	O
(	O
5	O
-	O
20	O
microg	B-UNK
per	O
mouse	B-UNK
,	O
i.c.v	B-UNK
.	O
)	O
was	O
also	O
able	O
to	O
prevent	B-UNK
antimuscarine	O
-	O
induced	O
amnesia	B-UNK
,	O
demonstrating	O
a	O
central	B-UNK
localization	B-UNK
of	O
the	O
activity	B-UNK
.	O
At	O
the	O
highest	B-UNK
effective	B-UNK
doses	B-UNK
,	O
PG-9	O
did	O
not	O
produce	B-UNK
any	O
collateral	O
symptoms	B-UNK
as	O
revealed	O
by	O
the	O
Irwin	O
test	B-UNK
,	O
and	O
it	O
did	O
not	O
modify	O
spontaneous	B-UNK
motility	B-UNK
and	O
inspection	O
activity	B-UNK
,	O
as	O
revealed	O
by	O
the	O
hole	O
-	O
board	O
test	B-UNK
.	O
PG-9	O
was	O
also	O
able	O
to	O
increase	B-UNK
the	O
amount	O
of	O
NGF	B-UNK
secreted	O
in	O
vitro	B-UNK
by	O
astrocytes	B-UNK
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
manner	I-UNK
.	O
The	O
maximal	B-UNK
NGF	B-UNK
contents	O
obtained	B-UNK
by	O
PG-9	O
were	O
17.6-fold	O
of	O
the	O
control	B-UNK
value	O
.	O
During	O
culture	B-UNK
,	O
no	O
morphological	B-UNK
changes	O
were	O
found	O
at	O
effective	B-UNK
concentrations	B-UNK
of	O
PG-9	O
.	O
The	O
current	B-UNK
work	O
indicates	O
the	O
ability	B-UNK
of	O
PG-9	O
to	O
induce	B-UNK
beneficial	B-UNK
effects	I-UNK
on	O
cognitive	B-UNK
processes	B-UNK
and	O
stimulate	O
activity	B-UNK
of	O
NGF	B-UNK
synthesis	B-UNK
in	O
astroglial	O
cells	B-UNK
.	O
Therefore	O
,	O
PG-9	O
could	O
represent	O
a	O
potential	B-UNK
useful	O
drug	B-UNK
able	O
to	O
improve	B-UNK
the	O
function	B-UNK
of	O
impaired	B-UNK
cognitive	B-UNK
processes	B-UNK
.	O

Angioedema	B-UNK
due	O
to	O
ACE	B-UNK
inhibitors	B-UNK
:	O
common	B-UNK
and	O
inadequately	O
diagnosed	B-UNK
.	O
The	O
estimated	O
incidence	B-UNK
of	O
angioedema	B-DISEASE
during	O
angiotensin	O
-	O
converting	B-UNK
enzyme	I-UNK
(	O
ACE	B-UNK
)	O
inhibitor	B-UNK
treatment	B-UNK
is	O
between	O
1	O
and	O
7	O
per	O
thousand	O
patients	B-UNK
.	O
This	O
potentially	O
serious	O
adverse	B-UNK
effect	I-UNK
is	O
often	O
preceded	B-UNK
by	O
minor	B-UNK
manifestations	B-UNK
that	O
may	O
serve	O
as	O
a	O
warning	O
.	O

Recurarization	O
in	O
the	O
recovery	B-UNK
room	B-UNK
.	O
A	O
case	B-UNK
of	O
recurarization	O
in	O
the	O
recovery	B-UNK
room	B-UNK
is	O
reported	B-UNK
.	O
Accumulation	B-UNK
of	O
atracurium	B-CHEMICAL
in	O
the	O
intravenous	B-UNK
line	B-UNK
led	B-UNK
to	O
recurarization	O
after	O
flushing	B-DISEASE
the	O
line	B-UNK
in	O
the	O
recovery	B-UNK
room	B-UNK
.	O
A	O
respiratory	B-UNK
arrest	B-UNK
with	O
severe	B-UNK
desaturation	B-DISEASE
and	O
bradycardia	B-DISEASE
occurred	B-UNK
.	O
Circumstances	O
leading	B-UNK
to	O
this	O
event	B-UNK
and	O
the	O
mechanisms	B-UNK
enabling	O
a	O
neuromuscular	B-UNK
blockade	B-UNK
to	O
occur	O
,	O
following	O
the	O
administration	O
of	O
a	O
small	B-UNK
dose	B-UNK
of	O
relaxant	O
,	O
are	O
discussed	O
.	O

Recurrent	B-UNK
use	O
of	O
newer	O
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
and	O
the	O
risk	B-UNK
of	O
venous	B-UNK
thromboembolism	I-UNK
.	O
The	O
epidemiological	O
studies	B-UNK
that	O
assessed	B-UNK
the	O
risk	B-UNK
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
(	O
VTE	B-DISEASE
)	O
associated	O
with	O
newer	O
oral	B-UNK
contraceptives	I-UNK
(	O
OC	B-UNK
)	O
did	O
not	O
distinguish	O
between	O
patterns	B-UNK
of	O
OC	B-UNK
use	O
,	O
namely	O
first	O
-	O
time	O
users	B-UNK
,	O
repeaters	O
and	O
switchers	O
.	O
Data	B-UNK
from	O
a	O
Transnational	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
were	O
used	O
to	O
assess	B-UNK
the	O
risk	B-UNK
of	O
VTE	B-UNK
for	O
the	O
latter	O
patterns	B-UNK
of	O
use	O
,	O
while	O
accounting	O
for	O
duration	B-UNK
of	O
use	O
.	O
Over	O
the	O
period	B-UNK
1993	O
-	O
1996	O
,	O
551	O
cases	B-UNK
of	O
VTE	B-UNK
were	O
identified	B-UNK
in	O
Germany	O
and	O
the	O
UK	O
along	O
with	O
2066	O
controls	B-UNK
.	O
Totals	O
of	O
128	O
cases	B-UNK
and	O
650	O
controls	B-UNK
were	O
analysed	B-UNK
for	O
repeat	B-UNK
use	O
and	O
135	O
cases	B-UNK
and	O
622	O
controls	B-UNK
for	O
switching	B-UNK
patterns	B-UNK
.	O
The	O
adjusted	B-UNK
rate	B-UNK
ratio	B-UNK
of	O
VTE	B-UNK
for	O
repeat	B-UNK
users	B-UNK
of	O
third	B-UNK
generation	I-UNK
OC	B-UNK
was	O
0.6	O
(	O
95	O
%	O
CI:0.3	O
-	O
1.2	O
)	O
relative	B-UNK
to	O
repeat	B-UNK
users	B-UNK
of	O
second	B-UNK
generation	I-UNK
pills	O
,	O
whereas	O
it	O
was	O
1.3	O
(	O
95	O
%	O
CI:0.7	O
-	O
2.4	O
)	O
for	O
switchers	O
from	O
second	O
to	O
third	B-UNK
generation	I-UNK
pills	O
relative	B-UNK
to	O
switchers	O
from	O
third	O
to	O
second	B-UNK
generation	I-UNK
pills	O
.	O
We	O
conclude	O
that	O
second	O
and	O
third	B-UNK
generation	I-UNK
agents	B-UNK
are	O
associated	O
with	O
equivalent	O
risks	B-UNK
of	O
VTE	B-DISEASE
when	O
the	O
same	O
agent	B-UNK
is	O
used	O
repeatedly	B-UNK
after	O
interruption	O
periods	O
or	O
when	O
users	B-UNK
are	O
switched	O
between	O
the	O
two	O
generations	O
of	O
pills	O
.	O
These	O
analyses	B-UNK
suggest	B-UNK
that	O
the	O
higher	B-UNK
risk	B-UNK
observed	O
for	O
the	O
newer	O
OC	B-UNK
in	O
other	O
studies	B-UNK
may	O
be	O
the	O
result	B-UNK
of	O
inadequate	O
comparisons	O
of	O
pill	O
users	B-UNK
with	O
different	O
patterns	B-UNK
of	O
pill	O
use	O
.	O

Development	B-UNK
of	O
apomorphine	B-UNK
-	O
induced	O
aggressive	B-DISEASE
behavior	I-DISEASE
:	O
comparison	B-UNK
of	O
adult	B-UNK
male	I-UNK
and	O
female	B-UNK
Wistar	B-UNK
rats	I-UNK
.	O
The	O
development	B-UNK
of	O
apomorphine	B-UNK
-	O
induced	O
(	O
1.0	O
mg	B-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
once	O
daily	B-UNK
)	O
aggressive	B-DISEASE
behavior	I-DISEASE
of	O
adult	B-UNK
male	I-UNK
and	O
female	B-UNK
Wistar	B-UNK
rats	I-UNK
obtained	B-UNK
from	O
the	O
same	O
breeder	O
was	O
studied	O
in	O
two	O
consecutive	B-UNK
sets	O
.	O
In	O
male	B-UNK
animals	B-UNK
,	O
repeated	B-UNK
apomorphine	B-UNK
treatment	B-UNK
induced	O
a	O
gradual	B-UNK
development	B-UNK
of	O
aggressive	B-DISEASE
behavior	I-DISEASE
as	O
evidenced	O
by	O
the	O
increased	B-UNK
intensity	B-UNK
of	O
aggressiveness	B-DISEASE
and	O
shortened	O
latency	B-UNK
before	O
the	O
first	O
attack	B-UNK
toward	O
the	O
opponent	O
.	O
In	O
female	B-UNK
rats	I-UNK
,	O
only	O
a	O
weak	O
tendency	O
toward	O
aggressiveness	B-DISEASE
was	O
found	O
.	O
In	O
conclusion	B-UNK
,	O
the	O
present	B-UNK
study	B-UNK
demonstrates	O
gender	B-UNK
differences	B-UNK
in	O
the	O
development	B-UNK
of	O
the	O
apomorphine	B-UNK
-	O
induced	O
aggressive	B-DISEASE
behavior	I-DISEASE
and	O
indicates	O
that	O
the	O
female	B-UNK
rats	I-UNK
do	O
not	O
fill	O
the	O
validation	O
criteria	B-UNK
for	O
use	O
in	O
this	O
method	B-UNK
.	O

Serotonergic	B-UNK
antidepressants	B-UNK
and	O
urinary	B-DISEASE
incontinence	I-DISEASE
.	O
Many	O
new	O
serotonergic	B-UNK
antidepressants	B-UNK
have	O
been	O
introduced	O
over	O
the	O
past	B-UNK
decade	O
.	O
Although	O
urinary	B-DISEASE
incontinence	I-DISEASE
is	O
listed	O
as	O
one	O
side	O
effect	B-UNK
of	O
these	O
drugs	B-UNK
in	O
their	O
package	O
inserts	O
there	O
is	O
only	O
one	O
report	B-UNK
in	O
the	O
literature	B-UNK
.	O
This	O
concerns	B-UNK
2	O
male	B-UNK
patients	B-UNK
who	O
experienced	B-UNK
incontinence	B-UNK
while	O
taking	B-UNK
venlafaxine	B-UNK
.	O
In	O
the	O
present	B-UNK
paper	B-UNK
the	O
authors	B-UNK
describe	O
2	O
female	B-UNK
patients	B-UNK
who	O
developed	O
incontinence	B-UNK
secondary	B-UNK
to	O
the	O
selective	B-UNK
serotonin	B-UNK
reuptake	I-UNK
inhibitors	B-UNK
paroxetine	B-CHEMICAL
and	O
sertraline	B-UNK
,	O
as	O
well	O
as	O
a	O
third	O
who	O
developed	O
this	O
side	O
effect	B-UNK
on	O
venlafaxine	B-UNK
.	O
In	O
2	O
of	O
the	O
3	O
cases	B-UNK
the	O
patients	B-UNK
were	O
also	O
taking	B-UNK
lithium	B-UNK
carbonate	O
and	O
beta-blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	B-UNK
to	O
the	O
incontinence	B-DISEASE
.	O
Animal	B-UNK
studies	B-UNK
suggest	B-UNK
that	O
incontinence	B-UNK
secondary	B-UNK
to	O
serotonergic	B-UNK
antidepressants	B-UNK
could	O
be	O
mediated	B-UNK
by	O
the	O
5HT4	O
receptors	B-UNK
found	O
on	O
the	O
bladder	B-UNK
.	O
Further	O
research	B-UNK
is	O
needed	B-UNK
to	O
delineate	O
the	O
frequency	B-UNK
of	O
this	O
troubling	O
side	O
effect	B-UNK
and	O
how	O
best	O
to	O
treat	B-UNK
it	O
.	O

Hypotension	B-UNK
following	O
the	O
initiation	B-UNK
of	O
tizanidine	O
in	O
a	O
patient	B-UNK
treated	O
with	O
an	O
angiotensin	B-UNK
converting	I-UNK
enzyme	I-UNK
inhibitor	I-UNK
for	O
chronic	B-UNK
hypertension	B-UNK
.	O
Centrally	B-UNK
acting	O
alpha-2	O
adrenergic	B-CHEMICAL
agonists	I-CHEMICAL
are	O
one	O
of	O
several	O
pharmacologic	O
agents	B-UNK
used	O
in	O
the	O
treatment	B-UNK
of	O
spasticity	O
related	O
to	O
disorders	B-DISEASE
of	I-DISEASE
the	I-DISEASE
central	I-DISEASE
nervous	I-DISEASE
system	I-DISEASE
.	O
In	O
addition	B-UNK
to	O
their	O
effects	O
on	O
spasticity	O
,	O
certain	O
adverse	B-UNK
cardiorespiratory	O
effects	O
have	O
been	O
reported	B-UNK
.	O
Adults	B-UNK
chronically	B-UNK
treated	O
with	O
angiotensin	B-UNK
converting	I-UNK
enzyme	I-UNK
inhibitors	B-UNK
may	O
have	O
a	O
limited	B-UNK
ability	B-UNK
to	O
respond	O
to	O
hypotension	B-UNK
when	O
the	O
sympathetic	B-UNK
response	B-UNK
is	O
simultaneously	B-UNK
blocked	B-UNK
.	O
The	O
authors	B-UNK
present	B-UNK
a	O
10-year	O
-	O
old	O
boy	B-UNK
chronically	B-UNK
treated	O
with	O
lisinopril	O
,	O
an	O
angiotensin	B-UNK
converting	I-UNK
enzyme	I-UNK
inhibitor	I-UNK
,	O
to	O
control	B-UNK
hypertension	B-UNK
who	O
developed	O
hypotension	B-DISEASE
following	O
the	O
addition	B-UNK
of	O
tizanidine	O
,	O
an	O
alpha-2	O
agonist	B-UNK
,	O
for	O
the	O
treatment	B-UNK
of	O
spasticity	O
.	O
The	O
possible	O
interaction	B-UNK
of	O
tizanidine	O
and	O
other	O
antihypertensive	B-CHEMICAL
agents	I-CHEMICAL
should	O
be	O
kept	O
in	O
mind	O
when	O
prescribing	B-UNK
therapy	O
to	O
treat	B-UNK
either	O
hypertension	B-UNK
or	O
spasticity	O
in	O
such	O
patients	B-UNK
.	O

Peritubular	O
capillary	B-UNK
basement	B-UNK
membrane	I-UNK
reduplication	O
in	O
allografts	O
and	O
native	O
kidney	B-UNK
disease	B-UNK
:	O
a	O
clinicopathologic	O
study	B-UNK
of	O
278	O
consecutive	B-UNK
renal	B-UNK
specimens	O
.	O
BACKGROUND	B-UNK
:	O
An	O
association	B-UNK
has	O
been	O
found	O
between	O
transplant	B-UNK
glomerulopathy	O
(	O
TG	B-UNK
)	O
and	O
reduplication	O
of	O
peritubular	O
capillary	B-UNK
basement	B-UNK
membranes	B-UNK
(	O
PTCR	O
)	O
.	O
Although	O
such	O
an	O
association	B-UNK
is	O
of	O
practical	O
and	O
theoretical	O
importance	B-UNK
,	O
only	O
one	O
prospective	B-UNK
study	I-UNK
has	O
tried	O
to	O
confirm	B-UNK
it	O
.	O
METHODS	B-UNK
:	O
We	O
examined	B-UNK
278	O
consecutive	B-UNK
renal	B-UNK
specimens	O
(	O
from	O
135	O
transplants	O
and	O
143	O
native	O
kidneys	B-UNK
)	O
for	O
ultrastructural	B-UNK
evidence	B-UNK
of	O
PTCR	O
.	O
In	O
addition	B-UNK
to	O
renal	B-UNK
allografts	O
with	O
TG	B-UNK
,	O
we	O
also	O
examined	B-UNK
grafts	O
with	O
acute	B-UNK
rejection	B-UNK
,	O
recurrent	B-UNK
glomerulonephritis	B-UNK
,	O
chronic	B-DISEASE
allograft	I-DISEASE
nephropathy	I-DISEASE
and	O
stable	B-UNK
grafts	O
(	O
"	O
protocol	O
biopsies	B-UNK
"	O
)	O
.	O
Native	O
kidney	B-UNK
specimens	O
included	B-UNK
a	O
wide	O
range	B-UNK
of	O
glomerulopathies	O
as	O
well	O
as	O
cases	B-UNK
of	O
thrombotic	B-UNK
microangiopathy	I-UNK
,	O
malignant	B-UNK
hypertension	B-UNK
,	O
acute	B-UNK
interstitial	I-UNK
nephritis	I-UNK
,	O
and	O
acute	B-DISEASE
tubular	I-DISEASE
necrosis	I-DISEASE
.	O
RESULTS	B-UNK
:	O
We	O
found	O
PTCR	O
in	O
14	O
of	O
15	O
cases	B-UNK
of	O
TG	B-UNK
,	O
in	O
7	O
transplant	B-UNK
biopsy	B-UNK
specimens	O
without	O
TG	B-UNK
,	O
and	O
in	O
13	O
of	O
143	O
native	O
kidney	B-UNK
biopsy	B-UNK
specimens	O
.	O
These	O
13	O
included	B-UNK
cases	B-UNK
of	O
malignant	B-UNK
hypertension	B-UNK
,	O
thrombotic	B-UNK
microangiopathy	I-UNK
,	O
lupus	B-DISEASE
nephritis	I-DISEASE
,	O
Henoch	O
-	O
Schonlein	O
nephritis	B-DISEASE
,	O
crescentic	O
glomerulonephritis	B-UNK
,	O
and	O
cocaine	B-UNK
-	O
related	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O
Mild	B-UNK
PTCR	O
in	O
allografts	O
without	O
TG	B-UNK
did	O
not	O
predict	B-UNK
renal	B-UNK
failure	I-UNK
or	O
significant	B-UNK
proteinuria	B-UNK
after	O
follow	O
-	O
up	O
periods	O
of	O
between	O
3	O
months	B-UNK
and	O
1	O
year	O
.	O
CONCLUSIONS	B-UNK
:	O
We	O
conclude	O
that	O
in	O
transplants	O
,	O
there	O
is	O
a	O
strong	B-UNK
association	B-UNK
between	O
well	O
-	O
developed	O
PTCR	O
and	O
TG	B-UNK
,	O
while	O
the	O
significance	B-UNK
of	O
mild	B-UNK
PTCR	O
and	O
its	O
predictive	B-UNK
value	O
in	O
the	O
absence	O
of	O
TG	B-UNK
is	O
unclear	O
.	O
PTCR	O
also	O
occurs	O
in	O
certain	O
native	O
kidney	B-DISEASE
diseases	I-DISEASE
,	O
though	O
the	O
association	B-UNK
is	O
not	O
as	O
strong	B-UNK
as	O
that	O
for	O
TG	B-UNK
.	O
We	O
suggest	B-UNK
that	O
repeated	B-UNK
endothelial	B-DISEASE
injury	I-DISEASE
,	O
including	O
immunologic	O
injury	B-UNK
,	O
may	O
be	O
the	O
cause	O
of	O
this	O
lesion	B-UNK
both	O
in	O
allografts	O
and	O
native	O
kidneys	B-UNK
.	O

Conformationally	O
restricted	B-UNK
analogs	O
of	O
BD1008	O
and	O
an	O
antisense	O
oligodeoxynucleotide	O
targeting	B-UNK
sigma1	O
receptors	B-UNK
produce	B-UNK
anti-cocaine	O
effects	O
in	O
mice	B-UNK
.	O
Cocaine'	O
s	O
ability	B-UNK
to	O
interact	O
with	O
sigma	O
receptors	B-UNK
suggests	O
that	O
these	O
proteins	B-UNK
mediate	B-UNK
some	O
of	O
its	O
behavioral	B-UNK
effects	O
.	O
Therefore	O
,	O
three	O
novel	O
sigma	O
receptor	B-UNK
ligands	B-UNK
with	O
antagonist	B-UNK
activity	B-UNK
were	O
evaluated	B-UNK
in	O
Swiss	B-UNK
Webster	O
mice	B-UNK
:	O
BD1018	O
(	O
3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	B-CHEMICAL
)	O
,	O
BD1063	O
(	O
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine	B-CHEMICAL
)	O
,	O
and	O
LR132	O
(	O
1R,2S-(+)-cis	O
-	O
N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine	O
)	O
.	O
Competition	O
binding	B-UNK
assays	O
demonstrated	O
that	O
all	O
three	O
compounds	B-UNK
have	O
high	B-UNK
affinities	O
for	O
sigma1	O
receptors	B-UNK
.	O
The	O
three	O
compounds	B-UNK
vary	O
in	O
their	O
affinities	O
for	O
sigma2	O
receptors	B-UNK
and	O
exhibit	B-UNK
negligible	O
affinities	O
for	O
dopamine	B-CHEMICAL
,	O
opioid	B-UNK
,	O
GABA(A	O
)	O
and	O
NMDA	B-UNK
receptors	I-UNK
.	O
In	O
behavioral	B-UNK
studies	B-UNK
,	O
pre	B-UNK
-	O
treatment	B-UNK
of	O
mice	B-UNK
with	O
BD1018	O
,	O
BD1063	O
,	O
or	O
LR132	O
significantly	B-UNK
attenuated	I-UNK
cocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsions	I-UNK
and	O
lethality	B-UNK
.	O
Moreover	O
,	O
post-treatment	O
with	O
LR132	O
prevented	B-UNK
cocaine	B-UNK
-	O
induced	O
lethality	B-UNK
in	O
a	O
significant	B-UNK
proportion	B-UNK
of	O
animals	B-UNK
.	O
In	O
contrast	B-UNK
to	O
the	O
protection	B-UNK
provided	O
by	O
the	O
putative	O
antagonists	B-UNK
,	O
the	O
well	O
-	O
characterized	B-UNK
sigma	O
receptor	B-UNK
agonist	I-UNK
di-o-tolylguanidine	O
(	O
DTG	O
)	O
and	O
the	O
novel	O
sigma	O
receptor	B-UNK
agonist	I-UNK
BD1031	O
(	O
3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	B-CHEMICAL
)	O
each	O
worsened	O
the	O
behavioral	B-UNK
toxicity	B-DISEASE
of	O
cocaine	B-UNK
.	O
At	O
doses	B-UNK
where	O
alone	O
,	O
they	O
produced	B-UNK
no	O
significant	B-UNK
effects	O
on	O
locomotion	B-UNK
,	O
BD1018	O
,	O
BD1063	O
and	O
LR132	O
significantly	B-UNK
attenuated	I-UNK
the	O
locomotor	B-UNK
stimulatory	O
effects	O
of	O
cocaine	B-UNK
.	O
To	O
further	O
validate	O
the	O
hypothesis	B-UNK
that	O
the	O
anti-cocaine	O
effects	O
of	O
the	O
novel	O
ligands	B-UNK
involved	B-UNK
antagonism	B-UNK
of	O
sigma	O
receptors	B-UNK
,	O
an	O
antisense	O
oligodeoxynucleotide	O
against	O
sigma1	O
receptors	B-UNK
was	O
also	O
shown	B-UNK
to	O
significantly	B-UNK
attenuate	O
the	O
convulsive	B-UNK
and	O
locomotor	B-UNK
stimulatory	O
effects	O
of	O
cocaine	B-CHEMICAL
.	O
Together	O
,	O
the	O
data	B-UNK
suggests	O
that	O
functional	B-UNK
antagonism	B-UNK
of	O
sigma	O
receptors	B-UNK
is	O
capable	O
of	O
attenuating	O
a	O
number	B-UNK
of	O
cocaine	B-UNK
-	O
induced	O
behaviors	B-UNK
.	O

Pharmacokinetic	B-UNK
/	O
pharmacodynamic	O
assessment	B-UNK
of	O
the	O
effects	O
of	O
E4031	O
,	O
cisapride	B-CHEMICAL
,	O
terfenadine	B-CHEMICAL
and	O
terodiline	B-CHEMICAL
on	O
monophasic	O
action	B-UNK
potential	I-UNK
duration	B-UNK
in	O
dog	B-UNK
.	O
1	O
.	O
Torsades	B-UNK
de	I-UNK
pointes	I-UNK
(	O
TDP	B-DISEASE
)	O
is	O
a	O
potentially	O
fatal	B-UNK
ventricular	B-DISEASE
tachycardia	I-DISEASE
associated	O
with	O
increases	B-UNK
in	O
QT	B-UNK
interval	I-UNK
and	O
monophasic	O
action	B-UNK
potential	I-UNK
duration	B-UNK
(	O
MAPD	O
)	O
.	O
TDP	B-DISEASE
is	O
a	O
side	O
-	O
effect	B-UNK
that	O
has	O
led	B-UNK
to	O
withdrawal	B-UNK
of	O
several	O
drugs	B-UNK
from	O
the	O
market	O
(	O
e.g	B-UNK
.	O
terfenadine	B-CHEMICAL
and	O
terodiline	B-CHEMICAL
)	O
.	O
2	O
.	O
The	O
potential	B-UNK
of	O
compounds	B-UNK
to	O
cause	O
TDP	B-UNK
was	O
evaluated	B-UNK
by	O
monitoring	B-UNK
their	O
effects	O
on	O
MAPD	O
in	O
dog	B-UNK
.	O
Four	O
compounds	B-UNK
known	O
to	O
increase	B-UNK
QT	B-UNK
interval	I-UNK
and	O
cause	O
TDP	B-UNK
were	O
investigated	B-UNK
:	O
terfenadine	B-CHEMICAL
,	O
terodiline	B-CHEMICAL
,	O
cisapride	B-UNK
and	O
E4031	O
.	O
On	O
the	O
basis	B-UNK
that	O
only	O
free	B-UNK
drug	B-UNK
in	O
the	O
systemic	B-UNK
circulation	B-UNK
will	O
elicit	O
a	O
pharmacological	B-UNK
response	B-UNK
target	O
,	O
free	B-UNK
concentrations	B-UNK
in	O
plasma	B-UNK
were	O
selected	O
to	O
mimic	O
the	O
free	B-UNK
drug	B-UNK
exposures	O
in	O
man	B-UNK
.	O
Infusion	B-UNK
regimens	B-UNK
were	O
designed	B-UNK
that	O
rapidly	O
achieved	O
and	O
maintained	O
target	O
-	O
free	B-UNK
concentrations	B-UNK
of	O
these	O
drugs	B-UNK
in	O
plasma	B-UNK
and	O
data	B-UNK
on	O
the	O
relationship	B-UNK
between	O
free	B-UNK
concentration	B-UNK
and	O
changes	O
in	O
MAPD	O
were	O
obtained	B-UNK
for	O
these	O
compounds	B-UNK
.	O
3	O
.	O
These	O
data	B-UNK
indicate	O
that	O
the	O
free	B-UNK
ED50	B-UNK
in	O
plasma	B-UNK
for	O
terfenadine	B-CHEMICAL
(	O
1.9	O
nM	B-UNK
)	O
,	O
terodiline	B-CHEMICAL
(	O
76	O
nM	B-UNK
)	O
,	O
cisapride	B-UNK
(	O
11	O
nM	B-UNK
)	O
and	O
E4031	O
(	O
1.9	O
nM	B-UNK
)	O
closely	O
correlate	B-UNK
with	O
the	O
free	B-UNK
concentration	B-UNK
in	O
man	B-UNK
causing	O
QT	B-UNK
effects	O
.	O
For	O
compounds	B-UNK
that	O
have	O
shown	B-UNK
TDP	B-DISEASE
in	O
the	O
clinic	B-UNK
(	O
terfenadine	B-CHEMICAL
,	O
terodiline	B-CHEMICAL
,	O
cisapride	B-UNK
)	O
there	O
is	O
little	O
differentiation	O
between	O
the	O
dog	B-UNK
ED50	B-UNK
and	O
the	O
efficacious	B-UNK
free	B-UNK
plasma	B-UNK
concentrations	I-UNK
in	O
man	B-UNK
(	O
<	O
10-fold	O
)	O
reflecting	O
their	O
limited	B-UNK
safety	B-UNK
margins	O
.	O
These	O
data	B-UNK
underline	O
the	O
need	O
to	O
maximize	O
the	O
therapeutic	B-UNK
ratio	B-UNK
with	O
respect	B-UNK
to	O
TDP	B-UNK
in	O
potential	B-UNK
development	B-UNK
candidates	O
and	O
the	O
importance	B-UNK
of	O
using	O
free	B-UNK
drug	B-UNK
concentrations	B-UNK
in	O
pharmacokinetic	B-UNK
/	O
pharmacodynamic	O
studies	B-UNK
.	O

Fatal	B-UNK
myeloencephalopathy	O
due	O
to	O
accidental	O
intrathecal	B-UNK
vincristin	O
administration	O
:	O
a	O
report	B-UNK
of	O
two	O
cases	B-UNK
.	O
We	O
report	B-UNK
on	O
two	O
fatal	B-UNK
cases	B-UNK
of	O
accidental	O
intrathecal	B-UNK
vincristine	B-CHEMICAL
instillation	B-UNK
in	O
a	O
5-year	O
old	O
girl	B-UNK
with	O
recurrent	B-UNK
acute	B-DISEASE
lymphoblastic	I-DISEASE
leucemia	I-DISEASE
and	O
a	O
57-year	O
old	O
man	B-UNK
with	O
lymphoblastic	B-UNK
lymphoma	B-DISEASE
.	O
The	O
girl	B-UNK
died	O
seven	O
days	B-UNK
,	O
the	O
man	B-UNK
four	O
weeks	B-UNK
after	O
intrathecal	B-UNK
injection	B-UNK
of	O
vincristine	B-UNK
.	O
Clinically	B-UNK
,	O
the	O
onset	B-UNK
was	O
characterized	B-UNK
by	O
the	O
signs	B-UNK
of	O
opistothonus	O
,	O
sensory	O
and	O
motor	B-UNK
dysfunction	B-UNK
and	O
ascending	O
paralysis	B-DISEASE
.	O
Histological	B-UNK
and	O
immunohistochemical	B-UNK
investigations	B-UNK
(	O
HE	O
-	O
LFB	O
,	O
CD-68	O
,	O
Neurofilament	O
)	O
revealed	O
degeneration	B-UNK
of	O
myelin	O
and	O
axons	O
as	O
well	O
as	O
pseudocystic	O
transformation	B-UNK
in	O
areas	B-UNK
exposed	B-UNK
to	O
vincristine	B-UNK
,	O
accompanied	B-UNK
by	O
secondary	B-UNK
changes	O
with	O
numerous	B-UNK
prominent	B-UNK
macrophages	O
.	O
The	O
clinical	B-UNK
course	O
and	O
histopathological	B-UNK
results	B-UNK
of	O
the	O
two	O
cases	B-UNK
are	O
presented	B-UNK
.	O
A	O
review	B-UNK
of	O
all	O
reported	B-UNK
cases	B-UNK
in	O
the	O
literature	B-UNK
is	O
given	O
.	O
A	O
better	O
controlled	B-UNK
regimen	B-UNK
for	O
administering	O
vincristine	B-UNK
and	O
intrathecal	B-UNK
chemotherapy	O
is	O
recommended	O
.	O

Intravenous	B-UNK
administration	O
of	O
prochlorperazine	B-CHEMICAL
by	O
15-minute	O
infusion	B-UNK
versus	O
2-minute	O
bolus	B-UNK
does	O
not	O
affect	B-UNK
the	O
incidence	B-UNK
of	O
akathisia	B-UNK
:	O
a	O
prospective	B-UNK
,	O
randomized	B-UNK
,	O
controlled	B-UNK
trial	I-UNK
.	O
STUDY	B-UNK
OBJECTIVE	B-UNK
:	O
We	O
sought	O
to	O
compare	B-UNK
the	O
rate	B-UNK
of	O
akathisia	B-UNK
after	O
administration	O
of	O
intravenous	B-UNK
prochlorperazine	B-CHEMICAL
as	O
a	O
2-minute	O
bolus	B-UNK
or	O
15-minute	O
infusion	B-UNK
.	O
METHODS	B-UNK
:	O
We	O
conducted	B-UNK
a	O
prospective	B-UNK
,	O
randomized	B-UNK
,	O
double-blind	O
study	B-UNK
in	O
the	O
emergency	B-UNK
department	I-UNK
of	O
a	O
central	B-UNK
-	O
city	O
teaching	O
hospital	B-UNK
.	O
Patients	B-UNK
aged	B-UNK
18	O
years	B-UNK
or	O
older	B-UNK
treated	O
with	O
prochlorperazine	B-CHEMICAL
for	O
headache	B-DISEASE
,	O
nausea	B-UNK
,	O
or	O
vomiting	B-DISEASE
were	O
eligible	O
for	O
inclusion	O
.	O
Study	B-UNK
participants	B-UNK
were	O
randomized	B-UNK
to	I-UNK
receive	I-UNK
10	O
mg	B-UNK
of	O
prochlorperazine	B-CHEMICAL
administered	O
intravenously	O
by	O
means	B-UNK
of	O
2-minute	O
push	O
(	O
bolus	B-UNK
group	B-UNK
)	O
or	O
10	O
mg	B-UNK
diluted	O
in	O
50	O
mL	B-UNK
of	O
normal	B-UNK
saline	I-UNK
solution	B-UNK
administered	O
by	O
means	B-UNK
of	O
intravenous	B-UNK
infusion	B-UNK
during	O
a	O
15-minute	O
period	B-UNK
(	O
infusion	B-UNK
group	B-UNK
)	O
.	O
The	O
main	B-UNK
outcome	B-UNK
was	O
the	O
number	B-UNK
of	O
study	B-UNK
participants	B-UNK
experiencing	O
akathisia	B-UNK
within	O
60	O
minutes	B-UNK
of	O
administration	O
.	O
Akathisia	B-UNK
was	O
defined	B-UNK
as	O
either	O
a	O
spontaneous	B-UNK
report	B-UNK
of	O
restlessness	B-DISEASE
or	O
agitation	B-UNK
or	O
a	O
change	B-UNK
of	O
2	O
or	O
more	O
in	O
the	O
patient	B-UNK
-	O
reported	B-UNK
akathisia	B-UNK
rating	B-UNK
scale	I-UNK
and	O
a	O
change	B-UNK
of	O
at	O
least	O
1	O
in	O
the	O
investigator	O
-	O
observed	O
akathisia	B-UNK
rating	B-UNK
scale	I-UNK
.	O
The	O
intensity	B-UNK
of	O
headache	B-UNK
and	O
nausea	B-UNK
was	O
measured	B-UNK
with	O
a	O
100-mm	O
visual	B-UNK
analog	B-UNK
scale	B-UNK
.	O
RESULTS	B-UNK
:	O
One	O
hundred	O
patients	B-UNK
were	O
enrolled	O
.	O
One	O
study	B-UNK
participant	O
was	O
excluded	B-UNK
after	O
protocol	O
violation	O
.	O
Seventy	B-UNK
-	O
three	O
percent	B-UNK
(	O
73/99	O
)	O
of	O
the	O
study	B-UNK
participants	B-UNK
were	O
treated	O
for	O
headache	B-UNK
and	O
70	O
%	O
(	O
70/99	O
)	O
for	O
nausea	B-UNK
.	O
In	O
the	O
bolus	B-UNK
group	B-UNK
,	O
26.0	O
%	O
(	O
13/50	O
)	O
had	O
akathisia	B-UNK
compared	O
with	O
32.7	O
%	O
(	O
16/49	O
)	O
in	O
the	O
infusion	B-UNK
group	B-UNK
(	O
Delta=-6.7	O
%	O
;	O
95	O
%	O
confidence	O
interval	B-UNK
[	O
CI	B-UNK
]	O
-24.6	O
%	O
to	O
11.2	O
%	O
)	O
.	O
The	O
difference	B-UNK
between	O
the	O
bolus	B-UNK
and	O
infusion	B-UNK
groups	B-UNK
in	O
the	O
percentage	B-UNK
of	O
participants	B-UNK
who	O
saw	O
a	O
50	O
%	O
reduction	O
in	O
their	O
headache	B-UNK
intensity	B-UNK
within	O
30	O
minutes	B-UNK
was	O
11.8	O
%	O
(	O
95	O
%	O
CI	B-UNK
-9.6	O
%	O
to	O
33.3	O
%	O
)	O
.	O
The	O
difference	B-UNK
in	O
the	O
percentage	B-UNK
of	O
patients	B-UNK
with	O
a	O
50	O
%	O
reduction	O
in	O
their	O
nausea	B-UNK
was	O
12.6	O
%	O
(	O
95	O
%	O
CI	B-UNK
-4.6	O
%	O
to	O
29.8	O
%	O
)	O
.	O
CONCLUSION	B-UNK
:	O
A	O
50	O
%	O
reduction	O
in	O
the	O
incidence	B-UNK
of	O
akathisia	B-UNK
when	O
prochlorperazine	B-CHEMICAL
was	O
administered	O
by	O
means	B-UNK
of	O
15-minute	O
intravenous	B-UNK
infusion	B-UNK
versus	O
a	O
2-minute	O
intravenous	B-UNK
push	O
was	O
not	O
detected	B-UNK
.	O
The	O
efficacy	B-UNK
of	O
prochlorperazine	B-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
headache	B-UNK
and	O
nausea	B-DISEASE
likewise	O
did	O
not	O
appear	O
to	O
be	O
affected	B-UNK
by	O
the	O
rate	B-UNK
of	O
administration	O
,	O
although	O
no	O
formal	O
statistical	B-UNK
comparisons	O
were	O
made	O
.	O

Antithymocyte	O
globulin	B-UNK
in	O
the	O
treatment	B-UNK
of	O
D	O
-	O
penicillamine	B-UNK
-	O
induced	O
aplastic	B-UNK
anemia	I-UNK
.	O
A	O
patient	B-UNK
who	O
received	O
antithymocyte	O
globulin	B-UNK
therapy	O
for	O
aplastic	B-UNK
anemia	I-UNK
due	O
to	O
D	O
-	O
penicillamine	B-UNK
therapy	O
is	O
described	O
.	O
Bone	B-UNK
marrow	I-UNK
recovery	B-UNK
and	O
peripheral	B-UNK
blood	I-UNK
recovery	B-UNK
were	O
complete	B-UNK
1	O
month	B-UNK
and	O
3	O
months	B-UNK
,	O
respectively	O
,	O
after	O
treatment	B-UNK
,	O
and	O
blood	B-UNK
transfusion	B-UNK
or	O
other	O
therapies	B-UNK
were	O
not	O
necessary	O
in	O
a	O
follow	O
-	O
up	O
period	B-UNK
of	O
more	O
than	O
2	O
years	B-UNK
.	O
Use	O
of	O
antithymocyte	O
globulin	B-UNK
may	O
be	O
the	O
optimal	B-UNK
treatment	B-UNK
of	O
D	O
-	O
penicillamine	B-UNK
-	O
induced	O
aplastic	B-UNK
anemia	I-UNK
.	O

The	O
relationship	B-UNK
between	O
hippocampal	B-UNK
acetylcholine	B-UNK
release	B-UNK
and	O
cholinergic	B-UNK
convulsant	B-UNK
sensitivity	B-UNK
in	O
withdrawal	B-UNK
seizure	B-UNK
-	O
prone	O
and	O
withdrawal	B-UNK
seizure	B-DISEASE
-	O
resistant	B-UNK
selected	O
mouse	B-UNK
lines	B-UNK
.	O
BACKGROUND	B-UNK
:	O
The	O
septo	O
-	O
hippocampal	B-UNK
cholinergic	B-UNK
pathway	B-UNK
has	O
been	O
implicated	B-UNK
in	O
epileptogenesis	O
,	O
and	O
genetic	B-UNK
factors	B-UNK
influence	B-UNK
the	O
response	B-UNK
to	O
cholinergic	B-CHEMICAL
agents	I-CHEMICAL
,	O
but	O
limited	B-UNK
data	B-UNK
are	O
available	O
on	O
cholinergic	B-UNK
involvement	B-UNK
in	O
alcohol	B-UNK
withdrawal	B-UNK
severity	B-UNK
.	O
Thus	O
,	O
the	O
relationship	B-UNK
between	O
cholinergic	B-UNK
activity	B-UNK
and	O
responsiveness	B-UNK
and	O
alcohol	B-UNK
withdrawal	B-UNK
was	O
investigated	B-UNK
in	O
a	O
genetic	B-UNK
animal	B-UNK
model	I-UNK
of	O
ethanol	B-CHEMICAL
withdrawal	B-UNK
severity	B-UNK
.	O
METHODS	B-UNK
:	O
Cholinergic	B-UNK
convulsant	B-UNK
sensitivity	B-UNK
was	O
examined	B-UNK
in	O
alcohol	B-UNK
-	O
na	B-UNK
 	O
ve	B-UNK
Withdrawal	B-UNK
Seizure	B-UNK
-	O
Prone	O
(	O
WSP	O
)	O
and	O
-	O
Resistant	B-UNK
(	O
WSR	O
)	O
mice	B-UNK
.	O
Animals	B-UNK
were	O
administered	O
nicotine	B-UNK
,	O
carbachol	B-UNK
,	O
or	O
neostigmine	O
via	O
timed	O
tail	B-UNK
vein	B-UNK
infusion	B-UNK
,	O
and	O
the	O
latencies	B-UNK
to	O
onset	B-UNK
of	O
tremor	B-UNK
and	O
clonus	O
were	O
recorded	O
and	O
converted	O
to	O
threshold	B-UNK
dose	B-UNK
.	O
We	O
also	O
used	O
microdialysis	O
to	O
measure	B-UNK
basal	B-UNK
and	O
potassium	B-CHEMICAL
-	O
stimulated	B-UNK
acetylcholine	B-UNK
(	O
ACh	B-CHEMICAL
)	O
release	B-UNK
in	O
the	O
CA1	B-UNK
region	B-UNK
of	O
the	O
hippocampus	B-UNK
.	O
Potassium	B-CHEMICAL
was	O
applied	O
by	O
reverse	B-UNK
dialysis	B-UNK
twice	O
,	O
separated	O
by	O
75	O
min	B-UNK
.	O
Hippocampal	B-UNK
ACh	B-UNK
also	O
was	O
measured	B-UNK
during	O
testing	B-UNK
for	O
handling	O
-	O
induced	B-UNK
convulsions	I-UNK
.	O
RESULTS	B-UNK
:	O
Sensitivity	B-UNK
to	O
several	O
convulsion	B-DISEASE
endpoints	O
induced	O
by	O
nicotine	B-UNK
,	O
carbachol	B-UNK
,	O
and	O
neostigmine	O
were	O
significantly	B-UNK
greater	I-UNK
in	O
WSR	O
versus	O
WSP	O
mice	B-UNK
.	O
In	O
microdialysis	O
experiments	B-UNK
,	O
the	O
lines	B-UNK
did	O
not	O
differ	B-UNK
in	O
basal	B-UNK
release	B-UNK
of	O
ACh	B-UNK
,	O
and	O
50	O
mM	B-UNK
KCl	O
increased	B-UNK
ACh	B-UNK
output	B-UNK
in	O
both	O
lines	B-UNK
of	O
mice	B-UNK
.	O
However	O
,	O
the	O
increase	B-UNK
in	O
release	B-UNK
of	O
ACh	B-CHEMICAL
produced	B-UNK
by	O
the	O
first	O
application	B-UNK
of	O
KCl	O
was	O
2-fold	O
higher	B-UNK
in	O
WSP	O
versus	O
WSR	O
mice	B-UNK
.	O
When	O
hippocampal	B-UNK
ACh	B-CHEMICAL
was	O
measured	B-UNK
during	O
testing	B-UNK
for	O
handling	O
-	O
induced	B-UNK
convulsions	I-UNK
,	O
extracellular	B-UNK
ACh	B-CHEMICAL
was	O
significantly	B-UNK
elevated	B-UNK
(	O
192	O
%	O
)	O
in	O
WSP	O
mice	B-UNK
,	O
but	O
was	O
nonsignificantly	O
elevated	B-UNK
(	O
59	O
%	O
)	O
in	O
WSR	O
mice	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
These	O
results	B-UNK
suggest	B-UNK
that	O
differences	B-UNK
in	O
cholinergic	B-UNK
activity	B-UNK
and	O
postsynaptic	B-UNK
sensitivity	B-UNK
to	O
cholinergic	B-UNK
convulsants	B-DISEASE
may	O
be	O
associated	O
with	O
ethanol	B-CHEMICAL
withdrawal	B-UNK
severity	B-UNK
and	O
implicate	O
cholinergic	B-UNK
mechanisms	B-UNK
in	O
alcohol	B-UNK
withdrawal	B-UNK
.	O
Specifically	O
,	O
WSP	O
mice	B-UNK
may	O
have	O
lower	B-UNK
sensitivity	B-UNK
to	O
cholinergic	B-UNK
convulsants	B-DISEASE
compared	O
with	O
WSR	O
because	O
of	O
postsynaptic	B-UNK
receptor	B-UNK
desensitization	O
brought	O
on	O
by	O
higher	B-UNK
activity	B-UNK
of	O
cholinergic	B-UNK
neurons	B-UNK
.	O

Prenatal	B-UNK
dexamethasone	B-CHEMICAL
programs	O
hypertension	B-UNK
and	O
renal	B-UNK
injury	I-UNK
in	O
the	O
rat	B-UNK
.	O
Dexamethasone	B-UNK
is	O
frequently	B-UNK
administered	O
to	O
the	O
developing	B-UNK
fetus	O
to	O
accelerate	O
pulmonary	B-UNK
development	B-UNK
.	O
The	O
purpose	B-UNK
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
determine	B-UNK
if	O
prenatal	B-UNK
dexamethasone	B-UNK
programmed	O
a	O
progressive	B-UNK
increase	B-UNK
in	O
blood	B-UNK
pressure	I-UNK
and	O
renal	B-UNK
injury	I-UNK
in	O
rats	B-UNK
.	O
Pregnant	B-UNK
rats	B-UNK
were	O
given	O
either	O
vehicle	B-UNK
or	O
2	O
daily	B-UNK
intraperitoneal	B-UNK
injections	B-UNK
of	O
dexamethasone	B-CHEMICAL
(	O
0.2	O
mg	B-UNK
/	O
kg	B-UNK
body	B-DISEASE
weight	I-DISEASE
)	O
on	O
gestational	O
days	B-UNK
11	O
and	O
12	O
,	O
13	O
and	O
14	O
,	O
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
or	O
19	O
and	O
20	O
.	O
Offspring	B-UNK
of	O
rats	B-UNK
administered	O
dexamethasone	B-CHEMICAL
on	O
days	B-UNK
15	O
and	O
16	O
gestation	B-UNK
had	O
a	O
20	O
%	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
compared	O
with	O
control	B-UNK
at	O
6	O
to	O
9	O
months	B-UNK
of	O
age	B-UNK
(	O
22	O
527+/-509	O
versus	O
28	O
050+/-561	O
,	O
P<0.05	O
)	O
,	O
which	O
was	O
comparable	O
to	O
the	O
percent	B-UNK
reduction	O
in	O
glomeruli	B-UNK
measured	B-UNK
at	O
3	O
weeks	B-UNK
of	O
age	B-UNK
.	O
Six-	O
to	O
9-month	O
old	O
rats	B-UNK
receiving	B-UNK
prenatal	B-UNK
dexamethasone	B-CHEMICAL
on	O
days	B-UNK
17	O
and	O
18	O
of	O
gestation	B-UNK
had	O
a	B-CHEMICAL
17	I-CHEMICAL
%	O
reduction	O
in	O
glomeruli	B-UNK
(	O
23	O
380+/-587	O
)	O
compared	O
with	O
control	B-UNK
rats	B-UNK
(	O
P<0.05	O
)	O
.	O
Male	B-UNK
rats	I-UNK
that	O
received	O
prenatal	B-UNK
dexamethasone	B-UNK
on	O
days	B-UNK
15	O
and	O
16	O
,	O
17	O
and	O
18	O
,	O
and	O
13	O
and	O
14	O
of	O
gestation	B-UNK
had	O
elevated	B-DISEASE
blood	I-DISEASE
pressures	I-DISEASE
at	O
6	O
months	B-UNK
of	O
age	B-UNK
;	O
the	O
latter	O
group	B-UNK
did	O
not	O
have	O
a	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
.	O
Adult	B-UNK
rats	B-UNK
given	O
dexamethasone	B-UNK
on	O
days	B-UNK
15	O
and	O
16	O
of	O
gestation	B-UNK
had	O
more	O
glomeruli	B-UNK
with	O
glomerulosclerosis	B-UNK
than	O
control	B-UNK
rats	B-UNK
.	O
This	O
study	B-UNK
shows	O
that	O
prenatal	B-UNK
dexamethasone	B-CHEMICAL
in	O
rats	B-UNK
results	B-UNK
in	O
a	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
,	O
glomerulosclerosis	B-UNK
,	O
and	O
hypertension	B-DISEASE
when	O
administered	O
at	O
specific	B-UNK
points	B-UNK
during	O
gestation	B-UNK
.	O
Hypertension	B-UNK
was	O
observed	O
in	O
animals	B-UNK
that	O
had	O
a	O
reduction	O
in	O
glomeruli	B-UNK
as	O
well	O
as	O
in	O
a	O
group	B-UNK
that	O
did	O
not	O
have	O
a	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
,	O
suggesting	O
that	O
a	O
reduction	B-DISEASE
in	I-DISEASE
glomerular	I-DISEASE
number	I-DISEASE
is	O
not	O
the	O
sole	O
cause	O
for	O
the	O
development	B-UNK
of	O
hypertension	B-UNK
.	O

The	O
risk	B-UNK
of	O
venous	B-UNK
thromboembolism	I-UNK
in	O
women	B-UNK
prescribed	B-UNK
cyproterone	O
acetate	B-UNK
in	O
combination	B-UNK
with	O
ethinyl	B-UNK
estradiol	I-UNK
:	O
a	O
nested	O
cohort	B-UNK
analysis	B-UNK
and	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Cyproterone	O
acetate	B-UNK
combined	B-UNK
with	O
ethinyl	B-UNK
estradiol	I-UNK
(	O
CPA	B-UNK
/	O
EE	B-UNK
)	O
is	O
licensed	O
in	O
the	O
UK	O
for	O
the	O
treatment	B-UNK
of	O
women	B-UNK
with	O
acne	B-DISEASE
and	O
hirsutism	B-DISEASE
and	O
is	O
also	O
a	O
treatment	B-UNK
option	O
for	O
polycystic	B-DISEASE
ovary	I-DISEASE
syndrome	I-DISEASE
(	O
PCOS	B-DISEASE
)	O
.	O
Previous	B-UNK
studies	I-UNK
have	O
demonstrated	O
an	O
increased	B-UNK
risk	B-UNK
of	O
venous	B-UNK
thromboembolism	I-UNK
(	O
VTE	B-DISEASE
)	O
associated	O
with	O
CPA	B-UNK
/	O
EE	B-UNK
compared	O
with	O
conventional	B-UNK
combined	B-UNK
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
(	O
COCs	B-UNK
)	O
.	O
We	O
believe	O
the	O
results	B-UNK
of	O
those	O
studies	B-UNK
may	O
have	O
been	O
affected	B-UNK
by	O
residual	B-UNK
confounding	B-UNK
.	O
METHODS	B-UNK
:	O
Using	O
the	O
General	B-UNK
Practice	B-UNK
Research	B-UNK
Database	B-UNK
we	O
conducted	B-UNK
a	O
cohort	B-UNK
analysis	B-UNK
and	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
nested	O
within	O
a	O
population	B-UNK
of	O
women	B-UNK
aged	B-UNK
between	O
15	O
and	O
39	O
years	B-UNK
with	O
acne	B-DISEASE
,	O
hirsutism	B-DISEASE
or	O
PCOS	B-DISEASE
to	O
estimate	B-UNK
the	O
risk	B-UNK
of	O
VTE	B-UNK
associated	O
with	O
CPA	B-UNK
/	O
EE	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
age	B-UNK
-	O
adjusted	B-UNK
incidence	B-UNK
rate	B-UNK
ratio	B-UNK
for	O
CPA	B-UNK
/	O
EE	B-UNK
versus	O
conventional	B-UNK
COCs	B-UNK
was	O
2.20	O
[	O
95	O
%	O
confidence	O
interval	B-UNK
(	O
CI	B-UNK
)	O
1.35	O
-	O
3.58].	O
Using	O
as	O
the	O
reference	B-UNK
group	B-UNK
women	B-UNK
who	O
were	O
not	O
using	O
oral	B-UNK
contraception	O
,	O
had	O
no	O
recent	B-UNK
pregnancy	B-UNK
or	O
menopausal	O
symptoms	B-UNK
,	O
the	O
case	B-UNK
-	O
control	B-UNK
analysis	B-UNK
gave	O
an	O
adjusted	B-UNK
odds	B-UNK
ratio	I-UNK
(	O
OR(adj	O
)	O
)	O
of	O
7.44	O
(	O
95	O
%	O
CI	B-UNK
3.67	O
-	O
15.08	O
)	O
for	O
CPA	B-CHEMICAL
/	O
EE	B-UNK
use	O
compared	O
with	O
an	O
OR(adj	O
)	O
of	O
2.58	O
(	O
95	O
%	O
CI	B-UNK
1.60	O
-	O
4.18	O
)	O
for	O
use	O
of	O
conventional	B-UNK
COCs	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
We	O
have	O
demonstrated	O
an	O
increased	B-UNK
risk	B-UNK
of	O
VTE	B-UNK
associated	O
with	O
the	O
use	O
of	O
CPA	B-CHEMICAL
/	O
EE	B-UNK
in	O
women	B-UNK
with	O
acne	B-DISEASE
,	O
hirsutism	B-DISEASE
or	O
PCOS	B-DISEASE
although	O
residual	B-UNK
confounding	B-UNK
by	O
indication	O
cannot	O
be	O
excluded	B-UNK
.	O

Pseudoacromegaly	B-DISEASE
induced	O
by	O
the	O
long	B-UNK
-	O
term	O
use	O
of	O
minoxidil	O
.	O
Acromegaly	B-DISEASE
is	O
an	O
endocrine	B-DISEASE
disorder	I-DISEASE
caused	B-UNK
by	O
chronic	B-UNK
excessive	B-UNK
growth	B-UNK
hormone	B-UNK
secretion	B-UNK
from	O
the	O
anterior	B-UNK
pituitary	B-UNK
gland	O
.	O
Significant	B-UNK
disfiguring	O
changes	O
occur	O
as	O
a	O
result	B-UNK
of	O
bone	B-UNK
,	O
cartilage	O
,	O
and	O
soft	O
tissue	B-UNK
hypertrophy	B-UNK
,	O
including	O
the	O
thickening	O
of	O
the	O
skin	B-UNK
,	O
coarsening	O
of	O
facial	B-UNK
features	B-UNK
,	O
and	O
cutis	B-DISEASE
verticis	I-DISEASE
gyrata	I-DISEASE
.	O
Pseudoacromegaly	B-DISEASE
,	O
on	O
the	O
other	O
hand	B-UNK
,	O
is	O
the	O
presence	O
of	O
similar	B-UNK
acromegaloid	O
features	B-UNK
in	O
the	O
absence	O
of	O
elevated	B-UNK
growth	B-UNK
hormone	B-UNK
or	O
insulin	B-UNK
-	O
like	O
growth	B-UNK
factor	I-UNK
levels	O
.	O
We	O
present	B-UNK
a	O
patient	B-UNK
with	O
pseudoacromegaly	B-DISEASE
that	O
resulted	B-UNK
from	O
the	O
long	B-UNK
-	O
term	O
use	O
of	O
minoxidil	O
at	O
an	O
unusually	O
high	B-UNK
dose	I-UNK
.	O
This	O
is	O
the	O
first	O
case	B-UNK
report	I-UNK
of	O
pseudoacromegaly	B-DISEASE
as	O
a	O
side	O
effect	B-UNK
of	O
minoxidil	O
use	O
.	O

Combined	B-UNK
androgen	B-UNK
blockade	B-UNK
-	O
induced	O
anemia	B-UNK
in	O
prostate	B-UNK
cancer	I-UNK
patients	B-UNK
without	O
bone	B-UNK
involvement	B-UNK
.	O
BACKGROUND	B-UNK
:	O
To	O
determine	B-UNK
the	O
onset	B-UNK
and	O
extent	B-UNK
of	O
combined	B-UNK
androgen	B-UNK
blockade	B-UNK
(	O
CAB)-induced	O
anemia	B-DISEASE
in	O
prostate	B-UNK
cancer	I-UNK
patients	B-UNK
without	O
bone	B-UNK
involvement	B-UNK
.	O
PATIENTS	B-UNK
AND	I-UNK
METHODS	I-UNK
:	O
Forty	O
-	O
two	O
patients	B-UNK
with	O
biopsy	B-UNK
-	O
proven	B-UNK
prostatic	O
adenocarcinoma	B-DISEASE
[	O
26	O
with	O
stage	B-UNK
C	O
(	O
T3N0M0	O
)	O
and	O
16	O
with	O
stage	B-UNK
D1	B-UNK
(	O
T3N1M0	O
)	O
]	O
were	O
included	B-UNK
in	O
this	O
study	B-UNK
.	O
All	O
patients	B-UNK
received	O
CAB	B-UNK
[	O
leuprolide	O
acetate	B-UNK
(	O
LHRH	O
-	O
A	O
)	O
3.75	O
mg	B-UNK
,	O
intramuscularly	O
,	O
every	O
28	O
days	B-UNK
plus	O
250	O
mg	B-UNK
flutamide	O
,	O
tid	O
,	O
per	O
Os	O
]	O
and	O
were	O
evaluated	B-UNK
for	O
anemia	B-UNK
by	O
physical	B-UNK
examination	I-UNK
and	O
laboratory	B-UNK
tests	B-UNK
at	O
baseline	B-UNK
and	O
4	O
subsequent	B-UNK
intervals	B-UNK
(	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	B-UNK
post-CAB	O
)	O
.	O
Hb	O
,	O
PSA	O
and	O
Testosterone	B-CHEMICAL
measurements	B-UNK
were	O
recorded	O
.	O
Patients	B-UNK
with	O
stage	B-UNK
D2	B-UNK
-	O
3	O
disease	B-DISEASE
,	O
abnormal	B-UNK
hemoglobin	B-UNK
level	B-UNK
or	O
renal	B-UNK
and	O
liver	B-UNK
function	I-UNK
tests	I-UNK
that	O
were	O
higher	B-UNK
than	O
the	O
upper	B-UNK
limits	O
were	O
excluded	B-UNK
from	O
the	O
study	B-UNK
.	O
The	O
duration	B-UNK
of	O
the	O
study	B-UNK
was	O
six	O
months	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
mean	O
hemoglobin	B-UNK
(	O
Hb	O
)	O
levels	O
were	O
significantly	B-UNK
declined	O
in	O
all	O
patients	B-UNK
from	O
baseline	B-UNK
of	O
14.2	O
g	O
/	O
dl	B-UNK
to	O
14.0	O
g	O
/	O
dl	B-UNK
,	O
13.5	O
g	O
/	O
dl	B-UNK
,	O
13.2	O
g	O
/	O
dl	B-UNK
and	O
12.7	O
g	O
/	O
dl	B-UNK
at	O
1	O
,	O
2	O
,	O
3	O
and	O
6	O
months	B-UNK
post-CAB	O
,	O
respectively	O
.	O
Severe	B-UNK
and	O
clinically	B-UNK
evident	O
anemia	B-UNK
of	O
Hb	O
<	O
11	O
g	O
/	O
dl	B-UNK
with	O
clinical	B-UNK
symptoms	B-UNK
was	O
detected	B-UNK
in	O
6	O
patients	B-UNK
(	O
14.3	O
%	O
)	O
.	O
This	O
CAB	B-UNK
-	O
induced	O
anemia	B-DISEASE
was	O
normochromic	O
and	O
normocytic	O
.	O
At	O
six	O
months	B-UNK
post-CAB	O
,	O
patients	B-UNK
with	O
severe	B-UNK
anemia	B-UNK
had	O
a	O
Hb	O
mean	O
value	O
of	O
10.2	O
+	O
/-	O
0.1	O
g	O
/	O
dl	B-UNK
(	O
X	O
+	O
/-	O
SE	B-UNK
)	O
,	O
whereas	O
the	O
other	O
patients	B-UNK
had	O
mild	B-UNK
anemia	B-DISEASE
with	O
Hb	O
mean	O
value	O
of	O
13.2	O
+	O
/-	O
0.17	O
(	O
X	O
+	O
/-	O
SE	B-DISEASE
)	O
.	O
The	O
development	B-UNK
of	O
severe	B-UNK
anemia	B-DISEASE
at	O
6	O
months	B-UNK
post-CAB	O
was	O
predictable	O
by	O
the	O
reduction	O
of	O
Hb	O
baseline	B-UNK
value	O
of	O
more	O
than	O
2.5	O
g	O
/	O
dl	B-UNK
after	O
3	O
months	B-UNK
of	O
CAB	B-UNK
(	O
p	O
=	O
0.01	O
)	O
.	O
The	O
development	B-UNK
of	O
severe	B-UNK
CAB	B-UNK
-	O
induced	O
anemia	B-DISEASE
in	O
prostate	B-UNK
cancer	I-UNK
patients	B-UNK
did	O
not	O
correlate	B-UNK
with	O
T	O
baseline	B-UNK
values	O
(	O
T	O
<	O
3	O
ng	B-UNK
/	O
ml	B-UNK
versus	O
T	O
>	O
or	O
=	O
3	O
ng	B-UNK
/	O
ml	B-UNK
)	O
,	O
with	O
age	B-UNK
(	O
<	O
76	O
yrs	O
versus	O
>	O
or	O
=	O
76	O
yrs	O
)	O
,	O
and	O
clinical	B-UNK
stage	B-UNK
(	O
stage	B-UNK
C	O
versus	O
stage	B-UNK
D1	B-UNK
)	O
.	O
Severe	B-UNK
and	O
clinically	B-UNK
evident	O
anemia	B-DISEASE
was	O
easily	O
corrected	B-UNK
by	O
subcutaneous	B-UNK
injections	B-UNK
(	O
3	O
times	B-UNK
/	O
week	B-UNK
for	O
1	O
month	B-UNK
)	O
of	O
recombinant	O
erythropoietin	O
(	O
rHuEPO	O
-	O
beta	B-UNK
)	O
.	O
CONCLUSION	B-UNK
:	O
Our	O
data	B-UNK
suggest	I-UNK
that	O
rHuEPO	O
-	O
beta	B-UNK
correctable	O
CAB	B-UNK
-	O
induced	O
anemia	B-UNK
occurs	O
in	O
14.3	O
%	O
of	O
prostate	B-UNK
cancer	I-UNK
patients	B-UNK
after	O
6	O
months	B-UNK
of	O
therapy	O
.	O

Reversible	B-UNK
dilated	B-UNK
cardiomyopathy	I-UNK
related	O
to	O
amphotericin	B-UNK
B	I-UNK
therapy	O
.	O
We	O
describe	O
a	O
patient	B-UNK
who	O
developed	O
dilated	B-UNK
cardiomyopathy	I-UNK
and	O
clinical	B-UNK
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
after	O
2	O
months	B-UNK
of	O
therapy	O
with	O
amphotericin	B-UNK
B	I-UNK
(	O
AmB	B-UNK
)	O
for	O
disseminated	O
coccidioidomycosis	B-DISEASE
.	O
His	O
echocardiographic	B-UNK
abnormalities	B-UNK
and	O
heart	B-UNK
failure	I-UNK
resolved	O
after	O
posaconazole	O
was	O
substituted	O
for	O
AmB.	O
It	O
is	O
important	B-UNK
to	O
recognize	O
the	O
rare	B-UNK
and	O
potentially	O
reversible	B-UNK
toxicity	B-DISEASE
of	O
AmB.	O

Risks	B-UNK
of	O
the	O
consumption	B-UNK
of	O
beverages	O
containing	O
quinine	B-UNK
.	O
Although	O
the	O
United	O
States	B-UNK
Food	B-UNK
and	O
Drug	B-UNK
Administration	O
banned	O
its	O
use	O
for	O
nocturnal	O
leg	B-DISEASE
cramps	I-DISEASE
due	O
to	O
lack	B-UNK
of	O
safety	B-UNK
and	I-UNK
efficacy	I-UNK
,	O
quinine	B-UNK
is	O
widely	B-UNK
available	O
in	O
beverages	O
including	O
tonic	B-UNK
water	B-UNK
and	O
bitter	O
lemon	O
.	O
Numerous	B-UNK
anecdotal	O
reports	B-UNK
suggest	B-UNK
that	O
products	B-UNK
containing	O
quinine	B-CHEMICAL
may	O
produce	B-UNK
neurological	B-UNK
complications	B-DISEASE
,	O
including	O
confusion	B-UNK
,	O
altered	B-UNK
mental	B-UNK
status	I-UNK
,	O
seizures	B-UNK
,	O
and	O
coma	B-UNK
,	O
particularly	O
in	O
older	B-UNK
women	B-UNK
.	O
Psychologists	O
need	O
to	O
inquire	O
about	O
consumption	B-UNK
of	O
quinine	B-UNK
-	O
containing	O
beverages	O
as	O
part	O
of	O
an	O
evaluation	B-UNK
process	O
.	O

Organophosphate	O
-	O
induced	B-UNK
convulsions	I-UNK
and	O
prevention	B-UNK
of	O
neuropathological	O
damages	O
.	O
Such	O
organophosphorus	O
(	O
OP	O
)	O
compounds	B-UNK
as	O
diisopropylfluorophosphate	B-CHEMICAL
(	O
DFP	B-UNK
)	O
,	O
sarin	O
and	O
soman	O
are	O
potent	B-UNK
inhibitors	B-UNK
of	O
acetylcholinesterases	O
(	O
AChEs	O
)	O
and	O
butyrylcholinesterases	O
(	O
BChEs	O
)	O
.	O
The	O
acute	B-UNK
toxicity	B-UNK
of	O
OPs	O
is	O
the	O
result	B-UNK
of	O
their	O
irreversible	B-UNK
binding	B-UNK
with	O
AChEs	O
in	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
(	O
CNS	B-UNK
)	O
,	O
which	O
elevates	O
acetylcholine	B-UNK
(	O
ACh	B-CHEMICAL
)	O
levels	O
.	O
The	O
protective	B-UNK
action	B-UNK
of	O
subcutaneously	B-UNK
(	O
SC	B-UNK
)	O
administered	O
antidotes	O
or	O
their	O
combinations	B-UNK
in	O
DFP	B-UNK
(	O
2.0	O
mg	B-UNK
/	O
kg	B-UNK
BW	B-UNK
)	O
intoxication	B-UNK
was	O
studied	O
in	O
9	O
-	O
10-weeks	O
-	O
old	O
Han	O
-	O
Wistar	B-UNK
male	B-UNK
rats	I-UNK
.	O
The	O
rats	B-UNK
received	O
AChE	B-UNK
reactivator	O
pralidoxime-2-chloride	O
(	O
2PAM	B-CHEMICAL
)	O
(	O
30.0	O
mg	B-UNK
/	O
kg	B-UNK
BW	B-UNK
)	O
,	O
anticonvulsant	B-UNK
diazepam	B-CHEMICAL
(	O
2.0	O
mg	B-UNK
/	O
kg	B-UNK
BW	B-UNK
)	O
,	O
A(1)-adenosine	O
receptor	B-UNK
agonist	I-UNK
N(6)-cyclopentyl	O
adenosine	B-UNK
(	O
CPA	B-CHEMICAL
)	O
(	O
2.0	O
mg	B-UNK
/	O
kg	B-UNK
BW	B-UNK
)	O
,	O
NMDA	B-UNK
-	O
receptor	B-UNK
antagonist	I-UNK
dizocilpine	O
maleate	B-UNK
(	O
+	O
-MK801	O
hydrogen	B-UNK
maleate	B-UNK
)	O
(	O
2.0	O
mg	B-UNK
/	O
kg	B-UNK
BW	B-UNK
)	O
or	O
their	O
combinations	B-UNK
with	O
cholinolytic	O
drug	B-UNK
atropine	B-UNK
sulfate	B-UNK
(	O
50.0	O
mg	B-UNK
/	O
kg	B-UNK
BW	B-UNK
)	O
immediately	B-UNK
or	O
30	O
min	B-UNK
after	O
the	O
single	B-UNK
SC	B-UNK
injection	B-UNK
of	O
DFP	B-UNK
.	O
The	O
control	B-UNK
rats	B-UNK
received	O
atropine	B-UNK
sulfate	B-UNK
,	O
but	O
also	O
saline	B-UNK
and	O
olive	O
oil	B-UNK
instead	O
of	O
other	O
antidotes	O
and	O
DFP	B-UNK
,	O
respectively	O
.	O
All	O
rats	B-UNK
were	O
terminated	O
either	O
24	O
h	O
or	O
3	O
weeks	B-UNK
after	O
the	O
DFP	B-UNK
injection	B-UNK
.	O
The	O
rats	B-UNK
treated	O
with	O
DFP	B-UNK
-	O
atropine	B-UNK
showed	O
severe	B-UNK
typical	B-UNK
OP	O
-	O
induced	O
toxicity	B-UNK
signs	B-UNK
.	O
When	O
CPA	B-CHEMICAL
,	O
diazepam	B-CHEMICAL
or	O
2PAM	B-CHEMICAL
was	O
given	O
immediately	B-UNK
after	O
DFP	B-UNK
-	O
atropine	B-UNK
,	O
these	O
treatments	O
prevented	B-UNK
,	O
delayed	B-UNK
or	O
shortened	O
the	O
occurrence	B-UNK
of	O
serious	O
signs	B-UNK
of	O
poisoning	B-UNK
.	O
Atropine	B-UNK
-	O
MK801	O
did	O
not	O
offer	O
any	O
additional	B-UNK
protection	B-UNK
against	O
DFP	B-UNK
toxicity	B-UNK
.	O
In	O
conclusion	B-UNK
,	O
CPA	B-CHEMICAL
,	O
diazepam	B-CHEMICAL
and	O
2PAM	B-CHEMICAL
in	O
combination	B-UNK
with	O
atropine	B-UNK
prevented	B-UNK
the	O
occurrence	B-UNK
of	O
serious	O
signs	B-UNK
of	O
poisoning	B-UNK
and	O
thus	O
reduced	B-UNK
the	O
toxicity	B-DISEASE
of	O
DFP	B-UNK
in	O
rat	B-UNK
.	O

Differential	B-UNK
modulation	B-UNK
by	O
estrogen	B-UNK
of	O
alpha2-adrenergic	O
and	O
I1-imidazoline	O
receptor	B-UNK
-	O
mediated	B-UNK
hypotension	B-UNK
in	O
female	B-UNK
rats	I-UNK
.	O
We	O
have	O
recently	B-UNK
shown	B-UNK
that	O
estrogen	B-UNK
negatively	O
modulates	O
the	O
hypotensive	B-DISEASE
effect	B-UNK
of	O
clonidine	B-UNK
(	O
mixed	B-UNK
alpha2-/I1-receptor	O
agonist	B-UNK
)	O
in	O
female	B-UNK
rats	I-UNK
and	O
implicates	O
the	O
cardiovascular	B-UNK
autonomic	B-UNK
control	B-UNK
in	O
this	O
interaction	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
investigated	B-UNK
whether	O
this	O
effect	B-UNK
of	O
estrogen	B-UNK
involves	O
interaction	B-UNK
with	O
alpha2-	O
and	O
/	O
or	O
I1-receptors	O
.	O
Changes	O
evoked	B-UNK
by	O
a	O
single	B-UNK
intraperitoneal	B-UNK
injection	B-UNK
of	O
rilmenidine	O
(	O
600	O
microg	B-UNK
/	O
kg	B-UNK
)	O
or	O
alpha	B-UNK
-	O
methyldopa	B-CHEMICAL
(	O
100	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
selective	B-UNK
I1-	O
and	O
alpha2-receptor	O
agonists	B-UNK
,	O
respectively	O
,	O
in	O
blood	B-UNK
pressure	I-UNK
,	O
hemodynamic	B-UNK
variability	B-UNK
,	O
and	O
locomotor	B-UNK
activity	I-UNK
were	O
assessed	B-UNK
in	O
radiotelemetered	O
sham	B-UNK
-	O
operated	O
and	O
ovariectomized	O
(	O
Ovx	O
)	O
Sprague	O
-	O
Dawley	O
female	B-UNK
rats	I-UNK
with	O
or	O
without	O
12-wk	O
estrogen	B-CHEMICAL
replacement	B-UNK
.	O
Three	O
time	O
domain	O
indexes	O
of	O
hemodynamic	B-UNK
variability	B-UNK
were	O
employed	B-UNK
:	O
the	O
standard	B-UNK
deviation	O
of	O
mean	O
arterial	B-UNK
pressure	I-UNK
as	O
a	O
measure	B-UNK
of	O
blood	B-UNK
pressure	I-UNK
variability	B-UNK
and	O
the	O
standard	B-UNK
deviation	O
of	O
beat	O
-	O
to	O
-	O
beat	O
intervals	B-UNK
(	O
SDRR	O
)	O
and	O
the	O
root	O
mean	O
square	O
of	O
successive	O
differences	B-UNK
in	O
R	O
-	O
wave	B-UNK
-	O
to	O
-	O
R	O
-	O
wave	B-UNK
intervals	B-UNK
as	O
measures	B-UNK
of	O
heart	B-UNK
rate	I-UNK
variability	B-UNK
.	O
In	O
sham	B-UNK
-	O
operated	O
rats	B-UNK
,	O
rilmenidine	O
or	O
alpha	B-UNK
-	O
methyldopa	B-CHEMICAL
elicited	B-UNK
similar	B-UNK
hypotension	B-UNK
that	O
lasted	B-UNK
at	O
least	O
5	O
h	O
and	O
was	O
associated	O
with	O
reductions	B-UNK
in	O
standard	B-UNK
deviation	O
of	O
mean	O
arterial	B-UNK
pressure	I-UNK
.	O
SDRR	O
was	O
reduced	B-UNK
only	O
by	O
alpha	B-UNK
-	O
methyldopa	B-UNK
.	O
Ovx	O
significantly	B-UNK
enhanced	B-UNK
the	O
hypotensive	B-UNK
response	B-UNK
to	O
alpha	B-UNK
-	O
methyldopa	B-UNK
,	O
in	O
contrast	B-UNK
to	O
no	O
effect	B-UNK
on	O
rilmenidine	O
hypotension	B-DISEASE
.	O
The	O
enhanced	B-UNK
alpha	B-UNK
-	O
methyldopa	B-CHEMICAL
hypotension	B-UNK
in	O
Ovx	O
rats	B-UNK
was	O
paralleled	O
with	O
further	O
reduction	O
in	O
SDRR	O
and	O
a	B-DISEASE
reduced	I-DISEASE
locomotor	I-DISEASE
activity	I-DISEASE
.	O
Estrogen	B-UNK
replacement	B-UNK
(	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
subcutaneous	B-UNK
pellet	O
,	O
14.2	O
microg	B-UNK
/	O
day	O
,	O
12	O
wk	B-UNK
)	O
of	O
Ovx	O
rats	B-UNK
restored	B-UNK
the	O
hemodynamic	B-UNK
and	O
locomotor	B-UNK
effects	O
of	O
alpha	B-UNK
-	O
methyldopa	B-UNK
to	O
sham	B-UNK
-	O
operated	O
levels	O
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
estrogen	B-UNK
downregulates	O
alpha2-	O
but	O
not	O
I1-receptor	O
-	O
mediated	B-UNK
hypotension	B-UNK
and	O
highlight	O
a	O
role	O
for	O
the	O
cardiac	B-UNK
autonomic	B-UNK
control	B-UNK
in	O
alpha	B-UNK
-	O
methyldopa	B-UNK
-	O
estrogen	B-UNK
interaction	B-UNK
.	O

Cardioprotective	B-UNK
effect	B-UNK
of	O
tincture	O
of	O
Crataegus	O
on	O
isoproterenol	B-UNK
-	O
induced	B-UNK
myocardial	I-UNK
infarction	I-UNK
in	I-UNK
rats	I-UNK
.	O
Tincture	O
of	O
Crataegus	O
(	O
TCR	O
)	O
,	O
an	O
alcoholic	O
extract	B-UNK
of	O
the	O
berries	O
of	O
hawthorn	O
(	O
Crataegus	O
oxycantha	O
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
done	O
to	O
investigate	B-UNK
the	O
protective	B-UNK
effect	I-UNK
of	O
TCR	O
on	O
experimentally	O
induced	B-UNK
myocardial	I-UNK
infarction	I-UNK
in	I-UNK
rats	I-UNK
.	O
Pretreatment	B-UNK
of	O
TCR	O
,	O
at	O
a	O
dose	B-UNK
of	O
0.5	O
mL/100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	B-UNK
,	O
prevented	B-UNK
the	O
increase	B-UNK
in	O
lipid	B-UNK
peroxidation	I-UNK
and	O
activity	B-UNK
of	O
marker	B-UNK
enzymes	B-UNK
observed	O
in	O
isoproterenol	B-UNK
-	O
induced	O
rats	B-UNK
(	O
85	O
mg	B-UNK
kg(-1	O
)	O
s.	O
c.	O
for	O
2	O
days	B-UNK
at	O
an	O
interval	B-UNK
of	O
24	O
h	O
)	O
.	O
TCR	O
prevented	B-UNK
the	O
isoproterenol	B-CHEMICAL
-	O
induced	O
decrease	B-UNK
in	O
antioxidant	B-UNK
enzymes	B-UNK
in	O
the	O
heart	B-UNK
and	O
increased	B-UNK
the	O
rate	B-UNK
of	O
ADP	B-CHEMICAL
-	O
stimulated	B-UNK
oxygen	B-CHEMICAL
uptake	B-UNK
and	O
respiratory	B-UNK
coupling	O
ratio	B-UNK
.	O
TCR	O
protected	B-UNK
against	O
pathological	B-UNK
changes	O
induced	O
by	O
isoproterenol	B-CHEMICAL
in	O
rat	B-UNK
heart	I-UNK
.	O
The	O
results	B-UNK
show	O
that	O
pretreatment	B-UNK
with	O
TCR	O
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	B-UNK
induced	O
by	O
isoproterenol	B-UNK
in	O
rat	B-UNK
heart	I-UNK
.	O

Safety	B-UNK
and	O
adverse	B-UNK
effects	I-UNK
associated	O
with	O
raloxifene	B-UNK
:	O
multiple	B-UNK
outcomes	B-UNK
of	O
raloxifene	B-UNK
evaluation	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
To	O
examine	B-UNK
the	O
effect	B-UNK
of	O
raloxifene	B-UNK
on	O
major	B-UNK
adverse	B-UNK
events	I-UNK
that	O
occur	O
with	O
postmenopausal	B-UNK
estrogen	B-UNK
therapy	O
or	O
tamoxifen	B-CHEMICAL
.	O
METHODS	B-UNK
:	O
The	O
Multiple	B-UNK
Outcomes	B-UNK
of	O
Raloxifene	B-UNK
Evaluation	B-UNK
,	O
a	O
multicenter	B-UNK
,	O
randomized	B-UNK
,	O
double-blind	O
trial	B-UNK
,	O
enrolled	O
7,705	O
postmenopausal	B-UNK
women	I-UNK
with	O
osteoporosis	B-DISEASE
.	O
Women	B-UNK
were	O
randomly	B-UNK
assigned	I-UNK
to	I-UNK
raloxifene	B-UNK
60	O
mg	B-UNK
/	O
d	O
or	O
120	O
mg	B-UNK
/	O
d	O
or	O
placebo	B-UNK
.	O
Outcomes	B-UNK
included	B-UNK
venous	B-UNK
thromboembolism	I-UNK
,	O
cataracts	B-DISEASE
,	O
gallbladder	B-UNK
disease	B-UNK
,	O
and	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
or	O
cancer	B-DISEASE
.	O
RESULTS	B-UNK
:	O
During	O
a	O
mean	O
follow	O
-	O
up	O
of	O
3.3	O
years	B-UNK
,	O
raloxifene	B-UNK
was	O
associated	O
with	O
an	O
increased	B-UNK
risk	B-UNK
for	O
venous	B-UNK
thromboembolism	I-UNK
(	O
relative	B-UNK
risk	I-UNK
[	O
RR	B-UNK
]	O
2.1	O
;	O
95	O
%	O
confidence	O
interval	B-UNK
[	O
CI	B-UNK
]	O
1.2	O
-	O
3.8	O
)	O
.	O
The	O
excess	B-UNK
event	B-UNK
rate	B-UNK
was	O
1.8	O
per	O
1,000	O
woman	B-UNK
-	O
years	B-UNK
(	O
95	O
%	O
CI	B-UNK
-0.5	O
-	O
4.1	O
)	O
,	O
and	O
the	O
number	B-UNK
needed	B-UNK
to	O
treat	B-UNK
to	O
cause	O
1	O
event	B-UNK
was	O
170	O
(	O
95	O
%	O
CI	B-UNK
100	O
-	O
582	O
)	O
over	O
3.3	O
years	B-UNK
.	O
Risk	B-UNK
in	O
the	O
raloxifene	B-UNK
group	B-UNK
was	O
higher	B-UNK
than	O
in	O
the	O
placebo	B-UNK
group	B-UNK
for	O
the	O
first	O
2	O
years	B-UNK
,	O
but	O
decreased	B-UNK
to	O
about	O
the	O
same	O
rate	B-UNK
as	O
in	O
the	O
placebo	B-UNK
group	B-UNK
thereafter	O
.	O
Raloxifene	B-UNK
did	O
not	O
increase	B-UNK
risk	B-UNK
for	O
cataracts	B-DISEASE
(	O
RR	B-UNK
0.9	O
;	O
95	O
%	O
CI	B-UNK
0.8	O
-	O
1.1	O
)	O
,	O
gallbladder	B-UNK
disease	B-UNK
(	O
RR	B-UNK
1.0	O
;	O
95	O
%	O
CI	B-UNK
0.7	O
-	O
1.3	O
)	O
,	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
(	O
RR	B-UNK
1.3	O
;	O
95	O
%	O
CI	B-UNK
0.4	O
-	O
5.1	O
)	O
,	O
or	O
endometrial	B-DISEASE
cancer	I-DISEASE
(	O
RR	B-UNK
0.9	O
;	O
95	O
%	O
CI	B-UNK
0.3	O
-	O
2.7	O
)	O
.	O
CONCLUSION	B-UNK
:	O
Raloxifene	B-UNK
was	O
associated	O
with	O
an	O
increased	B-UNK
risk	B-UNK
for	O
venous	B-DISEASE
thromboembolism	I-DISEASE
,	O
but	O
there	O
was	O
no	O
increased	B-UNK
risk	B-UNK
for	O
cataracts	B-DISEASE
,	O
gallbladder	B-UNK
disease	B-UNK
,	O
endometrial	B-DISEASE
hyperplasia	I-DISEASE
,	O
or	O
endometrial	B-UNK
cancer	I-UNK
.	O
LEVEL	B-UNK
OF	O
EVIDENCE	B-UNK
:	O
I	O

Ceftriaxone	B-CHEMICAL
-	O
associated	O
biliary	B-DISEASE
pseudolithiasis	I-DISEASE
in	O
paediatric	O
surgical	B-UNK
patients	B-UNK
.	O
It	O
is	O
well	O
known	O
that	O
ceftriaxone	B-CHEMICAL
leads	B-UNK
to	O
pseudolithiasis	B-DISEASE
in	O
some	O
patients	B-UNK
.	O
Clinical	B-UNK
and	O
experimental	B-UNK
studies	B-UNK
also	O
suggest	B-UNK
that	O
situations	O
causing	O
gallbladder	B-UNK
dysfunction	B-UNK
,	O
such	O
as	O
fasting	O
,	O
may	O
have	O
a	O
role	O
for	O
the	O
development	B-UNK
of	O
pseudolithiasis	B-DISEASE
.	O
In	O
this	O
study	B-UNK
,	O
we	O
prospectively	O
evaluated	B-UNK
the	O
incidence	B-UNK
and	O
clinical	B-UNK
importance	B-UNK
of	O
pseudolithiasis	B-DISEASE
in	O
paediatric	O
surgical	B-UNK
patients	B-UNK
receiving	B-UNK
ceftriaxone	B-CHEMICAL
treatment	B-UNK
,	O
who	O
often	O
had	O
to	O
fast	O
in	O
the	O
post-operative	O
period	B-UNK
.	O
Fifty	B-UNK
children	B-UNK
who	O
were	O
given	O
ceftriaxone	B-CHEMICAL
were	O
evaluated	B-UNK
by	O
serial	B-UNK
abdominal	B-UNK
sonograms	O
.	O
Of	O
those	O
,	O
13	O
(	O
26	O
%	O
)	O
developed	O
biliary	B-UNK
pathology	B-UNK
.	O
Comparison	B-UNK
of	O
the	O
patients	B-UNK
with	O
or	O
without	O
pseudolithiasis	B-DISEASE
revealed	O
no	O
significant	B-UNK
difference	I-UNK
with	O
respect	B-UNK
to	O
age	B-UNK
,	O
sex	B-UNK
,	O
duration	B-UNK
of	O
the	O
treatment	B-UNK
and	O
starvation	B-DISEASE
variables	B-UNK
.	O
After	O
cessation	B-UNK
of	O
the	O
treatment	B-UNK
,	O
pseudolithiasis	B-DISEASE
resolved	O
spontaneously	B-UNK
within	O
a	O
short	B-UNK
period	B-UNK
.	O
The	O
incidence	B-UNK
of	O
pseudolithiasis	B-DISEASE
is	O
not	O
affected	B-UNK
by	O
fasting	O
.	O

Evaluation	B-UNK
of	O
the	O
anticocaine	O
monoclonal	O
antibody	B-UNK
GNC92H2	O
as	O
an	O
immunotherapy	O
for	O
cocaine	B-DISEASE
overdose	I-DISEASE
.	O
The	O
illicit	O
use	O
of	O
cocaine	B-UNK
continues	O
in	O
epidemic	O
proportions	O
and	O
treatment	B-UNK
for	O
cocaine	B-DISEASE
overdose	I-DISEASE
remains	O
elusive	O
.	O
Current	B-UNK
protein	B-UNK
-	O
based	B-UNK
technology	O
offers	O
a	O
new	O
therapeutic	B-UNK
venue	O
by	O
which	O
antibodies	B-UNK
bind	O
the	O
drug	B-UNK
in	O
the	O
blood	B-UNK
stream	O
,	O
inactivating	O
its	O
toxic	B-UNK
effects	I-UNK
.	O
The	O
therapeutic	B-UNK
potential	B-UNK
of	O
the	O
anticocaine	O
antibody	B-UNK
GNC92H2	O
was	O
examined	B-UNK
using	O
a	O
model	B-UNK
of	O
cocaine	B-DISEASE
overdose	I-DISEASE
.	O
Swiss	B-UNK
albino	B-UNK
mice	B-UNK
prepared	O
with	O
intrajugular	O
catheters	O
were	O
tested	B-UNK
in	O
photocell	O
cages	O
after	O
administration	O
of	O
93	O
mg	B-UNK
/	O
kg	B-UNK
(	O
LD50	O
)	O
of	O
cocaine	B-CHEMICAL
and	O
GNC92H2	O
infusions	B-UNK
ranging	O
from	O
30	O
to	O
190	O
mg	B-UNK
/	O
kg	B-UNK
.	O
GNC92H2	O
was	O
delivered	O
30	O
min	B-UNK
before	O
,	O
concomitantly	B-UNK
or	O
3	O
min	B-UNK
after	O
cocaine	B-UNK
treatment	B-UNK
.	O
Significant	B-UNK
blockade	B-UNK
of	O
cocaine	B-UNK
toxicity	B-UNK
was	O
observed	O
with	O
the	O
higher	B-UNK
dose	B-UNK
of	O
GNC92H2	O
(	O
190	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
where	O
premorbid	O
behaviors	B-UNK
were	O
reduced	B-UNK
up	O
to	O
40	O
%	O
,	O
seizures	B-UNK
up	O
to	O
77	O
%	O
and	O
death	B-UNK
by	O
72	O
%	O
.	O
Importantly	O
,	O
GNC92H2	O
prevented	B-UNK
death	B-DISEASE
even	O
post-cocaine	O
injection	B-UNK
.	O
The	O
results	B-UNK
support	B-UNK
the	O
important	B-UNK
potential	B-UNK
of	O
GNC92H2	O
as	O
a	O
therapeutic	B-UNK
tool	O
against	O
cocaine	B-DISEASE
overdose	I-DISEASE
.	O

The	O
effects	O
of	O
short	B-UNK
-	O
term	O
raloxifene	B-UNK
therapy	O
on	O
fibrinolysis	O
markers	B-UNK
:	O
TAFI	O
,	O
tPA	O
,	O
and	O
PAI-1	O
.	O
BACKGROUND	B-UNK
:	O
Markers	B-UNK
of	O
fibrinolysis	O
,	O
thrombin	B-UNK
-	O
activatable	O
fibrinolysis	O
inhibitor	B-UNK
(	O
TAFI	O
)	O
,	O
tissue	B-UNK
-	O
type	B-UNK
plasminogen	O
activator	O
(	O
tPA	O
)	O
,	O
and	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	B-UNK
of	O
short	B-UNK
-	O
term	O
effects	O
of	O
raloxifene	B-UNK
administration	O
in	O
postmenopausal	B-UNK
women	I-UNK
.	O
METHODS	B-UNK
:	O
Thirty	B-UNK
-	O
nine	O
postmenopausal	B-UNK
women	I-UNK
with	O
osteopenia	O
or	O
osteoporosis	B-DISEASE
were	O
included	B-UNK
in	O
this	O
prospective	B-UNK
,	O
controlled	B-UNK
clinical	B-UNK
study	B-UNK
.	O
Twenty	O
-	O
five	O
women	B-UNK
were	O
given	O
raloxifene	B-UNK
hydrochloride	B-UNK
(	O
60	O
mg	B-UNK
/	O
day	O
)	O
plus	O
calcium	B-CHEMICAL
(	O
500	O
mg	B-UNK
/	O
day	O
)	O
.	O
Age	B-UNK
-	O
matched	O
controls	B-UNK
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	B-UNK
.	O
Plasma	B-UNK
TAFI	O
,	O
tPA	O
,	O
and	O
PAI-1	O
antigen	B-UNK
levels	O
were	O
measured	B-UNK
at	O
baseline	B-UNK
and	O
after	O
3	O
months	B-UNK
of	O
treatment	B-UNK
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O
Variations	O
of	O
individuals	B-UNK
were	O
assessed	B-UNK
by	O
Wilcoxon'	O
s	O
test	B-UNK
.	O
Relationship	B-UNK
between	O
those	O
markers	B-UNK
and	O
demographic	O
characteristics	B-UNK
were	O
investigated	B-UNK
.	O
RESULTS	B-UNK
:	O
Three	O
months	B-UNK
of	O
raloxifene	B-UNK
treatment	B-UNK
was	O
associated	O
with	O
a	O
significant	B-UNK
decrease	B-UNK
in	O
the	O
plasma	B-UNK
TAFI	O
antigen	B-UNK
concentrations	B-UNK
(	O
16	O
%	O
change	B-UNK
,	O
P	O
<	O
0.01	O
)	O
,	O
and	O
a	O
significant	B-UNK
increase	B-UNK
in	O
tPA	O
antigen	B-UNK
concentrations	B-UNK
(	O
25	O
%	O
change	B-UNK
,	O
P	O
<	O
0.05	O
)	O
.	O
A	O
significant	B-UNK
correlation	B-UNK
was	O
found	O
between	O
baseline	B-UNK
TAFI	O
antigen	B-UNK
concentrations	B-UNK
and	O
the	O
duration	B-UNK
of	O
amenorrhea	B-DISEASE
(	O
P	O
<	O
0.05	O
;	O
r	O
=	O
0.33	O
)	O
.	O
CONCLUSION	B-UNK
:	O
We	O
suggest	B-UNK
that	O
the	O
increased	B-UNK
risk	B-UNK
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
due	O
to	O
raloxifene	B-UNK
treatment	B-UNK
may	O
be	O
related	O
to	O
increased	B-UNK
tPA	O
levels	O
,	O
but	O
not	O
TAFI	O
levels	O
.	O

Ketoconazole	B-UNK
induced	O
torsades	B-UNK
de	I-UNK
pointes	I-UNK
without	O
concomitant	B-UNK
use	O
of	O
QT	B-UNK
interval	I-UNK
-	O
prolonging	O
drug	B-UNK
.	O
Ketoconazole	B-CHEMICAL
is	O
not	O
known	O
to	O
be	O
proarrhythmic	O
without	O
concomitant	B-UNK
use	O
of	O
QT	B-UNK
interval	I-UNK
-	O
prolonging	O
drugs	B-UNK
.	O
We	O
report	B-UNK
a	O
woman	B-UNK
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
who	O
developed	O
a	O
markedly	O
prolonged	B-UNK
QT	B-UNK
interval	I-UNK
and	O
torsades	B-UNK
de	I-UNK
pointes	I-UNK
(	O
TdP	B-DISEASE
)	O
after	O
taking	B-UNK
ketoconazole	B-CHEMICAL
for	O
treatment	B-UNK
of	O
fungal	O
infection	B-DISEASE
.	O
Her	O
QT	B-UNK
interval	I-UNK
returned	B-UNK
to	O
normal	O
upon	O
withdrawal	B-UNK
of	O
ketoconazole	B-UNK
.	O
Genetic	B-UNK
study	B-UNK
did	O
not	O
find	O
any	O
mutation	B-UNK
in	O
her	O
genes	B-UNK
that	O
encode	O
cardiac	B-UNK
IKr	O
channel	B-UNK
proteins	B-UNK
.	O
We	O
postulate	O
that	O
by	O
virtue	O
of	O
its	O
direct	B-UNK
blocking	B-UNK
action	B-UNK
on	O
IKr	O
,	O
ketoconazole	B-UNK
alone	O
may	O
prolong	O
QT	B-UNK
interval	I-UNK
and	O
induce	B-UNK
TdP.	O
This	O
calls	O
for	O
attention	B-UNK
when	O
ketoconazole	B-UNK
is	O
administered	O
to	O
patients	B-UNK
with	O
risk	B-UNK
factors	I-UNK
for	O
acquired	B-UNK
long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
.	O

Pharmacological	B-UNK
evidence	B-UNK
for	O
the	O
potential	B-UNK
of	O
Daucus	O
carota	O
in	O
the	O
management	B-UNK
of	O
cognitive	B-UNK
dysfunctions	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
aimed	B-UNK
at	O
investigating	O
the	O
effects	O
of	O
Daucus	O
carota	O
seeds	O
on	O
cognitive	B-UNK
functions	I-UNK
,	O
total	B-UNK
serum	B-UNK
cholesterol	B-CHEMICAL
levels	O
and	O
brain	B-UNK
cholinesterase	B-UNK
activity	B-UNK
in	O
mice	B-UNK
.	O
The	O
ethanolic	O
extract	B-UNK
of	O
Daucus	O
carota	O
seeds	O
(	O
DCE	O
)	O
was	O
administered	O
orally	O
in	O
three	O
doses	B-UNK
(	O
100	O
,	O
200	O
,	O
400	O
mg	B-UNK
/	O
kg	B-UNK
)	O
for	O
seven	O
successive	O
days	B-UNK
to	O
different	O
groups	B-UNK
of	O
young	B-UNK
and	O
aged	B-UNK
mice	B-UNK
.	O
Elevated	B-UNK
plus	I-UNK
maze	I-UNK
and	O
passive	B-UNK
avoidance	I-UNK
apparatus	O
served	O
as	O
the	O
exteroceptive	O
behavioral	B-UNK
models	B-UNK
for	O
testing	B-UNK
memory	B-UNK
.	O
Diazepam-	O
,	O
scopolamine-	O
and	O
ageing	O
-	O
induced	O
amnesia	B-UNK
served	O
as	O
the	O
interoceptive	O
behavioral	B-UNK
models	B-UNK
.	O
DCE	O
(	O
200	O
,	O
400	O
mg	B-UNK
/	O
kg	B-UNK
,	O
p.o	B-UNK
.	O
)	O
showed	O
significant	B-UNK
improvement	B-UNK
in	O
memory	B-UNK
scores	O
of	O
young	B-UNK
and	O
aged	B-UNK
mice	B-UNK
.	O
The	O
extent	B-UNK
of	O
memory	B-UNK
improvement	B-UNK
evoked	B-UNK
by	O
DCE	O
was	O
23	O
%	O
at	O
the	O
dose	B-UNK
of	O
200	O
mg	B-UNK
/	O
kg	B-UNK
and	O
35	O
%	O
at	O
the	O
dose	B-UNK
of	O
400	O
mg	B-UNK
/	O
kg	B-UNK
in	O
young	B-UNK
mice	B-UNK
using	O
elevated	B-UNK
plus	I-UNK
maze	I-UNK
.	O
Similarly	B-UNK
,	O
significant	B-UNK
improvements	B-UNK
in	O
memory	B-UNK
scores	O
were	O
observed	O
using	O
passive	B-UNK
avoidance	I-UNK
apparatus	O
and	O
aged	B-UNK
mice	B-UNK
.	O
Furthermore	O
,	O
DCE	O
reversed	B-UNK
the	O
amnesia	B-DISEASE
induced	O
by	O
scopolamine	B-UNK
(	O
0.4	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
and	O
diazepam	B-CHEMICAL
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
.	O
Daucus	O
carota	O
extract	B-UNK
(	O
200	O
,	O
400	O
mg	B-UNK
/	O
kg	B-UNK
,	O
p.o	B-UNK
.	O
)	O
reduced	B-UNK
significantly	B-UNK
the	O
brain	B-UNK
acetylcholinesterase	O
activity	B-UNK
and	O
cholesterol	B-UNK
levels	O
in	O
young	B-UNK
and	O
aged	B-UNK
mice	B-UNK
.	O
The	O
extent	B-UNK
of	O
inhibition	B-UNK
of	O
brain	B-UNK
cholinesterase	B-UNK
activity	B-UNK
evoked	B-UNK
by	O
DCE	O
at	O
the	O
dose	B-UNK
of	O
400	O
mg	B-UNK
/	O
kg	B-UNK
was	O
22	O
%	O
in	O
young	B-UNK
and	O
19	O
%	O
in	O
aged	B-UNK
mice	B-UNK
.	O
There	O
was	O
a	O
remarkable	O
reduction	O
in	O
total	B-UNK
cholesterol	B-CHEMICAL
level	B-UNK
as	O
well	O
,	O
to	O
the	O
extent	B-UNK
of	O
23	O
%	O
in	O
young	B-UNK
and	O
21	O
%	O
in	O
aged	B-UNK
animals	B-UNK
with	O
this	O
dose	B-UNK
of	O
DCE	O
.	O
Therefore	O
,	O
DCE	O
may	O
prove	O
to	O
be	O
a	O
useful	O
remedy	O
for	O
the	O
management	B-UNK
of	O
cognitive	B-UNK
dysfunctions	B-UNK
on	O
account	O
of	O
its	O
multifarious	O
beneficial	B-UNK
effects	I-UNK
such	O
as	O
,	O
memory	B-UNK
improving	B-UNK
property	O
,	O
cholesterol	B-UNK
lowering	B-UNK
property	O
and	O
anticholinesterase	O
activity	B-UNK
.	O

Cauda	B-DISEASE
equina	I-DISEASE
syndrome	I-DISEASE
after	O
epidural	B-UNK
steroid	B-CHEMICAL
injection	B-UNK
:	O
a	O
case	B-UNK
report	I-UNK
.	O
OBJECTIVE	B-UNK
:	O
Conventional	B-UNK
treatment	B-UNK
methods	B-UNK
of	O
lumbusacral	O
radiculopathy	B-DISEASE
are	O
physical	B-UNK
therapy	O
,	O
epidural	B-UNK
steroid	B-UNK
injections	B-UNK
,	O
oral	B-UNK
medications	B-UNK
,	O
and	O
spinal	B-UNK
manipulative	O
therapy	O
.	O
Cauda	B-DISEASE
equina	I-DISEASE
syndrome	I-DISEASE
is	O
a	O
rare	B-UNK
complication	B-UNK
of	O
epidural	B-UNK
anesthesia	B-UNK
.	O
The	O
following	O
case	B-UNK
is	O
a	O
report	B-UNK
of	O
cauda	B-DISEASE
equina	I-DISEASE
syndrome	I-DISEASE
possibly	O
caused	B-UNK
by	O
epidural	B-UNK
injection	B-UNK
of	O
triamcinolone	O
and	O
bupivacaine	B-UNK
.	O
CLINICAL	B-UNK
FEATURES	B-UNK
:	O
A	O
50-year	O
-	O
old	O
woman	B-UNK
with	O
low	B-UNK
back	O
and	O
right	O
leg	B-UNK
pain	B-UNK
was	O
scheduled	O
for	O
epidural	B-UNK
steroid	B-CHEMICAL
injection	B-UNK
.	O
INTERVENTION	B-UNK
AND	O
OUTCOME	B-UNK
:	O
An	O
18-gauge	O
Touhy	O
needle	B-UNK
was	O
inserted	O
until	O
loss	B-UNK
of	O
resistance	B-UNK
occurred	B-UNK
at	O
the	O
L4	O
-	O
5	O
level	B-UNK
.	O
Spread	O
of	O
the	O
contrast	B-UNK
medium	I-UNK
within	O
the	O
epidural	B-UNK
space	B-UNK
was	O
determined	B-UNK
by	O
radiographic	O
imaging	B-UNK
.	O
After	O
verifying	O
the	O
epidural	B-UNK
space	B-UNK
,	O
bupivacaine	B-UNK
and	O
triamcinolone	B-CHEMICAL
diacetate	I-CHEMICAL
were	O
injected	B-UNK
.	O
After	O
the	O
injection	B-UNK
,	O
there	O
was	O
a	O
reduction	O
in	O
radicular	O
symptoms	B-UNK
.	O
Three	O
hours	B-UNK
later	O
,	O
she	O
complained	O
of	O
perineal	O
numbness	O
and	O
lower	B-UNK
extremity	O
weakness	B-DISEASE
.	O
The	O
neurologic	B-UNK
evaluation	B-UNK
revealed	O
loss	B-UNK
of	O
sensation	B-UNK
in	O
the	O
saddle	O
area	B-UNK
and	O
medial	B-UNK
aspect	O
of	O
her	O
right	O
leg	B-UNK
.	O
There	O
was	O
a	O
decrease	B-UNK
in	O
the	O
perception	O
of	O
pinprick	O
test	B-UNK
.	O
Deep	B-UNK
-	O
tendon	O
reflexes	O
were	O
decreased	B-UNK
especially	O
in	O
the	O
right	O
leg	B-UNK
.	O
She	O
was	O
unable	O
to	O
urinate	O
.	O
The	O
patient'	B-UNK
s	I-UNK
symptoms	B-UNK
improved	O
slightly	O
over	O
the	O
next	O
few	O
hours	B-UNK
.	O
She	O
had	O
a	O
gradual	B-UNK
return	B-UNK
of	O
motor	B-UNK
function	B-UNK
and	O
ability	B-UNK
of	O
feeling	O
Foley	O
catheter	B-UNK
.	O
All	O
of	O
the	O
symptoms	B-UNK
were	O
completely	O
resolved	O
over	O
the	O
next	O
8	O
hours	B-UNK
.	O
CONCLUSION	B-UNK
:	O
Complications	B-UNK
associated	O
with	O
epidural	B-UNK
steroid	B-CHEMICAL
injections	B-UNK
are	O
rare	B-UNK
.	O
Clinical	B-UNK
examination	B-UNK
and	O
continued	O
vigilance	O
for	O
neurologic	B-UNK
deterioration	B-UNK
after	O
epidural	B-UNK
steroid	B-UNK
injections	B-UNK
is	O
important	B-UNK
.	O

High	B-UNK
-	O
dose	B-UNK
testosterone	B-UNK
is	O
associated	O
with	O
atherosclerosis	B-UNK
in	O
postmenopausal	B-UNK
women	I-UNK
.	O
OBJECTIVES	B-UNK
:	O
To	O
study	B-UNK
the	O
long	B-UNK
-	O
term	O
effects	O
of	O
androgen	B-UNK
treatment	B-UNK
on	O
atherosclerosis	B-DISEASE
in	O
postmenopausal	B-UNK
women	I-UNK
.	O
METHODS	B-UNK
:	O
In	O
a	O
population	B-UNK
-	O
based	B-UNK
study	B-UNK
in	O
513	O
naturally	O
postmenopausal	B-UNK
women	I-UNK
aged	B-UNK
54	O
-	O
67	O
years	B-UNK
,	O
we	O
studied	O
the	O
association	B-UNK
between	O
self	O
-	O
reported	B-UNK
intramuscularly	O
administered	O
high	B-UNK
-	O
dose	B-UNK
estrogen	B-CHEMICAL
-	O
testosterone	B-CHEMICAL
therapy	O
(	O
estradiol-	O
and	O
testosterone	B-CHEMICAL
esters	O
)	O
and	O
aortic	B-UNK
atherosclerosis	B-UNK
.	O
Aortic	B-UNK
atherosclerosis	B-UNK
was	O
diagnosed	B-UNK
by	O
radiographic	O
detection	B-UNK
of	O
calcified	O
deposits	B-UNK
in	O
the	O
abdominal	B-UNK
aorta	B-UNK
,	O
which	O
have	O
been	O
shown	B-UNK
to	O
reflect	O
intima	O
atherosclerosis	B-UNK
.	O
Hormone	B-UNK
therapy	O
users	B-UNK
were	O
compared	O
with	O
never	O
users	B-UNK
.	O
RESULTS	B-UNK
:	O
Intramuscular	B-UNK
hormone	B-UNK
therapy	O
use	O
for	O
1	O
year	O
or	O
longer	O
was	O
reported	B-UNK
by	O
25	O
women	B-UNK
.	O
In	O
almost	O
half	B-UNK
of	O
these	O
women	B-UNK
severe	B-UNK
atherosclerosis	B-UNK
of	O
the	O
aorta	B-UNK
was	O
present	B-UNK
(	O
n=11	O
)	O
,	O
while	O
in	O
women	B-UNK
without	O
hormone	B-UNK
use	O
severe	B-UNK
atherosclerosis	B-UNK
of	O
the	O
aorta	B-UNK
was	O
present	B-UNK
in	O
less	O
than	O
20	O
%	O
(	O
OR	O
3.1	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.1	O
-	O
8.5	O
,	O
adjusted	B-UNK
for	O
age	B-UNK
,	O
years	B-UNK
since	O
menopause	B-DISEASE
,	O
smoking	B-UNK
,	O
and	O
body	B-UNK
mass	B-UNK
index	B-UNK
)	O
.	O
The	O
association	B-UNK
remained	B-UNK
after	O
additional	B-UNK
adjustment	B-UNK
for	O
diabetes	B-DISEASE
,	O
cholesterol	B-CHEMICAL
level	B-UNK
,	O
systolic	B-UNK
blood	I-UNK
pressure	I-UNK
,	O
or	O
alcohol	B-UNK
use	O
.	O
No	O
association	B-UNK
was	O
found	O
for	O
hormone	B-UNK
use	O
less	O
than	O
1	O
year	O
.	O
CONCLUSION	B-UNK
:	O
Our	O
results	B-UNK
suggest	B-UNK
that	O
high	B-UNK
-	O
dose	B-UNK
testosterone	B-UNK
therapy	O
may	O
adversely	O
affect	B-UNK
atherosclerosis	B-DISEASE
in	O
postmenopausal	B-UNK
women	I-UNK
and	O
indicate	O
that	O
androgen	B-UNK
replacement	B-UNK
in	O
these	O
women	B-UNK
may	O
not	O
be	O
harmless	O
.	O

Sirolimus	B-UNK
-	O
associated	O
proteinuria	B-UNK
and	O
renal	B-UNK
dysfunction	I-UNK
.	O
Sirolimus	B-CHEMICAL
is	O
a	O
novel	O
immunosuppressant	O
with	O
potent	B-UNK
antiproliferative	O
actions	B-UNK
through	O
its	O
ability	B-UNK
to	O
inhibit	O
the	O
raptor	O
-	O
containing	O
mammalian	O
target	O
of	O
rapamycin	B-CHEMICAL
protein	B-UNK
kinase	B-UNK
.	O
Sirolimus	B-CHEMICAL
represents	B-UNK
a	O
major	B-UNK
therapeutic	B-UNK
advance	O
in	O
the	O
prevention	B-UNK
of	O
acute	B-UNK
renal	B-UNK
allograft	B-UNK
rejection	B-UNK
and	O
chronic	B-DISEASE
allograft	I-DISEASE
nephropathy	I-DISEASE
.	O
Its	O
role	O
in	O
the	O
therapy	O
of	O
glomerulonephritis	B-DISEASE
,	O
autoimmunity	B-DISEASE
,	O
cystic	B-DISEASE
renal	I-DISEASE
diseases	I-DISEASE
and	O
renal	B-UNK
cancer	B-UNK
is	O
under	O
investigation	B-UNK
.	O
Because	O
sirolimus	B-CHEMICAL
does	O
not	O
share	O
the	O
vasomotor	O
renal	B-UNK
adverse	B-UNK
effects	I-UNK
exhibited	O
by	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
,	O
it	O
has	O
been	O
designated	O
a	O
'	O
non-nephrotoxic	O
drug	B-UNK
'	O
.	O
However	O
,	O
clinical	B-UNK
reports	B-UNK
suggest	B-UNK
that	O
,	O
under	O
some	O
circumstances	O
,	O
sirolimus	B-UNK
is	O
associated	O
with	O
proteinuria	B-UNK
and	O
acute	B-DISEASE
renal	I-DISEASE
dysfunction	I-DISEASE
.	O
A	O
common	B-UNK
risk	B-UNK
factor	I-UNK
appears	B-UNK
to	O
be	O
presence	O
of	O
pre	B-UNK
-	O
existing	B-UNK
chronic	B-DISEASE
renal	I-DISEASE
damage	I-DISEASE
.	O
The	O
mechanisms	B-UNK
of	O
sirolimus	B-CHEMICAL
-	O
associated	O
proteinuria	B-DISEASE
are	O
multifactorial	O
and	O
may	O
be	O
due	O
to	O
an	O
increase	B-UNK
in	O
glomerular	B-UNK
capillary	B-UNK
pressure	B-UNK
following	O
calcineurin	B-UNK
inhibitor	I-UNK
withdrawal	B-UNK
.	O
It	O
has	O
also	O
been	O
suggested	B-UNK
that	O
sirolimus	B-CHEMICAL
directly	O
causes	O
increased	B-UNK
glomerular	B-UNK
permeability	B-UNK
/	O
injury	B-UNK
,	O
but	O
evidence	B-UNK
for	O
this	O
mechanism	B-UNK
is	O
currently	O
inconclusive	O
.	O
The	O
acute	B-DISEASE
renal	I-DISEASE
dysfunction	I-DISEASE
associated	O
with	O
sirolimus	B-CHEMICAL
(	O
such	O
as	O
in	O
delayed	B-DISEASE
graft	I-DISEASE
function	I-DISEASE
)	O
may	O
be	O
due	O
to	O
suppression	B-UNK
of	O
compensatory	B-UNK
renal	B-UNK
cell	B-UNK
proliferation	I-UNK
and	O
survival	B-UNK
/	O
repair	B-UNK
processes	B-UNK
.	O
Although	O
these	O
adverse	B-UNK
effects	I-UNK
occur	O
in	O
some	O
patients	B-UNK
,	O
their	O
occurrence	B-UNK
could	O
be	O
minimised	O
by	O
knowledge	O
of	O
the	O
molecular	B-UNK
effects	O
of	O
sirolimus	B-CHEMICAL
on	O
the	O
kidney	B-UNK
,	O
the	O
use	O
of	O
sirolimus	B-UNK
in	O
appropriate	O
patient	B-UNK
populations	O
,	O
close	B-UNK
monitoring	B-UNK
of	O
proteinuria	B-UNK
and	O
renal	B-UNK
function	I-UNK
,	O
use	O
of	O
angiotensin	O
-	O
converting	B-UNK
enzyme	I-UNK
inhibitors	B-UNK
or	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	B-UNK
blockers	B-UNK
if	O
proteinuria	B-UNK
occurs	O
and	O
withdrawal	B-UNK
if	O
needed	B-UNK
.	O
Further	O
long	B-UNK
-	O
term	O
analysis	B-UNK
of	O
renal	B-UNK
allograft	B-UNK
studies	B-UNK
using	O
sirolimus	B-CHEMICAL
as	O
de	B-UNK
novo	I-UNK
immunosuppression	B-UNK
along	O
with	O
clinical	B-UNK
and	O
laboratory	B-UNK
studies	B-UNK
will	O
refine	O
these	O
issues	O
in	O
the	O
future	B-UNK
.	O

Progressive	B-UNK
myopathy	B-DISEASE
with	O
up	O
-	O
regulation	B-UNK
of	O
MHC	O
-	O
I	O
associated	O
with	O
statin	B-CHEMICAL
therapy	O
.	O
Statins	B-CHEMICAL
can	O
cause	O
a	O
necrotizing	B-UNK
myopathy	B-DISEASE
and	O
hyperCKaemia	O
which	O
is	O
reversible	B-UNK
on	O
cessation	B-UNK
of	O
the	O
drug	B-UNK
.	O
What	O
is	O
less	O
well	O
known	O
is	O
a	O
phenomenon	B-UNK
whereby	O
statins	B-UNK
may	O
induce	B-UNK
a	O
myopathy	B-UNK
,	O
which	O
persists	O
or	O
may	O
progress	O
after	O
stopping	B-UNK
the	O
drug	B-UNK
.	O
We	O
investigated	B-UNK
the	O
muscle	B-UNK
pathology	B-UNK
in	O
8	O
such	O
cases	B-UNK
.	O
All	O
had	O
myofibre	O
necrosis	B-DISEASE
but	O
only	O
3	O
had	O
an	O
inflammatory	B-UNK
infiltrate	O
.	O
In	O
all	O
cases	B-UNK
there	O
was	O
diffuse	B-UNK
or	O
multifocal	O
up	O
-	O
regulation	B-UNK
of	O
MHC	O
-	O
I	O
expression	B-UNK
even	O
in	O
non-necrotic	O
fibres	O
.	O
Progressive	B-UNK
improvement	B-UNK
occurred	B-UNK
in	O
7	O
cases	B-UNK
after	O
commencement	O
of	O
prednisolone	B-UNK
and	O
methotrexate	B-UNK
,	O
and	O
in	O
one	O
case	B-UNK
spontaneously	B-UNK
.	O
These	O
observations	B-UNK
suggest	B-UNK
that	O
statins	B-UNK
may	O
initiate	O
an	O
immune	B-UNK
-	O
mediated	B-UNK
myopathy	B-DISEASE
that	O
persists	O
after	O
withdrawal	B-UNK
of	O
the	O
drug	B-UNK
and	O
responds	O
to	O
immunosuppressive	B-UNK
therapy	O
.	O
The	O
mechanism	B-UNK
of	O
this	O
myopathy	B-UNK
is	O
uncertain	O
but	O
may	O
involve	B-UNK
the	O
induction	B-UNK
by	O
statins	B-CHEMICAL
of	O
an	O
endoplasmic	O
reticulum	O
stress	B-DISEASE
response	B-UNK
with	O
associated	O
up	O
-	O
regulation	B-UNK
of	O
MHC	O
-	O
I	O
expression	B-UNK
and	O
antigen	B-UNK
presentation	B-UNK
by	O
muscle	B-UNK
fibres	O
.	O

Direct	B-UNK
inhibition	B-UNK
of	O
cardiac	B-UNK
hyperpolarization	O
-	O
activated	B-UNK
cyclic	B-UNK
nucleotide	O
-	O
gated	O
pacemaker	B-UNK
channels	B-UNK
by	O
clonidine	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Inhibition	B-UNK
of	O
cardiac	B-UNK
sympathetic	B-UNK
tone	B-UNK
represents	B-UNK
an	O
important	B-UNK
strategy	B-UNK
for	O
treatment	B-UNK
of	O
cardiovascular	B-UNK
disease	I-UNK
,	O
including	O
arrhythmia	B-UNK
,	O
coronary	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
,	O
and	O
chronic	B-UNK
heart	B-UNK
failure	I-UNK
.	O
Activation	B-UNK
of	O
presynaptic	O
alpha2-adrenoceptors	O
is	O
the	O
most	O
widely	B-UNK
accepted	O
mechanism	B-UNK
of	O
action	B-UNK
of	O
the	O
antisympathetic	O
drug	B-UNK
clonidine	B-CHEMICAL
;	O
however	O
,	O
other	O
target	O
proteins	B-UNK
have	O
been	O
postulated	O
to	O
contribute	B-UNK
to	O
the	O
in	O
vivo	B-UNK
actions	B-UNK
of	O
clonidine	B-UNK
.	O
METHODS	B-UNK
AND	O
RESULTS	B-UNK
:	O
To	O
test	B-UNK
whether	O
clonidine	B-CHEMICAL
elicits	O
pharmacological	B-UNK
effects	O
independent	B-UNK
of	O
alpha2-adrenoceptors	O
,	O
we	O
have	O
generated	B-UNK
mice	B-UNK
with	O
a	O
targeted	B-UNK
deletion	O
of	O
all	O
3	O
alpha2-adrenoceptor	O
subtypes	O
(	O
alpha2ABC-/-	O
)	O
.	O
Alpha2ABC-/-	O
mice	B-UNK
were	O
completely	O
unresponsive	O
to	O
the	O
analgesic	B-UNK
and	O
hypnotic	O
effects	O
of	O
clonidine	B-CHEMICAL
;	O
however	O
,	O
clonidine	B-UNK
significantly	B-UNK
lowered	B-UNK
heart	B-UNK
rate	I-UNK
in	O
alpha2ABC-/-	O
mice	B-UNK
by	O
up	O
to	O
150	O
bpm	O
.	O
Clonidine	B-UNK
-	O
induced	O
bradycardia	B-UNK
in	O
conscious	B-UNK
alpha2ABC-/-	O
mice	B-UNK
was	O
32.3	O
%	O
(	O
10	O
microg	B-UNK
/	O
kg	B-UNK
)	O
and	O
26.6	O
%	O
(	O
100	O
microg	B-UNK
/	O
kg	B-UNK
)	O
of	O
the	O
effect	B-UNK
in	O
wild	O
-	O
type	B-UNK
mice	B-UNK
.	O
A	O
similar	B-UNK
bradycardic	B-DISEASE
effect	B-UNK
of	O
clonidine	B-UNK
was	O
observed	O
in	O
isolated	B-UNK
spontaneously	B-UNK
beating	B-UNK
right	O
atria	O
from	O
alpha2ABC	O
-	O
knockout	B-UNK
and	O
wild	O
-	O
type	B-UNK
mice	B-UNK
.	O
Clonidine	B-CHEMICAL
inhibited	B-UNK
the	O
native	O
pacemaker	B-UNK
current	B-UNK
(	O
I(f	O
)	O
)	O
in	O
isolated	B-UNK
sinoatrial	B-UNK
node	B-UNK
pacemaker	B-UNK
cells	B-UNK
and	O
the	O
I(f)-generating	O
hyperpolarization	O
-	O
activated	B-UNK
cyclic	B-UNK
nucleotide	O
-	O
gated	O
(	O
HCN	O
)	O
2	O
and	O
HCN4	O
channels	B-UNK
in	O
transfected	O
HEK293	O
cells	B-UNK
.	O
As	O
a	O
consequence	B-UNK
of	O
blocking	B-UNK
I(f	O
)	O
,	O
clonidine	B-UNK
reduced	B-UNK
the	O
slope	O
of	O
the	O
diastolic	B-UNK
depolarization	O
and	O
the	O
frequency	B-UNK
of	O
pacemaker	B-UNK
potentials	B-UNK
in	O
sinoatrial	B-UNK
node	B-UNK
cells	B-UNK
from	O
wild	O
-	O
type	B-UNK
and	O
alpha2ABC	O
-	O
knockout	B-UNK
mice	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Direct	B-UNK
inhibition	B-UNK
of	O
cardiac	B-UNK
HCN	O
pacemaker	B-UNK
channels	B-UNK
contributes	B-UNK
to	O
the	O
bradycardic	B-DISEASE
effects	O
of	O
clonidine	B-UNK
gene	B-UNK
-	O
targeted	B-UNK
mice	B-UNK
in	O
vivo	B-UNK
,	O
and	O
thus	O
,	O
clonidine	B-UNK
-	O
like	O
drugs	B-UNK
represent	O
novel	O
structures	B-UNK
for	O
future	B-UNK
HCN	O
channel	B-UNK
inhibitors	B-UNK
.	O

Influence	B-UNK
of	O
smoking	B-CHEMICAL
on	O
developing	B-UNK
cochlea	O
.	O
Does	O
smoking	B-CHEMICAL
during	O
pregnancy	B-UNK
affect	B-UNK
the	O
amplitudes	O
of	O
transient	B-UNK
evoked	B-UNK
otoacoustic	O
emissions	O
in	O
newborns	O
?	O
OBJECTIVE	B-UNK
:	O
Maternal	B-UNK
tobacco	O
smoking	B-UNK
has	O
negative	B-UNK
effects	O
on	O
fetal	B-UNK
growth	B-UNK
.	O
The	O
influence	B-UNK
of	O
smoking	B-UNK
during	O
pregnancy	B-UNK
on	O
the	O
developing	B-UNK
cochlea	O
has	O
not	O
been	O
estimated	O
,	O
although	O
smoking	B-CHEMICAL
has	O
been	O
positively	O
associated	O
with	O
hearing	B-UNK
loss	I-UNK
in	O
adults	B-UNK
.	O
The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
determine	B-UNK
the	O
effects	O
of	O
maternal	B-UNK
smoking	B-CHEMICAL
on	O
transient	B-UNK
evoked	B-UNK
otoacoustic	O
emissions	O
(	O
TEOAEs	O
)	O
of	O
healthy	B-UNK
neonates	B-UNK
.	O
METHODS	B-UNK
:	O
This	O
study	B-UNK
was	O
undertaken	B-UNK
as	O
part	O
of	O
neonatal	B-UNK
screening	B-UNK
for	O
hearing	B-UNK
impairment	B-UNK
and	O
involved	B-UNK
both	O
ears	O
of	O
200	O
newborns	O
.	O
Newborns	O
whose	O
mothers	O
reported	B-UNK
smoking	B-CHEMICAL
during	O
pregnancy	B-UNK
(	O
n=200	O
ears	O
)	O
were	O
compared	O
to	O
a	O
control	B-UNK
group	B-UNK
of	O
newborns	O
(	O
n=200	O
ears	O
)	O
,	O
whose	O
mothers	O
were	O
non-smokers	O
.	O
Exposure	B-UNK
to	O
tobacco	O
was	O
characterized	B-UNK
as	O
low	B-UNK
(	O
<	O
5	O
cigarettes	O
per	O
day	O
,	O
n=88	O
ears	O
)	O
,	O
moderate	B-UNK
(	O
5	O
<	O
or	O
=	O
cigarettes	O
per	O
day<10	O
,	O
n=76	O
)	O
or	O
high	B-UNK
(	O
>	O
or	O
=	O
10	O
cigarettes	O
per	O
day	O
,	O
n=36	O
)	O
.	O
RESULTS	B-UNK
:	O
In	O
exposed	B-UNK
neonates	B-UNK
,	O
TEOAEs	O
mean	O
response	B-UNK
(	O
across	O
frequency	B-UNK
)	O
and	O
mean	O
amplitude	B-UNK
at	O
4000Hz	O
was	O
significantly	B-UNK
lower	I-UNK
than	O
in	O
non-exposed	O
neonates	B-UNK
.	O
Comparisons	O
between	O
exposed	B-UNK
newborns	O
'	O
subgroups	B-UNK
revealed	O
no	O
significant	B-UNK
differences	B-UNK
.	O
However	O
,	O
by	O
comparing	B-UNK
each	O
subgroup	B-UNK
to	O
control	B-UNK
group	B-UNK
,	O
we	O
found	O
statistically	B-UNK
significant	I-UNK
decreases	B-DISEASE
of	I-DISEASE
TEOAEs	I-DISEASE
amplitudes	I-DISEASE
at	O
4000Hz	O
for	O
all	O
three	O
groups	B-UNK
.	O
Mean	O
TEOAEs	O
responses	O
of	O
highly	B-UNK
exposed	B-UNK
newborns	O
were	O
also	O
significantly	B-UNK
lower	I-UNK
in	O
comparison	B-UNK
to	O
our	O
control	B-UNK
group	B-UNK
.	O
CONCLUSION	B-UNK
:	O
In	O
utero	O
,	O
exposure	B-UNK
to	O
tobacco	O
smoking	B-UNK
seems	O
to	O
have	O
a	O
small	B-UNK
impact	B-UNK
on	O
outer	O
hair	O
cells	B-UNK
.	O
These	O
effects	O
seem	O
to	O
be	O
equally	B-UNK
true	O
for	O
all	O
exposed	B-UNK
newborns	O
,	O
regardless	O
of	O
the	O
degree	B-UNK
of	O
exposure	B-UNK
.	O
Further	O
studies	B-UNK
are	O
needed	B-UNK
in	O
order	B-UNK
to	O
establish	O
a	O
potential	B-UNK
negative	B-UNK
effect	B-UNK
of	O
maternal	B-UNK
smoking	B-UNK
on	O
the	O
neonate'	O
s	O
hearing	B-UNK
acuity	B-UNK
.	O

Neuroinflammation	O
and	O
behavioral	B-DISEASE
abnormalities	I-DISEASE
after	O
neonatal	B-UNK
terbutaline	B-CHEMICAL
treatment	B-UNK
in	O
rats	B-UNK
:	O
implications	B-UNK
for	O
autism	B-UNK
.	O
Autism	B-UNK
is	O
a	O
neurodevelopmental	O
disorder	B-UNK
presenting	O
before	O
3	O
years	B-UNK
of	I-UNK
age	I-UNK
with	O
deficits	B-DISEASE
in	I-DISEASE
communication	I-DISEASE
and	I-DISEASE
social	I-DISEASE
skills	I-DISEASE
and	O
repetitive	B-UNK
behaviors	B-UNK
.	O
In	O
addition	B-UNK
to	O
genetic	B-UNK
influences	O
,	O
recent	B-UNK
studies	B-UNK
suggest	B-UNK
that	O
prenatal	B-UNK
drug	B-UNK
or	O
chemical	B-UNK
exposures	O
are	O
risk	B-UNK
factors	I-UNK
for	O
autism	B-DISEASE
.	O
Terbutaline	B-UNK
,	O
a	O
beta2-adrenoceptor	O
agonist	B-UNK
used	O
to	O
arrest	B-UNK
preterm	B-UNK
labor	O
,	O
has	O
been	O
associated	O
with	O
increased	B-UNK
concordance	O
for	O
autism	B-DISEASE
in	O
dizygotic	O
twins	O
.	O
We	O
studied	O
the	O
effects	O
of	O
terbutaline	B-CHEMICAL
on	O
microglial	B-UNK
activation	B-UNK
in	O
different	O
brain	B-UNK
regions	B-UNK
and	O
behavioral	B-UNK
outcomes	B-UNK
in	O
developing	B-UNK
rats	B-UNK
.	O
Newborn	B-UNK
rats	B-UNK
were	O
given	O
terbutaline	B-CHEMICAL
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
)	O
daily	B-UNK
on	O
postnatal	O
days	B-UNK
(	O
PN	O
)	O
2	O
to	O
5	O
or	O
PN	O
11	O
to	O
14	O
and	O
examined	B-UNK
24	O
h	O
after	O
the	O
last	O
dose	B-UNK
and	O
at	O
PN	O
30	O
.	O
Immunohistochemical	B-UNK
studies	B-UNK
showed	O
that	O
administration	O
of	O
terbutaline	B-CHEMICAL
on	O
PN	O
2	O
to	O
5	O
produced	B-UNK
a	O
robust	O
increase	B-UNK
in	O
microglial	B-UNK
activation	B-UNK
on	O
PN	O
30	O
in	O
the	O
cerebral	B-UNK
cortex	B-UNK
,	O
as	O
well	O
as	O
in	O
cerebellar	B-UNK
and	O
cerebrocortical	O
white	B-UNK
matter	I-UNK
.	O
None	O
of	O
these	O
effects	O
occurred	B-UNK
in	O
animals	B-UNK
given	O
terbutaline	B-UNK
on	O
PN	O
11	O
to	O
14	O
.	O
In	O
behavioral	B-UNK
tests	B-UNK
,	O
animals	B-UNK
treated	O
with	O
terbutaline	B-UNK
on	O
PN	O
2	O
to	O
5	O
showed	O
consistent	B-UNK
patterns	B-UNK
of	O
hyper-reactivity	O
to	O
novelty	O
and	O
aversive	O
stimuli	B-UNK
when	O
assessed	B-UNK
in	O
a	O
novel	O
open	B-UNK
field	B-UNK
,	O
as	O
well	O
as	O
in	O
the	O
acoustic	O
startle	O
response	B-UNK
test	B-UNK
.	O
Our	O
findings	B-UNK
indicate	O
that	O
beta2-adrenoceptor	O
overstimulation	O
during	O
an	O
early	B-UNK
critical	B-UNK
period	B-UNK
results	B-UNK
in	O
microglial	B-UNK
activation	B-UNK
associated	O
with	O
innate	O
neuroinflammatory	O
pathways	B-UNK
and	O
behavioral	B-DISEASE
abnormalities	I-DISEASE
,	O
similar	B-UNK
to	O
those	O
described	O
in	O
autism	B-UNK
.	O
This	O
study	B-UNK
provides	O
a	O
useful	O
animal	B-UNK
model	I-UNK
for	O
understanding	O
the	O
neuropathological	O
processes	B-UNK
underlying	B-UNK
autism	B-DISEASE
spectrum	I-DISEASE
disorders	I-DISEASE
.	O

Acute	B-UNK
myocarditis	B-DISEASE
associated	O
with	O
clozapine	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
A	O
case	B-UNK
of	O
acute	B-UNK
myocarditis	B-UNK
associated	O
with	O
the	O
commencement	O
of	O
clozapine	B-UNK
is	O
described	O
,	O
highlighting	O
the	O
onset	B-UNK
,	O
course	O
and	O
possible	O
contributing	O
factors	B-UNK
.	O
There	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
about	O
this	O
potentially	O
fatal	B-UNK
complication	B-UNK
of	O
clozapine	B-UNK
use	O
.	O
RESULTS	B-UNK
:	O
A	O
20-year	O
-	O
old	O
male	B-UNK
with	O
schizophrenia	B-DISEASE
developed	O
a	O
sudden	B-UNK
onset	B-UNK
of	O
myocarditis	B-UNK
after	O
commencement	O
of	O
clozapine	B-UNK
.	O
The	O
patient	B-UNK
recovered	O
with	O
intensive	B-UNK
medical	B-UNK
support	B-UNK
.	O
The	O
symptoms	B-UNK
occurred	B-UNK
around	O
2	O
weeks	B-UNK
after	O
starting	B-UNK
clozapine	B-UNK
in	O
an	O
inpatient	B-UNK
setting	B-UNK
.	O
Possible	O
contributing	O
factors	B-UNK
may	O
have	O
been	O
concomitant	B-UNK
antidepressant	B-UNK
use	O
and	O
unaccustomed	O
physical	B-UNK
activity	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Myocarditis	B-DISEASE
is	O
an	O
increasingly	O
recognized	O
complication	B-UNK
associated	O
with	O
the	O
use	O
of	O
clozapine	B-UNK
.	O
It	O
can	O
be	O
fatal	B-UNK
if	O
not	O
recognized	O
and	O
treated	O
early	B-UNK
.	O
Considering	O
that	O
clozapine	B-UNK
remains	O
the	O
gold	O
standard	B-UNK
in	O
treatment	B-UNK
of	O
resistant	B-UNK
psychosis	B-UNK
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
raise	O
awareness	O
among	O
medical	B-UNK
and	O
paramedical	O
staff	O
involved	B-UNK
in	O
the	O
care	B-UNK
of	O
these	O
patients	B-UNK
.	O
There	O
are	O
also	O
implications	B-UNK
for	O
recommendations	O
and	O
regulations	O
regarding	O
the	O
use	O
of	O
clozapine	B-UNK
.	O

Encephalopathy	B-UNK
induced	O
by	O
levetiracetam	B-UNK
added	B-UNK
to	O
valproate	B-UNK
.	O
BACKGROUND	B-UNK
:	O
We	O
report	B-UNK
on	O
the	O
manifestation	B-UNK
of	O
a	O
levetiracetam	B-UNK
(	O
LEV)-induced	O
encephalopathy	B-DISEASE
.	O
FINDINGS	B-UNK
:	O
A	O
28-year	O
-	O
old	O
man	B-UNK
suffering	O
from	O
idiopathic	B-DISEASE
epilepsy	I-DISEASE
with	O
generalized	O
seizures	B-UNK
was	O
treated	O
with	O
LEV	O
(	O
3000	O
mg	B-UNK
)	O
added	B-UNK
to	O
valproate	B-UNK
(	O
VPA	B-UNK
)	O
(	O
2000	O
mg	B-UNK
)	O
.	O
Frequency	B-UNK
of	O
generalized	O
tonic	B-DISEASE
-	I-DISEASE
clonic	I-DISEASE
seizures	I-DISEASE
increased	B-UNK
from	O
one	O
per	O
6	O
months	B-UNK
to	O
two	O
per	O
month	B-UNK
.	O
Neuropsychological	O
testing	B-UNK
showed	O
impaired	B-UNK
word	B-UNK
fluency	O
,	O
psychomotor	O
speed	B-UNK
and	O
working	B-UNK
memory	B-UNK
.	O
The	O
interictal	O
electroencephalogram	O
(	O
EEG	B-UNK
)	O
showed	O
a	O
generalized	O
slowing	O
to	O
5	O
per	O
second	O
theta	O
rhythms	O
with	O
bilateral	B-UNK
generalized	O
high	B-UNK
-	O
amplitude	B-UNK
discharges	O
.	O
OUTCOME	B-UNK
:	O
Following	O
discontinuation	B-UNK
of	O
LEV	O
,	O
EEG	B-UNK
and	O
neuropsychological	O
findings	B-UNK
improved	O
and	O
seizure	B-UNK
frequency	B-UNK
decreased	B-UNK
.	O

Norepinephrine	B-UNK
signaling	B-UNK
through	O
beta-adrenergic	O
receptors	B-UNK
is	O
critical	B-UNK
for	O
expression	B-UNK
of	O
cocaine	B-CHEMICAL
-	O
induced	O
anxiety	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Cocaine	B-CHEMICAL
is	O
a	O
widely	B-UNK
abused	O
psychostimulant	O
that	O
has	O
both	O
rewarding	O
and	O
aversive	O
properties	B-UNK
.	O
While	O
the	O
mechanisms	B-UNK
underlying	B-UNK
cocaine'	O
s	O
rewarding	O
effects	O
have	O
been	O
studied	O
extensively	O
,	O
less	O
attention	B-UNK
has	O
been	O
paid	O
to	O
the	O
unpleasant	O
behavioral	B-UNK
states	B-UNK
induced	O
by	O
cocaine	B-CHEMICAL
,	O
such	O
as	O
anxiety	B-UNK
.	O
METHODS	B-UNK
:	O
In	O
this	O
study	B-UNK
,	O
we	O
evaluated	B-UNK
the	O
performance	B-UNK
of	O
dopamine	B-CHEMICAL
beta-hydroxylase	O
knockout	B-UNK
(	O
Dbh	O
-/-	O
)	O
mice	B-UNK
,	O
which	O
lack	B-UNK
norepinephrine	B-UNK
(	O
NE	O
)	O
,	O
in	O
the	O
elevated	B-UNK
plus	I-UNK
maze	I-UNK
(	O
EPM	O
)	O
to	O
examine	B-UNK
the	O
contribution	B-UNK
of	O
noradrenergic	B-UNK
signaling	B-UNK
to	O
cocaine	B-CHEMICAL
-	O
induced	O
anxiety	B-UNK
.	O
RESULTS	B-UNK
:	O
We	O
found	O
that	O
cocaine	B-CHEMICAL
dose	B-UNK
-	O
dependently	B-UNK
increased	B-UNK
anxiety	B-DISEASE
-	O
like	O
behavior	B-UNK
in	O
control	B-UNK
(	O
Dbh	O
+	O
/-	O
)	O
mice	B-UNK
,	O
as	O
measured	B-UNK
by	O
a	O
decrease	B-UNK
in	O
open	B-UNK
arm	O
exploration	O
.	O
The	O
Dbh	O
-/-	O
mice	B-UNK
had	O
normal	O
baseline	B-UNK
performance	B-UNK
in	O
the	O
EPM	O
but	O
were	O
completely	O
resistant	B-UNK
to	O
the	O
anxiogenic	B-UNK
effects	O
of	O
cocaine	B-CHEMICAL
.	O
Cocaine	B-CHEMICAL
-	O
induced	O
anxiety	B-UNK
was	O
also	O
attenuated	B-UNK
in	O
Dbh	O
+	O
/-	O
mice	B-UNK
following	O
administration	O
of	O
disulfiram	B-CHEMICAL
,	O
a	O
dopamine	B-UNK
beta-hydroxylase	O
(	O
DBH	O
)	O
inhibitor	B-UNK
.	O
In	O
experiments	B-UNK
using	O
specific	B-UNK
adrenergic	B-CHEMICAL
antagonists	I-CHEMICAL
,	O
we	O
found	O
that	O
pretreatment	B-UNK
with	O
the	O
beta-adrenergic	O
receptor	B-UNK
antagonist	I-UNK
propranolol	B-UNK
blocked	B-UNK
cocaine	B-UNK
-	O
induced	O
anxiety	B-UNK
-	O
like	O
behavior	B-UNK
in	O
Dbh	O
+	O
/-	O
and	O
wild	O
-	O
type	B-UNK
C57BL6	O
/	O
J	O
mice	B-UNK
,	O
while	O
the	O
alpha(1	O
)	O
antagonist	B-UNK
prazosin	B-CHEMICAL
and	O
the	O
alpha(2	O
)	O
antagonist	B-UNK
yohimbine	B-UNK
had	O
no	O
effect	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
These	O
results	B-UNK
indicate	O
that	O
noradrenergic	B-UNK
signaling	B-UNK
via	O
beta-adrenergic	O
receptors	B-UNK
is	O
required	B-UNK
for	O
cocaine	B-UNK
-	O
induced	O
anxiety	B-DISEASE
in	O
mice	B-UNK
.	O

Clonidine	B-UNK
for	O
attention	B-DISEASE
-	I-DISEASE
deficit	I-DISEASE
/	I-DISEASE
hyperactivity	I-DISEASE
disorder	I-DISEASE
:	O
II	B-UNK
.	O
ECG	B-UNK
changes	O
and	O
adverse	B-UNK
events	I-UNK
analysis	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
To	O
examine	B-UNK
the	O
safety	B-UNK
and	O
tolerability	B-UNK
of	O
clonidine	B-UNK
used	O
alone	O
or	O
with	O
methylphenidate	B-UNK
in	O
children	B-UNK
with	O
attention	B-DISEASE
-	I-DISEASE
deficit	I-DISEASE
/	I-DISEASE
hyperactivity	I-DISEASE
disorder	I-DISEASE
(	O
ADHD	B-DISEASE
)	O
.	O
METHOD	B-UNK
:	O
In	O
a	O
16-week	O
multicenter	B-UNK
,	O
double-blind	O
trial	B-UNK
,	O
122	O
children	B-UNK
with	O
ADHD	B-DISEASE
were	O
randomly	B-UNK
assigned	I-UNK
to	I-UNK
clonidine	B-CHEMICAL
(	O
n	O
=	O
31	O
)	O
,	O
methylphenidate	B-CHEMICAL
(	O
n	O
=	O
29	O
)	O
,	O
clonidine	B-CHEMICAL
and	O
methylphenidate	B-UNK
(	O
n	O
=	O
32	O
)	O
,	O
or	O
placebo	B-UNK
(	O
n	O
=	O
30	O
)	O
.	O
Doses	B-UNK
were	O
flexibly	O
titrated	O
up	O
to	O
0.6	O
mg	B-UNK
/	O
day	O
for	O
clonidine	B-UNK
and	O
60	O
mg	B-UNK
/	O
day	O
for	O
methylphenidate	B-CHEMICAL
(	O
both	O
with	O
divided	B-UNK
dosing	O
)	O
.	O
Groups	B-UNK
were	O
compared	O
regarding	O
adverse	B-UNK
events	I-UNK
and	O
changes	O
from	O
baseline	B-UNK
to	O
week	B-UNK
16	O
in	O
electrocardiograms	O
and	O
vital	O
signs	B-UNK
.	O
RESULTS	B-UNK
:	O
There	O
were	O
more	O
incidents	O
of	O
bradycardia	B-DISEASE
in	O
subjects	B-UNK
treated	O
with	O
clonidine	B-UNK
compared	O
with	O
those	O
not	O
treated	O
with	O
clonidine	B-UNK
(	O
17.5	O
%	O
versus	O
3.4	O
%	O
;	O
p	O
=	O
.02	O
)	O
,	O
but	O
no	O
other	O
significant	B-UNK
group	B-UNK
differences	B-UNK
regarding	O
electrocardiogram	O
and	O
other	O
cardiovascular	B-UNK
outcomes	B-UNK
.	O
There	O
were	O
no	O
suggestions	O
of	O
interactions	B-UNK
between	O
clonidine	B-UNK
and	O
methylphenidate	B-CHEMICAL
regarding	O
cardiovascular	B-UNK
outcomes	B-UNK
.	O
Moderate	B-UNK
or	O
severe	B-UNK
adverse	B-UNK
events	I-UNK
were	O
more	O
common	B-UNK
in	O
subjects	B-UNK
on	O
clonidine	B-UNK
(	O
79.4	O
%	O
versus	O
49.2	O
%	O
;	O
p	O
=	O
.0006	O
)	O
but	O
not	O
associated	O
with	O
higher	B-UNK
rates	B-UNK
of	O
early	B-UNK
study	B-UNK
withdrawal	B-UNK
.	O
Drowsiness	B-UNK
was	O
common	B-UNK
on	O
clonidine	B-UNK
,	O
but	O
generally	B-UNK
resolved	O
by	O
6	O
to	O
8	O
weeks	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Clonidine	B-CHEMICAL
,	O
used	O
alone	O
or	O
with	O
methylphenidate	B-UNK
,	O
appears	B-UNK
safe	O
and	O
well	O
tolerated	B-UNK
in	O
childhood	O
ADHD	B-DISEASE
.	O
Physicians	B-UNK
prescribing	B-UNK
clonidine	B-UNK
should	O
monitor	B-UNK
for	O
bradycardia	B-UNK
and	O
advise	O
patients	B-UNK
about	O
the	O
high	B-UNK
likelihood	O
of	O
initial	B-UNK
drowsiness	B-UNK
.	O

Thalidomide	B-UNK
has	O
limited	B-UNK
single	B-UNK
-	O
agent	B-UNK
activity	B-UNK
in	O
relapsed	B-UNK
or	O
refractory	B-UNK
indolent	O
non-Hodgkin	O
lymphomas	O
:	O
a	O
phase	B-UNK
II	I-UNK
trial	B-UNK
of	O
the	O
Cancer	B-UNK
and	O
Leukemia	B-DISEASE
Group	B-UNK
B.	O
Thalidomide	B-UNK
is	O
an	O
immunomodulatory	O
agent	B-UNK
with	O
demonstrated	O
activity	B-UNK
in	O
multiple	B-DISEASE
myeloma	I-DISEASE
,	O
mantle	O
cell	B-UNK
lymphoma	B-UNK
and	O
lymphoplasmacytic	O
lymphoma	B-DISEASE
.	O
Its	O
activity	B-UNK
is	O
believed	O
to	O
be	O
due	O
modulation	B-UNK
of	O
the	O
tumour	O
milieu	O
,	O
including	O
downregulation	O
of	O
angiogenesis	B-UNK
and	O
inflammatory	B-UNK
cytokines	O
.	O
Between	O
July	O
2001	O
and	O
April	O
2004	O
,	O
24	O
patients	B-UNK
with	O
relapsed	B-UNK
/	O
refractory	B-UNK
indolent	O
lymphomas	O
received	O
thalidomide	B-UNK
200	O
mg	B-UNK
daily	B-UNK
with	O
escalation	O
by	O
100	O
mg	B-UNK
daily	B-UNK
every	O
1	O
-	O
2	O
weeks	B-UNK
as	O
tolerated	B-UNK
,	O
up	O
to	O
a	O
maximum	B-UNK
of	O
800	O
mg	B-UNK
daily	B-UNK
.	O
Patients	B-UNK
had	O
received	O
a	O
median	B-UNK
of	O
2	O
(	O
range	B-UNK
,	O
1	O
-	O
4	O
)	O
prior	B-UNK
regimens	B-UNK
.	O
Of	O
24	O
evaluable	B-UNK
patients	B-UNK
,	O
two	O
achieved	O
a	O
complete	B-UNK
remission	I-UNK
and	O
one	O
achieved	O
a	O
partial	B-UNK
remission	B-UNK
for	O
an	O
overall	O
response	B-UNK
rate	B-UNK
of	O
12.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	B-UNK
:	O
2.6	O
-	O
32.4	O
%	O
)	O
.	O
Eleven	O
patients	B-UNK
progressed	O
during	O
therapy	O
.	O
Grade	B-UNK
3	O
-	O
4	O
adverse	B-UNK
effects	I-UNK
included	B-UNK
myelosuppression	B-UNK
,	O
fatigue	B-DISEASE
,	O
somnolence	B-DISEASE
/	O
depressed	B-DISEASE
mood	I-DISEASE
,	O
neuropathy	B-DISEASE
and	O
dyspnea	B-DISEASE
.	O
Of	O
concern	B-UNK
was	O
the	O
occurrence	B-UNK
of	O
four	O
thromboembolic	B-UNK
events	B-UNK
.	O
Our	O
results	B-UNK
failed	B-UNK
to	O
demonstrate	O
an	O
important	B-UNK
response	B-UNK
rate	B-UNK
to	O
single	B-UNK
agent	I-UNK
thalidomide	B-UNK
in	O
indolent	O
lymphomas	O
and	O
contrast	B-UNK
with	O
the	O
higher	B-UNK
activity	B-UNK
level	B-UNK
reported	B-UNK
with	O
the	O
second	B-UNK
generation	I-UNK
immunomodulatory	O
agent	B-UNK
,	O
lenalidomide	O
.	O

Intracavernous	O
epinephrine	B-CHEMICAL
:	O
a	O
minimally	O
invasive	B-UNK
treatment	B-UNK
for	O
priapism	B-DISEASE
in	O
the	O
emergency	B-UNK
department	I-UNK
.	O
Priapism	B-DISEASE
is	O
the	O
prolonged	B-UNK
erection	O
of	O
the	O
penis	O
in	O
the	O
absence	O
of	O
sexual	B-UNK
arousal	O
.	O
A	O
45-year	O
-	O
old	O
man	B-UNK
,	O
an	O
admitted	B-UNK
frequent	B-UNK
cocaine	B-CHEMICAL
user	O
,	O
presented	B-UNK
to	O
the	O
Emergency	B-DISEASE
Department	I-DISEASE
(	O
ED	B-UNK
)	O
on	O
two	O
separate	B-UNK
occasions	B-UNK
with	O
a	O
history	B-UNK
of	O
priapism	B-DISEASE
after	O
cocaine	B-UNK
use	O
.	O
The	O
management	B-UNK
options	O
in	O
the	O
ED	B-UNK
,	O
as	O
exemplified	O
by	O
four	O
individual	B-UNK
case	B-UNK
reports	I-UNK
,	O
in	O
particular	O
the	O
use	O
of	O
a	O
minimally	O
invasive	B-UNK
method	B-UNK
of	O
intracorporal	O
epinephrine	B-CHEMICAL
instillation	B-UNK
,	O
are	O
discussed	O
.	O

Effect	B-UNK
of	O
green	B-CHEMICAL
tea	I-CHEMICAL
and	O
vitamin	B-UNK
E	I-UNK
combination	B-UNK
in	O
isoproterenol	B-UNK
induced	B-UNK
myocardial	I-UNK
infarction	I-UNK
in	I-UNK
rats	I-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
aimed	B-UNK
to	O
investigate	B-UNK
the	O
combined	B-UNK
effects	O
of	O
green	B-CHEMICAL
tea	I-CHEMICAL
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
on	O
heart	B-UNK
weight	B-UNK
,	O
body	B-UNK
weight	I-UNK
,	O
serum	B-UNK
marker	B-UNK
enzymes	B-UNK
,	O
lipid	B-UNK
peroxidation	I-UNK
,	O
endogenous	B-UNK
antioxidants	B-UNK
and	O
membrane	B-UNK
bound	O
ATPases	O
in	O
isoproterenol	B-UNK
(	O
ISO)-induced	O
myocardial	B-UNK
infarction	I-UNK
in	O
rats	B-UNK
.	O
Adult	B-UNK
male	I-UNK
albino	B-UNK
rats	B-UNK
,	O
treated	O
with	O
ISO	B-UNK
(	O
200	O
mg	B-UNK
/	O
kg	B-UNK
,	O
s.c	B-UNK
.	O
)	O
for	O
2	O
days	B-UNK
at	O
an	O
interval	B-UNK
of	O
24	O
h	O
caused	B-UNK
a	O
significant	B-UNK
(	O
P<0.05	O
)	O
elevation	B-UNK
of	O
heart	B-UNK
weight	B-UNK
,	O
serum	B-UNK
marker	B-UNK
enzymes	B-UNK
,	O
lipid	B-UNK
peroxidation	I-UNK
and	O
Ca+2	O
ATPase	B-UNK
level	B-UNK
whereas	O
there	O
was	O
a	O
significant	B-UNK
(	O
P<0.05	O
)	O
decrease	B-UNK
in	O
body	B-UNK
weight	I-UNK
,	O
endogenous	B-UNK
antioxidants	B-UNK
,	O
Na+/	O
K+	O
ATPase	B-UNK
and	O
Mg+2	O
ATPase	B-UNK
levels	O
.	O
Administration	O
of	O
green	B-CHEMICAL
tea	I-CHEMICAL
(	O
100	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
,	O
p.o	B-UNK
.	O
)	O
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
(	O
100	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
,	O
p.o	B-UNK
.	O
)	O
together	O
for	O
30	O
consecutive	B-UNK
days	I-UNK
and	O
challenged	O
with	O
ISO	B-UNK
on	O
the	O
day	O
29th	O
and	O
30th	O
,	O
showed	O
a	O
significant	B-UNK
(	O
P<0.05	O
)	O
decrease	B-UNK
in	O
heart	B-UNK
weight	B-UNK
,	O
serum	B-UNK
marker	B-UNK
enzymes	B-UNK
,	O
lipid	B-UNK
peroxidation	I-UNK
,	O
Ca+2	O
ATPase	B-UNK
and	O
a	O
significant	B-UNK
increase	B-UNK
in	O
the	O
body	B-UNK
weight	I-UNK
,	O
endogenous	B-UNK
antioxidants	B-CHEMICAL
,	O
Na+/K+	O
ATPase	B-UNK
and	O
Mg+2	O
ATPase	B-UNK
when	O
compared	O
with	O
ISO	B-UNK
treated	O
group	B-UNK
and	O
green	B-CHEMICAL
tea	I-CHEMICAL
or	O
vitamin	B-UNK
E	I-UNK
alone	O
treated	O
groups	B-UNK
.	O
These	O
findings	B-UNK
indicate	O
the	O
synergistic	O
protective	B-UNK
effect	I-UNK
of	O
green	B-CHEMICAL
tea	I-CHEMICAL
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
during	O
ISO	B-UNK
induced	B-UNK
myocardial	I-UNK
infarction	I-UNK
in	I-UNK
rats	I-UNK
.	O

Development	B-UNK
of	O
ocular	B-UNK
myasthenia	O
during	O
pegylated	B-UNK
interferon	B-UNK
and	O
ribavirin	B-UNK
treatment	B-UNK
for	O
chronic	B-DISEASE
hepatitis	I-DISEASE
C.	O
A	O
63-year	O
-	O
old	O
male	B-UNK
experienced	B-UNK
sudden	B-UNK
diplopia	B-DISEASE
after	O
9	O
weeks	B-UNK
of	O
administration	O
of	O
pegylated	B-UNK
interferon	B-UNK
(	O
IFN	O
)	O
alpha-2b	O
and	O
ribavirin	B-UNK
for	O
chronic	B-DISEASE
hepatitis	I-DISEASE
C	I-DISEASE
(	O
CHC	O
)	O
.	O
Ophthalmologic	O
examinations	B-UNK
showed	O
ptosis	O
on	O
the	O
right	O
upper	B-UNK
lid	B-UNK
and	O
restricted	B-UNK
right	O
eye	B-UNK
movement	B-UNK
without	O
any	O
other	O
neurological	B-UNK
signs	B-UNK
.	O
A	O
brain	B-UNK
imaging	B-UNK
study	B-UNK
and	O
repetitive	B-UNK
nerve	B-UNK
stimulation	B-UNK
test	B-UNK
indicated	O
no	O
abnormality	B-UNK
.	O
The	O
acetylcholine	B-UNK
receptor	B-UNK
antibody	B-UNK
titer	O
and	O
response	B-UNK
to	O
acetylcholinesterase	O
inhibitors	B-UNK
were	O
negative	B-UNK
,	O
and	O
the	O
results	B-UNK
of	O
thyroid	B-UNK
function	B-UNK
tests	B-UNK
were	O
normal	O
.	O
The	O
patient'	B-UNK
s	I-UNK
ophthalmological	O
symptoms	B-UNK
improved	O
rapidly	O
3	O
weeks	B-UNK
after	O
discontinuation	B-UNK
of	O
pegylated	B-UNK
IFN	O
alpha-2b	O
and	O
ribavirin	B-CHEMICAL
.	O
The	O
ocular	B-UNK
myasthenia	O
associated	O
with	O
combination	B-UNK
therapy	I-UNK
of	O
pegylated	B-UNK
IFN	O
alpha-2b	O
and	O
ribavirin	B-CHEMICAL
for	O
CHC	O
is	O
very	O
rarely	O
reported	B-UNK
;	O
therefore	O
,	O
we	O
present	B-UNK
this	O
case	B-UNK
with	O
a	O
review	B-UNK
of	O
the	O
various	O
eye	B-UNK
complications	B-UNK
of	O
IFN	O
therapy	O
.	O

The	O
glycine	B-CHEMICAL
transporter-1	O
inhibitor	B-UNK
SSR103800	O
displays	O
a	O
selective	B-UNK
and	O
specific	B-UNK
antipsychotic	B-UNK
-	O
like	O
profile	B-UNK
in	O
normal	O
and	O
transgenic	B-UNK
mice	B-UNK
.	O
Schizophrenia	B-UNK
has	O
been	O
initially	B-UNK
associated	O
with	O
dysfunction	B-UNK
in	O
dopamine	B-UNK
neurotransmission	B-UNK
.	O
However	O
,	O
the	O
observation	B-UNK
that	O
antagonists	B-UNK
of	O
the	O
glutamate	B-CHEMICAL
N	O
-	O
methyl	B-UNK
-	O
D	O
-	O
aspartate	B-UNK
(	O
NMDA	B-UNK
)	O
receptor	B-UNK
produce	B-UNK
schizophrenic	B-DISEASE
-	O
like	O
symptoms	B-UNK
in	O
humans	B-UNK
has	O
led	B-UNK
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	B-UNK
system	O
via	O
its	O
NMDA	B-UNK
receptor	I-UNK
.	O
As	O
a	O
result	B-UNK
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	B-UNK
of	O
pharmacological	B-UNK
agents	B-UNK
with	O
potential	B-UNK
antipsychotic	B-UNK
properties	B-UNK
that	O
enhance	B-UNK
the	O
activity	B-UNK
of	O
the	O
glutamatergic	B-UNK
system	O
via	O
a	O
modulation	B-UNK
of	O
the	O
NMDA	B-UNK
receptor	I-UNK
.	O
Among	O
them	O
are	O
glycine	B-CHEMICAL
transporter-1	O
(	O
GlyT1	O
)	O
inhibitors	B-UNK
such	O
as	O
SSR103800	O
,	O
which	O
indirectly	O
enhance	B-UNK
NMDA	B-UNK
receptor	I-UNK
function	B-UNK
by	O
increasing	B-UNK
the	O
glycine	B-CHEMICAL
(	O
a	O
co-agonist	O
for	O
the	O
NMDA	B-UNK
receptor	I-UNK
)	O
levels	O
in	O
the	O
synapse	O
.	O
This	O
study	B-UNK
aimed	B-UNK
at	O
investigating	O
the	O
potential	B-UNK
antipsychotic	B-UNK
-	O
like	O
properties	B-UNK
of	O
SSR103800	O
,	O
with	O
a	O
particular	O
focus	O
on	O
models	B-UNK
of	O
hyperactivity	B-UNK
,	O
involving	O
either	O
drug	B-UNK
challenge	B-UNK
(	O
ie	O
,	O
amphetamine	B-UNK
and	O
MK-801	O
)	O
or	O
transgenic	B-UNK
mice	B-UNK
(	O
ie	O
,	O
NMDA	B-UNK
Nr1(neo-/-	O
)	O
and	O
DAT(-/-	O
)	O
)	O
.	O
Results	B-UNK
showed	O
that	O
SSR103800	O
(	O
10	O
-	O
30	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
)	O
blocked	B-UNK
hyperactivity	B-UNK
induced	O
by	O
the	O
non-competitive	O
NMDA	B-UNK
receptor	I-UNK
antagonist	B-UNK
,	O
MK-801	O
and	O
partially	O
reversed	B-UNK
spontaneous	B-UNK
hyperactivity	B-UNK
of	O
NMDA	B-UNK
Nr1(neo-/-	O
)	O
mice	B-UNK
.	O
In	O
contrast	B-UNK
,	O
SSR103800	O
failed	B-UNK
to	O
affect	B-UNK
hyperactivity	B-UNK
induced	O
by	O
amphetamine	B-UNK
or	O
naturally	O
observed	O
in	O
dopamine	B-CHEMICAL
transporter	B-UNK
(	O
DAT(-/-	O
)	O
)	O
knockout	B-UNK
mice	B-UNK
(	O
10	O
-	O
30	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
)	O
.	O
Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	B-UNK
)	O
and	O
atypical	B-UNK
(	O
olanzapine	B-UNK
,	O
clozapine	B-CHEMICAL
and	O
aripiprazole	O
)	O
antipsychotics	B-CHEMICAL
were	O
effective	B-UNK
in	O
all	O
these	O
models	B-UNK
of	O
hyperactivity	B-UNK
.	O
However	O
,	O
unlike	B-UNK
these	O
latter	O
,	O
SSR103800	O
did	O
not	O
produce	B-UNK
catalepsy	B-UNK
(	O
retention	B-UNK
on	O
the	O
bar	O
test	B-UNK
)	O
up	O
to	O
30	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
Together	O
these	O
findings	B-UNK
show	O
that	O
the	O
GlyT1	O
inhibitor	B-UNK
,	O
SSR103800	O
,	O
produces	O
antipsychotic	B-UNK
-	O
like	O
effects	O
,	O
which	O
differ	B-UNK
from	O
those	O
observed	O
with	O
compounds	B-UNK
primarily	O
targeting	B-UNK
the	O
dopaminergic	B-UNK
system	O
,	O
and	O
has	O
a	O
reduced	B-UNK
side	O
-	O
effect	B-UNK
potential	B-UNK
as	O
compared	O
with	O
these	O
latter	O
drugs	B-UNK
.	O

Phenylephrine	B-UNK
but	O
not	O
ephedrine	B-UNK
reduces	O
frontal	B-UNK
lobe	B-UNK
oxygenation	O
following	O
anesthesia	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
.	O
BACKGROUND	B-UNK
:	O
Vasopressor	O
agents	B-UNK
are	O
used	O
to	O
correct	O
anesthesia	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
.	O
We	O
describe	O
the	O
effect	B-UNK
of	O
phenylephrine	B-UNK
and	O
ephedrine	B-CHEMICAL
on	O
frontal	B-UNK
lobe	B-UNK
oxygenation	O
(	O
S(c)O(2	O
)	O
)	O
following	O
anesthesia	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
.	O
METHODS	B-UNK
:	O
Following	O
induction	B-UNK
of	O
anesthesia	B-UNK
by	O
fentanyl	B-CHEMICAL
(	O
0.15	O
mg	B-UNK
kg(-1	O
)	O
)	O
and	O
propofol	B-CHEMICAL
(	O
2.0	O
mg	B-UNK
kg(-1	O
)	O
)	O
,	O
13	O
patients	B-UNK
received	O
phenylephrine	B-UNK
(	O
0.1	O
mg	B-UNK
iv	B-UNK
)	O
and	O
12	O
patients	B-UNK
received	O
ephedrine	B-UNK
(	O
10	O
mg	B-UNK
iv	B-UNK
)	O
to	O
restore	O
mean	O
arterial	B-UNK
pressure	I-UNK
(	O
MAP	B-UNK
)	O
.	O
Heart	B-UNK
rate	I-UNK
(	O
HR	B-UNK
)	O
,	O
MAP	B-UNK
,	O
stroke	B-UNK
volume	B-UNK
(	O
SV	O
)	O
,	O
cardiac	B-UNK
output	I-UNK
(	O
CO	B-CHEMICAL
)	O
,	O
and	O
frontal	B-UNK
lobe	B-UNK
oxygenation	O
(	O
S(c)O(2	O
)	O
)	O
were	O
registered	O
.	O
RESULTS	B-UNK
:	O
Induction	B-UNK
of	O
anesthesia	B-UNK
was	O
followed	O
by	O
a	O
decrease	B-UNK
in	O
MAP	B-UNK
,	O
HR	B-UNK
,	O
SV	O
,	O
and	O
CO	B-CHEMICAL
concomitant	B-UNK
with	O
an	O
elevation	B-UNK
in	O
S(c)O(2	O
)	O
.	O
After	O
administration	O
of	O
phenylephrine	B-UNK
,	O
MAP	B-UNK
increased	B-UNK
(	O
51	O
+	O
/-	O
12	O
to	O
81	O
+	O
/-	O
13	O
mmHg	B-UNK
;	O
P	O
<	O
0.001	O
;	O
mean	O
+	O
/-	O
SD	B-DISEASE
)	O
.	O
However	O
,	O
a	O
14	O
%	O
(	O
from	O
70	O
+	O
/-	O
8	O
%	O
to	O
60	O
+	O
/-	O
7	O
%	O
)	O
reduction	O
in	O
S(c)O(2	O
)	O
(	O
P	O
<	O
0.05	O
)	O
followed	O
with	O
no	O
change	B-UNK
in	O
CO	B-CHEMICAL
(	O
3.7	O
+	O
/-	O
1.1	O
to	O
3.4	O
+	O
/-	O
0.9	O
l	O
min(-1	O
)	O
)	O
.	O
The	O
administration	O
of	O
ephedrine	B-UNK
led	B-UNK
to	O
a	O
similar	B-UNK
increase	B-UNK
in	O
MAP	B-UNK
(	O
53	O
+	O
/-	O
9	O
to	O
79	O
+	O
/-	O
8	O
mmHg	B-UNK
;	O
P	O
<	O
0.001	O
)	O
,	O
restored	B-UNK
CO	B-CHEMICAL
(	O
3.2	O
+	O
/-	O
1.2	O
to	O
5.0	O
+	O
/-	O
1.3	O
l	O
min(-1	O
)	O
)	O
,	O
and	O
preserved	B-UNK
S(c)O(2	O
)	O
.	O
CONCLUSIONS	B-UNK
:	O
The	O
utilization	O
of	O
phenylephrine	B-UNK
to	O
correct	O
hypotension	B-DISEASE
induced	O
by	O
anesthesia	B-UNK
has	O
a	O
negative	B-UNK
impact	B-UNK
on	O
S(c)O(2	O
)	O
while	O
ephedrine	B-CHEMICAL
maintains	O
frontal	B-UNK
lobe	B-UNK
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	B-UNK
in	O
CO	B-CHEMICAL
.	O

A	O
novel	O
,	O
multiple	B-UNK
symptom	B-UNK
model	B-UNK
of	O
obsessive	O
-	O
compulsive	O
-	O
like	O
behaviors	B-UNK
in	O
animals	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Current	B-UNK
animal	B-UNK
models	I-UNK
of	O
obsessive	B-DISEASE
-	I-DISEASE
compulsive	I-DISEASE
disorder	I-DISEASE
(	O
OCD	B-DISEASE
)	O
typically	O
involve	B-UNK
acute	B-UNK
,	O
drug	B-UNK
-	O
induced	O
symptom	B-UNK
provocation	O
or	O
a	O
genetic	B-UNK
association	B-UNK
with	O
stereotypies	O
or	O
anxiety	B-UNK
.	O
None	O
of	O
these	O
current	B-UNK
models	B-UNK
demonstrate	O
multiple	B-UNK
OCD	B-DISEASE
-	O
like	O
behaviors	B-UNK
.	O
METHODS	B-UNK
:	O
Neonatal	B-UNK
rats	B-UNK
were	O
treated	O
with	O
the	O
tricyclic	B-UNK
antidepressant	I-UNK
clomipramine	B-CHEMICAL
or	O
vehicle	B-UNK
between	O
days	B-UNK
9	O
and	O
16	O
twice	O
daily	B-UNK
and	O
behaviorally	O
tested	B-UNK
in	O
adulthood	O
.	O
RESULTS	B-UNK
:	O
Clomipramine	B-CHEMICAL
exposure	B-UNK
in	O
immature	O
rats	B-UNK
produced	B-UNK
significant	B-UNK
behavioral	B-UNK
and	O
biochemical	B-UNK
changes	O
that	O
include	O
enhanced	B-UNK
anxiety	B-UNK
(	O
elevated	B-UNK
plus	I-UNK
maze	I-UNK
and	O
marble	B-CHEMICAL
burying	O
)	O
,	O
behavioral	B-DISEASE
inflexibility	I-DISEASE
(	O
perseveration	O
in	O
the	O
spontaneous	B-UNK
alternation	B-UNK
task	B-UNK
and	O
impaired	B-UNK
reversal	B-UNK
learning	B-UNK
)	O
,	O
working	B-UNK
memory	B-UNK
impairment	I-UNK
(	O
e.g	B-UNK
.	O
,	O
win	O
-	O
shift	O
paradigm	B-UNK
)	O
,	O
hoarding	O
,	O
and	O
corticostriatal	B-DISEASE
dysfunction	I-DISEASE
.	O
Dopamine	B-UNK
D2	I-UNK
receptors	B-UNK
were	O
elevated	B-UNK
in	O
the	O
striatum	B-UNK
,	O
whereas	O
serotonin	B-UNK
2C	O
,	O
but	O
not	O
serotonin	B-UNK
1A	O
,	O
receptors	B-UNK
were	O
elevated	B-UNK
in	O
the	O
orbital	O
frontal	B-UNK
cortex	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
multiple	B-UNK
symptoms	B-UNK
consistent	B-UNK
with	O
an	O
OCD	B-DISEASE
-	O
like	O
profile	B-UNK
in	O
animals	B-UNK
.	O
Moreover	O
,	O
these	O
behaviors	B-UNK
are	O
accompanied	B-UNK
by	O
biochemical	B-UNK
changes	O
in	O
brain	B-UNK
regions	B-UNK
previously	B-UNK
identified	B-UNK
as	O
relevant	B-UNK
to	O
OCD	B-DISEASE
.	O
This	O
novel	O
model	B-UNK
of	O
OCD	B-DISEASE
demonstrates	O
that	O
drug	B-UNK
exposure	B-UNK
during	O
a	O
sensitive	B-UNK
period	B-UNK
can	O
program	O
disease	B-UNK
-	O
like	O
systems	B-UNK
permanently	O
,	O
which	O
could	O
have	O
implications	B-UNK
for	O
current	B-UNK
and	O
future	B-UNK
therapeutic	B-UNK
strategies	B-UNK
for	O
this	O
and	O
other	O
psychiatric	B-UNK
disorders	B-UNK
.	O

Late	B-UNK
recovery	B-UNK
of	O
renal	B-UNK
function	I-UNK
in	O
a	O
woman	B-UNK
with	O
the	O
hemolytic	B-UNK
uremic	I-UNK
syndrome	I-UNK
.	O
A	O
case	B-UNK
is	O
reported	B-UNK
of	O
the	O
hemolytic	B-UNK
uremic	I-UNK
syndrome	I-UNK
(	O
HUS	O
)	O
in	O
a	O
woman	B-UNK
taking	B-UNK
oral	B-CHEMICAL
contraceptives	I-CHEMICAL
.	O
She	O
was	O
treated	O
with	O
heparin	B-UNK
,	O
dipyridamole	B-UNK
and	O
hemodialysis	B-UNK
;	O
and	O
after	O
more	O
than	O
three	O
months	B-UNK
,	O
her	O
urinary	B-UNK
output	B-UNK
rose	B-UNK
above	O
500	O
ml	B-UNK
;	O
and	O
six	O
months	B-UNK
after	O
the	O
onset	B-UNK
of	O
anuria	B-DISEASE
,	O
dialysis	B-UNK
treatment	B-UNK
was	O
stopped	O
.	O
This	O
case	B-UNK
emphasizes	O
the	O
possibility	O
that	O
HUS	O
in	O
adults	B-UNK
is	O
not	O
invariably	O
irreversible	B-UNK
and	O
that	O
,	O
despite	O
prolonged	B-UNK
oliguria	B-DISEASE
,	O
recovery	B-UNK
of	O
renal	B-UNK
function	I-UNK
can	O
be	O
obtained	B-UNK
.	O
Therefore	O
,	O
in	O
adult	B-UNK
patients	B-UNK
affected	B-UNK
by	O
HUS	O
,	O
dialysis	B-UNK
should	O
not	O
be	O
discontinued	O
prematurely	O
;	O
moreover	O
,	O
bilateral	B-UNK
nephrectomy	O
,	O
for	O
treatment	B-UNK
of	O
severe	B-UNK
hypertension	B-DISEASE
and	O
microangiopathic	O
hemolytic	B-UNK
anemia	I-UNK
,	O
should	O
be	O
performed	B-UNK
with	O
caution	B-UNK
.	O

Effects	O
of	O
acetylsalicylic	O
acid	B-UNK
,	O
dipyridamole	B-CHEMICAL
,	O
and	O
hydrocortisone	B-CHEMICAL
on	O
epinephrine	B-CHEMICAL
-	O
induced	O
myocardial	B-UNK
injury	I-UNK
in	O
dogs	B-UNK
.	O
A	O
reproducible	O
model	B-UNK
for	O
producing	O
diffuse	B-UNK
myocardial	B-UNK
injury	I-UNK
(	O
epinephrine	B-UNK
infusion	B-UNK
)	O
has	O
been	O
developed	O
to	O
study	B-UNK
the	O
cardioprotective	B-UNK
effects	O
of	O
agents	B-UNK
or	O
maneuvers	O
which	O
might	O
alter	O
the	O
evolution	O
of	O
acute	B-UNK
myocardial	I-UNK
infarction	I-UNK
.	O
Infusions	B-UNK
of	O
epinephrine	B-UNK
(	O
4	O
mug	B-UNK
per	O
kilogram	O
per	O
minute	B-UNK
for	O
6	O
hours	B-UNK
)	O
increased	B-UNK
radiocalcium	O
uptakes	O
into	O
intact	B-UNK
myocardium	B-UNK
and	O
each	O
of	O
its	O
subcellular	O
components	B-UNK
with	O
the	O
mitochondrial	B-UNK
fraction	B-UNK
showing	O
the	O
most	O
consistent	B-UNK
changes	O
when	O
compared	O
to	O
saline	B-UNK
-	O
infused	B-UNK
control	B-UNK
animals	I-UNK
(	O
4,957	O
vs	O
.	O
827	O
counts	B-UNK
per	O
minute	B-UNK
per	O
gram	O
of	O
dried	O
tissue	B-UNK
or	O
fraction	B-UNK
)	O
.	O
Myocardial	B-UNK
concentrations	B-UNK
of	O
calcium	B-CHEMICAL
also	O
increased	B-UNK
significantly	B-UNK
(	O
12.0	O
vs	O
.	O
5.0	O
mg.per	O
100	O
Gm	B-UNK
.	O
of	O
fat	O
-	O
free	B-UNK
dry	B-UNK
weight	B-UNK
)	O
.	O
Infusions	B-UNK
of	O
calcium	B-UNK
chloride	I-UNK
sufficient	B-UNK
to	O
raise	O
serum	B-UNK
calcium	I-UNK
concentrations	B-UNK
2	O
mEq	B-UNK
.	O
per	O
liter	O
failed	B-UNK
to	O
increase	B-UNK
calcium	B-UNK
influx	O
into	O
the	O
myocardial	B-UNK
cell	B-UNK
.	O
Mitochondrial	B-UNK
radiocalcium	O
uptakes	O
were	O
significantly	B-UNK
decreased	B-UNK
in	O
animals	B-UNK
pretreated	B-UNK
with	O
acetylsalicylic	O
acid	B-UNK
or	O
dipyridamole	B-CHEMICAL
or	O
when	O
hydrocortisone	B-UNK
was	O
added	B-UNK
to	O
the	O
epinephrine	B-UNK
infusion	B-UNK
(	O
2,682,2,803	O
,	O
and	O
3,424	O
counts	B-UNK
per	O
minute	B-UNK
per	O
gram	O
of	O
dried	O
fraction	B-UNK
,	O
respectively	O
)	O
.	O
Myocardial	B-UNK
calcium	B-CHEMICAL
concentrations	B-UNK
also	O
were	O
decreased	B-UNK
(	O
11.2	O
,	O
8.3	O
,	O
and	O
8.9	O
mg	B-UNK
.	O
per	O
100	O
Gm	B-UNK
.	O
of	O
fat	O
-	O
free	B-UNK
dry	B-UNK
weight	B-UNK
,	O
respectively	O
)	O
in	O
the	O
three	O
treatment	B-UNK
groups	B-UNK
,	O
being	O
significantly	B-UNK
decreased	B-UNK
only	O
in	O
the	O
last	O
two	O
.	O
Evidence	B-UNK
of	O
microscopic	B-UNK
damage	B-UNK
was	O
graded	O
as	O
less	O
severe	B-UNK
in	O
the	O
three	O
treatment	B-UNK
groups	B-UNK
.	O
Acetylsalicylic	O
acid	B-UNK
,	O
dipyridamole	B-UNK
,	O
and	O
hydrocortisone	B-CHEMICAL
all	O
appear	O
to	O
have	O
cardioprotective	B-UNK
effects	O
when	O
tested	B-UNK
in	O
this	O
model	B-UNK
.	O

Changes	O
in	O
depressive	B-UNK
status	B-UNK
associated	O
with	O
topical	B-UNK
beta-blockers	O
.	O
Depression	B-UNK
and	O
sexual	B-UNK
dysfunction	I-UNK
have	O
been	O
related	O
to	O
side	O
effects	O
of	O
topical	B-UNK
beta-blockers	O
.	O
We	O
performed	B-UNK
a	O
preliminary	B-UNK
study	B-UNK
in	O
order	B-UNK
to	O
determine	B-UNK
any	O
difference	B-UNK
between	O
a	O
non	O
selective	B-UNK
beta-blocker	O
(	O
timolol	B-UNK
)	O
and	O
a	O
selective	B-UNK
beta-blocker	O
(	O
betaxolol	B-CHEMICAL
)	O
regarding	O
CNS	B-UNK
side	O
effects	O
.	O
Eight	O
glaucomatous	O
patients	B-UNK
chronically	B-UNK
treated	O
with	O
timolol	B-CHEMICAL
0.5%/12h	O
,	O
suffering	O
from	O
depression	B-DISEASE
diagnosed	B-UNK
through	O
DMS	O
-	O
III	B-UNK
-	O
R	O
criteria	B-UNK
,	O
were	O
included	B-UNK
in	O
the	O
study	B-UNK
.	O
During	O
the	O
six	O
-	O
month	B-UNK
follow	O
up	O
,	O
depression	B-UNK
was	O
quantified	O
through	O
the	O
Beck	O
and	O
Zung	O
-	O
Conde	O
scales	O
every	O
two	O
months	B-UNK
.	O
In	O
a	O
double	B-UNK
blind	I-UNK
cross-over	O
study	B-UNK
with	O
control	B-UNK
group	B-UNK
,	O
the	O
patients	B-UNK
under	O
timolol	B-UNK
treatment	B-UNK
presented	B-UNK
higher	B-UNK
depression	B-DISEASE
values	O
measured	B-UNK
through	O
the	O
Beck	O
and	O
the	O
Zung	O
-	O
Conde	O
scales	O
(	O
p	O
<	O
0.001	O
vs	O
control	B-UNK
)	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
betaxolol	B-CHEMICAL
could	O
be	O
less	O
of	O
a	O
depression	B-UNK
-	O
inducer	O
than	O
timolol	B-UNK
in	O
predisposed	O
patients	B-UNK
.	O

Long	B-UNK
-	O
term	O
follow	O
-	O
up	O
of	O
ifosfamide	B-CHEMICAL
renal	B-DISEASE
toxicity	I-DISEASE
in	O
children	B-UNK
treated	O
for	O
malignant	B-UNK
mesenchymal	O
tumors	B-UNK
:	O
an	O
International	O
Society	O
of	O
Pediatric	B-UNK
Oncology	B-UNK
report	B-UNK
.	O
The	O
renal	B-UNK
function	I-UNK
of	O
74	O
children	B-UNK
with	O
malignant	B-UNK
mesenchymal	O
tumors	B-UNK
in	O
complete	B-UNK
remission	I-UNK
and	O
who	O
have	O
received	O
the	O
same	O
ifosfamide	B-CHEMICAL
chemotherapy	O
protocol	O
(	O
International	O
Society	O
of	O
Pediatric	B-UNK
Oncology	B-UNK
Malignant	B-DISEASE
Mesenchymal	I-DISEASE
Tumor	I-DISEASE
Study	B-UNK
84	O
[	O
SIOP	O
MMT	O
84	O
]	O
)	O
were	O
studied	O
1	O
year	O
after	O
the	O
completion	O
of	O
treatment	B-UNK
.	O
Total	B-UNK
cumulative	B-UNK
doses	B-UNK
were	O
36	O
or	O
60	O
g	O
/	O
m2	B-UNK
of	O
ifosfamide	B-CHEMICAL
(	O
six	O
or	O
10	O
cycles	B-UNK
of	O
ifosfamide	B-CHEMICAL
,	O
vincristine	B-UNK
,	O
and	O
dactinomycin	O
[	O
IVA	O
]	O
)	O
.	O
None	O
of	O
them	O
had	O
received	O
cisplatin	B-CHEMICAL
chemotherapy	O
.	O
Ages	B-UNK
ranged	B-UNK
from	O
4	O
months	B-UNK
to	O
17	O
years	B-UNK
;	O
58	O
patients	B-UNK
were	O
males	B-UNK
and	O
42	O
females	B-UNK
.	O
The	O
most	O
common	B-UNK
primary	B-UNK
tumor	B-UNK
site	B-UNK
was	O
the	O
head	B-UNK
and	I-UNK
neck	I-UNK
.	O
Renal	B-UNK
function	I-UNK
was	O
investigated	B-UNK
by	O
measuring	B-UNK
plasma	B-UNK
and	O
urinary	B-UNK
electrolytes	O
,	O
glucosuria	O
,	O
proteinuria	B-UNK
,	O
aminoaciduria	B-DISEASE
,	O
urinary	B-UNK
pH	B-UNK
,	O
osmolarity	O
,	O
creatinine	B-UNK
clearance	I-UNK
,	O
phosphate	B-UNK
tubular	B-UNK
reabsorption	B-UNK
,	O
beta	B-UNK
2	O
microglobulinuria	O
,	O
and	O
lysozymuria	O
.	O
Fifty	B-UNK
-	O
eight	O
patients	B-UNK
(	O
78	O
%	O
)	O
had	O
normal	O
renal	B-UNK
tests	B-UNK
,	O
whereas	O
16	O
patients	B-UNK
(	O
22	O
%	O
)	O
had	O
renal	B-UNK
abnormalities	B-UNK
.	O
Two	O
subsets	O
of	O
patients	B-UNK
were	O
identified	B-UNK
from	O
this	O
latter	O
group	B-UNK
:	O
the	O
first	O
included	B-UNK
four	O
patients	B-UNK
(	O
5	O
%	O
of	O
the	O
total	B-UNK
population	B-UNK
)	O
who	O
developed	O
major	B-UNK
toxicity	B-DISEASE
resulting	B-UNK
in	O
Fanconi'	O
s	O
syndrome	B-UNK
(	O
TDFS	B-DISEASE
)	O
;	O
and	O
the	O
second	O
group	B-UNK
included	B-UNK
five	O
patients	B-UNK
with	O
elevated	B-UNK
beta	B-UNK
2	O
microglobulinuria	O
and	O
low	B-UNK
phosphate	B-CHEMICAL
reabsorption	B-UNK
.	O
The	O
remaining	O
seven	O
patients	B-UNK
had	O
isolated	B-UNK
beta	B-UNK
2	O
microglobulinuria	O
.	O
Severe	B-UNK
toxicity	B-DISEASE
was	O
correlated	B-UNK
with	O
the	O
higher	B-UNK
cumulative	B-UNK
dose	I-UNK
of	O
60	O
g	O
/	O
m2	B-UNK
of	O
ifosfamide	B-CHEMICAL
,	O
a	O
younger	B-UNK
age	B-UNK
(	O
less	O
than	O
2	O
1/2	O
years	B-UNK
old	O
)	O
,	O
and	O
a	O
predominance	O
of	O
vesicoprostatic	O
tumor	B-UNK
involvement	B-UNK
.	O
This	O
low	B-UNK
percentage	B-UNK
(	O
5	O
%	O
)	O
of	O
TDFS	B-DISEASE
must	O
be	O
evaluated	B-UNK
with	O
respect	B-UNK
to	O
the	O
efficacy	B-UNK
of	O
ifosfamide	B-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
mesenchymal	O
tumors	B-UNK
in	O
children	B-UNK
.	O

Evidence	B-UNK
for	O
an	O
involvement	B-UNK
of	O
D1	B-UNK
and	O
D2	B-UNK
dopamine	B-CHEMICAL
receptors	B-UNK
in	O
mediating	O
nicotine	B-CHEMICAL
-	O
induced	B-UNK
hyperactivity	I-UNK
in	O
rats	B-UNK
.	O
Previous	B-UNK
studies	I-UNK
have	O
suggested	B-UNK
that	O
repeated	B-UNK
exposure	B-UNK
of	O
rats	B-UNK
to	O
the	O
drug	B-UNK
or	O
to	O
the	O
experimental	B-UNK
environment	O
is	O
necessary	O
to	O
observe	O
nicotine	B-CHEMICAL
-	O
induced	O
locomotor	B-UNK
stimulation	B-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
the	O
role	O
of	O
habituation	O
to	O
the	O
experimental	B-UNK
environment	O
on	O
the	O
stimulant	B-UNK
effect	B-UNK
of	O
nicotine	B-UNK
in	O
rats	B-UNK
was	O
examined	B-UNK
.	O
In	O
addition	B-UNK
,	O
the	O
role	O
of	O
dopamine	B-UNK
receptors	B-UNK
in	O
mediating	O
nicotine	B-UNK
-	O
induced	O
locomotor	B-UNK
stimulation	B-UNK
was	O
investigated	B-UNK
by	O
examining	O
the	O
effects	O
of	O
selective	B-UNK
D1	B-UNK
and	O
D2	B-UNK
dopamine	B-UNK
receptor	B-UNK
antagonists	I-UNK
on	O
activity	B-UNK
induced	O
by	O
nicotine	B-CHEMICAL
.	O
Locomotor	B-UNK
activity	I-UNK
was	O
assessed	B-UNK
in	O
male	B-UNK
Sprague	O
-	O
Dawley	O
rats	B-UNK
tested	B-UNK
in	O
photocell	O
cages	O
.	O
Nicotine	B-UNK
(	O
1.0	O
mg	B-UNK
/	O
kg	B-UNK
)	O
caused	B-UNK
a	O
significant	B-UNK
increase	B-UNK
in	O
locomotor	B-UNK
activity	I-UNK
in	O
rats	B-UNK
that	O
were	O
habituated	O
to	O
the	O
test	B-UNK
environment	O
,	O
but	O
had	O
only	O
a	O
weak	O
and	O
delayed	B-UNK
stimulant	B-UNK
action	B-UNK
in	O
rats	B-UNK
that	O
were	O
unfamiliar	O
with	O
the	O
test	B-UNK
environment	O
.	O
The	O
stimulant	B-UNK
action	B-UNK
of	O
nicotine	B-UNK
was	O
blocked	B-UNK
by	O
the	O
central	B-UNK
nicotinic	B-UNK
antagonist	B-UNK
mecamylamine	O
but	O
not	O
by	O
the	O
peripheral	B-UNK
nicotinic	B-UNK
blocker	B-UNK
hexamethonium	B-UNK
,	O
indicating	O
that	O
the	O
response	B-UNK
is	O
probably	O
mediated	B-UNK
by	O
central	B-UNK
nicotinic	B-UNK
receptors	B-UNK
.	O
Nicotine	B-CHEMICAL
-	O
induced	B-UNK
hyperactivity	I-UNK
was	O
blocked	B-UNK
by	O
the	O
selective	B-UNK
D1	B-UNK
antagonist	B-UNK
SCH	O
23390	O
,	O
the	O
selective	B-UNK
D2	B-UNK
antagonist	B-UNK
raclopride	O
and	O
the	O
D1	B-UNK
/	O
D2	B-UNK
antagonist	B-UNK
fluphenazine	O
.	O
Pretreatment	B-UNK
with	O
the	O
D2	B-UNK
agonist	B-UNK
PHNO	O
enhanced	B-UNK
nicotine	B-UNK
-	O
induced	B-UNK
hyperactivity	I-UNK
,	O
whereas	O
the	O
D1	B-UNK
agonist	B-UNK
SKF	O
38393	O
had	O
no	O
effect	B-UNK
.	O
The	O
results	B-UNK
indicate	O
that	O
acute	B-UNK
nicotine	B-CHEMICAL
injection	B-UNK
induces	O
a	O
pronounced	B-UNK
hyperactivity	B-UNK
in	O
rats	B-UNK
habituated	O
to	O
the	O
test	B-UNK
environment	O
.	O
The	O
effect	B-UNK
appears	B-UNK
to	O
be	O
mediated	B-UNK
by	O
central	B-UNK
nicotine	B-CHEMICAL
receptors	B-UNK
,	O
possibly	O
located	O
on	O
dopaminergic	B-UNK
neurons	B-UNK
,	O
and	O
also	O
requires	O
the	O
activation	B-UNK
of	O
both	O
D1	B-UNK
and	O
D2	B-UNK
dopamine	B-UNK
receptors	B-UNK
.	O

Neuropsychiatric	B-UNK
side	O
effects	O
after	O
the	O
use	O
of	O
mefloquine	B-CHEMICAL
.	O
This	O
study	B-UNK
describes	B-UNK
neuropsychiatric	B-UNK
side	O
effects	O
in	O
patients	B-UNK
after	O
treatment	B-UNK
with	O
mefloquine	B-CHEMICAL
.	O
Reactions	B-UNK
consisted	B-UNK
mainly	O
of	O
seizures	B-UNK
,	O
acute	B-UNK
psychoses	B-DISEASE
,	O
anxiety	B-DISEASE
neurosis	I-DISEASE
,	O
and	O
major	B-UNK
disturbances	B-DISEASE
of	I-DISEASE
sleep	I-DISEASE
-	I-DISEASE
wake	I-DISEASE
rhythm	I-DISEASE
.	O
Side	O
effects	O
occurred	B-UNK
after	O
both	O
therapeutic	B-UNK
and	O
prophylactic	B-UNK
intake	B-UNK
and	O
were	O
graded	O
from	O
moderate	B-UNK
to	I-UNK
severe	I-UNK
.	O
In	O
a	O
risk	B-UNK
analysis	B-UNK
of	O
neuropsychiatric	B-UNK
side	O
effects	O
in	O
Germany	O
,	O
it	O
is	O
estimated	O
that	O
one	O
of	O
8,000	O
mefloquine	B-CHEMICAL
users	B-UNK
suffers	O
from	O
such	O
reactions	B-UNK
.	O
The	O
incidence	B-UNK
calculation	O
revealed	O
that	O
one	O
of	O
215	O
therapeutic	B-UNK
users	B-UNK
had	O
reactions	B-UNK
,	O
compared	O
with	O
one	O
of	O
13,000	O
in	O
the	O
prophylaxis	O
group	B-UNK
,	O
making	O
the	O
risk	B-UNK
of	O
neuropsychiatric	B-UNK
reactions	B-UNK
after	O
mefloquine	B-CHEMICAL
treatment	B-UNK
60	O
times	B-UNK
higher	B-UNK
than	O
after	O
prophylaxis	O
.	O
Therefore	O
,	O
certain	O
limitations	O
for	O
malaria	B-DISEASE
prophylaxis	O
and	O
treatment	B-UNK
with	O
mefloquine	B-CHEMICAL
are	O
recommended	O
.	O

Reduction	O
in	O
injection	B-UNK
pain	B-UNK
using	O
buffered	O
lidocaine	B-UNK
as	O
a	O
local	B-UNK
anesthetic	I-UNK
before	O
cardiac	B-UNK
catheterization	O
.	O
Previous	B-UNK
reports	B-UNK
have	O
suggested	B-UNK
that	O
pain	B-DISEASE
associated	O
with	O
the	O
injection	B-UNK
of	O
lidocaine	B-UNK
is	O
related	O
to	O
the	O
acidic	B-UNK
pH	B-UNK
of	O
the	O
solution	B-UNK
.	O
To	O
determine	B-UNK
if	O
the	O
addition	B-UNK
of	O
a	O
buffering	O
solution	B-UNK
to	O
adjust	O
the	O
pH	B-UNK
of	O
lidocaine	B-CHEMICAL
into	O
the	O
physiologic	O
range	B-UNK
would	O
reduce	B-UNK
pain	B-UNK
during	O
injection	B-UNK
,	O
we	O
performed	B-UNK
a	O
blinded	B-UNK
randomized	B-UNK
study	B-UNK
in	O
patients	B-UNK
undergoing	B-UNK
cardiac	B-UNK
catheterization	O
.	O
Twenty	O
patients	B-UNK
were	O
asked	O
to	O
quantify	B-UNK
the	O
severity	B-UNK
of	O
pain	B-UNK
after	O
receiving	B-UNK
standard	B-UNK
lidocaine	B-UNK
in	O
one	O
femoral	O
area	B-UNK
and	O
buffered	O
lidocaine	B-UNK
in	O
the	O
opposite	O
femoral	O
area	B-UNK
.	O
The	O
mean	O
pain	B-UNK
score	O
for	O
buffered	O
lidocaine	B-CHEMICAL
was	O
significantly	B-UNK
lower	I-UNK
than	O
the	O
mean	O
score	O
for	O
standard	B-UNK
lidocaine	B-UNK
(	O
2.7	O
+	O
/-	O
1.9	O
vs	O
.	O
3.8	O
+	O
/-	O
2.2	O
,	O
P	O
=	O
0.03	O
)	O
.	O
The	O
pH	B-UNK
adjustment	B-UNK
of	O
standard	B-UNK
lidocaine	B-UNK
can	O
be	O
accomplished	O
easily	O
in	O
the	O
catheterization	O
laboratory	B-UNK
before	O
injection	B-UNK
and	O
results	B-UNK
in	O
a	O
reduction	O
of	O
the	O
pain	B-UNK
occurring	O
during	O
the	O
infiltration	B-UNK
of	O
tissues	B-UNK
.	O

Randomized	B-UNK
,	O
double-blind	O
trial	B-UNK
of	O
mazindol	B-CHEMICAL
in	O
Duchenne	O
dystrophy	B-UNK
.	O
There	O
is	O
evidence	B-UNK
that	O
growth	B-UNK
hormone	B-UNK
may	O
be	O
related	O
to	O
the	O
progression	B-UNK
of	O
weakness	B-DISEASE
in	O
Duchenne	O
dystrophy	B-UNK
.	O
We	O
conducted	B-UNK
a	O
12-month	O
controlled	B-UNK
trial	I-UNK
of	O
mazindol	B-UNK
,	O
a	O
putative	O
growth	B-UNK
hormone	B-UNK
secretion	B-UNK
inhibitor	B-UNK
,	O
in	O
83	O
boys	O
with	O
Duchenne	O
dystrophy	B-UNK
.	O
Muscle	B-UNK
strength	O
,	O
contractures	B-DISEASE
,	O
functional	B-UNK
ability	B-UNK
and	O
pulmonary	B-DISEASE
function	I-DISEASE
were	O
tested	B-UNK
at	O
baseline	B-UNK
,	O
and	O
6	O
and	O
12	O
months	B-UNK
after	O
treatment	B-UNK
with	O
mazindol	B-UNK
(	O
3	O
mg	B-UNK
/	O
d	O
)	O
or	O
placebo	B-UNK
.	O
The	O
study	B-UNK
was	O
designed	B-UNK
to	O
have	O
a	O
power	B-UNK
of	O
greater	B-UNK
than	O
0.90	O
to	O
detect	B-UNK
a	O
slowing	O
to	O
25	O
%	O
of	O
the	O
expected	B-UNK
rate	B-UNK
of	O
progression	B-UNK
of	O
weakness	B-UNK
at	O
P	O
less	O
than	O
0.05	O
.	O
Mazindol	B-UNK
did	O
not	O
benefit	O
strength	O
at	O
any	O
point	B-UNK
in	O
the	O
study	B-UNK
.	O
Side	O
effects	O
attributable	B-UNK
to	O
mazindol	B-UNK
included	B-UNK
decreased	B-DISEASE
appetite	I-DISEASE
(	O
36	O
%	O
)	O
,	O
dry	B-DISEASE
mouth	I-DISEASE
(	O
10	O
%	O
)	O
,	O
behavioral	B-UNK
change	B-UNK
(	O
22	O
%	O
)	O
,	O
and	O
gastrointestinal	B-UNK
symptoms	B-UNK
(	O
18	O
%	O
)	O
;	O
mazindol	B-UNK
dosage	B-UNK
was	O
reduced	B-UNK
in	O
43	O
%	O
of	O
patients	B-UNK
.	O
The	O
effect	B-UNK
of	O
mazindol	B-UNK
on	O
GH	O
secretion	B-UNK
was	O
estimated	O
indirectly	O
by	O
comparing	B-UNK
the	O
postabsorptive	O
IGF	B-UNK
-	O
I	O
levels	O
obtained	B-UNK
following	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
months	B-UNK
in	O
the	O
mazindol	B-CHEMICAL
treated	O
to	O
those	O
in	O
the	O
placebo	B-UNK
groups	B-UNK
.	O
Although	O
mazindol	B-UNK
-	O
treated	O
patients	B-UNK
gained	O
less	O
weight	B-UNK
and	O
height	O
than	O
placebo	B-UNK
-	O
treated	O
patients	B-UNK
,	O
no	O
significant	B-UNK
effect	B-UNK
on	O
IGF	B-UNK
-	O
I	O
levels	O
was	O
observed	O
.	O
Mazindol	B-UNK
doses	B-UNK
not	O
slow	B-UNK
the	O
progression	B-UNK
of	O
weakness	B-UNK
in	O
Duchenne	O
dystrophy	B-UNK
.	O

Pentoxifylline	B-CHEMICAL
(	O
Trental	O
)	O
does	O
not	O
inhibit	O
dipyridamole	B-CHEMICAL
-	O
induced	O
coronary	B-UNK
hyperemia	B-DISEASE
:	O
implications	B-UNK
for	O
dipyridamole	B-CHEMICAL
-	O
thallium-201	O
myocardial	B-UNK
imaging	B-UNK
.	O
Dipyridamole	B-UNK
-	O
thallium-201	O
imaging	B-UNK
is	O
often	O
performed	B-UNK
in	O
patients	B-UNK
unable	O
to	O
exercise	B-UNK
because	O
of	O
peripheral	B-DISEASE
vascular	I-DISEASE
disease	I-DISEASE
.	O
Many	O
of	O
these	O
patients	B-UNK
are	O
taking	B-UNK
pentoxifylline	B-CHEMICAL
(	O
Trental	O
)	O
,	O
a	O
methylxanthine	O
derivative	O
which	O
may	O
improve	B-UNK
intermittent	B-DISEASE
claudication	I-DISEASE
.	O
Whether	O
pentoxifylline	B-CHEMICAL
inhibits	B-UNK
dipyridamole	B-CHEMICAL
-	O
induced	O
coronary	B-UNK
hyperemia	B-DISEASE
like	O
other	O
methylxanthines	O
such	O
as	O
theophylline	B-UNK
and	O
should	O
be	O
stopped	O
prior	B-UNK
to	O
dipyridamole	B-UNK
-	O
thallium-201	O
imaging	B-UNK
is	O
unknown	O
.	O
Therefore	O
,	O
we	O
studied	O
the	O
hyperemic	O
response	B-UNK
to	O
dipyridamole	B-UNK
in	O
seven	O
open	B-UNK
-	O
chest	B-UNK
anesthetized	B-UNK
dogs	B-UNK
after	O
pretreatment	B-UNK
with	O
either	O
pentoxifylline	B-CHEMICAL
(	O
0	O
,	O
7.5	O
,	O
or	O
15	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
or	O
theophylline	B-CHEMICAL
(	O
3	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
.	O
Baseline	B-UNK
circumflex	O
coronary	B-UNK
blood	B-UNK
flows	O
did	O
not	O
differ	B-UNK
significantly	B-UNK
among	O
treatment	B-UNK
groups	B-UNK
.	O
Dipyridamole	B-UNK
significantly	B-UNK
increased	B-UNK
coronary	B-UNK
blood	B-UNK
flow	I-UNK
before	O
and	O
after	O
7.5	O
or	O
15	O
mm	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
pentoxifylline	B-CHEMICAL
(	O
p	O
less	O
than	O
0.002	O
)	O
.	O
Neither	O
dose	B-UNK
of	O
pentoxifylline	B-CHEMICAL
significantly	B-UNK
decreased	B-UNK
the	O
dipyridamole	B-CHEMICAL
-	O
induced	O
hyperemia	B-DISEASE
,	O
while	O
peak	B-UNK
coronary	B-UNK
blood	B-UNK
flow	I-UNK
was	O
significantly	B-UNK
lower	I-UNK
after	O
theophylline	B-CHEMICAL
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O
We	O
conclude	O
that	O
pentoxyifylline	O
does	O
not	O
inhibit	O
dipyridamole	B-CHEMICAL
-	O
induced	O
coronary	B-UNK
hyperemia	B-DISEASE
even	O
at	O
high	B-UNK
doses	I-UNK
.	O

Cause	O
of	O
death	B-DISEASE
among	O
patients	B-UNK
with	O
Parkinson'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
:	O
a	O
rare	B-UNK
mortality	B-UNK
due	O
to	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
.	O
Causes	O
of	O
death	B-UNK
,	O
with	O
special	B-UNK
reference	B-UNK
to	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
,	O
among	O
240	O
patients	B-UNK
with	O
pathologically	O
verified	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
were	O
investigated	B-UNK
using	O
the	O
Annuals	O
of	O
the	O
Pathological	B-UNK
Autopsy	B-UNK
Cases	B-UNK
in	O
Japan	O
from	O
1981	O
to	O
1985	O
.	O
The	O
leading	B-UNK
causes	O
of	O
death	B-UNK
were	O
pneumonia	B-DISEASE
and	O
bronchitis	B-DISEASE
(	O
44.1	O
%	O
)	O
,	O
malignant	B-UNK
neoplasms	B-DISEASE
(	O
11.6	O
%	O
)	O
,	O
heart	B-DISEASE
diseases	I-DISEASE
(	O
4.1	O
%	O
)	O
,	O
cerebral	B-DISEASE
infarction	I-DISEASE
(	O
3.7	O
%	O
)	O
and	O
septicaemia	O
(	O
3.3	O
%	O
)	O
.	O
Cerebral	B-DISEASE
haemorrhage	I-DISEASE
was	O
the	O
11th	O
most	O
frequent	B-UNK
cause	O
of	O
death	B-UNK
,	O
accounting	O
for	O
only	O
0.8	O
%	O
of	O
deaths	B-UNK
among	O
the	O
patients	B-UNK
,	O
whereas	O
it	O
was	O
the	O
5th	O
most	O
common	B-UNK
cause	O
of	O
death	B-DISEASE
among	O
the	O
Japanese	B-UNK
general	B-UNK
population	B-UNK
in	O
1985	O
.	O
The	O
low	B-UNK
incidence	B-UNK
of	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
as	O
a	O
cause	O
of	O
death	B-UNK
in	O
patients	B-UNK
with	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
may	O
reflect	O
the	O
hypotensive	B-DISEASE
effect	B-UNK
of	O
levodopa	B-UNK
and	O
a	O
hypotensive	B-UNK
mechanism	B-UNK
due	O
to	O
reduced	B-UNK
noradrenaline	B-CHEMICAL
levels	O
in	O
the	O
parkinsonian	B-UNK
brain	B-UNK
.	O

Tolerance	B-UNK
and	O
antiviral	B-UNK
effect	B-UNK
of	O
ribavirin	B-UNK
in	O
patients	B-UNK
with	O
Argentine	O
hemorrhagic	B-UNK
fever	B-DISEASE
.	O
Tolerance	B-UNK
and	O
antiviral	B-UNK
effect	B-UNK
of	O
ribavirin	B-UNK
was	O
studied	O
in	O
6	O
patients	B-UNK
with	O
Argentine	O
hemorrhagic	B-UNK
fever	B-UNK
(	O
AHF	O
)	O
of	O
more	O
than	O
8	O
days	B-UNK
of	O
evolution	O
.	O
Administration	O
of	O
ribavirin	B-UNK
resulted	B-UNK
in	O
a	O
neutralization	O
of	O
viremia	B-DISEASE
and	O
a	O
drop	B-UNK
of	O
endogenous	B-UNK
interferon	B-UNK
titers	O
.	O
The	O
average	B-UNK
time	O
of	O
death	B-DISEASE
was	O
delayed	B-UNK
.	O
A	O
reversible	B-UNK
anemia	B-DISEASE
was	O
the	O
only	O
adverse	B-UNK
effect	I-UNK
observed	O
.	O
From	O
these	O
results	B-UNK
,	O
we	O
conclude	O
that	O
ribavirin	B-UNK
has	O
an	O
antiviral	B-UNK
effect	B-UNK
in	O
advanced	B-UNK
cases	B-UNK
of	O
AHF	O
,	O
and	O
that	O
anemia	B-UNK
,	O
the	O
only	O
secondary	B-UNK
reaction	B-UNK
observed	O
,	O
can	O
be	O
easily	O
managed	O
.	O
The	O
possible	O
beneficial	B-UNK
effect	I-UNK
of	O
ribavirin	B-CHEMICAL
during	O
the	O
initial	B-UNK
days	B-UNK
of	O
AHF	O
is	O
discussed	O
.	O

Dipyridamole	B-UNK
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O
Angina	B-UNK
and	O
ischemic	B-UNK
electrocardiographic	B-UNK
changes	O
occurred	B-UNK
after	O
administration	O
of	O
oral	B-UNK
dipyridamole	B-UNK
in	O
four	O
patients	B-UNK
awaiting	O
urgent	O
myocardial	B-UNK
revascularization	O
procedures	B-UNK
.	O
To	O
our	O
knowledge	O
,	O
this	O
has	O
not	O
previously	B-UNK
been	O
reported	B-UNK
as	O
a	O
side	O
effect	B-UNK
of	O
preoperative	B-UNK
dipyridamole	B-CHEMICAL
therapy	O
,	O
although	O
dipyridamole	B-UNK
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
has	O
been	O
demonstrated	O
to	O
occur	O
in	O
animals	B-UNK
and	O
humans	B-UNK
with	O
coronary	B-UNK
artery	I-UNK
disease	I-UNK
.	O
Epicardial	O
coronary	B-UNK
collateral	O
vessels	B-UNK
were	O
demonstrated	O
in	O
all	O
four	O
patients	B-UNK
;	O
a	O
coronary	B-UNK
"	O
steal	O
"	O
phenomenon	B-UNK
may	O
be	O
the	O
mechanism	B-UNK
of	O
the	O
dipyridamole	B-CHEMICAL
-	O
induced	O
ischemia	B-UNK
observed	O
.	O

Inhibition	B-UNK
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	B-UNK
factor	B-UNK
secretion	B-UNK
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	B-UNK
by	O
delayed	B-UNK
glucocorticoid	B-UNK
feedback	O
.	O
Nitroprusside	B-CHEMICAL
-	O
induced	B-UNK
hypotension	I-UNK
evokes	O
ACTH	O
secretion	B-UNK
which	O
is	O
primarily	O
mediated	B-UNK
by	O
enhanced	B-UNK
secretion	B-UNK
of	O
immunoreactive	O
corticotropin	O
-	O
releasing	B-UNK
factor	B-UNK
(	O
irCRF	O
)	O
into	O
the	O
hypophysial	O
-	O
portal	O
circulation	B-UNK
.	O
Portal	O
plasma	B-UNK
concentrations	I-UNK
of	O
neither	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
nor	O
oxytocin	B-UNK
are	O
significantly	B-UNK
altered	B-UNK
in	O
this	O
paradigm	B-UNK
.	O
Application	B-UNK
of	O
a	O
delayed	B-UNK
feedback	O
signal	B-UNK
,	O
in	O
the	O
form	B-UNK
of	O
a	O
2-h	O
systemic	B-UNK
corticosterone	B-UNK
infusion	B-UNK
in	O
urethane	O
-	O
anesthetized	B-UNK
rats	I-UNK
with	O
pharmacological	B-UNK
blockade	B-UNK
of	O
glucocorticoid	B-UNK
synthesis	B-UNK
,	O
is	O
without	O
effect	B-UNK
on	O
the	O
resting	B-UNK
secretion	B-UNK
of	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
and	O
oxytocin	B-CHEMICAL
at	O
any	O
corticosterone	B-UNK
feedback	O
dose	B-UNK
tested	B-UNK
.	O
Resting	B-UNK
irCRF	O
levels	O
are	O
suppressed	O
only	O
at	O
the	O
highest	B-UNK
corticosterone	B-CHEMICAL
infusion	B-UNK
rate	B-UNK
,	O
which	O
resulted	B-UNK
in	O
systemic	B-UNK
corticosterone	B-UNK
levels	O
of	O
40	O
micrograms	B-UNK
/	O
dl	B-UNK
.	O
Suppression	B-UNK
of	O
irCRF	O
secretion	B-UNK
in	O
response	B-UNK
to	O
nitroprusside	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
is	O
observed	O
and	O
occurs	O
at	O
a	O
plasma	B-UNK
corticosterone	B-UNK
level	B-UNK
between	O
8	O
-	O
12	O
micrograms	B-UNK
/	O
dl	B-UNK
.	O
These	O
studies	B-UNK
provide	O
further	O
evidence	B-UNK
for	O
a	O
strong	B-UNK
central	B-UNK
component	B-UNK
of	O
the	O
delayed	B-UNK
feedback	O
process	O
which	O
is	O
mediated	B-UNK
by	O
modulation	B-UNK
of	O
irCRF	O
release	B-UNK
.	O

Noradrenergic	B-UNK
involvement	B-UNK
in	O
catalepsy	B-UNK
induced	O
by	O
delta	B-UNK
9-tetrahydrocannabinol	O
.	O
In	O
order	B-UNK
to	O
elucidate	O
the	O
role	O
of	O
the	O
catecholaminergic	O
system	O
in	O
the	O
cataleptogenic	O
effect	B-UNK
of	O
delta	B-UNK
9-tetrahydrocannabinol	O
(	O
THC	O
)	O
,	O
the	O
effect	B-UNK
of	O
pretreatment	B-UNK
with	O
6-hydroxydopamine	B-CHEMICAL
(	O
6-OHDA	B-CHEMICAL
)	O
or	O
with	O
desipramine	B-UNK
and	O
6-OHDA	B-CHEMICAL
and	O
lesions	B-UNK
of	O
the	O
locus	O
coeruleus	O
were	O
investigated	B-UNK
in	O
rats	B-UNK
.	O
The	O
cataleptogenic	O
effect	B-UNK
of	O
THC	O
was	O
significantly	B-UNK
reduced	I-UNK
in	O
rats	B-UNK
treated	O
with	O
6-OHDA	B-CHEMICAL
and	O
in	O
rats	B-UNK
with	O
lesions	B-UNK
of	O
the	O
locus	O
coeruleus	O
but	O
not	O
in	O
rats	B-UNK
treated	O
with	O
desipramine	B-UNK
and	O
6-OHDA	B-CHEMICAL
,	O
as	O
compared	O
with	O
control	B-UNK
rats	B-UNK
.	O
On	O
the	O
contrary	O
,	O
the	O
cataleptogenic	O
effect	B-UNK
of	O
haloperidol	B-CHEMICAL
was	O
significantly	B-UNK
reduced	I-UNK
in	O
rats	B-UNK
treated	O
with	O
desipramine	B-UNK
and	O
6-OHDA	B-CHEMICAL
but	O
not	O
in	O
rats	B-UNK
treated	O
with	O
6-OHDA	B-CHEMICAL
or	O
in	O
rats	B-UNK
with	O
lesions	B-UNK
of	O
the	O
locus	O
coeruleus	O
.	O
These	O
results	B-UNK
indicate	O
that	O
noradrenergic	B-UNK
neurons	B-UNK
have	O
an	O
important	B-UNK
role	O
in	O
the	O
manifestation	B-UNK
of	O
catalepsy	B-DISEASE
induced	O
by	O
THC	O
,	O
whereas	O
dopaminergic	B-UNK
neurons	B-UNK
are	O
important	B-UNK
in	O
catalepsy	B-UNK
induced	O
by	O
haloperidol	B-CHEMICAL
.	O

Intracranial	B-UNK
pressure	B-UNK
increases	B-UNK
during	O
alfentanil	B-UNK
-	O
induced	O
rigidity	B-UNK
.	O
Intracranial	B-UNK
pressure	B-UNK
(	O
ICP	O
)	O
was	O
measured	B-UNK
during	O
alfentanil	B-UNK
-	O
induced	O
rigidity	B-DISEASE
in	O
rats	B-UNK
.	O
Ten	O
rats	B-UNK
had	O
arterial	B-UNK
,	O
central	B-UNK
venous	B-UNK
(	O
CVP	O
)	O
,	O
and	O
subdural	O
cannulae	O
inserted	O
under	O
halothane	B-UNK
anesthesia	B-UNK
.	O
The	O
animals	B-UNK
were	O
mechanically	O
ventilated	O
to	O
achieve	B-UNK
normocarbia	O
(	O
PCO2	O
=	O
42	O
+	O
/-	O
1	O
mmHg	B-UNK
,	O
mean	O
+	O
/-	O
SE	B-UNK
)	O
.	O
Following	O
instrumentation	O
,	O
halothane	B-UNK
was	O
discontinued	O
and	O
alfentanil	B-UNK
(	O
125	O
mu	B-UNK
/	O
kg	B-UNK
)	O
administered	O
iv	B-UNK
during	O
emergence	O
from	O
halothane	B-UNK
anesthesia	B-UNK
.	O
In	O
the	O
five	O
rats	B-UNK
that	O
developed	O
somatic	O
rigidity	B-UNK
,	O
ICP	O
and	O
CVP	O
increased	B-UNK
significantly	B-UNK
above	O
baseline	B-UNK
(	O
delta	B-UNK
ICP	O
7.5	O
+	O
/-	O
1.0	O
mmHg	B-UNK
,	O
delta	B-UNK
CVP	O
5.9	O
+	O
/-	O
1.3	O
mmHg	B-UNK
)	O
.	O
These	O
variables	B-UNK
returned	B-UNK
to	O
baseline	B-UNK
when	O
rigidity	B-UNK
was	O
abolished	O
with	O
metocurine	O
.	O
In	O
five	O
rats	B-UNK
that	O
did	O
not	O
become	O
rigid	O
,	O
ICP	O
and	O
CVP	O
did	O
not	O
change	B-UNK
following	O
alfentanil	B-UNK
.	O
These	O
observations	B-UNK
suggest	B-UNK
that	O
rigidity	B-DISEASE
should	O
be	O
prevented	B-UNK
when	O
alfentanil	B-UNK
,	O
and	O
,	O
presumably	O
,	O
other	O
opiates	B-CHEMICAL
,	O
are	O
used	O
in	O
the	O
anesthetic	B-UNK
management	B-UNK
of	O
patients	B-UNK
with	O
ICP	O
problems	B-UNK
.	O

Adverse	B-UNK
cardiac	B-UNK
effects	O
during	O
induction	B-UNK
chemotherapy	O
treatment	B-UNK
with	O
cis	B-UNK
-	O
platin	O
and	O
5-fluorouracil	B-CHEMICAL
.	O
Survival	B-UNK
for	O
patients	B-UNK
with	O
advanced	B-UNK
head	B-UNK
and	I-UNK
neck	I-UNK
carcinoma	B-UNK
and	O
esophageal	B-DISEASE
carcinoma	I-DISEASE
is	O
poor	O
with	O
radiotherapy	B-UNK
and	O
/	O
or	O
surgery	B-UNK
.	O
Obviously	O
,	O
there	O
is	O
a	O
need	O
for	O
effective	B-UNK
chemotherapy	O
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
cis	B-UNK
-	O
platin	O
(	O
80	O
-	O
120	O
mg	B-UNK
/	O
m2BSA	O
)	O
and	O
5-FU	B-CHEMICAL
(	O
1000	O
mg	B-UNK
/	O
m2BSA	O
daily	B-UNK
as	O
a	O
continuous	B-UNK
infusion	I-UNK
during	O
5	O
days	B-UNK
)	O
were	O
given	O
to	O
76	O
patients	B-UNK
before	O
radiotherapy	B-UNK
and	O
surgery	B-UNK
.	O
The	O
aim	B-UNK
of	O
the	O
study	B-UNK
was	O
to	O
clarify	O
the	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
adverse	B-UNK
cardiac	B-UNK
effects	O
to	O
this	O
treatment	B-UNK
.	O
Before	O
treatment	B-UNK
all	O
patients	B-UNK
had	O
a	O
cardiac	B-UNK
evaluation	B-UNK
and	O
during	O
treatment	B-UNK
serial	B-UNK
ECG	B-UNK
recordings	O
were	O
performed	B-UNK
.	O
In	O
the	O
pre	B-UNK
-	O
treatment	B-UNK
evaluation	B-UNK
,	O
signs	B-UNK
of	O
cardiovascular	B-UNK
disease	I-UNK
were	O
found	O
in	O
33	O
patients	B-UNK
(	O
43	O
%	O
)	O
.	O
During	O
treatment	B-UNK
,	O
adverse	B-UNK
cardiac	B-UNK
effects	O
were	O
observed	O
in	O
14	O
patients	B-UNK
(	O
18	O
%	O
)	O
.	O
The	O
mean	O
age	B-UNK
of	O
these	O
patients	B-UNK
was	O
the	O
same	O
as	O
for	O
the	O
entire	O
group	B-UNK
,	O
64	O
years	B-UNK
.	O
The	O
incidence	B-UNK
of	O
cardiotoxicity	B-UNK
was	O
not	O
higher	B-UNK
in	O
patients	B-UNK
with	O
signs	B-UNK
of	O
cardiovascular	B-UNK
disease	I-UNK
than	O
in	O
those	O
without	O
in	O
the	O
pre	B-UNK
-	O
treatment	B-UNK
evaluation	B-UNK
.	O
The	O
most	O
common	B-UNK
signs	B-UNK
of	O
cardiotoxicity	B-UNK
were	O
chest	B-DISEASE
pain	I-DISEASE
,	O
ST	B-UNK
-T	O
wave	B-UNK
changes	O
and	O
atrial	B-UNK
fibrillation	I-UNK
.	O
This	O
was	O
followed	O
by	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
in	O
one	O
patient	B-UNK
and	O
sudden	B-UNK
death	B-UNK
in	O
another	O
.	O
It	O
is	O
concluded	O
that	O
patients	B-UNK
on	O
5-FU	B-CHEMICAL
treatment	B-UNK
should	O
be	O
under	O
close	B-UNK
supervision	O
and	O
that	O
the	O
treatment	B-UNK
should	O
be	O
discontinued	O
if	O
chest	B-UNK
pain	I-UNK
or	O
tachyarrhythmia	O
is	O
observed	O
.	O

Verapamil	B-UNK
-	O
induced	O
carbamazepine	B-UNK
neurotoxicity	B-UNK
.	O
A	O
report	B-UNK
of	O
two	O
cases	B-UNK
.	O
Two	O
patients	B-UNK
with	O
signs	B-UNK
of	O
carbamazepine	B-UNK
neurotoxicity	B-UNK
after	O
combined	B-UNK
treatment	B-UNK
with	O
verapamil	B-UNK
showed	O
complete	B-UNK
recovery	B-UNK
after	O
discontinuation	B-UNK
of	O
the	O
calcium	B-UNK
entry	O
blocker	B-UNK
.	O
Use	O
of	O
verapamil	B-UNK
in	O
combination	B-UNK
with	O
carbamazepine	B-UNK
should	O
either	O
be	O
avoided	O
or	O
prescribed	B-UNK
only	O
with	O
appropriate	O
adjustment	B-UNK
of	O
the	O
carbamazepine	B-UNK
dose	B-UNK
(	O
usually	O
reduction	O
of	O
the	O
carbamazepine	B-CHEMICAL
dose	B-UNK
by	O
one	O
half	B-UNK
)	O
.	O

Serial	B-UNK
studies	B-UNK
of	O
auditory	B-DISEASE
neurotoxicity	I-DISEASE
in	O
patients	B-UNK
receiving	B-UNK
deferoxamine	B-CHEMICAL
therapy	O
.	O
Visual	B-UNK
and	O
auditory	B-DISEASE
neurotoxicity	I-DISEASE
was	O
previously	B-UNK
documented	O
in	O
42	O
of	O
89	O
patients	B-UNK
with	O
transfusion	B-UNK
-	O
dependent	B-UNK
anemia	B-UNK
who	O
were	O
receiving	B-UNK
iron	B-UNK
chelation	O
therapy	O
with	O
daily	B-UNK
subcutaneous	B-UNK
deferoxamine	B-UNK
.	O
Twenty	O
-	O
two	O
patients	B-UNK
in	O
the	O
affected	B-UNK
group	B-UNK
had	O
abnormal	B-DISEASE
audiograms	I-DISEASE
with	I-DISEASE
deficits	I-DISEASE
mostly	I-DISEASE
in	I-DISEASE
the	I-DISEASE
high	I-DISEASE
frequency	I-DISEASE
range	I-DISEASE
of	I-DISEASE
4,000	I-DISEASE
to	I-DISEASE
8,000	I-DISEASE
Hz	I-DISEASE
and	O
in	O
the	O
hearing	B-UNK
threshold	B-UNK
levels	O
of	O
30	O
to	O
100	O
decibels	O
.	O
When	O
deferoxamine	B-CHEMICAL
therapy	O
was	O
discontinued	O
and	O
serial	B-UNK
studies	B-UNK
were	O
performed	B-UNK
,	O
audiograms	O
in	O
seven	O
cases	B-UNK
reverted	O
to	O
normal	O
or	O
near	O
normal	O
within	O
two	O
to	O
three	O
weeks	B-UNK
,	O
and	O
nine	O
of	O
13	O
patients	B-UNK
with	O
symptoms	B-UNK
became	O
asymptomatic	O
.	O
Audiograms	O
from	O
15	O
patients	B-UNK
remained	B-UNK
abnormal	B-UNK
and	O
four	O
patients	B-UNK
required	B-UNK
hearing	B-UNK
aids	B-UNK
because	O
of	O
permanent	B-UNK
disability	B-UNK
.	O
Since	O
18	O
of	O
the	O
22	O
patients	B-UNK
were	O
initially	B-UNK
receiving	B-UNK
deferoxamine	B-CHEMICAL
doses	B-UNK
in	O
excess	B-UNK
of	O
the	O
commonly	B-UNK
recommended	O
50	O
mg	B-UNK
/	O
kg	B-UNK
per	O
dose	B-UNK
,	O
therapy	O
was	O
restarted	O
with	O
lower	B-UNK
doses	B-UNK
,	O
usually	O
50	O
mg	B-UNK
/	O
kg	B-UNK
per	O
dose	B-UNK
or	O
less	O
depending	O
on	O
the	O
degree	B-UNK
of	O
auditory	B-DISEASE
abnormality	I-DISEASE
,	O
and	O
with	O
the	O
exception	O
of	O
two	O
cases	B-UNK
no	O
further	O
toxicity	B-DISEASE
was	O
demonstrated	O
.	O
Auditory	B-UNK
deterioration	B-UNK
and	O
improvement	B-UNK
,	O
demonstrated	O
serially	O
in	O
individual	B-UNK
patients	B-UNK
receiving	B-UNK
and	O
not	O
receiving	B-UNK
deferoxamine	B-UNK
,	O
respectively	O
,	O
provided	O
convincing	O
evidence	B-UNK
for	O
a	O
cause	O
-	O
and	O
-	O
effect	B-UNK
relation	B-UNK
between	O
deferoxamine	B-UNK
administration	O
and	O
ototoxicity	B-UNK
.	O
Based	B-UNK
on	O
these	O
data	B-UNK
,	O
a	O
plan	O
of	O
management	B-UNK
was	O
developed	O
that	O
allows	O
effective	B-UNK
yet	O
safe	O
administration	O
of	O
deferoxamine	B-UNK
.	O
A	O
dose	B-UNK
of	O
50	O
mg	B-UNK
/	O
kg	B-UNK
is	O
recommended	O
in	O
those	O
without	O
audiogram	O
abnormalities	B-UNK
.	O
With	O
mild	B-UNK
toxicity	B-UNK
,	O
a	O
reduction	O
to	O
30	O
or	O
40	O
mg	B-UNK
/	O
kg	B-UNK
per	O
dose	B-UNK
should	O
result	B-UNK
in	O
a	O
reversal	B-UNK
of	O
the	O
abnormal	B-UNK
results	B-UNK
to	O
normal	O
within	O
four	O
weeks	B-UNK
.	O
Moderate	B-UNK
abnormalities	B-UNK
require	O
a	O
reduction	O
of	O
deferoxamine	B-CHEMICAL
to	O
25	O
mg	B-UNK
/	O
kg	B-UNK
per	O
dose	B-UNK
with	O
careful	B-UNK
monitoring	B-UNK
.	O
In	O
those	O
with	O
symptoms	B-UNK
of	O
hearing	B-UNK
loss	I-UNK
,	O
the	O
drug	B-UNK
should	O
be	O
stopped	O
for	O
four	O
weeks	B-UNK
,	O
and	O
when	O
the	O
audiogram	O
is	O
stable	B-UNK
or	O
improved	O
,	O
therapy	O
should	O
be	O
restarted	O
at	O
10	O
to	O
25	O
mg	B-UNK
/	O
kg	B-UNK
per	O
dose	B-UNK
.	O
Serial	B-UNK
audiograms	O
should	O
be	O
performed	B-UNK
every	O
six	O
months	B-UNK
in	O
those	O
without	O
problems	B-UNK
and	O
more	O
frequently	B-UNK
in	O
young	B-UNK
patients	B-UNK
with	O
normal	O
serum	B-UNK
ferritin	O
values	O
and	O
in	O
those	O
with	O
auditory	B-DISEASE
dysfunction	I-DISEASE
.	O

Flurbiprofen	O
in	O
the	O
treatment	B-UNK
of	O
juvenile	O
rheumatoid	B-UNK
arthritis	I-UNK
.	O
Thirty	B-UNK
-	O
four	O
patients	B-UNK
with	O
juvenile	O
rheumatoid	B-UNK
arthritis	I-UNK
,	O
who	O
were	O
treated	O
with	O
flurbiprofen	O
at	O
a	O
maximum	B-UNK
dose	B-UNK
of	O
4	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
,	O
had	O
statistically	B-UNK
significant	I-UNK
decreases	B-UNK
from	O
baseline	B-UNK
in	O
6	O
arthritis	B-DISEASE
indices	B-UNK
after	O
12	O
weeks	B-UNK
of	O
treatment	B-UNK
.	O
Improvements	B-UNK
were	O
seen	O
in	O
the	O
number	B-UNK
of	O
tender	O
joints	O
,	O
the	O
severity	B-UNK
of	O
swelling	B-DISEASE
and	O
tenderness	O
,	O
the	O
time	O
of	O
walk	O
50	O
feet	O
,	O
the	O
duration	B-UNK
of	O
morning	B-UNK
stiffness	O
and	O
the	O
circumference	O
of	O
the	O
left	B-UNK
knee	O
.	O
The	O
most	O
frequently	B-UNK
observed	O
side	O
effect	B-UNK
was	O
fecal	B-DISEASE
occult	I-DISEASE
blood	I-DISEASE
(	O
25	O
%	O
of	O
patients	B-UNK
)	O
;	O
however	O
,	O
there	O
was	O
no	O
other	O
evidence	B-UNK
of	O
gastrointestinal	B-UNK
(	O
GI	B-UNK
)	O
bleeding	B-UNK
in	O
these	O
patients	B-UNK
.	O
One	O
patient	B-UNK
was	O
prematurely	O
discontinued	O
from	O
the	O
study	B-UNK
for	O
severe	B-UNK
headache	B-UNK
and	O
abdominal	B-UNK
pain	I-UNK
.	O
Most	O
side	O
effects	O
were	O
mild	B-UNK
and	O
related	O
to	O
the	O
GI	B-UNK
tract	B-UNK
.	O

The	O
correlation	B-UNK
between	O
neurotoxic	B-UNK
esterase	O
inhibition	B-UNK
and	O
mipafox	O
-	O
induced	O
neuropathic	B-UNK
damage	B-UNK
in	O
rats	B-UNK
.	O
The	O
correlation	B-UNK
between	O
neuropathic	B-UNK
damage	B-UNK
and	O
inhibition	B-UNK
of	O
neurotoxic	B-DISEASE
esterase	O
or	O
neuropathy	B-UNK
target	O
enzyme	B-UNK
(	O
NTE	O
)	O
was	O
examined	B-UNK
in	O
rats	B-UNK
acutely	O
exposed	B-UNK
to	O
Mipafox	O
(	O
N	O
,	O
N'-diisopropylphosphorodiamidofluoridate	O
)	O
,	O
a	O
neurotoxic	B-UNK
organophosphate	O
.	O
Brain	B-UNK
and	O
spinal	B-UNK
cord	I-UNK
NTE	O
activities	B-UNK
were	O
measured	B-UNK
in	O
Long	B-UNK
-	O
Evans	O
male	B-UNK
rats	I-UNK
1	O
hr	B-UNK
post-exposure	O
to	O
various	O
dosages	B-UNK
of	O
Mipafox	O
(	O
ip	B-UNK
,	O
1	O
-	O
15	O
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
These	O
data	B-UNK
were	O
correlated	B-UNK
with	O
histologically	O
scored	B-UNK
cervical	O
cord	B-DISEASE
damage	I-DISEASE
in	O
a	O
separate	B-UNK
group	B-UNK
of	O
similarly	B-UNK
dosed	O
rats	B-UNK
sampled	O
14	O
-	O
21	O
days	B-UNK
post-exposure	O
.	O
Those	O
dosages	B-UNK
(	O
greater	B-UNK
than	O
or	O
equal	B-UNK
to	O
10	O
mg	B-UNK
/	O
kg	B-UNK
)	O
that	O
inhibited	B-UNK
mean	O
NTE	O
activity	B-UNK
in	O
the	O
spinal	B-UNK
cord	I-UNK
greater	B-UNK
than	O
or	O
equal	B-UNK
to	O
73	O
%	O
and	O
brain	B-UNK
greater	B-UNK
than	O
or	O
equal	B-UNK
to	O
67	O
%	O
of	O
control	B-UNK
values	O
produced	B-UNK
severe	B-UNK
(	O
greater	B-UNK
than	O
or	O
equal	B-UNK
to	O
3	O
)	O
cervical	O
cord	B-UNK
pathology	B-UNK
in	O
85	O
%	O
of	O
the	O
rats	B-UNK
.	O
In	O
contrast	B-UNK
,	O
dosages	B-UNK
of	O
Mipafox	O
(	O
less	O
than	O
or	O
equal	B-UNK
to	O
5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
which	O
inhibited	B-UNK
mean	O
NTE	O
activity	B-UNK
in	O
spinal	B-UNK
cord	I-UNK
less	O
than	O
or	O
equal	B-UNK
to	O
61	O
%	O
and	O
brain	B-UNK
less	O
than	O
or	O
equal	B-UNK
to	O
60	O
%	O
produced	B-UNK
this	O
degree	B-UNK
of	O
cord	B-DISEASE
damage	I-DISEASE
in	O
only	O
9	O
%	O
of	O
the	O
animals	B-UNK
.	O
These	O
data	B-UNK
indicate	O
that	O
a	O
critical	B-UNK
percentage	B-UNK
of	O
NTE	O
inhibition	B-UNK
in	O
brain	B-UNK
and	O
spinal	B-UNK
cord	I-UNK
sampled	O
shortly	B-UNK
after	O
Mipafox	O
exposure	B-UNK
can	O
predict	B-UNK
neuropathic	B-UNK
damage	B-UNK
in	O
rats	B-UNK
several	O
weeks	B-UNK
later	O
.	O

Cerebral	B-DISEASE
infarction	I-DISEASE
with	O
a	O
single	B-UNK
oral	B-UNK
dose	B-UNK
of	O
phenylpropanolamine	B-CHEMICAL
.	O
Phenylpropanolamine	B-CHEMICAL
(	O
PPA	B-UNK
)	O
,	O
a	O
synthetic	O
sympathomimetic	O
that	O
is	O
structurally	O
similar	B-UNK
to	O
amphetamine	B-UNK
,	O
is	O
available	O
over	O
the	O
counter	O
in	O
anorectics	O
,	O
nasal	O
congestants	O
,	O
and	O
cold	O
preparations	B-UNK
.	O
Its	O
prolonged	B-UNK
use	O
or	O
overuse	O
has	O
been	O
associated	O
with	O
seizures	B-UNK
,	O
intracerebral	B-UNK
hemorrhage	I-UNK
,	O
neuropsychiatric	B-UNK
symptoms	B-UNK
,	O
and	O
nonhemorrhagic	O
cerebral	B-DISEASE
infarction	I-DISEASE
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
young	B-UNK
woman	B-UNK
who	O
suffered	O
a	O
cerebral	B-DISEASE
infarction	I-DISEASE
after	O
taking	B-UNK
a	O
single	B-UNK
oral	B-UNK
dose	B-UNK
of	O
PPA	B-UNK
.	O

Treatment	B-UNK
of	O
psoriasis	B-DISEASE
with	O
azathioprine	B-UNK
.	O
Azathioprine	B-UNK
treatment	B-UNK
benefited	O
19	O
(	O
66	O
%	O
)	O
out	O
of	O
29	O
patients	B-UNK
suffering	O
from	O
severe	B-UNK
psoriasis	B-DISEASE
.	O
Haematological	B-UNK
complications	B-DISEASE
were	O
not	O
troublesome	O
and	O
results	B-UNK
of	O
biochemical	B-UNK
liver	B-UNK
function	I-UNK
tests	I-UNK
remained	B-UNK
normal	O
.	O
Minimal	B-UNK
cholestasis	B-UNK
was	O
seen	O
in	O
two	O
cases	B-UNK
and	O
portal	O
fibrosis	B-DISEASE
of	O
a	O
reversible	B-UNK
degree	B-UNK
in	O
eight	O
.	O
Liver	B-UNK
biopsies	B-UNK
should	O
be	O
undertaken	B-UNK
at	O
regular	B-UNK
intervals	B-UNK
if	O
azathioprine	B-UNK
therapy	O
is	O
continued	O
so	O
that	O
structural	B-UNK
liver	B-DISEASE
damage	I-DISEASE
may	O
be	O
detected	B-UNK
at	O
an	O
early	B-UNK
and	O
reversible	B-UNK
stage	B-UNK
.	O

Maternal	B-UNK
lithium	B-CHEMICAL
and	O
neonatal	B-UNK
Ebstein'	B-DISEASE
s	I-DISEASE
anomaly	I-DISEASE
:	O
evaluation	B-UNK
with	O
cross-sectional	O
echocardiography	B-UNK
.	O
Cross-sectional	O
echocardiography	B-UNK
was	O
used	O
to	O
evaluate	B-UNK
two	O
neonates	B-UNK
whose	O
mothers	O
ingested	O
lithium	B-CHEMICAL
during	O
pregnancy	B-UNK
.	O
In	O
one	O
infant	B-UNK
,	O
Ebstein'	B-DISEASE
s	I-DISEASE
anomaly	I-DISEASE
of	O
the	O
tricuspid	O
valve	B-UNK
was	O
identified	B-UNK
.	O
In	O
the	O
other	O
infant	B-UNK
cross-sectional	O
echocardiography	B-UNK
provided	O
reassurance	O
that	O
the	O
infant	B-UNK
did	O
not	O
have	O
Ebstein'	B-DISEASE
s	I-DISEASE
anomaly	I-DISEASE
.	O
Cross-sectional	O
echocardiographic	B-UNK
screening	B-UNK
of	O
newborns	O
exposed	B-UNK
to	O
lithium	B-UNK
during	O
gestation	B-UNK
can	O
provide	O
highly	B-UNK
accurate	O
,	O
noninvasive	O
assessment	B-UNK
of	O
the	O
presence	O
or	O
absence	O
of	O
lithium	B-UNK
-	O
induced	O
cardiac	B-DISEASE
malformations	I-DISEASE
.	O

Effects	O
of	O
training	B-UNK
on	O
the	O
extent	B-UNK
of	O
experimental	B-UNK
myocardial	B-UNK
infarction	I-UNK
in	O
aging	O
rats	B-UNK
.	O
The	O
effects	O
of	O
exercise	B-UNK
on	O
the	O
severity	B-UNK
of	O
isoproterenol	B-UNK
-	O
induced	O
myocardial	B-UNK
infarction	I-UNK
were	O
studied	O
in	O
female	B-UNK
albino	B-UNK
rats	B-UNK
of	O
20,40,60	O
and	O
80	O
weeks	B-UNK
of	O
age	B-UNK
.	O
The	O
rats	B-UNK
were	O
trained	B-UNK
to	O
swim	O
for	O
a	O
specific	B-UNK
duration	B-UNK
and	O
for	O
a	O
particular	O
period	B-UNK
.	O
The	O
occurrence	B-UNK
of	O
infarcts	O
were	O
confirmed	B-UNK
by	O
histological	B-UNK
methods	B-UNK
.	O
Elevations	B-UNK
in	O
the	O
serum	B-UNK
GOT	O
and	O
GPT	O
were	O
maximum	B-UNK
in	O
the	O
sedentary	O
-	O
isoproterenols	O
and	O
minimum	B-UNK
in	O
the	O
exercise	B-UNK
-	O
controls	B-UNK
.	O
These	O
changes	O
in	O
the	O
serum	B-UNK
transaminases	O
were	O
associated	O
with	O
corresponding	O
depletions	O
in	O
the	O
cardiac	B-UNK
GOT	O
and	O
GPT	O
.	O
However	O
,	O
age	B-UNK
was	O
seen	O
to	O
interfere	O
with	O
the	O
responses	O
exhibited	O
by	O
the	O
young	B-UNK
and	O
old	O
rats	B-UNK
.	O
Studies	B-UNK
dealing	O
with	O
myocardial	B-UNK
infarction	I-UNK
are	O
more	O
informative	O
when	O
dealt	O
with	O
age	B-UNK
.	O

Effect	B-UNK
of	O
polyethylene	B-CHEMICAL
glycol	I-CHEMICAL
400	I-CHEMICAL
on	O
adriamycin	B-UNK
toxicity	B-UNK
in	O
mice	B-UNK
.	O
The	O
effect	B-UNK
of	O
a	O
widely	B-UNK
used	O
organic	B-UNK
solvent	O
,	O
polyethylene	B-CHEMICAL
glycol	I-CHEMICAL
400	I-CHEMICAL
(	O
PEG	B-CHEMICAL
400	I-CHEMICAL
)	O
,	O
on	O
the	O
toxic	B-UNK
action	B-UNK
of	O
an	O
acute	B-UNK
or	O
chronic	B-UNK
treatment	B-UNK
with	O
adriamycin	B-UNK
(	O
ADR	B-UNK
)	O
was	O
evaluated	B-UNK
in	O
mice	B-UNK
.	O
PEG	B-CHEMICAL
400	I-CHEMICAL
impressively	O
decreased	B-UNK
both	O
acute	B-UNK
high	B-UNK
-	O
dose	B-UNK
and	O
chronic	B-UNK
low	B-UNK
-	O
dose	B-UNK
-	O
ADR	B-UNK
-	O
associated	O
lethality	B-UNK
.	O
Light	B-UNK
microscopic	B-UNK
analysis	B-UNK
showed	O
a	O
significant	B-UNK
protection	B-UNK
against	O
ADR	B-UNK
-	O
induced	O
cardiac	B-DISEASE
morphological	I-DISEASE
alterations	I-DISEASE
.	O
Such	O
treatment	B-UNK
did	O
not	O
diminish	O
the	O
ADR	B-UNK
antitumor	B-UNK
activity	I-UNK
in	O
L1210	O
leukemia	B-UNK
and	O
in	O
Ehrlich	O
ascites	B-DISEASE
tumor	B-UNK
.	O

Intra-arterial	O
BCNU	B-CHEMICAL
chemotherapy	O
for	O
treatment	B-UNK
of	O
malignant	B-UNK
gliomas	O
of	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
.	O
Because	O
of	O
the	O
rapid	B-UNK
systemic	B-UNK
clearance	B-UNK
of	O
BCNU	B-UNK
(	O
1,3-bis-(2-chloroethyl)-1-nitrosourea	B-CHEMICAL
)	O
,	O
intra-arterial	O
administration	O
should	O
provide	O
a	O
substantial	O
advantage	O
over	O
intravenous	B-UNK
administration	O
for	O
the	O
treatment	B-UNK
of	O
malignant	B-UNK
gliomas	O
.	O
Thirty	B-UNK
-	O
six	O
patients	B-UNK
were	O
treated	O
with	O
BCNU	B-CHEMICAL
every	O
6	O
to	O
8	O
weeks	B-UNK
,	O
either	O
by	O
transfemoral	O
catheterization	O
of	O
the	O
internal	B-UNK
carotid	B-UNK
or	O
vertebral	O
artery	B-UNK
or	O
through	O
a	O
fully	B-UNK
implantable	O
intracarotid	O
drug	B-UNK
delivery	B-UNK
system	O
,	O
beginning	B-UNK
with	O
a	O
dose	B-UNK
of	O
200	O
mg	B-UNK
/	O
sq	O
m	O
body	B-UNK
surface	I-UNK
area	I-UNK
.	O
Twelve	O
patients	B-UNK
with	O
Grade	B-UNK
III	B-UNK
or	O
IV	B-UNK
astrocytomas	B-DISEASE
were	O
treated	O
after	O
partial	B-UNK
resection	O
of	O
the	O
tumor	B-UNK
without	O
prior	B-UNK
radiation	B-UNK
therapy	O
.	O
After	O
two	O
to	O
seven	O
cycles	B-UNK
of	O
chemotherapy	O
,	O
nine	O
patients	B-UNK
showed	O
a	O
decrease	B-UNK
in	O
tumor	B-DISEASE
size	B-UNK
and	O
surrounding	O
edema	B-UNK
on	O
contrast	B-UNK
-	O
enhanced	B-UNK
computerized	O
tomography	B-UNK
scans	O
.	O
In	O
the	O
nine	O
responders	O
,	O
median	B-UNK
duration	B-UNK
of	O
chemotherapy	O
response	B-UNK
from	O
the	O
time	O
of	O
operation	O
was	O
25	O
weeks	B-UNK
(	O
range	B-UNK
12	O
to	O
more	O
than	O
91	O
weeks	B-UNK
)	O
.	O
The	O
median	B-UNK
duration	B-UNK
of	O
survival	B-UNK
in	O
the	O
12	O
patients	B-UNK
was	O
54	O
weeks	B-UNK
(	O
range	B-UNK
21	O
to	O
more	O
than	O
156	O
weeks	B-UNK
)	O
,	O
with	O
an	O
18-month	O
survival	B-UNK
rate	B-UNK
of	O
42	O
%	O
.	O
Twenty	O
-	O
four	O
patients	B-UNK
with	O
recurrent	B-UNK
Grade	B-UNK
I	O
to	O
IV	B-UNK
astrocytomas	B-DISEASE
,	O
whose	O
resection	O
and	O
irradiation	O
therapy	O
had	O
failed	B-UNK
,	O
received	O
two	O
to	O
eight	O
courses	B-UNK
of	O
intra-arterial	O
BCNU	B-CHEMICAL
therapy	O
.	O
Seventeen	O
of	O
these	O
had	O
a	O
response	B-UNK
or	O
were	O
stable	B-UNK
for	O
a	O
median	B-UNK
of	O
20	O
weeks	B-UNK
(	O
range	B-UNK
6	O
to	O
more	O
than	O
66	O
weeks	B-UNK
)	O
.	O
The	O
catheterization	O
procedure	B-UNK
is	O
safe	O
,	O
with	O
no	O
immediate	O
complication	B-UNK
in	O
111	O
infusions	B-UNK
of	O
BCNU	B-CHEMICAL
.	O
A	O
delayed	B-UNK
complication	B-UNK
in	O
nine	O
patients	B-UNK
has	O
been	O
unilateral	B-UNK
loss	B-UNK
of	O
vision	B-UNK
secondary	B-UNK
to	O
a	O
retinal	B-DISEASE
vasculitis	I-DISEASE
.	O
The	O
frequency	B-UNK
of	O
visual	B-DISEASE
loss	I-DISEASE
decreased	B-UNK
after	O
the	O
concentration	B-UNK
of	O
the	O
ethanol	B-UNK
diluent	O
was	O
lowered	B-UNK
.	O

Blood	B-UNK
pressure	I-UNK
response	B-UNK
to	O
chronic	B-UNK
low	B-UNK
-	O
dose	B-UNK
intrarenal	B-UNK
noradrenaline	B-UNK
infusion	B-UNK
in	O
conscious	B-UNK
rats	I-UNK
.	O
Sodium	B-UNK
chloride	I-UNK
solution	B-UNK
(	O
0.9	O
%	O
)	O
or	O
noradrenaline	B-CHEMICAL
in	O
doses	B-UNK
of	O
4	O
,	O
12	O
and	O
36	O
micrograms	B-UNK
h-1	O
kg-1	O
was	O
infused	B-UNK
for	O
five	O
consecutive	B-UNK
days	I-UNK
,	O
either	O
intrarenally	O
(	O
by	O
a	O
new	O
technique	B-UNK
)	O
or	O
intravenously	O
into	O
rats	B-UNK
with	O
one	O
kidney	B-UNK
removed	B-UNK
.	O
Intrarenal	B-UNK
infusion	B-UNK
of	O
noradrenaline	B-CHEMICAL
caused	B-UNK
hypertension	B-UNK
at	O
doses	B-UNK
which	O
did	O
not	O
do	O
so	O
when	O
infused	B-UNK
intravenously	O
.	O
Intrarenal	B-UNK
compared	O
with	O
intravenous	B-UNK
infusion	B-UNK
of	O
noradrenaline	B-UNK
caused	B-UNK
higher	B-UNK
plasma	B-UNK
noradrenaline	B-CHEMICAL
concentrations	B-UNK
and	O
a	O
shift	O
of	O
the	O
plasma	B-UNK
noradrenaline	B-UNK
concentration	B-UNK
-	O
blood	B-UNK
pressure	I-UNK
effect	B-UNK
curve	B-UNK
towards	O
lower	B-UNK
plasma	B-UNK
noradrenaline	B-CHEMICAL
levels	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
hypertension	B-DISEASE
after	O
chronic	B-UNK
intrarenal	B-UNK
noradrenaline	B-CHEMICAL
infusion	B-UNK
is	O
produced	B-UNK
by	O
relatively	O
higher	B-UNK
levels	O
of	O
circulating	O
noradrenaline	B-CHEMICAL
and	O
by	O
triggering	O
of	O
an	O
additional	B-UNK
intrarenal	B-UNK
pressor	B-UNK
mechanism	B-UNK
.	O

Age	B-UNK
and	O
renal	B-UNK
clearance	B-UNK
of	O
cimetidine	B-CHEMICAL
.	O
In	O
35	O
patients	B-UNK
(	O
ages	B-UNK
20	O
to	O
86	O
yr	B-UNK
)	O
receiving	B-UNK
cimetidine	B-UNK
therapeutically	O
two	O
serum	B-UNK
samples	O
and	O
all	O
urine	B-UNK
formed	B-UNK
in	O
the	O
interim	O
were	O
collected	O
for	O
analysis	B-UNK
of	O
cimetidine	B-UNK
by	O
high	B-UNK
-	O
pressure	B-UNK
liquid	O
chromatography	O
and	O
for	O
creatinine	B-CHEMICAL
.	O
Cimetidine	B-UNK
clearance	B-UNK
decreased	B-UNK
with	O
age	B-UNK
.	O
The	O
extrapolated	O
6-hr	O
serum	B-UNK
concentration	B-UNK
of	O
cimetidine	B-UNK
per	O
unit	B-UNK
dose	B-UNK
,	O
after	O
intravenous	B-UNK
cimetidine	B-CHEMICAL
,	O
increased	B-UNK
with	O
age	B-UNK
of	O
the	O
patients	B-UNK
.	O
The	O
ratio	B-UNK
of	O
cimetidine	B-CHEMICAL
clearance	B-UNK
to	O
creatinine	B-UNK
clearance	I-UNK
(	O
Rc	O
)	O
averaged	O
4.8	O
+	O
/-	O
2.0	O
,	O
indicating	O
net	B-UNK
tubular	B-UNK
secretion	B-UNK
for	O
cimetidine	B-UNK
.	O
Rc	O
seemed	O
to	O
be	O
independent	B-UNK
of	O
age	B-UNK
and	O
decreased	B-UNK
with	O
increasing	B-UNK
serum	B-UNK
concentration	B-UNK
of	O
cimetidine	B-CHEMICAL
,	O
suggesting	O
that	O
secretion	B-UNK
of	O
cimetidine	B-UNK
is	O
a	O
saturable	O
process	O
.	O
There	O
was	O
only	O
one	O
case	B-UNK
of	O
dementia	B-DISEASE
possibly	O
due	O
to	O
cimetidine	B-UNK
(	O
with	O
a	O
drug	B-UNK
level	B-UNK
of	O
1.9	O
microgram	B-UNK
/	O
ml	B-UNK
6	O
hr	B-UNK
after	O
a	O
dose	B-UNK
)	O
in	O
a	O
group	B-UNK
of	O
13	O
patients	B-UNK
without	O
liver	B-UNK
or	O
kidney	B-UNK
disease	B-UNK
who	O
had	O
cimetidine	B-UNK
levels	O
above	O
1.25	O
microgram	B-UNK
/	O
ml	B-UNK
.	O
Thus	O
,	O
high	B-UNK
cimetidine	B-UNK
levels	O
alone	O
do	O
not	O
always	O
induce	B-UNK
dementia	B-UNK
.	O

Development	B-UNK
of	O
clear	B-DISEASE
cell	I-DISEASE
adenocarcinoma	I-DISEASE
in	O
DES-exposed	O
offspring	B-UNK
under	O
observation	B-UNK
.	O
Two	O
cases	B-UNK
of	O
clear	B-DISEASE
cell	I-DISEASE
adenocarcinoma	I-DISEASE
of	O
the	O
vagina	O
detected	B-UNK
at	O
follow	O
-	O
up	O
in	O
young	B-UNK
women	B-UNK
exposed	B-UNK
in	O
utero	O
to	O
diethylstilbestrol	B-CHEMICAL
are	O
reported	B-UNK
.	O
One	O
patient	B-UNK
,	O
aged	B-UNK
23	O
,	O
had	O
been	O
followed	O
for	O
2	O
years	B-UNK
before	O
carcinoma	B-UNK
was	O
diagnosed	B-UNK
;	O
the	O
second	O
patient	B-UNK
,	O
aged	B-UNK
22	O
,	O
had	O
been	O
seen	O
on	O
a	O
regular	B-UNK
basis	B-UNK
for	O
5	O
years	B-UNK
,	O
8	O
months	B-UNK
.	O
In	O
both	O
instances	O
,	O
suspicion	O
of	O
the	O
presence	O
of	O
carcinoma	B-UNK
was	O
aroused	O
by	O
the	O
palpation	O
of	O
a	O
small	B-UNK
nodule	O
in	O
the	O
vaginal	O
fornix	O
.	O
Hysterosalpingography	O
was	O
performed	B-UNK
on	O
both	O
patients	B-UNK
and	O
,	O
in	O
1	O
instance	O
,	O
an	O
abnormal	B-UNK
x	O
-	O
ray	O
film	O
was	O
reflected	O
by	O
the	O
gross	O
appearance	B-UNK
of	O
the	O
uterine	O
cavity	O
found	O
in	O
the	O
surgical	B-UNK
specimen	O
.	O

Phenobarbitone	B-UNK
-	O
induced	O
enlargement	B-DISEASE
of	I-DISEASE
the	I-DISEASE
liver	I-DISEASE
in	O
the	O
rat	B-UNK
:	O
its	O
relationship	B-UNK
to	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
-	O
induced	O
cirrhosis	B-UNK
.	O
The	O
yield	O
of	O
severe	B-UNK
cirrhosis	B-DISEASE
of	I-DISEASE
the	I-DISEASE
liver	I-DISEASE
(	O
defined	B-UNK
as	O
a	O
shrunken	O
finely	O
nodular	O
liver	B-UNK
with	O
micronodular	O
histology	B-UNK
,	O
ascites	B-DISEASE
greater	B-UNK
than	O
30	O
ml	B-UNK
,	O
plasma	B-UNK
albumin	B-UNK
less	O
than	O
2.2	O
g	O
/	O
dl	B-UNK
,	O
splenomegaly	B-DISEASE
2	O
-	O
3	O
times	B-UNK
normal	O
,	O
and	O
testicular	O
atrophy	B-UNK
approximately	B-UNK
half	B-UNK
normal	O
weight	B-UNK
)	O
after	O
12	O
doses	B-UNK
of	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
given	O
intragastrically	O
in	O
the	O
phenobarbitone	B-UNK
-	O
primed	O
rat	B-UNK
was	O
increased	B-UNK
from	O
25	O
%	O
to	O
56	O
%	O
by	O
giving	O
the	O
initial	B-UNK
"	O
calibrating	O
"	O
dose	B-UNK
of	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
at	O
the	O
peak	B-UNK
of	O
the	O
phenobarbitone	B-UNK
-	O
induced	O
enlargement	B-DISEASE
of	I-DISEASE
the	I-DISEASE
liver	I-DISEASE
.	O
At	O
this	O
point	B-UNK
it	O
was	O
assumed	O
that	O
the	O
cytochrome	B-UNK
P450	B-UNK
/	O
CCl4	O
toxic	B-UNK
state	B-UNK
was	O
both	O
maximal	B-UNK
and	O
stable	B-UNK
.	O
The	O
optimal	B-UNK
rat	B-UNK
size	B-UNK
to	O
begin	O
phenobarbitone	B-UNK
was	O
determined	B-UNK
as	O
100	O
g	O
,	O
and	O
this	O
size	B-UNK
as	O
a	O
group	B-UNK
had	O
a	O
mean	O
maximum	B-UNK
relative	B-UNK
liver	B-UNK
weight	B-UNK
increase	B-UNK
47	O
%	O
greater	B-UNK
than	O
normal	O
rats	B-UNK
of	O
the	O
same	O
body	B-UNK
weight	I-UNK
.	O
The	O
optimal	B-UNK
time	O
for	O
the	O
initial	B-UNK
dose	B-UNK
of	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
was	O
after	O
14	O
days	B-UNK
on	O
phenobarbitone	B-CHEMICAL
.	O

Attenuation	O
of	O
the	O
lithium	B-UNK
-	O
induced	O
diabetes	B-DISEASE
-	I-DISEASE
insipidus	I-DISEASE
-	I-DISEASE
like	I-DISEASE
syndrome	I-DISEASE
by	O
amiloride	B-UNK
in	O
rats	B-UNK
.	O
The	O
effect	B-UNK
of	O
amiloride	B-UNK
on	O
lithium	B-UNK
-	O
induced	O
polydipsia	B-DISEASE
and	O
polyuria	B-UNK
and	O
on	O
the	O
lithium	B-UNK
concentration	B-UNK
in	O
the	O
plasma	B-UNK
,	O
brain	B-UNK
,	O
kidney	B-UNK
,	O
thyroid	B-UNK
and	O
red	B-UNK
blood	B-UNK
cells	B-UNK
was	O
investigated	B-UNK
in	O
rats	B-UNK
,	O
chronically	B-UNK
treated	O
with	O
LiCl	O
.	O
Amiloride	B-UNK
reduced	B-UNK
the	O
drinking	B-UNK
and	O
urine	B-UNK
volume	B-UNK
of	O
rats	B-UNK
in	O
an	O
acute	B-UNK
(	O
6	O
or	O
12	O
h	O
)	O
and	O
a	O
subacute	B-UNK
(	O
3	O
days	B-UNK
)	O
experiment	B-UNK
.	O
6	O
h	O
after	O
the	O
administration	O
of	O
amiloride	B-UNK
,	O
a	O
reduction	O
was	O
observed	O
in	O
the	O
lithium	B-CHEMICAL
content	B-UNK
of	O
the	O
renal	B-UNK
medulla	B-UNK
but	O
not	O
in	O
the	O
other	O
organs	O
studied	O
.	O
At	O
12	O
h	O
,	O
all	O
the	O
tissues	B-UNK
showed	O
a	O
slight	B-UNK
increase	B-UNK
in	O
lithium	B-UNK
levels	O
.	O
After	O
3	O
days	B-UNK
of	O
combined	B-UNK
treatment	B-UNK
,	O
a	O
marked	O
elevation	B-UNK
in	O
plasma	B-UNK
and	O
tissue	B-UNK
lithium	B-CHEMICAL
levels	O
accompanied	B-UNK
a	O
reduction	O
in	O
water	B-UNK
intake	B-UNK
.	O
In	O
all	O
the	O
experiments	B-UNK
,	O
the	O
attenuation	O
of	O
the	O
lithium	B-CHEMICAL
-	O
induced	O
diabetes	B-DISEASE
-	I-DISEASE
insipidus	I-DISEASE
-	I-DISEASE
like	I-DISEASE
syndrome	I-DISEASE
by	O
amiloride	B-UNK
was	O
accompanied	B-UNK
by	O
a	O
reduction	O
of	O
the	O
ratio	B-UNK
between	O
the	O
lithium	B-CHEMICAL
concentration	B-UNK
in	O
the	O
renal	B-UNK
medulla	B-UNK
and	O
its	O
levels	O
in	O
the	O
blood	B-UNK
and	O
an	O
elevation	B-UNK
in	O
the	O
plasma	B-UNK
potassium	B-UNK
level	B-UNK
.	O
It	O
is	O
concluded	O
that	O
acute	B-UNK
amiloride	B-UNK
administration	O
to	O
lithium	B-UNK
-	O
treated	O
patients	B-UNK
suffering	O
from	O
polydipsia	B-DISEASE
and	O
polyuria	B-UNK
might	O
relieve	O
these	O
patients	B-UNK
but	O
prolonged	B-UNK
amiloride	B-UNK
supplementation	B-UNK
would	O
result	B-UNK
in	O
elevated	B-UNK
lithium	B-UNK
levels	O
and	O
might	O
be	O
hazardous	O
.	O

Safety	B-UNK
and	O
side	O
-	O
effects	O
of	O
alprazolam	B-CHEMICAL
.	O
Controlled	B-UNK
study	B-UNK
in	O
agoraphobia	B-DISEASE
with	O
panic	B-DISEASE
disorder	I-DISEASE
.	O
BACKGROUND	B-UNK
:	O
The	O
widespread	B-UNK
use	O
of	O
benzodiazepines	B-UNK
has	O
led	B-UNK
to	O
increasing	B-UNK
recognition	B-UNK
of	O
their	O
unwanted	O
effects	O
.	O
The	O
efficacy	B-UNK
of	O
alprazolam	B-UNK
and	O
placebo	B-UNK
in	O
panic	B-DISEASE
disorder	I-DISEASE
with	O
agoraphobia	B-DISEASE
,	O
and	O
the	O
side	O
-	O
effect	B-UNK
and	O
adverse	B-UNK
effect	I-UNK
profiles	B-UNK
of	O
both	O
drug	B-UNK
groups	B-UNK
were	O
measured	B-UNK
.	O
METHOD	B-UNK
:	O
In	O
London	O
and	O
Toronto	O
154	O
patients	B-UNK
who	O
met	B-UNK
DSM	B-UNK
-	O
III	B-UNK
criteria	B-UNK
for	O
panic	B-DISEASE
disorder	I-DISEASE
with	O
agoraphobia	B-DISEASE
were	O
randomised	B-UNK
to	O
alprazolam	B-CHEMICAL
or	O
placebo	B-UNK
.	O
Subjects	B-UNK
in	O
each	O
drug	B-UNK
group	B-UNK
also	O
received	O
either	O
exposure	B-UNK
or	O
relaxation	O
.	O
Treatment	B-UNK
was	O
from	O
weeks	B-UNK
0	O
to	O
8	O
and	O
was	O
then	O
tapered	O
from	O
weeks	B-UNK
8	O
to	O
16	O
.	O
RESULTS	B-UNK
:	O
Mean	O
alprazolam	B-UNK
dose	B-UNK
was	O
5	O
mg	B-UNK
daily	B-UNK
.	O
Compared	O
with	O
placebo	B-UNK
subjects	B-UNK
,	O
alprazolam	B-CHEMICAL
patients	B-UNK
developed	O
more	O
adverse	B-UNK
reactions	I-UNK
(	O
21	O
%	O
v.	O
0	O
%	O
)	O
of	O
depression	B-UNK
,	O
enuresis	B-DISEASE
,	O
disinhibition	O
and	O
aggression	B-DISEASE
;	O
and	O
more	O
side	O
-	O
effects	O
,	O
particularly	O
sedation	B-UNK
,	O
irritability	B-DISEASE
,	O
impaired	B-UNK
memory	B-UNK
,	O
weight	B-DISEASE
loss	I-DISEASE
and	O
ataxia	B-DISEASE
.	O
Side	O
-	O
effects	O
tended	O
to	O
diminish	O
during	O
treatment	B-UNK
but	O
remained	B-UNK
significant	B-UNK
at	O
week	B-UNK
8	O
.	O
Despite	O
this	O
,	O
the	O
drop	B-UNK
-	O
out	O
rate	B-UNK
was	O
low	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Alprazolam	B-CHEMICAL
caused	B-UNK
side	O
-	O
effects	O
and	O
adverse	B-UNK
effects	I-UNK
during	O
treatment	B-UNK
but	O
many	O
patients	B-UNK
were	O
willing	O
to	O
accept	O
these	O
.	O

Dup	O
753	O
prevents	O
the	O
development	B-UNK
of	O
puromycin	B-UNK
aminonucleoside	I-UNK
-	O
induced	O
nephrosis	B-DISEASE
.	O
The	O
appearance	B-UNK
of	O
nephrotic	B-DISEASE
syndromes	B-UNK
such	O
as	O
proteinuria	B-UNK
,	O
hypoalbuminemia	B-DISEASE
,	O
hypercholesterolemia	B-DISEASE
and	O
increase	B-UNK
in	O
blood	B-UNK
nitrogen	B-UNK
urea	B-CHEMICAL
,	O
induced	O
in	O
rats	B-UNK
by	O
injection	B-UNK
of	O
puromycin	B-UNK
aminonucleoside	I-UNK
was	O
markedly	O
inhibited	B-UNK
by	O
oral	B-UNK
administration	O
of	O
Dup	O
753	O
(	O
losartan	B-UNK
)	O
,	O
a	O
novel	O
angiotensin	B-UNK
II	I-UNK
receptor	B-UNK
antagonist	I-UNK
,	O
at	O
a	O
dose	B-UNK
of	O
1	O
or	O
2	O
mg	B-UNK
/	O
kg	B-UNK
per	O
day	O
.	O
The	O
results	B-UNK
suggest	B-UNK
a	O
possible	O
involvement	B-UNK
of	O
the	O
renin	B-UNK
-	O
angiotensin	O
system	O
in	O
the	O
development	B-UNK
of	O
puromycin	B-UNK
aminonucleoside	I-UNK
-	O
induced	O
nephrosis	B-DISEASE
.	O

Sodium	B-UNK
bicarbonate	B-UNK
alleviates	O
penile	B-DISEASE
pain	I-DISEASE
induced	O
by	O
intracavernous	O
injections	B-UNK
for	O
erectile	B-UNK
dysfunction	I-UNK
.	O
In	O
an	O
attempt	O
to	O
determine	B-UNK
whether	O
penile	B-DISEASE
pain	I-DISEASE
associated	O
with	O
intracorporeal	O
injections	B-UNK
could	O
be	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
we	O
performed	B-UNK
a	O
randomized	B-UNK
study	B-UNK
comparing	B-UNK
the	O
incidence	B-UNK
of	O
penile	B-DISEASE
pain	I-DISEASE
following	O
intracorporeal	O
injections	B-UNK
with	O
or	O
without	O
the	O
addition	B-UNK
of	O
sodium	B-UNK
bicarbonate	B-UNK
to	O
the	O
intracorporeal	O
medications	B-UNK
.	O
A	O
total	B-UNK
of	O
38	O
consecutive	B-UNK
patients	B-UNK
who	O
presented	B-UNK
to	O
our	O
clinic	B-UNK
with	O
impotence	B-DISEASE
received	O
0.2	O
ml	B-UNK
.	O
of	O
a	O
combination	B-UNK
of	O
3	O
drugs	B-UNK
:	O
6	O
mg	B-UNK
.	O
papaverine	B-UNK
,	O
100	O
micrograms	B-UNK
.	O
phentolamine	O
and	O
10	O
micrograms	B-UNK
.	O
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
with	O
(	O
pH	B-UNK
7.05	O
)	O
or	O
without	O
(	O
pH	B-UNK
4.17	O
)	O
the	O
addition	B-UNK
of	O
sodium	B-CHEMICAL
bicarbonate	B-UNK
(	O
0.03	O
mEq	B-UNK
.	O
)	O
.	O
Of	O
the	O
19	O
patients	B-UNK
without	O
sodium	B-UNK
bicarbonate	B-UNK
added	B-UNK
to	O
the	O
medication	O
11	O
(	O
58	O
%	O
)	O
complained	O
of	O
penile	B-DISEASE
pain	I-DISEASE
due	O
to	O
the	O
medication	O
,	O
while	O
only	O
1	O
of	O
the	O
19	O
men	B-UNK
(	O
5	O
%	O
)	O
who	O
received	O
sodium	B-UNK
bicarbonate	B-UNK
complained	O
of	O
penile	B-DISEASE
pain	I-DISEASE
.	O
From	O
these	O
data	B-UNK
we	O
conclude	O
that	O
the	O
penile	B-DISEASE
pain	I-DISEASE
following	O
intracorporeal	O
injections	B-UNK
is	O
most	O
likely	O
due	O
to	O
the	O
acidity	O
of	O
the	O
medication	O
,	O
which	O
can	O
be	O
overcome	O
by	O
elevating	O
the	O
pH	B-UNK
to	O
a	O
neutral	O
level	B-UNK
.	O

Prospective	B-UNK
study	I-UNK
of	O
the	O
long	B-UNK
-	O
term	O
effects	O
of	O
somatostatin	B-CHEMICAL
analog	B-UNK
(	O
octreotide	B-CHEMICAL
)	O
on	O
gallbladder	B-UNK
function	B-UNK
and	O
gallstone	O
formation	B-UNK
in	O
Chinese	B-UNK
acromegalic	B-DISEASE
patients	B-UNK
.	O
This	O
article	O
reports	B-UNK
the	O
changes	O
in	O
gallbladder	B-UNK
function	B-UNK
examined	B-UNK
by	O
ultrasonography	O
in	O
20	O
Chinese	B-UNK
patients	B-UNK
with	O
active	B-UNK
acromegaly	B-DISEASE
treated	O
with	O
sc	B-UNK
injection	B-UNK
of	O
the	O
somatostatin	B-CHEMICAL
analog	B-UNK
octreotide	B-UNK
in	O
dosages	B-UNK
of	O
300	O
-	O
1500	O
micrograms	B-UNK
/	O
day	O
for	O
a	O
mean	O
of	O
24.2	O
+	O
/-	O
13.9	O
months	B-UNK
.	O
During	O
treatment	B-UNK
with	O
octreotide	B-UNK
,	O
17	O
patients	B-UNK
developed	O
sludge	O
,	O
10	O
had	O
gallstones	B-DISEASE
,	O
and	O
1	O
developed	O
acute	B-DISEASE
cholecystitis	I-DISEASE
requiring	O
surgery	B-UNK
.	O
In	O
all	O
of	O
7	O
patients	B-UNK
examined	B-UNK
acutely	O
,	O
gallbladder	B-UNK
contractility	B-UNK
was	O
inhibited	B-UNK
after	O
a	O
single	B-UNK
100-micrograms	O
injection	B-UNK
.	O
In	O
8	O
patients	B-UNK
followed	O
for	O
24	O
weeks	B-UNK
,	O
gallbladder	B-UNK
contractility	B-UNK
remained	B-UNK
depressed	B-UNK
throughout	O
therapy	O
.	O
After	O
withdrawal	B-UNK
of	O
octreotide	B-UNK
in	O
10	O
patients	B-UNK
without	O
gallstones	B-DISEASE
,	O
8	O
patients	B-UNK
assessed	B-UNK
had	O
return	B-UNK
of	O
normal	O
gallbladder	B-UNK
contractility	B-UNK
within	O
1	O
month	B-UNK
.	O
In	O
8	O
of	O
the	O
remaining	O
10	O
patients	B-UNK
who	O
developed	O
gallstones	B-DISEASE
during	O
treatment	B-UNK
,	O
gallbladder	B-UNK
contractility	B-UNK
normalized	B-UNK
in	O
5	O
patients	B-UNK
(	O
3	O
of	O
whom	O
has	O
disappearance	O
of	O
their	O
stones	B-UNK
within	O
3	O
weeks	B-UNK
)	O
,	O
and	O
remained	B-UNK
depressed	B-DISEASE
in	O
3	O
(	O
2	O
of	O
whom	O
had	O
stones	B-UNK
present	B-UNK
at	O
6	O
months	B-UNK
)	O
.	O
Our	O
results	B-UNK
suggest	B-UNK
that	O
the	O
suppression	B-UNK
of	O
gallbladder	B-UNK
contractility	B-UNK
is	O
the	O
cause	O
of	O
the	O
successive	O
formation	B-UNK
of	O
bile	B-UNK
sludge	O
,	O
gallstones	B-DISEASE
,	O
and	O
cholecystitis	B-DISEASE
during	O
octreotide	B-CHEMICAL
therapy	O
in	O
Chinese	B-UNK
acromegalic	B-DISEASE
patients	B-UNK
.	O
It	O
is	O
therefore	O
very	O
important	B-UNK
to	O
follow	O
the	O
changes	O
of	O
gallbladder	B-UNK
function	B-UNK
during	O
long	B-UNK
-	O
term	O
octreotide	B-CHEMICAL
therapy	O
of	O
acromegalic	B-DISEASE
patients	B-UNK
.	O

Improvement	B-UNK
of	O
levodopa	B-UNK
-	O
induced	O
dyskinesia	B-DISEASE
by	O
propranolol	B-UNK
in	O
Parkinson'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
.	O
Seven	O
patients	B-UNK
suffering	O
from	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
(	O
PD	B-UNK
)	O
with	O
severely	O
disabling	O
dyskinesia	B-UNK
received	O
low	B-UNK
-	O
dose	B-UNK
propranolol	B-UNK
as	O
an	O
adjunct	O
to	O
the	O
currently	O
used	O
medical	B-UNK
treatment	B-UNK
.	O
There	O
was	O
a	O
significant	B-UNK
40	O
%	O
improvement	B-UNK
in	O
the	O
dyskinesia	B-UNK
score	O
without	O
increase	B-UNK
of	O
parkinsonian	B-DISEASE
motor	B-DISEASE
disability	I-DISEASE
.	O
Ballistic	O
and	O
choreic	O
dyskinesia	B-UNK
were	O
markedly	O
ameliorated	B-UNK
,	O
whereas	O
dystonia	B-UNK
was	O
not	O
.	O
This	O
study	B-UNK
suggests	O
that	O
administration	O
of	O
low	B-UNK
doses	I-UNK
of	O
beta-blockers	O
may	O
improve	B-UNK
levodopa	B-UNK
-	O
induced	O
ballistic	O
and	O
choreic	O
dyskinesia	B-UNK
in	O
PD	B-UNK
.	O

Morphological	B-UNK
features	B-UNK
of	O
encephalopathy	B-UNK
after	O
chronic	B-UNK
administration	O
of	O
the	O
antiepileptic	B-UNK
drug	I-UNK
valproate	B-UNK
to	O
rats	B-UNK
.	O
A	O
transmission	B-UNK
electron	B-UNK
microscopic	B-UNK
study	B-UNK
of	O
capillaries	O
in	O
the	O
cerebellar	B-UNK
cortex	B-UNK
.	O
Long	B-UNK
-	O
term	O
intragastric	O
application	B-UNK
of	O
the	O
antiepileptic	B-UNK
drug	I-UNK
sodium	B-UNK
valproate	B-UNK
(	O
Vupral	O
"	O
Polfa	O
"	O
)	O
at	O
the	O
effective	B-UNK
dose	B-UNK
of	O
200	O
mg	B-UNK
/	O
kg	B-UNK
b.	O
w.	O
once	O
daily	B-UNK
to	O
rats	B-UNK
for	O
1	O
,	O
3	O
,	O
6	O
,	O
9	O
and	O
12	O
months	B-UNK
revealed	O
neurological	B-UNK
disorders	B-UNK
indicating	O
cerebellum	B-DISEASE
damage	I-DISEASE
(	O
"	O
valproate	B-UNK
encephalopathy	B-UNK
"	O
)	O
.	O
The	O
first	O
ultrastructural	B-UNK
changes	O
in	O
structural	B-UNK
elements	O
of	O
the	O
blood	B-UNK
-	O
brain	B-UNK
-	O
barrier	B-UNK
(	O
BBB	B-UNK
)	O
in	O
the	O
cerebellar	B-UNK
cortex	B-UNK
were	O
detectable	O
after	O
3	O
months	B-UNK
of	O
the	O
experiment	B-UNK
.	O
They	O
became	O
more	O
severe	B-UNK
in	O
the	O
later	O
months	B-UNK
of	O
the	O
experiment	B-UNK
,	O
and	O
were	O
most	O
severe	B-UNK
after	O
12	O
months	B-UNK
,	O
located	O
mainly	O
in	O
the	O
molecular	B-UNK
layer	B-UNK
of	O
the	O
cerebellar	B-UNK
cortex	B-UNK
.	O
Lesions	B-UNK
of	O
the	O
capillary	B-UNK
included	B-UNK
necrosis	B-UNK
of	O
endothelial	B-UNK
cells	I-UNK
.	O
Organelles	O
of	O
these	O
cells	B-UNK
,	O
in	O
particular	O
the	O
mitochondria	B-UNK
(	O
increased	B-UNK
number	B-UNK
and	O
size	B-UNK
,	O
distinct	O
degeneration	B-UNK
of	O
their	O
matrix	B-UNK
and	O
cristae	O
)	O
and	O
Golgi	O
apparatus	O
were	O
altered	B-UNK
.	O
Reduced	B-UNK
size	B-UNK
of	O
capillary	B-UNK
lumen	O
and	O
occlusion	B-UNK
were	O
caused	B-UNK
by	O
swollen	O
endothelial	B-UNK
cells	I-UNK
which	O
had	O
luminal	B-CHEMICAL
protrusions	O
and	O
swollen	O
microvilli	O
.	O
Pressure	B-UNK
on	O
the	O
vessel	O
wall	B-UNK
was	O
produced	B-UNK
by	O
enlarged	O
perivascular	O
astrocytic	O
processes	B-UNK
.	O
Fragments	O
of	O
necrotic	B-DISEASE
endothelial	B-UNK
cells	I-UNK
were	O
in	O
the	O
vascular	B-UNK
lumens	O
and	O
in	O
these	O
there	O
was	O
loosening	O
and	O
breaking	O
of	O
tight	O
cellular	B-UNK
junctions	O
.	O
Damage	B-UNK
to	O
the	O
vascular	B-UNK
basement	B-UNK
lamina	B-UNK
was	O
also	O
observed	O
.	O
Damage	B-UNK
to	O
the	O
capillary	B-UNK
was	O
accompanied	B-UNK
by	O
marked	O
damage	B-UNK
to	O
neuroglial	O
cells	B-UNK
,	O
mainly	O
to	O
perivascular	O
processes	B-UNK
of	O
astrocytes	B-UNK
.	O
The	O
proliferation	B-UNK
of	O
astrocytes	B-UNK
(	O
Bergmann'	O
s	O
in	O
particular	O
)	O
and	O
occasionally	O
of	O
oligodendrocytes	O
was	O
found	O
.	O
Alterations	B-UNK
in	O
the	O
structural	B-UNK
elements	O
of	O
the	O
BBB	B-UNK
coexisted	O
with	O
marked	O
lesions	B-UNK
of	O
neurons	B-UNK
of	O
the	O
cerebellum	B-UNK
(	O
Purkinje	O
cells	B-UNK
are	O
earliest	O
)	O
.	O
In	O
electron	B-UNK
micrographs	O
both	O
luminal	B-CHEMICAL
and	O
antiluminal	O
sides	O
of	O
the	O
BBB	B-UNK
of	O
the	O
cerebellar	B-UNK
cortex	B-UNK
had	O
similar	B-UNK
lesions	B-UNK
.	O
The	O
possible	O
influence	B-UNK
of	O
the	O
hepatic	B-UNK
damage	B-UNK
,	O
mainly	O
hyperammonemia	B-DISEASE
,	O
upon	O
the	O
development	B-UNK
of	O
valproate	B-UNK
encephalopathy	B-DISEASE
is	O
discussed	O
.	O

Macula	O
toxicity	B-DISEASE
after	O
intravitreal	O
amikacin	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Although	O
intravitreal	O
aminoglycosides	O
have	O
substantially	O
improved	O
visual	B-UNK
prognosis	O
in	O
endophthalmitis	B-DISEASE
,	O
macular	O
infarction	B-DISEASE
may	O
impair	O
full	O
visual	B-UNK
recovery	B-UNK
.	O
METHODS	B-UNK
:	O
We	O
present	B-UNK
a	O
case	B-UNK
of	O
presumed	B-UNK
amikacin	B-UNK
retinal	B-UNK
toxicity	B-UNK
following	O
treatment	B-UNK
with	O
amikacin	B-UNK
and	O
vancomycin	B-CHEMICAL
for	O
alpha	B-UNK
-	O
haemolytic	O
streptococcal	O
endophthalmitis	B-DISEASE
.	O
RESULTS	B-UNK
:	O
Endophthalmitis	B-DISEASE
resolved	O
with	O
improvement	B-UNK
in	O
visual	B-UNK
acuity	I-UNK
to	O
6/24	O
at	O
three	O
months	B-UNK
.	O
Fundus	O
fluorescein	B-CHEMICAL
angiography	B-UNK
confirmed	B-UNK
macular	O
capillary	B-UNK
closure	O
and	O
telangiectasis	B-DISEASE
.	O
CONCLUSIONS	B-UNK
:	O
Currently	O
accepted	O
intravitreal	O
antibiotic	B-UNK
regimens	B-UNK
may	O
cause	O
retinal	B-UNK
toxicity	B-UNK
and	O
macular	O
ischaemia	O
.	O
Treatment	B-UNK
strategies	B-UNK
aimed	B-UNK
at	O
avoiding	O
retinal	B-UNK
toxicity	B-DISEASE
are	O
discussed	O
.	O

Iatrogenically	O
induced	O
intractable	O
atrioventricular	B-DISEASE
reentrant	I-DISEASE
tachycardia	I-DISEASE
after	O
verapamil	B-UNK
and	O
catheter	B-UNK
ablation	O
in	O
a	O
patient	B-UNK
with	O
Wolff	B-DISEASE
-	I-DISEASE
Parkinson	I-DISEASE
-	I-DISEASE
White	I-DISEASE
syndrome	I-DISEASE
and	O
idiopathic	B-UNK
dilated	B-UNK
cardiomyopathy	I-UNK
.	O
In	O
a	O
patient	B-UNK
with	O
WPW	B-DISEASE
syndrome	I-DISEASE
and	O
idiopathic	B-UNK
dilated	B-UNK
cardiomyopathy	I-UNK
,	O
intractable	O
atrioventricular	B-DISEASE
reentrant	I-DISEASE
tachycardia	I-DISEASE
(	O
AVRT	O
)	O
was	O
iatrogenically	O
induced	O
.	O
QRS	O
without	O
preexcitation	O
,	O
caused	B-UNK
by	O
junctional	O
escape	B-UNK
beats	B-UNK
after	O
verapamil	B-UNK
or	O
unidirectional	O
antegrade	O
block	B-UNK
of	O
accessory	O
pathway	B-UNK
after	O
catheter	B-UNK
ablation	O
,	O
established	B-UNK
frequent	B-UNK
AVRT	O
attack	B-UNK
.	O

Epidemic	O
of	O
liver	B-DISEASE
disease	I-DISEASE
caused	B-UNK
by	O
hydrochlorofluorocarbons	O
used	O
as	O
ozone	O
-	O
sparing	O
substitutes	O
of	O
chlorofluorocarbons	O
.	O
BACKGROUND	B-UNK
:	O
Hydrochlorofluorocarbons	O
(	O
HCFCs	O
)	O
are	O
used	O
increasingly	O
in	O
industry	O
as	O
substitutes	O
for	O
ozone	O
-	O
depleting	O
chlorofluorocarbons	O
(	O
CFCs	O
)	O
.	O
Limited	B-UNK
studies	B-UNK
in	O
animals	B-UNK
indicate	O
potential	B-UNK
hepatotoxicity	B-UNK
of	O
some	O
of	O
these	O
compounds	B-UNK
.	O
We	O
investigated	B-UNK
an	O
epidemic	O
of	O
liver	B-UNK
disease	I-UNK
in	O
nine	O
industrial	O
workers	O
who	O
had	O
had	O
repeated	B-UNK
accidental	O
exposure	B-UNK
to	O
a	O
mixture	O
of	O
1,1-dichloro-2,2,2-trifluoroethane	B-CHEMICAL
(	O
HCFC	O
123	O
)	O
and	O
1-chloro-1,2,2,2-tetrafluoroethane	B-CHEMICAL
(	O
HCFC	O
124	O
)	O
.	O
All	O
nine	O
exposed	B-UNK
workers	O
were	O
affected	B-UNK
to	O
various	O
degrees	B-UNK
.	O
Both	O
compounds	B-UNK
are	O
metabolised	O
in	O
the	O
same	O
way	O
as	O
1-bromo-1-chloro-2,2,2-trifluoroethane	B-CHEMICAL
(	O
halothane	B-CHEMICAL
)	O
to	O
form	B-UNK
reactive	B-UNK
trifluoroacetyl	O
halide	O
intermediates	O
,	O
which	O
have	O
been	O
implicated	B-UNK
in	O
the	O
hepatotoxicity	B-UNK
of	O
halothane	B-UNK
.	O
We	O
aimed	B-UNK
to	O
test	B-UNK
whether	O
HCFCs	O
123	O
and	O
124	O
can	O
result	B-UNK
in	O
serious	O
liver	B-UNK
disease	I-UNK
.	O
METHODS	B-UNK
:	O
For	O
one	O
severely	O
affected	B-UNK
worker	O
liver	B-UNK
biopsy	I-UNK
and	O
immunohistochemical	B-UNK
stainings	O
for	O
the	O
presence	O
of	O
trifluoroacetyl	O
protein	B-UNK
adducts	O
were	O
done	O
.	O
The	O
serum	B-UNK
of	O
six	O
affected	B-UNK
workers	O
and	O
five	O
controls	B-UNK
was	O
tested	B-UNK
for	O
autoantibodies	O
that	O
react	O
with	O
human	B-UNK
liver	B-UNK
cytochrome	B-UNK
-	O
P450	B-UNK
2E1	O
(	O
P450	B-UNK
2E1	O
)	O
and	O
P58	O
protein	B-UNK
disulphide	O
isomerase	O
isoform	O
(	O
P58	O
)	O
.	O
FINDINGS	B-UNK
:	O
The	O
liver	B-UNK
biopsy	I-UNK
sample	B-UNK
showed	O
hepatocellular	B-UNK
necrosis	B-UNK
which	O
was	O
prominent	B-UNK
in	O
perivenular	O
zone	O
three	O
and	O
extended	B-UNK
focally	O
from	O
portal	O
tracts	O
to	O
portal	O
tracts	O
and	O
centrilobular	O
areas	B-UNK
(	O
bridging	O
necrosis	B-DISEASE
)	O
.	O
Trifluoroacetyl	O
-	O
adducted	O
proteins	B-UNK
were	O
detected	B-UNK
in	O
surviving	O
hepatocytes	B-UNK
.	O
Autoantibodies	O
against	O
P450	B-UNK
2E1	O
or	O
P58	O
,	O
previously	B-UNK
associated	O
with	O
halothane	B-DISEASE
hepatitis	I-DISEASE
,	O
were	O
detected	B-UNK
in	O
the	O
serum	B-UNK
of	O
five	O
affected	B-UNK
workers	O
.	O
INTERPRETATION	O
:	O
Repeated	B-UNK
exposure	B-UNK
of	O
human	B-UNK
beings	O
to	O
HCFCs	O
123	O
and	O
124	O
can	O
result	B-UNK
in	O
serious	O
liver	B-UNK
injury	I-UNK
in	O
a	O
large	B-UNK
proportion	B-UNK
of	O
the	O
exposed	B-UNK
population	B-UNK
.	O
Although	O
the	O
exact	O
mechanism	B-UNK
of	O
hepatotoxicity	B-UNK
of	O
these	O
agents	B-UNK
is	O
not	O
known	O
,	O
the	O
results	B-UNK
suggest	B-UNK
that	O
trifluoroacetyl	O
-	O
altered	B-UNK
liver	B-UNK
proteins	B-UNK
are	O
involved	B-UNK
.	O
In	O
view	B-UNK
of	O
the	O
potentially	O
widespread	B-UNK
use	O
of	O
these	O
compounds	B-UNK
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	B-UNK
safer	O
alternatives	O
.	O

The	O
effect	B-UNK
of	O
different	O
anaesthetic	B-UNK
agents	B-UNK
in	O
hearing	B-UNK
loss	I-UNK
following	O
spinal	B-UNK
anaesthesia	I-UNK
.	O
The	O
cause	O
of	O
hearing	B-UNK
loss	I-UNK
after	O
spinal	B-UNK
anaesthesia	I-UNK
is	O
unknown	O
.	O
Up	O
until	O
now	O
,	O
the	O
only	O
factor	B-UNK
studied	O
has	O
been	O
the	O
effect	B-UNK
of	O
the	O
diameter	B-UNK
of	O
the	O
spinal	B-UNK
needle	B-UNK
on	O
post-operative	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
describe	O
this	O
hearing	B-UNK
loss	I-UNK
and	O
to	O
investigate	B-UNK
other	O
factors	B-UNK
influencing	O
the	O
degree	B-UNK
of	O
hearing	B-UNK
loss	I-UNK
.	O
Two	O
groups	B-UNK
of	O
22	O
similar	B-UNK
patients	B-UNK
were	O
studied	O
:	O
one	O
group	B-UNK
received	O
6	O
mL	B-UNK
prilocaine	B-CHEMICAL
2	O
%	O
;	O
and	O
the	O
other	O
received	O
3	O
mL	B-UNK
bupivacaine	B-UNK
0.5	O
%	O
.	O
Patients	B-UNK
given	O
prilocaine	B-CHEMICAL
were	O
more	O
likely	O
to	O
develop	B-UNK
hearing	B-UNK
loss	I-UNK
(	O
10	O
out	O
of	O
22	O
)	O
than	O
those	O
given	O
bupivacaine	B-UNK
(	O
4	O
out	O
of	O
22	O
)	O
(	O
P	O
<	O
0.05	O
)	O
.	O
The	O
average	B-UNK
hearing	B-UNK
loss	I-UNK
for	O
speech	O
frequencies	B-UNK
was	O
about	O
10	O
dB	B-UNK
after	O
prilocaine	B-UNK
and	O
15	O
dB	B-UNK
after	O
bupivacaine	B-UNK
.	O
None	O
of	O
the	O
patients	B-UNK
complained	O
of	O
subjective	B-UNK
hearing	B-UNK
loss	I-UNK
.	O
Long	B-UNK
-	O
term	O
follow	O
-	O
up	O
of	O
the	O
patients	B-UNK
was	O
not	O
possible	O
.	O

A	O
transient	B-UNK
neurological	B-UNK
deficit	B-UNK
following	O
intrathecal	B-UNK
injection	B-UNK
of	O
1	O
%	O
hyperbaric	B-UNK
bupivacaine	B-UNK
for	O
unilateral	B-UNK
spinal	B-UNK
anaesthesia	I-UNK
.	O
We	O
describe	O
a	O
case	B-UNK
of	O
transient	B-UNK
neurological	B-UNK
deficit	B-UNK
that	O
occurred	B-UNK
after	O
unilateral	B-UNK
spinal	B-UNK
anaesthesia	I-UNK
with	O
8	O
mg	B-UNK
of	O
1	O
%	O
hyperbaric	B-UNK
bupivacaine	B-UNK
slowly	O
injected	B-UNK
through	O
a	O
25-gauge	O
pencil	O
-	O
point	B-UNK
spinal	B-UNK
needle	B-UNK
.	O
The	O
surgery	B-UNK
and	O
anaesthesia	B-UNK
were	O
uneventful	O
,	O
but	O
3	O
days	B-UNK
after	O
surgery	B-UNK
,	O
the	O
patient	B-UNK
reported	B-UNK
an	O
area	B-UNK
of	O
hypoaesthesia	O
over	O
L3-L4	O
dermatomes	O
of	O
the	O
leg	B-UNK
which	O
had	O
been	O
operated	O
on	O
(	O
loss	B-UNK
of	O
pinprick	O
sensation	B-UNK
)	O
without	O
reduction	O
in	O
muscular	B-UNK
strength	O
.	O
Sensation	B-UNK
in	O
this	O
area	B-UNK
returned	B-UNK
to	O
normal	O
over	O
the	O
following	O
2	O
weeks	B-UNK
.	O
Prospective	B-UNK
multicentre	O
studies	B-UNK
with	O
a	O
large	B-UNK
population	B-UNK
and	O
a	O
long	B-UNK
follow	O
-	O
up	O
should	O
be	O
performed	B-UNK
in	O
order	B-UNK
to	O
evaluate	B-UNK
the	O
incidence	B-UNK
of	O
this	O
unusual	B-UNK
side	O
effect	B-UNK
.	O
However	O
,	O
we	O
suggest	B-UNK
that	O
a	O
low	B-UNK
solution	B-UNK
concentration	B-UNK
should	O
be	O
preferred	O
for	O
unilateral	B-UNK
spinal	B-UNK
anaesthesia	I-UNK
with	O
a	O
hyperbaric	B-UNK
anaesthetic	B-UNK
solution	B-UNK
(	O
if	O
pencil	O
-	O
point	B-UNK
needle	B-UNK
and	O
slow	B-UNK
injection	B-UNK
rate	B-UNK
are	O
employed	B-UNK
)	O
,	O
in	O
order	B-UNK
to	O
minimize	O
the	O
risk	B-UNK
of	O
a	O
localized	B-UNK
high	B-UNK
peak	B-UNK
anaesthetic	B-UNK
concentration	B-UNK
,	O
which	O
might	O
lead	B-UNK
to	O
a	O
transient	B-UNK
neurological	B-UNK
deficit	B-UNK
.	O

Pethidine	B-UNK
-	O
associated	O
seizure	B-UNK
in	O
a	O
healthy	B-UNK
adolescent	O
receiving	B-UNK
pethidine	B-UNK
for	O
postoperative	B-UNK
pain	B-UNK
control	B-UNK
.	O
A	O
healthy	B-UNK
17-year	O
-	O
old	O
male	B-UNK
received	O
standard	B-UNK
intermittent	B-UNK
doses	B-UNK
of	O
pethidine	B-UNK
via	O
a	O
patient	B-UNK
-	O
controlled	B-UNK
analgesia	B-UNK
(	O
PCA	O
)	O
pump	O
for	O
management	B-UNK
of	O
postoperative	B-UNK
pain	B-UNK
control	B-UNK
.	O
Twenty	O
-	O
three	O
h	O
postoperatively	B-UNK
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	B-UNK
seizure	B-DISEASE
.	O
Both	O
plasma	B-UNK
pethidine	B-CHEMICAL
and	O
norpethidine	O
were	O
elevated	B-UNK
in	O
the	O
range	B-UNK
associated	O
with	O
clinical	B-UNK
manifestations	B-UNK
of	O
central	B-UNK
nervous	I-UNK
system	I-UNK
excitation	O
.	O
No	O
other	O
risk	B-UNK
factors	I-UNK
for	O
CNS	B-UNK
toxicity	B-DISEASE
were	O
identified	B-UNK
.	O
This	O
method	B-UNK
allowed	O
frequent	B-UNK
self	O
-	O
dosing	O
of	O
pethidine	B-UNK
at	O
short	B-UNK
time	O
intervals	B-UNK
and	O
rapid	B-UNK
accumulation	B-UNK
of	O
pethidine	B-UNK
and	O
norpethidine	O
.	O
The	O
routine	B-UNK
use	O
of	O
pethidine	B-UNK
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	B-UNK
analgesia	B-DISEASE
should	O
be	O
reconsidered	O
.	O

Drug	B-UNK
-	O
associated	O
acute	B-UNK
-	O
onset	B-UNK
vanishing	O
bile	B-UNK
duct	I-UNK
and	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndromes	I-DISEASE
in	O
a	O
child	B-UNK
.	O
Acute	B-UNK
vanishing	O
bile	B-UNK
duct	I-UNK
syndrome	B-UNK
is	O
a	O
rare	B-UNK
but	O
established	B-UNK
cause	O
of	O
progressive	B-UNK
cholestasis	B-UNK
in	O
adults	B-UNK
,	O
is	O
most	O
often	O
drug	B-UNK
or	O
toxin	O
related	O
,	O
and	O
is	O
of	O
unknown	O
pathogenesis	B-UNK
.	O
It	O
has	O
not	O
been	O
reported	B-UNK
previously	B-UNK
in	O
children	B-UNK
.	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndrome	I-DISEASE
is	O
a	O
well	O
-	O
recognized	O
immune	B-UNK
complex	B-UNK
-	O
mediated	B-UNK
hypersensitivity	B-UNK
reaction	B-UNK
that	O
affects	O
all	O
age	B-UNK
groups	B-UNK
,	O
is	O
drug	B-UNK
or	O
infection	B-UNK
induced	O
,	O
and	O
has	O
classic	B-UNK
systemic	B-UNK
,	O
mucosal	O
,	O
and	O
dermatologic	O
manifestations	B-UNK
.	O
A	O
previously	B-UNK
healthy	B-UNK
child	B-UNK
who	O
developed	O
acute	B-UNK
,	O
severe	B-UNK
,	O
rapidly	O
progressive	B-UNK
vanishing	O
bile	B-UNK
duct	I-UNK
syndrome	B-DISEASE
shortly	B-UNK
after	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndrome	I-DISEASE
is	O
described	O
;	O
this	O
was	O
temporally	O
associated	O
with	O
ibuprofen	B-UNK
use	O
.	O
Despite	O
therapy	O
with	O
ursodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
prednisone	B-CHEMICAL
,	O
and	O
then	O
tacrolimus	B-CHEMICAL
,	O
her	O
cholestatic	B-DISEASE
disease	I-DISEASE
was	O
unrelenting	O
,	O
with	O
cirrhosis	B-DISEASE
shown	B-UNK
by	O
biopsy	B-UNK
6	O
months	B-UNK
after	O
presentation	B-UNK
.	O
This	O
case	B-UNK
documents	O
acute	B-UNK
drug	B-UNK
-	O
related	O
vanishing	O
bile	B-UNK
duct	I-UNK
syndrome	B-UNK
in	O
the	O
pediatric	B-UNK
age	B-UNK
group	B-UNK
and	O
suggests	O
shared	O
immune	B-UNK
mechanisms	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
both	O
Stevens	B-DISEASE
-	I-DISEASE
Johnson	I-DISEASE
syndrome	I-DISEASE
and	O
vanishing	O
bile	B-UNK
duct	I-UNK
syndrome	B-DISEASE
.	O

High	B-UNK
incidence	B-UNK
of	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
associated	O
with	O
appetite	B-UNK
suppressants	I-UNK
in	O
Belgium	O
.	O
Primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
is	O
a	O
rare	B-UNK
,	O
progressive	B-UNK
and	O
incurable	O
disease	B-DISEASE
,	O
which	O
has	O
been	O
associated	O
with	O
the	O
intake	B-UNK
of	O
appetite	B-UNK
suppressant	O
drugs	B-UNK
.	O
The	O
importance	B-UNK
of	O
this	O
association	B-UNK
was	O
evaluated	B-UNK
in	O
Belgium	O
while	O
this	O
country	O
still	O
had	O
no	O
restriction	O
on	O
the	O
prescription	O
of	O
appetite	B-UNK
suppressants	I-UNK
.	O
Thirty	B-UNK
-	O
five	O
patients	B-UNK
with	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
and	O
85	O
matched	O
controls	B-UNK
were	O
recruited	O
over	O
32	O
months	B-UNK
(	O
1992	O
-	O
1994	O
)	O
in	O
Belgium	O
.	O
Exposure	B-UNK
to	O
appetite	B-UNK
-	O
suppressants	O
was	O
assessed	B-UNK
on	O
the	O
basis	B-UNK
of	O
hospital	B-UNK
records	B-UNK
and	O
standardized	O
interview	O
.	O
Twenty	O
-	O
three	O
of	O
the	O
patients	B-UNK
had	O
previously	B-UNK
taken	O
appetite	B-UNK
suppressants	I-UNK
,	O
mainly	O
fenfluramines	O
,	O
as	O
compared	O
with	O
only	O
5	O
of	O
the	O
controls	B-UNK
(	O
66	O
versus	O
6	O
%	O
,	O
p<0.0001	O
)	O
.	O
Five	O
patients	B-UNK
died	O
before	O
the	O
interview	O
,	O
all	O
of	O
them	O
had	O
taken	O
appetite	B-UNK
suppressants	I-UNK
.	O
In	O
8	O
patients	B-UNK
the	O
diagnosis	B-UNK
of	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
was	O
uncertain	O
,	O
5	O
of	O
them	O
had	O
taken	O
appetite	B-UNK
suppressants	I-UNK
.	O
The	O
patients	B-UNK
who	O
had	O
been	O
exposed	B-UNK
to	O
appetite	B-UNK
suppressants	I-UNK
tended	O
to	O
be	O
on	O
average	B-UNK
more	O
severely	O
ill	O
,	O
and	O
to	O
have	O
a	O
shorter	O
median	B-UNK
delay	B-UNK
between	O
onset	B-UNK
of	O
symptoms	B-UNK
and	O
diagnosis	B-UNK
.	O
A	O
policy	O
of	O
unrestricted	O
prescription	O
of	O
appetite	B-UNK
suppressants	I-UNK
may	O
lead	B-UNK
to	O
a	O
high	B-UNK
incidence	B-UNK
of	O
associated	O
primary	B-DISEASE
pulmonary	I-DISEASE
hypertension	I-DISEASE
.	O
Intake	B-UNK
of	O
appetite	B-UNK
suppressants	I-UNK
may	O
accelerate	O
the	O
progression	B-UNK
of	O
the	O
disease	B-UNK
.	O

Choreoathetoid	B-DISEASE
movements	I-DISEASE
associated	O
with	O
rapid	B-UNK
adjustment	B-UNK
to	O
methadone	B-UNK
.	O
Choreatiform	O
hyperkinesias	O
are	O
known	O
to	O
be	O
occasional	O
movement	B-UNK
abnormalities	B-UNK
during	O
intoxications	O
with	O
cocaine	B-UNK
but	O
not	O
opiates	B-CHEMICAL
.	O
This	O
is	O
a	O
case	B-UNK
report	I-UNK
of	O
euphoria	O
and	O
choreoathetoid	B-DISEASE
movements	I-DISEASE
both	O
transiently	O
induced	O
by	O
rapid	B-UNK
adjustment	B-UNK
to	O
the	O
selective	B-UNK
mu	B-UNK
-	O
opioid	B-UNK
receptor	B-UNK
agonist	I-UNK
methadone	B-UNK
in	O
an	O
inpatient	B-UNK
previously	B-UNK
abusing	O
heroine	O
and	O
cocaine	B-UNK
.	O
In	O
addition	B-UNK
,	O
minor	B-UNK
EEG	B-UNK
abnormalities	B-UNK
occurred	B-UNK
.	O
Possible	O
underlying	B-UNK
neurobiological	O
phenomena	O
are	O
discussed	O
.	O

Cocaine	B-UNK
-	O
induced	O
mood	B-UNK
disorder	B-UNK
:	O
prevalence	B-UNK
rates	B-UNK
and	O
psychiatric	B-UNK
symptoms	B-UNK
in	O
an	O
outpatient	O
cocaine	B-CHEMICAL
-	O
dependent	B-UNK
sample	B-UNK
.	O
This	O
paper	B-UNK
attempts	O
to	O
examine	B-UNK
and	O
compare	B-UNK
prevalence	B-UNK
rates	B-UNK
and	O
symptom	B-UNK
patterns	B-UNK
of	O
DSM	B-UNK
substance	B-UNK
-	O
induced	O
and	O
other	O
mood	B-DISEASE
disorders	I-DISEASE
.	O
243	O
cocaine	B-CHEMICAL
-	O
dependent	B-UNK
outpatients	O
with	O
cocaine	B-CHEMICAL
-	O
induced	O
mood	B-UNK
disorder	B-UNK
(	O
CIMD	B-DISEASE
)	O
,	O
other	O
mood	B-DISEASE
disorders	I-DISEASE
,	O
or	O
no	O
mood	B-UNK
disorder	B-UNK
were	O
compared	O
on	O
measures	B-UNK
of	O
psychiatric	B-UNK
symptoms	B-UNK
.	O
The	O
prevalence	B-UNK
rate	B-UNK
for	O
CIMD	B-DISEASE
was	O
12	O
%	O
at	O
baseline	B-UNK
.	O
Introduction	B-UNK
of	O
the	O
DSM	B-UNK
-	O
IV	B-UNK
diagnosis	B-UNK
of	O
CIMD	B-DISEASE
did	O
not	O
substantially	O
affect	B-UNK
rates	B-UNK
of	O
the	O
other	O
depressive	B-UNK
disorders	B-UNK
.	O
Patients	B-UNK
with	O
CIMD	B-DISEASE
had	O
symptom	B-UNK
severity	B-UNK
levels	O
between	O
those	O
of	O
patients	B-UNK
with	O
and	O
without	O
a	O
mood	B-UNK
disorder	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
some	O
validity	O
for	O
the	O
new	O
DSM	B-UNK
-	O
IV	B-UNK
diagnosis	B-UNK
of	O
CIMD	B-DISEASE
,	O
but	O
also	O
suggest	B-UNK
that	O
it	O
requires	O
further	O
specification	O
and	O
replication	B-UNK
.	O

Hemolysis	B-UNK
of	O
human	B-UNK
erythrocytes	B-UNK
induced	O
by	O
tamoxifen	B-CHEMICAL
is	O
related	O
to	O
disruption	B-UNK
of	O
membrane	B-UNK
structure	B-UNK
.	O
Tamoxifen	B-CHEMICAL
(	O
TAM	B-UNK
)	O
,	O
the	O
antiestrogenic	O
drug	B-UNK
most	O
widely	B-UNK
prescribed	B-UNK
in	O
the	O
chemotherapy	O
of	O
breast	B-UNK
cancer	I-UNK
,	O
induces	O
changes	O
in	O
normal	O
discoid	O
shape	O
of	O
erythrocytes	B-UNK
and	O
hemolytic	B-UNK
anemia	I-UNK
.	O
This	O
work	O
evaluates	O
the	O
effects	O
of	O
TAM	B-UNK
on	O
isolated	B-UNK
human	B-UNK
erythrocytes	B-UNK
,	O
attempting	O
to	O
identify	B-UNK
the	O
underlying	B-UNK
mechanisms	B-UNK
on	O
TAM	B-UNK
-	O
induced	O
hemolytic	B-UNK
anemia	I-UNK
and	O
the	O
involvement	B-UNK
of	O
biomembranes	O
in	O
its	O
cytostatic	O
action	B-UNK
mechanisms	B-UNK
.	O
TAM	B-UNK
induces	O
hemolysis	B-UNK
of	O
erythrocytes	B-UNK
as	O
a	O
function	B-UNK
of	O
concentration	B-UNK
.	O
The	O
extension	B-UNK
of	O
hemolysis	B-DISEASE
is	O
variable	B-UNK
with	O
erythrocyte	O
samples	O
,	O
but	O
12.5	O
microM	B-UNK
TAM	B-UNK
induces	O
total	B-UNK
hemolysis	B-UNK
of	O
all	O
tested	B-UNK
suspensions	O
.	O
Despite	O
inducing	O
extensive	B-UNK
erythrocyte	O
lysis	O
,	O
TAM	B-UNK
does	O
not	O
shift	O
the	O
osmotic	O
fragility	O
curves	B-UNK
of	O
erythrocytes	B-UNK
.	O
The	O
hemolytic	B-UNK
effect	B-UNK
of	O
TAM	B-UNK
is	O
prevented	B-UNK
by	O
low	B-UNK
concentrations	B-UNK
of	O
alpha	B-UNK
-	O
tocopherol	O
(	O
alpha	B-UNK
-T	O
)	O
and	O
alpha	B-UNK
-	O
tocopherol	O
acetate	B-UNK
(	O
alpha	B-UNK
-	O
TAc	B-UNK
)	O
(	O
inactivated	O
functional	B-UNK
hydroxyl	O
)	O
indicating	O
that	O
TAM	B-UNK
-	O
induced	O
hemolysis	B-UNK
is	O
not	O
related	O
to	O
oxidative	B-UNK
membrane	B-UNK
damage	B-UNK
.	O
This	O
was	O
further	O
evidenced	O
by	O
absence	O
of	O
oxygen	B-UNK
consumption	I-UNK
and	O
hemoglobin	B-UNK
oxidation	O
both	O
determined	B-UNK
in	O
parallel	O
with	O
TAM	B-UNK
-	O
induced	O
hemolysis	B-UNK
.	O
Furthermore	O
,	O
it	O
was	O
observed	O
that	O
TAM	B-UNK
inhibits	B-UNK
the	O
peroxidation	B-UNK
of	O
human	B-UNK
erythrocytes	B-UNK
induced	O
by	O
AAPH	O
,	O
thus	O
ruling	O
out	O
TAM	B-UNK
-	O
induced	O
cell	B-UNK
oxidative	B-UNK
stress	I-UNK
.	O
Hemolysis	B-UNK
caused	B-UNK
by	O
TAM	B-UNK
was	O
not	O
preceded	B-UNK
by	O
the	O
leakage	O
of	O
K(+	O
)	O
from	O
the	O
cells	B-UNK
,	O
also	O
excluding	O
a	O
colloid	O
-	O
osmotic	O
type	B-UNK
mechanism	B-UNK
of	O
hemolysis	B-UNK
,	O
according	O
to	O
the	O
effects	O
on	O
osmotic	O
fragility	O
curves	B-UNK
.	O
However	O
,	O
TAM	B-UNK
induces	O
release	B-UNK
of	O
peripheral	B-UNK
proteins	B-UNK
of	O
membrane	B-UNK
-	O
cytoskeleton	O
and	O
cytosol	O
proteins	B-UNK
essentially	O
bound	O
to	O
band	O
3	O
.	O
Either	O
alpha	B-UNK
-T	O
or	O
alpha	B-UNK
-	O
TAc	B-UNK
increases	B-UNK
membrane	B-UNK
packing	O
and	O
prevents	O
TAM	B-UNK
partition	O
into	O
model	B-UNK
membranes	B-UNK
.	O
These	O
effects	O
suggest	B-UNK
that	O
the	O
protection	B-UNK
from	O
hemolysis	B-DISEASE
by	O
tocopherols	O
is	O
related	O
to	O
a	O
decreased	B-UNK
TAM	B-UNK
incorporation	O
in	O
condensed	O
membranes	B-UNK
and	O
the	O
structural	B-UNK
damage	B-UNK
of	O
the	O
erythrocyte	O
membrane	B-UNK
is	O
consequently	O
avoided	O
.	O
Therefore	O
,	O
TAM	B-UNK
-	O
induced	O
hemolysis	B-DISEASE
results	B-UNK
from	O
a	O
structural	B-UNK
perturbation	O
of	O
red	B-UNK
cell	B-UNK
membrane	B-UNK
,	O
leading	B-UNK
to	O
changes	O
in	O
the	O
framework	O
of	O
the	O
erythrocyte	O
membrane	B-UNK
and	O
its	O
cytoskeleton	O
caused	B-UNK
by	O
its	O
high	B-UNK
partition	O
in	O
the	O
membrane	B-UNK
.	O
These	O
defects	B-UNK
explain	O
the	O
abnormal	B-UNK
erythrocyte	O
shape	O
and	O
decreased	B-UNK
mechanical	B-UNK
stability	B-UNK
promoted	O
by	O
TAM	B-UNK
,	O
resulting	B-UNK
in	O
hemolytic	B-UNK
anemia	I-UNK
.	O
Additionally	B-UNK
,	O
since	O
membrane	B-UNK
leakage	O
is	O
a	O
final	B-UNK
stage	B-UNK
of	O
cytotoxicity	B-DISEASE
,	O
the	O
disruption	B-UNK
of	O
the	O
structural	B-UNK
characteristics	B-UNK
of	O
biomembranes	O
by	O
TAM	B-UNK
may	O
contribute	B-UNK
to	O
the	O
multiple	B-UNK
mechanisms	B-UNK
of	O
its	O
anticancer	O
action	B-UNK
.	O

Changes	O
of	O
sodium	B-CHEMICAL
and	O
ATP	B-UNK
affinities	O
of	O
the	O
cardiac	B-UNK
(	O
Na	B-UNK
,	O
K)-ATPase	O
during	O
and	O
after	O
nitric	B-UNK
oxide	I-UNK
deficient	B-UNK
hypertension	B-UNK
.	O
In	O
the	O
cardiovascular	B-UNK
system	O
,	O
NO	O
is	O
involved	B-UNK
in	O
the	O
regulation	B-UNK
of	O
a	O
variety	O
of	O
functions	B-UNK
.	O
Inhibition	B-UNK
of	O
NO	O
synthesis	B-UNK
induces	O
sustained	B-UNK
hypertension	B-UNK
.	O
In	O
several	O
models	B-UNK
of	O
hypertension	B-DISEASE
,	O
elevation	B-UNK
of	O
intracellular	B-UNK
sodium	B-UNK
level	B-UNK
was	O
documented	O
in	O
cardiac	B-UNK
tissue	B-UNK
.	O
To	O
assess	B-UNK
the	O
molecular	B-UNK
basis	B-UNK
of	O
disturbances	B-UNK
in	O
transmembraneous	O
transport	B-UNK
of	O
Na+	O
,	O
we	O
studied	O
the	O
response	B-UNK
of	O
cardiac	B-UNK
(	O
Na	B-UNK
,	O
K)-ATPase	O
to	O
NO	O
-	O
deficient	B-UNK
hypertension	B-UNK
induced	O
in	O
rats	B-UNK
by	O
NO	O
-	O
synthase	B-UNK
inhibition	B-UNK
with	O
40	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
N(G)-nitro	O
-	O
L	O
-	O
arginine	O
methyl	B-UNK
ester	B-UNK
(	O
L	O
-	O
NAME	O
)	O
for	O
4	O
four	O
weeks	B-UNK
.	O
After	O
4-week	O
administration	O
of	O
L	O
-	O
NAME	O
,	O
the	O
systolic	B-UNK
blood	I-UNK
pressure	I-UNK
(	O
SBP	B-UNK
)	O
increased	B-UNK
by	O
36	O
%	O
.	O
Two	O
weeks	B-UNK
after	O
terminating	O
the	O
treatment	B-UNK
,	O
the	O
SBP	B-UNK
recovered	O
to	O
control	B-UNK
value	O
.	O
When	O
activating	O
the	O
(	O
Na	B-UNK
,	O
K)-ATPase	O
with	O
its	O
substrate	B-UNK
ATP	B-CHEMICAL
,	O
no	O
changes	O
in	O
Km	O
and	O
Vmax	O
values	O
were	O
observed	O
in	O
NO	O
-	O
deficient	B-UNK
rats	B-UNK
.	O
During	O
activation	B-UNK
with	O
Na+	O
,	O
the	O
Vmax	O
remained	B-UNK
unchanged	I-UNK
,	O
however	O
the	O
K(Na	O
)	O
increased	B-UNK
by	O
50	O
%	O
,	O
indicating	O
a	O
profound	B-UNK
decrease	B-UNK
in	O
the	O
affinity	B-UNK
of	O
the	O
Na+-binding	O
site	B-UNK
in	O
NO	O
-	O
deficient	B-UNK
rats	B-UNK
.	O
After	O
recovery	B-UNK
from	O
hypertension	B-UNK
,	O
the	O
activity	B-UNK
of	O
(	O
Na	B-UNK
,	O
K)-ATPase	O
increased	B-UNK
,	O
due	O
to	O
higher	B-UNK
affinity	B-UNK
of	O
the	O
ATP	B-UNK
-	O
binding	B-UNK
site	B-UNK
,	O
as	O
revealed	O
from	O
the	O
lowered	B-UNK
Km	O
value	O
for	O
ATP	B-UNK
.	O
The	O
K(Na	O
)	O
value	O
for	O
Na+	O
returned	B-UNK
to	O
control	B-UNK
value	O
.	O
Inhibition	B-UNK
of	O
NO	O
-	O
synthase	B-UNK
induced	O
a	O
reversible	B-UNK
hypertension	B-UNK
accompanied	B-UNK
by	O
depressed	B-UNK
Na+-extrusion	O
from	O
cardiac	B-UNK
cells	B-UNK
as	O
a	O
consequence	B-UNK
of	O
deteriorated	O
Na+-binding	O
properties	B-UNK
of	O
the	O
(	O
Na	B-UNK
,	O
K)-ATPase	O
.	O
After	O
recovery	B-UNK
of	O
blood	B-UNK
pressure	I-UNK
to	O
control	B-UNK
values	O
,	O
the	O
extrusion	O
of	O
Na+	O
from	O
cardiac	B-UNK
cells	B-UNK
was	O
normalized	B-UNK
,	O
as	O
revealed	O
by	O
restoration	O
of	O
the	O
(	O
Na	B-UNK
,	O
K)-ATPase	O
activity	B-UNK
.	O

Effects	O
of	O
long	B-UNK
-	O
term	O
pretreatment	B-UNK
with	O
isoproterenol	B-CHEMICAL
on	O
bromocriptine	B-UNK
-	O
induced	O
tachycardia	B-UNK
in	O
conscious	B-UNK
rats	I-UNK
.	O
It	O
has	O
been	O
shown	B-UNK
that	O
bromocriptine	B-UNK
-	O
induced	O
tachycardia	B-DISEASE
,	O
which	O
persisted	O
after	O
adrenalectomy	O
,	O
is	O
(	O
i	O
)	O
mediated	B-UNK
by	O
central	B-UNK
dopamine	B-UNK
D2	I-UNK
receptor	B-UNK
activation	B-UNK
and	O
(	O
ii	B-UNK
)	O
reduced	B-UNK
by	O
5-day	O
isoproterenol	B-CHEMICAL
pretreatment	B-UNK
,	O
supporting	O
therefore	O
the	O
hypothesis	B-UNK
that	O
this	O
effect	B-UNK
is	O
dependent	B-UNK
on	O
sympathetic	B-UNK
outflow	O
to	O
the	O
heart	B-UNK
.	O
This	O
study	B-UNK
was	O
conducted	B-UNK
to	O
examine	B-UNK
whether	O
prolonged	B-UNK
pretreatment	B-UNK
with	O
isoproterenol	B-UNK
could	O
abolish	O
bromocriptine	B-UNK
-	O
induced	O
tachycardia	B-UNK
in	O
conscious	B-UNK
rats	I-UNK
.	O
Isoproterenol	B-UNK
pretreatment	B-UNK
for	O
15	O
days	B-UNK
caused	B-UNK
cardiac	B-DISEASE
hypertrophy	I-DISEASE
without	O
affecting	O
baseline	B-UNK
blood	B-UNK
pressure	I-UNK
and	I-UNK
heart	I-UNK
rate	I-UNK
.	O
In	O
control	B-UNK
rats	B-UNK
,	O
intravenous	B-UNK
bromocriptine	B-UNK
(	O
150	O
microg	B-UNK
/	O
kg	B-UNK
)	O
induced	O
significant	B-UNK
hypotension	B-DISEASE
and	O
tachycardia	B-UNK
.	O
Bromocriptine	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
was	O
unaffected	B-UNK
by	O
isoproterenol	B-CHEMICAL
pretreatment	B-UNK
,	O
while	O
tachycardia	B-UNK
was	O
reversed	B-UNK
to	O
significant	B-UNK
bradycardia	B-UNK
,	O
an	O
effect	B-UNK
that	O
was	O
partly	O
reduced	B-UNK
by	O
i.v	B-UNK
.	O
domperidone	B-CHEMICAL
(	O
0.5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
Neither	O
cardiac	B-UNK
vagal	O
nor	O
sympathetic	B-UNK
tone	B-UNK
was	O
altered	B-UNK
by	O
isoproterenol	B-CHEMICAL
pretreatment	B-UNK
.	O
In	O
isolated	B-UNK
perfused	B-UNK
heart	B-UNK
preparations	B-UNK
from	O
isoproterenol	B-UNK
-	O
pretreated	B-UNK
rats	B-UNK
,	O
the	O
isoproterenol	B-UNK
-	O
induced	O
maximal	B-UNK
increase	B-UNK
in	O
left	B-UNK
ventricular	I-UNK
systolic	B-UNK
pressure	B-UNK
was	O
significantly	B-UNK
reduced	I-UNK
,	O
compared	O
with	O
saline	B-UNK
-	O
pretreated	B-UNK
rats	B-UNK
(	O
the	O
EC50	O
of	O
the	O
isoproterenol	B-UNK
-	O
induced	O
increase	B-UNK
in	O
left	B-UNK
ventricular	I-UNK
systolic	B-UNK
pressure	B-UNK
was	O
enhanced	B-UNK
approximately	B-UNK
22-fold	O
)	O
.	O
These	O
results	B-UNK
show	O
that	O
15-day	O
isoproterenol	B-UNK
pretreatment	B-UNK
not	O
only	O
abolished	O
but	O
reversed	B-UNK
bromocriptine	B-UNK
-	O
induced	O
tachycardia	B-DISEASE
to	O
bradycardia	B-UNK
,	O
an	O
effect	B-UNK
that	O
is	O
mainly	O
related	O
to	O
further	O
cardiac	B-UNK
beta-adrenoceptor	O
desensitization	O
rather	O
than	O
to	O
impairment	B-UNK
of	O
autonomic	B-UNK
regulation	B-UNK
of	O
the	O
heart	B-UNK
.	O
They	O
suggest	B-UNK
that	O
,	O
in	O
normal	O
conscious	B-UNK
rats	I-UNK
,	O
the	O
central	B-UNK
tachycardia	B-UNK
of	O
bromocriptine	B-UNK
appears	B-UNK
to	O
predominate	O
and	O
to	O
mask	O
the	O
bradycardia	B-DISEASE
of	O
this	O
agonist	B-UNK
at	O
peripheral	B-UNK
dopamine	B-UNK
D2	I-UNK
receptors	B-UNK
.	O

A	O
developmental	B-UNK
analysis	B-UNK
of	O
clonidine'	O
s	O
effects	O
on	O
cardiac	B-UNK
rate	B-UNK
and	O
ultrasound	B-UNK
production	B-UNK
in	O
infant	B-UNK
rats	B-UNK
.	O
Under	O
controlled	B-UNK
conditions	O
,	O
infant	B-UNK
rats	B-UNK
emit	O
ultrasonic	O
vocalizations	O
during	O
extreme	O
cold	O
exposure	B-UNK
and	O
after	O
administration	O
of	O
the	O
alpha(2	O
)	O
adrenoceptor	B-UNK
agonist	B-UNK
,	O
clonidine	B-CHEMICAL
.	O
Previous	B-UNK
investigations	B-UNK
have	O
determined	B-UNK
that	O
,	O
in	O
response	B-UNK
to	O
clonidine	B-UNK
,	O
ultrasound	B-UNK
production	B-UNK
increases	B-UNK
through	O
the	O
2nd	O
-	O
week	B-UNK
postpartum	O
and	O
decreases	B-UNK
thereafter	O
.	O
Given	O
that	O
sympathetic	B-UNK
neural	B-UNK
dominance	O
exhibits	O
a	O
similar	B-UNK
developmental	B-UNK
pattern	B-UNK
,	O
and	O
given	O
that	O
clonidine	B-UNK
induces	O
sympathetic	B-UNK
withdrawal	B-UNK
and	O
bradycardia	B-UNK
,	O
we	O
hypothesized	B-UNK
that	O
clonidine'	O
s	O
developmental	B-UNK
effects	O
on	O
cardiac	B-UNK
rate	B-UNK
and	O
ultrasound	B-UNK
production	B-UNK
would	O
mirror	O
each	O
other	O
.	O
Therefore	O
,	O
in	O
the	O
present	B-UNK
experiment	B-UNK
,	O
the	O
effects	O
of	O
clonidine	B-CHEMICAL
administration	O
(	O
0.5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
on	O
cardiac	B-UNK
rate	B-UNK
and	O
ultrasound	B-UNK
production	B-UNK
were	O
examined	B-UNK
in	O
2-	O
,	O
8-	O
,	O
15-	O
,	O
and	O
20-day	O
-	O
old	O
rats	B-UNK
.	O
Age	B-UNK
-	O
related	O
changes	O
in	O
ultrasound	B-UNK
production	B-UNK
corresponded	O
with	O
changes	O
in	O
cardiovascular	B-UNK
variables	B-UNK
,	O
including	O
baseline	B-UNK
cardiac	B-UNK
rate	B-UNK
and	O
clonidine	B-CHEMICAL
-	O
induced	O
bradycardia	B-UNK
.	O
This	O
experiment	B-UNK
is	O
discussed	O
with	O
regard	B-UNK
to	O
the	O
hypothesis	B-UNK
that	O
ultrasound	B-UNK
production	B-UNK
is	O
the	O
acoustic	O
by	O
-	O
product	B-UNK
of	O
a	O
physiological	B-UNK
maneuver	O
that	O
compensates	O
for	O
clonidine'	O
s	O
detrimental	O
effects	O
on	O
cardiovascular	B-UNK
function	B-UNK
.	O

Differential	B-UNK
effects	O
of	O
systemically	O
administered	O
ketamine	B-CHEMICAL
and	O
lidocaine	B-CHEMICAL
on	O
dynamic	B-UNK
and	O
static	O
hyperalgesia	B-UNK
induced	O
by	O
intradermal	B-UNK
capsaicin	B-UNK
in	O
humans	B-UNK
.	O
We	O
have	O
examined	B-UNK
the	O
effect	B-UNK
of	O
systemic	B-UNK
administration	O
of	O
ketamine	B-CHEMICAL
and	O
lidocaine	B-UNK
on	O
brush	O
-	O
evoked	B-UNK
(	O
dynamic	B-UNK
)	O
pain	B-UNK
and	O
punctate	O
-	O
evoked	B-UNK
(	O
static	O
)	O
hyperalgesia	B-UNK
induced	O
by	O
capsaicin	B-CHEMICAL
.	O
In	O
a	O
randomized	B-UNK
,	O
double-blind	O
,	O
placebo	B-UNK
-	O
controlled	B-UNK
,	O
crossover	B-UNK
study	I-UNK
,	O
we	O
studied	O
12	O
volunteers	B-UNK
in	O
three	O
experiments	B-UNK
.	O
Capsaicin	B-CHEMICAL
100	O
micrograms	B-UNK
was	O
injected	B-UNK
intradermally	O
on	O
the	O
volar	O
forearm	B-UNK
followed	O
by	O
an	O
i.v	B-UNK
.	O
infusion	B-UNK
of	O
ketamine	B-UNK
(	O
bolus	B-UNK
0.1	O
mg	B-UNK
kg-1	O
over	O
10	O
min	B-UNK
followed	O
by	O
infusion	B-UNK
of	O
7	O
micrograms	B-UNK
kg-1	O
min-1	O
)	O
,	O
lidocaine	B-CHEMICAL
5	O
mg	B-UNK
kg-1	O
or	O
saline	B-UNK
for	O
50	O
min	B-UNK
.	O
Infusion	B-UNK
started	O
15	O
min	B-UNK
after	O
injection	B-UNK
of	O
capsaicin	B-UNK
.	O
The	O
following	O
were	O
measured	B-UNK
:	O
spontaneous	B-UNK
pain	B-UNK
,	O
pain	B-UNK
evoked	B-UNK
by	O
punctate	O
and	O
brush	O
stimuli	B-UNK
(	O
VAS	B-UNK
)	O
,	O
and	O
areas	B-UNK
of	O
brush	O
-	O
evoked	B-UNK
and	O
punctate	O
-	O
evoked	B-UNK
hyperalgesia	B-UNK
.	O
Ketamine	B-UNK
reduced	B-UNK
both	O
the	O
area	B-UNK
of	O
brush	O
-	O
evoked	B-UNK
and	O
punctate	O
-	O
evoked	B-UNK
hyperalgesia	B-UNK
significantly	B-UNK
and	O
it	O
tended	O
to	O
reduce	B-UNK
brush	O
-	O
evoked	B-UNK
pain	B-UNK
.	O
Lidocaine	B-UNK
reduced	B-UNK
the	O
area	B-UNK
of	O
punctate	O
-	O
evoked	B-UNK
hyperalgesia	B-UNK
significantly	B-UNK
.	O
It	O
tended	O
to	O
reduce	B-UNK
VAS	B-UNK
scores	O
of	O
spontaneous	B-UNK
pain	B-UNK
but	O
had	O
no	O
effect	B-UNK
on	O
evoked	B-UNK
pain	B-UNK
.	O
The	O
differential	B-UNK
effects	O
of	O
ketamine	B-UNK
and	O
lidocaine	B-UNK
on	O
static	O
and	O
dynamic	B-UNK
hyperalgesia	B-UNK
suggest	B-UNK
that	O
the	O
two	O
types	B-UNK
of	O
hyperalgesia	B-UNK
are	O
mediated	B-UNK
by	O
separate	B-UNK
mechanisms	B-UNK
and	O
have	O
a	O
distinct	O
pharmacology	B-UNK
.	O

Cyclosporine	B-UNK
and	O
tacrolimus	B-CHEMICAL
-	O
associated	O
thrombotic	B-UNK
microangiopathy	I-UNK
.	O
The	O
development	B-UNK
of	O
thrombotic	B-UNK
microangiopathy	I-UNK
(	O
TMA	B-DISEASE
)	O
associated	O
with	O
the	O
use	O
of	O
cyclosporine	B-UNK
has	O
been	O
well	O
documented	O
.	O
Treatments	O
have	O
included	B-UNK
discontinuation	B-UNK
or	O
reduction	O
of	O
cyclosporine	B-CHEMICAL
dose	B-UNK
with	O
or	O
without	O
concurrent	B-UNK
plasma	B-UNK
exchange	O
,	O
plasma	B-UNK
infusion	B-UNK
,	O
anticoagulation	B-UNK
,	O
and	O
intravenous	B-UNK
immunoglobulin	O
G	O
infusion	B-UNK
.	O
However	O
,	O
for	O
recipients	B-UNK
of	O
organ	B-UNK
transplantation	B-UNK
,	O
removing	O
the	O
inciting	O
agent	B-UNK
is	O
not	O
without	O
the	O
attendant	O
risk	B-UNK
of	O
precipitating	O
acute	B-UNK
rejection	B-UNK
and	O
graft	B-UNK
loss	B-UNK
.	O
The	O
last	O
decade	O
has	O
seen	O
the	O
emergence	O
of	O
tacrolimus	B-CHEMICAL
as	O
a	O
potent	B-UNK
immunosuppressive	B-UNK
agent	B-UNK
with	O
mechanisms	B-UNK
of	O
action	B-UNK
virtually	O
identical	B-UNK
to	O
those	O
of	O
cyclosporine	B-UNK
.	O
As	O
a	O
result	B-UNK
,	O
switching	B-UNK
to	O
tacrolimus	B-CHEMICAL
has	O
been	O
reported	B-UNK
to	O
be	O
a	O
viable	O
therapeutic	B-UNK
option	O
in	O
the	O
setting	B-UNK
of	O
cyclosporine	B-CHEMICAL
-	O
induced	O
TMA	B-DISEASE
.	O
With	O
the	O
more	O
widespread	B-UNK
application	B-UNK
of	O
tacrolimus	B-UNK
in	O
organ	B-UNK
transplantation	B-UNK
,	O
tacrolimus	B-CHEMICAL
-	O
associated	O
TMA	B-DISEASE
has	O
also	O
been	O
recognized	O
.	O
However	O
,	O
literature	B-UNK
regarding	O
the	O
incidence	B-UNK
of	O
the	O
recurrence	B-DISEASE
of	O
TMA	B-DISEASE
in	O
patients	B-UNK
exposed	B-UNK
sequentially	O
to	O
cyclosporine	B-UNK
and	O
tacrolimus	B-UNK
is	O
limited	B-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
a	O
living	B-UNK
donor	B-UNK
renal	B-UNK
transplant	I-UNK
recipient	O
who	O
developed	O
cyclosporine	B-UNK
-	O
induced	O
TMA	B-DISEASE
that	O
responded	O
to	O
the	O
withdrawal	B-UNK
of	O
cyclosporine	B-CHEMICAL
in	O
conjunction	B-UNK
with	O
plasmapheresis	O
and	O
fresh	O
frozen	O
plasma	B-UNK
replacement	B-UNK
therapy	O
.	O
Introduction	B-UNK
of	O
tacrolimus	B-UNK
as	O
an	O
alternative	B-UNK
immunosuppressive	B-UNK
agent	B-UNK
resulted	B-UNK
in	O
the	O
recurrence	B-UNK
of	O
TMA	B-DISEASE
and	O
the	O
subsequent	B-UNK
loss	B-UNK
of	O
the	O
renal	B-UNK
allograft	B-UNK
.	O
Patients	B-UNK
who	O
are	O
switched	O
from	O
cyclosporine	B-CHEMICAL
to	O
tacrolimus	B-UNK
or	O
vice	O
versa	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
of	O
recurrent	B-UNK
TMA	B-DISEASE
.	O

Repeated	B-UNK
transient	B-UNK
anuria	B-DISEASE
following	O
losartan	B-UNK
administration	O
in	O
a	O
patient	B-UNK
with	O
a	O
solitary	B-DISEASE
kidney	I-DISEASE
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
70-year	O
-	O
old	O
hypertensive	B-DISEASE
man	B-UNK
with	O
a	O
solitary	B-DISEASE
kidney	I-DISEASE
and	O
chronic	B-DISEASE
renal	I-DISEASE
insufficiency	I-DISEASE
who	O
developed	O
two	O
episodes	B-UNK
of	O
transient	B-UNK
anuria	B-UNK
after	O
losartan	B-CHEMICAL
administration	O
.	O
He	O
was	O
hospitalized	B-UNK
for	O
a	O
myocardial	B-DISEASE
infarction	I-DISEASE
with	O
pulmonary	B-DISEASE
edema	I-DISEASE
,	O
treated	O
with	O
high	B-UNK
-	O
dose	B-UNK
diuretics	O
.	O
Due	O
to	O
severe	B-UNK
systolic	B-UNK
dysfunction	B-UNK
losartan	B-CHEMICAL
was	O
prescribed	B-UNK
.	O
Surprisingly	O
,	O
the	O
first	O
dose	B-UNK
of	O
50	O
mg	B-UNK
of	O
losartan	B-UNK
resulted	B-UNK
in	O
a	O
sudden	B-UNK
anuria	B-UNK
,	O
which	O
lasted	B-UNK
eight	O
hours	B-UNK
despite	O
high	B-UNK
-	O
dose	B-UNK
furosemide	B-UNK
and	O
amine	O
infusion	B-UNK
.	O
One	O
week	B-UNK
later	O
,	O
by	O
mistake	O
,	O
losartan	B-UNK
was	O
prescribed	B-UNK
again	O
and	O
after	O
the	O
second	O
dose	B-UNK
of	O
50	O
mg	B-UNK
,	O
the	O
patient	B-UNK
developed	O
a	O
second	O
episode	B-UNK
of	O
transient	B-UNK
anuria	B-UNK
lasting	B-UNK
10	O
hours	B-UNK
.	O
During	O
these	O
two	O
episodes	B-UNK
,	O
his	O
blood	B-UNK
pressure	I-UNK
diminished	B-UNK
but	O
no	O
severe	B-UNK
hypotension	B-UNK
was	O
noted	B-UNK
.	O
Ultimately	O
,	O
an	O
arteriography	O
showed	O
a	O
70	O
-	O
80	O
%	O
renal	B-UNK
artery	B-UNK
stenosis	B-UNK
.	O
In	O
this	O
patient	B-UNK
,	O
renal	B-UNK
artery	B-UNK
stenosis	B-UNK
combined	B-UNK
with	O
heart	B-UNK
failure	I-UNK
and	O
diuretic	B-UNK
therapy	O
certainly	O
resulted	B-UNK
in	O
a	O
strong	B-UNK
activation	B-UNK
of	O
the	O
renin	B-UNK
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
.	O
Under	O
such	O
conditions	O
,	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	B-UNK
blockade	B-UNK
by	O
losartan	B-CHEMICAL
probably	O
induced	O
a	O
critical	B-UNK
fall	B-UNK
in	O
glomerular	B-UNK
filtration	I-UNK
pressure	B-UNK
.	O
This	O
case	B-UNK
report	I-UNK
highlights	O
the	O
fact	B-UNK
that	O
the	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	B-UNK
antagonist	I-UNK
losartan	B-UNK
can	O
cause	O
serious	O
unexpected	O
complications	B-UNK
in	O
patients	B-UNK
with	O
renovascular	O
disease	B-DISEASE
and	O
should	O
be	O
used	O
with	O
extreme	O
caution	B-UNK
in	O
this	O
setting	B-UNK
.	O

In	O
vivo	B-UNK
protection	B-UNK
of	O
dna	B-UNK
damage	B-UNK
associated	O
apoptotic	B-UNK
and	O
necrotic	B-DISEASE
cell	B-UNK
deaths	B-UNK
during	O
acetaminophen	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-UNK
,	O
amiodarone	B-UNK
-	O
induced	O
lung	B-UNK
toxicity	B-UNK
and	O
doxorubicin	B-CHEMICAL
-	O
induced	O
cardiotoxicity	B-UNK
by	O
a	O
novel	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	B-UNK
.	O
Grape	O
seed	O
extract	B-UNK
,	O
primarily	O
a	O
mixture	O
of	O
proanthocyanidins	O
,	O
has	O
been	O
shown	B-UNK
to	O
modulate	B-UNK
a	O
wide	O
-	O
range	B-UNK
of	O
biological	B-UNK
,	O
pharmacological	B-UNK
and	O
toxicological	O
effects	O
which	O
are	O
mainly	O
cytoprotective	O
.	O
This	O
study	B-UNK
assessed	B-UNK
the	O
ability	B-UNK
of	O
IH636	O
grape	O
seed	O
proanthocyanidin	O
extract	B-UNK
(	O
GSPE	O
)	O
to	O
prevent	B-UNK
acetaminophen	B-UNK
(	O
AAP)-induced	O
nephrotoxicity	B-UNK
,	O
amiodarone	B-UNK
(	O
AMI)-induced	O
lung	B-UNK
toxicity	B-UNK
,	O
and	O
doxorubicin	B-UNK
(	O
DOX)-induced	O
cardiotoxicity	B-UNK
in	O
mice	B-UNK
.	O
Experimental	B-UNK
design	B-UNK
consisted	B-UNK
of	O
four	O
groups	B-UNK
:	O
control	B-UNK
(	O
vehicle	B-UNK
alone	O
)	O
,	O
GSPE	O
alone	O
,	O
drug	B-UNK
alone	O
and	O
GSPE+drug	O
.	O
For	O
the	O
cytoprotection	O
study	B-UNK
,	O
animals	B-UNK
were	O
orally	O
gavaged	O
100	O
mg	B-UNK
/	O
Kg	B-UNK
GSPE	O
for	O
7	O
-	O
10	O
days	B-UNK
followed	O
by	O
i.p	B-UNK
.	O
injections	B-UNK
of	O
organ	B-UNK
specific	B-UNK
three	O
drugs	B-UNK
(	O
AAP	B-UNK
:	O
500	O
mg	B-UNK
/	O
Kg	B-UNK
for	O
24	O
h	O
;	O
AMI	B-UNK
:	O
50	O
mg	B-UNK
/	O
Kg	B-UNK
/	O
day	O
for	O
four	O
days	B-UNK
;	O
DOX	B-UNK
:	O
20	O
mg	B-UNK
/	O
Kg	B-UNK
for	O
48	O
h	O
)	O
.	O
Parameters	O
of	O
study	B-UNK
included	B-UNK
analysis	B-UNK
of	O
serum	B-UNK
chemistry	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
orderly	O
fragmentation	O
of	O
genomic	O
DNA	B-UNK
(	O
both	O
endonuclease	O
-	O
dependent	B-UNK
and	O
independent	B-UNK
)	O
in	O
addition	B-UNK
to	O
microscopic	B-UNK
evaluation	B-UNK
of	O
damage	B-UNK
and	O
/	O
or	O
protection	B-UNK
in	O
corresponding	O
PAS	O
stained	O
tissues	B-UNK
.	O
Results	B-UNK
indicate	O
that	O
GSPE	O
preexposure	O
prior	B-UNK
to	O
AAP	B-UNK
,	O
AMI	B-UNK
and	O
DOX	B-UNK
,	O
provided	O
near	O
complete	B-UNK
protection	B-UNK
in	O
terms	B-UNK
of	O
serum	B-UNK
chemistry	O
changes	O
(	O
ALT	O
,	O
BUN	O
and	O
CPK	O
)	O
,	O
and	O
significantly	B-UNK
reduced	I-UNK
DNA	B-UNK
fragmentation	O
.	O
Histopathological	B-UNK
examination	B-UNK
of	O
kidney	B-UNK
,	O
heart	B-UNK
and	O
lung	B-UNK
sections	B-UNK
revealed	O
moderate	B-UNK
to	O
massive	B-UNK
tissue	B-UNK
damage	B-UNK
with	O
a	O
variety	O
of	O
morphological	B-UNK
aberrations	O
by	O
all	O
the	O
three	O
drugs	B-UNK
in	O
the	O
absence	O
of	O
GSPE	O
preexposure	O
than	O
in	O
its	O
presence	O
.	O
GSPE+drug	O
exposed	B-UNK
tissues	B-UNK
exhibited	O
minor	B-UNK
residual	B-UNK
damage	B-UNK
or	O
near	O
total	B-UNK
recovery	B-UNK
.	O
Additionally	B-UNK
,	O
histopathological	B-UNK
alterations	B-UNK
mirrored	O
both	O
serum	B-UNK
chemistry	O
changes	O
and	O
the	O
pattern	B-UNK
of	O
DNA	B-UNK
fragmentation	O
.	O
Interestingly	O
,	O
all	O
the	O
drugs	B-UNK
,	O
such	O
as	O
,	O
AAP	B-UNK
,	O
AMI	B-UNK
and	O
DOX	B-UNK
induced	O
apoptotic	B-UNK
death	B-UNK
in	O
addition	B-UNK
to	O
necrosis	B-UNK
in	O
the	O
respective	O
organs	O
which	O
was	O
very	O
effectively	B-UNK
blocked	B-UNK
by	O
GSPE	O
.	O
Since	O
AAP	B-UNK
,	O
AMI	B-CHEMICAL
and	O
DOX	B-UNK
undergo	O
biotransformation	O
and	O
are	O
known	O
to	O
produce	B-UNK
damaging	O
radicals	O
in	O
vivo	B-UNK
,	O
the	O
protection	B-UNK
by	O
GSPE	O
may	O
be	O
linked	B-UNK
to	O
both	O
inhibition	B-UNK
of	O
metabolism	B-UNK
and	O
/	O
or	O
detoxification	O
of	O
cytotoxic	B-UNK
radicals	O
.	O
In	O
addition	B-UNK
,	O
its	O
'	O
presumed	B-UNK
contribution	B-UNK
to	O
DNA	B-UNK
repair	B-UNK
may	O
be	O
another	O
important	B-UNK
attribute	O
,	O
which	O
played	O
a	O
role	O
in	O
the	O
chemoprevention	O
process	O
.	O
Additionally	B-UNK
,	O
this	O
may	O
have	O
been	O
the	O
first	O
report	B-UNK
on	O
AMI	B-CHEMICAL
-	O
induced	O
apoptotic	B-UNK
death	B-UNK
in	O
the	O
lung	B-UNK
tissue	B-UNK
.	O
Taken	O
together	O
,	O
these	O
events	B-UNK
undoubtedly	O
establish	O
GSPE'	O
s	O
abundant	O
bioavailability	O
,	O
and	O
the	O
power	B-UNK
to	O
defend	O
multiple	B-UNK
target	O
organs	O
from	O
toxic	B-UNK
assaults	O
induced	O
by	O
structurally	O
diverse	O
and	O
functionally	O
different	O
entities	O
in	O
vivo	B-UNK
.	O

Palpebral	O
twitching	O
in	O
a	O
depressed	B-UNK
adolescent	O
on	O
citalopram	B-CHEMICAL
.	O
Current	B-UNK
estimates	O
suggest	B-UNK
that	O
between	O
0.4	O
%	O
and	O
8.3	O
%	O
of	O
children	B-UNK
and	O
adolescents	O
are	O
affected	B-UNK
by	O
major	B-DISEASE
depression	I-DISEASE
.	O
We	O
report	B-UNK
a	O
favorable	O
response	B-UNK
to	O
treatment	B-UNK
with	O
citalopram	B-CHEMICAL
by	O
a	O
15-year	O
-	O
old	O
boy	B-UNK
with	O
major	B-DISEASE
depression	I-DISEASE
who	O
exhibited	O
palpebral	O
twitching	O
during	O
his	O
first	O
2	O
weeks	B-UNK
of	O
treatment	B-UNK
.	O
This	O
may	O
have	O
been	O
a	O
side	O
effect	B-UNK
of	O
citalopram	B-CHEMICAL
as	O
it	O
remitted	O
with	O
redistribution	O
of	O
doses	B-UNK
.	O

Metamizol	O
potentiates	O
morphine	B-CHEMICAL
antinociception	O
but	O
not	O
constipation	B-DISEASE
after	O
chronic	B-UNK
treatment	B-UNK
.	O
This	O
work	O
evaluates	O
the	O
antinociceptive	B-UNK
and	O
constipating	B-DISEASE
effects	O
of	O
the	O
combination	B-UNK
of	O
3.2	O
mg	B-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
morphine	B-CHEMICAL
with	O
177.8	O
mg	B-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
metamizol	O
in	O
acutely	O
and	O
chronically	B-UNK
treated	O
(	O
once	O
a	O
day	O
for	O
12	O
days	B-UNK
)	O
rats	B-UNK
.	O
On	O
the	O
13th	O
day	O
,	O
antinociceptive	B-UNK
effects	O
were	O
assessed	B-UNK
using	O
a	O
model	B-UNK
of	O
inflammatory	B-UNK
nociception	O
,	O
pain	B-DISEASE
-	O
induced	O
functional	B-UNK
impairment	B-UNK
model	B-UNK
,	O
and	O
the	O
charcoal	O
meal	O
test	B-UNK
was	O
used	O
to	O
evaluate	B-UNK
the	O
intestinal	B-UNK
transit	O
.	O
Simultaneous	B-UNK
administration	O
of	O
morphine	B-UNK
with	O
metamizol	O
resulted	B-UNK
in	O
a	O
markedly	O
antinociceptive	B-UNK
potentiation	B-UNK
and	O
an	O
increasing	B-UNK
of	O
the	O
duration	B-UNK
of	O
action	B-UNK
after	O
a	O
single	B-UNK
(	O
298+/-7	O
vs	O
.	O
139+/-36	O
units	B-UNK
area	B-UNK
(	O
ua	O
)	O
;	O
P<0.001	O
)	O
and	O
repeated	B-UNK
administration	O
(	O
280+/-17	O
vs	O
.	O
131+/-22	O
ua	O
;	O
P<0.001	O
)	O
.	O
Antinociceptive	B-UNK
effect	B-UNK
of	O
morphine	B-CHEMICAL
was	O
reduced	B-UNK
in	O
chronically	B-UNK
treated	B-UNK
rats	I-UNK
(	O
39+/-10	O
vs	O
.	O
18+/-5	O
au	O
)	O
while	O
the	O
combination	B-UNK
-	O
induced	O
antinociception	O
was	O
remained	B-UNK
similar	B-UNK
as	O
an	O
acute	B-UNK
treatment	B-UNK
(	O
298+/-7	O
vs	O
.	O
280+/-17	O
au	O
)	O
.	O
Acute	B-UNK
antinociceptive	B-UNK
effects	O
of	O
the	O
combination	B-UNK
were	O
partially	O
prevented	B-UNK
by	O
3.2	O
mg	B-UNK
/	O
kg	B-UNK
naloxone	B-CHEMICAL
s.c	B-UNK
.	O
(	O
P<0.05	O
)	O
,	O
suggesting	O
the	O
partial	B-UNK
involvement	B-UNK
of	O
the	O
opioidergic	O
system	O
in	O
the	O
synergism	O
observed	O
.	O
In	O
independent	B-UNK
groups	B-UNK
,	O
morphine	B-UNK
inhibited	B-UNK
the	O
intestinal	B-UNK
transit	O
in	O
48+/-4	O
%	O
and	O
38+/-4	O
%	O
after	O
acute	B-UNK
and	O
chronic	B-UNK
treatment	B-UNK
,	O
respectively	O
,	O
suggesting	O
that	O
tolerance	B-UNK
did	O
not	O
develop	B-UNK
to	O
the	O
constipating	B-DISEASE
effects	O
.	O
The	O
combination	B-UNK
inhibited	B-UNK
intestinal	B-UNK
transit	O
similar	B-UNK
to	O
that	O
produced	B-UNK
by	O
morphine	B-CHEMICAL
regardless	O
of	O
the	O
time	O
of	O
treatment	B-UNK
,	O
suggesting	O
that	O
metamizol	O
did	O
not	O
potentiate	O
morphine	B-CHEMICAL
-	O
induced	O
constipation	B-DISEASE
.	O
These	O
findings	B-UNK
show	O
a	O
significant	B-UNK
interaction	B-UNK
between	O
morphine	B-CHEMICAL
and	O
metamizol	O
in	O
chronically	B-UNK
treated	B-UNK
rats	I-UNK
,	O
suggesting	O
that	O
this	O
combination	B-UNK
could	O
be	O
useful	O
for	O
the	O
treatment	B-UNK
of	O
chronic	B-DISEASE
pain	I-DISEASE
.	O

Ifosfamide	B-UNK
encephalopathy	B-DISEASE
presenting	O
with	O
asterixis	B-DISEASE
.	O
CNS	B-UNK
toxic	B-UNK
effects	I-UNK
of	O
the	O
antineoplastic	B-UNK
agent	B-UNK
ifosfamide	B-UNK
(	O
IFX	O
)	O
are	O
frequent	B-UNK
and	O
include	O
a	O
variety	O
of	O
neurological	B-UNK
symptoms	B-UNK
that	O
can	O
limit	B-UNK
drug	B-UNK
use	O
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
a	O
51-year	O
-	O
old	O
man	B-UNK
who	O
developed	O
severe	B-UNK
,	O
disabling	O
negative	B-UNK
myoclonus	B-UNK
of	O
the	O
upper	B-UNK
and	O
lower	B-UNK
extremities	O
after	O
the	O
infusion	B-UNK
of	O
ifosfamide	B-UNK
for	O
plasmacytoma	B-DISEASE
.	O
He	O
was	O
awake	O
,	O
revealed	O
no	O
changes	O
of	O
mental	B-UNK
status	I-UNK
and	O
at	O
rest	B-UNK
there	O
were	O
no	O
further	O
motor	B-UNK
symptoms	B-UNK
.	O
Cranial	B-UNK
magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
and	O
extensive	B-UNK
laboratory	B-UNK
studies	B-UNK
failed	B-UNK
to	O
reveal	O
structural	B-UNK
lesions	B-UNK
of	O
the	O
brain	B-UNK
and	O
metabolic	B-UNK
abnormalities	B-UNK
.	O
An	O
electroencephalogram	O
showed	O
continuous	B-UNK
,	O
generalized	O
irregular	O
slowing	O
with	O
admixed	O
periodic	O
triphasic	O
waves	O
indicating	O
symptomatic	B-UNK
encephalopathy	B-UNK
.	O
The	O
administration	O
of	O
ifosfamide	B-UNK
was	O
discontinued	O
and	O
within	O
12	O
h	O
the	O
asterixis	B-DISEASE
resolved	O
completely	O
.	O
In	O
the	O
patient	B-UNK
described	O
,	O
the	O
presence	O
of	O
asterixis	B-DISEASE
during	O
infusion	B-UNK
of	O
ifosfamide	B-UNK
,	O
normal	O
laboratory	B-UNK
findings	B-UNK
and	O
imaging	B-UNK
studies	B-UNK
and	O
the	O
resolution	B-UNK
of	O
symptoms	B-UNK
following	O
the	O
discontinuation	B-UNK
of	O
the	O
drug	B-UNK
suggest	B-UNK
that	O
negative	B-UNK
myoclonus	B-UNK
is	O
associated	O
with	O
the	O
use	O
of	O
IFX	O
.	O

Sub-chronic	O
low	B-UNK
dose	I-UNK
gamma	B-UNK
-	O
vinyl	O
GABA	B-UNK
(	O
vigabatrin	B-CHEMICAL
)	O
inhibits	B-UNK
cocaine	B-UNK
-	O
induced	O
increases	B-UNK
in	O
nucleus	B-UNK
accumbens	B-UNK
dopamine	B-UNK
.	O
RATIONALE	B-UNK
:	O
gamma	B-UNK
-	O
Vinyl	O
GABA	B-UNK
(	O
GVG	O
)	O
irreversibly	O
inhibits	B-UNK
GABA	B-UNK
-	O
transaminase	B-UNK
.	O
This	O
non-receptor	O
mediated	B-UNK
inhibition	B-UNK
requires	O
de	B-UNK
novo	I-UNK
synthesis	B-UNK
for	O
restoration	O
of	O
functional	B-UNK
GABA	B-UNK
catabolism	O
.	O
OBJECTIVES	B-UNK
:	O
Given	O
its	O
preclinical	B-UNK
success	B-UNK
for	O
treating	O
substance	B-UNK
abuse	B-UNK
and	O
the	O
increased	B-UNK
risk	B-UNK
of	O
visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
(	O
VFD	B-DISEASE
)	O
associated	O
with	O
cumulative	B-UNK
lifetime	B-UNK
exposure	B-UNK
,	O
we	O
explored	O
the	O
effects	O
of	O
sub-chronic	O
low	B-UNK
dose	I-UNK
GVG	O
on	O
cocaine	B-CHEMICAL
-	O
induced	O
increases	B-UNK
in	O
nucleus	B-UNK
accumbens	B-UNK
(	O
NAcc	O
)	O
dopamine	B-CHEMICAL
(	O
DA	B-UNK
)	O
.	O
METHODS	B-UNK
:	O
Using	O
in	O
vivo	B-UNK
microdialysis	O
,	O
we	O
compared	O
acute	B-UNK
exposure	B-UNK
(	O
450	O
mg	B-UNK
/	O
kg	B-UNK
)	O
to	O
an	O
identical	B-UNK
sub-chronic	O
exposure	B-UNK
(	O
150	O
mg	B-UNK
/	O
kg	B-UNK
per	O
day	O
for	O
3	O
days	B-UNK
)	O
,	O
followed	O
by	O
1-	O
or	O
3-day	O
washout	O
.	O
Finally	B-UNK
,	O
we	O
examined	B-UNK
the	O
low	B-UNK
dose	I-UNK
of	O
150	O
mg	B-UNK
/	O
kg	B-UNK
(	O
50	O
mg	B-UNK
/	O
kg	B-UNK
per	O
day	O
)	O
using	O
a	O
similar	B-UNK
washout	O
period	B-UNK
.	O
RESULTS	B-UNK
:	O
Sub-chronic	O
GVG	O
exposure	B-UNK
inhibited	B-UNK
the	O
effect	B-UNK
of	O
cocaine	B-UNK
for	O
3	O
days	B-UNK
,	O
which	O
exceeded	O
in	O
magnitude	B-UNK
and	O
duration	B-UNK
the	O
identical	B-UNK
acute	B-UNK
dose	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Sub-chronic	O
low	B-UNK
dose	I-UNK
GVG	O
potentiates	O
and	O
extends	O
the	O
inhibition	B-UNK
of	O
cocaine	B-UNK
-	O
induced	O
increases	B-UNK
in	O
dopamine	B-UNK
,	O
effectively	B-UNK
reducing	B-UNK
cumulative	B-UNK
exposures	O
and	O
the	O
risk	B-UNK
for	O
VFDS	O
.	O

Amount	O
of	O
bleeding	B-DISEASE
and	O
hematoma	B-UNK
size	B-UNK
in	O
the	O
collagenase	O
-	O
induced	O
intracerebral	B-UNK
hemorrhage	I-UNK
rat	B-UNK
model	B-UNK
.	O
The	O
aggravated	O
risk	B-UNK
on	O
intracerebral	B-UNK
hemorrhage	I-UNK
(	O
ICH	B-DISEASE
)	O
with	O
drugs	B-UNK
used	O
for	O
stroke	B-DISEASE
patients	B-UNK
should	O
be	O
estimated	O
carefully	B-UNK
.	O
We	O
therefore	O
established	B-UNK
sensitive	B-UNK
quantification	O
methods	B-UNK
and	O
provided	O
a	O
rat	B-UNK
ICH	B-UNK
model	B-UNK
for	O
detection	B-UNK
of	O
ICH	B-UNK
deterioration	B-UNK
.	O
In	O
ICH	B-UNK
intrastriatally	O
induced	O
by	O
0.014-unit	O
,	O
0.070-unit	O
,	O
and	O
0.350-unit	O
collagenase	O
,	O
the	O
amount	O
of	O
bleeding	B-UNK
was	O
measured	B-UNK
using	O
a	O
hemoglobin	B-UNK
assay	B-UNK
developed	O
in	O
the	O
present	B-UNK
study	B-UNK
and	O
was	O
compared	O
with	O
the	O
morphologically	O
determined	B-UNK
hematoma	B-UNK
volume	B-UNK
.	O
The	O
blood	B-UNK
amounts	B-UNK
and	O
hematoma	B-UNK
volumes	O
were	O
significantly	B-UNK
correlated	B-UNK
,	O
and	O
the	O
hematoma	B-DISEASE
induced	O
by	O
0.014-unit	O
collagenase	O
was	O
adequate	B-UNK
to	O
detect	B-UNK
ICH	B-UNK
deterioration	B-UNK
.	O
In	O
ICH	B-DISEASE
induction	B-UNK
using	O
0.014-unit	O
collagenase	O
,	O
heparin	B-UNK
enhanced	B-UNK
the	O
hematoma	B-UNK
volume	B-UNK
3.4-fold	O
over	O
that	O
seen	O
in	O
control	B-UNK
ICH	B-UNK
animals	B-UNK
and	O
the	O
bleeding	B-UNK
7.6-fold	O
.	O
Data	B-UNK
suggest	I-UNK
that	O
this	O
sensitive	B-UNK
hemoglobin	B-UNK
assay	B-UNK
is	O
useful	O
for	O
ICH	B-UNK
detection	B-UNK
,	O
and	O
that	O
a	O
model	B-UNK
with	O
a	O
small	B-UNK
ICH	B-UNK
induced	O
with	O
a	O
low	B-UNK
-	O
dose	B-UNK
collagenase	O
should	O
be	O
used	O
for	O
evaluation	B-UNK
of	O
drugs	B-UNK
that	O
may	O
affect	B-UNK
ICH	B-UNK
.	O

Estradiol	B-UNK
reduces	O
seizure	B-DISEASE
-	O
induced	O
hippocampal	B-UNK
injury	B-UNK
in	O
ovariectomized	O
female	B-UNK
but	O
not	O
in	O
male	B-UNK
rats	I-UNK
.	O
Estrogens	O
protect	B-UNK
ovariectomized	O
rats	B-UNK
from	O
hippocampal	B-UNK
injury	B-UNK
induced	O
by	O
kainic	O
acid	B-UNK
-	O
induced	O
status	B-UNK
epilepticus	I-UNK
(	O
SE	B-DISEASE
)	O
.	O
We	O
compared	O
the	O
effects	O
of	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
in	O
adult	B-UNK
male	I-UNK
and	O
ovariectomized	O
female	B-UNK
rats	I-UNK
subjected	O
to	O
lithium	B-CHEMICAL
-	O
pilocarpine	B-UNK
-	O
induced	O
SE	B-DISEASE
.	O
Rats	B-UNK
received	O
subcutaneous	B-UNK
injections	B-UNK
of	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
(	O
2	O
microg	B-UNK
/	O
rat	B-UNK
)	O
or	O
oil	B-UNK
once	O
daily	B-UNK
for	O
four	O
consecutive	B-UNK
days	I-UNK
.	O
SE	B-UNK
was	O
induced	O
20	O
h	O
following	O
the	O
second	O
injection	B-UNK
and	O
terminated	O
3	O
h	O
later	O
.	O
The	O
extent	B-UNK
of	O
silver	O
-	O
stained	O
CA3	O
and	O
CA1	B-UNK
hippocampal	B-UNK
neurons	B-UNK
was	O
evaluated	B-UNK
2	O
days	B-UNK
after	O
SE	B-UNK
.	O
17beta	B-CHEMICAL
-	I-CHEMICAL
Estradiol	I-CHEMICAL
did	O
not	O
alter	O
the	O
onset	B-UNK
of	O
first	O
clonus	O
in	O
ovariectomized	O
rats	B-UNK
but	O
accelerated	B-UNK
it	O
in	O
males	B-UNK
.	O
17beta	B-CHEMICAL
-	I-CHEMICAL
Estradiol	I-CHEMICAL
reduced	B-UNK
the	O
argyrophilic	O
neurons	B-UNK
in	O
the	O
CA1	B-UNK
and	O
CA3-C	O
sectors	O
of	O
ovariectomized	O
rats	B-UNK
.	O
In	O
males	B-UNK
,	O
estradiol	B-UNK
increased	B-UNK
the	O
total	B-UNK
damage	B-UNK
score	O
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
the	O
effects	O
of	O
estradiol	B-CHEMICAL
on	O
seizure	B-UNK
threshold	B-UNK
and	O
damage	B-UNK
may	O
be	O
altered	B-UNK
by	O
sex	B-UNK
-	O
related	O
differences	B-UNK
in	O
the	O
hormonal	O
environment	O
.	O

Delirium	B-UNK
during	O
clozapine	B-CHEMICAL
treatment	B-UNK
:	O
incidence	B-UNK
and	O
associated	O
risk	B-UNK
factors	I-UNK
.	O
BACKGROUND	B-UNK
:	O
Incidence	B-UNK
and	O
risk	B-UNK
factors	I-UNK
for	O
delirium	B-UNK
during	O
clozapine	B-UNK
treatment	B-UNK
require	O
further	O
clarification	O
.	O
METHODS	B-UNK
:	O
We	O
used	O
computerized	O
pharmacy	O
records	B-UNK
to	O
identify	B-UNK
all	O
adult	B-UNK
psychiatric	B-UNK
inpatients	O
treated	O
with	O
clozapine	B-CHEMICAL
(	O
1995	O
-	O
96	O
)	O
,	O
reviewed	B-UNK
their	O
medical	B-UNK
records	I-UNK
to	O
score	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
delirium	B-DISEASE
,	O
and	O
tested	B-UNK
associations	B-UNK
with	O
potential	B-UNK
risk	B-UNK
factors	I-UNK
.	O
RESULTS	B-UNK
:	O
Subjects	B-UNK
(	O
n	O
=	O
139	O
)	O
were	O
72	O
women	B-UNK
and	O
67	O
men	B-UNK
,	O
aged	B-UNK
40.8	O
+	O
/-	O
12.1	O
years	B-UNK
,	O
hospitalized	B-UNK
for	O
24.9	O
+	O
/-	O
23.3	O
days	B-UNK
,	O
and	O
given	O
clozapine	B-UNK
,	O
gradually	O
increased	B-UNK
to	O
an	O
average	B-UNK
daily	B-UNK
dose	I-UNK
of	O
282	O
+	O
/-	O
203	O
mg	B-UNK
(	O
3.45	O
+	O
/-	O
2.45	O
mg	B-UNK
/	O
kg	B-UNK
)	O
for	O
18.9	O
+	O
/-	O
16.4	O
days	B-UNK
.	O
Delirium	B-UNK
was	O
diagnosed	B-UNK
in	O
14	O
(	O
10.1	O
%	O
incidence	B-UNK
,	O
or	O
1.48	O
cases	B-UNK
/	O
person	O
-	O
years	B-UNK
of	O
exposure	B-UNK
)	O
;	O
71.4	O
%	O
of	O
cases	B-UNK
were	O
moderate	B-UNK
or	O
severe	B-UNK
.	O
Associated	O
factors	B-UNK
were	O
co-treatment	O
with	O
other	O
centrally	B-UNK
antimuscarinic	O
agents	B-UNK
,	O
poor	O
clinical	B-UNK
outcome	B-UNK
,	O
older	B-UNK
age	B-UNK
,	O
and	O
longer	O
hospitalization	B-UNK
(	O
by	O
17.5	O
days	B-UNK
,	O
increasing	B-UNK
cost	B-UNK
)	O
;	O
sex	B-UNK
,	O
diagnosis	B-UNK
or	O
medical	B-UNK
co-morbidity	O
,	O
and	O
daily	B-UNK
clozapine	B-UNK
dose	B-UNK
,	O
which	O
fell	B-UNK
with	O
age	B-UNK
,	O
were	O
unrelated	O
.	O
CONCLUSIONS	B-UNK
:	O
Delirium	B-UNK
was	O
found	O
in	O
10	O
%	O
of	O
clozapine	B-UNK
-	O
treated	O
inpatients	O
,	O
particularly	O
in	O
older	B-UNK
patients	B-UNK
exposed	B-UNK
to	O
other	O
central	B-UNK
anticholinergics	O
.	O
Delirium	B-UNK
was	O
inconsistently	O
recognized	O
clinically	B-UNK
in	O
milder	O
cases	B-UNK
and	O
was	O
associated	O
with	O
increased	B-UNK
length	B-UNK
-	O
of	O
-	O
stay	O
and	O
higher	B-UNK
costs	O
,	O
and	O
inferior	B-UNK
clinical	B-UNK
outcome	B-UNK
.	O

Ketoconazole	B-UNK
-	O
induced	O
neurologic	B-UNK
sequelae	B-UNK
.	O
A	O
77-y	O
-	O
old	O
patient	B-UNK
developed	O
weakness	B-UNK
of	O
extremities	O
,	O
legs	O
paralysis	B-UNK
,	O
dysarthria	B-DISEASE
and	O
tremor	B-UNK
1	O
h	O
after	O
ingestion	B-UNK
of	O
200	O
mg	B-UNK
ketoconazole	B-CHEMICAL
for	O
the	O
first	O
time	O
in	O
his	O
life	B-UNK
.	O
All	O
complaints	O
faded	O
away	O
within	O
24	O
h.	O
Few	O
days	B-UNK
later	O
,	O
the	O
patient	B-UNK
used	O
another	O
200	O
mg	B-UNK
ketoconazole	B-UNK
tablet	O
,	O
and	O
within	O
an	O
hour	B-UNK
experienced	B-UNK
a	O
similar	B-UNK
clinical	B-UNK
picture	O
,	O
which	O
resolved	O
again	O
spontaneously	B-UNK
within	O
hours	B-UNK
.	O
Laboratory	B-UNK
evaluations	O
,	O
including	O
head	B-UNK
CT	B-UNK
scan	O
,	O
were	O
normal	O
.	O
This	O
case	B-UNK
illustrates	O
the	O
need	O
for	O
close	B-UNK
vigilance	O
in	O
adverse	B-DISEASE
drug	I-DISEASE
reactions	I-DISEASE
,	O
particularly	O
in	O
the	O
elderly	B-UNK
.	O

Noxious	O
chemical	B-UNK
stimulation	B-UNK
of	O
rat	B-UNK
facial	B-UNK
mucosa	O
increases	B-UNK
intracranial	B-UNK
blood	B-UNK
flow	I-UNK
through	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	B-UNK
--	O
an	O
experimental	B-UNK
model	B-UNK
for	O
vascular	B-UNK
dysfunctions	B-UNK
in	O
cluster	B-DISEASE
headache	I-DISEASE
.	O
Cluster	B-DISEASE
headache	I-DISEASE
is	O
characterized	B-UNK
by	O
typical	B-UNK
autonomic	B-UNK
dysfunctions	B-UNK
including	O
facial	B-UNK
and	O
intracranial	B-UNK
vascular	B-UNK
disturbances	B-UNK
.	O
Both	O
the	O
trigeminal	O
and	O
the	O
cranial	B-UNK
parasympathetic	O
systems	B-UNK
may	O
be	O
involved	B-UNK
in	O
mediating	O
these	O
dysfunctions	B-UNK
.	O
An	O
experimental	B-UNK
model	B-UNK
was	O
developed	O
in	O
the	O
rat	B-UNK
to	O
measure	B-UNK
changes	O
in	O
lacrimation	O
and	O
intracranial	B-UNK
blood	B-UNK
flow	I-UNK
following	O
noxious	O
chemical	B-UNK
stimulation	B-UNK
of	O
facial	B-UNK
mucosa	O
.	O
Blood	B-UNK
flow	I-UNK
was	O
monitored	O
in	O
arteries	B-UNK
of	O
the	O
exposed	B-UNK
cranial	B-UNK
dura	O
mater	O
and	O
the	O
parietal	O
cortex	B-UNK
using	O
laser	B-UNK
Doppler	O
flowmetry	O
.	O
Capsaicin	B-CHEMICAL
(	O
0.01	O
-	O
1	O
mm	B-UNK
)	O
applied	O
to	O
oral	B-UNK
or	O
nasal	O
mucosa	O
induced	O
increases	B-UNK
in	O
dural	O
and	O
cortical	B-UNK
blood	B-UNK
flow	I-UNK
and	O
provoked	O
lacrimation	O
.	O
These	O
responses	O
were	O
blocked	B-UNK
by	O
systemic	B-UNK
pre	B-UNK
-	O
administration	O
of	O
hexamethonium	B-CHEMICAL
chloride	B-UNK
(	O
20	O
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
The	O
evoked	B-UNK
increases	B-UNK
in	O
dural	O
blood	B-UNK
flow	I-UNK
were	O
also	O
abolished	O
by	O
topical	B-UNK
pre	B-UNK
-	O
administration	O
of	O
atropine	B-UNK
(	O
1	O
mm	B-UNK
)	O
and	O
[	O
Lys1	O
,	O
Pro2,5	O
,	O
Arg3,4	O
,	O
Tyr6]-VIP	O
(	O
0.1	O
mm	B-UNK
)	O
,	O
a	O
vasoactive	B-UNK
intestinal	B-UNK
polypeptide	O
(	O
VIP	B-UNK
)	O
antagonist	B-UNK
,	O
onto	O
the	O
exposed	B-UNK
dura	O
mater	O
.	O
We	O
conclude	O
that	O
noxious	O
stimulation	B-UNK
of	O
facial	B-UNK
mucosa	O
increases	B-UNK
intracranial	B-UNK
blood	B-UNK
flow	I-UNK
and	O
lacrimation	O
via	O
a	O
trigemino	O
-	O
parasympathetic	O
reflex	B-UNK
.	O
The	O
blood	B-UNK
flow	I-UNK
responses	O
seem	O
to	O
be	O
mediated	B-UNK
by	O
the	O
release	B-UNK
of	O
acetylcholine	B-UNK
and	O
VIP	B-UNK
within	O
the	O
meninges	O
.	O
Similar	B-UNK
mechanisms	B-UNK
may	O
be	O
involved	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
cluster	B-DISEASE
headache	I-DISEASE
.	O

Recurrent	B-UNK
excitation	O
in	O
the	O
dentate	B-UNK
gyrus	I-UNK
of	O
a	O
murine	B-UNK
model	B-UNK
of	O
temporal	B-UNK
lobe	I-UNK
epilepsy	I-UNK
.	O
Similar	B-UNK
to	O
rats	B-UNK
,	O
systemic	B-UNK
pilocarpine	B-UNK
injection	B-UNK
causes	O
status	B-DISEASE
epilepticus	I-DISEASE
(	O
SE	B-UNK
)	O
and	O
the	O
eventual	O
development	B-UNK
of	O
spontaneous	B-UNK
seizures	B-UNK
and	O
mossy	O
fiber	O
sprouting	O
in	O
C57BL/6	O
and	O
CD1	O
mice	B-UNK
,	O
but	O
the	O
physiological	B-UNK
correlates	B-UNK
of	O
these	O
events	B-UNK
have	O
not	O
been	O
identified	B-UNK
in	O
mice	B-UNK
.	O
Population	B-UNK
responses	O
in	O
granule	B-UNK
cells	I-UNK
of	O
the	O
dentate	B-UNK
gyrus	I-UNK
were	O
examined	B-UNK
in	O
transverse	O
slices	O
of	O
the	O
ventral	B-UNK
hippocampus	B-UNK
from	O
pilocarpine	B-CHEMICAL
-	O
treated	O
and	O
untreated	B-UNK
mice	B-UNK
.	O
In	O
Mg(2+)-free	O
bathing	O
medium	B-UNK
containing	O
bicuculline	O
,	O
conditions	O
designed	B-UNK
to	O
increase	B-UNK
excitability	B-UNK
in	O
the	O
slices	O
,	O
electrical	B-UNK
stimulation	B-UNK
of	O
the	O
hilus	O
resulted	B-UNK
in	O
a	O
single	B-UNK
population	B-UNK
spike	O
in	O
granule	B-UNK
cells	I-UNK
from	O
control	B-UNK
mice	B-UNK
and	O
pilocarpine	B-UNK
-	O
treated	O
mice	B-UNK
that	O
did	O
not	O
experience	B-UNK
SE	B-DISEASE
.	O
In	O
SE	B-DISEASE
survivors	B-UNK
,	O
similar	B-UNK
stimulation	B-UNK
resulted	B-UNK
in	O
a	O
population	B-UNK
spike	O
followed	O
,	O
at	O
a	O
variable	B-UNK
latency	B-UNK
,	O
by	O
negative	B-UNK
DC	O
shifts	O
and	O
repetitive	B-UNK
afterdischarges	O
of	O
3	O
-	O
60	O
s	O
duration	B-UNK
,	O
which	O
were	O
blocked	B-UNK
by	O
ionotropic	O
glutamate	B-UNK
receptor	B-UNK
antagonists	I-UNK
.	O
Focal	B-UNK
glutamate	B-UNK
photostimulation	O
of	O
the	O
granule	B-UNK
cell	I-UNK
layer	B-UNK
at	O
sites	B-UNK
distant	O
from	O
the	O
recording	B-UNK
pipette	O
resulted	B-UNK
in	O
population	B-UNK
responses	O
of	O
1	O
-	O
30	O
s	O
duration	B-UNK
in	O
slices	O
from	O
SE	B-DISEASE
survivors	B-UNK
but	O
not	O
other	O
groups	B-UNK
.	O
These	O
data	B-UNK
support	B-UNK
the	O
hypothesis	B-UNK
that	O
SE	B-UNK
-	O
induced	O
mossy	O
fiber	O
sprouting	O
and	O
synaptic	B-UNK
reorganization	O
are	O
relevant	B-UNK
characteristics	B-UNK
of	O
seizure	B-UNK
development	B-UNK
in	O
these	O
murine	B-UNK
strains	B-UNK
,	O
resembling	O
rat	B-UNK
models	B-UNK
of	O
human	B-UNK
temporal	B-UNK
lobe	I-UNK
epilepsy	I-UNK
.	O

The	O
alpha3	O
and	O
beta4	O
nicotinic	B-UNK
acetylcholine	B-UNK
receptor	B-UNK
subunits	B-UNK
are	O
necessary	O
for	O
nicotine	B-UNK
-	O
induced	O
seizures	B-UNK
and	O
hypolocomotion	O
in	O
mice	B-UNK
.	O
Binding	B-UNK
of	O
nicotine	B-UNK
to	O
nicotinic	B-UNK
acetylcholine	B-UNK
receptors	B-UNK
(	O
nAChRs	O
)	O
elicits	O
a	O
series	B-UNK
of	O
dose	B-UNK
-	O
dependent	B-UNK
behaviors	B-UNK
that	O
go	O
from	O
altered	B-UNK
exploration	O
,	O
sedation	B-UNK
,	O
and	O
tremors	B-DISEASE
,	O
to	O
seizures	B-DISEASE
and	O
death	B-DISEASE
.	O
nAChRs	O
are	O
pentameric	O
ion	O
channels	B-UNK
usually	O
composed	O
of	O
alpha	B-UNK
and	O
beta	B-UNK
subunits	B-UNK
.	O
A	O
gene	B-UNK
cluster	O
comprises	O
the	O
alpha3	O
,	O
alpha5	O
and	O
beta4	O
subunits	B-UNK
,	O
which	O
coassemble	O
to	O
form	B-UNK
functional	B-UNK
receptors	B-UNK
.	O
We	O
examined	B-UNK
the	O
role	O
of	O
the	O
beta4	O
subunits	B-UNK
in	O
nicotine	B-UNK
-	O
induced	O
seizures	B-UNK
and	O
hypolocomotion	O
in	O
beta4	O
homozygous	O
null	O
(	O
beta4	O
-/-	O
)	O
and	O
alpha3	O
heterozygous	O
(	O
+	O
/-	O
)	O
mice	B-UNK
.	O
beta4	O
-/-	O
mice	B-UNK
were	O
less	O
sensitive	B-UNK
to	O
the	O
effects	O
of	O
nicotine	B-UNK
both	O
at	O
low	B-UNK
doses	I-UNK
,	O
measured	B-UNK
as	O
decreased	B-UNK
exploration	O
in	O
an	O
open	B-UNK
field	B-UNK
,	O
and	O
at	O
high	B-UNK
doses	I-UNK
,	O
measured	B-UNK
as	O
sensitivity	B-UNK
to	O
nicotine	B-UNK
-	O
induced	O
seizures	B-UNK
.	O
Using	O
in	O
situ	O
hybridization	O
probes	O
for	O
the	O
alpha3	O
and	O
alpha5	O
subunits	B-UNK
,	O
we	O
showed	O
that	O
alpha5	O
mRNA	B-UNK
levels	I-UNK
are	O
unchanged	B-UNK
,	O
whereas	O
alpha3	O
mRNA	B-UNK
levels	I-UNK
are	O
selectively	B-UNK
decreased	B-UNK
in	O
the	O
mitral	B-UNK
cell	B-UNK
layer	B-UNK
of	O
the	O
olfactory	O
bulb	O
,	O
and	O
the	O
inferior	B-UNK
and	O
the	O
superior	B-UNK
colliculus	O
of	O
beta4	O
-/-	O
brains	B-UNK
.	O
alpha3	O
+	O
/-	O
mice	B-UNK
were	O
partially	O
resistant	B-UNK
to	O
nicotine	B-UNK
-	O
induced	O
seizures	B-UNK
when	O
compared	O
to	O
wild	O
-	O
type	B-UNK
littermates	O
.	O
mRNA	B-UNK
levels	I-UNK
for	O
the	O
alpha5	O
and	O
the	O
beta4	O
subunits	B-UNK
were	O
unchanged	B-UNK
in	O
alpha3	O
+	O
/-	O
brains	B-UNK
.	O
Together	O
,	O
these	O
results	B-UNK
suggest	B-UNK
that	O
the	O
beta4	O
and	O
the	O
alpha3	O
subunits	B-UNK
are	O
mediators	O
of	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	B-UNK
and	O
hypolocomotion	O
.	O

Recurrent	B-UNK
acute	B-UNK
interstitial	I-UNK
nephritis	I-UNK
induced	O
by	O
azithromycin	O
.	O
A	O
14-year	O
-	O
old	O
girl	B-UNK
is	O
reported	B-UNK
with	O
recurrent	B-UNK
,	O
azithromycin	O
-	O
induced	O
,	O
acute	B-UNK
interstitial	I-UNK
nephritis	I-UNK
.	O
The	O
second	O
episode	B-UNK
was	O
more	O
severe	B-UNK
than	O
the	O
first	O
;	O
and	O
although	O
both	O
were	O
treated	O
with	O
intensive	B-UNK
corticosteroid	B-UNK
therapy	O
,	O
renal	B-UNK
function	I-UNK
remained	B-UNK
impaired	B-UNK
.	O
Although	O
most	O
cases	B-UNK
of	O
antibiotic	B-UNK
induced	O
acute	B-UNK
interstitial	I-UNK
nephritis	I-UNK
are	O
benign	O
and	O
self	O
-	O
limited	B-UNK
,	O
some	O
patients	B-UNK
are	O
at	O
risk	B-UNK
for	O
permanent	B-UNK
renal	B-UNK
injury	I-UNK
.	O

Valproate	B-UNK
-	O
induced	O
encephalopathy	B-UNK
.	O
Valproate	B-UNK
-	O
induced	O
encephalopathy	B-UNK
is	O
a	O
rare	B-UNK
syndrome	B-UNK
that	O
may	O
manifest	O
in	O
otherwise	O
normal	O
epileptic	B-UNK
individuals	B-UNK
.	O
It	O
may	O
even	O
present	B-UNK
in	O
patients	B-UNK
who	O
have	O
tolerated	B-UNK
this	O
medicine	B-UNK
well	O
in	O
the	O
past	B-UNK
.	O
It	O
is	O
usually	O
but	O
not	O
necessarily	O
associated	O
with	O
hyperammonemia	B-DISEASE
.	O
The	O
EEG	B-UNK
shows	O
characteristic	B-UNK
triphasic	O
waves	O
in	O
most	O
patients	B-UNK
with	O
this	O
complication	B-UNK
.	O
A	O
case	B-UNK
of	O
valproate	B-UNK
-	O
induced	O
encephalopathy	B-UNK
is	O
presented	B-UNK
.	O
The	O
problems	B-UNK
in	O
diagnosing	O
this	O
condition	B-UNK
are	O
subsequently	B-UNK
discussed	O
.	O

Nitro	O
-	O
L	O
-	O
arginine	O
methyl	B-UNK
ester	B-UNK
:	O
a	O
potential	B-UNK
protector	O
against	O
gentamicin	B-CHEMICAL
ototoxicity	B-UNK
.	O
The	O
nitric	B-UNK
oxide	I-UNK
(	O
NO	O
)	O
inhibitor	B-UNK
nitro	O
-	O
L	O
-	O
arginine	O
methyl	B-UNK
ester	B-UNK
(	O
L	O
-	O
NAME	O
)	O
may	O
act	B-UNK
as	O
an	O
otoprotectant	O
against	O
high	B-UNK
-	O
frequency	B-UNK
hearing	B-UNK
loss	I-UNK
caused	B-UNK
by	O
gentamicin	B-UNK
,	O
but	O
further	O
studies	B-UNK
are	O
needed	B-UNK
to	O
confirm	B-UNK
this	O
.	O
Aminoglycoside	B-UNK
antibiotics	B-UNK
are	O
still	O
widely	B-UNK
used	O
by	O
virtue	O
of	O
their	O
efficacy	B-UNK
and	O
low	B-UNK
cost	B-UNK
.	O
Their	O
ototoxicity	B-UNK
is	O
a	O
serious	O
health	B-UNK
problem	O
and	O
,	O
as	O
their	O
ototoxic	O
mechanism	B-UNK
involves	O
the	O
production	B-UNK
of	O
NO	O
,	O
we	O
need	O
to	O
assess	B-UNK
the	O
use	O
of	O
NO	O
inhibitors	B-UNK
for	O
the	O
prevention	B-UNK
of	O
aminoglycoside	B-UNK
-	O
induced	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O
In	O
this	O
experimental	B-UNK
study	B-UNK
we	O
used	O
30	O
Sprague	O
-	O
Dawley	O
rats	B-UNK
,	O
27	O
of	O
which	O
had	O
gentamicin	B-UNK
instilled	O
into	O
the	O
middle	B-UNK
ear	O
.	O
The	O
otoprotectant	O
L	O
-	O
NAME	O
was	O
administered	O
topically	O
to	O
12/27	O
animals	B-UNK
.	O
Its	O
effect	B-UNK
was	O
determined	B-UNK
in	O
terms	B-UNK
of	O
attenuation	O
of	O
hearing	B-UNK
loss	I-UNK
,	O
measured	B-UNK
by	O
shifts	O
in	O
the	O
auditory	B-UNK
brainstem	B-UNK
response	B-UNK
threshold	B-UNK
.	O
L	O
-	O
NAME	O
reduced	B-UNK
gentamicin	B-CHEMICAL
-	O
induced	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
high	B-UNK
-	O
frequency	B-UNK
range	B-UNK
,	O
but	O
gave	O
no	O
protection	B-UNK
in	O
the	O
middle	B-UNK
or	O
low	B-UNK
frequencies	B-UNK
.	O

Cerebral	B-DISEASE
vasculitis	I-DISEASE
following	O
oral	B-UNK
methylphenidate	B-UNK
intake	B-UNK
in	O
an	O
adult	B-UNK
:	O
a	O
case	B-UNK
report	I-UNK
.	O
Methylphenidate	B-CHEMICAL
is	O
structurally	O
and	O
functionally	O
similar	B-UNK
to	O
amphetamine	B-UNK
.	O
Cerebral	B-DISEASE
vasculitis	I-DISEASE
associated	O
with	O
amphetamine	B-DISEASE
abuse	I-DISEASE
is	O
well	O
documented	O
,	O
and	O
in	O
rare	B-UNK
cases	B-UNK
ischaemic	B-UNK
stroke	B-DISEASE
has	O
been	O
reported	B-UNK
after	O
methylphenidate	B-CHEMICAL
intake	B-UNK
in	O
children	B-UNK
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
63-year	O
-	O
old	O
female	B-UNK
who	O
was	O
treated	O
with	O
methylphenidate	B-CHEMICAL
due	O
to	O
hyperactivity	B-UNK
and	O
suffered	O
from	O
multiple	B-UNK
ischaemic	B-UNK
strokes	B-UNK
.	O
We	O
consider	O
drug	B-UNK
-	O
induced	O
cerebral	B-DISEASE
vasculitis	I-DISEASE
as	O
the	O
most	O
likely	O
cause	O
of	O
recurrent	B-UNK
ischaemic	B-UNK
strokes	B-DISEASE
in	O
the	O
absence	O
of	O
any	O
pathological	B-UNK
findings	B-UNK
during	O
the	O
diagnostic	B-UNK
work	O
-	O
up	O
.	O
We	O
conclude	O
that	O
methylphenidate	B-CHEMICAL
mediated	B-UNK
vasculitis	B-UNK
should	O
be	O
considered	B-UNK
in	O
patients	B-UNK
with	O
neurological	B-UNK
symptoms	B-UNK
and	O
a	O
history	B-UNK
of	O
methylphenidate	B-CHEMICAL
therapy	O
.	O
This	O
potential	B-UNK
side	O
-	O
effect	B-UNK
,	O
though	O
very	O
rare	B-UNK
,	O
represents	B-UNK
one	O
more	O
reason	O
to	O
be	O
very	O
restrictive	O
in	O
the	O
use	O
of	O
methylphenidate	B-UNK
.	O

Cerebral	B-DISEASE
haemorrhage	I-DISEASE
induced	O
by	O
warfarin	B-UNK
-	O
the	O
influence	B-UNK
of	O
drug	B-UNK
-	O
drug	B-UNK
interactions	I-UNK
.	O
PURPOSE	B-UNK
:	O
To	O
evaluate	B-UNK
the	O
frequency	B-UNK
,	O
severity	B-UNK
and	O
preventability	O
of	O
warfarin	B-UNK
-	O
induced	O
cerebral	B-DISEASE
haemorrhages	I-DISEASE
due	O
to	O
warfarin	B-UNK
and	O
warfarin	B-CHEMICAL
-	O
drug	B-UNK
interactions	I-UNK
in	O
patients	B-UNK
living	B-UNK
in	O
the	O
county	O
of	O
Osterg	O
 	O
tland	O
,	O
Sweden	O
.	O
METHODS	B-UNK
:	O
All	O
patients	B-UNK
with	O
a	O
diagnosed	B-UNK
cerebral	B-DISEASE
haemorrhage	I-DISEASE
at	O
three	O
hospitals	B-UNK
during	O
the	O
period	B-UNK
2000	O
-	O
2002	O
were	O
identified	B-UNK
.	O
Medical	B-UNK
records	I-UNK
were	O
studied	O
retrospectively	O
to	O
evaluate	B-UNK
whether	O
warfarin	B-UNK
and	O
warfarin	B-UNK
-	O
drug	B-UNK
interactions	I-UNK
could	O
have	O
caused	B-UNK
the	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
.	O
The	O
proportion	B-UNK
of	O
possibly	O
avoidable	O
cases	B-UNK
due	O
to	O
drug	B-UNK
interactions	I-UNK
was	O
estimated	O
.	O
RESULTS	B-UNK
:	O
Among	O
593	O
patients	B-UNK
with	O
cerebral	B-DISEASE
haemorrhage	I-DISEASE
,	O
59	O
(	O
10	O
%	O
)	O
were	O
assessed	B-UNK
as	O
related	O
to	O
warfarin	B-CHEMICAL
treatment	B-UNK
.	O
This	O
imply	O
an	O
incidence	B-UNK
of	O
1.7/100,000	O
treatment	B-UNK
years	B-UNK
.	O
Of	O
the	O
59	O
cases	B-UNK
,	O
26	O
(	O
44	O
%	O
)	O
had	O
a	O
fatal	B-UNK
outcome	B-UNK
,	O
compared	O
to	O
136	O
(	O
25	O
%	O
)	O
among	O
the	O
non-warfarin	O
patients	B-UNK
(	O
p	O
<	O
0.01	O
)	O
.	O
A	O
warfarin	B-CHEMICAL
-	O
drug	B-UNK
interaction	I-UNK
could	O
have	O
contributed	B-UNK
to	O
the	O
haemorrhage	B-UNK
in	O
24	O
(	O
41	O
%	O
)	O
of	O
the	O
warfarin	B-UNK
patients	B-UNK
and	O
in	O
7	O
of	O
these	O
(	O
12	O
%	O
)	O
the	O
bleeding	B-UNK
complication	B-UNK
was	O
considered	B-UNK
being	O
possible	O
to	O
avoid	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Warfarin	B-UNK
-	O
induced	O
cerebral	B-DISEASE
haemorrhages	I-DISEASE
are	O
a	O
major	B-UNK
clinical	B-UNK
problem	O
with	O
a	O
high	B-UNK
fatality	O
rate	B-UNK
.	O
Almost	O
half	B-UNK
of	O
the	O
cases	B-UNK
was	O
related	O
to	O
a	O
warfarin	B-UNK
-	O
drug	B-UNK
interaction	I-UNK
.	O
A	O
significant	B-UNK
proportion	B-UNK
of	O
warfarin	B-CHEMICAL
-	O
related	O
cerebral	B-DISEASE
haemorrhages	I-DISEASE
might	O
have	O
been	O
prevented	B-UNK
if	O
greater	B-UNK
caution	B-UNK
had	O
been	O
taken	O
when	O
prescribing	B-UNK
drugs	B-UNK
known	O
to	O
interact	O
with	O
warfarin	B-UNK
.	O

Side	O
effects	O
of	O
postoperative	B-UNK
administration	O
of	O
methylprednisolone	B-CHEMICAL
and	O
gentamicin	B-CHEMICAL
into	O
the	O
posterior	B-UNK
sub-Tenon's	O
space	B-UNK
.	O
PURPOSE	B-UNK
:	O
To	O
assess	B-UNK
the	O
incidence	B-UNK
of	O
postoperative	B-UNK
emetic	O
side	O
effects	O
after	O
the	O
administration	O
of	O
methylprednisolone	B-UNK
and	O
gentamicin	B-UNK
into	O
the	O
posterior	B-UNK
sub-Tenon's	O
space	B-UNK
at	O
the	O
end	B-UNK
of	O
routine	B-UNK
cataract	B-DISEASE
surgery	B-UNK
.	O
SETTING	B-UNK
:	O
St.	O
Luke'	O
s	O
Hospital	B-UNK
,	O
Gwardamangia	O
,	O
Malta	O
.	O
METHODS	B-UNK
:	O
A	O
double-blind	O
double-armed	O
prospective	B-UNK
study	I-UNK
comprised	O
40	O
patients	B-UNK
who	O
had	O
uneventful	O
sutureless	O
phacoemulsification	O
under	O
sub-Tenon's	O
local	B-UNK
infiltration	B-UNK
of	O
3	O
mL	B-UNK
of	O
plain	O
lignocaine	B-CHEMICAL
.	O
At	O
the	O
end	B-UNK
of	O
the	O
procedure	B-UNK
,	O
Group	B-UNK
A	O
(	O
n	O
=	O
20	O
)	O
had	O
20	O
mg/0.5	O
mL	B-UNK
of	O
methylprednisolone	B-CHEMICAL
and	O
10	O
mg/0.5	O
mL	B-UNK
of	O
gentamicin	B-UNK
injected	B-UNK
into	O
the	O
posterior	B-UNK
sub-Tenon's	O
space	B-UNK
and	O
Group	B-UNK
B	O
(	O
n	O
=	O
20	O
)	O
had	O
the	O
same	O
combination	B-UNK
injected	B-UNK
into	O
the	O
anterior	B-UNK
sub-Tenon's	O
space	B-UNK
.	O
Postoperatively	B-UNK
,	O
all	O
patients	B-UNK
were	O
assessed	B-UNK
for	O
symptoms	B-UNK
of	O
nausea	B-DISEASE
,	O
vomiting	B-UNK
,	O
and	O
headache	B-UNK
.	O
A	O
chi	O
-	O
square	O
test	B-UNK
was	O
used	O
to	O
assess	B-UNK
the	O
statistical	B-UNK
significance	I-UNK
of	O
results	B-UNK
.	O
RESULTS	B-UNK
:	O
Sixty	O
percent	B-UNK
in	O
Group	B-UNK
A	O
developed	O
postoperative	B-UNK
emetic	O
symptoms	B-UNK
,	O
headache	B-UNK
,	O
or	O
both	O
;	O
1	O
patient	B-UNK
in	O
Group	B-UNK
B	O
developed	O
symptoms	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
The	O
administration	O
of	O
methylprednisolone	B-CHEMICAL
and	O
gentamicin	B-UNK
in	O
the	O
posterior	B-UNK
sub-Tenon's	O
space	B-UNK
was	O
related	O
to	O
a	O
high	B-UNK
incidence	B-UNK
of	O
side	O
effects	O
including	O
nausea	B-DISEASE
,	O
vomiting	B-UNK
,	O
and	O
headache	B-UNK
.	O
All	O
adverse	B-UNK
effects	I-UNK
were	O
self	O
-	O
limiting	B-UNK
.	O

Cardiac	B-UNK
Angiography	B-UNK
in	O
Renally	O
Impaired	B-UNK
Patients	B-UNK
(	O
CARE	B-UNK
)	O
study	B-UNK
:	O
a	O
randomized	B-UNK
double-blind	O
trial	B-UNK
of	O
contrast	B-UNK
-	O
induced	O
nephropathy	B-UNK
in	O
patients	B-UNK
with	O
chronic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
.	O
BACKGROUND	B-UNK
:	O
No	O
direct	B-UNK
comparisons	O
exist	O
of	O
the	O
renal	B-UNK
tolerability	B-UNK
of	O
the	O
low	B-UNK
-	O
osmolality	B-UNK
contrast	B-UNK
medium	I-UNK
iopamidol	B-CHEMICAL
with	O
that	O
of	O
the	O
iso	B-UNK
-	O
osmolality	B-UNK
contrast	B-UNK
medium	I-UNK
iodixanol	B-UNK
in	O
high	B-UNK
-	O
risk	B-UNK
patients	B-UNK
.	O
METHODS	B-UNK
AND	O
RESULTS	B-UNK
:	O
The	O
present	B-UNK
study	B-UNK
is	O
a	O
multicenter	B-UNK
,	O
randomized	B-UNK
,	O
double-blind	O
comparison	B-UNK
of	O
iopamidol	B-CHEMICAL
and	O
iodixanol	B-UNK
in	O
patients	B-UNK
with	O
chronic	B-DISEASE
kidney	I-DISEASE
disease	I-DISEASE
(	O
estimated	O
glomerular	B-UNK
filtration	I-UNK
rate	I-UNK
,	O
20	O
to	O
59	O
mL	B-UNK
/	O
min	B-UNK
)	O
who	O
underwent	O
cardiac	B-UNK
angiography	B-UNK
or	O
percutaneous	B-UNK
coronary	B-UNK
interventions	B-UNK
.	O
Serum	B-UNK
creatinine	I-UNK
(	O
SCr	B-UNK
)	O
levels	O
and	O
estimated	O
glomerular	B-UNK
filtration	I-UNK
rate	I-UNK
were	O
assessed	B-UNK
at	O
baseline	B-UNK
and	O
2	O
to	O
5	O
days	B-UNK
after	O
receiving	B-UNK
medications	B-UNK
.	O
The	O
primary	B-UNK
outcome	B-UNK
was	O
a	O
postdose	O
SCr	B-UNK
increase	B-UNK
>	O
or	O
=	O
0.5	O
mg	B-UNK
/	O
dL	B-UNK
(	O
44.2	O
micromol	B-UNK
/	O
L	O
)	O
over	O
baseline	B-UNK
.	O
Secondary	B-UNK
outcomes	B-UNK
were	O
a	O
postdose	O
SCr	B-UNK
increase	B-UNK
>	O
or	O
=	O
25	O
%	O
,	O
a	O
postdose	O
estimated	O
glomerular	B-UNK
filtration	I-UNK
rate	I-UNK
decrease	B-UNK
of	O
>	O
or	O
=	O
25	O
%	O
,	O
and	O
the	O
mean	O
peak	B-UNK
change	B-UNK
in	O
SCr	B-UNK
.	O
In	O
414	O
patients	B-UNK
,	O
contrast	B-UNK
volume	B-UNK
,	O
presence	O
of	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
use	O
of	O
N	O
-	O
acetylcysteine	B-CHEMICAL
,	O
mean	O
baseline	B-UNK
SCr	B-UNK
,	O
and	O
estimated	O
glomerular	B-UNK
filtration	I-UNK
rate	I-UNK
were	O
comparable	O
in	O
the	O
2	O
groups	B-UNK
.	O
SCr	B-UNK
increases	B-UNK
>	O
or	O
=	O
0.5	O
mg	B-UNK
/	O
dL	B-UNK
occurred	B-UNK
in	O
4.4	O
%	O
(	O
9	O
of	O
204	O
patients	B-UNK
)	O
after	O
iopamidol	B-CHEMICAL
and	O
6.7	O
%	O
(	O
14	O
of	O
210	O
patients	B-UNK
)	O
after	O
iodixanol	B-UNK
(	O
P=0.39	O
)	O
,	O
whereas	O
rates	B-UNK
of	O
SCr	B-UNK
increases	B-UNK
>	O
or	O
=	O
25	O
%	O
were	O
9.8	O
%	O
and	O
12.4	O
%	O
,	O
respectively	O
(	O
P=0.44	O
)	O
.	O
In	O
patients	B-UNK
with	O
diabetes	B-DISEASE
,	O
SCr	B-UNK
increases	B-UNK
>	O
or	O
=	O
0.5	O
mg	B-UNK
/	O
dL	B-UNK
were	O
5.1	O
%	O
(	O
4	O
of	O
78	O
patients	B-UNK
)	O
with	O
iopamidol	B-CHEMICAL
and	O
13.0	O
%	O
(	O
12	O
of	O
92	O
patients	B-UNK
)	O
with	O
iodixanol	B-CHEMICAL
(	O
P=0.11	O
)	O
,	O
whereas	O
SCr	B-UNK
increases	B-UNK
>	O
or	O
=	O
25	O
%	O
were	O
10.3	O
%	O
and	O
15.2	O
%	O
,	O
respectively	O
(	O
P=0.37	O
)	O
.	O
Mean	O
post-SCr	O
increases	B-UNK
were	O
significantly	B-UNK
less	O
with	O
iopamidol	B-CHEMICAL
(	O
all	O
patients	B-UNK
:	O
0.07	O
versus	O
0.12	O
mg	B-UNK
/	O
dL	B-UNK
,	O
6.2	O
versus	O
10.6	O
micromol	B-UNK
/	O
L	O
,	O
P=0.03	O
;	O
patients	B-UNK
with	O
diabetes	B-UNK
:	O
0.07	O
versus	O
0.16	O
mg	B-UNK
/	O
dL	B-UNK
,	O
6.2	O
versus	O
14.1	O
micromol	B-UNK
/	O
L	O
,	O
P=0.01	O
)	O
.	O
CONCLUSIONS	B-UNK
:	O
The	O
rate	B-UNK
of	O
contrast	B-UNK
-	O
induced	O
nephropathy	B-DISEASE
,	O
defined	B-UNK
by	O
multiple	B-UNK
end	B-UNK
points	B-UNK
,	O
is	O
not	O
statistically	B-UNK
different	O
after	O
the	O
intraarterial	O
administration	O
of	O
iopamidol	B-CHEMICAL
or	O
iodixanol	B-CHEMICAL
to	O
high	B-UNK
-	O
risk	B-UNK
patients	B-UNK
,	O
with	O
or	O
without	O
diabetes	B-UNK
mellitus	I-UNK
.	O
Any	O
true	O
difference	B-UNK
between	O
the	O
agents	B-UNK
is	O
small	B-UNK
and	O
not	O
likely	O
to	O
be	O
clinically	B-UNK
significant	I-UNK
.	O

A	O
novel	O
compound	B-UNK
,	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
,	O
attenuates	O
cognitive	B-UNK
deficits	I-UNK
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	B-UNK
and	O
in	O
vivo	B-UNK
dementia	B-UNK
models	B-UNK
.	O
To	O
develop	B-UNK
a	O
novel	O
and	O
effective	B-UNK
drug	B-UNK
that	O
could	O
enhance	B-UNK
cognitive	B-UNK
function	I-UNK
and	O
neuroprotection	O
,	O
we	O
newly	B-UNK
synthesized	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
by	O
the	O
esterification	O
of	O
maltol	O
and	O
p	O
-	O
coumaric	O
acid	B-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
we	O
investigated	B-UNK
whether	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
could	O
improve	B-UNK
cognitive	B-UNK
decline	B-UNK
in	O
scopolamine	B-UNK
-	O
injected	B-UNK
rats	B-UNK
and	O
in	O
amyloid	O
beta	B-UNK
peptide(1	O
-	O
42)-infused	O
rats	B-UNK
.	O
Maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
was	O
found	O
to	O
attenuate	O
cognitive	B-UNK
deficits	I-UNK
in	O
both	O
rat	B-UNK
models	B-UNK
using	O
passive	B-UNK
avoidance	I-UNK
test	B-UNK
and	O
to	O
reduce	B-UNK
apoptotic	B-UNK
cell	B-UNK
death	I-UNK
observed	O
in	O
the	O
hippocampus	B-UNK
of	O
the	O
amyloid	O
beta	B-UNK
peptide(1	O
-	O
42)-infused	O
rats	B-UNK
.	O
We	O
also	O
examined	B-UNK
the	O
neuroprotective	O
effects	O
of	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
in	O
vitro	B-UNK
using	O
SH	O
-	O
SY5Y	O
cells	B-UNK
.	O
Cells	B-UNK
were	O
pretreated	B-UNK
with	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
,	O
before	O
exposed	B-UNK
to	O
amyloid	O
beta	B-UNK
peptide(1	O
-	O
42	O
)	O
,	O
glutamate	B-UNK
or	O
H2O2	O
.	O
We	O
found	O
that	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
significantly	B-UNK
decreased	B-UNK
apoptotic	B-UNK
cell	B-UNK
death	I-UNK
and	O
reduced	B-UNK
reactive	B-UNK
oxygen	I-UNK
species	I-UNK
,	O
cytochrome	B-UNK
c	O
release	B-UNK
,	O
and	O
caspase	B-UNK
3	I-UNK
activation	B-UNK
.	O
Taking	B-UNK
these	O
in	O
vitro	B-UNK
and	O
in	O
vivo	B-UNK
results	B-UNK
together	O
,	O
our	O
study	B-UNK
suggests	O
that	O
maltolyl	B-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
coumarate	I-CHEMICAL
is	O
a	O
potentially	O
effective	B-UNK
candidate	O
against	O
Alzheimer'	B-UNK
s	I-UNK
disease	I-UNK
that	O
is	O
characterized	B-UNK
by	O
wide	O
spread	O
neuronal	B-UNK
death	B-UNK
and	O
progressive	B-UNK
decline	B-DISEASE
of	I-DISEASE
cognitive	I-DISEASE
function	I-DISEASE
.	O

Interaction	B-UNK
between	O
warfarin	B-UNK
and	O
levofloxacin	B-UNK
:	O
case	B-UNK
series	I-UNK
.	O
Warfarin	B-UNK
is	O
the	O
most	O
widely	B-UNK
used	O
oral	B-UNK
anticoagulant	B-UNK
and	O
is	O
indicated	O
for	O
many	O
clinical	B-UNK
conditions	O
.	O
Levofloxacin	B-UNK
,	O
a	O
fluoroquinolone	O
,	O
is	O
one	O
of	O
the	O
most	O
commonly	B-UNK
prescribed	B-UNK
antibiotics	B-UNK
in	O
clinical	B-UNK
practice	I-UNK
and	O
is	O
effective	B-UNK
against	O
Gram	O
-	O
positive	B-UNK
,	O
Gram	O
-	O
negative	B-UNK
,	O
and	O
atypical	B-UNK
bacteria	O
.	O
While	O
small	B-UNK
prospective	B-UNK
studies	B-UNK
have	O
not	O
revealed	O
any	O
significant	B-UNK
drug	B-UNK
-	O
drug	B-UNK
interaction	I-UNK
between	O
warfarin	B-UNK
and	O
levofloxacin	B-UNK
,	O
several	O
case	B-UNK
reports	I-UNK
have	O
indicated	O
that	O
levofloxacin	B-UNK
may	O
significantly	B-UNK
potentiate	O
the	O
anticoagulation	B-UNK
effect	B-UNK
of	O
warfarin	B-UNK
.	O
We	O
report	B-UNK
3	O
cases	B-UNK
of	O
serious	O
bleeding	B-DISEASE
complications	B-UNK
that	O
appear	O
to	O
be	O
the	O
result	B-UNK
of	O
the	O
interaction	B-UNK
between	O
warfarin	B-UNK
and	O
levofloxacin	B-UNK
.	O
Physicians	B-UNK
should	O
be	O
aware	B-UNK
of	O
this	O
potential	B-UNK
interaction	B-UNK
and	O
use	O
caution	B-UNK
when	O
prescribing	B-UNK
levofloxacin	B-CHEMICAL
to	O
patients	B-UNK
taking	B-UNK
warfarin	B-CHEMICAL
.	O

Mutations	B-UNK
associated	O
with	O
lamivudine	B-UNK
-	O
resistance	B-UNK
in	O
therapy	O
-	O
na	B-UNK
 	O
ve	B-UNK
hepatitis	B-UNK
B	I-UNK
virus	I-UNK
(	O
HBV	B-UNK
)	O
infected	B-UNK
patients	B-UNK
with	O
and	O
without	O
HIV	B-DISEASE
co-infection	O
:	O
implications	B-UNK
for	O
antiretroviral	O
therapy	O
in	O
HBV	B-UNK
and	O
HIV	B-UNK
co-infected	O
South	O
African	O
patients	B-UNK
.	O
This	O
was	O
an	O
exploratory	O
study	B-UNK
to	O
investigate	B-UNK
lamivudine	B-UNK
-	O
resistant	B-UNK
hepatitis	B-UNK
B	I-UNK
virus	I-UNK
(	O
HBV	B-UNK
)	O
strains	B-UNK
in	O
selected	O
lamivudine	B-UNK
-	O
na	B-UNK
 	O
ve	B-UNK
HBV	B-UNK
carriers	B-UNK
with	O
and	O
without	O
human	B-UNK
immunodeficiency	B-UNK
virus	I-UNK
(	O
HIV	B-UNK
)	O
co-infection	O
in	O
South	O
African	O
patients	B-UNK
.	O
Thirty	B-UNK
-	O
five	O
lamivudine	B-CHEMICAL
-	O
na	B-UNK
 	O
ve	B-UNK
HBV	B-UNK
infected	B-UNK
patients	B-UNK
with	O
or	O
without	O
HIV	B-DISEASE
co-infection	O
were	O
studied	O
:	O
15	O
chronic	B-UNK
HBV	B-UNK
mono-infected	O
patients	B-UNK
and	O
20	O
HBV	B-UNK
-	O
HIV	B-UNK
co-infected	O
patients	B-UNK
.	O
The	O
latter	O
group	B-UNK
was	O
further	O
sub-divided	O
into	O
13	O
occult	O
HBV	B-UNK
(	O
HBsAg	B-UNK
-	O
negative	B-UNK
)	O
and	O
7	O
overt	O
HBV	B-UNK
(	O
HBsAg-	O
positive	B-UNK
)	O
patients	B-UNK
.	O
HBsAg	B-UNK
,	O
anti-HBs	O
,	O
anti-HBc	O
,	O
and	O
anti-HIV	O
1/2	O
were	O
determined	B-UNK
as	O
part	O
of	O
routine	B-UNK
diagnosis	B-UNK
using	O
Axsym	O
assays	O
(	O
Abbott	O
Laboratories	O
,	O
North	B-UNK
Chicago	O
,	O
IL	B-UNK
)	O
.	O
Serum	B-UNK
samples	O
were	O
PCR	B-UNK
amplified	O
with	O
HBV	B-UNK
reverse	B-UNK
transcriptase	O
(	O
RT	O
)	O
primers	O
,	O
followed	O
by	O
direct	B-UNK
sequencing	O
across	O
the	O
tyrosine	B-UNK
-	O
methionine	O
-	O
aspartate	B-UNK
-	O
aspartate	B-UNK
(	O
YMDD	O
)	O
motif	O
of	O
the	O
major	B-UNK
catalytic	O
region	B-UNK
in	O
the	O
C	O
domain	O
of	O
the	O
HBV	B-UNK
RT	O
enzyme	B-UNK
.	O
HBV	B-UNK
viral	B-UNK
load	O
was	O
performed	B-UNK
with	O
Amplicor	O
HBV	B-UNK
Monitor	B-UNK
test	B-UNK
v2.0	O
(	O
Roche	O
Diagnostics	O
,	O
Penzberg	O
,	O
Germany	O
)	O
.	O
HBV	B-UNK
lamivudine	B-CHEMICAL
-	O
resistant	B-UNK
strains	B-UNK
were	O
detected	B-UNK
in	O
3	O
of	O
15	O
mono-infected	O
chronic	B-DISEASE
hepatitis	I-DISEASE
B	I-DISEASE
patients	B-UNK
and	O
10	O
of	O
20	O
HBV	B-UNK
-	O
HIV	B-DISEASE
co-infected	O
patients	B-UNK
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
report	B-UNK
of	O
HBV	B-UNK
lamivudine	B-CHEMICAL
-	O
resistant	B-UNK
strains	B-UNK
in	O
therapy	O
-	O
na	B-UNK
 	O
ve	B-UNK
HBV	B-UNK
-	O
HIV	B-UNK
co-infected	O
patients	B-UNK
.	O
The	O
HBV	B-UNK
viral	B-UNK
loads	O
for	O
mono-infected	O
and	O
co-infected	O
patients	B-UNK
ranged	B-UNK
from	O
3.32	O
x	O
10(2	O
)	O
to	O
3.82	O
x	O
10(7	O
)	O
and	O
<	O
200	O
to	O
4.40	O
x	O
10(3	O
)	O
copies	O
/	O
ml	B-UNK
,	O
respectively	O
.	O
It	O
remains	O
to	O
be	O
seen	O
whether	O
such	O
pre	B-UNK
-	O
existing	B-UNK
antiviral	B-UNK
mutations	B-UNK
could	O
result	B-UNK
in	O
widespread	B-UNK
emergence	O
of	O
HBV	B-UNK
resistant	B-UNK
strains	B-UNK
when	O
lamivudine	B-UNK
-	O
containing	O
highly	B-UNK
active	B-UNK
antiretroviral	O
(	O
ARV	O
)	O
treatment	B-UNK
(	O
HAART	B-UNK
)	O
regimens	B-UNK
become	O
widely	B-UNK
applied	O
in	O
South	O
Africa	O
,	O
as	O
this	O
is	O
likely	O
to	O
have	O
potential	B-UNK
implications	B-UNK
in	O
the	O
management	B-UNK
of	O
HBV	B-UNK
-	O
HIV	B-UNK
co-infected	O
patients	B-UNK
.	O

Sex	B-UNK
differences	B-UNK
in	O
NMDA	B-UNK
antagonist	B-UNK
enhancement	B-UNK
of	O
morphine	B-CHEMICAL
antihyperalgesia	O
in	O
a	O
capsaicin	B-UNK
model	B-UNK
of	O
persistent	B-UNK
pain	B-UNK
:	O
comparisons	O
to	O
two	O
models	B-UNK
of	O
acute	B-DISEASE
pain	I-DISEASE
.	O
In	O
acute	B-DISEASE
pain	I-DISEASE
models	B-UNK
,	O
N	O
-	O
methyl	B-UNK
-	O
D	O
-	O
aspartate	B-UNK
(	O
NMDA	B-UNK
)	O
antagonists	B-UNK
enhance	B-UNK
the	O
antinociceptive	B-UNK
effects	O
of	O
morphine	B-UNK
to	O
a	O
greater	B-UNK
extent	B-UNK
in	O
males	B-UNK
than	O
females	B-UNK
.	O
The	O
purpose	B-UNK
of	O
this	O
investigation	B-UNK
was	O
to	O
extend	O
these	O
findings	B-UNK
to	O
a	O
persistent	B-UNK
pain	B-DISEASE
model	B-UNK
which	O
could	O
be	O
distinguished	O
from	O
acute	B-DISEASE
pain	I-DISEASE
models	B-UNK
on	O
the	O
basis	B-UNK
of	O
the	O
nociceptive	B-UNK
fibers	O
activated	B-UNK
,	O
neurochemical	O
substrates	O
,	O
and	O
duration	B-UNK
of	O
the	O
nociceptive	B-UNK
stimulus	B-UNK
.	O
To	O
this	O
end	B-UNK
,	O
persistent	B-UNK
hyperalgesia	B-UNK
was	O
induced	O
by	O
administration	O
of	O
capsaicin	B-CHEMICAL
in	O
the	O
tail	B-UNK
of	O
gonadally	O
intact	B-UNK
F344	B-UNK
rats	B-UNK
,	O
following	O
which	O
the	O
tail	B-UNK
was	O
immersed	O
in	O
a	O
mildly	O
noxious	O
thermal	O
stimulus	B-UNK
,	O
and	O
tail	B-UNK
-	O
withdrawal	B-UNK
latencies	B-UNK
measured	B-UNK
.	O
For	O
comparison	B-UNK
,	O
tests	B-UNK
were	O
conducted	B-UNK
in	O
two	O
acute	B-DISEASE
pain	I-DISEASE
models	B-UNK
,	O
the	O
hotplate	O
and	O
warm	O
water	B-UNK
tail	B-UNK
-	O
withdrawal	B-UNK
procedures	B-UNK
.	O
In	O
males	B-UNK
,	O
the	O
non-competitive	O
NMDA	B-UNK
antagonist	B-UNK
dextromethorphan	B-CHEMICAL
enhanced	B-UNK
the	O
antihyperalgesic	O
effect	B-UNK
of	O
low	B-UNK
to	O
moderate	B-UNK
doses	B-UNK
of	O
morphine	B-CHEMICAL
in	O
a	O
dose	B-UNK
-	O
and	O
time	O
-	O
dependent	B-UNK
manner	I-UNK
.	O
Across	O
the	O
doses	B-UNK
and	O
pretreatment	B-UNK
times	B-UNK
examined	B-UNK
,	O
enhancement	B-UNK
was	O
not	O
observed	O
in	O
females	B-UNK
.	O
Enhancement	B-UNK
of	O
morphine	B-CHEMICAL
antinociception	O
by	O
dextromethorphan	B-CHEMICAL
was	O
seen	O
in	O
both	O
males	B-UNK
and	O
females	B-UNK
in	O
the	O
acute	B-DISEASE
pain	I-DISEASE
models	B-UNK
,	O
with	O
the	O
magnitude	B-UNK
of	O
this	O
effect	B-UNK
being	O
greater	B-UNK
in	O
males	B-UNK
.	O
These	O
findings	B-UNK
demonstrate	O
a	O
sexually	O
-	O
dimorphic	O
interaction	B-UNK
between	O
NMDA	B-UNK
antagonists	B-UNK
and	O
morphine	B-CHEMICAL
in	O
a	O
persistent	B-UNK
pain	B-UNK
model	B-UNK
that	O
can	O
be	O
distinguished	O
from	O
those	O
observed	O
in	O
acute	B-DISEASE
pain	I-DISEASE
models	B-UNK
.	O

Development	B-UNK
of	O
proteinuria	B-DISEASE
after	O
switch	O
to	O
sirolimus	B-CHEMICAL
-	O
based	B-UNK
immunosuppression	B-UNK
in	O
long	B-UNK
-	O
term	O
cardiac	B-UNK
transplant	B-UNK
patients	B-UNK
.	O
Calcineurin	B-UNK
-	O
inhibitor	B-UNK
therapy	O
can	O
lead	B-UNK
to	O
renal	B-UNK
dysfunction	I-UNK
in	O
heart	B-UNK
transplantation	B-UNK
patients	B-UNK
.	O
The	O
novel	O
immunosuppressive	B-UNK
(	O
IS	O
)	O
drug	B-UNK
sirolmus	O
(	O
Srl	B-UNK
)	O
lacks	O
nephrotoxic	B-UNK
effects	O
;	O
however	O
,	O
proteinuria	B-UNK
associated	O
with	O
Srl	B-UNK
has	O
been	O
reported	B-UNK
following	O
renal	B-UNK
transplantation	B-UNK
.	O
In	O
cardiac	B-UNK
transplantation	B-UNK
,	O
the	O
incidence	B-UNK
of	O
proteinuria	B-UNK
associated	O
with	O
Srl	B-UNK
is	O
unknown	O
.	O
In	O
this	O
study	B-UNK
,	O
long	B-UNK
-	O
term	O
cardiac	B-UNK
transplant	B-UNK
patients	B-UNK
were	O
switched	O
from	O
cyclosporine	B-CHEMICAL
to	O
Srl	B-UNK
-	O
based	B-UNK
IS	O
.	O
Concomitant	B-UNK
IS	O
consisted	B-UNK
of	O
mycophenolate	O
mofetil	O
+	O
/-	O
steroids	B-CHEMICAL
.	O
Proteinuria	B-DISEASE
increased	B-UNK
significantly	B-UNK
from	O
a	O
median	B-UNK
of	O
0.13	O
g	O
/	O
day	O
(	O
range	B-UNK
0	O
-	O
5.7	O
)	O
preswitch	O
to	O
0.23	O
g	O
/	O
day	O
(	O
0	O
-	O
9.88	O
)	O
at	O
24	O
months	B-UNK
postswitch	O
(	O
p	O
=	O
0.0024	O
)	O
.	O
Before	O
the	O
switch	O
,	O
11.5	O
%	O
of	O
patients	B-UNK
had	O
high	B-UNK
-	O
grade	B-UNK
proteinuria	B-UNK
(	O
>	O
1.0	O
g	O
/	O
day	O
)	O
;	O
this	O
increased	B-UNK
to	O
22.9	O
%	O
postswitch	O
(	O
p	O
=	O
0.006	O
)	O
.	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
and	O
angiotensin	O
-	O
releasing	B-UNK
blocker	B-UNK
(	O
ARB	O
)	O
therapy	O
reduced	B-UNK
proteinuria	B-UNK
development	B-UNK
.	O
Patients	B-UNK
without	O
proteinuria	B-UNK
had	O
increased	B-UNK
renal	B-UNK
function	I-UNK
(	O
median	B-UNK
42.5	O
vs	O
.	O
64.1	O
,	O
p	O
=	O
0.25	O
)	O
,	O
whereas	O
patients	B-UNK
who	O
developed	O
high	B-UNK
-	O
grade	B-UNK
proteinuria	B-UNK
showed	O
decreased	B-DISEASE
renal	I-DISEASE
function	I-DISEASE
at	O
the	O
end	B-UNK
of	O
follow	O
-	O
up	O
(	O
median	B-UNK
39.6	O
vs	O
.	O
29.2	O
,	O
p	O
=	O
0.125	O
)	O
.	O
Thus	O
,	O
proteinuria	B-UNK
may	O
develop	B-UNK
in	O
cardiac	B-UNK
transplant	B-UNK
patients	B-UNK
after	O
switch	O
to	O
Srl	B-UNK
,	O
which	O
may	O
have	O
an	O
adverse	B-UNK
effect	I-UNK
on	O
renal	B-UNK
function	I-UNK
in	O
these	O
patients	B-UNK
.	O
Srl	B-UNK
should	O
be	O
used	O
with	O
ACEi	O
/	O
ARB	O
therapy	O
and	O
patients	B-UNK
monitored	O
for	O
proteinuria	B-DISEASE
and	O
increased	B-UNK
renal	B-DISEASE
dysfunction	I-DISEASE
.	O

Synthesis	B-UNK
of	O
N	O
-	O
pyrimidinyl-2-phenoxyacetamides	O
as	O
adenosine	B-UNK
A2A	O
receptor	B-UNK
antagonists	I-UNK
.	O
A	O
series	B-UNK
of	O
N	O
-	O
pyrimidinyl-2-phenoxyacetamide	O
adenosine	B-UNK
A(2A	O
)	O
antagonists	B-UNK
is	O
described	O
.	O
SAR	O
studies	B-UNK
led	B-UNK
to	O
compound	B-UNK
14	O
with	O
excellent	O
potency	B-UNK
(	O
K(i	O
)	O
=	O
0.4	O
nM	B-UNK
)	O
,	O
selectivity	O
(	O
A(1)/A(2A	O
)	O
>	O
100	O
)	O
,	O
and	O
efficacy	B-UNK
(	O
MED	B-UNK
10	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
)	O
in	O
the	O
rat	B-UNK
haloperidol	B-UNK
-	O
induced	O
catalepsy	B-DISEASE
model	B-UNK
for	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
.	O

Methamphetamine	B-UNK
-	O
induced	O
neurotoxicity	B-UNK
and	O
microglial	B-UNK
activation	B-UNK
are	O
not	O
mediated	B-UNK
by	O
fractalkine	O
receptor	B-UNK
signaling	B-UNK
.	O
Methamphetamine	B-CHEMICAL
(	O
METH	B-UNK
)	O
damages	O
dopamine	B-UNK
(	O
DA	B-UNK
)	O
nerve	B-UNK
endings	O
by	O
a	O
process	O
that	O
has	O
been	O
linked	B-UNK
to	O
microglial	B-UNK
activation	B-UNK
but	O
the	O
signaling	B-UNK
pathways	B-UNK
that	O
mediate	B-UNK
this	O
response	B-UNK
have	O
not	O
yet	O
been	O
delineated	O
.	O
Cardona	O
et	O
al	B-UNK
.	O
[	O
Nat	O
.	O
Neurosci	O
.	O
9	O
(	O
2006	O
)	O
,	O
917	O
]	O
recently	B-UNK
identified	B-UNK
the	O
microglial	B-UNK
-	O
specific	B-UNK
fractalkine	O
receptor	B-UNK
(	O
CX3CR1	O
)	O
as	O
an	O
important	B-UNK
mediator	O
of	O
MPTP	B-UNK
-	O
induced	O
neurodegeneration	O
of	O
DA	B-UNK
neurons	B-UNK
.	O
Because	O
the	O
CNS	B-UNK
damage	B-UNK
caused	B-UNK
by	O
METH	B-UNK
and	O
MPTP	B-UNK
is	O
highly	B-UNK
selective	B-UNK
for	O
the	O
DA	B-UNK
neuronal	B-UNK
system	O
in	O
mouse	B-UNK
models	B-UNK
of	O
neurotoxicity	B-DISEASE
,	O
we	O
hypothesized	B-UNK
that	O
the	O
CX3CR1	O
plays	O
a	O
role	O
in	O
METH	B-UNK
-	O
induced	O
neurotoxicity	B-UNK
and	O
microglial	B-UNK
activation	B-UNK
.	O
Mice	B-UNK
in	O
which	O
the	O
CX3CR1	O
gene	B-UNK
has	O
been	O
deleted	O
and	O
replaced	O
with	O
a	O
cDNA	O
encoding	O
enhanced	B-UNK
green	B-UNK
fluorescent	O
protein	B-UNK
(	O
eGFP	O
)	O
were	O
treated	O
with	O
METH	B-UNK
and	O
examined	B-UNK
for	O
striatal	B-UNK
neurotoxicity	B-UNK
.	O
METH	B-UNK
depleted	B-UNK
DA	B-UNK
,	O
caused	B-UNK
microglial	B-UNK
activation	B-UNK
,	O
and	O
increased	B-UNK
body	B-UNK
temperature	B-UNK
in	O
CX3CR1	O
knockout	B-UNK
mice	B-UNK
to	O
the	O
same	O
extent	B-UNK
and	O
over	O
the	O
same	O
time	O
course	O
seen	O
in	O
wild	O
-	O
type	B-UNK
controls	B-UNK
.	O
The	O
effects	O
of	O
METH	B-UNK
in	O
CX3CR1	O
knockout	B-UNK
mice	B-UNK
were	O
not	O
gender	B-UNK
-	O
dependent	B-UNK
and	O
did	O
not	O
extend	O
beyond	O
the	O
striatum	B-UNK
.	O
Striatal	B-UNK
microglia	O
expressing	O
eGFP	O
constitutively	O
show	O
morphological	B-UNK
changes	O
after	O
METH	B-UNK
that	O
are	O
characteristic	B-UNK
of	O
activation	B-UNK
.	O
This	O
response	B-UNK
was	O
restricted	B-UNK
to	O
the	O
striatum	B-UNK
and	O
contrasted	O
sharply	O
with	O
unresponsive	O
eGFP	O
-	O
microglia	O
in	O
surrounding	O
brain	B-UNK
areas	B-UNK
that	O
are	O
not	O
damaged	O
by	O
METH	B-UNK
.	O
We	O
conclude	O
from	O
these	O
studies	B-UNK
that	O
CX3CR1	O
signaling	B-UNK
does	O
not	O
modulate	B-UNK
METH	B-UNK
neurotoxicity	B-UNK
or	O
microglial	B-UNK
activation	B-UNK
.	O
Furthermore	O
,	O
it	O
appears	B-UNK
that	O
striatal	B-UNK
-	O
resident	O
microglia	O
respond	O
to	O
METH	B-UNK
with	O
an	O
activation	B-UNK
cascade	O
and	O
then	O
return	B-UNK
to	O
a	O
surveying	O
state	B-UNK
without	O
undergoing	B-UNK
apoptosis	B-UNK
or	O
migration	O
.	O

Recovery	B-UNK
of	O
tacrolimus	B-UNK
-	O
associated	O
brachial	B-DISEASE
neuritis	I-DISEASE
after	O
conversion	B-UNK
to	O
everolimus	B-CHEMICAL
in	O
a	O
pediatric	B-UNK
renal	B-UNK
transplant	I-UNK
recipient	O
--	O
case	B-UNK
report	I-UNK
and	O
review	B-UNK
of	O
the	O
literature	B-UNK
.	O
TAC	B-UNK
has	O
been	O
shown	B-UNK
to	O
be	O
a	O
potent	B-UNK
immunosuppressive	B-UNK
agent	B-UNK
for	O
solid	O
organ	B-UNK
transplantation	B-UNK
in	O
pediatrics	O
.	O
Neurotoxicity	B-DISEASE
is	O
a	O
potentially	O
serious	O
toxic	B-UNK
effect	B-UNK
.	O
It	O
is	O
characterized	B-UNK
by	O
encephalopathy	B-UNK
,	O
headaches	B-DISEASE
,	O
seizures	B-UNK
,	O
or	O
neurological	B-UNK
deficits	B-UNK
.	O
Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	B-UNK
-	O
yr	B-UNK
-	O
old	O
male	B-UNK
renal	B-UNK
transplant	I-UNK
recipient	O
with	O
right	O
BN	B-UNK
.	O
MRI	B-UNK
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	B-UNK
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	B-DISEASE
and	O
right	O
brachial	B-DISEASE
plexitis	I-DISEASE
.	O
Symptoms	B-UNK
persisted	O
for	O
three	O
months	B-UNK
despite	O
TAC	B-UNK
dose	B-UNK
reduction	I-UNK
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	B-UNK
of	O
methylprednisolone	B-CHEMICAL
pulse	B-UNK
therapy	O
.	O
Improvement	B-UNK
and	O
eventually	O
full	O
recovery	B-UNK
only	O
occurred	B-UNK
after	O
TAC	B-UNK
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	B-CHEMICAL
.	O

Valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
in	O
patients	B-UNK
with	O
Parkinson'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
treated	O
with	O
pergolide	B-UNK
.	O
Course	O
following	O
treatment	B-UNK
modifications	B-UNK
.	O
Valvular	B-DISEASE
heart	I-DISEASE
abnormalities	I-DISEASE
have	O
been	O
reported	B-UNK
in	O
patients	B-UNK
with	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
(	O
PD	B-UNK
)	O
treated	O
with	O
pergolide	B-UNK
.	O
However	O
,	O
the	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
these	O
abnormalities	B-UNK
vary	O
from	O
study	B-UNK
to	O
study	B-UNK
and	O
their	O
course	O
after	O
drug	B-UNK
withdrawal	B-UNK
has	O
not	O
been	O
systematically	O
assessed	B-UNK
.	O
OBJECTIVES	B-UNK
:	O
To	O
estimate	B-UNK
the	O
frequency	B-UNK
and	O
severity	B-UNK
of	O
valvular	B-UNK
heart	B-UNK
abnormality	B-UNK
and	O
its	O
possible	O
reversibility	O
after	O
drug	B-UNK
withdrawal	B-UNK
in	O
a	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
.	O
METHODS	B-UNK
:	O
All	O
PD	B-UNK
patients	B-UNK
in	O
the	O
Amiens	O
area	B-UNK
treated	O
with	O
pergolide	B-UNK
were	O
invited	O
to	O
attend	O
a	O
cardiologic	O
assessment	B-UNK
including	O
transthoracic	O
echocardiography	B-UNK
.	O
Thirty	B-UNK
PD	B-UNK
patients	B-UNK
participated	O
in	O
the	O
study	B-UNK
.	O
A	O
second	O
echocardiography	B-UNK
was	O
performed	B-UNK
(	O
median	B-UNK
interval	B-UNK
:	O
13	O
months	B-UNK
)	O
after	O
pergolide	B-UNK
withdrawal	B-UNK
(	O
n=10	O
patients	B-UNK
)	O
.	O
Controls	B-UNK
were	O
age-	O
and	O
sex	B-UNK
-	O
matched	O
non-PD	O
patients	B-UNK
referred	B-UNK
to	O
the	O
cardiology	O
department	B-UNK
.	O
RESULTS	B-UNK
:	O
Compared	O
to	O
controls	B-UNK
,	O
aortic	B-DISEASE
regurgitation	I-DISEASE
(	O
OR	O
:	O
3.1	O
;	O
95	O
%	O
IC	O
:	O
1.1	O
-	O
8.8	O
)	O
and	O
mitral	B-DISEASE
regurgitation	I-DISEASE
(	O
OR	O
:	O
10.7	O
;	O
95	O
%	O
IC	O
:	O
2.1	O
-	O
53	O
)	O
were	O
more	O
frequent	B-UNK
in	O
PD	B-UNK
patients	B-UNK
(	O
tricuspid	O
:	O
NS	B-UNK
)	O
.	O
The	O
number	B-UNK
of	O
affected	B-UNK
valves	O
(	O
n=2.4+/-0.7	O
)	O
and	O
the	O
sum	O
of	O
regurgitation	B-UNK
grades	O
(	O
n=2.8+/-1.09	O
)	O
were	O
higher	B-UNK
(	O
p=0.008	O
and	O
p=0.006	O
,	O
respectively	O
)	O
in	O
the	O
pergolide	B-UNK
group	B-UNK
.	O
Severity	B-UNK
of	O
regurgitation	B-UNK
was	O
not	O
correlated	B-UNK
with	O
pergolide	B-UNK
cumulative	B-UNK
dose	I-UNK
.	O
A	O
restrictive	O
pattern	B-UNK
of	O
valvular	B-UNK
regurgitation	B-UNK
,	O
suggestive	B-UNK
of	O
the	O
role	O
of	O
pergolide	B-UNK
,	O
was	O
observed	O
in	O
12/30	O
(	O
40	O
%	O
)	O
patients	B-UNK
including	O
two	O
with	O
heart	B-UNK
failure	I-UNK
.	O
Pergolide	B-UNK
was	O
discontinued	O
in	O
10	O
patients	B-UNK
with	O
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
,	O
resulting	B-UNK
in	O
a	O
lower	B-UNK
regurgitation	B-UNK
grade	B-UNK
(	O
p=0.01	O
)	O
at	O
the	O
second	O
transthoracic	O
echocardiography	B-UNK
and	O
the	O
two	O
patients	B-UNK
with	O
heart	B-UNK
failure	I-UNK
returned	B-UNK
to	O
nearly	O
normal	O
clinical	B-UNK
examination	B-UNK
.	O
This	O
study	B-UNK
supports	O
the	O
high	B-UNK
frequency	I-UNK
of	O
restrictive	O
valve	B-UNK
regurgitation	B-UNK
in	O
PD	B-UNK
patients	B-UNK
treated	O
with	O
pergolide	B-CHEMICAL
and	O
reveals	O
that	O
a	O
significant	B-UNK
improvement	B-UNK
is	O
usual	O
when	O
the	O
treatment	B-UNK
is	O
converted	O
to	O
non-ergot	O
dopamine	B-UNK
agonists	B-UNK
.	O

Adverse	B-UNK
effects	I-UNK
of	O
topical	B-UNK
papaverine	B-UNK
on	O
auditory	B-UNK
nerve	B-UNK
function	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Papaverine	B-CHEMICAL
hydrochloride	B-UNK
is	O
a	O
direct	B-UNK
-	O
acting	O
vasodilator	O
used	O
to	O
manage	O
vasospasm	B-DISEASE
during	O
various	O
neurosurgical	O
operations	O
.	O
Transient	B-UNK
cranial	B-DISEASE
nerve	I-DISEASE
dysfunction	I-DISEASE
has	O
been	O
described	O
in	O
a	O
few	O
cases	B-UNK
with	O
topical	B-UNK
papaverine	B-UNK
.	O
This	O
study	B-UNK
supports	O
previous	B-UNK
reports	B-UNK
and	O
provides	O
neurophysiological	O
evidence	B-UNK
of	O
an	O
adverse	B-UNK
effect	I-UNK
on	O
the	O
auditory	B-UNK
nerve	B-UNK
.	O
METHODS	B-UNK
:	O
We	O
conducted	B-UNK
a	O
retrospective	B-UNK
review	B-UNK
of	O
70	O
consecutive	B-UNK
microvascular	O
decompression	O
operations	O
and	O
studied	O
those	O
patients	B-UNK
who	O
received	O
topical	B-UNK
papaverine	B-UNK
for	O
vasospasm	B-DISEASE
.	O
Topical	B-UNK
papaverine	B-CHEMICAL
was	O
used	O
as	O
a	O
direct	B-UNK
therapeutic	B-UNK
action	B-UNK
to	O
manage	O
vasospasm	B-DISEASE
in	O
a	O
total	B-UNK
of	O
11	O
patients	B-UNK
.	O
The	O
timing	O
of	O
papaverine	B-UNK
application	B-UNK
and	O
ongoing	O
operative	B-UNK
events	B-UNK
was	O
reviewed	B-UNK
relative	B-UNK
to	O
changes	O
in	O
neurophysiological	O
recordings	O
.	O
Brainstem	B-UNK
auditory	B-UNK
evoked	B-UNK
potentials	B-UNK
(	O
BAEPs	O
)	O
were	O
routinely	O
used	O
to	O
monitor	B-UNK
cochlear	O
nerve	B-UNK
function	B-UNK
during	O
these	O
operations	O
.	O
FINDINGS	B-UNK
:	O
A	O
temporal	B-UNK
relationship	B-UNK
was	O
found	O
between	O
topical	B-UNK
papaverine	B-UNK
and	O
BAEP	O
changes	O
leading	B-UNK
to	O
complete	B-UNK
waveform	O
loss	B-UNK
.	O
The	O
average	B-UNK
temporal	B-UNK
delay	B-UNK
between	O
papaverine	B-UNK
and	O
the	O
onset	B-UNK
of	O
an	O
adverse	B-UNK
BAEP	O
change	B-UNK
was	O
5	O
min	B-UNK
.	O
In	O
10	O
of	O
11	O
patients	B-UNK
,	O
BAEP	O
waves	O
II	B-UNK
/	O
III	B-UNK
-	O
V	O
completely	O
disappeared	O
within	O
2	O
to	O
25	O
min	B-UNK
after	O
papaverine	B-CHEMICAL
.	O
Eight	O
of	O
these	O
10	O
patients	B-UNK
had	O
complete	B-UNK
loss	B-UNK
of	O
BAEP	O
waveforms	O
within	O
10	O
min	B-UNK
.	O
One	O
patient	B-UNK
showed	O
no	O
recovery	B-UNK
of	O
later	O
waves	O
and	O
a	O
delayed	B-UNK
profound	B-UNK
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O
The	O
average	B-UNK
recovery	B-UNK
time	O
of	O
BAEP	O
waveforms	O
to	O
pre	B-UNK
-	O
papaverine	B-UNK
baseline	B-UNK
values	O
was	O
39	O
min	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Topical	B-UNK
papaverine	B-UNK
for	O
the	O
treatment	B-UNK
of	O
vasospasm	B-UNK
was	O
associated	O
with	O
the	O
onset	B-UNK
of	O
a	O
transient	B-UNK
disturbance	B-UNK
in	O
neurophysiological	O
function	B-UNK
of	O
the	O
ascending	O
auditory	B-UNK
brainstem	B-UNK
pathway	B-UNK
.	O
The	O
complete	B-UNK
disappearance	O
of	O
BAEP	O
waveforms	O
with	O
a	O
consistent	B-UNK
temporal	B-UNK
delay	B-UNK
suggests	O
a	O
possible	O
adverse	B-DISEASE
effect	I-DISEASE
on	I-DISEASE
the	I-DISEASE
proximal	I-DISEASE
eighth	I-DISEASE
nerve	I-DISEASE
.	O
Recommendations	O
to	O
avoid	B-UNK
potential	B-UNK
cranial	B-DISEASE
nerve	I-DISEASE
deficits	I-DISEASE
from	O
papaverine	B-UNK
are	O
provided	O
.	O

Massive	B-UNK
proteinuria	B-UNK
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
after	O
oral	B-UNK
bisphosphonate	O
(	O
alendronate	B-CHEMICAL
)	O
administration	O
in	O
a	O
patient	B-UNK
with	O
focal	B-UNK
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
.	O
A	O
61-year	O
-	O
old	O
Japanese	B-UNK
man	B-UNK
with	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
due	O
to	O
focal	B-UNK
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
was	O
initially	B-UNK
responding	O
well	O
to	O
steroid	B-CHEMICAL
therapy	O
.	O
The	O
amount	O
of	O
daily	B-UNK
urinary	B-UNK
protein	I-UNK
decreased	B-UNK
from	O
15.6	O
to	O
2.8	O
g.	O
Within	O
14	O
days	B-UNK
of	O
the	O
oral	B-UNK
bisphosphonate	O
(	O
alendronate	B-CHEMICAL
sodium	B-CHEMICAL
)	O
administration	O
,	O
the	O
amount	O
of	O
daily	B-UNK
urinary	B-UNK
protein	I-UNK
increased	B-UNK
rapidly	O
up	O
to	O
12.8	O
g	O
with	O
acute	B-UNK
renal	I-UNK
failure	I-UNK
.	O
After	O
discontinuing	O
the	O
oral	B-UNK
alendronate	B-CHEMICAL
,	O
the	O
patient	B-UNK
underwent	O
six	O
cycles	B-UNK
of	O
hemodialysis	B-UNK
and	O
four	O
cycles	B-UNK
of	O
LDL	B-UNK
apheresis	O
.	O
Urinary	B-UNK
volume	B-UNK
and	O
serum	B-UNK
creatinine	I-UNK
levels	I-UNK
recovered	O
to	O
the	O
normal	O
range	B-UNK
,	O
with	O
urinary	B-UNK
protein	I-UNK
disappearing	O
completely	O
within	O
40	O
days	B-UNK
.	O
This	O
report	B-UNK
demonstrates	O
that	O
not	O
only	O
intravenous	B-UNK
,	O
but	O
also	O
oral	B-UNK
bisphosphonates	O
can	O
aggravate	O
proteinuria	B-DISEASE
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O

Serum-	O
and	O
glucocorticoid	B-UNK
-	O
inducible	B-UNK
kinase	B-UNK
1	O
in	O
doxorubicin	B-CHEMICAL
-	O
induced	O
nephrotic	B-UNK
syndrome	I-UNK
.	O
Doxorubicin	B-UNK
-	O
induced	O
nephropathy	B-DISEASE
leads	B-UNK
to	O
epithelial	B-UNK
sodium	B-UNK
channel	I-UNK
(	O
ENaC)-dependent	O
volume	B-UNK
retention	B-UNK
and	O
renal	B-UNK
fibrosis	B-DISEASE
.	O
The	O
aldosterone	B-UNK
-	O
sensitive	B-UNK
serum-	O
and	O
glucocorticoid	B-UNK
-	O
inducible	B-UNK
kinase	B-UNK
SGK1	B-UNK
has	O
been	O
shown	B-UNK
to	O
participate	O
in	O
the	O
stimulation	B-UNK
of	O
ENaC	B-UNK
and	O
to	O
mediate	B-UNK
renal	B-UNK
fibrosis	B-DISEASE
following	O
mineralocorticoid	O
and	O
salt	B-CHEMICAL
excess	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
performed	B-UNK
to	O
elucidate	O
the	O
role	O
of	O
SGK1	B-UNK
in	O
the	O
volume	B-UNK
retention	B-UNK
and	O
fibrosis	B-UNK
during	O
nephrotic	B-UNK
syndrome	I-UNK
.	O
To	O
this	O
end	B-UNK
,	O
doxorubicin	B-CHEMICAL
(	O
15	O
mug	B-UNK
/	O
g	O
body	B-UNK
wt	B-UNK
)	O
was	O
injected	B-UNK
intravenously	O
into	O
gene	B-UNK
-	O
targeted	B-UNK
mice	B-UNK
lacking	B-UNK
SGK1	B-UNK
(	O
sgk1(-/-	O
)	O
)	O
and	O
their	O
wild	O
-	O
type	B-UNK
littermates	O
(	O
sgk1(+/+	O
)	O
)	O
.	O
Doxorubicin	B-UNK
treatment	B-UNK
resulted	B-UNK
in	O
heavy	B-UNK
proteinuria	B-DISEASE
(	O
>	O
100	O
mg	B-UNK
protein	B-UNK
/	O
mg	B-UNK
crea	O
)	O
in	O
15/44	O
of	O
sgk1(+/+	O
)	O
and	O
15/44	O
of	O
sgk1(-/-	O
)	O
mice	B-UNK
leading	B-UNK
to	O
severe	B-UNK
nephrotic	B-UNK
syndrome	I-UNK
with	O
ascites	B-DISEASE
,	O
lipidemia	O
,	O
and	O
hypoalbuminemia	B-DISEASE
in	O
both	O
genotypes	O
.	O
Plasma	B-UNK
aldosterone	B-UNK
levels	O
increased	B-UNK
in	O
nephrotic	B-UNK
mice	B-UNK
of	O
both	O
genotypes	O
and	O
was	O
followed	O
by	O
increased	B-UNK
SGK1	B-UNK
protein	B-UNK
expression	I-UNK
in	O
sgk1(+/+	O
)	O
mice	B-UNK
.	O
Urinary	B-UNK
sodium	B-UNK
excretion	B-UNK
reached	O
signficantly	O
lower	B-UNK
values	O
in	O
sgk1(+/+	O
)	O
mice	B-UNK
(	O
15	O
+	O
/-	O
5	O
mumol	B-UNK
/	O
mg	B-UNK
crea	O
)	O
than	O
in	O
sgk1(-/-	O
)	O
mice	B-UNK
(	O
35	O
+	O
/-	O
5	O
mumol	B-UNK
/	O
mg	B-UNK
crea	O
)	O
and	O
was	O
associated	O
with	O
a	O
significantly	B-UNK
higher	I-UNK
body	B-DISEASE
weight	I-DISEASE
gain	B-UNK
in	O
sgk1(+/+	O
)	O
compared	O
with	O
sgk1(-/-	O
)	O
mice	B-UNK
(	O
+6.6	O
+	O
/-	O
0.7	O
vs	O
.	O
+4.1	O
+	O
/-	O
0.8	O
g	O
)	O
.	O
During	O
the	O
course	O
of	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
,	O
serum	B-UNK
urea	B-CHEMICAL
concentrations	B-UNK
increased	B-UNK
significantly	B-UNK
faster	O
in	O
sgk1(-/-	O
)	O
mice	B-UNK
than	O
in	O
sgk1(+/+	O
)	O
mice	B-UNK
leading	B-UNK
to	O
uremia	B-DISEASE
and	O
a	O
reduced	B-UNK
median	B-UNK
survival	B-UNK
in	O
sgk1(-/-	O
)	O
mice	B-UNK
(	O
29	O
vs	O
.	O
40	O
days	B-UNK
in	O
sgk1(+/+	O
)	O
mice	B-UNK
)	O
.	O
In	O
conclusion	B-UNK
,	O
gene	B-UNK
-	O
targeted	B-UNK
mice	B-UNK
lacking	B-UNK
SGK1	B-UNK
showed	O
blunted	O
volume	B-UNK
retention	B-UNK
,	O
yet	O
were	O
not	O
protected	B-UNK
against	O
renal	B-UNK
fibrosis	B-UNK
during	O
experimental	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O

Severe	B-UNK
and	O
long	B-UNK
lasting	I-UNK
cholestasis	B-UNK
after	O
high	B-UNK
-	O
dose	B-UNK
co-trimoxazole	O
treatment	B-UNK
for	O
Pneumocystis	B-DISEASE
pneumonia	I-DISEASE
in	O
HIV	B-DISEASE
-	O
infected	B-UNK
patients	B-UNK
--	O
a	O
report	B-UNK
of	O
two	O
cases	B-UNK
.	O
Pneumocystis	B-DISEASE
pneumonia	I-DISEASE
(	O
PCP	O
)	O
,	O
a	O
common	B-UNK
opportunistic	O
infection	B-UNK
in	O
HIV	B-UNK
-	O
infected	B-UNK
individuals	B-UNK
,	O
is	O
generally	B-UNK
treated	O
with	O
high	B-UNK
doses	I-UNK
of	O
co-trimoxazole	O
.	O
However	O
,	O
treatment	B-UNK
is	O
often	O
limited	B-UNK
by	O
adverse	B-UNK
effects	I-UNK
.	O
Here	O
,	O
we	O
report	B-UNK
two	O
cases	B-UNK
of	O
severely	O
immunocompromised	O
HIV	B-DISEASE
-	O
infected	B-UNK
patients	B-UNK
who	O
developed	O
severe	B-UNK
intrahepatic	O
cholestasis	B-UNK
,	O
and	O
in	O
one	O
patient	B-UNK
lesions	B-UNK
mimicking	O
liver	B-DISEASE
abscess	I-DISEASE
formation	B-UNK
on	O
radiologic	O
exams	O
,	O
during	O
co-trimoxazole	O
treatment	B-UNK
for	O
PCP	O
.	O
Whereas	O
patient	B-UNK
1	O
showed	O
lesions	B-UNK
of	O
up	O
to	O
1	O
cm	B-UNK
readily	O
detectable	O
on	O
magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
under	O
prolonged	B-UNK
co-trimoxazole	O
treatment	B-UNK
,	O
therapy	O
of	O
patient	B-UNK
2	O
was	O
switched	O
early	B-UNK
.	O

Clinically	B-UNK
significant	I-UNK
proteinuria	B-DISEASE
following	O
the	O
administration	O
of	O
sirolimus	B-CHEMICAL
to	O
renal	B-UNK
transplant	I-UNK
recipients	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Sirolimus	B-CHEMICAL
is	O
the	O
latest	O
immunosuppressive	B-UNK
agent	B-UNK
used	O
to	O
prevent	B-UNK
rejection	B-UNK
,	O
and	O
may	O
have	O
less	O
nephrotoxicity	B-UNK
than	O
calcineurin	B-UNK
inhibitor	I-UNK
(	O
CNI)-based	O
regimens	B-UNK
.	O
To	O
date	B-UNK
there	O
has	O
been	O
little	O
documentation	O
of	O
clinically	B-UNK
significant	I-UNK
proteinuria	B-UNK
linked	B-UNK
with	O
the	O
use	O
of	O
sirolimus	B-UNK
.	O
We	O
have	O
encountered	O
several	O
patients	B-UNK
who	O
developed	O
substantial	O
proteinuria	B-UNK
associated	O
with	O
sirolimus	B-CHEMICAL
use	O
.	O
In	O
each	O
patient	B-UNK
,	O
the	O
close	B-UNK
temporal	B-UNK
association	B-UNK
between	O
the	O
commencement	O
of	O
sirolimus	B-UNK
therapy	O
and	O
proteinuria	B-UNK
implicated	B-UNK
sirolimus	B-CHEMICAL
as	O
the	O
most	O
likely	O
etiology	B-UNK
of	O
the	O
proteinuria	B-UNK
.	O
METHODS	B-UNK
:	O
We	O
analyzed	O
the	O
clinical	B-UNK
and	O
laboratory	B-UNK
information	B-UNK
available	O
for	O
all	O
119	O
patients	B-UNK
transplanted	B-UNK
at	O
the	O
Washington	O
Hospital	B-UNK
Center	B-UNK
between	O
1999	O
-	O
2003	O
for	O
whom	O
sirolimus	B-UNK
was	O
a	O
component	B-UNK
of	O
their	O
immunosuppressant	O
regimen	B-UNK
.	O
In	O
these	O
patients	B-UNK
,	O
the	O
magnitude	B-UNK
of	O
proteinuria	B-UNK
was	O
assessed	B-UNK
on	O
morning	B-UNK
urine	B-UNK
samples	O
by	O
turbidometric	O
measurement	B-UNK
or	O
random	O
urine	B-UNK
protein	B-UNK
:	O
creatinine	B-UNK
ratios	O
,	O
an	O
estimate	B-UNK
of	O
grams	O
of	O
proteinuria	B-UNK
/	O
day	O
.	O
Laboratory	B-UNK
results	B-UNK
were	O
compared	O
between	O
prior	B-UNK
,	O
during	O
and	O
following	O
sirolimus	B-CHEMICAL
use	O
.	O
RESULTS	B-UNK
:	O
Twenty	O
-	O
eight	O
patients	B-UNK
(	O
24	O
%	O
)	O
developed	O
increased	B-UNK
proteinuria	B-DISEASE
from	O
baseline	B-UNK
during	O
their	O
post-transplantation	O
course	O
.	O
In	O
21	O
patients	B-UNK
an	O
alternative	B-UNK
cause	O
of	O
proteinuria	B-UNK
was	O
either	O
obvious	O
or	O
insufficient	O
data	B-UNK
was	O
available	O
to	O
be	O
conclusive	O
.	O
In	O
7	O
of	O
the	O
28	O
patients	B-UNK
there	O
was	O
a	O
striking	O
temporal	B-UNK
association	B-UNK
between	O
the	O
initiation	B-UNK
of	O
sirolimus	B-CHEMICAL
and	O
the	O
development	B-UNK
of	O
nephrotic	B-UNK
-	O
range	B-UNK
proteinuria	B-UNK
.	O
Proteinuria	B-DISEASE
correlated	B-UNK
most	O
strongly	O
with	O
sirolimus	B-CHEMICAL
therapy	O
when	O
compared	O
to	O
other	O
demographic	O
and	O
clinical	B-UNK
variables	B-UNK
.	O
In	O
most	O
patients	B-UNK
,	O
discontinuation	B-UNK
of	O
sirolimus	B-UNK
resulted	B-UNK
in	O
a	O
decrease	B-UNK
,	O
but	O
not	O
resolution	B-UNK
,	O
of	O
proteinuria	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Sirolimus	B-CHEMICAL
induces	O
or	O
aggravates	O
pre	B-UNK
-	O
existing	B-UNK
proteinuria	B-UNK
in	O
an	O
unpredictable	O
subset	B-UNK
of	O
renal	B-UNK
allograft	B-UNK
recipients	B-UNK
.	O
Proteinuria	B-UNK
may	O
improve	B-UNK
,	O
but	O
does	O
not	O
resolve	O
,	O
when	O
sirolimus	B-CHEMICAL
is	O
withdrawn	O
.	O

Comparative	B-UNK
cognitive	B-UNK
and	O
subjective	B-UNK
side	O
effects	O
of	O
immediate	O
-	O
release	B-UNK
oxycodone	B-CHEMICAL
in	O
healthy	B-UNK
middle	B-UNK
-	O
aged	B-UNK
and	O
older	B-UNK
adults	B-UNK
.	O
This	O
study	B-UNK
measured	B-UNK
the	O
objective	B-UNK
and	O
subjective	B-UNK
neurocognitive	O
effects	O
of	O
a	O
single	B-UNK
10-mg	O
dose	B-UNK
of	O
immediate	O
-	O
release	B-UNK
oxycodone	B-CHEMICAL
in	O
healthy	B-UNK
,	O
older	B-UNK
(	O
>	O
65	O
years	B-UNK
)	O
,	O
and	O
middle	B-UNK
-	O
aged	B-UNK
(	O
35	O
to	O
55	O
years	B-UNK
)	O
adults	B-UNK
who	O
were	O
not	O
suffering	O
from	O
chronic	B-UNK
or	O
significant	B-UNK
daily	B-UNK
pain	B-DISEASE
.	O
Seventy	B-UNK
-	O
one	O
participants	B-UNK
completed	O
2	O
separate	B-UNK
study	B-UNK
days	B-UNK
and	O
were	O
blind	B-UNK
to	O
medication	O
condition	B-UNK
(	O
placebo	B-UNK
,	O
10-mg	O
oxycodone	B-CHEMICAL
)	O
.	O
Plasma	B-UNK
oxycodone	B-CHEMICAL
concentration	B-UNK
peaked	O
between	O
60	O
and	O
90	O
minutes	B-UNK
postdose	O
(	O
P	O
<	O
.01	O
)	O
and	O
pupil	B-UNK
size	B-UNK
,	O
an	O
indication	O
of	O
physiological	B-UNK
effects	O
of	O
the	O
medication	O
,	O
peaked	O
at	O
approximately	B-UNK
90	O
to	O
120	O
minutes	B-UNK
postdose	O
(	O
P	O
<	O
.01	O
)	O
.	O
Significant	B-UNK
declines	O
in	O
simple	O
and	O
sustained	B-UNK
attention	B-UNK
,	O
working	B-UNK
memory	B-UNK
,	O
and	O
verbal	B-UNK
memory	B-UNK
were	O
observed	O
at	O
1	O
hour	B-UNK
postdose	O
compared	O
to	O
baseline	B-UNK
for	O
both	O
age	B-UNK
groups	B-UNK
with	O
a	O
trend	O
toward	O
return	B-UNK
to	O
baseline	B-UNK
by	O
5	O
hours	B-UNK
postdose	O
.	O
For	O
almost	O
all	O
cognitive	B-UNK
measures	B-UNK
,	O
there	O
were	O
no	O
medication	O
by	O
age	B-UNK
-	O
interaction	B-UNK
effects	O
,	O
which	O
indicates	O
that	O
the	O
2	O
age	B-UNK
groups	B-UNK
exhibited	O
similar	B-UNK
responses	O
to	O
the	O
medication	O
challenge	B-UNK
.	O
This	O
study	B-UNK
suggests	O
that	O
for	O
healthy	B-UNK
older	B-UNK
adults	B-UNK
who	O
are	O
not	O
suffering	O
from	O
chronic	B-DISEASE
pain	I-DISEASE
,	O
neurocognitive	O
and	O
pharmacodynamic	O
changes	O
in	O
response	B-UNK
to	O
a	O
10-mg	O
dose	B-UNK
of	O
immediate	O
-	O
release	B-UNK
oxycodone	B-CHEMICAL
are	O
similar	B-UNK
to	O
those	O
observed	O
for	O
middle	B-UNK
-	O
aged	B-UNK
adults	B-UNK
.	O
PERSPECTIVE	O
:	O
Study	B-UNK
findings	B-UNK
indicate	O
that	O
the	O
metabolism	B-UNK
,	O
neurocognitive	O
effects	O
,	O
and	O
physical	B-UNK
side	O
effects	O
of	O
oral	B-UNK
oxycodone	B-CHEMICAL
are	O
similar	B-UNK
for	O
healthy	B-UNK
middle	B-UNK
-	O
aged	B-UNK
and	O
older	B-UNK
adults	B-UNK
.	O
Therefore	O
,	O
clinicians	B-UNK
should	O
not	O
avoid	B-UNK
prescribing	B-UNK
oral	B-UNK
opioids	O
to	O
older	B-UNK
adults	B-UNK
based	B-UNK
on	O
the	O
belief	O
that	O
older	B-UNK
adults	B-UNK
are	O
at	O
higher	B-UNK
risk	B-UNK
for	O
side	O
effects	O
than	O
younger	B-UNK
adults	B-UNK
.	O

Normalizing	O
effects	O
of	O
modafinil	B-CHEMICAL
on	O
sleep	B-UNK
in	O
chronic	B-UNK
cocaine	B-UNK
users	I-UNK
.	O
OBJECTIVE	B-UNK
:	O
The	O
purpose	B-UNK
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
determine	B-UNK
the	O
effect	B-UNK
of	O
morning	B-UNK
-	O
dosed	O
modafinil	B-CHEMICAL
on	O
sleep	B-UNK
and	O
daytime	B-DISEASE
sleepiness	I-DISEASE
in	O
chronic	B-UNK
cocaine	B-UNK
users	I-UNK
.	O
METHOD	B-UNK
:	O
Twenty	O
cocaine	B-UNK
-	O
dependent	B-UNK
participants	B-UNK
were	O
randomly	B-UNK
assigned	I-UNK
to	I-UNK
receive	B-UNK
modafinil	B-CHEMICAL
,	O
400	O
mg	B-UNK
(	O
N=10	O
)	O
,	O
or	O
placebo	B-UNK
(	O
N=10	O
)	O
every	O
morning	B-UNK
at	O
7:30	O
a.m	O
.	O
for	O
16	O
days	B-UNK
in	O
an	O
inpatient	B-UNK
,	O
double-blind	O
randomized	B-UNK
trial	B-UNK
.	O
Participants	B-UNK
underwent	O
polysomnographic	O
sleep	B-UNK
recordings	O
on	O
days	B-UNK
1	O
to	O
3	O
,	O
7	O
to	O
9	O
,	O
and	O
14	O
to	O
16	O
(	O
first	O
,	O
second	O
,	O
and	O
third	O
weeks	B-UNK
of	O
abstinence	O
)	O
.	O
The	O
Multiple	B-UNK
Sleep	B-UNK
Latency	B-UNK
Test	B-UNK
was	O
performed	B-UNK
at	O
11:30	O
a.m	O
.	O
,	O
2:00	O
p.m	O
.	O
,	O
and	O
4:30	O
p.m	O
.	O
on	O
days	B-UNK
2	O
,	O
8	O
,	O
and	O
15	O
.	O
For	O
comparison	B-UNK
of	O
sleep	B-UNK
architecture	O
variables	B-UNK
,	O
12	O
healthy	B-UNK
comparison	B-UNK
participants	B-UNK
underwent	O
a	O
single	B-UNK
night	B-UNK
of	O
experimental	B-UNK
polysomnography	O
that	O
followed	O
1	O
night	B-UNK
of	O
accommodation	O
polysomnography	O
.	O
RESULTS	B-UNK
:	O
Progressive	B-UNK
abstinence	O
from	O
cocaine	B-CHEMICAL
was	O
associated	O
with	O
worsening	B-UNK
of	O
all	O
measured	B-UNK
polysomnographic	O
sleep	B-UNK
outcomes	B-UNK
.	O
Compared	O
with	O
placebo	B-UNK
,	O
modafinil	B-CHEMICAL
decreased	B-UNK
nighttime	O
sleep	B-UNK
latency	B-UNK
and	O
increased	B-UNK
slow	B-UNK
-	O
wave	B-UNK
sleep	B-UNK
time	O
in	O
cocaine	B-UNK
-	O
dependent	B-UNK
participants	B-UNK
.	O
The	O
effect	B-UNK
of	O
modafinil	B-CHEMICAL
interacted	O
with	O
the	O
abstinence	O
week	B-UNK
and	O
was	O
associated	O
with	O
longer	O
total	B-UNK
sleep	B-UNK
time	O
and	O
shorter	O
REM	O
sleep	B-UNK
latency	B-UNK
in	O
the	O
third	O
week	B-UNK
of	O
abstinence	O
.	O
Comparison	B-UNK
of	O
slow	B-UNK
-	O
wave	B-UNK
sleep	B-UNK
time	O
,	O
total	B-UNK
sleep	B-UNK
time	O
,	O
and	O
sleep	B-UNK
latency	B-UNK
in	O
cocaine	B-UNK
-	O
dependent	B-UNK
and	O
healthy	B-UNK
participants	B-UNK
revealed	O
a	O
normalizing	O
effect	B-UNK
of	O
modafinil	B-CHEMICAL
in	O
cocaine	B-CHEMICAL
-	O
dependent	B-UNK
participants	B-UNK
.	O
Modafinil	B-CHEMICAL
was	O
associated	O
with	O
increased	B-UNK
daytime	O
sleep	B-UNK
latency	B-UNK
,	O
as	O
measured	B-UNK
by	O
the	O
Multiple	B-UNK
Sleep	B-UNK
Latency	B-UNK
Test	B-UNK
,	O
and	O
a	O
nearly	O
significant	B-UNK
decrease	B-UNK
in	O
subjective	B-UNK
daytime	B-DISEASE
sleepiness	I-DISEASE
.	O
CONCLUSIONS	B-UNK
:	O
Morning	B-UNK
-	O
dosed	O
modafinil	B-CHEMICAL
promotes	O
nocturnal	O
sleep	B-UNK
,	O
normalizes	O
sleep	B-UNK
architecture	O
,	O
and	O
decreases	B-UNK
daytime	B-DISEASE
sleepiness	I-DISEASE
in	O
abstinent	O
cocaine	B-UNK
users	I-UNK
.	O
These	O
effects	O
may	O
be	O
relevant	B-UNK
in	O
the	O
treatment	B-UNK
of	O
cocaine	B-CHEMICAL
dependence	B-UNK
.	O

Efficacy	B-UNK
and	I-UNK
safety	I-UNK
of	O
asenapine	B-UNK
in	O
a	O
placebo-	O
and	O
haloperidol	B-UNK
-	O
controlled	B-UNK
trial	I-UNK
in	O
patients	B-UNK
with	O
acute	B-UNK
exacerbation	O
of	O
schizophrenia	B-UNK
.	O
Asenapine	B-UNK
is	O
approved	O
by	O
the	O
Food	B-UNK
and	O
Drugs	B-UNK
Administration	O
in	O
adults	B-UNK
for	O
acute	B-UNK
treatment	B-UNK
of	O
schizophrenia	B-UNK
or	O
of	O
manic	B-UNK
or	O
mixed	B-UNK
episodes	B-UNK
associated	O
with	O
bipolar	B-DISEASE
I	I-DISEASE
disorder	I-DISEASE
with	O
or	O
without	O
psychotic	B-UNK
features	B-UNK
.	O
In	O
a	O
double-blind	O
6-week	O
trial	B-UNK
,	O
458	O
patients	B-UNK
with	O
acute	B-UNK
schizophrenia	B-UNK
were	O
randomly	B-UNK
assigned	I-UNK
to	I-UNK
fixed	B-UNK
-	O
dose	B-UNK
treatment	B-UNK
with	O
asenapine	B-UNK
at	O
5	O
mg	B-UNK
twice	O
daily	B-UNK
(	O
BID	B-UNK
)	O
,	O
asenapine	B-UNK
at	O
10	O
mg	B-UNK
BID	I-UNK
,	O
placebo	B-UNK
,	O
or	O
haloperidol	B-CHEMICAL
at	O
4	O
mg	B-UNK
BID	I-UNK
(	O
to	O
verify	O
assay	B-UNK
sensitivity	B-UNK
)	O
.	O
With	O
last	O
observations	B-UNK
carried	O
forward	O
(	O
LOCF	O
)	O
,	O
mean	O
Positive	B-UNK
and	O
Negative	B-UNK
Syndrome	B-UNK
Scale	B-UNK
total	B-UNK
score	O
reductions	B-UNK
from	O
baseline	B-UNK
to	O
endpoint	O
were	O
significantly	B-UNK
greater	I-UNK
with	O
asenapine	B-UNK
at	O
5	O
mg	B-UNK
BID	I-UNK
(	O
-16.2	O
)	O
and	O
haloperidol	B-CHEMICAL
(	O
-15.4	O
)	O
than	O
placebo	B-UNK
(	O
-10.7	O
;	O
both	O
P	O
<	O
0.05	O
)	O
;	O
using	O
mixed	B-UNK
model	B-UNK
for	O
repeated	B-UNK
measures	B-UNK
(	O
MMRM	O
)	O
,	O
changes	O
at	O
day	O
42	O
were	O
significantly	B-UNK
greater	I-UNK
with	O
asenapine	B-UNK
at	O
5	O
and	O
10	O
mg	B-UNK
BID	I-UNK
(	O
-21.3	O
and	O
-19.4	O
,	O
respectively	O
)	O
and	O
haloperidol	B-UNK
(	O
-20.0	O
)	O
than	O
placebo	B-UNK
(	O
-14.6	O
;	O
all	O
P	O
<	O
0.05	O
)	O
.	O
On	O
the	O
Positive	B-UNK
and	O
Negative	B-UNK
Syndrome	B-UNK
Scale	B-UNK
positive	B-UNK
subscale	O
,	O
all	O
treatments	O
were	O
superior	B-UNK
to	O
placebo	B-UNK
with	O
LOCF	O
and	O
MMRM	O
;	O
asenapine	B-UNK
at	O
5	O
mg	B-UNK
BID	I-UNK
was	O
superior	B-UNK
to	O
placebo	B-UNK
on	O
the	O
negative	B-UNK
subscale	O
with	O
MMRM	O
and	O
on	O
the	O
general	B-UNK
psychopathology	O
subscale	O
with	O
LOCF	O
and	O
MMRM	O
.	O
Treatment	B-UNK
-	O
related	O
adverse	B-UNK
events	I-UNK
(	O
AEs	O
)	O
occurred	B-UNK
in	O
44	O
%	O
and	O
52	O
%	O
,	O
57	O
%	O
,	O
and	O
41	O
%	O
of	O
the	O
asenapine	B-UNK
at	O
5	O
and	O
10	O
mg	B-UNK
BID	I-UNK
,	O
haloperidol	B-CHEMICAL
,	O
and	O
placebo	B-UNK
groups	B-UNK
,	O
respectively	O
.	O
Extrapyramidal	B-UNK
symptoms	I-UNK
reported	B-UNK
as	O
AEs	O
occurred	B-UNK
in	O
15	O
%	O
and	O
18	O
%	O
,	O
34	O
%	O
,	O
and	O
10	O
%	O
of	O
the	O
asenapine	B-UNK
at	O
5	O
and	O
10	O
mg	B-UNK
BID	I-UNK
,	O
haloperidol	B-CHEMICAL
,	O
and	O
placebo	B-UNK
groups	B-UNK
,	O
respectively	O
.	O
Across	O
all	O
groups	B-UNK
,	O
no	O
more	O
than	O
5	O
%	O
of	O
patients	B-UNK
had	O
clinically	B-UNK
significant	I-UNK
weight	B-UNK
change	B-UNK
.	O
Post	B-UNK
hoc	O
analyses	B-UNK
indicated	O
that	O
efficacy	B-UNK
was	O
similar	B-UNK
with	O
asenapine	B-UNK
and	O
haloperidol	B-CHEMICAL
;	O
greater	B-UNK
contrasts	O
were	O
seen	O
in	O
AEs	O
,	O
especially	O
extrapyramidal	B-UNK
symptoms	I-UNK
.	O

Permeability	B-UNK
,	O
ultrastructural	B-UNK
changes	O
,	O
and	O
distribution	B-UNK
of	O
novel	O
proteins	B-UNK
in	O
the	O
glomerular	B-UNK
barrier	B-UNK
in	O
early	B-UNK
puromycin	B-UNK
aminonucleoside	I-UNK
nephrosis	B-UNK
.	O
BACKGROUND	B-UNK
/	O
AIMS	B-UNK
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-UNK
starts	O
.	O
Using	O
puromycin	B-UNK
aminonucleoside	I-UNK
nephrosis	B-UNK
(	O
PAN	B-UNK
)	O
rats	B-UNK
,	O
we	O
studied	O
early	B-UNK
ultrastructural	B-UNK
and	O
permeability	B-UNK
changes	O
in	O
relation	B-UNK
to	O
the	O
expression	B-UNK
of	O
the	O
podocyte	B-UNK
-	O
associated	O
molecules	O
nephrin	O
,	O
a	O
-	O
actinin	O
,	O
dendrin	O
,	O
and	O
plekhh2	O
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	B-UNK
discovered	O
in	O
podocytes	O
.	O
METHODS	B-UNK
:	O
Using	O
immune	B-UNK
stainings	O
,	O
semiquantitative	O
measurement	B-UNK
was	O
performed	B-UNK
under	O
the	O
electron	B-UNK
microscope	O
.	O
Permeability	B-UNK
was	O
assessed	B-UNK
using	O
isolated	B-UNK
kidney	B-UNK
perfusion	B-UNK
with	O
tracers	O
.	O
Possible	O
effects	O
of	O
ACE	B-UNK
inhibition	B-UNK
were	O
tested	B-UNK
.	O
RESULTS	B-UNK
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	B-UNK
process	O
effacement	O
,	O
but	O
no	O
proteinuria	B-UNK
,	O
appeared	B-UNK
.	O
The	O
amount	O
of	O
nephrin	O
was	O
reduced	B-UNK
in	O
both	O
diseased	O
and	O
normal	O
areas	B-UNK
.	O
The	O
other	O
proteins	B-UNK
showed	O
few	O
changes	O
,	O
which	O
were	O
limited	B-UNK
to	O
diseased	O
areas	B-UNK
.	O
By	O
day	O
4	O
,	O
foot	B-UNK
process	O
effacement	O
was	O
complete	B-UNK
and	O
proteinuria	B-UNK
appeared	B-UNK
in	O
parallel	O
with	O
signs	B-UNK
of	O
size	B-UNK
barrier	B-UNK
damage	B-UNK
.	O
Nephrin	O
decreased	B-UNK
further	O
,	O
while	O
dendrin	O
and	O
plekhh2	O
also	O
decreased	B-UNK
but	O
a	O
-	O
actinin	O
remained	B-UNK
unchanged	I-UNK
.	O
ACE	B-UNK
inhibition	B-UNK
had	O
no	O
significant	B-UNK
protective	B-UNK
effect	I-UNK
.	O
CONCLUSIONS	B-UNK
:	O
PAN	B-UNK
glomeruli	B-UNK
already	O
showed	O
significant	B-UNK
pathology	B-UNK
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	B-UNK
proteinuria	B-UNK
.	O
This	O
was	O
preceded	B-UNK
by	O
altered	B-UNK
nephrin	O
expression	B-UNK
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	B-UNK
morphology	O
.	O
The	O
novel	O
proteins	B-UNK
dendrin	O
and	O
plekhh2	O
were	O
both	O
reduced	B-UNK
,	O
suggesting	O
roles	O
in	O
PAN	B-UNK
,	O
whereas	O
a	O
-	O
actinin	O
was	O
unchanged	B-UNK
.	O

Twin	O
preterm	B-UNK
neonates	B-UNK
with	O
cardiac	B-UNK
toxicity	I-UNK
related	O
to	O
lopinavir	O
/	O
ritonavir	B-UNK
therapy	O
.	O
We	O
report	B-UNK
twin	O
neonates	B-UNK
who	O
were	O
born	B-UNK
prematurely	O
at	O
32	O
weeks	B-UNK
of	O
gestation	B-UNK
to	O
a	O
mother	B-UNK
with	O
human	B-UNK
immunodeficiency	B-UNK
virus	I-UNK
infection	B-DISEASE
.	O
One	O
of	O
the	O
twins	O
developed	O
complete	B-UNK
heart	B-UNK
block	I-UNK
and	O
dilated	B-UNK
cardiomyopathy	I-UNK
related	O
to	O
lopinavir	O
/	O
ritonavir	B-UNK
therapy	O
,	O
a	O
boosted	O
protease	B-UNK
-	O
inhibitor	B-UNK
agent	B-UNK
,	O
while	O
the	O
other	O
twin	O
developed	O
mild	B-UNK
bradycardia	B-DISEASE
.	O
We	O
recommend	O
caution	B-UNK
in	O
the	O
use	O
of	O
lopinavir	O
/	O
ritonavir	B-UNK
in	O
the	O
immediate	O
neonatal	B-UNK
period	B-UNK
.	O

Learning	B-UNK
of	O
rats	B-UNK
under	O
amnesia	B-UNK
caused	B-UNK
by	O
pentobarbital	B-UNK
.	O
Dissociated	O
learning	B-UNK
of	O
rats	B-UNK
in	O
the	O
normal	O
state	B-UNK
and	O
the	O
state	B-UNK
of	O
amnesia	B-UNK
produced	B-UNK
by	O
pentobarbital	B-CHEMICAL
(	O
15	O
mg	B-UNK
/	O
kg	B-UNK
,	O
ip	B-UNK
)	O
was	O
carried	O
out	O
.	O
Rats	B-UNK
were	O
trained	B-UNK
to	O
approach	O
a	O
shelf	O
where	O
they	O
received	O
food	B-UNK
reinforcement	O
.	O
In	O
Group	B-UNK
1	O
the	O
rats	B-UNK
were	O
trained	B-UNK
under	O
the	O
influence	B-UNK
of	O
pentobarbital	B-CHEMICAL
to	O
run	O
to	O
the	O
same	O
shelf	O
as	O
in	O
the	O
normal	O
state	B-UNK
.	O
In	O
Group	B-UNK
2	O
the	O
rats	B-UNK
were	O
trained	B-UNK
to	O
approach	O
different	O
shelves	O
in	O
different	O
drug	B-UNK
states	B-UNK
.	O
It	O
was	O
shown	B-UNK
that	O
memory	B-UNK
dissociation	O
occurred	B-UNK
in	O
both	O
groups	B-UNK
.	O
Differences	B-UNK
in	O
the	O
parameters	O
of	O
training	B-UNK
under	O
the	O
influence	B-UNK
of	O
pentobarbital	B-UNK
between	O
Groups	B-UNK
1	O
and	O
2	O
were	O
revealed	O
.	O
These	O
findings	B-UNK
show	O
that	O
the	O
brain	B-UNK
-	O
dissociated	O
state	B-UNK
induced	O
by	O
pentobarbital	B-UNK
is	O
formed	B-UNK
with	O
the	O
participation	O
of	O
the	O
mechanisms	B-UNK
of	O
information	B-UNK
perception	O
.	O

Angiosarcoma	O
of	O
the	O
liver	B-UNK
associated	O
with	O
diethylstilbestrol	B-CHEMICAL
.	O
Angiosarcoma	O
of	O
the	O
liver	B-UNK
occurred	B-UNK
in	O
a	O
76-year	O
-	O
old	O
man	B-UNK
who	O
had	O
been	O
treated	O
for	O
a	O
well	O
-	O
differentiated	O
adenocarcinoma	B-DISEASE
of	O
the	O
liver	B-UNK
with	O
diethylstilbestrol	B-CHEMICAL
for	O
13	O
years	B-UNK
.	O
Angiosarcoma	O
was	O
also	O
present	B-UNK
within	O
pulmonary	B-UNK
and	O
renal	B-UNK
arteries	B-UNK
.	O
The	O
possibility	O
that	O
the	O
intraarterial	O
lesions	B-UNK
might	O
represent	O
independent	B-UNK
primary	B-UNK
tumors	B-UNK
is	O
considered	B-UNK
.	O

Role	O
of	O
xanthine	O
oxidase	B-UNK
in	O
dexamethasone	B-CHEMICAL
-	O
induced	O
hypertension	B-UNK
in	O
rats	B-UNK
.	O
1	O
.	O
Glucocorticoid	B-UNK
-	O
induced	O
hypertension	B-DISEASE
(	O
GC	O
-	O
HT	B-UNK
)	O
in	O
the	O
rat	B-UNK
is	O
associated	O
with	O
nitric	B-UNK
oxide	I-UNK
-	O
redox	O
imbalance	O
.	O
2	O
.	O
We	O
studied	O
the	O
role	O
of	O
xanthine	O
oxidase	B-UNK
(	O
XO	O
)	O
,	O
which	O
is	O
implicated	B-UNK
in	O
the	O
production	B-UNK
of	O
reactive	B-UNK
oxygen	I-UNK
species	I-UNK
,	O
in	O
dexamethasone	B-CHEMICAL
-	O
induced	O
hypertension	B-UNK
(	O
dex	B-CHEMICAL
-	O
HT	B-UNK
)	O
.	O
3	O
.	O
Thirty	B-UNK
male	B-UNK
Sprague	O
-	O
Dawley	O
rats	B-UNK
were	O
divided	B-UNK
randomly	B-UNK
into	O
four	O
treatment	B-UNK
groups	B-UNK
:	O
saline	B-UNK
,	O
dexamethasone	B-CHEMICAL
(	O
dex	B-UNK
)	O
,	O
allopurinol	O
plus	O
saline	B-UNK
,	O
and	O
allopurinol	O
plus	O
dex	B-UNK
.	O
4	O
.	O
Systolic	B-UNK
blood	B-UNK
pressures	B-UNK
(	O
SBP	B-UNK
)	O
and	O
bodyweights	O
were	O
recorded	O
each	O
alternate	O
day	O
.	O
Thymus	O
weight	B-UNK
was	O
used	O
as	O
a	O
marker	B-UNK
of	O
glucocorticoid	B-UNK
activity	B-UNK
,	O
and	O
serum	B-UNK
urate	O
to	O
assess	B-UNK
XO	O
inhibition	B-UNK
.	O
5	O
.	O
Dex	B-CHEMICAL
increased	B-UNK
SBP	B-UNK
(	O
110	O
+	O
/-	O
2	O
-	O
126	O
+	O
/-	O
3	O
mmHg	B-UNK
;	O
P	O
<	O
0.001	O
)	O
and	O
decreased	B-DISEASE
thymus	I-DISEASE
(	I-DISEASE
P	I-DISEASE
<	I-DISEASE
0.001	I-DISEASE
)	I-DISEASE
and	I-DISEASE
bodyweights	I-DISEASE
(	O
P	O
"	O
<	O
0.01	O
)	O
.	O
Allopurinol	O
decreased	B-UNK
serum	B-UNK
urate	O
from	O
76	O
+	O
/-	O
5	O
to	O
30	O
+	O
/-	O
3	O
micromol	B-UNK
/	O
L	O
(	O
P	O
<	O
0.001	O
)	O
in	O
saline	B-UNK
and	O
from	O
84	O
+	O
/-	O
13	O
to	O
28	O
+	O
/-	O
2	O
micromol	B-UNK
/	O
L	O
in	O
dex	B-UNK
-	O
treated	O
(	O
P	O
<	O
0.01	O
)	O
groups	B-UNK
.	O
6	O
.	O
Allopurinol	O
did	O
not	O
prevent	B-UNK
dex	B-UNK
-	O
HT	B-UNK
.	O
This	O
,	O
together	O
with	O
our	O
previous	B-UNK
findings	B-UNK
that	O
allopurinol	O
failed	B-UNK
to	O
prevent	B-UNK
adrenocorticotrophic	O
hormone	B-UNK
induced	O
hypertension	B-UNK
,	O
suggests	O
that	O
XO	O
activity	B-UNK
is	O
not	O
a	O
major	B-UNK
determinant	O
of	O
GC	O
-	O
HT	B-UNK
in	O
the	O
rat	B-UNK
.	O

Extrapyramidal	B-UNK
side	I-UNK
effects	I-UNK
with	O
risperidone	B-UNK
and	O
haloperidol	B-CHEMICAL
at	O
comparable	O
D2	B-UNK
receptor	I-UNK
occupancy	O
levels	O
.	O
Risperidone	B-UNK
is	O
an	O
antipsychotic	B-UNK
drug	B-UNK
with	O
high	B-UNK
affinity	B-UNK
at	O
dopamine	B-UNK
D2	I-UNK
and	O
serotonin	B-UNK
5-HT2	O
receptors	B-UNK
.	O
Previous	B-UNK
clinical	B-UNK
studies	B-UNK
have	O
proposed	B-UNK
that	O
risperidone'	O
s	O
pharmacologic	O
profile	B-UNK
may	O
produce	B-UNK
improved	O
efficacy	B-UNK
for	O
negative	B-UNK
psychotic	B-DISEASE
symptoms	I-DISEASE
and	O
decreased	B-UNK
propensity	O
for	O
extrapyramidal	B-UNK
side	I-UNK
effects	I-UNK
;	O
features	B-UNK
shared	O
by	O
so	O
-	O
called	O
'	O
atypical	B-UNK
'	O
neuroleptics	B-CHEMICAL
.	O
To	O
determine	B-UNK
if	O
routine	B-UNK
risperidone	B-CHEMICAL
treatment	B-UNK
is	O
associated	O
with	O
a	O
unique	B-UNK
degree	B-UNK
of	O
D2	B-UNK
receptor	I-UNK
occupancy	O
and	O
pattern	B-UNK
of	O
clinical	B-UNK
effects	O
,	O
we	O
used	O
[	O
123I]IBZM	O
SPECT	B-UNK
to	O
determine	B-UNK
D2	B-UNK
occupancy	O
in	O
subjects	B-UNK
treated	O
with	O
routine	B-UNK
clinical	B-UNK
doses	B-UNK
of	O
risperidone	B-UNK
(	O
n	O
=	O
12	O
)	O
or	O
haloperidol	B-CHEMICAL
(	O
n	O
=	O
7	O
)	O
.	O
Both	O
risperidone	B-CHEMICAL
and	O
haloperidol	B-UNK
produced	B-UNK
D2	B-UNK
occupancy	O
levels	O
between	O
approximately	B-UNK
60	O
and	O
90	O
%	O
at	O
standard	B-UNK
clinical	B-UNK
doses	B-UNK
.	O
There	O
was	O
no	O
significant	B-UNK
difference	I-UNK
between	O
occupancy	O
levels	O
obtained	B-UNK
with	O
haloperidol	B-UNK
or	O
risperidone	B-UNK
.	O
Drug	B-UNK
-	O
induced	O
parkinsonism	B-DISEASE
was	O
observed	O
in	O
subjects	B-UNK
treated	O
with	O
risperidone	B-CHEMICAL
(	O
42	O
%	O
)	O
and	O
haloperidol	B-CHEMICAL
(	O
29	O
%	O
)	O
and	O
was	O
observed	O
at	O
occupancy	O
levels	O
above	O
60	O
%	O
.	O
Based	B-UNK
on	O
these	O
observations	B-UNK
,	O
it	O
is	O
concluded	O
that	O
5-HT2	O
blockade	B-UNK
obtained	B-UNK
with	O
risperidone	B-UNK
at	O
D2	B-UNK
occupancy	O
rates	B-UNK
of	O
60	O
%	O
and	O
above	O
does	O
not	O
appear	O
to	O
protect	B-UNK
against	O
the	O
risk	B-UNK
for	O
extrapyramidal	B-UNK
side	I-UNK
effects	I-UNK
.	O

Simvastatin	B-UNK
-	O
ezetimibe	B-CHEMICAL
-	O
induced	O
hepatic	B-UNK
failure	I-UNK
necessitating	O
liver	B-UNK
transplantation	I-UNK
.	O
Abstract	B-UNK
Serum	B-UNK
aminotransferase	B-UNK
elevations	B-UNK
are	O
a	O
commonly	B-UNK
known	O
adverse	B-UNK
effect	I-UNK
of	O
3-hydroxy-3-methylglutaryl	O
coenzyme	B-UNK
A	O
reductase	O
inhibitor	B-UNK
(	O
statin	B-CHEMICAL
)	O
therapy	O
.	O
However	O
,	O
hepatotoxic	O
events	B-UNK
have	O
not	O
been	O
widely	B-UNK
published	B-UNK
with	O
ezetimibe	B-CHEMICAL
or	O
the	O
combination	B-UNK
agent	B-UNK
simvastatin	B-UNK
-	O
ezetimibe	B-CHEMICAL
.	O
We	O
describe	O
a	O
70-year	O
-	O
old	O
Hispanic	O
woman	B-UNK
who	O
developed	O
fulminant	B-UNK
hepatic	I-UNK
failure	I-UNK
necessitating	O
liver	B-UNK
transplantation	I-UNK
10	O
weeks	B-UNK
after	O
conversion	B-UNK
from	O
simvastatin	B-UNK
40	O
mg	B-UNK
/	O
day	O
to	O
simvastatin	B-CHEMICAL
10	O
mg	B-UNK
-	O
ezetimibe	B-CHEMICAL
40	O
mg	B-UNK
/	O
day	O
.	O
The	O
patient'	B-UNK
s	I-UNK
lipid	B-UNK
panel	O
had	O
been	O
maintained	O
with	O
simvastatin	B-CHEMICAL
for	O
18	O
months	B-UNK
before	O
the	O
conversion	B-UNK
without	O
evidence	B-UNK
of	O
hepatotoxicity	B-UNK
.	O
A	O
routine	B-UNK
laboratory	B-UNK
work	O
-	O
up	O
10	O
weeks	B-UNK
after	O
conversion	B-UNK
revealed	O
elevated	B-UNK
serum	B-UNK
aminotransferase	B-UNK
levels	O
.	O
Simvastatinezetimibe	O
and	O
escitalopram	O
(	O
which	O
she	O
was	O
taking	B-UNK
for	O
depression	B-UNK
)	O
were	O
discontinued	O
,	O
and	O
other	O
potential	B-UNK
causes	O
of	O
hepatotoxicity	B-UNK
were	O
excluded	B-UNK
.	O
A	O
repeat	B-UNK
work	O
-	O
up	O
revealed	O
further	O
elevations	B-UNK
in	O
aminotransferase	B-UNK
levels	O
,	O
and	O
liver	B-UNK
biopsy	I-UNK
revealed	O
evidence	B-UNK
of	O
moderate	B-UNK
-	O
to	O
-	O
severe	B-UNK
drug	B-DISEASE
toxicity	I-DISEASE
.	O
She	O
underwent	O
liver	B-UNK
transplantation	I-UNK
with	O
an	O
uneventful	O
postoperative	B-UNK
course	O
.	O
Her	O
aminotransferase	B-UNK
levels	O
returned	B-UNK
to	O
normal	O
by	O
postoperative	B-UNK
day	O
23	O
,	O
and	O
her	O
2-year	O
follow	O
-	O
up	O
showed	O
no	O
adverse	B-UNK
events	I-UNK
.	O
Ezetimibe	B-CHEMICAL
undergoes	O
extensive	B-UNK
glucuronidation	O
by	O
uridine	O
diphosphate	O
glucoronosyltransferases	O
(	O
UGT	O
)	O
in	O
the	O
intestine	O
and	O
liver	B-UNK
and	O
may	O
have	O
inhibited	B-UNK
the	O
glucuronidation	O
of	O
simvastatin	B-UNK
hydroxy	B-UNK
acid	B-UNK
,	O
resulting	B-UNK
in	O
increased	B-UNK
simvastatin	B-UNK
exposure	B-UNK
and	O
subsequent	B-UNK
hepatotoxicity	B-UNK
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	B-UNK
report	I-UNK
of	O
simvastatin	B-UNK
-	O
ezetimibe	B-CHEMICAL
-	O
induced	O
liver	B-UNK
failure	I-UNK
that	O
resulted	B-UNK
in	O
liver	B-UNK
transplantation	I-UNK
.	O
We	O
postulate	O
that	O
the	O
mechanism	B-UNK
of	O
the	O
simvastatinezetimibe	O
-	O
induced	O
hepatotoxicity	B-UNK
is	O
the	O
increased	B-UNK
simvastatin	B-CHEMICAL
exposure	B-UNK
by	O
ezetimibe	B-CHEMICAL
inhibition	B-UNK
of	O
UGT	O
enzymes	B-UNK
.	O
Clinicians	B-UNK
should	O
be	O
aware	B-UNK
of	O
potential	B-UNK
hepatotoxicity	B-UNK
with	O
simvastatin	B-CHEMICAL
-	O
ezetimibe	B-CHEMICAL
especially	O
in	O
elderly	B-UNK
patients	B-UNK
and	O
should	O
carefully	B-UNK
monitor	B-UNK
serum	B-UNK
aminotransferase	B-UNK
levels	O
when	O
starting	B-UNK
therapy	O
and	O
titrating	O
the	O
dosage	B-UNK
.	O

Oral	B-DISEASE
manifestations	I-DISEASE
of	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
"	O
:	O
a	O
case	B-UNK
report	I-UNK
.	O
AIM	B-UNK
:	O
The	O
aim	B-UNK
of	O
the	O
documentation	O
of	O
this	O
clinical	B-UNK
case	B-UNK
is	O
to	O
make	O
clinicians	B-UNK
aware	B-UNK
of	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
"	O
and	O
the	O
medical	B-UNK
risks	B-UNK
associated	O
with	O
this	O
serious	O
condition	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Methamphetamine	B-CHEMICAL
is	O
a	O
very	O
addictive	O
,	O
powerful	O
stimulant	B-UNK
that	O
increases	B-UNK
wakefulness	O
and	O
physical	B-UNK
activity	B-UNK
and	O
can	O
produce	B-UNK
other	O
effects	O
such	O
as	O
cardiac	B-DISEASE
dysrhythmias	I-DISEASE
,	O
hypertension	B-DISEASE
,	O
hallucinations	B-UNK
,	O
and	O
violent	O
behavior	B-UNK
.	O
Dental	O
patients	B-UNK
abusing	O
methamphetamine	B-UNK
can	O
present	B-UNK
with	O
poor	O
oral	B-UNK
hygiene	O
,	O
xerostomia	B-DISEASE
,	O
rampant	O
caries	B-DISEASE
(	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
"	O
)	O
,	O
and	O
excessive	B-UNK
tooth	B-DISEASE
wear	I-DISEASE
.	O
Oral	B-UNK
rehabilitation	O
of	O
patients	B-UNK
using	O
methamphetamine	B-CHEMICAL
can	O
be	O
challenging	O
.	O
CASE	B-UNK
DESCRIPTION	O
:	O
A	O
30-year	O
-	O
old	O
Caucasian	O
woman	B-UNK
presented	B-UNK
with	O
dental	O
pain	B-UNK
,	O
bad	B-DISEASE
breath	I-DISEASE
,	O
and	O
self	O
-	O
reported	B-UNK
poor	O
esthetics	O
.	O
A	O
comprehensive	O
examination	B-UNK
including	O
her	O
medical	B-UNK
history	B-UNK
,	O
panoramic	O
radiograph	O
,	O
and	O
intraoral	O
examination	B-UNK
revealed	O
19	O
carious	B-DISEASE
lesions	I-DISEASE
,	O
which	O
is	O
not	O
very	O
common	B-UNK
for	O
a	O
healthy	B-UNK
adult	B-UNK
.	O
She	O
reported	B-UNK
her	O
use	O
of	O
methamphetamine	B-CHEMICAL
for	O
five	O
years	B-UNK
and	O
had	O
not	O
experienced	B-UNK
any	O
major	B-UNK
carious	B-DISEASE
episodes	I-DISEASE
before	O
she	O
started	O
using	O
the	O
drug	B-UNK
.	O
SUMMARY	B-UNK
:	O
The	O
patient'	B-UNK
s	I-UNK
medical	B-UNK
and	O
dental	O
histories	O
along	O
with	O
radiographic	O
and	O
clinical	B-UNK
findings	B-UNK
lead	B-UNK
to	O
a	O
diagnosis	B-UNK
of	O
"	O
meth	B-DISEASE
mouth	I-DISEASE
.	O
"	O
Although	O
three	O
different	O
dental	O
treatment	B-UNK
modalities	O
(	O
either	O
conventional	B-UNK
or	O
implant	B-UNK
-	O
supported	O
)	O
have	O
been	O
offered	O
to	O
the	O
patient	B-UNK
since	O
August	O
2007	O
,	O
the	O
patient	B-UNK
has	O
yet	O
to	O
initiate	O
any	O
treatment	B-UNK
.	O
CLINICAL	B-UNK
SIGNIFICANCE	B-UNK
:	O
This	O
clinical	B-UNK
case	B-UNK
showing	O
oral	B-DISEASE
manifestations	I-DISEASE
of	O
meth	B-DISEASE
mouth	I-DISEASE
was	O
presented	B-UNK
to	O
help	O
dental	O
practitioners	O
recognize	O
and	O
manage	O
patients	B-UNK
who	O
may	O
be	O
abusing	O
methamphetamines	O
.	O
Dental	O
practitioners	O
also	O
may	O
be	O
skeptical	O
about	O
the	O
reliability	O
of	O
appointment	O
keeping	O
by	O
these	O
patients	B-UNK
,	O
as	O
they	O
frequently	B-UNK
miss	O
their	O
appointments	O
without	O
reasonable	O
justification	O
.	O

Thyroxine	B-CHEMICAL
abuse	B-UNK
:	O
an	O
unusual	B-UNK
case	B-UNK
of	O
thyrotoxicosis	B-DISEASE
in	O
pregnancy	B-UNK
.	O
Eating	B-DISEASE
disorders	I-DISEASE
and	O
the	O
associated	O
behavioural	O
problems	B-UNK
and	O
drug	B-DISEASE
abuse	I-DISEASE
are	O
uncommon	O
in	O
pregnancy	B-UNK
.	O
When	O
they	O
do	O
occur	O
they	O
are	O
often	O
unrecognized	O
because	O
of	O
denial	O
but	O
when	O
significant	B-UNK
may	O
pose	O
a	O
risk	B-UNK
to	O
both	O
the	O
mother	B-UNK
and	O
her	O
fetus	O
.	O
This	O
case	B-UNK
illustrates	O
a	O
number	B-UNK
of	O
problems	B-UNK
that	O
may	O
be	O
encountered	O
in	O
women	B-UNK
with	O
eating	B-DISEASE
disorders	I-DISEASE
in	O
pregnancy	B-UNK
,	O
including	O
prolonged	B-UNK
and	O
recurrent	B-UNK
metabolic	B-UNK
disturbances	B-UNK
and	O
diuretic	B-UNK
abuse	B-UNK
.	O
In	O
particular	O
it	O
illustrates	O
the	O
derangements	O
of	O
thyroid	B-UNK
function	B-UNK
seen	O
in	O
pregnant	B-UNK
women	B-UNK
with	O
eating	B-DISEASE
disorders	I-DISEASE
and	O
reminds	O
us	O
that	O
when	O
a	O
cause	O
for	O
thyrotoxicosis	B-DISEASE
remains	O
obscure	O
,	O
thyroxine	B-CHEMICAL
abuse	B-UNK
should	O
be	O
considered	B-UNK
and	O
explored	O
.	O

Attenuation	O
of	O
methamphetamine	B-CHEMICAL
-	O
induced	O
nigrostriatal	O
dopaminergic	B-UNK
neurotoxicity	B-UNK
in	O
mice	B-UNK
by	O
lipopolysaccharide	B-CHEMICAL
pretreatment	B-UNK
.	O
Immunological	O
activation	B-UNK
has	O
been	O
proposed	B-UNK
to	O
play	O
a	O
role	O
in	O
methamphetamine	B-CHEMICAL
-	O
induced	O
dopaminergic	B-DISEASE
terminal	I-DISEASE
damage	I-DISEASE
.	O
In	O
this	O
study	B-UNK
,	O
we	O
examined	B-UNK
the	O
roles	O
of	O
lipopolysaccharide	B-CHEMICAL
,	O
a	O
pro-inflammatory	O
and	O
inflammatory	B-UNK
factor	B-UNK
,	O
treatment	B-UNK
in	O
modulating	O
the	O
methamphetamine	B-CHEMICAL
-	O
induced	O
nigrostriatal	O
dopamine	B-CHEMICAL
neurotoxicity	B-DISEASE
.	O
Lipopolysaccharide	B-CHEMICAL
pretreatment	B-UNK
did	O
not	O
affect	B-UNK
the	O
basal	B-UNK
body	B-UNK
temperature	B-UNK
or	O
methamphetamine	B-CHEMICAL
-	O
elicited	B-UNK
hyperthermia	B-UNK
three	O
days	B-UNK
later	O
.	O
Such	O
systemic	B-UNK
lipopolysaccharide	B-CHEMICAL
treatment	B-UNK
mitigated	O
methamphetamine	B-UNK
-	O
induced	O
striatal	B-UNK
dopamine	B-CHEMICAL
and	O
3,4-dihydroxyphenylacetic	B-CHEMICAL
acid	I-CHEMICAL
depletions	O
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
manner	I-UNK
.	O
As	O
the	O
most	O
potent	B-UNK
dose	B-UNK
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
)	O
of	O
lipopolysaccharide	B-CHEMICAL
was	O
administered	O
two	O
weeks	B-UNK
,	O
one	O
day	O
before	O
or	O
after	O
the	O
methamphetamine	B-UNK
dosing	O
regimen	B-UNK
,	O
methamphetamine	B-UNK
-	O
induced	O
striatal	B-UNK
dopamine	B-CHEMICAL
and	O
3,4-dihydroxyphenylacetic	B-CHEMICAL
acid	I-CHEMICAL
depletions	O
remained	B-UNK
unaltered	O
.	O
Moreover	O
,	O
systemic	B-UNK
lipopolysaccharide	B-CHEMICAL
pretreatment	B-UNK
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
)	O
attenuated	B-UNK
local	B-UNK
methamphetamine	B-UNK
infusion	B-UNK
-	O
produced	B-UNK
dopamine	B-UNK
and	O
3,4-dihydroxyphenylacetic	B-CHEMICAL
acid	I-CHEMICAL
depletions	O
in	O
the	O
striatum	B-UNK
,	O
indicating	O
that	O
the	O
protective	B-UNK
effect	I-UNK
of	O
lipopolysaccharide	B-CHEMICAL
is	O
less	O
likely	O
due	O
to	O
interrupted	O
peripheral	B-UNK
distribution	B-UNK
or	O
metabolism	B-UNK
of	O
methamphetamine	B-UNK
.	O
We	O
concluded	O
a	O
critical	B-UNK
time	O
window	O
for	O
systemic	B-UNK
lipopolysaccharide	B-CHEMICAL
pretreatment	B-UNK
in	O
exerting	O
effective	B-UNK
protection	B-UNK
against	O
methamphetamine	B-UNK
-	O
induced	O
nigrostriatal	O
dopamine	B-UNK
neurotoxicity	B-UNK
.	O

Effect	B-UNK
of	O
converting	B-UNK
enzyme	I-UNK
inhibition	B-UNK
on	O
the	O
course	O
of	O
adriamycin	B-UNK
-	O
induced	O
nephropathy	B-UNK
.	O
The	O
effect	B-UNK
of	O
the	O
converting	B-UNK
enzyme	I-UNK
inhibitor	I-UNK
(	O
CEI	O
)	O
enalapril	B-CHEMICAL
was	O
assessed	B-UNK
in	O
Munich	O
-	O
Wistar	B-UNK
rats	I-UNK
with	O
established	B-UNK
adriamycin	B-CHEMICAL
nephrosis	B-UNK
.	O
Rats	B-UNK
were	O
given	O
a	O
single	B-UNK
dose	B-UNK
of	O
adriamycin	B-CHEMICAL
and	O
one	O
month	B-UNK
later	O
divided	B-UNK
into	I-UNK
four	O
groups	B-UNK
matched	O
for	O
albuminuria	B-DISEASE
,	O
blood	B-UNK
pressure	I-UNK
,	O
and	O
plasma	B-UNK
albumin	B-UNK
concentration	B-UNK
.	O
Groups	B-UNK
1	O
and	O
3	O
remained	B-UNK
untreated	B-UNK
while	O
groups	B-UNK
2	O
and	O
4	O
received	O
enalapril	B-CHEMICAL
.	O
Groups	B-UNK
1	O
and	O
2	O
underwent	O
micropuncture	O
studies	B-UNK
after	O
10	O
days	B-UNK
.	O
These	O
short	B-UNK
-	O
term	O
studies	B-UNK
showed	O
that	O
enalapril	B-CHEMICAL
reduced	B-UNK
arterial	B-UNK
blood	I-UNK
pressure	I-UNK
(	O
101	O
+	O
/-	O
2	O
vs	O
.	O
124	O
+	O
/-	O
3	O
mm	B-UNK
Hg	I-UNK
,	O
group	B-UNK
2	O
vs	O
.	O
1	O
,	O
P	O
less	O
than	O
0.05	O
)	O
and	O
glomerular	B-UNK
capillary	B-UNK
pressure	B-UNK
(	O
54	O
+	O
/-	O
1	O
vs	O
.	O
61	O
+	O
/-	O
2	O
mm	B-UNK
Hg	I-UNK
,	O
P	O
less	O
than	O
0.05	O
)	O
without	O
reducing	B-UNK
albuminuria	B-DISEASE
(	O
617	O
+	O
/-	O
50	O
vs	O
.	O
570	O
+	O
/-	O
47	O
mg	B-UNK
/	O
day	O
)	O
or	O
GFR	B-UNK
(	O
1.03	O
+	O
/-	O
0.04	O
vs	O
.	O
1.04	O
+	O
/-	O
0.11	O
ml	B-UNK
/	O
min	B-UNK
)	O
.	O
Groups	B-UNK
3	O
and	O
4	O
were	O
studied	O
at	O
four	O
and	O
at	O
six	O
months	B-UNK
to	O
assess	B-UNK
the	O
effect	B-UNK
of	O
enalapril	B-UNK
on	O
progression	B-UNK
of	O
renal	B-UNK
injury	I-UNK
in	O
adriamycin	B-UNK
nephrosis	B-UNK
.	O
Chronic	B-UNK
enalapril	B-UNK
treatment	B-UNK
reduced	B-UNK
blood	B-UNK
pressure	I-UNK
without	O
reducing	B-UNK
albuminuria	B-DISEASE
in	O
group	B-UNK
4	O
.	O
Untreated	B-UNK
group	B-UNK
3	O
rats	B-UNK
exhibited	O
a	O
progressive	B-UNK
reduction	O
in	O
GFR	B-UNK
(	O
0.35	O
+	O
/-	O
0.08	O
ml	B-UNK
/	O
min	B-UNK
at	O
4	O
months	B-UNK
,	O
0.27	O
+	O
/-	O
0.07	O
ml	B-UNK
/	O
min	B-UNK
at	O
6	O
months	B-UNK
)	O
.	O
Enalapril	B-UNK
treatment	B-UNK
blunted	O
but	O
did	O
not	O
prevent	B-UNK
reduction	O
in	O
GFR	B-UNK
in	O
group	B-UNK
4	O
(	O
0.86	O
+	O
/-	O
0.15	O
ml	B-UNK
/	O
min	B-UNK
at	O
4	O
months	B-UNK
,	O
0.69	O
+	O
/-	O
0.13	O
ml	B-UNK
/	O
min	B-UNK
at	O
6	O
months	B-UNK
,	O
both	O
P	O
less	O
than	O
0.05	O
vs	O
.	O
group	B-UNK
3	O
)	O
.	O
Reduction	O
in	O
GFR	B-UNK
was	O
associated	O
with	O
the	O
development	B-UNK
of	O
glomerular	B-UNK
sclerosis	B-UNK
in	O
both	O
treated	O
and	O
untreated	B-UNK
rats.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	B-UNK
)	O

Butyrylcholinesterase	O
gene	B-UNK
mutations	B-UNK
in	O
patients	B-UNK
with	O
prolonged	B-UNK
apnea	B-UNK
after	O
succinylcholine	B-UNK
for	O
electroconvulsive	O
therapy	O
.	O
BACKGROUND	B-UNK
:	O
patients	B-UNK
undergoing	B-UNK
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
often	O
receive	B-UNK
succinylcholine	B-UNK
as	O
part	O
of	O
the	O
anesthetic	B-UNK
procedure	B-UNK
.	O
The	O
duration	B-UNK
of	O
action	B-UNK
may	O
be	O
prolonged	B-UNK
in	O
patients	B-UNK
with	O
genetic	B-UNK
variants	B-UNK
of	O
the	O
butyrylcholinesterase	O
enzyme	B-UNK
(	O
BChE	B-UNK
)	O
,	O
the	O
most	O
common	B-UNK
being	O
the	O
K-	O
and	O
the	O
A	O
-	O
variants	B-UNK
.	O
The	O
aim	B-UNK
of	O
the	O
study	B-UNK
was	O
to	O
assess	B-UNK
the	O
clinical	B-UNK
significance	B-UNK
of	O
genetic	B-UNK
variants	B-UNK
in	O
butyrylcholinesterase	O
gene	B-UNK
(	O
BCHE	B-UNK
)	O
in	O
patients	B-UNK
with	O
a	O
suspected	O
prolonged	B-UNK
duration	B-UNK
of	O
action	B-UNK
of	O
succinylcholine	B-UNK
after	O
ECT	O
.	O
METHODS	B-UNK
:	O
a	O
total	B-UNK
of	O
13	O
patients	B-UNK
were	O
referred	B-UNK
to	O
the	O
Danish	O
Cholinesterase	B-UNK
Research	B-UNK
Unit	B-UNK
after	O
ECT	O
during	O
38	O
months	B-UNK
.	O
We	O
determined	B-UNK
the	O
BChE	B-UNK
activity	B-UNK
and	O
the	O
BCHE	B-UNK
genotype	O
using	O
molecular	B-UNK
genetic	B-UNK
methods	B-UNK
,	O
the	O
duration	B-UNK
of	O
apnea	B-DISEASE
,	O
time	O
to	O
sufficient	B-UNK
spontaneous	B-UNK
ventilation	B-UNK
and	O
whether	O
neuromuscular	B-UNK
monitoring	B-UNK
was	O
used	O
.	O
The	O
duration	B-UNK
of	O
apnea	B-UNK
was	O
compared	O
with	O
published	B-UNK
data	B-UNK
on	O
normal	O
subjects	B-UNK
.	O
RESULTS	B-UNK
:	O
in	O
11	O
patients	B-UNK
,	O
mutations	B-UNK
were	O
found	O
in	O
the	O
BCHE	B-UNK
gene	B-UNK
,	O
the	O
K	O
-	O
variant	B-UNK
being	O
the	O
most	O
frequent	B-UNK
.	O
The	O
duration	B-UNK
of	O
apnea	B-DISEASE
was	O
5	O
-	O
15	O
min	B-UNK
compared	O
with	O
3	O
-	O
5.3	O
min	B-UNK
from	O
the	O
literature	B-UNK
.	O
Severe	B-UNK
distress	O
was	O
noted	B-UNK
in	O
the	O
recovery	B-UNK
phase	B-UNK
in	O
two	O
patients	B-UNK
.	O
Neuromuscular	B-UNK
monitoring	B-UNK
was	O
used	O
in	O
two	O
patients	B-UNK
.	O
CONCLUSION	B-UNK
:	O
eleven	O
of	O
13	O
patients	B-UNK
with	O
a	O
prolonged	B-UNK
duration	B-UNK
of	O
action	B-UNK
of	O
succinylcholine	B-UNK
had	O
mutations	B-UNK
in	O
BCHE	B-UNK
,	O
indicating	O
that	O
this	O
is	O
the	O
possible	O
reason	O
for	O
a	O
prolonged	B-UNK
period	B-UNK
of	O
apnea	B-DISEASE
.	O
We	O
recommend	O
objective	B-UNK
neuromuscular	B-UNK
monitoring	B-UNK
during	O
the	O
first	O
ECT	O
.	O

Ketamine	B-UNK
sedation	B-UNK
for	O
the	O
reduction	O
of	O
children'	B-UNK
s	I-UNK
fractures	B-UNK
in	O
the	O
emergency	B-UNK
department	I-UNK
.	O
BACKGROUND	B-UNK
:	O
There	O
recently	B-UNK
has	O
been	O
a	O
resurgence	O
in	O
the	O
utilization	O
of	O
ketamine	B-UNK
,	O
a	O
unique	B-UNK
anesthetic	B-UNK
,	O
for	O
emergency	B-UNK
-	O
department	B-UNK
procedures	B-UNK
requiring	O
sedation	B-UNK
.	O
The	O
purpose	B-UNK
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
examine	B-UNK
the	O
safety	B-UNK
and	I-UNK
efficacy	I-UNK
of	O
ketamine	B-UNK
for	O
sedation	B-UNK
in	O
the	O
treatment	B-UNK
of	O
children'	B-UNK
s	I-UNK
fractures	B-UNK
in	O
the	O
emergency	B-UNK
department	I-UNK
.	O
METHODS	B-UNK
:	O
One	O
hundred	O
and	O
fourteen	B-UNK
children	B-UNK
(	O
average	B-UNK
age	B-UNK
,	O
5.3	O
years	B-UNK
;	O
range	B-UNK
,	O
twelve	O
months	B-UNK
to	O
ten	O
years	B-UNK
and	O
ten	O
months	B-UNK
)	O
who	O
underwent	O
closed	O
reduction	O
of	O
an	O
isolated	B-UNK
fracture	O
or	O
dislocation	B-DISEASE
in	O
the	O
emergency	B-DISEASE
department	I-DISEASE
at	O
a	O
level	B-UNK
-	O
I	O
trauma	O
center	B-UNK
were	O
prospectively	O
evaluated	B-UNK
.	O
Ketamine	B-UNK
hydrochloride	B-UNK
was	O
administered	O
intravenously	O
(	O
at	O
a	O
dose	B-UNK
of	O
two	O
milligrams	O
per	O
kilogram	O
of	O
body	B-UNK
weight	I-UNK
)	O
in	O
ninety	B-UNK
-	O
nine	O
of	O
the	O
patients	B-UNK
and	O
intramuscularly	O
(	O
at	O
a	O
dose	B-UNK
of	O
four	O
milligrams	O
per	O
kilogram	O
of	O
body	B-UNK
weight	I-UNK
)	O
in	O
the	O
other	O
fifteen	O
.	O
A	O
board	O
-	O
certified	O
emergency	B-UNK
physician	O
skilled	O
in	O
airway	B-UNK
management	B-UNK
supervised	O
administration	O
of	O
the	O
anesthetic	B-UNK
,	O
and	O
the	O
patients	B-UNK
were	O
monitored	O
by	O
a	O
registered	O
nurse	O
.	O
Any	O
pain	B-DISEASE
during	O
the	O
reduction	O
was	O
rated	O
by	O
the	O
orthopaedic	O
surgeon	O
treating	O
the	O
patient	B-UNK
according	O
to	O
the	O
Children'	B-UNK
s	I-UNK
Hospital	B-UNK
of	O
Eastern	O
Ontario	O
Pain	B-DISEASE
Scale	B-UNK
(	O
CHEOPS	O
)	O
.	O
RESULTS	B-UNK
:	O
The	O
average	B-UNK
time	O
from	O
intravenous	B-UNK
administration	O
of	O
ketamine	B-CHEMICAL
to	O
manipulation	O
of	O
the	O
fracture	O
or	O
dislocation	B-DISEASE
was	O
one	O
minute	B-UNK
and	O
thirty	B-UNK
-	O
six	O
seconds	B-UNK
(	O
range	B-UNK
,	O
twenty	O
seconds	B-UNK
to	O
five	O
minutes	B-UNK
)	O
,	O
and	O
the	O
average	B-UNK
time	O
from	O
intramuscular	B-UNK
administration	O
to	O
manipulation	O
was	O
four	O
minutes	B-UNK
and	O
forty	O
-	O
two	O
seconds	B-UNK
(	O
range	B-UNK
,	O
sixty	O
seconds	B-UNK
to	O
fifteen	O
minutes	B-UNK
)	O
.	O
The	O
average	B-UNK
score	O
according	O
to	O
the	O
Children'	B-UNK
s	I-UNK
Hospital	B-UNK
of	O
Eastern	O
Ontario	O
Pain	B-UNK
Scale	B-UNK
was	O
6.4	O
points	B-UNK
(	O
range	B-UNK
,	O
5	O
to	O
10	O
points	B-UNK
)	O
,	O
reflecting	O
minimal	B-UNK
or	O
no	O
pain	B-DISEASE
during	O
fracture	O
reduction	O
.	O
Adequate	B-UNK
fracture	O
reduction	O
was	O
obtained	B-UNK
in	O
111	O
of	O
the	O
children	B-UNK
.	O
Ninety	B-UNK
-	O
nine	O
percent	B-UNK
(	O
sixty	O
-	O
eight	O
)	O
of	O
the	O
sixty	O
-	O
nine	O
parents	O
present	B-UNK
during	O
the	O
reduction	O
were	O
pleased	O
with	O
the	O
sedation	B-UNK
and	O
would	O
allow	O
it	O
to	O
be	O
used	O
again	O
in	O
a	O
similar	B-UNK
situation	O
.	O
Patency	O
of	O
the	O
airway	B-UNK
and	O
independent	B-UNK
respiration	O
were	O
maintained	O
in	O
all	O
of	O
the	O
patients	B-UNK
.	O
Blood	B-UNK
pressure	I-UNK
and	I-UNK
heart	I-UNK
rate	I-UNK
remained	B-UNK
stable	B-UNK
.	O
Minor	B-UNK
side	O
effects	O
included	B-UNK
nausea	B-UNK
(	O
thirteen	B-UNK
patients	B-UNK
)	O
,	O
emesis	B-DISEASE
(	O
eight	O
of	O
the	O
thirteen	B-UNK
patients	B-UNK
with	O
nausea	B-UNK
)	O
,	O
clumsiness	B-DISEASE
(	O
evident	O
as	O
ataxic	B-DISEASE
movements	I-DISEASE
in	O
ten	O
patients	B-UNK
)	O
,	O
and	O
dysphoric	B-DISEASE
reaction	I-DISEASE
(	O
one	O
patient	B-UNK
)	O
.	O
No	O
long	B-UNK
-	O
term	O
sequelae	B-UNK
were	O
noted	B-UNK
,	O
and	O
no	O
patients	B-UNK
had	O
hallucinations	B-UNK
or	O
nightmares	O
.	O
CONCLUSIONS	B-UNK
:	O
Ketamine	B-UNK
reliably	O
,	O
safely	B-UNK
,	O
and	O
quickly	O
provided	O
adequate	B-UNK
sedation	B-UNK
to	O
effectively	B-UNK
facilitate	O
the	O
reduction	O
of	O
children'	B-UNK
s	I-UNK
fractures	B-UNK
in	O
the	O
emergency	B-UNK
department	I-UNK
at	O
our	O
institution	B-UNK
.	O
Ketamine	B-CHEMICAL
should	O
only	O
be	O
used	O
in	O
an	O
environment	O
such	O
as	O
the	O
emergency	B-UNK
department	I-UNK
,	O
where	O
proper	O
one	O
-	O
on	O
-	O
one	O
monitoring	B-UNK
is	O
used	O
and	O
board	O
-	O
certified	O
physicians	B-UNK
skilled	O
in	O
airway	B-UNK
management	B-UNK
are	O
directly	O
involved	B-UNK
in	O
the	O
care	B-UNK
of	O
the	O
patient	B-UNK
.	O

Prophylactic	B-UNK
use	O
of	O
lamivudine	B-UNK
with	O
chronic	B-UNK
immunosuppressive	B-UNK
therapy	O
for	O
rheumatologic	O
disorders	B-UNK
.	O
The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
report	B-UNK
our	O
experience	B-UNK
concerning	O
the	O
effectiveness	B-UNK
of	O
the	O
prophylactic	B-UNK
administration	O
of	O
lamivudine	B-UNK
in	O
hepatitis	B-UNK
B	I-UNK
virus	I-UNK
surface	B-UNK
antigen	B-UNK
(	O
HBs	O
Ag	O
)	O
positive	B-UNK
patients	B-UNK
with	O
rheumatologic	O
disease	B-UNK
.	O
From	O
June	B-UNK
2004	O
to	O
October	O
2006	O
,	O
11	O
HBs	O
Ag	O
positive	B-UNK
patients	B-UNK
with	O
rheumatologic	O
diseases	B-DISEASE
,	O
who	O
were	O
on	O
both	O
immunosuppressive	B-UNK
and	O
prophylactic	B-UNK
lamivudine	B-UNK
therapies	B-UNK
,	O
were	O
retrospectively	O
assessed	B-UNK
.	O
Liver	B-UNK
function	I-UNK
tests	I-UNK
,	O
hepatitis	B-UNK
B	I-UNK
virus	I-UNK
(	O
HBV	B-UNK
)	O
serologic	O
markers	B-UNK
,	O
and	O
HBV	B-UNK
DNA	B-UNK
levels	O
of	O
the	O
patients	B-UNK
during	O
follow	O
-	O
up	O
were	O
obtained	B-UNK
from	O
hospital	B-UNK
file	O
records	B-UNK
.	O
Eleven	O
patients	B-UNK
(	O
six	O
male	B-UNK
)	O
with	O
median	B-UNK
age	I-UNK
47	O
years	B-UNK
(	O
range	B-UNK
27	O
-	O
73	O
)	O
,	O
median	B-UNK
disease	B-DISEASE
duration	B-UNK
50	O
months	B-UNK
(	O
range	B-UNK
9	O
-	O
178	O
)	O
and	O
median	B-UNK
follow	O
-	O
up	O
period	B-UNK
of	O
patients	B-UNK
13.8	O
months	B-UNK
(	O
range	B-UNK
5	O
-	O
27	O
)	O
were	O
enrolled	O
in	O
this	O
study	B-UNK
.	O
Lamivudine	B-UNK
therapy	O
was	O
started	O
3	O
-	O
7	O
days	B-UNK
prior	B-UNK
to	O
immunosuppressive	B-UNK
therapy	O
in	O
all	O
patients	B-UNK
.	O
Baseline	B-UNK
,	O
liver	B-UNK
function	I-UNK
tests	I-UNK
were	O
elevated	B-UNK
in	O
two	O
patients	B-UNK
(	O
fourth	B-UNK
patient	B-UNK
:	O
ALT:122	O
IU	B-UNK
/	O
l	O
,	O
AST:111	O
IU	B-UNK
/	O
l	O
,	O
tenth	O
patient	B-UNK
:	O
ALT:294	O
IU	B-UNK
/	O
l	O
,	O
AST:274	O
IU	B-UNK
/	O
l	O
,	O
with	O
minimal	B-UNK
changes	O
in	O
the	O
liver	B-UNK
biopsy	I-UNK
in	O
both	O
)	O
.	O
Shortly	B-UNK
after	O
treatment	B-UNK
their	O
tests	B-UNK
normalized	B-UNK
and	O
during	O
follow	O
-	O
up	O
period	B-UNK
none	O
of	O
the	O
patients	B-UNK
had	O
abnormal	B-DISEASE
liver	I-DISEASE
function	I-DISEASE
tests	B-UNK
.	O
In	O
four	O
patients	B-UNK
HBV	B-UNK
DNA	B-UNK
levels	O
were	O
higher	B-UNK
than	O
normal	O
at	O
baseline	B-UNK
.	O
Two	O
of	O
these	O
normalized	B-UNK
and	O
the	O
others	O
increased	B-UNK
later	O
.	O
In	O
three	O
additional	B-UNK
patients	B-UNK
,	O
HBV	B-UNK
DNA	B-UNK
levels	O
were	O
increased	B-UNK
during	O
follow	O
-	O
up	O
.	O
None	O
of	O
the	O
patients	B-UNK
had	O
significant	B-UNK
clinical	B-UNK
sings	O
of	O
HBV	B-UNK
activation	B-UNK
.	O
Lamivudine	B-UNK
was	O
well	O
tolerated	B-UNK
and	O
was	O
continued	O
in	O
all	O
patients	B-UNK
.	O
Prophylactic	B-UNK
administration	O
of	O
lamivudine	B-CHEMICAL
in	O
patients	B-UNK
who	O
required	B-UNK
immunosuppressive	B-UNK
therapy	O
seems	O
to	O
be	O
safe	O
,	O
well	O
tolerated	B-UNK
and	O
effective	B-UNK
in	O
preventing	O
HBV	B-UNK
reactivation	O
.	O

Safety	B-UNK
of	O
transesophageal	O
echocardiography	B-UNK
in	O
adults	B-UNK
:	O
study	B-UNK
in	O
a	O
multidisciplinary	O
hospital	B-UNK
.	O
BACKGROUND	B-UNK
:	O
TEE	O
is	O
a	O
semi-invasive	O
tool	O
broadly	O
used	O
and	O
its	O
utilization	O
associated	O
to	O
sedatives	O
drugs	B-UNK
might	O
to	O
affect	B-UNK
the	O
procedure	B-UNK
safety	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
to	O
analyze	O
aspects	O
of	O
TEE	O
safety	B-UNK
associated	O
to	O
the	O
use	O
of	O
Midazolan	O
(	O
MZ	O
)	O
and	O
Flumazenil	B-UNK
(	O
FL	O
)	O
and	O
the	O
influence	B-UNK
of	O
the	O
clinical	B-UNK
variables	B-UNK
on	O
the	O
event	B-UNK
rate	B-UNK
.	O
METHOD	B-UNK
:	O
prospective	B-UNK
study	I-UNK
with	O
137	O
patients	B-UNK
that	O
underwent	O
TEE	O
with	O
MZ	O
associated	O
to	O
moderate	B-UNK
sedation	B-UNK
.	O
We	O
analyzed	O
the	O
following	O
events	B-UNK
:	O
complications	B-UNK
related	O
with	O
the	O
topical	B-UNK
anesthesia	B-UNK
,	O
with	O
MZ	O
use	O
and	O
with	O
the	O
procedure	B-UNK
.	O
Uni-	O
and	O
multivariate	B-UNK
analyses	B-UNK
were	O
used	O
to	O
test	B-UNK
the	O
influence	B-UNK
of	O
the	O
clinical	B-UNK
variables	B-UNK
:	O
age	B-UNK
,	O
sex	B-UNK
,	O
stroke	B-DISEASE
,	O
myocardiopathy	O
(	O
MP	B-UNK
)	O
,	O
duration	B-UNK
of	O
the	O
test	B-UNK
,	O
mitral	B-DISEASE
regurgitation	I-DISEASE
(	O
MR	B-UNK
)	O
and	O
the	O
MZ	O
dose	B-UNK
.	O
RESULTS	B-UNK
:	O
All	O
patients	B-UNK
(	O
65+/-16	O
yrs	O
;	O
58	O
%	O
males	B-UNK
)	O
finished	O
the	O
examination	B-UNK
.	O
The	O
mean	O
doses	B-UNK
of	O
MZ	O
and	O
FL	O
were	O
4.3+/-1.9	O
mg	B-UNK
and	O
0.28+/-0.2	O
mg	B-UNK
,	O
respectively	O
.	O
The	O
duration	B-UNK
of	O
the	O
examination	B-UNK
and	O
the	O
mean	O
ejection	B-UNK
fraction	I-UNK
(	O
EF	O
)	O
were	O
16.4+/-6.1	O
minutes	B-UNK
and	O
60+/-9	O
%	O
,	O
respectively	O
.	O
Mild	B-UNK
hypoxia	B-UNK
(	O
SO2<90	O
%	O
)	O
was	O
the	O
most	O
common	B-UNK
event	B-UNK
(	O
11	O
patients	B-UNK
)	O
;	O
3	O
patients	B-UNK
(	O
2	O
%	O
)	O
presented	B-UNK
transient	B-UNK
hypoxia	B-UNK
due	O
to	O
upper	B-UNK
airway	B-DISEASE
obstruction	I-DISEASE
by	O
probe	O
introduction	B-UNK
and	O
8	O
(	O
5.8	O
%	O
)	O
due	O
to	O
hypoxia	B-UNK
caused	B-UNK
by	O
MZ	O
use	O
.	O
Transient	B-UNK
hypotension	B-UNK
(	O
SAP<90mmHg	O
)	O
occurred	B-UNK
in	O
1	O
patient	B-UNK
(	O
0.7	O
%	O
)	O
.	O
The	O
multivariate	B-UNK
analysis	B-UNK
showed	O
that	O
severe	B-UNK
MR	B-UNK
,	O
MP	B-UNK
(	O
EF<45	O
%	O
)	O
and	O
high	B-UNK
doses	I-UNK
of	O
MZ	O
(	O
>	O
5	O
mg	B-UNK
)	O
were	O
associated	O
with	O
events	B-UNK
(	O
p<0.001	O
)	O
.	O
The	O
EF	O
was	O
40	O
%	O
,	O
in	O
the	O
group	B-UNK
with	O
MP	B-UNK
and	O
44	O
%	O
in	O
the	O
group	B-UNK
with	O
severe	B-UNK
MR	B-UNK
and	O
it	O
can	O
be	O
a	O
factor	B-UNK
associated	O
with	O
clinical	B-UNK
events	B-UNK
in	O
the	O
last	O
group	B-UNK
.	O
CONCLUSION	B-UNK
:	O
TEE	O
with	O
sedation	B-UNK
presents	B-UNK
a	O
low	B-UNK
rate	B-UNK
of	O
events	B-UNK
.	O
There	O
were	O
no	O
severe	B-UNK
events	B-UNK
and	O
there	O
was	O
no	O
need	O
to	O
interrupt	O
the	O
examinations	B-UNK
.	O

Effects	O
of	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
on	O
bupivacaine	B-UNK
-	O
induced	O
toxicity	B-UNK
.	O
The	O
purpose	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
investigate	B-UNK
the	O
influence	B-UNK
of	O
calcium	B-UNK
channel	I-UNK
blockers	I-UNK
on	O
bupivacaine	B-UNK
-	O
induced	O
acute	B-UNK
toxicity	B-UNK
.	O
For	O
each	O
of	O
the	O
three	O
tested	B-UNK
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
(	O
diltiazem	B-UNK
,	O
verapamil	B-CHEMICAL
and	O
bepridil	B-UNK
)	O
6	O
groups	B-UNK
of	O
mice	B-UNK
were	O
treated	O
by	O
two	O
different	O
doses	B-UNK
,	O
i.e	B-UNK
.	O
2	O
and	O
10	O
mg	B-UNK
/	O
kg	B-UNK
/	O
i.p	B-UNK
.	O
,	O
or	O
an	O
equal	B-UNK
volume	B-UNK
of	O
saline	B-UNK
for	O
the	O
control	B-UNK
group	B-UNK
(	O
n	O
=	O
20	O
)	O
;	O
15	O
minutes	B-UNK
later	O
,	O
all	O
the	O
animals	B-UNK
were	O
injected	B-UNK
with	O
a	O
single	B-UNK
50	O
mg	B-UNK
/	O
kg	B-UNK
/	O
i.p	B-UNK
.	O
dose	B-UNK
of	O
bupivacaine	B-UNK
.	O
The	O
convulsant	B-UNK
activity	B-UNK
,	O
the	O
time	O
of	O
latency	B-UNK
to	O
convulse	O
and	O
the	O
mortality	B-UNK
rate	I-UNK
were	O
assessed	B-UNK
in	O
each	O
group	B-UNK
.	O
The	O
local	B-UNK
anesthetic	I-UNK
-	O
induced	O
mortality	B-UNK
was	O
significantly	B-UNK
increased	B-UNK
by	O
the	O
three	O
different	O
calcium	B-UNK
channel	I-UNK
blockers	I-UNK
.	O
The	O
convulsant	B-UNK
activity	B-UNK
of	O
bupivacaine	B-UNK
was	O
not	O
significantly	B-UNK
modified	B-UNK
but	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
decreased	B-UNK
the	O
time	O
of	O
latency	B-UNK
to	O
obtain	O
bupivacaine	B-UNK
-	O
induced	B-UNK
convulsions	I-UNK
;	O
this	O
effect	B-UNK
was	O
less	O
pronounced	B-UNK
with	O
bepridil	B-UNK
.	O

Selegiline	B-UNK
-	O
induced	O
postural	O
hypotension	B-UNK
in	O
Parkinson'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
:	O
a	O
longitudinal	O
study	B-UNK
on	O
the	O
effects	O
of	O
drug	B-UNK
withdrawal	B-UNK
.	O
OBJECTIVES	B-UNK
:	O
The	O
United	O
Kingdom	O
Parkinson'	B-UNK
s	I-UNK
Disease	I-UNK
Research	B-UNK
Group	B-UNK
(	O
UKPDRG	O
)	O
trial	B-UNK
found	O
an	O
increased	B-UNK
mortality	B-UNK
in	O
patients	B-UNK
with	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
(	O
PD	B-UNK
)	O
randomized	B-UNK
to	I-UNK
receive	I-UNK
10	O
mg	B-UNK
selegiline	B-CHEMICAL
per	O
day	O
and	O
L	O
-	O
dopa	B-UNK
compared	O
with	O
those	O
taking	B-UNK
L	O
-	O
dopa	B-UNK
alone	O
.	O
Recently	B-UNK
,	O
we	O
found	O
that	O
therapy	O
with	O
selegiline	B-UNK
and	O
L	O
-	O
dopa	B-UNK
was	O
associated	O
with	O
selective	B-UNK
systolic	B-UNK
orthostatic	B-UNK
hypotension	I-UNK
which	O
was	O
abolished	O
by	O
withdrawal	B-UNK
of	O
selegiline	B-CHEMICAL
.	O
This	O
unwanted	O
effect	B-UNK
on	O
postural	O
blood	B-UNK
pressure	I-UNK
was	O
not	O
the	O
result	B-UNK
of	O
underlying	B-UNK
autonomic	B-UNK
failure	B-UNK
.	O
The	O
aims	B-UNK
of	O
this	O
study	B-UNK
were	O
to	O
confirm	B-UNK
our	O
previous	B-UNK
findings	B-UNK
in	O
a	O
separate	B-UNK
cohort	B-UNK
of	O
patients	B-UNK
and	O
to	O
determine	B-UNK
the	O
time	O
course	O
of	O
the	O
cardiovascular	B-UNK
consequences	B-UNK
of	O
stopping	B-UNK
selegiline	B-CHEMICAL
in	O
the	O
expectation	O
that	O
this	O
might	O
shed	O
light	B-UNK
on	O
the	O
mechanisms	B-UNK
by	O
which	O
the	O
drug	B-UNK
causes	O
orthostatic	B-UNK
hypotension	I-UNK
.	O
METHODS	B-UNK
:	O
The	O
cardiovascular	B-UNK
responses	O
to	O
standing	O
and	O
head	B-UNK
-	O
up	O
tilt	O
were	O
studied	O
repeatedly	B-UNK
in	O
PD	B-UNK
patients	B-UNK
receiving	B-UNK
selegiline	B-CHEMICAL
and	O
as	O
the	O
drug	B-UNK
was	O
withdrawn	O
.	O
RESULTS	B-UNK
:	O
Head	B-UNK
-	O
up	O
tilt	O
caused	B-UNK
systolic	B-UNK
orthostatic	B-UNK
hypotension	I-UNK
which	O
was	O
marked	O
in	O
six	O
of	O
20	O
PD	B-UNK
patients	B-UNK
on	O
selegiline	B-CHEMICAL
,	O
one	O
of	O
whom	O
lost	O
consciousness	B-UNK
with	O
unrecordable	O
blood	B-UNK
pressures	B-UNK
.	O
A	O
lesser	O
degree	B-UNK
of	O
orthostatic	B-DISEASE
hypotension	I-DISEASE
occurred	B-UNK
with	O
standing	O
.	O
Orthostatic	B-UNK
hypotension	I-UNK
was	O
ameliorated	B-UNK
4	O
days	B-UNK
after	O
withdrawal	B-UNK
of	O
selegiline	B-CHEMICAL
and	O
totally	O
abolished	O
7	O
days	B-UNK
after	O
discontinuation	B-UNK
of	O
the	O
drug	B-UNK
.	O
Stopping	B-UNK
selegiline	B-UNK
also	O
significantly	B-UNK
reduced	I-UNK
the	O
supine	O
systolic	B-UNK
and	I-UNK
diastolic	I-UNK
blood	B-UNK
pressures	B-UNK
consistent	B-UNK
with	O
a	O
previously	B-UNK
undescribed	O
supine	O
pressor	B-UNK
action	B-UNK
.	O
CONCLUSION	B-UNK
:	O
This	O
study	B-UNK
confirms	O
our	O
previous	B-UNK
finding	O
that	O
selegiline	B-CHEMICAL
in	O
combination	B-UNK
with	O
L	O
-	O
dopa	B-UNK
is	O
associated	O
with	O
selective	B-UNK
orthostatic	B-UNK
hypotension	I-UNK
.	O
The	O
possibilities	O
that	O
these	O
cardiovascular	B-UNK
findings	B-UNK
might	O
be	O
the	O
result	B-UNK
of	O
non-selective	O
inhibition	B-UNK
of	O
monoamine	O
oxidase	B-UNK
or	O
of	O
amphetamine	B-UNK
and	O
metamphetamine	O
are	O
discussed	O
.	O

Explicit	O
episodic	O
memory	B-UNK
for	O
sensory	O
-	O
discriminative	O
components	B-UNK
of	O
capsaicin	B-UNK
-	O
induced	O
pain	B-UNK
:	O
immediate	O
and	O
delayed	B-UNK
ratings	B-UNK
.	O
Pain	B-UNK
memory	B-UNK
is	O
thought	B-UNK
to	O
affect	B-UNK
future	B-UNK
pain	B-UNK
sensitivity	B-UNK
and	O
thus	O
contribute	B-UNK
to	O
clinical	B-UNK
pain	B-UNK
conditions	O
.	O
Systematic	B-UNK
investigations	B-UNK
of	O
the	O
human	B-UNK
capacity	O
to	O
remember	O
sensory	O
features	B-UNK
of	O
experimental	B-UNK
pain	B-UNK
are	O
sparse	O
.	O
In	O
order	B-UNK
to	O
address	O
long	B-UNK
-	O
term	O
pain	B-UNK
memory	B-UNK
,	O
nine	O
healthy	B-UNK
male	B-UNK
volunteers	B-UNK
received	O
intradermal	B-UNK
injections	B-UNK
of	O
three	O
doses	B-UNK
of	O
capsaicin	B-CHEMICAL
(	O
0.05	O
,	O
1	O
and	O
20	O
microg	B-UNK
,	O
separated	O
by	O
15	O
min	B-UNK
breaks	O
)	O
,	O
each	O
given	O
three	O
times	B-UNK
in	O
a	O
balanced	O
design	B-UNK
across	O
three	O
sessions	O
at	O
one	O
week	B-UNK
intervals	B-UNK
.	O
Pain	B-UNK
rating	B-UNK
was	O
performed	B-UNK
using	O
a	O
computerized	O
visual	B-UNK
analogue	B-UNK
scale	B-UNK
(	O
0	O
-	O
100	O
)	O
digitized	O
at	O
1	O
/	O
s	O
,	O
either	O
immediately	B-UNK
online	O
or	O
one	O
hour	B-UNK
or	O
one	O
day	O
after	O
injection	B-UNK
.	O
Subjects	B-UNK
also	O
recalled	O
their	O
pains	O
one	O
week	B-UNK
later	O
.	O
Capsaicin	B-UNK
injection	B-UNK
reliably	O
induced	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
flare	O
(	O
p<0.001	O
)	O
without	O
any	O
difference	B-UNK
within	O
or	O
across	O
sessions	O
.	O
The	O
strong	B-UNK
burning	O
pain	B-DISEASE
decayed	O
exponentially	O
within	O
a	O
few	O
minutes	B-UNK
.	O
Subjects	B-UNK
were	O
able	O
to	O
reliably	O
discriminate	O
pain	B-DISEASE
magnitude	B-UNK
and	O
duration	B-UNK
across	O
capsaicin	B-CHEMICAL
doses	B-UNK
(	O
both	O
p<0.001	O
)	O
,	O
regardless	O
of	O
whether	O
first	O
-	O
time	O
ratings	B-UNK
were	O
requested	O
immediately	B-UNK
,	O
after	O
one	O
hour	B-UNK
or	O
after	O
one	O
day	O
.	O
Pain	B-UNK
recall	B-UNK
after	O
one	O
week	B-UNK
was	O
similarly	B-UNK
precise	O
(	O
magnitude	B-UNK
:	O
p<0.01	O
,	O
duration	B-UNK
:	O
p<0.05	O
)	O
.	O
Correlation	B-UNK
with	O
rating	B-UNK
recall	B-UNK
after	O
one	O
week	B-UNK
was	O
best	O
when	O
first	O
-	O
time	O
ratings	B-UNK
were	O
requested	O
as	O
late	B-UNK
as	O
one	O
day	O
after	O
injection	B-UNK
(	O
R(2)=0.79	O
)	O
indicating	O
that	O
both	O
rating	B-UNK
retrievals	O
utilized	O
similar	B-UNK
memory	B-UNK
traces	O
.	O
These	O
results	B-UNK
indicate	O
a	O
reliable	O
memory	B-UNK
for	O
magnitude	B-UNK
and	O
duration	B-UNK
of	O
experimentally	O
induced	O
pain	B-DISEASE
.	O
The	O
data	B-UNK
further	O
suggest	B-UNK
that	O
the	O
consolidation	B-UNK
of	O
this	O
memory	B-UNK
is	O
an	O
important	B-UNK
interim	O
stage	B-UNK
,	O
and	O
may	O
take	O
up	O
to	O
one	O
day	O
.	O

Reversibility	O
of	O
captopril	B-UNK
-	O
induced	O
renal	B-UNK
insufficiency	I-UNK
after	O
prolonged	B-UNK
use	O
in	O
an	O
unusual	B-UNK
case	B-UNK
of	O
renovascular	O
hypertension	B-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
severe	B-UNK
hypertension	B-DISEASE
with	O
an	O
occluded	O
renal	B-UNK
artery	B-UNK
to	O
a	O
solitary	B-DISEASE
kidney	I-DISEASE
,	O
who	O
developed	O
sudden	B-UNK
deterioration	B-DISEASE
of	I-DISEASE
renal	I-DISEASE
function	I-DISEASE
following	O
treatment	B-UNK
with	O
captopril	B-UNK
.	O
His	O
renal	B-UNK
function	I-UNK
remained	B-UNK
impaired	B-UNK
but	O
stable	B-UNK
during	O
2	O
years	B-UNK
'	O
treatment	B-UNK
with	O
captopril	B-CHEMICAL
but	O
returned	B-UNK
to	O
pre	B-UNK
-	O
treatment	B-UNK
levels	O
soon	O
after	O
cessation	B-UNK
of	O
the	O
drug	B-UNK
.	O
This	O
indicates	O
reversibility	O
in	O
captopril	B-CHEMICAL
-	O
induced	O
renal	B-UNK
failure	I-UNK
even	O
after	O
its	O
prolonged	B-UNK
use	O
and	O
suggests	O
that	O
no	O
organic	B-UNK
damage	B-UNK
occurs	O
to	O
glomerular	B-UNK
arterioles	O
following	O
chronic	B-UNK
ACE	B-UNK
inhibition	B-UNK
.	O

Liver	B-UNK
disease	I-UNK
caused	B-UNK
by	O
propylthiouracil	B-UNK
.	O
This	O
report	B-UNK
presents	B-UNK
the	O
clinical	B-UNK
,	O
laboratory	B-UNK
,	O
and	O
light	B-UNK
and	O
electron	B-UNK
microscopic	B-UNK
observations	B-UNK
on	O
a	O
patient	B-UNK
with	O
chronic	B-DISEASE
active	I-DISEASE
(	I-DISEASE
aggressive	I-DISEASE
)	I-DISEASE
hepatitis	I-DISEASE
caused	B-UNK
by	O
the	O
administration	O
of	O
propylthiouracil	B-UNK
.	O
This	O
is	O
an	O
addition	B-UNK
to	O
the	O
list	O
of	O
drugs	B-UNK
that	O
must	O
be	O
considered	B-UNK
in	O
the	O
evaluation	B-UNK
of	O
chronic	B-DISEASE
liver	I-DISEASE
disease	I-DISEASE
.	O

Capsaicin	B-UNK
-	O
induced	O
muscle	B-UNK
pain	B-UNK
alters	O
the	O
excitability	B-UNK
of	O
the	O
human	B-UNK
jaw	O
-	O
stretch	O
reflex	B-UNK
.	O
The	O
pathophysiology	B-UNK
of	O
painful	O
temporomandibular	O
disorders	B-UNK
is	O
not	O
fully	B-UNK
understood	O
,	O
but	O
evidence	B-UNK
suggests	O
that	O
muscle	B-UNK
pain	B-UNK
modulates	O
motor	B-UNK
function	B-UNK
in	O
characteristic	B-UNK
ways	O
.	O
This	O
study	B-UNK
tested	B-UNK
the	O
hypothesis	B-UNK
that	O
activation	B-UNK
of	O
nociceptive	B-UNK
muscle	B-UNK
afferent	B-UNK
fibers	O
would	O
be	O
linked	B-UNK
to	O
an	O
increased	B-UNK
excitability	B-UNK
of	O
the	O
human	B-UNK
jaw	O
-	O
stretch	O
reflex	B-UNK
and	O
whether	O
this	O
process	O
would	O
be	O
sensitive	B-UNK
to	O
length	B-UNK
and	O
velocity	B-UNK
of	O
the	O
stretch	O
.	O
Capsaicin	B-UNK
(	O
10	O
micro	O
g	O
)	O
was	O
injected	B-UNK
into	O
the	O
masseter	O
muscle	B-UNK
to	O
induce	B-UNK
pain	B-UNK
in	O
11	O
healthy	B-UNK
volunteers	I-UNK
.	O
Short	B-UNK
-	O
latency	B-UNK
reflex	B-UNK
responses	O
were	O
evoked	B-UNK
in	O
the	O
masseter	O
and	O
temporalis	O
muscles	B-UNK
by	O
a	O
stretch	O
device	O
with	O
different	O
velocities	O
and	O
displacements	O
before	O
,	O
during	O
,	O
and	O
after	O
the	O
pain	B-DISEASE
.	O
The	O
normalized	B-UNK
reflex	B-UNK
amplitude	B-UNK
increased	B-UNK
with	O
an	O
increase	B-UNK
in	O
velocity	B-UNK
at	O
a	O
given	O
displacement	O
,	O
but	O
remained	B-UNK
constant	O
with	O
different	O
displacements	O
at	O
a	O
given	O
velocity	B-UNK
.	O
The	O
normalized	B-UNK
reflex	B-UNK
amplitude	B-UNK
was	O
significantly	B-UNK
higher	I-UNK
during	O
pain	B-DISEASE
,	O
but	O
only	O
at	O
faster	O
stretches	O
in	O
the	O
painful	O
muscle	B-UNK
.	O
Increased	B-UNK
sensitivity	B-UNK
of	O
the	O
fusimotor	O
system	O
during	O
acute	B-UNK
muscle	B-UNK
pain	B-UNK
could	O
be	O
one	O
likely	O
mechanism	B-UNK
to	O
explain	O
the	O
findings	B-UNK
.	O

Repetitive	B-UNK
transcranial	O
magnetic	O
stimulation	B-UNK
for	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-UNK
in	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
.	O
In	O
a	O
placebo	B-UNK
-	O
controlled	B-UNK
,	O
single	B-UNK
-	O
blinded	B-UNK
,	O
crossover	B-UNK
study	I-UNK
,	O
we	O
assessed	B-UNK
the	O
effect	B-UNK
of	O
"	O
real	B-UNK
"	O
repetitive	B-UNK
transcranial	O
magnetic	O
stimulation	B-UNK
(	O
rTMS	B-UNK
)	O
versus	O
"	O
sham	B-UNK
"	O
rTMS	B-UNK
(	O
placebo	B-UNK
)	O
on	O
peak	B-UNK
dose	B-UNK
dyskinesias	B-UNK
in	O
patients	B-UNK
with	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
(	O
PD	B-UNK
)	O
.	O
Ten	O
patients	B-UNK
with	O
PD	B-UNK
and	O
prominent	B-UNK
dyskinesias	B-UNK
had	O
rTMS	B-UNK
(	O
1,800	O
pulses	O
;	O
1	O
Hz	B-UNK
rate	B-UNK
)	O
delivered	O
over	O
the	O
motor	B-UNK
cortex	B-UNK
for	O
4	O
consecutive	B-UNK
days	I-UNK
twice	O
,	O
once	O
real	B-UNK
stimuli	B-UNK
and	O
once	O
sham	B-UNK
stimulation	B-UNK
were	O
used	O
;	O
evaluations	O
were	O
done	O
at	O
the	O
baseline	B-UNK
and	O
1	O
day	O
after	O
the	O
end	B-UNK
of	O
each	O
of	O
the	O
treatment	B-UNK
series	B-UNK
.	O
Direct	B-UNK
comparison	B-UNK
between	O
sham	B-UNK
and	O
real	B-UNK
rTMS	B-UNK
effects	O
showed	O
no	O
significant	B-UNK
difference	I-UNK
in	O
clinician	O
-	O
assessed	B-UNK
dyskinesia	B-DISEASE
severity	B-UNK
.	O
However	O
,	O
comparison	B-UNK
with	O
the	O
baseline	B-UNK
showed	O
small	B-UNK
but	O
significant	B-UNK
reduction	O
in	O
dyskinesia	B-UNK
severity	B-UNK
following	O
real	B-UNK
rTMS	B-UNK
but	O
not	O
placebo	B-UNK
.	O
The	O
major	B-UNK
effect	B-UNK
was	O
on	O
dystonia	B-UNK
subscore	O
.	O
Similarly	B-UNK
,	O
in	O
patient	B-UNK
diaries	O
,	O
although	O
both	O
treatments	O
caused	B-UNK
reduction	O
in	O
subjective	B-UNK
dyskinesia	B-UNK
scores	O
during	O
the	O
days	B-UNK
of	O
intervention	B-UNK
,	O
the	O
effect	B-UNK
was	O
sustained	B-UNK
for	O
3	O
days	B-UNK
after	O
the	O
intervention	B-UNK
for	O
the	O
real	B-UNK
rTMS	B-UNK
only	O
.	O
Following	O
rTMS	B-UNK
,	O
no	O
side	O
effects	O
and	O
no	O
adverse	B-UNK
effects	I-UNK
on	O
motor	B-UNK
function	B-UNK
and	O
PD	B-UNK
symptoms	B-UNK
were	O
noted	B-UNK
.	O
The	O
results	B-UNK
suggest	B-UNK
the	O
existence	O
of	O
residual	B-UNK
beneficial	B-UNK
clinical	B-UNK
aftereffects	O
of	O
consecutive	B-UNK
daily	B-UNK
applications	O
of	O
low	B-UNK
-	O
frequency	B-UNK
rTMS	B-UNK
on	O
dyskinesias	B-DISEASE
in	O
PD	B-UNK
.	O
The	O
effects	O
may	O
be	O
further	O
exploited	O
for	O
potential	B-UNK
therapeutic	B-UNK
uses	O
.	O

Disulfiram	B-UNK
-	O
like	O
syndrome	B-UNK
after	O
hydrogen	B-UNK
cyanamide	O
professional	O
skin	B-UNK
exposure	B-UNK
:	O
two	O
case	B-UNK
reports	I-UNK
in	O
France	O
.	O
Hydrogen	B-UNK
cyanamide	O
is	O
a	O
plant	O
growth	B-UNK
regulator	O
used	O
in	O
agriculture	O
to	O
induce	B-UNK
bud	O
break	O
in	O
fruit	O
trees	O
.	O
Contact	O
with	O
the	O
skin	B-UNK
can	O
result	B-UNK
in	O
percutaneous	B-UNK
absorption	O
of	O
the	O
substance	B-UNK
that	O
inhibits	B-UNK
aldehyde	B-CHEMICAL
dehydrogenase	I-CHEMICAL
and	O
can	O
induce	B-UNK
acetaldehyde	O
syndrome	B-UNK
in	O
case	B-UNK
of	O
alcohol	B-UNK
use	O
.	O
The	O
purpose	B-UNK
of	O
this	O
report	B-UNK
is	O
to	O
describe	O
two	O
cases	B-UNK
of	O
a	O
disulfiram	B-UNK
-	O
like	O
syndrome	B-UNK
following	O
occupational	O
exposure	B-UNK
to	O
hydrogen	B-UNK
cyanamide	O
.	O
The	O
first	O
case	B-UNK
involved	B-UNK
a	O
59-year	O
-	O
old	O
man	B-UNK
who	O
used	O
Dormex	O
,	O
which	O
contains	O
hydrogen	B-UNK
cyanamide	O
,	O
without	O
protection	B-UNK
after	O
consuming	O
a	O
large	B-UNK
amount	O
of	O
alcohol	B-UNK
during	O
a	O
meal	O
.	O
In	O
less	O
than	O
1	O
hour	B-UNK
after	O
the	O
ingestion	B-UNK
of	O
alcohol	B-UNK
,	O
he	O
developed	O
malaise	O
with	O
flushing	B-DISEASE
of	O
the	O
face	B-UNK
,	O
tachycardia	B-UNK
,	O
and	O
dyspnea	B-DISEASE
.	O
Manifestations	B-UNK
regressed	O
spontaneously	B-UNK
under	O
surveillance	B-UNK
in	O
the	O
hospital	B-UNK
.	O
The	O
second	O
case	B-UNK
occurred	B-UNK
in	O
a	O
55-year	O
-	O
old	O
farmer	O
following	O
cutaneous	B-UNK
contact	O
with	O
Dormex	O
.	O
Five	O
hours	B-UNK
after	O
exposure	B-UNK
,	O
he	O
developed	O
disulfiram	B-CHEMICAL
-	O
like	O
syndrome	B-DISEASE
with	O
flushing	B-DISEASE
,	O
tachycardia	B-DISEASE
,	O
and	O
arterial	B-DISEASE
hypotension	I-DISEASE
after	O
consuming	O
three	O
glasses	O
of	O
wine	O
.	O
The	O
patient	B-UNK
recovered	O
spontaneously	B-UNK
in	O
3	O
hours	B-UNK
under	O
surveillance	B-UNK
in	O
the	O
hospital	B-UNK
.	O
These	O
cases	B-UNK
confirm	B-UNK
the	O
necessity	O
of	O
avoiding	O
alcohol	B-UNK
consumption	B-UNK
as	O
recommended	O
in	O
the	O
instructions	O
for	O
use	O
of	O
Dormex	O
and	O
of	O
preventing	O
cutaneous	B-UNK
contact	O
during	O
use	O
.	O

Repeated	B-UNK
trimipramine	O
induces	O
dopamine	B-UNK
D2	I-UNK
/	O
D3	B-UNK
and	O
alpha1-adrenergic	O
up	O
-	O
regulation	B-UNK
.	O
Trimipramine	O
(	O
TRI	B-UNK
)	O
,	O
which	O
shows	O
a	O
clinical	B-UNK
antidepressant	B-UNK
activity	B-UNK
,	O
is	O
chemically	O
related	O
to	O
imipramine	O
but	O
does	O
not	O
inhibit	O
the	O
reuptake	B-UNK
of	O
noradrenaline	B-UNK
and	O
5-hydroxytryptamine	B-CHEMICAL
,	O
nor	O
does	O
it	O
induce	B-UNK
beta-adrenergic	O
down	O
-	O
regulation	B-UNK
.	O
The	O
mechanism	B-UNK
of	O
its	O
antidepressant	B-UNK
activity	B-UNK
is	O
still	O
unknown	O
.	O
The	O
aim	B-UNK
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
find	O
out	O
whether	O
TRI	B-UNK
given	O
repeatedly	B-UNK
was	O
able	O
to	O
induce	B-UNK
adaptive	O
changes	O
in	O
the	O
dopaminergic	B-UNK
and	O
alpha1-adrenergic	O
systems	B-UNK
,	O
demonstrated	O
by	O
us	O
previously	B-UNK
for	O
various	O
antidepressants	B-UNK
.	O
TRI	B-UNK
was	O
given	O
to	O
male	B-UNK
Wistar	I-UNK
rats	I-UNK
and	O
male	B-UNK
Albino	B-UNK
Swiss	B-UNK
mice	B-UNK
perorally	O
twice	O
daily	B-UNK
for	O
14	O
days	B-UNK
.	O
In	O
the	O
acute	B-UNK
experiment	B-UNK
TRI	B-UNK
(	O
given	O
i.p	B-UNK
.	O
)	O
does	O
not	O
antagonize	O
the	O
reserpine	B-UNK
hypothermia	B-UNK
in	O
mice	B-UNK
and	O
does	O
not	O
potentiate	O
the	O
5-hydroxytryptophan	B-CHEMICAL
head	B-UNK
twitches	O
in	O
rats	B-UNK
.	O
TRI	B-UNK
given	O
repeatedly	B-UNK
to	O
rats	B-UNK
increases	B-UNK
the	O
locomotor	B-DISEASE
hyperactivity	I-DISEASE
induced	O
by	O
d	O
-	O
amphetamine	B-UNK
,	O
quinpirole	O
and	O
(	O
+	O
)	O
-7-hydroxy	O
-	O
dipropyloaminotetralin	O
(	O
dopamine	B-UNK
D2	I-UNK
and	O
D3	B-UNK
effects	O
)	O
.	O
The	O
stereotypies	O
induced	O
by	O
d	O
-	O
amphetamine	B-UNK
or	O
apomorphine	B-UNK
are	O
not	O
potentiated	B-UNK
by	O
TRI	B-UNK
.	O
It	O
increases	B-UNK
the	O
behaviour	B-UNK
stimulation	B-UNK
evoked	B-UNK
by	O
phenylephrine	B-CHEMICAL
(	O
given	O
intraventricularly	O
)	O
in	O
rats	B-UNK
,	O
evaluated	B-UNK
in	O
the	O
open	B-UNK
field	B-UNK
test	B-UNK
as	O
well	O
as	O
the	O
aggressiveness	B-DISEASE
evoked	B-UNK
by	O
clonidine	B-CHEMICAL
in	O
mice	B-UNK
,	O
both	O
these	O
effects	O
being	O
mediated	B-UNK
by	O
an	O
alpha1-adrenergic	O
receptor	B-UNK
.	O
It	O
may	O
be	O
concluded	O
that	O
,	O
like	O
other	O
tricyclic	B-UNK
antidepressants	B-UNK
studied	O
previously	B-UNK
,	O
TRI	B-UNK
given	O
repeatedly	B-UNK
increases	B-UNK
the	O
responsiveness	B-UNK
of	O
brain	B-UNK
dopamine	B-UNK
D2	I-UNK
and	O
D3	B-UNK
(	O
locomotor	B-UNK
activity	I-UNK
but	O
not	O
stereotypy	O
)	O
as	O
well	O
as	O
alpha1-adrenergic	O
receptors	B-UNK
to	O
their	O
agonists	B-UNK
.	O
A	O
question	O
arises	O
whether	O
the	O
reuptake	B-UNK
inhibition	B-UNK
is	O
of	O
any	O
importance	B-UNK
to	O
the	O
adaptive	O
changes	O
induced	O
by	O
repeated	B-UNK
antidepressants	B-UNK
,	O
suggested	B-UNK
to	O
be	O
responsible	B-UNK
for	O
the	O
antidepressant	B-UNK
activity	B-UNK
.	O

Ranitidine	B-UNK
-	O
induced	O
acute	B-UNK
interstitial	I-UNK
nephritis	I-UNK
in	O
a	O
cadaveric	O
renal	B-UNK
allograft	B-UNK
.	O
Ranitidine	B-UNK
frequently	B-UNK
is	O
used	O
for	O
preventing	O
peptic	O
ulceration	O
after	O
renal	B-UNK
transplantation	B-UNK
.	O
This	O
drug	B-UNK
occasionally	O
has	O
been	O
associated	O
with	O
acute	B-UNK
interstitial	I-UNK
nephritis	I-UNK
in	O
native	O
kidneys	B-UNK
.	O
There	O
are	O
no	O
similar	B-UNK
reports	B-UNK
with	O
renal	B-UNK
transplantation	B-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
ranitidine	B-CHEMICAL
-	O
induced	O
acute	B-UNK
interstitial	I-UNK
nephritis	I-UNK
in	O
a	O
recipient	O
of	O
a	O
cadaveric	O
renal	B-UNK
allograft	B-UNK
presenting	O
with	O
acute	B-UNK
allograft	B-UNK
dysfunction	B-UNK
within	O
48	O
hours	B-UNK
of	O
exposure	B-UNK
to	O
the	O
drug	B-UNK
.	O
The	O
biopsy	B-UNK
specimen	O
showed	O
pathognomonic	O
features	B-UNK
,	O
including	O
eosinophilic	B-DISEASE
infiltration	B-UNK
of	O
the	O
interstitial	B-UNK
compartment	O
.	O
Allograft	B-UNK
function	B-UNK
improved	O
rapidly	O
and	O
returned	B-UNK
to	O
baseline	B-UNK
after	O
stopping	B-UNK
the	O
drug	B-UNK
.	O

Late	B-UNK
,	O
late	B-UNK
doxorubicin	B-UNK
cardiotoxicity	B-UNK
.	O
Cardiac	B-UNK
toxicity	I-UNK
is	O
a	O
major	B-UNK
complication	B-UNK
which	O
limits	O
the	O
use	O
of	O
adriamycin	B-UNK
as	O
a	O
chemotherapeutic	B-UNK
agent	B-UNK
.	O
Cardiomyopathy	B-UNK
is	O
frequent	B-UNK
when	O
the	O
total	B-UNK
dose	B-UNK
exceeds	O
600	O
mg	B-UNK
/	O
m2	B-UNK
and	O
occurs	O
within	O
one	O
to	O
six	O
months	B-UNK
after	O
cessation	B-UNK
of	O
therapy	O
.	O
A	O
patient	B-UNK
is	O
reported	B-UNK
who	O
developed	O
progressive	B-UNK
cardiomyopathy	B-UNK
two	O
and	O
one	O
-	O
half	B-UNK
years	B-UNK
after	O
receiving	B-UNK
580	O
mg	B-UNK
/	O
m2	B-UNK
which	O
apparently	O
represents	B-UNK
late	B-UNK
,	O
late	B-UNK
cardiotoxicity	B-UNK
.	O

Acetazolamide	O
-	O
induced	O
nephrolithiasis	B-UNK
:	O
implications	B-UNK
for	O
treatment	B-UNK
of	O
neuromuscular	B-UNK
disorders	B-UNK
.	O
Carbonic	B-CHEMICAL
anhydrase	I-CHEMICAL
inhibitors	I-CHEMICAL
can	O
cause	O
nephrolithiasis	B-UNK
.	O
We	O
studied	O
20	O
patients	B-UNK
receiving	B-UNK
long	B-UNK
-	O
term	O
carbonic	O
anhydrase	O
inhibitor	B-UNK
treatment	B-UNK
for	O
periodic	O
paralysis	B-DISEASE
and	O
myotonia	B-DISEASE
.	O
Three	O
patients	B-UNK
on	O
acetazolamide	O
(	O
15	O
%	O
)	O
developed	O
renal	B-DISEASE
calculi	I-DISEASE
.	O
Extracorporeal	O
lithotripsy	O
successfully	O
removed	B-UNK
a	O
renal	B-DISEASE
calculus	I-DISEASE
in	O
one	O
patient	B-UNK
and	O
surgery	B-UNK
removed	B-UNK
a	O
staghorn	O
calculus	B-DISEASE
in	O
another	O
,	O
permitting	O
continued	O
treatment	B-UNK
.	O
Renal	B-UNK
function	I-UNK
remained	B-UNK
normal	O
in	O
all	O
patients	B-UNK
.	O
Nephrolithiasis	B-UNK
is	O
a	O
complication	B-UNK
of	O
acetazolamide	O
but	O
does	O
not	O
preclude	O
its	O
use	O
.	O

Is	O
the	O
treatment	B-UNK
of	O
scabies	B-DISEASE
hazardous	O
?	O
Treatment	B-UNK
for	O
scabies	B-DISEASE
is	O
usually	O
initiated	O
by	O
general	B-UNK
practitioners	O
;	O
most	O
consider	O
lindane	B-UNK
(	O
gamma	B-UNK
benzene	O
hexachloride	O
)	O
the	O
treatment	B-UNK
of	O
choice	B-UNK
.	O
Lindane	B-UNK
is	O
also	O
widely	B-UNK
used	O
as	O
an	O
agricultural	O
and	O
industrial	O
pesticide	O
,	O
and	O
as	O
a	O
result	B-UNK
the	O
toxic	B-UNK
profile	B-UNK
of	O
this	O
insecticide	O
is	O
well	O
understood	O
.	O
Evidence	B-UNK
is	O
accumulating	O
that	O
lindane	B-CHEMICAL
can	O
be	O
toxic	B-UNK
to	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
and	O
may	O
be	O
associated	O
with	O
aplastic	B-DISEASE
anaemia	I-DISEASE
.	O
Preparations	B-UNK
containing	O
lindane	B-CHEMICAL
continue	B-UNK
to	O
be	O
sold	O
over	O
the	O
counter	O
and	O
may	O
represent	O
a	O
hazard	O
to	O
poorly	B-UNK
informed	O
patients	B-UNK
.	O
This	O
literature	B-UNK
review	B-UNK
suggests	O
that	O
general	B-UNK
practitioners	O
should	O
prescribe	O
scabicides	O
with	O
increased	B-UNK
caution	B-UNK
for	O
certain	O
at	O
-	O
risk	B-UNK
groups	B-UNK
,	O
and	O
give	O
adequate	B-UNK
warnings	O
regarding	O
potential	B-UNK
toxicity	B-UNK
.	O

Anaesthetists	O
'	O
nightmare	O
:	O
masseter	O
spasm	B-DISEASE
after	O
induction	B-UNK
in	O
an	O
undiagnosed	O
case	B-UNK
of	O
myotonia	B-DISEASE
congenita	I-DISEASE
.	O
We	O
report	B-UNK
an	O
undiagnosed	O
case	B-UNK
of	O
myotonia	B-DISEASE
congenita	I-DISEASE
in	O
a	O
24-year	O
-	O
old	O
previously	B-UNK
healthy	B-UNK
primigravida	O
,	O
who	O
developed	O
life	B-UNK
threatening	I-UNK
masseter	O
spasm	B-DISEASE
following	O
a	O
standard	B-UNK
dose	B-UNK
of	O
intravenous	B-UNK
suxamethonium	B-UNK
for	O
induction	B-UNK
of	O
anaesthesia	B-UNK
.	O
Neither	O
the	O
patient	B-UNK
nor	O
the	O
anaesthetist	O
was	O
aware	B-UNK
of	O
the	O
diagnosis	B-UNK
before	O
this	O
potentially	O
lethal	B-UNK
complication	B-UNK
occurred	B-UNK
.	O

Toxicity	B-UNK
in	O
rhesus	O
monkeys	B-UNK
following	O
administration	O
of	O
the	O
8-aminoquinoline	B-CHEMICAL
8-[(4-amino	B-CHEMICAL
-	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
methylbutyl)amino]-	I-CHEMICAL
5-(l	I-CHEMICAL
-	I-CHEMICAL
hexyloxy)-6-methoxy-4-methylquinoline	I-CHEMICAL
(	O
WR242511	O
)	O
.	O
INTRODUCTION	B-UNK
:	O
Many	O
substances	O
that	O
form	B-UNK
methemoglobin	O
(	O
MHb	O
)	O
effectively	B-UNK
counter	O
cyanide	O
(	O
CN	B-UNK
)	O
toxicity	B-UNK
.	O
Although	O
MHb	O
formers	O
are	O
generally	B-UNK
applied	O
as	O
treatments	O
for	O
CN	B-UNK
poisoning	B-UNK
,	O
it	O
has	O
been	O
proposed	B-UNK
that	O
a	O
stable	B-UNK
,	O
long	B-UNK
-	O
acting	O
MHb	O
former	O
could	O
serve	O
as	O
a	O
CN	B-UNK
pretreatment	B-UNK
.	O
Using	O
this	O
rationale	B-UNK
,	O
the	O
8-aminoquinoline	B-CHEMICAL
WR242511	O
,	O
a	O
potent	B-UNK
long	B-UNK
-	O
lasting	B-UNK
MHb	O
former	O
in	O
rodents	B-UNK
and	O
beagle	O
dogs	B-UNK
,	O
was	O
studied	O
in	O
the	O
rhesus	O
monkey	O
for	O
advanced	B-UNK
development	B-UNK
as	O
a	O
potential	B-UNK
CN	B-UNK
pretreatment	B-UNK
.	O
METHODS	B-UNK
:	O
In	O
this	O
study	B-UNK
,	O
WR242511	O
was	O
administered	O
intravenously	O
(	O
IV	B-UNK
)	O
in	O
2	O
female	B-UNK
and	O
4	O
male	B-UNK
rhesus	O
monkeys	B-UNK
in	O
doses	B-UNK
of	O
3.5	O
and	O
/	O
or	O
7.0	O
mg	B-UNK
/	O
kg	B-UNK
;	O
a	O
single	B-UNK
male	B-UNK
also	O
received	O
WR242511	O
orally	O
(	O
PO	O
)	O
at	O
7.0	O
mg	B-UNK
/	O
kg	B-UNK
.	O
Health	B-UNK
status	B-UNK
and	O
MHb	O
levels	O
were	O
monitored	O
following	O
exposure	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
selected	O
doses	B-UNK
of	O
WR242511	O
,	O
which	O
produced	B-UNK
significant	B-UNK
methemoglobinemia	B-DISEASE
in	O
beagle	O
dogs	B-UNK
in	O
earlier	B-UNK
studies	B-UNK
conducted	B-UNK
elsewhere	O
,	O
produced	B-UNK
very	O
little	O
MHb	O
(	O
mean	O
<	O
2.0	O
%	O
)	O
in	O
the	O
rhesus	O
monkey	O
.	O
Furthermore	O
,	O
transient	B-UNK
hemoglobinuria	B-DISEASE
was	O
noted	B-UNK
approximately	B-UNK
60	O
minutes	B-UNK
postinjection	O
of	O
WR242511	O
(	O
3.5	O
or	O
7.0	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
and	O
2	O
lethalities	O
occurred	B-UNK
(	O
one	O
IV	B-UNK
and	O
one	O
PO	O
)	O
following	O
the	O
7.0	O
mg	B-UNK
/	O
kg	B-UNK
dose	B-UNK
.	O
Myoglobinuria	B-DISEASE
was	O
also	O
observed	O
following	O
the	O
7.0	O
mg	B-UNK
/	O
kg	B-UNK
dose	B-UNK
.	O
Histopathology	O
analyses	B-UNK
in	O
the	O
2	O
animals	B-UNK
that	O
died	O
revealed	O
liver	B-UNK
and	O
kidney	B-UNK
toxicity	B-DISEASE
,	O
with	O
greater	B-UNK
severity	B-UNK
in	O
the	O
orally	O
-	O
treated	O
animal	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
These	O
data	B-UNK
demonstrate	O
direct	B-UNK
and	O
/	O
or	O
indirect	O
drug	B-UNK
-	O
induced	O
toxicity	B-UNK
.	O
It	O
is	O
concluded	O
that	O
WR242511	O
should	O
not	O
be	O
pursued	O
as	O
a	O
pretreatment	B-UNK
for	O
CN	B-UNK
poisoning	B-UNK
unless	O
the	O
anti-CN	O
characteristics	B-UNK
of	O
this	O
compound	B-UNK
can	O
be	O
successfully	O
dissociated	O
from	O
those	O
producing	O
undesirable	O
toxicity	B-UNK
.	O

Neuroplasticity	O
of	O
the	O
adult	B-UNK
primate	O
auditory	B-UNK
cortex	B-UNK
following	O
cochlear	O
hearing	B-UNK
loss	I-UNK
.	O
Tonotopic	O
organization	B-UNK
is	O
an	O
essential	B-UNK
feature	O
of	O
the	O
primary	B-UNK
auditory	B-UNK
area	B-UNK
(	O
A1	B-UNK
)	O
of	O
primate	O
cortex	B-UNK
.	O
In	O
A1	B-UNK
of	O
macaque	O
monkeys	B-UNK
,	O
low	B-UNK
frequencies	B-UNK
are	O
represented	O
rostrolaterally	O
and	O
high	B-UNK
frequencies	B-UNK
are	O
represented	O
caudomedially	O
.	O
The	O
purpose	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
determine	B-UNK
if	O
changes	O
occur	O
in	O
this	O
tonotopic	O
organization	B-UNK
following	O
cochlear	O
hearing	B-UNK
loss	I-UNK
.	O
Under	O
anesthesia	B-UNK
,	O
the	O
superior	B-UNK
temporal	B-UNK
gyrus	B-UNK
of	O
adult	B-UNK
macaque	O
monkeys	B-UNK
was	O
exposed	B-UNK
,	O
and	O
the	O
tonotopic	O
organization	B-UNK
of	O
A1	B-UNK
was	O
mapped	O
using	O
conventional	B-UNK
microelectrode	O
recording	B-UNK
techniques	O
.	O
Following	O
recovery	B-UNK
,	O
the	O
monkeys	B-UNK
were	O
selectively	B-UNK
deafened	O
for	O
high	B-UNK
frequencies	B-UNK
using	O
kanamycin	B-UNK
and	O
furosemide	B-UNK
.	O
The	O
actual	O
frequencies	B-UNK
deafened	O
were	O
determined	B-UNK
by	O
the	O
loss	B-UNK
of	O
tone	B-UNK
-	O
burst	O
elicited	B-UNK
auditory	B-UNK
brainstem	B-UNK
responses	O
.	O
Three	O
months	B-UNK
after	O
deafening	O
,	O
A1	B-UNK
was	O
remapped	O
.	O
Postmortem	O
cytoarchitectural	O
features	B-UNK
identifying	O
A1	B-UNK
were	O
correlated	B-UNK
with	O
the	O
electrophysiologic	O
data	B-UNK
.	O
The	O
results	B-UNK
indicate	O
that	O
the	O
deprived	O
area	B-UNK
of	O
A1	B-UNK
undergoes	O
extensive	B-UNK
reorganization	O
and	O
becomes	O
responsive	O
to	O
intact	B-UNK
cochlear	O
frequencies	B-UNK
.	O
The	O
region	B-UNK
of	O
cortex	B-UNK
that	O
represents	B-UNK
the	O
low	B-UNK
frequencies	B-UNK
was	O
not	O
obviously	O
affected	B-UNK
by	O
the	O
cochlear	O
hearing	B-UNK
loss	I-UNK
.	O

The	O
site	B-UNK
of	O
common	B-UNK
side	O
effects	O
of	O
sumatriptan	B-CHEMICAL
.	O
Atypical	B-UNK
sensations	O
following	O
the	O
use	O
of	O
subcutaneous	B-UNK
sumatriptan	B-CHEMICAL
are	O
common	B-UNK
,	O
but	O
of	O
uncertain	O
origin	B-UNK
.	O
They	O
are	O
almost	O
always	O
benign	O
,	O
but	O
can	O
be	O
mistaken	O
for	O
a	O
serious	O
adverse	B-UNK
event	I-UNK
by	O
the	O
patient	B-UNK
.	O
Two	O
patients	B-UNK
are	O
presented	B-UNK
with	O
tingling	O
or	O
burning	O
sensations	O
limited	B-UNK
to	O
areas	B-UNK
of	O
heat	O
exposure	B-UNK
or	O
sunburn	B-DISEASE
.	O
In	O
these	O
individuals	B-UNK
,	O
side	O
effects	O
are	O
most	O
likely	O
generated	B-UNK
superficially	O
in	O
the	O
skin	B-UNK
.	O

Tremor	B-UNK
side	O
effects	O
of	O
salbutamol	B-UNK
,	O
quantified	O
by	O
a	O
laser	B-UNK
pointer	O
technique	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
To	O
study	B-UNK
tremor	B-DISEASE
side	O
effects	O
of	O
salbutamol	B-UNK
an	O
easily	O
applicable	O
,	O
quick	O
and	O
low	B-UNK
-	O
priced	O
method	B-UNK
is	O
needed	B-UNK
.	O
A	O
new	O
method	B-UNK
using	O
a	O
commercially	O
available	O
,	O
pen	O
-	O
shaped	O
laser	B-UNK
pointer	O
was	O
developed	O
.	O
Aim	B-UNK
of	O
the	O
study	B-UNK
was	O
to	O
determine	B-UNK
sensitivity	B-UNK
,	O
reproducibility	O
,	O
reference	B-UNK
values	O
and	O
the	O
agreement	O
with	O
a	O
questionnaire	B-UNK
.	O
METHODS	B-UNK
:	O
Tremor	B-DISEASE
was	O
measured	B-UNK
using	O
a	O
laser	B-UNK
pointer	O
technique	B-UNK
.	O
To	O
determine	B-UNK
sensitivity	B-UNK
we	O
assessed	B-UNK
tremor	B-UNK
in	O
44	O
patients	B-UNK
with	O
obstructive	B-UNK
lung	B-DISEASE
disease	I-DISEASE
after	O
administration	O
of	O
cumulative	B-UNK
doses	B-UNK
of	O
salbutamol	B-UNK
.	O
Subjects	B-UNK
were	O
asked	O
to	O
aim	B-UNK
at	O
the	O
centre	O
of	O
a	O
target	O
,	O
subdivided	O
in	O
concentric	O
circles	O
,	O
from	O
5	O
m	O
distance	O
.	O
The	O
circle	O
in	O
which	O
the	O
participant	O
succeeded	O
to	O
aim	B-UNK
was	O
recorded	O
in	O
millimetres	O
radius	O
.	O
In	O
another	O
series	B-UNK
of	O
measurements	B-UNK
,	O
reproducibility	O
and	O
reference	B-UNK
values	O
of	O
the	O
tremor	B-UNK
was	O
assessed	B-UNK
in	O
65	O
healthy	B-UNK
subjects	I-UNK
in	O
three	O
sessions	O
,	O
at	O
9	O
a.m	O
.	O
,	O
4	O
p.m	O
.	O
and	O
9	O
a.m	O
.	O
,	O
respectively	O
,	O
1	O
week	B-UNK
later	O
.	O
Postural	O
tremor	B-UNK
was	O
measured	B-UNK
with	O
the	O
arm	O
horizontally	O
outstretched	O
rest	B-UNK
tremor	B-UNK
with	O
the	O
arm	O
supported	O
by	O
an	O
armrest	O
and	O
finally	B-UNK
tremor	B-DISEASE
was	O
measured	B-UNK
after	O
holding	O
a	O
2-kg	O
weight	B-UNK
until	O
exhaustion	O
.	O
Inter-observer	O
variability	B-UNK
was	O
measured	B-UNK
in	O
a	O
series	B-UNK
of	O
10	O
healthy	B-UNK
subjects	I-UNK
.	O
Tremor	B-UNK
was	O
measured	B-UNK
simultaneously	B-UNK
by	O
two	O
independent	B-UNK
observers	O
.	O
RESULTS	B-UNK
:	O
Salbutamol	B-UNK
significantly	B-UNK
increased	B-UNK
tremor	B-DISEASE
severity	B-UNK
in	O
patients	B-UNK
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
way	O
.	O
Within	O
healthy	B-UNK
adults	B-UNK
no	O
age	B-UNK
-	O
dependency	O
could	O
be	O
found	O
(	O
b	O
=	O
0.262	O
mm	B-UNK
/	O
year	O
;	O
P	O
=	O
0.72	O
)	O
.	O
There	O
was	O
no	O
agreement	O
between	O
the	O
questionnaire	B-UNK
and	O
tremor	B-UNK
severity	B-UNK
(	O
r	O
=	O
0.093	O
;	O
P	O
=	O
0.53	O
)	O
.	O
Postural	O
tremor	B-DISEASE
showed	O
no	O
significant	B-UNK
difference	I-UNK
between	O
the	O
first	O
and	O
third	O
session	B-UNK
(	O
P	O
=	O
0.07	O
)	O
.	O
Support	B-UNK
of	O
the	O
arm	O
decreased	B-UNK
tremor	B-UNK
severity	B-UNK
,	O
exhaustion	O
increased	B-UNK
tremor	B-UNK
severity	B-UNK
significantly	B-UNK
.	O
A	O
good	O
agreement	O
was	O
found	O
between	O
two	O
independent	B-UNK
observers	O
(	O
interclass	O
correlation	B-UNK
coefficient	O
0.72	O
)	O
.	O
DISCUSSION	B-UNK
:	O
Quantifying	O
tremor	B-UNK
by	O
using	O
an	O
inexpensive	O
laser	B-UNK
pointer	O
is	O
,	O
with	O
the	O
exception	O
of	O
children	B-UNK
(	O
<	O
12	O
years	B-UNK
)	O
a	O
sensitive	B-UNK
and	O
reproducible	O
method	B-UNK
.	O

Increased	B-UNK
frequency	B-UNK
of	O
venous	B-UNK
thromboembolism	I-UNK
with	O
the	O
combination	B-UNK
of	O
docetaxel	B-CHEMICAL
and	O
thalidomide	B-UNK
in	O
patients	B-UNK
with	O
metastatic	B-UNK
androgen	B-UNK
-	O
independent	B-UNK
prostate	B-UNK
cancer	I-UNK
.	O
STUDY	B-UNK
OBJECTIVE	B-UNK
:	O
To	O
evaluate	B-UNK
the	O
frequency	B-UNK
of	O
venous	B-UNK
thromboembolism	I-UNK
(	O
VTE	B-UNK
)	O
in	O
patients	B-UNK
with	O
advanced	B-UNK
androgen	B-UNK
-	O
independent	B-UNK
prostate	B-UNK
cancer	I-UNK
who	O
were	O
treated	O
with	O
docetaxel	B-CHEMICAL
alone	O
or	O
in	O
combination	B-UNK
with	O
thalidomide	B-UNK
.	O
DESIGN	B-UNK
:	O
Retrospective	B-UNK
analysis	B-UNK
of	O
a	O
randomized	B-UNK
phase	B-UNK
II	I-UNK
trial	B-UNK
.	O
SETTING	B-UNK
:	O
National	B-UNK
Institutes	O
of	O
Health	B-UNK
clinical	B-UNK
research	B-UNK
center	B-UNK
.	O
PATIENTS	B-UNK
:	O
Seventy	B-UNK
men	B-UNK
,	O
aged	B-UNK
50	O
-	O
80	O
years	B-UNK
,	O
with	O
advanced	B-UNK
androgen	B-UNK
-	O
independent	B-UNK
prostate	B-UNK
cancer	I-UNK
.	O
INTERVENTION	B-UNK
:	O
Each	O
patient	B-UNK
received	O
either	O
intravenous	B-UNK
docetaxel	B-CHEMICAL
30	O
mg	B-UNK
/	O
m2	B-UNK
/	O
week	B-UNK
for	O
3	O
consecutive	B-UNK
weeks	B-UNK
,	O
followed	O
by	O
1	O
week	B-UNK
off	O
,	O
or	O
the	O
combination	B-UNK
of	O
continuous	B-UNK
oral	B-UNK
thalidomide	B-UNK
200	O
mg	B-UNK
every	O
evening	O
plus	O
the	O
same	O
docetaxel	B-CHEMICAL
regimen	B-UNK
.	O
This	O
4-week	O
cycle	B-UNK
was	O
repeated	B-UNK
until	O
there	O
was	O
evidence	B-UNK
of	O
excessive	B-UNK
toxicity	B-UNK
or	O
disease	B-UNK
progression	I-UNK
.	O
MEASUREMENTS	B-UNK
AND	O
MAIN	B-UNK
RESULTS	B-UNK
:	O
None	O
of	O
23	O
patients	B-UNK
who	O
received	O
docetaxel	B-CHEMICAL
alone	O
developed	O
VTE	B-UNK
,	O
whereas	O
9	O
of	O
47	O
patients	B-UNK
(	O
19	O
%	O
)	O
who	O
received	O
docetaxel	B-CHEMICAL
plus	O
thalidomide	B-UNK
developed	O
VTE	B-UNK
(	O
p=0.025	O
)	O
.	O
CONCLUSION	B-UNK
:	O
The	O
addition	B-UNK
of	O
thalidomide	B-CHEMICAL
to	O
docetaxel	B-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
prostate	B-DISEASE
cancer	I-DISEASE
significantly	B-UNK
increases	B-UNK
the	O
frequency	B-UNK
of	O
VTE	B-UNK
.	O
Clinicians	B-UNK
should	O
be	O
aware	B-UNK
of	O
this	O
potential	B-UNK
complication	B-UNK
when	O
adding	O
thalidomide	B-CHEMICAL
to	O
chemotherapeutic	B-UNK
regimens	B-UNK
.	O

Sublingual	O
absorption	O
of	O
the	O
quaternary	O
ammonium	O
antiarrhythmic	B-UNK
agent	B-UNK
,	O
UM-272	O
.	O
UM-272	O
(	O
N	O
,	O
N	O
-	O
dimethylpropranolol	O
)	O
,	O
a	O
quaternary	O
antiarrhythmic	B-UNK
agent	B-UNK
,	O
was	O
administered	O
sublingually	O
to	O
dogs	B-UNK
with	O
ouabain	B-UNK
-	O
induced	O
ventricular	B-UNK
tachycardias	O
.	O
Both	O
anti-arrhythmic	O
efficacy	B-UNK
and	O
bioavailability	O
were	O
compared	O
to	O
oral	B-UNK
drug	B-UNK
.	O
Sublingual	O
UM-272	O
converted	O
ventricular	B-UNK
tachycardia	I-UNK
to	O
sinus	B-UNK
rhythm	I-UNK
in	O
all	O
5	O
dogs	B-UNK
.	O
The	O
area	B-UNK
under	O
the	O
plasma	B-UNK
concentration	I-UNK
time	O
curve	B-UNK
at	O
90	O
min	B-UNK
was	O
4	O
-	O
12	O
times	B-UNK
greater	B-UNK
than	O
for	O
oral	B-UNK
drug	B-UNK
,	O
suggesting	O
the	O
existence	O
of	O
an	O
absorption	O
-	O
limiting	B-UNK
process	O
in	O
the	O
intestine	O
,	O
and	O
providing	O
an	O
alternate	O
form	B-UNK
of	O
administration	O
for	O
quaternary	O
drugs	B-UNK
.	O

Severe	B-UNK
thrombocytopenia	B-UNK
and	O
haemolytic	O
anaemia	B-UNK
associated	O
with	O
ciprofloxacin	B-CHEMICAL
:	O
a	O
case	B-UNK
report	I-UNK
with	O
fatal	B-UNK
outcome	B-UNK
.	O
Haematological	B-UNK
adverse	B-UNK
reactions	I-UNK
associated	O
with	O
fatal	B-UNK
outcome	B-UNK
are	O
rare	B-UNK
during	O
treatment	B-UNK
with	O
ciprofloxacin	B-UNK
.	O
A	O
30-year	O
old	O
Caucasian	O
man	B-UNK
reported	B-UNK
with	O
abdominal	B-UNK
pain	I-UNK
and	O
jaundice	B-UNK
after	O
3-day	O
administration	O
of	O
oral	B-UNK
ciprofloxacin	B-UNK
for	O
a	O
suspect	O
of	O
urinary	B-DISEASE
tract	I-DISEASE
infection	I-DISEASE
.	O
Clinical	B-UNK
evaluations	O
suggested	B-UNK
an	O
initial	B-UNK
diagnosis	B-UNK
of	O
severe	B-UNK
thrombocytopenia	B-UNK
and	O
haemolysis	B-DISEASE
.	O
The	O
patient	B-UNK
progressively	O
developed	O
petechiae	O
and	O
purpura	B-DISEASE
on	O
thorax	O
and	O
lower	B-UNK
limbs	B-UNK
.	O
Despite	O
pharmacological	B-UNK
and	O
supportive	O
interventions	B-UNK
,	O
laboratory	B-UNK
parameters	O
worsened	O
and	O
the	O
patient	B-UNK
died	O
17	O
hours	B-UNK
after	O
admission	B-UNK
.	O
An	O
accurate	O
autopsy	B-UNK
revealed	O
most	O
organs	O
with	O
diffuse	B-UNK
petechial	O
haemorrhages	O
.	O
No	O
signs	B-UNK
of	O
bone	B-DISEASE
marrow	I-DISEASE
depression	I-DISEASE
were	O
found	O
.	O
No	O
thrombi	B-DISEASE
or	O
signs	B-UNK
of	O
microangiopathies	O
were	O
observed	O
in	O
arterial	B-UNK
vessels	B-UNK
.	O
Blood	B-UNK
and	O
urine	B-UNK
cultures	B-UNK
did	O
not	O
show	O
any	O
bacterial	B-UNK
growth	B-UNK
.	O
This	O
case	B-UNK
report	I-UNK
shows	O
that	O
ciprofloxacin	B-CHEMICAL
may	O
precipitate	O
life	B-UNK
-	O
threatening	O
thrombocytopenia	B-UNK
and	O
haemolytic	O
anaemia	B-UNK
,	O
even	O
in	O
the	O
early	B-UNK
phases	O
of	O
treatment	B-UNK
and	O
without	O
apparent	B-UNK
previous	B-UNK
exposures	O
.	O

Simvastatin	B-UNK
-	O
induced	O
bilateral	B-UNK
leg	B-UNK
compartment	B-DISEASE
syndrome	I-DISEASE
and	O
myonecrosis	O
associated	O
with	O
hypothyroidism	B-DISEASE
.	O
A	O
54-year	O
-	O
old	O
hypothyroid	B-DISEASE
male	B-UNK
taking	B-UNK
thyroxine	B-CHEMICAL
and	O
simvastatin	B-UNK
presented	B-UNK
with	O
bilateral	B-UNK
leg	B-UNK
compartment	B-DISEASE
syndrome	I-DISEASE
and	O
myonecrosis	O
.	O
Urgent	O
fasciotomies	O
were	O
performed	B-UNK
and	O
the	O
patient	B-UNK
made	O
an	O
uneventful	O
recovery	B-UNK
with	O
the	O
withdrawal	B-UNK
of	O
simvastatin	B-CHEMICAL
.	O
It	O
is	O
likely	O
that	O
this	O
complication	B-UNK
will	O
be	O
seen	O
more	O
often	O
with	O
the	O
increased	B-UNK
worldwide	O
use	O
of	O
this	O
drug	B-UNK
and	O
its	O
approval	O
for	O
all	O
arteriopathic	B-DISEASE
patients	B-UNK
.	O

Bile	B-UNK
duct	I-UNK
hamartoma	B-DISEASE
occurring	O
in	O
association	B-UNK
with	O
long	B-UNK
-	O
term	O
treatment	B-UNK
with	O
danazol	B-CHEMICAL
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
bile	B-UNK
duct	I-UNK
hamartoma	B-DISEASE
which	O
developed	O
in	O
a	O
patient	B-UNK
who	O
had	O
been	O
on	O
long	B-UNK
-	O
term	O
danazol	B-CHEMICAL
treatment	B-UNK
.	O
Such	O
patients	B-UNK
should	O
be	O
under	O
close	B-UNK
follow	O
-	O
up	O
,	O
preferably	O
with	O
periodic	O
ultrasound	B-UNK
examination	B-UNK
of	O
the	O
liver	B-UNK
.	O
If	O
the	O
patient	B-UNK
develops	O
a	O
liver	B-UNK
mass	B-UNK
,	O
because	O
of	O
non-specific	O
clinical	B-UNK
features	B-UNK
and	O
imaging	B-UNK
appearances	O
,	O
biopsy	B-UNK
may	O
be	O
the	O
only	O
way	O
to	O
achieve	B-UNK
a	O
definitive	O
diagnosis	B-UNK
.	O

Granulomatous	O
hepatitis	B-DISEASE
due	O
to	O
combination	B-UNK
of	O
amoxicillin	O
and	O
clavulanic	B-CHEMICAL
acid	I-CHEMICAL
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
patient	B-UNK
with	O
amoxicillin	O
-	O
clavulanic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
hepatitis	B-UNK
with	O
histologic	B-UNK
multiple	B-UNK
granulomas	O
.	O
This	O
type	B-UNK
of	O
lesion	B-UNK
broadens	O
the	O
spectrum	B-UNK
of	O
liver	B-DISEASE
injury	I-DISEASE
due	O
to	O
this	O
drug	B-UNK
combination	B-UNK
,	O
mainly	O
represented	O
by	O
a	O
benign	O
cholestatic	B-DISEASE
syndrome	I-DISEASE
.	O
The	O
association	B-UNK
of	O
granulomas	O
and	O
eosinophilia	B-DISEASE
favor	O
an	O
immunoallergic	O
mechanism	B-UNK
.	O
As	O
penicillin	B-UNK
derivatives	O
and	O
amoxicillin	O
alone	O
are	O
known	O
to	O
induce	B-UNK
such	O
types	B-UNK
of	O
lesions	B-UNK
,	O
the	O
amoxicillin	O
component	B-UNK
,	O
with	O
or	O
without	O
a	O
potentiating	O
effect	B-UNK
of	O
clavulanic	B-CHEMICAL
acid	I-CHEMICAL
,	O
might	O
have	O
a	O
major	B-UNK
role	O
.	O

Intracranial	B-DISEASE
aneurysms	I-DISEASE
and	O
cocaine	B-DISEASE
abuse	I-DISEASE
:	O
analysis	B-UNK
of	O
prognostic	O
indicators	O
.	O
OBJECTIVE	B-UNK
:	O
The	O
outcome	B-UNK
of	O
subarachnoid	B-UNK
hemorrhage	I-UNK
associated	O
with	O
cocaine	B-DISEASE
abuse	I-DISEASE
is	O
reportedly	O
poor	O
.	O
However	O
,	O
no	O
study	B-UNK
in	O
the	O
literature	B-UNK
has	O
reported	B-UNK
the	O
use	O
of	O
a	O
statistical	B-UNK
model	B-UNK
to	O
analyze	O
the	O
variables	B-UNK
that	O
influence	B-UNK
outcome	B-UNK
.	O
METHODS	B-UNK
:	O
A	O
review	B-UNK
of	O
admissions	O
during	O
a	O
6-year	O
period	B-UNK
revealed	O
14	O
patients	B-UNK
with	O
cocaine	B-UNK
-	O
related	O
aneurysms	B-UNK
.	O
This	O
group	B-UNK
was	O
compared	O
with	O
a	O
control	B-UNK
group	B-UNK
of	O
135	O
patients	B-UNK
with	O
ruptured	B-DISEASE
aneurysms	I-DISEASE
and	O
no	O
history	B-UNK
of	O
cocaine	B-DISEASE
abuse	I-DISEASE
.	O
Age	B-UNK
at	O
presentation	B-UNK
,	O
time	O
of	O
ictus	O
after	O
intoxication	B-UNK
,	O
Hunt	O
and	O
Hess	O
grade	B-UNK
of	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
,	O
size	B-UNK
of	O
the	O
aneurysm	B-UNK
,	O
location	O
of	O
the	O
aneurysm	B-UNK
,	O
and	O
the	O
Glasgow	O
Outcome	B-UNK
Scale	B-UNK
score	O
were	O
assessed	B-UNK
and	O
compared	O
.	O
RESULTS	B-UNK
:	O
The	O
patients	B-UNK
in	O
the	O
study	B-UNK
group	B-UNK
were	O
significantly	B-UNK
younger	B-UNK
than	O
the	O
patients	B-UNK
in	O
the	O
control	B-UNK
group	B-UNK
(	O
P	O
<	O
0.002	O
)	O
.	O
In	O
patients	B-UNK
in	O
the	O
study	B-UNK
group	B-UNK
,	O
all	O
aneurysms	B-UNK
were	O
located	O
in	O
the	O
anterior	B-UNK
circulation	B-UNK
.	O
The	O
majority	O
of	O
these	O
aneurysms	B-UNK
were	O
smaller	B-UNK
than	O
those	O
of	O
the	O
control	B-UNK
group	B-UNK
(	O
8	O
+	O
/-	O
6.08	O
mm	B-UNK
versus	O
11	O
+	O
/-	O
5.4	O
mm	B-UNK
;	O
P	O
=	O
0.05	O
)	O
.	O
The	O
differences	B-UNK
in	O
mortality	B-UNK
and	O
morbidity	B-UNK
between	O
the	O
two	O
groups	B-UNK
were	O
not	O
significant	B-UNK
.	O
Hunt	O
and	O
Hess	O
grade	B-UNK
(	O
P	O
<	O
0.005	O
)	O
and	O
age	B-UNK
(	O
P	O
<	O
0.007	O
)	O
were	O
significant	B-UNK
predictors	B-UNK
of	O
outcome	B-UNK
for	O
the	O
patients	B-UNK
with	O
cocaine	B-CHEMICAL
-	O
related	O
aneurysms	B-UNK
.	O
CONCLUSION	B-UNK
:	O
Cocaine	B-CHEMICAL
use	O
predisposed	O
aneurysmal	B-DISEASE
rupture	I-DISEASE
at	O
a	O
significantly	B-UNK
earlier	B-UNK
age	B-UNK
and	O
in	O
much	O
smaller	B-UNK
aneurysms	B-UNK
.	O
Contrary	O
to	O
the	O
published	B-UNK
literature	B-UNK
,	O
this	O
group	B-UNK
did	O
reasonably	O
well	O
with	O
aggressive	B-UNK
management	B-UNK
.	O

Anti-epileptic	O
drugs	B-UNK
-	O
induced	O
de	B-UNK
novo	I-UNK
absence	B-DISEASE
seizures	I-DISEASE
.	O
The	O
authors	B-UNK
present	B-UNK
three	O
patients	B-UNK
with	O
de	B-UNK
novo	I-UNK
absence	B-DISEASE
epilepsy	I-DISEASE
after	O
administration	O
of	O
carbamazepine	B-UNK
and	O
vigabatrin	B-CHEMICAL
.	O
Despite	O
the	O
underlying	B-UNK
diseases	B-DISEASE
,	O
the	O
prognosis	O
for	O
drug	B-UNK
-	O
induced	O
de	B-UNK
novo	I-UNK
absence	B-DISEASE
seizure	I-DISEASE
is	O
good	O
because	O
it	O
subsides	O
rapidly	O
after	O
discontinuing	O
the	O
use	O
of	O
the	O
offending	O
drugs	B-UNK
.	O
The	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
-	O
transmitted	O
thalamocortical	O
circuitry	O
accounts	O
for	O
a	O
major	B-UNK
part	O
of	O
the	O
underlying	B-UNK
neurophysiology	O
of	O
the	O
absence	B-DISEASE
epilepsy	I-DISEASE
.	O
Because	O
drug	B-UNK
-	O
induced	O
de	B-UNK
novo	I-UNK
absence	B-DISEASE
seizure	I-DISEASE
is	O
rare	B-UNK
,	O
pro-absence	O
drugs	B-UNK
can	O
only	O
be	O
considered	B-UNK
a	O
promoting	O
factor	B-UNK
.	O
The	O
underlying	B-UNK
epileptogenecity	O
of	O
the	O
patients	B-UNK
or	O
the	O
synergistic	O
effects	O
of	O
the	O
accompanying	O
drugs	B-UNK
is	O
required	B-UNK
to	O
trigger	O
the	O
de	B-UNK
novo	I-UNK
absence	B-DISEASE
seizure	I-DISEASE
.	O
The	O
possibility	O
of	O
drug	B-UNK
-	O
induced	O
aggravation	O
should	O
be	O
considered	B-UNK
whenever	O
an	O
unexpected	O
increase	B-UNK
in	O
seizure	B-UNK
frequency	B-UNK
and	O
/	O
or	O
new	O
seizure	B-UNK
types	B-UNK
appear	O
following	O
a	O
change	B-UNK
in	O
drug	B-UNK
treatment	B-UNK
.	O
By	O
understanding	O
the	O
underlying	B-UNK
mechanism	B-UNK
of	O
absence	B-DISEASE
epilepsy	I-DISEASE
,	O
we	O
can	O
avoid	B-UNK
the	O
inappropriate	B-UNK
use	O
of	O
anticonvulsants	O
in	O
children	B-UNK
with	O
epilepsy	B-UNK
and	O
prevent	B-UNK
drug	B-UNK
-	O
induced	O
absence	B-DISEASE
seizures	I-DISEASE
.	O

Procainamide	B-CHEMICAL
-	O
induced	O
polymorphous	O
ventricular	B-UNK
tachycardia	I-UNK
.	O
Seven	O
cases	B-UNK
of	O
procainamide	B-CHEMICAL
-	O
induced	O
polymorphous	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
are	O
presented	B-UNK
.	O
In	O
four	O
patients	B-UNK
,	O
polymorphous	O
ventricular	B-UNK
tachycardia	I-UNK
appeared	B-UNK
after	O
intravenous	B-UNK
administration	O
of	O
200	O
to	O
400	O
mg	B-UNK
of	O
procainamide	B-CHEMICAL
for	O
the	O
treatment	B-UNK
of	O
sustained	B-UNK
ventricular	B-UNK
tachycardia	I-UNK
.	O
In	O
the	O
remaining	O
three	O
patients	B-UNK
,	O
procainamide	B-CHEMICAL
was	O
administered	O
orally	O
for	O
treatment	B-UNK
of	O
chronic	B-UNK
premature	B-UNK
ventricular	B-UNK
contractions	B-UNK
or	O
atrial	B-DISEASE
flutter	I-DISEASE
.	O
These	O
patients	B-UNK
had	O
Q	O
-T	O
prolongation	B-UNK
and	O
recurrent	B-UNK
syncope	B-UNK
due	O
to	O
polymorphous	O
ventricular	B-UNK
tachycardia	I-UNK
.	O
In	O
four	O
patients	B-UNK
,	O
the	O
arrhythmia	B-UNK
was	O
rapidly	O
diagnosed	B-UNK
and	O
treated	O
with	O
disappearance	O
of	O
further	O
episodes	B-UNK
of	O
the	O
arrhythmia	B-UNK
.	O
In	O
two	O
patients	B-UNK
,	O
the	O
arrhythmia	B-UNK
degenerated	O
into	O
irreversible	B-UNK
ventricular	B-UNK
fibrillation	I-UNK
and	O
both	O
patients	B-UNK
died	O
.	O
In	O
the	O
seventh	O
patient	B-UNK
,	O
a	O
permanent	B-UNK
ventricular	B-UNK
pacemaker	B-UNK
was	O
inserted	O
and	O
,	O
despite	O
continuation	O
of	O
procainamide	B-CHEMICAL
therapy	O
,	O
polymorphous	O
ventricular	B-UNK
tachycardia	I-UNK
did	O
not	O
reoccur	O
.	O
These	O
seven	O
cases	B-UNK
demonstrate	O
that	O
procainamide	B-CHEMICAL
can	O
produce	B-UNK
an	O
acquired	B-UNK
prolonged	B-UNK
Q	O
-T	O
syndrome	B-DISEASE
with	O
polymorphous	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
.	O

Role	O
of	O
activation	B-UNK
of	O
bradykinin	B-UNK
B2	B-UNK
receptors	B-UNK
in	O
disruption	B-UNK
of	O
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
during	O
acute	B-UNK
hypertension	B-DISEASE
.	O
Cellular	B-UNK
mechanisms	B-UNK
which	O
account	O
for	O
disruption	B-UNK
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
during	O
acute	B-UNK
hypertension	B-DISEASE
are	O
not	O
clear	B-UNK
.	O
The	O
goal	O
of	O
this	O
study	B-UNK
was	O
to	O
determine	B-UNK
the	O
role	O
of	O
synthesis	B-UNK
/	O
release	B-UNK
of	O
bradykinin	B-CHEMICAL
to	O
activate	O
B2	B-UNK
receptors	B-UNK
in	O
disruption	B-UNK
of	O
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
during	O
acute	B-UNK
hypertension	B-UNK
.	O
Permeability	B-UNK
of	O
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
was	O
quantitated	O
by	O
clearance	B-UNK
of	O
fluorescent	O
-	O
labeled	O
dextran	B-UNK
before	O
and	O
during	O
phenylephrine	B-CHEMICAL
-	O
induced	O
acute	B-UNK
hypertension	B-UNK
in	O
rats	B-UNK
treated	O
with	O
vehicle	B-UNK
and	O
Hoe-140	O
(	O
0.1	O
microM	B-UNK
)	O
.	O
Phenylephrine	B-CHEMICAL
infusion	B-UNK
increased	B-UNK
arterial	B-UNK
pressure	I-UNK
,	O
arteriolar	O
diameter	B-UNK
and	O
clearance	B-UNK
of	O
fluorescent	O
dextran	B-UNK
by	O
a	O
similar	B-UNK
magnitude	B-UNK
in	O
both	O
groups	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
disruption	B-UNK
of	O
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
during	O
acute	B-UNK
hypertension	B-UNK
is	O
not	O
related	O
to	O
the	O
synthesis	B-UNK
/	O
release	B-UNK
of	O
bradykinin	B-UNK
to	O
activate	O
B2	B-UNK
receptors	B-UNK
.	O

5-azacytidine	B-CHEMICAL
potentiates	O
initiation	B-UNK
induced	O
by	O
carcinogens	O
in	O
rat	B-UNK
liver	B-UNK
.	O
To	O
test	B-UNK
the	O
validity	O
of	O
the	O
hypothesis	B-UNK
that	O
hypomethylation	O
of	O
DNA	B-UNK
plays	O
an	O
important	B-UNK
role	O
in	O
the	O
initiation	B-UNK
of	O
carcinogenic	B-DISEASE
process	O
,	O
5-azacytidine	B-CHEMICAL
(	O
5-AzC	B-CHEMICAL
)	O
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
an	O
inhibitor	B-UNK
of	O
DNA	B-UNK
methylation	O
,	O
was	O
given	O
to	O
rats	B-UNK
during	O
the	O
phase	B-UNK
of	O
repair	B-UNK
synthesis	B-UNK
induced	O
by	O
the	O
three	O
carcinogens	O
,	O
benzo[a]-pyrene	O
(	O
200	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
N	O
-	O
methyl	B-UNK
-	O
N	O
-	O
nitrosourea	O
(	O
60	O
mg	B-UNK
/	O
kg	B-UNK
)	O
and	O
1,2-dimethylhydrazine	B-CHEMICAL
(	O
1,2-DMH	B-CHEMICAL
)	O
(	O
100	O
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
The	O
initiated	O
hepatocytes	B-UNK
in	O
the	O
liver	B-UNK
were	O
assayed	O
as	O
the	O
gamma	B-UNK
-	O
glutamyltransferase	O
(	O
gamma	B-UNK
-	O
GT	O
)	O
positive	B-UNK
foci	B-UNK
formed	B-UNK
following	O
a	O
2-week	O
selection	O
regimen	B-UNK
consisting	O
of	O
dietary	B-UNK
0.02	O
%	O
2-acetylaminofluorene	B-CHEMICAL
coupled	O
with	O
a	O
necrogenic	O
dose	B-UNK
of	O
CCl4	O
.	O
The	O
results	B-UNK
obtained	B-UNK
indicate	O
that	O
with	O
all	O
three	O
carcinogens	O
,	O
administration	O
of	O
5-AzC	B-CHEMICAL
during	O
repair	B-UNK
synthesis	B-UNK
increased	B-UNK
the	O
incidence	B-UNK
of	O
initiated	O
hepatocytes	B-UNK
,	O
for	O
example	O
10	O
-	O
20	O
foci	B-UNK
/	O
cm2	O
in	O
5-AzC	B-CHEMICAL
and	O
carcinogen	O
-	O
treated	B-UNK
rats	I-UNK
compared	O
with	O
3	O
-	O
5	O
foci	B-UNK
/	O
cm2	O
in	O
rats	B-UNK
treated	O
with	O
carcinogen	O
only	O
.	O
Administration	O
of	O
[	O
3H]-5-azadeoxycytidine	O
during	O
the	O
repair	B-UNK
synthesis	B-UNK
induced	O
by	O
1,2-DMH	B-CHEMICAL
further	O
showed	O
that	O
0.019	O
mol	O
%	O
of	O
cytosine	O
residues	O
in	O
DNA	B-UNK
were	O
substituted	O
by	O
the	O
analogue	B-UNK
,	O
indicating	O
that	O
incorporation	O
of	O
5-AzC	B-CHEMICAL
occurs	O
during	O
repair	B-UNK
synthesis	B-UNK
.	O
In	O
the	O
absence	O
of	O
the	O
carcinogen	O
,	O
5-AzC	B-CHEMICAL
given	O
after	O
a	O
two	O
thirds	O
partial	B-UNK
hepatectomy	O
,	O
when	O
its	O
incorporation	O
should	O
be	O
maximum	B-UNK
,	O
failed	B-UNK
to	O
induce	B-UNK
any	O
gamma	B-UNK
-	O
GT	O
positive	B-UNK
foci	B-UNK
.	O
The	O
results	B-UNK
suggest	B-UNK
that	O
hypomethylation	O
of	O
DNA	B-UNK
per	O
se	B-UNK
may	O
not	O
be	O
sufficient	B-UNK
for	O
initiation	B-UNK
.	O
Perhaps	O
two	O
events	B-UNK
might	O
be	O
necessary	O
for	O
initiation	B-UNK
,	O
the	O
first	O
caused	B-UNK
by	O
the	O
carcinogen	O
and	O
a	O
second	O
involving	O
hypomethylation	O
of	O
DNA	B-UNK
.	O

Withdrawal	B-UNK
-	O
emergent	O
rabbit	B-DISEASE
syndrome	I-DISEASE
during	O
dose	B-UNK
reduction	I-UNK
of	O
risperidone	B-UNK
.	O
Rabbit	B-DISEASE
syndrome	I-DISEASE
(	O
RS	B-DISEASE
)	O
is	O
a	O
rare	B-UNK
extrapyramidal	B-UNK
side	I-UNK
effect	B-UNK
caused	B-UNK
by	O
prolonged	B-UNK
neuroleptic	B-UNK
medication	O
.	O
Here	O
we	O
present	B-UNK
a	O
case	B-UNK
of	O
withdrawal	B-UNK
-	O
emergent	O
RS	B-UNK
,	O
which	O
is	O
the	O
first	O
of	O
its	O
kind	O
to	O
be	O
reported	B-UNK
.	O
The	O
patient	B-UNK
developed	O
RS	B-UNK
during	O
dose	B-UNK
reduction	I-UNK
of	O
risperidone	B-UNK
.	O
The	O
symptom	B-UNK
was	O
treated	O
successfully	O
with	O
trihexyphenidyl	B-CHEMICAL
anticholinergic	B-UNK
therapy	O
.	O
The	O
underlying	B-UNK
mechanism	B-UNK
of	O
withdrawal	B-UNK
-	O
emergent	O
RS	B-UNK
in	O
the	O
present	B-UNK
case	B-UNK
may	O
have	O
been	O
related	O
to	O
the	O
pharmacological	B-UNK
profile	B-UNK
of	O
risperidone	B-UNK
,	O
a	O
serotonin	B-UNK
-	O
dopamine	B-UNK
antagonist	B-UNK
,	O
suggesting	O
the	O
pathophysiologic	O
influence	B-UNK
of	O
the	O
serotonin	B-UNK
system	O
in	O
the	O
development	B-UNK
of	O
RS	B-DISEASE
.	O

Verapamil	B-UNK
withdrawal	B-UNK
as	O
a	O
possible	O
cause	O
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
a	O
hypertensive	B-DISEASE
woman	B-UNK
with	O
a	O
normal	O
coronary	B-UNK
angiogram	O
.	O
Verapamil	B-UNK
is	O
an	O
effective	B-UNK
and	O
relatively	O
-	O
safe	O
antihypertensive	B-UNK
drug	B-UNK
.	O
Serious	O
adverse	B-UNK
effects	I-UNK
are	O
uncommon	O
and	O
mainly	O
have	O
been	O
related	O
to	O
the	O
depression	B-DISEASE
of	O
cardiac	B-UNK
contractility	B-UNK
and	O
conduction	B-UNK
,	O
especially	O
when	O
the	O
drug	B-UNK
is	O
combined	B-UNK
with	O
beta-blocking	O
agents	B-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
in	O
which	O
myocardial	B-UNK
infarction	I-UNK
coincided	O
with	O
the	O
introduction	B-UNK
of	O
captopril	B-UNK
and	O
the	O
withdrawal	B-UNK
of	O
verapamil	B-UNK
in	O
a	O
previously	B-UNK
asymptomatic	O
woman	B-UNK
with	O
severe	B-UNK
hypertension	B-UNK
.	O
Possible	O
mechanisms	B-UNK
that	O
involve	B-UNK
a	O
verapamil	B-UNK
-	O
related	O
increase	B-UNK
in	O
platelet	B-UNK
and	O
/	O
or	O
vascular	B-UNK
alpha	B-UNK
2-adrenoreceptor	O
affinity	B-UNK
for	O
catecholamines	B-UNK
are	O
discussed	O
.	O

Remission	B-UNK
induction	B-UNK
of	O
meningeal	O
leukemia	B-UNK
with	O
high	B-UNK
-	O
dose	B-UNK
intravenous	B-UNK
methotrexate	B-CHEMICAL
.	O
Twenty	O
children	B-UNK
with	O
acute	B-UNK
lymphoblastic	I-UNK
leukemia	I-UNK
who	O
developed	O
meningeal	O
disease	B-UNK
were	O
treated	O
with	O
a	O
high	B-UNK
-	O
dose	B-UNK
intravenous	B-UNK
methotrexate	B-UNK
regimen	B-UNK
that	O
was	O
designed	B-UNK
to	O
achieve	B-UNK
and	O
maintain	O
CSF	O
methotrexate	B-CHEMICAL
concentrations	B-UNK
of	O
10(-5	O
)	O
mol	O
/	O
L	O
without	O
the	O
need	O
for	O
concomitant	B-UNK
intrathecal	B-UNK
dosing	O
.	O
The	O
methotrexate	B-UNK
was	O
administered	O
as	O
a	O
loading	B-UNK
dose	B-UNK
of	O
6,000	O
mg	B-UNK
/	O
m2	B-UNK
for	O
a	O
period	B-UNK
of	O
one	O
hour	B-UNK
followed	O
by	O
an	O
infusion	B-UNK
of	O
1,200	O
mg	B-UNK
/	O
m2	B-UNK
/	O
h	O
for	O
23	O
hours	B-UNK
.	O
Leucovorin	O
rescue	O
was	O
initiated	O
12	O
hours	B-UNK
after	O
the	O
end	B-UNK
of	O
the	O
infusion	B-UNK
with	O
a	O
loading	B-UNK
dose	B-UNK
of	O
200	O
mg	B-UNK
/	O
m2	B-UNK
followed	O
by	O
12	O
mg	B-UNK
/	O
m2	B-UNK
every	O
three	O
hours	B-UNK
for	O
six	O
doses	B-UNK
and	O
then	O
every	O
six	O
hours	B-UNK
until	O
the	O
plasma	B-UNK
methotrexate	B-CHEMICAL
level	B-UNK
decreased	B-UNK
to	O
less	O
than	O
1	O
X	O
10(-7	O
)	O
mol	O
/	O
L.	O
The	O
mean	O
steady	O
-	O
state	B-UNK
plasma	B-UNK
and	O
CSF	O
methotrexate	B-UNK
concentrations	B-UNK
achieved	O
were	O
1.1	O
X	O
10(-3	O
)	O
mol	O
/	O
L	O
and	O
3.6	O
X	O
10(-5	O
)	O
mol	O
/	O
L	O
,	O
respectively	O
.	O
All	O
20	O
patients	B-UNK
responded	O
to	O
this	O
regimen	B-UNK
,	O
16/20	O
(	O
80	O
%	O
)	O
achieved	O
a	O
complete	B-UNK
remission	I-UNK
,	O
and	O
20	O
%	O
obtained	B-UNK
a	O
partial	B-UNK
remission	B-UNK
.	O
The	O
most	O
common	B-UNK
toxicities	B-UNK
encountered	O
were	O
transient	B-UNK
serum	B-UNK
transaminase	B-UNK
and	O
bilirubin	B-UNK
elevations	B-UNK
,	O
neutropenia	B-DISEASE
,	O
and	O
mucositis	B-DISEASE
.	O
One	O
patient	B-UNK
had	O
focal	B-UNK
seizures	B-UNK
and	O
transient	B-UNK
hemiparesis	O
but	O
recovered	O
completely	O
.	O
High	B-UNK
-	O
dose	B-UNK
intravenous	B-UNK
methotrexate	B-UNK
is	O
an	O
effective	B-UNK
treatment	B-UNK
for	O
the	O
induction	B-UNK
of	O
remission	B-UNK
after	O
meningeal	O
relapse	B-UNK
in	O
acute	B-DISEASE
lymphoblastic	I-DISEASE
leukemia	I-DISEASE
.	O

Hypersensitivity	B-UNK
to	O
carbamazepine	B-UNK
presenting	O
with	O
a	O
leukemoid	B-DISEASE
reaction	I-DISEASE
,	O
eosinophilia	B-DISEASE
,	O
erythroderma	B-DISEASE
,	O
and	O
renal	B-UNK
failure	I-UNK
.	O
We	O
report	B-UNK
a	O
patient	B-UNK
in	O
whom	O
hypersensitivity	B-UNK
to	O
carbamazepine	B-UNK
presented	B-UNK
with	O
generalized	O
erythroderma	B-DISEASE
,	O
a	O
severe	B-UNK
leukemoid	B-DISEASE
reaction	I-DISEASE
,	O
eosinophilia	B-DISEASE
,	O
hyponatremia	B-DISEASE
,	O
and	O
renal	B-UNK
failure	I-UNK
.	O
This	O
is	O
the	O
first	O
report	B-UNK
of	O
such	O
an	O
unusual	B-UNK
reaction	B-UNK
to	O
carbamazepine	B-UNK
.	O

The	O
interpeduncular	O
nucleus	B-UNK
regulates	O
nicotine'	O
s	O
effects	O
on	O
free	B-UNK
-	O
field	B-UNK
activity	B-UNK
.	O
Partial	B-UNK
lesions	B-UNK
were	O
made	O
with	O
kainic	O
acid	B-UNK
in	O
the	O
interpeduncular	O
nucleus	B-UNK
of	O
the	O
ventral	B-UNK
midbrain	O
of	O
the	O
rat	B-UNK
.	O
Compared	O
with	O
sham	B-UNK
-	O
operated	O
controls	B-UNK
,	O
lesions	B-UNK
significantly	B-UNK
(	O
p	O
<	O
0.25	O
)	O
blunted	O
the	O
early	B-UNK
(	O
<	O
60	O
min	B-UNK
)	O
free	B-UNK
-	O
field	B-UNK
locomotor	B-UNK
hypoactivity	O
caused	B-UNK
by	O
nicotine	B-CHEMICAL
(	O
0.5	O
mg	B-UNK
kg(-1	O
)	O
,	O
i.m	O
.	O
)	O
,	O
enhanced	B-UNK
the	O
later	O
(	O
60	O
-	O
120	O
min	B-UNK
)	O
nicotine	B-UNK
-	O
induced	B-UNK
hyperactivity	I-UNK
,	O
and	O
raised	B-UNK
spontaneous	B-UNK
nocturnal	O
activity	B-UNK
.	O
Lesions	B-UNK
reduced	B-UNK
the	O
extent	B-UNK
of	O
immunohistological	O
staining	B-UNK
for	O
choline	B-UNK
acetyltransferase	O
in	O
the	O
interpeduncular	O
nucleus	B-UNK
(	O
p	O
<	O
0.025	O
)	O
,	O
but	O
not	O
for	O
tyrosine	B-UNK
hydroxylase	B-UNK
in	O
the	O
surrounding	O
catecholaminergic	O
A10	O
region	B-UNK
.	O
We	O
conclude	O
that	O
the	O
interpeduncular	O
nucleus	B-UNK
mediates	O
nicotinic	B-UNK
depression	B-UNK
of	O
locomotor	B-UNK
activity	I-UNK
and	O
dampens	O
nicotinic	B-UNK
arousal	O
mechanisms	B-UNK
located	O
elsewhere	O
in	O
the	O
brain	B-UNK
.	O

Assessment	B-UNK
of	O
a	O
new	O
non-invasive	O
index	B-UNK
of	O
cardiac	B-UNK
performance	B-UNK
for	O
detection	B-UNK
of	O
dobutamine	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O
BACKGROUND	B-UNK
:	O
Electrocardiography	O
has	O
a	O
very	O
low	B-UNK
sensitivity	B-UNK
in	O
detecting	O
dobutamine	B-UNK
-	O
induced	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O
OBJECTIVES	B-UNK
:	O
To	O
assess	B-UNK
the	O
added	B-UNK
diagnostic	B-UNK
value	O
of	O
a	O
new	O
cardiac	B-UNK
performance	B-UNK
index	B-UNK
(	O
dP	B-UNK
/	O
dtejc	O
)	O
measurement	B-UNK
,	O
based	B-UNK
on	O
brachial	O
artery	B-UNK
flow	B-UNK
changes	O
,	O
as	O
compared	O
to	O
standard	B-UNK
12-lead	O
ECG	B-UNK
,	O
for	O
detecting	O
dobutamine	B-CHEMICAL
-	O
induced	O
myocardial	B-UNK
ischemia	I-UNK
,	O
using	O
Tc99m	O
-	O
Sestamibi	O
single	B-UNK
-	O
photon	O
emission	O
computed	O
tomography	B-UNK
as	O
the	O
gold	O
standard	B-UNK
of	O
comparison	B-UNK
to	O
assess	B-UNK
the	O
presence	O
or	O
absence	O
of	O
ischemia	B-UNK
.	O
METHODS	B-UNK
:	O
The	O
study	B-UNK
group	B-UNK
comprised	O
40	O
patients	B-UNK
undergoing	B-UNK
Sestamibi	O
-	O
SPECT	B-UNK
/	O
dobutamine	B-UNK
stress	I-UNK
test	B-UNK
.	O
Simultaneous	B-UNK
measurements	B-UNK
of	O
ECG	B-UNK
and	O
brachial	O
artery	B-UNK
dP	B-UNK
/	O
dtejc	O
were	O
performed	B-UNK
at	O
each	O
dobutamine	B-UNK
level	B-UNK
.	O
In	O
19	O
of	O
the	O
40	O
patients	B-UNK
perfusion	B-UNK
defects	B-UNK
compatible	O
with	O
ischemia	B-UNK
were	O
detected	B-UNK
on	O
SPECT	B-UNK
.	O
The	O
increase	B-UNK
in	O
dP	B-UNK
/	O
dtejc	O
during	O
infusion	B-UNK
of	O
dobutamine	B-UNK
in	O
this	O
group	B-UNK
was	O
severely	O
impaired	B-UNK
as	O
compared	O
to	O
the	O
non-ischemic	O
group	B-UNK
.	O
dP	B-UNK
/	O
dtejc	O
outcome	B-UNK
was	O
combined	B-UNK
with	O
the	O
ECG	B-UNK
results	B-UNK
,	O
giving	O
an	O
ECG	B-UNK
-	O
enhanced	B-UNK
value	O
,	O
and	O
compared	O
to	O
ECG	B-UNK
alone	O
.	O
RESULTS	B-UNK
:	O
The	O
sensitivity	B-UNK
improved	O
dramatically	O
from	O
16	O
%	O
to	O
79	O
%	O
,	O
positive	B-UNK
predictive	B-UNK
value	O
increased	B-UNK
from	O
60	O
%	O
to	O
68	O
%	O
and	O
negative	B-UNK
predictive	B-UNK
value	O
from	O
54	O
%	O
to	O
78	O
%	O
,	O
and	O
specificity	O
decreased	B-UNK
from	O
90	O
%	O
to	O
67	O
%	O
.	O
CONCLUSIONS	B-UNK
:	O
If	O
ECG	B-UNK
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	B-UNK
with	O
dP	B-UNK
/	O
dtejc	O
improved	O
the	O
sensitivity	B-UNK
of	O
the	O
test	B-UNK
and	O
could	O
be	O
a	O
cost	B-UNK
-	O
savings	O
alternative	B-UNK
to	O
cardiac	B-UNK
imaging	B-UNK
or	O
perfusion	B-UNK
studies	B-UNK
to	O
detect	B-UNK
myocardial	B-UNK
ischemia	I-UNK
,	O
especially	O
in	O
patients	B-UNK
unable	O
to	O
exercise	B-UNK
.	O

Acute	B-UNK
liver	I-UNK
failure	I-UNK
in	O
two	O
patients	B-UNK
with	O
regular	B-UNK
alcohol	B-UNK
consumption	B-UNK
ingesting	O
paracetamol	B-UNK
at	O
therapeutic	B-UNK
dosage	B-UNK
.	O
BACKGROUND	B-UNK
:	O
The	O
possible	O
role	O
of	O
alcohol	B-UNK
in	O
the	O
development	B-UNK
of	O
hepatotoxicity	B-UNK
associated	O
with	O
therapeutic	B-UNK
doses	B-UNK
of	O
paracetamol	B-CHEMICAL
(	O
acetaminophen	B-UNK
)	O
is	O
currently	O
debated	O
.	O
CASE	B-UNK
REPORT	I-UNK
:	O
We	O
describe	O
2	O
patients	B-UNK
who	O
were	O
regular	B-UNK
consumers	O
of	O
alcohol	B-UNK
and	O
who	O
developed	O
liver	B-UNK
failure	I-UNK
within	O
3	O
-	O
5	O
days	B-UNK
after	O
hospitalization	B-UNK
and	O
stopping	B-UNK
alcohol	B-UNK
consumption	B-UNK
while	O
being	O
treated	O
with	O
4	O
g	O
paracetamol	B-CHEMICAL
/	O
day	O
.	O
A	O
paracetamol	B-CHEMICAL
serum	B-UNK
level	B-UNK
obtained	B-UNK
in	O
one	O
of	O
these	O
patients	B-UNK
was	O
not	O
in	O
the	O
toxic	B-UNK
range	B-UNK
.	O
Possible	O
risk	B-UNK
factors	I-UNK
for	O
the	O
development	B-UNK
of	O
hepatotoxicity	B-UNK
in	O
patients	B-UNK
treated	O
with	O
therapeutic	B-UNK
doses	B-UNK
of	O
paracetamol	B-CHEMICAL
are	O
discussed	O
.	O
CONCLUSION	B-UNK
:	O
In	O
patients	B-UNK
with	O
risk	B-UNK
factors	I-UNK
,	O
e.g	B-UNK
.	O
regular	B-UNK
consumption	B-UNK
of	O
alcohol	B-UNK
,	O
liver	B-UNK
failure	I-UNK
is	O
possible	O
when	O
therapeutic	B-UNK
doses	B-UNK
are	O
ingested	O
.	O
We	O
propose	O
that	O
the	O
paracetamol	B-UNK
dose	B-UNK
should	O
not	O
exceed	O
2	O
g	O
/	O
day	O
in	O
such	O
patients	B-UNK
and	O
that	O
their	O
liver	B-UNK
function	B-UNK
should	O
be	O
monitored	O
closely	O
while	O
being	O
treated	O
with	O
paracetamol	B-CHEMICAL
.	O

Cocaine	B-UNK
related	O
chest	B-UNK
pain	I-UNK
:	O
are	O
we	O
seeing	O
the	O
tip	O
of	O
an	O
iceberg	O
?	O
The	O
recreational	B-UNK
use	O
of	O
cocaine	B-UNK
is	O
on	O
the	O
increase	B-UNK
.	O
The	O
emergency	B-UNK
nurse	O
ought	O
to	O
be	O
familiar	O
with	O
some	O
of	O
the	O
cardiovascular	B-UNK
consequences	B-UNK
of	O
cocaine	B-CHEMICAL
use	O
.	O
In	O
particular	O
,	O
the	O
tendency	O
of	O
cocaine	B-CHEMICAL
to	O
produce	B-UNK
chest	B-UNK
pain	I-UNK
ought	O
to	O
be	O
in	O
the	O
mind	O
of	O
the	O
emergency	B-UNK
nurse	O
when	O
faced	O
with	O
a	O
young	B-UNK
victim	O
of	O
chest	B-UNK
pain	I-UNK
who	O
is	O
otherwise	O
at	O
low	B-UNK
risk	B-UNK
.	O
The	O
mechanism	B-UNK
of	O
chest	B-DISEASE
pain	I-DISEASE
related	O
to	O
cocaine	B-UNK
use	O
is	O
discussed	O
and	O
treatment	B-UNK
dilemmas	O
are	O
discussed	O
.	O
Finally	B-UNK
,	O
moral	O
issues	O
relating	O
to	O
the	O
testing	B-UNK
of	O
potential	B-UNK
cocaine	B-UNK
users	I-UNK
will	O
be	O
addressed	O
.	O

Severe	B-UNK
rhabdomyolysis	B-UNK
and	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
secondary	B-UNK
to	O
concomitant	B-UNK
use	O
of	O
simvastatin	B-UNK
,	O
amiodarone	B-CHEMICAL
,	O
and	O
atazanavir	O
.	O
OBJECTIVE	B-UNK
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
a	O
severe	B-UNK
interaction	B-UNK
between	O
simvastatin	B-CHEMICAL
,	O
amiodarone	B-UNK
,	O
and	O
atazanavir	O
resulting	B-UNK
in	O
rhabdomyolysis	B-UNK
and	O
acute	B-UNK
renal	I-UNK
failure	I-UNK
.	O
BACKGROUND	B-UNK
:	O
A	O
72-year	O
-	O
old	O
white	B-UNK
man	B-UNK
with	O
underlying	B-UNK
human	B-UNK
immunodeficiency	B-UNK
virus	I-UNK
,	O
atrial	B-UNK
fibrillation	I-UNK
,	O
coronary	B-UNK
artery	I-UNK
disease	I-UNK
,	O
and	O
hyperlipidemia	O
presented	B-UNK
with	O
generalized	O
pain	B-DISEASE
,	O
fatigue	B-DISEASE
,	O
and	O
dark	O
orange	O
urine	B-UNK
for	O
3	O
days	B-UNK
.	O
The	O
patient	B-UNK
was	O
taking	B-UNK
80	O
mg	B-UNK
simvastatin	B-CHEMICAL
at	O
bedtime	O
(	O
initiated	O
27	O
days	B-UNK
earlier	B-UNK
)	O
;	O
amiodarone	B-CHEMICAL
at	O
a	O
dose	B-UNK
of	O
400	O
mg	B-UNK
daily	B-UNK
for	O
7	O
days	B-UNK
,	O
then	O
200	O
mg	B-UNK
daily	B-UNK
(	O
initiated	O
19	O
days	B-UNK
earlier	B-UNK
)	O
;	O
and	O
400	O
mg	B-UNK
atazanavir	O
daily	B-UNK
(	O
initiated	O
at	O
least	O
2	O
years	B-UNK
previously	B-UNK
)	O
.	O
Laboratory	B-UNK
evaluation	B-UNK
revealed	O
66,680	O
U	O
/	O
L	O
creatine	B-UNK
kinase	I-UNK
,	O
93	O
mg	B-UNK
/	O
dL	B-UNK
blood	B-UNK
urea	I-UNK
nitrogen	B-UNK
,	O
4.6	O
mg	B-UNK
/	O
dL	B-UNK
creatinine	B-CHEMICAL
,	O
1579	O
U	O
/	O
L	O
aspartate	B-UNK
aminotransferase	B-UNK
,	O
and	O
738	O
U	O
/	O
L	O
alanine	B-UNK
aminotransferase	B-UNK
.	O
Simvastatin	B-CHEMICAL
,	O
amiodarone	B-UNK
,	O
and	O
the	O
patient'	B-UNK
s	I-UNK
human	B-UNK
immunodeficiency	B-UNK
virus	I-UNK
medications	B-UNK
were	O
all	O
temporarily	O
discontinued	O
and	O
the	O
patient	B-UNK
was	O
given	O
forced	O
alkaline	B-UNK
diuresis	O
and	O
started	O
on	O
dialysis	B-UNK
.	O
Nine	O
days	B-UNK
later	O
the	O
patient'	B-UNK
s	I-UNK
creatine	B-UNK
kinase	I-UNK
had	O
dropped	O
to	O
1695	O
U	O
/	O
L	O
and	O
creatinine	B-UNK
was	O
3.3	O
mg	B-UNK
/	O
dL.	O
The	O
patient	B-UNK
was	O
discharged	B-UNK
and	O
continued	O
outpatient	O
dialysis	B-UNK
for	O
1	O
month	B-UNK
until	O
his	O
renal	B-UNK
function	I-UNK
recovered	O
.	O
DISCUSSION	B-UNK
:	O
The	O
risk	B-UNK
of	O
rhabdomyolysis	B-UNK
is	O
increased	B-UNK
in	O
the	O
presence	O
of	O
concomitant	B-UNK
drugs	B-UNK
that	O
inhibit	O
simvastatin	B-CHEMICAL
metabolism	B-UNK
.	O
Simvastatin	B-UNK
is	O
metabolized	O
by	O
CYP3A4	B-UNK
.	O
Amiodarone	B-CHEMICAL
and	O
atazanavir	O
are	O
recognized	O
CYP3A4	B-UNK
inhibitors	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Pharmacokinetic	B-UNK
differences	B-UNK
in	O
statins	B-UNK
are	O
an	O
important	B-UNK
consideration	O
for	O
assessing	O
the	O
risk	B-UNK
of	O
potential	B-UNK
drug	B-UNK
interactions	I-UNK
.	O
In	O
patients	B-UNK
requiring	O
the	O
concurrent	B-UNK
use	O
of	O
statins	B-UNK
and	O
CYP3A4	B-UNK
inhibitors	B-UNK
,	O
pravastatin	B-CHEMICAL
,	O
fluvastatin	O
,	O
and	O
rosuvastatin	O
carry	O
the	O
lowest	O
risk	B-UNK
of	O
drug	B-UNK
interactions	I-UNK
;	O
atorvastatin	O
carries	O
moderate	B-UNK
risk	B-UNK
,	O
whereas	O
simvastatin	B-UNK
and	O
lovastatin	B-CHEMICAL
have	O
the	O
highest	B-UNK
risk	B-UNK
and	O
should	O
be	O
avoided	O
in	O
patients	B-UNK
taking	B-UNK
concomitant	B-UNK
CYP3A4	B-UNK
inhibitors	B-UNK
.	O

Phase	B-UNK
II	I-UNK
trial	B-UNK
of	O
vinorelbine	B-CHEMICAL
in	O
metastatic	B-UNK
squamous	O
cell	B-UNK
esophageal	B-DISEASE
carcinoma	I-DISEASE
.	O
European	O
Organization	B-UNK
for	O
Research	B-UNK
and	O
Treatment	B-UNK
of	O
Cancer	B-UNK
Gastrointestinal	B-UNK
Treat	B-UNK
Cancer	B-UNK
Cooperative	O
Group	B-UNK
.	O
PURPOSE	B-UNK
:	O
To	O
evaluate	B-UNK
the	O
response	B-UNK
rate	B-UNK
and	O
toxic	B-UNK
effects	I-UNK
of	O
vinorelbine	B-CHEMICAL
(	O
VNB	O
)	O
administered	O
as	O
a	O
single	B-UNK
agent	I-UNK
in	O
metastatic	B-UNK
squamous	O
cell	B-UNK
esophageal	B-DISEASE
carcinoma	I-DISEASE
.	O
PATIENTS	B-UNK
AND	I-UNK
METHODS	I-UNK
:	O
Forty	O
-	O
six	O
eligible	O
patients	B-UNK
with	O
measurable	O
lesions	B-UNK
were	O
included	B-UNK
and	O
were	O
stratified	O
according	O
to	O
previous	B-UNK
chemotherapy	O
.	O
Thirty	B-UNK
patients	B-UNK
without	O
prior	B-UNK
chemotherapy	O
and	O
16	O
pretreated	B-UNK
with	O
cisplatin	B-UNK
-	O
based	B-UNK
chemotherapy	O
were	O
assessable	O
for	O
toxicity	B-DISEASE
and	O
response	B-UNK
.	O
VNB	O
was	O
administered	O
weekly	B-UNK
as	O
a	O
25-mg	O
/	O
m2	B-UNK
short	B-UNK
intravenous	B-UNK
(	O
i.v	B-UNK
.	O
)	O
infusion	B-UNK
.	O
RESULTS	B-UNK
:	O
Six	O
of	O
30	O
patients	B-UNK
(	O
20	O
%	O
)	O
without	O
prior	B-UNK
chemotherapy	O
achieved	O
a	O
partial	B-UNK
response	I-UNK
(	O
PR	B-UNK
)	O
(	O
95	O
%	O
confidence	O
interval	B-UNK
[	O
CI	B-UNK
]	O
,	O
8	O
%	O
to	O
39	O
%	O
)	O
.	O
The	O
median	B-UNK
duration	B-UNK
of	O
response	B-UNK
was	O
21	O
weeks	B-UNK
(	O
range	B-UNK
,	O
17	O
to	O
28	O
)	O
.	O
One	O
of	O
16	O
patients	B-UNK
(	O
6	O
%	O
)	O
with	O
prior	B-UNK
chemotherapy	O
had	O
a	O
complete	B-UNK
response	B-UNK
(	O
CR	B-UNK
)	O
of	O
31	O
weeks	B-UNK
'	O
duration	B-UNK
(	O
95	O
%	O
CI	B-UNK
,	O
0	O
%	O
to	O
30	O
%	O
)	O
.	O
The	O
overall	O
response	B-UNK
rate	B-UNK
(	O
World	B-UNK
Health	B-UNK
Organization	B-UNK
[	O
WHO	O
]	O
criteria	B-UNK
)	O
was	O
15	O
%	O
(	O
CR	B-UNK
,	O
2	O
%	O
;	O
PR	B-UNK
13	O
%	O
;	O
95	O
%	O
CI	B-UNK
,	O
6	O
%	O
to	O
29	O
%	O
)	O
.	O
The	O
median	B-UNK
dose	B-UNK
-	O
intensity	B-UNK
(	O
DI	B-UNK
)	O
was	O
20	O
mg	B-UNK
/	O
m2	B-UNK
/	O
wk	B-UNK
.	O
VNB	O
was	O
well	O
tolerated	B-UNK
and	O
zero	O
instances	O
of	O
WHO	O
grade	B-UNK
4	O
nonhematologic	O
toxicity	B-UNK
occurred	B-UNK
.	O
At	O
least	O
one	O
episode	B-UNK
of	O
grade	B-UNK
3	O
or	O
4	O
granulocytopenia	O
was	O
seen	O
in	O
59	O
%	O
of	O
patients	B-UNK
.	O
A	O
grade	B-UNK
2	O
or	O
3	O
infection	B-DISEASE
occurred	B-UNK
in	O
16	O
%	O
of	O
patients	B-UNK
,	O
but	O
no	O
toxic	B-UNK
deaths	B-UNK
occurred	B-UNK
.	O
Other	O
side	O
effects	O
were	O
rare	B-UNK
,	O
and	O
peripheral	B-UNK
neurotoxicity	B-UNK
has	O
been	O
minor	B-UNK
(	O
26	O
%	O
grade	B-UNK
1	O
)	O
.	O
CONCLUSION	B-UNK
:	O
These	O
data	B-UNK
indicate	O
that	O
VNB	O
is	O
an	O
active	B-UNK
agent	B-UNK
in	O
metastatic	B-UNK
esophageal	B-DISEASE
squamous	I-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
.	O
Given	O
its	O
excellent	O
tolerance	B-UNK
profile	B-UNK
and	O
low	B-UNK
toxicity	B-UNK
,	O
further	O
evaluation	B-UNK
of	O
VNB	O
in	O
combination	B-UNK
therapy	I-UNK
is	O
warranted	O
.	O

Paclitaxel	B-UNK
,	O
cisplatin	B-CHEMICAL
,	O
and	O
gemcitabine	B-CHEMICAL
combination	B-UNK
chemotherapy	O
within	O
a	O
multidisciplinary	O
therapeutic	B-UNK
approach	O
in	O
metastatic	B-UNK
nonsmall	O
cell	B-UNK
lung	I-UNK
carcinoma	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Cisplatin	B-UNK
-	O
based	B-UNK
chemotherapy	O
combinations	B-UNK
improve	B-UNK
quality	B-UNK
of	I-UNK
life	I-UNK
and	O
survival	B-UNK
in	O
advanced	B-UNK
nonsmall	O
cell	B-UNK
lung	I-UNK
carcinoma	B-UNK
(	O
NSCLC	B-UNK
)	O
.	O
The	O
emergence	O
of	O
new	O
active	B-UNK
drugs	B-UNK
might	O
translate	O
into	O
more	O
effective	B-UNK
regimens	B-UNK
for	O
the	O
treatment	B-UNK
of	O
this	O
disease	B-UNK
.	O
METHODS	B-UNK
:	O
The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
determine	B-UNK
the	O
feasibility	O
,	O
response	B-UNK
rate	B-UNK
,	O
and	O
toxicity	B-UNK
of	O
a	O
paclitaxel	B-UNK
,	O
cisplatin	B-UNK
,	O
and	O
gemcitabine	B-CHEMICAL
combination	B-UNK
to	O
treat	B-UNK
metastatic	B-UNK
NSCLC	B-UNK
.	O
Thirty	B-UNK
-	O
five	O
consecutive	B-UNK
chemotherapy	O
-	O
naive	O
patients	B-UNK
with	O
Stage	B-UNK
IV	B-UNK
NSCLC	B-UNK
and	O
an	O
Eastern	O
Cooperative	O
Oncology	B-UNK
Group	B-UNK
performance	B-UNK
status	B-UNK
of	O
0	O
-	O
2	O
were	O
treated	O
with	O
a	O
combination	B-UNK
of	O
paclitaxel	B-UNK
(	O
135	O
mg	B-UNK
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
3	O
hours	B-UNK
)	O
on	O
Day	O
1	O
,	O
cisplatin	B-CHEMICAL
(	O
120	O
mg	B-UNK
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
6	O
hours	B-UNK
)	O
on	O
Day	O
1	O
,	O
and	O
gemcitabine	B-UNK
(	O
800	O
mg	B-UNK
/	O
m(2	O
)	O
given	O
intravenously	O
in	O
30	O
minutes	B-UNK
)	O
on	O
Days	B-UNK
1	O
and	O
8	O
,	O
every	O
4	O
weeks	B-UNK
.	O
Although	O
responding	O
patients	B-UNK
were	O
scheduled	O
to	O
receive	B-UNK
consolidation	B-UNK
radiotherapy	B-UNK
and	O
24	O
patients	B-UNK
received	O
preplanned	O
second	O
-	O
line	B-UNK
chemotherapy	O
after	O
disease	B-UNK
progression	I-UNK
,	O
the	O
response	B-UNK
and	O
toxicity	B-UNK
rates	B-UNK
reported	B-UNK
refer	O
only	O
to	O
the	O
chemotherapy	O
regimen	B-UNK
given	O
.	O
RESULTS	B-UNK
:	O
All	O
the	O
patients	B-UNK
were	O
examined	B-UNK
for	O
toxicity	B-UNK
;	O
34	O
were	O
examinable	O
for	O
response	B-UNK
.	O
An	O
objective	B-UNK
response	B-UNK
was	O
observed	O
in	O
73.5	O
%	O
of	O
the	O
patients	B-UNK
(	O
95	O
%	O
confidence	O
interval	B-UNK
[	O
CI	B-UNK
]	O
,	O
55.6	O
-	O
87.1	O
%	O
)	O
,	O
including	O
4	O
complete	B-UNK
responses	O
(	O
11.7	O
%	O
)	O
.	O
According	O
to	O
intention	O
-	O
to	O
-	O
treat	B-UNK
,	O
the	O
overall	O
response	B-UNK
rate	B-UNK
was	O
71.4	O
%	O
(	O
95	O
%	O
CI	B-UNK
,	O
53	O
.	O
7	O
-	O
85.4	O
%	O
)	O
.	O
After	O
154	O
courses	B-UNK
of	O
therapy	O
,	O
the	O
median	B-UNK
dose	B-UNK
intensity	B-UNK
was	O
131	O
mg	B-UNK
/	O
m(2	O
)	O
for	O
paclitaxel	B-UNK
(	O
97.3	O
%	O
)	O
,	O
117	O
mg	B-UNK
/	O
m(2	O
)	O
for	O
cisplatin	B-UNK
(	O
97.3	O
%	O
)	O
,	O
and	O
1378	O
mg	B-UNK
/	O
m(2	O
)	O
for	O
gemcitabine	B-CHEMICAL
(	O
86.2	O
%	O
)	O
.	O
World	B-UNK
Health	B-UNK
Organization	B-UNK
Grade	B-UNK
3	O
-	O
4	O
neutropenia	B-UNK
and	O
thrombocytopenia	B-UNK
occurred	B-UNK
in	O
39.9	O
%	O
and	O
11.4	O
%	O
of	O
patients	B-UNK
,	O
respectively	O
.	O
There	O
was	O
one	O
treatment	B-UNK
-	O
related	O
death	B-UNK
.	O
Nonhematologic	O
toxicities	B-UNK
were	O
mild	B-UNK
.	O
After	O
a	O
median	B-UNK
follow	O
-	O
up	O
of	O
22	O
months	B-UNK
,	O
the	O
median	B-UNK
progression	B-UNK
free	B-UNK
survival	B-UNK
rate	B-UNK
was	O
7	O
months	B-UNK
,	O
and	O
the	O
median	B-UNK
survival	B-UNK
time	O
was	O
16	O
months	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
The	O
combination	B-UNK
of	O
paclitaxel	B-CHEMICAL
,	O
cisplatin	B-CHEMICAL
,	O
and	O
gemcitabine	B-CHEMICAL
is	O
well	O
tolerated	B-UNK
and	O
shows	O
high	B-UNK
activity	B-UNK
in	O
metastatic	B-UNK
NSCLC	B-UNK
.	O
This	O
treatment	B-UNK
merits	O
further	O
comparison	B-UNK
with	O
other	O
cisplatin	B-UNK
-	O
based	B-UNK
regimens	B-UNK
.	O

Evaluation	B-UNK
of	O
adverse	B-UNK
reactions	I-UNK
of	O
aponidine	O
hydrochloride	B-UNK
ophthalmic	B-UNK
solution	B-UNK
.	O
We	O
prospectively	O
evaluated	B-UNK
the	O
adverse	B-UNK
reactions	I-UNK
of	O
apraclonidine	O
in	O
20	O
normal	O
volunteers	B-UNK
by	O
instilling	O
a	O
single	B-UNK
drop	B-UNK
of	O
1	O
%	O
apraclonidine	O
in	O
their	O
right	O
eyes	B-UNK
.	O
Examinations	B-UNK
,	O
including	O
blood	B-UNK
pressure	I-UNK
,	O
pulse	B-UNK
rate	B-UNK
,	O
conjunctiva	O
and	O
cornea	O
,	O
intraocular	B-UNK
pressure	I-UNK
(	O
IOP	B-UNK
)	O
,	O
pupil	B-UNK
diameter	B-UNK
,	O
basal	B-UNK
tear	O
secretion	B-UNK
and	O
margin	O
reflex	B-UNK
distance	O
of	O
both	O
upper	B-UNK
and	O
lower	B-UNK
eyelids	O
,	O
were	O
performed	B-UNK
prior	B-UNK
to	O
entry	O
and	O
at	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
hours	B-UNK
after	O
instillation	B-UNK
.	O
The	O
ocular	B-UNK
hypotensive	B-UNK
effects	O
were	O
statistically	B-UNK
significant	I-UNK
for	O
apraclonidine	O
-	O
treated	O
eyes	B-UNK
throughout	O
the	O
study	B-UNK
and	O
also	O
statistically	B-UNK
significant	I-UNK
for	O
contralateral	B-UNK
eyes	B-UNK
from	O
three	O
hours	B-UNK
after	O
topical	B-UNK
administration	O
of	O
1	O
%	O
apraclonidine	O
.	O
Decreases	B-UNK
in	O
systolic	B-UNK
blood	I-UNK
pressure	I-UNK
were	O
statistically	B-UNK
,	O
but	O
not	O
clinically	B-UNK
,	O
significant	B-UNK
.	O
No	O
significant	B-UNK
changes	O
in	O
diastolic	B-UNK
blood	B-UNK
pressure	I-UNK
,	O
pulse	B-UNK
rate	B-UNK
and	O
basal	B-UNK
tear	O
secretion	B-UNK
were	O
noted	B-UNK
.	O
Conjunctival	O
blanching	O
and	O
mydriasis	B-DISEASE
were	O
commonly	B-UNK
found	O
.	O
Upper	B-UNK
lid	B-UNK
retraction	O
was	O
frequently	B-UNK
noted	B-UNK
.	O
While	O
the	O
elevations	B-UNK
of	O
the	O
upper	B-UNK
lid	B-UNK
margin	O
in	O
most	O
subjects	B-UNK
were	O
not	O
more	O
than	O
2	O
mm	B-UNK
and	O
did	O
not	O
cause	O
noticeable	O
change	B-UNK
in	O
appearance	B-UNK
,	O
one	O
subject	O
suffered	O
from	O
mechanical	B-UNK
entropion	B-DISEASE
and	O
marked	O
corneal	B-DISEASE
abrasion	I-DISEASE
3	O
hours	B-UNK
after	O
instillation	B-UNK
of	O
the	O
medication	O
.	O
This	O
may	O
well	O
be	O
a	O
particularly	O
notable	O
finding	O
in	O
Asian	O
people	O
.	O

Carmofur	O
-	O
induced	O
organic	B-UNK
mental	B-DISEASE
disorders	I-DISEASE
.	O
Organic	B-UNK
mental	B-UNK
disorder	B-UNK
was	O
observed	O
in	O
a	O
29-year	O
-	O
old	O
female	B-UNK
in	O
the	O
prognostic	O
period	B-UNK
after	O
the	O
onset	B-UNK
of	O
carmofur	O
-	O
induced	O
leukoencephalopathy	B-DISEASE
.	O
Symptoms	B-UNK
such	O
as	O
euphoria	O
,	O
emotional	B-UNK
lability	O
and	O
puerile	O
attitude	O
noted	B-UNK
in	O
the	O
patient	B-UNK
were	O
diagnosed	B-UNK
as	O
organic	B-UNK
personality	O
syndrome	B-UNK
according	O
to	O
the	O
criteria	B-UNK
defined	B-UNK
in	O
the	O
DSM	B-UNK
-	O
III	B-UNK
-	O
R.	O
It	O
is	O
referred	B-UNK
to	O
as	O
a	O
frontal	B-UNK
lobe	B-UNK
syndrome	B-UNK
.	O
Brain	B-UNK
CT	B-UNK
revealed	O
a	O
periventricular	O
low	B-UNK
density	B-UNK
area	B-UNK
in	O
the	O
frontal	B-UNK
white	B-UNK
matter	I-UNK
and	O
moderate	B-UNK
dilatation	O
of	O
the	O
lateral	B-UNK
ventricles	O
especially	O
at	O
the	O
bilateral	B-UNK
anterior	B-UNK
horns	O
.	O
Consequently	O
,	O
carmofur	O
-	O
induced	O
leukoencephalopathy	B-UNK
may	O
uncommonly	O
result	B-UNK
in	O
organic	B-UNK
personality	O
syndrome	B-DISEASE
in	O
the	O
residual	B-UNK
state	B-UNK
.	O
It	O
may	O
be	O
attributed	B-UNK
to	O
the	O
structural	B-UNK
damage	B-UNK
to	O
the	O
frontal	B-UNK
lobe	B-UNK
.	O

International	O
mexiletine	B-CHEMICAL
and	O
placebo	B-UNK
antiarrhythmic	B-UNK
coronary	B-UNK
trial	B-UNK
:	O
I.	O
Report	B-UNK
on	O
arrhythmia	B-UNK
and	O
other	O
findings	B-UNK
.	O
Impact	B-UNK
Research	B-UNK
Group	B-UNK
.	O
The	O
antiarrhythmic	B-UNK
effects	O
of	O
the	O
sustained	B-UNK
release	I-UNK
form	B-UNK
of	O
mexiletine	B-CHEMICAL
(	O
Mexitil	O
-	O
Perlongets	O
)	O
were	O
evaluated	B-UNK
in	O
a	O
double-blind	O
placebo	B-UNK
trial	B-UNK
in	O
630	O
patients	B-UNK
with	O
recent	B-UNK
documented	O
myocardial	B-DISEASE
infarction	I-DISEASE
.	O
The	O
primary	B-UNK
response	B-UNK
variable	B-UNK
was	O
based	B-UNK
on	O
central	B-UNK
reading	O
of	O
24	O
hour	B-UNK
ambulatory	B-UNK
electrocardiographic	B-UNK
recordings	O
and	O
was	O
defined	B-UNK
as	O
the	O
occurrence	B-UNK
of	O
30	O
or	O
more	O
single	B-UNK
premature	B-UNK
ventricular	B-UNK
complexes	O
in	O
any	O
two	O
consecutive	B-UNK
30	O
minute	B-UNK
blocks	B-UNK
or	O
one	O
or	O
more	O
runs	O
of	O
two	O
or	O
more	O
premature	B-UNK
ventricular	B-UNK
complexes	O
in	O
the	O
entire	O
24	O
hour	B-UNK
electrocardiographic	B-UNK
recording	B-UNK
.	O
Large	B-UNK
differences	B-UNK
,	O
regarded	O
as	O
statistically	B-UNK
significant	I-UNK
,	O
between	O
the	O
mexiletine	B-CHEMICAL
and	O
placebo	B-UNK
groups	B-UNK
were	O
noted	B-UNK
in	O
that	O
end	B-UNK
point	B-UNK
at	O
months	B-UNK
1	O
and	O
4	O
,	O
but	O
only	O
trends	O
were	O
observed	O
at	O
month	B-UNK
12	O
.	O
These	O
differences	B-UNK
were	O
observed	O
even	O
though	O
the	O
serum	B-UNK
mexiletine	B-CHEMICAL
levels	O
obtained	B-UNK
in	O
this	O
study	B-UNK
were	O
generally	B-UNK
lower	B-UNK
than	O
those	O
observed	O
in	O
studies	B-UNK
that	O
have	O
used	O
the	O
regular	B-UNK
form	B-UNK
of	O
the	O
drug	B-UNK
.	O
There	O
were	O
more	O
deaths	B-UNK
in	O
the	O
mexiletine	B-CHEMICAL
group	B-UNK
(	O
7.6	O
%	O
)	O
than	O
in	O
the	O
placebo	B-UNK
group	B-UNK
(	O
4.8	O
%	O
)	O
;	O
the	O
difference	B-UNK
was	O
not	O
statistically	B-UNK
significant	I-UNK
.	O
The	O
incidence	B-UNK
of	O
coronary	B-UNK
events	B-UNK
was	O
similar	B-UNK
in	O
both	O
groups	B-UNK
.	O
Previously	B-UNK
recognized	O
side	O
effects	O
,	O
particularly	O
tremor	B-UNK
and	O
gastrointestinal	B-UNK
problems	B-UNK
,	O
were	O
more	O
frequent	B-UNK
in	O
the	O
mexiletine	B-CHEMICAL
group	B-UNK
than	O
in	O
the	O
placebo	B-UNK
group	B-UNK
.	O

Regional	B-UNK
localization	B-UNK
of	O
the	O
antagonism	B-UNK
of	O
amphetamine	B-UNK
-	O
induced	B-UNK
hyperactivity	I-UNK
by	O
intracerebral	B-UNK
calcitonin	B-UNK
injections	B-UNK
.	O
Calcitonin	B-UNK
receptors	B-UNK
are	O
found	O
in	O
the	O
brain	B-UNK
,	O
and	O
intracerebral	B-UNK
infusions	B-UNK
of	O
calcitonin	B-UNK
can	O
produce	B-UNK
behavioral	B-UNK
effects	O
.	O
Among	O
these	O
behavioral	B-UNK
effects	O
are	O
decreases	B-UNK
in	O
food	B-UNK
intake	B-UNK
and	O
decreases	B-UNK
in	O
amphetamine	B-UNK
-	O
induced	O
locomotor	B-UNK
activity	I-UNK
.	O
In	O
previous	B-UNK
experiments	B-UNK
we	O
found	O
that	O
decreases	B-UNK
in	O
food	B-UNK
intake	B-UNK
were	O
induced	O
by	O
local	B-UNK
administration	O
of	O
calcitonin	B-UNK
into	O
several	O
hypothalamic	O
sites	B-UNK
and	O
into	O
the	O
nucleus	B-UNK
accumbens	B-UNK
.	O
In	O
the	O
present	B-UNK
experiment	B-UNK
calcitonin	B-UNK
decreased	B-UNK
locomotor	B-UNK
activity	I-UNK
when	O
locally	O
injected	B-UNK
into	O
the	O
same	O
sites	B-UNK
where	O
it	O
decreases	B-UNK
food	B-UNK
intake	B-UNK
.	O
The	O
areas	B-UNK
where	O
calcitonin	B-UNK
is	O
most	O
effective	B-UNK
in	O
decreasing	B-UNK
locomotor	B-UNK
activity	I-UNK
are	O
located	O
in	O
the	O
hypothalamus	O
and	O
nucleus	B-UNK
accumbens	B-UNK
,	O
suggesting	O
that	O
these	O
areas	B-UNK
are	O
the	O
major	B-UNK
sites	B-UNK
of	O
action	B-UNK
of	O
calcitonin	B-UNK
in	O
inhibiting	O
amphetamine	B-UNK
-	O
induced	O
locomotor	B-UNK
activity	I-UNK
.	O

Fatal	B-UNK
intracranial	B-UNK
bleeding	B-UNK
associated	O
with	O
prehospital	O
use	O
of	O
epinephrine	B-UNK
.	O
We	O
present	B-UNK
a	O
case	B-UNK
of	O
paramedic	O
misjudgment	O
in	O
the	O
execution	O
of	O
a	O
protocol	O
for	O
the	O
treatment	B-UNK
of	O
allergic	B-DISEASE
reaction	I-DISEASE
in	O
a	O
case	B-UNK
of	O
pulmonary	B-DISEASE
edema	I-DISEASE
with	O
wheezing	O
.	O
The	O
sudden	B-UNK
onset	B-UNK
of	O
respiratory	B-UNK
distress	O
,	O
rash	B-UNK
,	O
and	O
a	O
history	B-UNK
of	O
a	O
new	O
medicine	B-UNK
led	B-UNK
the	O
two	O
paramedics	O
on	O
the	O
scene	O
to	O
administer	O
subcutaneous	B-UNK
epinephrine	B-UNK
.	O
Subsequently	B-UNK
,	O
acute	B-UNK
cardiac	B-UNK
arrest	I-UNK
and	O
fatal	B-UNK
subarachnoid	B-UNK
hemorrhage	I-UNK
occurred	B-UNK
.	O
Epinephrine	B-UNK
has	O
a	O
proven	B-UNK
role	O
in	O
cardiac	B-UNK
arrest	I-UNK
in	O
prehospital	O
care	B-UNK
;	O
however	O
,	O
use	O
by	O
paramedics	O
in	O
patients	B-UNK
with	O
suspected	O
allergic	B-DISEASE
reaction	I-DISEASE
and	O
severe	B-UNK
hypertension	B-DISEASE
should	O
be	O
viewed	O
with	O
caution	B-UNK
.	O

A	O
case	B-UNK
of	O
massive	B-UNK
rhabdomyolysis	B-UNK
following	O
molindone	O
administration	O
.	O
Rhabdomyolysis	B-UNK
is	O
a	O
potentially	O
lethal	B-UNK
syndrome	B-DISEASE
that	O
psychiatric	B-UNK
patients	B-UNK
seem	O
predisposed	O
to	O
develop	B-UNK
.	O
The	O
clinical	B-UNK
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
,	O
typical	B-UNK
laboratory	B-UNK
features	B-UNK
,	O
and	O
complications	B-UNK
of	O
rhabdomyolysis	B-UNK
are	O
presented	B-UNK
.	O
The	O
case	B-UNK
of	O
a	O
schizophrenic	B-UNK
patient	B-UNK
is	O
reported	B-UNK
to	O
illustrate	O
massive	B-UNK
rhabdomyolysis	B-UNK
and	O
subsequent	B-UNK
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
following	O
molindone	O
administration	O
.	O
Physicians	B-UNK
who	O
prescribe	O
molindone	O
should	O
be	O
aware	B-UNK
of	O
this	O
reaction	B-UNK
.	O

Cardiovascular	B-DISEASE
alterations	I-DISEASE
in	O
rat	B-UNK
fetuses	B-UNK
exposed	B-UNK
to	O
calcium	B-UNK
channel	I-UNK
blockers	I-UNK
.	O
Preclinical	B-UNK
toxicologic	O
investigation	B-UNK
suggested	B-UNK
that	O
a	O
new	O
calcium	B-UNK
channel	I-UNK
blocker	B-UNK
,	O
Ro	O
40	O
-	O
5967	O
,	O
induced	O
cardiovascular	B-DISEASE
alterations	I-DISEASE
in	O
rat	B-UNK
fetuses	B-UNK
exposed	B-UNK
to	O
this	O
agent	B-UNK
during	O
organogenesis	O
.	O
The	O
present	B-UNK
study	B-UNK
was	O
designed	B-UNK
to	O
investigate	B-UNK
the	O
hypothesis	B-UNK
that	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
in	O
general	B-UNK
induce	B-UNK
cardiovascular	B-DISEASE
malformations	I-DISEASE
indicating	O
a	O
pharmacologic	O
class	B-UNK
effect	B-UNK
.	O
We	O
studied	O
three	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
of	O
different	O
structure	B-UNK
,	O
nifedipine	B-UNK
,	O
diltiazem	B-CHEMICAL
,	O
and	O
verapamil	B-UNK
,	O
along	O
with	O
the	O
new	O
agent	B-UNK
.	O
Pregnant	B-UNK
rats	B-UNK
were	O
administered	O
one	O
of	O
these	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
during	O
the	O
period	B-UNK
of	O
cardiac	B-UNK
morphogenesis	O
and	O
the	O
offspring	B-UNK
examined	B-UNK
on	O
day	O
20	O
of	O
gestation	B-UNK
for	O
cardiovascular	B-DISEASE
malformations	I-DISEASE
.	O
A	O
low	B-UNK
incidence	B-UNK
of	O
cardiovascular	B-DISEASE
malformations	I-DISEASE
was	O
observed	O
after	O
exposure	B-UNK
to	O
each	O
of	O
the	O
four	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
,	O
but	O
this	O
incidence	B-UNK
was	O
statistically	B-UNK
significant	I-UNK
only	O
for	O
verapamil	B-UNK
and	O
nifedipine	B-UNK
.	O
All	O
four	O
agents	B-UNK
were	O
associated	O
with	O
aortic	B-UNK
arch	O
branching	O
variants	B-UNK
,	O
although	O
significantly	B-UNK
increased	B-UNK
only	O
for	O
Ro	O
40	O
-	O
5967	O
and	O
verapamil	B-UNK
.	O

Differential	B-UNK
impact	B-UNK
of	O
immune	B-UNK
escape	B-UNK
mutations	B-UNK
G145R	O
and	O
P120	O
T	O
on	O
the	O
replication	B-UNK
of	O
lamivudine	B-UNK
-	O
resistant	B-UNK
hepatitis	B-UNK
B	I-UNK
virus	I-UNK
e	O
antigen	B-UNK
-	O
positive	B-UNK
and	O
-negative	O
strains	B-UNK
.	O
Immune	B-UNK
escape	B-UNK
variants	B-UNK
of	O
the	O
hepatitis	B-UNK
B	I-UNK
virus	I-UNK
(	O
HBV	B-UNK
)	O
represent	O
an	O
emerging	O
clinical	B-UNK
challenge	B-UNK
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	B-UNK
,	O
HBV	B-UNK
reactivation	O
,	O
and	O
failure	B-UNK
of	O
diagnostic	B-UNK
tests	B-UNK
.	O
Recent	B-UNK
data	B-UNK
suggest	I-UNK
a	O
preferential	O
selection	O
of	O
immune	B-UNK
escape	B-UNK
mutants	B-UNK
in	O
distinct	O
peripheral	B-UNK
blood	I-UNK
leukocyte	O
compartments	O
of	O
infected	B-UNK
individuals	B-UNK
.	O
We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	B-UNK
impact	B-UNK
of	O
the	O
most	O
prevalent	O
immune	B-UNK
escape	B-UNK
variants	B-UNK
,	O
the	O
sG145R	O
and	O
sP120	O
T	O
mutants	B-UNK
,	O
on	O
the	O
viral	B-UNK
replication	B-UNK
efficacy	B-UNK
and	O
antiviral	B-UNK
drug	B-UNK
susceptibility	B-UNK
of	O
common	B-UNK
treatment	B-UNK
-	O
associated	O
mutants	B-UNK
with	O
resistance	B-UNK
to	O
lamivudine	B-UNK
(	O
LAM	O
)	O
and	O
/	O
or	O
HBeAg	B-UNK
negativity	O
.	O
Replication	B-UNK
-	O
competent	O
HBV	B-UNK
strains	B-UNK
with	O
sG145R	O
or	O
sP120	O
T	O
and	O
LAM	O
resistance	B-UNK
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	B-UNK
on	O
an	O
HBeAg	B-UNK
-	O
positive	B-UNK
and	O
an	O
HBeAg	B-UNK
-	O
negative	B-UNK
background	B-UNK
with	O
precore	O
(	O
PC	O
)	O
and	O
basal	B-UNK
core	B-UNK
promoter	O
(	O
BCP	O
)	O
mutants	B-UNK
.	O
The	O
sG145R	O
mutation	B-UNK
strongly	O
reduced	B-UNK
HBsAg	B-UNK
levels	O
and	O
was	O
able	O
to	O
fully	B-UNK
restore	O
the	O
impaired	B-UNK
replication	B-UNK
of	O
LAM	O
-	O
resistant	B-UNK
HBV	B-UNK
mutants	B-UNK
to	O
the	O
levels	O
of	O
wild	O
-	O
type	B-UNK
HBV	B-UNK
,	O
and	O
PC	O
or	O
BCP	O
mutations	B-UNK
further	O
enhanced	B-UNK
viral	B-UNK
replication	B-UNK
.	O
Although	O
the	O
sP120	O
T	O
substitution	O
also	O
impaired	B-UNK
HBsAg	B-UNK
secretion	B-UNK
,	O
it	O
did	O
not	O
enhance	B-UNK
the	O
replication	B-UNK
of	O
LAM	O
-	O
resistant	B-UNK
clones	O
.	O
However	O
,	O
the	O
concomitant	B-UNK
occurrence	B-UNK
of	O
HBeAg	B-UNK
negativity	O
(	O
PC	O
/	O
BCP	O
)	O
,	O
sP120	O
T	O
,	O
and	O
LAM	O
resistance	B-UNK
resulted	B-UNK
in	O
the	O
restoration	O
of	O
replication	B-UNK
to	O
levels	O
of	O
wild	O
-	O
type	B-UNK
HBV	B-UNK
.	O
In	O
all	O
clones	O
with	O
combined	B-UNK
immune	B-UNK
escape	B-UNK
and	O
LAM	O
resistance	B-UNK
mutations	B-UNK
,	O
the	O
nucleotide	O
analogues	O
adefovir	O
and	O
tenofovir	O
remained	B-UNK
effective	B-UNK
in	O
suppressing	O
viral	B-UNK
replication	B-UNK
in	O
vitro	B-UNK
.	O
These	O
findings	B-UNK
reveal	O
the	O
differential	B-UNK
impact	B-UNK
of	O
immune	B-UNK
escape	B-UNK
variants	B-UNK
on	O
the	O
replication	B-UNK
and	O
drug	B-UNK
susceptibility	B-UNK
of	O
complex	B-UNK
HBV	B-UNK
mutants	B-UNK
,	O
supporting	O
the	O
need	O
of	O
close	B-UNK
surveillance	B-UNK
and	O
treatment	B-UNK
adjustment	B-UNK
in	O
response	B-UNK
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	B-UNK
.	O

The	O
effects	O
of	O
sevoflurane	B-UNK
on	O
lidocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsions	I-UNK
.	O
The	O
influence	B-UNK
of	O
sevoflurane	B-CHEMICAL
on	O
lidocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsions	I-UNK
was	O
studied	O
in	O
cats	B-UNK
.	O
The	O
convulsive	B-DISEASE
threshold	B-UNK
(	O
mean	O
+	O
/-	O
SD	B-UNK
)	O
was	O
41.4	O
+	O
/-	O
6.5	O
mg	B-UNK
.	O
l(-1	O
)	O
with	O
lidocaine	B-CHEMICAL
infusion	B-UNK
(	O
6	O
mg.kg(-1).min(-1	O
)	O
)	O
,	O
increasing	B-UNK
significantly	B-UNK
to	O
66.6	O
+	O
/-	O
10.9	O
mg	B-UNK
.	O
l(-1	O
)	O
when	O
the	O
end	B-UNK
-	O
tidal	O
concentration	B-UNK
of	O
sevoflurane	B-CHEMICAL
was	O
0.8	O
%	O
.	O
However	O
,	O
the	O
threshold	B-UNK
(	O
61.6	O
+	O
/-	O
8.7	O
mg	B-UNK
.	O
l(-1	O
)	O
)	O
during	O
1.6	O
%	O
sevoflurane	B-UNK
was	O
not	O
significant	B-UNK
from	O
that	O
during	O
0.8	O
%	O
sevoflurane	B-UNK
,	O
indicating	O
a	O
celling	O
effect	B-UNK
.	O
There	O
was	O
no	O
significant	B-UNK
difference	I-UNK
in	O
the	O
convulsive	B-UNK
threshold	B-UNK
between	O
sevoflurane	B-UNK
and	O
enflurane	B-UNK
.	O
The	O
rise	B-UNK
in	O
blood	B-UNK
pressure	I-UNK
became	O
less	O
marked	O
when	O
higher	B-UNK
concentrations	B-UNK
of	O
sevoflurane	B-UNK
or	O
enflurane	B-CHEMICAL
were	O
administered	O
and	O
the	O
blood	B-UNK
pressure	I-UNK
at	O
convulsions	B-DISEASE
decreased	B-UNK
significantly	B-UNK
in	O
1.6	O
%	O
sevoflurane	B-UNK
,	O
and	O
in	O
0.8	O
%	O
and	O
1.6	O
%	O
enflurane	B-CHEMICAL
.	O
However	O
,	O
there	O
was	O
no	O
significant	B-UNK
difference	I-UNK
in	O
the	O
lidocaine	B-CHEMICAL
concentrations	B-UNK
measured	B-UNK
when	O
the	O
systolic	B-UNK
blood	I-UNK
pressure	I-UNK
became	O
70	O
mmHg	B-UNK
.	O
Apamin	O
,	O
a	O
selective	B-UNK
blocker	B-UNK
of	O
calcium	B-UNK
-	O
dependent	B-UNK
potassium	B-CHEMICAL
channels	B-UNK
,	O
was	O
administered	O
intracerebroventricularly	O
in	O
rats	B-UNK
anesthetized	B-UNK
with	O
0.8	O
%	O
sevoflurane	B-CHEMICAL
to	O
investigate	B-UNK
the	O
mechanism	B-UNK
of	O
the	O
anticonvulsive	O
effects	O
.	O
Apamin	O
(	O
10	O
ng	B-UNK
)	O
had	O
a	O
tendency	O
to	O
decrease	B-UNK
the	O
convulsive	B-UNK
threshold	B-UNK
(	O
21.6	O
+	O
/-	O
2.2	O
to	O
19.9	O
+	O
/-	O
2.5	O
mg	B-UNK
.	O
l(-1	O
)	O
)	O
but	O
this	O
was	O
not	O
statistically	B-UNK
significant	I-UNK
.	O
It	O
is	O
suggested	B-UNK
that	O
sevoflurane	B-UNK
reduces	O
the	O
convulsive	B-DISEASE
effect	B-UNK
of	O
lidocaine	B-CHEMICAL
toxicity	B-UNK
but	O
carries	O
some	O
risk	B-UNK
due	O
to	O
circulatory	O
depression	B-DISEASE
.	O

Anti-oxidant	O
effects	O
of	O
atorvastatin	O
in	O
dexamethasone	B-CHEMICAL
-	O
induced	O
hypertension	B-UNK
in	O
the	O
rat	B-UNK
.	O
1	O
.	O
Dexamethasone	B-CHEMICAL
(	O
Dex)-induced	O
hypertension	B-UNK
is	O
characterized	B-UNK
by	O
endothelial	B-UNK
dysfunction	B-UNK
associated	O
with	O
nitric	B-UNK
oxide	I-UNK
(	O
NO	O
)	O
deficiency	B-UNK
and	O
increased	B-UNK
superoxide	B-CHEMICAL
(	O
O2-	O
)	O
production	B-UNK
.	O
Atorvastatin	O
(	O
Ato	B-CHEMICAL
)	O
possesses	O
pleiotropic	O
properties	B-UNK
that	O
have	O
been	O
reported	B-UNK
to	O
improve	B-UNK
endothelial	B-UNK
function	B-UNK
through	O
increased	B-UNK
availability	O
of	O
NO	O
and	O
reduced	B-UNK
O2-	O
production	B-UNK
in	O
various	O
forms	O
of	O
hypertension	B-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
we	O
investigated	B-UNK
whether	O
50	O
mg	B-UNK
/	O
kg	B-UNK
per	O
day	O
,	O
p.o	B-UNK
.	O
,	O
Ato	B-CHEMICAL
could	O
prevent	B-UNK
endothelial	B-UNK
NO	O
synthase	B-UNK
(	O
eNOS	B-UNK
)	O
downregulation	O
and	O
the	O
increase	B-UNK
in	O
O2-	O
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	B-UNK
)	O
rats	B-UNK
,	O
thereby	O
reducing	B-UNK
blood	B-UNK
pressure	I-UNK
.	O
2	O
.	O
Male	B-UNK
SD	B-UNK
rats	I-UNK
(	O
n	O
=	O
30	O
)	O
were	O
treated	O
with	O
Ato	B-CHEMICAL
(	O
50	O
mg	B-UNK
/	O
kg	B-UNK
per	O
day	O
in	O
drinking	B-UNK
water	B-UNK
)	O
or	O
tap	O
water	B-UNK
for	O
15	O
days	B-UNK
.	O
Dexamethasone	B-UNK
(	O
10	O
microg	B-UNK
/	O
kg	B-UNK
per	O
day	O
,	O
s.c	B-UNK
.	O
)	O
or	O
saline	B-UNK
was	O
started	O
after	O
4	O
days	B-UNK
in	O
Ato	B-CHEMICAL
-	O
treated	O
and	O
non-treated	O
rats	B-UNK
and	O
continued	O
for	O
11	O
-	O
13	O
days	B-UNK
.	O
Systolic	B-UNK
blood	I-UNK
pressure	I-UNK
(	O
SBP	B-UNK
)	O
was	O
measured	B-UNK
on	O
alternate	O
days	B-UNK
using	O
the	O
tail	B-UNK
-	O
cuff	O
method	B-UNK
.	O
Endothelial	B-UNK
function	B-UNK
was	O
assessed	B-UNK
by	O
acetylcholine	B-UNK
-	O
induced	O
vasorelaxation	O
and	O
phenylephrine	B-UNK
-	O
induced	O
vasoconstriction	B-UNK
in	O
aortic	B-UNK
segments	B-UNK
.	O
Vascular	B-UNK
eNOS	B-UNK
mRNA	B-UNK
was	O
assessed	B-UNK
by	O
semi-quantitative	O
reverse	B-UNK
transcription	O
-	O
polymerase	B-UNK
chain	B-UNK
reaction	B-UNK
.	O
3	O
.	O
In	O
rats	B-UNK
treated	O
with	O
Dex	B-UNK
alone	O
,	O
SBP	B-UNK
was	O
increased	B-UNK
from	O
109	O
+	O
/-	O
2	O
to	O
133	O
+	O
/-	O
2	O
mmHg	B-UNK
on	O
Days	B-UNK
4	O
and	O
Day	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
.	O
In	O
the	O
Ato	B-CHEMICAL
+	O
Dex	B-UNK
group	B-UNK
,	O
SBP	B-UNK
was	O
increased	B-UNK
from	O
113	O
+	O
/-	O
2	O
to	O
119	O
+	O
/-	O
2	O
mmHg	B-UNK
on	O
Days	B-UNK
4	O
to	O
14	O
,	O
respectively	O
(	O
P	O
<	O
0.001	O
)	O
,	O
but	O
was	O
significantly	B-UNK
lower	I-UNK
than	O
SBP	B-UNK
in	O
the	O
group	B-UNK
treated	O
with	O
Dex	B-CHEMICAL
alone	O
(	O
P	O
<	O
0.05	O
)	O
.	O
Endothelial	B-UNK
-	O
dependent	B-UNK
relaxation	O
and	O
eNOS	B-UNK
mRNA	B-UNK
expression	B-UNK
were	O
greater	B-UNK
in	O
the	O
Dex	B-CHEMICAL
+	O
Ato	B-CHEMICAL
group	B-UNK
than	O
in	O
the	O
Dex	B-UNK
only	O
group	B-UNK
(	O
P	O
<	O
0.05	O
and	O
P	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O
Aortic	B-UNK
superoxide	B-UNK
production	B-UNK
was	O
lower	B-UNK
in	O
the	O
Dex	B-CHEMICAL
+	O
Ato	B-CHEMICAL
group	B-UNK
compared	O
with	O
the	O
group	B-UNK
treated	O
with	O
Dex	B-CHEMICAL
alone	O
(	O
P	O
<	O
0.0001	O
)	O
.	O
4	O
.	O
Treatment	B-UNK
with	O
Ato	B-CHEMICAL
improved	O
endothelial	B-UNK
function	B-UNK
,	O
reduced	B-UNK
superoxide	B-UNK
production	B-UNK
and	O
reduced	B-UNK
SBP	B-UNK
in	O
Dex	B-CHEMICAL
-	O
treated	O
SD	B-UNK
rats	I-UNK
.	O

99mTc	B-CHEMICAL
-	I-CHEMICAL
glucarate	I-CHEMICAL
for	O
detection	B-UNK
of	O
isoproterenol	B-CHEMICAL
-	O
induced	B-UNK
myocardial	I-UNK
infarction	I-UNK
in	I-UNK
rats	I-UNK
.	O
Infarct	O
-	O
avid	O
radiopharmaceuticals	O
are	O
necessary	O
for	O
rapid	B-UNK
and	O
timely	O
diagnosis	B-UNK
of	O
acute	B-UNK
myocardial	I-UNK
infarction	I-UNK
.	O
The	O
animal	B-UNK
model	I-UNK
used	O
to	O
produce	B-UNK
infarction	B-UNK
implies	O
artery	B-UNK
ligation	O
but	O
chemical	B-UNK
induction	B-UNK
can	O
be	O
easily	O
obtained	B-UNK
with	O
isoproterenol	B-UNK
.	O
A	O
new	O
infarct	O
-	O
avid	O
radiopharmaceutical	O
based	B-UNK
on	O
glucaric	O
acid	B-UNK
was	O
prepared	O
in	O
the	O
hospital	B-UNK
radiopharmacy	O
of	O
the	O
INCMNSZ	O
.	O
99mTc	B-CHEMICAL
-	I-CHEMICAL
glucarate	I-CHEMICAL
was	O
easy	O
to	O
prepare	O
,	O
stable	B-UNK
for	O
96	O
h	O
and	O
was	O
used	O
to	O
study	B-UNK
its	O
biodistribution	O
in	O
rats	B-UNK
with	O
isoproterenol	B-UNK
-	O
induced	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O
Histological	B-UNK
studies	B-UNK
demonstrated	O
that	O
the	O
rats	B-UNK
developed	O
an	O
infarct	O
18	O
h	O
after	O
isoproterenol	B-CHEMICAL
administration	O
.	O
The	O
rat	B-UNK
biodistribution	O
studies	B-UNK
showed	O
a	O
rapid	B-UNK
blood	B-UNK
clearance	B-UNK
via	O
the	O
kidneys	B-UNK
.	O
Thirty	B-UNK
minutes	B-UNK
after	O
99mTc	B-CHEMICAL
-	I-CHEMICAL
glucarate	I-CHEMICAL
administration	O
the	O
standardised	O
heart	B-UNK
uptake	B-UNK
value	O
S(h)UV	O
was	O
4.7	O
in	O
infarcted	O
rat	B-UNK
heart	I-UNK
which	O
is	O
six	O
times	B-UNK
more	O
than	O
in	O
normal	O
rats	B-UNK
.	O
ROIs	O
drawn	O
over	O
the	O
gamma	B-UNK
camera	O
images	B-UNK
showed	O
a	O
ratio	B-UNK
of	O
4.4	O
.	O
The	O
high	B-UNK
image	O
quality	B-UNK
suggests	O
that	O
high	B-UNK
contrast	B-UNK
images	B-UNK
can	O
be	O
obtained	B-UNK
in	O
humans	B-UNK
and	O
the	O
96	O
h	O
stability	B-UNK
makes	O
it	O
an	O
ideal	O
agent	B-UNK
to	O
detect	B-UNK
,	O
in	O
patients	B-UNK
,	O
early	B-UNK
cardiac	B-DISEASE
infarction	I-DISEASE
.	O

A	O
randomized	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
dose	B-UNK
-	O
comparison	B-UNK
trial	B-UNK
of	O
haloperidol	B-UNK
for	O
psychosis	B-UNK
and	O
disruptive	B-DISEASE
behaviors	I-DISEASE
in	O
Alzheimer'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
.	O
OBJECTIVE	B-UNK
:	O
The	O
goal	O
of	O
this	O
study	B-UNK
was	O
to	O
compare	B-UNK
the	O
efficacy	B-UNK
and	O
side	O
effects	O
of	O
two	O
doses	B-UNK
of	O
haloperidol	B-CHEMICAL
and	O
placebo	B-UNK
in	O
the	O
treatment	B-UNK
of	O
psychosis	B-UNK
and	O
disruptive	B-DISEASE
behaviors	I-DISEASE
in	O
patients	B-UNK
with	O
Alzheimer'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
.	O
METHOD	B-UNK
:	O
In	O
a	O
6-week	O
random	O
-	O
assignment	O
,	O
double-blind	O
,	O
placebo	B-UNK
-	O
controlled	B-UNK
trial	I-UNK
(	O
phase	B-UNK
A	O
)	O
,	O
haloperidol	B-UNK
,	O
2	O
-	O
3	O
mg	B-UNK
/	O
day	O
(	O
standard	B-UNK
dose	B-UNK
)	O
,	O
and	O
haloperidol	B-CHEMICAL
,	O
0.50	O
-	O
0.75	O
mg	B-UNK
/	O
day	O
(	O
low	B-UNK
dose	I-UNK
)	O
,	O
were	O
compared	O
in	O
71	O
outpatients	O
with	O
Alzheimer'	B-UNK
s	I-UNK
disease	I-UNK
.	O
For	O
the	O
subsequent	B-UNK
6-week	O
double-blind	O
crossover	B-UNK
phase	B-UNK
(	O
phase	B-UNK
B	O
)	O
,	O
patients	B-UNK
taking	B-UNK
standard-	O
or	O
low	B-UNK
-	O
dose	B-UNK
haloperidol	B-CHEMICAL
were	O
switched	O
to	O
placebo	B-UNK
,	O
and	O
patients	B-UNK
taking	B-UNK
placebo	B-UNK
were	O
randomly	B-UNK
assigned	I-UNK
to	I-UNK
standard-	O
or	O
low	B-UNK
-	O
dose	B-UNK
haloperidol	B-UNK
.	O
RESULTS	B-UNK
:	O
For	O
the	O
60	O
patients	B-UNK
who	O
completed	O
phase	B-UNK
A	O
,	O
standard	B-UNK
-	O
dose	B-UNK
haloperidol	B-CHEMICAL
was	O
efficacious	B-UNK
and	O
superior	B-UNK
to	O
both	O
low	B-UNK
-	O
dose	B-UNK
haloperidol	B-CHEMICAL
and	O
placebo	B-UNK
for	O
scores	O
on	O
the	O
Brief	O
Psychiatric	B-UNK
Rating	B-UNK
Scale	I-UNK
psychosis	B-DISEASE
factor	B-UNK
and	O
on	O
psychomotor	B-DISEASE
agitation	I-DISEASE
.	O
Response	B-UNK
rates	B-UNK
according	O
to	O
three	O
sets	O
of	O
criteria	B-UNK
were	O
greater	B-UNK
with	O
the	O
standard	B-UNK
dose	B-UNK
(	O
55%-60	O
%	O
)	O
than	O
the	O
low	B-UNK
dose	I-UNK
(	O
25%-35	O
%	O
)	O
and	O
placebo	B-UNK
(	O
25%-30	O
%	O
)	O
.	O
The	O
advantage	O
of	O
standard	B-UNK
dose	B-UNK
over	O
low	B-UNK
dose	I-UNK
was	O
replicated	O
in	O
phase	B-UNK
B.	O
In	O
phase	B-UNK
A	O
,	O
extrapyramidal	B-DISEASE
signs	I-DISEASE
tended	O
to	O
be	O
greater	B-UNK
with	O
the	O
standard	B-UNK
dose	B-UNK
than	O
in	O
the	O
other	O
two	O
conditions	O
,	O
primarily	O
because	O
of	O
a	O
subgroup	B-UNK
(	O
20	O
%	O
)	O
who	O
developed	O
moderate	B-UNK
to	I-UNK
severe	I-UNK
signs	B-UNK
.	O
Low	B-UNK
-	O
dose	B-UNK
haloperidol	B-UNK
did	O
not	O
differ	B-UNK
from	O
placebo	B-UNK
on	O
any	O
measure	B-UNK
of	O
efficacy	B-UNK
or	O
side	O
effects	O
.	O
CONCLUSIONS	B-UNK
:	O
The	O
results	B-UNK
indicated	O
a	O
favorable	O
therapeutic	B-UNK
profile	B-UNK
for	O
haloperidol	B-CHEMICAL
in	O
doses	B-UNK
of	O
2	O
-	O
3	O
mg	B-UNK
/	O
day	O
,	O
although	O
a	O
subgroup	B-UNK
developed	O
moderate	B-UNK
to	I-UNK
severe	I-UNK
extrapyramidal	B-DISEASE
signs	I-DISEASE
.	O
A	O
starting	B-UNK
dose	B-UNK
of	O
1	O
mg	B-UNK
/	O
day	O
with	O
gradual	B-UNK
,	O
upward	O
dose	B-UNK
titration	O
is	O
recommended	O
.	O
The	O
narrow	O
therapeutic	B-UNK
window	O
observed	O
with	O
haloperidol	B-CHEMICAL
may	O
also	O
apply	O
to	O
other	O
neuroleptics	B-CHEMICAL
used	O
in	O
Alzheimer'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
patients	B-UNK
with	O
psychosis	B-UNK
and	O
disruptive	B-DISEASE
behaviors	I-DISEASE
.	O

Individual	B-UNK
differences	B-UNK
in	O
renal	B-UNK
ACE	B-UNK
activity	B-UNK
in	O
healthy	B-UNK
rats	B-UNK
predict	B-UNK
susceptibility	B-UNK
to	O
adriamycin	B-CHEMICAL
-	O
induced	O
renal	B-DISEASE
damage	I-DISEASE
.	O
BACKGROUND	B-UNK
:	O
In	O
man	B-UNK
,	O
differences	B-UNK
in	O
angiotensin	O
-	O
converting	B-UNK
enzyme	I-UNK
(	O
ACE	B-UNK
)	O
levels	O
,	O
related	O
to	O
ACE	B-UNK
(	O
I	O
/	O
D	O
)	O
genotype	O
,	O
are	O
associated	O
with	O
renal	B-UNK
prognosis	O
.	O
This	O
raises	O
the	O
hypothesis	B-UNK
that	O
individual	B-UNK
differences	B-UNK
in	O
renal	B-UNK
ACE	B-UNK
activity	B-UNK
are	O
involved	B-UNK
in	O
renal	B-UNK
susceptibility	B-UNK
to	O
inflicted	O
damage	B-UNK
.	O
Therefore	O
,	O
we	O
studied	O
the	O
predictive	B-UNK
effect	B-UNK
of	O
renal	B-UNK
ACE	B-UNK
activity	B-UNK
for	O
the	O
severity	B-UNK
of	O
renal	B-UNK
damage	I-UNK
induced	O
by	O
a	O
single	B-UNK
injection	I-UNK
of	O
adriamycin	B-CHEMICAL
in	O
rats	B-UNK
.	O
METHODS	B-UNK
:	O
Renal	B-UNK
ACE	B-UNK
activity	B-UNK
(	O
Hip	O
-	O
His	O
-	O
Leu	O
cleavage	O
by	O
cortical	B-UNK
homogenates	O
)	O
was	O
determined	B-UNK
by	O
renal	B-UNK
biopsy	B-UNK
in	O
27	O
adult	B-UNK
male	B-UNK
Wistar	I-UNK
rats	I-UNK
.	O
After	O
1	O
week	B-UNK
of	O
recovery	B-UNK
,	O
proteinuria	B-UNK
was	O
induced	O
by	O
adriamycin	B-CHEMICAL
[	O
1.5	O
mg	B-UNK
/	O
kg	B-UNK
intravenously	O
(	O
i.v	B-UNK
.	O
)	O
n	O
=	O
18	O
;	O
controls	B-UNK
,	O
saline	B-UNK
i.v	B-UNK
.	O
n	O
=	O
9].	O
Proteinuria	B-DISEASE
was	O
measured	B-UNK
every	O
2	O
weeks	B-UNK
.	O
After	O
12	O
weeks	B-UNK
,	O
rats	B-UNK
were	O
sacrificed	O
and	O
their	O
kidneys	B-UNK
harvested	O
.	O
RESULTS	B-UNK
:	O
As	O
anticipated	O
,	O
adriamycin	B-UNK
elicited	B-UNK
nephrotic	B-DISEASE
range	B-UNK
proteinuria	B-DISEASE
,	O
renal	B-UNK
interstitial	B-UNK
damage	B-UNK
and	O
mild	B-UNK
focal	B-UNK
glomerulosclerosis	B-UNK
.	O
Baseline	B-UNK
renal	B-UNK
ACE	B-UNK
positively	O
correlated	B-UNK
with	O
the	O
relative	B-UNK
rise	B-UNK
in	O
proteinuria	B-UNK
after	O
adriamycin	B-UNK
(	O
r	O
=	O
0.62	O
,	O
P<0.01	O
)	O
,	O
renal	B-UNK
interstitial	B-UNK
alpha	B-UNK
-	O
smooth	B-UNK
muscle	I-UNK
actin	O
(	O
r	O
=	O
0.49	O
,	O
P<0.05	O
)	O
,	O
interstitial	B-UNK
macrophage	O
influx	O
(	O
r	O
=	O
0.56	O
,	O
P<0.05	O
)	O
,	O
interstitial	B-UNK
collagen	O
III	B-UNK
(	O
r	O
=	O
0.53	O
,	O
P<0.05	O
)	O
,	O
glomerular	B-UNK
alpha	B-UNK
-	O
smooth	B-UNK
muscle	I-UNK
actin	O
(	O
r	O
=	O
0.74	O
,	O
P<0.01	O
)	O
and	O
glomerular	B-UNK
desmin	O
(	O
r	O
=	O
0.48	O
,	O
P<0.05	O
)	O
.	O
Baseline	B-UNK
renal	B-UNK
ACE	B-UNK
did	O
not	O
correlate	B-UNK
with	O
focal	B-UNK
glomerulosclerosis	B-UNK
(	O
r	O
=	O
0.22	O
,	O
NS	B-UNK
)	O
.	O
In	O
controls	B-UNK
,	O
no	O
predictive	B-UNK
values	O
for	O
renal	B-UNK
parameters	O
were	O
observed	O
.	O
CONCLUSION	B-UNK
:	O
Individual	B-UNK
differences	B-UNK
in	O
renal	B-UNK
ACE	B-UNK
activity	B-UNK
predict	B-UNK
the	O
severity	B-UNK
of	O
adriamycin	B-CHEMICAL
-	O
induced	O
renal	B-UNK
damage	I-UNK
in	O
this	O
outbred	O
rat	B-UNK
strain	B-UNK
.	O
This	O
supports	O
the	O
assumption	O
that	O
differences	B-UNK
in	O
renal	B-UNK
ACE	B-UNK
activity	B-UNK
predispose	O
to	O
a	O
less	O
favourable	O
course	O
of	O
renal	B-DISEASE
damage	I-DISEASE
.	O

Clinical	B-UNK
nephrotoxicity	B-UNK
of	O
tobramycin	B-UNK
and	O
gentamicin	B-CHEMICAL
.	O
A	O
prospective	B-UNK
study	I-UNK
.	O
Nearly	O
3.2	O
million	O
people	O
in	O
this	O
country	O
receive	B-UNK
aminoglycoside	B-UNK
antibiotics	B-UNK
annually	O
.	O
Gentamicin	B-CHEMICAL
sulfate	B-UNK
and	O
tobramycin	B-UNK
sulfate	B-UNK
continue	B-UNK
to	O
demonstrate	O
ototoxicity	B-UNK
and	O
nephrotoxicity	B-UNK
in	O
both	O
animal	B-UNK
and	O
clinical	B-UNK
studies	B-UNK
.	O
In	O
this	O
study	B-UNK
,	O
62	O
patients	B-UNK
with	O
confirmed	B-UNK
initial	B-UNK
normal	O
renal	B-UNK
function	I-UNK
and	O
treated	O
with	O
2	O
to	O
5	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
of	O
gentamicin	B-CHEMICAL
sulfate	B-UNK
or	O
tobramycin	B-UNK
sulfate	B-UNK
for	O
a	O
minimum	B-UNK
of	O
seven	O
days	B-UNK
were	O
followed	O
up	O
prospectively	O
for	O
the	O
development	B-UNK
of	O
aminoglycoside	B-UNK
-	O
related	O
renal	B-UNK
failure	I-UNK
,	O
defined	B-UNK
as	O
at	O
least	O
a	O
one	O
-	O
third	O
reduction	O
in	O
renal	B-UNK
function	I-UNK
.	O
In	O
these	O
62	O
patients	B-UNK
,	O
no	O
other	O
causes	O
for	O
renal	B-UNK
failure	I-UNK
could	O
be	O
identified	B-UNK
.	O
Five	O
of	O
33	O
(	O
15	O
%	O
)	O
of	O
the	O
tobramycin	B-UNK
-	O
treated	O
patients	B-UNK
and	O
16	O
of	O
29	O
(	O
55.2	O
%	O
)	O
of	O
the	O
gentamicin	B-CHEMICAL
-	O
treated	O
patients	B-UNK
had	O
renal	B-UNK
failure	I-UNK
.	O
Thus	O
,	O
gentamicin	B-UNK
was	O
associated	O
with	O
renal	B-UNK
failure	I-UNK
more	O
than	O
three	O
times	B-UNK
as	O
often	O
as	O
was	O
tobramycin	B-CHEMICAL
.	O

Neuroprotective	O
action	B-UNK
of	O
MPEP	O
,	O
a	O
selective	B-UNK
mGluR5	O
antagonist	B-UNK
,	O
in	O
methamphetamine	B-UNK
-	O
induced	O
dopaminergic	B-UNK
neurotoxicity	B-UNK
is	O
associated	O
with	O
a	O
decrease	B-UNK
in	O
dopamine	B-UNK
outflow	O
and	O
inhibition	B-UNK
of	O
hyperthermia	B-UNK
in	O
rats	B-UNK
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
examine	B-UNK
the	O
role	O
of	O
metabotropic	O
glutamate	B-CHEMICAL
receptor	B-UNK
5	O
(	O
mGluR5	O
)	O
in	O
the	O
toxic	B-UNK
action	B-UNK
of	O
methamphetamine	B-UNK
on	O
dopaminergic	B-UNK
neurones	O
in	O
rats	B-UNK
.	O
Methamphetamine	B-CHEMICAL
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
sc	B-UNK
)	O
,	O
administered	O
five	O
times	B-UNK
,	O
reduced	B-UNK
the	O
levels	O
of	O
dopamine	B-CHEMICAL
and	O
its	O
metabolites	B-UNK
in	O
striatal	B-UNK
tissue	B-UNK
when	O
measured	B-UNK
72	O
h	O
after	O
the	O
last	O
injection	B-UNK
.	O
A	O
selective	B-UNK
antagonist	B-UNK
of	O
mGluR5	O
,	O
2-methyl-6-(phenylethynyl)pyridine	B-CHEMICAL
(	O
MPEP	O
;	O
5	O
mg	B-UNK
/	O
kg	B-UNK
ip	B-UNK
)	O
,	O
when	O
administered	O
five	O
times	B-UNK
immediately	B-UNK
before	O
each	O
methamphetamine	B-UNK
injection	B-UNK
reversed	B-UNK
the	O
above	O
-	O
mentioned	O
methamphetamine	B-CHEMICAL
effects	O
.	O
A	O
single	B-UNK
MPEP	O
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
ip	B-UNK
)	O
injection	B-UNK
reduced	B-UNK
the	O
basal	B-UNK
extracellular	B-UNK
dopamine	B-UNK
level	B-UNK
in	O
the	O
striatum	B-UNK
,	O
as	O
well	O
as	O
dopamine	B-UNK
release	B-UNK
stimulated	B-UNK
either	O
by	O
methamphetamine	B-CHEMICAL
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
sc	B-UNK
)	O
or	O
by	O
intrastriatally	O
administered	O
veratridine	O
(	O
100	O
microM	B-UNK
)	O
.	O
Moreover	O
,	O
it	O
transiently	O
diminished	B-UNK
the	O
methamphetamine	B-UNK
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
sc)-induced	O
hyperthermia	B-UNK
and	O
reduced	B-UNK
basal	B-UNK
body	B-UNK
temperature	B-UNK
.	O
MPEP	O
administered	O
into	O
the	O
striatum	B-UNK
at	O
high	B-UNK
concentrations	B-UNK
(	O
500	O
microM	B-UNK
)	O
increased	B-UNK
extracellular	B-UNK
dopamine	B-UNK
levels	O
,	O
while	O
lower	B-UNK
concentrations	B-UNK
(	O
50	O
-	O
100	O
microM	B-UNK
)	O
were	O
devoid	O
of	O
any	O
effect	B-UNK
.	O
The	O
results	B-UNK
of	O
this	O
study	B-UNK
suggest	B-UNK
that	O
the	O
blockade	B-UNK
of	O
mGluR5	O
by	O
MPEP	O
may	O
protect	B-UNK
dopaminergic	B-UNK
neurones	O
against	O
methamphetamine	B-CHEMICAL
-	O
induced	O
toxicity	B-UNK
.	O
Neuroprotection	O
rendered	O
by	O
MPEP	O
may	O
be	O
associated	O
with	O
the	O
reduction	O
of	O
the	O
methamphetamine	B-UNK
-	O
induced	O
dopamine	B-CHEMICAL
efflux	O
in	O
the	O
striatum	B-UNK
due	O
to	O
the	O
blockade	B-UNK
of	O
extrastriatal	O
mGluR5	O
,	O
and	O
with	O
a	O
decrease	B-UNK
in	O
hyperthermia	B-UNK
.	O

Pharmacokinetics	B-UNK
of	O
desipramine	B-CHEMICAL
HCl	B-UNK
when	O
administered	O
with	O
cinacalcet	B-CHEMICAL
HCl	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
In	O
vitro	B-UNK
work	O
has	O
demonstrated	O
that	O
cinacalcet	B-UNK
is	O
a	O
strong	B-UNK
inhibitor	B-UNK
of	O
cytochrome	B-UNK
P450	B-UNK
isoenzyme	O
(	O
CYP	B-UNK
)	O
2D6	O
.	O
The	O
purpose	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
evaluate	B-UNK
the	O
effect	B-UNK
of	O
cinacalcet	B-CHEMICAL
on	O
CYP2D6	O
activity	B-UNK
,	O
using	O
desipramine	B-UNK
as	O
a	O
probe	O
substrate	B-UNK
,	O
in	O
healthy	B-UNK
subjects	I-UNK
.	O
METHODS	B-UNK
:	O
Seventeen	O
subjects	B-UNK
who	O
were	O
genotyped	O
as	O
CYP2D6	O
extensive	B-UNK
metabolizers	O
were	O
enrolled	O
in	O
this	O
randomized	B-UNK
,	O
open	B-UNK
-	O
label	B-UNK
,	O
crossover	B-UNK
study	I-UNK
to	O
receive	B-UNK
a	O
single	B-UNK
oral	B-UNK
dose	B-UNK
of	O
desipramine	B-UNK
(	O
50	O
mg	B-UNK
)	O
on	O
two	O
separate	B-UNK
occasions	B-UNK
,	O
once	O
alone	O
and	O
once	O
after	O
multiple	B-UNK
doses	B-UNK
of	O
cinacalcet	B-UNK
(	O
90	O
mg	B-UNK
for	O
7	O
days	B-UNK
)	O
.	O
Blood	B-UNK
samples	O
were	O
obtained	B-UNK
predose	O
and	O
up	O
to	O
72	O
h	O
postdose	O
.	O
RESULTS	B-UNK
:	O
Fourteen	B-UNK
subjects	B-UNK
completed	O
both	O
treatment	B-UNK
arms	O
.	O
Relative	B-UNK
to	O
desipramine	B-CHEMICAL
alone	O
,	O
mean	O
AUC	B-UNK
and	O
C(max	O
)	O
of	O
desipramine	B-CHEMICAL
increased	B-UNK
3.6-	O
and	O
1.8-fold	O
when	O
coadministered	O
with	O
cinacalcet	B-CHEMICAL
.	O
The	O
t	O
(	O
1/2,z	O
)	O
of	O
desipramine	B-UNK
was	O
longer	O
when	O
desipramine	B-UNK
was	O
coadministered	O
with	O
cinacalcet	B-CHEMICAL
(	O
21.0	O
versus	O
43.3	O
hs	O
)	O
.	O
The	O
t	O
(	O
max	O
)	O
was	O
similar	B-UNK
between	O
the	O
regimens	B-UNK
.	O
Fewer	B-UNK
subjects	B-UNK
reported	B-UNK
adverse	B-UNK
events	I-UNK
following	O
treatment	B-UNK
with	O
desipramine	B-UNK
alone	O
than	O
when	O
receiving	B-UNK
desipramine	B-UNK
with	O
cinacalcet	B-UNK
(	O
33	O
versus	O
86	O
%	O
)	O
,	O
the	O
most	O
frequent	B-UNK
of	O
which	O
(	O
nausea	B-UNK
and	O
headache	B-UNK
)	O
have	O
been	O
reported	B-UNK
for	O
patients	B-UNK
treated	O
with	O
either	O
desipramine	B-UNK
or	O
cinacalcet	B-UNK
.	O
CONCLUSION	B-UNK
:	O
This	O
study	B-UNK
demonstrates	O
that	O
cinacalcet	B-UNK
is	O
a	O
strong	B-UNK
inhibitor	B-UNK
of	O
CYP2D6	O
.	O
These	O
data	B-UNK
suggest	I-UNK
that	O
during	O
concomitant	B-UNK
treatment	B-UNK
with	O
cinacalcet	B-UNK
,	O
dose	B-UNK
adjustment	B-UNK
may	O
be	O
necessary	O
for	O
drugs	B-UNK
that	O
demonstrate	O
a	O
narrow	O
therapeutic	B-UNK
index	B-UNK
and	O
are	O
metabolized	O
by	O
CYP2D6	O
.	O

Proteomic	O
analysis	B-UNK
of	O
striatal	B-UNK
proteins	B-UNK
in	O
the	O
rat	B-UNK
model	B-UNK
of	O
L	O
-	O
DOPA	B-UNK
-	O
induced	O
dyskinesia	B-UNK
.	O
L	O
-	O
DOPA	B-UNK
-	O
induced	O
dyskinesia	B-UNK
(	O
LID	B-UNK
)	O
is	O
among	O
the	O
motor	B-UNK
complications	B-UNK
that	O
arise	O
in	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
(	O
PD	B-UNK
)	O
patients	B-UNK
after	O
a	O
prolonged	B-UNK
treatment	B-UNK
with	O
L	O
-	O
DOPA	B-UNK
.	O
To	O
this	O
day	O
,	O
transcriptome	O
analysis	B-UNK
has	O
been	O
performed	B-UNK
in	O
a	O
rat	B-UNK
model	B-UNK
of	O
LID	B-UNK
[	O
Neurobiol	O
.	O
Dis	O
.	O
,	O
17	O
(	O
2004	O
)	O
,	O
219	O
]	O
but	O
information	B-UNK
regarding	O
the	O
proteome	O
is	O
still	O
lacking	B-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
we	O
investigated	B-UNK
the	O
changes	O
occurring	O
at	O
the	O
protein	B-UNK
level	B-UNK
in	O
striatal	B-UNK
samples	O
obtained	B-UNK
from	O
the	O
unilaterally	O
6-hydroxydopamine	B-CHEMICAL
-	O
lesion	B-UNK
rat	B-UNK
model	B-UNK
of	O
PD	B-UNK
treated	O
with	O
saline	B-UNK
,	O
L	O
-	O
DOPA	B-UNK
or	O
bromocriptine	B-UNK
using	O
two	O
-	O
dimensional	O
difference	B-UNK
gel	O
electrophoresis	O
and	O
mass	B-UNK
spectrometry	O
(	O
MS	B-DISEASE
)	O
.	O
Rats	B-UNK
treated	O
with	O
L	O
-	O
DOPA	B-UNK
were	O
allocated	O
to	O
two	O
groups	B-UNK
based	B-UNK
on	O
the	O
presence	O
or	O
absence	O
of	O
LID	B-UNK
.	O
Among	O
the	O
2000	O
spots	O
compared	O
for	O
statistical	B-UNK
difference	B-UNK
,	O
67	O
spots	O
were	O
significantly	B-UNK
changed	O
in	O
abundance	B-UNK
and	O
identified	B-UNK
using	O
matrix	B-UNK
-	O
assisted	O
laser	B-UNK
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
MS	B-DISEASE
,	O
atmospheric	O
pressure	B-UNK
matrix	B-UNK
-	O
assisted	O
laser	B-UNK
desorption	O
/	O
ionization	O
and	O
HPLC	O
coupled	O
tandem	O
MS	B-UNK
(	O
LC	O
/	O
MS	B-UNK
/	O
MS	B-UNK
)	O
.	O
Out	O
of	O
these	O
67	O
proteins	B-UNK
,	O
LID	B-UNK
significantly	B-UNK
changed	O
the	O
expression	B-UNK
level	B-UNK
of	O
five	O
proteins	B-UNK
:	O
alphabeta	O
-	O
crystalin	O
,	O
gamma	B-UNK
-	O
enolase	O
,	O
guanidoacetate	O
methyltransferase	O
,	O
vinculin	O
,	O
and	O
proteasome	O
alpha-2	O
subunit	O
.	O
Complementary	O
techniques	O
such	O
as	O
western	B-UNK
immunoblotting	O
and	O
immunohistochemistry	B-UNK
were	O
performed	B-UNK
to	O
investigate	B-UNK
the	O
validity	O
of	O
the	O
data	B-UNK
obtained	B-UNK
using	O
the	O
proteomic	O
approach	O
.	O
In	O
conclusion	B-UNK
,	O
this	O
study	B-UNK
provides	O
new	O
insights	O
into	O
the	O
protein	B-UNK
changes	O
occurring	O
in	O
LID	B-UNK
.	O

Pseudo-allergic	O
reactions	B-UNK
to	O
corticosteroids	B-UNK
:	O
diagnosis	B-UNK
and	O
alternatives	O
.	O
Two	O
patients	B-UNK
treated	O
with	O
parenteral	B-UNK
paramethasone	B-CHEMICAL
(	O
Triniol	O
)	O
and	O
dexamethasone	B-CHEMICAL
(	O
Sedionbel	O
)	O
are	O
described	O
.	O
A	O
few	O
minutes	B-UNK
after	O
administration	O
of	O
the	O
drugs	B-UNK
,	O
they	O
presented	B-UNK
urticaria	B-UNK
(	O
patients	B-UNK
1	O
and	O
2	O
)	O
and	O
conjunctivitis	B-DISEASE
(	O
patient	B-UNK
1	O
)	O
.	O
The	O
purpose	B-UNK
of	O
our	O
study	B-UNK
was	O
to	O
determine	B-UNK
the	O
cause	O
of	O
the	O
patients	B-UNK
'	O
reactions	B-UNK
,	O
the	O
immunological	O
mechanisms	B-UNK
involved	B-UNK
and	O
whether	O
these	O
patients	B-UNK
would	O
be	O
able	O
to	O
tolerate	O
any	O
kind	O
of	O
corticoid	O
.	O
Clinical	B-UNK
examinations	B-UNK
and	O
skin	B-UNK
,	O
oral	B-UNK
and	O
parenteral	B-UNK
challenges	O
with	O
different	O
corticosteroids	B-UNK
and	O
ELISA	O
tests	B-UNK
were	O
performed	B-UNK
.	O
In	O
the	O
two	O
patients	B-UNK
,	O
skin	B-UNK
and	O
ELISA	O
tests	B-UNK
with	O
paramethasone	B-CHEMICAL
were	O
negative	B-UNK
,	O
as	O
was	O
the	O
prick	O
test	B-UNK
with	O
each	O
of	O
its	O
excipients	B-CHEMICAL
.	O
A	O
single	B-UNK
-	O
blind	B-UNK
parenteral	B-UNK
challenge	B-UNK
with	O
Triniol	O
was	O
positive	B-UNK
in	O
both	O
patients	B-UNK
after	O
the	O
administration	O
of	O
1	O
ml	B-UNK
of	O
the	O
drug	B-UNK
,	O
and	O
negative	B-UNK
with	O
its	O
excipients	B-CHEMICAL
.	O
We	O
also	O
carried	O
out	O
oral	B-UNK
and	O
parenteral	B-UNK
challenges	O
with	O
other	O
corticosteroids	B-CHEMICAL
and	O
found	O
intolerance	O
to	O
some	O
of	O
them	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
paramethasone	B-CHEMICAL
caused	B-UNK
pseudoallergic	O
reactions	B-UNK
in	O
our	O
patients	B-UNK
.	O
Corticosteroids	B-UNK
different	O
from	O
paramethasone	B-CHEMICAL
also	O
produced	B-UNK
hypersensitivity	B-DISEASE
reactions	B-UNK
in	O
these	O
patients	B-UNK
;	O
however	O
,	O
a	O
few	O
of	O
them	O
were	O
tolerated	B-UNK
.	O
The	O
basic	B-UNK
mechanisms	B-UNK
of	O
those	O
reactions	B-UNK
are	O
not	O
yet	O
fully	B-UNK
understood	O
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	B-UNK
of	O
a	O
pseudo-allergy	O
caused	B-UNK
by	O
paramethasone	B-CHEMICAL
.	O

Valproic	B-UNK
acid	I-UNK
induced	O
encephalopathy--19	O
new	O
cases	B-UNK
in	O
Germany	O
from	O
1994	O
to	O
2003	O
-	O
-a	O
side	O
effect	B-UNK
associated	O
to	O
VPA	B-UNK
-	O
therapy	O
not	O
only	O
in	O
young	B-UNK
children	B-UNK
.	O
Valproic	B-UNK
acid	I-UNK
(	O
VPA	B-UNK
)	O
is	O
a	O
broad	O
-	O
spectrum	B-UNK
antiepileptic	B-UNK
drug	I-UNK
and	O
is	O
usually	O
well	O
-	O
tolerated	B-UNK
.	O
Rare	B-UNK
serious	O
complications	B-UNK
may	O
occur	O
in	O
some	O
patients	B-UNK
,	O
including	O
haemorrhagic	O
pancreatitis	B-DISEASE
,	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
,	O
VPA	B-UNK
-	O
induced	O
hepatotoxicity	B-UNK
and	O
VPA	B-UNK
-	O
induced	O
encephalopathy	B-UNK
.	O
The	O
typical	B-UNK
signs	B-UNK
of	O
VPA	B-UNK
-	O
induced	O
encephalopathy	B-UNK
are	O
impaired	B-UNK
consciousness	B-UNK
,	O
sometimes	O
marked	O
EEG	B-UNK
background	B-UNK
slowing	O
,	O
increased	B-UNK
seizure	B-UNK
frequency	B-UNK
,	O
with	O
or	O
without	O
hyperammonemia	B-DISEASE
.	O
There	O
is	O
still	O
no	O
proof	O
of	O
causative	O
effect	B-UNK
of	O
VPA	B-UNK
in	O
patients	B-UNK
with	O
encephalopathy	B-UNK
,	O
but	O
only	O
of	O
an	O
association	B-UNK
with	O
an	O
assumed	O
causal	O
relation	B-UNK
.	O
We	O
report	B-UNK
19	O
patients	B-UNK
with	O
VPA	B-UNK
-	O
associated	O
encephalopathy	B-DISEASE
in	O
Germany	O
from	O
the	O
years	B-UNK
1994	O
to	O
2003	O
,	O
none	O
of	O
whom	O
had	O
been	O
published	B-UNK
previously	B-UNK
.	O

Haemolytic	O
-	O
uraemic	O
syndrome	B-UNK
after	O
treatment	B-UNK
with	O
metronidazole	B-UNK
.	O
This	O
paper	B-UNK
describes	B-UNK
the	O
clinical	B-UNK
features	B-UNK
of	O
six	O
children	B-UNK
who	O
developed	O
the	O
haemolytic	O
-	O
uraemic	O
syndrome	B-DISEASE
after	O
treatment	B-UNK
with	O
metronidazole	B-UNK
.	O
These	O
children	B-UNK
were	O
older	B-UNK
and	O
were	O
more	O
likely	O
to	O
have	O
undergone	B-UNK
recent	B-UNK
bowel	B-UNK
surgery	B-UNK
than	O
are	O
other	O
children	B-UNK
with	O
this	O
condition	B-UNK
.	O
While	O
the	O
involvement	B-UNK
of	O
metronidazole	B-CHEMICAL
in	O
the	O
aetiology	O
of	O
the	O
haemolytic	O
-	O
uraemic	O
syndrome	B-DISEASE
is	O
not	O
established	B-UNK
firmly	O
,	O
the	O
action	B-UNK
of	O
this	O
drug	B-UNK
in	O
sensitizing	O
tissues	B-UNK
to	O
oxidation	O
injury	B-UNK
and	O
the	O
reported	B-UNK
evidence	B-UNK
of	O
oxidation	O
changes	O
in	O
the	O
haemolytic	O
-	O
uraemic	O
syndrome	B-UNK
suggest	B-UNK
a	O
possible	O
link	O
between	O
metronidazole	B-UNK
treatment	B-UNK
and	O
some	O
cases	B-UNK
of	O
the	O
haemolytic	O
-	O
uraemic	O
syndrome	B-UNK
.	O

Risk	B-UNK
factors	I-UNK
of	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
preterm	B-UNK
infants	B-UNK
.	O
Among	O
547	O
preterm	B-UNK
infants	B-UNK
of	O
<	O
or	O
=	O
34	O
weeks	B-UNK
gestation	B-UNK
born	B-UNK
between	O
1987	O
and	O
1991	O
,	O
8	O
children	B-UNK
(	O
1.46	O
%	O
)	O
developed	O
severe	B-UNK
progressive	B-UNK
and	O
bilateral	B-UNK
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O
Perinatal	O
risk	B-UNK
factors	I-UNK
of	O
infants	B-UNK
with	O
hearing	B-UNK
loss	I-UNK
were	O
compared	O
with	O
those	O
of	O
two	O
control	B-UNK
groups	I-UNK
matched	O
for	O
gestation	B-UNK
and	O
birth	B-DISEASE
weight	I-DISEASE
and	O
for	O
perinatal	O
complications	B-UNK
.	O
Our	O
observations	B-UNK
demonstrated	O
an	O
association	B-UNK
of	O
hearing	B-UNK
loss	I-UNK
with	O
a	O
higher	B-UNK
incidence	B-UNK
of	O
perinatal	O
complications	B-UNK
.	O
Ototoxicity	B-UNK
appeared	B-UNK
closely	O
related	O
to	O
a	O
prolonged	B-UNK
administration	O
and	O
higher	B-UNK
total	B-UNK
dose	B-UNK
of	O
ototoxic	O
drugs	B-UNK
,	O
particularly	O
aminoglycosides	O
and	O
furosemide	B-UNK
.	O
Finally	B-UNK
,	O
we	O
strongly	O
recommend	O
to	O
prospectively	O
and	O
regularly	O
perform	O
audiologic	O
assessment	B-UNK
in	O
sick	O
preterm	B-UNK
children	B-UNK
as	O
hearing	B-UNK
loss	I-UNK
is	O
of	O
delayed	B-UNK
onset	B-UNK
and	O
in	O
most	O
cases	B-UNK
bilateral	B-UNK
and	O
severe	B-UNK
.	O

Pharmacokinetic	B-UNK
and	O
clinical	B-UNK
studies	B-UNK
in	O
patients	B-UNK
with	O
cimetidine	B-CHEMICAL
-	O
associated	O
mental	B-UNK
confusion	B-UNK
.	O
15	O
cases	B-UNK
of	O
cimetidine	B-UNK
-	O
associated	O
mental	B-UNK
confusion	B-UNK
have	O
been	O
reported	B-UNK
.	O
In	O
order	B-UNK
that	O
this	O
syndrome	B-DISEASE
might	O
be	O
investigated	B-UNK
changes	O
in	O
mental	B-UNK
status	I-UNK
(	O
M.S.	O
)	O
were	O
correlated	B-UNK
with	O
serum	B-UNK
concentrations	I-UNK
and	O
renal	B-UNK
and	O
hepatic	B-UNK
function	B-UNK
in	O
36	O
patients	B-UNK
,	O
30	O
patients	B-UNK
had	O
no	O
M.S.	O
change	B-UNK
on	O
cimetidine	B-CHEMICAL
and	O
6	O
had	O
moderate	B-UNK
to	I-UNK
severe	I-UNK
changes	O
.	O
These	O
6	O
patients	B-UNK
had	O
both	O
renal	B-UNK
and	O
liver	B-UNK
dysfunction	B-UNK
(	O
P	O
less	O
than	O
0.05	O
)	O
,	O
as	O
well	O
as	O
cimetidine	B-UNK
trough	B-UNK
-	O
concentrations	B-UNK
of	O
more	O
than	O
1.25	O
microgram	B-UNK
/	O
ml	B-UNK
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
The	O
severity	B-UNK
of	O
M.S.	O
changes	O
increased	B-UNK
as	O
trough	B-UNK
-	O
concentrations	B-UNK
rose	B-UNK
,	O
5	O
patients	B-UNK
had	O
lumbar	O
puncture	O
.	O
The	O
cerebrospinal	B-UNK
fluid	I-UNK
:	O
serum	B-UNK
ratio	B-UNK
of	O
cimetidine	B-CHEMICAL
concentrations	B-UNK
was	O
0.24:1	O
and	O
indicates	O
that	O
cimetidine	B-CHEMICAL
passes	O
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
;	O
it	O
also	O
raises	O
the	O
possibility	O
that	O
M.S.	O
changes	O
are	O
due	O
to	O
blockade	B-UNK
of	O
histamine	B-UNK
H2-receptors	O
in	O
the	O
central	B-UNK
nervous	I-UNK
system	I-UNK
.	O
Patients	B-UNK
likely	O
to	O
have	O
both	O
raised	B-UNK
trough	B-UNK
-	O
concentrations	B-UNK
and	O
mental	B-UNK
confusion	B-UNK
are	O
those	O
with	O
both	O
severe	B-UNK
renal	B-UNK
and	O
hepatic	B-UNK
dysfunction	B-UNK
.	O
They	O
should	O
be	O
closely	O
observed	O
and	O
should	O
be	O
given	O
reduced	B-UNK
doses	B-UNK
of	O
cimetidine	B-CHEMICAL
.	O

Different	O
lobular	O
distributions	O
of	O
altered	B-UNK
hepatocyte	B-UNK
tight	O
junctions	O
in	O
rat	B-UNK
models	B-UNK
of	O
intrahepatic	O
and	O
extrahepatic	B-DISEASE
cholestasis	I-DISEASE
.	O
Hepatocyte	B-UNK
tight	O
junctions	O
(	O
TJs	O
)	O
,	O
the	O
only	O
intercellular	O
barrier	B-UNK
between	O
the	O
sinusoidal	O
and	O
the	O
canalicular	O
spaces	O
,	O
play	O
a	O
key	O
role	O
in	O
bile	B-UNK
formation	B-UNK
.	O
Although	O
hepatocyte	B-UNK
TJs	O
are	O
impaired	B-UNK
in	O
cholestasis	B-UNK
,	O
attempts	O
to	O
localize	O
the	O
precise	O
site	B-UNK
of	O
hepatocyte	B-UNK
TJ	O
damage	B-UNK
by	O
freeze	O
-	O
fracture	O
electron	B-UNK
microscopy	I-UNK
have	O
produced	B-UNK
limited	B-UNK
information	B-UNK
.	O
Recently	B-UNK
,	O
several	O
TJ	O
-	O
associated	O
proteins	B-UNK
like	O
ZO-1	O
and	O
7H6	O
have	O
been	O
identified	B-UNK
and	O
characterized	B-UNK
.	O
Immunolocalization	O
of	O
7H6	O
appears	B-UNK
to	O
closely	O
correlate	B-UNK
with	O
paracellular	O
permeability	B-UNK
.	O
We	O
used	O
rat	B-UNK
models	B-UNK
of	O
intrahepatic	O
cholestasis	B-DISEASE
by	O
ethinyl	B-UNK
estradiol	I-UNK
(	O
EE	B-UNK
)	O
treatment	B-UNK
and	O
extrahepatic	B-DISEASE
cholestasis	I-DISEASE
by	O
bile	B-UNK
duct	I-UNK
ligation	O
(	O
BDL	O
)	O
to	O
precisely	O
determine	B-UNK
the	O
site	B-UNK
of	O
TJ	O
damage	B-UNK
.	O
Alterations	B-UNK
in	O
hepatocyte	B-UNK
TJs	O
were	O
assessed	B-UNK
by	O
double-immunolabeling	O
for	O
7H6	O
and	O
ZO-1	O
using	O
a	O
confocal	O
laser	B-UNK
scanning	O
microscope	O
.	O
In	O
control	B-UNK
rats	B-UNK
,	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
colocalized	O
to	O
outline	O
bile	B-UNK
canaliculi	O
in	O
a	O
continuous	B-UNK
fashion	O
.	O
In	O
contrast	B-UNK
,	O
7H6	O
and	O
ZO-1	O
immunostaining	O
was	O
more	O
discontinuous	O
,	O
outlining	O
the	O
bile	B-UNK
canaliculi	O
after	O
BDL	O
.	O
Immunostaining	O
for	O
7H6	O
,	O
not	O
ZO-1	O
,	O
decreased	B-UNK
and	O
predominantly	B-UNK
appeared	B-UNK
as	O
discrete	O
signals	O
in	O
the	O
submembranous	O
cytoplasm	O
of	O
periportal	O
hepatocytes	B-UNK
after	O
BDL	O
.	O
After	O
EE	B-UNK
treatment	B-UNK
,	O
changes	O
in	O
immunostaining	O
for	O
7H6	O
and	O
ZO-1	O
were	O
similar	B-UNK
to	O
those	O
seen	O
in	O
periportal	O
hepatocytes	B-UNK
after	O
BDL	O
,	O
but	O
distributed	O
more	O
diffusely	O
throughout	O
the	O
lobule	O
.	O
This	O
study	B-UNK
is	O
the	O
first	O
to	O
demonstrate	O
that	O
impairment	B-UNK
of	O
hepatocyte	B-UNK
TJs	O
occurs	O
heterogenously	O
in	O
the	O
liver	B-UNK
lobule	O
after	O
BDL	O
and	O
suggests	O
that	O
BDL	O
and	O
EE	B-UNK
treatments	O
produce	B-UNK
different	O
lobular	O
distributions	O
of	O
increased	B-UNK
paracellular	O
permeability	B-UNK
.	O

Long	B-UNK
term	I-UNK
audiological	O
evaluation	B-UNK
of	O
beta-thalassemic	O
patients	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
identify	B-UNK
the	O
incidence	B-UNK
and	O
to	O
monitor	B-UNK
the	O
progression	B-UNK
of	O
hearing	B-UNK
loss	I-UNK
in	O
children	B-UNK
and	O
young	B-UNK
adults	B-UNK
with	O
beta-thalassemia	B-DISEASE
major	B-UNK
.	O
METHODS	B-UNK
:	O
One	O
hundred	O
and	O
four	O
(	O
104	O
)	O
patients	B-UNK
aged	B-UNK
6	O
-	O
35	O
years	B-UNK
(	O
mean	O
17,2	O
years	B-UNK
)	O
participated	O
in	O
the	O
study	B-UNK
.	O
All	O
patients	B-UNK
were	O
on	O
a	O
regular	B-UNK
transfusion	B-UNK
-	O
chelation	O
program	O
maintaining	O
a	O
mean	O
hemoglobin	B-UNK
level	B-UNK
of	O
9.5	O
gr	B-UNK
/	O
dl	B-UNK
.	O
Subjects	B-UNK
were	O
receiving	B-UNK
desferrioxamine	B-CHEMICAL
(	O
DFO	O
)	O
chelation	O
treatment	B-UNK
with	O
a	O
mean	O
daily	B-UNK
dose	I-UNK
of	O
50	O
-	O
60	O
mg	B-UNK
/	O
kg	B-UNK
,	O
5	O
-	O
6	O
days	B-UNK
a	O
week	B-UNK
during	O
the	O
first	O
six	O
years	B-UNK
of	O
the	O
study	B-UNK
,	O
which	O
was	O
then	O
reduced	B-UNK
to	O
40	O
-	O
50	O
mg	B-UNK
/	O
kg	B-UNK
for	O
the	O
following	O
eight	O
years	B-UNK
.	O
Patients	B-UNK
were	O
followed	O
for	O
8	O
-	O
14	O
years	B-UNK
.	O
RESULTS	B-UNK
:	O
Overall	O
,	O
21	O
out	O
of	O
104	O
patients	B-UNK
(	O
20.2	O
%	O
)	O
presented	B-UNK
with	O
high	B-UNK
frequency	I-UNK
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
SNHL	B-DISEASE
)	O
,	O
either	O
unilateral	B-UNK
or	O
bilateral	B-UNK
.	O
No	O
ototoxic	O
factor	B-UNK
,	O
other	O
than	O
DFO	O
,	O
was	O
present	B-UNK
in	O
any	O
of	O
the	O
patients	B-UNK
.	O
Patients	B-UNK
with	O
SNHL	B-DISEASE
presented	B-UNK
with	O
relatively	O
lower	B-UNK
serum	B-UNK
ferritin	O
levels	O
than	O
those	O
with	O
normal	O
hearing	B-UNK
,	O
however	O
,	O
no	O
statistically	B-UNK
significant	I-UNK
difference	B-UNK
was	O
observed	O
.	O
Subjects	B-UNK
with	O
SNHL	B-DISEASE
were	O
submitted	O
to	O
DFO	O
reduction	O
or	O
temporary	B-UNK
withdrawal	B-UNK
.	O
Following	O
intervention	B-UNK
,	O
7	O
out	O
of	O
21	O
affected	B-UNK
patients	B-UNK
recovered	O
,	O
10	O
remained	B-UNK
stable	B-UNK
and	O
4	O
demonstrated	O
aggravation	O
.	O
CONCLUSION	B-UNK
:	O
The	O
findings	B-UNK
are	O
indicative	O
of	O
DFO'	O
s	O
contributing	O
role	O
in	O
the	O
development	B-UNK
of	O
hearing	B-UNK
impairment	B-UNK
.	O
Regular	B-UNK
audiologic	O
evaluation	B-UNK
is	O
imperative	O
in	O
all	O
thalassemic	O
patients	B-UNK
so	O
that	O
early	B-UNK
changes	O
may	O
be	O
recognized	O
and	O
treatment	B-UNK
may	O
be	O
judiciously	O
adjusted	B-UNK
in	O
order	B-UNK
to	O
prevent	B-UNK
or	O
reverse	B-UNK
hearing	B-UNK
impairment	B-UNK
.	O

Design	B-UNK
and	O
analysis	B-UNK
of	O
the	O
HYPREN	O
-	O
trial	B-UNK
:	O
safety	B-UNK
of	O
enalapril	B-UNK
and	O
prazosin	B-CHEMICAL
in	O
the	O
initial	B-UNK
treatment	B-UNK
phase	B-UNK
of	O
patients	B-UNK
with	O
congestive	B-UNK
heart	I-UNK
failure	I-UNK
.	O
Since	O
the	O
introduction	B-UNK
of	O
angiotensin	B-UNK
converting	I-UNK
enzyme	I-UNK
(	O
ACE	B-UNK
)	O
inhibitors	B-UNK
into	O
the	O
adjunctive	O
treatment	B-UNK
of	O
patients	B-UNK
with	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
,	O
cases	B-UNK
of	O
severe	B-UNK
hypotension	B-UNK
,	O
especially	O
on	O
the	O
first	O
day	O
of	O
treatment	B-UNK
,	O
have	O
occasionally	O
been	O
reported	B-UNK
.	O
To	O
assess	B-UNK
the	O
safety	B-UNK
of	O
the	O
ACE	B-CHEMICAL
inhibitor	I-CHEMICAL
enalapril	B-UNK
a	O
multicenter	B-UNK
,	O
randomized	B-UNK
,	O
prazosin	B-UNK
-	O
controlled	B-UNK
trial	I-UNK
was	O
designed	B-UNK
that	O
compared	O
the	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
symptomatic	B-UNK
hypotension	B-DISEASE
on	O
the	O
first	O
day	O
of	O
treatment	B-UNK
.	O
Trial	B-UNK
medication	O
was	O
2.5	O
mg	B-UNK
enalapril	B-UNK
or	O
0.5	O
prazosin	B-UNK
.	O
Subjects	B-UNK
were	O
1210	O
inpatients	O
with	O
New	O
York	O
Heart	B-UNK
Association	B-UNK
(	O
NYHA	O
)	O
functional	B-UNK
class	B-UNK
II	B-UNK
and	O
III	B-UNK
.	O
Patients	B-UNK
who	O
received	O
enalapril	B-UNK
experienced	B-UNK
clinically	B-UNK
and	O
statistically	B-UNK
significantly	B-UNK
less	O
symptomatic	B-UNK
hypotension	B-UNK
(	O
5.2	O
%	O
)	O
than	O
the	O
patients	B-UNK
who	O
received	O
prazosin	B-UNK
(	O
12.9	O
%	O
)	O
.	O
All	O
patients	B-UNK
recovered	O
.	O
It	O
was	O
concluded	O
that	O
treatment	B-UNK
with	O
enalapril	B-CHEMICAL
was	O
well	O
tolerated	B-UNK
and	O
it	O
is	O
,	O
therefore	O
,	O
unreasonable	O
to	O
restrict	O
the	O
initiation	B-UNK
of	O
treatment	B-UNK
with	O
enalapril	B-UNK
to	O
inpatients	O
.	O

Antagonism	B-UNK
between	O
interleukin	O
3	O
and	O
erythropoietin	O
in	O
mice	B-UNK
with	O
azidothymidine	O
-	O
induced	O
anemia	B-UNK
and	O
in	O
bone	B-UNK
marrow	I-UNK
endothelial	B-UNK
cells	I-UNK
.	O
Azidothymidine	O
(	O
AZT)-induced	O
anemia	B-DISEASE
in	O
mice	B-UNK
can	O
be	O
reversed	B-UNK
by	O
the	O
administration	O
of	O
IGF	B-UNK
-	O
IL-3	O
(	O
fusion	O
protein	B-UNK
of	O
insulin	B-UNK
-	O
like	O
growth	B-UNK
factor	I-UNK
II	B-UNK
(	O
IGF	B-UNK
II	B-UNK
)	O
and	O
interleukin	O
3	O
)	O
.	O
Although	O
interleukin	O
3	O
(	O
IL-3	O
)	O
and	O
erythropoietin	O
(	O
EPO	B-UNK
)	O
are	O
known	O
to	O
act	B-UNK
synergistically	O
on	O
hematopoietic	O
cell	B-UNK
proliferation	I-UNK
in	O
vitro	B-UNK
,	O
injection	B-UNK
of	O
IGF	B-UNK
-	O
IL-3	O
and	O
EPO	B-UNK
in	O
AZT	B-CHEMICAL
-	O
treated	O
mice	B-UNK
resulted	B-UNK
in	O
a	O
reduction	O
of	O
red	B-UNK
cells	B-UNK
and	O
an	O
increase	B-UNK
of	O
plasma	B-UNK
EPO	B-UNK
levels	O
as	O
compared	O
to	O
animals	B-UNK
treated	O
with	O
IGF	B-UNK
-	O
IL-3	O
or	O
EPO	B-UNK
alone	O
.	O
We	O
tested	B-UNK
the	O
hypothesis	B-UNK
that	O
the	O
antagonistic	O
effect	B-UNK
of	O
IL-3	O
and	O
EPO	B-UNK
on	O
erythroid	O
cells	B-UNK
may	O
be	O
mediated	B-UNK
by	O
endothelial	B-UNK
cells	I-UNK
.	O
Bovine	O
liver	B-UNK
erythroid	O
cells	B-UNK
were	O
cultured	B-UNK
on	O
monolayers	O
of	O
human	B-UNK
bone	B-UNK
marrow	I-UNK
endothelial	B-UNK
cells	I-UNK
previously	B-UNK
treated	O
with	O
EPO	B-UNK
and	O
IGF	B-UNK
-	O
IL-3	O
.	O
There	O
was	O
a	O
significant	B-UNK
reduction	O
of	O
thymidine	B-CHEMICAL
incorporation	O
into	O
both	O
erythroid	O
and	O
endothelial	B-UNK
cells	I-UNK
in	O
cultures	B-UNK
pre	B-UNK
-	O
treated	O
with	O
IGF	B-UNK
-	O
IL-3	O
and	O
EPO	B-UNK
.	O
Endothelial	B-UNK
cell	B-UNK
culture	B-UNK
supernatants	O
separated	O
by	O
ultrafiltration	O
and	O
ultracentrifugation	O
from	O
cells	B-UNK
treated	O
with	O
EPO	B-UNK
and	O
IL-3	O
significantly	B-UNK
reduced	I-UNK
thymidine	B-CHEMICAL
incorporation	O
into	O
erythroid	O
cells	B-UNK
as	O
compared	O
to	O
identical	B-UNK
fractions	O
obtained	B-UNK
from	O
the	O
media	B-UNK
of	O
cells	B-UNK
cultured	B-UNK
with	O
EPO	B-UNK
alone	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
endothelial	B-UNK
cells	I-UNK
treated	O
simultaneously	B-UNK
with	O
EPO	B-UNK
and	O
IL-3	O
have	O
a	O
negative	B-UNK
effect	B-UNK
on	O
erythroid	O
cell	B-UNK
production	B-UNK
.	O

Interactive	O
effects	O
of	O
variations	O
in	O
[	O
Na]o	O
and	O
[	O
Ca]o	O
on	O
rat	B-UNK
atrial	B-UNK
spontaneous	B-UNK
frequency	B-UNK
.	O
The	O
effects	O
of	O
varying	O
the	O
extracellular	B-UNK
concentrations	B-UNK
of	O
Na	B-UNK
and	O
Ca	B-UNK
(	O
[	O
Na]o	O
and	O
[	O
Ca]o	O
)	O
on	O
both	O
,	O
the	O
spontaneous	B-UNK
beating	B-UNK
and	O
the	O
negative	B-UNK
chronotropic	O
action	B-UNK
of	O
verapamil	B-UNK
,	O
were	O
studied	O
in	O
the	O
isolated	B-UNK
rat	B-UNK
atria	O
.	O
Basal	B-UNK
frequency	B-UNK
(	O
BF	O
)	O
evaluated	B-UNK
by	O
surface	B-UNK
electrogram	O
was	O
223	O
+	O
/-	O
4	O
beats	B-UNK
/	O
min	B-UNK
.	O
in	O
control	B-UNK
Krebs	O
-	O
Ringer	O
containing	O
137	O
mM	B-UNK
Na	B-UNK
and	O
1.35	O
mM	B-UNK
Ca	B-CHEMICAL
(	O
N	O
)	O
.	O
It	O
decreased	B-UNK
by	O
16	O
+	O
/-	O
3	O
%	O
by	O
lowering	B-UNK
[	O
Na]o	O
to	O
78	O
mM	B-UNK
(	O
LNa	B-UNK
)	O
,	O
23	O
+	O
/-	O
2	O
%	O
by	O
lowering	B-UNK
simultaneously	B-UNK
[	O
Na]o	O
to	O
78	O
mM	B-UNK
and	O
[	O
Ca]o	O
to	O
0.675	O
mM	B-UNK
(	O
LNa+LCa	O
)	O
and	O
31	O
+	O
/-	O
5	O
%	O
by	O
lowering	B-UNK
[	O
Na]o	O
to	O
78	O
mM	B-UNK
plus	O
increasing	B-UNK
[	O
Ca]o	O
to	O
3.6	O
mM	B-UNK
(	O
LNa+HCa	O
)	O
.	O
At	O
normal	O
[	O
Na]o	O
,	O
decrease	B-UNK
(	O
0.675	O
mM	B-UNK
)	O
or	O
increase	B-UNK
(	O
3.6	O
mM	B-UNK
)	O
of	O
[	O
Ca]o	O
did	O
not	O
modify	O
BF	O
;	O
a	O
reduction	O
of	O
ten	O
times	B-UNK
(	O
0.135	O
mM	B-UNK
of	O
normal	O
[	O
Ca]o	O
was	O
effective	B-UNK
to	O
reduce	B-UNK
BF	O
by	O
40	O
+	O
/-	O
13	O
%	O
.	O
All	O
negative	B-UNK
chronotropic	O
effects	O
were	O
BF	O
-	O
dependent	B-UNK
.	O
Dose	B-UNK
-	O
dependent	B-UNK
bradycardia	B-UNK
induced	O
by	O
verapamil	B-UNK
was	O
potentiated	B-UNK
by	O
LNa	B-UNK
,	O
LCa	O
,	O
and	O
HCa	O
.	O
Independent	B-UNK
but	O
not	O
additive	O
effects	O
of	O
Na	B-UNK
and	O
Ca	B-CHEMICAL
are	O
shown	B-UNK
by	O
decreases	B-UNK
in	O
the	O
values	O
of	O
[	O
verapamil]o	O
needed	B-UNK
to	O
reduce	B-UNK
BF	O
by	O
30	O
%	O
(	O
IC30	O
)	O
with	O
the	O
following	O
order	B-UNK
of	O
inhibitory	B-UNK
potency	B-UNK
:	O
LNa	B-UNK
>	O
LCa	O
>	O
HCa	O
>	O
N	O
,	O
resulting	B-UNK
LNa+HCa	O
similar	B-UNK
to	O
LNa	B-UNK
.	O
The	O
[	O
verapamil]o	O
that	O
arrested	O
atrial	B-UNK
beating	B-UNK
(	O
AC	O
)	O
was	O
also	O
potentiated	B-UNK
with	O
the	O
order	B-UNK
LNa	B-UNK
=	O
LNa+LCa	O
=	O
LNa+HCa	O
=	O
LCa	O
>	O
HCa	O
=	O
N.	O
The	O
results	B-UNK
indicate	O
that	O
rat	B-UNK
atrial	B-UNK
spontaneous	B-UNK
beating	B-UNK
is	O
more	O
dependent	B-UNK
on	O
[	O
Na]o	O
than	O
on	O
[	O
Ca]o	O
in	O
a	O
range	B-UNK
of	O
+	O
/-	O
50	O
%	O
of	O
their	O
normal	O
concentration	B-UNK
.	O
Also	O
the	O
enhancement	B-UNK
of	O
verapamil	B-UNK
effects	O
on	O
atrial	B-UNK
beating	B-UNK
was	O
more	O
pronounced	B-UNK
at	O
LNa	B-UNK
than	O
at	O
LCa.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	B-UNK
)	O

Sodium	B-UNK
status	B-UNK
influences	O
chronic	B-UNK
amphotericin	B-CHEMICAL
B	I-CHEMICAL
nephrotoxicity	B-DISEASE
in	O
rats	B-UNK
.	O
The	O
nephrotoxic	B-UNK
potential	B-UNK
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
per	O
day	O
intraperitoneally	B-UNK
for	O
3	O
weeks	B-UNK
)	O
has	O
been	O
investigated	B-UNK
in	O
salt	B-UNK
-	O
depleted	B-UNK
,	O
normal	O
-	O
salt	B-CHEMICAL
,	O
and	O
salt	B-CHEMICAL
-	O
loaded	B-UNK
rats	B-UNK
.	O
In	O
salt	B-UNK
-	O
depleted	B-UNK
rats	B-UNK
,	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
decreased	B-UNK
creatinine	B-UNK
clearance	I-UNK
linearly	O
with	O
time	O
,	O
with	O
an	O
85	O
%	O
reduction	O
by	O
week	B-UNK
3	O
.	O
In	O
contrast	B-UNK
,	O
in	O
normal	O
-	O
salt	B-CHEMICAL
rats	B-UNK
creatinine	B-UNK
clearance	I-UNK
was	O
decreased	B-UNK
but	O
to	O
a	O
lesser	O
extent	B-UNK
at	O
week	B-UNK
2	O
and	O
3	O
,	O
and	O
in	O
salt	B-UNK
-	O
loaded	B-UNK
rats	B-UNK
creatinine	B-UNK
clearance	I-UNK
did	O
not	O
change	B-UNK
for	O
2	O
weeks	B-UNK
and	O
was	O
decreased	B-UNK
by	O
43	O
%	O
at	O
week	B-UNK
3	O
.	O
All	O
rats	B-UNK
in	O
the	O
sodium	B-CHEMICAL
-	O
depleted	B-UNK
group	B-UNK
had	O
histopathological	B-UNK
evidence	B-UNK
of	O
patchy	O
tubular	B-UNK
cytoplasmic	B-UNK
degeneration	B-UNK
in	O
tubules	O
that	O
was	O
not	O
observed	O
in	O
any	O
normal	O
-	O
salt	B-UNK
or	O
salt	B-UNK
-	O
loaded	B-UNK
rat	B-UNK
.	O
Concentrations	B-UNK
of	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
in	O
plasma	B-UNK
were	O
not	O
significantly	B-UNK
different	O
among	O
the	O
three	O
groups	B-UNK
at	O
any	O
time	O
during	O
the	O
study	B-UNK
.	O
However	O
,	O
at	O
the	O
end	B-UNK
of	O
3	O
weeks	B-UNK
,	O
amphotericin	B-CHEMICAL
B	I-CHEMICAL
levels	O
in	O
the	O
kidneys	B-UNK
and	O
liver	B-UNK
were	O
significantly	B-UNK
higher	I-UNK
in	O
salt	B-UNK
-	O
depleted	B-UNK
and	O
normal	O
-	O
salt	B-CHEMICAL
rats	B-UNK
than	O
those	O
in	O
salt	B-UNK
-	O
loaded	B-UNK
rats	B-UNK
,	O
with	O
plasma	B-UNK
/	O
kidney	B-UNK
ratios	O
of	O
21	O
,	O
14	O
,	O
and	O
8	O
in	O
salt	B-CHEMICAL
-	O
depleted	B-UNK
,	O
normal	O
-	O
salt	B-UNK
,	O
and	O
salt	B-UNK
-	O
loaded	B-UNK
rats	B-UNK
,	O
respectively	O
.	O
In	O
conclusion	B-UNK
,	O
reductions	B-UNK
in	O
creatinine	B-UNK
clearance	I-UNK
and	O
renal	B-UNK
amphotericin	B-CHEMICAL
B	I-CHEMICAL
accumulation	B-UNK
after	O
chronic	B-UNK
amphotericin	B-CHEMICAL
B	I-CHEMICAL
administration	O
were	O
enhanced	B-UNK
by	O
salt	B-CHEMICAL
depletion	B-UNK
and	O
attenuated	B-UNK
by	O
sodium	B-UNK
loading	B-UNK
in	O
rats	B-UNK
.	O

Reversible	B-UNK
inferior	B-UNK
colliculus	O
lesion	B-UNK
in	O
metronidazole	B-CHEMICAL
-	O
induced	O
encephalopathy	B-UNK
:	O
magnetic	B-UNK
resonance	I-UNK
findings	B-UNK
on	O
diffusion	B-UNK
-	O
weighted	B-UNK
and	O
fluid	B-UNK
attenuated	B-UNK
inversion	O
recovery	B-UNK
imaging	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
This	O
is	O
to	O
present	B-UNK
reversible	B-UNK
inferior	B-UNK
colliculus	O
lesions	B-UNK
in	O
metronidazole	B-UNK
-	O
induced	O
encephalopathy	B-UNK
,	O
to	O
focus	O
on	O
the	O
diffusion	B-UNK
-	O
weighted	B-UNK
imaging	B-UNK
(	O
DWI	O
)	O
and	O
fluid	B-UNK
attenuated	B-UNK
inversion	O
recovery	B-UNK
(	O
FLAIR	O
)	O
imaging	B-UNK
.	O
MATERIALS	B-UNK
AND	I-UNK
METHODS	I-UNK
:	O
From	O
November	B-UNK
2005	O
to	O
September	O
2007	O
,	O
8	O
patients	B-UNK
(	O
5	O
men	B-UNK
and	O
3	O
women	B-UNK
)	O
were	O
diagnosed	B-UNK
as	O
having	O
metronidazole	B-UNK
-	O
induced	O
encephalopathy	B-DISEASE
(	O
age	B-UNK
range	B-UNK
;	O
43	O
-	O
78	O
years	B-UNK
)	O
.	O
They	O
had	O
been	O
taking	B-UNK
metronidazole	B-UNK
(	O
total	B-UNK
dosage	B-UNK
,	O
45	O
-	O
120	O
g	O
;	O
duration	B-UNK
,	O
30	O
days	B-UNK
to	O
2	O
months	B-UNK
)	O
to	O
treat	B-UNK
the	O
infection	B-DISEASE
in	O
various	O
organs	O
.	O
Initial	B-UNK
brain	B-UNK
magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
(	O
MRI	B-UNK
)	O
were	O
obtained	B-UNK
after	O
the	O
hospitalization	B-UNK
,	O
including	O
DWI	O
(	O
8/8	O
)	O
,	O
apparent	B-UNK
diffusion	B-UNK
coefficient	O
(	O
ADC	O
)	O
map	B-UNK
(	O
4/8	O
)	O
,	O
FLAIR	O
(	O
7/8	O
)	O
,	O
and	O
T2-weighted	O
image	O
(	O
8/8	O
)	O
.	O
Follow	O
-	O
up	O
MRIs	O
were	O
performed	B-UNK
on	O
5	O
patients	B-UNK
from	O
third	O
to	O
14th	O
days	B-UNK
after	O
discontinuation	B-UNK
of	O
metronidazole	B-CHEMICAL
administration	O
.	O
Findings	B-UNK
of	O
initial	B-UNK
and	O
follow	O
-	O
up	O
MRIs	O
were	O
retrospectively	O
evaluated	B-UNK
by	O
2	O
neuroradiologists	O
by	O
consensus	O
,	O
to	O
analyze	O
the	O
presence	O
of	O
abnormal	B-UNK
signal	B-UNK
intensities	O
,	O
their	O
locations	O
,	O
and	O
signal	B-UNK
changes	O
on	O
follow	O
-	O
up	O
images	B-UNK
.	O
RESULTS	B-UNK
:	O
Initial	B-UNK
MRIs	O
showed	O
abnormal	B-UNK
high	B-UNK
signal	B-UNK
intensities	O
on	O
DWI	O
and	O
FLAIR	O
(	O
or	O
T2-weighted	O
image	O
)	O
at	O
the	O
dentate	B-UNK
nucleus	B-UNK
(	O
8/8	O
)	O
,	O
inferior	B-UNK
colliculus	O
(	O
6/8	O
)	O
,	O
corpus	O
callosum	O
(	O
2/8	O
)	O
,	O
pons	O
(	O
2/8	O
)	O
,	O
medulla	B-UNK
(	O
1/8	O
)	O
,	O
and	O
bilateral	B-UNK
cerebral	B-UNK
white	B-UNK
matter	I-UNK
(	O
1/8	O
)	O
.	O
High	B-UNK
-	O
signal	B-UNK
intensity	B-UNK
lesions	B-UNK
on	O
DWI	O
tended	O
to	O
show	O
low	B-UNK
signal	B-UNK
intensity	B-UNK
on	O
ADC	O
map	B-UNK
(	O
3/4	O
)	O
,	O
but	O
in	O
one	O
patient	B-UNK
,	O
high	B-UNK
signal	B-UNK
intensity	B-UNK
was	O
shown	B-UNK
at	O
bilateral	B-UNK
dentate	B-UNK
nuclei	B-UNK
on	O
not	O
only	O
DWI	O
but	O
also	O
ADC	O
map	B-UNK
.	O
All	O
the	O
lesions	B-UNK
in	O
dentate	B-UNK
,	O
inferior	B-UNK
colliculus	O
,	O
pons	O
,	O
and	O
medullas	O
had	O
been	O
resolved	O
completely	O
on	O
follow	O
-	O
up	O
MRIs	O
in	O
5	O
patients	B-UNK
,	O
but	O
in	O
1	O
patient	B-UNK
of	O
them	O
,	O
corpus	O
callosal	B-DISEASE
lesion	I-DISEASE
persisted	O
.	O
CONCLUSIONS	B-UNK
:	O
Reversible	B-UNK
inferior	B-UNK
colliculus	O
lesions	B-UNK
could	O
be	O
considered	B-UNK
as	O
the	O
characteristic	B-UNK
for	O
metronidazole	B-CHEMICAL
-	O
induced	O
encephalopathy	B-UNK
,	O
next	O
to	O
the	O
dentate	B-UNK
nucleus	B-UNK
involvement	B-UNK
.	O

Comparison	B-UNK
of	O
the	O
respiratory	B-UNK
effects	O
of	O
i.v	B-UNK
.	O
infusions	B-UNK
of	O
morphine	B-UNK
and	O
regional	B-UNK
analgesia	B-UNK
by	O
extradural	O
block	B-UNK
.	O
The	O
incidence	B-UNK
of	O
postoperative	B-UNK
respiratory	B-UNK
apnoea	B-DISEASE
was	O
compared	O
between	O
five	O
patients	B-UNK
receiving	B-UNK
a	O
continuous	B-UNK
i.v	B-UNK
.	O
infusion	B-UNK
of	O
morphine	B-UNK
(	O
mean	O
73.6	O
mg	B-UNK
)	O
and	O
five	O
patients	B-UNK
receiving	B-UNK
a	O
continuous	B-UNK
extradural	O
infusion	B-UNK
of	O
0.25	O
%	O
bupivacaine	B-UNK
(	O
mean	O
192	O
mg	B-UNK
)	O
in	O
the	O
24-h	O
period	B-UNK
following	O
upper	B-UNK
abdominal	B-UNK
surgery	B-UNK
.	O
Monitoring	B-UNK
consisted	B-UNK
of	O
airflow	O
detection	B-UNK
by	O
a	O
carbon	B-CHEMICAL
dioxide	I-CHEMICAL
analyser	O
,	O
chest	B-UNK
wall	B-UNK
movement	B-UNK
detected	B-UNK
by	O
pneumatic	O
capsules	O
,	O
and	O
continuous	B-UNK
electrocardiograph	O
recorded	O
with	O
a	O
Holter	O
ambulatory	B-UNK
monitor	B-UNK
.	O
Both	O
obstructive	B-UNK
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
central	B-UNK
apnoea	B-DISEASE
(	O
P	O
less	O
than	O
0.05	O
)	O
occurred	B-UNK
more	O
frequently	B-UNK
in	O
patients	B-UNK
who	O
had	O
a	O
morphine	B-UNK
infusion	B-UNK
.	O
There	O
was	O
also	O
a	O
higher	B-UNK
incidence	B-UNK
of	O
tachyarrhythmias	B-UNK
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
ventricular	B-UNK
ectopic	O
beats	B-UNK
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
the	O
morphine	B-UNK
infusion	B-UNK
group	B-UNK
.	O

Magnetic	B-UNK
resonance	I-UNK
volumetry	O
of	O
the	O
cerebellum	B-UNK
in	O
epileptic	B-UNK
patients	B-UNK
after	O
phenytoin	B-CHEMICAL
overdosages	O
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
evaluate	B-UNK
the	O
relationship	B-UNK
between	O
phenytoin	B-CHEMICAL
medication	O
and	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
in	O
patients	B-UNK
who	O
had	O
experienced	B-UNK
clinical	B-UNK
intoxication	B-UNK
.	O
Five	O
females	B-UNK
and	O
6	O
males	B-UNK
,	O
21	O
-	O
59	O
years	B-UNK
of	I-UNK
age	I-UNK
,	O
were	O
examined	B-UNK
with	O
a	O
1.5-T	O
whole	O
-	O
body	B-UNK
system	O
using	O
a	O
circular	O
polarized	O
head	B-UNK
coil	O
.	O
Conventional	B-UNK
spin	O
echo	O
images	B-UNK
were	O
acquired	B-UNK
in	O
the	O
sagittal	O
and	O
transverse	O
orientation	O
.	O
In	O
addition	B-UNK
,	O
we	O
performed	B-UNK
a	O
high	B-UNK
-	O
resolution	B-UNK
3D	O
gradient	O
echo	O
,	O
T1-weighted	O
sequences	O
at	O
a	O
1-mm	O
slice	O
thickness	B-UNK
.	O
The	O
images	B-UNK
were	O
subsequently	B-UNK
processed	O
to	O
obtain	O
volumetric	O
data	B-UNK
for	O
the	O
cerebellum	B-UNK
.	O
Cerebellar	B-UNK
volume	B-UNK
for	O
the	O
patient	B-UNK
group	B-UNK
ranged	B-UNK
between	O
67.66	O
and	O
131.08	O
ml	B-UNK
(	O
mean	O
108.9	O
ml	B-UNK
)	O
.	O
In	O
addition	B-UNK
3D	O
gradient	O
echo	O
data	B-UNK
sets	O
from	O
10	O
healthy	B-UNK
male	B-UNK
and	O
10	O
healthy	B-UNK
female	B-UNK
age	B-UNK
-	O
matched	O
volunteers	B-UNK
were	O
used	O
to	O
compare	B-UNK
cerebellar	B-UNK
volumes	O
.	O
Using	O
linear	O
regression	B-UNK
we	O
found	O
that	O
no	O
correlation	B-UNK
exists	O
between	O
seizure	B-UNK
duration	B-UNK
,	O
elevation	B-UNK
of	O
phenytoin	B-CHEMICAL
serum	B-UNK
levels	O
and	O
cerebellar	B-UNK
volume	B-UNK
.	O
However	O
,	O
multiple	B-UNK
regression	B-UNK
for	O
the	O
daily	B-UNK
dosage	B-UNK
,	O
duration	B-UNK
of	O
phenytoin	B-CHEMICAL
treatment	B-UNK
and	O
cerebellar	B-UNK
volume	B-UNK
revealed	O
a	O
correlation	B-UNK
of	O
these	O
parameters	O
.	O
We	O
conclude	O
that	O
phenytoin	B-CHEMICAL
overdosage	O
does	O
not	O
necessarily	O
result	B-UNK
in	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
and	O
it	O
is	O
unlikely	O
that	O
phenytoin	B-UNK
medication	O
was	O
the	O
only	O
cause	O
of	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
in	O
the	O
remaining	O
patients	B-UNK
.	O
Quantitative	B-UNK
morphometric	O
studies	B-UNK
of	O
the	O
cerebellum	B-UNK
provide	O
valuable	O
insights	O
into	O
the	O
pathogenesis	B-UNK
of	O
cerebellar	B-DISEASE
disorders	I-DISEASE
.	O

Evaluation	B-UNK
of	O
cardiac	B-UNK
troponin	B-UNK
I	O
and	O
T	O
levels	O
as	O
markers	B-UNK
of	O
myocardial	B-DISEASE
damage	I-DISEASE
in	O
doxorubicin	B-UNK
-	O
induced	O
cardiomyopathy	B-DISEASE
rats	B-UNK
,	O
and	O
their	O
relationship	B-UNK
with	O
echocardiographic	B-UNK
and	O
histological	B-UNK
findings	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Cardiac	B-UNK
troponins	O
I	O
(	O
cTnI	B-UNK
)	O
and	O
T	O
(	O
cTnT	B-UNK
)	O
have	O
been	O
shown	B-UNK
to	O
be	O
highly	B-UNK
sensitive	B-UNK
and	O
specific	B-UNK
markers	B-UNK
of	O
myocardial	B-UNK
cell	B-UNK
injury	B-UNK
.	O
We	O
investigated	B-UNK
the	O
diagnostic	B-UNK
value	O
of	O
cTnI	B-UNK
and	O
cTnT	B-UNK
for	O
the	O
diagnosis	B-UNK
of	O
myocardial	B-DISEASE
damage	I-DISEASE
in	O
a	O
rat	B-UNK
model	B-UNK
of	O
doxorubicin	B-CHEMICAL
(	O
DOX)-induced	O
cardiomyopathy	B-UNK
,	O
and	O
we	O
examined	B-UNK
the	O
relationship	B-UNK
between	O
serial	B-UNK
cTnI	B-UNK
and	O
cTnT	B-UNK
with	O
the	O
development	B-UNK
of	O
cardiac	B-DISEASE
disorders	I-DISEASE
monitored	O
by	O
echocardiography	B-UNK
and	O
histological	B-UNK
examinations	B-UNK
in	O
this	O
model	B-UNK
.	O
METHODS	B-UNK
:	O
Thirty	B-UNK
-	O
five	O
Wistar	B-UNK
rats	I-UNK
were	O
given	O
1.5	O
mg	B-UNK
/	O
kg	B-UNK
DOX	B-UNK
,	O
i.v	B-UNK
.	O
,	O
weekly	B-UNK
for	O
up	O
to	O
8	O
weeks	B-UNK
for	O
a	O
total	B-UNK
cumulative	B-UNK
dose	I-UNK
of	O
12	O
mg	B-UNK
/	O
kg	B-UNK
BW	B-UNK
.	O
Ten	O
rats	B-UNK
received	O
saline	B-UNK
as	O
a	O
control	B-UNK
group	B-UNK
.	O
cTnI	B-UNK
was	O
measured	B-UNK
with	O
Access(R	O
)	O
(	O
ng	B-UNK
/	O
ml	B-UNK
)	O
and	O
a	O
research	B-UNK
immunoassay	O
(	O
pg	B-UNK
/	O
ml	B-UNK
)	O
,	O
and	O
compared	O
with	O
cTnT	B-UNK
,	O
CK	B-UNK
-	O
MB	B-UNK
mass	B-UNK
and	O
CK	B-UNK
.	O
By	O
using	O
transthoracic	O
echocardiography	B-UNK
,	O
anterior	B-UNK
and	O
posterior	B-UNK
wall	B-UNK
thickness	B-UNK
,	O
LV	B-UNK
diameters	O
and	O
LV	B-UNK
fractional	B-UNK
shortening	B-UNK
(	O
FS	B-UNK
)	O
were	O
measured	B-UNK
in	O
all	O
rats	B-UNK
before	O
DOX	B-UNK
or	O
saline	B-UNK
,	O
and	O
at	O
weeks	B-UNK
6	O
and	O
9	O
after	O
treatment	B-UNK
in	O
all	O
surviving	O
rats	B-UNK
.	O
Histology	B-UNK
was	O
performed	B-UNK
in	O
DOX	B-UNK
-	O
rats	B-UNK
at	O
6	O
and	O
9	O
weeks	B-UNK
after	O
the	O
last	O
DOX	B-UNK
dose	B-UNK
and	O
in	O
all	O
controls	B-UNK
.	O
RESULTS	B-UNK
:	O
Eighteen	O
of	O
the	O
DOX	B-UNK
rats	B-UNK
died	O
prematurely	O
of	O
general	B-UNK
toxicity	B-UNK
during	O
the	O
9-week	O
period	B-UNK
.	O
End	B-UNK
-	O
diastolic	B-UNK
(	O
ED	B-UNK
)	O
and	O
end	B-UNK
-	O
systolic	B-UNK
(	O
ES	O
)	O
LV	B-UNK
diameters	O
/	O
BW	B-UNK
significantly	B-UNK
increased	B-UNK
,	O
whereas	O
LV	B-UNK
FS	B-UNK
was	O
decreased	B-UNK
after	O
9	O
weeks	B-UNK
in	O
the	O
DOX	B-UNK
group	B-UNK
(	O
p<0.001	O
)	O
.	O
These	O
parameters	O
remained	B-UNK
unchanged	I-UNK
in	O
controls	B-UNK
.	O
Histological	B-UNK
evaluation	B-UNK
of	O
hearts	B-UNK
from	O
all	O
rats	B-UNK
given	O
DOX	B-UNK
revealed	O
significant	B-UNK
slight	B-UNK
degrees	B-UNK
of	O
perivascular	O
and	O
interstitial	B-UNK
fibrosis	B-UNK
.	O
In	O
7	O
of	O
the	O
18	O
rats	B-UNK
,	O
degeneration	B-UNK
and	O
myocyte	O
vacuolisation	O
were	O
found	O
.	O
Only	O
five	O
of	O
the	O
controls	B-UNK
exhibited	O
evidence	B-UNK
of	O
very	O
slight	B-UNK
perivascular	O
fibrosis	B-UNK
.	O
A	O
significant	B-UNK
rise	B-UNK
in	O
cTnT	B-UNK
was	O
found	O
in	O
DOX	B-UNK
rats	B-UNK
after	O
cumulative	B-UNK
doses	B-UNK
of	O
7.5	O
and	O
12	O
mg	B-UNK
/	O
kg	B-UNK
in	O
comparison	B-UNK
with	O
baseline	B-UNK
(	O
p<0.05	O
)	O
.	O
cTnT	B-UNK
found	O
in	O
rats	B-UNK
after	O
12	O
mg	B-UNK
/	O
kg	B-UNK
were	O
significantly	B-UNK
greater	I-UNK
than	O
that	O
found	O
after	O
7.5	O
mg	B-UNK
/	O
kg	B-UNK
DOX	B-UNK
.	O
Maximal	B-UNK
cTnI	B-UNK
(	O
pg	B-UNK
/	O
ml	B-UNK
)	O
and	O
cTnT	B-UNK
levels	O
were	O
significantly	B-UNK
increased	B-UNK
in	O
DOX	B-UNK
rats	B-UNK
compared	O
with	O
controls	B-UNK
(	O
p=0.006	O
,	O
0.007	O
)	O
.	O
cTnI	B-UNK
(	O
ng	B-UNK
/	O
ml	B-UNK
)	O
,	O
CK	B-UNK
-	O
MB	B-UNK
mass	B-UNK
and	O
CK	B-UNK
remained	B-UNK
unchanged	I-UNK
in	O
DOX	B-UNK
rats	B-UNK
compared	O
with	O
controls	B-UNK
.	O
All	O
markers	B-UNK
remained	B-UNK
stable	B-UNK
in	O
controls	B-UNK
.	O
Analysis	B-UNK
of	O
data	B-UNK
revealed	O
a	O
significant	B-UNK
correlation	B-UNK
between	O
maximal	B-UNK
cTnT	B-UNK
and	O
ED	B-UNK
and	O
ES	O
LV	B-UNK
diameters	O
/	O
BW	B-UNK
(	O
r=0.81	O
and	O
0.65	O
;	O
p<0.0001	O
)	O
.	O
A	O
significant	B-UNK
relationship	B-UNK
was	O
observed	O
between	O
maximal	B-UNK
cTnT	B-UNK
and	O
the	O
extent	B-UNK
of	O
myocardial	B-UNK
morphological	B-UNK
changes	O
,	O
and	O
between	O
LV	B-UNK
diameters	O
/	O
BW	B-UNK
and	O
histological	B-UNK
findings	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Among	O
markers	B-UNK
of	O
ischemic	B-UNK
injury	B-UNK
after	O
DOX	B-UNK
in	O
rats	B-UNK
,	O
cTnT	B-UNK
showed	O
the	O
greatest	B-UNK
ability	B-UNK
to	O
detect	B-UNK
myocardial	B-DISEASE
damage	I-DISEASE
assessed	B-UNK
by	O
echocardiographic	B-UNK
detection	B-UNK
and	O
histological	B-UNK
changes	O
.	O
Although	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
amount	O
of	O
cTnI	B-UNK
and	O
cTnT	B-UNK
after	O
DOX	B-UNK
,	O
probably	O
due	O
to	O
heterogeneity	O
in	O
cross-reactivities	O
of	O
mAbs	O
to	O
various	O
cTnI	B-UNK
and	O
cTnT	B-UNK
forms	O
,	O
it	O
is	O
likely	O
that	O
cTnT	B-UNK
in	O
rats	B-UNK
after	O
DOX	B-UNK
indicates	O
cell	B-UNK
damage	B-UNK
determined	B-UNK
by	O
the	O
magnitude	B-UNK
of	O
injury	B-UNK
induced	O
and	O
that	O
cTnT	B-UNK
should	O
be	O
a	O
useful	O
marker	B-UNK
for	O
the	O
prediction	O
of	O
experimentally	O
induced	O
cardiotoxicity	B-UNK
and	O
possibly	O
for	O
cardioprotective	B-UNK
experiments	B-UNK
.	O

Calcineurin	B-UNK
-	O
inhibitor	B-UNK
induced	O
pain	B-UNK
syndrome	B-UNK
(	O
CIPS	O
):	O
a	O
severe	B-UNK
disabling	O
complication	B-UNK
after	O
organ	B-UNK
transplantation	B-UNK
.	O
Bone	B-UNK
pain	B-UNK
after	O
transplantation	B-UNK
is	O
a	O
frequent	B-UNK
complication	B-UNK
that	O
can	O
be	O
caused	B-UNK
by	O
several	O
diseases	B-UNK
.	O
Treatment	B-UNK
strategies	B-UNK
depend	O
on	O
the	O
correct	O
diagnosis	B-UNK
of	O
the	O
pain	B-UNK
.	O
Nine	O
patients	B-UNK
with	O
severe	B-UNK
pain	B-UNK
in	O
their	O
feet	O
,	O
which	O
was	O
registered	O
after	O
transplantation	B-UNK
,	O
were	O
investigated	B-UNK
.	O
Bone	B-UNK
scans	O
showed	O
an	O
increased	B-UNK
tracer	O
uptake	B-UNK
of	O
the	O
foot	B-UNK
bones	O
.	O
Magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
demonstrated	O
bone	B-UNK
marrow	I-UNK
oedema	O
in	O
the	O
painful	O
bones	O
.	O
Pain	B-UNK
was	O
not	O
explained	O
by	O
other	O
diseases	B-UNK
causing	O
foot	B-UNK
pain	B-UNK
,	O
like	O
reflex	B-DISEASE
sympathetic	I-DISEASE
dystrophy	I-DISEASE
,	O
polyneuropathy	B-DISEASE
,	O
Morton'	O
s	O
neuralgia	B-DISEASE
,	O
gout	B-DISEASE
,	O
osteoporosis	B-UNK
,	O
avascular	B-DISEASE
necrosis	I-DISEASE
,	O
intermittent	B-DISEASE
claudication	I-DISEASE
,	O
orthopaedic	O
foot	B-DISEASE
deformities	I-DISEASE
,	O
stress	B-UNK
fractures	B-UNK
,	O
and	O
hyperparathyroidism	B-DISEASE
.	O
The	O
reduction	O
of	O
cyclosporine-	O
or	O
tacrolimus	B-UNK
trough	B-UNK
levels	O
and	O
the	O
administration	O
of	O
calcium	B-UNK
channel	I-UNK
blockers	I-UNK
led	B-UNK
to	O
relief	O
of	O
pain	B-DISEASE
.	O
The	O
Calcineurin	B-UNK
-	O
inhibitor	B-UNK
Induced	O
Pain	B-UNK
Syndrome	B-UNK
(	O
CIPS	O
)	O
is	O
a	O
rare	B-UNK
but	O
severe	B-UNK
side	O
effect	B-UNK
of	O
cyclosporine	B-CHEMICAL
or	O
tacrolimus	B-CHEMICAL
and	O
is	O
accurately	O
diagnosed	B-UNK
by	O
its	O
typical	B-UNK
presentation	B-UNK
,	O
magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
and	O
bone	B-UNK
scans	O
.	O
Incorrect	O
diagnosis	B-UNK
of	O
the	O
syndrome	B-DISEASE
will	O
lead	B-UNK
to	O
a	O
significant	B-UNK
reduction	O
of	O
life	B-UNK
quality	B-UNK
in	O
patients	B-UNK
suffering	O
from	O
CIPS	O
.	O

The	O
haemodynamic	O
effects	O
of	O
propofol	B-UNK
in	O
combination	B-UNK
with	O
ephedrine	B-CHEMICAL
in	O
elderly	B-UNK
patients	B-UNK
(	O
ASA	B-CHEMICAL
groups	B-UNK
3	O
and	O
4	O
)	O
.	O
The	O
marked	O
vasodilator	O
and	O
negative	B-UNK
inotropic	O
effects	O
of	O
propofol	B-UNK
are	O
disadvantages	O
in	O
frail	O
elderly	B-UNK
patients	B-UNK
.	O
We	O
investigated	B-UNK
the	O
safety	B-UNK
and	I-UNK
efficacy	I-UNK
of	O
adding	O
different	O
doses	B-UNK
of	O
ephedrine	B-UNK
to	O
propofol	B-UNK
in	O
order	B-UNK
to	O
obtund	O
the	O
hypotensive	B-UNK
response	B-UNK
.	O
The	O
haemodynamic	O
effects	O
of	O
adding	O
15	O
,	O
20	O
or	O
25	O
mg	B-UNK
of	O
ephedrine	B-UNK
to	O
200	O
mg	B-UNK
of	O
propofol	B-UNK
were	O
compared	O
to	O
control	B-UNK
in	O
40	O
ASA	B-UNK
3/4	O
patients	B-UNK
over	O
60	O
years	B-UNK
presenting	O
for	O
genito	O
-	O
urinary	B-UNK
surgery	B-UNK
.	O
The	O
addition	B-UNK
of	O
ephedrine	B-CHEMICAL
to	O
propofol	B-UNK
appears	B-UNK
to	O
be	O
an	O
effective	B-UNK
method	B-UNK
of	O
obtunding	O
the	O
hypotensive	B-UNK
response	B-UNK
to	O
propofol	B-CHEMICAL
at	O
all	O
doses	B-UNK
used	O
in	O
this	O
study	B-UNK
.	O
However	O
,	O
marked	O
tachycardia	B-UNK
associated	O
with	O
the	O
use	O
of	O
ephedrine	B-CHEMICAL
in	O
combination	B-UNK
with	O
propofol	B-CHEMICAL
occurred	B-UNK
in	O
the	O
majority	O
of	O
patients	B-UNK
,	O
occasionally	O
reaching	O
high	B-UNK
levels	O
in	O
individual	B-UNK
patients	B-UNK
.	O
Due	O
to	O
the	O
risk	B-UNK
of	O
this	O
tachycardia	B-UNK
inducing	O
myocardial	B-DISEASE
ischemia	I-DISEASE
,	O
we	O
would	O
not	O
recommend	O
the	O
use	O
in	O
elderly	B-UNK
patients	B-UNK
of	O
any	O
of	O
the	O
ephedrine	B-UNK
/	O
propofol	B-UNK
/	O
mixtures	O
studied	O
.	O

Neurotoxicity	B-UNK
of	O
halogenated	O
hydroxyquinolines	O
:	O
clinical	B-UNK
analysis	B-UNK
of	O
cases	B-UNK
reported	B-UNK
outside	O
Japan	O
.	O
An	O
analysis	B-UNK
is	O
presented	B-UNK
of	O
220	O
cases	B-UNK
of	O
possible	O
neurotoxic	B-UNK
reactions	B-UNK
to	O
halogenated	O
hydroxyquinolines	O
reported	B-UNK
from	O
outside	O
Japan	O
.	O
In	O
80	O
cases	B-UNK
insufficient	O
information	B-UNK
was	O
available	O
for	O
adequate	B-UNK
comment	O
and	O
in	O
29	O
a	O
relationship	B-UNK
to	O
the	O
administration	O
of	O
clioquinol	O
could	O
be	O
excluded	B-UNK
.	O
Of	O
the	O
remainder	O
,	O
a	O
relationship	B-UNK
to	O
clioquinol	O
was	O
considered	B-UNK
probable	O
in	O
42	O
and	O
possible	O
in	O
69	O
cases	B-UNK
.	O
In	O
six	O
of	O
the	O
probable	O
cases	B-UNK
the	O
neurological	B-UNK
disturbance	B-UNK
consisted	B-UNK
of	O
an	O
acute	B-UNK
reversible	B-UNK
encephalopathy	B-UNK
usually	O
related	O
to	O
the	O
ingestion	B-UNK
of	O
a	O
high	B-UNK
dose	I-UNK
of	O
clioquinol	O
over	O
a	O
short	B-UNK
period	B-UNK
.	O
The	O
most	O
common	B-UNK
manifestation	B-UNK
,	O
observed	O
in	O
15	O
further	O
cases	B-UNK
,	O
was	O
isolated	B-UNK
optic	B-DISEASE
atrophy	I-DISEASE
.	O
This	O
was	O
most	O
frequently	B-UNK
found	O
in	O
children	B-UNK
,	O
many	O
of	O
whom	O
had	O
received	O
clioquinol	O
as	O
treatment	B-UNK
for	O
acrodermatitis	B-DISEASE
enteropathica	I-DISEASE
.	O
In	O
the	O
remaining	O
cases	B-UNK
,	O
a	O
combination	B-UNK
of	O
myelopathy	O
,	O
visual	B-UNK
disturbance	B-UNK
,	O
and	O
peripheral	B-UNK
neuropathy	I-UNK
was	O
the	O
most	O
common	B-UNK
manifestation	B-UNK
.	O
Isolated	B-UNK
myelopathy	O
or	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
,	O
or	O
these	O
manifestations	B-UNK
occurring	O
together	O
,	O
were	O
infrequent	O
.	O
The	O
onset	B-UNK
of	O
all	O
manifestations	B-UNK
(	O
except	O
toxic	B-UNK
encephalopathy	B-UNK
)	O
was	O
usually	O
subacute	B-UNK
,	O
with	O
subsequent	B-UNK
partial	B-UNK
recovery	B-UNK
.	O
Older	B-UNK
subjects	B-UNK
tended	O
to	O
display	O
more	O
side	O
effects	O
.	O
The	O
full	O
syndrome	B-UNK
of	O
subacute	B-UNK
myelo	O
-	O
optic	B-UNK
neuropathy	I-UNK
was	O
more	O
frequent	B-UNK
in	O
women	B-UNK
,	O
but	O
they	O
tended	O
to	O
have	O
taken	O
greater	B-UNK
quantities	O
of	O
the	O
drug	B-UNK
.	O

Epileptic	B-DISEASE
seizures	I-DISEASE
following	O
cortical	B-UNK
application	B-UNK
of	O
fibrin	B-UNK
sealants	O
containing	O
tranexamic	B-UNK
acid	I-UNK
in	O
rats	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Fibrin	B-UNK
sealants	O
(	O
FS	B-UNK
)	O
derived	O
from	O
human	B-UNK
plasma	B-UNK
are	O
frequently	B-UNK
used	O
in	O
neurosurgery	O
.	O
In	O
order	B-UNK
to	O
increase	B-UNK
clot	O
stability	B-UNK
,	O
FS	B-UNK
typically	O
contain	O
aprotinin	B-UNK
,	O
a	O
natural	B-UNK
fibrinolysis	O
inhibitor	B-UNK
.	O
Recently	B-UNK
,	O
synthetic	O
fibrinolysis	O
inhibitors	B-UNK
such	O
as	O
tranexamic	B-UNK
acid	I-UNK
(	O
tAMCA	B-CHEMICAL
)	O
have	O
been	O
considered	B-UNK
as	O
substitutes	O
for	O
aprotinin	B-UNK
.	O
However	O
,	O
tAMCA	B-CHEMICAL
has	O
been	O
shown	B-UNK
to	O
cause	O
epileptic	B-DISEASE
seizures	I-DISEASE
.	O
We	O
wanted	O
to	O
study	B-UNK
whether	O
tAMCA	B-CHEMICAL
retains	O
its	O
convulsive	B-UNK
action	B-UNK
if	O
incorporated	O
into	O
a	O
FS	B-UNK
.	O
METHOD	B-UNK
:	O
FS	B-UNK
containing	O
aprotinin	B-UNK
or	O
different	O
concentrations	B-UNK
of	O
tAMCA	B-CHEMICAL
(	O
0.5	O
-	O
47.5	O
mg	B-UNK
/	O
ml	B-UNK
)	O
were	O
applied	O
to	O
the	O
pial	O
surface	B-UNK
of	O
the	O
cortex	B-UNK
of	O
anaesthetized	O
rats	B-UNK
.	O
The	O
response	B-UNK
of	O
the	O
animals	B-UNK
was	O
evaluated	B-UNK
using	O
electroencephalography	O
and	O
by	O
monitoring	B-UNK
the	O
clinical	B-UNK
behaviour	B-UNK
during	O
and	O
after	O
recovery	B-UNK
from	O
anaesthesia	B-UNK
.	O
FINDINGS	B-UNK
:	O
FS	B-UNK
containing	O
tAMCA	B-CHEMICAL
caused	B-UNK
paroxysmal	O
brain	B-UNK
activity	B-UNK
which	O
was	O
associated	O
with	O
distinct	O
convulsive	B-UNK
behaviours	O
.	O
The	O
degree	B-UNK
of	O
these	O
seizures	B-UNK
increased	B-UNK
with	O
increasing	B-UNK
concentration	B-UNK
of	O
tAMCA	B-CHEMICAL
.	O
Thus	O
,	O
FS	B-UNK
containing	O
47.5	O
mg	B-UNK
/	O
ml	B-UNK
tAMCA	B-CHEMICAL
evoked	B-UNK
generalized	O
seizures	B-UNK
in	O
all	O
tested	B-UNK
rats	B-UNK
(	O
n=6	O
)	O
while	O
the	O
lowest	O
concentration	B-UNK
of	O
tAMCA	B-CHEMICAL
(	O
0.5	O
mg	B-UNK
/	O
ml	B-UNK
)	O
only	O
evoked	B-UNK
brief	O
episodes	B-UNK
of	O
jerk	O
-	O
correlated	B-UNK
convulsive	B-UNK
potentials	B-UNK
in	O
1	O
of	O
6	O
rats	B-UNK
.	O
In	O
contrast	B-UNK
,	O
FS	B-UNK
containing	O
aprotinin	B-UNK
did	O
not	O
evoke	O
any	O
paroxysmal	O
activity	B-UNK
.	O
INTERPRETATION	O
:	O
Tranexamic	B-UNK
acid	I-UNK
retains	O
its	O
convulsive	B-UNK
action	B-UNK
within	O
FS	B-UNK
.	O
Thus	O
,	O
use	O
of	O
FS	B-UNK
containing	O
tAMCA	B-CHEMICAL
for	O
surgery	B-UNK
within	O
or	O
close	B-UNK
to	O
the	O
CNS	B-UNK
may	O
pose	O
a	O
substantial	O
risk	B-UNK
to	O
the	O
patient	B-UNK
.	O

A	O
diet	B-UNK
promoting	O
sugar	O
dependency	O
causes	O
behavioral	B-UNK
cross-sensitization	O
to	O
a	O
low	B-UNK
dose	I-UNK
of	O
amphetamine	B-UNK
.	O
Previous	B-UNK
research	B-UNK
in	O
this	O
laboratory	B-UNK
has	O
shown	B-UNK
that	O
a	O
diet	B-UNK
of	O
intermittent	B-UNK
excessive	B-UNK
sugar	O
consumption	B-UNK
produces	O
a	O
state	B-UNK
with	O
neurochemical	O
and	O
behavioral	B-UNK
similarities	O
to	O
drug	B-DISEASE
dependency	I-DISEASE
.	O
The	O
present	B-UNK
study	B-UNK
examined	B-UNK
whether	O
female	B-UNK
rats	I-UNK
on	O
various	O
regimens	B-UNK
of	O
sugar	O
access	O
would	O
show	O
behavioral	B-UNK
cross-sensitization	O
to	O
a	O
low	B-UNK
dose	I-UNK
of	O
amphetamine	B-UNK
.	O
After	O
a	O
30-min	O
baseline	B-UNK
measure	B-UNK
of	O
locomotor	B-UNK
activity	I-UNK
(	O
day	O
0	O
)	O
,	O
animals	B-UNK
were	O
maintained	O
on	O
a	O
cyclic	B-UNK
diet	B-UNK
of	O
12-h	O
deprivation	B-UNK
followed	O
by	O
12-h	O
access	O
to	O
10	O
%	O
sucrose	O
solution	B-UNK
and	O
chow	B-UNK
pellets	O
(	O
12	O
h	O
access	O
starting	B-UNK
4	O
h	O
after	O
onset	B-UNK
of	O
the	O
dark	O
period	B-UNK
)	O
for	O
21	O
days	B-UNK
.	O
Locomotor	B-UNK
activity	I-UNK
was	O
measured	B-UNK
again	O
for	O
30	O
min	B-UNK
at	O
the	O
beginning	B-UNK
of	O
days	B-UNK
1	O
and	O
21	O
of	O
sugar	O
access	O
.	O
Beginning	B-UNK
on	O
day	O
22	O
,	O
all	O
rats	B-UNK
were	O
maintained	O
on	O
ad	O
libitum	O
chow	B-UNK
.	O
Nine	O
days	B-UNK
later	O
locomotor	B-UNK
activity	I-UNK
was	O
measured	B-UNK
in	O
response	B-UNK
to	O
a	O
single	B-UNK
low	B-UNK
dose	I-UNK
of	O
amphetamine	B-UNK
(	O
0.5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
The	O
animals	B-UNK
that	O
had	O
experienced	B-UNK
cyclic	B-UNK
sucrose	O
and	O
chow	B-UNK
were	O
hyperactive	O
in	O
response	B-UNK
to	O
amphetamine	B-UNK
compared	O
with	O
four	O
control	B-UNK
groups	I-UNK
(	O
ad	O
libitum	O
10	O
%	O
sucrose	O
and	O
chow	B-UNK
followed	O
by	O
amphetamine	B-UNK
injection	B-UNK
,	O
cyclic	B-UNK
chow	B-UNK
followed	O
by	O
amphetamine	B-UNK
injection	B-UNK
,	O
ad	O
libitum	O
chow	B-UNK
with	O
amphetamine	B-UNK
,	O
or	O
cyclic	B-UNK
10	O
%	O
sucrose	O
and	O
chow	B-UNK
with	O
a	O
saline	B-UNK
injection	B-UNK
)	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
a	O
diet	B-UNK
comprised	O
of	O
alternating	O
deprivation	B-UNK
and	O
access	O
to	O
a	O
sugar	O
solution	B-UNK
and	O
chow	B-UNK
produces	O
bingeing	O
on	O
sugar	O
that	O
leads	B-UNK
to	O
a	O
long	B-UNK
lasting	I-UNK
state	B-UNK
of	O
increased	B-UNK
sensitivity	B-UNK
to	O
amphetamine	B-UNK
,	O
possibly	O
due	O
to	O
a	O
lasting	B-UNK
alteration	B-UNK
in	O
the	O
dopamine	B-UNK
system	O
.	O

D	O
-	O
penicillamine	B-CHEMICAL
-	O
induced	O
angiopathy	B-DISEASE
in	O
rats	B-UNK
.	O
The	O
effect	B-UNK
of	O
high	B-UNK
dose	I-UNK
D	O
-	O
penicillamine	B-UNK
treatment	B-UNK
on	O
aortic	B-UNK
permeability	B-UNK
to	O
albumin	B-UNK
and	O
on	O
the	O
ultrastructure	O
of	O
the	O
vessel	O
.	O
Male	B-UNK
Sprague	O
-	O
Dawley	O
rats	B-UNK
were	O
treated	O
with	O
D	O
-	O
penicillamine	B-CHEMICAL
(	O
D	O
-	O
pen	O
)	O
500	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
for	O
10	O
or	O
42	O
days	B-UNK
.	O
Pair	O
fed	B-UNK
rats	B-UNK
served	O
as	O
controls	B-UNK
.	O
Changes	O
in	O
aortic	B-UNK
morphology	O
were	O
examined	B-UNK
by	O
light-	O
and	O
transmission	B-UNK
-	O
electron	B-UNK
microscopy	I-UNK
(	O
TEM	O
)	O
.	O
In	O
addition	B-UNK
,	O
the	O
endothelial	B-UNK
permeability	B-UNK
and	O
the	O
penetration	O
through	O
the	O
aortic	B-UNK
wall	B-UNK
of	O
albumin	B-UNK
were	O
studied	O
10	O
minutes	B-UNK
,	O
24	O
and	O
48	O
hours	B-UNK
after	O
i.	O
v.	O
injection	B-UNK
of	O
human	B-UNK
serum	B-UNK
131I	O
-	O
albumin	B-UNK
(	O
131I	O
-	O
HSA	O
)	O
.	O
TEM	O
revealed	O
extensive	B-UNK
elastolysis	O
in	O
the	O
arterial	B-UNK
wall	B-UNK
of	O
D	O
-	O
pen	O
-	O
treated	B-UNK
rats	I-UNK
,	O
consistent	B-UNK
with	O
an	O
inhibitory	B-UNK
effect	B-UNK
on	O
crosslink	O
formation	B-UNK
.	O
In	O
experimental	B-UNK
animals	B-UNK
excess	B-UNK
deposition	O
of	O
collagen	O
and	O
glycoaminoglycans	O
was	O
observed	O
in	O
the	O
subendothelial	O
and	O
medial	B-UNK
layer	B-UNK
of	O
the	O
aortic	B-UNK
wall	B-UNK
,	O
together	O
with	O
prominent	B-UNK
basal	B-UNK
membrane	B-UNK
substance	B-UNK
around	O
aortic	B-UNK
smooth	B-UNK
muscle	I-UNK
cells	B-UNK
.	O
The	O
aorta	B-UNK
/	O
serum	B-UNK
-	O
ratio	B-UNK
and	O
the	O
radioactive	O
build	O
-	O
up	O
24	O
and	O
48	O
hours	B-UNK
after	O
injection	B-UNK
of	O
131I	O
-	O
HSA	O
was	O
reduced	B-UNK
in	O
animals	B-UNK
treated	O
with	O
D	O
-	O
pen	O
for	O
42	O
days	B-UNK
,	O
indicating	O
an	O
impeded	O
transmural	O
transport	B-UNK
of	O
tracer	O
which	O
may	O
be	O
caused	B-UNK
by	O
a	O
steric	O
exclusion	O
effect	B-UNK
of	O
abundant	O
hyaluronate	O
.	O
The	O
endothelial	B-UNK
ultrastructure	O
was	O
unaffected	B-UNK
by	O
D	O
-	O
pen	O
,	O
and	O
no	O
differences	B-UNK
in	O
aortic	B-UNK
131I	O
-	O
HSA	O
radioactivity	O
or	O
aorta	B-UNK
/	O
serum	B-UNK
-	O
ratio	B-UNK
were	O
recorded	O
between	O
experimental	B-UNK
and	O
control	B-UNK
groups	I-UNK
10	O
minutes	B-UNK
after	O
tracer	O
injection	B-UNK
,	O
indicating	O
that	O
the	O
permeability	B-UNK
of	O
the	O
endothelial	B-UNK
barrier	B-UNK
to	O
albumin	B-UNK
remained	B-UNK
unaffected	B-UNK
by	O
D	O
-	O
pen	O
treatment	B-UNK
.	O
These	O
observations	B-UNK
support	B-UNK
the	O
hypothesis	B-UNK
that	O
treatment	B-UNK
with	O
high	B-UNK
doses	I-UNK
of	O
D	O
-	O
pen	O
may	O
induce	B-UNK
a	O
fibroproliferative	O
response	B-UNK
in	O
rat	B-UNK
aorta	B-UNK
,	O
possibly	O
by	O
an	O
inhibitory	B-UNK
effect	B-UNK
on	O
the	O
cross-linking	O
of	O
collagen	O
and	O
elastin	O
.	O

Brain	B-UNK
natriuretic	B-UNK
peptide	B-UNK
is	O
a	O
predictor	O
of	O
anthracycline	B-UNK
-	O
induced	O
cardiotoxicity	B-UNK
.	O
Anthracyclines	O
are	O
effective	B-UNK
antineoplastic	B-CHEMICAL
drugs	I-CHEMICAL
,	O
but	O
they	O
frequently	B-UNK
cause	O
dose	B-UNK
-	O
related	O
cardiotoxicity	B-DISEASE
.	O
The	O
cardiotoxicity	B-UNK
of	O
conventional	B-UNK
anthracycline	B-UNK
therapy	O
highlights	O
a	O
need	O
to	O
search	B-UNK
for	O
methods	B-UNK
that	O
are	O
highly	B-UNK
sensitive	B-UNK
and	O
capable	O
of	O
predicting	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
.	O
We	O
measured	B-UNK
the	O
plasma	B-UNK
level	B-UNK
of	O
brain	B-UNK
natriuretic	B-UNK
peptide	B-UNK
(	O
BNP	O
)	O
to	O
determine	B-UNK
whether	O
BNP	O
might	O
serve	O
as	O
a	O
simple	O
diagnostic	B-UNK
indicator	O
of	O
anthracycline	B-UNK
-	O
induced	O
cardiotoxicity	B-DISEASE
in	O
patients	B-UNK
with	O
acute	B-DISEASE
leukemia	I-DISEASE
treated	O
with	O
a	O
daunorubicin	B-CHEMICAL
(	O
DNR)-containing	O
regimen	B-UNK
.	O
Thirteen	B-UNK
patients	B-UNK
with	O
acute	B-DISEASE
leukemia	I-DISEASE
were	O
treated	O
with	O
a	O
DNR	O
-	O
containing	O
regimen	B-UNK
.	O
Cardiac	B-UNK
functions	B-UNK
were	O
evaluated	B-UNK
with	O
radionuclide	O
angiography	B-UNK
before	O
chemotherapies	O
.	O
The	O
plasma	B-UNK
levels	O
of	O
atrial	B-UNK
natriuretic	B-UNK
peptide	B-UNK
(	O
ANP	B-UNK
)	O
and	O
BNP	O
were	O
measured	B-UNK
at	O
the	O
time	O
of	O
radionuclide	O
angiography	B-UNK
.	O
Three	O
patients	B-UNK
developed	O
congestive	B-UNK
heart	I-UNK
failure	I-UNK
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O
Five	O
patients	B-UNK
were	O
diagnosed	B-UNK
as	O
having	O
subclinical	O
heart	B-UNK
failure	I-UNK
after	O
the	O
completion	O
of	O
chemotherapy	O
.	O
The	O
plasma	B-UNK
levels	O
of	O
BNP	O
in	O
all	O
the	O
patients	B-UNK
with	O
clinical	B-UNK
and	O
subclinical	O
heart	B-UNK
failure	I-UNK
increased	B-UNK
above	O
the	O
normal	O
limit	B-UNK
(	O
40	O
pg	B-UNK
/	O
ml	B-UNK
)	O
before	O
the	O
detection	B-UNK
of	O
clinical	B-UNK
or	O
subclinical	O
heart	B-DISEASE
failure	I-DISEASE
by	O
radionuclide	O
angiography	B-UNK
.	O
On	O
the	O
other	O
hand	B-UNK
,	O
BNP	O
did	O
not	O
increase	B-UNK
in	O
the	O
patients	B-UNK
without	O
heart	B-UNK
failure	I-UNK
given	O
DNR	O
,	O
even	O
at	O
more	O
than	O
700	O
mg	B-UNK
/	O
m(2	O
)	O
.	O
The	O
plasma	B-UNK
level	B-UNK
of	O
ANP	B-CHEMICAL
did	O
not	O
always	O
increase	B-UNK
in	O
all	O
the	O
patients	B-UNK
with	O
clinical	B-UNK
and	O
subclinical	O
heart	B-UNK
failure	I-UNK
.	O
These	O
preliminary	B-UNK
results	B-UNK
suggest	B-UNK
that	O
BNP	O
may	O
be	O
useful	O
as	O
an	O
early	B-UNK
and	O
sensitive	B-UNK
indicator	O
of	O
anthracycline	B-UNK
-	O
induced	O
cardiotoxicity	B-UNK
.	O

Antibacterial	O
medication	O
use	O
during	O
pregnancy	B-UNK
and	O
risk	B-UNK
of	O
birth	B-DISEASE
defects	I-DISEASE
:	O
National	B-UNK
Birth	B-DISEASE
Defects	I-DISEASE
Prevention	B-UNK
Study	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
To	O
estimate	B-UNK
the	O
association	B-UNK
between	O
antibacterial	O
medications	B-UNK
and	O
selected	O
birth	B-DISEASE
defects	I-DISEASE
.	O
DESIGN	B-UNK
,	O
SETTING	B-UNK
,	O
AND	O
PARTICIPANTS	B-UNK
:	O
Population	B-UNK
-	O
based	B-UNK
,	O
multisite	O
,	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
of	O
women	B-UNK
who	O
had	O
pregnancies	B-UNK
affected	B-UNK
by	O
1	O
of	O
more	O
than	O
30	O
eligible	O
major	B-UNK
birth	B-DISEASE
defects	I-DISEASE
identified	B-UNK
via	O
birth	B-DISEASE
defect	I-DISEASE
surveillance	B-UNK
programs	O
in	O
10	O
states	B-UNK
(	O
n	O
=	O
13	O
155	O
)	O
and	O
control	B-UNK
women	B-UNK
randomly	B-UNK
selected	O
from	O
the	O
same	O
geographical	O
regions	B-UNK
(	O
n	O
=	O
4941	O
)	O
.	O
MAIN	B-UNK
EXPOSURE	B-UNK
:	O
Reported	B-UNK
maternal	B-UNK
use	O
of	O
antibacterials	O
(	O
1	O
month	B-UNK
before	O
pregnancy	B-UNK
through	O
the	O
end	B-UNK
of	O
the	O
first	O
trimester	O
)	O
.	O
MAIN	B-UNK
OUTCOME	B-UNK
MEASURE	B-UNK
:	O
Odds	B-UNK
ratios	O
(	O
ORs	O
)	O
measuring	B-UNK
the	O
association	B-UNK
between	O
antibacterial	O
use	O
and	O
selected	O
birth	B-DISEASE
defects	I-DISEASE
adjusted	B-UNK
for	O
potential	B-UNK
confounders	O
.	O
RESULTS	B-UNK
:	O
The	O
reported	B-UNK
use	O
of	O
antibacterials	O
increased	B-UNK
during	O
pregnancy	B-UNK
,	O
peaking	O
during	O
the	O
third	O
month	B-UNK
.	O
Sulfonamides	O
were	O
associated	O
with	O
anencephaly	B-DISEASE
(	O
adjusted	B-UNK
OR	O
[	O
AOR	O
]	O
=	O
3.4	O
;	O
95	O
%	O
confidence	O
interval	B-UNK
[	O
CI	B-UNK
]	O
,	O
1.3	O
-	O
8.8	O
)	O
,	O
hypoplastic	B-DISEASE
left	I-DISEASE
heart	I-DISEASE
syndrome	I-DISEASE
(	O
AOR	B-UNK
=	I-UNK
3.2	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.3	O
-	O
7.6	O
)	O
,	O
coarctation	B-DISEASE
of	I-DISEASE
the	I-DISEASE
aorta	I-DISEASE
(	O
AOR	B-UNK
=	I-UNK
2.7	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.3	O
-	O
5.6	O
)	O
,	O
choanal	B-DISEASE
atresia	I-DISEASE
(	O
AOR	B-UNK
=	I-UNK
8.0	O
;	O
95	O
%	O
CI	B-UNK
,	O
2.7	O
-	O
23.5	O
)	O
,	O
transverse	O
limb	O
deficiency	B-UNK
(	O
AOR	B-UNK
=	I-UNK
2.5	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.0	O
-	O
5.9	O
)	O
,	O
and	O
diaphragmatic	B-DISEASE
hernia	I-DISEASE
(	O
AOR	B-UNK
=	I-UNK
2.4	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.1	O
-	O
5.4	O
)	O
.	O
Nitrofurantoins	O
were	O
associated	O
with	O
anophthalmia	B-DISEASE
or	O
microphthalmos	B-DISEASE
(	O
AOR	B-UNK
=	I-UNK
3.7	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.1	O
-	O
12.2	O
)	O
,	O
hypoplastic	B-DISEASE
left	I-DISEASE
heart	I-DISEASE
syndrome	I-DISEASE
(	O
AOR	B-UNK
=	I-UNK
4.2	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.9	O
-	O
9.1	O
)	O
,	O
atrial	B-DISEASE
septal	I-DISEASE
defects	I-DISEASE
(	O
AOR	B-UNK
=	I-UNK
1.9	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.1	O
-	O
3.4	O
)	O
,	O
and	O
cleft	B-DISEASE
lip	I-DISEASE
with	O
cleft	B-DISEASE
palate	I-DISEASE
(	O
AOR	B-UNK
=	I-UNK
2.1	O
;	O
95	O
%	O
CI	B-UNK
,	O
1.2	O
-	O
3.9	O
)	O
.	O
Other	O
antibacterial	O
agents	B-UNK
that	O
showed	O
associations	B-UNK
included	B-UNK
erythromycins	O
(	O
2	O
defects	B-UNK
)	O
,	O
penicillins	O
(	O
1	O
defect	B-UNK
)	O
,	O
cephalosporins	B-CHEMICAL
(	O
1	O
defect	B-UNK
)	O
,	O
and	O
quinolones	O
(	O
1	O
defect	B-UNK
)	O
.	O
CONCLUSIONS	B-UNK
:	O
Reassuringly	O
,	O
penicillins	O
,	O
erythromycins	O
,	O
and	O
cephalosporins	B-CHEMICAL
,	O
although	O
used	O
commonly	B-UNK
by	O
pregnant	B-UNK
women	B-UNK
,	O
were	O
not	O
associated	O
with	O
many	O
birth	B-DISEASE
defects	I-DISEASE
.	O
Sulfonamides	O
and	O
nitrofurantoins	O
were	O
associated	O
with	O
several	O
birth	B-DISEASE
defects	I-DISEASE
,	O
indicating	O
a	O
need	O
for	O
additional	B-UNK
scrutiny	O
.	O

Incidence	B-UNK
of	O
neoplasms	B-DISEASE
in	O
patients	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
exposed	B-UNK
to	O
different	O
treatment	B-UNK
regimens	B-UNK
.	O
Immunosuppressive	B-UNK
drugs	B-UNK
have	O
been	O
used	O
during	O
the	O
last	O
30	O
years	B-UNK
in	O
treatment	B-UNK
of	O
patients	B-UNK
with	O
severe	B-UNK
rheumatoid	B-UNK
arthritis	I-UNK
.	O
The	O
drugs	B-UNK
commonly	B-UNK
used	O
are	O
cyclophosphamide	B-CHEMICAL
and	O
chlorambucil	O
(	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
)	O
,	O
azathioprine	B-UNK
(	O
purine	O
analogue	B-UNK
)	O
,	O
and	O
methotrexate	B-UNK
(	O
folic	B-UNK
acid	I-UNK
analogue	B-UNK
)	O
.	O
There	O
is	O
evidence	B-UNK
that	O
all	O
four	O
immunosuppressive	B-UNK
drugs	B-UNK
can	O
reduce	B-UNK
synovitis	B-DISEASE
,	O
but	O
disease	B-DISEASE
activity	B-UNK
almost	O
always	O
recurs	O
after	O
therapy	O
is	O
stopped	O
.	O
Since	O
adverse	B-UNK
reactions	I-UNK
are	O
frequent	B-UNK
,	O
less	O
than	O
50	O
percent	B-UNK
of	O
patients	B-UNK
are	O
able	O
to	O
continue	B-UNK
a	O
particular	O
drug	B-UNK
for	O
more	O
than	O
one	O
year	O
.	O
Since	O
it	O
takes	O
three	O
to	O
12	O
months	B-UNK
to	O
achieve	B-UNK
maximal	B-UNK
effects	O
,	O
those	O
patients	B-UNK
who	O
are	O
unable	O
to	O
continue	B-UNK
the	O
drug	B-UNK
receive	B-UNK
little	O
benefit	O
from	O
it	O
.	O
Patients	B-UNK
treated	O
with	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
have	O
an	O
increased	B-UNK
risk	B-UNK
of	O
development	B-UNK
of	O
acute	B-DISEASE
nonlymphocytic	I-DISEASE
leukemia	I-DISEASE
,	O
and	O
both	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
and	O
azathioprine	B-CHEMICAL
are	O
associated	O
with	O
the	O
development	B-UNK
of	O
non-Hodgkin's	O
lymphoma	B-UNK
.	O
Cyclophosphamide	B-UNK
therapy	O
increases	B-UNK
the	O
risk	B-UNK
of	O
carcinoma	B-UNK
of	O
the	O
bladder	B-UNK
.	O
There	O
have	O
been	O
several	O
long	B-UNK
-	O
term	O
studies	B-UNK
of	O
patients	B-UNK
with	O
rheumatoid	B-UNK
arthritis	I-UNK
treated	O
with	O
azathioprine	B-UNK
and	O
cyclophosphamide	B-CHEMICAL
and	O
the	O
incidence	B-UNK
of	O
most	O
of	O
the	O
common	B-UNK
cancers	B-UNK
is	O
not	O
increased	B-UNK
.	O
Data	B-UNK
on	O
the	O
possible	O
increased	B-UNK
risk	B-UNK
of	O
malignancy	B-DISEASE
in	O
rheumatoid	B-UNK
arthritis	I-UNK
are	O
still	O
being	O
collected	O
,	O
and	O
until	O
further	O
information	B-UNK
is	O
available	O
,	O
the	O
use	O
of	O
immunosuppressive	B-UNK
drugs	B-UNK
,	O
particularly	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
,	O
in	O
the	O
treatment	B-UNK
of	O
rheumatoid	B-UNK
arthritis	I-UNK
should	O
be	O
reserved	O
for	O
patients	B-UNK
with	O
severe	B-UNK
progressive	B-UNK
disease	B-UNK
or	O
life	B-UNK
-	O
threatening	O
complications	B-UNK
.	O

Patterns	B-UNK
of	O
hepatic	B-UNK
injury	I-UNK
induced	O
by	O
methyldopa	B-CHEMICAL
.	O
Twelve	O
patients	B-UNK
with	O
liver	B-UNK
disease	I-UNK
related	O
to	O
methyldopa	B-CHEMICAL
were	O
seen	O
between	O
1967	O
and	O
1977	O
.	O
Illness	B-UNK
occurred	B-UNK
within	O
1	O
-	O
-9	O
weeks	B-UNK
of	O
commencement	O
of	O
therapy	O
in	O
9	O
patients	B-UNK
,	O
the	O
remaining	O
3	O
patients	B-UNK
having	O
received	O
the	O
drug	B-UNK
for	O
13	O
months	B-UNK
,	O
15	O
months	B-UNK
and	O
7	O
years	B-UNK
before	O
experiencing	O
symptoms	B-UNK
.	O
Jaundice	B-UNK
with	O
tender	O
hepatomegaly	B-DISEASE
,	O
usually	O
preceded	B-UNK
by	O
symptoms	B-UNK
of	O
malaise	O
,	O
anorexia	B-DISEASE
,	O
nausea	B-UNK
and	I-UNK
vomiting	I-UNK
,	O
and	O
associated	O
with	O
upper	B-UNK
abdominal	B-UNK
pain	I-UNK
,	O
was	O
an	O
invariable	O
finding	O
in	O
all	O
patients	B-UNK
.	O
Biochemical	B-UNK
liver	B-UNK
function	I-UNK
tests	I-UNK
indicated	O
hepatocellular	B-UNK
necrosis	B-UNK
and	O
correlated	B-UNK
with	O
histopathological	B-UNK
evidence	B-UNK
of	O
hepatic	B-UNK
injury	I-UNK
,	O
the	O
spectrum	B-UNK
of	O
which	O
ranged	B-UNK
from	O
fatty	B-DISEASE
change	I-DISEASE
and	O
focal	B-UNK
hepatocellular	B-UNK
necrosis	B-UNK
to	O
massive	B-DISEASE
hepatic	I-DISEASE
necrosis	I-DISEASE
.	O
Most	O
patients	B-UNK
showed	O
moderate	B-UNK
to	I-UNK
severe	I-UNK
acute	B-UNK
hepatitis	I-UNK
or	O
chronic	B-DISEASE
active	I-DISEASE
hepatitis	I-DISEASE
with	O
associated	O
cholestasis	B-UNK
.	O
The	O
drug	B-UNK
was	O
withdrawn	O
on	O
presentation	B-UNK
to	O
hospital	B-UNK
in	O
11	O
patients	B-UNK
,	O
with	O
rapid	B-UNK
clinical	B-UNK
improvement	B-UNK
in	O
9	O
.	O
One	O
patient	B-UNK
died	O
,	O
having	O
presented	B-UNK
in	O
hepatic	B-UNK
failure	I-UNK
,	O
and	O
another	O
,	O
who	O
had	O
been	O
taking	B-UNK
methyldopa	B-UNK
for	O
7	O
years	B-UNK
,	O
showed	O
slower	O
clinical	B-UNK
and	O
biochemical	B-UNK
resolution	B-UNK
over	O
a	O
period	B-UNK
of	O
several	O
months	B-UNK
.	O
The	O
remaining	O
patient	B-UNK
in	O
the	O
series	B-UNK
developed	O
fulminant	B-UNK
hepatitis	B-UNK
when	O
the	O
drug	B-UNK
was	O
accidentally	O
recommenced	O
1	O
year	O
after	O
a	O
prior	B-UNK
episode	B-UNK
of	O
methyldopa	B-CHEMICAL
-	O
induced	O
hepatitis	B-UNK
.	O
In	O
this	O
latter	O
patient	B-UNK
,	O
and	O
in	O
2	O
others	O
,	O
the	O
causal	O
relationship	B-UNK
between	O
methyldopa	B-UNK
and	O
hepatic	B-UNK
dysfunction	B-UNK
was	O
proved	O
with	O
the	O
recurrence	B-UNK
of	O
hepatitis	B-UNK
within	O
2	O
weeks	B-UNK
of	O
re-exposure	O
to	O
the	O
drug	B-UNK
.	O

A	O
phase	B-UNK
I	O
/	O
II	B-UNK
study	B-UNK
of	O
paclitaxel	B-CHEMICAL
plus	O
cisplatin	B-UNK
as	O
first	O
-	O
line	B-UNK
therapy	O
for	O
head	B-UNK
and	I-UNK
neck	I-UNK
cancers	B-UNK
:	O
preliminary	B-UNK
results	B-UNK
.	O
Improved	O
outcomes	B-UNK
among	O
patients	B-UNK
with	O
head	B-UNK
and	I-UNK
neck	I-UNK
carcinomas	O
require	O
investigations	B-UNK
of	O
new	O
drugs	B-UNK
for	O
induction	B-UNK
therapy	O
.	O
Preliminary	B-UNK
results	B-UNK
of	O
an	O
Eastern	O
Cooperative	O
Oncology	B-UNK
Group	B-UNK
study	B-UNK
of	O
single	B-UNK
-	O
agent	B-UNK
paclitaxel	B-UNK
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
reported	B-UNK
a	O
37	O
%	O
response	B-UNK
rate	B-UNK
in	O
patients	B-UNK
with	O
head	B-DISEASE
and	I-DISEASE
neck	I-DISEASE
cancer	I-DISEASE
,	O
and	O
the	O
paclitaxel	B-UNK
/	O
cisplatin	B-CHEMICAL
combination	B-UNK
has	O
been	O
used	O
successfully	O
and	O
has	O
significantly	B-UNK
improved	O
median	B-UNK
response	B-UNK
duration	B-UNK
in	O
ovarian	B-UNK
cancer	I-UNK
patients	B-UNK
.	O
We	O
initiated	O
a	O
phase	B-UNK
I	O
/	O
II	B-UNK
trial	B-UNK
to	O
determine	B-UNK
the	O
response	B-UNK
and	O
toxicity	B-UNK
of	O
escalating	O
paclitaxel	B-CHEMICAL
doses	B-UNK
combined	B-UNK
with	O
fixed	B-UNK
-	O
dose	B-UNK
cisplatin	B-UNK
with	O
granulocyte	O
colony	O
-	O
stimulating	B-UNK
factor	B-UNK
support	B-UNK
in	O
patients	B-UNK
with	O
untreated	B-UNK
locally	O
advanced	B-UNK
inoperable	O
head	B-UNK
and	I-UNK
neck	I-UNK
carcinoma	B-UNK
.	O
To	O
date	B-UNK
,	O
23	O
men	B-UNK
with	O
a	O
median	B-UNK
age	I-UNK
of	O
50	O
years	B-UNK
and	O
good	O
performance	B-UNK
status	B-UNK
have	O
entered	O
the	O
trial	B-UNK
.	O
Primary	B-UNK
tumor	B-DISEASE
sites	B-UNK
were	O
oropharynx	O
,	O
10	O
patients	B-UNK
;	O
hypopharynx	O
,	O
four	O
;	O
larynx	O
,	O
two	O
;	O
oral	B-UNK
cavity	O
,	O
three	O
;	O
unknown	O
primary	B-UNK
,	O
two	O
;	O
and	O
nasal	O
cavity	O
and	O
parotid	O
gland	O
,	O
one	O
each	O
.	O
Of	O
20	O
patients	B-UNK
evaluable	B-UNK
for	O
toxicity	B-UNK
,	O
four	O
had	O
stage	B-UNK
III	B-UNK
and	O
16	O
had	O
stage	B-UNK
IV	B-UNK
disease	B-UNK
.	O
Treatment	B-UNK
,	O
given	O
every	O
21	O
days	B-UNK
for	O
a	O
maximum	B-UNK
of	O
three	O
cycles	B-UNK
,	O
consisted	B-UNK
of	O
paclitaxel	B-UNK
by	O
3-hour	O
infusion	B-UNK
followed	O
the	O
next	O
day	O
by	O
a	O
fixed	B-UNK
dose	B-UNK
of	O
cisplatin	B-CHEMICAL
(	O
75	O
mg	B-UNK
/	O
m2	B-UNK
)	O
.	O
The	O
dose	B-UNK
levels	O
incorporate	O
escalating	O
paclitaxel	B-CHEMICAL
doses	B-UNK
,	O
and	O
intrapatient	O
escalations	O
within	O
a	O
given	O
dose	B-UNK
level	B-UNK
are	O
permitted	O
if	O
toxicity	B-UNK
permits	O
.	O
At	O
the	O
time	O
of	O
this	O
writing	O
,	O
dose	B-UNK
level	B-UNK
4	O
(	O
260	O
,	O
270	O
,	O
and	O
280	O
mg	B-UNK
/	O
m2	B-UNK
)	O
is	O
being	O
evaluated	B-UNK
;	O
three	O
patients	B-UNK
from	O
this	O
level	B-UNK
are	O
evaluable	B-UNK
.	O
With	O
paclitaxel	B-UNK
doses	B-UNK
of	O
200	O
mg	B-UNK
/	O
m2	B-UNK
and	O
higher	B-UNK
,	O
granulocyte	O
colony	O
-	O
stimulating	B-UNK
factor	B-UNK
5	O
micrograms	B-UNK
/	O
kg	B-UNK
/	O
d	O
is	O
given	O
(	O
days	B-UNK
4	O
through	O
12	O
)	O
.	O
Of	O
18	O
patients	B-UNK
evaluable	B-UNK
for	O
response	B-UNK
,	O
seven	O
(	O
39	O
%	O
)	O
achieved	O
a	O
complete	B-UNK
response	B-UNK
and	O
six	O
(	O
33	O
%	O
)	O
achieved	O
a	O
partial	B-UNK
response	I-UNK
.	O
Three	O
patients	B-UNK
had	O
no	O
change	B-UNK
and	O
disease	B-UNK
progressed	O
in	O
two	O
.	O
The	O
overall	O
response	B-UNK
rate	B-UNK
is	O
72	O
%	O
.	O
Eleven	O
responding	O
patients	B-UNK
had	O
subsequent	B-UNK
surgery	B-UNK
/	O
radiotherapy	B-UNK
or	O
radical	B-UNK
radiotherapy	B-UNK
.	O
Two	O
pathologic	O
complete	B-UNK
responses	O
were	O
observed	O
in	O
patients	B-UNK
who	O
had	O
achieved	O
clinical	B-UNK
complete	B-UNK
responses	O
.	O
Alopecia	B-DISEASE
,	O
paresthesias	O
,	O
and	O
arthralgias	B-DISEASE
/	O
myalgias	O
have	O
occurred	B-UNK
frequently	B-UNK
,	O
but	O
with	O
one	O
exception	O
(	O
a	O
grade	B-UNK
3	O
myalgia	B-UNK
)	O
they	O
have	O
been	O
grade	B-UNK
1	O
or	O
2	O
.	O
No	O
dose	B-UNK
-	O
limiting	B-UNK
hematologic	B-UNK
toxicity	B-DISEASE
has	O
been	O
seen	O
.	O
Paclitaxel	B-UNK
/	O
cisplatin	B-UNK
is	O
an	O
effective	B-UNK
first	O
-	O
line	B-UNK
regimen	B-UNK
for	O
locoregionally	O
advanced	B-UNK
head	B-DISEASE
and	I-DISEASE
neck	I-DISEASE
cancer	I-DISEASE
and	O
continued	O
study	B-UNK
is	O
warranted	O
.	O
Results	B-UNK
thus	O
far	O
suggest	B-UNK
no	O
dose	B-UNK
-	O
response	B-UNK
effect	B-UNK
for	O
paclitaxel	B-CHEMICAL
doses	B-UNK
above	O
200	O
mg	B-UNK
/	O
m2	B-UNK
.	O

A	O
phase	B-UNK
I	O
study	B-UNK
of	O
4'-0-tetrahydropyranyladriamycin	B-CHEMICAL
.	O
Clinical	B-UNK
pharmacology	B-UNK
and	O
pharmacokinetics	B-UNK
.	O
A	O
Phase	B-UNK
I	O
study	B-UNK
of	O
intravenous	B-UNK
(	O
IV	B-UNK
)	O
bolus	B-UNK
4'-0-tetrahydropyranyladriamycin	B-CHEMICAL
(	O
Pirarubicin	B-CHEMICAL
)	O
was	O
done	O
in	O
55	O
patients	B-UNK
in	O
good	O
performance	B-UNK
status	B-UNK
with	O
refractory	B-UNK
tumors	B-UNK
.	O
Twenty	O
-	O
six	O
had	O
minimal	B-UNK
prior	B-UNK
therapy	O
(	O
good	O
risk	B-UNK
)	O
,	O
23	O
had	O
extensive	B-UNK
prior	B-UNK
therapy	O
(	O
poor	O
risk	B-UNK
)	O
,	O
and	O
six	O
had	O
renal	B-UNK
and	O
/	O
or	O
hepatic	B-UNK
dysfunction	B-UNK
.	O
A	O
total	B-UNK
of	O
167	O
courses	B-UNK
at	O
doses	B-UNK
of	O
15	O
to	O
70	O
mg	B-UNK
/	O
m2	B-UNK
were	O
evaluable	B-UNK
.	O
Maximum	B-UNK
tolerated	B-UNK
dose	B-UNK
in	O
good	O
-	O
risk	B-UNK
patients	B-UNK
was	O
70	O
mg	B-UNK
/	O
m2	B-UNK
,	O
and	O
in	O
poor	O
-	O
risk	B-UNK
patients	B-UNK
,	O
60	O
mg	B-UNK
/	O
m2	B-UNK
.	O
The	O
dose	B-UNK
-	O
limiting	B-UNK
toxic	B-UNK
effect	B-UNK
was	O
transient	B-UNK
noncumulative	O
granulocytopenia	O
.	O
Granulocyte	O
nadir	O
was	O
on	O
day	O
14	O
(	O
range	B-UNK
,	O
4	O
-	O
22	O
)	O
.	O
Less	O
frequent	B-UNK
toxic	B-UNK
effects	I-UNK
included	B-UNK
thrombocytopenia	B-UNK
,	O
anemia	B-UNK
,	O
nausea	B-DISEASE
,	O
mild	B-UNK
alopecia	B-DISEASE
,	O
phlebitis	B-DISEASE
,	O
and	O
mucositis	B-DISEASE
.	O
Myelosuppression	B-DISEASE
was	O
more	O
in	O
patients	B-UNK
with	O
hepatic	B-UNK
dysfunction	B-UNK
.	O
Pharmacokinetic	B-UNK
analyses	B-UNK
in	O
21	O
patients	B-UNK
revealed	O
Pirarubicin	B-CHEMICAL
plasma	B-UNK
T	O
1/2	O
alpha	B-UNK
(	O
+	O
/-	O
SE	B-UNK
)	O
of	O
2.5	O
+	O
/-	O
0.85	O
minutes	B-UNK
,	O
T	O
beta	B-UNK
1/2	O
of	O
25.6	O
+	O
/-	O
6.5	O
minutes	B-UNK
,	O
and	O
T	O
1/2	O
gamma	B-UNK
of	O
23.6	O
+	O
/-	O
7.6	O
hours	B-UNK
.	O
The	O
area	B-UNK
under	O
the	O
curve	B-UNK
was	O
537	O
+	O
/-	O
149	O
ng	B-UNK
/	O
ml	B-UNK
x	O
hours	B-UNK
,	O
volume	B-UNK
of	O
distribution	B-UNK
(	O
Vd	O
)	O
3504	O
+	O
/-	O
644	O
l	O
/	O
m2	B-UNK
,	O
and	O
total	B-UNK
clearance	B-UNK
(	O
ClT	O
)	O
was	O
204	O
+	O
39.3	O
l	O
/	O
hour	B-UNK
/	O
m2	B-UNK
.	O
Adriamycinol	B-CHEMICAL
,	O
doxorubicin	B-CHEMICAL
,	O
adriamycinone	O
,	O
and	O
tetrahydropyranyladriamycinol	O
were	O
the	O
metabolites	B-UNK
detected	B-UNK
in	O
plasma	B-UNK
and	O
the	O
amount	O
of	O
doxorubicin	B-UNK
was	O
less	O
than	O
or	O
equal	B-UNK
to	O
10	O
%	O
of	O
the	O
total	B-UNK
metabolites	B-UNK
.	O
Urinary	B-UNK
excretion	B-UNK
of	O
Pirarubicin	B-CHEMICAL
in	O
the	O
first	O
24	O
hours	B-UNK
was	O
less	O
than	O
or	O
equal	B-UNK
to	O
10	O
%	O
.	O
Activity	B-UNK
was	O
noted	B-UNK
in	O
mesothelioma	B-DISEASE
,	O
leiomyosarcoma	B-DISEASE
,	O
and	O
basal	B-DISEASE
cell	I-DISEASE
carcinoma	I-DISEASE
.	O
The	O
recommended	O
starting	B-UNK
dose	B-UNK
for	O
Phase	B-UNK
II	I-UNK
trials	B-UNK
is	O
60	O
mg	B-UNK
/	O
m2	B-UNK
IV	B-UNK
bolus	B-UNK
every	O
3	O
weeks	B-UNK
.	O

Differential	B-UNK
effects	O
of	O
gamma	B-UNK
-	O
hexachlorocyclohexane	O
(	O
lindane	B-CHEMICAL
)	O
on	O
pharmacologically	O
-	O
induced	O
seizures	B-UNK
.	O
Gamma	B-UNK
-	O
hexachlorocyclohexane	O
(	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
)	O
,	O
the	O
active	B-UNK
ingredient	O
of	O
the	O
insecticide	O
lindane	B-UNK
,	O
has	O
been	O
shown	B-UNK
to	O
decrease	B-UNK
seizure	B-UNK
threshold	B-UNK
to	O
pentylenetrazol	O
(	O
PTZ	B-UNK
)	O
3	O
h	O
after	O
exposure	B-UNK
to	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
and	O
conversely	O
increase	B-UNK
threshold	B-UNK
to	O
PTZ	B-UNK
-	O
induced	O
seizures	B-UNK
24	O
h	O
after	O
exposure	B-UNK
to	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
(	O
Vohland	O
et	O
al	B-UNK
.	O
1981	O
)	O
.	O
In	O
this	O
study	B-UNK
,	O
the	O
severity	B-UNK
of	O
response	B-UNK
to	O
other	O
seizure	B-UNK
-	O
inducing	O
agents	B-UNK
was	O
tested	B-UNK
in	O
mice	B-UNK
1	O
and	O
24	O
h	O
after	O
intraperitoneal	B-UNK
administration	O
of	O
80	O
mg	B-UNK
/	O
kg	B-UNK
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
.	O
One	O
hour	B-UNK
after	O
the	O
administration	O
of	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
,	O
the	O
activity	B-UNK
of	O
seizure	B-DISEASE
-	O
inducing	O
agents	B-UNK
was	O
increased	B-UNK
,	O
regardless	O
of	O
their	O
mechanism	B-UNK
,	O
while	O
24	O
h	O
after	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
a	O
differential	B-UNK
response	B-UNK
was	O
observed	O
.	O
Seizure	B-UNK
activity	B-UNK
due	O
to	O
PTZ	B-UNK
and	O
picrotoxin	B-UNK
(	O
PTX	O
)	O
was	O
significantly	B-UNK
decreased	B-UNK
;	O
however	O
,	O
seizure	B-DISEASE
activity	B-UNK
due	O
to	O
3-mercaptopropionic	B-CHEMICAL
acid	I-CHEMICAL
(	O
MPA	O
)	O
,	O
bicuculline	O
(	O
BCC	O
)	O
,	O
methyl	B-UNK
6,7-dimethoxy-4-ethyl	O
-	O
B	O
-	O
carboline-3-carboxylate	O
(	O
DMCM	O
)	O
,	O
or	O
strychnine	O
(	O
STR	O
)	O
was	O
not	O
different	O
from	O
control	B-UNK
.	O
In	O
vitro	B-UNK
,	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
,	O
pentylenetetrazol	O
and	O
picrotoxin	B-UNK
were	O
shown	B-UNK
to	O
inhibit	O
3H	B-CHEMICAL
-	I-CHEMICAL
TBOB	I-CHEMICAL
binding	B-UNK
in	O
mouse	B-UNK
whole	O
brain	B-UNK
,	O
with	O
IC50	O
values	O
of	O
4.6	O
,	O
404	O
and	O
9.4	O
microM	B-UNK
,	O
respectively	O
.	O
MPA	O
,	O
BCC	O
,	O
DMCM	O
,	O
and	O
STR	O
showed	O
no	O
inhibition	B-UNK
of	O
3H	B-CHEMICAL
-	I-CHEMICAL
TBOB	I-CHEMICAL
(	O
t	O
-	O
butyl	O
bicyclo	O
-	O
orthobenzoate	O
)	O
binding	B-UNK
at	O
concentrations	B-UNK
of	O
100	O
micron	O
.	O
The	O
pharmacological	B-UNK
challenge	B-UNK
data	B-UNK
suggest	I-UNK
that	O
tolerance	B-UNK
may	O
occur	O
to	O
seizure	B-UNK
activity	B-UNK
induced	O
by	O
PTZ	B-UNK
and	O
PTX	O
24	O
h	O
after	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
,	O
since	O
the	O
response	B-UNK
to	O
only	O
these	O
two	O
seizure	B-UNK
-	O
inducing	O
agents	B-UNK
is	O
decreased	B-UNK
.	O
The	O
in	O
vitro	B-UNK
data	B-UNK
suggest	I-UNK
that	O
the	O
site	B-UNK
responsible	B-UNK
for	O
the	O
decrease	B-UNK
in	O
seizure	B-UNK
activity	B-UNK
24	O
h	O
after	O
gamma	B-CHEMICAL
-	I-CHEMICAL
HCH	I-CHEMICAL
may	O
be	O
the	O
GABA	B-UNK
-	O
A	O
receptor	B-UNK
-	O
linked	B-UNK
chloride	B-UNK
channel	B-UNK
.	O

Severe	B-UNK
ocular	B-UNK
and	O
orbital	O
toxicity	B-UNK
after	O
intracarotid	O
injection	B-UNK
of	O
carboplatin	B-UNK
for	O
recurrent	B-UNK
glioblastomas	O
.	O
BACKGROUND	B-UNK
:	O
Glioblastoma	B-DISEASE
is	O
a	O
malignant	B-UNK
tumor	B-UNK
that	O
occurs	O
in	O
the	O
cerebrum	O
during	O
adulthood	O
.	O
With	O
current	B-UNK
treatment	B-UNK
regimens	B-UNK
including	O
combined	B-UNK
surgery	B-UNK
,	O
radiation	B-UNK
and	O
chemotherapy	O
,	O
the	O
average	B-UNK
life	B-UNK
expectancy	O
of	O
the	O
patients	B-UNK
is	O
limited	B-UNK
to	O
approximately	B-UNK
1	O
year	O
.	O
Therefore	O
,	O
patients	B-UNK
with	O
glioblastoma	B-DISEASE
sometimes	O
have	O
intracarotid	O
injection	B-UNK
of	O
carcinostatics	O
added	B-UNK
to	O
the	O
treatment	B-UNK
regimen	B-UNK
.	O
Generally	B-UNK
,	O
carboplatin	B-UNK
is	O
said	O
to	O
have	O
milder	O
side	O
effects	O
than	O
cisplatin	B-CHEMICAL
,	O
whose	O
ocular	B-UNK
and	O
orbital	O
toxicity	B-UNK
are	O
well	O
known	O
.	O
However	O
,	O
we	O
experienced	B-UNK
a	O
case	B-UNK
of	O
severe	B-UNK
ocular	B-UNK
and	O
orbital	O
toxicity	B-UNK
after	O
intracarotid	O
injection	B-UNK
of	O
carboplatin	B-UNK
,	O
which	O
is	O
infrequently	O
reported	B-UNK
.	O
CASE	B-UNK
:	O
A	O
58-year	O
-	O
old	O
man	B-UNK
received	O
an	O
intracarotid	O
injection	B-UNK
of	O
carboplatin	B-UNK
for	O
recurrent	B-UNK
glioblastomas	O
in	O
his	O
left	B-UNK
temporal	B-UNK
lobe	I-UNK
.	O
He	O
complained	O
of	O
pain	B-UNK
and	O
visual	B-UNK
disturbance	B-UNK
in	O
the	O
ipsilateral	B-UNK
eye	B-UNK
30	O
h	O
after	O
the	O
injection	B-UNK
.	O
Various	O
ocular	B-UNK
symptoms	B-UNK
and	O
findings	B-UNK
caused	B-UNK
by	O
carboplatin	B-UNK
toxicity	B-UNK
were	O
seen	O
.	O
RESULTS	B-UNK
:	O
He	O
was	O
treated	O
with	O
intravenous	B-UNK
administration	O
of	O
corticosteroids	B-UNK
and	O
glycerin	O
for	O
6	O
days	B-UNK
after	O
the	O
injection	B-UNK
.	O
Although	O
the	O
intraocular	B-UNK
pressure	I-UNK
elevation	B-UNK
caused	B-UNK
by	O
secondary	B-UNK
acute	B-UNK
angle	O
-	O
closure	O
glaucoma	B-UNK
decreased	B-UNK
and	O
ocular	B-UNK
pain	B-UNK
diminished	B-UNK
,	O
inexorable	O
papilledema	B-DISEASE
and	O
exudative	O
retinal	B-DISEASE
detachment	I-DISEASE
continued	O
for	O
3	O
weeks	B-UNK
.	O
Finally	B-UNK
,	O
6	O
weeks	B-UNK
later	O
,	O
diffuse	B-UNK
chorioretinal	B-DISEASE
atrophy	I-DISEASE
with	O
optic	B-DISEASE
atrophy	I-DISEASE
occurred	B-UNK
and	O
the	O
vision	B-UNK
in	O
his	O
left	B-UNK
eye	B-UNK
was	O
lost	O
.	O
CONCLUSION	B-UNK
:	O
When	O
performing	O
intracarotid	O
injection	B-UNK
of	O
carboplatin	B-UNK
,	O
we	O
must	O
be	O
aware	B-UNK
of	O
its	O
potentially	O
blinding	O
ocular	B-DISEASE
toxicity	I-DISEASE
.	O
It	O
is	O
recommended	O
that	O
further	O
studies	B-UNK
and	O
investigations	B-UNK
are	O
undertaken	B-UNK
in	O
the	O
effort	O
to	O
minimize	O
such	O
severe	B-UNK
side	O
effects	O
.	O

Phase	B-UNK
II	I-UNK
study	I-UNK
of	O
the	O
amsacrine	O
analogue	B-UNK
CI-921	O
(	O
NSC	O
343499	O
)	O
in	O
non-small	O
cell	B-UNK
lung	I-UNK
cancer	B-UNK
.	O
CI-921	O
(	O
NSC	O
343499	O
;	O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino	B-CHEMICAL
]	I-CHEMICAL
-N,5-dimethyl-	I-CHEMICAL
4-acridinecarboxamide	I-CHEMICAL
)	O
is	O
a	O
topoisomerase	O
II	B-UNK
poison	O
with	O
high	B-UNK
experimental	B-UNK
antitumour	O
activity	B-UNK
.	O
It	O
was	O
administered	O
by	O
15	O
min	B-UNK
infusion	B-UNK
to	O
16	O
evaluable	B-UNK
patients	B-UNK
with	O
non-small	O
cell	B-UNK
lung	I-UNK
cancer	B-UNK
(	O
NSCLC	B-UNK
)	O
(	O
7	O
with	O
no	O
prior	B-UNK
treatment	B-UNK
,	O
9	O
patients	B-UNK
in	O
relapse	B-UNK
following	O
surgery	B-UNK
/	O
radiotherapy	B-UNK
)	O
at	O
a	O
dose	B-UNK
(	O
648	O
mg	B-UNK
/	O
m2	B-UNK
divided	B-UNK
over	O
3	O
days	B-UNK
,	O
repeated	B-UNK
every	O
3	O
weeks	B-UNK
)	O
determined	B-UNK
by	O
phase	B-UNK
I	O
trial	B-UNK
.	O
Patients	B-UNK
had	O
a	O
median	B-UNK
performance	B-UNK
status	B-UNK
of	O
1	O
(	O
WHO	O
)	O
,	O
and	O
median	B-UNK
age	I-UNK
of	O
61	O
years	B-UNK
.	O
The	O
histology	B-UNK
comprised	O
squamous	O
carcinoma	B-DISEASE
(	O
11	O
)	O
,	O
adenocarcinoma	B-DISEASE
(	O
1	O
)	O
,	O
mixed	B-UNK
histology	B-UNK
(	O
2	O
)	O
,	O
bronchio	B-DISEASE
-	I-DISEASE
alveolar	I-DISEASE
carcinoma	I-DISEASE
(	O
1	O
)	O
and	O
large	B-UNK
cell	B-UNK
undifferentiated	O
carcinoma	B-DISEASE
(	O
1	O
)	O
.	O
Neutropenia	B-DISEASE
grade	B-UNK
greater	B-UNK
than	O
or	O
equal	B-UNK
to	O
3	O
was	O
seen	O
in	O
15	O
patients	B-UNK
,	O
infections	B-UNK
with	O
recovery	B-UNK
in	O
3	O
,	O
and	O
grand	O
mal	O
seizures	B-DISEASE
in	O
1	O
patient	B-UNK
.	O
Grade	B-UNK
less	O
than	O
or	O
equal	B-UNK
to	O
2	O
nausea	B-UNK
and	I-UNK
vomiting	I-UNK
occurred	B-UNK
in	O
66	O
%	O
courses	B-UNK
and	O
phlebitis	B-DISEASE
in	O
the	O
infusion	B-UNK
arm	O
in	O
37	O
%	O
.	O
1	O
patient	B-UNK
with	O
squamous	O
cell	B-UNK
carcinoma	B-UNK
achieved	O
a	O
partial	B-UNK
response	I-UNK
lasting	B-UNK
5	O
months	B-UNK
.	O
Further	O
testing	B-UNK
in	O
this	O
and	O
other	O
tumour	O
types	B-UNK
using	O
multiple	B-UNK
daily	B-UNK
schedules	O
is	O
warranted	O
.	O

Alpha	B-UNK
-	O
lipoic	O
acid	B-UNK
prevents	O
mitochondrial	B-UNK
damage	B-UNK
and	O
neurotoxicity	B-UNK
in	O
experimental	B-UNK
chemotherapy	O
neuropathy	B-UNK
.	O
The	O
study	B-UNK
investigates	O
if	O
alpha	B-UNK
-	O
lipoic	O
acid	B-UNK
is	O
neuroprotective	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-UNK
,	O
if	O
mitochondrial	B-UNK
damage	B-UNK
plays	O
a	O
critical	B-UNK
role	O
in	O
toxic	B-UNK
neurodegenerative	O
cascade	O
,	O
and	O
if	O
neuroprotective	O
effects	O
of	O
alpha	B-UNK
-	O
lipoic	O
acid	B-UNK
depend	O
on	O
mitochondria	B-UNK
protection	B-UNK
.	O
We	O
used	O
an	O
in	O
vitro	B-UNK
model	B-UNK
of	O
chemotherapy	O
induced	O
peripheral	B-UNK
neuropathy	I-UNK
that	O
closely	O
mimic	O
the	O
in	O
vivo	B-UNK
condition	B-UNK
by	O
exposing	O
primary	B-UNK
cultures	B-UNK
of	O
dorsal	B-UNK
root	O
ganglion	O
(	O
DRG	B-UNK
)	O
sensory	O
neurons	B-UNK
to	O
paclitaxel	B-CHEMICAL
and	O
cisplatin	B-UNK
,	O
two	O
widely	B-UNK
used	O
and	O
highly	B-UNK
effective	B-UNK
chemotherapeutic	B-UNK
drugs	B-UNK
.	O
This	O
approach	O
allowed	O
investigating	O
the	O
efficacy	B-UNK
of	O
alpha	B-UNK
-	O
lipoic	O
acid	B-UNK
in	O
preventing	O
axonal	B-DISEASE
damage	I-DISEASE
and	O
apoptosis	B-UNK
and	O
the	O
function	B-UNK
and	O
ultrastructural	B-UNK
morphology	O
of	O
mitochondria	B-UNK
after	O
exposure	B-UNK
to	O
toxic	B-UNK
agents	B-UNK
and	O
alpha	B-UNK
-	O
lipoic	O
acid	B-UNK
.	O
Our	O
results	B-UNK
demonstrate	O
that	O
both	O
cisplatin	B-CHEMICAL
and	O
paclitaxel	B-UNK
cause	O
early	B-UNK
mitochondrial	B-UNK
impairment	B-UNK
with	O
loss	B-UNK
of	O
membrane	B-UNK
potential	B-UNK
and	O
induction	B-UNK
of	O
autophagic	O
vacuoles	O
in	O
neurons	B-UNK
.	O
Alpha	B-UNK
-	O
lipoic	O
acid	B-UNK
exerts	B-UNK
neuroprotective	O
effects	O
against	O
chemotherapy	O
induced	O
neurotoxicity	B-UNK
in	O
sensory	O
neurons	B-UNK
:	O
it	O
rescues	O
the	O
mitochondrial	B-UNK
toxicity	B-DISEASE
and	O
induces	O
the	O
expression	B-UNK
of	O
frataxin	O
,	O
an	O
essential	B-UNK
mitochondrial	B-UNK
protein	B-UNK
with	O
anti-oxidant	O
and	O
chaperone	O
properties	B-UNK
.	O
In	O
conclusion	B-UNK
mitochondrial	B-UNK
toxicity	B-UNK
is	O
an	O
early	B-UNK
common	B-UNK
event	B-UNK
both	O
in	O
paclitaxel	B-UNK
and	O
cisplatin	B-UNK
induced	O
neurotoxicity	B-DISEASE
.	O
Alpha	B-UNK
-	O
lipoic	O
acid	B-UNK
protects	B-UNK
sensory	O
neurons	B-UNK
through	O
its	O
anti-oxidant	O
and	O
mitochondrial	B-UNK
regulatory	O
functions	B-UNK
,	O
possibly	O
inducing	O
the	O
expression	B-UNK
of	O
frataxin	O
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
alpha	B-UNK
-	O
lipoic	O
acid	B-UNK
might	O
reduce	B-UNK
the	O
risk	B-UNK
of	O
developing	B-UNK
peripheral	B-UNK
nerve	B-UNK
toxicity	B-UNK
in	O
patients	B-UNK
undergoing	B-UNK
chemotherapy	O
and	O
encourage	O
further	O
confirmatory	O
clinical	B-UNK
trials	I-UNK
.	O

Optimising	O
stroke	B-UNK
prevention	B-UNK
in	O
non-valvular	O
atrial	B-UNK
fibrillation	I-UNK
.	O
Atrial	B-DISEASE
fibrillation	I-DISEASE
is	O
associated	O
with	O
substantial	O
morbidity	B-UNK
and	I-UNK
mortality	I-UNK
.	O
Pooled	O
data	B-UNK
from	O
trials	B-UNK
comparing	B-UNK
antithrombotic	B-UNK
treatment	B-UNK
with	O
placebo	B-UNK
have	O
shown	B-UNK
that	O
warfarin	B-UNK
reduces	O
the	O
risk	B-UNK
of	O
stroke	B-UNK
by	O
62	O
%	O
,	O
and	O
that	O
aspirin	B-UNK
alone	O
reduces	O
the	O
risk	B-UNK
by	O
22	O
%	O
.	O
Overall	O
,	O
in	O
high	B-UNK
-	O
risk	B-UNK
patients	B-UNK
,	O
warfarin	B-UNK
is	O
superior	B-UNK
to	O
aspirin	B-UNK
in	O
preventing	O
strokes	B-UNK
,	O
with	O
a	O
relative	B-UNK
risk	I-UNK
reduction	O
of	O
36	O
%	O
.	O
Ximelagatran	O
,	O
an	O
oral	B-UNK
direct	B-CHEMICAL
thrombin	I-CHEMICAL
inhibitor	I-CHEMICAL
,	O
was	O
found	O
to	O
be	O
as	O
efficient	O
as	O
vitamin	B-UNK
K	O
antagonist	B-UNK
drugs	B-UNK
in	O
the	O
prevention	B-UNK
of	O
embolic	B-DISEASE
events	I-DISEASE
,	O
but	O
has	O
been	O
recently	B-UNK
withdrawn	O
because	O
of	O
abnormal	B-DISEASE
liver	I-DISEASE
function	I-DISEASE
tests	B-UNK
.	O
The	O
ACTIVE	B-UNK
-	O
W	O
(	O
Atrial	B-UNK
Fibrillation	I-UNK
Clopidogrel	B-CHEMICAL
Trial	B-UNK
with	O
Irbesartan	O
for	O
Prevention	B-UNK
of	O
Vascular	B-UNK
Events	B-UNK
)	O
study	B-UNK
has	O
demonstrated	O
that	O
warfarin	B-UNK
is	O
superior	B-UNK
to	O
platelet	B-UNK
therapy	O
(	O
clopidogrel	B-CHEMICAL
plus	O
aspirin	B-UNK
)	O
in	O
the	O
prevention	B-UNK
af	B-UNK
embolic	B-DISEASE
events	I-DISEASE
.	O
Idraparinux	O
,	O
a	O
Factor	B-CHEMICAL
Xa	I-CHEMICAL
inhibitor	B-UNK
,	O
is	O
being	O
evaluated	B-UNK
in	O
patients	B-UNK
with	O
atrial	B-DISEASE
fibrillation	I-DISEASE
.	O
Angiotensin	O
-	O
converting	B-UNK
enzyme	I-UNK
inhibitors	B-UNK
and	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
receptor	B-UNK
-	O
blocking	B-UNK
drugs	B-UNK
hold	O
promise	O
in	O
atrial	B-UNK
fibrillation	I-UNK
through	O
cardiac	B-DISEASE
remodelling	I-DISEASE
.	O
Preliminary	B-UNK
studies	B-UNK
suggest	B-UNK
that	O
statins	B-CHEMICAL
could	O
interfere	O
with	O
the	O
risk	B-UNK
of	O
recurrence	B-DISEASE
after	O
electrical	B-UNK
cardioversion	O
.	O
Finally	B-UNK
,	O
percutaneous	B-UNK
methods	B-UNK
for	O
the	O
exclusion	O
of	O
left	B-UNK
atrial	B-UNK
appendage	O
are	O
under	O
investigation	B-UNK
in	O
high	B-UNK
-	O
risk	B-UNK
patients	B-UNK
.	O

Interaction	B-UNK
of	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
with	O
antineoplastic	B-CHEMICAL
agents	I-CHEMICAL
.	O
A	O
synergistic	O
effect	B-UNK
of	O
etoposide	B-UNK
and	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
was	O
observed	O
in	O
a	O
patient	B-UNK
with	O
acute	B-DISEASE
T	I-DISEASE
-	I-DISEASE
lymphocytic	I-DISEASE
leukemia	I-DISEASE
in	O
relapse	B-UNK
.	O
The	O
concomitant	B-UNK
administration	O
of	O
etoposide	B-UNK
and	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
resulted	B-UNK
in	O
eradication	O
of	O
hitherto	O
refractory	B-UNK
leukemic	B-DISEASE
infiltration	I-DISEASE
of	O
bone	B-UNK
marrow	I-UNK
.	O
Severe	B-UNK
side	O
effects	O
in	O
terms	B-UNK
of	O
mental	B-UNK
confusion	B-DISEASE
and	O
progressive	B-UNK
hyperbilirubinemia	B-DISEASE
,	O
however	O
,	O
point	B-UNK
to	O
an	O
enhancement	B-UNK
not	O
only	O
of	O
antineoplastic	B-UNK
effects	O
but	O
also	O
of	O
toxicity	B-UNK
in	O
normal	O
tissues	B-UNK
.	O
This	O
report	B-UNK
demonstrates	O
for	O
the	O
first	O
time	O
that	O
the	O
pharmacodynamic	O
properties	B-UNK
of	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
may	O
not	O
be	O
confined	O
strictly	O
to	O
suppression	B-UNK
of	O
normal	O
T	O
-	O
cell	B-UNK
functions	B-UNK
.	O

The	O
hematologic	B-UNK
effects	O
of	O
cefonicid	B-CHEMICAL
and	O
cefazedone	B-CHEMICAL
in	O
the	O
dog	B-UNK
:	O
a	O
potential	B-UNK
model	B-UNK
of	O
cephalosporin	O
hematotoxicity	O
in	O
man	B-UNK
.	O
Cephalosporin	O
antibiotics	B-UNK
cause	O
a	O
variety	O
of	O
hematologic	B-UNK
disturbances	B-UNK
in	O
man	B-UNK
,	O
the	O
pathogeneses	O
and	O
hematopathology	O
of	O
which	O
remain	O
poorly	B-UNK
characterized	B-UNK
.	O
There	O
is	O
a	O
need	O
for	O
a	O
well	O
-	O
defined	B-UNK
animal	B-UNK
model	I-UNK
in	O
which	O
these	O
blood	B-DISEASE
dyscrasias	I-DISEASE
can	O
be	O
studied	O
.	O
In	O
four	O
subacute	B-UNK
toxicity	B-UNK
studies	B-UNK
,	O
the	O
intravenous	B-UNK
administration	O
of	O
cefonicid	B-CHEMICAL
or	O
cefazedone	B-CHEMICAL
to	O
beagle	O
dogs	B-UNK
caused	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
incidence	B-UNK
of	O
anemia	B-DISEASE
,	O
neutropenia	B-UNK
,	O
and	O
thrombocytopenia	B-UNK
after	O
1	O
-	O
3	O
months	B-UNK
of	O
treatment	B-UNK
.	O
A	O
nonregenerative	O
anemia	B-UNK
was	O
the	O
most	O
compromising	O
of	O
the	O
cytopenias	B-DISEASE
and	O
occurred	B-UNK
in	O
approximately	B-UNK
50	O
%	O
of	O
dogs	B-UNK
receiving	B-UNK
400	O
-	O
500	O
mg	B-UNK
/	O
kg	B-UNK
cefonicid	B-CHEMICAL
or	O
540	O
-	O
840	O
mg	B-UNK
/	O
kg	B-UNK
cefazedone	B-CHEMICAL
.	O
All	O
three	O
cytopenias	B-DISEASE
were	O
completely	O
reversible	B-UNK
following	O
cessation	B-UNK
of	O
treatment	B-UNK
;	O
the	O
time	O
required	B-UNK
for	O
recovery	B-UNK
of	O
the	O
erythron	O
(	O
approximately	B-UNK
1	O
month	B-UNK
)	O
was	O
considerably	O
longer	O
than	O
that	O
of	O
the	O
granulocytes	O
and	O
platelets	O
(	O
hours	B-UNK
to	O
a	O
few	O
days	B-UNK
)	O
.	O
Upon	O
rechallenge	O
with	O
either	O
cephalosporin	O
,	O
the	O
hematologic	B-UNK
syndrome	B-UNK
was	O
reproduced	O
in	O
most	O
dogs	B-UNK
tested	B-UNK
;	O
cefonicid	B-CHEMICAL
(	O
but	O
not	O
cefazedone)-treated	O
dogs	B-UNK
showed	O
a	O
substantially	O
reduced	B-UNK
induction	B-UNK
period	B-UNK
(	O
15	O
+	O
/-	O
5	O
days	B-UNK
)	O
compared	O
to	O
that	O
of	O
the	O
first	O
exposure	B-UNK
to	O
the	O
drug	B-UNK
(	O
61	O
+	O
/-	O
24	O
days	B-UNK
)	O
.	O
This	O
observation	B-UNK
,	O
along	O
with	O
the	O
rapid	B-UNK
rate	B-UNK
of	O
decline	B-UNK
in	O
red	B-UNK
cell	B-UNK
mass	B-UNK
parameters	O
of	O
affected	B-UNK
dogs	B-UNK
,	O
suggests	O
that	O
a	O
hemolytic	B-UNK
component	B-UNK
complicated	O
the	O
red	B-UNK
cell	B-UNK
production	B-UNK
problem	O
and	O
that	O
multiple	B-UNK
toxicologic	O
mechanisms	B-UNK
contributed	B-UNK
to	O
the	O
cytopenia	B-DISEASE
.	O
We	O
conclude	O
that	O
the	O
administration	O
of	O
high	B-UNK
doses	I-UNK
of	O
cefonicid	B-CHEMICAL
or	O
cefazedone	B-CHEMICAL
to	O
dogs	B-UNK
can	O
induce	B-UNK
hematotoxicity	O
similar	B-UNK
to	O
the	O
cephalosporin	O
-	O
induced	O
blood	B-DISEASE
dyscrasias	I-DISEASE
described	O
in	O
man	B-UNK
and	O
thus	O
provides	O
a	O
useful	O
model	B-UNK
for	O
studying	O
the	O
mechanisms	B-UNK
of	O
these	O
disorders	B-UNK
.	O

A	O
pyridoxine	B-CHEMICAL
-	O
dependent	B-UNK
behavioral	B-DISEASE
disorder	I-DISEASE
unmasked	O
by	O
isoniazid	B-UNK
.	O
A	O
3-year	O
-	O
old	O
girl	B-UNK
had	O
behavioral	B-DISEASE
deterioration	I-DISEASE
,	O
with	O
hyperkinesis	B-DISEASE
,	O
irritability	B-DISEASE
,	O
and	O
sleeping	O
difficulties	O
after	O
the	O
therapeutic	B-UNK
administration	O
of	O
isoniazid	B-UNK
.	O
The	O
administration	O
of	O
pharmacologic	O
doses	B-UNK
of	O
pyridoxine	B-CHEMICAL
hydrochloride	I-CHEMICAL
led	B-UNK
to	O
a	O
disappearance	O
of	O
symptoms	B-UNK
.	O
After	O
discontinuing	O
isoniazid	B-CHEMICAL
therapy	O
a	O
similar	B-UNK
pattern	B-UNK
of	O
behavior	B-UNK
was	O
noted	B-UNK
that	O
was	O
controlled	B-UNK
by	O
pyridoxine	B-CHEMICAL
.	O
A	O
placebo	B-UNK
had	O
no	O
effect	B-UNK
,	O
but	O
niacinamide	B-CHEMICAL
was	O
as	O
effective	B-UNK
as	O
pyridoxine	B-CHEMICAL
.	O
Periodic	O
withdrawal	B-UNK
of	O
pyridoxine	B-CHEMICAL
was	O
associated	O
with	O
return	B-UNK
of	O
the	O
hyperkinesis	B-DISEASE
.	O
The	O
level	B-UNK
of	O
pyridoxal	O
in	O
the	O
blood	B-UNK
was	O
normal	O
during	O
the	O
periods	O
of	O
relapse	B-UNK
.	O
Metabolic	B-UNK
studies	B-UNK
suggested	B-UNK
a	O
block	B-UNK
in	O
the	O
kynurenine	O
pathway	B-UNK
of	O
tryptophan	O
metabolism	B-UNK
.	O
The	O
patient	B-UNK
has	O
been	O
followed	O
for	O
six	O
years	B-UNK
and	O
has	O
required	B-UNK
pharmacologic	O
doses	B-UNK
of	O
pyridoxine	B-CHEMICAL
to	O
control	B-UNK
her	O
behavior	B-UNK
.	O

A	O
selective	B-UNK
dopamine	B-CHEMICAL
D4	O
receptor	B-UNK
antagonist	I-UNK
,	O
NRA0160	B-UNK
:	O
a	O
preclinical	B-UNK
neuropharmacological	O
profile	B-UNK
.	O
NRA0160	B-UNK
,	O
5	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2-	I-CHEMICAL
(	I-CHEMICAL
4-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
fluorobenzylidene	I-CHEMICAL
)	I-CHEMICAL
piperidin-1-yl	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-(4-fluorophenyl	I-CHEMICAL
)	I-CHEMICAL
thiazole-2-carboxamide	I-CHEMICAL
,	O
has	O
a	O
high	B-UNK
affinity	B-UNK
for	O
human	B-UNK
cloned	O
dopamine	B-CHEMICAL
D4.2	O
,	O
D4.4	O
and	O
D4.7	O
receptors	B-UNK
,	O
with	O
Ki	O
values	O
of	O
0.5	O
,	O
0.9	O
and	O
2.7	O
nM	B-UNK
,	O
respectively	O
.	O
NRA0160	B-UNK
is	O
over	O
20,000fold	O
more	O
potent	B-UNK
at	O
the	O
dopamine	B-CHEMICAL
D4.2	O
receptor	B-UNK
compared	O
with	O
the	O
human	B-UNK
cloned	O
dopamine	B-CHEMICAL
D2L	O
receptor	B-UNK
.	O
NRA0160	B-UNK
has	O
negligible	O
affinity	B-UNK
for	O
the	O
human	B-UNK
cloned	O
dopamine	B-CHEMICAL
D3	B-UNK
receptor	B-UNK
(	O
Ki=39	O
nM	B-UNK
)	O
,	O
rat	B-UNK
serotonin	B-CHEMICAL
(	O
5-HT)2A	O
receptors	B-UNK
(	O
Ki=180	O
nM	B-UNK
)	O
and	O
rat	B-UNK
alpha1	O
adrenoceptor	B-UNK
(	O
Ki=237	O
nM	B-UNK
)	O
.	O
NRA0160	B-UNK
and	O
clozapine	B-CHEMICAL
antagonized	B-UNK
locomotor	B-DISEASE
hyperactivity	I-DISEASE
induced	O
by	O
methamphetamine	B-UNK
(	O
MAP	B-UNK
)	O
in	O
mice	B-UNK
.	O
NRA0160	B-UNK
and	O
clozapine	B-UNK
antagonized	B-UNK
MAP	B-UNK
-	O
induced	O
stereotyped	O
behavior	B-UNK
in	O
mice	B-UNK
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
inhibition	B-UNK
,	O
even	O
at	O
the	O
highest	B-UNK
dose	B-UNK
given	O
.	O
NRA0160	B-UNK
and	O
clozapine	B-CHEMICAL
significantly	B-UNK
induced	O
catalepsy	B-UNK
in	O
rats	B-UNK
,	O
although	O
their	O
effects	O
did	O
not	O
exceed	O
50	O
%	O
induction	B-UNK
even	O
at	O
the	O
highest	B-UNK
dose	B-UNK
given	O
.	O
NRA0160	B-UNK
and	O
clozapine	B-CHEMICAL
significantly	B-UNK
reversed	B-UNK
the	O
disruption	B-UNK
of	O
prepulse	O
inhibition	B-UNK
(	O
PPI	O
)	O
in	O
rats	B-UNK
produced	B-UNK
by	O
apomorphine	B-UNK
.	O
NRA0160	B-UNK
and	O
clozapine	B-UNK
significantly	B-UNK
shortened	O
the	O
phencyclidine	O
(	O
PCP)-induced	O
prolonged	B-UNK
swimming	O
latency	B-UNK
in	O
rats	B-UNK
in	O
a	O
water	B-UNK
maze	B-UNK
task	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
NRA0160	B-UNK
may	O
have	O
unique	B-UNK
antipsychotic	B-UNK
activities	B-UNK
without	O
the	O
liability	O
of	O
motor	B-UNK
side	O
effects	O
typical	B-UNK
of	O
classical	O
antipsychotics	B-CHEMICAL
.	O

Prolonged	B-UNK
cholestasis	B-DISEASE
after	O
troleandomycin	O
-	O
induced	O
acute	B-UNK
hepatitis	I-UNK
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
patient	B-UNK
in	O
whom	O
troleandomycin	O
-	O
induced	O
hepatitis	B-UNK
was	O
followed	O
by	O
prolonged	B-UNK
anicteric	O
cholestasis	B-UNK
.	O
Jaundice	B-DISEASE
occurred	B-UNK
after	O
administration	O
of	O
troleandomycin	O
for	O
7	O
days	B-UNK
and	O
was	O
associated	O
with	O
hypereosinophilia	O
.	O
Jaundice	B-UNK
disappeared	O
within	O
3	O
months	B-UNK
but	O
was	O
followed	O
by	O
prolonged	B-UNK
anicteric	O
cholestasis	B-UNK
marked	O
by	O
pruritus	B-DISEASE
and	O
high	B-UNK
levels	O
of	O
alkaline	B-CHEMICAL
phosphatase	I-CHEMICAL
and	O
gammaglutamyltransferase	O
activities	B-UNK
.	O
Finally	B-UNK
,	O
pruritus	B-DISEASE
disappeared	O
within	O
19	O
months	B-UNK
,	O
and	O
liver	B-UNK
tests	B-UNK
returned	B-UNK
to	O
normal	O
27	O
months	B-UNK
after	O
the	O
onset	B-UNK
of	O
hepatitis	B-UNK
.	O
This	O
observation	B-UNK
demonstrates	O
that	O
prolonged	B-UNK
cholestasis	B-UNK
can	O
follow	O
troleandomycin	O
-	O
induced	O
acute	B-UNK
hepatitis	I-UNK
.	O

HMG	O
CoA	O
reductase	O
inhibitors	B-UNK
.	O
Current	B-UNK
clinical	B-UNK
experience	B-UNK
.	O
Lovastatin	B-UNK
and	O
simvastatin	B-UNK
are	O
the	O
2	O
best-known	O
members	O
of	O
the	O
class	B-UNK
of	O
hypolipidaemic	O
agents	B-UNK
known	O
as	O
HMG	O
CoA	O
reductase	O
inhibitors	B-UNK
.	O
Clinical	B-UNK
experience	B-UNK
with	O
lovastatin	B-CHEMICAL
includes	O
over	O
5000	O
patients	B-UNK
,	O
700	O
of	O
whom	O
have	O
been	O
treated	O
for	O
2	O
years	B-UNK
or	O
more	O
,	O
and	O
experience	B-UNK
with	O
simvastatin	B-UNK
includes	O
over	O
3500	O
patients	B-UNK
,	O
of	O
whom	O
350	O
have	O
been	O
treated	O
for	O
18	O
months	B-UNK
or	O
more	O
.	O
Lovastatin	B-UNK
has	O
been	O
marketed	O
in	O
the	O
United	O
States	B-UNK
for	O
over	O
6	O
months	B-UNK
.	O
Both	O
agents	B-UNK
show	O
substantial	O
clinical	B-UNK
efficacy	B-UNK
,	O
with	O
reductions	B-UNK
in	O
total	B-UNK
cholesterol	B-UNK
of	O
over	O
30	O
%	O
and	O
in	O
LDL	B-UNK
-	O
cholesterol	B-CHEMICAL
of	O
40	O
%	O
in	O
clinical	B-UNK
studies	B-UNK
.	O
Modest	O
increases	B-UNK
in	O
HDL	B-UNK
-	O
cholesterol	B-UNK
levels	O
of	O
about	O
10	O
%	O
are	O
also	O
reported	B-UNK
.	O
Clinical	B-UNK
tolerability	B-UNK
of	O
both	O
agents	B-UNK
has	O
been	O
good	O
,	O
with	O
fewer	B-UNK
than	O
3	O
%	O
of	O
patients	B-UNK
withdrawn	O
from	O
treatment	B-UNK
because	O
of	O
clinical	B-UNK
adverse	B-UNK
experiences	O
.	O
Ophthalmological	O
examinations	B-UNK
in	O
over	O
1100	O
patients	B-UNK
treated	O
with	O
one	O
or	O
the	O
other	O
agent	B-UNK
have	O
revealed	O
no	O
evidence	B-UNK
of	O
significant	B-UNK
short	B-UNK
term	I-UNK
(	O
up	O
to	O
2	O
years	B-UNK
)	O
cataractogenic	O
potential	B-UNK
.	O
One	O
to	O
2	O
%	O
of	O
patients	B-UNK
have	O
elevations	B-UNK
of	O
serum	B-UNK
transaminases	O
to	O
greater	B-UNK
than	O
3	O
times	B-UNK
the	O
upper	B-UNK
limit	B-UNK
of	O
normal	O
.	O
These	O
episodes	B-UNK
are	O
asymptomatic	O
and	O
reversible	B-UNK
when	O
therapy	O
is	O
discontinued	O
.	O
Minor	B-UNK
elevations	B-UNK
of	O
creatine	B-UNK
kinase	I-UNK
levels	O
are	O
reported	B-UNK
in	O
about	O
5	O
%	O
of	O
patients	B-UNK
.	O
Myopathy	B-UNK
,	O
associated	O
in	O
some	O
cases	B-UNK
with	O
myoglobinuria	B-DISEASE
,	O
and	O
in	O
2	O
cases	B-UNK
with	O
transient	B-UNK
renal	B-UNK
failure	I-UNK
,	O
has	O
been	O
rarely	O
reported	B-UNK
with	O
lovastatin	B-CHEMICAL
,	O
especially	O
in	O
patients	B-UNK
concomitantly	B-UNK
treated	O
with	O
cyclosporin	B-UNK
,	O
gemfibrozil	O
or	O
niacin	O
.	O
Lovastatin	B-CHEMICAL
and	O
simvastatin	B-CHEMICAL
are	O
both	O
effective	B-UNK
and	O
well	O
-	O
tolerated	B-UNK
agents	B-UNK
for	O
lowering	B-UNK
elevated	B-UNK
levels	O
of	O
serum	B-UNK
cholesterol	B-CHEMICAL
.	O
As	O
wider	O
use	O
confirms	O
their	O
safety	B-UNK
profile	B-UNK
,	O
they	O
will	O
gain	B-UNK
increasing	B-UNK
importance	B-UNK
in	O
the	O
therapeutic	B-UNK
approach	O
to	O
hypercholesterolaemia	O
and	O
its	O
consequences	B-UNK
.	O

Sulfasalazine	B-UNK
-	O
induced	O
lupus	B-UNK
erythematosus	O
.	O
Pneumonitis	B-DISEASE
,	O
bilateral	B-UNK
pleural	B-DISEASE
effusions	I-DISEASE
,	O
echocardiographic	B-UNK
evidence	B-UNK
of	O
cardiac	B-DISEASE
tamponade	I-DISEASE
,	O
and	O
positive	B-UNK
autoantibodies	O
developed	O
in	O
a	O
43-year	O
-	O
old	O
man	B-UNK
,	O
who	O
was	O
receiving	B-UNK
long	B-UNK
-	O
term	O
sulfasalazine	B-UNK
therapy	O
for	O
chronic	B-UNK
ulcerative	B-DISEASE
colitis	I-DISEASE
.	O
After	O
cessation	B-UNK
of	O
the	O
sulfasalazine	B-UNK
and	O
completion	O
of	O
a	O
six	O
-	O
week	B-UNK
course	O
of	O
corticosteroids	B-CHEMICAL
,	O
these	O
problems	B-UNK
resolved	O
over	O
a	O
period	B-UNK
of	O
four	O
to	O
six	O
months	B-UNK
.	O
It	O
is	O
suggested	B-UNK
that	O
the	O
patient	B-UNK
had	O
sulfasalazine	B-UNK
-	O
induced	O
lupus	B-UNK
,	O
which	O
manifested	O
with	O
serositis	B-DISEASE
and	O
pulmonary	B-UNK
parenchymal	O
involvement	B-UNK
in	O
the	O
absence	O
of	O
joint	O
symptoms	B-UNK
.	O
Physicians	B-UNK
who	O
use	O
sulfasalazine	B-UNK
to	O
treat	B-UNK
patients	B-UNK
with	O
inflammatory	B-UNK
bowel	B-UNK
disease	B-DISEASE
should	O
be	O
aware	B-UNK
of	O
the	O
signs	B-UNK
of	O
sulfasalazine	B-UNK
-	O
induced	O
lupus	B-UNK
syndrome	B-UNK
.	O

Optimization	O
of	O
levodopa	B-UNK
therapy	O
.	O
While	O
there	O
is	O
no	O
single	B-UNK
correct	O
starting	B-UNK
dose	B-UNK
for	O
levodopa	B-CHEMICAL
therapy	O
,	O
many	O
individuals	B-UNK
can	O
be	O
started	O
on	O
either	O
the	O
25/100	O
or	O
controlled	B-UNK
-	O
release	B-UNK
formula	O
,	O
following	O
the	O
general	B-UNK
rule	O
not	O
to	O
attempt	O
to	O
titrate	O
carbidopa	O
-	O
levodopa	B-CHEMICAL
to	O
the	O
point	B-UNK
of	O
"	O
normality	O
,	O
"	O
which	O
can	O
lead	B-UNK
to	O
toxicity	B-DISEASE
.	O
The	O
physician	O
should	O
also	O
determine	B-UNK
the	O
proper	O
use	O
of	O
any	O
adjunctive	O
medications	B-UNK
;	O
such	O
combined	B-UNK
therapy	O
has	O
become	O
the	O
standard	B-UNK
approach	O
to	O
treatment	B-UNK
.	O
Following	O
the	O
initial	B-UNK
period	B-UNK
of	O
therapy	O
,	O
emerging	O
difficulties	O
require	O
a	O
reassessment	O
of	O
therapeutic	B-UNK
approaches	O
,	O
such	O
as	O
dosage	B-UNK
adjustment	B-UNK
or	O
introduction	B-UNK
of	O
a	O
dopamine	B-CHEMICAL
agonist	B-UNK
.	O
Other	O
possible	O
adverse	B-UNK
effects	I-UNK
--	O
such	O
as	O
gastrointestinal	B-UNK
disorders	B-UNK
,	O
orthostatic	B-UNK
hypotension	I-UNK
,	O
levodopa	B-UNK
-	O
induced	B-UNK
psychosis	I-UNK
,	O
sleep	B-UNK
disturbances	B-UNK
or	O
parasomnias	B-DISEASE
,	O
or	O
drug	B-UNK
interactions	I-UNK
--	O
also	O
require	O
carefully	B-UNK
monitored	O
individual	B-UNK
treatment	B-UNK
.	O
Nonpharmacologic	O
concerns	B-UNK
can	O
help	O
the	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
patient	B-UNK
achieve	B-UNK
and	O
maintain	O
optimal	B-UNK
functioning	B-UNK
,	O
including	O
daily	B-UNK
exercise	B-UNK
,	O
physical	B-UNK
therapy	O
,	O
and	O
involvement	B-UNK
with	O
support	B-UNK
groups	B-UNK
.	O

Alpha	B-UNK
and	O
beta	B-UNK
coma	B-UNK
in	O
drug	B-UNK
intoxication	B-UNK
uncomplicated	O
by	O
cerebral	B-DISEASE
hypoxia	I-DISEASE
.	O
Four	O
patients	B-UNK
who	O
were	O
rendered	O
comatose	B-DISEASE
or	O
stuporous	O
by	O
drug	B-UNK
intoxication	B-UNK
,	O
but	O
who	O
were	O
not	O
hypoxic	O
,	O
are	O
described	O
.	O
Three	O
patients	B-UNK
received	O
high	B-UNK
doses	I-UNK
of	O
chlormethiazole	O
for	O
alcohol	B-UNK
withdrawal	B-UNK
symptoms	B-UNK
,	O
and	O
one	O
took	O
a	O
suicidal	O
overdose	B-UNK
of	O
nitrazepam	O
.	O
The	O
patient	B-UNK
with	O
nitrazepam	O
overdose	B-UNK
and	O
two	O
of	O
those	O
with	O
chlormethiazole	O
intoxication	B-UNK
conformed	O
to	O
the	O
criteria	B-UNK
of	O
'	O
alpha	B-UNK
coma	B-UNK
'	O
,	O
showing	O
non-reactive	O
generalized	O
or	O
frontally	O
predominant	B-UNK
alpha	B-UNK
activity	B-UNK
in	O
the	O
EEG	B-UNK
.	O
The	O
fourth	B-UNK
patient	B-UNK
who	O
was	O
unconscious	O
after	O
chlormethiazole	O
administration	O
exhibite	O
generalized	O
non-reactive	O
activity	B-UNK
in	O
the	O
slow	B-UNK
beta	B-UNK
range	B-UNK
.	O
All	O
four	O
recovered	O
completely	O
without	O
neurological	B-UNK
sequelae	B-UNK
following	O
the	O
withdrawal	B-UNK
of	O
the	O
offending	O
agents	B-UNK
.	O
The	O
similarities	O
between	O
the	O
effects	O
of	O
structural	B-UNK
lesions	B-UNK
and	O
pharmacological	B-UNK
depression	B-UNK
of	O
the	O
brain	B-UNK
stem	B-UNK
reticular	O
formation	B-UNK
are	O
discussed	O
.	O
It	O
is	O
suggested	B-UNK
that	O
in	O
both	O
situations	O
disturbed	O
reticulo	O
-	O
thalamic	O
interactions	B-UNK
are	O
important	B-UNK
in	O
the	O
pathogenesis	B-UNK
of	O
alpha	B-UNK
coma	B-UNK
.	O
It	O
is	O
concluded	O
that	O
when	O
this	O
electroencephalographic	O
and	O
behavioural	O
picture	O
is	O
seen	O
in	O
drug	B-UNK
intoxication	B-UNK
,	O
in	O
the	O
absence	O
of	O
significant	B-UNK
hypoxaemia	O
,	O
a	O
favourable	O
outcome	B-UNK
may	O
be	O
anticipated	O
.	O

Omitting	O
fentanyl	B-CHEMICAL
reduces	O
nausea	B-UNK
and	I-UNK
vomiting	I-UNK
,	O
without	O
increasing	B-UNK
pain	B-UNK
,	O
after	O
sevoflurane	B-CHEMICAL
for	O
day	O
surgery	B-UNK
.	O
BACKGROUND	B-UNK
AND	O
OBJECTIVE	B-UNK
:	O
Despite	O
advantages	O
of	O
induction	B-UNK
and	O
maintenance	B-UNK
of	O
anaesthesia	B-UNK
with	O
sevoflurane	B-UNK
,	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
occurs	O
frequently	B-UNK
.	O
Fentanyl	B-CHEMICAL
is	O
a	O
commonly	B-UNK
used	O
supplement	O
that	O
may	O
contribute	B-UNK
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	B-UNK
analgesia	B-DISEASE
.	O
METHODS	B-UNK
:	O
This	O
double-blind	O
study	B-UNK
examined	B-UNK
the	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
and	O
pain	B-UNK
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	B-CHEMICAL
anaesthesia	B-UNK
in	O
216	O
adult	B-UNK
day	O
surgery	B-UNK
patients	B-UNK
.	O
Patients	B-UNK
were	O
randomly	B-UNK
allocated	I-UNK
to	O
either	O
receive	B-UNK
or	O
not	O
receive	B-UNK
1	O
1	O
fentanyl	B-CHEMICAL
,	O
while	O
a	O
third	O
group	B-UNK
received	O
dexamethasone	B-CHEMICAL
in	O
addition	B-UNK
to	O
fentanyl	B-CHEMICAL
.	O
RESULTS	B-UNK
:	O
Omission	O
of	O
fentanyl	B-UNK
did	O
not	O
reduce	B-UNK
the	O
overall	O
incidence	B-UNK
of	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
,	O
but	O
did	O
reduce	B-UNK
the	O
incidence	B-UNK
of	O
vomiting	B-UNK
and	O
/	O
or	O
moderate	B-UNK
to	I-UNK
severe	I-UNK
nausea	B-UNK
prior	B-UNK
to	O
discharge	B-UNK
from	O
20	O
%	O
and	O
17	O
%	O
with	O
fentanyl	B-CHEMICAL
and	O
fentanyl	B-CHEMICAL
-	O
dexamethasone	B-UNK
,	O
respectively	O
,	O
to	O
5	O
%	O
(	O
P	O
=	O
0.013	O
)	O
.	O
Antiemetic	O
requirements	O
were	O
reduced	B-UNK
from	O
24	O
%	O
and	O
31	O
%	O
to	O
7	O
%	O
(	O
P	O
=	O
0.0012	O
)	O
.	O
Dexamethasone	B-UNK
had	O
no	O
significant	B-UNK
effect	B-UNK
on	O
the	O
incidence	B-UNK
or	O
severity	B-UNK
of	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
.	O
Combining	O
the	O
two	O
fentanyl	B-UNK
groups	B-UNK
revealed	O
further	O
significant	B-UNK
benefits	B-UNK
from	O
the	O
avoidance	B-UNK
of	O
opioids	O
,	O
reducing	B-UNK
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
and	O
nausea	B-UNK
prior	B-UNK
to	O
discharge	B-UNK
from	O
35	O
%	O
and	O
33	O
%	O
to	O
22	O
%	O
and	O
19	O
%	O
(	O
P	O
=	O
0.049	O
and	O
P	O
=	O
0.035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	B-UNK
in	O
the	O
first	O
24	O
h	O
was	O
decreased	B-UNK
from	O
42	O
%	O
to	O
27	O
%	O
(	O
P	O
=	O
0.034	O
)	O
.	O
Pain	B-UNK
severity	B-UNK
and	O
analgesic	B-UNK
requirements	O
were	O
unaffected	B-UNK
by	O
the	O
omission	O
of	O
fentanyl	B-CHEMICAL
.	O
Fentanyl	B-UNK
did	O
reduce	B-UNK
minor	B-UNK
intraoperative	B-UNK
movement	B-UNK
but	O
had	O
no	O
sevoflurane	B-UNK
-	O
sparing	O
effect	B-UNK
and	O
increased	B-UNK
respiratory	B-DISEASE
depression	I-DISEASE
,	O
hypotension	B-DISEASE
and	O
bradycardia	B-DISEASE
.	O
CONCLUSION	B-UNK
:	O
As	O
fentanyl	B-UNK
exacerbated	O
postoperative	B-DISEASE
nausea	I-DISEASE
and	I-DISEASE
vomiting	I-DISEASE
without	O
an	O
improvement	B-UNK
in	O
postoperative	B-UNK
pain	B-DISEASE
and	O
also	O
had	O
adverse	B-UNK
cardiorespiratory	O
effects	O
,	O
it	O
appears	B-UNK
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	B-CHEMICAL
in	O
day	O
surgery	B-UNK
.	O

Renal	B-DISEASE
Fanconi	I-DISEASE
syndrome	I-DISEASE
and	O
myopathy	B-UNK
after	O
liver	B-UNK
transplantation	I-UNK
:	O
drug	B-UNK
-	O
related	O
mitochondrial	B-DISEASE
cytopathy	I-DISEASE
?	O
Advances	O
in	O
the	O
field	B-UNK
of	O
transplantation	B-UNK
provide	O
a	O
better	O
quality	B-UNK
of	I-UNK
life	I-UNK
and	O
allow	O
more	O
favorable	O
conditions	O
for	O
growth	B-UNK
and	O
development	B-UNK
in	O
children	B-UNK
.	O
However	O
,	O
combinations	B-UNK
of	O
different	O
therapeutic	B-UNK
regimens	B-UNK
require	O
consideration	O
of	O
potential	B-UNK
adverse	B-UNK
reactions	I-UNK
.	O
We	O
describe	O
a	O
15-yr	O
-	O
old	O
girl	B-UNK
who	O
had	O
orthotopic	O
liver	B-UNK
transplantation	I-UNK
because	O
of	O
Wilson'	O
s	O
disease	B-DISEASE
.	O
Tacrolimus	B-CHEMICAL
,	O
MMF	O
,	O
and	O
steroids	B-CHEMICAL
were	O
given	O
as	O
immunosuppressant	O
.	O
Lamivudine	B-UNK
was	O
added	B-UNK
because	O
of	O
de	O
nova	O
hepatitis	B-UNK
B	I-UNK
infection	B-DISEASE
during	O
her	O
follow	O
-	O
up	O
.	O
Three	O
yr	B-UNK
after	O
transplantation	B-UNK
she	O
developed	O
renal	B-DISEASE
Fanconi	I-DISEASE
syndrome	I-DISEASE
with	O
severe	B-UNK
metabolic	B-DISEASE
acidosis	I-DISEASE
,	O
hypophosphatemia	B-DISEASE
,	O
glycosuria	B-DISEASE
,	O
and	O
aminoaciduria	B-DISEASE
.	O
Although	O
tacrolimus	B-CHEMICAL
was	O
suspected	O
to	O
be	O
the	O
cause	O
of	O
late	B-UNK
post-transplant	O
renal	B-UNK
acidosis	B-UNK
and	O
was	O
replaced	O
by	O
sirolimus	B-UNK
,	O
acidosis	B-UNK
,	O
and	O
electrolyte	B-UNK
imbalance	O
got	O
worse	O
.	O
Proximal	B-UNK
muscle	B-DISEASE
weakness	I-DISEASE
has	O
developed	O
during	O
her	O
follow	O
-	O
up	O
.	O
Fanconi	B-DISEASE
syndrome	I-DISEASE
,	O
as	O
well	O
as	O
myopathy	B-DISEASE
,	O
is	O
well	O
recognized	O
in	O
patients	B-UNK
with	O
mitochondrial	B-UNK
disorders	B-UNK
and	O
caused	B-UNK
by	O
depletion	B-UNK
of	O
mtDNA	B-UNK
.	O
We	O
suggest	B-UNK
that	O
our	O
patient'	B-UNK
s	I-UNK
tubular	B-UNK
dysfunction	B-UNK
and	O
myopathy	B-DISEASE
may	O
have	O
resulted	B-UNK
from	O
mitochondrial	B-DISEASE
dysfunction	I-DISEASE
which	O
is	O
triggered	O
by	O
tacrolimus	B-CHEMICAL
and	O
augmented	O
by	O
lamivudine	B-UNK
.	O

Antipsychotic	B-UNK
-	O
like	O
profile	B-UNK
of	O
thioperamide	O
,	O
a	O
selective	B-UNK
H3-receptor	O
antagonist	B-UNK
in	O
mice	B-UNK
.	O
Experimental	B-UNK
and	O
clinical	B-UNK
evidence	B-UNK
points	B-UNK
to	O
a	O
role	O
of	O
central	B-UNK
histaminergic	O
system	O
in	O
the	O
pathogenesis	B-UNK
of	O
schizophrenia	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
designed	B-UNK
to	O
study	B-UNK
the	O
effect	B-UNK
of	O
histamine	B-UNK
H(3)-receptor	O
ligands	B-UNK
on	O
neuroleptic	B-UNK
-	O
induced	O
catalepsy	B-UNK
,	O
apomorphine	B-UNK
-	O
induced	O
climbing	B-UNK
behavior	B-UNK
and	O
amphetamine	B-UNK
-	O
induced	O
locomotor	B-UNK
activities	B-UNK
in	O
mice	B-UNK
.	O
Catalepsy	B-DISEASE
was	O
induced	O
by	O
haloperidol	B-CHEMICAL
(	O
2	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
)	O
,	O
while	O
apomorphine	B-UNK
(	O
1.5	O
mg	B-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
)	O
and	O
amphetamine	B-UNK
(	O
2	O
mg	B-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
)	O
were	O
used	O
for	O
studying	O
climbing	B-UNK
behavior	B-UNK
and	O
locomotor	B-UNK
activities	B-UNK
,	O
respectively	O
.	O
(	B-CHEMICAL
R)-alpha	I-CHEMICAL
-	I-CHEMICAL
methylhistamine	I-CHEMICAL
(	O
RAMH	O
)	O
(	O
5	O
microg	B-UNK
i.c.v	B-UNK
.	O
)	O
and	O
thioperamide	O
(	O
THP	B-UNK
)	O
(	O
15	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
,	O
per	O
se	B-UNK
did	O
not	O
cause	O
catalepsy	B-DISEASE
.	O
Administration	O
of	O
THP	B-UNK
(	O
3.75	O
,	O
7.5	O
and	O
15	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
1	O
h	O
prior	B-UNK
to	O
haloperidol	B-UNK
resulted	B-UNK
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
increase	B-UNK
in	O
the	O
catalepsy	B-UNK
times	B-UNK
(	O
P	O
<	O
0.05	O
)	O
.	O
However	O
,	O
pretreatment	B-UNK
with	O
RAMH	O
significantly	B-UNK
reversed	B-UNK
such	O
an	O
effect	B-UNK
of	O
THP	B-UNK
(	O
15	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
.	O
RAMH	O
per	O
se	B-UNK
showed	O
significant	B-UNK
reduction	O
in	O
locomotor	B-UNK
time	O
,	O
distance	O
traveled	O
and	O
average	B-UNK
speed	B-UNK
but	O
THP	B-UNK
(	O
15	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
per	O
se	B-UNK
had	O
no	O
effect	B-UNK
on	O
these	O
parameters	O
.	O
On	O
amphetamine	B-UNK
-	O
induced	B-UNK
hyperactivity	I-UNK
,	O
THP	B-UNK
(	O
3.75	O
and	O
7.5	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
reduced	B-UNK
locomotor	B-UNK
time	O
,	O
distance	O
traveled	O
and	O
average	B-UNK
speed	B-UNK
(	O
P	O
<	O
0.05	O
)	O
.	O
Pretreatment	B-UNK
with	O
RAMH	O
(	O
5	O
microg	B-UNK
i.c.v	B-UNK
.	O
)	O
could	O
partially	O
reverse	B-UNK
such	O
effects	O
of	O
THP	B-UNK
(	O
3.75	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
.	O
Climbing	B-UNK
behavior	B-UNK
induced	O
by	O
apomorphine	B-UNK
was	O
reduced	B-UNK
in	O
animals	B-UNK
treated	O
with	O
THP	B-UNK
.	O
Such	O
an	O
effect	B-UNK
was	O
,	O
however	O
,	O
reversed	B-UNK
in	O
presence	O
of	O
RAMH	O
.	O
THP	B-UNK
exhibited	O
an	O
antipsychotic	B-UNK
-	O
like	O
profile	B-UNK
by	O
potentiating	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-UNK
,	O
reducing	B-UNK
amphetamine	B-UNK
-	O
induced	B-UNK
hyperactivity	I-UNK
and	O
reducing	B-UNK
apomorphine	B-UNK
-	O
induced	O
climbing	B-UNK
in	O
mice	B-UNK
.	O
Such	O
effects	O
of	O
THP	B-UNK
were	O
reversed	B-UNK
by	O
RAMH	O
indicating	O
the	O
involvement	B-UNK
of	O
histamine	B-UNK
H(3)-receptors	O
.	O
Findings	B-UNK
suggest	B-UNK
a	O
potential	B-UNK
for	O
H(3)-receptor	O
antagonists	B-UNK
in	O
improving	B-UNK
the	O
refractory	B-UNK
cases	B-UNK
of	O
schizophrenia	B-UNK
.	O

Transient	B-UNK
platypnea	B-DISEASE
-	O
orthodeoxia	B-DISEASE
-	O
like	O
syndrome	B-UNK
induced	O
by	O
propafenone	O
overdose	B-DISEASE
in	O
a	O
young	B-UNK
woman	B-UNK
with	O
Ebstein'	B-DISEASE
s	I-DISEASE
anomaly	I-DISEASE
.	O
In	O
this	O
report	B-UNK
we	O
describe	O
the	O
case	B-UNK
of	O
a	O
37-year	O
-	O
old	O
white	B-UNK
woman	B-UNK
with	O
Ebstein'	B-DISEASE
s	I-DISEASE
anomaly	I-DISEASE
,	O
who	O
developed	O
a	O
rare	B-UNK
syndrome	B-DISEASE
called	O
platypnea	B-DISEASE
-	O
orthodeoxia	B-DISEASE
,	O
characterized	B-UNK
by	O
massive	B-UNK
right	O
-	O
to	O
-	O
left	B-UNK
interatrial	O
shunting	O
with	O
transient	B-UNK
profound	B-UNK
hypoxia	B-DISEASE
and	O
cyanosis	B-DISEASE
.	O
This	O
shunt	O
of	O
blood	B-UNK
via	O
a	O
patent	O
foramen	O
ovale	O
occurred	B-UNK
in	O
the	O
presence	O
of	O
a	O
normal	O
pulmonary	B-UNK
artery	B-UNK
pressure	B-UNK
,	O
and	O
was	O
probably	O
precipitated	O
by	O
a	O
propafenone	O
overdose	B-DISEASE
.	O
This	O
drug	B-UNK
caused	B-UNK
biventricular	B-DISEASE
dysfunction	I-DISEASE
,	O
due	O
to	O
its	O
negative	B-UNK
inotropic	O
effect	B-UNK
,	O
and	O
hypotension	B-UNK
,	O
due	O
to	O
its	O
peripheral	B-UNK
vasodilatory	O
effect	B-UNK
.	O
These	O
effects	O
gave	O
rise	B-UNK
to	O
an	O
increase	B-UNK
in	O
the	O
right	O
atrial	B-UNK
pressure	B-UNK
and	O
a	O
decrease	B-UNK
in	O
the	O
left	B-UNK
one	O
with	O
a	O
consequent	O
stretching	O
of	O
the	O
foramen	O
ovale	O
and	O
the	O
creation	O
of	O
massive	B-UNK
right	O
-	O
to	O
-	O
left	B-UNK
shunting	O
.	O
In	O
our	O
case	B-UNK
this	O
interatrial	O
shunt	O
was	O
very	O
accurately	O
detected	B-UNK
at	O
bubble	O
contrast	B-UNK
echocardiography	B-UNK
.	O

A	O
Phase	B-UNK
II	I-UNK
trial	B-UNK
of	O
cisplatin	B-CHEMICAL
plus	O
WR-2721	O
(	O
amifostine	O
)	O
for	O
metastatic	B-UNK
breast	B-DISEASE
carcinoma	I-DISEASE
:	O
an	O
Eastern	O
Cooperative	O
Oncology	B-UNK
Group	B-UNK
Study	B-UNK
(	O
E8188	O
)	O
.	O
BACKGROUND	B-UNK
:	O
Cisplatin	B-UNK
has	O
minimal	B-UNK
antitumor	B-UNK
activity	I-UNK
when	O
used	O
as	O
second-	O
or	O
third	O
-	O
line	B-UNK
treatment	B-UNK
of	O
metastatic	B-UNK
breast	B-DISEASE
carcinoma	I-DISEASE
.	O
Older	B-UNK
reports	B-UNK
suggest	B-UNK
an	O
objective	B-UNK
response	B-UNK
rate	B-UNK
of	O
8	O
%	O
when	O
60	O
-	O
120	O
mg	B-UNK
/	O
m2	B-UNK
of	O
cisplatin	B-CHEMICAL
is	O
administered	O
every	O
3	O
-	O
4	O
weeks	B-UNK
.	O
Although	O
a	O
dose	B-UNK
-	O
response	B-UNK
effect	B-UNK
has	O
been	O
observed	O
with	O
cisplatin	B-UNK
,	O
the	O
dose	B-UNK
-	O
limiting	B-UNK
toxicities	B-UNK
associated	O
with	O
cisplatin	B-CHEMICAL
(	O
e.g	B-UNK
.	O
,	O
nephrotoxicity	B-UNK
,	O
ototoxicity	B-UNK
,	O
and	O
neurotoxicity	B-UNK
)	O
have	O
limited	B-UNK
its	O
use	O
as	O
a	O
treatment	B-UNK
for	O
breast	B-DISEASE
carcinoma	I-DISEASE
.	O
WR-2721	O
or	O
amifostine	O
initially	B-UNK
was	O
developed	O
to	O
protect	B-UNK
military	O
personnel	O
in	O
the	O
event	B-UNK
of	O
nuclear	B-UNK
war	O
.	O
Amifostine	O
subsequently	B-UNK
was	O
shown	B-UNK
to	O
protect	B-UNK
normal	O
tissues	B-UNK
from	O
the	O
toxic	B-UNK
effects	I-UNK
of	O
alkylating	B-CHEMICAL
agents	I-CHEMICAL
and	O
cisplatin	B-UNK
without	O
decreasing	B-UNK
the	O
antitumor	B-UNK
effect	B-UNK
of	O
the	O
chemotherapy	O
.	O
Early	B-UNK
trials	B-UNK
of	O
cisplatin	B-UNK
and	O
amifostine	O
also	O
suggested	B-UNK
that	O
the	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
cisplatin	B-CHEMICAL
-	O
induced	O
nephrotoxicity	B-DISEASE
,	O
ototoxicity	B-UNK
,	O
and	O
neuropathy	B-UNK
were	O
reduced	B-UNK
.	O
METHODS	B-UNK
:	O
A	O
Phase	B-UNK
II	I-UNK
study	I-UNK
of	O
the	O
combination	B-UNK
of	O
cisplatin	B-CHEMICAL
plus	O
amifostine	O
was	O
conducted	B-UNK
in	O
patients	B-UNK
with	O
progressive	B-UNK
metastatic	B-UNK
breast	B-DISEASE
carcinoma	I-DISEASE
who	O
had	O
received	O
one	O
,	O
but	O
not	O
more	O
than	O
one	O
,	O
chemotherapy	O
regimen	B-UNK
for	O
metastatic	B-UNK
disease	B-UNK
.	O
Patients	B-UNK
received	O
amifostine	O
,	O
910	O
mg	B-UNK
/	O
m2	B-UNK
intravenously	O
over	O
15	O
minutes	B-UNK
.	O
After	O
completion	O
of	O
the	O
amifostine	O
infusion	B-UNK
,	O
cisplatin	B-UNK
120	O
mg	B-UNK
/	O
m2	B-UNK
was	O
administered	O
over	O
30	O
minutes	B-UNK
.	O
Intravenous	B-UNK
hydration	O
and	O
mannitol	B-UNK
was	O
administered	O
before	O
and	O
after	O
cisplatin	B-CHEMICAL
.	O
Treatment	B-UNK
was	O
administered	O
every	O
3	O
weeks	B-UNK
until	O
disease	B-UNK
progression	I-UNK
.	O
RESULTS	B-UNK
:	O
Forty	O
-	O
four	O
patients	B-UNK
were	O
enrolled	O
in	O
the	O
study	B-UNK
of	O
which	O
7	O
(	O
16	O
%	O
)	O
were	O
ineligible	O
.	O
A	O
median	B-UNK
of	O
2	O
cycles	B-UNK
of	O
therapy	O
was	O
administered	O
to	O
the	O
37	O
eligible	O
patients	B-UNK
.	O
Six	O
partial	B-UNK
responses	O
were	O
observed	O
for	O
an	O
overall	O
response	B-UNK
rate	B-UNK
of	O
16	O
%	O
.	O
Most	O
patients	B-UNK
(	O
57	O
%	O
)	O
stopped	O
treatment	B-UNK
because	O
of	O
disease	B-DISEASE
progression	I-DISEASE
.	O
Neurologic	B-UNK
toxicity	B-UNK
was	O
reported	B-UNK
in	O
52	O
%	O
of	O
patients	B-UNK
.	O
Seven	O
different	O
life	B-UNK
-	O
threatening	O
toxicities	B-UNK
were	O
observed	O
in	O
patients	B-UNK
while	O
receiving	B-UNK
treatment	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
The	O
combination	B-UNK
of	O
cisplatin	B-CHEMICAL
and	O
amifostine	O
in	O
this	O
study	B-UNK
resulted	B-UNK
in	O
an	O
overall	O
response	B-UNK
rate	B-UNK
of	O
16	O
%	O
.	O
Neither	O
a	O
tumor	B-DISEASE
-	O
protective	B-UNK
effect	I-UNK
nor	O
reduced	B-UNK
toxicity	B-DISEASE
to	O
normal	O
tissues	B-UNK
was	O
observed	O
with	O
the	O
addition	B-UNK
of	O
amifostine	O
to	O
cisplatin	B-UNK
in	O
this	O
trial	B-UNK
.	O

Warfarin	B-UNK
-	O
induced	O
iliopsoas	O
hemorrhage	B-UNK
with	O
subsequent	B-UNK
femoral	B-DISEASE
nerve	I-DISEASE
palsy	I-DISEASE
.	O
We	O
present	B-UNK
the	O
case	B-UNK
of	O
a	O
28-year	O
-	O
old	O
man	B-UNK
on	O
chronic	B-UNK
warfarin	B-UNK
therapy	O
who	O
sustained	B-UNK
a	O
minor	B-UNK
muscle	B-UNK
tear	O
and	O
developed	O
increasing	B-UNK
pain	B-UNK
and	O
a	O
flexure	O
contracture	B-DISEASE
of	O
the	O
right	O
hip	O
.	O
Surgical	B-UNK
exploration	O
revealed	O
an	O
iliopsoas	O
hematoma	B-UNK
and	O
femoral	O
nerve	B-UNK
entrapment	O
,	O
resulting	B-UNK
in	O
a	O
femoral	B-DISEASE
nerve	I-DISEASE
palsy	I-DISEASE
and	O
partial	B-UNK
loss	B-UNK
of	O
quadriceps	O
functions	B-UNK
.	O
Anticoagulant	B-UNK
-	O
induced	O
femoral	B-DISEASE
nerve	I-DISEASE
palsy	I-DISEASE
represents	B-UNK
the	O
most	O
common	B-UNK
form	B-UNK
of	O
warfarin	B-UNK
-	O
induced	O
peripheral	B-UNK
neuropathy	I-UNK
;	O
it	O
is	O
characterized	B-UNK
by	O
severe	B-UNK
pain	B-UNK
in	O
the	O
inguinal	O
region	B-UNK
,	O
varying	O
degrees	B-UNK
of	O
motor	B-UNK
and	O
sensory	O
impairment	B-UNK
,	O
and	O
flexure	O
contracture	B-DISEASE
of	O
the	O
involved	B-UNK
extremity	O
.	O

Myasthenia	B-DISEASE
gravis	I-DISEASE
caused	B-UNK
by	O
penicillamine	B-UNK
and	O
chloroquine	B-UNK
therapy	O
for	O
rheumatoid	B-UNK
arthritis	I-UNK
.	O
We	O
have	O
described	O
a	O
unique	B-UNK
patient	B-UNK
who	O
had	O
reversible	B-UNK
and	O
dose	B-UNK
-	O
related	O
myasthenia	B-DISEASE
gravis	I-DISEASE
after	O
penicillamine	B-UNK
and	O
chloroquine	B-UNK
therapy	O
for	O
rheumatoid	B-UNK
arthritis	I-UNK
.	O
Although	O
acetylcholine	B-UNK
receptor	B-UNK
antibodies	B-UNK
were	O
not	O
detectable	O
,	O
the	O
time	O
course	O
was	O
consistent	B-UNK
with	O
an	O
autoimmune	B-UNK
process	O
.	O

Nephrotoxicity	B-UNK
of	O
combined	B-UNK
cephalothin	B-CHEMICAL
-	O
gentamicin	B-UNK
regimen	B-UNK
.	O
Two	O
patients	B-UNK
developed	O
acute	B-DISEASE
tubular	I-DISEASE
necrosis	I-DISEASE
,	O
characterized	B-UNK
clinically	B-UNK
by	O
acute	B-UNK
oliguric	O
renal	B-UNK
failure	I-UNK
,	O
while	O
they	O
were	O
receiving	B-UNK
a	O
combination	B-UNK
of	O
cephalothin	B-CHEMICAL
sodium	B-UNK
and	O
gentamicin	B-CHEMICAL
sulfate	B-UNK
therapy	O
.	O
Patients	B-UNK
who	O
are	O
given	O
this	O
drug	B-UNK
regimen	B-UNK
should	O
be	O
observed	O
very	O
carefully	B-UNK
for	O
early	B-UNK
signs	B-UNK
of	O
nephrotoxicity	B-UNK
.	O
High	B-UNK
doses	I-UNK
of	O
this	O
antibiotic	B-UNK
combination	B-UNK
should	O
be	O
avoided	O
especially	O
in	O
elderly	B-UNK
patients	B-UNK
.	O
Patients	B-UNK
with	O
renal	B-DISEASE
insufficiency	I-DISEASE
should	O
not	O
be	O
given	O
this	O
regimen	B-UNK
.	O

Components	B-UNK
of	O
lemon	O
essential	B-UNK
oil	B-UNK
attenuate	O
dementia	B-UNK
induced	O
by	O
scopolamine	B-UNK
.	O
The	O
anti-dementia	O
effects	O
of	O
s	O
-	O
limonene	O
and	O
s	O
-	O
perillyl	B-CHEMICAL
alcohol	I-CHEMICAL
were	O
observed	O
using	O
the	O
passive	B-UNK
avoidance	I-UNK
test	B-UNK
(	O
PA	O
)	O
and	O
the	O
open	B-UNK
field	B-UNK
habituation	O
test	B-UNK
(	O
OFH	O
)	O
.	O
These	O
lemon	O
essential	B-UNK
oils	B-CHEMICAL
showed	O
strong	B-UNK
ability	B-UNK
to	O
improve	B-UNK
memory	B-UNK
impaired	B-UNK
by	O
scopolamine	B-UNK
;	O
however	O
,	O
s	O
-	O
perillyl	B-CHEMICAL
alcohol	I-CHEMICAL
relieved	O
the	O
deficit	B-DISEASE
of	I-DISEASE
associative	I-DISEASE
memory	I-DISEASE
in	O
PA	O
only	O
,	O
and	O
did	O
not	O
improve	B-UNK
non-associative	O
memory	B-UNK
significantly	B-UNK
in	O
OFH	O
.	O
Analysis	B-UNK
of	O
neurotransmitter	B-UNK
concentration	B-UNK
in	O
some	O
brain	B-UNK
regions	B-UNK
on	O
the	O
test	B-UNK
day	O
showed	O
that	O
dopamine	B-CHEMICAL
concentration	B-UNK
of	O
the	O
vehicle	B-UNK
/	O
scopolamine	B-UNK
group	B-UNK
was	O
significantly	B-UNK
lower	I-UNK
than	O
that	O
of	O
the	O
vehicle	B-UNK
/	O
vehicle	B-UNK
group	B-UNK
,	O
but	O
this	O
phenomenon	B-UNK
was	O
reversed	B-UNK
when	O
s	O
-	O
limonene	O
or	O
s	O
-	O
perillyl	B-CHEMICAL
alcohol	I-CHEMICAL
were	O
administered	O
before	O
the	O
injection	B-UNK
of	O
scopolamine	B-UNK
.	O
Simultaneously	B-UNK
,	O
we	O
found	O
that	O
these	O
two	O
lemon	O
essential	B-UNK
oil	B-UNK
components	B-UNK
could	O
inhibit	O
acetylcholinesterase	O
activity	B-UNK
in	O
vitro	B-UNK
using	O
the	O
Ellman	O
method	B-UNK
.	O

The	O
selective	B-UNK
5-HT6	O
receptor	B-UNK
antagonist	I-UNK
Ro4368554	O
restores	O
memory	B-UNK
performance	B-UNK
in	O
cholinergic	B-UNK
and	O
serotonergic	B-UNK
models	B-UNK
of	O
memory	B-UNK
deficiency	B-UNK
in	O
the	O
rat	B-UNK
.	O
Antagonists	B-UNK
at	O
serotonin	B-CHEMICAL
type	B-UNK
6	O
(	O
5-HT(6	O
)	O
)	O
receptors	B-UNK
show	O
activity	B-UNK
in	O
models	B-UNK
of	O
learning	B-UNK
and	I-UNK
memory	I-UNK
.	O
Although	O
the	O
underlying	B-UNK
mechanism(s	O
)	O
are	O
not	O
well	O
understood	O
,	O
these	O
effects	O
may	O
involve	B-UNK
an	O
increase	B-UNK
in	O
acetylcholine	B-UNK
(	O
ACh	B-UNK
)	O
levels	O
.	O
The	O
present	B-UNK
study	B-UNK
sought	O
to	O
characterize	O
the	O
cognitive	B-UNK
-	O
enhancing	B-UNK
effects	O
of	O
the	O
5-HT(6	O
)	O
antagonist	B-UNK
Ro4368554	O
(	O
3-benzenesulfonyl-7-(4-methyl	B-CHEMICAL
-	I-CHEMICAL
piperazin-1-yl)1H	I-CHEMICAL
-	I-CHEMICAL
indole	I-CHEMICAL
)	O
in	O
a	O
rat	B-UNK
object	O
recognition	B-UNK
task	B-UNK
employing	O
a	O
cholinergic	B-UNK
(	O
scopolamine	B-CHEMICAL
pretreatment	B-UNK
)	O
and	O
a	O
serotonergic-	O
(	O
tryptophan	O
(	O
TRP	O
)	O
depletion	B-UNK
)	O
deficient	B-UNK
model	B-UNK
,	O
and	O
compared	O
its	O
pattern	B-UNK
of	O
action	B-UNK
with	O
that	O
of	O
the	O
acetylcholinesterase	O
inhibitor	B-UNK
metrifonate	O
.	O
Initial	B-UNK
testing	B-UNK
in	O
a	O
time	O
-	O
dependent	B-UNK
forgetting	O
task	B-UNK
employing	O
a	O
24-h	O
delay	B-UNK
between	O
training	B-UNK
and	O
testing	B-UNK
showed	O
that	O
metrifonate	O
improved	O
object	O
recognition	B-UNK
(	O
at	O
10	O
and	O
30	O
mg	B-UNK
/	O
kg	B-UNK
,	O
p.o	B-UNK
.	O
)	O
,	O
whereas	O
Ro4368554	O
was	O
inactive	O
.	O
Both	O
,	O
Ro4368554	O
(	O
3	O
and	O
10	O
mg	B-UNK
/	O
kg	B-UNK
,	O
intraperitoneally	B-UNK
(	O
i.p	B-UNK
.	O
)	O
)	O
and	O
metrifonate	O
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
,	O
p.o	B-UNK
.	O
,	O
respectively	O
)	O
reversed	B-UNK
memory	B-UNK
deficits	B-UNK
induced	O
by	O
scopolamine	B-UNK
and	O
TRP	O
depletion	B-UNK
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
,	O
and	O
3	O
mg	B-UNK
/	O
kg	B-UNK
,	O
p.o	B-UNK
.	O
,	O
respectively	O
)	O
.	O
In	O
conclusion	B-UNK
,	O
although	O
Ro4368554	O
did	O
not	O
improve	B-UNK
a	O
time	O
-	O
related	O
retention	B-UNK
deficit	B-UNK
,	O
it	O
reversed	B-UNK
a	O
cholinergic	B-UNK
and	O
a	O
serotonergic	B-UNK
memory	B-UNK
deficit	B-UNK
,	O
suggesting	O
that	O
both	O
mechanisms	B-UNK
may	O
be	O
involved	B-UNK
in	O
the	O
facilitation	O
of	O
object	O
memory	B-UNK
by	O
Ro4368554	O
and	O
,	O
possibly	O
,	O
other	O
5-HT(6	O
)	O
receptor	B-UNK
antagonists	I-UNK
.	O

Lone	O
atrial	B-UNK
fibrillation	I-UNK
associated	O
with	O
creatine	B-CHEMICAL
monohydrate	O
supplementation	B-UNK
.	O
Atrial	B-UNK
fibrillation	I-UNK
in	O
young	B-UNK
patients	B-UNK
without	O
structural	B-UNK
heart	B-UNK
disease	I-UNK
is	O
rare	B-UNK
.	O
Therefore	O
,	O
when	O
the	O
arrhythmia	B-DISEASE
is	O
present	B-UNK
in	O
this	O
population	B-UNK
,	O
reversible	B-UNK
causes	O
must	O
be	O
identified	B-UNK
and	O
resolved	O
.	O
Thyroid	B-DISEASE
disorders	I-DISEASE
,	O
illicit	O
drug	B-UNK
or	O
stimulant	B-UNK
use	O
,	O
and	O
acute	B-DISEASE
alcohol	I-DISEASE
intoxication	I-DISEASE
are	O
among	O
these	O
causes	O
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
30-year	O
-	O
old	O
Caucasian	O
man	B-UNK
who	O
came	O
to	O
the	O
emergency	B-UNK
department	I-UNK
in	O
atrial	B-UNK
fibrillation	I-UNK
with	O
rapid	B-UNK
ventricular	B-UNK
response	B-UNK
.	O
His	O
medical	B-UNK
history	B-UNK
was	O
unremarkable	O
,	O
except	O
for	O
minor	B-UNK
fractures	B-UNK
of	O
the	O
fingers	O
and	O
foot	B-UNK
.	O
Thyroid	B-UNK
-	O
stimulating	B-UNK
hormone	B-UNK
,	O
magnesium	B-CHEMICAL
,	O
and	O
potassium	B-UNK
levels	O
were	O
within	O
normal	O
limits	O
,	O
urine	B-UNK
drug	B-UNK
screen	O
was	O
negative	B-UNK
,	O
and	O
alcohol	B-UNK
use	O
was	O
denied	O
.	O
However	O
,	O
when	O
the	O
patient	B-UNK
was	O
questioned	O
about	O
use	O
of	O
herbal	O
products	B-UNK
and	O
supplements	O
,	O
the	O
use	O
of	O
creatine	B-UNK
monohydrate	O
was	O
revealed	O
.	O
The	O
patient	B-UNK
was	O
admitted	B-UNK
to	O
the	O
hospital	B-UNK
,	O
anticoagulated	O
with	O
unfractionated	O
heparin	B-UNK
,	O
and	O
given	O
intravenous	B-UNK
diltiazem	B-CHEMICAL
for	O
rate	B-UNK
control	B-UNK
and	O
intravenous	B-UNK
amiodarone	B-UNK
for	O
rate	B-UNK
and	O
rhythm	B-UNK
control	B-UNK
.	O
When	O
discharged	B-UNK
less	O
than	O
24	O
hours	B-UNK
later	O
,	O
he	O
was	O
receiving	B-UNK
metoprolol	B-CHEMICAL
and	O
aspirin	B-UNK
,	O
with	O
follow	O
-	O
up	O
plans	O
for	O
echocardiography	B-UNK
and	O
nuclear	B-UNK
imaging	B-UNK
to	O
assess	B-UNK
perfusion	B-UNK
.	O
Exogenous	O
creatine	B-UNK
is	O
used	O
by	O
athletes	O
to	O
theoretically	O
improve	B-UNK
exercise	B-UNK
performance	B-UNK
.	O
Vegetarians	O
may	O
also	O
take	O
creatine	B-CHEMICAL
to	O
replace	O
what	O
they	O
are	O
not	O
consuming	O
from	O
meat	O
,	O
fish	O
,	O
and	O
other	O
animal	B-UNK
products	B-UNK
.	O
Previous	B-UNK
anecdotal	O
reports	B-UNK
have	O
linked	B-UNK
creatine	B-UNK
to	O
the	O
development	B-UNK
of	O
arrhythmia	B-UNK
.	O
Clinicians	B-UNK
must	O
be	O
diligent	O
when	O
interviewing	O
patients	B-UNK
about	O
their	O
drug	B-UNK
therapy	O
histories	O
and	O
include	O
questions	O
about	O
their	O
use	O
of	O
herbal	O
products	B-UNK
and	O
dietary	B-UNK
supplements	O
.	O
In	O
addition	B-UNK
,	O
it	O
is	O
important	B-UNK
to	O
report	B-UNK
adverse	B-UNK
effects	I-UNK
associated	O
with	O
frequently	B-UNK
consumed	O
supplements	O
and	O
herbal	O
products	B-UNK
to	O
the	O
Food	B-UNK
and	O
Drug	B-UNK
Administration	O
and	O
in	O
the	O
literature	B-UNK
.	O

Comparison	B-UNK
of	O
developmental	B-UNK
toxicity	B-UNK
of	O
selective	B-UNK
and	O
non-selective	O
cyclooxygenase-2	O
inhibitors	B-UNK
in	O
CRL:(WI)WUBR	O
Wistar	B-UNK
rats	I-UNK
--	O
DFU	O
and	O
piroxicam	B-CHEMICAL
study	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Cyclooxygenase	B-UNK
(	O
COX	B-UNK
)	O
inhibitors	B-UNK
are	O
one	O
of	O
the	O
most	O
often	O
ingested	O
drugs	B-UNK
during	O
pregnancy	B-UNK
.	O
Unlike	B-UNK
general	B-UNK
toxicity	B-UNK
data	B-UNK
,	O
their	O
prenatal	B-UNK
toxic	B-UNK
effects	I-UNK
were	O
not	O
extensively	O
studied	O
before	O
.	O
The	O
aim	B-UNK
of	O
the	O
experiment	B-UNK
was	O
to	O
evaluate	B-UNK
the	O
developmental	B-UNK
toxicity	B-UNK
of	O
the	O
non-selective	O
(	O
piroxicam	B-CHEMICAL
)	O
and	O
selective	B-UNK
(	O
DFU	O
;	O
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl	B-CHEMICAL
)	I-CHEMICAL
phenyl-2(5H)-furanon	I-CHEMICAL
)	O
COX-2	O
inhibitors	B-UNK
.	O
METHODS	B-UNK
:	O
Drugs	B-UNK
were	O
separately	O
,	O
orally	O
once	O
daily	B-UNK
dosed	O
to	O
pregnant	B-UNK
rats	B-UNK
from	O
day	O
8	O
to	O
21	O
(	O
GD1	O
=	O
plug	O
day	O
)	O
.	O
Doses	B-UNK
were	O
set	O
at	O
0.3	O
,	O
3.0	O
and	O
30.0mg	O
/	O
kg	B-UNK
for	O
piroxicam	B-CHEMICAL
and	O
0.2	O
,	O
2.0	O
and	O
20.0mg	O
/	O
kg	B-UNK
for	O
DFU	O
.	O
Fetuses	B-UNK
were	O
delivered	O
on	O
GD	O
21	O
and	O
routinely	O
examined	B-UNK
.	O
Comprehensive	O
clinical	B-UNK
and	O
developmental	B-UNK
measurements	B-UNK
were	O
done	O
.	O
The	O
pooled	O
statistical	B-UNK
analysis	B-UNK
for	O
ventricular	B-UNK
septal	B-UNK
(	O
VSD	B-DISEASE
)	O
and	O
midline	O
(	O
MD	B-UNK
)	O
defects	B-UNK
was	O
performed	B-UNK
for	O
rat	B-UNK
fetuses	B-UNK
exposed	B-UNK
to	O
piroxicam	B-CHEMICAL
,	O
selective	B-UNK
and	O
non-selective	O
COX-2	O
inhibitor	B-UNK
based	B-UNK
on	O
present	B-UNK
and	O
historic	O
data	B-UNK
.	O
RESULTS	B-UNK
:	O
Maternal	B-UNK
toxicity	B-DISEASE
,	O
intrauterine	O
growth	B-UNK
retardation	O
,	O
and	O
increase	B-UNK
of	O
external	O
and	O
skeletal	O
variations	O
were	O
found	O
in	O
rats	B-UNK
treated	O
with	O
the	O
highest	B-UNK
dose	B-UNK
of	O
piroxicam	B-CHEMICAL
.	O
Decrease	B-UNK
of	O
fetal	B-UNK
length	B-UNK
was	O
the	O
only	O
signs	B-UNK
of	O
the	O
DFU	O
developmental	B-UNK
toxicity	B-UNK
observed	O
in	O
pups	O
exposed	B-UNK
to	O
the	O
highest	B-UNK
compound	B-UNK
dose	B-UNK
.	O
Lack	B-UNK
of	O
teratogenicity	O
was	O
found	O
in	O
piroxicam	B-CHEMICAL
and	O
DFU	O
-	O
exposed	B-UNK
groups	B-UNK
.	O
Prenatal	B-UNK
exposure	B-UNK
to	O
non-selective	O
COX	B-UNK
inhibitors	B-UNK
increases	B-UNK
the	O
risk	B-UNK
of	O
VSD	B-DISEASE
and	O
MD	B-UNK
when	O
compared	O
to	O
historic	O
control	B-UNK
but	O
not	O
with	O
selective	B-UNK
COX-2	O
inhibitors	B-UNK
.	O
CONCLUSION	B-UNK
:	O
Both	O
selective	B-UNK
and	O
non-selective	O
COX-2	O
inhibitors	B-UNK
were	O
toxic	B-UNK
for	O
rats	B-UNK
fetuses	B-UNK
when	O
administered	O
in	O
the	O
highest	B-UNK
dose	B-UNK
.	O
Unlike	B-UNK
DFU	O
,	O
piroxicam	B-CHEMICAL
was	O
also	O
highly	B-UNK
toxic	B-UNK
to	O
the	O
dams	O
.	O
Prenatal	B-UNK
exposure	B-UNK
to	O
selective	B-UNK
COX-2	O
inhibitors	B-UNK
does	O
not	O
increase	B-UNK
the	O
risk	B-UNK
of	O
ventricular	B-UNK
septal	B-UNK
and	O
midline	O
defects	B-UNK
in	O
rat	B-UNK
when	O
compared	O
to	O
non-selective	O
drugs	B-UNK
and	O
historic	O
control	B-UNK
.	O

Protective	B-UNK
efficacy	B-UNK
of	O
neuroactive	O
steroids	B-UNK
against	O
cocaine	B-CHEMICAL
kindled	B-UNK
-	O
seizures	B-UNK
in	O
mice	B-UNK
.	O
Neuroactive	O
steroids	B-UNK
demonstrate	O
pharmacological	B-UNK
actions	B-UNK
that	O
have	O
relevance	O
for	O
a	O
host	O
of	O
neurological	B-UNK
and	O
psychiatric	B-UNK
disorders	B-UNK
.	O
They	O
offer	O
protection	B-UNK
against	O
seizures	B-UNK
in	O
a	O
range	B-UNK
of	O
models	B-UNK
and	O
seem	O
to	O
inhibit	O
certain	O
stages	B-UNK
of	O
drug	B-DISEASE
dependence	I-DISEASE
in	O
preclinical	B-UNK
assessments	O
.	O
The	O
present	B-UNK
study	B-UNK
was	O
designed	B-UNK
to	O
evaluate	B-UNK
two	O
endogenous	B-UNK
and	O
one	O
synthetic	O
neuroactive	O
steroid	B-CHEMICAL
that	O
positively	O
modulate	B-UNK
the	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
(	O
GABA(A	O
)	O
)	O
receptor	B-UNK
against	O
the	O
increase	B-UNK
in	O
sensitivity	B-UNK
to	O
the	O
convulsant	B-UNK
effects	O
of	O
cocaine	B-UNK
engendered	O
by	O
repeated	B-UNK
cocaine	B-UNK
administration	O
(	O
seizure	B-DISEASE
kindling	O
)	O
.	O
Allopregnanolone	O
(	O
3alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxy-5alpha	I-CHEMICAL
-	I-CHEMICAL
pregnan-20-one	I-CHEMICAL
)	O
,	O
pregnanolone	B-CHEMICAL
(	O
3alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxy-5beta	I-CHEMICAL
-	I-CHEMICAL
pregnan-20-one	I-CHEMICAL
)	O
and	O
ganaxolone	O
(	O
a	O
synthetic	O
derivative	O
of	O
allopregnanolone	O
3alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxy-3beta	I-CHEMICAL
-	I-CHEMICAL
methyl-5alpha	I-CHEMICAL
-	I-CHEMICAL
pregnan-20-one	I-CHEMICAL
)	O
were	O
tested	B-UNK
for	O
their	O
ability	B-UNK
to	O
suppress	O
the	O
expression	B-UNK
(	O
anticonvulsant	B-UNK
effect	B-UNK
)	O
and	O
development	B-UNK
(	O
antiepileptogenic	O
effect	B-UNK
)	O
of	O
cocaine	B-UNK
-	O
kindled	B-UNK
seizures	B-UNK
in	O
male	B-UNK
,	O
Swiss	B-UNK
-	O
Webster	O
mice	B-UNK
.	O
Kindled	B-UNK
seizures	B-UNK
were	O
induced	O
by	O
daily	B-UNK
administration	O
of	O
60	O
mg	B-UNK
/	O
kg	B-UNK
cocaine	B-UNK
for	O
5	O
days	B-UNK
.	O
All	O
of	O
these	O
positive	B-UNK
GABA(A	O
)	O
modulators	O
suppressed	O
the	O
expression	B-UNK
of	O
kindled	B-UNK
seizures	B-UNK
,	O
whereas	O
only	O
allopregnanolone	O
and	O
ganaxolone	O
inhibited	B-UNK
the	O
development	B-UNK
of	O
kindling	O
.	O
Allopregnanolone	O
and	O
pregnanolone	B-CHEMICAL
,	O
but	O
not	O
ganaxolone	O
,	O
also	O
reduced	B-UNK
cumulative	B-UNK
lethality	B-UNK
associated	O
with	O
kindling	O
.	O
These	O
findings	B-UNK
demonstrate	O
that	O
some	O
neuroactive	O
steroids	B-UNK
attenuate	O
convulsant	B-UNK
and	O
sensitizing	O
properties	B-UNK
of	O
cocaine	B-UNK
and	O
add	O
to	O
a	O
growing	O
literature	B-UNK
on	O
their	O
potential	B-UNK
use	O
in	O
the	O
modulation	B-UNK
of	O
effects	O
of	O
drugs	B-UNK
of	O
abuse	B-UNK
.	O

Kidney	B-UNK
function	B-UNK
and	O
morphology	O
after	O
short	B-UNK
-	O
term	O
combination	B-UNK
therapy	I-UNK
with	O
cyclosporine	B-UNK
A	O
,	O
tacrolimus	B-UNK
and	O
sirolimus	B-UNK
in	O
the	O
rat	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Sirolimus	B-CHEMICAL
(	O
SRL	B-UNK
)	O
may	O
supplement	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
in	O
clinical	B-UNK
organ	B-UNK
transplantation	B-UNK
.	O
These	O
are	O
nephrotoxic	B-UNK
,	O
but	O
SRL	B-UNK
seems	O
to	O
act	B-UNK
differently	O
displaying	O
only	O
minor	B-UNK
nephrotoxic	B-UNK
effects	O
,	O
although	O
this	O
question	O
is	O
still	O
open	B-UNK
.	O
In	O
a	O
number	B-UNK
of	O
treatment	B-UNK
protocols	B-UNK
where	O
SRL	B-UNK
was	O
combined	B-UNK
with	O
a	O
calcineurin	B-UNK
inhibitor	I-UNK
indications	O
of	O
a	O
synergistic	O
nephrotoxic	B-UNK
effect	B-UNK
were	O
described	O
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
examine	B-UNK
further	O
the	O
renal	B-UNK
function	I-UNK
,	O
including	O
morphological	B-UNK
analysis	B-UNK
of	O
the	O
kidneys	B-UNK
of	O
male	B-UNK
Sprague	O
-	O
Dawley	O
rats	B-UNK
treated	O
with	O
either	O
cyclosporine	B-UNK
A	O
(	O
CsA	B-UNK
)	O
,	O
tacrolimus	B-UNK
(	O
FK506	B-UNK
)	O
or	O
SRL	B-UNK
as	O
monotherapies	O
or	O
in	O
different	O
combinations	B-UNK
.	O
METHODS	B-UNK
:	O
For	O
a	O
period	B-UNK
of	O
2	O
weeks	B-UNK
,	O
CsA	B-UNK
15	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
(	O
given	O
orally	O
)	O
,	O
FK506	B-UNK
3.0	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
(	O
given	O
orally	O
)	O
or	O
SRL	B-UNK
0.4	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
(	O
given	O
intraperitoneally	B-UNK
)	O
was	O
administered	O
once	O
a	O
day	O
as	O
these	O
doses	B-UNK
have	O
earlier	B-UNK
been	O
found	O
to	O
achieve	B-UNK
a	O
significant	B-UNK
immunosuppressive	B-UNK
effect	B-UNK
in	O
Sprague	O
-	O
Dawley	O
rats	B-UNK
.	O
In	O
the	O
'	O
conscious	B-UNK
catheterized	O
rat	B-UNK
'	O
model	B-UNK
,	O
the	O
glomerular	B-UNK
filtration	I-UNK
rate	I-UNK
(	O
GFR	B-UNK
)	O
was	O
measured	B-UNK
as	O
the	O
clearance	B-UNK
of	O
Cr(EDTA	O
)	O
.	O
The	O
morphological	B-UNK
analysis	B-UNK
of	O
the	O
kidneys	B-UNK
included	B-UNK
a	O
semi-quantitative	O
scoring	O
system	O
analysing	O
the	O
degree	B-UNK
of	O
striped	O
fibrosis	B-UNK
,	O
subcapsular	O
fibrosis	B-UNK
and	O
the	O
number	B-UNK
of	O
basophilic	O
tubules	O
,	O
plus	O
an	O
additional	B-UNK
stereological	O
analysis	B-UNK
of	O
the	O
total	B-UNK
grade	B-UNK
of	O
fibrosis	B-UNK
in	O
the	O
cortex	B-UNK
stained	O
with	O
Sirius	O
Red	B-UNK
.	O
RESULTS	B-UNK
:	O
CsA	B-UNK
,	O
FK506	B-UNK
and	O
SRL	B-UNK
all	O
significantly	B-UNK
decreased	B-UNK
the	O
GFR	B-UNK
.	O
A	O
further	O
deterioration	B-UNK
was	O
seen	O
when	O
CsA	B-UNK
was	O
combined	B-UNK
with	O
either	O
FK506	B-UNK
or	O
SRL	B-UNK
,	O
whereas	O
the	O
GFR	B-UNK
remained	B-UNK
unchanged	I-UNK
in	O
the	O
group	B-UNK
treated	O
with	O
FK506	B-UNK
plus	O
SRL	B-UNK
when	O
compared	O
with	O
treatment	B-UNK
with	O
any	O
of	O
the	O
single	B-UNK
substances	O
.	O
The	O
morphological	B-UNK
changes	O
presented	B-UNK
a	O
similar	B-UNK
pattern	B-UNK
.	O
The	O
semi-quantitative	O
scoring	O
was	O
significantly	B-UNK
worst	O
in	O
the	O
group	B-UNK
treated	O
with	O
CsA	B-UNK
plus	O
SRL	B-UNK
(	O
P<0.001	O
compared	O
with	O
controls	B-UNK
)	O
and	O
the	O
analysis	B-UNK
of	O
the	O
total	B-UNK
grade	B-UNK
of	O
fibrosis	B-UNK
also	O
showed	O
the	O
highest	B-UNK
proportion	B-UNK
in	O
the	O
same	O
group	B-UNK
and	O
was	O
significantly	B-UNK
different	O
from	O
controls	B-UNK
(	O
P<0.02	O
)	O
.	O
The	O
FK506	B-UNK
plus	O
SRL	B-UNK
combination	B-UNK
showed	O
only	O
a	O
marginally	O
higher	B-UNK
degree	B-UNK
of	O
fibrosis	B-UNK
as	O
compared	O
with	O
controls	B-UNK
(	O
P=0.05	O
)	O
.	O
CONCLUSION	B-UNK
:	O
This	O
rat	B-UNK
study	B-UNK
demonstrated	O
a	O
synergistic	O
nephrotoxic	B-UNK
effect	B-UNK
of	O
CsA	B-UNK
plus	O
SRL	B-UNK
,	O
whereas	O
FK506	B-UNK
plus	O
SRL	B-UNK
was	O
better	O
tolerated	B-UNK
.	O

Effect	B-UNK
of	O
fucoidan	O
treatment	B-UNK
on	O
collagenase	O
-	O
induced	O
intracerebral	B-UNK
hemorrhage	I-UNK
in	O
rats	B-UNK
.	O
Inflammatory	B-UNK
cells	B-UNK
are	O
postulated	O
to	O
mediate	B-UNK
some	O
of	O
the	O
brain	B-UNK
damage	I-UNK
following	O
ischemic	B-DISEASE
stroke	I-DISEASE
.	O
Intracerebral	B-UNK
hemorrhage	I-UNK
is	O
associated	O
with	O
more	O
inflammation	B-UNK
than	O
ischemic	B-DISEASE
stroke	I-DISEASE
.	O
We	O
tested	B-UNK
the	O
sulfated	O
polysaccharide	O
fucoidan	O
,	O
which	O
has	O
been	O
reported	B-UNK
to	O
reduce	B-UNK
inflammatory	B-UNK
brain	B-UNK
damage	I-UNK
,	O
in	O
a	O
rat	B-UNK
model	B-UNK
of	O
intracerebral	B-UNK
hemorrhage	I-UNK
induced	O
by	O
injection	B-UNK
of	O
bacterial	B-UNK
collagenase	O
into	O
the	O
caudate	O
nucleus	B-UNK
.	O
Rats	B-UNK
were	O
treated	O
with	O
seven	O
day	O
intravenous	B-UNK
infusion	B-UNK
of	O
fucoidan	O
(	O
30	O
micrograms	B-UNK
h-1	O
)	O
or	O
vehicle	B-UNK
.	O
The	O
hematoma	B-UNK
was	O
assessed	B-UNK
in	O
vivo	B-UNK
by	O
magnetic	B-UNK
resonance	I-UNK
imaging	I-UNK
.	O
Motor	B-UNK
behavior	B-UNK
,	O
passive	B-UNK
avoidance	I-UNK
,	O
and	O
skilled	O
forelimb	O
function	B-UNK
were	O
tested	B-UNK
repeatedly	B-UNK
for	O
six	O
weeks	B-UNK
.	O
Fucoidan	O
-	O
treated	B-UNK
rats	I-UNK
exhibited	O
evidence	B-UNK
of	O
impaired	B-UNK
blood	B-UNK
clotting	O
and	O
hemodilution	O
,	O
had	O
larger	B-UNK
hematomas	O
,	O
and	O
tended	O
to	O
have	O
less	O
inflammation	B-UNK
in	O
the	O
vicinity	O
of	O
the	O
hematoma	B-DISEASE
after	O
three	O
days	B-UNK
.	O
They	O
showed	O
significantly	B-UNK
more	O
rapid	B-UNK
improvement	B-UNK
of	O
motor	B-UNK
function	B-UNK
in	O
the	O
first	O
week	B-UNK
following	O
hemorrhage	B-UNK
and	O
better	O
memory	B-UNK
retention	B-UNK
in	O
the	O
passive	B-UNK
avoidance	I-UNK
test	B-UNK
.	O
Acute	B-UNK
white	B-UNK
matter	I-UNK
edema	B-UNK
and	O
eventual	O
neuronal	B-UNK
loss	B-UNK
in	O
the	O
striatum	B-UNK
adjacent	O
to	O
the	O
hematoma	B-UNK
did	O
not	O
differ	B-UNK
between	O
the	O
two	O
groups	B-UNK
.	O
Investigation	B-UNK
of	O
more	O
specific	B-UNK
anti-inflammatory	O
agents	B-UNK
and	O
hemodiluting	O
agents	B-UNK
are	O
warranted	O
in	O
intracerebral	B-UNK
hemorrhage	I-UNK
.	O

Paracetamol	B-UNK
-	O
associated	O
coma	B-UNK
,	O
metabolic	B-DISEASE
acidosis	I-DISEASE
,	O
renal	B-UNK
and	O
hepatic	B-UNK
failure	I-UNK
.	O
A	O
case	B-UNK
of	O
metabolic	B-DISEASE
acidosis	I-DISEASE
,	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
and	O
hepatic	B-UNK
failure	I-UNK
following	O
paracetamol	B-UNK
ingestion	B-UNK
is	O
presented	B-UNK
.	O
The	O
diagnostic	B-UNK
difficulty	O
at	O
presentation	B-UNK
is	O
highlighted	O
.	O
Continuous	B-UNK
arteriovenous	O
haemofiltration	O
proved	O
a	O
valuable	O
means	B-UNK
of	O
maintaining	O
fluid	B-UNK
and	O
electrolyte	B-UNK
balance	O
.	O
The	O
patient	B-UNK
recovered	O
.	O

Hepatic	B-UNK
reactions	B-UNK
associated	O
with	O
ketoconazole	B-UNK
in	O
the	O
United	O
Kingdom	O
.	O
Ketoconazole	B-CHEMICAL
was	O
introduced	O
in	O
the	O
United	O
Kingdom	O
in	O
1981	O
.	O
By	O
November	B-UNK
1984	O
the	O
Committee	O
on	O
Safety	B-UNK
of	O
Medicines	O
had	O
received	O
82	O
reports	B-UNK
of	O
possible	O
hepatotoxicity	B-UNK
associated	O
with	O
the	O
drug	B-UNK
,	O
including	O
five	O
deaths	B-DISEASE
.	O
An	O
analysis	B-UNK
of	O
the	O
75	O
cases	B-UNK
that	O
had	O
been	O
adequately	O
followed	O
up	O
suggested	B-UNK
that	O
16	O
,	O
including	O
three	O
deaths	B-UNK
,	O
were	O
probably	O
related	O
to	O
treatment	B-UNK
with	O
the	O
drug	B-UNK
.	O
Of	O
the	O
remainder	O
,	O
48	O
were	O
possibly	O
related	O
to	O
treatment	B-UNK
,	O
five	O
were	O
unlikely	O
to	O
be	O
so	O
,	O
and	O
six	O
were	O
unclassifiable	O
.	O
The	O
mean	O
age	B-UNK
of	O
patients	B-UNK
in	O
the	O
16	O
probable	O
cases	B-UNK
was	O
57.9	O
,	O
with	O
hepatotoxicity	B-UNK
being	O
more	O
common	B-UNK
in	O
women	B-UNK
.	O
The	O
average	B-UNK
duration	B-UNK
of	O
treatment	B-UNK
before	O
the	O
onset	B-UNK
of	O
jaundice	B-DISEASE
was	O
61	O
days	B-UNK
.	O
None	O
of	O
these	O
well	O
validated	O
cases	B-UNK
occurred	B-UNK
within	O
the	O
first	O
10	O
days	B-UNK
after	O
treatment	B-UNK
.	O
The	O
results	B-UNK
of	O
serum	B-UNK
liver	B-UNK
function	I-UNK
tests	I-UNK
suggested	B-UNK
hepatocellular	B-UNK
injury	B-UNK
in	O
10	O
(	O
63	O
%	O
)	O
;	O
the	O
rest	B-UNK
showed	O
a	O
mixed	B-UNK
pattern	B-UNK
.	O
In	O
contrast	B-UNK
,	O
the	O
results	B-UNK
of	O
histological	B-UNK
examination	B-UNK
of	O
the	O
liver	B-UNK
often	O
showed	O
evidence	B-UNK
of	O
cholestasis	B-DISEASE
.	O
The	O
characteristics	B-UNK
of	O
the	O
48	O
patients	B-UNK
in	O
the	O
possible	O
cases	B-UNK
were	O
similar	B-UNK
.	O
Allergic	B-UNK
manifestations	B-UNK
such	O
as	O
rash	B-UNK
and	O
eosinophilia	B-DISEASE
were	O
rare	B-UNK
.	O
Hepatitis	B-UNK
was	O
usually	O
reversible	B-UNK
when	O
treatment	B-UNK
was	O
stopped	O
,	O
with	O
the	O
results	B-UNK
of	O
liver	B-UNK
function	I-UNK
tests	I-UNK
returning	O
to	O
normal	O
after	O
an	O
average	B-UNK
of	O
3.1	O
months	B-UNK
.	O
In	O
two	O
of	O
the	O
three	O
deaths	B-UNK
probably	O
associated	O
with	O
ketoconazole	B-UNK
treatment	B-UNK
the	O
drug	B-UNK
had	O
been	O
continued	O
after	O
the	O
onset	B-UNK
of	O
jaundice	B-DISEASE
and	O
other	O
symptoms	B-UNK
of	O
hepatitis	B-UNK
.	O
Clinical	B-UNK
and	O
biochemical	B-UNK
monitoring	B-UNK
at	O
regular	B-UNK
intervals	B-UNK
for	O
evidence	B-UNK
of	O
hepatitis	B-UNK
is	O
advised	O
during	O
long	B-UNK
term	I-UNK
treatment	B-UNK
with	O
ketoconazole	B-CHEMICAL
to	O
prevent	B-UNK
possible	O
serious	O
hepatic	B-UNK
injury	I-UNK
.	O

Combined	B-UNK
effects	O
of	O
prolonged	B-UNK
prostaglandin	B-UNK
E1-induced	O
hypotension	B-DISEASE
and	O
haemodilution	O
on	O
human	B-UNK
hepatic	B-UNK
function	B-UNK
.	O
Combined	B-UNK
effects	O
of	O
prolonged	B-UNK
prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
(	O
PGE1)-induced	O
hypotension	B-UNK
and	O
haemodilution	O
on	O
hepatic	B-UNK
function	B-UNK
were	O
studied	O
in	O
30	O
patients	B-UNK
undergoing	B-UNK
hip	O
surgery	B-UNK
.	O
The	O
patients	B-UNK
were	O
randomly	B-UNK
allocated	I-UNK
to	O
one	O
of	O
three	O
groups	B-UNK
;	O
those	O
in	O
group	B-UNK
A	O
(	O
n	O
=	O
10	O
)	O
were	O
subjected	O
to	O
controlled	B-UNK
hypotension	B-DISEASE
alone	O
,	O
those	O
in	O
group	B-UNK
B	O
(	O
n	O
=	O
10	O
)	O
to	O
haemodilution	O
alone	O
and	O
those	O
in	O
group	B-UNK
C	O
(	O
n	O
=	O
10	O
)	O
to	O
both	O
controlled	B-UNK
hypotension	B-UNK
and	O
haemodilution	O
.	O
Haemodilution	O
in	O
groups	B-UNK
B	O
and	O
C	O
was	O
produced	B-UNK
by	O
withdrawing	O
approximately	B-UNK
1000	O
mL	B-UNK
of	O
blood	B-UNK
and	O
replacing	O
it	O
with	O
the	O
same	O
amount	O
of	O
dextran	B-UNK
solution	B-UNK
,	O
and	O
final	B-UNK
haematocrit	O
values	O
were	O
21	O
or	O
22	O
%	O
.	O
Controlled	B-UNK
hypotension	B-DISEASE
in	O
groups	B-UNK
A	O
and	O
C	O
was	O
induced	O
with	O
PGE1	O
to	O
maintain	O
mean	O
arterial	B-UNK
blood	I-UNK
pressure	I-UNK
at	O
55	O
mmHg	B-UNK
for	O
180	O
min	B-UNK
.	O
Measurements	B-UNK
included	B-UNK
arterial	B-UNK
ketone	O
body	B-UNK
ratio	B-UNK
(	O
AKBR	O
,	O
aceto	O
-	O
acetate/3-hydroxybutyrate	O
)	O
and	O
clinical	B-UNK
hepatic	B-UNK
function	B-UNK
parameters	O
.	O
AKBR	O
and	O
biological	B-UNK
hepatic	B-UNK
function	B-UNK
tests	B-UNK
showed	O
no	O
change	B-UNK
throughout	O
the	O
time	O
course	O
in	O
groups	B-UNK
A	O
and	O
B.	O
In	O
group	B-UNK
C	O
,	O
AKBR	O
showed	O
a	O
significant	B-UNK
decrease	B-UNK
at	O
120	O
min	B-UNK
(	O
-40	O
%	O
)	O
and	O
at	O
180	O
min	B-UNK
(	O
-49	O
%	O
)	O
after	O
the	O
start	B-UNK
of	O
hypotension	B-UNK
and	O
at	O
60	O
min	B-UNK
(	O
-32	O
%	O
)	O
after	O
recovery	B-UNK
of	O
normotension	O
,	O
and	O
SGOT	O
,	O
SGPT	O
,	O
LDH	O
and	O
total	B-UNK
bilirubin	B-UNK
showed	O
significant	B-UNK
increases	I-UNK
after	O
operation	O
.	O
The	O
results	B-UNK
suggest	B-UNK
that	O
a	O
prolonged	B-UNK
combination	B-UNK
of	O
more	O
than	O
120	O
min	B-UNK
of	O
PGE1-induced	O
hypotension	B-DISEASE
and	O
moderate	B-UNK
haemodilution	O
would	O
cause	O
impairment	B-UNK
of	O
hepatic	B-UNK
function	B-UNK
.	O

Levodopa	B-UNK
-	O
induced	O
dyskinesias	B-UNK
in	O
patients	B-UNK
with	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
:	O
filling	O
the	O
bench	O
-	O
to	O
-	O
bedside	O
gap	O
.	O
Levodopa	B-UNK
is	O
the	O
most	O
effective	B-UNK
drug	B-UNK
for	O
the	O
treatment	B-UNK
of	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
.	O
However	O
,	O
the	O
long	B-UNK
-	O
term	O
use	O
of	O
this	O
dopamine	B-CHEMICAL
precursor	O
is	O
complicated	O
by	O
highly	B-UNK
disabling	O
fluctuations	B-UNK
and	O
dyskinesias	B-DISEASE
.	O
Although	O
preclinical	B-UNK
and	O
clinical	B-UNK
findings	B-UNK
suggest	B-UNK
pulsatile	O
stimulation	B-UNK
of	O
striatal	B-UNK
postsynaptic	B-UNK
receptors	B-UNK
as	O
a	O
key	O
mechanism	B-UNK
underlying	B-UNK
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-UNK
,	O
their	O
pathogenesis	B-UNK
is	O
still	O
unclear	O
.	O
In	O
recent	B-UNK
years	B-UNK
,	O
evidence	B-UNK
from	O
animal	B-UNK
models	I-UNK
of	O
Parkinson'	B-DISEASE
s	I-DISEASE
disease	I-DISEASE
has	O
provided	O
important	B-UNK
information	B-UNK
to	O
understand	O
the	O
effect	B-UNK
of	O
specific	B-UNK
receptor	B-UNK
and	O
post-receptor	O
molecular	B-UNK
mechanisms	B-UNK
underlying	B-UNK
the	O
development	B-UNK
of	O
dyskinetic	B-DISEASE
movements	I-DISEASE
.	O
Recent	B-UNK
preclinical	B-UNK
and	O
clinical	B-UNK
data	B-UNK
from	O
promising	O
lines	B-UNK
of	O
research	B-UNK
focus	O
on	O
the	O
differential	B-UNK
role	O
of	O
presynaptic	O
versus	O
postsynaptic	B-UNK
mechanisms	B-UNK
,	O
dopamine	B-CHEMICAL
receptor	B-UNK
subtypes	O
,	O
ionotropic	O
and	O
metabotropic	O
glutamate	B-UNK
receptors	B-UNK
,	O
and	O
non-dopaminergic	O
neurotransmitter	B-UNK
systems	B-UNK
in	O
the	O
pathophysiology	B-UNK
of	O
levodopa	B-UNK
-	O
induced	O
dyskinesias	B-DISEASE
.	O

Prevention	B-UNK
of	O
seizures	B-DISEASE
and	O
reorganization	O
of	O
hippocampal	B-UNK
functions	B-UNK
by	O
transplantation	B-UNK
of	O
bone	B-UNK
marrow	I-UNK
cells	B-UNK
in	O
the	O
acute	B-UNK
phase	B-UNK
of	O
experimental	B-UNK
epilepsy	B-UNK
.	O
In	O
this	O
study	B-UNK
,	O
we	O
investigated	B-UNK
the	O
therapeutic	B-UNK
potential	B-UNK
of	O
bone	B-UNK
marrow	I-UNK
mononuclear	O
cells	B-UNK
(	O
BMCs	O
)	O
in	O
a	O
model	B-UNK
of	O
epilepsy	B-DISEASE
induced	O
by	O
pilocarpine	B-UNK
in	O
rats	B-UNK
.	O
BMCs	O
obtained	B-UNK
from	O
green	B-UNK
fluorescent	O
protein	B-UNK
(	O
GFP	O
)	O
transgenic	B-UNK
mice	B-UNK
or	O
rats	B-UNK
were	O
transplanted	B-UNK
intravenously	O
after	O
induction	B-UNK
of	O
status	B-UNK
epilepticus	I-UNK
(	O
SE	B-UNK
)	O
.	O
Spontaneous	B-DISEASE
recurrent	I-DISEASE
seizures	I-DISEASE
(	O
SRS	B-DISEASE
)	O
were	O
monitored	O
using	O
Racine'	O
s	O
seizure	B-UNK
severity	B-UNK
scale	B-UNK
.	O
All	O
of	O
the	O
rats	B-UNK
in	O
the	O
saline	B-UNK
-	O
treated	O
epileptic	B-UNK
control	B-UNK
group	B-UNK
developed	O
SRS	B-DISEASE
,	O
whereas	O
none	O
of	O
the	O
BMC	O
-	O
treated	O
epileptic	B-UNK
animals	B-UNK
had	O
seizures	B-UNK
in	O
the	O
short	B-UNK
term	I-UNK
(	O
15	O
days	B-UNK
after	O
transplantation	B-UNK
)	O
,	O
regardless	O
of	O
the	O
BMC	O
source	O
.	O
Over	O
the	O
long	B-UNK
-	O
term	O
chronic	B-UNK
phase	B-UNK
(	O
120	O
days	B-UNK
after	O
transplantation	B-UNK
)	O
,	O
only	O
25	O
%	O
of	O
BMC	O
-	O
treated	O
epileptic	B-UNK
animals	B-UNK
had	O
seizures	B-UNK
,	O
but	O
with	O
a	O
lower	B-UNK
frequency	B-UNK
and	O
duration	B-UNK
compared	O
to	O
the	O
epileptic	B-UNK
control	B-UNK
group	B-UNK
.	O
The	O
density	B-UNK
of	O
hippocampal	B-UNK
neurons	B-UNK
in	O
the	O
brains	B-UNK
of	O
animals	B-UNK
treated	O
with	O
BMCs	O
was	O
markedly	O
preserved	B-UNK
.	O
At	O
hippocampal	B-UNK
Schaeffer	O
collateral	O
-	O
CA1	B-UNK
synapses	O
,	O
long	B-UNK
-	O
term	O
potentiation	B-UNK
was	O
preserved	B-UNK
in	O
BMC	O
-	O
transplanted	B-UNK
rats	B-UNK
compared	O
to	O
epileptic	B-UNK
controls	B-UNK
.	O
The	O
donor	B-UNK
-	O
derived	O
GFP(+	O
)	O
cells	B-UNK
were	O
rarely	O
found	O
in	O
the	O
brains	B-UNK
of	O
transplanted	B-UNK
epileptic	B-UNK
rats	B-UNK
.	O
In	O
conclusion	B-UNK
,	O
treatment	B-UNK
with	O
BMCs	O
can	O
prevent	B-UNK
the	O
development	B-UNK
of	O
chronic	B-UNK
seizures	B-UNK
,	O
reduce	B-UNK
neuronal	B-UNK
loss	B-UNK
,	O
and	O
influence	B-UNK
the	O
reorganization	O
of	O
the	O
hippocampal	B-UNK
neuronal	B-UNK
network	O
.	O

Cardioprotective	B-UNK
effect	B-UNK
of	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
on	O
isoproterenol	B-CHEMICAL
-	O
induced	B-UNK
myocardial	I-UNK
infarction	I-UNK
in	I-UNK
rats	I-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
designed	B-UNK
to	O
evaluate	B-UNK
the	O
cardioprotective	B-UNK
potential	B-UNK
of	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
on	O
isoproterenol	B-UNK
-	O
induced	B-UNK
myocardial	I-UNK
infarction	I-UNK
in	I-UNK
rats	I-UNK
.	O
Hemodynamic	B-UNK
parameters	O
and	O
lead	B-UNK
II	B-UNK
electrocardiograph	O
were	O
monitored	O
and	O
recorded	O
continuously	B-UNK
.	O
Cardiac	B-UNK
marker	B-UNK
enzymes	B-UNK
and	O
antioxidative	O
parameters	O
in	O
serum	B-UNK
and	O
heart	B-UNK
tissues	B-UNK
were	O
measured	B-UNK
.	O
Assay	B-UNK
for	O
mitochondrial	B-UNK
respiratory	B-UNK
function	B-UNK
and	O
histopathological	B-UNK
examination	B-UNK
of	O
heart	B-UNK
tissues	B-UNK
were	O
performed	B-UNK
.	O
Isoproterenol	B-CHEMICAL
-	O
treated	B-UNK
rats	I-UNK
showed	O
significant	B-UNK
increases	I-UNK
in	O
the	O
levels	O
of	O
lactate	B-UNK
dehydrogenase	B-UNK
,	O
aspartate	B-UNK
transaminase	B-UNK
,	O
creatine	B-UNK
kinase	I-UNK
and	O
malondialdehyde	B-CHEMICAL
and	O
significant	B-UNK
decreases	B-UNK
in	O
the	O
activities	B-UNK
of	O
superoxide	B-UNK
dismutase	I-UNK
,	O
catalase	O
and	O
glutathione	B-CHEMICAL
peroxidase	O
in	O
serum	B-UNK
and	O
heart	B-UNK
.	O
These	O
rats	B-UNK
also	O
showed	O
declines	O
in	O
left	B-UNK
ventricular	I-UNK
systolic	B-UNK
pressure	B-UNK
,	O
maximum	B-UNK
and	O
minimum	B-UNK
rate	B-UNK
of	O
developed	O
left	B-UNK
ventricular	I-UNK
pressure	B-UNK
,	O
and	O
elevation	B-UNK
of	O
left	B-UNK
ventricular	I-UNK
end	B-UNK
-	O
diastolic	B-UNK
pressure	B-UNK
and	O
ST	B-UNK
-	O
segment	B-UNK
.	O
In	O
addition	B-UNK
,	O
mitochondrial	B-UNK
respiratory	B-UNK
dysfunction	B-UNK
characterized	B-UNK
by	O
decreased	B-UNK
respiratory	B-UNK
control	B-UNK
ratio	B-UNK
and	O
ADP	B-CHEMICAL
/	O
O	O
was	O
observed	O
in	O
isoproterenol	B-CHEMICAL
-	O
treated	B-UNK
rats	I-UNK
.	O
Administration	O
of	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
for	O
a	O
period	B-UNK
of	O
8	O
days	B-UNK
significantly	B-UNK
attenuated	I-UNK
isoproterenol	B-CHEMICAL
-	O
induced	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
and	O
myocardial	B-DISEASE
injury	I-DISEASE
and	O
improved	O
mitochondrial	B-UNK
respiratory	B-UNK
function	B-UNK
.	O
The	O
protective	B-UNK
role	I-UNK
of	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
against	O
isoproterenol	B-CHEMICAL
-	O
induced	O
myocardial	B-DISEASE
damage	I-DISEASE
was	O
further	O
confirmed	B-UNK
by	O
histopathological	B-UNK
examination	B-UNK
.	O
The	O
results	B-UNK
of	O
our	O
study	B-UNK
suggest	B-UNK
that	O
salvianolic	B-CHEMICAL
acid	I-CHEMICAL
A	I-CHEMICAL
possessing	O
antioxidant	B-UNK
activity	B-UNK
has	O
a	O
significant	B-UNK
protective	B-UNK
effect	I-UNK
against	O
isoproterenol	B-UNK
-	O
induced	O
myocardial	B-UNK
infarction	I-UNK
.	O

Acute	B-UNK
effects	O
of	O
N-(2-propylpentanoyl)urea	O
on	O
hippocampal	B-UNK
amino	B-UNK
acid	I-UNK
neurotransmitters	O
in	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizure	B-UNK
in	O
rats	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
aimed	B-UNK
to	O
investigate	B-UNK
the	O
anticonvulsant	B-UNK
activity	B-UNK
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	B-UNK
of	O
hippocampal	B-UNK
amino	B-UNK
acid	I-UNK
neurotransmitters	O
(	O
glutamate	B-CHEMICAL
,	O
aspartate	B-UNK
,	O
glycine	B-CHEMICAL
and	O
GABA	B-UNK
)	O
of	O
N-(2-propylpentanoyl)urea	O
(	O
VPU	O
)	O
in	O
comparison	B-UNK
to	O
its	O
parent	O
compound	B-UNK
,	O
valproic	B-UNK
acid	I-UNK
(	O
VPA	B-UNK
)	O
.	O
VPU	O
was	O
more	O
potent	B-UNK
than	O
VPA	B-UNK
,	O
exhibiting	O
the	O
median	B-UNK
effective	B-UNK
dose	B-UNK
(	O
ED(50	O
)	O
)	O
of	O
49	O
mg	B-UNK
/	O
kg	B-UNK
in	O
protecting	O
rats	B-UNK
against	O
pilocarpine	B-UNK
-	O
induced	O
seizure	B-DISEASE
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	B-UNK
was	O
322	O
mg	B-UNK
/	O
kg	B-UNK
.	O
In	O
vivo	B-UNK
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	B-UNK
administration	O
of	O
pilocarpine	B-UNK
induced	O
a	O
pronounced	B-UNK
increment	O
of	O
hippocampal	B-UNK
glutamate	B-UNK
and	O
aspartate	B-UNK
whereas	O
no	O
significant	B-UNK
change	B-UNK
was	O
observed	O
on	O
the	O
level	B-UNK
of	O
glycine	B-UNK
and	O
GABA	B-UNK
.	O
Pretreatment	B-UNK
with	O
either	O
VPU	O
(	O
50	O
and	O
100	O
mg	B-UNK
/	O
kg	B-UNK
)	O
or	O
VPA	B-UNK
(	O
300	O
and	O
600	O
mg	B-UNK
/	O
kg	B-UNK
)	O
completely	O
abolished	O
pilocarpine	B-UNK
-	O
evoked	B-UNK
increases	B-UNK
in	O
extracellular	B-UNK
glutamate	B-CHEMICAL
and	O
aspartate	B-UNK
.	O
In	O
addition	B-UNK
,	O
a	O
statistically	B-UNK
significant	I-UNK
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	B-UNK
of	O
GABA	B-UNK
and	O
glycine	B-CHEMICAL
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	B-CHEMICAL
and	O
aspartate	B-UNK
level	B-UNK
.	O
Based	B-UNK
on	O
the	O
finding	O
that	O
VPU	O
and	O
VPA	B-UNK
could	O
protect	B-UNK
the	O
animals	B-UNK
against	O
pilocarpine	B-UNK
-	O
induced	O
seizure	B-DISEASE
it	O
is	O
suggested	B-UNK
that	O
the	O
reduction	O
of	O
inhibitory	B-UNK
amino	B-UNK
acid	I-UNK
neurotransmitters	O
was	O
comparatively	O
minor	B-UNK
and	O
offset	O
by	O
a	O
pronounced	B-UNK
reduction	O
of	O
glutamate	B-UNK
and	O
aspartate	B-UNK
.	O
Therefore	O
,	O
like	O
VPA	B-UNK
,	O
the	O
finding	O
that	O
VPU	O
could	O
drastically	O
reduce	B-UNK
pilocarpine	B-CHEMICAL
-	O
induced	O
increases	B-UNK
in	O
glutamate	B-UNK
and	O
aspartate	B-UNK
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	B-UNK
activity	B-UNK
observed	O
in	O
pilocarpine	B-UNK
-	O
induced	O
seizure	B-UNK
in	O
experimental	B-UNK
animals	B-UNK
.	O
Some	O
other	O
mechanism	B-UNK
than	O
those	O
being	O
reported	B-UNK
herein	O
should	O
be	O
further	O
investigated	B-UNK
.	O

Acute	B-UNK
hepatitis	I-UNK
attack	B-UNK
after	O
exposure	B-UNK
to	O
telithromycin	B-CHEMICAL
.	O
INTRODUCTION	B-UNK
:	O
Antibiotic	B-UNK
-	O
associated	O
hepatotoxicity	B-UNK
is	O
rare	B-UNK
.	O
With	O
widespread	B-UNK
use	O
of	O
antimicrobial	B-UNK
agents	B-UNK
,	O
however	O
,	O
hepatic	B-UNK
injury	I-UNK
occurs	O
frequently	B-UNK
,	O
and	O
among	O
adverse	B-DISEASE
drug	I-DISEASE
reactions	I-DISEASE
,	O
idiosyncratic	O
reactions	B-UNK
are	O
the	O
most	O
serious	O
.	O
CASE	B-UNK
SUMMARY	I-UNK
:	O
A	O
25-year	O
-	O
old	O
male	B-UNK
patient	B-UNK
,	O
with	O
a	O
height	O
of	O
175	O
cm	B-UNK
and	O
weight	B-UNK
of	O
72	O
kg	B-UNK
presented	B-UNK
to	O
Marmara	O
University	B-UNK
Hospital	B-UNK
Emergency	B-UNK
Department	I-UNK
,	O
Istanbul	O
,	O
Turkey	O
,	O
with	O
5	O
days	B-UNK
'	O
history	B-UNK
of	O
jaundice	B-DISEASE
,	O
malaise	O
,	O
nausea	B-UNK
,	O
and	O
vomiting	B-UNK
.	O
He	O
had	O
been	O
prescribed	B-UNK
telithromycin	B-CHEMICAL
400	O
mg	B-UNK
/	O
d	O
PO	O
to	O
treat	B-UNK
an	O
upper	B-UNK
respiratory	B-UNK
tract	B-UNK
infection	B-UNK
7	O
days	B-UNK
prior	B-UNK
.	O
Admission	B-UNK
laboratory	B-UNK
tests	B-UNK
were	O
as	O
follows	O
:	O
alanine	B-UNK
aminotransferase	B-UNK
,	O
67	O
U	O
/	O
L	O
(	O
reference	B-UNK
range	B-UNK
,	O
10	O
-	O
37	O
U	O
/	O
L	O
)	O
;	O
aspartate	B-UNK
aminotransferase	B-UNK
,	O
98	O
U	O
/	O
L	O
(	O
10	O
-	O
40	O
U	O
/	O
L	O
)	O
;	O
alkaline	B-CHEMICAL
phosphatase	I-CHEMICAL
,	O
513	O
U	O
/	O
L	O
(	O
0	O
-	O
270	O
U	O
/	O
L	O
)	O
;	O
gamma	B-UNK
-	O
glutamyltransferase	O
,	O
32	O
U	O
/	O
L	O
(	O
7	O
-	O
49	O
U	O
/	O
L	O
)	O
;	O
amylase	O
,	O
46	O
U	O
/	O
L	O
(	O
0	O
-	O
220	O
U	O
/	O
L	O
)	O
;	O
total	B-UNK
bilirubin	B-UNK
,	O
20.1	O
mg	B-UNK
/	O
dL	B-UNK
(	O
0.2	O
-	O
1.0	O
mg	B-UNK
/	O
dL	B-UNK
)	O
;	O
direct	B-UNK
bilirubin	B-UNK
,	O
14.8	O
mg	B-UNK
/	O
dL	B-UNK
(	O
0	O
-	O
0.3	O
mg	B-UNK
/	O
dL	B-UNK
)	O
;	O
and	O
albumin	B-UNK
,	O
4.7	O
mg	B-UNK
/	O
dL	B-UNK
(	O
3.5	O
-	O
5.4	O
mg	B-UNK
/	O
dL	B-UNK
)	O
.	O
No	O
toxin	O
,	O
alcohol	B-UNK
,	O
or	O
other	O
drugs	B-UNK
were	O
reported	B-UNK
.	O
The	O
patient	B-UNK
had	O
suffered	O
a	O
previous	B-UNK
episode	B-UNK
of	O
"	O
acute	B-UNK
hepatitis	I-UNK
of	O
unknown	O
origin	B-UNK
,	O
"	O
that	O
occurred	B-UNK
after	O
telithromycin	B-CHEMICAL
usage	B-UNK
.	O
Both	O
incidents	O
occurred	B-UNK
within	O
a	O
year	O
.	O
DISCUSSION	B-UNK
:	O
Telithromycin	B-CHEMICAL
is	O
the	O
first	O
of	O
the	O
ketolide	O
antibacterials	O
to	O
receive	B-UNK
US	O
Food	B-UNK
and	O
Drug	B-UNK
Administration	O
approval	O
for	O
clinical	B-UNK
use	O
.	O
It	O
has	O
been	O
associated	O
with	O
infrequent	O
and	O
usually	O
reversible	B-UNK
severe	B-UNK
hepatic	B-UNK
dysfunction	B-UNK
.	O
Based	B-UNK
on	O
a	O
score	O
of	O
8	O
on	O
the	O
Naranjo	O
adverse	B-UNK
drug	I-UNK
reaction	I-UNK
probability	B-UNK
scale	B-UNK
,	O
telithromycin	B-CHEMICAL
was	O
the	O
probable	O
cause	O
of	O
acute	B-DISEASE
hepatitis	I-DISEASE
in	O
this	O
patient	B-UNK
,	O
and	O
pathological	B-UNK
findings	B-UNK
suggested	B-UNK
drug	B-UNK
-	O
induced	O
toxic	B-DISEASE
hepatitis	I-DISEASE
.	O
Recurrence	B-UNK
of	O
hepatitis	B-DISEASE
attack	B-UNK
might	O
have	O
been	O
avoided	O
if	O
the	O
initial	B-UNK
incident	O
had	O
been	O
communicated	O
to	O
the	O
attending	O
physician	O
who	O
prescribed	B-UNK
telithromycin	B-CHEMICAL
the	O
second	O
time	O
.	O
CONCLUSION	B-UNK
:	O
Here	O
we	O
report	B-UNK
a	O
case	B-UNK
of	O
acute	B-UNK
hepatitis	I-UNK
probably	O
associated	O
with	O
the	O
administration	O
of	O
telithromycin	B-CHEMICAL
.	O

Spironolactone	B-UNK
-	O
induced	O
renal	B-UNK
insufficiency	I-UNK
and	O
hyperkalemia	B-DISEASE
in	O
patients	B-UNK
with	O
heart	B-UNK
failure	I-UNK
.	O
BACKGROUND	B-UNK
:	O
A	O
previous	B-UNK
randomized	B-UNK
controlled	B-UNK
trial	I-UNK
evaluating	O
the	O
use	O
of	O
spironolactone	B-CHEMICAL
in	O
heart	B-UNK
failure	I-UNK
patients	B-UNK
reported	B-UNK
a	O
low	B-UNK
risk	B-UNK
of	O
hyperkalemia	B-UNK
(	O
2	O
%	O
)	O
and	O
renal	B-UNK
insufficiency	I-UNK
(	O
0	O
%	O
)	O
.	O
Because	O
treatments	O
for	O
heart	B-UNK
failure	I-UNK
have	O
changed	O
since	O
the	O
benefits	B-UNK
of	O
spironolactone	B-UNK
were	O
reported	B-UNK
,	O
the	O
prevalence	B-UNK
of	O
these	O
complications	B-UNK
may	O
differ	B-UNK
in	O
current	B-UNK
clinical	B-UNK
practice	I-UNK
.	O
We	O
therefore	O
sought	O
to	O
determine	B-UNK
the	O
prevalence	B-UNK
and	O
clinical	B-UNK
associations	B-UNK
of	O
hyperkalemia	B-UNK
and	O
renal	B-UNK
insufficiency	I-UNK
in	O
heart	B-UNK
failure	I-UNK
patients	B-UNK
treated	O
with	O
spironolactone	B-UNK
.	O
METHODS	B-UNK
:	O
We	O
performed	B-UNK
a	O
case	B-UNK
control	I-UNK
study	I-UNK
of	O
heart	B-DISEASE
failure	I-DISEASE
patients	B-UNK
treated	O
with	O
spironolactone	B-CHEMICAL
in	O
our	O
clinical	B-UNK
practice	I-UNK
.	O
Cases	B-UNK
were	O
patients	B-UNK
who	O
developed	O
hyperkalemia	B-UNK
(	O
K(+	O
)	O
>	O
5.0	O
mEq	B-UNK
/	O
L	O
)	O
or	O
renal	B-UNK
insufficiency	I-UNK
(	O
Cr	B-UNK
>	O
or=2.5	O
mg	B-UNK
/	O
dL	B-UNK
)	O
,	O
and	O
they	O
were	O
compared	O
to	O
2	O
randomly	B-UNK
selected	O
controls	B-UNK
per	O
case	B-UNK
.	O
Clinical	B-UNK
characteristics	B-UNK
,	O
medications	B-UNK
,	O
and	O
serum	B-UNK
chemistries	O
at	O
baseline	B-UNK
and	O
follow	O
-	O
up	O
time	O
periods	O
were	O
compared	O
.	O
RESULTS	B-UNK
:	O
Sixty	O
-	O
seven	O
of	O
926	O
patients	B-UNK
(	O
7.2	O
%	O
)	O
required	B-UNK
discontinuation	B-UNK
of	O
spironolactone	B-CHEMICAL
due	O
to	O
hyperkalemia	B-UNK
(	O
n	O
=	O
33	O
)	O
or	O
renal	B-DISEASE
failure	I-DISEASE
(	O
n	O
=	O
34	O
)	O
.	O
Patients	B-UNK
who	O
developed	O
hyperkalemia	B-UNK
were	O
older	B-UNK
and	O
more	O
likely	O
to	O
have	O
diabetes	B-DISEASE
,	O
had	O
higher	B-UNK
baseline	B-UNK
serum	B-UNK
potassium	I-UNK
levels	O
and	O
lower	B-UNK
baseline	B-UNK
potassium	B-UNK
supplement	O
doses	B-UNK
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
beta-blockers	O
than	O
controls	B-UNK
(	O
n	O
=	O
134	O
)	O
.	O
Patients	B-UNK
who	O
developed	O
renal	B-UNK
insufficiency	I-UNK
had	O
lower	B-UNK
baseline	B-UNK
body	B-DISEASE
weight	I-DISEASE
and	O
higher	B-UNK
baseline	B-UNK
serum	B-UNK
creatinine	I-UNK
,	O
required	B-UNK
higher	B-UNK
doses	I-UNK
of	O
loop	O
diuretics	O
,	O
and	O
were	O
more	O
likely	O
to	O
be	O
treated	O
with	O
thiazide	O
diuretics	O
than	O
controls	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Spironolactone	B-CHEMICAL
-	O
induced	O
hyperkalemia	B-DISEASE
and	O
renal	B-UNK
insufficiency	I-UNK
are	O
more	O
common	B-UNK
in	O
our	O
clinical	B-UNK
experience	B-UNK
than	O
reported	B-UNK
previously	B-UNK
.	O
This	O
difference	B-UNK
is	O
explained	O
by	O
patient	B-UNK
comorbidities	O
and	O
more	O
frequent	B-UNK
use	O
of	O
beta-blockers	O
.	O

End	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-DISEASE
)	O
after	O
orthotopic	O
liver	B-UNK
transplantation	I-UNK
(	O
OLTX	O
)	O
using	O
calcineurin	B-UNK
-	O
based	B-UNK
immunotherapy	O
:	O
risk	B-UNK
of	O
development	B-UNK
and	O
treatment	B-UNK
.	O
BACKGROUND	B-UNK
:	O
The	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
cyclosporine	B-UNK
and	O
tacrolimus	B-CHEMICAL
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B-UNK
.	O
Their	O
use	O
in	O
orthotopic	O
liver	B-UNK
transplantation	I-UNK
(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	B-UNK
rates	B-UNK
.	O
Recently	B-UNK
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	B-UNK
of	O
patients	B-UNK
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	B-UNK
)	O
.	O
This	O
retrospective	B-UNK
study	I-UNK
examines	O
the	O
incidence	B-UNK
and	O
treatment	B-UNK
of	O
ESRD	B-UNK
and	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
(	O
CRF	B-UNK
)	O
in	O
OLTX	O
patients	B-UNK
.	O
METHODS	B-UNK
:	O
Patients	B-UNK
receiving	B-UNK
an	O
OLTX	O
only	O
from	O
June	B-UNK
1985	O
through	O
December	B-UNK
of	O
1994	O
who	O
survived	O
6	O
months	B-UNK
postoperatively	B-UNK
were	O
studied	O
(	O
n=834	O
)	O
.	O
Our	O
prospectively	O
collected	O
database	B-UNK
was	O
the	O
source	O
of	O
information	B-UNK
.	O
Patients	B-UNK
were	O
divided	B-UNK
into	I-UNK
three	O
groups	B-UNK
:	O
Controls	B-UNK
,	O
no	O
CRF	B-UNK
or	O
ESRD	B-UNK
,	O
n=748	O
;	O
CRF	B-UNK
,	O
sustained	B-UNK
serum	B-UNK
creatinine	I-UNK
>	O
2.5	O
mg	B-UNK
/	O
dl	B-UNK
,	O
n=41	O
;	O
and	O
ESRD	B-UNK
,	O
n=45	O
.	O
Groups	B-UNK
were	O
compared	O
for	O
preoperative	B-UNK
laboratory	B-UNK
variables	B-UNK
,	O
diagnosis	B-UNK
,	O
postoperative	B-UNK
variables	B-UNK
,	O
survival	B-UNK
,	O
type	B-UNK
of	O
ESRD	B-DISEASE
therapy	O
,	O
and	O
survival	B-UNK
from	O
onset	B-UNK
of	O
ESRD	B-DISEASE
.	O
RESULTS	B-UNK
:	O
At	O
13	O
years	B-UNK
after	O
OLTX	O
,	O
the	O
incidence	B-UNK
of	O
severe	B-UNK
renal	B-UNK
dysfunction	I-UNK
was	O
18.1	O
%	O
(	O
CRF	B-UNK
8.6	O
%	O
and	O
ESRD	B-UNK
9.5	O
%	O
)	O
.	O
Compared	O
with	O
control	B-UNK
patients	B-UNK
,	O
CRF	B-UNK
and	O
ESRD	B-UNK
patients	B-UNK
had	O
higher	B-UNK
preoperative	B-UNK
serum	B-UNK
creatinine	I-UNK
levels	I-UNK
,	O
a	O
greater	B-UNK
percentage	B-UNK
of	O
patients	B-UNK
with	O
hepatorenal	B-DISEASE
syndrome	I-DISEASE
,	O
higher	B-UNK
percentage	B-UNK
requirement	O
for	O
dialysis	B-UNK
in	O
the	O
first	O
3	O
months	B-UNK
postoperatively	B-UNK
,	O
and	O
a	O
higher	B-UNK
1-year	O
serum	B-UNK
creatinine	I-UNK
.	O
Multivariate	B-UNK
stepwise	O
logistic	B-UNK
regression	I-UNK
analysis	B-UNK
using	O
preoperative	B-UNK
and	O
postoperative	B-UNK
variables	B-UNK
identified	B-UNK
that	O
an	O
increase	B-UNK
of	O
serum	B-UNK
creatinine	I-UNK
compared	O
with	O
average	B-UNK
at	O
1	O
year	O
,	O
3	O
months	B-UNK
,	O
and	O
4	O
weeks	B-UNK
postoperatively	B-UNK
were	O
independent	B-UNK
risk	B-UNK
factors	I-UNK
for	O
the	O
development	B-UNK
of	O
CRF	B-UNK
or	O
ESRD	B-UNK
with	O
odds	B-UNK
ratios	O
of	O
2.6	O
,	O
2.2	O
,	O
and	O
1.6	O
,	O
respectively	O
.	O
Overall	O
survival	B-UNK
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	B-UNK
different	O
among	O
groups	B-UNK
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	B-UNK
of	O
the	O
patients	B-UNK
who	O
had	O
ESRD	B-UNK
was	O
only	O
28.2	O
%	O
compared	O
with	O
54.6	O
%	O
in	O
the	O
control	B-UNK
group	B-UNK
.	O
Patients	B-UNK
developing	B-UNK
ESRD	B-DISEASE
had	O
a	O
6-year	O
survival	B-UNK
after	O
onset	B-UNK
of	O
ESRD	B-UNK
of	O
27	O
%	O
for	O
the	O
patients	B-UNK
receiving	B-UNK
hemodialysis	B-UNK
versus	O
71.4	O
%	O
for	O
the	O
patients	B-UNK
developing	B-UNK
ESRD	B-DISEASE
who	O
subsequently	B-UNK
received	O
kidney	B-UNK
transplants	O
.	O
CONCLUSIONS	B-UNK
:	O
Patients	B-UNK
who	O
are	O
more	O
than	O
10	O
years	B-UNK
post-OLTX	O
have	O
CRF	B-UNK
and	O
ESRD	B-UNK
at	O
a	O
high	B-UNK
rate	B-UNK
.	O
The	O
development	B-UNK
of	O
ESRD	B-UNK
decreases	B-UNK
survival	B-UNK
,	O
particularly	O
in	O
those	O
patients	B-UNK
treated	O
with	O
dialysis	B-UNK
only	O
.	O
Patients	B-UNK
who	O
develop	B-UNK
ESRD	B-UNK
have	O
a	O
higher	B-UNK
preoperative	B-UNK
and	O
1-year	O
serum	B-UNK
creatinine	I-UNK
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-DISEASE
syndrome	I-DISEASE
.	O
However	O
,	O
an	O
increase	B-UNK
of	O
serum	B-UNK
creatinine	I-UNK
at	O
various	O
times	B-UNK
postoperatively	B-UNK
is	O
more	O
predictive	B-UNK
of	O
the	O
development	B-UNK
of	O
CRF	B-DISEASE
or	O
ESRD	B-UNK
.	O
New	O
strategies	B-UNK
for	O
long	B-UNK
-	O
term	O
immunosuppression	B-UNK
may	O
be	O
needed	B-UNK
to	O
decrease	B-UNK
this	O
complication	B-UNK
.	O

Effect	B-UNK
of	O
intravenous	B-UNK
nimodipine	B-UNK
on	O
blood	B-UNK
pressure	I-UNK
and	O
outcome	B-UNK
after	O
acute	B-DISEASE
stroke	I-DISEASE
.	O
BACKGROUND	B-UNK
AND	O
PURPOSE	B-UNK
:	O
The	O
Intravenous	B-UNK
Nimodipine	B-CHEMICAL
West	O
European	O
Stroke	B-UNK
Trial	B-UNK
(	O
INWEST	O
)	O
found	O
a	O
correlation	B-UNK
between	O
nimodipine	B-UNK
-	O
induced	O
reduction	O
in	O
blood	B-UNK
pressure	I-UNK
(	O
BP	B-UNK
)	O
and	O
an	O
unfavorable	O
outcome	B-UNK
in	O
acute	B-DISEASE
stroke	I-DISEASE
.	O
We	O
sought	O
to	O
confirm	B-UNK
this	O
correlation	B-UNK
with	O
and	O
without	O
adjustment	B-UNK
for	O
prognostic	O
variables	B-UNK
and	O
to	O
investigate	B-UNK
outcome	B-UNK
in	O
subgroups	B-UNK
with	O
increasing	B-UNK
levels	O
of	O
BP	B-UNK
reduction	O
.	O
METHODS	B-UNK
:	O
Patients	B-UNK
with	O
a	O
clinical	B-UNK
diagnosis	B-UNK
of	O
ischemic	B-DISEASE
stroke	I-DISEASE
(	O
within	O
24	O
hours	B-UNK
)	O
were	O
consecutively	O
allocated	O
to	O
receive	B-UNK
placebo	B-UNK
(	O
n=100	O
)	O
,	O
1	O
mg	B-UNK
/	O
h	O
(	O
low	B-UNK
-	O
dose	B-UNK
)	O
nimodipine	B-CHEMICAL
(	O
n=101	O
)	O
,	O
or	O
2	O
mg	B-UNK
/	O
h	O
(	O
high	B-UNK
-	O
dose	B-UNK
)	O
nimodipine	B-UNK
(	O
n=94	O
)	O
.	O
The	O
correlation	B-UNK
between	O
average	B-UNK
BP	B-UNK
change	B-UNK
during	O
the	O
first	O
2	O
days	B-UNK
and	O
the	O
outcome	B-UNK
at	O
day	O
21	O
was	O
analyzed	O
.	O
RESULTS	B-UNK
:	O
Two	O
hundred	O
sixty	O
-	O
five	O
patients	B-UNK
were	O
included	B-UNK
in	O
this	O
analysis	B-UNK
(	O
n=92	O
,	O
93	O
,	O
and	O
80	O
for	O
placebo	B-UNK
,	O
low	B-UNK
dose	I-UNK
,	O
and	O
high	B-UNK
dose	I-UNK
,	O
respectively	O
)	O
.	O
Nimodipine	B-UNK
treatment	B-UNK
resulted	B-UNK
in	O
a	O
statistically	B-UNK
significant	I-UNK
reduction	O
in	O
systolic	B-UNK
BP	B-UNK
(	O
SBP	B-UNK
)	O
and	O
diastolic	B-UNK
BP	B-UNK
(	O
DBP	O
)	O
from	O
baseline	B-UNK
compared	O
with	O
placebo	B-UNK
during	O
the	O
first	O
few	O
days	B-UNK
.	O
In	O
multivariate	B-UNK
analysis	B-UNK
,	O
a	O
significant	B-UNK
correlation	B-UNK
between	O
DBP	O
reduction	O
and	O
worsening	B-UNK
of	O
the	O
neurological	B-UNK
score	O
was	O
found	O
for	O
the	O
high	B-UNK
-	O
dose	B-UNK
group	B-UNK
(	O
beta=0.49	O
,	O
P=0	O
.	O
048	O
)	O
.	O
Patients	B-UNK
with	O
a	O
DBP	O
reduction	O
of	O
>	O
or	O
=	O
20	O
%	O
in	O
the	O
high	B-UNK
-	O
dose	B-UNK
group	B-UNK
had	O
a	O
significantly	B-UNK
increased	B-UNK
adjusted	B-UNK
OR	O
for	O
the	O
compound	B-UNK
outcome	B-UNK
variable	B-UNK
death	B-UNK
or	O
dependency	O
(	O
Barthel	O
Index	B-UNK
<	O
60	O
)	O
(	O
n	O
/	O
N=25/26	O
,	O
OR	O
10	O
.	O
16	O
,	O
95	O
%	O
CI	B-UNK
1.02	O
to	O
101.74	O
)	O
and	O
death	B-UNK
alone	O
(	O
n	O
/	O
N=9/26	O
,	O
OR	O
4.336	O
,	O
95	O
%	O
CI	B-UNK
1.131	O
16.619	O
)	O
compared	O
with	O
all	O
placebo	B-UNK
patients	B-UNK
(	O
n	O
/	O
N=62/92	O
and	O
14/92	O
,	O
respectively	O
)	O
.	O
There	O
was	O
no	O
correlation	B-UNK
between	O
SBP	B-UNK
change	B-UNK
and	O
outcome	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
DBP	O
,	O
but	O
not	O
SBP	B-UNK
,	O
reduction	O
was	O
associated	O
with	O
neurological	B-UNK
worsening	B-UNK
after	O
the	O
intravenous	B-UNK
administration	O
of	O
high	B-UNK
-	O
dose	B-UNK
nimodipine	B-CHEMICAL
after	O
acute	B-DISEASE
stroke	I-DISEASE
.	O
For	O
low	B-UNK
-	O
dose	B-UNK
nimodipine	B-CHEMICAL
,	O
the	O
results	B-UNK
were	O
not	O
conclusive	O
.	O
These	O
results	B-UNK
do	O
not	O
confirm	B-UNK
or	O
exclude	O
a	O
neuroprotective	O
property	O
of	O
nimodipine	B-UNK
.	O

Transient	B-DISEASE
neurologic	I-DISEASE
symptoms	I-DISEASE
after	O
spinal	B-UNK
anesthesia	B-UNK
:	O
a	O
lower	B-UNK
incidence	B-UNK
with	O
prilocaine	B-UNK
and	O
bupivacaine	B-UNK
than	O
with	O
lidocaine	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Recent	B-UNK
evidence	B-UNK
suggests	O
that	O
transient	B-DISEASE
neurologic	I-DISEASE
symptoms	I-DISEASE
(	O
TNSs	B-DISEASE
)	O
frequently	B-UNK
follow	O
lidocaine	B-UNK
spinal	B-UNK
anesthesia	B-UNK
but	O
are	O
infrequent	O
with	O
bupivacaine	B-UNK
.	O
However	O
,	O
identification	O
of	O
a	O
short	B-UNK
-	O
acting	O
local	B-UNK
anesthetic	I-UNK
to	O
substitute	O
for	O
lidocaine	B-UNK
for	O
brief	O
surgical	B-UNK
procedures	B-UNK
remains	O
an	O
important	B-UNK
goal	O
.	O
Prilocaine	B-CHEMICAL
is	O
an	O
amide	O
local	B-UNK
anesthetic	I-UNK
with	O
a	O
duration	B-UNK
of	O
action	B-UNK
similar	B-UNK
to	O
that	O
of	O
lidocaine	B-UNK
.	O
Accordingly	O
,	O
the	O
present	B-UNK
,	O
prospective	B-UNK
double-blind	O
study	B-UNK
compares	O
prilocaine	B-UNK
with	O
lidocaine	B-UNK
and	O
bupivacaine	B-UNK
with	O
respect	B-UNK
to	O
duration	B-UNK
of	O
action	B-UNK
and	O
relative	B-UNK
risk	I-UNK
of	O
TNSs	B-DISEASE
.	O
METHODS	B-UNK
:	O
Ninety	B-UNK
patients	B-UNK
classified	O
as	O
American	O
Society	O
of	O
Anesthesiologists	O
physical	B-UNK
status	B-UNK
I	O
or	O
II	B-UNK
who	O
were	O
scheduled	O
for	O
short	B-UNK
gynecologic	O
procedures	B-UNK
under	O
spinal	B-UNK
anesthesia	B-UNK
were	O
randomly	B-UNK
allocated	I-UNK
to	O
receive	B-UNK
2.5	O
ml	B-UNK
2	O
%	O
lidocaine	B-CHEMICAL
in	O
7.5	O
%	O
glucose	B-UNK
,	O
2	O
%	O
prilocaine	B-UNK
in	O
7.5	O
%	O
glucose	B-CHEMICAL
,	O
or	O
0.5	O
%	O
bupivacaine	B-UNK
in	O
7.5	O
%	O
glucose	B-UNK
.	O
All	O
solutions	O
were	O
provided	O
in	O
blinded	B-UNK
vials	O
by	O
the	O
hospital	B-UNK
pharmacy	O
.	O
Details	O
of	O
spinal	B-UNK
puncture	O
,	O
extension	B-UNK
and	O
regression	B-UNK
of	O
spinal	B-UNK
block	B-UNK
,	O
and	O
the	O
times	B-UNK
to	O
reach	B-UNK
discharge	B-UNK
criteria	B-UNK
were	O
noted	B-UNK
.	O
In	O
the	O
evening	O
of	O
postoperative	B-UNK
day	O
1	O
,	O
patients	B-UNK
were	O
evaluated	B-UNK
for	O
TNSs	B-DISEASE
by	O
a	O
physician	O
unaware	O
of	O
the	O
drug	B-UNK
administered	O
and	O
the	O
details	O
of	O
the	O
anesthetic	B-UNK
procedure	B-UNK
.	O
RESULTS	B-UNK
:	O
Nine	O
of	O
30	O
patients	B-UNK
receiving	B-UNK
lidocaine	B-UNK
experienced	B-UNK
TNSs	B-DISEASE
,	O
1	O
of	O
30	O
patients	B-UNK
receiving	B-UNK
prilocaine	B-UNK
(	O
P	O
=	O
0.03	O
)	O
had	O
them	O
,	O
and	O
none	O
of	O
30	O
patients	B-UNK
receiving	B-UNK
bupivacaine	B-UNK
had	O
TNSs	B-DISEASE
.	O
Times	B-UNK
to	O
ambulate	O
and	O
to	O
void	O
were	O
similar	B-UNK
after	O
lidocaine	B-CHEMICAL
and	O
prilocaine	B-CHEMICAL
(	O
150	O
vs	O
.	O
165	O
min	B-UNK
and	O
238	O
vs	O
.	O
253	O
min	B-UNK
,	O
respectively	O
)	O
but	O
prolonged	B-UNK
after	O
bupivacaine	B-UNK
(	O
200	O
and	O
299	O
min	B-UNK
,	O
respectively	O
;	O
P	O
<	O
0.05	O
)	O
.	O
CONCLUSIONS	B-UNK
:	O
Prilocaine	B-UNK
may	O
be	O
preferable	O
to	O
lidocaine	B-CHEMICAL
for	O
short	B-UNK
surgical	B-UNK
procedures	B-UNK
because	O
it	O
has	O
a	O
similar	B-UNK
duration	B-UNK
of	O
action	B-UNK
but	O
a	O
lower	B-UNK
incidence	B-UNK
of	O
TNSs	B-DISEASE
.	O

The	O
role	O
of	O
nicotine	B-UNK
in	O
smoking	B-CHEMICAL
-	O
related	O
cardiovascular	B-DISEASE
disease	I-DISEASE
.	O
Nicotine	B-UNK
activates	O
the	O
sympathetic	B-UNK
nervous	B-UNK
system	I-UNK
and	O
in	O
this	O
way	O
could	O
contribute	B-UNK
to	O
cardiovascular	B-UNK
disease	I-UNK
.	O
Animal	B-UNK
studies	B-UNK
and	O
mechanistic	O
studies	B-UNK
indicate	O
that	O
nicotine	B-CHEMICAL
could	O
play	O
a	O
role	O
in	O
accelerating	O
atherosclerosis	B-UNK
,	O
but	O
evidence	B-UNK
among	O
humans	B-UNK
is	O
too	O
inadequate	O
to	O
be	O
definitive	O
about	O
such	O
an	O
effect	B-UNK
.	O
Almost	O
certainly	O
,	O
nicotine	B-CHEMICAL
via	O
its	O
hemodynamic	B-UNK
effects	O
contributes	B-UNK
to	O
acute	B-UNK
cardiovascular	B-UNK
events	B-UNK
,	O
although	O
current	B-UNK
evidence	B-UNK
suggests	O
that	O
the	O
effects	O
of	O
nicotine	B-UNK
are	O
much	O
less	O
important	B-UNK
than	O
are	O
the	O
prothrombotic	O
effects	O
of	O
cigarette	O
smoking	B-UNK
or	O
the	O
effects	O
of	O
carbon	B-CHEMICAL
monoxide	I-CHEMICAL
.	O
Nicotine	B-UNK
does	O
not	O
appear	O
to	O
enhance	B-UNK
thrombosis	B-UNK
among	O
humans	B-UNK
.	O
Clinical	B-UNK
studies	B-UNK
of	O
pipe	O
smokers	O
and	O
people	O
using	O
transdermal	O
nicotine	B-UNK
support	B-UNK
the	O
idea	O
that	O
toxins	O
other	O
than	O
nicotine	B-UNK
are	O
the	O
most	O
important	B-UNK
causes	O
of	O
acute	B-UNK
cardiovascular	B-UNK
events	B-UNK
.	O
Finally	B-UNK
,	O
the	O
dose	B-UNK
response	B-UNK
for	O
cardiovascular	B-UNK
events	B-UNK
of	O
nicotine	B-UNK
appears	B-UNK
to	O
be	O
flat	O
,	O
suggesting	O
that	O
if	O
nicotine	B-CHEMICAL
is	O
involved	B-UNK
,	O
adverse	B-UNK
effects	I-UNK
might	O
be	O
seen	O
with	O
relatively	O
low	B-UNK
-	O
level	B-UNK
cigarette	O
exposures	O
.	O

Seizure	B-UNK
resulting	B-UNK
from	O
a	O
venlafaxine	B-UNK
overdose	B-DISEASE
.	O
OBJECTIVE	B-UNK
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
venlafaxine	B-CHEMICAL
overdose	B-DISEASE
.	O
CASE	B-UNK
SUMMARY	I-UNK
:	O
A	O
40-year	O
-	O
old	O
woman	B-UNK
with	O
major	B-DISEASE
depression	I-DISEASE
took	O
an	O
overdose	B-UNK
of	O
venlafaxine	B-UNK
in	O
an	O
apparent	B-UNK
suicide	B-DISEASE
attempt	O
.	O
After	O
the	O
ingestion	B-UNK
of	O
26	O
venlafaxine	B-UNK
50-mg	O
tablets	B-UNK
,	O
the	O
patient	B-UNK
experienced	B-UNK
a	O
witnessed	O
generalized	O
seizure	B-UNK
.	O
She	O
was	O
admitted	B-UNK
to	O
the	O
medical	B-UNK
intensive	B-UNK
care	I-UNK
unit	I-UNK
,	O
venlafaxine	B-CHEMICAL
was	O
discontinued	O
,	O
and	O
no	O
further	O
sequelae	B-UNK
were	O
seen	O
.	O
DISCUSSION	B-UNK
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	B-UNK
case	B-UNK
of	O
venlafaxine	B-UNK
overdose	B-UNK
that	O
resulted	B-UNK
in	O
a	O
generalized	O
seizure	B-DISEASE
.	O
Based	B-UNK
on	O
nonoverdose	O
pharmacokinetics	B-UNK
and	O
pharmacodynamics	O
of	O
venlafaxine	B-CHEMICAL
and	O
the	O
potential	B-UNK
risks	B-UNK
of	O
available	O
interventions	B-UNK
,	O
no	O
emergent	O
therapy	O
was	O
instituted	O
.	O
CONCLUSIONS	B-UNK
:	O
The	O
venlafaxine	B-UNK
overdose	B-DISEASE
in	O
our	O
patient	B-UNK
resulted	B-UNK
in	O
a	O
single	B-UNK
episode	B-UNK
of	O
generalized	O
seizure	B-UNK
but	O
elicited	B-UNK
no	O
further	O
sequelae	B-UNK
.	O

Effect	B-UNK
of	O
nifedipine	B-CHEMICAL
on	O
renal	B-UNK
function	I-UNK
in	O
liver	B-UNK
transplant	I-UNK
recipients	B-UNK
receiving	B-UNK
tacrolimus	B-UNK
.	O
The	O
effect	B-UNK
of	O
nifedipine	B-UNK
on	O
renal	B-UNK
function	I-UNK
in	O
liver	B-UNK
transplant	I-UNK
recipients	B-UNK
who	O
were	O
receiving	B-UNK
tacrolimus	B-UNK
was	O
evaluated	B-UNK
between	O
January	B-UNK
1992	O
and	O
January	B-UNK
1996	O
.	O
Two	O
groups	B-UNK
of	O
patients	B-UNK
receiving	B-UNK
tacrolimus	B-UNK
were	O
compared	O
over	O
a	O
period	B-UNK
of	O
1	O
year	O
,	O
one	O
group	B-UNK
comprising	O
hypertensive	B-UNK
patients	B-UNK
who	O
were	O
receiving	B-UNK
nifedipine	B-CHEMICAL
,	O
and	O
the	O
other	O
comprising	O
nonhypertensive	O
patients	B-UNK
not	O
receiving	B-UNK
nifedipine	B-UNK
.	O
The	O
time	O
from	O
transplant	B-UNK
to	O
baseline	B-UNK
was	O
similar	B-UNK
in	O
all	O
patients	B-UNK
.	O
Nifedipine	B-UNK
significantly	B-UNK
improved	O
kidney	B-UNK
function	B-UNK
as	O
indicated	O
by	O
a	O
significant	B-UNK
lowering	B-UNK
of	O
serum	B-UNK
creatinine	I-UNK
levels	I-UNK
at	O
6	O
and	O
12	O
months	B-UNK
.	O
The	O
observed	O
positive	B-UNK
impact	B-UNK
of	O
nifedipine	B-UNK
on	O
reducing	B-UNK
the	O
nephrotoxicity	B-UNK
associated	O
with	O
tacrolimus	B-UNK
in	O
liver	B-UNK
transplant	I-UNK
recipients	B-UNK
should	O
be	O
an	O
important	B-UNK
factor	B-UNK
in	O
selecting	O
an	O
agent	B-UNK
to	O
treat	B-UNK
hypertension	B-UNK
in	O
this	O
population	B-UNK
.	O

Sinus	B-DISEASE
arrest	I-DISEASE
associated	O
with	O
continuous	B-UNK
-	O
infusion	B-UNK
cimetidine	B-UNK
.	O
The	O
administration	O
of	O
intermittent	B-UNK
intravenous	B-UNK
infusions	B-UNK
of	O
cimetidine	B-UNK
is	O
infrequently	O
associated	O
with	O
the	O
development	B-UNK
of	O
bradyarrhythmias	B-DISEASE
.	O
A	O
40-year	O
-	O
old	O
man	B-UNK
with	O
leukemia	B-UNK
and	O
no	O
history	B-UNK
of	O
cardiac	B-DISEASE
disease	I-DISEASE
developed	O
recurrent	B-UNK
,	O
brief	O
episodes	B-UNK
of	O
apparent	B-UNK
sinus	B-DISEASE
arrest	I-DISEASE
while	O
receiving	B-UNK
continuous	B-UNK
-	O
infusion	B-UNK
cimetidine	B-UNK
50	O
mg	B-UNK
/	O
hour	B-UNK
.	O
The	O
arrhythmias	B-DISEASE
were	O
temporally	O
related	O
to	O
cimetidine	B-CHEMICAL
administration	O
,	O
disappeared	O
after	O
dechallenge	O
,	O
and	O
did	O
not	O
recur	O
during	O
ranitidine	B-UNK
treatment	B-UNK
.	O
This	O
is	O
the	O
first	O
reported	B-UNK
case	B-UNK
of	O
sinus	B-DISEASE
arrest	I-DISEASE
associated	O
with	O
continuous	B-UNK
-	O
infusion	B-UNK
cimetidine	B-UNK
.	O

Composition	O
of	O
gall	B-UNK
bladder	B-UNK
stones	B-UNK
associated	O
with	O
octreotide	B-CHEMICAL
:	O
response	B-UNK
to	O
oral	B-UNK
ursodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
.	O
Octreotide	B-CHEMICAL
,	O
an	O
effective	B-UNK
treatment	B-UNK
for	O
acromegaly	B-DISEASE
,	O
induces	O
gall	B-UNK
bladder	B-UNK
stones	B-UNK
in	O
13	O
-	O
60	O
%	O
of	O
patients	B-UNK
.	O
Because	O
knowledge	O
of	O
stone	O
composition	O
is	O
essential	B-UNK
for	O
studies	B-UNK
of	O
their	O
pathogenesis	B-UNK
,	O
treatment	B-UNK
,	O
and	O
prevention	B-UNK
,	O
this	O
was	O
investigated	B-UNK
by	O
direct	B-UNK
and	O
indirect	O
methods	B-UNK
in	O
14	O
octreotide	B-UNK
treated	O
acromegalic	B-DISEASE
patients	B-UNK
with	O
gall	B-UNK
stones	B-UNK
.	O
Chemical	B-UNK
analysis	B-UNK
of	O
gall	B-UNK
stones	B-UNK
retrieved	O
at	O
cholecystectomy	O
from	O
two	O
patients	B-UNK
,	O
showed	O
that	O
they	O
contained	B-UNK
71	O
%	O
and	O
87	O
%	O
cholesterol	B-UNK
by	O
weight	B-UNK
.	O
In	O
the	O
remaining	O
12	O
patients	B-UNK
,	O
localised	O
computed	O
tomography	B-UNK
of	O
the	O
gall	B-UNK
bladder	B-UNK
showed	O
that	O
eight	O
had	O
stones	B-UNK
with	O
maximum	B-UNK
attenuation	O
scores	O
of	O
<	O
100	O
Hounsfield	O
units	B-UNK
(	O
values	O
of	O
<	O
100	O
HU	O
predict	B-UNK
cholesterol	B-CHEMICAL
rich	O
,	O
dissolvable	O
stones	B-UNK
)	O
.	O
Gall	B-UNK
bladder	B-UNK
bile	B-UNK
was	O
obtained	B-UNK
by	O
ultrasound	B-UNK
guided	O
,	O
fine	O
needle	B-UNK
puncture	O
from	O
six	O
patients	B-UNK
.	O
All	O
six	O
patients	B-UNK
had	O
supersaturated	O
bile	B-UNK
(	O
mean	O
(	O
SEM	B-UNK
)	O
cholesterol	B-UNK
saturation	O
index	B-UNK
of	O
1.19	O
(	O
0.08	O
)	O
(	O
range	B-UNK
1.01	O
-	O
1.53	O
)	O
)	O
and	O
all	O
had	O
abnormally	O
rapid	B-UNK
cholesterol	B-UNK
microcrystal	O
nucleation	O
times	B-UNK
(	O
<	O
4	O
days	B-UNK
(	O
range	B-UNK
1	O
-	O
4	O
)	O
)	O
,	O
whilst	O
in	O
four	O
,	O
the	O
bile	B-UNK
contained	B-UNK
cholesterol	B-CHEMICAL
microcrystals	O
immediately	B-UNK
after	O
sampling	O
.	O
Of	O
the	O
12	O
patients	B-UNK
considered	B-UNK
for	O
oral	B-UNK
ursodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
(	O
UDCA	O
)	O
treatment	B-UNK
,	O
two	O
had	O
a	O
blocked	B-UNK
cystic	O
duct	B-UNK
and	O
were	O
not	O
started	O
on	O
UDCA	O
while	O
one	O
was	O
lost	O
to	O
follow	O
up	O
.	O
After	O
one	O
year	O
of	O
treatment	B-UNK
,	O
five	O
of	O
the	O
remaining	O
nine	O
patients	B-UNK
showed	O
either	O
partial	B-UNK
(	O
n	O
=	O
3	O
)	O
or	O
complete	B-UNK
(	O
n	O
=	O
2	O
)	O
gall	B-UNK
stone	O
dissolution	O
,	O
suggesting	O
that	O
their	O
stones	B-UNK
were	O
cholesterol	B-UNK
rich	O
.	O
This	O
corresponds	O
,	O
by	O
actuarial	O
(	O
life	B-UNK
table	O
)	O
analysis	B-UNK
,	O
to	O
a	O
combined	B-UNK
gall	B-UNK
stone	O
dissolution	O
rate	B-UNK
of	O
58.3	O
(	O
15.9	O
%	O
)	O
.	O
In	O
conclusion	B-UNK
,	O
octreotide	B-UNK
induced	O
gall	B-UNK
stones	B-UNK
are	O
generally	B-UNK
small	B-UNK
,	O
multiple	B-UNK
,	O
and	O
cholesterol	B-UNK
rich	O
although	O
,	O
in	O
common	B-UNK
with	O
spontaneous	B-UNK
gall	B-UNK
stone	O
disease	B-DISEASE
,	O
at	O
presentation	B-UNK
some	O
patients	B-UNK
will	O
have	O
a	O
blocked	B-UNK
cystic	O
duct	B-UNK
and	O
some	O
gall	B-UNK
stones	B-UNK
containing	O
calcium	B-UNK
.	O

Cardiovascular	B-DISEASE
complications	I-DISEASE
associated	O
with	O
terbutaline	B-UNK
treatment	B-UNK
for	O
preterm	B-UNK
labor	O
.	O
Severe	B-UNK
cardiovascular	B-DISEASE
complications	I-DISEASE
occurred	B-UNK
in	O
eight	O
of	O
160	O
patients	B-UNK
treated	O
with	O
terbutaline	B-UNK
for	O
preterm	B-UNK
labor	O
.	O
Associated	O
corticosteroid	B-UNK
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	B-UNK
.	O
Potential	B-UNK
mechanisms	B-UNK
of	O
the	O
pathophysiology	B-UNK
are	O
briefly	O
discussed	O
.	O

Neurologic	B-UNK
effects	O
of	O
subarachnoid	B-UNK
administration	O
of	O
2-chloroprocaine	O
-CE	O
,	O
bupivacaine	B-UNK
,	O
and	O
low	B-UNK
pH	B-UNK
normal	B-UNK
saline	I-UNK
in	O
dogs	B-UNK
.	O
The	O
purpose	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
evaluate	B-UNK
the	O
neurologic	B-UNK
consequences	B-UNK
of	O
deliberate	O
subarachnoid	B-UNK
injection	B-UNK
of	O
large	B-UNK
volumes	O
of	O
2-chloroprocaine	O
-CE	O
in	O
experimental	B-UNK
animals	B-UNK
.	O
The	O
possible	O
role	O
of	O
low	B-UNK
pH	B-UNK
as	O
well	O
as	O
total	B-UNK
volume	B-UNK
as	O
potential	B-UNK
factors	B-UNK
in	O
causing	O
neurotoxicity	B-UNK
was	O
evaluated	B-UNK
.	O
The	O
65	O
dogs	B-UNK
in	O
the	O
study	B-UNK
received	O
injections	B-UNK
in	O
the	O
subarachnoid	B-UNK
space	B-UNK
as	O
follows	O
:	O
6	O
to	O
8	O
ml	B-UNK
of	O
bupivacaine	B-UNK
(	O
N	O
=	O
15	O
)	O
,	O
2-chloroprocaine	O
-CE	O
(	O
N	O
=	O
20	O
)	O
,	O
low	B-UNK
pH	B-UNK
normal	B-UNK
saline	I-UNK
(	O
pH	B-UNK
3.0	O
)	O
(	O
N	O
=	O
20	O
)	O
,	O
or	O
normal	B-UNK
saline	I-UNK
(	O
N	O
=	O
10	O
)	O
.	O
Of	O
the	O
20	O
animals	B-UNK
that	O
received	O
subarachnoid	B-UNK
injection	B-UNK
of	O
2-chloroprocaine	O
-CE	O
seven	O
(	O
35	O
%	O
)	O
developed	O
hind	O
-	O
limb	O
paralysis	B-UNK
.	O
None	O
of	O
the	O
animals	B-UNK
that	O
received	O
bupivacaine	B-UNK
,	O
normal	B-UNK
saline	I-UNK
,	O
or	O
normal	B-UNK
saline	I-UNK
titrated	O
to	O
a	O
pH	B-UNK
3.0	O
developed	O
hind	O
-	O
limb	O
paralysis	B-UNK
.	O
Of	O
the	O
15	O
spinal	B-UNK
cords	O
of	O
the	O
animals	B-UNK
that	O
received	O
2-chloroprocaine	O
-CE	O
,	O
13	O
showed	O
subpial	O
necrosis	B-DISEASE
;	O
the	O
nerve	B-UNK
roots	O
and	O
subarachnoid	B-UNK
vessels	B-UNK
were	O
normal	O
.	O
The	O
spinal	B-UNK
cords	O
of	O
the	O
animals	B-UNK
that	O
received	O
bupivacaine	B-UNK
,	O
low	B-UNK
pH	B-UNK
normal	B-UNK
saline	I-UNK
(	O
pH	B-UNK
3.0	O
)	O
,	O
or	O
normal	B-UNK
saline	I-UNK
did	O
not	O
show	O
abnormal	B-UNK
findings	B-UNK
.	O

Early	B-UNK
adjuvant	O
adriamycin	B-CHEMICAL
in	O
superficial	O
bladder	B-UNK
carcinoma	B-DISEASE
.	O
A	O
multicenter	B-UNK
study	B-UNK
was	O
performed	B-UNK
in	O
110	O
patients	B-UNK
with	O
superficial	O
transitional	O
cell	B-UNK
carcinoma	B-UNK
of	O
the	O
bladder	B-UNK
.	O
Adriamycin	B-UNK
(	O
50	O
mg/50	O
ml	B-UNK
)	O
was	O
administered	O
intravesically	O
within	O
24	O
h	O
after	O
transurethral	O
resection	O
of	O
TA	O
-	O
T1	O
(	O
O	O
-	O
A	O
)	O
bladder	B-DISEASE
tumors	I-DISEASE
.	O
Instillation	B-UNK
was	O
repeated	B-UNK
twice	O
during	O
the	O
first	O
week	B-UNK
,	O
then	O
weekly	B-UNK
during	O
the	O
first	O
month	B-UNK
and	O
afterwards	O
monthly	O
for	O
1	O
year	O
.	O
The	O
tolerance	B-UNK
was	O
evaluated	B-UNK
in	O
these	O
110	O
patients	B-UNK
,	O
and	O
29	O
patients	B-UNK
presented	B-UNK
with	O
local	B-UNK
side	O
-	O
effects	O
.	O
In	O
24	O
of	O
these	O
patients	B-UNK
chemical	B-UNK
cystitis	B-UNK
was	O
severe	B-UNK
enough	O
for	O
them	O
to	O
drop	B-UNK
out	O
of	O
the	O
study	B-UNK
.	O
No	O
systemic	B-UNK
side	O
-	O
effects	O
were	O
observed	O
.	O
Recurrence	B-DISEASE
was	O
studied	O
in	O
82	O
evaluable	B-UNK
patients	B-UNK
after	O
1	O
year	O
of	O
follow	O
-	O
up	O
and	O
in	O
72	O
patients	B-UNK
followed	O
for	O
2	O
-	O
3	O
years	B-UNK
(	O
mean	O
32	O
months	B-UNK
)	O
.	O
Of	O
the	O
82	O
patients	B-UNK
studied	O
after	O
1	O
year	O
,	O
23	O
had	O
primary	B-UNK
and	O
59	O
recurrent	B-UNK
disease	B-DISEASE
.	O
Of	O
the	O
82	O
evaluable	B-UNK
patients	B-UNK
,	O
50	O
did	O
not	O
show	O
any	O
recurrence	B-UNK
after	O
1	O
year	O
(	O
61	O
%	O
)	O
,	O
while	O
32	O
presented	B-UNK
with	O
one	O
or	O
more	O
recurrences	O
(	O
39	O
%	O
)	O
.	O
Of	O
these	O
recurrences	O
,	O
27	O
were	O
T1	O
tumors	B-UNK
while	O
five	O
progressed	O
to	O
more	O
highly	B-UNK
invasive	B-UNK
lesions	B-UNK
.	O
In	O
patients	B-UNK
that	O
were	O
free	B-UNK
of	O
recurrence	B-UNK
during	O
the	O
first	O
year	O
,	O
80	O
%	O
remained	B-UNK
tumor	B-UNK
-	O
free	B-UNK
during	O
the	O
2-	O
to	O
3-year	O
follow	O
-	O
up	O
period	B-UNK
.	O
Of	O
the	O
patients	B-UNK
developing	B-UNK
one	O
or	O
more	O
recurrences	O
during	O
the	O
first	O
year	O
,	O
only	O
50	O
%	O
presented	B-UNK
with	O
further	O
recurrence	B-UNK
once	O
the	O
instillations	O
were	O
stopped	O
.	O
The	O
beneficial	B-UNK
effect	I-UNK
of	O
Adriamycin	B-UNK
appears	B-UNK
obvious	O
and	O
might	O
be	O
related	O
to	O
the	O
drug	B-UNK
itself	O
,	O
the	O
early	B-UNK
and	O
repeated	B-UNK
instillations	O
after	O
TUR	O
,	O
or	O
both	O
.	O

Hyperkalemia	B-UNK
associated	O
with	O
sulindac	B-UNK
therapy	O
.	O
Hyperkalemia	B-UNK
has	O
recently	B-UNK
been	O
recognized	O
as	O
a	O
complication	B-UNK
of	O
nonsteroidal	B-UNK
antiinflammatory	B-UNK
agents	B-UNK
(	O
NSAID	B-UNK
)	O
such	O
as	O
indomethacin	B-UNK
.	O
Several	O
recent	B-UNK
studies	B-UNK
have	O
stressed	O
the	O
renal	B-UNK
sparing	O
features	B-UNK
of	O
sulindac	B-UNK
,	O
owing	O
to	O
its	O
lack	B-UNK
of	O
interference	B-UNK
with	O
renal	B-UNK
prostacyclin	O
synthesis	B-UNK
.	O
We	O
describe	O
4	O
patients	B-UNK
in	O
whom	O
hyperkalemia	B-UNK
ranging	O
from	O
6.1	O
to	O
6.9	O
mEq	B-UNK
/	O
l	O
developed	O
within	O
3	O
to	O
8	O
days	B-UNK
of	O
sulindac	B-CHEMICAL
administration	O
.	O
In	O
all	O
of	O
them	O
normal	O
serum	B-UNK
potassium	I-UNK
levels	O
reached	O
within	O
2	O
to	O
4	O
days	B-UNK
of	O
stopping	B-UNK
sulindac	B-UNK
.	O
As	O
no	O
other	O
medications	B-UNK
known	O
to	O
effect	B-UNK
serum	B-UNK
potassium	I-UNK
had	O
been	O
given	O
concomitantly	B-UNK
,	O
this	O
course	O
of	O
events	B-UNK
is	O
suggestive	B-UNK
of	O
a	O
cause	O
-	O
and	O
-	O
effect	B-UNK
relationship	B-UNK
between	O
sulindac	B-UNK
and	O
hyperkalemia	B-UNK
.	O
These	O
observations	B-UNK
indicate	O
that	O
initial	B-UNK
hopes	O
that	O
sulindac	B-UNK
may	O
not	O
be	O
associated	O
with	O
the	O
adverse	B-UNK
renal	B-UNK
effects	O
of	O
other	O
NSAID	B-UNK
are	O
probably	O
not	O
justified	O
.	O

Ventricular	B-DISEASE
tachyarrhythmias	I-DISEASE
during	O
cesarean	O
section	O
after	O
ritodrine	B-CHEMICAL
therapy	O
:	O
interaction	B-UNK
with	O
anesthetics	B-UNK
.	O
This	O
case	B-UNK
illustrates	O
that	O
patients	B-UNK
receiving	B-UNK
ritodrine	B-CHEMICAL
for	O
preterm	B-UNK
labor	O
may	O
risk	B-UNK
interactions	B-UNK
between	O
the	O
residual	B-UNK
betamimetic	O
effects	O
of	O
ritodrine	B-CHEMICAL
and	O
the	O
effects	O
of	O
anesthetics	B-UNK
during	O
cesarean	O
section	O
.	O
Such	O
interactions	B-UNK
may	O
result	B-UNK
in	O
serious	O
cardiovascular	B-DISEASE
complications	I-DISEASE
even	O
after	O
cessation	B-UNK
of	O
an	O
infusion	B-UNK
of	O
ritodrine	B-CHEMICAL
.	O
Preoperative	B-UNK
assessment	B-UNK
should	O
focus	O
on	O
cardiovascular	B-UNK
status	B-UNK
and	O
serum	B-UNK
potassium	I-UNK
level	B-UNK
.	O
Delaying	O
induction	B-UNK
of	O
anesthesia	B-UNK
should	O
be	O
considered	B-UNK
whenever	O
possible	O
.	O
Careful	B-UNK
fluid	B-UNK
administration	O
and	O
cautious	O
use	O
of	O
titrated	O
doses	B-UNK
of	O
ephedrine	B-UNK
are	O
advised	O
.	O
After	O
delivery	B-UNK
of	O
the	O
infant	B-UNK
,	O
there	O
should	O
be	O
no	O
contraindication	O
to	O
the	O
use	O
of	O
an	O
alpha	B-UNK
-	O
adrenergic	B-UNK
vasopressor	O
such	O
as	O
phenylephrine	B-UNK
to	O
treat	B-UNK
hypotensive	B-DISEASE
patients	B-UNK
with	O
tachycardia	B-UNK
.	O

Immunohistochemical	B-UNK
,	O
electron	B-UNK
microscopic	B-UNK
and	O
morphometric	O
studies	B-UNK
of	O
estrogen	B-CHEMICAL
-	O
induced	O
rat	B-UNK
prolactinomas	O
after	O
bromocriptine	B-UNK
treatment	B-UNK
.	O
To	O
clarify	O
the	O
effects	O
of	O
bromocriptine	B-UNK
on	O
prolactinoma	B-DISEASE
cells	B-UNK
in	O
vivo	B-UNK
,	O
immunohistochemical	B-UNK
,	O
ultrastructural	B-UNK
and	O
morphometrical	O
analyses	B-UNK
were	O
applied	O
to	O
estrogen	B-CHEMICAL
-	O
induced	O
rat	B-UNK
prolactinoma	B-DISEASE
cells	B-UNK
1	O
h	O
and	O
6	O
h	O
after	O
injection	B-UNK
of	O
bromocriptine	B-UNK
(	O
3	O
mg	B-UNK
/	O
kg	B-UNK
of	O
body	B-UNK
weight	I-UNK
)	O
.	O
One	O
h	O
after	O
treatment	B-UNK
,	O
serum	B-UNK
prolactin	B-UNK
levels	I-UNK
decreased	B-UNK
markedly	O
.	O
Electron	B-UNK
microscopy	I-UNK
disclosed	O
many	O
secretory	O
granules	O
,	O
slightly	O
distorted	O
rough	O
endoplasmic	O
reticulum	O
,	O
and	O
partially	O
dilated	B-UNK
Golgi	O
cisternae	O
in	O
the	O
prolactinoma	B-DISEASE
cells	B-UNK
.	O
Morphometric	O
analysis	B-UNK
revealed	O
that	O
the	O
volume	B-UNK
density	B-UNK
of	O
secretory	O
granules	O
increased	B-UNK
,	O
while	O
the	O
volume	B-UNK
density	B-UNK
of	O
cytoplasmic	B-UNK
microtubules	O
decreased	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
lowered	B-UNK
serum	B-UNK
prolactin	B-UNK
levels	I-UNK
in	O
the	O
early	B-UNK
phase	B-UNK
of	O
bromocriptine	B-UNK
treatment	B-UNK
may	O
result	B-UNK
from	O
an	O
impaired	B-UNK
secretion	B-UNK
of	O
prolactin	B-UNK
due	O
to	O
decreasing	B-UNK
numbers	B-UNK
of	O
cytoplasmic	B-UNK
microtubules	O
.	O
At	O
6	O
h	O
after	O
injection	B-UNK
,	O
serum	B-UNK
prolactin	B-UNK
levels	I-UNK
were	O
still	O
considerably	O
lower	B-UNK
than	O
in	O
controls	B-UNK
.	O
The	O
prolactinoma	B-DISEASE
cells	B-UNK
at	O
this	O
time	O
were	O
well	O
granulated	O
,	O
with	O
vesiculated	O
rough	O
endoplasmic	O
reticulum	O
and	O
markedly	O
dilated	B-UNK
Golgi	O
cisternae	O
.	O
Electron	B-UNK
microscopical	O
immunohistochemistry	B-UNK
revealed	O
positive	B-UNK
reaction	B-UNK
products	B-UNK
noted	B-UNK
on	O
the	O
secretory	O
granules	O
,	O
Golgi	O
cisternae	O
,	O
and	O
endoplasmic	O
reticulum	O
of	O
the	O
untreated	B-UNK
rat	B-UNK
prolactinoma	B-DISEASE
cells	B-UNK
.	O
However	O
,	O
only	O
secretory	O
granules	O
showed	O
the	O
positive	B-UNK
reaction	B-UNK
products	B-UNK
for	O
prolactin	B-UNK
6	O
h	O
after	O
bromocriptine	B-UNK
treatment	B-UNK
of	O
the	O
adenoma	B-DISEASE
cells	B-UNK
.	O
An	O
increase	B-UNK
in	O
the	O
volume	B-UNK
density	B-UNK
of	O
secretory	O
granules	O
and	O
a	O
decrease	B-UNK
in	O
the	O
volume	B-UNK
densities	O
of	O
rough	O
endoplasmic	O
reticulum	O
and	O
microtubules	O
was	O
determined	B-UNK
by	O
morphometric	O
analysis	B-UNK
,	O
suggesting	O
that	O
bromocriptine	B-UNK
inhibits	B-UNK
protein	B-UNK
synthesis	B-UNK
as	O
well	O
as	O
bringing	O
about	O
a	O
disturbance	B-UNK
of	O
the	O
prolactin	B-UNK
secretion	B-UNK
.	O

On	O
two	O
paradoxical	B-UNK
side	O
-	O
effects	O
of	O
prednisolone	B-UNK
in	O
rats	B-UNK
,	O
ribosomal	O
RNA	B-UNK
biosyntheses	O
,	O
and	O
a	O
mechanism	B-UNK
of	O
action	B-UNK
.	O
Liver	B-UNK
enlargement	O
and	O
muscle	B-UNK
wastage	O
occurred	B-UNK
in	O
Wistar	B-UNK
rats	I-UNK
following	O
the	O
subcutaneous	B-UNK
administration	O
of	O
prednisolone	B-UNK
.	O
In	O
the	O
liver	B-UNK
both	O
the	O
content	B-UNK
of	O
RNA	B-UNK
and	O
the	O
biosynthesis	O
of	O
ribosomal	O
RNA	B-UNK
increased	B-UNK
while	O
both	O
the	O
RNA	B-UNK
content	B-UNK
and	O
ribosomal	O
RNA	B-UNK
biosynthesis	O
were	O
reduced	B-UNK
in	O
the	O
gastrocnemius	O
muscle	B-UNK
.	O
It	O
is	O
suggested	B-UNK
that	O
the	O
drug	B-UNK
acted	O
in	O
a	O
selective	B-UNK
and	O
tissue	B-UNK
-	O
specific	B-UNK
manner	B-UNK
to	O
enhance	B-UNK
ribosomal	O
RNA	B-UNK
synthesis	B-UNK
in	O
the	O
liver	B-UNK
and	O
depress	O
such	O
synthesis	B-UNK
in	O
the	O
muscle	B-UNK
.	O
This	O
view	B-UNK
supports	O
the	O
contention	O
that	O
the	O
liver	B-UNK
and	O
muscle	B-UNK
are	O
independent	B-UNK
sites	B-UNK
of	O
prednisolone	B-UNK
action	B-UNK
.	O

Possible	O
intramuscular	B-UNK
midazolam	B-UNK
-	O
associated	O
cardiorespiratory	B-DISEASE
arrest	I-DISEASE
and	O
death	B-UNK
.	O
Midazolam	B-UNK
hydrochloride	B-UNK
is	O
commonly	B-UNK
used	O
for	O
dental	O
or	O
endoscopic	O
procedures	B-UNK
.	O
Although	O
generally	B-UNK
consisted	B-UNK
safe	O
when	O
given	O
intramuscularly	O
,	O
intravenous	B-UNK
administration	O
is	O
known	O
to	O
cause	O
respiratory	B-UNK
and	O
cardiovascular	B-DISEASE
depression	I-DISEASE
.	O
This	O
report	B-UNK
describes	I-UNK
the	O
first	O
published	B-UNK
case	B-UNK
of	O
cardiorespiratory	B-DISEASE
arrest	I-DISEASE
and	O
death	B-UNK
associated	O
with	O
intramuscular	B-UNK
administration	O
of	O
midazolam	B-CHEMICAL
.	O
Information	B-UNK
regarding	O
midazolam	B-CHEMICAL
use	O
is	O
reviewed	B-UNK
to	O
provide	O
recommendation	O
for	O
safe	O
administration	O
.	O

Serial	B-UNK
epilepsy	B-DISEASE
caused	B-UNK
by	O
levodopa	B-UNK
/	O
carbidopa	O
administration	O
in	O
two	O
patients	B-UNK
on	O
hemodialysis	B-UNK
.	O
Two	O
patients	B-UNK
with	O
similar	B-UNK
clinical	B-UNK
features	B-UNK
are	O
presented	B-UNK
:	O
both	O
patients	B-UNK
had	O
chronic	B-UNK
renal	I-UNK
failure	I-UNK
,	O
on	O
hemodialysis	B-UNK
for	O
many	O
years	B-UNK
but	O
recently	B-UNK
begun	O
on	O
a	O
high	B-UNK
-	O
flux	O
dialyzer	O
;	O
both	O
had	O
been	O
receiving	B-UNK
a	O
carbidopa	O
/	O
levodopa	B-CHEMICAL
preparation	O
;	O
and	O
both	O
had	O
the	O
onset	B-UNK
of	O
hallucinosis	O
and	O
recurrent	B-UNK
seizures	B-UNK
,	O
which	O
were	O
refractory	B-UNK
to	O
anticonvulsants	O
.	O
The	O
first	O
patient	B-UNK
died	O
without	O
a	O
diagnosis	B-UNK
;	O
the	O
second	O
patient	B-UNK
had	O
a	O
dramatic	O
recovery	B-UNK
following	O
the	O
administration	O
of	O
vitamin	B-UNK
B6	O
.	O
Neither	O
patient	B-UNK
was	O
considered	B-UNK
to	O
have	O
a	O
renal	B-UNK
state	B-UNK
sufficiently	O
severe	B-UNK
enough	O
to	O
explain	O
their	O
presentation	B-UNK
.	O

Effect	B-UNK
of	O
L	O
-	O
alpha	B-UNK
-	O
glyceryl	B-UNK
-	O
phosphorylcholine	O
on	O
amnesia	B-DISEASE
caused	B-UNK
by	O
scopolamine	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
carried	O
out	O
to	O
test	B-UNK
the	O
effects	O
of	O
L	O
-	O
alpha	B-UNK
-	O
glycerylphosphorylcholine	O
(	O
L	O
-	O
alpha	B-UNK
-	O
GFC	O
)	O
on	O
memory	B-DISEASE
impairment	I-DISEASE
induced	O
by	O
scopolamine	B-CHEMICAL
in	O
man	B-UNK
.	O
Thirty	B-UNK
-	O
two	O
healthy	B-UNK
young	B-UNK
volunteers	B-UNK
were	O
randomly	B-UNK
allocated	I-UNK
to	O
four	O
different	O
groups	B-UNK
.	O
They	O
were	O
given	O
a	O
ten	O
day	O
pretreatment	B-UNK
with	O
either	O
L	O
-	O
alpha	B-UNK
-	O
GFC	O
or	O
placebo	B-UNK
,	O
p.o	B-UNK
.	O
,	O
and	O
on	O
the	O
eleventh	O
day	O
either	O
scopolamine	B-UNK
or	O
placebo	B-UNK
,	O
i.m	O
.	O
Before	O
and	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
h	O
after	O
injection	B-UNK
the	O
subjects	B-UNK
were	O
given	O
attention	B-UNK
and	O
mnemonic	O
tests	B-UNK
.	O
The	O
findings	B-UNK
of	O
this	O
study	B-UNK
indicate	O
that	O
the	O
drug	B-UNK
is	O
able	O
to	O
antagonize	O
impairment	B-UNK
of	O
attention	B-UNK
and	O
memory	B-UNK
induced	O
by	O
scopolamine	B-UNK
.	O

Seizures	B-UNK
induced	O
by	O
the	O
cocaine	B-UNK
metabolite	B-UNK
benzoylecgonine	O
in	O
rats	B-UNK
.	O
The	O
half	B-UNK
-	O
life	B-UNK
(	O
t1/2	O
)	O
of	O
cocaine	B-UNK
is	O
relatively	O
short	B-UNK
,	O
but	O
some	O
of	O
the	O
consequences	B-UNK
of	O
its	O
use	O
,	O
such	O
as	O
seizures	B-UNK
and	O
strokes	B-UNK
,	O
can	O
occur	O
hours	B-UNK
after	O
exposure	B-UNK
.	O
This	O
led	B-UNK
us	O
to	O
hypothesize	O
that	O
a	O
metabolite	B-UNK
of	O
cocaine	B-UNK
may	O
be	O
responsible	B-UNK
for	O
some	O
of	O
those	O
delayed	B-UNK
sequelae	B-UNK
.	O
We	O
evaluated	B-UNK
the	O
potential	B-UNK
of	O
the	O
major	B-UNK
metabolite	B-UNK
of	O
cocaine	B-CHEMICAL
,	O
benzoylecgonine	O
(	O
BE	O
)	O
,	O
to	O
cause	O
seizures	B-UNK
.	O
Two	O
separate	B-UNK
equimolar	O
doses	B-UNK
(	O
0.2	O
and	O
0.4	O
mumol	B-UNK
)	O
of	O
either	O
cocaine	B-UNK
or	O
BE	O
were	O
injected	B-UNK
ventricularly	O
in	O
unanesthetized	O
juvenile	O
rats	B-UNK
.	O
Treated	B-UNK
rats	I-UNK
were	O
then	O
evaluated	B-UNK
for	O
incidence	B-UNK
,	O
latency	B-UNK
,	O
and	O
seizure	B-UNK
pattern	B-UNK
or	O
for	O
locomotor	B-UNK
activity	I-UNK
in	O
animals	B-UNK
without	O
seizures	B-DISEASE
.	O
BE-Induced	O
seizures	B-DISEASE
occurred	B-UNK
more	O
frequently	B-UNK
and	O
had	O
significantly	B-UNK
longer	O
latencies	B-UNK
than	O
those	O
induced	O
by	O
equimolar	O
amounts	B-UNK
of	O
cocaine	B-CHEMICAL
.	O
Whereas	O
cocaine	B-UNK
-	O
induced	O
seizures	B-UNK
were	O
best	O
characterized	B-UNK
as	O
brief	O
,	O
generalized	O
,	O
and	O
tonic	B-UNK
and	O
resulted	B-UNK
in	O
death	B-UNK
,	O
those	O
induced	O
by	O
BE	O
were	O
prolonged	B-UNK
,	O
often	O
multiple	B-UNK
and	O
mixed	B-UNK
in	O
type	B-UNK
,	O
and	O
rarely	O
resulted	B-UNK
in	O
death	B-DISEASE
.	O
Electrical	B-UNK
recordings	O
from	O
the	O
hippocampus	B-UNK
showed	O
a	O
rhythmic	O
progression	B-UNK
in	O
EEG	B-UNK
frequency	B-UNK
and	O
voltage	O
with	O
clinical	B-UNK
seizure	B-UNK
expression	B-UNK
.	O
BE-Injected	O
rats	B-UNK
that	O
did	O
not	O
have	O
seizures	B-DISEASE
had	O
significantly	B-UNK
more	O
locomotor	B-UNK
activity	I-UNK
than	O
cocaine	B-UNK
-	O
injected	B-UNK
animals	B-UNK
without	O
seizures	B-UNK
.	O
The	O
finding	O
that	O
cocaine-	O
and	O
BE-induced	O
seizures	B-UNK
differ	B-UNK
in	O
several	O
respects	O
suggests	O
more	O
than	O
one	O
mechanism	B-UNK
for	O
cocaine	B-UNK
-	O
induced	O
seizures	B-UNK
and	O
emphasizes	O
the	O
importance	B-UNK
of	O
a	O
cocaine	B-CHEMICAL
metabolite	B-UNK
,	O
BE	O
.	O

Protection	B-UNK
against	O
amphetamine	B-UNK
-	O
induced	O
neurotoxicity	B-UNK
toward	O
striatal	B-UNK
dopamine	B-CHEMICAL
neurons	B-UNK
in	O
rodents	B-UNK
by	O
LY274614	O
,	O
an	O
excitatory	O
amino	B-UNK
acid	I-UNK
antagonist	B-UNK
.	O
LY274614	O
,	O
3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr	B-CHEMICAL
oisoquinoline-3-	I-CHEMICAL
carboxylic	I-CHEMICAL
acid	I-CHEMICAL
,	O
has	O
been	O
described	O
as	O
a	O
potent	B-UNK
antagonist	B-UNK
of	O
the	O
N	O
-	O
methyl	B-UNK
-	O
D	O
-	O
aspartate	B-UNK
(	O
NMDA	B-UNK
)	O
subtype	O
of	O
glutamate	B-UNK
receptor	B-UNK
.	O
Here	O
its	O
ability	B-UNK
to	O
antagonize	O
the	O
prolonged	B-UNK
depletion	B-UNK
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	B-UNK
by	O
amphetamine	B-UNK
in	O
iprindole	B-CHEMICAL
-	O
treated	B-UNK
rats	I-UNK
is	O
reported	B-UNK
.	O
A	O
single	B-UNK
18.4	O
mg	B-UNK
/	O
kg	B-UNK
(	O
i.p	B-UNK
.	O
)	O
dose	B-UNK
of	O
(	O
+	O
/-)-amphetamine	O
hemisulfate	O
,	O
given	O
to	O
rats	B-UNK
pretreated	B-UNK
with	O
iprindole	B-CHEMICAL
,	O
resulted	B-UNK
in	O
persistent	B-UNK
depletion	B-UNK
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	B-UNK
1	O
week	B-UNK
later	O
.	O
This	O
prolonged	B-UNK
depletion	B-UNK
of	O
dopamine	B-UNK
in	O
the	O
striatum	B-UNK
was	O
antagonized	B-UNK
by	O
dizocilpine	O
(	O
MK-801	O
,	O
a	O
non-competitive	O
antagonist	B-UNK
of	O
NMDA	B-UNK
receptors	I-UNK
)	O
or	O
by	O
LY274614	O
(	O
a	O
competitive	O
antagonist	B-UNK
of	O
NMDA	B-UNK
receptors	I-UNK
)	O
.	O
The	O
protective	B-UNK
effect	I-UNK
of	O
LY274614	O
was	O
dose	B-UNK
-	O
dependent	B-UNK
,	O
being	O
maximum	B-UNK
at	O
10	O
-	O
40	O
mgkg	O
(	O
i.p	B-UNK
.	O
)	O
.	O
A	O
10	O
mg	B-UNK
/	O
kg	B-UNK
dose	B-UNK
of	O
LY274614	O
was	O
effective	B-UNK
in	O
antagonizing	O
the	O
depletion	B-UNK
of	O
dopamine	B-UNK
in	O
the	O
striatum	B-UNK
,	O
when	O
given	O
as	O
long	B-UNK
as	B-CHEMICAL
8	I-CHEMICAL
hr	B-UNK
prior	B-UNK
to	O
amphetamine	B-UNK
but	O
not	O
when	O
given	O
24	O
hr	B-UNK
prior	B-UNK
to	O
amphetamine	B-UNK
.	O
Depletion	B-UNK
of	O
dopamine	B-UNK
in	O
the	O
striatum	B-UNK
was	O
also	O
antagonized	B-UNK
when	O
LY274614	O
was	O
given	O
after	O
the	O
injection	B-UNK
of	O
amphetamine	B-UNK
;	O
LY274614	O
protected	B-UNK
when	O
given	O
up	O
to	O
4	O
hr	B-UNK
after	O
but	O
not	O
when	O
given	O
8	O
or	O
24	O
hr	B-UNK
after	O
amphetamine	B-UNK
.	O
The	O
prolonged	B-UNK
depletion	B-UNK
of	O
dopamine	B-UNK
in	O
the	O
striatum	B-UNK
in	O
mice	B-UNK
,	O
given	O
multiple	B-UNK
injections	B-UNK
of	O
methamphetamine	B-UNK
,	O
was	O
also	O
antagonized	B-UNK
dose	B-UNK
-	O
dependently	B-UNK
and	O
completely	O
by	O
LY274614	O
.	O
The	O
data	B-UNK
strengthen	O
the	O
evidence	B-UNK
that	O
the	O
neurotoxic	B-DISEASE
effect	B-UNK
of	O
amphetamine	B-UNK
and	O
related	O
compounds	B-UNK
toward	O
nigrostriatal	O
dopamine	B-UNK
neurons	B-UNK
involves	O
NMDA	B-UNK
receptors	I-UNK
and	O
that	O
LY274614	O
is	O
an	O
NMDA	B-UNK
receptor	I-UNK
antagonist	B-UNK
with	O
long	B-UNK
-	O
lasting	B-UNK
in	O
vivo	B-UNK
effects	O
in	O
rats	B-UNK
.	O

Neonatal	B-UNK
pyridoxine	B-CHEMICAL
responsive	O
convulsions	B-UNK
due	O
to	O
isoniazid	B-UNK
therapy	O
.	O
A	O
17-day	O
-	O
old	O
infant	B-UNK
on	O
isoniazid	B-CHEMICAL
therapy	O
13	O
mg	B-UNK
/	O
kg	B-UNK
daily	B-UNK
from	O
birth	B-UNK
because	O
of	O
maternal	B-UNK
tuberculosis	B-UNK
was	O
admitted	B-UNK
after	O
4	O
days	B-UNK
of	O
clonic	B-DISEASE
fits	I-DISEASE
.	O
No	O
underlying	B-UNK
infective	O
or	O
biochemical	B-UNK
cause	O
could	O
be	O
found	O
.	O
The	O
fits	O
ceased	O
within	O
4	O
hours	B-UNK
of	O
administering	O
intramuscular	B-UNK
pyridoxine	B-CHEMICAL
,	O
suggesting	O
an	O
aetiology	O
of	O
pyridoxine	B-CHEMICAL
deficiency	B-UNK
secondary	B-UNK
to	O
isoniazid	B-CHEMICAL
medication	O
.	O

Reversal	B-UNK
by	O
phenylephrine	B-CHEMICAL
of	O
the	O
beneficial	B-UNK
effects	I-UNK
of	O
intravenous	B-UNK
nitroglycerin	B-UNK
in	O
patients	B-UNK
with	O
acute	B-UNK
myocardial	I-UNK
infarction	I-UNK
.	O
Nitroglycerin	B-CHEMICAL
has	O
been	O
shown	B-UNK
to	O
reduce	B-UNK
ST	B-UNK
-	O
segment	B-UNK
elevation	B-UNK
during	O
acute	B-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
,	O
an	O
effect	B-UNK
potentiated	B-UNK
in	O
the	O
dog	B-UNK
by	O
agents	B-UNK
that	O
reverse	B-UNK
nitroglycerin	B-UNK
-	O
induced	B-UNK
hypotension	I-UNK
.	O
Our	O
study	B-UNK
was	O
designed	B-UNK
to	O
determine	B-UNK
the	O
effects	O
of	O
combined	B-UNK
nitroglycerin	B-CHEMICAL
and	O
phenylephrine	B-UNK
therapy	O
.	O
Ten	O
patients	B-UNK
with	O
acute	B-UNK
transmural	O
myocardial	B-UNK
infarctions	O
received	O
intravenous	B-UNK
nitroglycerin	B-CHEMICAL
,	O
sufficient	B-UNK
to	O
reduce	B-UNK
mean	O
arterial	B-UNK
pressure	I-UNK
from	O
107	O
+	O
/-	O
6	O
to	O
85	O
+	O
/-	O
6	O
mm	B-UNK
Hg	I-UNK
(	O
P	O
less	O
than	O
0.001	O
)	O
,	O
for	O
60	O
minutes	B-UNK
.	O
Left	B-UNK
ventricular	I-UNK
filling	O
pressure	B-UNK
decreased	B-UNK
from	O
19	O
+	O
/-	O
2	O
to	O
11	O
+	O
/-	O
2	O
mm	B-UNK
Hg	I-UNK
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O
SigmaST	O
,	O
the	O
sum	O
of	O
ST	B-UNK
-	O
segment	B-UNK
elevations	B-UNK
in	O
16	O
precordial	O
leads	B-UNK
,	O
decreased	B-UNK
(	O
P	O
less	O
than	O
0.02	O
)	O
with	O
intravenous	B-UNK
nitroglycerin	B-UNK
.	O
Subsequent	B-UNK
addition	B-UNK
of	O
phenylephrine	B-UNK
infusion	B-UNK
,	O
sufficient	B-UNK
to	O
re-elevate	O
mean	O
arterial	B-UNK
pressure	I-UNK
to	O
106	O
+	O
/-	O
4	O
mm	B-UNK
Hg	I-UNK
(	O
P	O
less	O
than	O
0.001	O
)	O
for	O
30	O
minutes	B-UNK
,	O
increased	B-UNK
left	B-UNK
ventricular	I-UNK
filling	O
pressure	B-UNK
to	O
17	O
+	O
/-	O
2	O
mm	B-UNK
Hg	I-UNK
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
also	O
significantly	B-UNK
increased	B-UNK
sigmaST	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O
Our	O
results	B-UNK
suggest	B-UNK
that	O
addition	B-UNK
of	O
phenylephrine	B-UNK
to	O
nitroglycerin	B-UNK
is	O
not	O
beneficial	B-UNK
in	O
the	O
treatment	B-UNK
of	O
patients	B-UNK
with	O
acute	B-UNK
myocardial	I-UNK
infarction	I-UNK
.	O

Elevation	B-UNK
of	O
ADAM10	O
,	O
ADAM17	O
,	O
MMP-2	O
and	O
MMP-9	O
expression	B-UNK
with	O
media	B-UNK
degeneration	B-UNK
features	B-UNK
CaCl2-induced	O
thoracic	O
aortic	B-DISEASE
aneurysm	I-DISEASE
in	O
a	O
rat	B-UNK
model	B-UNK
.	O
PURPOSE	B-UNK
:	O
This	O
study	B-UNK
was	O
designed	B-UNK
to	O
establish	O
a	O
rat	B-UNK
model	B-UNK
of	O
thoracic	O
aortic	B-DISEASE
aneurysm	I-DISEASE
(	O
TAA	B-DISEASE
)	O
by	O
calcium	B-UNK
chloride	I-UNK
(	O
CaCl(2))-induced	O
arterial	B-DISEASE
injury	I-DISEASE
and	O
to	O
explore	B-UNK
the	O
potential	B-UNK
role	O
of	O
a	O
disintegrin	O
and	O
metalloproteinase	O
(	O
ADAM	O
)	O
,	O
matrix	B-UNK
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
their	O
endogenous	B-UNK
inhibitors	B-UNK
(	O
TIMPs	O
)	O
in	O
TAA	B-DISEASE
formation	B-UNK
.	O
METHODS	B-UNK
:	O
Thoracic	O
aorta	B-UNK
of	O
male	B-UNK
Sprague	O
-	O
Dawley	O
rats	B-UNK
was	O
exposed	B-UNK
to	O
0.5	O
M	O
CaCl(2	B-CHEMICAL
)	I-CHEMICAL
or	O
normal	B-UNK
saline	I-UNK
(	O
NaCl	O
)	O
.	O
After	O
12weeks	O
,	O
animals	B-UNK
were	O
euthanized	O
,	O
and	O
CaCl(2)-treated	O
,	O
CaCl(2)-untreated	O
(	O
n=12	O
)	O
and	O
NaCl	O
-	O
treated	O
aortic	B-UNK
segments	B-UNK
(	O
n=12	O
)	O
were	O
collected	O
for	O
histological	B-UNK
and	O
molecular	B-UNK
assessments	O
.	O
MMP	O
-	O
TIMP	O
and	O
ADAM	O
mRNAs	O
were	O
semi-quantitatively	O
analyzed	O
and	O
protein	B-UNK
expressions	O
were	O
determined	B-UNK
by	O
immunohistochemistry	B-UNK
.	O
RESULTS	B-UNK
:	O
Despite	O
similar	B-UNK
external	O
diameters	O
among	O
CaCl(2)-treated	O
,	O
non	O
-	O
CaCl(2)-treated	O
and	O
NaCl	O
-	O
treated	O
segments	B-UNK
,	O
aneurymal	O
alteration	B-UNK
(	O
n=6	O
,	O
50	O
%	O
)	O
,	O
media	B-UNK
degeneration	B-UNK
with	O
regional	B-UNK
disruption	B-UNK
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	B-UNK
collagen	O
deposition	O
(	O
n=12	O
,	O
100	O
%	O
)	O
were	O
demonstrated	O
in	O
CaCl(2)-treated	O
segments	B-UNK
.	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM-10	O
and	O
ADAM-17	O
mRNA	B-UNK
levels	I-UNK
were	O
increased	B-UNK
in	O
CaCl(2)-treated	O
segments	B-UNK
(	O
all	O
p<0.01	O
)	O
,	O
with	O
trends	O
of	O
elevation	B-UNK
in	O
CaCl(2)-untreated	O
segments	B-UNK
,	O
as	O
compared	O
with	O
NaCl	O
-	O
treated	O
segments	B-UNK
.	O
Immunohistochemistry	B-UNK
displayed	O
significantly	B-UNK
increased	B-UNK
expressions	O
of	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM-10	O
and	O
ADAM-17	O
(	O
all	O
p<0.01	O
)	O
in	O
intima	O
and	O
media	B-UNK
for	O
CaCl(2)-treated	O
segments	B-UNK
.	O
TIMP	O
mRNA	B-UNK
and	O
tissue	B-UNK
levels	O
did	O
not	O
differ	B-UNK
obviously	O
among	O
the	O
three	O
aortic	B-UNK
segments	B-UNK
.	O
CONCLUSION	B-UNK
:	O
This	O
study	B-UNK
establishes	O
a	O
TAA	B-DISEASE
model	B-UNK
by	O
periarterial	O
CaCl(2	B-CHEMICAL
)	I-CHEMICAL
exposure	B-UNK
in	O
rats	B-UNK
,	O
and	O
demonstrates	O
a	O
significant	B-UNK
elevation	B-UNK
of	O
expression	B-UNK
of	O
MMP-2	O
,	O
MMP-9	O
,	O
ADAM10	O
and	O
ADAM17	O
in	O
the	O
pathogenesis	B-UNK
of	O
vascular	B-DISEASE
remodeling	I-DISEASE
.	O

When	O
drugs	B-UNK
disappear	O
from	O
the	O
patient	B-UNK
:	O
elimination	O
of	O
intravenous	B-UNK
medication	O
by	O
hemodiafiltration	O
.	O
Twenty	O
-	O
three	O
hours	B-UNK
after	O
heart	B-UNK
transplantation	B-UNK
,	O
life	B-UNK
-	O
threatening	O
acute	B-UNK
right	O
heart	B-UNK
failure	I-UNK
was	O
diagnosed	B-UNK
in	O
a	O
patient	B-UNK
requiring	O
continuous	B-UNK
venovenous	O
hemodiafiltration	O
(	O
CVVHDF	O
)	O
.	O
Increasing	B-UNK
doses	B-UNK
of	O
catecholamines	B-UNK
,	O
sedatives	O
,	O
and	O
muscle	B-UNK
relaxants	O
administered	O
through	O
a	O
central	B-UNK
venous	B-UNK
catheter	B-UNK
were	O
ineffective	B-UNK
.	O
However	O
,	O
a	O
bolus	B-UNK
of	O
epinephrine	B-CHEMICAL
injected	B-UNK
through	O
an	O
alternative	B-UNK
catheter	B-UNK
provoked	O
a	O
hypertensive	B-UNK
crisis	O
.	O
Thus	O
,	O
interference	B-UNK
with	O
the	O
central	B-UNK
venous	B-UNK
infusion	B-UNK
by	O
the	O
dialysis	B-UNK
catheter	B-UNK
was	O
suspected	O
.	O
The	O
catheters	O
were	O
changed	O
,	O
and	O
hemodynamics	B-UNK
stabilized	O
at	O
lower	B-UNK
catecholamine	B-UNK
doses	B-UNK
.	O
When	O
the	O
effects	O
of	O
IV	B-UNK
drugs	B-UNK
are	O
inadequate	O
in	O
patients	B-UNK
receiving	B-UNK
CVVHDF	O
,	O
interference	B-UNK
with	O
adjacent	O
catheters	O
resulting	B-UNK
in	O
elimination	O
of	O
the	O
drug	B-UNK
by	O
CVVHDF	O
should	O
be	O
suspected	O
.	O

Long	B-UNK
-	O
term	O
glutamate	B-UNK
supplementation	B-UNK
failed	B-UNK
to	O
protect	B-UNK
against	O
peripheral	B-UNK
neurotoxicity	B-UNK
of	O
paclitaxel	B-CHEMICAL
.	O
Toxic	B-UNK
peripheral	B-DISEASE
neuropathy	I-DISEASE
is	O
still	O
a	O
significant	B-UNK
limiting	B-UNK
factor	B-UNK
for	O
chemotherapy	O
with	O
paclitaxel	B-UNK
(	O
PAC	O
)	O
,	O
although	O
glutamate	B-UNK
and	O
its	O
closely	O
related	O
amino	B-UNK
acid	I-UNK
glutamine	O
were	O
claimed	O
to	O
ameliorate	O
PAC	O
neurotoxicity	B-UNK
.	O
This	O
pilot	B-UNK
trial	B-UNK
aimed	B-UNK
to	O
evaluate	B-UNK
the	O
role	O
of	O
glutamate	B-CHEMICAL
supplementation	B-UNK
for	O
preventing	O
PAC	O
-	O
induced	O
peripheral	B-UNK
neuropathy	I-UNK
in	O
a	O
randomized	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
,	O
double-blinded	O
clinical	B-UNK
and	O
electro-diagnostic	O
study	B-UNK
.	O
Forty	O
-	O
three	O
ovarian	B-UNK
cancer	I-UNK
patients	B-UNK
were	O
available	O
for	O
analysis	B-UNK
following	O
six	O
cycles	B-UNK
of	O
the	O
same	O
PAC	O
-	O
containing	O
regimen	B-UNK
:	O
23	O
had	O
been	O
supplemented	O
by	O
glutamate	B-CHEMICAL
all	O
along	O
the	O
treatment	B-UNK
period	B-UNK
,	O
at	O
a	O
daily	B-UNK
dose	I-UNK
of	O
three	O
times	B-UNK
500	O
mg	B-UNK
(	O
group	B-UNK
G	O
)	O
,	O
and	O
20	O
had	O
received	O
a	O
placebo	B-UNK
(	O
group	B-UNK
P	O
)	O
.	O
Patients	B-UNK
were	O
evaluated	B-UNK
by	O
neurological	B-UNK
examinations	B-UNK
,	O
questionnaires	O
and	O
sensory	O
-	O
motor	B-UNK
nerve	B-UNK
conduction	B-UNK
studies	B-UNK
.	O
There	O
was	O
no	O
significant	B-UNK
difference	I-UNK
in	O
the	O
frequency	B-UNK
of	O
signs	B-UNK
or	O
symptoms	B-UNK
between	O
the	O
two	O
groups	B-UNK
although	O
neurotoxicity	B-DISEASE
symptoms	B-UNK
presented	B-UNK
mostly	O
with	O
lower	B-UNK
scores	O
of	O
severity	B-UNK
in	O
group	B-UNK
G.	O
However	O
,	O
this	O
difference	B-UNK
reached	O
statistical	B-UNK
significance	I-UNK
only	O
with	O
regard	B-UNK
to	O
reported	B-UNK
pain	B-DISEASE
sensation	B-UNK
(	O
P	O
=	O
0.011	O
)	O
.	O
Also	O
the	O
frequency	B-UNK
of	O
abnormal	B-UNK
electro-diagnostic	O
findings	B-UNK
showed	O
similarity	O
between	O
the	O
two	O
groups	B-UNK
(	O
G	O
:	O
7/23	O
=	O
30.4	O
%	O
;	O
P	O
:	O
6/20	O
=	O
30	O
%	O
)	O
.	O
This	O
pilot	B-UNK
study	I-UNK
leads	B-UNK
to	O
the	O
conclusion	B-UNK
that	O
glutamate	B-UNK
supplementation	B-UNK
at	O
the	O
chosen	O
regimen	B-UNK
fails	O
to	O
protect	B-UNK
against	O
peripheral	B-UNK
neurotoxicity	B-UNK
of	O
PAC	O
.	O

Attentional	O
modulation	B-UNK
of	O
perceived	O
pain	B-UNK
intensity	B-UNK
in	O
capsaicin	B-UNK
-	O
induced	O
secondary	B-UNK
hyperalgesia	I-UNK
.	O
Perceived	O
pain	B-DISEASE
intensity	B-UNK
is	O
modulated	O
by	O
attention	B-UNK
.	O
However	O
,	O
it	O
is	O
not	O
known	O
that	O
how	O
pain	B-DISEASE
intensity	B-UNK
ratings	B-UNK
are	O
affected	B-UNK
by	O
attention	B-UNK
in	O
capsaicin	B-UNK
-	O
induced	O
secondary	B-DISEASE
hyperalgesia	I-DISEASE
.	O
Here	O
we	O
show	O
that	O
perceived	O
pain	B-UNK
intensity	B-UNK
in	O
secondary	B-UNK
hyperalgesia	I-UNK
is	O
decreased	B-UNK
when	O
attention	B-UNK
is	O
distracted	O
away	O
from	O
the	O
painful	O
pinprick	O
stimulus	B-UNK
with	O
a	O
visual	B-UNK
task	B-UNK
.	O
Furthermore	O
,	O
it	O
was	O
found	O
that	O
the	O
magnitude	B-UNK
of	O
attentional	O
modulation	B-UNK
in	O
secondary	B-UNK
hyperalgesia	I-UNK
is	O
very	O
similar	B-UNK
to	O
that	O
of	O
capsaicin	B-UNK
-	O
untreated	B-UNK
,	O
control	B-UNK
condition	B-UNK
.	O
Our	O
findings	B-UNK
,	O
showing	O
no	O
interaction	B-UNK
between	O
capsaicin	B-UNK
treatment	B-UNK
and	O
attentional	O
modulation	B-UNK
suggest	B-UNK
that	O
capsaicin	B-CHEMICAL
-	O
induced	O
secondary	B-UNK
hyperalgesia	I-UNK
and	O
attention	B-UNK
might	O
affect	B-UNK
mechanical	B-UNK
pain	B-DISEASE
through	O
independent	B-UNK
mechanisms	B-UNK
.	O

Testosterone	B-UNK
-	O
dependent	B-UNK
hypertension	B-UNK
and	O
upregulation	B-UNK
of	O
intrarenal	B-UNK
angiotensinogen	B-UNK
in	O
Dahl	O
salt	B-UNK
-	O
sensitive	B-UNK
rats	B-UNK
.	O
Blood	B-UNK
pressure	I-UNK
(	O
BP	B-UNK
)	O
is	O
more	O
salt	B-CHEMICAL
sensitive	B-UNK
in	O
men	B-UNK
than	O
in	O
premenopausal	O
women	B-UNK
.	O
In	O
Dahl	O
salt	B-CHEMICAL
-	O
sensitive	B-UNK
rats	B-UNK
(	O
DS	O
)	O
,	O
high	B-UNK
-	O
salt	B-CHEMICAL
(	O
HS	O
)	O
diet	B-UNK
increases	B-UNK
BP	B-UNK
more	O
in	O
males	B-UNK
than	O
females	B-UNK
.	O
In	O
contrast	B-UNK
to	O
the	O
systemic	B-UNK
renin	B-UNK
-	O
angiotensin	O
system	O
,	O
which	O
is	O
suppressed	O
in	O
response	B-UNK
to	O
HS	O
in	O
male	B-UNK
DS	O
,	O
intrarenal	B-UNK
angiotensinogen	B-UNK
expression	B-UNK
is	O
increased	B-UNK
,	O
and	O
intrarenal	B-UNK
levels	O
of	O
ANG	O
II	B-UNK
are	O
not	O
suppressed	O
.	O
In	O
this	O
study	B-UNK
,	O
the	O
hypothesis	B-UNK
was	O
tested	B-UNK
that	O
there	O
is	O
a	O
sexual	B-UNK
dimorphism	O
in	O
HS	O
-	O
induced	O
upregulation	B-UNK
of	O
intrarenal	B-UNK
angiotensinogen	B-UNK
mediated	B-UNK
by	O
testosterone	B-UNK
that	O
also	O
causes	O
increases	B-UNK
in	O
BP	B-UNK
and	O
renal	B-DISEASE
injury	I-DISEASE
.	O
On	O
a	O
low	B-UNK
-	O
salt	B-UNK
(	O
LS	O
)	O
diet	B-UNK
,	O
male	B-UNK
DS	O
had	O
higher	B-UNK
levels	O
of	O
intrarenal	B-UNK
angiotensinogen	B-UNK
mRNA	B-UNK
than	O
females	B-UNK
.	O
HS	O
diet	B-UNK
for	O
4	O
wk	B-UNK
increased	B-UNK
renal	B-UNK
cortical	B-UNK
angiotensinogen	B-UNK
mRNA	B-UNK
and	O
protein	B-UNK
only	O
in	O
male	B-UNK
DS	O
,	O
which	O
was	O
prevented	B-UNK
by	O
castration	O
.	O
Ovariectomy	O
of	O
female	B-UNK
DS	O
had	O
no	O
effect	B-UNK
on	O
intrarenal	B-UNK
angiotensinogen	B-UNK
expression	B-UNK
on	O
either	O
diet	B-UNK
.	O
Radiotelemetric	O
BP	B-UNK
was	O
similar	B-UNK
between	O
males	B-UNK
and	O
castrated	O
rats	B-UNK
on	O
LS	O
diet	B-UNK
.	O
HS	O
diet	B-UNK
for	O
4	O
wk	B-UNK
caused	B-UNK
a	O
progressive	B-UNK
increase	B-UNK
in	O
BP	B-UNK
,	O
protein	B-UNK
and	O
albumin	B-UNK
excretion	B-UNK
,	O
and	O
glomerular	B-UNK
sclerosis	B-UNK
in	O
male	B-UNK
DS	O
rats	B-UNK
,	O
which	O
were	O
attenuated	B-UNK
by	O
castration	O
.	O
Testosterone	B-CHEMICAL
replacement	B-UNK
in	O
castrated	O
DS	O
rats	B-UNK
increased	B-UNK
BP	B-UNK
,	O
renal	B-UNK
injury	I-UNK
,	O
and	O
upregulation	B-UNK
of	O
renal	B-UNK
angiotensinogen	B-UNK
associated	O
with	O
HS	O
diet	B-UNK
.	O
Testosterone	B-UNK
contributes	B-UNK
to	O
the	O
development	B-UNK
of	O
hypertension	B-DISEASE
and	O
renal	B-DISEASE
injury	I-DISEASE
in	O
male	B-UNK
DS	O
rats	B-UNK
on	O
HS	O
diet	B-UNK
possibly	O
through	O
upregulation	B-UNK
of	O
the	O
intrarenal	B-UNK
renin	B-UNK
-	O
angiotensin	O
system	O
.	O

Prenatal	B-UNK
protein	B-UNK
deprivation	B-UNK
alters	O
dopamine	B-UNK
-	O
mediated	B-UNK
behaviors	B-UNK
and	O
dopaminergic	B-UNK
and	O
glutamatergic	B-UNK
receptor	B-UNK
binding	B-UNK
.	O
Epidemiological	O
evidence	B-UNK
indicates	O
that	O
prenatal	B-UNK
nutritional	O
deprivation	B-UNK
may	O
increase	B-UNK
the	O
risk	B-UNK
of	O
schizophrenia	B-UNK
.	O
The	O
goal	O
of	O
these	O
studies	B-UNK
was	O
to	O
use	O
an	O
animal	B-UNK
model	I-UNK
to	O
examine	B-UNK
the	O
effects	O
of	O
prenatal	B-UNK
protein	B-UNK
deprivation	B-UNK
on	O
behaviors	B-UNK
and	O
receptor	B-UNK
binding	B-UNK
with	O
relevance	O
to	O
schizophrenia	B-DISEASE
.	O
We	O
report	B-UNK
that	O
prenatally	O
protein	B-UNK
deprived	O
(	O
PD	B-UNK
)	O
female	B-UNK
rats	I-UNK
showed	O
an	O
increased	B-UNK
stereotypic	O
response	B-UNK
to	O
apomorphine	B-UNK
and	O
an	O
increased	B-UNK
locomotor	B-UNK
response	B-UNK
to	O
amphetamine	B-UNK
in	O
adulthood	O
.	O
These	O
differences	B-UNK
were	O
not	O
observed	O
during	O
puberty	O
.	O
No	O
changes	O
in	O
haloperidol	B-CHEMICAL
-	O
induced	O
catalepsy	B-UNK
or	O
MK-801-induced	O
locomotion	B-UNK
were	O
seen	O
following	O
PD	B-UNK
.	O
In	O
addition	B-UNK
,	O
PD	B-UNK
female	B-UNK
rats	I-UNK
showed	O
increased	B-UNK
(	O
3)H	O
-	O
MK-801	O
binding	B-UNK
in	O
the	O
striatum	B-UNK
and	O
hippocampus	B-UNK
,	O
but	O
not	O
in	O
the	O
cortex	B-UNK
.	O
PD	B-UNK
female	B-UNK
rats	I-UNK
also	O
showed	O
increased	B-UNK
(	O
3)H	O
-	O
haloperidol	B-UNK
binding	B-UNK
and	O
decreased	B-UNK
dopamine	B-UNK
transporter	B-UNK
binding	B-UNK
in	O
striatum	B-UNK
.	O
No	O
statistically	B-UNK
significant	I-UNK
changes	O
in	O
behavior	B-UNK
or	O
receptor	B-UNK
binding	B-UNK
were	O
found	O
in	O
PD	B-UNK
males	B-UNK
with	O
the	O
exception	O
of	O
increased	B-UNK
(	O
3)H	O
-	O
MK-801	O
binding	B-UNK
in	O
cortex	B-UNK
.	O
This	O
animal	B-UNK
model	I-UNK
may	O
be	O
useful	O
to	O
explore	B-UNK
the	O
mechanisms	B-UNK
by	O
which	O
prenatal	B-UNK
nutritional	O
deficiency	B-UNK
enhances	B-UNK
risk	B-UNK
for	O
schizophrenia	B-DISEASE
in	O
humans	B-UNK
and	O
may	O
also	O
have	O
implications	B-UNK
for	O
developmental	B-UNK
processes	B-UNK
leading	B-UNK
to	O
differential	B-UNK
sensitivity	B-UNK
to	O
drugs	B-UNK
of	O
abuse	B-UNK
.	O

mToR	B-UNK
inhibitors	B-UNK
-	O
induced	O
proteinuria	B-UNK
:	O
mechanisms	B-UNK
,	O
significance	B-UNK
,	O
and	O
management	B-UNK
.	O
Massive	B-UNK
urinary	B-UNK
protein	I-UNK
excretion	B-UNK
has	O
been	O
observed	O
after	O
conversion	B-UNK
from	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
to	O
mammalian	O
target	O
of	O
rapamycin	B-CHEMICAL
(	O
mToR	B-UNK
)	O
inhibitors	B-UNK
,	O
especially	O
sirolimus	B-UNK
,	O
in	O
renal	B-UNK
transplant	I-UNK
recipients	B-UNK
with	O
chronic	B-DISEASE
allograft	I-DISEASE
nephropathy	I-DISEASE
.	O
Because	O
proteinuria	B-UNK
is	O
a	O
major	B-UNK
predictive	B-UNK
factor	B-UNK
of	O
poor	O
transplantation	B-UNK
outcome	B-UNK
,	O
many	O
studies	B-UNK
focused	O
on	O
this	O
adverse	B-UNK
event	I-UNK
during	O
the	O
past	B-UNK
years	B-UNK
.	O
Whether	O
proteinuria	B-UNK
was	O
due	O
to	O
sirolimus	B-CHEMICAL
or	O
only	O
a	O
consequence	B-UNK
of	O
calcineurin	B-CHEMICAL
inhibitors	I-CHEMICAL
withdrawal	B-UNK
remained	B-UNK
unsolved	O
until	O
high	B-UNK
range	B-UNK
proteinuria	B-UNK
has	O
been	O
observed	O
during	O
sirolimus	B-UNK
therapy	O
in	O
islet	O
transplantation	B-UNK
and	O
in	O
patients	B-UNK
who	O
received	O
sirolimus	B-CHEMICAL
de	B-UNK
novo	I-UNK
.	O
Podocyte	B-UNK
injury	B-UNK
and	O
focal	B-UNK
segmental	B-DISEASE
glomerulosclerosis	I-DISEASE
have	O
been	O
related	O
to	O
mToR	B-UNK
inhibition	B-UNK
in	O
some	O
patients	B-UNK
,	O
but	O
the	O
pathways	B-UNK
underlying	B-UNK
these	O
lesions	B-UNK
remain	O
hypothetic	O
.	O
We	O
discuss	B-UNK
herein	O
the	O
possible	O
mechanisms	B-UNK
and	O
the	O
significance	B-UNK
of	O
mToR	B-UNK
blockade	B-UNK
-	O
induced	O
proteinuria	B-UNK
.	O

Hypothalamic	O
prolactin	B-UNK
receptor	B-UNK
messenger	O
ribonucleic	O
acid	B-UNK
levels	O
,	O
prolactin	B-UNK
signaling	B-UNK
,	O
and	O
hyperprolactinemic	O
inhibition	B-UNK
of	O
pulsatile	O
luteinizing	O
hormone	B-UNK
secretion	B-UNK
are	O
dependent	B-UNK
on	O
estradiol	B-UNK
.	O
Hyperprolactinemia	B-DISEASE
can	O
reduce	B-UNK
fertility	O
and	O
libido	O
.	O
Although	O
central	B-UNK
prolactin	B-UNK
actions	B-UNK
are	O
thought	B-UNK
to	O
contribute	B-UNK
to	O
this	O
,	O
the	O
mechanisms	B-UNK
are	O
poorly	B-UNK
understood	O
.	O
We	O
first	O
tested	B-UNK
whether	O
chronic	B-UNK
hyperprolactinemia	B-UNK
inhibited	B-UNK
two	O
neuroendocrine	O
parameters	O
necessary	O
for	O
female	B-UNK
fertility	O
:	O
pulsatile	O
LH	B-UNK
secretion	B-UNK
and	O
the	O
estrogen	B-UNK
-	O
induced	O
LH	B-UNK
surge	O
.	O
Chronic	B-UNK
hyperprolactinemia	B-UNK
induced	O
by	O
the	O
dopamine	B-UNK
antagonist	B-UNK
sulpiride	B-CHEMICAL
caused	B-UNK
a	O
40	O
%	O
reduction	O
LH	B-UNK
pulse	B-UNK
frequency	B-UNK
in	O
ovariectomized	O
rats	B-UNK
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
chronic	B-UNK
low	B-UNK
levels	O
of	O
estradiol	B-CHEMICAL
.	O
Sulpiride	B-CHEMICAL
did	O
not	O
affect	B-UNK
the	O
magnitude	B-UNK
of	O
a	O
steroid	B-UNK
-	O
induced	O
LH	B-UNK
surge	O
or	O
the	O
percentage	B-UNK
of	O
GnRH	O
neurons	B-UNK
activated	B-UNK
during	O
the	O
surge	O
.	O
Estradiol	B-CHEMICAL
is	O
known	O
to	O
influence	B-UNK
expression	B-UNK
of	O
the	O
long	B-UNK
form	B-UNK
of	O
prolactin	B-UNK
receptors	B-UNK
(	O
PRL	B-UNK
-	O
R	O
)	O
and	O
components	B-UNK
of	O
prolactin'	O
s	O
signaling	B-UNK
pathway	B-UNK
.	O
To	O
test	B-UNK
the	O
hypothesis	B-UNK
that	O
estrogen	B-UNK
increases	B-UNK
PRL	B-UNK
-	O
R	O
expression	B-UNK
and	O
sensitivity	B-UNK
to	O
prolactin	B-UNK
,	O
we	O
next	O
demonstrated	O
that	O
estradiol	B-CHEMICAL
greatly	O
augments	O
prolactin	B-UNK
-	O
induced	O
STAT5	O
activation	B-UNK
.	O
Lastly	O
,	O
we	O
measured	B-UNK
PRL	B-UNK
-	O
R	O
and	O
suppressor	O
of	O
cytokine	O
signaling	B-UNK
(	O
SOCS-1	O
and	O
-3	O
and	O
CIS	B-UNK
,	O
which	O
reflect	O
the	O
level	B-UNK
of	O
prolactin	B-UNK
signaling	B-UNK
)	O
mRNAs	O
in	O
response	B-UNK
to	O
sulpiride	B-CHEMICAL
and	O
estradiol	B-UNK
.	O
Sulpiride	B-CHEMICAL
induced	O
only	O
SOCS-1	O
in	O
the	O
medial	B-UNK
preoptic	O
area	B-UNK
,	O
where	O
GnRH	O
neurons	B-UNK
are	O
regulated	O
,	O
but	O
in	O
the	O
arcuate	O
nucleus	B-UNK
and	O
choroid	O
plexus	O
,	O
PRL	B-UNK
-	O
R	O
,	O
SOCS-3	O
,	O
and	O
CIS	B-UNK
mRNA	B-UNK
levels	I-UNK
were	O
also	O
induced	O
.	O
Estradiol	B-CHEMICAL
enhanced	B-UNK
these	O
effects	O
on	O
SOCS-3	O
and	O
CIS	B-UNK
.	O
Interestingly	O
,	O
estradiol	B-CHEMICAL
also	O
induced	O
PRL	B-UNK
-	O
R	O
,	O
SOCS-3	O
,	O
and	O
CIS	B-UNK
mRNA	B-UNK
levels	I-UNK
independently	O
.	O
These	O
data	B-UNK
show	O
that	O
GnRH	O
pulse	B-UNK
frequency	B-UNK
is	O
inhibited	B-UNK
by	O
chronic	B-UNK
hyperprolactinemia	B-UNK
in	O
a	O
steroid	B-UNK
-	O
dependent	B-UNK
manner	I-UNK
.	O
They	O
also	O
provide	O
evidence	B-UNK
for	O
estradiol	B-CHEMICAL
-	O
dependent	B-UNK
and	O
brain	B-UNK
region	B-UNK
-	O
specific	B-UNK
regulation	B-UNK
of	O
PRL	B-UNK
-	O
R	O
expression	B-UNK
and	O
signaling	B-UNK
responses	O
by	O
prolactin	B-UNK
.	O

Estrogen	B-UNK
prevents	O
cholesteryl	O
ester	B-UNK
accumulation	B-UNK
in	O
macrophages	O
induced	O
by	O
the	O
HIV	B-UNK
protease	B-UNK
inhibitor	B-UNK
ritonavir	B-CHEMICAL
.	O
Individuals	B-UNK
with	O
HIV	B-DISEASE
can	O
now	O
live	O
long	B-UNK
lives	O
with	O
drug	B-UNK
therapy	O
that	O
often	O
includes	O
protease	B-UNK
inhibitors	B-UNK
such	O
as	O
ritonavir	B-CHEMICAL
.	O
Many	O
patients	B-UNK
,	O
however	O
,	O
develop	B-UNK
negative	B-UNK
long	B-UNK
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-UNK
atherosclerosis	B-DISEASE
.	O
We	O
have	O
previously	B-UNK
demonstrated	O
that	O
ritonavir	B-CHEMICAL
treatment	B-UNK
increases	B-UNK
atherosclerotic	B-DISEASE
lesion	I-DISEASE
formation	B-UNK
in	O
male	B-UNK
mice	B-UNK
to	O
a	O
greater	B-UNK
extent	B-UNK
than	O
in	O
female	B-UNK
mice	B-UNK
.	O
Furthermore	O
,	O
peripheral	B-UNK
blood	I-UNK
monocytes	O
isolated	B-UNK
from	O
ritonavir	B-UNK
-	O
treated	O
females	B-UNK
had	O
less	O
cholesteryl	O
ester	B-UNK
accumulation	B-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
we	O
have	O
investigated	B-UNK
the	O
molecular	B-UNK
mechanisms	B-UNK
by	O
which	O
female	B-UNK
hormones	B-CHEMICAL
influence	B-UNK
cholesterol	B-UNK
metabolism	B-UNK
in	O
macrophages	O
in	O
response	B-UNK
to	O
the	O
HIV	B-UNK
protease	B-UNK
inhibitor	B-UNK
ritonavir	B-UNK
.	O
We	O
have	O
utilized	O
the	O
human	B-UNK
monocyte	O
cell	B-UNK
line	B-UNK
,	O
THP-1	O
as	O
a	O
model	B-UNK
to	O
address	O
this	O
question	O
.	O
Briefly	O
,	O
cells	B-UNK
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	B-UNK
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	B-UNK
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	B-UNK
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
(	O
E2	B-UNK
)	O
,	O
100	O
nM	B-UNK
progesterone	B-UNK
or	O
vehicle	B-UNK
(	O
0.01	O
%	O
ethanol	B-UNK
)	O
.	O
Cells	B-UNK
were	O
then	O
treated	O
with	O
30	O
ng	B-UNK
/	O
ml	B-UNK
ritonavir	B-CHEMICAL
or	O
vehicle	B-UNK
in	O
the	O
presence	O
of	O
aggregated	O
LDL	B-UNK
for	O
24	O
h.	O
Cell	B-CHEMICAL
extracts	I-CHEMICAL
were	O
harvested	O
,	O
and	O
lipid	B-UNK
or	O
total	B-UNK
RNA	B-UNK
was	O
isolated	B-UNK
.	O
E2	B-UNK
decreased	B-UNK
the	O
accumulation	B-UNK
of	O
cholesteryl	O
esters	O
in	O
macrophages	O
following	O
ritonavir	B-CHEMICAL
treatment	B-UNK
.	O
Ritonavir	B-CHEMICAL
increased	B-UNK
the	O
expression	B-UNK
of	O
the	O
scavenger	O
receptor	B-UNK
,	O
CD36	O
mRNA	B-UNK
,	O
responsible	B-UNK
for	O
the	O
uptake	B-UNK
of	O
LDL	B-UNK
.	O
Additionally	B-UNK
,	O
ritonavir	B-CHEMICAL
treatment	B-UNK
selectively	B-UNK
increased	B-UNK
the	O
relative	B-UNK
levels	O
of	O
PPARgamma	O
mRNA	B-UNK
,	O
a	O
transcription	O
factor	B-UNK
responsible	B-UNK
for	O
the	O
regulation	B-UNK
of	O
CD36	O
mRNA	B-UNK
expression	B-UNK
.	O
Treatment	B-UNK
with	O
E2	B-UNK
,	O
however	O
,	O
failed	B-UNK
to	O
prevent	B-UNK
these	O
increases	B-UNK
at	O
the	O
mRNA	B-UNK
level	B-UNK
.	O
E2	B-UNK
did	O
,	O
however	O
,	O
significantly	B-UNK
suppress	O
CD36	O
protein	B-UNK
levels	O
as	O
measured	B-UNK
by	O
fluorescent	O
immunocytochemistry	O
.	O
This	O
data	B-UNK
suggests	O
that	O
E2	B-UNK
modifies	O
the	O
expression	B-UNK
of	O
CD36	O
at	O
the	O
level	B-UNK
of	O
protein	B-UNK
expression	I-UNK
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	B-UNK
in	O
reduced	B-UNK
cholesteryl	O
ester	B-UNK
accumulation	B-UNK
following	O
ritonavir	B-UNK
treatment	B-UNK
.	O

Upregulation	B-UNK
of	O
brain	B-UNK
expression	B-UNK
of	O
P	O
-	O
glycoprotein	O
in	O
MRP2-deficient	O
TR(-	O
)	O
rats	B-UNK
resembles	O
seizure	B-UNK
-	O
induced	O
up	O
-	O
regulation	B-UNK
of	O
this	O
drug	B-UNK
efflux	O
transporter	B-UNK
in	O
normal	O
rats	B-UNK
.	O
PURPOSE	B-UNK
:	O
The	O
multidrug	O
resistance	B-UNK
protein	B-UNK
2	O
(	O
MRP2	B-UNK
)	O
is	O
a	O
drug	B-UNK
efflux	O
transporter	B-UNK
that	O
is	O
expressed	B-UNK
predominantly	B-UNK
at	O
the	O
apical	B-UNK
domain	O
of	O
hepatocytes	B-UNK
but	O
seems	O
also	O
to	O
be	O
expressed	B-UNK
at	O
the	O
apical	B-UNK
membrane	B-UNK
of	O
brain	B-UNK
capillary	B-UNK
endothelial	B-UNK
cells	I-UNK
that	O
form	B-UNK
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
(	O
BBB	B-UNK
)	O
.	O
MRP2	B-UNK
is	O
absent	B-UNK
in	O
the	O
transport	B-UNK
-	O
deficient	B-UNK
(	O
TR(-	O
)	O
)	O
Wistar	B-UNK
rat	B-UNK
mutant	O
,	O
so	O
that	O
this	O
rat	B-UNK
strain	B-UNK
was	O
very	O
helpful	O
in	O
defining	O
substrates	O
of	O
MRP2	B-UNK
by	O
comparing	B-UNK
tissue	B-UNK
concentrations	B-UNK
or	O
functional	B-UNK
activities	B-UNK
of	O
compounds	B-UNK
in	O
MRP2-deficient	O
rats	B-UNK
with	O
those	O
in	O
transport	B-UNK
-	O
competent	O
Wistar	B-UNK
rats	I-UNK
.	O
By	O
using	O
this	O
strategy	B-UNK
to	O
study	B-UNK
the	O
involvement	B-UNK
of	O
MRP2	B-UNK
in	O
brain	B-UNK
access	O
of	O
antiepileptic	B-UNK
drugs	B-UNK
(	O
AEDs	O
)	O
,	O
we	O
recently	B-UNK
reported	B-UNK
that	O
phenytoin	B-UNK
is	O
a	O
substrate	B-UNK
for	O
MRP2	B-UNK
in	O
the	O
BBB	B-UNK
.	O
However	O
,	O
one	O
drawback	O
of	O
such	O
studies	B-UNK
in	O
genetically	O
deficient	B-UNK
rats	B-UNK
is	O
the	O
fact	B-UNK
that	O
compensatory	B-UNK
changes	O
with	O
upregulation	B-UNK
of	O
other	O
transporters	O
can	O
occur	O
.	O
This	O
prompted	O
us	O
to	O
study	B-UNK
the	O
brain	B-UNK
expression	B-UNK
of	O
P	O
-	O
glycoprotein	O
(	O
Pgp	B-UNK
)	O
,	O
a	O
major	B-UNK
drug	B-UNK
efflux	O
transporter	B-UNK
in	O
many	O
tissues	B-UNK
,	O
including	O
the	O
BBB	B-UNK
,	O
in	O
TR(-	O
)	O
rats	B-UNK
compared	O
with	O
nonmutant	O
(	O
wild	O
-	O
type	B-UNK
)	O
Wistar	B-UNK
rats	I-UNK
.	O
METHODS	B-UNK
:	O
The	O
expression	B-UNK
of	O
MRP2	B-UNK
and	O
Pgp	B-UNK
in	O
brain	B-UNK
and	O
liver	B-UNK
sections	B-UNK
of	O
TR(-	O
)	O
rats	B-UNK
and	O
normal	O
Wistar	B-UNK
rats	I-UNK
was	O
determined	B-UNK
with	O
immunohistochemistry	B-UNK
,	O
by	O
using	O
a	O
novel	O
,	O
highly	B-UNK
selective	B-UNK
monoclonal	O
MRP2	B-UNK
antibody	B-UNK
and	O
the	O
monoclonal	O
Pgp	B-UNK
antibody	B-UNK
C219	O
,	O
respectively	O
.	O
RESULTS	B-UNK
:	O
Immunofluorescence	O
staining	B-UNK
with	O
the	O
MRP2	B-UNK
antibody	B-UNK
was	O
found	O
to	O
label	B-UNK
a	O
high	B-UNK
number	B-UNK
of	O
microvessels	O
throughout	O
the	O
brain	B-UNK
in	O
normal	O
Wistar	B-UNK
rats	I-UNK
,	O
whereas	O
such	O
labeling	O
was	O
absent	B-UNK
in	O
TR(-	O
)	O
rats	B-UNK
.	O
TR(-	O
)	O
rats	B-UNK
exhibited	O
a	O
significant	B-UNK
up	O
-	O
regulation	B-UNK
of	O
Pgp	B-UNK
in	O
brain	B-UNK
capillary	B-UNK
endothelial	B-UNK
cells	I-UNK
compared	O
with	O
wild	O
-	O
type	B-UNK
controls	B-UNK
.	O
No	O
such	O
obvious	O
upregulation	B-UNK
of	O
Pgp	B-UNK
was	O
observed	O
in	O
liver	B-UNK
sections	B-UNK
.	O
A	O
comparable	O
overexpression	O
of	O
Pgp	B-UNK
in	O
the	O
BBB	B-UNK
was	O
obtained	B-UNK
after	O
pilocarpine	B-UNK
-	O
induced	O
seizures	B-UNK
in	O
wild	O
-	O
type	B-UNK
Wistar	B-UNK
rats	I-UNK
.	O
Experiments	B-UNK
with	O
systemic	B-UNK
administration	O
of	O
the	O
Pgp	B-UNK
substrate	B-UNK
phenobarbital	B-CHEMICAL
and	O
the	O
selective	B-UNK
Pgp	B-UNK
inhibitor	B-UNK
tariquidar	O
in	O
TR(-	O
)	O
rats	B-UNK
substantiated	O
that	O
Pgp	B-UNK
is	O
functional	B-UNK
and	O
compensates	O
for	O
the	O
lack	B-UNK
of	O
MRP2	B-UNK
in	O
the	O
BBB	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
The	O
data	B-UNK
on	O
TR(-	O
)	O
rats	B-UNK
indicate	O
that	O
Pgp	B-UNK
plays	O
an	O
important	B-UNK
role	O
in	O
the	O
compensation	O
of	O
MRP2	B-UNK
deficiency	B-UNK
in	O
the	O
BBB	B-UNK
.	O
Because	O
such	O
a	O
compensatory	B-UNK
mechanism	B-UNK
most	O
likely	O
occurs	O
to	O
reduce	B-UNK
injury	B-UNK
to	O
the	O
brain	B-UNK
from	O
cytotoxic	B-UNK
compounds	B-UNK
,	O
the	O
present	B-UNK
data	B-UNK
substantiate	O
the	O
concept	O
that	O
MRP2	B-UNK
performs	O
a	O
protective	B-UNK
role	I-UNK
in	O
the	O
BBB	B-UNK
.	O
Furthermore	O
,	O
our	O
data	B-UNK
suggest	I-UNK
that	O
TR(-	O
)	O
rats	B-UNK
are	O
an	O
interesting	O
tool	O
to	O
study	B-UNK
consequences	B-UNK
of	O
overexpression	O
of	O
Pgp	B-UNK
in	O
the	O
BBB	B-UNK
on	O
access	O
of	O
drugs	B-UNK
in	O
the	O
brain	B-UNK
,	O
without	O
the	O
need	O
of	O
inducing	O
seizures	B-UNK
or	O
other	O
Pgp	B-UNK
-	O
enhancing	B-UNK
events	B-UNK
for	O
this	O
purpose	B-UNK
.	O

Use	O
of	O
chromosome	O
substitution	O
strains	B-UNK
to	O
identify	B-UNK
seizure	B-UNK
susceptibility	B-UNK
loci	O
in	O
mice	B-UNK
.	O
Seizure	B-UNK
susceptibility	B-UNK
varies	O
among	O
inbred	B-UNK
mouse	B-UNK
strains	B-UNK
.	O
Chromosome	O
substitution	O
strains	B-UNK
(	O
CSS	O
)	O
,	O
in	O
which	O
a	O
single	B-UNK
chromosome	O
from	O
one	O
inbred	B-UNK
strain	B-UNK
(	O
donor	B-UNK
)	O
has	O
been	O
transferred	O
onto	O
a	O
second	O
strain	B-UNK
(	O
host	O
)	O
by	O
repeated	B-UNK
backcrossing	O
,	O
may	O
be	O
used	O
to	O
identify	B-UNK
quantitative	B-UNK
trait	O
loci	O
(	O
QTLs	O
)	O
that	O
contribute	B-UNK
to	O
seizure	B-UNK
susceptibility	B-UNK
.	O
QTLs	O
for	O
susceptibility	B-UNK
to	O
pilocarpine	B-UNK
-	O
induced	O
seizures	B-DISEASE
,	O
a	O
model	B-UNK
of	O
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
,	O
have	O
not	O
been	O
reported	B-UNK
,	O
and	O
CSS	O
have	O
not	O
previously	B-UNK
been	O
used	O
to	O
localize	O
seizure	B-UNK
susceptibility	B-UNK
genes	B-UNK
.	O
We	O
report	B-UNK
QTLs	O
identified	B-UNK
using	O
a	O
B6	O
(	O
host	O
)	O
x	O
A	O
/	O
J	O
(	O
donor	B-UNK
)	O
CSS	O
panel	O
to	O
localize	O
genes	B-UNK
involved	B-UNK
in	O
susceptibility	B-UNK
to	O
pilocarpine	B-CHEMICAL
-	O
induced	O
seizures	B-UNK
.	O
Three	O
hundred	O
fifty	B-UNK
-	O
five	O
adult	B-UNK
male	I-UNK
CSS	O
mice	B-UNK
,	O
58	O
B6	O
,	O
and	O
39	O
A	O
/	O
J	O
were	O
tested	B-UNK
for	O
susceptibility	B-UNK
to	O
pilocarpine	B-UNK
-	O
induced	O
seizures	B-UNK
.	O
Highest	B-UNK
stage	B-UNK
reached	O
and	O
latency	B-UNK
to	O
each	O
stage	B-UNK
were	O
recorded	O
for	O
all	O
mice	B-UNK
.	O
B6	O
mice	B-UNK
were	O
resistant	B-UNK
to	O
seizures	B-UNK
and	O
slower	O
to	O
reach	B-UNK
stages	B-UNK
compared	O
to	O
A	O
/	O
J	O
mice	B-UNK
.	O
The	O
CSS	O
for	O
Chromosomes	O
10	O
and	O
18	O
progressed	O
to	O
the	O
most	O
severe	B-UNK
stages	B-UNK
,	O
diverging	O
dramatically	O
from	O
the	O
B6	O
phenotype	B-UNK
.	O
Latencies	B-UNK
to	O
stages	B-UNK
were	O
also	O
significantly	B-UNK
shorter	O
for	O
CSS10	O
and	O
CSS18	O
mice	B-UNK
.	O
CSS	O
mapping	O
suggests	O
seizure	B-UNK
susceptibility	B-UNK
loci	O
on	O
mouse	B-UNK
Chromosomes	O
10	O
and	O
18	O
.	O
This	O
approach	O
provides	O
a	O
framework	O
for	O
identifying	O
potentially	O
novel	O
homologous	O
candidate	O
genes	B-UNK
for	O
human	B-UNK
temporal	B-DISEASE
lobe	I-DISEASE
epilepsy	I-DISEASE
.	O

Investigation	B-UNK
of	O
mitochondrial	B-UNK
involvement	B-UNK
in	O
the	O
experimental	B-UNK
model	B-UNK
of	O
epilepsy	B-UNK
induced	O
by	O
pilocarpine	B-CHEMICAL
.	O
Mitochondrial	B-UNK
abnormalities	B-UNK
have	O
been	O
associated	O
with	O
several	O
aspects	O
of	O
epileptogenesis	O
,	O
such	O
as	O
energy	O
generation	B-UNK
,	O
control	B-UNK
of	O
cell	B-UNK
death	I-UNK
,	O
neurotransmitter	B-UNK
synthesis	B-UNK
,	O
and	O
free	B-UNK
radical	B-UNK
(	O
FR	O
)	O
production	B-UNK
.	O
Increased	B-UNK
production	B-UNK
of	O
FRs	O
may	O
cause	O
mtDNA	B-UNK
damage	B-UNK
leading	B-UNK
to	O
decreased	B-UNK
activities	B-UNK
of	O
oxidative	B-UNK
phosphorylation	O
complexes	O
containing	O
mtDNA	B-UNK
-	O
encoded	B-UNK
subunits	B-UNK
.	O
In	O
this	O
study	B-UNK
,	O
we	O
investigated	B-UNK
whether	O
increased	B-UNK
generation	B-UNK
of	O
FR	O
during	O
status	B-DISEASE
epilepticus	I-DISEASE
would	O
be	O
sufficient	B-UNK
to	O
provoke	O
abnormalities	B-UNK
in	O
mtDNA	B-UNK
and	O
in	O
the	O
expression	B-UNK
and	O
activity	B-UNK
of	O
cytochrome	B-UNK
c	O
oxidase	B-UNK
(	O
CCO	O
)	O
,	O
complex	B-UNK
IV	B-UNK
of	O
the	O
respiratory	B-UNK
chain	B-UNK
,	O
in	O
the	O
chronic	B-UNK
phase	B-UNK
of	O
the	O
pilocarpine	B-UNK
model	B-UNK
of	O
temporal	B-UNK
lobe	I-UNK
epilepsy	I-UNK
.	O
DNA	B-UNK
analysis	B-UNK
revealed	O
low	B-UNK
amounts	B-UNK
of	O
a	O
4.8	O
kb	O
mtDNA	B-UNK
deletion	O
but	O
with	O
no	O
differences	B-UNK
in	O
frequency	B-UNK
or	O
quantity	O
in	O
the	O
control	B-UNK
and	O
experimental	B-UNK
groups	B-UNK
.	O
We	O
did	O
not	O
find	O
abnormalities	B-UNK
in	O
the	O
expression	B-UNK
and	O
distribution	B-UNK
of	O
an	O
mtDNA	B-UNK
-	O
encoded	B-UNK
subunit	O
of	O
CCO	O
(	O
CCO	O
-	O
I	O
)	O
or	O
a	O
relative	B-UNK
decrease	B-UNK
in	O
CCO	O
-	O
I	O
when	O
compared	O
with	O
nuclear	B-UNK
-	O
encoded	B-UNK
subunits	B-UNK
(	O
CCO	O
-	O
IV	B-UNK
and	O
SDH	O
-	O
fp	O
)	O
.	O
No	O
abnormality	B-UNK
in	O
CCO	O
activity	B-UNK
was	O
observed	O
through	O
histochemistry	O
.	O
Although	O
evidences	O
of	O
mitochondrial	B-UNK
abnormalities	B-UNK
were	O
found	O
in	O
previously	B-UNK
published	B-UNK
studies	B-UNK
,	O
our	O
results	B-UNK
do	O
not	O
suggest	B-UNK
that	O
the	O
FRs	O
,	O
generated	B-UNK
during	O
the	O
acute	B-UNK
phase	B-UNK
,	O
determined	B-UNK
important	B-UNK
abnormalities	B-UNK
in	O
mtDNA	B-UNK
,	O
in	O
expression	B-UNK
of	O
CCO	O
-	O
I	O
,	O
and	O
in	O
CCO	O
activity	B-UNK
.	O

Causes	O
of	O
acute	B-UNK
thrombotic	B-UNK
microangiopathy	I-UNK
in	O
patients	B-UNK
receiving	B-UNK
kidney	B-UNK
transplantation	B-UNK
.	O
OBJECTIVES	B-UNK
:	O
Thrombotic	B-UNK
microangiopathy	I-UNK
is	O
a	O
well	O
-	O
known	O
problem	O
in	O
patients	B-UNK
following	O
renal	B-UNK
transplantation	B-UNK
.	O
In	O
postrenal	O
transplantation	B-UNK
,	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
is	O
often	O
a	O
reflection	O
of	O
hemolytic	B-UNK
uremic	I-UNK
syndrome	I-UNK
.	O
We	O
aimed	B-UNK
to	O
determine	B-UNK
the	O
causes	O
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
in	O
a	O
population	B-UNK
of	O
renal	B-UNK
transplantation	B-UNK
recipients	B-UNK
and	O
discuss	B-UNK
the	O
literature	B-UNK
.	O
MATERIALS	B-UNK
AND	I-UNK
METHODS	I-UNK
:	O
We	O
investigated	B-UNK
the	O
causes	O
of	O
thrombotic	B-UNK
microangiopathy	I-UNK
during	O
a	O
1-year	O
period	B-UNK
,	O
from	O
June	B-UNK
2003	O
to	O
June	B-UNK
2004	O
,	O
at	O
the	O
King	O
Fahad	O
National	B-UNK
Guard	O
Hospital	B-UNK
in	O
Riyadh	O
,	O
Saudi	O
Arabia	O
,	O
by	O
reviewing	O
the	O
slides	O
of	O
all	O
transplant	B-UNK
biopsies	B-UNK
(	O
n=25	O
)	O
performed	B-UNK
during	O
this	O
interval	B-UNK
.	O
Pre-	O
and	O
posttransplant	O
crossmatching	O
was	O
done	O
when	O
possible	O
.	O
RESULTS	B-UNK
:	O
Five	O
cases	B-UNK
of	O
thrombotic	B-UNK
microangiopathy	I-UNK
were	O
found	O
.	O
Three	O
of	O
these	O
cases	B-UNK
were	O
from	O
the	O
25	O
transplantations	O
performed	B-UNK
at	O
King	O
Fahad	O
National	B-UNK
Guard	O
Hospital	B-UNK
,	O
while	O
the	O
other	O
2	O
transplantations	O
had	O
been	O
performed	B-UNK
abroad	O
and	O
were	O
referred	B-UNK
to	O
us	O
for	O
follow	O
-	O
up	O
.	O
Three	O
cases	B-UNK
were	O
related	O
to	O
cyclosporine	B-UNK
,	O
and	O
1	O
case	B-UNK
was	O
secondary	B-UNK
to	O
both	O
cyclosporine	B-UNK
and	O
tacrolimus	B-UNK
.	O
The	O
fifth	O
case	B-UNK
had	O
features	B-UNK
of	O
thrombotic	B-UNK
microangiopathy	I-UNK
related	O
to	O
an	O
antiphospholipid	B-DISEASE
syndrome	I-DISEASE
in	O
a	O
patient	B-UNK
with	O
systemic	B-UNK
lupus	B-UNK
erythematosus	O
.	O
CONCLUSIONS	B-UNK
:	O
In	O
the	O
literature	B-UNK
,	O
the	O
most	O
-	O
frequent	B-UNK
cause	O
of	O
hemolytic	B-UNK
uremic	I-UNK
syndrome	I-UNK
in	O
patients	B-UNK
following	O
renal	B-UNK
transplantation	B-UNK
is	O
recurrence	B-UNK
of	O
the	O
hemolytic	B-UNK
uremic	I-UNK
syndrome	I-UNK
.	O
Other	O
causes	O
include	O
drug	B-UNK
-	O
related	O
(	O
cyclosporine	B-UNK
,	O
tacrolimus	B-UNK
)	O
toxicity	B-UNK
,	O
procoagulant	O
status	B-UNK
,	O
and	O
antibody	B-UNK
-	O
mediated	B-UNK
rejection	B-UNK
.	O
We	O
found	O
that	O
the	O
most	O
-	O
frequent	B-UNK
cause	O
of	O
thrombotic	B-UNK
microangiopathy	I-UNK
was	O
drug	B-UNK
related	O
,	O
secondary	B-UNK
mainly	O
to	O
cyclosporine	B-UNK
.	O
In	O
the	O
current	B-UNK
study	B-UNK
,	O
the	O
frequency	B-UNK
of	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
was	O
similar	B-UNK
to	O
the	O
percentage	B-UNK
reported	B-UNK
in	O
the	O
literature	B-UNK
(	O
20	O
%	O
)	O
.	O

Severe	B-UNK
reversible	B-UNK
left	B-UNK
ventricular	I-UNK
systolic	B-UNK
and	I-UNK
diastolic	I-UNK
dysfunction	B-UNK
due	O
to	O
accidental	O
iatrogenic	O
epinephrine	B-UNK
overdose	B-UNK
.	O
Catecholamine	B-UNK
-	O
induced	O
cardiomyopathy	B-UNK
due	O
to	O
chronic	B-UNK
excess	B-UNK
of	O
endogenous	B-UNK
catecholamines	B-UNK
has	O
been	O
recognized	O
for	O
decades	O
as	O
a	O
clinical	B-UNK
phenomenon	B-UNK
.	O
In	O
contrast	B-UNK
,	O
reports	B-UNK
of	O
myocardial	B-UNK
dysfunction	B-UNK
due	O
to	O
acute	B-UNK
iatrogenic	O
overdose	B-DISEASE
are	O
rare	B-UNK
.	O
A	O
35-year	O
-	O
old	O
woman	B-UNK
whose	O
cervix	O
uteri	O
was	O
inadvertently	O
injected	B-UNK
with	O
8	O
mg	B-UNK
of	O
epinephrine	B-CHEMICAL
developed	O
myocardial	B-DISEASE
stunning	I-DISEASE
that	O
was	O
characterized	B-UNK
by	O
severe	B-UNK
hemodynamic	B-UNK
compromise	O
,	O
profound	B-UNK
,	O
albeit	O
transient	B-UNK
,	O
left	B-UNK
ventricular	I-UNK
systolic	B-UNK
and	I-UNK
diastolic	I-UNK
dysfunction	B-UNK
,	O
and	O
only	O
modestly	O
elevated	B-UNK
biochemical	B-UNK
markers	B-UNK
of	O
myocardial	B-UNK
necrosis	B-UNK
.	O
Our	O
case	B-UNK
illustrates	O
the	O
serious	O
consequences	B-UNK
of	O
medical	B-UNK
errors	O
that	O
can	O
be	O
avoided	O
through	O
improved	O
medication	O
labeling	O
and	O
staff	O
supervision	O
.	O

Urinary	B-DISEASE
bladder	I-DISEASE
cancer	I-DISEASE
in	O
Wegener'	O
s	O
granulomatosis	O
:	O
risks	B-UNK
and	O
relation	B-UNK
to	O
cyclophosphamide	B-CHEMICAL
.	O
OBJECTIVE	B-UNK
:	O
To	O
assess	B-UNK
and	O
characterise	O
the	O
risk	B-UNK
of	O
bladder	B-DISEASE
cancer	I-DISEASE
,	O
and	O
its	O
relation	B-UNK
to	O
cyclophosphamide	B-UNK
,	O
in	O
patients	B-UNK
with	O
Wegener'	O
s	O
granulomatosis	O
.	O
METHODS	B-UNK
:	O
In	O
the	O
population	B-UNK
based	B-UNK
,	O
nationwide	O
Swedish	O
Inpatient	B-UNK
Register	O
a	O
cohort	B-UNK
of	O
1065	O
patients	B-UNK
with	O
Wegener'	O
s	O
granulomatosis	O
,	O
1969	O
-	O
95	O
,	O
was	O
identified	B-UNK
.	O
Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	B-UNK
Register	O
,	O
all	O
subjects	B-UNK
in	O
this	O
cohort	B-UNK
diagnosed	B-UNK
with	O
bladder	B-UNK
cancer	I-UNK
were	O
identified	B-UNK
.	O
Nested	O
within	O
the	O
cohort	B-UNK
,	O
a	O
matched	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
was	O
performed	B-UNK
to	O
estimate	B-UNK
the	O
association	B-UNK
between	O
cyclophosphamide	B-CHEMICAL
and	O
bladder	B-UNK
cancer	I-UNK
using	O
odds	B-UNK
ratios	O
(	O
ORs	O
)	O
as	O
relative	B-UNK
risk	I-UNK
.	O
In	O
the	O
cohort	B-UNK
the	O
cumulative	B-UNK
risk	B-UNK
of	O
bladder	B-DISEASE
cancer	I-DISEASE
after	O
Wegener'	O
s	O
granulomatosis	O
,	O
and	O
the	O
relative	B-UNK
prevalence	B-UNK
of	O
a	O
history	B-UNK
of	O
bladder	B-UNK
cancer	I-UNK
at	O
the	O
time	O
of	O
diagnosis	B-UNK
of	O
Wegener'	O
s	O
granulomatosis	O
,	O
were	O
also	O
estimated	O
.	O
RESULTS	B-UNK
:	O
The	O
median	B-UNK
cumulative	B-UNK
doses	B-UNK
of	O
cyclophosphamide	B-UNK
among	O
cases	B-UNK
(	O
n	O
=	O
11	O
)	O
and	O
controls	B-UNK
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O
The	O
risk	B-UNK
of	O
bladder	B-UNK
cancer	I-UNK
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	B-CHEMICAL
(	O
OR	O
=	O
2.0	O
,	O
95	O
%	O
confidence	O
interval	B-UNK
(	O
CI	B-UNK
)	O
0.8	O
to	O
4.9	O
)	O
.	O
Treatment	B-UNK
duration	B-UNK
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	B-UNK
risk	B-UNK
(	O
OR	O
=	O
7.7	O
,	O
95	O
%	O
CI	B-UNK
0.9	O
to	O
69	O
)	O
.	O
The	O
absolute	B-UNK
risk	B-UNK
for	O
bladder	B-UNK
cancer	I-UNK
in	O
the	O
cohort	B-UNK
reached	O
10	O
%	O
16	O
years	B-UNK
after	O
diagnosis	B-UNK
of	O
Wegener'	O
s	O
granulomatosis	O
,	O
and	O
a	O
history	B-UNK
of	O
bladder	B-UNK
cancer	I-UNK
was	O
(	O
non-significantly	O
)	O
twice	O
as	O
common	B-UNK
as	O
expected	B-UNK
at	O
the	O
time	O
of	O
diagnosis	B-UNK
of	O
Wegener'	O
s	O
granulomatosis	O
.	O
CONCLUSION	B-UNK
:	O
The	O
results	B-UNK
indicate	O
a	O
dose	B-UNK
-	O
response	B-UNK
relationship	B-UNK
between	O
cyclophosphamide	B-UNK
and	O
the	O
risk	B-UNK
of	O
bladder	B-UNK
cancer	I-UNK
,	O
high	B-UNK
cumulative	B-UNK
risks	B-UNK
in	O
the	O
entire	O
cohort	B-UNK
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	B-UNK
factors	I-UNK
operating	O
even	O
before	O
Wegener'	O
s	O
granulomatosis	O
.	O

L	O
-	O
arginine	O
transport	B-UNK
in	O
humans	B-UNK
with	O
cortisol	B-CHEMICAL
-	O
induced	O
hypertension	B-UNK
.	O
A	O
deficient	B-UNK
L	O
-	O
arginine	O
-	O
nitric	B-UNK
oxide	I-UNK
system	O
is	O
implicated	B-UNK
in	O
cortisol	B-CHEMICAL
-	O
induced	O
hypertension	B-UNK
.	O
We	O
investigate	B-UNK
whether	O
abnormalities	B-UNK
in	O
L	O
-	O
arginine	O
uptake	B-UNK
contribute	B-UNK
to	O
this	O
deficiency	B-UNK
.	O
Eight	O
healthy	B-UNK
men	B-UNK
were	O
recruited	O
.	O
Hydrocortisone	B-CHEMICAL
acetate	I-CHEMICAL
(	O
50	O
mg	B-UNK
)	O
was	O
given	O
orally	O
every	O
6	O
hours	B-UNK
for	O
24	O
hours	B-UNK
after	O
a	O
5-day	O
fixed	B-UNK
-	O
salt	B-CHEMICAL
diet	B-UNK
(	O
150	O
mmol	B-UNK
/	O
d	O
)	O
.	O
Crossover	B-UNK
studies	B-UNK
were	O
performed	B-UNK
2	O
weeks	B-UNK
apart	O
.	O
Thirty	B-UNK
milliliters	O
of	O
blood	B-UNK
was	O
obtained	B-UNK
for	O
isolation	O
of	O
peripheral	B-UNK
blood	I-UNK
mononuclear	O
cells	B-UNK
after	O
each	O
treatment	B-UNK
period	B-UNK
.	O
L	O
-	O
arginine	O
uptake	B-UNK
was	O
assessed	B-UNK
in	O
mononuclear	O
cells	B-UNK
incubated	O
with	O
L	O
-	O
arginine	O
(	O
1	O
to	O
300	O
micromol	B-UNK
/	O
L	O
)	O
,	O
incorporating	O
100	O
nmol	B-UNK
/	O
L	O
[	O
3H]-l	O
-	O
arginine	O
for	O
a	O
period	B-UNK
of	O
5	O
minutes	B-UNK
at	O
37	O
degrees	B-UNK
C.	O
Forearm	B-UNK
[	O
3H]-L	O
-	O
arginine	O
extraction	O
was	O
calculated	B-UNK
after	O
infusion	B-UNK
of	O
[	O
3H]-L	O
-	O
arginine	O
into	O
the	O
brachial	O
artery	B-UNK
at	O
a	O
rate	B-UNK
of	O
100	O
nCi	O
/	O
min	B-UNK
for	O
80	O
minutes	B-UNK
.	O
Deep	B-UNK
forearm	B-UNK
venous	B-UNK
samples	O
were	O
collected	O
for	O
determination	B-UNK
of	O
L	O
-	O
arginine	O
extraction	O
.	O
Plasma	B-UNK
cortisol	B-UNK
concentrations	B-UNK
were	O
significantly	B-UNK
raised	B-UNK
during	O
the	O
active	B-UNK
phase	B-UNK
(	O
323+/-43	O
to	O
1082+/-245	O
mmol	B-UNK
/	O
L	O
,	O
P<0.05	O
)	O
.	O
Systolic	B-UNK
blood	I-UNK
pressure	I-UNK
was	O
elevated	B-UNK
by	O
an	O
average	B-UNK
of	O
7	O
mm	B-UNK
Hg	I-UNK
.	O
Neither	O
L	O
-	O
arginine	O
transport	B-UNK
into	O
mononuclear	O
cells	B-UNK
(	O
placebo	B-UNK
vs	O
active	B-UNK
,	O
26.3+/-3.6	O
vs	O
29.0+/-2.1	O
pmol/10	O
000	O
cells	B-UNK
per	O
5	O
minutes	B-UNK
,	O
respectively	O
,	O
at	O
an	O
l	O
-	O
arginine	O
concentration	B-UNK
of	O
300	O
micromol	B-UNK
/	O
L	O
)	O
nor	O
L	O
-	O
arginine	O
extraction	O
in	O
the	O
forearm	B-UNK
(	O
at	O
80	O
minutes	B-UNK
,	O
placebo	B-UNK
vs	O
active	B-UNK
,	O
1	O
868	O
904+/-434	O
962	O
vs	O
2	O
013	O
910+/-770	O
619	O
disintegrations	O
per	O
minute	B-UNK
)	O
was	O
affected	B-UNK
by	O
cortisol	B-UNK
treatment	B-UNK
;	O
ie	O
,	O
that	O
L	O
-	O
arginine	O
uptake	B-UNK
is	O
not	O
affected	B-UNK
by	O
short	B-UNK
-	O
term	O
cortisol	B-UNK
treatment	B-UNK
.	O
We	O
conclude	O
that	O
cortisol	B-CHEMICAL
-	O
induced	O
increases	B-UNK
in	O
blood	B-UNK
pressure	I-UNK
are	O
not	O
associated	O
with	O
abnormalities	B-UNK
in	O
the	O
l	O
-	O
arginine	O
transport	B-UNK
system	O
.	O

MR	B-UNK
imaging	B-UNK
with	O
quantitative	B-UNK
diffusion	B-UNK
mapping	O
of	O
tacrolimus	B-CHEMICAL
-	O
induced	O
neurotoxicity	B-UNK
in	O
organ	B-UNK
transplant	B-UNK
patients	B-UNK
.	O
Our	O
objective	B-UNK
was	O
to	O
investigate	B-UNK
brain	B-UNK
MR	B-UNK
imaging	B-UNK
findings	B-UNK
and	O
the	O
utility	B-UNK
of	O
diffusion	B-UNK
-	O
weighted	B-UNK
(	O
DW	O
)	O
imaging	B-UNK
in	O
organ	B-UNK
transplant	B-UNK
patients	B-UNK
who	O
developed	O
neurologic	B-UNK
symptoms	B-UNK
during	O
tacrolimus	B-CHEMICAL
therapy	O
.	O
Brain	B-UNK
MR	B-UNK
studies	B-UNK
,	O
including	O
DW	O
imaging	B-UNK
,	O
were	O
prospectively	O
performed	B-UNK
in	O
14	O
organ	B-UNK
transplant	B-UNK
patients	B-UNK
receiving	B-UNK
tacrolimus	B-CHEMICAL
who	O
developed	O
neurologic	B-UNK
complications	B-DISEASE
.	O
In	O
each	O
patient	B-UNK
who	O
had	O
abnormalities	B-UNK
on	O
the	O
initial	B-UNK
MR	B-UNK
study	B-UNK
,	O
a	O
follow	O
-	O
up	O
MR	B-UNK
study	B-UNK
was	O
performed	B-UNK
1	O
month	B-UNK
later	O
.	O
Apparent	B-UNK
diffusion	B-UNK
coefficient	O
(	O
ADC	O
)	O
values	O
on	O
the	O
initial	B-UNK
MR	B-UNK
study	B-UNK
were	O
correlated	B-UNK
with	O
reversibility	O
of	O
the	O
lesions	B-UNK
.	O
Of	O
the	O
14	O
patients	B-UNK
,	O
5	O
(	O
35.7	O
%	O
)	O
had	O
white	B-UNK
matter	I-UNK
abnormalities	B-UNK
,	O
1	O
(	O
7.1	O
%	O
)	O
had	O
putaminal	B-DISEASE
hemorrhage	I-DISEASE
,	O
and	O
8	O
(	O
57.1	O
%	O
)	O
had	O
normal	O
findings	B-UNK
on	O
initial	B-UNK
MR	B-UNK
images	B-UNK
.	O
Among	O
the	O
5	O
patients	B-UNK
with	O
white	B-UNK
matter	I-UNK
abnormalities	B-UNK
,	O
4	O
patients	B-UNK
(	O
80.0	O
%	O
)	O
showed	O
higher	B-UNK
than	O
normal	O
ADC	O
values	O
on	O
initial	B-UNK
MR	B-UNK
images	B-UNK
,	O
and	O
all	O
showed	O
complete	B-UNK
resolution	B-UNK
on	O
follow	O
-	O
up	O
images	B-UNK
.	O
The	O
remaining	O
1	O
patient	B-UNK
(	O
20.0	O
%	O
)	O
showed	O
lower	B-UNK
than	O
normal	O
ADC	O
value	O
and	O
showed	O
incomplete	O
resolution	B-UNK
with	O
cortical	B-DISEASE
laminar	I-DISEASE
necrosis	I-DISEASE
.	O
Diffusion	B-UNK
-	O
weighted	B-UNK
imaging	B-UNK
may	O
be	O
useful	O
in	O
predicting	O
the	O
outcomes	B-UNK
of	O
the	O
lesions	B-UNK
of	O
tacrolimus	B-CHEMICAL
-	O
induced	O
neurotoxicity	B-UNK
.	O

Octreotide	B-UNK
-	O
induced	O
hypoxemia	B-DISEASE
and	O
pulmonary	B-UNK
hypertension	I-UNK
in	O
premature	B-UNK
neonates	B-UNK
.	O
The	O
authors	B-UNK
report	B-UNK
2	O
cases	B-UNK
of	O
premature	B-UNK
neonates	B-UNK
who	O
had	O
enterocutaneous	O
fistula	B-DISEASE
complicating	O
necrotizing	B-UNK
enterocolitis	B-DISEASE
.	O
Pulmonary	B-UNK
hypertension	I-UNK
developed	O
after	O
administration	O
of	O
a	O
somatostatin	B-CHEMICAL
analogue	B-UNK
,	O
octreotide	B-UNK
,	O
to	O
enhance	B-UNK
resolution	B-UNK
of	O
the	O
fistula	B-DISEASE
.	O
The	O
authors	B-UNK
discuss	B-UNK
the	O
mechanism	B-UNK
of	O
the	O
occurrence	B-UNK
of	O
this	O
complication	B-UNK
and	O
recommend	O
caution	B-UNK
of	O
its	O
use	O
in	O
high	B-UNK
-	O
risk	B-UNK
premature	B-UNK
neonates	B-UNK
.	O

Sequential	O
observations	B-UNK
of	O
exencephaly	B-DISEASE
and	O
subsequent	B-UNK
morphological	B-UNK
changes	O
by	O
mouse	B-UNK
exo	O
utero	O
development	B-UNK
system	O
:	O
analysis	B-UNK
of	O
the	O
mechanism	B-UNK
of	O
transformation	B-UNK
from	O
exencephaly	B-DISEASE
to	O
anencephaly	B-DISEASE
.	O
Anencephaly	B-DISEASE
has	O
been	O
suggested	B-UNK
to	O
develop	B-UNK
from	O
exencephaly	B-DISEASE
;	O
however	O
,	O
there	O
is	O
little	O
direct	B-UNK
experimental	B-UNK
evidence	B-UNK
to	O
support	B-UNK
this	O
,	O
and	O
the	O
mechanism	B-UNK
of	O
transformation	B-UNK
remains	O
unclear	O
.	O
We	O
examined	B-UNK
this	O
theory	O
using	O
the	O
exo	O
utero	O
development	B-UNK
system	O
that	O
allows	O
direct	B-UNK
and	O
sequential	O
observations	B-UNK
of	O
mid-	O
to	O
late	B-UNK
-	O
gestation	B-UNK
mouse	B-UNK
embryos	O
.	O
We	O
observed	O
the	O
exencephaly	B-DISEASE
induced	O
by	O
5-azacytidine	B-CHEMICAL
at	O
embryonic	O
day	O
13.5	O
(	O
E13.5	O
)	O
,	O
let	O
the	O
embryos	O
develop	B-UNK
exo	O
utero	O
until	O
E18.5	O
,	O
and	O
re-observed	O
the	O
same	O
embryos	O
at	O
E18.5	O
.	O
We	O
confirmed	B-UNK
several	O
cases	B-UNK
of	O
transformation	B-UNK
from	O
exencephaly	B-DISEASE
to	O
anencephaly	B-DISEASE
.	O
However	O
,	O
in	O
many	O
cases	B-UNK
,	O
the	O
exencephalic	B-DISEASE
brain	B-UNK
tissue	B-UNK
was	O
preserved	B-UNK
with	O
more	O
or	O
less	O
reduction	O
during	O
this	O
period	B-UNK
.	O
To	O
analyze	O
the	O
transformation	B-UNK
patterns	B-UNK
,	O
we	O
classified	O
the	O
exencephaly	B-DISEASE
by	O
size	B-UNK
and	O
shape	O
of	O
the	O
exencephalic	B-DISEASE
tissue	B-UNK
into	O
several	O
types	B-UNK
at	O
E13.5	O
and	O
E18.5	O
.	O
It	O
was	O
found	O
that	O
the	O
transformation	B-UNK
of	O
exencephalic	B-DISEASE
tissue	B-UNK
was	O
not	O
simply	O
size	B-UNK
-	O
dependent	B-UNK
,	O
and	O
all	O
cases	B-UNK
of	O
anencephaly	B-DISEASE
at	O
E18.5	O
resulted	B-UNK
from	O
embryos	O
with	O
a	O
large	B-UNK
amount	O
of	O
exencephalic	B-DISEASE
tissue	B-UNK
at	O
E13.5	O
.	O
Microscopic	B-UNK
observation	B-UNK
showed	O
the	O
configuration	O
of	O
exencephaly	B-DISEASE
at	O
E13.5	O
,	O
frequent	B-UNK
hemorrhaging	O
and	O
detachment	O
of	O
the	O
neural	B-UNK
plate	O
from	O
surface	B-UNK
ectoderm	O
in	O
the	O
exencephalic	B-DISEASE
head	B-UNK
at	O
E15.5	O
,	O
and	O
multiple	B-UNK
modes	O
of	O
reduction	O
in	O
the	O
exencephalic	B-DISEASE
tissue	B-UNK
at	O
E18.5	O
.	O
From	O
observations	B-UNK
of	O
the	O
vasculature	O
,	O
altered	B-UNK
distribution	B-UNK
patterns	B-UNK
of	O
vessels	B-UNK
were	O
identified	B-UNK
in	O
the	O
exencephalic	B-DISEASE
head	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
overgrowth	O
of	O
the	O
exencephalic	B-DISEASE
neural	B-UNK
tissue	B-UNK
causes	O
the	O
altered	B-UNK
distribution	B-UNK
patterns	B-UNK
of	O
vessels	B-UNK
,	O
subsequent	B-UNK
peripheral	B-UNK
circulatory	B-DISEASE
failure	I-DISEASE
and	O
/	O
or	O
hemorrhaging	O
in	O
various	O
parts	O
of	O
the	O
exencephalic	B-DISEASE
head	B-UNK
,	O
leading	B-UNK
to	O
the	O
multiple	B-UNK
modes	O
of	O
tissue	B-UNK
reduction	O
during	O
transformation	B-UNK
from	O
exencephaly	B-DISEASE
to	O
anencephaly	B-DISEASE
.	O

Acute	B-UNK
cocaine	B-CHEMICAL
-	O
induced	O
seizures	B-UNK
:	O
differential	B-UNK
sensitivity	B-UNK
of	O
six	O
inbred	B-UNK
mouse	B-UNK
strains	B-UNK
.	O
Mature	O
male	B-UNK
and	O
female	B-UNK
mice	B-UNK
from	O
six	O
inbred	B-UNK
stains	O
were	O
tested	B-UNK
for	O
susceptibility	B-UNK
to	O
behavioral	B-UNK
seizures	B-DISEASE
induced	O
by	O
a	O
single	B-UNK
injection	I-UNK
of	O
cocaine	B-UNK
.	O
Cocaine	B-CHEMICAL
was	O
injected	B-UNK
ip	B-UNK
over	O
a	O
range	B-UNK
of	O
doses	B-UNK
(	O
50	O
-	O
100	O
mg	B-UNK
/	O
kg	B-UNK
)	O
and	O
behavior	B-UNK
was	O
monitored	O
for	O
20	O
minutes	B-UNK
.	O
Seizure	B-UNK
end	B-UNK
points	B-UNK
included	B-UNK
latency	B-UNK
to	O
forelimb	O
or	O
hindlimb	O
clonus	O
,	O
latency	B-UNK
to	O
clonic	B-UNK
running	O
seizure	B-DISEASE
and	O
latency	B-UNK
to	O
jumping	O
bouncing	O
seizure	B-DISEASE
.	O
A	O
range	B-UNK
of	O
strain	B-UNK
specific	B-UNK
sensitivities	O
was	O
documented	O
with	O
A	O
/	O
J	O
and	O
SJL	O
mice	B-UNK
being	O
most	O
sensitive	B-UNK
and	O
C57BL/6J	O
most	O
resistant	B-UNK
.	O
DBA/2J	O
,	O
BALB	B-UNK
/	O
cByJ	O
and	O
NZW	O
/	O
LacJ	O
strains	B-UNK
exhibited	O
intermediate	B-UNK
sensitivity	B-UNK
.	O
EEG	B-UNK
recordings	O
were	O
made	O
in	O
SJL	O
,	O
A	O
/	O
J	O
and	O
C57BL/6J	O
mice	B-UNK
revealing	O
a	O
close	B-UNK
correspondence	O
between	O
electrical	B-UNK
activity	B-UNK
and	O
behavior	B-UNK
.	O
Additionally	B-UNK
,	O
levels	O
of	O
cocaine	B-UNK
determined	B-UNK
in	O
hippocampus	B-UNK
and	O
cortex	B-UNK
were	O
not	O
different	O
between	O
sensitive	B-UNK
and	O
resistant	B-UNK
strains	B-UNK
.	O
Additional	B-UNK
studies	B-UNK
of	O
these	O
murine	B-UNK
strains	B-UNK
may	O
be	O
useful	O
for	O
investigating	O
genetic	B-UNK
influences	O
on	O
cocaine	B-CHEMICAL
-	O
induced	O
seizures	B-UNK
.	O

Microangiopathic	O
hemolytic	B-UNK
anemia	I-UNK
complicating	O
FK506	B-UNK
(	O
tacrolimus	B-UNK
)	O
therapy	O
.	O
We	O
describe	O
3	O
episodes	B-UNK
of	O
microangiopathic	O
hemolytic	B-UNK
anemia	I-UNK
(	O
MAHA	O
)	O
in	O
2	O
solid	O
organ	B-UNK
recipients	B-UNK
under	O
FK506	B-UNK
(	O
tacrolimus	B-CHEMICAL
)	O
therapy	O
.	O
In	O
both	O
cases	B-UNK
,	O
discontinuation	B-UNK
of	O
FK506	B-UNK
and	O
treatment	B-UNK
with	O
plasma	B-UNK
exchange	O
,	O
fresh	O
frozen	O
plasma	B-UNK
replacement	B-UNK
,	O
corticosteroids	B-CHEMICAL
,	O
aspirin	B-UNK
,	O
and	O
dipyridamole	B-CHEMICAL
led	B-UNK
to	O
resolution	B-UNK
of	O
MAHA	O
.	O
In	O
one	O
patient	B-UNK
,	O
reintroduction	O
of	O
FK506	B-UNK
led	B-UNK
to	O
rapid	B-UNK
recurrence	B-UNK
of	O
MAHA	O
.	O
FK506-associated	O
MAHA	O
is	O
probably	O
rare	B-UNK
but	O
physicians	B-UNK
must	O
be	O
aware	B-UNK
of	O
this	O
severe	B-UNK
complication	B-UNK
.	O
In	O
our	O
experience	B-UNK
and	O
according	O
to	O
the	O
literature	B-UNK
,	O
FK506	B-UNK
does	O
not	O
seem	O
to	O
cross-react	O
with	O
cyclosporin	B-CHEMICAL
A	I-CHEMICAL
(	O
CyA	B-UNK
)	O
,	O
an	O
immuno	O
-	O
suppressive	O
drug	B-UNK
already	O
known	O
to	O
induce	B-UNK
MAHA	O
.	O

Variant	B-UNK
ventricular	B-UNK
tachycardia	I-UNK
in	O
desipramine	B-UNK
toxicity	B-DISEASE
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
variant	B-UNK
ventricular	B-UNK
tachycardia	I-UNK
induced	O
by	O
desipramine	B-UNK
toxicity	B-UNK
.	O
Unusual	B-UNK
features	B-UNK
of	O
the	O
arrhythmia	B-DISEASE
are	O
repetitive	B-UNK
group	B-UNK
beating	B-UNK
,	O
progressive	B-UNK
shortening	B-UNK
of	O
the	O
R	O
-	O
R	O
interval	B-UNK
,	O
progressive	B-UNK
widening	O
of	O
the	O
QRS	O
complex	B-UNK
with	O
eventual	O
failure	B-UNK
of	O
intraventricular	O
conduction	B-UNK
,	O
and	O
changes	O
in	O
direction	O
of	O
the	O
QRS	O
axis	O
.	O
Recognition	B-UNK
of	O
variant	B-UNK
ventricular	B-UNK
tachycardia	I-UNK
is	O
important	B-UNK
because	O
therapy	O
differs	O
from	O
that	O
of	O
classic	B-UNK
ventricular	B-UNK
tachycardia	I-UNK
.	O

Desipramine	B-UNK
-	O
induced	O
delirium	B-UNK
at	O
"	O
subtherapeutic	O
"	O
concentrations	B-UNK
:	O
a	O
case	B-UNK
report	I-UNK
.	O
An	O
elderly	B-UNK
patient	B-UNK
treated	O
with	O
low	B-UNK
dose	I-UNK
Desipramine	B-UNK
developed	O
a	O
delirium	B-DISEASE
while	O
her	O
plasma	B-UNK
level	B-UNK
was	O
in	O
the	O
"	O
subtherapeutic	O
"	O
range	B-UNK
.	O
Delirium	B-UNK
,	O
which	O
may	O
be	O
induced	O
by	O
tricyclic	B-UNK
drug	B-UNK
therapy	O
in	O
the	O
elderly	B-UNK
,	O
can	O
be	O
caused	B-UNK
by	O
tricyclics	O
with	O
low	B-UNK
anticholinergic	B-UNK
potency	B-UNK
.	O
Therapeutic	B-UNK
ranges	O
for	O
antidepressants	B-UNK
that	O
have	O
been	O
derived	O
from	O
general	B-UNK
adult	B-UNK
population	B-UNK
studies	B-UNK
may	O
not	O
be	O
appropriate	O
for	O
the	O
elderly	B-UNK
.	O
Further	O
studies	B-UNK
of	O
specifically	O
elderly	B-UNK
patients	B-UNK
are	O
now	O
required	B-UNK
to	O
establish	O
safer	O
and	O
more	O
appropriate	O
guidelines	O
for	O
drug	B-UNK
therapy	O
.	O

Mouse	B-UNK
strain	B-UNK
-	O
dependent	B-UNK
effect	B-UNK
of	O
amantadine	B-UNK
on	O
motility	B-UNK
and	O
brain	B-UNK
biogenic	B-CHEMICAL
amines	I-CHEMICAL
.	O
The	O
effect	B-UNK
of	O
amantadine	B-UNK
hydrochloride	B-UNK
,	O
injected	B-UNK
i.p	B-UNK
.	O
in	O
6	O
increments	O
of	O
100	O
mg	B-UNK
/	O
kg	B-UNK
each	O
over	O
30	O
hr	B-UNK
,	O
on	O
mouse	B-UNK
motility	B-UNK
and	O
whole	O
brain	B-UNK
content	B-UNK
of	O
selected	O
biogenic	B-CHEMICAL
amines	I-CHEMICAL
and	O
major	B-UNK
metabolites	B-UNK
was	O
studied	O
in	O
4	O
strains	B-UNK
of	O
mice	B-UNK
.	O
These	O
were	O
the	O
albino	B-UNK
Sprague	O
-	O
Dawley	O
ICR	O
and	O
BALB	B-UNK
/	O
C	O
,	O
the	O
black	O
C57BL/6	O
and	O
the	O
brown	O
CDF	O
-	O
I	O
mouse	B-UNK
strains	B-UNK
.	O
Amantadine	B-UNK
treatment	B-UNK
produced	B-UNK
a	O
biphasic	O
effect	B-UNK
on	O
mouse	B-UNK
motility	B-UNK
.	O
The	O
initial	B-UNK
dose	B-UNK
of	O
amantadine	B-UNK
depressed	B-UNK
locomotor	B-UNK
activity	I-UNK
in	O
all	O
mouse	B-UNK
strains	B-UNK
studied	O
with	O
the	O
BALB	B-UNK
/	O
C	O
mice	B-UNK
being	O
the	O
most	O
sensitive	B-UNK
.	O
Subsequent	B-UNK
amantadine	B-UNK
treatments	O
produced	B-UNK
enhancement	B-UNK
of	O
motility	B-UNK
from	O
corresponding	O
control	B-UNK
in	O
all	O
mouse	B-UNK
strains	B-UNK
with	O
the	O
BALB	B-UNK
/	O
C	O
mice	B-UNK
being	O
the	O
least	O
sensitive	B-UNK
.	O
The	O
locomotor	B-UNK
activity	I-UNK
was	O
decreased	B-UNK
from	O
corresponding	O
controls	B-UNK
in	O
all	O
strains	B-UNK
studied	O
,	O
except	O
for	O
the	O
ICR	O
mice	B-UNK
,	O
during	O
an	O
overnight	O
drug	B-UNK
-	O
free	B-UNK
period	B-UNK
following	O
the	O
fourth	B-UNK
amantadine	B-UNK
treatment	B-UNK
.	O
Readministration	O
of	O
amantadine	B-UNK
,	O
after	O
a	O
drug	B-UNK
-	O
free	B-UNK
overnight	O
period	B-UNK
,	O
increased	B-UNK
motility	B-UNK
from	O
respective	O
saline	B-UNK
control	B-UNK
in	O
all	O
strains	B-UNK
with	O
exception	O
of	O
the	O
BALB	B-UNK
/	O
C	O
mice	B-UNK
where	O
suppression	B-UNK
of	O
motility	B-UNK
occurred	B-UNK
.	O
Treatment	B-UNK
with	O
amantadine	B-UNK
did	O
not	O
alter	O
whole	O
brain	B-UNK
dopamine	B-CHEMICAL
levels	O
but	O
decreased	B-UNK
the	O
amounts	B-UNK
of	O
3,4-dihydroxyphenylacetic	B-CHEMICAL
acid	I-CHEMICAL
in	O
the	O
BALB	B-UNK
/	O
C	O
mice	B-UNK
compared	O
to	O
saline	B-UNK
control	B-UNK
.	O
Conversely	O
,	O
brain	B-UNK
normetanephrine	O
concentration	B-UNK
was	O
increased	B-UNK
from	O
saline	B-UNK
control	B-UNK
by	O
amantadine	B-UNK
in	O
the	O
BALB	B-UNK
/	O
C	O
mice	B-UNK
.	O
The	O
results	B-UNK
suggest	B-UNK
a	O
strain	B-UNK
-	O
dependent	B-UNK
effect	B-UNK
of	O
amantadine	B-UNK
on	O
motility	B-UNK
and	O
indicate	O
a	O
differential	B-UNK
response	B-UNK
to	O
the	O
acute	B-UNK
and	O
multiple	B-UNK
dose	B-UNK
regimens	B-UNK
used	O
.	O
The	O
BALB	B-UNK
/	O
C	O
mouse	B-UNK
was	O
the	O
most	O
sensitive	B-UNK
strain	B-UNK
and	O
could	O
serve	O
as	O
the	O
strain	B-UNK
of	O
choice	B-UNK
for	O
evaluating	O
the	O
side	O
effects	O
of	O
amantadine	B-UNK
.	O
The	O
biochemical	B-UNK
results	B-UNK
of	O
brain	B-UNK
biogenic	B-CHEMICAL
amines	I-CHEMICAL
of	O
BALB	B-UNK
/	O
C	O
mouse	B-UNK
strain	B-UNK
suggest	B-UNK
a	O
probable	O
decrease	B-UNK
of	O
catecholamine	B-UNK
turnover	B-UNK
rate	B-UNK
and	O
/	O
or	O
metabolism	B-UNK
by	O
monoamine	O
oxidase	B-UNK
and	O
a	O
resulting	B-UNK
increase	B-UNK
in	O
O	O
-	O
methylation	O
of	O
norepinephrine	B-UNK
which	O
may	O
account	O
for	O
a	O
behavioral	B-DISEASE
depression	I-DISEASE
caused	B-UNK
by	O
amantadine	B-UNK
in	O
the	O
BALB	B-UNK
/	O
C	O
mice	B-UNK
.	O

No	O
enhancement	B-UNK
by	O
phenobarbital	B-UNK
of	O
the	O
hepatocarcinogenicity	O
of	O
a	O
choline	B-UNK
-	O
devoid	O
diet	B-UNK
in	O
the	O
rat	B-UNK
.	O
An	O
experiment	B-UNK
was	O
performed	B-UNK
to	O
test	B-UNK
whether	O
inclusion	O
of	O
phenobarbital	B-UNK
in	O
a	O
choline	B-CHEMICAL
-	O
devoid	O
diet	B-UNK
would	O
increase	B-UNK
the	O
hepatocarcinogenicity	O
of	O
the	O
diet	B-UNK
.	O
Groups	B-UNK
of	O
5-week	O
old	O
male	B-UNK
Fischer-344	O
rats	B-UNK
were	O
fed	B-UNK
for	O
7	O
-	O
25	O
months	B-UNK
semipurified	O
choline	B-CHEMICAL
-	O
devoid	O
or	O
choline	B-CHEMICAL
-	O
supplemented	O
diets	O
,	O
containing	O
or	O
not	O
0.06	O
%	O
phenobarbital	B-CHEMICAL
.	O
No	O
hepatic	B-UNK
preneoplastic	O
nodules	O
or	O
hepatocellular	B-UNK
carcinomas	O
developed	O
in	O
rats	B-UNK
fed	B-UNK
the	O
plain	O
choline	B-UNK
-	O
supplemented	O
diet	B-UNK
,	O
while	O
one	O
preneoplastic	O
nodule	O
and	O
one	O
hepatocellular	B-UNK
carcinoma	B-DISEASE
developed	O
in	O
two	O
rats	B-UNK
fed	B-UNK
the	O
same	O
diet	B-UNK
containing	O
phenobarbital	B-CHEMICAL
.	O
The	O
incidence	B-UNK
of	O
preneoplastic	O
nodules	O
and	O
of	O
hepatocellular	B-UNK
carcinomas	O
was	O
10	O
%	O
and	O
37	O
%	O
,	O
respectively	O
,	O
in	O
rats	B-UNK
fed	B-UNK
the	O
plain	O
choline	B-UNK
-	O
devoid	O
diet	B-UNK
,	O
and	O
17	O
%	O
and	O
30	O
%	O
,	O
in	O
rats	B-UNK
fed	B-UNK
the	O
phenobarbital	B-CHEMICAL
-	O
containing	O
choline	B-UNK
-	O
devoid	O
diet	B-UNK
.	O
The	O
results	B-UNK
evinced	O
no	O
enhancement	B-UNK
of	O
the	O
hepatocarcinogenicity	O
of	O
the	O
choline	B-UNK
-	O
devoid	O
diet	B-UNK
by	O
phenobarbital	B-CHEMICAL
.	O
Sporadic	O
neoplastic	O
lesions	B-UNK
were	O
observed	O
in	O
organs	O
other	O
than	O
the	O
liver	B-UNK
of	O
some	O
of	O
the	O
animals	B-UNK
,	O
irrespective	O
of	O
the	O
diet	B-UNK
fed	B-UNK
.	O

Effect	B-UNK
of	O
direct	B-UNK
intracoronary	B-UNK
administration	O
of	O
methylergonovine	O
in	O
patients	B-UNK
with	O
and	O
without	O
variant	B-DISEASE
angina	I-DISEASE
.	O
The	O
effects	O
of	O
intracoronary	B-UNK
administration	O
of	O
methylergonovine	O
were	O
studied	O
in	O
21	O
patients	B-UNK
with	O
variant	B-DISEASE
angina	I-DISEASE
and	O
22	O
patients	B-UNK
with	O
atypical	B-UNK
chest	B-DISEASE
pain	I-DISEASE
and	O
in	O
others	O
without	O
angina	B-DISEASE
pectoris	I-DISEASE
(	O
control	B-UNK
group	B-UNK
)	O
.	O
Methylergonovine	O
was	O
administered	O
continuously	B-UNK
at	O
a	O
rate	B-UNK
of	O
10	O
micrograms	B-UNK
/	O
min	B-UNK
up	O
to	O
50	O
micrograms	B-UNK
.	O
In	O
all	O
patients	B-UNK
with	O
variant	B-DISEASE
angina	I-DISEASE
,	O
coronary	B-DISEASE
spasm	I-DISEASE
was	O
provoked	O
at	O
a	O
mean	O
dose	B-UNK
of	O
28	O
+	O
/-	O
13	O
micrograms	B-UNK
(	O
mean	O
+	O
/-	O
SD	B-UNK
)	O
.	O
In	O
the	O
control	B-UNK
group	B-UNK
neither	O
ischemic	B-UNK
ST	B-UNK
change	B-UNK
nor	O
localized	B-UNK
spasm	B-UNK
occurred	B-UNK
.	O
The	O
basal	B-UNK
tone	B-UNK
of	O
the	O
right	O
coronary	B-UNK
artery	I-UNK
was	O
significantly	B-UNK
lower	I-UNK
than	O
that	O
of	O
the	O
left	B-UNK
coronary	B-UNK
artery	I-UNK
.	O
The	O
percentage	B-UNK
of	O
vasoconstriction	B-UNK
of	O
the	O
right	O
coronary	B-UNK
artery	I-UNK
was	O
significantly	B-UNK
higher	I-UNK
than	O
that	O
of	O
the	O
left	B-UNK
coronary	B-UNK
artery	I-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
spasm	B-UNK
provocation	O
tests	B-UNK
,	O
which	O
use	O
an	O
intracoronary	B-UNK
injection	B-UNK
of	O
a	O
relatively	O
low	B-UNK
dose	I-UNK
of	O
methylergonovine	O
,	O
have	O
a	O
high	B-UNK
sensitivity	B-UNK
in	O
variant	B-DISEASE
angina	I-DISEASE
and	O
the	O
vasoreactivity	O
of	O
the	O
right	O
coronary	B-UNK
artery	I-UNK
may	O
be	O
greater	B-UNK
than	O
that	O
of	O
the	O
other	O
coronary	B-UNK
arteries	B-UNK
.	O

Dobutamine	B-UNK
stress	I-UNK
echocardiography	B-UNK
:	O
a	O
sensitive	B-UNK
indicator	O
of	O
diminished	B-UNK
myocardial	B-UNK
function	B-UNK
in	O
asymptomatic	O
doxorubicin	B-CHEMICAL
-	O
treated	O
long	B-UNK
-	O
term	O
survivors	B-UNK
of	O
childhood	O
cancer	B-UNK
.	O
Doxorubicin	B-CHEMICAL
is	O
an	O
effective	B-UNK
anticancer	O
chemotherapeutic	B-UNK
agent	B-UNK
known	O
to	O
cause	O
acute	B-UNK
and	O
chronic	B-UNK
cardiomyopathy	B-UNK
.	O
To	O
develop	B-UNK
a	O
more	O
sensitive	B-UNK
echocardiographic	B-UNK
screening	B-UNK
test	B-UNK
for	O
cardiac	B-DISEASE
damage	I-DISEASE
due	O
to	O
doxorubicin	B-CHEMICAL
,	O
a	O
cohort	B-UNK
study	B-UNK
was	O
performed	B-UNK
using	O
dobutamine	B-CHEMICAL
infusion	B-UNK
to	O
differentiate	O
asymptomatic	O
long	B-UNK
-	O
term	O
survivors	B-UNK
of	O
childhood	O
cancer	B-UNK
treated	O
with	O
doxorubicin	B-UNK
from	O
healthy	B-UNK
control	B-UNK
subjects	I-UNK
.	O
Echocardiographic	B-UNK
data	B-UNK
from	O
the	O
experimental	B-UNK
group	B-UNK
of	O
21	O
patients	B-UNK
(	O
mean	O
age	B-UNK
16	O
+	O
/-	O
5	O
years	B-UNK
)	O
treated	O
from	O
1.6	O
to	O
14.3	O
years	B-UNK
(	O
median	B-UNK
5.3	O
)	O
before	O
this	O
study	B-UNK
with	O
27	O
to	O
532	O
mg	B-UNK
/	O
m2	B-UNK
of	O
doxorubicin	B-UNK
(	O
mean	O
196	O
)	O
were	O
compared	O
with	O
echocardiographic	B-UNK
data	B-UNK
from	O
12	O
normal	O
age	B-UNK
-	O
matched	O
control	B-UNK
subjects	I-UNK
.	O
Graded	O
dobutamine	B-CHEMICAL
infusions	B-UNK
of	O
0.5	O
,	O
2.5	O
,	O
5	O
and	O
10	O
micrograms	B-UNK
/	O
kg	B-UNK
per	O
min	B-UNK
were	O
administered	O
.	O
Echocardiographic	B-UNK
Doppler	O
studies	B-UNK
were	O
performed	B-UNK
before	O
infusion	B-UNK
and	O
after	O
15	O
min	B-UNK
of	O
infusion	B-UNK
at	O
each	O
rate	B-UNK
.	O
Dobutamine	B-CHEMICAL
infusion	B-UNK
at	O
10	O
micrograms	B-UNK
/	O
kg	B-UNK
per	O
min	B-UNK
was	O
discontinued	O
after	O
six	O
studies	B-UNK
secondary	B-UNK
to	O
a	O
50	O
%	O
incidence	B-UNK
rate	B-UNK
of	O
adverse	B-UNK
symptoms	B-UNK
.	O
The	O
most	O
important	B-UNK
findings	B-UNK
were	O
that	O
compared	O
with	O
values	O
in	O
control	B-UNK
subjects	I-UNK
,	O
end	B-UNK
-	O
systolic	B-UNK
left	B-UNK
ventricular	I-UNK
posterior	B-UNK
wall	B-UNK
dimension	O
and	O
percent	B-UNK
of	O
left	B-UNK
ventricular	I-UNK
posterior	B-UNK
wall	B-UNK
thickening	O
in	O
doxorubicin	B-UNK
-	O
treated	O
patients	B-UNK
were	O
decreased	B-UNK
at	O
baseline	B-UNK
study	B-UNK
and	O
these	O
findings	B-UNK
were	O
more	O
clearly	O
delineated	O
with	O
dobutamine	B-UNK
stimulation	B-UNK
.	O
End	B-UNK
-	O
systolic	B-UNK
left	B-UNK
ventricular	I-UNK
posterior	B-UNK
wall	B-UNK
dimension	O
at	O
baseline	B-UNK
for	O
the	O
doxorubicin	B-CHEMICAL
-	O
treated	O
group	B-UNK
was	O
11	O
+	O
/-	O
1.9	O
mm	B-UNK
versus	O
13.1	O
+	O
/-	O
1.5	O
mm	B-UNK
for	O
control	B-UNK
subjects	I-UNK
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O
End	B-UNK
-	O
systolic	B-UNK
left	B-UNK
ventricular	I-UNK
posterior	B-UNK
wall	B-UNK
dimension	O
at	O
the	O
5-micrograms	O
/	O
kg	B-UNK
per	O
min	B-UNK
dobutamine	B-UNK
infusion	B-UNK
for	O
the	O
doxorubicin	B-CHEMICAL
-	O
treated	O
group	B-UNK
was	O
14.1	O
+	O
/-	O
2.4	O
mm	B-UNK
versus	O
19.3	O
+	O
/-	O
2.6	O
mm	B-UNK
for	O
control	B-UNK
subjects	I-UNK
(	O
p	O
less	O
than	O
0.01).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	B-UNK
)	O

Effects	O
of	O
aminophylline	O
on	O
the	O
threshold	B-UNK
for	O
initiating	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
during	O
respiratory	B-UNK
failure	I-UNK
.	O
Cardiac	B-DISEASE
arrhythmias	I-DISEASE
have	O
frequently	B-UNK
been	O
reported	B-UNK
in	O
association	B-UNK
with	O
respiratory	B-DISEASE
failure	I-DISEASE
.	O
The	O
possible	O
additive	O
role	O
of	O
pharmacologic	O
agents	B-UNK
in	O
precipitating	O
cardiac	B-DISEASE
disturbances	I-DISEASE
in	O
patients	B-UNK
with	O
respiratory	B-UNK
failure	I-UNK
has	O
only	O
recently	B-UNK
been	O
emphasized	O
.	O
The	O
effects	O
of	O
aminophylline	O
on	O
the	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
threshold	B-UNK
during	O
normal	O
acid	B-UNK
-	O
base	B-UNK
conditions	O
and	O
during	O
respiratory	B-UNK
failure	I-UNK
were	O
studied	O
in	O
anesthetized	B-UNK
open	B-UNK
chest	B-UNK
dogs	B-UNK
.	O
The	O
ventricular	B-UNK
fibrillation	I-UNK
threshold	B-UNK
was	O
measured	B-UNK
by	O
passing	O
a	O
gated	O
train	O
of	O
12	O
constant	O
current	B-UNK
pulses	O
through	O
the	O
ventricular	B-UNK
myocardium	B-UNK
during	O
the	O
vulnerable	O
period	B-UNK
of	O
the	O
cardiac	B-UNK
cycle	B-UNK
.	O
During	O
the	O
infusion	B-UNK
of	O
aminophylline	O
,	O
the	O
ventricular	B-UNK
fibrillation	I-UNK
threshold	B-UNK
was	O
reduced	B-UNK
by	O
30	O
to	O
40	O
percent	B-UNK
of	O
the	O
control	B-UNK
when	O
pH	B-UNK
and	O
partial	B-UNK
pressures	B-UNK
of	O
oxygen	B-CHEMICAL
(	O
PO2	O
)	O
and	O
carbon	B-CHEMICAL
dioxide	I-CHEMICAL
(	O
CO2	B-CHEMICAL
)	O
were	O
kept	O
within	O
normal	O
limits	O
.	O
When	O
respiratory	B-UNK
failure	I-UNK
was	O
produced	B-UNK
by	O
hypoventilation	B-DISEASE
(	O
pH	B-UNK
7.05	O
to	O
7.25	O
;	O
PC02	O
70	O
to	O
100	O
mm	B-UNK
Hg	I-UNK
:	O
P02	O
20	O
to	O
40	O
mm	B-UNK
Hg	I-UNK
)	O
,	O
infusion	B-UNK
of	O
aminophylline	O
resulted	B-UNK
in	O
an	O
even	O
greater	B-UNK
decrease	B-UNK
in	O
ventricular	B-UNK
fibrillation	I-UNK
threshold	B-UNK
to	O
60	O
percent	B-UNK
of	O
the	O
control	B-UNK
level	B-UNK
.	O
These	O
experiments	B-UNK
suggest	B-UNK
that	O
although	O
many	O
factors	B-UNK
may	O
contribute	B-UNK
to	O
the	O
increased	B-UNK
incidence	B-UNK
of	O
ventricular	B-UNK
arrhythmias	I-UNK
in	O
respiratory	B-UNK
failure	I-UNK
,	O
pharmacologic	O
agents	B-UNK
,	O
particularly	O
aminophylline	O
,	O
may	O
play	O
a	O
significant	B-UNK
role	O
.	O

Case	B-UNK
report	I-UNK
:	O
acute	B-UNK
unintentional	O
carbachol	B-UNK
intoxication	B-UNK
.	O
INTRODUCTION	B-UNK
:	O
Intoxications	O
with	O
carbachol	B-UNK
,	O
a	O
muscarinic	B-UNK
cholinergic	B-UNK
receptor	B-UNK
agonist	I-UNK
are	O
rare	B-UNK
.	O
We	O
report	B-UNK
an	O
interesting	O
case	B-UNK
investigating	O
a	O
(	O
near	O
)	O
fatal	B-UNK
poisoning	B-UNK
.	O
METHODS	B-UNK
:	O
The	O
son	O
of	O
an	O
84-year	O
-	O
old	O
male	B-UNK
discovered	O
a	O
newspaper	O
report	B-UNK
stating	O
clinical	B-UNK
success	B-UNK
with	O
plant	O
extracts	O
in	O
Alzheimer'	B-UNK
s	I-UNK
disease	I-UNK
.	O
The	O
mode	O
of	O
action	B-UNK
was	O
said	O
to	O
be	O
comparable	O
to	O
that	O
of	O
the	O
synthetic	O
compound	B-UNK
'	O
carbamylcholin	O
'	O
;	O
that	O
is	O
,	O
carbachol	B-UNK
.	O
He	O
bought	O
25	O
g	O
of	O
carbachol	B-UNK
as	O
pure	O
substance	B-UNK
in	O
a	O
pharmacy	O
,	O
and	O
the	O
father	O
was	O
administered	O
400	O
to	O
500	O
mg	B-UNK
.	O
Carbachol	B-UNK
concentrations	B-UNK
in	O
serum	B-UNK
and	O
urine	B-UNK
on	O
day	O
1	O
and	O
2	O
of	O
hospital	B-UNK
admission	B-UNK
were	O
analysed	B-UNK
by	O
HPLC	O
-	O
mass	B-UNK
spectrometry	O
.	O
RESULTS	B-UNK
:	O
Minutes	B-UNK
after	O
oral	B-UNK
administration	O
,	O
the	O
patient	B-UNK
developed	O
nausea	B-UNK
,	O
sweating	O
and	O
hypotension	B-DISEASE
,	O
and	O
finally	B-UNK
collapsed	O
.	O
Bradycardia	B-UNK
,	O
cholinergic	B-UNK
symptoms	B-UNK
and	O
asystole	B-UNK
occurred	B-UNK
.	O
Initial	B-UNK
cardiopulmonary	B-UNK
resuscitation	B-UNK
and	O
immediate	O
treatment	B-UNK
with	O
adrenaline	B-UNK
(	O
epinephrine	B-UNK
)	O
,	O
atropine	B-UNK
and	O
furosemide	B-UNK
was	O
successful	O
.	O
On	O
hospital	B-UNK
admission	B-UNK
,	O
blood	B-UNK
pressure	I-UNK
of	O
the	O
intubated	O
,	O
bradyarrhythmic	O
patient	B-UNK
was	O
100/65	O
mmHg	B-UNK
.	O
Further	O
signs	B-UNK
were	O
hyperhidrosis	B-DISEASE
,	O
hypersalivation	O
,	O
bronchorrhoea	B-DISEASE
,	O
and	O
severe	B-UNK
miosis	B-DISEASE
;	O
the	O
electrocardiographic	B-UNK
finding	O
was	O
atrio	B-DISEASE
-	I-DISEASE
ventricular	I-DISEASE
dissociation	I-DISEASE
.	O
High	B-UNK
doses	I-UNK
of	O
atropine	B-UNK
(	O
up	O
to	O
50	O
mg	B-UNK
per	O
24	O
hours	B-UNK
)	O
,	O
adrenaline	B-UNK
and	O
dopamine	B-UNK
were	O
necessary	O
.	O
The	O
patient	B-UNK
was	O
extubated	O
1	O
week	B-UNK
later	O
.	O
However	O
,	O
increased	B-UNK
dyspnoea	B-DISEASE
and	O
bronchospasm	B-DISEASE
necessitated	O
reintubation	O
.	O
Respiratory	B-DISEASE
insufficiency	I-DISEASE
was	O
further	O
worsened	O
by	O
Proteus	B-DISEASE
mirabilis	I-DISEASE
infection	I-DISEASE
and	O
severe	B-UNK
bronchoconstriction	O
.	O
One	O
week	B-UNK
later	O
,	O
the	O
patient	B-UNK
was	O
again	O
extubated	O
and	O
3	O
days	B-UNK
later	O
was	O
transferred	O
to	O
a	O
peripheral	B-UNK
ward	O
.	O
On	O
the	O
next	O
day	O
he	O
died	O
,	O
probably	O
as	O
a	O
result	B-UNK
of	O
heart	B-UNK
failure	I-UNK
.	O
Serum	B-UNK
samples	O
from	O
the	O
first	O
and	O
second	O
days	B-UNK
contained	B-UNK
3.6	O
and	O
1.9	O
mg	B-UNK
/	O
l	O
carbachol	B-UNK
,	O
respectively	O
.	O
The	O
corresponding	O
urine	B-UNK
concentrations	B-UNK
amounted	O
to	O
374	O
and	O
554	O
mg	B-UNK
/	O
l.	O
CONCLUSION	B-UNK
:	O
This	O
case	B-UNK
started	O
with	O
a	O
media	B-UNK
report	B-UNK
in	O
a	O
popular	O
newspaper	O
,	O
initiated	O
by	O
published	B-UNK
,	O
peer	O
-	O
reviewed	B-UNK
research	B-UNK
on	O
herbals	O
,	O
and	O
involved	B-UNK
human	B-UNK
failure	B-UNK
in	O
a	O
case	B-UNK
history	B-UNK
,	O
medical	B-UNK
examination	B-UNK
and	O
clinical	B-UNK
treatment	B-UNK
.	O
For	O
the	O
first	O
time	O
,	O
an	O
analytical	O
method	B-UNK
for	O
the	O
determination	B-UNK
of	O
carbachol	B-UNK
in	O
plasma	B-UNK
and	O
urine	B-UNK
has	O
been	O
developed	O
.	O
The	O
analysed	B-UNK
carbachol	B-UNK
concentration	B-UNK
exceeded	O
the	O
supposed	O
serum	B-UNK
level	B-UNK
resulting	B-UNK
from	O
a	O
therapeutic	B-UNK
dose	B-UNK
by	O
a	O
factor	B-UNK
of	O
130	O
to	O
260	O
.	O
Especially	O
in	O
old	O
patients	B-UNK
,	O
intensivists	O
should	O
consider	O
intoxications	O
(	O
with	O
cholinergics	B-CHEMICAL
)	O
as	O
a	O
cause	O
of	O
acute	B-DISEASE
cardiovascular	I-DISEASE
failure	I-DISEASE
.	O

Crossover	B-UNK
comparison	B-UNK
of	O
efficacy	B-UNK
and	O
preference	B-UNK
for	O
rizatriptan	B-CHEMICAL
10	O
mg	B-UNK
versus	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
in	O
migraine	B-UNK
.	O
Rizatriptan	B-CHEMICAL
is	O
a	O
selective	B-UNK
5-HT(1B/1D	O
)	O
receptor	B-UNK
agonist	I-UNK
with	O
rapid	B-UNK
oral	B-UNK
absorption	O
and	O
early	B-UNK
onset	B-UNK
of	O
action	B-UNK
in	O
the	O
acute	B-UNK
treatment	B-UNK
of	O
migraine	B-UNK
.	O
This	O
randomized	B-UNK
double-	O
blind	B-UNK
crossover	B-UNK
outpatient	O
study	B-UNK
assessed	B-UNK
the	O
preference	B-UNK
for	O
1	O
rizatriptan	B-UNK
10	O
mg	B-UNK
tablet	O
to	O
2	O
ergotamine	B-CHEMICAL
1	O
mg	B-UNK
/	O
caffeine	B-UNK
100	O
mg	B-UNK
tablets	B-UNK
in	O
439	O
patients	B-UNK
treating	O
a	O
single	B-UNK
migraine	B-UNK
attack	I-UNK
with	O
each	O
therapy	O
.	O
Of	O
patients	B-UNK
expressing	O
a	O
preference	B-UNK
(	O
89.1	O
%	O
)	O
,	O
more	O
than	O
twice	O
as	O
many	O
preferred	O
rizatriptan	B-UNK
to	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
(	O
69.9	O
vs	O
.	O
30.1	O
%	O
,	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O
Faster	O
relief	O
of	O
headache	B-DISEASE
was	O
the	O
most	O
important	B-UNK
reason	O
for	O
preference	B-UNK
,	O
cited	O
by	O
67.3	O
%	O
of	O
patients	B-UNK
preferring	O
rizatriptan	B-UNK
and	O
54.2	O
%	O
of	O
patients	B-UNK
who	O
preferred	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-UNK
.	O
The	O
co-primary	O
endpoint	O
of	O
being	O
pain	B-UNK
free	B-UNK
at	O
2	O
h	O
was	O
also	O
in	O
favor	O
of	O
rizatriptan	B-UNK
.	O
Forty	O
-	O
nine	O
percent	B-UNK
of	O
patients	B-UNK
were	O
pain	B-UNK
free	B-UNK
2	O
h	O
after	O
rizatriptan	B-CHEMICAL
,	O
compared	O
with	O
24.3	O
%	O
treated	O
with	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-UNK
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
,	O
rizatriptan	B-CHEMICAL
being	O
superior	B-UNK
within	O
1	O
h	O
of	O
treatment	B-UNK
.	O
Headache	B-UNK
relief	O
at	O
2	O
h	O
was	O
75.9	O
%	O
for	O
rizatriptan	B-UNK
and	O
47.3	O
%	O
for	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-UNK
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
,	O
with	O
rizatriptan	B-CHEMICAL
being	O
superior	B-UNK
to	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-UNK
within	O
30	O
min	B-UNK
of	O
dosing	O
.	O
Almost	O
36	O
%	O
of	O
patients	B-UNK
taking	B-UNK
rizatriptan	B-CHEMICAL
were	O
pain	B-UNK
free	B-UNK
at	O
2	O
h	O
and	O
had	O
no	O
recurrence	B-DISEASE
or	O
need	O
for	O
additional	B-UNK
medication	O
within	O
24	O
h	O
,	O
compared	O
to	O
20	O
%	O
of	O
patients	B-UNK
on	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O
Rizatriptan	B-CHEMICAL
was	O
also	O
superior	B-UNK
to	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
in	O
the	O
proportions	O
of	O
patients	B-UNK
with	O
no	O
nausea	B-UNK
,	O
vomiting	B-UNK
,	O
phonophobia	O
or	O
photophobia	B-DISEASE
and	O
for	O
patients	B-UNK
with	O
normal	O
function	B-UNK
2	O
h	O
after	O
drug	B-UNK
intake	B-UNK
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O
More	O
patients	B-UNK
were	O
(	O
completely	O
,	O
very	O
or	O
somewhat	O
)	O
satisfied	O
2	O
h	O
after	O
treatment	B-UNK
with	O
rizatriptan	B-UNK
(	O
69.8	O
%	O
)	O
than	O
at	O
2	O
h	O
after	O
treatment	B-UNK
with	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
(	O
38.6	O
%	O
,	O
p	O
<	O
or	O
=	O
0.001	O
)	O
.	O
Recurrence	B-DISEASE
rates	B-UNK
were	O
31.4	O
%	O
with	O
rizatriptan	B-CHEMICAL
and	O
15.3	O
%	O
with	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
.	O
Both	O
active	B-UNK
treatments	O
were	O
well	O
tolerated	B-UNK
.	O
The	O
most	O
common	B-UNK
adverse	B-UNK
events	I-UNK
(	O
incidence	B-UNK
>	O
or	O
=	O
5	O
%	O
in	O
one	O
group	B-UNK
)	O
after	O
rizatriptan	B-CHEMICAL
and	O
ergotamine	B-CHEMICAL
/	O
caffeine	B-CHEMICAL
,	O
respectively	O
,	O
were	O
dizziness	B-UNK
(	O
6.7	O
and	O
5.3	O
%	O
)	O
,	O
nausea	B-UNK
(	O
4.2	O
and	O
8.5	O
%	O
)	O
and	O
somnolence	B-DISEASE
(	O
5.5	O
and	O
2.3	O
%	O
)	O
.	O

Thrombotic	B-UNK
microangiopathy	I-UNK
and	O
renal	B-UNK
failure	I-UNK
associated	O
with	O
antineoplastic	B-UNK
chemotherapy	O
.	O
Five	O
patients	B-UNK
with	O
carcinoma	B-UNK
developed	O
thrombotic	B-DISEASE
microangiopathy	I-DISEASE
(	O
characterized	B-UNK
by	O
renal	B-UNK
insufficiency	I-UNK
,	O
microangiopathic	O
hemolytic	B-UNK
anemia	I-UNK
,	O
and	O
usually	O
thrombocytopenia	B-DISEASE
)	O
after	O
treatment	B-UNK
with	O
cisplatin	B-CHEMICAL
,	O
bleomycin	O
,	O
and	O
a	O
vinca	O
alkaloid	O
.	O
One	O
patient	B-UNK
had	O
thrombotic	B-UNK
thrombocytopenic	O
purpura	B-DISEASE
,	O
three	O
the	O
hemolytic	B-DISEASE
-	I-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
,	O
and	O
one	O
an	O
apparent	B-UNK
forme	O
fruste	O
of	O
one	O
of	O
these	O
disorders	B-UNK
.	O
Histologic	B-UNK
examination	B-UNK
of	O
the	O
renal	B-UNK
tissue	B-UNK
showed	O
evidence	B-UNK
of	O
intravascular	B-UNK
coagulation	B-UNK
,	O
primarily	O
affecting	O
the	O
small	B-UNK
arteries	B-UNK
,	O
arterioles	O
,	O
and	O
glomeruli	B-UNK
.	O
Because	O
each	O
patient	B-UNK
was	O
tumor	B-UNK
-	O
free	B-UNK
or	O
had	O
only	O
a	O
small	B-UNK
tumor	B-DISEASE
at	O
the	O
onset	B-UNK
of	O
this	O
syndrome	B-UNK
,	O
the	O
thrombotic	B-UNK
microangiopathy	I-UNK
may	O
have	O
been	O
induced	O
by	O
chemotherapy	O
.	O
Diagnosis	B-UNK
of	O
this	O
potentially	O
fatal	B-UNK
complication	B-UNK
may	O
be	O
delayed	B-UNK
or	O
missed	O
if	O
renal	B-UNK
tissue	B-UNK
or	O
the	O
peripheral	B-UNK
blood	I-UNK
smear	O
is	O
not	O
examined	B-UNK
,	O
because	O
renal	B-UNK
failure	I-UNK
may	O
be	O
ascribed	O
to	O
cisplatin	B-UNK
nephrotoxicity	B-DISEASE
and	O
the	O
anemia	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
to	O
drug	B-UNK
-	O
induced	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
.	O

Salvage	B-UNK
therapy	O
with	O
nelarabine	B-CHEMICAL
,	O
etoposide	B-UNK
,	O
and	O
cyclophosphamide	B-UNK
in	O
relapsed	B-UNK
/	O
refractory	B-UNK
paediatric	O
T	O
-	O
cell	B-UNK
lymphoblastic	B-UNK
leukaemia	O
and	O
lymphoma	B-DISEASE
.	O
A	O
combination	B-UNK
of	O
5	O
d	O
of	O
nelarabine	B-CHEMICAL
(	O
AraG	B-CHEMICAL
)	O
with	O
5	O
d	O
of	O
etoposide	B-UNK
(	O
VP	O
)	O
and	O
cyclophosphamide	B-UNK
(	O
CPM	O
)	O
and	O
prophylactic	B-UNK
intrathecal	B-UNK
chemotherapy	O
was	O
used	O
as	O
salvage	B-UNK
therapy	O
in	O
seven	O
children	B-UNK
with	O
refractory	B-UNK
or	O
relapsed	B-UNK
T	O
-	O
cell	B-UNK
leukaemia	O
or	O
lymphoma	B-DISEASE
.	O
The	O
most	O
common	B-UNK
side	O
effects	O
attributable	B-UNK
to	O
the	O
AraG	B-CHEMICAL
included	B-UNK
Grade	B-UNK
2	O
and	O
3	O
sensory	O
and	O
motor	B-UNK
neuropathy	B-UNK
and	O
musculoskeletal	B-DISEASE
pain	I-DISEASE
.	O
Haematological	B-UNK
toxicity	B-UNK
was	O
greater	B-UNK
for	O
the	O
combination	B-UNK
than	O
AraG	B-CHEMICAL
alone	O
,	O
although	O
median	B-UNK
time	O
to	O
neutrophil	B-UNK
and	O
platelet	B-UNK
recovery	B-UNK
was	O
consistent	B-UNK
with	O
other	O
salvage	B-UNK
therapies	B-UNK
.	O
All	O
patients	B-UNK
had	O
some	O
response	B-UNK
to	O
the	O
combined	B-UNK
therapy	O
and	O
five	O
of	O
the	O
seven	O
went	O
into	O
complete	B-UNK
remission	I-UNK
after	O
one	O
or	O
two	O
courses	B-UNK
of	O
AraG	B-CHEMICAL
/	O
VP	O
/	O
CPM	O
.	O
Our	O
experience	B-UNK
supports	O
the	O
safety	B-UNK
of	O
giving	O
AraG	B-CHEMICAL
as	O
salvage	B-UNK
therapy	O
in	O
synchrony	O
with	O
etoposide	B-UNK
and	O
cyclophosphamide	B-CHEMICAL
,	O
although	O
neurological	B-UNK
toxicity	B-DISEASE
must	O
be	O
closely	O
monitored	O
.	O

The	O
3-week	O
sulphasalazine	B-CHEMICAL
syndrome	B-UNK
strikes	O
again	O
.	O
A	O
34-year	O
-	O
old	O
lady	O
developed	O
a	O
constellation	O
of	O
dermatitis	B-UNK
,	O
fever	B-UNK
,	O
lymphadenopathy	B-DISEASE
and	O
hepatitis	B-UNK
,	O
beginning	B-UNK
on	O
the	O
17th	O
day	O
of	O
a	O
course	O
of	O
oral	B-UNK
sulphasalazine	B-CHEMICAL
for	O
sero	O
-	O
negative	B-UNK
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O
Cervical	O
and	O
inguinal	O
lymph	O
node	B-UNK
biopsies	B-UNK
showed	O
the	O
features	B-UNK
of	O
severe	B-UNK
necrotising	O
lymphadenitis	B-DISEASE
,	O
associated	O
with	O
erythrophagocytosis	O
and	O
prominent	B-UNK
eosinophilic	B-DISEASE
infiltrates	O
,	O
without	O
viral	B-UNK
inclusion	O
bodies	O
,	O
suggestive	B-UNK
of	O
an	O
adverse	B-UNK
drug	I-UNK
reaction	I-UNK
.	O
A	O
week	B-UNK
later	O
,	O
fulminant	B-UNK
drug	B-DISEASE
-	I-DISEASE
induced	I-DISEASE
hepatitis	I-DISEASE
,	O
associated	O
with	O
the	O
presence	O
of	O
anti-nuclear	O
autoantibodies	O
(	O
but	O
not	O
with	O
other	O
markers	B-UNK
of	O
autoimmunity	B-DISEASE
)	O
,	O
and	O
accompanied	B-UNK
by	O
multi-organ	O
failure	B-UNK
and	O
sepsis	B-DISEASE
,	O
supervened	O
.	O
She	O
subsequently	B-UNK
died	O
some	O
5	O
weeks	B-UNK
after	O
the	O
commencement	O
of	O
her	O
drug	B-UNK
therapy	O
.	O
Post	B-UNK
-	O
mortem	O
examination	B-UNK
showed	O
evidence	B-UNK
of	O
massive	B-UNK
hepatocellular	B-UNK
necrosis	B-UNK
,	O
acute	B-UNK
hypersensitivity	B-UNK
myocarditis	B-DISEASE
,	O
focal	B-UNK
acute	B-UNK
tubulo	O
-	O
interstitial	B-UNK
nephritis	I-UNK
and	O
extensive	B-UNK
bone	B-DISEASE
marrow	I-DISEASE
necrosis	I-DISEASE
,	O
with	O
no	O
evidence	B-UNK
of	O
malignancy	B-DISEASE
.	O
It	O
is	O
thought	B-UNK
that	O
the	O
clinico	O
-	O
pathological	B-UNK
features	B-UNK
and	O
chronology	O
of	O
this	O
case	B-UNK
bore	O
the	O
hallmarks	O
of	O
the	O
so	O
-	O
called	O
"	O
3-week	O
sulphasalazine	B-UNK
syndrome	B-UNK
"	O
,	O
a	O
rare	B-UNK
,	O
but	O
often	O
fatal	B-UNK
,	O
immunoallergic	O
reaction	B-UNK
to	O
sulphasalazine	B-CHEMICAL
.	O

Bupropion	B-UNK
(	O
Zyban	O
)	O
toxicity	B-UNK
.	O
Bupropion	B-UNK
is	O
a	O
monocyclic	O
antidepressant	B-UNK
structurally	O
related	O
to	O
amphetamine	B-UNK
.	O
Zyban	O
,	O
a	O
sustained	B-UNK
-	O
release	B-UNK
formulation	O
of	O
bupropion	B-UNK
hydrochloride	B-UNK
,	O
was	O
recently	B-UNK
released	O
in	O
Ireland	O
,	O
as	O
a	O
smoking	B-UNK
cessation	B-UNK
aid	O
.	O
In	O
the	O
initial	B-UNK
6	O
months	B-UNK
since	O
it'	O
s	O
introduction	B-UNK
,	O
12	O
overdose	B-DISEASE
cases	B-UNK
have	O
been	O
reported	B-UNK
to	O
The	O
National	B-UNK
Poisons	O
Information	B-UNK
Centre	O
.	O
8	O
patients	B-UNK
developed	O
symptoms	B-UNK
of	O
toxicity	B-UNK
.	O
Common	B-UNK
features	B-UNK
included	B-UNK
tachycardia	B-UNK
,	O
drowsiness	B-UNK
,	O
hallucinations	B-DISEASE
and	O
convulsions	B-DISEASE
.	O
Two	O
patients	B-UNK
developed	O
severe	B-UNK
cardiac	B-UNK
arrhythmias	I-UNK
,	O
including	O
one	O
patient	B-UNK
who	O
was	O
resuscitated	O
following	O
a	O
cardiac	B-UNK
arrest	I-UNK
.	O
All	O
patients	B-UNK
recovered	O
without	O
sequelae	B-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
a	O
31	O
year	O
old	O
female	B-UNK
who	O
required	B-UNK
admission	B-UNK
to	O
the	O
Intensive	B-UNK
Care	I-UNK
Unit	I-UNK
for	O
ventilation	B-UNK
and	O
full	O
supportive	O
therapy	O
,	O
following	O
ingestion	B-UNK
of	O
13.5	O
g	O
bupropion	B-UNK
.	O
Recurrent	B-UNK
seizures	B-DISEASE
were	O
treated	O
with	O
diazepam	B-CHEMICAL
and	O
broad	O
complex	B-UNK
tachycardia	B-UNK
was	O
successfully	O
treated	O
with	O
adenosine	B-UNK
.	O
Zyban	O
caused	B-UNK
significant	B-UNK
neurological	B-UNK
and	O
cardiovascular	B-DISEASE
toxicity	I-DISEASE
in	O
overdose	B-UNK
.	O
The	O
potential	B-UNK
toxic	B-UNK
effects	I-UNK
should	O
be	O
considered	B-UNK
when	O
prescribing	B-UNK
it	O
as	O
a	O
smoking	B-CHEMICAL
cessation	B-UNK
aid	O
.	O

Survey	O
of	O
complications	B-DISEASE
of	O
indocyanine	O
green	B-UNK
angiography	B-UNK
in	O
Japan	O
.	O
PURPOSE	B-UNK
:	O
We	O
evaluated	B-UNK
the	O
safety	B-UNK
of	O
indocyanine	O
green	B-UNK
for	O
use	O
in	O
fundus	O
angiography	B-UNK
.	O
METHODS	B-UNK
:	O
We	O
sent	O
a	O
questionnaire	B-UNK
concerning	O
complications	B-DISEASE
of	O
indocyanine	O
green	B-UNK
to	O
32	O
institutions	O
in	O
Japan	O
,	O
which	O
were	O
selected	O
on	O
the	O
basis	B-UNK
of	O
the	O
client	O
list	O
from	O
the	O
Topcon	O
Company	O
,	O
which	O
manufactures	O
the	O
indocyanine	O
green	B-UNK
fundus	O
camera	O
.	O
RESULTS	B-UNK
:	O
Ophthalmologists	O
at	O
15	O
institutions	O
responded	O
,	O
reporting	B-UNK
a	O
total	B-UNK
of	O
3,774	O
indocyanine	O
green	B-UNK
angiograms	O
performed	B-UNK
on	O
2,820	O
patients	B-UNK
between	O
June	B-UNK
1984	O
and	O
September	O
1992	O
.	O
Before	O
angiography	B-UNK
,	O
intradermal	B-UNK
or	O
intravenous	B-UNK
indocyanine	O
green	B-UNK
testing	B-UNK
,	O
or	O
both	O
was	O
performed	B-UNK
at	O
13	O
of	O
15	O
institutions	O
.	O
For	O
three	O
patients	B-UNK
,	O
the	O
decision	O
was	O
made	O
not	O
to	O
proceed	O
with	O
angiography	B-UNK
after	O
positive	B-UNK
preangiographic	O
testing	B-UNK
.	O
The	O
dosage	B-UNK
of	O
indocyanine	O
green	B-UNK
used	O
for	O
angiography	B-UNK
varied	O
from	O
25	O
to	O
75	O
mg	B-UNK
,	O
depending	O
upon	O
the	O
institution	B-UNK
.	O
There	O
were	O
13	O
cases	B-UNK
of	O
adverse	B-UNK
reactions	I-UNK
(	O
0.34	O
%	O
)	O
,	O
ten	O
of	O
which	O
were	O
mild	B-UNK
reactions	B-UNK
such	O
as	O
nausea	B-DISEASE
,	O
exanthema	B-DISEASE
,	O
urtication	O
,	O
itchiness	O
,	O
and	O
urgency	O
to	O
defecate	O
,	O
and	O
did	O
not	O
require	O
treatment	B-UNK
.	O
Also	O
recorded	O
were	O
one	O
case	B-UNK
of	O
pain	B-UNK
of	O
the	O
vein	B-UNK
,	O
which	O
required	B-UNK
treatment	B-UNK
,	O
and	O
two	O
cases	B-UNK
of	O
hypotension	B-UNK
.	O
The	O
two	O
hypotensive	B-DISEASE
patients	B-UNK
required	B-UNK
treatment	B-UNK
for	O
shock	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
A	O
comparison	B-UNK
of	O
frequency	B-UNK
of	O
adverse	B-UNK
reactions	I-UNK
to	O
indocyanine	O
green	B-UNK
with	O
the	O
previously	B-UNK
reported	I-UNK
frequency	B-UNK
of	O
such	O
reactions	B-UNK
to	O
fluorescein	B-CHEMICAL
sodium	B-UNK
indicated	O
that	O
indocyanine	O
green	B-UNK
is	O
a	O
safe	O
as	O
fluorescein	B-CHEMICAL
for	O
use	O
in	O
angiography	B-UNK
.	O

Bradykinin	B-UNK
receptors	B-UNK
antagonists	B-UNK
and	O
nitric	B-UNK
oxide	I-UNK
synthase	B-UNK
inhibitors	B-UNK
in	O
vincristine	B-UNK
and	O
streptozotocin	B-UNK
induced	I-UNK
hyperalgesia	B-UNK
in	O
chemotherapy	O
and	O
diabetic	B-DISEASE
neuropathy	I-DISEASE
rat	B-UNK
model	B-UNK
.	O
PURPOSE	B-UNK
:	O
The	O
influence	B-UNK
of	O
an	O
irreversible	B-UNK
inhibitor	B-UNK
of	O
constitutive	O
NO	O
synthase	B-UNK
(	O
L	O
-	O
NOArg	O
;	O
1.0	O
mg	B-UNK
/	O
kg	B-UNK
ip	B-UNK
)	O
,	O
a	O
relatively	O
selective	B-UNK
inhibitor	B-UNK
of	O
inducible	B-UNK
NO	O
synthase	B-UNK
(	O
L	O
-	O
NIL	O
;	O
1.0	O
mg	B-UNK
/	O
kg	B-UNK
ip	B-UNK
)	O
and	O
a	O
relatively	O
specific	B-UNK
inhibitor	B-UNK
of	O
neuronal	B-UNK
NO	O
synthase	B-UNK
(	O
7-NI	O
;	O
0.1	O
mg	B-UNK
/	O
kg	B-UNK
ip	B-UNK
)	O
,	O
on	O
antihyperalgesic	O
action	B-UNK
of	O
selective	B-UNK
antagonists	B-UNK
of	O
B2	B-UNK
and	O
B1	O
receptors	B-UNK
:	O
D	O
-	O
Arg-[Hyp3,Thi5,D	O
-	O
Tic7,Oic8	O
]	O
bradykinin	B-CHEMICAL
(	O
HOE	O
140	O
;	O
70	O
nmol	B-UNK
/	O
kg	B-UNK
ip	B-UNK
)	O
or	O
des	B-UNK
Arg10	O
HOE	O
140	O
(	O
70	O
nmol	B-UNK
/	O
kg	B-UNK
ip	B-UNK
)	O
respectively	O
,	O
in	O
model	B-UNK
of	O
diabetic	B-DISEASE
(	O
streptozotocin	B-CHEMICAL
-	O
induced	O
)	O
and	O
toxic	B-UNK
(	O
vincristine	B-CHEMICAL
-	O
induced	O
)	O
neuropathy	B-DISEASE
was	O
investigated	B-UNK
.	O
METHODS	B-UNK
:	O
The	O
changes	O
in	O
pain	B-UNK
thresholds	O
were	O
determined	B-UNK
using	O
mechanical	B-UNK
stimuli	B-UNK
--	O
the	O
modification	O
of	O
the	O
classic	B-UNK
paw	O
withdrawal	B-UNK
test	B-UNK
described	O
by	O
Randall	O
-	O
Selitto	O
.	O
RESULTS	B-UNK
:	O
The	O
results	B-UNK
of	O
this	O
paper	B-UNK
confirm	B-UNK
that	O
inhibition	B-UNK
of	O
bradykinin	B-UNK
receptors	B-UNK
and	O
inducible	B-UNK
NO	O
synthase	B-UNK
but	O
not	O
neuronal	B-UNK
NO	O
synthase	B-UNK
activity	B-UNK
reduces	O
diabetic	B-DISEASE
hyperalgesia	I-DISEASE
.	O
Pretreatment	B-UNK
with	O
L	O
-	O
NOArg	O
and	O
L	O
-	O
NIL	O
but	O
not	O
7-NI	O
,	O
significantly	B-UNK
increases	B-UNK
antihyperalgesic	O
activity	B-UNK
both	O
HOE	O
140	O
and	O
des	B-UNK
Arg10	O
HOE	O
140	O
.	O
It	O
was	O
also	O
shown	B-UNK
that	O
both	O
products	B-UNK
of	O
inducible	B-UNK
NO	O
synthase	B-UNK
and	O
neuronal	B-UNK
NO	O
synthase	B-UNK
activation	B-UNK
as	O
well	O
as	O
bradykinin	B-UNK
are	O
involved	B-UNK
in	O
hyperalgesia	B-UNK
produced	B-UNK
by	O
vincristine	B-UNK
.	O
Moreover	O
,	O
L	O
-	O
NOArg	O
and	O
7-NI	O
but	O
not	O
L	O
-	O
NIL	O
intensify	O
antihyperalgesic	O
activity	B-UNK
of	O
HOE	O
140	O
or	O
des	B-UNK
-	O
Arg10HOE	O
140	O
in	O
toxic	B-UNK
neuropathy	B-DISEASE
.	O
CONCLUSIONS	B-UNK
:	O
Results	B-UNK
of	O
these	O
studies	B-UNK
suggest	B-UNK
that	O
B1	O
and	O
B2	B-UNK
receptors	B-UNK
are	O
engaged	O
in	O
transmission	B-UNK
of	O
nociceptive	B-UNK
stimuli	B-UNK
in	O
both	O
diabetic	B-UNK
and	O
toxic	B-UNK
neuropathy	B-DISEASE
.	O
In	O
streptozotocin	B-CHEMICAL
-	O
induced	O
hyperalgesia	B-UNK
,	O
inducible	B-UNK
NO	O
synthase	B-UNK
participates	O
in	O
pronociceptive	O
activity	B-UNK
of	O
bradykinin	B-CHEMICAL
,	O
whereas	O
in	O
vincristine	B-UNK
-	O
induced	O
hyperalgesia	B-UNK
bradykinin	B-CHEMICAL
seemed	O
to	O
activate	O
neuronal	B-UNK
NO	O
synthase	B-UNK
pathway	B-UNK
.	O
Therefore	O
,	O
concomitant	B-UNK
administration	O
of	O
small	B-UNK
doses	B-UNK
of	O
bradykinin	B-CHEMICAL
receptor	I-CHEMICAL
antagonists	I-CHEMICAL
and	O
NO	O
synthase	B-UNK
inhibitors	B-UNK
can	O
be	O
effective	B-UNK
in	O
alleviation	O
of	O
neuropathic	B-DISEASE
pain	I-DISEASE
,	O
even	O
in	O
hospital	B-UNK
care	B-UNK
.	O

Cardiac	B-UNK
toxicity	I-UNK
observed	O
in	O
association	B-UNK
with	O
high	B-UNK
-	O
dose	B-UNK
cyclophosphamide	B-UNK
-	O
based	B-UNK
chemotherapy	O
for	O
metastatic	B-UNK
breast	I-UNK
cancer	I-UNK
.	O
INTRODUCTION	B-UNK
:	O
Cyclophosphamide	B-UNK
is	O
an	O
alkylating	O
agent	B-UNK
given	O
frequently	B-UNK
as	O
a	O
component	B-UNK
of	O
many	O
conditioning	O
regimens	B-UNK
.	O
In	O
high	B-UNK
doses	I-UNK
,	O
its	O
nonhematological	O
dose	B-UNK
-	O
limiting	B-UNK
toxicity	B-UNK
is	O
cardiomyopathy	B-UNK
.	O
STUDY	B-UNK
DESIGN	B-UNK
:	O
We	O
combined	B-UNK
paclitaxel	B-UNK
,	O
melphalan	B-CHEMICAL
and	O
high	B-UNK
-	O
dose	B-UNK
cyclophosphamide	B-CHEMICAL
,	O
thiotepa	O
,	O
and	O
carboplatin	B-UNK
in	O
a	O
triple	O
sequential	O
high	B-UNK
-	O
dose	B-UNK
regimen	B-UNK
for	O
patients	B-UNK
with	O
metastatic	B-UNK
breast	I-UNK
cancer	I-UNK
.	O
Analysis	B-UNK
was	O
performed	B-UNK
on	O
61	O
women	B-UNK
with	O
chemotherapy	O
-	O
responsive	O
metastatic	B-UNK
breast	I-UNK
cancer	I-UNK
receiving	B-UNK
96-h	O
infusional	O
cyclophosphamide	B-CHEMICAL
as	O
part	O
of	O
a	O
triple	O
sequential	O
high	B-UNK
-	O
dose	B-UNK
regimen	B-UNK
to	O
assess	B-UNK
association	B-UNK
between	O
presence	O
of	O
peritransplant	O
congestive	B-UNK
heart	I-UNK
failure	I-UNK
(	O
CHF	B-UNK
)	O
and	O
the	O
following	O
pretreatment	B-UNK
characteristics	B-UNK
:	O
presence	O
of	O
electrocardiogram	O
(	O
EKG	O
)	O
abnormalities	B-UNK
,	O
age	B-UNK
,	O
hypertension	B-DISEASE
,	O
prior	B-UNK
cardiac	B-UNK
history	B-UNK
,	O
smoking	B-UNK
,	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
prior	B-UNK
use	O
of	O
anthracyclines	O
,	O
and	O
left	B-UNK
-	O
sided	O
chest	B-UNK
irradiation	O
.	O
RESULTS	B-UNK
:	O
Six	O
of	O
61	O
women	B-UNK
(	O
10	O
%	O
)	O
developed	O
clinically	B-UNK
reversible	B-UNK
grade	B-UNK
3	O
CHF	B-UNK
following	O
infusional	O
cyclophosphamide	B-UNK
with	O
a	O
median	B-UNK
percent	B-UNK
decline	B-UNK
in	O
ejection	B-UNK
fraction	I-UNK
of	O
31	O
%	O
.	O
Incidence	B-UNK
of	O
transient	B-UNK
cyclophosphamide	B-CHEMICAL
-	O
related	O
cardiac	B-DISEASE
toxicity	I-DISEASE
(	O
10	O
%	O
)	O
is	O
comparable	O
to	O
previous	B-UNK
recorded	O
literature	B-UNK
.	O
Older	B-UNK
age	B-UNK
was	O
significantly	B-UNK
correlated	B-UNK
with	O
the	O
CHF	B-UNK
development	B-UNK
;	O
with	O
median	B-UNK
ages	B-UNK
for	O
the	O
entire	O
group	B-UNK
and	O
for	O
patients	B-UNK
developing	B-UNK
CHF	B-UNK
of	O
45	O
and	O
59	O
,	O
respectively	O
.	O
No	O
association	B-UNK
was	O
found	O
with	O
other	O
pretreatment	B-UNK
characteristics	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
As	O
a	O
result	B-UNK
of	O
these	O
findings	B-UNK
,	O
oncologists	O
should	O
carefully	B-UNK
monitor	B-UNK
fluid	B-UNK
balance	O
in	O
older	B-UNK
patients	B-UNK
.	O
Routine	B-UNK
EKG	O
monitoring	B-UNK
during	O
infusional	O
cyclophosphamide	B-CHEMICAL
did	O
not	O
predict	B-UNK
CHF	B-UNK
development	B-UNK
.	O

Inappropriate	B-UNK
use	O
of	O
carbamazepine	B-UNK
and	O
vigabatrin	B-UNK
in	O
typical	B-UNK
absence	B-DISEASE
seizures	I-DISEASE
.	O
Carbamazepine	B-CHEMICAL
and	O
vigabatrin	B-UNK
are	O
contraindicated	O
in	O
typical	B-UNK
absence	B-DISEASE
seizures	I-DISEASE
.	O
Of	O
18	O
consecutive	B-UNK
referrals	O
of	O
children	B-UNK
with	O
resistant	B-UNK
typical	B-UNK
absences	O
only	O
,	O
eight	O
were	O
erroneously	O
treated	O
with	O
carbamazepine	B-CHEMICAL
either	O
as	O
monotherapy	B-UNK
or	O
as	O
an	O
add	O
-on	O
.	O
Vigabatrin	B-UNK
was	O
also	O
used	O
in	O
the	O
treatment	B-UNK
of	O
two	O
children	B-UNK
.	O
Frequency	B-UNK
of	O
absences	O
increased	B-UNK
in	O
four	O
children	B-UNK
treated	O
with	O
carbamazepine	B-UNK
and	O
two	O
of	O
these	O
developed	O
myoclonic	B-DISEASE
jerks	I-DISEASE
,	O
which	O
resolved	O
on	O
withdrawal	B-UNK
of	O
carbamazepine	B-UNK
.	O
Absences	O
were	O
aggravated	O
in	O
both	O
cases	B-UNK
where	O
vigabatrin	B-UNK
was	O
added	B-UNK
on	O
to	O
concurrent	B-UNK
treatment	B-UNK
.	O
Optimal	B-UNK
control	B-UNK
of	O
the	O
absences	O
was	O
achieved	O
with	O
sodium	B-CHEMICAL
valproate	B-UNK
,	O
lamotrigine	O
,	O
or	O
ethosuximide	O
alone	O
or	O
in	O
combination	B-UNK
.	O

Hemolytic	B-UNK
anemia	I-UNK
associated	O
with	O
the	O
use	O
of	O
omeprazole	B-CHEMICAL
.	O
Omeprazole	B-CHEMICAL
is	O
the	O
first	O
drug	B-UNK
designed	B-UNK
to	O
block	B-UNK
the	O
final	B-UNK
step	B-UNK
in	O
the	O
acid	B-UNK
secretory	O
process	O
within	O
the	O
parietal	O
cell	B-UNK
.	O
It	O
has	O
been	O
shown	B-UNK
to	O
be	O
extremely	O
effective	B-UNK
in	O
the	O
treatment	B-UNK
of	O
peptic	B-DISEASE
ulcer	I-DISEASE
disease	B-UNK
,	O
reflux	O
esophagitis	B-DISEASE
,	O
and	O
the	O
Zollinger	B-DISEASE
-	I-DISEASE
Ellison	I-DISEASE
syndrome	I-DISEASE
.	O
Although	O
clinical	B-UNK
experience	B-UNK
with	O
omeprazole	B-CHEMICAL
is	O
still	O
limited	B-UNK
,	O
many	O
controlled	B-UNK
studies	B-UNK
have	O
established	B-UNK
the	O
short	B-UNK
-	O
term	O
safety	B-UNK
of	O
this	O
drug	B-UNK
.	O
We	O
report	B-UNK
the	O
first	O
case	B-UNK
of	O
a	O
serious	O
short	B-UNK
-	O
term	O
adverse	B-UNK
reaction	B-UNK
with	O
the	O
use	O
of	O
omeprazole	B-CHEMICAL
:	O
hemolytic	B-UNK
anemia	I-UNK
.	O
The	O
patient	B-UNK
developed	O
weakness	B-UNK
,	O
lethargy	B-DISEASE
,	O
and	O
shortness	B-DISEASE
of	I-DISEASE
breath	I-DISEASE
2	O
days	B-UNK
after	O
starting	B-UNK
therapy	O
with	O
omeprazole	B-CHEMICAL
.	O
Two	O
weeks	B-UNK
after	O
the	O
initiation	B-UNK
of	O
therapy	O
,	O
her	O
hematocrit	O
had	O
decreased	B-UNK
from	O
44.1	O
%	O
to	O
20.4	O
%	O
,	O
and	O
she	O
had	O
a	O
positive	B-UNK
direct	B-UNK
Coombs	O
antiglobulin	O
test	B-UNK
and	O
an	O
elevated	B-UNK
indirect	O
bilirubin	B-UNK
.	O
After	O
she	O
discontinued	O
the	O
omeprazole	B-CHEMICAL
,	O
her	O
hemoglobin	B-UNK
and	O
hematocrit	O
gradually	O
returned	B-UNK
to	O
normal	O
.	O
The	O
mechanism	B-UNK
by	O
which	O
omeprazole	B-CHEMICAL
caused	B-UNK
the	O
patient'	B-UNK
s	I-UNK
hemolytic	B-UNK
anemia	I-UNK
is	O
uncertain	O
,	O
but	O
physicians	B-UNK
should	O
be	O
alerted	O
to	O
this	O
possible	O
adverse	B-UNK
effect	I-UNK
.	O

The	O
use	O
and	O
toxicity	B-UNK
of	O
didanosine	B-CHEMICAL
(	O
ddI	O
)	O
in	O
HIV	B-UNK
antibody	B-UNK
-	O
positive	B-UNK
individuals	B-UNK
intolerant	O
to	O
zidovudine	B-CHEMICAL
(	O
AZT	B-CHEMICAL
)	O
One	O
hundred	O
and	O
fifty	B-UNK
-	O
one	O
patients	B-UNK
intolerant	O
to	O
zidovudine	B-UNK
(	O
AZT	B-UNK
)	O
received	O
didanosine	B-CHEMICAL
(	O
ddI	O
)	O
to	O
a	O
maximum	B-UNK
dose	B-UNK
of	O
12.5	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	O
.	O
Patient	B-UNK
response	B-UNK
was	O
assessed	B-UNK
using	O
changes	O
in	O
CD4	B-UNK
+	O
lymphocyte	B-UNK
subset	B-UNK
count	B-UNK
,	O
HIV	B-UNK
p24	O
antigen	B-UNK
,	O
weight	B-UNK
,	O
and	O
quality	B-UNK
of	I-UNK
life	I-UNK
.	O
Seventy	B-UNK
patients	B-UNK
developed	O
major	B-UNK
opportunistic	B-DISEASE
infections	I-DISEASE
whilst	O
on	O
therapy	O
;	O
this	O
was	O
the	O
first	O
AIDS	B-UNK
diagnosis	B-UNK
in	O
17	O
.	O
Only	O
minor	B-UNK
changes	O
in	O
CD4	B-UNK
+	O
lymphocyte	B-UNK
subset	B-UNK
count	B-UNK
were	O
observed	O
in	O
AIDS	B-UNK
patients	B-UNK
,	O
although	O
a	O
more	O
significant	B-UNK
rise	B-UNK
occurred	B-UNK
in	O
those	O
with	O
earlier	B-UNK
stages	B-UNK
of	O
disease	B-DISEASE
.	O
Of	O
those	O
positive	B-UNK
for	O
p24	O
antigen	B-UNK
at	O
the	O
commencement	O
of	O
the	O
study	B-UNK
67	O
%	O
showed	O
a	O
positive	B-UNK
response	B-UNK
,	O
and	O
this	O
was	O
most	O
likely	O
in	O
those	O
with	O
CD4	B-UNK
+	O
lymphocyte	B-UNK
subset	B-UNK
counts	B-UNK
above	O
100	O
mm3	B-UNK
.	O
A	O
positive	B-UNK
weight	B-UNK
response	B-UNK
was	O
seen	O
in	O
16	O
%	O
of	O
patients	B-UNK
.	O
Most	O
patients	B-UNK
showed	O
improvement	B-UNK
in	O
individual	B-UNK
parameters	O
and	O
global	B-UNK
score	O
of	O
quality	B-UNK
of	I-UNK
life	I-UNK
.	O
Adverse	B-UNK
reactions	I-UNK
possibly	O
attributable	B-UNK
to	O
didanosine	B-CHEMICAL
were	O
common	B-UNK
.	O
The	O
most	O
common	B-UNK
side	O
-	O
effect	B-UNK
was	O
diarrhoea	B-DISEASE
,	O
which	O
resulted	B-UNK
in	O
cessation	B-UNK
of	O
therapy	O
in	O
19	O
individuals	B-UNK
.	O
Peripheral	B-UNK
neuropathy	I-UNK
occurred	B-UNK
in	O
12	O
patients	B-UNK
and	O
pancreatitis	B-DISEASE
in	O
six	O
.	O
Thirteen	B-UNK
patients	B-UNK
developed	O
a	O
raised	B-UNK
serum	B-UNK
amylase	O
without	O
abdominal	B-UNK
pain	I-UNK
.	O
Seven	O
patients	B-UNK
developed	O
glucose	B-UNK
tolerance	B-UNK
curves	B-UNK
characteristic	B-UNK
of	O
diabetes	B-UNK
but	O
these	O
were	O
mild	B-UNK
,	O
did	O
not	O
require	O
treatment	B-UNK
and	O
returned	B-UNK
to	O
normal	O
on	O
ceasing	O
didanosine	B-CHEMICAL
.	O

Can	O
angiogenesis	B-UNK
be	O
a	O
target	O
of	O
treatment	B-UNK
for	O
ribavirin	B-CHEMICAL
associated	O
hemolytic	B-UNK
anemia	I-UNK
?	O
BACKGROUND	B-UNK
/	O
AIMS	B-UNK
:	O
Recently	B-UNK
ribavirin	B-UNK
has	O
been	O
found	O
to	O
inhibit	O
angiogenesis	B-UNK
and	O
a	O
number	B-UNK
of	O
angiogenesis	B-CHEMICAL
inhibitors	I-CHEMICAL
such	O
as	O
sunitinib	O
and	O
sorafenib	B-CHEMICAL
have	O
been	O
found	O
to	O
cause	O
acute	B-UNK
hemolysis	B-UNK
.	O
We	O
aimed	B-UNK
to	O
investigate	B-UNK
whether	O
there	O
is	O
a	O
relation	B-UNK
between	O
hemoglobin	B-UNK
,	O
haptoglobin	O
and	O
angiogenesis	B-UNK
soluble	O
markers	B-UNK
which	O
are	O
modifiable	O
and	O
can	O
help	O
in	O
developing	B-UNK
strategies	B-UNK
against	O
anemia	B-UNK
.	O
METHODS	B-UNK
:	O
Fourteen	B-UNK
patients	B-UNK
chronically	B-DISEASE
infected	I-DISEASE
with	I-DISEASE
hepatitis	I-DISEASE
C	I-DISEASE
virus	I-DISEASE
were	O
treated	O
by	O
pegylated	B-UNK
interferon	B-UNK
alpha	B-UNK
2a	B-UNK
and	O
ribavirin	B-UNK
.	O
Serum	B-UNK
hemoglobin	B-UNK
,	O
haptoglobin	O
and	O
angiogenesis	B-UNK
markers	B-UNK
of	O
vascular	B-UNK
endothelial	B-UNK
growth	B-UNK
factor	I-UNK
and	O
angiopoetin-2	O
were	O
investigated	B-UNK
before	O
and	O
after	O
therapy	O
.	O
RESULTS	B-UNK
:	O
We	O
observed	O
a	O
significant	B-UNK
decrease	B-UNK
in	O
haptoglobin	O
levels	O
at	O
the	O
end	B-UNK
of	O
the	O
treatment	B-UNK
period	B-UNK
.	O
Hemoglobin	B-UNK
levels	O
also	O
decreased	B-UNK
but	O
insignificantly	O
by	O
treatment	B-UNK
.	O
In	O
contrast	B-UNK
with	O
the	O
literature	B-UNK
,	O
serum	B-UNK
levels	O
of	O
angiogenesis	B-UNK
factors	B-UNK
did	O
not	O
change	B-UNK
significantly	B-UNK
by	O
pegylated	B-UNK
interferon	B-UNK
and	O
ribavirin	B-UNK
therapy	O
.	O
We	O
found	O
no	O
correlation	B-UNK
of	O
angiogenesis	B-UNK
soluble	O
markers	B-UNK
with	O
either	O
hemoglobin	B-UNK
or	O
haptoglobin	O
.	O
CONCLUSION	B-UNK
:	O
This	O
is	O
the	O
first	O
study	B-UNK
in	O
the	O
literature	B-UNK
investigating	O
a	O
link	O
between	O
angiogenesis	B-UNK
soluble	O
markers	B-UNK
and	O
ribavirin	B-CHEMICAL
induced	O
anemia	B-UNK
in	O
patients	B-UNK
with	O
hepatitis	B-UNK
C	I-UNK
and	O
we	O
could	O
not	O
find	O
any	O
relation	B-UNK
.	O
Future	B-UNK
research	B-UNK
with	O
larger	B-UNK
number	B-UNK
of	O
patients	B-UNK
is	O
needed	B-UNK
to	O
find	O
out	O
modifiable	O
factors	B-UNK
that	O
will	O
improve	B-UNK
the	O
safety	B-UNK
of	O
ribavirin	B-CHEMICAL
therapy	O
.	O

Cocaine	B-UNK
causes	O
memory	B-UNK
and	O
learning	B-UNK
impairments	B-UNK
in	O
rats	B-UNK
:	O
involvement	B-UNK
of	O
nuclear	B-UNK
factor	B-UNK
kappa	O
B	O
and	O
oxidative	B-UNK
stress	I-UNK
,	O
and	O
prevention	B-UNK
by	O
topiramate	O
.	O
Different	O
mechanisms	B-UNK
have	O
been	O
suggested	B-UNK
for	O
cocaine	B-UNK
toxicity	B-UNK
including	O
an	O
increase	B-UNK
in	O
oxidative	B-UNK
stress	I-UNK
but	O
the	O
association	B-UNK
between	O
oxidative	B-UNK
status	B-UNK
in	O
the	O
brain	B-UNK
and	O
cocaine	B-UNK
induced	O
-	O
behaviour	B-UNK
is	O
poorly	B-UNK
understood	O
.	O
Nuclear	B-UNK
factor	B-UNK
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
sensor	O
of	O
oxidative	B-UNK
stress	I-UNK
and	O
participates	O
in	O
memory	B-UNK
formation	B-UNK
that	O
could	O
be	O
involved	B-UNK
in	O
drug	B-DISEASE
toxicity	I-DISEASE
and	O
addiction	O
mechanisms	B-UNK
.	O
Therefore	O
NFkappaB	O
activity	B-UNK
,	O
oxidative	B-UNK
stress	I-UNK
,	O
neuronal	B-UNK
nitric	B-UNK
oxide	I-UNK
synthase	B-UNK
(	O
nNOS	O
)	O
activity	B-UNK
,	O
spatial	O
learning	B-UNK
and	I-UNK
memory	I-UNK
as	O
well	O
as	O
the	O
effect	B-UNK
of	O
topiramate	O
,	O
a	O
previously	B-UNK
proposed	B-UNK
therapy	O
for	O
cocaine	B-DISEASE
addiction	I-DISEASE
,	O
were	O
evaluated	B-UNK
in	O
an	O
experimental	B-UNK
model	B-UNK
of	O
cocaine	B-UNK
administration	O
in	O
rats	B-UNK
.	O
NFkappaB	O
activity	B-UNK
was	O
decreased	B-UNK
in	O
the	O
frontal	B-UNK
cortex	B-UNK
of	O
cocaine	B-UNK
treated	B-UNK
rats	I-UNK
,	O
as	O
well	O
as	O
GSH	B-UNK
concentration	B-UNK
and	O
glutathione	B-UNK
peroxidase	O
activity	B-UNK
in	O
the	O
hippocampus	B-UNK
,	O
whereas	O
nNOS	O
activity	B-UNK
in	O
the	O
hippocampus	B-UNK
was	O
increased	B-UNK
.	O
Memory	B-UNK
retrieval	O
of	O
experiences	O
acquired	B-UNK
prior	B-UNK
to	O
cocaine	B-UNK
administration	O
was	O
impaired	B-UNK
and	O
negatively	O
correlated	B-UNK
with	O
NFkappaB	O
activity	B-UNK
in	O
the	O
frontal	B-UNK
cortex	B-UNK
.	O
In	O
contrast	B-UNK
,	O
learning	B-UNK
of	O
new	O
tasks	B-UNK
was	O
enhanced	B-UNK
and	O
correlated	B-UNK
with	O
the	O
increase	B-UNK
of	O
nNOS	O
activity	B-UNK
and	O
the	O
decrease	B-UNK
of	O
glutathione	B-UNK
peroxidase	O
.	O
These	O
results	B-UNK
provide	O
evidence	B-UNK
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	B-UNK
and	O
nitrosative	O
stress	B-UNK
and	O
NFkappaB	O
in	O
the	O
alterations	B-UNK
induced	O
by	O
cocaine	B-CHEMICAL
.	O
Topiramate	O
prevented	B-UNK
all	O
the	O
alterations	B-UNK
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	B-UNK
.	O

Antinociceptive	B-UNK
and	O
antiamnesic	O
properties	B-UNK
of	O
the	O
presynaptic	O
cholinergic	B-UNK
amplifier	O
PG-9	O
.	O
The	O
antinociceptive	B-UNK
effect	B-UNK
of	O
3	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
tropyl	I-CHEMICAL
2-(p	I-CHEMICAL
-	I-CHEMICAL
bromophenyl)propionate	I-CHEMICAL
[	O
(	O
+	O
/-)-PG-9	O
]	O
(	O
10	O
-	O
40	O
mg	B-UNK
kg-1	O
s.c	B-UNK
.	O
;	O
30	O
-	O
60	O
mg	B-UNK
kg-1	O
p.o	B-UNK
.	O
;	O
10	O
-	O
30	O
mg	B-UNK
kg-1	O
i.v	B-UNK
.	O
;	O
10	O
-	O
30	O
micrograms	B-UNK
/	O
mouse	B-UNK
i.c.v	B-UNK
.	O
)	O
was	O
examined	B-UNK
in	O
mice	B-UNK
,	O
rats	B-UNK
and	O
guinea	O
pigs	O
by	O
use	O
of	O
the	O
hot	O
-	O
plate	O
,	O
abdominal	B-UNK
-	O
constriction	O
,	O
tail	B-UNK
-	O
flick	O
and	O
paw	O
-	O
pressure	B-UNK
tests	B-UNK
.	O
(	O
+	O
/-)-PG-9	O
antinociception	O
peaked	O
15	O
min	B-UNK
after	O
injection	B-UNK
and	O
then	O
slowly	O
diminished	B-UNK
.	O
The	O
antinociception	O
produced	B-UNK
by	O
(	O
+	O
/-)-PG-9	O
was	O
prevented	B-UNK
by	O
the	O
unselective	O
muscarinic	B-UNK
antagonist	B-UNK
atropine	B-UNK
,	O
the	O
M1-selective	O
antagonists	B-UNK
pirenzepine	O
and	O
dicyclomine	B-CHEMICAL
and	O
the	O
acetylcholine	B-UNK
depletor	O
hemicholinium-3	O
,	O
but	O
not	O
by	O
the	O
opioid	B-UNK
antagonist	B-UNK
naloxone	B-CHEMICAL
,	O
the	O
gamma	B-UNK
-	O
aminobutyric	O
acidB	O
antagonist	B-UNK
3-aminopropyl	B-CHEMICAL
-	I-CHEMICAL
diethoxy	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
phosphinic	I-CHEMICAL
acid	I-CHEMICAL
,	O
the	O
H3	O
agonist	B-UNK
R-(alpha)-methylhistamine	O
,	O
the	O
D2	B-UNK
antagonist	B-UNK
quinpirole	O
,	O
the	O
5-hydroxytryptamine4	B-CHEMICAL
antagonist	B-UNK
2-methoxy-4-amino-5-chlorobenzoic	B-CHEMICAL
acid	I-CHEMICAL
2-(diethylamino)ethyl	I-CHEMICAL
ester	I-CHEMICAL
hydrochloride	B-UNK
,	O
the	O
5-hydroxytryptamin1A	B-CHEMICAL
antagonist	B-UNK
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine	B-CHEMICAL
hydrobromide	O
and	O
the	O
polyamines	O
depletor	O
reserpine	B-UNK
.	O
Based	B-UNK
on	O
these	O
data	B-UNK
,	O
it	O
can	O
be	O
postulated	O
that	O
(	O
+	O
/-)-PG-9	O
exerted	O
an	O
antinociceptive	B-UNK
effect	B-UNK
mediated	B-UNK
by	O
a	O
central	B-UNK
potentiation	B-UNK
of	O
cholinergic	B-UNK
transmission	B-UNK
.	O
(	O
+	O
/-)-PG-9	O
(	O
10	O
-	O
40	O
mg	B-UNK
kg-1	O
i.p	B-UNK
.	O
)	O
was	O
able	O
to	O
prevent	B-UNK
amnesia	B-DISEASE
induced	O
by	O
scopolamine	B-CHEMICAL
(	O
1	O
mg	B-UNK
kg-1	O
i.p	B-UNK
.	O
)	O
and	O
dicyclomine	B-CHEMICAL
(	O
2	O
mg	B-UNK
kg-1	O
i.p	B-UNK
.	O
)	O
in	O
the	O
mouse	B-UNK
passive	B-UNK
-	O
avoidance	B-UNK
test	B-UNK
.	O
Affinity	B-UNK
profiles	B-UNK
of	O
(	O
+	O
/-)-PG-9	O
for	O
muscarinic	B-UNK
receptor	B-UNK
subtypes	O
,	O
determined	B-UNK
by	O
functional	B-UNK
studies	B-UNK
(	O
rabbit	B-UNK
vas	B-UNK
deferens	O
for	O
M1	B-UNK
,	O
guinea	O
pig	O
atrium	O
for	O
M2	B-UNK
,	O
guinea	O
pig	O
ileum	O
for	O
M3	O
and	O
immature	O
guinea	O
pig	O
uterus	O
for	O
putative	O
M4	O
)	O
,	O
have	O
shown	B-UNK
an	O
M4	O
/	O
M1	B-UNK
selectivity	O
ratio	B-UNK
of	O
10.2	O
that	O
might	O
be	O
responsible	B-UNK
for	O
the	O
antinociception	O
and	O
the	O
anti-amnesic	O
effect	B-UNK
induced	O
by	O
(	O
+	O
/-)-PG-9	O
through	O
an	O
increase	B-UNK
in	O
acetylcholine	B-UNK
extracellular	B-UNK
levels	O
.	O
In	O
the	O
antinociceptive	B-UNK
and	O
antiamnesic	O
dose	B-UNK
range	B-UNK
,	O
(	O
+	O
/-)-PG-9	O
did	O
not	O
impair	O
mouse	B-UNK
performance	B-UNK
evaluated	B-UNK
by	O
the	O
rota	O
-	O
rod	O
test	B-UNK
and	O
Animex	O
apparatus	O
.	O

Hyperbaric	B-UNK
oxygen	B-CHEMICAL
therapy	O
for	O
control	B-UNK
of	O
intractable	O
cyclophosphamide	B-UNK
-	O
induced	O
hemorrhagic	B-UNK
cystitis	I-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
intractable	O
hemorrhagic	B-UNK
cystitis	I-UNK
due	O
to	O
cyclophosphamide	B-UNK
therapy	O
for	O
Wegener'	O
s	O
granulomatosis	O
.	O
Conservative	O
treatment	B-UNK
,	O
including	O
bladder	B-UNK
irrigation	B-UNK
with	O
physiological	B-UNK
saline	B-UNK
and	O
instillation	B-UNK
of	O
prostaglandin	B-UNK
F2	O
alpha	B-UNK
,	O
failed	B-UNK
to	O
totally	O
control	B-UNK
hemorrhage	B-UNK
.	O
We	O
then	O
used	O
hyperbaric	B-UNK
oxygen	B-CHEMICAL
at	O
an	O
absolute	B-UNK
pressure	B-UNK
of	O
2	O
atm	O
,	O
5	O
days	B-UNK
a	O
week	B-UNK
for	O
8	O
consecutive	B-UNK
weeks	B-UNK
.	O
The	O
bleeding	B-DISEASE
ceased	O
completely	O
by	O
the	O
end	B-UNK
of	O
treatment	B-UNK
and	O
the	O
patient	B-UNK
remained	B-UNK
free	B-UNK
of	O
hematuria	B-DISEASE
thereafter	O
.	O
No	O
side	O
effect	B-UNK
was	O
noted	B-UNK
during	O
the	O
course	O
of	O
therapy	O
.	O
In	O
future	B-UNK
,	O
this	O
form	B-UNK
of	O
therapy	O
can	O
offer	O
a	O
safe	O
alternative	B-UNK
in	O
the	O
treatment	B-UNK
of	O
cyclophosphamide	B-UNK
-	O
induced	O
hemorrhagic	B-UNK
cystitis	I-UNK
.	O

Further	O
studies	B-UNK
on	O
effects	O
of	O
irrigation	B-UNK
solutions	O
on	O
rat	B-UNK
bladders	O
.	O
Further	O
studies	B-UNK
on	O
the	O
effects	O
of	O
certain	O
irrigating	O
fluids	O
on	O
the	O
rat	B-UNK
bladder	B-UNK
for	O
18	O
hours	B-UNK
are	O
reported	B-UNK
.	O
The	O
results	B-UNK
have	O
shown	B-UNK
that	O
the	O
degradation	O
product	B-UNK
p	O
-	O
choloroaniline	O
is	O
not	O
a	O
significant	B-UNK
factor	B-UNK
in	O
chlorhexidine	B-CHEMICAL
-	O
digluconate	O
associated	O
erosive	O
cystitis	B-DISEASE
.	O
A	O
high	B-UNK
percentage	B-UNK
of	O
kanamycin	B-UNK
-	O
colistin	O
and	O
povidone	O
-	O
iodine	O
irrigations	O
were	O
associated	O
with	O
erosive	O
cystitis	B-DISEASE
and	O
suggested	B-UNK
a	O
possible	O
complication	B-UNK
with	O
human	B-UNK
usage	B-UNK
.	O
Picloxydine	B-CHEMICAL
irrigations	O
appeared	B-UNK
to	O
have	O
a	O
lower	B-UNK
incidence	B-UNK
of	O
erosive	O
cystitis	B-UNK
but	O
further	O
studies	B-UNK
would	O
have	O
to	O
be	O
performed	B-UNK
before	O
it	O
could	O
be	O
recommended	O
for	O
use	O
in	O
urological	O
procedures	B-UNK
.	O

Clinical	B-UNK
experiences	O
in	O
an	O
open	B-UNK
and	O
a	O
double-blind	O
trial	B-UNK
.	O
A	O
total	B-UNK
of	O
sixty	O
patients	B-UNK
were	O
trated	O
with	O
bromperidol	O
first	O
in	O
open	B-UNK
conditions	O
(	O
20	O
patients	B-UNK
)	O
,	O
then	O
on	O
a	O
double	B-UNK
blind	I-UNK
basis	B-UNK
(	O
40	O
patients	B-UNK
)	O
with	O
haloperidol	B-CHEMICAL
as	O
the	O
reference	B-UNK
substance	B-UNK
.	O
The	O
open	B-UNK
study	B-UNK
lasted	B-UNK
for	O
four	O
weeks	B-UNK
;	O
the	O
drug	B-UNK
was	O
administrated	O
in	O
the	O
form	B-UNK
of	O
1	O
mg	B-UNK
tablets	B-UNK
.	O
The	O
daily	B-UNK
dose	I-UNK
(	O
initial	B-UNK
dose	B-UNK
:	O
1	O
mg	B-UNK
;	O
mean	O
dose	B-UNK
at	O
the	O
end	B-UNK
of	O
the	O
trial	B-UNK
:	O
4.47	O
mg	B-UNK
)	O
was	O
always	O
administered	O
in	O
one	O
single	B-UNK
dose	B-UNK
.	O
Nineteen	O
patients	B-UNK
finished	O
the	O
trial	B-UNK
,	O
and	O
in	O
18	O
cases	B-UNK
the	O
therapeutic	B-UNK
result	B-UNK
was	O
considered	B-UNK
very	O
good	O
to	O
good	O
.	O
These	O
results	B-UNK
were	O
confirmed	B-UNK
by	O
statistical	B-UNK
analysis	B-UNK
.	O
Nine	O
patients	B-UNK
exhibited	O
mild	B-UNK
to	O
moderate	B-UNK
extrapyramidal	B-DISEASE
concomitant	I-DISEASE
symptoms	I-DISEASE
;	O
no	O
other	O
side	O
effects	O
were	O
observed	O
.	O
The	O
results	B-UNK
of	O
detailed	O
laboratory	B-UNK
tests	B-UNK
and	O
evaluations	O
of	O
various	O
quantitative	B-UNK
and	O
qualitative	O
tolerability	B-UNK
parameters	O
were	O
not	O
indicative	O
of	O
toxic	B-UNK
effects	I-UNK
.	O
In	O
the	O
double	B-UNK
blind	I-UNK
study	I-UNK
with	O
haloperidol	B-UNK
,	O
both	O
substances	O
were	O
found	O
to	O
be	O
highly	B-UNK
effective	B-UNK
in	O
the	O
treatment	B-UNK
of	O
psychotic	B-UNK
syndromes	B-UNK
belonging	O
predominantly	B-UNK
to	O
the	O
schizophrenia	B-UNK
group	B-UNK
.	O
Certain	O
clues	O
,	O
including	O
the	O
onset	B-UNK
of	O
action	B-UNK
,	O
seem	O
to	O
be	O
indicative	O
of	O
the	O
superiority	O
of	O
bromperidol	O
.	O
No	O
differences	B-UNK
were	O
observed	O
with	O
respect	B-UNK
to	O
side	O
effects	O
and	O
general	B-UNK
tolerability	B-UNK
.	O

Curcumin	B-UNK
ameliorates	O
cognitive	B-DISEASE
dysfunction	I-DISEASE
and	O
oxidative	B-UNK
damage	B-UNK
in	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
administered	O
rats	B-UNK
.	O
The	O
antiepileptic	B-UNK
drugs	B-UNK
,	O
phenobarbitone	B-UNK
and	O
carbamazepine	B-UNK
are	O
well	O
known	O
to	O
cause	O
cognitive	B-UNK
impairment	I-UNK
on	O
chronic	B-UNK
use	O
.	O
The	O
increase	B-UNK
in	O
free	B-UNK
radical	B-UNK
generation	B-UNK
has	O
been	O
implicated	B-UNK
as	O
one	O
of	O
the	O
important	B-UNK
mechanisms	B-UNK
of	O
cognitive	B-UNK
impairment	I-UNK
by	O
antiepileptic	B-UNK
drugs	B-UNK
.	O
Curcumin	B-UNK
has	O
shown	B-UNK
antioxidant	B-UNK
,	O
anti-inflammatory	O
and	O
neuro-protective	O
properties	B-UNK
.	O
Therefore	O
,	O
the	O
present	B-UNK
study	B-UNK
was	O
carried	O
out	O
to	O
investigate	B-UNK
the	O
effect	B-UNK
of	O
chronic	B-UNK
curcumin	B-CHEMICAL
administration	O
on	O
phenobarbitone-	O
and	O
carbamazepine	B-CHEMICAL
-	O
induced	O
cognitive	B-UNK
impairment	I-UNK
and	O
oxidative	B-UNK
stress	I-UNK
in	O
rats	B-UNK
.	O
Pharmacokinetic	B-UNK
interactions	B-UNK
of	O
curcumin	B-CHEMICAL
with	O
phenobarbitone	B-CHEMICAL
and	O
carbamazepine	B-UNK
were	O
also	O
studied	O
.	O
Vehicle	B-UNK
/	O
drugs	B-UNK
were	O
administered	O
daily	B-UNK
for	O
21days	O
to	O
male	B-UNK
Wistar	I-UNK
rats	I-UNK
.	O
Passive	B-UNK
avoidance	I-UNK
paradigm	B-UNK
and	O
elevated	B-UNK
plus	I-UNK
maze	I-UNK
test	B-UNK
were	O
used	O
to	O
assess	B-UNK
cognitive	B-UNK
function	I-UNK
.	O
At	O
the	O
end	B-UNK
of	O
study	B-UNK
period	B-UNK
,	O
serum	B-UNK
phenobarbitone	B-UNK
and	O
carbamazepine	B-UNK
,	O
whole	O
brain	B-UNK
malondialdehyde	B-UNK
and	O
reduced	B-UNK
glutathione	B-UNK
levels	O
were	O
estimated	O
.	O
The	O
administration	O
of	O
phenobarbitone	B-UNK
and	O
carbamazepine	B-UNK
for	O
21days	O
caused	B-UNK
a	O
significant	B-UNK
impairment	B-UNK
of	O
learning	B-UNK
and	I-UNK
memory	I-UNK
as	O
well	O
as	O
an	O
increased	B-UNK
oxidative	B-UNK
stress	I-UNK
.	O
Concomitant	B-UNK
curcumin	B-UNK
administration	O
prevented	B-UNK
the	O
cognitive	B-UNK
impairment	I-UNK
and	O
decreased	B-UNK
the	O
increased	B-UNK
oxidative	B-UNK
stress	I-UNK
induced	O
by	O
these	O
antiepileptic	B-UNK
drugs	B-UNK
.	O
Curcumin	B-UNK
co-administration	O
did	O
not	O
cause	O
any	O
significant	B-UNK
alteration	B-UNK
in	O
the	O
serum	B-UNK
concentrations	I-UNK
of	O
both	O
phenobarbitone	B-CHEMICAL
as	O
well	O
as	O
carbamazepine	B-CHEMICAL
.	O
These	O
results	B-UNK
show	O
that	O
curcumin	B-CHEMICAL
has	O
beneficial	B-UNK
effect	I-UNK
in	O
mitigating	O
the	O
deterioration	B-DISEASE
of	I-DISEASE
cognitive	I-DISEASE
functions	I-DISEASE
and	O
oxidative	B-UNK
damage	B-UNK
in	O
rats	B-UNK
treated	O
with	O
phenobarbitone	B-UNK
and	O
carbamazepine	B-UNK
without	O
significantly	B-UNK
altering	B-UNK
their	O
serum	B-UNK
concentrations	I-UNK
.	O
The	O
findings	B-UNK
suggest	B-UNK
that	O
curcumin	B-UNK
can	O
be	O
considered	B-UNK
as	O
a	O
potential	B-UNK
safe	O
and	O
effective	B-UNK
adjuvant	O
to	O
phenobarbitone	B-UNK
and	O
carbamazepine	B-UNK
therapy	O
in	O
preventing	O
cognitive	B-UNK
impairment	I-UNK
associated	O
with	O
these	O
drugs	B-UNK
.	O

Pyrrolidine	O
dithiocarbamate	O
protects	B-UNK
the	O
piriform	O
cortex	B-UNK
in	O
the	O
pilocarpine	B-CHEMICAL
status	B-UNK
epilepticus	I-UNK
model	B-UNK
.	O
Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	B-UNK
)	O
has	O
a	O
dual	B-UNK
mechanism	B-UNK
of	O
action	B-UNK
as	O
an	O
antioxidant	B-UNK
and	O
an	O
inhibitor	B-UNK
of	O
the	O
transcription	O
factor	B-UNK
kappa	O
-	O
beta	B-UNK
.	O
Both	O
,	O
production	B-UNK
of	O
reactive	B-UNK
oxygen	I-UNK
species	I-UNK
as	O
well	O
as	O
activation	B-UNK
of	O
NF	B-UNK
-	O
kappaB	B-UNK
have	O
been	O
implicated	B-UNK
in	O
severe	B-UNK
neuronal	B-DISEASE
damage	I-DISEASE
in	O
different	O
sub-regions	O
of	O
the	O
hippocampus	B-UNK
as	O
well	O
as	O
in	O
the	O
surrounding	O
cortices	O
.	O
The	O
effect	B-UNK
of	O
PDTC	B-UNK
on	O
status	B-UNK
epilepticus	I-UNK
-	O
associated	O
cell	B-UNK
loss	B-UNK
in	O
the	O
hippocampus	B-UNK
and	O
piriform	O
cortex	B-UNK
was	O
evaluated	B-UNK
in	O
the	O
rat	B-UNK
fractionated	O
pilocarpine	B-CHEMICAL
model	B-UNK
.	O
Treatment	B-UNK
with	O
150	O
mg	B-UNK
/	O
kg	B-UNK
PDTC	B-UNK
before	O
and	O
following	O
status	B-UNK
epilepticus	I-UNK
significantly	B-UNK
increased	B-UNK
the	O
mortality	B-UNK
rate	I-UNK
to	O
100	O
%	O
.	O
Administration	O
of	O
50	O
mg	B-UNK
/	O
kg	B-UNK
PDTC	B-UNK
(	O
low	B-UNK
-	O
dose	B-UNK
)	O
did	O
not	O
exert	O
major	B-UNK
effects	O
on	O
the	O
development	B-UNK
of	O
a	O
status	B-UNK
epilepticus	I-UNK
or	O
the	O
mortality	B-UNK
rate	I-UNK
.	O
In	O
vehicle	B-UNK
-	O
treated	B-UNK
rats	I-UNK
,	O
status	B-UNK
epilepticus	I-UNK
caused	B-UNK
pronounced	B-UNK
neuronal	B-DISEASE
damage	I-DISEASE
in	O
the	O
piriform	O
cortex	B-UNK
comprising	O
both	O
pyramidal	O
cells	B-UNK
and	O
interneurons	O
.	O
Low	B-UNK
-	O
dose	B-UNK
PDTC	B-UNK
treatment	B-UNK
almost	O
completely	O
protected	B-UNK
from	O
lesions	B-UNK
in	O
the	O
piriform	O
cortex	B-UNK
.	O
A	O
significant	B-UNK
decrease	B-UNK
in	O
neuronal	B-UNK
density	B-UNK
of	O
the	O
hippocampal	B-UNK
hilar	B-UNK
formation	B-UNK
was	O
identified	B-UNK
in	O
vehicle-	O
and	O
PDTC	B-UNK
-	O
treated	B-UNK
rats	I-UNK
following	O
status	B-UNK
epilepticus	I-UNK
.	O
In	O
conclusion	B-UNK
,	O
the	O
NF	B-UNK
-	O
kappaB	B-UNK
inhibitor	B-UNK
and	O
antioxidant	B-UNK
PDTC	B-UNK
protected	B-UNK
the	O
piriform	O
cortex	B-UNK
,	O
whereas	O
it	O
did	O
not	O
affect	B-UNK
hilar	B-UNK
neuronal	B-UNK
loss	B-UNK
.	O
These	O
data	B-UNK
might	O
indicate	O
that	O
the	O
generation	B-UNK
of	O
reactive	B-UNK
oxygen	I-UNK
species	I-UNK
and	O
activation	B-UNK
of	O
NF	B-UNK
-	O
kappaB	B-UNK
plays	O
a	O
more	O
central	B-UNK
role	O
in	O
seizure	B-UNK
-	O
associated	O
neuronal	B-DISEASE
damage	I-DISEASE
in	O
the	O
temporal	B-UNK
cortex	B-UNK
as	O
compared	O
to	O
the	O
hippocampal	B-UNK
hilus	O
.	O
However	O
,	O
future	B-UNK
investigations	B-UNK
are	O
necessary	O
to	O
exactly	O
analyze	O
the	O
biochemical	B-UNK
mechanisms	B-UNK
by	O
which	O
PDTC	B-UNK
exerted	O
its	O
beneficial	B-UNK
effects	I-UNK
in	O
the	O
piriform	O
cortex	B-UNK
.	O

Safety	B-UNK
profile	B-UNK
of	O
a	O
nicotine	B-UNK
lozenge	B-UNK
compared	O
with	O
that	O
of	O
nicotine	B-CHEMICAL
gum	B-UNK
in	O
adult	B-UNK
smokers	O
with	O
underlying	B-UNK
medical	B-UNK
conditions	O
:	O
a	O
12-week	O
,	O
randomized	B-UNK
,	O
open	B-UNK
-	O
label	B-UNK
study	B-UNK
.	O
BACKGROUND	B-UNK
:	O
Nicotine	B-UNK
polacrilex	O
lozenges	O
deliver	O
25	O
%	O
to	O
27	O
%	O
more	O
nicotine	B-UNK
compared	O
with	O
equivalent	O
doses	B-UNK
of	O
nicotine	B-UNK
polacrilex	O
gum	B-UNK
.	O
The	O
increased	B-UNK
nicotine	B-UNK
exposure	B-UNK
from	O
the	O
lozenge	B-UNK
has	O
raised	B-UNK
questions	O
about	O
the	O
relative	B-UNK
safety	B-UNK
of	O
the	O
lozenge	B-UNK
and	O
gum	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
compare	B-UNK
the	O
safety	B-UNK
profiles	B-UNK
of	O
the	O
4-mg	O
nicotine	B-CHEMICAL
lozenge	B-UNK
and	O
4-mg	O
nicotine	B-UNK
gum	B-UNK
in	O
smokers	O
with	O
selected	O
label	B-UNK
-	O
restricted	B-UNK
diseases	B-UNK
.	O
METHODS	B-UNK
:	O
This	O
was	O
a	O
multicenter	B-UNK
,	O
randomized	B-UNK
,	O
open	B-UNK
-	O
label	B-UNK
study	B-UNK
in	O
adult	B-UNK
smokers	O
with	O
heart	B-UNK
disease	I-UNK
,	O
hypertension	B-UNK
not	O
controlled	B-UNK
by	O
medication	O
,	O
and	O
/	O
or	O
diabetes	B-UNK
mellitus	I-UNK
.	O
Patients	B-UNK
were	O
randomized	B-UNK
in	O
a	O
1:1	O
ratio	B-UNK
to	O
receive	B-UNK
the	O
4-mg	O
nicotine	B-CHEMICAL
lozenge	B-UNK
or	O
4-mg	O
nicotine	B-UNK
gum	B-UNK
.	O
Safety	B-UNK
assessments	O
were	O
made	O
at	O
baseline	B-UNK
and	O
at	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
12	O
weeks	B-UNK
after	O
the	O
start	B-UNK
of	O
product	B-UNK
use	O
.	O
RESULTS	B-UNK
:	O
Nine	O
hundred	O
one	O
patients	B-UNK
were	O
randomized	B-UNK
to	O
treatment	B-UNK
,	O
447	O
who	O
received	O
the	O
lozenge	B-UNK
and	O
454	O
who	O
received	O
the	O
gum	B-UNK
(	O
safety	B-UNK
population	B-UNK
)	O
.	O
The	O
majority	O
were	O
women	B-UNK
(	O
52.7	O
%	O
)	O
.	O
Patients	B-UNK
'	O
mean	O
age	B-UNK
was	O
53.9	O
years	B-UNK
,	O
their	O
mean	O
weight	B-UNK
was	O
193.9	O
pounds	O
,	O
and	O
they	O
smoked	O
a	O
mean	O
of	O
25.2	O
cigarettes	O
per	O
day	O
at	O
baseline	B-UNK
.	O
Five	O
hundred	O
fifty	B-UNK
-	O
three	O
patients	B-UNK
,	O
264	O
taking	B-UNK
the	O
lozenge	B-UNK
and	O
289	O
taking	B-UNK
the	O
gum	B-UNK
,	O
used	O
the	O
study	B-UNK
product	B-UNK
for	O
>	O
or	O
=	O
4	O
days	B-UNK
per	O
week	B-UNK
during	O
the	O
first	O
2	O
weeks	B-UNK
(	O
evaluable	B-UNK
population	B-UNK
)	O
.	O
The	O
nicotine	B-UNK
lozenge	B-UNK
and	O
nicotine	B-UNK
gum	B-UNK
were	O
equally	B-UNK
well	O
tolerated	B-UNK
,	O
despite	O
increased	B-UNK
nicotine	B-UNK
exposure	B-UNK
from	O
the	O
lozenge	B-UNK
.	O
The	O
incidence	B-UNK
of	O
adverse	B-UNK
events	I-UNK
in	O
the	O
2	O
groups	B-UNK
was	O
similar	B-UNK
during	O
the	O
first	O
2	O
weeks	B-UNK
of	O
product	B-UNK
use	O
(	O
evaluation	B-UNK
population	B-UNK
:	O
55.3	O
%	O
lozenge	B-UNK
,	O
54.7	O
%	O
gum	B-UNK
)	O
,	O
as	O
well	O
as	O
during	O
the	O
entire	O
study	B-UNK
(	O
safety	B-UNK
population	B-UNK
:	O
63.8	O
%	O
and	O
58.6	O
%	O
,	O
respectively	O
)	O
.	O
Stratification	O
of	O
patients	B-UNK
by	O
sex	B-UNK
,	O
age	B-UNK
,	O
extent	B-UNK
of	O
concurrent	B-UNK
smoking	B-CHEMICAL
,	O
extent	B-UNK
of	O
product	B-UNK
use	O
,	O
and	O
severity	B-UNK
of	O
adverse	B-UNK
events	I-UNK
revealed	O
no	O
clinically	B-UNK
significant	I-UNK
differences	B-UNK
between	O
the	O
lozenge	B-UNK
and	O
gum	B-UNK
.	O
The	O
most	O
common	B-UNK
adverse	B-UNK
events	I-UNK
were	O
nausea	B-UNK
(	O
17.2	O
%	O
and	O
16.1	O
%	O
;	O
95	O
%	O
CI	B-UNK
,	O
-3.7	O
to	O
6.0	O
)	O
,	O
hiccups	B-UNK
(	O
10.7	O
%	O
and	O
6.6	O
%	O
;	O
95	O
%	O
CI	B-UNK
,	O
0.5	O
to	O
7.8	O
)	O
,	O
and	O
headache	B-UNK
(	O
8.7	O
%	O
and	O
9.9	O
%	O
;	O
95	O
%	O
Cl	O
,	O
-5.0	O
to	O
2.6	O
)	O
.	O
Serious	O
adverse	B-UNK
events	I-UNK
were	O
reported	B-UNK
in	O
11	O
and	O
13	O
patients	B-UNK
in	O
the	O
respective	O
groups	B-UNK
.	O
Fewer	B-UNK
than	O
6	O
%	O
of	O
patients	B-UNK
in	O
either	O
group	B-UNK
were	O
considered	B-UNK
by	O
the	O
investigator	O
to	O
have	O
a	O
worsening	B-UNK
of	O
their	O
overall	O
disease	B-UNK
condition	B-UNK
during	O
the	O
study	B-UNK
.	O
The	O
majority	O
of	O
patients	B-UNK
(	O
>	O
60	O
%	O
)	O
experienced	B-UNK
no	O
change	B-UNK
in	O
their	O
disease	B-DISEASE
status	B-UNK
from	O
baseline	B-UNK
.	O
CONCLUSION	B-UNK
:	O
The	O
4-mg	O
nicotine	B-CHEMICAL
lozenge	B-UNK
and	O
4-mg	O
nicotine	B-CHEMICAL
gum	B-UNK
had	O
comparable	O
safety	B-UNK
profiles	B-UNK
in	O
these	O
patients	B-UNK
with	O
label	B-UNK
-	O
restricted	B-UNK
medical	B-UNK
conditions	O
.	O

Development	B-UNK
of	O
levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-UNK
in	O
parkinsonian	B-UNK
monkeys	B-UNK
may	O
depend	O
upon	O
rate	B-UNK
of	O
symptom	B-UNK
onset	B-UNK
and	O
/	O
or	O
duration	B-UNK
of	O
symptoms	B-UNK
.	O
Levodopa	B-CHEMICAL
-	O
induced	O
dyskinesias	B-UNK
(	O
LIDs	B-UNK
)	O
present	B-UNK
a	O
major	B-UNK
problem	O
for	O
the	O
long	B-UNK
-	O
term	O
management	B-UNK
of	O
Parkinson'	B-UNK
s	I-UNK
disease	I-UNK
(	O
PD	B-UNK
)	O
patients	B-UNK
.	O
Due	O
to	O
the	O
interdependence	O
of	O
risk	B-UNK
factors	I-UNK
in	O
clinical	B-UNK
populations	O
,	O
it	O
is	O
difficult	O
to	O
independently	O
examine	B-UNK
factors	B-UNK
that	O
may	O
influence	B-UNK
the	O
development	B-UNK
of	O
LIDs	B-UNK
.	O
Using	O
macaque	O
monkeys	B-UNK
with	O
different	O
types	B-UNK
of	O
MPTP	B-UNK
-	O
induced	O
parkinsonism	B-UNK
,	O
the	O
current	B-UNK
study	B-UNK
evaluated	B-UNK
the	O
degree	B-UNK
to	O
which	O
rate	B-UNK
of	O
symptom	B-UNK
progression	B-UNK
,	O
symptom	B-UNK
severity	B-UNK
,	O
and	O
response	B-UNK
to	O
and	O
duration	B-UNK
of	O
levodopa	B-CHEMICAL
therapy	O
may	O
be	O
involved	B-UNK
in	O
the	O
development	B-UNK
of	O
LIDs	B-UNK
.	O
Monkeys	B-UNK
with	O
acute	B-UNK
(	O
short	B-UNK
-	O
term	O
)	O
MPTP	B-UNK
exposure	B-UNK
,	O
rapid	B-UNK
symptom	B-UNK
onset	B-UNK
and	O
short	B-UNK
symptom	B-UNK
duration	B-UNK
prior	B-UNK
to	O
initiation	B-UNK
of	O
levodopa	B-UNK
therapy	O
developed	O
dyskinesia	B-UNK
between	O
11	O
and	O
24	O
days	B-UNK
of	O
daily	B-UNK
levodopa	B-CHEMICAL
administration	O
.	O
In	O
contrast	B-UNK
,	O
monkeys	B-UNK
with	O
long	B-UNK
-	O
term	O
MPTP	B-UNK
exposure	B-UNK
,	O
slow	B-UNK
symptom	B-UNK
progression	B-UNK
and	O
/	O
or	O
long	B-UNK
symptom	B-UNK
duration	B-UNK
prior	B-UNK
to	O
initiation	B-UNK
of	O
levodopa	B-CHEMICAL
therapy	O
were	O
more	O
resistant	B-UNK
to	O
developing	B-UNK
LIDs	B-UNK
(	O
e.g	B-UNK
.	O
,	O
dyskinesia	B-UNK
developed	O
no	O
sooner	O
than	O
146	O
days	B-UNK
of	O
chronic	B-UNK
levodopa	B-UNK
administration	O
)	O
.	O
All	O
animals	B-UNK
were	O
similarly	B-UNK
symptomatic	B-UNK
at	O
the	O
start	B-UNK
of	O
levodopa	B-UNK
treatment	B-UNK
and	O
had	O
similar	B-UNK
therapeutic	B-UNK
responses	O
to	O
the	O
drug	B-UNK
.	O
These	O
data	B-UNK
suggest	I-UNK
distinct	O
differences	B-UNK
in	O
the	O
propensity	O
to	O
develop	B-UNK
LIDs	B-UNK
in	O
monkeys	B-UNK
with	O
different	O
rates	B-UNK
of	O
symptom	B-UNK
progression	B-UNK
or	O
symptom	B-UNK
durations	O
prior	B-UNK
to	O
levodopa	B-CHEMICAL
and	O
demonstrate	O
the	O
value	O
of	O
these	O
models	B-UNK
for	O
further	O
studying	O
the	O
pathophysiology	B-UNK
of	O
LIDs	B-UNK
.	O

Propylthiouracil	B-UNK
-	O
induced	O
perinuclear	O
-	O
staining	B-UNK
antineutrophil	O
cytoplasmic	B-UNK
autoantibody	O
-	O
positive	B-UNK
vasculitis	B-DISEASE
in	O
conjunction	B-UNK
with	O
pericarditis	B-DISEASE
.	O
OBJECTIVE	B-UNK
:	O
To	O
describe	O
a	O
case	B-UNK
of	O
propylthiouracil	B-CHEMICAL
-	O
induced	O
vasculitis	B-UNK
manifesting	O
with	O
pericarditis	B-DISEASE
.	O
METHODS	B-UNK
:	O
We	O
present	B-UNK
the	O
first	O
case	B-UNK
report	I-UNK
of	O
a	O
woman	B-UNK
with	O
hyperthyroidism	B-DISEASE
treated	O
with	O
propylthiouracil	B-CHEMICAL
in	O
whom	O
a	O
syndrome	B-UNK
of	O
pericarditis	B-DISEASE
,	O
fever	B-UNK
,	O
and	O
glomerulonephritis	B-UNK
developed	O
.	O
Serologic	O
testing	B-UNK
and	O
immunologic	O
studies	B-UNK
were	O
done	O
,	O
and	O
a	O
pericardial	O
biopsy	B-UNK
was	O
performed	B-UNK
.	O
RESULTS	B-UNK
:	O
A	O
25-year	O
-	O
old	O
woman	B-UNK
with	O
Graves	B-UNK
'	O
disease	B-UNK
had	O
a	O
febrile	B-DISEASE
illness	I-DISEASE
and	O
evidence	B-UNK
of	O
pericarditis	B-DISEASE
,	O
which	O
was	O
confirmed	B-UNK
by	O
biopsy	B-UNK
.	O
Serologic	O
evaluation	B-UNK
revealed	O
the	O
presence	O
of	O
perinuclear	O
-	O
staining	B-UNK
antineutrophil	O
cytoplasmic	B-UNK
autoantibodies	O
(	O
pANCA	O
)	O
against	O
myeloperoxidase	O
(	O
MPO	B-UNK
)	O
.	O
Propylthiouracil	B-UNK
therapy	O
was	O
withdrawn	O
,	O
and	O
she	O
was	O
treated	O
with	O
a	O
1-month	O
course	O
of	O
prednisone	B-UNK
,	O
which	O
alleviated	O
her	O
symptoms	B-UNK
.	O
A	O
literature	B-UNK
review	B-UNK
revealed	O
no	O
prior	B-UNK
reports	B-UNK
of	O
pericarditis	B-DISEASE
in	O
anti-MPO	O
pANCA	O
-	O
positive	B-UNK
vasculitis	B-UNK
associated	O
with	O
propylthio-	O
uracil	B-CHEMICAL
therapy	O
.	O
CONCLUSION	B-UNK
:	O
Pericarditis	B-DISEASE
may	O
be	O
the	O
initial	B-UNK
manifestation	B-UNK
of	O
drug	B-UNK
-	O
induced	O
vasculitis	B-UNK
attributable	B-UNK
to	O
propylthio-	O
uracil	B-CHEMICAL
therapy	O
.	O

Two	O
mouse	B-UNK
lines	B-UNK
selected	O
for	O
differential	B-UNK
sensitivities	O
to	O
beta-carboline-induced	O
seizures	B-UNK
are	O
also	O
differentially	O
sensitive	B-UNK
to	O
various	O
pharmacological	B-UNK
effects	O
of	O
other	O
GABA(A	O
)	O
receptor	B-UNK
ligands	B-UNK
.	O
Two	O
mouse	B-UNK
lines	B-UNK
were	O
selectively	B-UNK
bred	O
according	O
to	O
their	O
sensitivity	B-UNK
(	O
BS	B-UNK
line	B-UNK
)	O
or	O
resistance	B-UNK
(	O
BR	O
line	B-UNK
)	O
to	O
seizures	B-UNK
induced	O
by	O
a	O
single	B-UNK
i.p	B-UNK
.	O
injection	B-UNK
of	O
methyl	B-UNK
beta	B-UNK
-	O
carboline-3-carboxylate	O
(	O
beta-CCM	O
)	O
,	O
an	O
inverse	O
agonist	B-UNK
of	O
the	O
GABA(A	O
)	O
receptor	B-UNK
benzodiazepine	B-UNK
site	B-UNK
.	O
Our	O
aim	B-UNK
was	O
to	O
characterize	O
both	O
lines	B-UNK
'	O
sensitivities	O
to	O
various	O
physiological	B-UNK
effects	O
of	O
other	O
ligands	B-UNK
of	O
the	O
GABA(A	O
)	O
receptor	B-UNK
.	O
We	O
measured	B-UNK
diazepam	B-UNK
-	O
induced	O
anxiolysis	O
with	O
the	O
elevated	B-UNK
plus	O
-	O
maze	B-UNK
test	B-UNK
,	O
diazepam	B-UNK
-	O
induced	O
sedation	B-UNK
by	O
recording	B-UNK
the	O
vigilance	O
states	B-UNK
,	O
and	O
picrotoxin-	O
and	O
pentylenetetrazol	O
-	O
induced	O
seizures	B-DISEASE
after	O
i.p	B-UNK
.	O
injections	B-UNK
.	O
Results	B-UNK
presented	B-UNK
here	O
show	O
that	O
the	O
differential	B-UNK
sensitivities	O
of	O
BS	B-UNK
and	O
BR	O
lines	B-UNK
to	O
beta-CCM	O
can	O
be	O
extended	B-UNK
to	O
diazepam	B-UNK
,	O
picrotoxin	B-CHEMICAL
,	O
and	O
pentylenetetrazol	O
,	O
suggesting	O
a	O
genetic	B-UNK
selection	O
of	O
a	O
general	B-UNK
sensitivity	B-UNK
and	O
resistance	B-UNK
to	O
several	O
ligands	B-UNK
of	O
the	O
GABA(A	O
)	O
receptor	B-UNK
.	O

Analgesic	B-UNK
effect	B-UNK
of	O
intravenous	B-UNK
ketamine	B-UNK
in	O
cancer	B-DISEASE
patients	B-UNK
on	O
morphine	B-UNK
therapy	O
:	O
a	O
randomized	B-UNK
,	O
controlled	B-UNK
,	O
double-blind	O
,	O
crossover	B-UNK
,	O
double-dose	O
study	B-UNK
.	O
Pain	B-DISEASE
not	O
responsive	O
to	O
morphine	B-UNK
is	O
often	O
problematic	O
.	O
Animal	B-UNK
and	O
clinical	B-UNK
studies	B-UNK
have	O
suggested	B-UNK
that	O
N	O
-	O
methyl	B-UNK
-	O
D	O
-	O
aspartate	B-UNK
(	O
NMDA	B-UNK
)	O
antagonists	B-UNK
,	O
such	O
as	O
ketamine	B-UNK
,	O
may	O
be	O
effective	B-UNK
in	O
improving	B-UNK
opioid	B-UNK
analgesia	B-DISEASE
in	O
difficult	O
pain	B-DISEASE
syndromes	B-UNK
,	O
such	O
as	O
neuropathic	B-DISEASE
pain	I-DISEASE
.	O
A	O
slow	B-UNK
bolus	B-UNK
of	O
subhypnotic	O
doses	B-UNK
of	O
ketamine	B-UNK
(	O
0.25	O
mg	B-UNK
/	O
kg	B-UNK
or	O
0.50	O
mg	B-UNK
/	O
kg	B-UNK
)	O
was	O
given	O
to	O
10	O
cancer	B-UNK
patients	B-UNK
whose	O
pain	B-UNK
was	O
unrelieved	O
by	O
morphine	B-UNK
in	O
a	O
randomized	B-UNK
,	O
double-blind	O
,	O
crossover	B-UNK
,	O
double-dose	O
study	B-UNK
.	O
Pain	B-UNK
intensity	B-UNK
on	O
a	O
0	O
to	O
10	O
numerical	O
scale	B-UNK
;	O
nausea	B-UNK
and	I-UNK
vomiting	I-UNK
,	O
drowsiness	B-UNK
,	O
confusion	B-UNK
,	O
and	O
dry	B-DISEASE
mouth	I-DISEASE
,	O
using	O
a	O
scale	B-UNK
from	O
0	O
to	O
3	O
(	O
not	O
at	O
all	O
,	O
slight	B-UNK
,	O
a	O
lot	O
,	O
awful	O
)	O
;	O
Mini-Mental	O
State	B-UNK
Examination	B-UNK
(	O
MMSE	O
)	O
(	O
0	O
-	O
30	O
)	O
;	O
and	O
arterial	B-UNK
pressure	I-UNK
were	O
recorded	O
before	O
administration	O
of	O
drugs	B-UNK
(	O
T0	O
)	O
and	O
after	O
30	O
minutes	B-UNK
(	O
T30	O
)	O
,	O
60	O
minutes	B-UNK
(	O
T60	O
)	O
,	O
120	O
minutes	B-UNK
(	O
T120	O
)	O
,	O
and	O
180	O
minutes	B-UNK
(	O
T180	O
)	O
.	O
Ketamine	B-UNK
,	O
but	O
not	O
saline	B-UNK
solution	B-UNK
,	O
significantly	B-UNK
reduced	I-UNK
the	O
pain	B-UNK
intensity	B-UNK
in	O
almost	O
all	O
the	O
patients	B-UNK
at	O
both	O
doses	B-UNK
.	O
This	O
effect	B-UNK
was	O
more	O
relevant	B-UNK
in	O
patients	B-UNK
treated	O
with	O
higher	B-UNK
doses	I-UNK
.	O
Hallucinations	B-UNK
occurred	B-UNK
in	O
4	O
patients	B-UNK
,	O
and	O
an	O
unpleasant	O
sensation	B-UNK
(	O
"	O
empty	O
head	B-UNK
"	O
)	O
was	O
also	O
reported	B-UNK
by	O
2	O
patients	B-UNK
.	O
These	O
episodes	B-UNK
reversed	B-UNK
after	O
the	O
administration	O
of	O
diazepam	B-CHEMICAL
1	O
mg	B-UNK
intravenously	O
.	O
Significant	B-UNK
increases	I-UNK
in	O
drowsiness	B-UNK
were	O
reported	B-UNK
in	O
patients	B-UNK
treated	O
with	O
ketamine	B-CHEMICAL
in	O
both	O
groups	B-UNK
and	O
were	O
more	O
marked	O
with	O
ketamine	B-UNK
0.50	O
mg	B-UNK
/	O
kg	B-UNK
.	O
A	O
significant	B-UNK
difference	I-UNK
in	O
MMSE	O
was	O
observed	O
at	O
T30	O
in	O
patients	B-UNK
who	O
received	O
0.50	O
mg	B-UNK
/	O
kg	B-UNK
of	O
ketamine	B-CHEMICAL
.	O
Ketamine	B-UNK
can	O
improve	B-UNK
morphine	B-CHEMICAL
analgesia	B-UNK
in	O
difficult	O
pain	B-UNK
syndromes	B-UNK
,	O
such	O
as	O
neuropathic	B-DISEASE
pain	I-DISEASE
.	O
However	O
,	O
the	O
occurrence	B-UNK
of	O
central	B-UNK
adverse	B-UNK
effects	I-UNK
should	O
be	O
taken	O
into	O
account	O
,	O
especially	O
when	O
using	O
higher	B-UNK
doses	I-UNK
.	O
This	O
observation	B-UNK
should	O
be	O
tested	B-UNK
in	O
studies	B-UNK
of	O
prolonged	B-UNK
ketamine	B-UNK
administration	O
.	O

Endocrine	O
screening	B-UNK
in	O
1,022	O
men	B-UNK
with	O
erectile	B-DISEASE
dysfunction	I-DISEASE
:	O
clinical	B-UNK
significance	B-UNK
and	O
cost	B-UNK
-	O
effective	B-UNK
strategy	B-UNK
.	O
PURPOSE	B-UNK
:	O
We	O
reviewed	B-UNK
the	O
results	B-UNK
of	O
serum	B-UNK
testosterone	B-UNK
and	O
prolactin	B-UNK
determination	B-UNK
in	O
1,022	O
patients	B-UNK
referred	B-UNK
because	O
of	O
erectile	B-DISEASE
dysfunction	I-DISEASE
and	O
compared	O
the	O
data	B-UNK
with	O
history	B-UNK
,	O
results	B-UNK
of	O
physical	B-UNK
examination	I-UNK
,	O
other	O
etiological	O
investigations	B-UNK
and	O
effects	O
of	O
endocrine	O
therapy	O
to	O
refine	O
the	O
rules	O
of	O
cost	B-UNK
-	O
effective	B-UNK
endocrine	O
screening	B-UNK
and	O
to	O
pinpoint	O
actual	O
responsibility	O
for	O
hormonal	O
abnormalities	B-UNK
.	O
MATERIALS	B-UNK
AND	I-UNK
METHODS	I-UNK
:	O
Testosterone	B-UNK
and	O
prolactin	B-UNK
were	O
determined	B-UNK
by	O
radioimmunoassay	O
.	O
Every	O
patient	B-UNK
was	O
screened	O
for	O
testosterone	B-CHEMICAL
and	O
451	O
were	O
screened	O
for	O
prolactin	B-UNK
on	O
the	O
basis	B-UNK
of	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
,	O
gynecomastia	B-DISEASE
or	O
testosterone	B-UNK
less	O
than	O
4	O
ng./ml	O
.	O
Determination	B-UNK
was	O
repeated	B-UNK
in	O
case	B-UNK
of	O
abnormal	B-UNK
first	O
results	B-UNK
.	O
Prolactin	B-UNK
results	B-UNK
were	O
compared	O
with	O
those	O
of	O
a	O
previous	B-UNK
personal	O
cohort	B-UNK
of	O
1,340	O
patients	B-UNK
with	O
erectile	B-UNK
dysfunction	I-UNK
and	O
systematic	B-UNK
prolactin	B-UNK
determination	B-UNK
.	O
Main	B-UNK
clinical	B-UNK
criteria	B-UNK
tested	B-UNK
regarding	O
efficiency	O
in	O
hormone	B-UNK
determination	B-UNK
were	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
,	O
small	B-UNK
testes	O
and	O
gynecomastia	B-DISEASE
.	O
Endocrine	O
therapy	O
consisted	B-UNK
of	O
testosterone	B-UNK
heptylate	O
or	O
human	B-UNK
chorionic	O
gonadotropin	O
for	O
hypogonadism	B-DISEASE
and	O
bromocriptine	B-UNK
for	O
hyperprolactinemia	B-UNK
.	O
RESULTS	B-UNK
:	O
Testosterone	B-UNK
was	O
less	O
than	O
3	O
ng./ml	O
.	O
in	O
107	O
patients	B-UNK
but	O
normal	O
in	O
40	O
%	O
at	O
repeat	B-UNK
determination	B-UNK
.	O
The	O
prevalence	B-UNK
of	O
repeatedly	B-UNK
low	B-UNK
testosterone	B-UNK
increased	B-UNK
with	O
age	B-UNK
(	O
4	O
%	O
before	O
age	B-UNK
50	O
years	B-UNK
and	O
9	O
%	O
50	O
years	B-UNK
or	O
older	B-UNK
)	O
.	O
Two	O
pituitary	B-DISEASE
tumors	I-DISEASE
were	O
discovered	O
after	O
testosterone	B-UNK
determination	B-UNK
.	O
Most	O
of	O
the	O
other	O
low	B-UNK
testosterone	B-UNK
levels	O
seemed	O
to	O
result	B-UNK
from	O
nonorganic	O
hypothalamic	O
dysfunction	B-UNK
because	O
of	O
normal	O
serum	B-UNK
luteinizing	O
hormone	B-UNK
and	O
prolactin	B-UNK
and	O
to	O
have	O
only	O
a	O
small	B-UNK
role	O
in	O
erectile	B-UNK
dysfunction	I-UNK
(	O
definite	O
improvement	B-UNK
in	O
only	O
16	O
of	O
44	O
[	O
36	O
%	O
]	O
after	O
androgen	B-UNK
therapy	O
,	O
normal	O
morning	B-UNK
or	O
nocturnal	O
erections	O
in	O
30	O
%	O
and	O
definite	O
vasculogenic	O
contributions	O
in	O
42	O
%	O
)	O
.	O
Determining	O
testosterone	B-UNK
only	O
in	O
cases	B-UNK
of	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
or	O
abnormal	B-UNK
physical	B-UNK
examination	I-UNK
would	O
have	O
missed	O
40	O
%	O
of	O
the	O
cases	B-UNK
with	O
low	B-UNK
testosterone	B-CHEMICAL
,	O
including	O
37	O
%	O
of	O
those	O
subsequently	B-UNK
improved	O
by	O
androgen	B-UNK
therapy	O
.	O
Prolactin	B-UNK
exceeded	O
20	O
ng./ml	O
.	O
in	O
5	O
men	B-UNK
and	O
was	O
normal	O
in	O
2	O
at	O
repeat	B-UNK
determination	B-UNK
.	O
Only	O
1	O
prolactinoma	B-DISEASE
was	O
discovered	O
.	O
These	O
data	B-UNK
are	O
lower	B-UNK
than	O
those	O
we	O
found	O
during	O
the	O
last	O
2	O
decades	O
(	O
overall	O
prolactin	B-UNK
greater	B-UNK
than	O
20	O
ng./ml	O
.	O
in	O
1.86	O
%	O
of	O
1,821	O
patients	B-UNK
,	O
prolactinomas	O
in	O
7	O
,	O
0.38	O
%	O
)	O
.	O
Bromocriptine	B-UNK
was	O
definitely	O
effective	B-UNK
in	O
cases	B-UNK
with	O
prolactin	B-UNK
greater	B-UNK
than	O
35	O
ng./ml	O
.	O
(	O
8	O
of	O
12	O
compared	O
to	O
only	O
9	O
of	O
22	O
cases	B-UNK
with	O
prolactin	B-UNK
between	O
20	O
and	O
35	O
ng./ml	O
.	O
)	O
.	O
Testosterone	B-CHEMICAL
was	O
low	B-UNK
in	O
less	O
than	O
50	O
%	O
of	O
cases	B-UNK
with	O
prolactin	B-UNK
greater	B-UNK
than	O
35	O
ng./ml	O
.	O
CONCLUSIONS	B-UNK
:	O
Low	B-UNK
prevalences	O
and	O
effects	O
of	O
low	B-UNK
testosterone	B-UNK
and	O
high	B-UNK
prolactin	B-UNK
in	O
erectile	B-UNK
dysfunction	I-UNK
cannot	O
justify	O
their	O
routine	B-UNK
determination	B-UNK
.	O
However	O
,	O
cost	B-UNK
-	O
effective	B-UNK
screening	B-UNK
strategies	B-UNK
recommended	O
so	O
far	O
missed	O
40	O
to	O
50	O
%	O
of	O
cases	B-UNK
improved	O
with	O
endocrine	O
therapy	O
and	O
the	O
pituitary	B-DISEASE
tumors	I-DISEASE
.	O
We	O
now	O
advocate	O
that	O
before	O
age	B-UNK
50	O
years	B-UNK
testosterone	B-CHEMICAL
be	O
determined	B-UNK
only	O
in	O
cases	B-UNK
of	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
and	O
abnormal	B-UNK
physical	B-UNK
examination	I-UNK
but	O
that	O
it	O
be	O
measured	B-UNK
in	O
all	O
men	B-UNK
older	B-UNK
than	O
50	O
years	B-UNK
.	O
Prolactin	B-UNK
should	O
be	O
determined	B-UNK
only	O
in	O
cases	B-UNK
of	O
low	B-DISEASE
sexual	I-DISEASE
desire	I-DISEASE
,	O
gynecomastia	B-DISEASE
and	O
/	O
or	O
testosterone	B-UNK
less	O
than	O
4	O
ng./ml	O
.	O

Thiopentone	B-UNK
pretreatment	B-UNK
for	O
propofol	B-UNK
injection	B-UNK
pain	B-UNK
in	O
ambulatory	B-UNK
patients	B-UNK
.	O
This	O
study	B-UNK
investigated	B-UNK
propofol	B-CHEMICAL
injection	B-UNK
pain	B-UNK
in	O
patients	B-UNK
undergoing	B-UNK
ambulatory	B-UNK
anaesthesia	B-UNK
.	O
In	O
a	O
randomized	B-UNK
,	O
double-blind	O
trial	B-UNK
,	O
90	O
women	B-UNK
were	O
allocated	O
to	O
receive	B-UNK
one	O
of	O
three	O
treatments	O
prior	B-UNK
to	O
induction	B-UNK
of	O
anaesthesia	B-UNK
with	O
propofol	B-CHEMICAL
.	O
Patients	B-UNK
in	I-UNK
Group	I-UNK
C	O
received	O
2	O
ml	B-UNK
normal	B-UNK
saline	I-UNK
,	O
Group	B-UNK
L	O
,	O
2	O
ml	B-UNK
,	O
lidocaine	B-UNK
2	O
%	O
(	O
40	O
mg	B-UNK
)	O
and	O
Group	B-UNK
T	O
,	O
2	O
ml	B-UNK
thiopentone	B-CHEMICAL
2.5	O
%	O
(	O
50	O
mg	B-UNK
)	O
.	O
Venous	B-UNK
discomfort	O
was	O
assessed	B-UNK
with	O
a	O
visual	B-UNK
analogue	B-UNK
scale	B-UNK
(	O
VAS	B-UNK
)	O
5	O
-	O
15	O
sec	O
after	O
commencing	O
propofol	B-CHEMICAL
administration	O
using	O
an	O
infusion	B-UNK
pump	O
(	O
rate	B-UNK
1000	O
micrograms.kg-1.min-1	O
)	O
.	O
Loss	B-UNK
of	O
consciousness	B-UNK
occurred	B-UNK
in	O
60	O
-	O
90	O
sec	O
.	O
Visual	B-UNK
analogue	B-UNK
scores	O
(	O
mean	O
+	O
/-	O
SD	B-UNK
)	O
during	O
induction	B-UNK
were	O
lower	B-UNK
in	O
Groups	B-UNK
L	O
(	O
3.3	O
+	O
/-	O
2.5	O
)	O
and	O
T	O
(	O
4.1	O
+	O
/-	O
2.7	O
)	O
than	O
in	O
Group	B-UNK
C	O
(	O
5.6	O
+	O
/-	O
2.3	O
)	O
;	O
P	O
=	O
0.0031	O
.	O
The	O
incidence	B-UNK
of	O
venous	B-UNK
discomfort	O
was	O
lower	B-UNK
in	O
Group	B-UNK
L	O
(	O
76.6	O
%	O
;	O
P	O
<	O
0.05	O
)	O
than	O
in	O
Group	B-UNK
C	O
(	O
100	O
%	O
)	O
but	O
not	O
different	O
from	O
Group	B-UNK
T	O
(	O
90	O
%	O
)	O
.	O
The	O
VAS	B-UNK
scores	O
for	O
recall	B-UNK
of	O
pain	B-UNK
in	O
the	O
recovery	B-UNK
room	B-UNK
were	O
correlated	B-UNK
with	O
the	O
VAS	B-UNK
scores	O
during	O
induction	B-UNK
(	O
r	O
=	O
0.7045	O
;	O
P	O
<	O
0.0001	O
)	O
.	O
Recovery	B-UNK
room	B-UNK
discharge	B-UNK
times	B-UNK
were	O
similar	B-UNK
:	O
C	O
(	O
75.9	O
+	O
/-	O
19.4	O
min	B-UNK
)	O
;	O
L	O
73.6	O
+	O
/-	O
21.6	O
min	B-UNK
)	O
;	O
T	O
(	O
77.1	O
+	O
/-	O
18.9	O
min	B-UNK
)	O
.	O
Assessing	O
their	O
overall	O
satisfaction	O
,	O
89.7	O
%	O
would	O
choose	O
propofol	B-UNK
anaesthesia	B-UNK
again	O
.	O
We	O
conclude	O
that	O
lidocaine	B-UNK
reduces	O
the	O
incidence	B-UNK
and	I-UNK
severity	I-UNK
of	O
propofol	B-UNK
injection	B-UNK
pain	B-UNK
in	O
ambulatory	B-UNK
patients	B-UNK
whereas	O
thiopentone	B-UNK
only	O
reduces	O
its	O
severity	B-UNK
.	O

Comparison	B-UNK
of	O
i.v	B-UNK
.	O
glycopyrrolate	B-UNK
and	O
atropine	B-UNK
in	O
the	O
prevention	B-UNK
of	O
bradycardia	B-UNK
and	O
arrhythmias	B-UNK
following	O
repeated	B-UNK
doses	B-UNK
of	O
suxamethonium	B-UNK
in	O
children	B-UNK
.	O
The	O
effectiveness	B-UNK
of	O
administration	O
of	O
glycopyrrolate	B-UNK
5	O
and	O
10	O
micrograms	B-UNK
kg-1	O
and	O
atropine	B-UNK
10	O
and	O
20	O
micrograms	B-UNK
kg-1	O
i.v	B-UNK
.	O
immediately	B-UNK
before	O
the	O
induction	B-UNK
of	O
anaesthesia	B-UNK
,	O
to	O
prevent	B-UNK
arrhythmia	B-UNK
and	O
bradycardia	B-UNK
following	O
repeated	B-UNK
doses	B-UNK
of	O
suxamethonium	B-UNK
in	O
children	B-UNK
,	O
was	O
studied	O
.	O
A	O
control	B-UNK
group	B-UNK
was	O
included	B-UNK
for	O
comparison	B-UNK
with	O
the	O
lower	B-UNK
dose	B-UNK
range	B-UNK
of	O
glycopyrrolate	B-CHEMICAL
and	O
atropine	B-UNK
.	O
A	O
frequency	B-UNK
of	O
bradycardia	B-UNK
of	O
50	O
%	O
was	O
noted	B-UNK
in	O
the	O
control	B-UNK
group	B-UNK
,	O
but	O
this	O
was	O
not	O
significantly	B-UNK
different	O
from	O
the	O
frequency	B-UNK
with	O
the	O
active	B-UNK
drugs	B-UNK
.	O
Bradycardia	B-UNK
(	O
defined	B-UNK
as	O
a	O
decrease	B-UNK
in	O
heart	B-UNK
rate	I-UNK
to	O
less	O
than	O
50	O
beat	O
min-1	O
)	O
was	O
prevented	B-UNK
when	O
the	O
larger	B-UNK
dose	B-UNK
of	O
either	O
active	B-UNK
drug	B-UNK
was	O
used	O
.	O
It	O
is	O
recommended	O
that	O
either	O
glycopyrrolate	B-UNK
10	O
micrograms	B-UNK
kg-1	O
or	O
atropine	B-UNK
20	O
micrograms	B-UNK
kg-1	O
i.v	B-UNK
.	O
should	O
immediately	B-UNK
precede	O
induction	B-UNK
of	O
anaesthesia	B-UNK
,	O
in	O
children	B-UNK
,	O
if	O
the	O
repeated	B-UNK
administration	O
of	O
suxamethonium	B-CHEMICAL
is	O
anticipated	O
.	O

Reduction	O
in	O
caffeine	B-CHEMICAL
toxicity	B-UNK
by	O
acetaminophen	B-CHEMICAL
.	O
A	O
patient	B-UNK
who	O
allegedly	O
consumed	O
100	O
tablets	B-UNK
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
analgesic	B-UNK
containing	O
sodium	B-CHEMICAL
acetylsalicylate	O
,	O
caffeine	B-UNK
,	O
and	O
acetaminophen	B-CHEMICAL
displayed	O
no	O
significant	B-UNK
CNS	B-UNK
stimulation	B-UNK
despite	O
the	O
presence	O
of	O
175	O
micrograms	B-UNK
of	O
caffeine	B-UNK
per	O
mL	B-UNK
of	O
serum	B-UNK
.	O
Because	O
salicylates	O
have	O
been	O
reported	B-UNK
to	O
augment	O
the	O
stimulatory	O
effects	O
of	O
caffeine	B-UNK
on	O
the	O
CNS	B-UNK
,	O
attention	B-UNK
was	O
focused	O
on	O
the	O
possibility	O
that	O
the	O
presence	O
of	O
acetaminophen	B-UNK
(	O
52	O
micrograms	B-UNK
/	O
mL	B-UNK
)	O
reduced	B-UNK
the	O
CNS	B-UNK
toxicity	B-DISEASE
of	O
caffeine	B-CHEMICAL
.	O
Studies	B-UNK
in	O
DBA/2J	O
mice	B-UNK
showed	O
that	O
:	O
1	O
)	O
pretreatment	B-UNK
with	O
acetaminophen	B-CHEMICAL
(	O
100	O
mg	B-UNK
/	O
kg	B-UNK
)	O
increased	B-UNK
the	O
interval	B-UNK
between	O
the	O
administration	O
of	O
caffeine	B-CHEMICAL
(	O
300	O
to	O
450	O
mg	B-UNK
/	O
kg	B-UNK
IP	B-UNK
)	O
and	O
the	O
onset	B-UNK
of	O
fatal	B-UNK
convulsions	B-UNK
by	O
a	O
factor	B-UNK
of	O
about	O
two	O
;	O
and	O
2	O
)	O
pretreatment	B-UNK
with	O
acetaminophen	B-CHEMICAL
(	O
75	O
mg	B-UNK
/	O
kg	B-UNK
)	O
reduced	B-UNK
the	O
incidence	B-UNK
of	O
audiogenic	O
seizures	B-DISEASE
produced	B-UNK
in	O
the	O
presence	O
of	O
caffeine	B-UNK
(	O
12.5	O
to	O
75	O
mg	B-UNK
/	O
kg	B-UNK
IP	B-UNK
)	O
.	O
The	O
frequency	B-UNK
of	O
sound	O
-	O
induced	O
seizures	B-DISEASE
after	O
12.5	O
or	O
25	O
mg	B-UNK
/	O
kg	B-UNK
caffeine	B-UNK
was	O
reduced	B-UNK
from	O
50	O
to	O
5	O
%	O
by	O
acetaminophen	B-CHEMICAL
.	O
In	O
the	O
absence	O
of	O
caffeine	B-UNK
,	O
acetaminophen	B-UNK
(	O
up	O
to	O
300	O
mg	B-UNK
/	O
kg	B-UNK
)	O
did	O
not	O
modify	O
the	O
seizures	B-UNK
induced	O
by	O
maximal	B-UNK
electroshock	O
and	O
did	O
not	O
alter	O
the	O
convulsant	B-UNK
dose	B-UNK
of	O
pentylenetetrezol	O
in	O
mice	B-UNK
(	O
tests	B-UNK
performed	B-UNK
by	O
the	O
Anticonvulsant	B-UNK
Screening	B-UNK
Project	O
of	O
NINCDS	O
)	O
.	O
Acetaminophen	B-UNK
(	O
up	O
to	O
150	O
micrograms	B-UNK
/	O
mL	B-UNK
)	O
did	O
not	O
retard	O
the	O
incorporation	O
of	O
radioactive	O
adenosine	B-UNK
into	O
ATP	B-UNK
in	O
slices	O
of	O
rat	B-UNK
cerebral	B-UNK
cortex	B-UNK
.	O
Thus	O
the	O
mechanism	B-UNK
by	O
which	O
acetaminophen	B-CHEMICAL
antagonizes	O
the	O
actions	B-UNK
of	O
caffeine	B-UNK
in	O
the	O
CNS	B-UNK
remains	O
unknown	O
.	O

Flestolol	B-UNK
:	O
an	O
ultra-short-acting	O
beta-adrenergic	O
blocking	B-UNK
agent	B-UNK
.	O
Flestolol	B-CHEMICAL
(	O
ACC-9089	O
)	O
is	O
a	O
nonselective	O
,	O
competitive	O
,	O
ultra-short-acting	O
beta-adrenergic	O
blocking	B-UNK
agent	B-UNK
,	O
without	O
any	O
intrinsic	O
sympathomimetic	O
activity	B-UNK
.	O
Flestolol	B-CHEMICAL
is	O
metabolized	O
by	O
plasma	B-UNK
esterases	O
and	O
has	O
an	O
elimination	O
half	B-UNK
-	O
life	B-UNK
of	O
approximately	B-UNK
6.5	O
minutes	B-UNK
.	O
This	O
agent	B-UNK
was	O
well	O
tolerated	B-UNK
in	O
healthy	B-UNK
volunteers	I-UNK
at	O
doses	B-UNK
up	O
to	O
100	O
micrograms	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
.	O
In	O
long	B-UNK
-	O
term	O
infusion	B-UNK
studies	B-UNK
,	O
flestolol	B-CHEMICAL
was	O
well	O
tolerated	B-UNK
at	O
the	O
effective	B-UNK
beta-blocking	O
dose	B-UNK
(	O
5	O
micrograms	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
)	O
for	O
up	O
to	O
seven	O
days	B-UNK
.	O
Flestolol	B-UNK
blood	B-UNK
concentrations	B-UNK
increased	B-UNK
linearly	O
with	O
increasing	B-UNK
dose	B-UNK
and	O
good	O
correlation	B-UNK
exists	O
between	O
blood	B-UNK
concentrations	B-UNK
of	O
flestolol	B-CHEMICAL
and	O
beta-adrenergic	O
blockade	B-UNK
.	O
Flestolol	B-UNK
produced	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
attenuation	O
of	O
isoproterenol	B-CHEMICAL
-	O
induced	O
tachycardia	B-UNK
.	O
Electrophysiologic	O
and	O
hemodynamic	B-UNK
effects	O
of	O
flestolol	B-CHEMICAL
are	O
similar	B-UNK
to	O
those	O
of	O
other	O
beta	B-UNK
blockers	I-UNK
.	O
In	O
contrast	B-UNK
with	O
other	O
beta	B-UNK
blockers	I-UNK
,	O
flestolol	B-UNK
-	O
induced	O
effects	O
reverse	B-UNK
rapidly	O
(	O
within	O
30	O
minutes	B-UNK
)	O
following	O
discontinuation	B-UNK
because	O
of	O
its	O
short	B-UNK
half	B-UNK
-	O
life	B-UNK
.	O
Flestolol	B-CHEMICAL
effectively	B-UNK
reduced	B-UNK
heart	B-UNK
rate	I-UNK
in	O
patients	B-UNK
with	O
supraventricular	O
tachyarrhythmia	O
.	O
In	O
patients	B-UNK
with	O
unstable	O
angina	B-UNK
,	O
flestolol	B-CHEMICAL
infusion	B-UNK
was	O
found	O
to	O
be	O
safe	O
and	O
effective	B-UNK
in	O
controlling	B-UNK
chest	B-UNK
pain	I-UNK
.	O
It	O
is	O
concluded	O
that	O
flestolol	B-UNK
is	O
a	O
potent	B-UNK
,	O
well	O
-	O
tolerated	B-UNK
,	O
ultra-short-acting	O
beta-adrenergic	O
blocking	B-UNK
agent	B-UNK
.	O
Use	O
of	O
flestolol	B-CHEMICAL
in	O
the	O
critical	B-UNK
care	B-UNK
setting	B-UNK
is	O
currently	O
undergoing	B-UNK
investigation	B-UNK
.	O

Adverse	B-UNK
effect	I-UNK
of	O
the	O
calcium	B-UNK
channel	I-UNK
blocker	B-UNK
nitrendipine	B-CHEMICAL
on	O
nephrosclerosis	B-DISEASE
in	O
rats	B-UNK
with	O
renovascular	O
hypertension	B-UNK
.	O
The	O
effect	B-UNK
of	O
a	O
6-week	O
treatment	B-UNK
with	O
the	O
calcium	B-UNK
channel	I-UNK
blocker	B-UNK
nitrendipine	B-CHEMICAL
or	O
the	O
angiotensin	B-UNK
converting	I-UNK
enzyme	I-UNK
inhibitor	I-UNK
enalapril	B-CHEMICAL
on	O
blood	B-UNK
pressure	I-UNK
,	O
albuminuria	B-DISEASE
,	O
renal	B-UNK
hemodynamics	B-UNK
,	O
and	O
morphology	O
of	O
the	O
nonclipped	O
kidney	B-UNK
was	O
studied	O
in	O
rats	B-UNK
with	O
two	O
-	O
kidney	B-UNK
,	O
one	O
clip	O
renovascular	O
hypertension	B-DISEASE
.	O
Six	O
weeks	B-UNK
after	O
clipping	O
of	O
one	O
renal	B-UNK
artery	B-UNK
,	O
hypertensive	B-DISEASE
rats	B-UNK
(	O
178	O
+	O
/-	O
4	O
mm	B-UNK
Hg	I-UNK
)	O
were	O
randomly	B-UNK
assigned	I-UNK
to	I-UNK
three	O
groups	B-UNK
:	O
untreated	B-UNK
hypertensive	B-DISEASE
controls	B-UNK
(	O
n	O
=	O
8)	O
,	O
enalapril	B-CHEMICAL
-	O
treated	O
(	O
n	O
=	O
8)	O
,	O
or	O
nitrendipine	B-CHEMICAL
-	O
treated	O
(	O
n	O
=	O
10	O
)	O
.	O
Sham	B-UNK
-	O
operated	O
rats	B-UNK
served	O
as	O
normotensive	B-UNK
controls	B-UNK
(	O
128	O
+	O
/-	O
3	O
mm	B-UNK
Hg	I-UNK
,	O
n	O
=	O
8)	O
.	O
After	O
6	O
weeks	B-UNK
of	O
treatment	B-UNK
,	O
renal	B-UNK
hemodynamics	B-UNK
(	O
glomerular	B-UNK
filtration	I-UNK
rate	I-UNK
and	O
renal	B-UNK
plasma	B-UNK
flow	B-UNK
)	O
were	O
measured	B-UNK
in	O
the	O
anesthetized	B-UNK
rats	I-UNK
.	O
Renal	B-UNK
tissue	B-UNK
was	O
obtained	B-UNK
for	O
determination	B-UNK
of	O
glomerular	B-UNK
size	B-UNK
and	O
sclerosis	B-DISEASE
.	O
Enalapril	B-CHEMICAL
but	O
not	O
nitrendipine	B-CHEMICAL
reduced	B-UNK
blood	B-UNK
pressure	I-UNK
significantly	B-UNK
.	O
After	O
6	O
weeks	B-UNK
of	O
therapy	O
,	O
glomerular	B-UNK
filtration	I-UNK
rate	I-UNK
was	O
not	O
different	O
among	O
the	O
studied	O
groups	B-UNK
.	O
Renal	B-UNK
plasma	B-UNK
flow	B-UNK
increased	B-UNK
,	O
but	O
albumin	B-UNK
excretion	B-UNK
and	O
glomerulosclerosis	B-UNK
did	O
not	O
change	B-UNK
after	O
enalapril	B-CHEMICAL
treatment	B-UNK
.	O
In	O
contrast	B-UNK
,	O
in	O
the	O
nitrendipine	B-CHEMICAL
-	O
treated	O
group	B-UNK
albuminuria	B-DISEASE
increased	B-UNK
from	O
12.8	O
+	O
/-	O
2	O
progressively	O
to	O
163	O
+	O
/-	O
55	O
compared	O
with	O
19.2	O
+	O
/-	O
9	O
mg/24	O
hr	B-UNK
in	O
the	O
hypertensive	B-UNK
controls	B-UNK
.	O
Furthermore	O
,	O
glomerulosclerosis	B-UNK
index	B-UNK
was	O
significantly	B-UNK
increased	B-UNK
in	O
the	O
nitrendipine	B-CHEMICAL
-	O
treated	O
group	B-UNK
compared	O
with	O
the	O
hypertensive	B-DISEASE
controls	B-UNK
(	O
0.38	O
+	O
/-	O
0.1	O
versus	O
0.13	O
+	O
/-	O
0.04	O
)	O
.	O
In	O
addition	B-UNK
,	O
glomerular	B-UNK
size	B-UNK
was	O
higher	B-UNK
in	O
the	O
nitrendipine	B-CHEMICAL
-	O
treated	O
group	B-UNK
(	O
14.9	O
+	O
/-	O
0.17	O
10(-3	O
)	O
mm2	O
)	O
but	O
lower	B-UNK
in	O
the	O
enalapril	B-CHEMICAL
-	O
treated	O
group	B-UNK
(	O
11.5	O
+	O
/-	O
0.15	O
10(-3	O
)	O
mm2	O
)	O
compared	O
with	O
the	O
hypertensive	B-UNK
controls	B-UNK
(	O
12.1	O
+	O
/-	O
0.17	O
10(-3	O
)	O
mm2).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	B-UNK
)	O

Treatment	B-UNK
of	O
tinnitus	B-DISEASE
by	O
intratympanic	O
instillation	B-UNK
of	O
lignocaine	B-UNK
(	O
lidocaine	B-UNK
)	O
2	O
per	B-UNK
cent	I-UNK
through	O
ventilation	B-UNK
tubes	O
.	O
Idiopathic	B-UNK
subjective	B-UNK
tinnitus	B-DISEASE
(	O
IST	O
)	O
is	O
one	O
of	O
the	O
most	O
obscure	O
otological	O
pathologies	O
.	O
This	O
paper	B-UNK
presents	B-UNK
the	O
results	B-UNK
of	O
treating	O
IST	O
by	O
intratympanic	O
instillation	B-UNK
of	O
lignocaine	B-UNK
(	O
lidocaine	B-CHEMICAL
)	O
2	O
per	B-UNK
cent	I-UNK
through	O
a	O
grommet	O
,	O
for	O
five	O
weekly	B-UNK
courses	B-UNK
.	O
Fifty	B-UNK
-	O
two	O
patients	B-UNK
suffering	O
from	O
intractable	O
tinnitus	B-DISEASE
entered	O
this	O
therapeutic	B-UNK
trial	B-UNK
,	O
but	O
only	O
nine	O
finished	O
all	O
five	O
courses	B-UNK
.	O
In	O
one	O
patient	B-UNK
,	O
the	O
tinnitus	B-DISEASE
was	O
almost	O
completely	O
abolished	O
,	O
but	O
in	O
all	O
the	O
nine	O
patients	B-UNK
the	O
decompensated	O
tinnitus	B-DISEASE
changed	O
to	O
a	O
compensated	O
one	O
.	O
We	O
suggest	B-UNK
this	O
mode	O
of	O
treatment	B-UNK
for	O
patients	B-UNK
that	O
were	O
previously	B-UNK
treated	O
by	O
drugs	B-UNK
,	O
acupuncture	O
and	O
biofeedback	O
,	O
with	O
disappointing	O
results	B-UNK
.	O
Patients	B-UNK
should	O
be	O
warned	O
about	O
the	O
side	O
effects	O
of	O
vertigo	B-DISEASE
and	O
vomiting	B-UNK
,	O
which	O
subsides	O
gradually	O
with	O
every	O
new	O
instillation	B-UNK
,	O
and	O
that	O
the	O
tinnitus	B-DISEASE
may	O
not	O
disappear	O
but	O
will	O
be	O
alleviated	O
,	O
enabling	O
them	O
to	O
cope	O
more	O
easily	O
with	O
the	O
disease	B-UNK
and	O
lead	B-UNK
a	O
more	O
normal	O
life	B-UNK
.	O

Perhexiline	B-CHEMICAL
maleate	I-CHEMICAL
and	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
.	O
Peripheral	B-UNK
neuropathy	I-UNK
has	O
been	O
noted	B-UNK
as	O
a	O
complication	B-UNK
of	O
therapy	O
with	O
perhexiline	B-CHEMICAL
maleate	I-CHEMICAL
,	O
a	O
drug	B-UNK
widely	B-UNK
used	O
in	O
France	O
(	O
and	O
in	O
clinical	B-UNK
trials	I-UNK
in	O
the	O
United	O
States	B-UNK
)	O
for	O
the	O
prophylactic	B-UNK
treatment	B-UNK
of	O
angina	B-DISEASE
pectoris	I-DISEASE
.	O
In	O
24	O
patients	B-UNK
with	O
this	O
complication	B-UNK
,	O
the	O
marked	O
slowing	O
of	O
motor	B-UNK
nerve	B-UNK
conduction	B-UNK
velocity	B-UNK
and	O
the	O
electromyographic	O
changes	O
imply	O
mainly	O
a	O
demyelinating	B-DISEASE
disorder	I-DISEASE
.	O
Improvement	B-UNK
was	O
noted	B-UNK
with	O
cessation	B-UNK
of	O
therapy	O
.	O
In	O
a	O
few	O
cases	B-UNK
the	O
presence	O
of	O
active	B-UNK
denervation	O
signified	O
a	O
poor	O
prognosis	O
,	O
with	O
only	O
slight	B-UNK
improvement	B-UNK
.	O
The	O
underlying	B-UNK
mechanism	B-UNK
causing	O
the	O
neuropathy	B-UNK
is	O
not	O
yet	O
fully	B-UNK
known	O
,	O
although	O
some	O
evidence	B-UNK
indicates	O
that	O
it	O
may	O
be	O
a	O
lipid	B-UNK
storage	O
process	O
.	O

Effect	B-UNK
of	O
humoral	O
modulators	O
of	O
morphine	B-CHEMICAL
-	O
induced	O
increase	B-UNK
in	O
locomotor	B-UNK
activity	I-UNK
of	O
mice	B-UNK
.	O
The	O
effect	B-UNK
of	O
humoral	O
modulators	O
on	O
the	O
morphine	B-UNK
-	O
induced	O
increase	B-UNK
in	O
locomotor	B-UNK
activity	I-UNK
of	O
mice	B-UNK
was	O
studied	O
.	O
The	O
subcutaneous	B-UNK
administration	O
of	O
10	O
mg	B-UNK
/	O
kg	B-UNK
of	O
morphine	B-CHEMICAL
-	O
HC1	O
produced	B-UNK
a	O
marked	O
increase	B-UNK
in	O
locomotor	B-UNK
activity	I-UNK
in	O
mice	B-UNK
.	O
The	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
hyperactivity	I-UNK
was	O
potentiated	B-UNK
by	O
scopolamine	B-CHEMICAL
and	O
attenuated	B-UNK
by	O
physostigmine	O
.	O
In	O
contrast	B-UNK
,	O
both	O
methscopolamine	O
and	O
neostigmine	O
,	O
which	O
do	O
not	O
penetrate	O
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
,	O
had	O
no	O
effect	B-UNK
on	O
the	O
hyperactivity	B-UNK
produced	B-UNK
by	O
morphine	B-UNK
.	O
Pretreatment	B-UNK
of	O
mice	B-UNK
with	O
alpha	B-UNK
-	O
methyltyrosine	O
(	O
20	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
,	O
one	O
hour	B-UNK
)	O
,	O
an	O
inhibitor	B-UNK
of	O
tyrosine	B-CHEMICAL
hydroxylase	B-UNK
,	O
significantly	B-UNK
decreased	B-UNK
the	O
activity	B-UNK
-	O
increasing	B-UNK
effects	O
of	O
morphine	B-CHEMICAL
.	O
On	O
the	O
other	O
hand	B-UNK
,	O
pretreatment	B-UNK
with	O
p	O
-	O
chlorophenylalamine	O
(	O
3	O
X	O
320	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
,	O
24	O
hr	B-UNK
)	O
,	O
a	O
serotonin	B-CHEMICAL
depletor	O
,	O
caused	B-UNK
no	O
significant	B-UNK
change	B-UNK
in	O
the	O
hyperactivity	B-UNK
.	O
The	O
study	B-UNK
suggests	O
that	O
the	O
activity	B-UNK
-	O
increasing	B-UNK
effects	O
of	O
morphine	B-CHEMICAL
are	O
mediated	B-UNK
by	O
the	O
release	B-UNK
of	O
catecholamines	B-UNK
from	O
adrenergic	B-UNK
neurons	B-UNK
in	O
the	O
brain	B-UNK
.	O
And	O
the	O
results	B-UNK
are	O
consistent	B-UNK
with	O
the	O
hypothesis	B-UNK
that	O
morphine	B-UNK
acts	B-UNK
by	O
retarding	O
the	O
release	B-UNK
of	O
acetylcholine	B-UNK
at	O
some	O
central	B-UNK
cholinergic	B-UNK
synapses	O
.	O
It	O
is	O
also	O
suggested	B-UNK
from	O
collected	O
evidence	B-UNK
that	O
the	O
activity	B-UNK
-	O
increasing	B-UNK
effects	O
of	O
morphine	B-CHEMICAL
in	O
mice	B-UNK
are	O
mediated	B-UNK
by	O
mechanisms	B-UNK
different	O
from	O
those	O
which	O
mediate	B-UNK
the	O
activity	B-UNK
-	O
increasing	B-UNK
effects	O
of	O
morphine	B-CHEMICAL
in	O
rats	B-UNK
.	O

Mechanisms	B-UNK
of	O
FK	O
506-induced	O
hypertension	B-UNK
in	O
the	O
rat	B-UNK
.	O
-Tacrolimus	O
(	O
FK	B-UNK
506	I-UNK
)	O
is	O
a	O
powerful	O
,	O
widely	B-UNK
used	O
immunosuppressant	O
.	O
The	O
clinical	B-UNK
utility	B-UNK
of	O
FK	B-UNK
506	I-UNK
is	O
complicated	O
by	O
substantial	O
hypertension	B-DISEASE
and	O
nephrotoxicity	B-UNK
.	O
To	O
clarify	O
the	O
mechanisms	B-UNK
of	O
FK	O
506-induced	O
hypertension	B-DISEASE
,	O
we	O
studied	O
the	O
chronic	B-UNK
effects	O
of	O
FK	B-UNK
506	I-UNK
on	O
the	O
synthesis	B-UNK
of	O
endothelin-1	O
(	O
ET-1	O
)	O
,	O
the	O
expression	B-UNK
of	O
mRNA	B-UNK
of	O
ET-1	O
and	O
endothelin	O
-	O
converting	O
enzyme-1	O
(	O
ECE-1	O
)	O
,	O
the	O
endothelial	B-UNK
nitric	B-UNK
oxide	I-UNK
synthase	B-UNK
(	O
eNOS	B-UNK
)	O
activity	B-UNK
,	O
and	O
the	O
expression	B-UNK
of	O
mRNA	B-UNK
of	O
eNOS	B-UNK
and	O
C	O
-	O
type	B-UNK
natriuretic	B-UNK
peptide	B-UNK
(	O
CNP	O
)	O
in	O
rat	B-UNK
blood	B-UNK
vessels	I-UNK
.	O
In	O
addition	B-UNK
,	O
the	O
effect	B-UNK
of	O
the	O
specific	B-UNK
endothelin	O
type	B-UNK
A	O
receptor	B-UNK
antagonist	I-UNK
FR	O
139317	O
on	O
FK	O
506-induced	O
hypertension	B-UNK
in	O
rats	B-UNK
was	O
studied	O
.	O
FK	B-UNK
506	I-UNK
,	O
5	O
mg	B-UNK
.	O
kg-1	O
.	O
d-1	O
given	O
for	O
4	O
weeks	B-UNK
,	O
elevated	B-UNK
blood	B-UNK
pressure	I-UNK
from	O
102+/-13	O
to	O
152+/-15	O
mm	B-UNK
Hg	I-UNK
and	O
increased	B-UNK
the	O
synthesis	B-UNK
of	O
ET-1	O
and	O
the	O
levels	O
of	O
ET-1	O
mRNA	B-UNK
in	O
the	O
mesenteric	O
artery	B-UNK
(	O
240	O
%	O
and	O
230	O
%	O
,	O
respectively	O
)	O
.	O
Little	O
change	B-UNK
was	O
observed	O
in	O
the	O
expression	B-UNK
of	O
ECE-1	O
mRNA	B-UNK
and	O
CNP	O
mRNA	B-UNK
.	O
FK	B-UNK
506	I-UNK
decreased	B-UNK
eNOS	B-UNK
activity	B-UNK
and	O
the	O
levels	O
of	O
eNOS	B-UNK
mRNA	B-UNK
in	O
the	O
aorta	B-UNK
(	O
48	O
%	O
and	O
55	O
%	O
,	O
respectively	O
)	O
.	O
The	O
administration	O
of	O
FR	O
139317	O
(	O
10	O
mg	B-UNK
.	O
kg-1	O
.	O
d-1	O
)	O
prevented	B-UNK
FK	O
506-induced	O
hypertension	B-DISEASE
in	O
rats	B-UNK
.	O
These	O
results	B-UNK
indicate	O
that	O
FK	B-UNK
506	I-UNK
may	O
increase	B-UNK
blood	B-UNK
pressure	I-UNK
not	O
only	O
by	O
increasing	B-UNK
ET-1	O
production	B-UNK
but	O
also	O
by	O
decreasing	B-UNK
NO	O
synthesis	B-UNK
in	O
the	O
vasculature	O
.	O

Suxamethonium	B-UNK
induced	O
prolonged	B-UNK
apnea	B-UNK
in	O
a	O
patient	B-UNK
receiving	B-UNK
electroconvulsive	O
therapy	O
.	O
Suxamethonium	B-CHEMICAL
causes	O
prolonged	B-UNK
apnea	B-DISEASE
in	O
patients	B-UNK
in	O
whom	O
pseudocholinesterase	O
enzyme	B-UNK
gets	O
deactivated	O
by	O
organophosphorus	O
(	O
OP	O
)	O
poisons	O
.	O
Here	O
,	O
we	O
present	B-UNK
a	O
similar	B-UNK
incident	O
in	O
a	O
severely	O
depressed	B-UNK
patient	B-UNK
who	O
received	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O
Prolonged	B-UNK
apnea	B-UNK
in	O
our	O
case	B-UNK
ensued	O
because	O
the	O
information	B-UNK
about	O
suicidal	O
attempt	O
by	O
OP	O
compound	B-UNK
was	O
concealed	O
from	O
the	O
treating	O
team	O
.	O

The	O
effects	O
of	O
the	O
adjunctive	O
bupropion	B-UNK
on	O
male	B-UNK
sexual	B-DISEASE
dysfunction	I-DISEASE
induced	O
by	O
a	O
selective	B-UNK
serotonin	B-UNK
reuptake	I-UNK
inhibitor	B-UNK
:	O
a	O
double-blind	O
placebo	B-UNK
-	O
controlled	B-UNK
and	O
randomized	B-UNK
study	B-UNK
.	O
OBJECTIVE	B-UNK
:	O
To	O
determine	B-UNK
the	O
safety	B-UNK
and	I-UNK
efficacy	I-UNK
of	O
adjunctive	O
bupropion	B-UNK
sustained	B-UNK
-	O
release	B-UNK
(	O
SR	O
)	O
on	O
male	B-UNK
sexual	B-UNK
dysfunction	I-UNK
(	O
SD	B-UNK
)	O
induced	O
by	O
a	O
selective	B-UNK
serotonin	B-UNK
reuptake	I-UNK
inhibitor	B-UNK
(	O
SSRI	O
)	O
,	O
as	O
SD	B-UNK
is	O
a	O
common	B-UNK
side	O
-	O
effect	B-UNK
of	O
SSRIs	O
and	O
the	O
most	O
effective	B-UNK
treatments	O
have	O
yet	O
to	O
be	O
determined	B-UNK
.	O
PATIENTS	B-UNK
AND	I-UNK
METHODS	I-UNK
:	O
The	O
randomized	B-UNK
sample	B-UNK
consisted	B-UNK
of	O
234	O
euthymic	O
men	B-UNK
who	O
were	O
receiving	B-UNK
some	O
type	B-UNK
of	O
SSRI	O
.	O
The	O
men	B-UNK
were	O
randomly	B-UNK
assigned	I-UNK
to	I-UNK
bupropion	B-UNK
SR	O
(	O
150	O
mg	B-UNK
twice	O
daily	B-UNK
,	O
117	O
)	O
or	O
placebo	B-UNK
(	O
twice	O
daily	B-UNK
,	O
117	O
)	O
for	O
12	O
weeks	B-UNK
.	O
Efficacy	B-UNK
was	O
evaluated	B-UNK
using	O
the	O
Clinical	B-UNK
Global	B-UNK
Impression	O
-	O
Sexual	B-UNK
Function	B-UNK
(	O
CGI	O
-	O
SF	O
;	O
the	O
primary	B-UNK
outcome	B-UNK
measure	B-UNK
)	O
,	O
the	O
International	O
Index	B-UNK
of	O
Erectile	B-UNK
Function	B-UNK
(	O
IIEF	O
)	O
,	O
Arizona	O
Sexual	B-UNK
Experience	B-UNK
Scale	B-UNK
(	O
ASEX	O
)	O
,	O
and	O
Erectile	B-UNK
Dysfunction	I-UNK
Inventory	O
of	O
Treatment	B-UNK
Satisfaction	O
(	O
EDITS	O
)	O
(	O
secondary	B-UNK
outcome	B-UNK
measures	B-UNK
)	O
.	O
Participants	B-UNK
were	O
followed	O
biweekly	O
during	O
study	B-UNK
period	B-UNK
.	O
RESULTS	B-UNK
:	O
After	O
12	O
weeks	B-UNK
of	O
treatment	B-UNK
,	O
the	O
mean	O
(	O
sd	B-UNK
)	O
scores	O
for	O
CGI	O
-	O
SF	O
were	O
significantly	B-UNK
lower	I-UNK
,	O
i.e	B-UNK
.	O
better	O
,	O
in	O
patients	B-UNK
on	O
bupropion	B-UNK
SR	O
,	O
at	O
2.4	O
(	O
1.2	O
)	O
,	O
than	O
in	O
the	O
placebo	B-UNK
group	B-UNK
,	O
at	O
3.9	O
(	O
1.1	O
)	O
(	O
P=	O
0.01	O
)	O
.	O
Men	B-UNK
who	O
received	O
bupropion	B-UNK
had	O
a	O
significant	B-UNK
increase	B-UNK
in	O
the	O
total	B-UNK
IIEF	O
score	O
(	O
54.4	O
%	O
vs	O
1.2	O
%	O
;	O
P=	O
0.003	O
)	O
,	O
and	O
in	O
the	O
five	O
different	O
domains	O
of	O
the	O
IIEF	O
.	O
Total	B-UNK
ASEX	O
scores	O
were	O
significantly	B-UNK
lower	I-UNK
,	O
i.e	B-UNK
.	O
better	O
,	O
among	O
men	B-UNK
who	O
received	O
bupropion	B-UNK
than	O
placebo	B-UNK
,	O
at	O
15.5	O
(	O
4.3	O
)	O
vs	O
21.5	O
(	O
4.7	O
)	O
(	O
P=	O
0.002	O
)	O
.	O
The	O
EDITS	O
scores	O
were	O
67.4	O
(	O
10.2	O
)	O
for	O
the	O
bupropion	B-UNK
and	O
36.3	O
(	O
11.7	O
)	O
for	O
the	O
placebo	B-UNK
group	B-UNK
(	O
P=	O
0.001	O
)	O
.	O
The	O
ASEX	O
score	O
and	O
CGI	O
-	O
SF	O
score	O
were	O
correlated	B-UNK
(	O
P=	O
0.003	O
)	O
.	O
In	O
linear	O
regression	B-UNK
analyses	B-UNK
the	O
CGI	O
-	O
SF	O
score	O
was	O
not	O
affected	B-UNK
significantly	B-UNK
by	O
the	O
duration	B-UNK
of	O
SD	B-DISEASE
,	O
type	B-UNK
of	O
SSRI	O
used	O
and	O
age	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
Bupropion	B-UNK
is	O
an	O
effective	B-UNK
treatment	B-UNK
for	O
male	B-UNK
SD	B-DISEASE
induced	O
by	O
SSRIs	O
.	O
These	O
results	B-UNK
provide	O
empirical	O
support	B-UNK
for	O
conducting	O
a	O
further	O
study	B-UNK
of	O
bupropion	B-UNK
.	O

Lamivudine	B-UNK
for	O
the	O
prevention	B-UNK
of	O
hepatitis	B-UNK
B	I-UNK
virus	I-UNK
reactivation	O
in	O
hepatitis	B-UNK
-	O
B	O
surface	B-UNK
antigen	B-UNK
(	O
HBSAG	B-UNK
)	O
seropositive	O
cancer	B-UNK
patients	B-UNK
undergoing	B-UNK
cytotoxic	B-UNK
chemotherapy	O
.	O
Hepatitis	B-UNK
B	I-UNK
virus	I-UNK
(	O
HBV	B-UNK
)	O
is	O
one	O
of	O
the	O
major	B-UNK
causes	O
of	O
chronic	B-DISEASE
liver	I-DISEASE
disease	I-DISEASE
worldwide	O
.	O
Cancer	B-DISEASE
patients	B-UNK
who	O
are	O
chronic	B-UNK
carriers	B-UNK
of	O
HBV	B-UNK
have	O
a	O
higher	B-UNK
hepatic	B-UNK
complication	B-UNK
rate	B-UNK
while	O
receiving	B-UNK
cytotoxic	B-UNK
chemotherapy	O
(	O
CT	B-UNK
)	O
and	O
this	O
has	O
mainly	O
been	O
attributed	B-UNK
to	O
HBV	B-UNK
reactivation	O
.	O
In	O
this	O
study	B-UNK
,	O
cancer	B-DISEASE
patients	B-UNK
who	O
have	O
solid	O
and	O
hematological	O
malignancies	B-DISEASE
with	O
chronic	B-UNK
HBV	B-UNK
infection	B-UNK
received	O
the	O
antiviral	B-UNK
agent	B-UNK
lamivudine	B-UNK
prior	B-UNK
and	O
during	O
CT	B-UNK
compared	O
with	O
historical	O
control	B-UNK
group	B-UNK
who	O
did	O
not	O
receive	B-UNK
lamivudine	B-UNK
.	O
The	O
objectives	B-UNK
were	O
to	O
assess	B-UNK
the	O
efficacy	B-UNK
of	O
lamivudine	B-UNK
in	O
reducing	B-UNK
the	O
incidence	B-UNK
of	O
HBV	B-UNK
reactivation	O
,	O
and	O
diminishing	O
morbidity	B-UNK
and	I-UNK
mortality	I-UNK
during	O
CT	B-UNK
.	O
Two	O
groups	B-UNK
were	O
compared	O
in	O
this	O
study	B-UNK
.	O
The	O
prophylactic	B-UNK
lamivudin	O
group	B-UNK
consisted	B-UNK
of	O
37	O
patients	B-UNK
who	O
received	O
prophylactic	B-UNK
lamivudine	B-UNK
treatment	B-UNK
.	O
The	O
historical	O
controls	B-UNK
consisted	B-UNK
of	O
50	O
consecutive	B-UNK
patients	B-UNK
who	O
underwent	O
CT	B-UNK
without	O
prophylactic	B-UNK
lamivudine	B-CHEMICAL
.	O
They	O
were	O
followed	O
up	O
during	O
and	O
for	O
8	O
weeks	B-UNK
after	O
CT	B-UNK
.	O
The	O
outcomes	B-UNK
were	O
compared	O
for	O
both	O
groups	B-UNK
.	O
Of	O
our	O
control	B-UNK
group	B-UNK
(	O
n=	O
50	O
)	O
,	O
21	O
patients	B-UNK
(	O
42	O
%	O
)	O
were	O
established	B-UNK
hepatitis	B-UNK
.	O
Twelve	O
(	O
24	O
%	O
)	O
of	O
them	O
were	O
evaluated	B-UNK
as	O
severe	B-UNK
hepatitis	B-UNK
.	O
In	O
the	O
prophylactic	B-UNK
lamivudine	B-UNK
group	B-UNK
severe	B-UNK
hepatitis	B-UNK
were	O
observed	O
only	O
in	O
1	O
patient	B-UNK
(	O
2.7	O
%	O
)	O
of	O
37	O
patients	B-UNK
(	O
p	O
<	O
0.006	O
)	O
.	O
Comparison	B-UNK
of	O
the	O
mean	O
ALT	O
values	O
revealed	O
significantly	B-UNK
higher	I-UNK
mean	O
alanine	B-UNK
aminotransferase	B-UNK
(	O
ALT	O
)	O
values	O
in	O
the	O
control	B-UNK
group	B-UNK
than	O
the	O
prophylactic	B-UNK
lamivudine	B-CHEMICAL
group	B-UNK
;	O
154:64	O
(	O
p	O
<	O
0.32	O
)	O
.	O
Our	O
study	B-UNK
suggests	O
that	O
prophylactic	B-UNK
lamivudine	B-UNK
significantly	B-UNK
decreases	B-UNK
the	O
incidence	B-UNK
of	O
HBV	B-UNK
reactivation	O
and	O
overall	O
morbidity	B-UNK
in	O
cancer	B-UNK
patients	B-UNK
during	O
and	O
after	O
immunosuppressive	B-UNK
therapy	O
.	O
Further	O
studies	B-UNK
are	O
needed	B-UNK
to	O
determine	B-UNK
the	O
most	O
appropriate	O
nucleoside	O
or	O
nucleotide	O
analogue	B-UNK
for	O
antiviral	B-UNK
prophylaxis	O
during	O
CT	B-UNK
and	O
the	O
optimal	B-UNK
duration	B-UNK
of	O
administration	O
after	O
completion	O
of	O
CT	B-UNK
.	O

Ginsenoside	B-CHEMICAL
Rg1	I-CHEMICAL
restores	O
the	O
impairment	B-UNK
of	O
learning	B-UNK
induced	O
by	O
chronic	B-UNK
morphine	B-CHEMICAL
administration	O
in	O
rats	B-UNK
.	O
Rg1	B-UNK
,	O
as	O
a	O
ginsenoside	O
extracted	O
from	O
Panax	O
ginseng	O
,	O
could	O
ameliorate	O
spatial	O
learning	B-UNK
impairment	B-UNK
.	O
Previous	B-UNK
studies	I-UNK
have	O
demonstrated	O
that	O
Rg1	B-UNK
might	O
be	O
a	O
useful	O
agent	B-UNK
for	O
the	O
prevention	B-UNK
and	O
treatment	B-UNK
of	O
the	O
adverse	B-UNK
effects	I-UNK
of	O
morphine	B-CHEMICAL
.	O
The	O
aim	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
investigate	B-UNK
the	O
effect	B-UNK
of	O
Rg1	B-UNK
on	O
learning	B-UNK
impairment	B-UNK
by	O
chronic	B-UNK
morphine	B-CHEMICAL
administration	O
and	O
the	O
mechanism	B-UNK
responsible	B-UNK
for	O
this	O
effect	B-UNK
.	O
Male	B-UNK
rats	I-UNK
were	O
subcutaneously	B-UNK
injected	B-UNK
with	O
morphine	B-CHEMICAL
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
)	O
twice	O
a	O
day	O
at	O
12	O
hour	B-UNK
intervals	B-UNK
for	O
10	O
days	B-UNK
,	O
and	O
Rg1	B-UNK
(	O
30	O
mg	B-UNK
/	O
kg	B-UNK
)	O
was	O
intraperitoneally	B-UNK
injected	B-UNK
2	O
hours	B-UNK
after	O
the	O
second	O
injection	B-UNK
of	O
morphine	B-UNK
once	O
a	O
day	O
for	O
10	O
days	B-UNK
.	O
Spatial	O
learning	B-UNK
capacity	O
was	O
assessed	B-UNK
in	O
the	O
Morris	O
water	B-UNK
maze	B-UNK
.	O
The	O
results	B-UNK
showed	O
that	O
rats	B-UNK
treated	O
with	O
Morphine	B-UNK
/	O
Rg1	B-UNK
decreased	B-UNK
escape	B-UNK
latency	B-UNK
and	O
increased	B-UNK
the	O
time	O
spent	O
in	O
platform	O
quadrant	O
and	O
entering	O
frequency	B-UNK
.	O
By	O
implantation	O
of	O
electrodes	O
and	O
electrophysiological	B-UNK
recording	B-UNK
in	O
vivo	B-UNK
,	O
the	O
results	B-UNK
showed	O
that	O
Rg1	B-UNK
restored	B-UNK
the	O
long	B-UNK
-	O
term	O
potentiation	B-UNK
(	O
LTP	O
)	O
impaired	B-UNK
by	O
morphine	B-CHEMICAL
in	O
both	O
freely	O
moving	B-UNK
and	O
anaesthetised	O
rats	B-UNK
.	O
The	O
electrophysiological	B-UNK
recording	B-UNK
in	O
vitro	B-UNK
showed	O
that	O
Rg1	B-UNK
restored	B-UNK
the	O
LTP	O
in	O
slices	O
from	O
the	O
rats	B-UNK
treated	O
with	O
morphine	B-UNK
,	O
but	O
not	O
changed	O
LTP	O
in	O
the	O
slices	O
from	O
normal	O
saline-	O
or	O
morphine	B-CHEMICAL
/	O
Rg1-treated	O
rats	B-UNK
;	O
this	O
restoration	O
could	O
be	O
inhibited	B-UNK
by	O
N	O
-	O
methyl	B-UNK
-	O
D	O
-	O
aspartate	B-UNK
(	O
NMDA	B-UNK
)	O
receptor	B-UNK
antagonist	I-UNK
MK801	O
.	O
We	O
conclude	O
that	O
Rg1	B-UNK
may	O
significantly	B-UNK
improve	B-UNK
the	O
spatial	O
learning	B-UNK
capacity	O
impaired	B-UNK
by	O
chonic	O
morphine	B-CHEMICAL
administration	O
and	O
restore	O
the	O
morphine	B-UNK
-	O
inhibited	B-UNK
LTP	O
.	O
This	O
effect	B-UNK
is	O
NMDA	B-UNK
receptor	I-UNK
dependent	B-UNK
.	O

A	O
study	B-UNK
on	O
the	O
effect	B-UNK
of	O
the	O
duration	B-UNK
of	O
subcutaneous	B-UNK
heparin	B-CHEMICAL
injection	B-UNK
on	O
bruising	B-DISEASE
and	O
pain	B-UNK
.	O
AIM	B-UNK
:	O
This	O
study	B-UNK
was	O
carried	O
out	O
to	O
determine	B-UNK
the	O
effect	B-UNK
of	O
injection	B-UNK
duration	B-UNK
on	O
bruising	B-DISEASE
and	O
pain	B-UNK
following	O
the	O
administration	O
of	O
the	O
subcutaneous	B-UNK
injection	B-UNK
of	O
heparin	B-CHEMICAL
.	O
BACKGROUND	B-UNK
:	O
Although	O
different	O
methods	B-UNK
to	O
prevent	B-UNK
bruising	B-DISEASE
and	O
pain	B-UNK
following	O
the	O
subcutaneous	B-UNK
injection	B-UNK
of	O
heparin	B-CHEMICAL
have	O
been	O
widely	B-UNK
studied	O
and	O
described	O
,	O
the	O
effect	B-UNK
of	O
injection	B-UNK
duration	B-UNK
on	O
the	O
occurrence	B-UNK
of	O
bruising	B-DISEASE
and	O
pain	B-UNK
is	O
little	O
documented	O
.	O
DESIGN	B-UNK
:	O
This	O
study	B-UNK
was	O
designed	B-UNK
as	O
within	O
-	O
subject	O
,	O
quasi-experimental	O
research	B-UNK
.	O
METHOD	B-UNK
:	O
The	O
sample	B-UNK
for	O
the	O
study	B-UNK
consisted	B-UNK
of	O
50	O
patients	B-UNK
to	O
whom	O
subcutaneous	B-UNK
heparin	B-CHEMICAL
was	O
administered	O
.	O
Heparin	B-UNK
was	O
injected	B-UNK
over	O
10	O
seconds	B-UNK
on	O
the	O
right	O
abdominal	B-UNK
site	B-UNK
and	O
30	O
seconds	B-UNK
on	O
the	O
left	B-UNK
abdominal	B-UNK
site	B-UNK
.	O
Injections	B-UNK
areas	B-UNK
were	O
assessed	B-UNK
for	O
the	O
presence	O
of	O
bruising	B-DISEASE
at	O
48	O
and	O
72	O
hours	B-UNK
after	O
each	O
injection	B-UNK
.	O
Dimensions	O
of	O
the	O
bruising	B-DISEASE
on	O
the	O
heparin	B-UNK
applied	O
areas	B-UNK
were	O
measured	B-UNK
using	O
transparent	O
millimetric	O
measuring	B-UNK
paper	B-UNK
.	O
The	O
visual	B-UNK
analog	B-UNK
scale	B-UNK
(	O
VAS	B-UNK
)	O
was	O
used	O
to	O
measure	B-UNK
pain	B-UNK
intensity	B-UNK
and	O
a	O
stop	O
-	O
watch	O
was	O
used	O
to	O
time	O
the	O
pain	B-DISEASE
period	B-UNK
.	O
Data	B-UNK
were	O
analysed	B-UNK
using	O
chi	O
-	O
square	O
test	B-UNK
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Wilcoxon	O
signed	O
ranks	O
tests	B-UNK
and	O
correlation	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
percentage	B-UNK
of	O
bruising	B-DISEASE
occurrence	B-UNK
was	O
64	O
%	O
with	O
the	O
injection	B-UNK
of	O
10	O
seconds	B-UNK
duration	B-UNK
and	O
42	O
%	O
in	O
the	O
30-second	O
injection	B-UNK
.	O
It	O
was	O
determined	B-UNK
that	O
the	O
size	B-UNK
of	O
the	O
bruising	B-DISEASE
was	O
smaller	B-UNK
in	O
the	O
30-second	O
injection	B-UNK
.	O
Pain	B-UNK
intensity	B-UNK
and	O
pain	B-UNK
period	B-UNK
were	O
statistically	B-UNK
significantly	B-UNK
lower	I-UNK
for	O
the	O
30-second	O
injection	B-UNK
than	O
for	O
the	O
10-second	O
injection	B-UNK
.	O
CONCLUSIONS	B-UNK
:	O
It	O
was	O
determined	B-UNK
that	O
injection	B-UNK
duration	B-UNK
had	O
an	O
effect	B-UNK
on	O
bruising	B-DISEASE
and	O
pain	B-DISEASE
following	O
the	O
subcutaneous	B-UNK
administration	O
of	O
heparin	B-UNK
.	O
This	O
study	B-UNK
should	O
be	O
repeated	B-UNK
on	O
a	O
larger	B-UNK
sample	B-UNK
.	O
RELEVANCE	O
TO	O
CLINICAL	B-UNK
PRACTICE	I-UNK
:	O
When	O
administering	O
subcutaneous	B-UNK
heparin	B-CHEMICAL
injections	B-UNK
,	O
it	O
is	O
important	B-UNK
to	O
extend	O
the	O
duration	B-UNK
of	O
the	O
injection	B-UNK
.	O

Acute	B-UNK
reserpine	B-CHEMICAL
and	O
subchronic	O
haloperidol	B-UNK
treatments	O
change	B-UNK
synaptosomal	O
brain	B-UNK
glutamate	B-UNK
uptake	B-UNK
and	O
elicit	O
orofacial	O
dyskinesia	B-UNK
in	O
rats	B-UNK
.	O
Reserpine-	O
and	O
haloperidol	B-UNK
-	O
induced	O
orofacial	O
dyskinesia	B-DISEASE
are	O
putative	O
animal	B-UNK
models	I-UNK
of	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
(	O
TD	B-UNK
)	O
whose	O
pathophysiology	B-UNK
has	O
been	O
related	O
to	O
free	B-UNK
radical	B-UNK
generation	B-UNK
and	O
oxidative	B-UNK
stress	I-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
the	O
authors	B-UNK
induced	O
orofacial	O
dyskinesia	B-DISEASE
by	O
acute	B-UNK
reserpine	B-CHEMICAL
and	O
subchronic	O
haloperidol	B-UNK
administration	O
to	O
rats	B-UNK
.	O
Reserpine	B-UNK
injection	B-UNK
(	O
one	O
dose	B-UNK
of	O
1	O
mg	B-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
)	O
every	O
other	O
day	O
for	O
3	O
days	B-UNK
caused	B-UNK
a	O
significant	B-UNK
increase	B-UNK
in	O
vacuous	O
chewing	O
,	O
tongue	B-UNK
protrusion	O
and	O
duration	B-UNK
of	O
facial	B-UNK
twitching	O
,	O
compared	O
to	O
the	O
control	B-UNK
.	O
Haloperidol	B-UNK
administration	O
(	O
one	O
dose	B-UNK
of	O
12	O
mg	B-UNK
/	O
kg	B-UNK
once	O
a	O
week	B-UNK
s.c	B-UNK
.	O
)	O
for	O
4	O
weeks	B-UNK
caused	B-UNK
an	O
increase	B-UNK
in	O
vacuous	O
chewing	O
,	O
tongue	B-UNK
protrusion	O
and	O
duration	B-UNK
of	O
facial	B-UNK
twitching	O
observed	O
in	O
four	O
weekly	B-UNK
evaluations	O
.	O
After	O
the	O
treatments	O
and	O
behavioral	B-UNK
observation	B-UNK
,	O
glutamate	B-UNK
uptake	B-UNK
by	O
segments	B-UNK
of	O
the	O
brain	B-UNK
was	O
analyzed	O
.	O
A	O
decreased	B-UNK
glutamate	B-UNK
uptake	B-UNK
was	O
observed	O
in	O
the	O
subcortical	O
parts	O
of	O
animals	B-UNK
treated	O
with	O
reserpine	B-UNK
and	O
haloperidol	B-CHEMICAL
,	O
compared	O
to	O
the	O
control	B-UNK
.	O
Importantly	O
,	O
a	O
decrease	B-UNK
in	O
glutamate	B-UNK
uptake	B-UNK
correlates	B-UNK
negatively	O
with	O
an	O
increase	B-UNK
in	O
the	O
incidence	B-UNK
of	O
orofacial	O
diskinesia	O
.	O
These	O
results	B-UNK
indicate	O
that	O
early	B-UNK
changes	O
in	O
glutamate	B-CHEMICAL
transport	B-UNK
may	O
be	O
related	O
to	O
the	O
development	B-UNK
of	O
vacuous	O
chewing	O
movements	B-UNK
in	O
rats	B-UNK
.	O

Acute	B-UNK
psychosis	B-DISEASE
due	O
to	O
treatment	B-UNK
with	O
phenytoin	B-UNK
in	O
a	O
nonepileptic	O
patient	B-UNK
.	O
The	O
development	B-UNK
of	O
psychosis	B-DISEASE
related	O
to	O
antiepileptic	B-UNK
drug	I-UNK
treatment	B-UNK
is	O
usually	O
attributed	B-UNK
to	O
the	O
interaction	B-UNK
between	O
the	O
epileptic	B-DISEASE
brain	B-UNK
substratum	O
and	O
the	O
antiepileptic	B-UNK
drugs	B-UNK
.	O
The	O
case	B-UNK
of	O
a	O
nonepileptic	O
patient	B-UNK
who	O
developed	O
psychosis	B-UNK
following	O
phenytoin	B-CHEMICAL
treatment	B-UNK
for	O
trigeminal	B-DISEASE
neuralgia	I-DISEASE
is	O
described	O
.	O
This	O
case	B-UNK
suggests	O
that	O
the	O
psychotic	B-DISEASE
symptoms	I-DISEASE
that	O
occur	O
following	O
phenytoin	B-CHEMICAL
treatment	B-UNK
in	O
some	O
epileptic	B-UNK
patients	B-UNK
may	O
be	O
the	O
direct	B-UNK
result	B-UNK
of	O
medication	O
,	O
unrelated	O
to	O
seizures	B-UNK
.	O

The	O
effect	B-UNK
of	O
treatment	B-UNK
with	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
on	O
gentamicin	B-CHEMICAL
nephrotoxicity	B-UNK
in	O
rats	B-UNK
:	O
a	O
preliminary	B-UNK
study	B-UNK
.	O
In	O
the	O
present	B-UNK
work	O
we	O
assessed	B-UNK
the	O
effect	B-UNK
of	O
treatment	B-UNK
of	O
rats	B-UNK
with	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
on	O
acute	B-UNK
renal	I-UNK
failure	I-UNK
induced	O
by	O
gentamicin	B-CHEMICAL
(	O
GM	B-UNK
)	O
nephrotoxicity	B-UNK
.	O
Rats	B-UNK
were	O
treated	O
with	O
the	O
vehicle	B-UNK
(	O
2	O
mL	B-UNK
/	O
kg	B-UNK
of	O
distilled	O
water	B-UNK
and	O
5	O
%	O
w	O
/	O
v	O
cellulose	O
,	O
10	O
days	B-UNK
)	O
,	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
(	O
2	O
mL	B-UNK
/	O
kg	B-UNK
of	O
a	O
10	O
%	O
w	O
/	O
v	O
aqueous	O
suspension	O
of	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
powder	O
,	O
orally	O
for	O
10	O
days	B-UNK
)	O
,	O
or	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
concomitantly	B-UNK
with	O
GM	B-UNK
(	O
80mg	O
/	O
kg	B-UNK
/	O
day	O
intramuscularly	O
,	O
during	O
the	O
last	O
six	O
days	B-UNK
of	O
the	O
treatment	B-UNK
period	B-UNK
)	O
.	O
Nephrotoxicity	B-UNK
was	O
assessed	B-UNK
by	O
measuring	B-UNK
the	O
concentrations	B-UNK
of	O
creatinine	B-CHEMICAL
and	O
urea	B-CHEMICAL
in	O
the	O
plasma	B-UNK
and	O
reduced	B-UNK
glutathione	B-CHEMICAL
(	O
GSH	B-UNK
)	O
in	O
the	O
kidney	B-UNK
cortex	B-UNK
,	O
and	O
by	O
light	B-UNK
microscopic	B-UNK
examination	B-UNK
of	O
kidney	B-UNK
sections	B-UNK
.	O
The	O
results	B-UNK
indicated	O
that	O
concomitant	B-UNK
treatment	B-UNK
with	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
and	O
GM	B-UNK
significantly	B-UNK
increased	B-UNK
creatinine	B-CHEMICAL
and	O
urea	B-UNK
by	O
about	O
183	O
and	O
239	O
%	O
,	O
respectively	O
(	O
compared	O
to	O
432	O
and	O
346	O
%	O
,	O
respectively	O
,	O
in	O
rats	B-UNK
treated	O
with	O
cellulose	O
and	O
GM	B-UNK
)	O
,	O
and	O
decreased	B-UNK
that	O
of	O
cortical	B-UNK
GSH	B-UNK
by	O
21	O
%	O
(	O
compared	O
to	O
27	O
%	O
in	O
the	O
cellulose	O
plus	O
GM	B-UNK
group	B-UNK
)	O
The	O
GM	B-UNK
-	O
induced	O
proximal	B-UNK
tubular	B-UNK
necrosis	I-UNK
appeared	B-UNK
to	O
be	O
slightly	O
less	O
severe	B-UNK
in	O
rats	B-UNK
given	O
GM	B-UNK
together	O
with	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
than	O
in	O
those	O
given	O
GM	B-UNK
and	O
cellulose	O
.	O
It	O
could	O
be	O
inferred	O
that	O
gum	B-CHEMICAL
Arabic	I-CHEMICAL
treatment	B-UNK
has	O
induced	O
a	O
modest	O
amelioration	O
of	O
some	O
of	O
the	O
histological	B-UNK
and	O
biochemical	B-UNK
indices	B-UNK
of	O
GM	B-UNK
nephrotoxicity	B-DISEASE
.	O
Further	O
work	O
is	O
warranted	O
on	O
the	O
effect	B-UNK
of	O
the	O
treatments	O
on	O
renal	B-UNK
functional	B-UNK
aspects	O
in	O
models	B-UNK
of	O
chronic	B-UNK
renal	I-UNK
failure	I-UNK
,	O
and	O
on	O
the	O
mechanism(s	O
)	O
involved	B-UNK
.	O

Visual	B-UNK
hallucinations	I-UNK
associated	O
with	O
zonisamide	B-CHEMICAL
.	O
Zonisamide	B-CHEMICAL
is	O
a	O
broad	O
-	O
spectrum	B-UNK
antiepileptic	B-UNK
drug	I-UNK
used	O
to	O
treat	B-UNK
various	O
types	B-UNK
of	O
seizures	B-UNK
.	O
Although	O
visual	B-DISEASE
hallucinations	I-DISEASE
have	O
not	O
been	O
reported	B-UNK
as	O
an	O
adverse	B-UNK
effect	I-UNK
of	O
this	O
agent	B-UNK
,	O
we	O
describe	O
three	O
patients	B-UNK
who	O
experienced	B-UNK
complex	B-UNK
visual	B-UNK
hallucinations	I-UNK
and	O
altered	B-UNK
mental	B-UNK
status	I-UNK
after	O
zonisamide	B-CHEMICAL
treatment	B-UNK
was	O
begun	O
or	O
its	O
dosage	B-UNK
increased	B-UNK
.	O
All	O
three	O
had	O
been	O
diagnosed	B-UNK
earlier	B-UNK
with	O
epilepsy	B-UNK
,	O
and	O
their	O
electroencephalogram	O
(	O
EEG	B-UNK
)	O
findings	B-UNK
were	O
abnormal	B-UNK
.	O
During	O
monitoring	B-UNK
,	O
visual	B-UNK
hallucinations	I-UNK
did	O
not	O
correlate	B-UNK
with	O
EEG	B-UNK
readings	O
,	O
nor	O
did	O
video	O
recording	B-UNK
capture	O
any	O
of	O
the	O
described	O
events	B-UNK
.	O
None	O
of	O
the	O
patients	B-UNK
had	O
experienced	B-UNK
visual	B-UNK
hallucinations	I-UNK
before	O
this	O
event	B-UNK
.	O
The	O
only	O
recent	B-UNK
change	B-UNK
in	O
their	O
treatment	B-UNK
was	O
the	O
introduction	B-UNK
or	O
increased	B-UNK
dosage	B-UNK
of	O
zonisamide	B-CHEMICAL
.	O
With	O
either	O
discontinuation	B-UNK
or	O
decreased	B-UNK
dosage	B-UNK
of	O
the	O
drug	B-UNK
the	O
symptoms	B-UNK
disappeared	O
and	O
did	O
not	O
recur	O
.	O
Further	O
observations	B-UNK
and	O
reports	B-UNK
will	O
help	O
clarify	O
this	O
adverse	B-UNK
effect	I-UNK
.	O
Until	O
then	O
,	O
clinicians	B-UNK
need	O
to	O
be	O
aware	B-UNK
of	O
this	O
possible	O
complication	B-UNK
associated	O
with	O
zonisamide	B-CHEMICAL
.	O

GLEPP1	B-UNK
receptor	B-UNK
tyrosine	B-CHEMICAL
phosphatase	B-UNK
(	O
Ptpro	O
)	O
in	O
rat	B-UNK
PAN	B-UNK
nephrosis	B-UNK
.	O
A	O
marker	B-UNK
of	O
acute	B-UNK
podocyte	B-UNK
injury	B-UNK
.	O
Glomerular	B-UNK
epithelial	B-UNK
protein	B-UNK
1	O
(	O
GLEPP1	B-UNK
)	O
is	O
a	O
podocyte	B-UNK
receptor	B-UNK
membrane	B-UNK
protein	B-UNK
tyrosine	B-UNK
phosphatase	B-UNK
located	O
on	O
the	O
apical	B-UNK
cell	B-UNK
membrane	B-UNK
of	O
visceral	O
glomerular	B-UNK
epithelial	B-UNK
cell	B-UNK
and	O
foot	B-UNK
processes	B-UNK
.	O
This	O
receptor	B-UNK
plays	O
a	O
role	O
in	O
regulating	O
the	O
structure	B-UNK
and	O
function	B-UNK
of	O
podocyte	B-UNK
foot	B-UNK
process	O
.	O
To	O
better	O
understand	O
the	O
utility	B-UNK
of	O
GLEPP1	B-UNK
as	O
a	O
marker	B-UNK
of	O
glomerular	B-UNK
injury	B-UNK
,	O
the	O
amount	O
and	O
distribution	B-UNK
of	O
GLEPP1	B-UNK
protein	B-UNK
and	O
mRNA	B-UNK
were	O
examined	B-UNK
by	O
immunohistochemistry	B-UNK
,	O
Western	B-UNK
blot	O
and	O
RNase	O
protection	B-UNK
assay	B-UNK
in	O
a	O
model	B-UNK
of	O
podocyte	B-UNK
injury	B-UNK
in	O
the	O
rat	B-UNK
.	O
Puromycin	B-UNK
aminonucleoside	I-UNK
nephrosis	B-DISEASE
was	O
induced	O
by	O
single	B-UNK
intraperitoneal	B-UNK
injection	B-UNK
of	O
puromycin	B-UNK
aminonucleoside	I-UNK
(	O
PAN	B-UNK
,	O
20	O
mg/100	O
g	O
BW	B-UNK
)	O
.	O
Tissues	B-UNK
were	O
analyzed	O
at	O
0	O
,	O
5	O
,	O
7	O
,	O
11	O
,	O
21	O
,	O
45	O
,	O
80	O
and	O
126	O
days	B-UNK
after	O
PAN	B-UNK
injection	B-UNK
so	O
as	O
to	O
include	O
both	O
the	O
acute	B-UNK
phase	B-UNK
of	O
proteinuria	B-UNK
associated	O
with	O
foot	B-UNK
process	O
effacement	O
(	O
days	B-UNK
5	O
-	O
11	O
)	O
and	O
the	O
chronic	B-UNK
phase	B-UNK
of	O
proteinuria	B-UNK
associated	O
with	O
glomerulosclerosis	B-UNK
(	O
days	B-UNK
45	O
-	O
126	O
)	O
.	O
At	O
day	O
5	O
,	O
GLEPP1	B-UNK
protein	B-UNK
and	O
mRNA	B-UNK
were	O
reduced	B-UNK
from	O
the	O
normal	O
range	B-UNK
(	O
265.2	O
+	O
/-	O
79.6	O
x	O
10(6	O
)	O
moles	O
/	O
glomerulus	O
and	O
100	O
%	O
)	O
to	O
15	O
%	O
of	O
normal	O
(	O
41.8	O
+	O
/-	O
4.8	O
x	O
10(6	O
)	O
moles	O
/	O
glomerulus	O
,	O
p	O
<	O
0.005	O
)	O
.	O
This	O
occurred	B-UNK
in	O
association	B-UNK
with	O
an	O
increase	B-UNK
in	O
urinary	B-UNK
protein	I-UNK
content	B-UNK
from	O
1.8	O
+	O
/-	O
1	O
to	O
99.0	O
+	O
/-	O
61	O
mg	B-UNK
/	O
day	O
(	O
p	O
<	O
0.001	O
)	O
.	O
In	O
contrast	B-UNK
,	O
podocalyxin	O
did	O
not	O
change	B-UNK
significantly	B-UNK
at	O
this	O
time	O
.	O
By	O
day	O
11	O
,	O
GLEPP1	B-UNK
protein	B-UNK
and	O
mRNA	B-UNK
had	O
begun	O
to	O
return	B-UNK
towards	O
baseline	B-UNK
.	O
By	O
day	O
45	O
-	O
126	O
,	O
at	O
a	O
time	O
when	O
glomerular	B-UNK
scarring	O
was	O
present	B-UNK
,	O
GLEPP1	B-UNK
was	O
absent	B-UNK
from	O
glomerulosclerotic	O
areas	B-UNK
although	O
the	O
total	B-UNK
glomerular	B-UNK
content	B-UNK
of	O
GLEPP1	B-UNK
was	O
not	O
different	O
from	O
normal	O
.	O
We	O
conclude	O
that	O
GLEPP1	B-UNK
expression	B-UNK
,	O
unlike	B-UNK
podocalyxin	O
,	O
reflects	O
podocyte	B-UNK
injury	B-UNK
induced	O
by	O
PAN	B-UNK
.	O
GLEPP1	B-UNK
expression	B-UNK
may	O
be	O
a	O
useful	O
marker	B-UNK
of	O
podocyte	B-UNK
injury	B-UNK
.	O

Ticlopidine	B-UNK
-	O
induced	O
aplastic	B-UNK
anemia	I-UNK
:	O
report	B-UNK
of	O
three	O
Chinese	B-UNK
patients	B-UNK
and	O
review	B-UNK
of	O
the	O
literature	B-UNK
.	O
In	O
this	O
study	B-UNK
,	O
three	O
Chinese	B-UNK
patients	B-UNK
with	O
ticlopidine	B-UNK
-	O
induced	O
aplastic	B-DISEASE
anemia	I-DISEASE
were	O
reported	B-UNK
and	O
another	O
13	O
patients	B-UNK
in	O
the	O
English	O
literature	B-UNK
were	O
reviewed	B-UNK
.	O
We	O
attempted	O
to	O
find	O
underlying	B-UNK
similarities	O
,	O
evaluate	B-UNK
the	O
risk	B-UNK
factors	I-UNK
,	O
and	O
identify	B-UNK
appropriate	O
treatment	B-UNK
for	O
this	O
complication	B-UNK
.	O
All	O
but	O
one	O
of	O
the	O
patients	B-UNK
were	O
over	O
60	O
years	B-UNK
old	O
,	O
and	O
the	O
6	O
who	O
died	O
were	O
all	O
older	B-UNK
than	O
65	O
.	O
Therefore	O
,	O
old	O
age	B-UNK
may	O
be	O
a	O
risk	B-UNK
factor	I-UNK
for	O
developing	B-UNK
this	O
complication	B-UNK
.	O
Agranulocytosis	B-DISEASE
occurred	B-UNK
3	O
-	O
20	O
weeks	B-UNK
after	O
initiation	B-UNK
of	O
ticlopidine	B-CHEMICAL
,	O
so	O
frequent	B-UNK
examination	B-UNK
of	O
white	B-UNK
cell	B-UNK
count	B-UNK
during	O
treatment	B-UNK
is	O
recommended	O
.	O
There	O
seemed	O
to	O
be	O
no	O
direct	B-UNK
correlation	B-UNK
between	O
the	O
dose	B-UNK
or	O
duration	B-UNK
used	O
and	O
the	O
severity	B-UNK
of	O
bone	B-DISEASE
marrow	I-DISEASE
suppression	I-DISEASE
.	O
Treatment	B-UNK
for	O
ticlopidine	B-CHEMICAL
-	O
induced	O
aplastic	B-UNK
anemia	I-UNK
with	O
colony	O
-	O
stimulating	B-UNK
factors	B-UNK
seemed	O
to	O
have	O
little	O
effect	B-UNK
.	O
The	O
fact	B-UNK
that	O
5	O
of	O
the	O
6	O
patients	B-UNK
who	O
received	O
concurrent	B-UNK
calcium	B-UNK
channel	I-UNK
blockers	I-UNK
died	O
,	O
should	O
alert	O
clinicians	B-UNK
to	O
be	O
more	O
cautious	O
when	O
using	O
these	O
two	O
drugs	B-UNK
simultaneously	B-UNK
.	O

Facilitation	O
of	O
memory	B-UNK
retrieval	O
by	O
pre	B-UNK
-	O
test	B-UNK
morphine	B-UNK
and	O
its	O
state	B-UNK
dependency	O
in	O
the	O
step	B-UNK
-	O
through	O
type	B-UNK
passive	B-UNK
avoidance	I-UNK
learning	B-UNK
test	B-UNK
in	O
mice	B-UNK
.	O
Amnesia	B-UNK
produced	B-UNK
by	O
scopolamine	B-CHEMICAL
and	O
cycloheximide	B-CHEMICAL
were	O
reversed	B-UNK
by	O
morphine	B-UNK
given	O
30	O
min	B-UNK
before	O
the	O
test	B-UNK
trial	B-UNK
(	O
pre	B-UNK
-	O
test	B-UNK
)	O
,	O
and	O
pre	B-UNK
-	O
test	B-UNK
morphine	B-UNK
also	O
facilitated	O
the	O
memory	B-UNK
retrieval	O
in	O
the	O
animals	B-UNK
administered	O
naloxone	B-UNK
during	O
the	O
training	B-UNK
trial	B-UNK
.	O
Similarly	B-UNK
,	O
pre	B-UNK
-	O
test	B-UNK
scopolamine	B-UNK
partially	O
reversed	B-UNK
the	O
scopolamine	B-UNK
-	O
induced	O
amnesia	B-UNK
,	O
but	O
not	O
significantly	B-UNK
;	O
and	O
pre	B-UNK
-	O
test	B-UNK
cycloheximide	B-CHEMICAL
failed	B-UNK
to	O
reverse	B-UNK
the	O
cycloheximide	B-CHEMICAL
-	O
induced	O
amnesia	B-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
the	O
facilitation	O
of	O
memory	B-UNK
retrieval	O
by	O
pre	B-UNK
-	O
test	B-UNK
morphine	B-UNK
might	O
be	O
the	O
direct	B-UNK
action	B-UNK
of	O
morphine	B-CHEMICAL
rather	O
than	O
a	O
state	B-UNK
dependent	B-UNK
effect	B-UNK
.	O

Test	B-UNK
conditions	O
influence	B-UNK
the	O
response	B-UNK
to	O
a	O
drug	B-UNK
challenge	B-UNK
in	O
rodents	B-UNK
.	O
These	O
studies	B-UNK
were	O
conducted	B-UNK
to	O
examine	B-UNK
the	O
differential	B-UNK
response	B-UNK
to	O
a	O
drug	B-UNK
challenge	B-UNK
under	O
varied	O
experimental	B-UNK
test	B-UNK
conditions	O
routinely	O
employed	B-UNK
to	O
study	B-UNK
drug	B-UNK
-	O
induced	O
behavioral	B-UNK
and	O
neurophysiological	O
responses	O
in	O
rodents	B-UNK
.	O
Apomorphine	B-UNK
,	O
a	O
nonselective	O
dopamine	B-UNK
agonist	B-UNK
,	O
was	O
selected	O
due	O
to	O
its	O
biphasic	O
behavioral	B-UNK
effects	O
,	O
its	O
ability	B-UNK
to	O
induce	B-UNK
hypothermia	B-UNK
,	O
and	O
to	O
produce	B-UNK
distinct	O
changes	O
to	O
dopamine	B-UNK
turnover	B-UNK
in	O
the	O
rodent	O
brain	B-UNK
.	O
From	O
such	O
experiments	B-UNK
there	O
is	O
evidence	B-UNK
that	O
characterization	O
and	O
detection	B-UNK
of	O
apomorphine	B-UNK
-	O
induced	O
activity	B-UNK
in	O
rodents	B-UNK
critically	O
depends	O
upon	O
the	O
test	B-UNK
conditions	O
employed	B-UNK
.	O
In	O
rats	B-UNK
,	O
detection	B-UNK
of	O
apomorphine	B-UNK
-	O
induced	B-UNK
hyperactivity	I-UNK
was	O
facilitated	O
by	O
a	O
period	B-UNK
of	O
acclimatization	O
to	O
the	O
test	B-UNK
conditions	O
.	O
Moreover	O
,	O
test	B-UNK
conditions	O
can	O
impact	B-UNK
upon	O
other	O
physiological	B-UNK
responses	O
to	O
apomorphine	B-UNK
such	O
as	O
drug	B-UNK
-	O
induced	O
hypothermia	B-UNK
.	O
In	O
mice	B-UNK
,	O
apomorphine	B-UNK
produced	B-UNK
qualitatively	O
different	O
responses	O
under	O
novel	O
conditions	O
when	O
compared	O
to	O
those	O
behaviors	B-UNK
elicited	B-UNK
in	O
the	O
home	B-UNK
test	B-UNK
cage	O
.	O
Drug	B-UNK
-	O
induced	O
gross	O
activity	B-UNK
counts	B-UNK
were	O
increased	B-UNK
in	O
the	O
novel	O
exploratory	O
box	O
only	O
,	O
while	O
measures	B-UNK
of	O
stereotypic	O
behavior	B-UNK
were	O
similar	B-UNK
in	O
both	O
.	O
By	O
contrast	B-UNK
,	O
apomorphine	B-UNK
-	O
induced	O
locomotion	B-UNK
was	O
more	O
prominent	B-UNK
in	O
the	O
novel	O
exploratory	O
box	O
.	O
Dopamine	B-UNK
turnover	B-UNK
ratios	O
(	O
DOPAC	B-CHEMICAL
:	O
DA	B-UNK
and	O
HVA	O
:	O
DA	B-UNK
)	O
were	O
found	O
to	O
be	O
lower	B-UNK
in	O
those	O
animals	B-UNK
exposed	B-UNK
to	O
the	O
exploratory	O
box	O
when	O
compared	O
to	O
their	O
home	B-UNK
cage	O
counterparts	O
.	O
However	O
,	O
apomorphine	B-UNK
-	O
induced	O
reductions	B-UNK
in	O
striatal	B-UNK
dopamine	B-CHEMICAL
turnover	B-UNK
were	O
detected	B-UNK
in	O
both	O
novel	O
and	O
home	B-UNK
cage	O
environments	O
.	O
The	O
implications	B-UNK
of	O
these	O
findings	B-UNK
are	O
discussed	O
with	O
particular	O
emphasis	O
upon	O
conducting	O
psychopharmacological	O
challenge	B-UNK
tests	B-UNK
in	O
rodents	B-UNK
.	O

